======================================================================
NEPHRO-AI MEDICAL KNOWLEDGE BASE - PROCESSED CHUNKS
======================================================================


======================================================================
CHUNK 1 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_0
Content Type: reference
Words: 470
Medical Entities: CKD,GFR,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
STAGES 14 Diabetes and Chronic Kidney Disease Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION KIDNEY STAGE DESCRIPTION RATE (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the What is diabetes? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your Are there different types of diabetes? . . . . . . . . . . . . . 4 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a How does diabetes affect my body? . . . . . . . . . . . . . . . 5 lab test that measures the amount of blood your What is chronic kidney disease? . . . . . . . . . . . . . . . . . . 6 kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Are people with diabetes at greater risk for getting kidney disease? . . . . . . . . . . . . . . . . . . . . . . . . . . 7 What can people with diabetes do to STAGES OF KIDNEY DISEASE prevent kidney disease? . . . . . . . . . . . . . . . . . . . . . . . . . 8 ESTIMATED GLOMERULAR How does diabetes harm the kidneys? . . . . . . . . . . . . 9 FILTRATION KIDNEY STAGE DESCRIPTION RATE (eGFR) FUNCTION How do I know if I have kidney damage? . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 2 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_1
Content Type: reference
Words: 494
Medical Entities: GFR,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
. . 8 ESTIMATED GLOMERULAR How does diabetes harm the kidneys? . . . . . . . . . . . . 9 FILTRATION KIDNEY STAGE DESCRIPTION RATE (eGFR) FUNCTION How do I know if I have kidney damage? . . . . . . . . . . 11 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function What can be done to keep my kidneys working as long as possible? . . . . . . . . . . . . . 13 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% What about cholesterol and lipids? . . . . . . . . . . . . . . . 16 Mild to moderate loss of What about pregnancy? . . . . . . . . . . . . . . . . . . . . . . . . 17 3a 45 to 59 kidney function 4559% Key points to remember. . . . . . . . . . . . . . . . . . . . . . . . 18 Moderate to severe loss of 3b 30 to 44 kidney function Where can I get more information? . . . . . . . . . . . . . . . 21 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 3 What is diabetes? Diabetes is a serious disease. It occurs when your body does not make enough insulin or cannot use the insulin it makes. Insulin is a hormone. It controls the amount of sugar (called glucose) in your blood. A high blood sugar level can cause problems in many parts of your body. Are there different types of diabetes? Yes. There are two main types: TYPE 1 DIABETES If you have this type of diabetes, your body does not make insulin. It usually starts when you are a child or young adult, but it can occur at any age. It is treated by taking daily insulin shots or using an insulin pump and by following a special meal plan. In America, 5. 2 percent of diagnosed adult diabetes cases are type 1. TYPE 2 DIABETES If you have this type of diabetes, your body makes some insulin but cannot use it properly. Type 2 is partially preventable and is typically brought on by poor diet and lack of exercise. Very often heredity plays a part. It usually starts when you are over age 40, but it can happen earlier. It is treated with exercise, weight loss, and special meal planning. People with type 2 diabetes may need insulin, but in most cases medications given in pills (called hypoglycemics) are prescribed if diet and exercise alone do not control the disease. Type 2 is the most common type of diabetes.
----------------------------------------------------------------------


======================================================================
CHUNK 3 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_2
Content Type: general
Words: 484
Medical Entities: CKD,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
It is treated with exercise, weight loss, and special meal planning. People with type 2 diabetes may need insulin, but in most cases medications given in pills (called hypoglycemics) are prescribed if diet and exercise alone do not control the disease. Type 2 is the most common type of diabetes. 4 NATIONAL KIDNEY FOUNDATION How does diabetes affect my body? When diabetes is not well controlled, the sugar level in your blood goes up. This is called hyperglycemia. High blood sugar can cause damage to many parts of your body, especially: kidneys eyes heart feet blood vessels nerves Diabetes can also cause high blood pressure and hardening of the arteries (called arteriosclerosis). These can lead to heart and blood vessel disease. KIDNEY. ORG 5 What is chronic kidney disease? Your kidneys are important because they keep the rest of your body in balance. They: Remove waste products from the body Balance the bodys fluids Help keep blood pressure under control Keep bones healthy Help make red blood cells Chronic kidney disease (CKD) means that the kidneys have been damaged. Kidneys can get damaged from a physical injury or a disease like diabetes or high blood pressure. Once your kidneys are damaged, they 6 NATIONAL KIDNEY FOUNDATION cannot filter your blood or do other jobs as well as they should. There are five stages of kidney disease (see ). Treatment in the early stages can help keep kidney disease from getting worse. Are people with diabetes at greater risk for getting kidney disease? Yes. About a third of people with diabetes may get chronic kidney disease. Certain groups may have a higher risk of getting kidney disease than others. Your risk may be greater if you: Are age 60 or older Have high blood pressure Have a family member who has kidney failure Are overweight or obese Usually, developing kidney disease is not because of any one single reason, but due to a number of physical, environmental, and social factors. KIDNEY. ORG 7 What can people with diabetes do to prevent kidney disease? People with diabetes can take steps to avoid developing kidney disease or kidney failure. Talk to your healthcare provider about your risks for developing kidney disease. The best way to prevent developing kidney disease from diabetes is to: Control your blood sugar level Keep blood pressure under control Ask your healthcare provider to test you for kidney disease at least once each year Take medicines to help control your blood glucose, cholesterol, and blood pressure if your healthcare provider orders them for you Follow your diet for diabetes Get regular exercise Avoid alcohol Do not smoke See your healthcare provider as often as you are told 8 NATIONAL KIDNEY FOUNDATION How does diabetes harm the kidneys? Diabetes can harm the kidneys by causing damage to: BLOOD VESSELS IN THE KIDNEYS The filtering units of the kidney are filled with tiny blood vessels.
----------------------------------------------------------------------


======================================================================
CHUNK 4 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_3
Content Type: general
Words: 498
Section: Diabetes can harm the kidneys by causing damage to:
Medical Entities: GFR,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
Diabetes can harm the kidneys by causing damage to: BLOOD VESSELS IN THE KIDNEYS The filtering units of the kidney are filled with tiny blood vessels. Over time, high sugar levels in the blood can cause these vessels to become narrow and clogged. Without enough blood, the kidneys become damaged and albumin (a type of protein) passes through these filters and ends up in the urine where it should not be. NERVES IN YOUR BODY Diabetes can also cause damage to the nerves in your body. Nerves carry messages between your brain and all other parts of your body, including your bladder. They let your brain know when your bladder is full. But if the nerves of the bladder are damaged, you may not be able to feel when your bladder is full. The pressure from a full bladder can damage your kidneys. KIDNEY. ORG 9 URINARY TRACT If urine stays in your bladder for a long time, you may get a urinary tract infection. This is because of bacteria. Bacteria are tiny organisms, like germs, that can cause disease. They grow rapidly in urine with a high sugar level. Most often these infections affect the bladder, but they can sometimes spread to the kidneys. 10 NATIONAL KIDNEY FOUNDATION How do I know if I have kidney damage? Most people with early kidney damage do not have symptoms. The best way to find early kidney damage is to have a urine test called uACR once a year. This test checks for very small amounts of protein in the urine. It helps detect kidney damage at an early stage in people with diabetes. If your uACR is positive, your healthcare professional will want to find out how well your kidneys are working. This will help to determine the best treatment for you. Your healthcare provider will start by: CHECKING YOUR eGFR (ESTIMATED GLOMERULAR FILTRATION RATE) eGFR is the best way to find out how well your kidneys are working. Your healthcare provider will begin by testing your blood for a waste product called creatinine. When the kidneys are damaged, they have trouble removing creatinine from your blood. Creatinine is stored in muscle tissue and blood. The blood test for creatinine will help your healthcare professional find out how well your kidneys are working. But it is only the first step of the eGFR test. Next, your healthcare professional or lab will take the result of your creatine test and put it into a math calculation that includes your age and gender. The number that results from this calculation is called your eGFR (estimated glomerular filtration rate). It tells your healthcare professional how well your kidneys are working. You should have this test at least once a year. KIDNEY. ORG 11 Once your eGFR is known, your healthcare professional can tell which stage of kidney disease you have. There are five stages of kidney disease (see the chart on ). Your treatment will depend on your stage of kidney disease.
----------------------------------------------------------------------


======================================================================
CHUNK 5 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_4
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
KIDNEY. ORG 11 Once your eGFR is known, your healthcare professional can tell which stage of kidney disease you have. There are five stages of kidney disease (see the chart on ). Your treatment will depend on your stage of kidney disease. ORDERING A KIDNEY BIOPSY Your healthcare professional may also order a kidney biopsy. This can help your healthcare professional find the main cause of your kidney disease. Not all kidney damage is caused by diabetes. Other diseases can be involved. If your kidney disease is caused by diabetes, it is called diabetic kidney disease. Your healthcare professional will begin treatment based on the stage of kidney disease you have and what caused it. With the right treatment, you and your healthcare professional can keep your kidneys working as long as possible. Not everyone with kidney disease gets kidney failure. With the right treatment, you can help keep kidney disease from getting worse. 12 NATIONAL KIDNEY FOUNDATION What can be done to keep my kidneys working as long as possible? Your healthcare professional should plan your treatment with you and your family. Some patients may be asked to see a kidney doctor, called a nephrologist. A kidney dietitian may be helpful too. The following things can help your kidneys work better and last longer: CONTROLLING YOUR BLOOD SUGAR The best way to prevent or slow kidney damage is to keep your blood sugar well controlled. This is usually done with diet, exercise, and, if needed, insulin or hypoglycemic pills (to lower your blood sugar level). Your healthcare professional may also recommend that you start taking an SGLT2 inhibitor. Originally, SGLT2 inhibitors were developed as oral antidiabetic (blood sugar lowering) drugs. Later clinical trial data showed significant improvement in kidney function in people with diabetes who already had diabetic nephropathy. SGLT2 inhibitors have been found to be effective at slowing the progression of kidney disease, reducing heart failure, and lowering the risk of kidney failure and death in people with kidney disease and type 2 diabetes. SGLT2 inhibitors also protect the kidneys in people with CKD who do not have diabetes. A test called hemoglobin A1C should be done every three to six months to check your blood sugar. Ask your healthcare professional what your test result KIDNEY. ORG 13 should be. Daily blood sugar levels should also be checked so that your medication doses can be adjusted as needed. CONTROLLING HIGH BLOOD PRESSURE High blood pressure can increase your chances of developing kidney failure. Ask your healthcare professional what your blood pressure target should be. You will probably need a medication called an ACE (angiotensin converting enzyme) inhibitor or an ARB (angiotensin receptor blocker) to control your blood pressure. In many cases, more than one high blood pressure medicine may be needed to reach this target. Studies have shown that the use of these medicines can slow the loss of kidney function in people with diabeteseven if your blood pressure is normal.
----------------------------------------------------------------------


======================================================================
CHUNK 6 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_5
Content Type: general
Words: 495
Medical Entities: diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
In many cases, more than one high blood pressure medicine may be needed to reach this target. Studies have shown that the use of these medicines can slow the loss of kidney function in people with diabeteseven if your blood pressure is normal. They also help reduce heart disease in people with diabetes. In addition, your healthcare professional may prescribe a diuretic (water pill) to help remove salt and water from your blood. PROTECTING KIDNEY FUNCTION BY TAKING ACE INHIBITORS OR ARBS Your healthcare professional may have you take high blood pressure medicines (called ACE inhibitors or ARBs) even if your blood pressure is normal. Research suggests that these medicines can slow the loss of kidney function in people with diabeteseven those with normal blood pressure. 14 NATIONAL KIDNEY FOUNDATION LIMITING HOW MUCH PROTEIN YOU EAT People with diabetes and kidney disease should eat enough protein for good health, but avoid overeating it. Research suggests that eating less protein can slow kidney damage. You should talk to your healthcare professional about this. If you need to go on a lowprotein diet, you must plan this with a dietitian who specializes in kidney disease. Do not go on this type of diet without talking to a dietitian so that you have a healthy approach to dietary changes. PROMPTLY REPORTING TO YOUR HEALTHCARE PROFESSIONAL ANY DIFFICULTY PASSING URINE Early treatment for urinary tract infections is important. Some signs of urinary infection could be: frequent need to urinate, burning or pain with urination, cloudy or blood-spotted urine, or a strong odor to your urine. LIMITING THE AMOUNT OF SALT IN YOUR DIET Help control high blood pressure and reduce body swelling by not eating as much salt. KIDNEY. ORG 15 NOT USING MEDICINES THAT MAY DAMAGE THE KIDNEYS NSAIDs (non-steroidal anti-inflammatory drugs), such as ibuprofen and naproxen, can be very hard on the kidneys. CHECKING WITH YOUR HEALTHCARE PROFESSIONAL Before taking any herbal supplements, make sure you speak with your doctor. PREVENTING FURTHER DAMAGE TO LARGER BLOOD VESSELS (such as those in the brain and heart) By keeping cholesterol and lipid levels under control, you can prevent any further damage to large blood vessels, including those in the brain and heart. What about cholesterol and lipids? Many people with diabetes and kidney disease have high levels of lipids in the blood. Lipids are fatty substances like cholesterol. High blood lipid levels can cause the blood vessels to become clogged. This lessens the blood supply to the heart and brain, and raises your chance of having a heart attack or stroke. Your healthcare professional will check your cholesterol and lipids at least once a year. If they are too high, you may need drugs called statins to help lower them. 16 NATIONAL KIDNEY FOUNDATION What about pregnancy? Having both diabetes and kidney disease is serious. It can affect your health and the health of your unborn child. If you are thinking about becoming pregnant, talk to your healthcare team.
----------------------------------------------------------------------


======================================================================
CHUNK 7 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_6
Content Type: reference
Words: 495
Medical Entities: GFR,dialysis,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
16 NATIONAL KIDNEY FOUNDATION What about pregnancy? Having both diabetes and kidney disease is serious. It can affect your health and the health of your unborn child. If you are thinking about becoming pregnant, talk to your healthcare team. If you become pregnant, you should be under the care of a specialist in highrisk pregnancy and a specialist in kidney disease. Some women may also have a higher risk for kidney failure during pregnancy. You should: Keep your blood sugar levels under control Ask your healthcare professional about using insulin to control your blood sugar while pregnant Tell your healthcare professional about any medicines you are taking, especially medicines for high blood pressure or high cholesterol With good healthcare and careful blood sugar control, it is possible to have a healthy pregnancy. KIDNEY. ORG 17 Key points to remember About a third of people with diabetes may develop kidney failure. Because diabetes may harm the blood vessels in the body, it can cause kidney damage. Early kidney damage from diabetes can be found by a test called uACR that checks for a tiny amount of protein in the urine. A test called eGFR lets your healthcare professional know how much kidney function you have. Treatment with some high blood pressure medicines called ACE inhibitors or ARBs can slow the loss of kidney function in people with diabetes, even in people with normal blood pressure. Treatment with oral antidiabetic (blood sugar lowering) drugs called SGLT2 inhibitors can slow the loss of kidney function in people with and without diabetes. Reducing the amount of sodium (salt) in your diet may be needed if there is kidney damage or high blood pressure. The most common form of sodium is found in table salt. Other things that can cause kidney damage and affect kidney function are: blocking of urine flow, urinary tract infection, and certain medicines (especially NSAIDs such as ibuprofen Motrin and naproxen Aleve). 18 NATIONAL KIDNEY FOUNDATION Early kidney disease rarely has symptoms. That is why it is so important to be tested regularly by your healthcare professional for kidney damage. An early sign of kidney damage is protein in the urine. If chronic kidney disease causes kidney failure, you will need hemodialysis, peritoneal dialysis, or a kidney transplant to replace the work of your kidneys. The type of treatment that is best depends on overall health, lifestyle, and personal preference. Diet is a very important part of the treatment for all patients with diabetes, even if they do not have chronic kidney disease. KIDNEY. ORG 19 Diabetes: A growing epidemic Did you know these facts about diabetes? As of 2018, over 34 million people in the United States (about 10. 5 per cent of the population) have diabetes, and 7. 3 million people do not even know they have the disease. Diabetes is the leading cause of chronic kidney disease. Diabetes accounts for 40 to 45 percent of kidney failure. Worldwide, 422 million people have diabetes.
----------------------------------------------------------------------


======================================================================
CHUNK 8 of 647
======================================================================
ID: 11_10_0209_2203_patbro_diabckd1_4p5_7
Content Type: recommendation
Words: 383
Medical Entities: dialysis,diabetes
Source: 11-10-0209_2203_patbro_diabckd1-4p5.pdf

----------------------------------------------------------------------
5 per cent of the population) have diabetes, and 7. 3 million people do not even know they have the disease. Diabetes is the leading cause of chronic kidney disease. Diabetes accounts for 40 to 45 percent of kidney failure. Worldwide, 422 million people have diabetes. Almost 37 percent of people older than 65 years have diabetes. 20 NATIONAL KIDNEY FOUNDATION Where can I get more information? If you have questions, speak with your healthcare team. They know your medical history best and can help to answer your questions. There are two ways to learn about the many free English and Spanish resources available to you: Call the NKF Cares Patient Information Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Learn more at kidney. org Becoming an educated patient is very important to being healthy! KIDNEY. ORG 21 Other Resources Association of Diabetes Care Education Specialists 125 S Wacker Dr Suite 600 Chicago, IL 60606 800. 338. 3633 diabeteseducator. org American Diabetes Association ATTN: Center for Information 2451 Crystal Drive, Suite 900 Alexandria, VA 22202 800. DIABETES (800. 342. 2383) diabetes. org 22 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 23 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2022 National Kidney Foundation, Inc. 11-10-0209_2203
----------------------------------------------------------------------


======================================================================
CHUNK 9 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_0
Content Type: general
Words: 462
Section: Travel Tips:
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
Travel Tips: A Guide for People Living with Chronic Kidney Disease Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Get support and hear from others who have experience with dialysis, transplant, living donation, and being a parent or care partneryou never know when youll inspire someone else! Join today at kidney. org/online-communities 2 NATIONAL KIDNEY FOUNDATION Contents Travel Tips: A Guide for People Living with Chronic Kidney Disease. . . . . . . . . . . . . . . . . . . . . . . . 4 Traveling is Good for You. . . . . . . . . . . . . . . . . . . . . . . . 5 Pre-Travel Considerations. . . . . . . . . . . . . . . . . . . . . . . . 5 Dialysis and Travel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Nutrition and Fluids. . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Managing Stress. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Different Cultures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Traveling with CKD and Other Common Medical Conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Kidney Transplant/Kidney Transplant Waitlist. . . . . . . 21 Practical Travel Tips. . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Preparing for Emergencies. . . . . . . . . . . . . . . . . . . . . . 27 Traveling with CKD. . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Travel Preparation Checklist. . . . . . . . . . . . . . . . . . . 29 We are Here to Help. . . . . . . . . . . . . . . . . . . . . . . . . . 34 KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 10 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_1
Content Type: recommendation
Words: 491
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
. . . . . . . . . . . . . . . . . 29 We are Here to Help. . . . . . . . . . . . . . . . . . . . . . . . . . 34 KIDNEY. ORG 3 Travel Tips: A Guide for People Living with Chronic Kidney Disease Traveling can require a bit more thought when you have chronic kidney disease (CKD), but rest assured, its very manageable and can be a fun and fantastic experience! CKD means your kidneys arent functioning at full capacity, which is why, when youre planning a trip, its important to plan a little more carefully. 4 NATIONAL KIDNEY FOUNDATION Traveling is Good for You Going on a trip is not just about exploring new places or visiting with friends and family who do not live nearby. Its also incredibly helpful for your mental and emotional well-being. And people who are living with CKD may find that stepping away from their usual routine and ongoing medical care can be truly wonderful. It offers a chance to unwind, enjoy yourself, and have fun experiences. Travel can lift your spirits and be very exciting. Just remember, its important to plan your trips well and to be mindful of any limitations associated with your illness thats how you can make sure your travel experience is as rewarding as the fun places you visit! Pre-Travel Considerations When you are living with CKD, getting ready for a trip means some extra steps to make sure you stay healthy. Its important to speak with your doctor about your travel plans, think about how managing your CKD will fit into your trip, and make sure you have everything you need. Whether adjusting your treatment, packing your medications, or choosing the right travel insurance, taking care of these details before you leave can help you have a smooth and enjoyable trip. KIDNEY. ORG 5 Talk to Your Healthcare Provider Before planning your trip, you should talk to your healthcare provider and dialysis center staff about your travel plans. They can assess your current health, adjust your treatment plan, and provide information and recommendations for your specific needs. Tips: Schedule a pre-travel checkup to discuss your travel plans. Ask about adjusting your treatment plan while you are away. Get a medical summary and a letter from your healthcare provider explaining your medical conditions. Make sure that you are up to date on all vaccines that your healthcare provider recommends. 6 NATIONAL KIDNEY FOUNDATION Preparation Preparing for travel means more than just packing your bags. Youll need to consider how having CKD can affect your travel plans. This means thinking about your medications, dialysis schedules, dietary needs, and how to handle any health issues while away from home. Tips Start planning early at least 6 to 8 weeks before your trip. Organize your medications and pack them in your carry-on luggage.
----------------------------------------------------------------------


======================================================================
CHUNK 11 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_2
Content Type: general
Words: 479
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
This means thinking about your medications, dialysis schedules, dietary needs, and how to handle any health issues while away from home. Tips Start planning early at least 6 to 8 weeks before your trip. Organize your medications and pack them in your carry-on luggage. Research and make a list of locations of medical facilities at your destination. Plan your travel schedule around your dialysis needs. Visit dialysisfinder. com to find dialysis locations in the US and globaldialysis. com for international travel. Work with your dialysis team to have home dialysis supplies ordered and shipped so theyre available when you arrive at your destination. Contact staff at your destination to ensure delivery and safe storage. Contact your airline or other transportation provider to discuss how to travel with your dialysis machine. If traveling by air, check the Transportation Security Administration website (tsa. gov/travel/securityscreening/whatcanibring/medical) for information about medical items that are allowed on an aircraft. Discuss with your airline or other transportation provider about access to a space where you can do dialysis if the need should arise. For example, delays during which you cant leave the airplane or during very long flights. KIDNEY. ORG 7 Medications/Medical Information When youre away from home, having easy access to your medications and important health information is vital. This ensures that you can manage your health well and respond quickly in case of an emergency. Tips Save the following information in your smartphone and also carry a hard copy that you keep on your person at all times, including your: Medical summary and letter from your healthcare provider explaining all of your medical conditions. Medication list, including dosages. Medical records and recent lab results. Healthcare providers contact information. Medical and pharmacy insurance cards. Include an ICE (in case of emergency) contact number in your phone. If you have a fistula, ask your dialysis team about getting a no-no wristband that warns medical staff not to use the fistula to draw blood or to give intravenous medications and not to use that arm to take blood pressure. Get a medical alert bracelet with the medical information your healthcare team says should be included. Consider laminating important cards, such as those with medical instructions and insurance cards. Include your healthcare facilitys contact information. These cards can be shown to airport security and others. 8 NATIONAL KIDNEY FOUNDATION Travel Insurance Finding the right travel insurance is important for everyone when away from home, but its an especially good idea for people with CKD. You will want to make sure that your insurance policy covers any medical treatments or emergencies that might occur during your trip, including dialysis and other CKD-related care. Tips: Look for travel insurance policies that specifically cover pre-existing conditions like CKD. Understand the extent of coverage, especially for dialysis and emergency services. Know how to file a claim and what documents you might need.
----------------------------------------------------------------------


======================================================================
CHUNK 12 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_3
Content Type: general
Words: 500
Section: Tips:
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
Tips: Look for travel insurance policies that specifically cover pre-existing conditions like CKD. Understand the extent of coverage, especially for dialysis and emergency services. Know how to file a claim and what documents you might need. Keep a copy of your travel insurance policy and insurance cards with you during your trip and save a copy to your phone or other mobile device. KIDNEY. ORG 9 Financial Planning Understanding your legal and financial rights is important for helping to reduce stress while traveling. Managing your finances well can help you handle unexpected situations better, especially regarding medical expenses that might come up during your travels. 10 NATIONAL KIDNEY FOUNDATION Tips: Patient Rights: Foreign countries usually have different healthcare systems and patient rights. Before traveling, research the healthcare rights in your destination country. This may include understanding how local healthcare systems work for nonresidents and any limitations you may have as a traveler. M edical Expenses: Plan your travel budget by considering potential medical expenses, including prescription refills, doctor visits, or emergency treatments. Its better to overestimate these costs so that you do not have any unforeseen financial problems while away. Emergency Funds: Know how to access money quickly if needed. This might involve carrying an emergency credit card, knowing international withdrawal limits on your bank accounts and credit cards, or using financial services that allow fast transfers between accounts. Carry Important Financial Documents: Keep a digital copy of important financial documents, like your insurance policy, bank contacts, and emergency credit card information, in a secure cloud service or encrypted drive. Also, keep a physical copy in a safe but accessible place in your luggage. Currency Considerations: If traveling abroad, understand the currency exchange rates and have some local currency on hand for immediate expenses. Consider using financial apps that help track expenses and conversions. KIDNEY. ORG 11 Dialysis and Travel Planning a trip when you are on dialysis takes a bit of effort, but you should still visit new places and see friends and relatives who do not live close to you. Whether you are on hemodialysis, peritoneal dialysis, or do your dialysis at home, its important to know how to handle your treatment while traveling. With preparation, you can keep to your dialysis schedule and have a great trip. Hemodialysis Organizing hemodialysis treatment while traveling is crucial. Start by researching dialysis centers at your destination. Contact the centers you find to arrange your sessions and do this well before your trip. Early planning ensures you can enjoy your trip without worrying about your treatment schedule. Tips: Make your dialysis appointments well in advance of your trip. Check that your medical records are sent to and received by the destination dialysis center. Make sure you have a backup plan in case something unexpected happens. 12 NATIONAL KIDNEY FOUNDATION Peritoneal Dialysis Traveling when youre on peritoneal dialysis (PD) offers more flexibility, but it still requires careful planning. Make sure you have enough medical/PD supplies for your entire trip, including some extras.
----------------------------------------------------------------------


======================================================================
CHUNK 13 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_4
Content Type: recommendation
Words: 484
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
Make sure you have a backup plan in case something unexpected happens. 12 NATIONAL KIDNEY FOUNDATION Peritoneal Dialysis Traveling when youre on peritoneal dialysis (PD) offers more flexibility, but it still requires careful planning. Make sure you have enough medical/PD supplies for your entire trip, including some extras. If flying, contact your airline in advance to transport your medical/PD supplies. Its also a good idea to find local healthcare providers at your destination for any urgent needs. Tips: Carefully calculate and organize your medical PD supplies. Confirm arrangements for your supplies with the airline. Keep a list of doctors and hospitals at your destination. KIDNEY. ORG 13 Home Hemodialysis For those who do hemodialysis at home, traveling requires additional preparation. Make sure that your hotel or the place you are staying can support your dialysis machine, particularly in terms of power supply and space. If traveling by air, talk to your airline about transporting your machine. Additionally, finding the nearest dialysis center to your destination provides a safety net. Tips: Make sure your hotel or place youre staying has room for your dialysis machine. Check with your airline about bringing your dialysis machine. Know the locations of dialysis centers close to your travel destination. 14 NATIONAL KIDNEY FOUNDATION International Dialysis Centers Finding and contacting dialysis centers before you leave is a top priority if youre traveling internationally. Look for dialysis centers near where you will be visiting and keep a list of their contact details. Tips: Keep updated with the policies and availability of dialysis centers at your destination. Learn basic healthcare and common CKD-related words in your destinations primary language. Nutrition and Fluids Eating well and managing fluid intake is very important when you have CKD and its even more important when traveling. Maintaining your usual diet and fluid needs can sometimes be hard when you are traveling. However, with the right information, you can continue making healthy food choices and taking in the right amount of fluids while away from home. Food Researching restaurants and menus before you travel can help you identify places that offer kidney-friendly options. Tips: Try to choose foods that your healthcare provider and kidney dietitian recommend. Look for restaurants that have healthy choices and ask if they can change certain ingredients if needed. Pack some of your favorite snacks for times when you cant find the right kinds of foods. KIDNEY. ORG 15 Fluids Managing your fluid intake well is very important, but it doesnt have to be difficult. While youre out exploring, keep track of all the drinks you have, including water, tea, coffee, and other beverages. Be aware of hidden fluids in foods, too, like soups or fruits. By staying mindful of your fluid intake and making smart choices, you can focus on enjoying your trip. Tips: Drink the right amount of liquids and try to stick to the limit your healthcare provider has set.
----------------------------------------------------------------------


======================================================================
CHUNK 14 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_5
Content Type: general
Words: 497
Medical Entities: CKD,diabetes
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
Be aware of hidden fluids in foods, too, like soups or fruits. By staying mindful of your fluid intake and making smart choices, you can focus on enjoying your trip. Tips: Drink the right amount of liquids and try to stick to the limit your healthcare provider has set. Have drinks that work with your kidney diet, especially if you need to limit certain minerals, such as potassium and/or phosphorus. Its a good idea to carry a water bottle with you, just remember to keep track of how much you drink. 16 NATIONAL KIDNEY FOUNDATION Managing Stress Traveling with advanced CKD can sometimes make you feel stressed. Its important to find simple ways to stay calm and enjoy your journey. Start by planning activities that you find relaxing and include them on your trip. Remember, you should also leave time for rest and relaxation. Tips: Practice deep breathing or meditation to help manage stress. Include activities in your itinerary that you find enjoyable and relaxing. Dont forget to take short breaks and rest when needed to help you feel refreshed. KIDNEY. ORG 17 Different Cultures While traveling to new places usually means having the opportunity to experience and learn about different cultures and customs, in reality, it can also be somewhat scary. New places are certainly exciting, but its also important to be prepared. Learning about the local customs, especially regarding CKD management, and knowing some key phrases in the local language can be very helpful. Before your trip, learn a bit about the local customs and healthcare practices. Learn important health-related phrases in the local language. Enjoy new experiences but be aware that you have health needs that must be met. Add translation apps to your smartphone 18 NATIONAL KIDNEY FOUNDATION Traveling with CKD and Other Common Medical Conditions Living with CKD can make traveling more complex, especially when you are also managing other health conditions like diabetes and/or heart problems. Of course, you need to make plans for your CKD treatment while you are away from home, but you also need to make sure any other health issues are well taken care of during your travels. This means understanding how your other conditions interact with CKD and what extra precautions you need to stay healthy on your trip. Most Common Medical Conditions with CKD When you have CKD, managing your health while traveling is important, this is especially true if you also have diabetes or heart problems, the two most common serious medical conditions associated with CKD. DIABETES AND CKD Having both diabetes and CKD means you need to be extra careful about your blood sugar levels. When you are traveling, your normal routine will likely change, which can affect your blood sugar. Thats why checking your levels more often and adjusting your medicine or insulin may be a good idea when youre on a trip. When planning your meals and snacks, make sure you have healthy foods to help keep blood sugar levels well-balanced.
----------------------------------------------------------------------


======================================================================
CHUNK 15 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_6
Content Type: recommendation
Words: 492
Medical Entities: CKD,diabetes
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
Thats why checking your levels more often and adjusting your medicine or insulin may be a good idea when youre on a trip. When planning your meals and snacks, make sure you have healthy foods to help keep blood sugar levels well-balanced. Planning your meals and snacks KIDNEY. ORG 19 carefully is a way to get the right balance of nutrients without overloading your kidneys or affecting your blood sugar. HEART DISEASE AND CKD Traveling can be tiring, and if you have heart problems, you should know just how much activity is safe. Its okay to take it slow and to take frequent breaks. Remember to keep your heart medicine close so you can take it as needed. If you start feeling chest pain, have trouble breathing, or feel very tired in a way thats not normal for you, get medical help right away. You should also know where the nearest hospital or clinic is, just in case. Tips for People with CKD and Diabetes, and/or Heart Conditions Use health apps for tracking blood sugar, food/drink intake, medication schedules, and blood pressure. Wear a medical alert bracelet or carry a card identifying your health conditions. Keep a supply of emergency medication, as recommended by your healthcare provider, readily available. Make sure your travel insurance covers all your medical conditions, including CKD, diabetes, and heart problems. Research the healthcare system and facilities at your destination, especially those specializing in kidneys, diabetes, and/or cardiology. 20 NATIONAL KIDNEY FOUNDATION Kidney Transplant/Kidney Transplant Waitlist Traveling can be a fun part of your life if you have had a kidney transplant or are waiting for one. Again, it just means that planning is important. This includes making sure you take your medicines on time if youve had a transplant and being able to be quickly reached if youre on a transplant waitlist. Kidney Transplant Recipients Traveling after receiving a kidney transplant requires careful planning. Your immune system is suppressed to prevent organ rejection, so you must be extra careful about infections and protecting your health. KIDNEY. ORG 21 Tips: Make sure you have more than enough anti-rejection medication. Keep to your medication schedule and set reminders on your smartphone. Be aware of your environment; avoid crowded places and practice good hygiene, such as washing your hands often. Another precaution against disease is to wear a face mask and carry hand sanitizer when you are out in public. Bring a blood pressure monitor on your trip to keep track of your levels. Your healthcare provider may also recommend using creatinine test strips to keep track of your levels while you are away. Well before your trip, talk to your transplant team they may have additional safe travel recommendations. 22 NATIONAL KIDNEY FOUNDATION Kidney Transplant Waitlist If you are on the kidney transplant waitlist, traveling requires additional considerations, particularly regarding your availability for a transplant. Tips: Make sure you are reachable by phone, text, and/or email at all times.
----------------------------------------------------------------------


======================================================================
CHUNK 16 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_7
Content Type: recommendation
Words: 496
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
22 NATIONAL KIDNEY FOUNDATION Kidney Transplant Waitlist If you are on the kidney transplant waitlist, traveling requires additional considerations, particularly regarding your availability for a transplant. Tips: Make sure you are reachable by phone, text, and/or email at all times. Stay within a reasonable distance from your transplant center or a hospital that can handle your transplant. Have a plan for quickly returning home if a kidney becomes available. Continue your regular CKD management, including dialysis if applicable, and follow your healthcare providers advice. KIDNEY. ORG 23 Practical Travel Tips Traveling with CKD involves more than just getting to your destination and back. Its also about making sure every part of your journey is smooth and safe for your health. From what you pack to how you move around and where you stay, each step has tips to make your travel easier. These practical travel tips are designed to help you manage your CKD while on the go. They include not only standard advice but also additional suggestions you might not have thought of, including ways to use your smartphone to aid your travel. Packing for your Trip When packing for your trip, consider everything youll need to manage your CKD. This means more than just clothes and toiletries; its about making sure you have all your medical necessities. Pack a sufficient supply of all your medications and consider packing some extra in case of delays. Make sure you have an appropriate place to store your medication and supplies for example, they should not be kept in cars due to extremely high or low temperatures. Bring a small bag with a travel-sized first aid kit, extra medication, and medical supplies, and keep it with you at all times. Use your smartphone to set reminders for medication times and to track your fluid intake. Carry a printed copy of your medical information and store a digital copy on your phone or other mobile device for easy access. 24 NATIONAL KIDNEY FOUNDATION If you have a fistula, avoid lifting heavy suitcases with that arm. Ask for help when lifting bags into overhead compartments. This is also important if you have a PD catheter. Airports and Public Transport Airports and public transport can be challenging, but there are ways to make it easier, including these ideas: Plan for extra time so youre not rushed, which can help reduce stress. If you need assistance at the airport or on public transport, dont hesitate to ask for it in advance. Use apps on your smartphone to track your travel schedules and look at maps of airports or bus/train stations. Stay well-hydrated but remember to balance your fluid intake with the recommendations from your healthcare provider. KIDNEY. ORG 25 Lodging Choosing the right place to stay can make a big difference in your CKD management while traveling. Look for lodging close to medical facilities or dialysis centers if needed. Make sure your room has a refrigerator to store medications or dietary items.
----------------------------------------------------------------------


======================================================================
CHUNK 17 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_8
Content Type: general
Words: 490
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
KIDNEY. ORG 25 Lodging Choosing the right place to stay can make a big difference in your CKD management while traveling. Look for lodging close to medical facilities or dialysis centers if needed. Make sure your room has a refrigerator to store medications or dietary items. Consider staying in a place with kitchen facilities so you can prepare your own meals. Use hotel or travel review apps to find hotels, motels, short-term rentals, and hostels that meet your health and financial needs. 26 NATIONAL KIDNEY FOUNDATION Preparing for Emergencies Traveling with CKD means being ready for unexpected situations, especially medical emergencies. Whether youre in another country or just in a different city, knowing how to respond to a health issue quickly and effectively can make a big difference. This part of your planning concerns being proactive and having the right information at your fingertips. It covers handling medical emergencies and keeping important contact information close by. Handling Medical Emergencies Abroad A medical emergency in a foreign country can be scary, but being prepared can help you navigate the situation more easily. Learn key health-related phrases in the local language, like I need a doctor or emergency. Keep a list of emergency numbers for the country youre visiting, as well as the address and contact info of the nearest embassy or consulate. Use your smartphone to store health information and emergency contacts, and download apps that can help in emergencies, like location-based hospital finders. Always carry a card or a digital note on your phone or other mobile device that explains your CKD condition, medications, and any allergies in the local language. KIDNEY. ORG 27 Important Contacts and Resources Having a list of contacts and resources can be a lifesaver during your travels. Compile a list of contacts, including your doctor, dialysis center, and a trusted person back home. Store these contacts in your phone and keep a copy in your travel bag. Download apps that provide travel health advice and access to medical professionals or that can connect you to local healthcare services. Keep the contact information for your travel insurance provider handy and know the steps and documents needed to process a claim. Being prepared for emergencies is a key part of traveling safely with CKD. With the right preparation, you can handle unexpected situations more confidently and make sure your health is always a priority Traveling with CKD Traveling when you have CKD means you have to plan a little more, but it doesnt mean you cant have great trips. You can go to amazing places and have fun. Its all about making the right preparations to care for your health and enjoy your time away. With good planning, you can see new things, make happy memories, and have fun traveling. 28 NATIONAL KIDNEY FOUNDATION Travel Preparation Checklist MEDICAL CONSULTATION: Pre-Travel Checkup: Schedule an appointment with your healthcare provider. Treatment Plan: Discuss adjustments to your treatment while traveling.
----------------------------------------------------------------------


======================================================================
CHUNK 18 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_9
Content Type: recommendation
Words: 499
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
With good planning, you can see new things, make happy memories, and have fun traveling. 28 NATIONAL KIDNEY FOUNDATION Travel Preparation Checklist MEDICAL CONSULTATION: Pre-Travel Checkup: Schedule an appointment with your healthcare provider. Treatment Plan: Discuss adjustments to your treatment while traveling. Medical Documentation: Get a medical summary and a letter detailing your treatment requirements and save to your smartphone. Vaccines: Make sure you are up to date with all vaccines recommended by your healthcare provider. Register for Smartphone Access: Your healthcare provider likely provides patient support and medical record access through an electronic health record system such as MyChart by Epic sign up so you can access your medical information whenever needed. TELEHEALTH OPTIONS: Pre-travel Arrangements: Check with your healthcare provider about telehealth options. App Setup: Ensure you have the necessary apps or tools installed on your mobile devices. Internet Access: Make sure you have reliable internet access for virtual consultations. NATIONALK KIDIDNNEEYY. O FROGUNDATION 29 MEDICATION MANAGEMENT: Organize Medications: Pack all medications in your carry-on luggage. Extra Supplies: Bring additional medication for unexpected delays. Medication Reminders: Use your phone to set medication times. Digital Health Apps: Use apps to keep track of your medical history and virtual consultations. DIALYSIS PLANNING (if applicable): Treatment Coordination: Arrange treatments at your destination. Home Dialysis Prep: Ensure suitable lodging to accommodate your equipment. Local Centers: Keep a list of dialysis centers near your travel destination. GPS Navigation: Use your smartphone to locate nearby healthcare facilities. KIDNEY TRANSPLANT WAITLIST: Stay Reachable: Make sure you can be reached by phone, text, and/or email. Location Planning: Only travel a reasonable distance from your transplant center. Emergency Travel Plan: Prepare for a quick return home if a kidney becomes available. CKD Management: Continue regular CKD treatments, including dialysis. 30 NATIONALK KIDIDNNEEYY. O FROGUNDATION KIDNEY TRANSPLANT RECIPIENT: Transplant Team Consultation: Discuss your travel plans with your transplant team for individual advice. Medication Management: Bring enough antirejection medications for the full length of time you plan to be away from home, plus extras. Medication Schedule Reminders: Use smartphone app reminders so you take your medications on time. Health Monitoring: Bring necessary medical supplies like blood pressure monitors and creatinine test strips. Infection Prevention: Practice good hygiene and consider carrying hand sanitizer and using face masks. DIET AND FLUID MANAGEMENT: Meal Planning: Carry kidney-friendly snacks. Hydration: Keep your fluid intake within restrictions. Fluid Tracking: Use a water bottle to measure how much you are drinking. Online Food Trackers: Use apps to track dietary intake. NATIONALK KIDIDNNEEYY. O FROGUNDATION 31 EMERGENCY PREPAREDNESS: Emergency Contacts: Include your healthcare provider and dialysis center. Medical Information: Carry details about your CKD and treatment. Local Healthcare: Know nearby hospitals or clinics. Emergency Alert Apps: Download apps that send your location to emergency services. TRAVEL INSURANCE: Appropriate Coverage: Make sure your policy covers CKD-related issues. Policy Understanding: Be familiar with your dialysis and emergency coverage. Policy Accessibility: Keep a copy of your insurance policy handy. ACCOMMODATION CONSIDERATIONS: Location: Choose lodging close to medical facilities.
----------------------------------------------------------------------


======================================================================
CHUNK 19 of 647
======================================================================
ID: 11_10_0513_2401_patbro_traveltip_t1_10
Content Type: recommendation
Words: 452
Section: TRAVEL INSURANCE:
Medical Entities: CKD,dialysis
Source: 11-10-0513_2401_patbro_traveltip_t1.pdf

----------------------------------------------------------------------
TRAVEL INSURANCE: Appropriate Coverage: Make sure your policy covers CKD-related issues. Policy Understanding: Be familiar with your dialysis and emergency coverage. Policy Accessibility: Keep a copy of your insurance policy handy. ACCOMMODATION CONSIDERATIONS: Location: Choose lodging close to medical facilities. Medication Storage: Look for lodgings that have refrigerators if needed. Meal Prep: Seek out lodgings with kitchen facilities. 32 NATIONALK KIDIDNNEEYY. O FROGUNDATION PACKING ESSENTIALS: First Aid Kit: Include a travel-sized kit. Special Hygiene Products: Pack any CKD-specific care items. Comfortable Clothing: Choose appropriate attire for your activities. Portable Medical Devices: Bring any necessary devices to sync with your phone. TRAVEL DOCUMENTS: Passport and Visas: Make sure they are up to date. Document Copies: Keep backups of your ID and medical info. Document Security: Plan for safekeeping while traveling. Digital Copies: Store digital versions of important documents in a secure cloud service. COMMUNICATION PREPARATION: Local Language: Learn healthcare-related phrases. Addresses and Directions: Save them in your phone. Phone Connectivity: Check roaming plans or local SIM options. Virtual Pharmacy Services: Familiarize with options for medication refills. KIDNEY. ORG 33 We are Here to Help There are two ways to learn about the many free resources available to you: Call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Learn more at kidney. org NKF PEERS Connect with a trained peer mentor who can share their experiences about dialysis, transplant, or living kidney donation with you. Call 855. NKF. PEER (855. 653. 7337) or go online kidney. org/patients/peers 34 NATIONAL KIDNEY FOUNDATION Setting a Standard for Care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 35 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2024 National Kidney Foundation, Inc. 11-10-0513__2401
----------------------------------------------------------------------


======================================================================
CHUNK 20 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_0
Content Type: general
Words: 490
Medical Entities: CKD,dialysis
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Chronic Kidney Disease, Dialysis, and Keeping Fit A Practical Guide Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Get support and hear from others who have experience with dialysis, transplant, living donation, and being a parent or care partneryou never know when youll inspire someone else! Join today at kidney. org/online-communities 2 NATIONAL KIDNEY FOUNDATION Contents The Importance of Exercise. . . . . . . . . . . . . . . . . . . . . . 5 Before You Start. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Types of Exercise. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Making an Exercise Plan. . . . . . . . . . . . . . . . . . . . . . . . 10 Patients on Dialysis and Exercise. . . . . . . . . . . . . . . . . 11 Exercise After Kidney Transplant. . . . . . . . . . . . . . . . . 15 Nutrition and Hydration. . . . . . . . . . . . . . . . . . . . . . . . . 17 Staying Safe While Exercising. . . . . . . . . . . . . . . . . . . . 19 Tracking Progress and Staying Motivated. . . . . . . . . . 22 We are Here to Help. . . . . . . . . . . . . . . . . . . . . . . . . . . 24 KIDNEY. ORG 3 Chronic kidney disease (CKD) is a long-term condition that affects the kidneys ability to function effectively. Over time, CKD can lead to a range of health issues, including high blood pressure, anemia, and bone health problems. The disease often progresses silently, making it crucial to manage it proactively. Exercise is important because it can improve some common health issues people with CKD face. Physical activity can help control blood pressure, improve muscle function, and enhance overall well-being. A simple 20-minute walk daily can make a big difference in your health. 4 NATIONAL KIDNEY FOUNDATION The Importance of Exercise Exercise isnt just for those who are already fit; its an important part of helping to manage chronic diseases, including CKD. Doing regular exercise is good for you in a number of ways. Its not just about getting stronger; it also helps you feel better emotionally and may also slow down the progression of CKD. Heres how: Physical Benefits Exercise is good for your body in many ways.
----------------------------------------------------------------------


======================================================================
CHUNK 21 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_1
Content Type: general
Words: 485
Medical Entities: CKD,diabetes
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Doing regular exercise is good for you in a number of ways. Its not just about getting stronger; it also helps you feel better emotionally and may also slow down the progression of CKD. Heres how: Physical Benefits Exercise is good for your body in many ways. It can strengthen your heart, help you build muscle, and give you more energy. Many people with CKD often feel tired and notice their muscles getting weaker. Exercise can help turn this around, making you feel more energetic and stronger. Psychological Benefits Regular exercise can also lift your spirits and help you feel less stressed or down. Many people with long-term health issues like CKD often feel anxious or sad, and exercise can make a big difference in improving these feelings. Plus, when you see what your body can achieve, it boosts your self-confidence. If you join a group for exercise, like a walking group or a fitness class, you also get the chance to meet new people and make friends, which can make you feel even better. KIDNEY. ORG 5 How Exercise Can Help Exercise can make a big difference in slowing down the effects of CKD. It can help keep your blood pressure in a healthy range and make sure your body uses sugar properly. This is really good for your kidneys. Plus, if you have other health problems like diabetes or heart issues, which many people with CKD do, exercise can help manage those too. Before You Start Talk to Your Doctor Before you start any kind of exercise program, its really important to talk to your doctor. Exercise may have an effect on how certain medicines work and other parts of your treatment. Some people have even needed to change their medicines to fit better with their new exercise routine. Check-Ups You Might Need Your doctor might want to do tests like blood work or heart checks to see how fit you are and what kind of exercise is safe for you. These tests give you and your doctor a starting point to make an exercise plan just for you. 6 NATIONAL KIDNEY FOUNDATION Make a Plan You Can Stick To After youve talked to your doctor and maybe had some tests, the next step is to make a plan. Choose goals that you can really achieve. It could be as simple as walking for 20 minutes a day or going to a yoga class once a week. When you set goals you can reach, youre more likely to stick with your exercise routine. KIDNEY. ORG 7 Types of Exercise When it comes to exercise, variety is key. Mixing up your routine with stretching, strength training, and cardiovascular activities can offer a well-rounded approach to fitness. This is especially helpful for people with conditions such as muscle stiffness or high blood pressure. Use this guide to help you choose the right mix of activities.
----------------------------------------------------------------------


======================================================================
CHUNK 22 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_2
Content Type: reference
Words: 493
Medical Entities: CKD,dialysis
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Mixing up your routine with stretching, strength training, and cardiovascular activities can offer a well-rounded approach to fitness. This is especially helpful for people with conditions such as muscle stiffness or high blood pressure. Use this guide to help you choose the right mix of activities. EXERCISE BENEFITS EXAMPLES TIPS Improve Stretching, Avoid Flexibility joint mobility Yoga overstretching Weightlifting, Strength Build Start with Resistance Training muscle mass lighter weights bands Improve Walking, Monitor Cardiovascular heart health Cycling heart rate 8 NATIONAL KIDNEY FOUNDATION Inherited diseases Stretching and Bending Stretching and yoga are great for making your joints move more easily and loosening stiff muscles. This is really good for people with CKD, who might get muscle cramps or feel stiff. Try doing 10 minutes of stretching and bending before and after you do any harder exercises to make your workout even better. Building Muscle Lifting light weights or using resistance bands helps build muscle and make your bones stronger. This is especially important for people with CKD, who might notice their muscles getting weaker. Just make sure to start with lighter weights and slowly work your way up to avoid hurting yourself. KIDNEY. ORG 9 Get Your Heart Pumping Walking, biking, and swimming are all good for your heart and can give you more energy. These are also good for helping to keep your blood pressure in check. Starting with a 30-minute walk, three times a week is a good way to get started. Making an Exercise Plan Creating a workout plan is a great first step. Its important to set up a daily exercise plan, figure out how much exercise you need every week, and understand why rest days are important. Setting Up a Routine Having a regular exercise schedule can help you get the most out of being active. You may think about doing different exercises at different times of the day. For example, you could stretch in the morning, lift some light weights in the afternoon, and take a walk in the evening. 10 NATIONAL KIDNEY FOUNDATION How Often and for How Long Most experts say you should aim for about 150 minutes of heart-pumping exercise each week. You can break this down in different ways to best fit your schedule. For example, you could do five 30-minute workouts or three longer ones that last about 50 minutes each. Taking Breaks Dont forget! Rest days are just as important as the days you exercise. Your muscles need time to recover so you dont get hurt. Make sure to take at least one or two days off each week to rest and recover. Patients on Dialysis and Exercise People on dialysis who exercise regularly report they sleep better, have more energy and more muscle strength, and are better able to do the things they need to do in their lives. Exercise Timing for People on Dialysis Timing your exercise around your dialysis sessions is important for avoiding fatigue and muscle cramps.
----------------------------------------------------------------------


======================================================================
CHUNK 23 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_3
Content Type: reference
Words: 498
Medical Entities: dialysis
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Exercise Timing for People on Dialysis Timing your exercise around your dialysis sessions is important for avoiding fatigue and muscle cramps. Its usually best to avoid working out right before or after your dialysis session. Some people find that exercising on non-dialysis days or at least 3 to 4 hours before or after a session works best for them. Some helpful tips include: Be careful about exercising right after hemodialysis, as it may lower your blood pressure too much. KIDNEY. ORG 11 If you want to do weight or resistance training, you should check with your dialysis team before starting, since people on: Hemodialysis should avoid any stress on your fistula or graft arm. Peritoneal dialysis need to make sure that your catheter stays securely in place. Ask your hemodialysis team about exercise with a minibike or any other exercises that can be done during treatments. If you are on peritoneal dialysis, you might be more comfortable exercising on an empty stomach. Skip exercise if youve missed a dialysis session and have extra fluid. Choose Low-Impact Exercises People on dialysis often find that low-impact exercises are the most comfortable. Swimming and cycling are good choices because theyre easier on your joints but still give you a solid workout. Water aerobics is another good choice that is easy on the joints and can improve strength and flexibility. If you are on peritoneal dialysis and would like to swim, talk to your dialysis team about how to protect your exit site and which kinds of water are safe to swim in. 12 NATIONAL KIDNEY FOUNDATION Keeping Track of Your Health Its really important to keep a close eye on how youre doing if youre on dialysis and starting to exercise. Your healthcare team should know about your exercise plans and may need to check your blood pressure, heart rate, and your dialysis prescription more often. This makes sure that the exercise you choose is both good for you and doesnt cause any problems with your dialysis treatment. KIDNEY. ORG 13 Talk to Your Kidney Dietitian Dialysis and exercise both have an impact on the nutrients in your body. Dialysis can remove some important nutrients, while exercise uses up energy and can affect things like your blood sugar and electrolyte levels. Sweating may also affect how much fluid you need. Thats why its a good idea to talk to a kidney dietitian. They can tell you which foods to eat and how much fluid to drink to keep everything well-balanced. This is especially important if youre planning to exercise more, as youll need the right fuel and fluid to keep you healthy and help your body recover well afterward. 14 NATIONAL KIDNEY FOUNDATION A dietitian can also help you adjust your meal timing around your exercise and dialysis schedules for the best results. Listen to Your Body Everyones different, so what works for one person might not work well for you. Pay attention to how you feel during and after exercise.
----------------------------------------------------------------------


======================================================================
CHUNK 24 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_4
Content Type: general
Words: 497
Medical Entities: CKD
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Listen to Your Body Everyones different, so what works for one person might not work well for you. Pay attention to how you feel during and after exercise. If something doesnt feel right, its important to stop and talk to your healthcare provider. Exercise After Kidney Transplant After a kidney transplant, staying active is still important for keeping healthy. However, there are some special things to think about: Talk to Your Healthcare Team: Talk to your healthcare provider before starting or changing your exercise routine. They can help you understand how your medications and new kidney will react to physical activity. Start Slow: Your body has been through a lot. Start with low-impact exercises and gradually build up your strength. Be Mindful of Surgical Sites: In the early months after a kidney transplant, avoid exercises that put pressure on or involve the surgical area. Monitor for Symptoms: Pay close attention to how you feel during and after exercise. If you notice anything unusual, contact your healthcare provider immediately. KIDNEY. ORG 15 Nutrition and Hydration: Your nutritional needs may be different post-transplant. Talk to your healthcare provider or a kidney dietitian about choosing foods and fluids that are best for you, especially when you are exercising. By paying attention to these important tips, you can exercise in a way thats safe for you and also helps your new kidney work well for a long time. 16 NATIONAL KIDNEY FOUNDATION Nutrition and Hydration Eating well and staying hydrated are important parts of an effective exercise routine. Here are some tips to help you make good choices before, during, and after your workouts. Plan Your Pre-exercise Meal Eating the right foods before you exercise can give you the energy you need to get through your workout. Try to eat a well-balanced meal about 1 to 2 hours before you start exercising. A meal with plenty of carbohydrates, a moderate amount of protein, and low fat is a good choice. For example, a sandwich made with whole-grain bread and lean meat, along with a side of fruit. Stay Well-hydrated Hydration is super important, especially for people with CKD who may have limits on how much fluid they can have. Always check with your healthcare provider to find out how much you should be drinking when you exercise. A small glass of water before and after your workout is usually a good idea, but your doctor can give you personalized advice. KIDNEY. ORG 17 Eating After Exercise Once youve finished your workout, its important to eat something to help your body recover. Your muscles need protein to repair themselves, and youll need carbohydrates to regain your energy. A lowsugar protein shake or a bowl of whole-grain cereal with skim milk are usually good options. Timing Matters The timing of your meals and hydration can also affect how well you perform and recover. Eating too close to your workout can make you feel sluggish, while not eating enough can leave you feeling weak.
----------------------------------------------------------------------


======================================================================
CHUNK 25 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_5
Content Type: reference
Words: 492
Medical Entities: CKD
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
Timing Matters The timing of your meals and hydration can also affect how well you perform and recover. Eating too close to your workout can make you feel sluggish, while not eating enough can leave you feeling weak. Similarly, drinking too much water can make you feel bloated, while not enough can lead to dehydration. Work with your healthcare provider to find the right balance for you. 18 NATIONAL KIDNEY FOUNDATION Special Foods and Supplements Some people consider using special sports drinks, nutrition bars, or dietary supplements such as vitamins and minerals to enhance their exercise performance and recovery. However, these products often contain added sugars, electrolytes, or other compounds that may not be best for people with CKD. Before using any products, check with your healthcare provider to make sure its right for you. Staying Safe While Exercising Safety is a top priority when exercising, especially for people with certain health conditions. Here are some guidelines to help you exercise safely and recognize warning signs. Warm-Up and Cool-Down Starting and finishing your workout the right way can make a big difference. A 5to 10-minute warm-up, like a brisk walk, gets your body ready. After your workout, take another 5 to 10 minutes to cool down with some easy stretches. This helps your muscles relax, and your heart rate returns to normal. KIDNEY. ORG 19 Listen to Your Body Being in tune with your body is key to a safe and effective workout. While exercise should challenge you, it shouldnt cause pain or extreme discomfort. Here are some things watch for: Breathing: Its normal to breathe faster when you exercise, but you should still be able to talk. If youre gasping for air, its a sign to slow down. Muscle Sensations: A mild burn in your muscles is a good sign theyre being worked, but sharp, sudden pain is a red flag. Energy Levels: Feeling tired is part of exercising, but theres a difference between workout fatigue and extreme exhaustion. If you feel like you cant go on, its time to stop. Mental State: Exercise often boosts mood, but if you feel irritable, agitated, or mentally drained, consider winding down your session. Heart Rate: While its normal for your heart rate to increase, it shouldnt feel like your heart is pounding. You may find it helpful to use a monitor to keep track of your heart rate. If you start to feel somethings not right, like youre too tired or hurting, its a good idea to stop exercising right away. Take a break, drink water, and see if you feel better. 20 NATIONAL KIDNEY FOUNDATION Getting Medical Attention Being aware of how you feel during exercise is key to your safety. If you notice any of the following symptoms, its important to stop exercising immediately: Shortness of breath Dizziness or lightheadedness Chest pain or pressure Sudden headache Extreme tiredness Nausea or vomiting These symptoms could be warning signs that something isnt right.
----------------------------------------------------------------------


======================================================================
CHUNK 26 of 647
======================================================================
ID: 11_10_0502_2312_patbro_keepingfit_t1_final_7
Content Type: recommendation
Words: 277
Medical Entities: dialysis
Source: 11-10_0502_2312_patbro_keepingfit_t1_final.pdf

----------------------------------------------------------------------
KIDNEY. ORG 23 We are Here to Help There are two ways to learn about the many free resources available to you: Call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Learn more at kidney. org NKF PEERS Connect with a trained peer mentor who can share their experiences about dialysis, transplant, or living kidney donation with you. Call 855. NKF. PEER (855. 653. 7337) or go online kidney. org/patients/peers 24 NATIONAL KIDNEY FOUNDATION Setting a Standard for Care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 25 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2024 National Kidney Foundation, Inc. 11-10_0502_2312
----------------------------------------------------------------------


======================================================================
CHUNK 27 of 647
======================================================================
ID: 1803.11253v1_0
Content Type: definition
Words: 481
Medical Entities: CKD,hypertension,diabetes
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
International Journal of Scientific and Technical Research in Engineering (IJSTRE) www. ijstre. com Volume 3 Issue 2  March 2018. A comprehensive review of Chronic Kidney Disease of Unknown Etiology Adoni Fernando1, Nivethika Sivakumaran1 1(Undergraduate Department of Biomedical Science, International College of Business and Technology, No. 36, De Kretser Place, Bambalapitiya, Sri Lanka) ABSTRACT: This review was written to provide a comprehensive summary of the suggested etiologies of Chronic Kidney Disease of Unknown Etiology (CKDu) in Sri Lanka. In this review, Chronic Kidney Disease (CKD) is explained in detail and its known etiologies are discussed. CKDu is defined and its epidemiology is discussed, with the compilation of statistic from over 15 research papers through the years 2000 to present. KEYWORDS: Chronic agrochemical nephrology, Chronic Kidney Disease, Chronic Kidney Disease of multifactorial origin, Chronic Kidney Disease of unknown etiology, Chronic interstitial nephritis of agricultural communities ABBREVIATIONS: CKDu: Chronic kidney disease of unknown etiology, CKD: Chronic Kidney Disease, CKDmfo: Chronic Kidney Disease of multifactorial origin, CINAC: Chronic Interstitial Nephritis in Agricultural Communities, NCP: North Central Province (of Sri Lanka), CRF: Chronic Renal Failure, CRDChronic Renal Disease, GFRGlomerular Filtration Rate, NFKNational Kidney Foundation (USA), KDQOIKidney Disease Quality Outcome Initiative, ESRDEnd Stage Renal Disease, BMIBody Mass Index, NSAIDNon Steroidal Anti Inflammatory Drug, DDTDichlorodiphenyltrichloroethane, CdCadmium, PbLead, UUranium, NNitrogen, KPotassium I. INTRODUCTION Chronic kidney disease (CKD) is defined as kidney damage or a decreased glomerular filtration rate. CKD is characterized by progressive destruction of renal mass, with irreversible sclerosis and loss of nephrons over a period of time, depending on the underlying etiology. Diabetes, hypertension and different forms of glomerular nephritis are known etiologies of CKD 1. The rising prevalence of non-infectious diseases such as diabetes mellitus and hypertension suggests that CKD incidence will continue to rise 2. Over the last two decades, the epidemic of a new strain of CKD of unknown etiology in rural farming communities of Sri Lanka, has elevated the concern of the disease. This new strain has been observed to be endemic in agricultural and rural regions. CKDu may also be referred to as CKD of multifactorial origin (CKDmfo), chronic agrochemical nephrology (CAN) or chronic interstitial nephritis of agricultural communities (CINAC) 3. The disease is prevalent especially in the North Central Province (NCP). It is observed in mainly the dry regions that may utilize irrigation methods for farming. It disproportionately affects males of poor socio-economic background and workers of paddy farming 4, 5. In Sri Lanka there is an estimated affected population of 400, 000 people and death toll of around 20, 000 people. CKDu is not exclusive to Sri Lanka, and many cases of CKD of unknown etiology have been reported in different parts of the world; e. g. , Costa Rica 6, India 7, Egypt 8, Nicaragua 9, and more. However, in Sri Lanka, there is limited knowledge on the exact prevalence and geographical distribution of CKDu at this time.
----------------------------------------------------------------------


======================================================================
CHUNK 28 of 647
======================================================================
ID: 1803.11253v1_1
Content Type: definition
Words: 500
Medical Entities: CKD,GFR
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
However, in Sri Lanka, there is limited knowledge on the exact prevalence and geographical distribution of CKDu at this time. Even with the suggestion of many etiologies, the limited supporting evidence means that the exact cause of the disease is still unknown. Water contamination is a popular suggestion, but the evidence supporting the claim is insufficient. The role of environmental exposure to high concentrations of nephrotoxicants (such as, Cd, Pb, and U), which may accumulate and cause functional and structural damage in renal tissue, is a weighty hypothesis Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 10. Farming and the use of fertilizer or other agrochemicals are also considered risk factors 11, 12. High levels of as exposure is also suggested to be an etiological factor in CKDu 13. Water used for consumption is thought to be a major source of contaminants that lead to CKD. The contaminants may seep into water from the natural environment (geological sources), but the intensive use of agrochemicals to increase the production of agricultural resources is also a significant possibility of water contamination. The local water bodies may be polluted with seepage from irrigation or farming, especially those that lay close to fields used for cultivation. A systematic assessment of water quality is therefore needed, in order to understand risk related to exposure and assess the potential health effects 14. This review attempts to provide a comprehensive understanding of CKDu and its prevalence in Sri Lanka. It attempts to document the possible etiologies of CKDu, put forward by research throughout the year 1997 to present. The endemic regions in North Western Province of Sri Lanka is shown in Fig. 1. Polpithigama is identified as a high risk geographic area for CKDu (Screening Guidelines Chronic Kidney Disease Sri Lanka 2017 Epidemiology Unit Ministry of Health, 2017). Nikawewa has a high prevalence of the disease and has two specialized nephrology units, catering to CKD patients. Figure 1. Nephrology units and satellite clinics for kidney diseases in Sri Lanka (Daily News, 2017) II. CHRONIC KIDNEY DISEASE Chronic Kidney Disease is recognized as a global public health problem. The disease is coined from the kidneys functions progressively diminishing over time due to the progressive damage of the renal mass. CKD is also known as Chronic Renal Failure (CRF), Chronic Renal Disease (CRD) and Chronic Kidney Failure (CKF). CKD can be defined as structural or functional anomalies of the kidneys or a decreased glomerular filtration rate (GFR), persisting for a period of three months, (60 ml/min or 1. 73 m2). Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 2. 1. Functions of the kidneys The main functions of the kidneys are; filtration of waste products and excess water from blood to be excreted through urine, regulation of blood pressure, production of erythropoietin (important for formation of red blood cells, and maintaining balance of salts and chemicals in bloodstream at the right level(NFK, www.
----------------------------------------------------------------------


======================================================================
CHUNK 29 of 647
======================================================================
ID: 1803.11253v1_2
Content Type: definition
Words: 497
Medical Entities: CKD,GFR,dialysis,hypertension,diabetes
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
kidney. org). CKD is a slowly progressing disease, and often goes unnoticed and underdiagnosed. It is usually asymptomatic until histopathological features such as tubulointestitial fibrosis and tubular atrophy, observed in renal biopsies. Usually when the signs and symptoms manifest, the disease has reached to a severity, for which the cure is a kidney transplant, without which there is a 100% mortality rate. The conditions of a CKD patient irreversibly worsen over time. 2. 2. Stages of CKD CKD is diagnosed based on definition of the Kidney Disease Quality Outcome Initiative (KDQOI) of the National Kidney Foundation (NFK). The functional damage of kidneys can be assessed by GFR, and the disease can be classified into 5 stages such as, stage 1: Kidney damage with normal or increased GFR (90 mL/min /1. 73 m2), stage 2: Mild reduction in GFR (60-89 mL/min/1. 73 m2), stage 3: Moderate reduction in GFR (30-59 mL/min/1. 73 m2), stage 4: Severe reduction in GFR (15-29 mL/min/1. 73 m2), and stage 5: Kidney failure (GFR 15 mL/min/1. 73 m2 or dialysis). CKD is usually detected when the kidneys function drops to 25% of normal kidney function, whereas symptoms appear when the function plummets to 1/10th of the normal level. Each kidney has approximately one million nephrons, the functional unit of kidney, which filter wastes from the body. The human body can maintain the normal GFR, even when there is a gradual destruction of the nephrons. This happens by mechanisms to compensate for the loss, such as hypertrophy of renal tissue and hyper filtration by the surviving nephrons. This occurs regardless of the underlying etiology of the CKD, and allows blood to be filtered and the plasma solutes to be cleared as it would in normal conditions. When GFR decreases to 50% of normal, the level of plasma solutes such as creatinine and urea show a significant increase. The creatinine in plasma will be approximately double that of normal, when GFR drops to 50%; i. e. , when the plasma creatinine reaches 1. 2 mg/dL from the baseline value of 0. 6 mg/dL, it represents halving of the functional nephron mass, although it is still within the defined reference range. 2. 3. Known etiologies of Chronic Kidney Disease Certain common chronic diseases can lead to chronic kidney disease. These diseases can damage the renal tissue permanently causing damage and giving rise to CKD. 2. 3. 1. Diabetes mellitus CKD was thought to develop as a result of diabetes and was known as diabetic nephropathy. The elevated levels of blood glucose leads to an increased strain on the nephrons of the kidneys when filtering blood. It is estimated that moderate to severe CKD is found in 15-23% of patients that have a history of diabetes 15. 2. 3. 2. Hypertension High blood pressure is a leading cause of CKD globally. Hypertension damages the blood vessels and may lead to a reduced blood flow to kidneys. The elevated pressure can also damage the nephrons assisting renal damage.
----------------------------------------------------------------------


======================================================================
CHUNK 30 of 647
======================================================================
ID: 1803.11253v1_3
Content Type: reference
Words: 477
Medical Entities: CKD,proteinuria,hypertension,diabetes
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
2. 3. 2. Hypertension High blood pressure is a leading cause of CKD globally. Hypertension damages the blood vessels and may lead to a reduced blood flow to kidneys. The elevated pressure can also damage the nephrons assisting renal damage. More than 50% of the CKD patients suffer from hypertension (High Blood Pressure and Chronic Kidney Disease www. kidney. org National Kidney Foundations Kidney disease outcomes Quality initiative, n. d. ). Diabetes mellitus and hypertension are the identified major etiologies of CKD. In addition, Tubulointerstitial disease has been seen to have a strong link to CKD in Sri Lanka. There has been a significant prevalence of CKD observed in toxic nephropathies due to tubulointerstitial disease. There are a few identified causes of tubulointerstitial disease such as heavy metals, radiation nephritis, chronic hyperkalemia, chronic hypercalcemia, etc. 16. Progressive kidney diseases that lead to CKD may also be caused by proteinuria, systemic hypertension, elevated nephrotoxins or decreased perfusion, smoking, uncontrolled diabetes, illegal drug abuse, physical injury, and many more. Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology III. CHRONIC KIDNEY DISEASE OF UNKNOWN ETIOLOGY (CKDu) The Health Ministry Circular defines CKDu as renal damage with no past history or current treatment for diabetes mellitus, chronic and/or severe hypertension, snake bites, urological disease of known etiology or glomerulonephritis; with normal HbA1C (glycated Hb6. 5%); and blood pressure at 160/100 mmHg or 140/90 mmHg on up to two antihypertensive drugs. CKDu endemic occurrences was noted recognized in 1990, and has been increasing to date. 3. 1. Epidemiology of Chronic Kidney Disease of Unknown Etiology (CKDu) The outbreak and prevalence of CKD of unknown etiology was first recognized in the early 1990s in the NCP, namely Dehiattakandiya, Padaviya, Girandurukotte, Kabithigollawa, Medawachiya, Medirigiriya and Nikawewa of Sri Lanka, according to hospital records as shown in Fig. 2. It was later found that the disease was endemic to agricultural communities. Figure 2. CKD/CKDu prevalence (2015) (Daily News, 2017) In February 2017, the Epidemiology Unit of the Ministry of Health, Nutrition Indigenous Medicine released an epidemiology report publication (Vol. 44 No. 07), highlighting the regions in which CKDu was endemic and had a very high prevalence (Screening Guidelines Chronic Kidney Disease Sri Lanka 2017 Epidemiology Unit Ministry of Health, 2017). The identified high risk geographic areas for CKDu in Sri Lanka are shown in Table 1. Table 1. High risk geographic areas for CKDu in Sri Lanka Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology Province District DS Division North Central Anuradhapura All Polonnaruwa All North Western Kurunegala PolpithigamaGiribawa Eastern Ampara Dehiattakandiya Trincomalee PadaviSripura Uva Badulla MahiyanganayaRideemaliyadda North Mullaitivu Welioya Vavuniya VavuniyaVavuniya South Central Matale Wilgamuwa The disease was seen to be prevalent in regions around water reservoirs that are used for irrigation purposes, and mostly among farmers 16.
----------------------------------------------------------------------


======================================================================
CHUNK 31 of 647
======================================================================
ID: 1803.11253v1_4
Content Type: evidence
Words: 485
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
A population screening of endemic regions shows that a cohort of the younger members of the population is also affected by the disease, with a distinctly high incidence reported in Medawachchiya. The prevalence of CKDu in the overall population was measured to be 3. 7% (n4107), whilst the prevalence of disease in the adult (18 years of age) population was noted to be 5% (n2600). The ratio of distribution of disease in respect to gender (female: male) was 1: 1. 3 17. According the WHO report on the Kidney Disease of Uncertain Etiology (CKDu) in Sri Lanka, there is a 16. 9% age standardized prevalence of CKDu among females within age group 15-70 years, and a 12. 9% prevalence of males in the same age group. The main sources of water used for consumption, in CKDu affected regions, are shallow and deep wells. It is reported that in the areas with very high prevalence of CKDu, nearly 87% of the population utilize either dug well and tube well water for their daily needs. Water is used in cooking and is usually boiled before consumption, but is otherwise untreated 18. The number of patients treated for kidney disease have shown an increase in the years 2001-02, and the main identified cause of renal damage is CKDu. In another report by Athuraliya, it was found that 2-3% of the population are affected by CKDu, in identified endemic areas. It was also reported around 5000 patients undergoing treatment, in places with high prevalence of CKDu, due to renal failure at the time, and more than 9000 patients are followed up at the regional hospitals. Each year there are about 2000 patients diagnosed with the end stage of renal disease, with urgent need of kidney transplantation; without which, there is a 100% mortality rate 17. Population screening carried out by a technique of multistage sampling, had resulted in a CKDu point prevalence of about 2-3% in subjects over 18 years of age 21. Grounds view 2012 reported around 1500 deaths due to CKD nationwide. There was a reported 12. 9% rate of CKDu increase 12. A hospital based CKD registry was established in Sri Lanka by the WHO in 2009, with four hospitals in Anuradhapura, Medirigiriya, Polonnaruwa and Medawachchiya, in the NCP. There was a total of 1997 CKD patients, of which 775 cases (39%) were CKDu cases. CKDu as a percentage of the total number of cases of CKD is as follows: Anuradhapura48%, Medirigiriya25%, Pollonaruwa14%, Medawachchiya13%. 72% of the total patients of CKDu was seen to be male, whilst 28% was female. Another study carried out by the WHO found that 15% of the population of the NCP are affected by CKDu 19, 20. CKDu was classified as a middle farmers disease, as the mean age of the male patients with CKDu was 45. 5 years, whilst it was found to be 47. 4 years in females 22.
----------------------------------------------------------------------


======================================================================
CHUNK 32 of 647
======================================================================
ID: 1803.11253v1_5
Content Type: recommendation
Words: 475
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
CKDu was classified as a middle farmers disease, as the mean age of the male patients with CKDu was 45. 5 years, whilst it was found to be 47. 4 years in females 22. However, in a previous study carried out in 2007, it was found that the mean age of male CKDu patients was 56. 7 years, and the mean age of females was found to be 54. 2 years 23. This decreasing mean age of the CKDu patients supports that CKDu is a suggestive of the possible cumulating effects of toxins in the pathogenesis of the disease 24. Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 3. 2. Suggested etiologies of Chronic Kidney Disease of Unknown Etiology (CKDu) There are many suggested explanations for the etiology of the CKDu, the hypotheses that have the highest significance in CKDu in Sri Lanka have been explained below. 3. 2. 1. Cadmium It was put forward that the high contents of cadmium being consumed by the population in the dry zone was the cause of the high prevalence of CKDu. It was reported that large amounts of cadmium entered the body through water, fish and lotus rhizomes 25. The study said that the high content of cadmium could be due to the mass use of phosphate fertilizer contaminated with cadmium. However, this theory was refuted in another 2010 study, which found out that there were higher cadmium levels in regions in the non-endemic region whilst compared to the endemic regions. The clinical evidence of this study, also didnt show any other diseases that appear when there is high exposure to cadmium, such as renal calculi, respiratory effects and bone disease, which usually manifest prior to renal damage. 3. 2. 2. Arsenic The presence of calcium arsenate crystals deposited in post-mortem test of CKD affected kidneys, suggested that consumption of arsenic and calcium in increased levels was the cause of CKDu. The areas that the study was carried out had an increased level of as and hardness of water. The calcium of the hard water, along with the arsenic leads to the formation of the calcium arsenate crystals that bind to arsenic transporters in the liver and moves to the renal tissue where it interrupts the kidneys antioxidant defense. The study found 0. 02-0. 1 ppm of arsenic in drinking water, greater than that of the WHO recommended value of 0. 01 ppm. The clinical assessment discovered a high level of arsenic in hair (mean of 460 ppb). Even though the Sri Lankan government has banned the use of arsenic in pesticides in 2001, there is speculation that it is still being used illegally. A study presented by Dr. Jayasumana, showed that there was 0. 18-2. 58 ppm of arsenic found in the agrochemicals used by Sri Lankan farmers.
----------------------------------------------------------------------


======================================================================
CHUNK 33 of 647
======================================================================
ID: 1803.11253v1_6
Content Type: reference
Words: 486
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
A study presented by Dr. Jayasumana, showed that there was 0. 18-2. 58 ppm of arsenic found in the agrochemicals used by Sri Lankan farmers. This study however brings to light, that these agrochemicals are used throughout Sri Lanka, but only certain regions show high prevalence of CKDu, whilst other regions remain non-endemic 24, 26. 3. 2. 3. Aluminium Fluoride According to one study, the CKDu endemic regions had fluoride rich water and the population relied on substandard utensils for cooking and storage of water. The acidic conditions during cooking, and the emanation of aluminum from these pots and pans during different levels of fluoride was studied. The amount of aluminum leached into the water in the absence of an acidic component was relatively small (1. 20 ppmafter 10 mins of boiling a 6ppm fluoride solution). In acidic conditions of pH 3. 02 (using tamarind), even in the absence of fluoride, there was 18 ppm aluminum leached from the utensils; with regular increases in the emanated aluminum with the increase in fluoride content. After 10 mins of boiling in a 6ppm fluoride solution, with acidic additives, the amount of aluminum that had seeped in to solution was 29 ppm. It was observed that the fluoride in water encourages aluminum leaching into the food being cooked, and the aluminofluoride complexes possibly can be an etiological factor causing CKDu. The hypothesis suggested that since there is greater use of inferior quality aluminium utensils, that are made of recycled scrap metal and alloys, there is high chance that they are also contaminated with other heavy metals, such as lead, which are potentially poisonous to the renal tissues, contributing to CKDu 14, 27, 28. However the study didnt explain how the CKDu is restricted to certain geographical regions, even though the use of these low quality utensils are present throughout the nation. 3. 2. 4. Hardness of water A strong positive correlation (p0. 008) was seen between hard water and the arsenic content of water in CKDu endemic regions, when compared to the regions with less prevalence of CKDu, which showed a weak correlation. This study also implicated that the consumption of the hard water along with the elevated levels of arsenic was a Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology possible etiological factor of CKDu 29. 96% of the CKDu patients consumed hard water for a minimum of 5 years 22. According to a preliminary study on the hard water of three districts of NCP Padaviya, Medawachchiya and Kabithigollawa and Ampara district of the WP. The study found high levels of calcium, magnesium and zinc in the water used for consumption. However there was no detectable traces of arsenic, lead or mercury. The water was tested from the regions with significantly high prevalence of CKD. The preliminary findings did include brittle bones, which is a symptom of hard water 19.
----------------------------------------------------------------------


======================================================================
CHUNK 34 of 647
======================================================================
ID: 1803.11253v1_7
Content Type: reference
Words: 482
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
However there was no detectable traces of arsenic, lead or mercury. The water was tested from the regions with significantly high prevalence of CKD. The preliminary findings did include brittle bones, which is a symptom of hard water 19. Figure 3-Distribution of hard water (left) and distribution and prevalence of CKDu in Sri Lanka (right)in Sri Lanka(Jayasumana, Gunatilake and Senanayake, 2014) 3. 2. 5. Low selenium Selenium concentration of 80-95 g/l is needed by the body and has been shown to protect the kidneys from oxidative stress. In the study carried out in 2013, it was seen that 38% of CKDu patients showed a serum selenium concentration below 80 g/land below 90 g/l in 63% of individuals affecting CKDu. Therefore it was suggested that low selenium levels may be a contributory factor making the kidneys more vulnerable to oxidative damage that can be caused by heavy metals and metalloids. Deficiency of selenium seen in individuals with CKD suggest that it is possibly a predisposition to the development of CKDu 12. 3. 2. 6. Pesticides The popular belief among the locals of the affected regions is that the use of pesticides and its bioaccumulation, is the causative factor of the renal complications and CKD they face. It is believed that the pesticides have leached into the drinking water and the food grown using these agrochemicals. The local fish varieties have perished and effects are even seen in their cattle. The Minneriya Irrigation System caused many people from the wet zones of the country to settle into the NCP in the 1950s. The older generation (settlers) in this area are not as affected as the younger cohort (mostly children of the settlers) who began farming in the endemic regions. The condition worsened after the introduction of the green revolution 19. The pesticide usage in paddy cultivation and Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology vegetable growing regions is significantly high, though there is no provincial data available. These regions include those that have recorded significantly higher levels of CKDu, such as Polonnaruwa, Anuradhapura, Ampara, and Badulla. 3. 2. 7. Ayurvedic medicine Aristolochic acid was suggested to be an etiological factor of BEN, as the wheat used in the Balkan regions was found to be contaminated with Aristolochia clemantis. Therefore, this initiated studies to be carried out into the ayurvedic medicine used in Sri Lanka, to test for the presence of Aristocholic acid to explain renal disease. Research conducted have observed that the use of these herbal medication produces nephrotoxic effects in experimental animals and patients. It was observed that around 90% of the ayurvedic practitioners used alternative medical remedies, whilst only 10% used Aristoclochiaindica (Sapsanda) as an ingredient in their recipes. Sapsanda was used as a remedy for few diseases as well as for poisonous bites, the most common method of use was external application.
----------------------------------------------------------------------


======================================================================
CHUNK 35 of 647
======================================================================
ID: 1803.11253v1_8
Content Type: evidence
Words: 494
Medical Entities: CKD,hypertension,diabetes
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
It was observed that around 90% of the ayurvedic practitioners used alternative medical remedies, whilst only 10% used Aristoclochiaindica (Sapsanda) as an ingredient in their recipes. Sapsanda was used as a remedy for few diseases as well as for poisonous bites, the most common method of use was external application. Therefore, it was concluded that the use of nephrotoxic herbal medication was not a causal factor for CKDu found in the NCP 30. 3. 2. 8. Glyphosate Glyphosate is the most widely used herbicide in the endemic areas of disease. Glyphosate and related compounds are known to have strong chelating properties, however, no serious consideration has been given to the possible effects of these compounds on human health. This could be due to the fact that glyphosate in its original form is known to be an easily degradable compound in the natural environment, and its effectiveness as an herbicide. The GMA lattice hypothesis states that glyphosate can be absorbed through the dermis or through inhalation into body directly. It can also leach into the water bodies to form glyphosate metal complexes (the endemic regions are known to have elevated hardness). This allows another route for glyphosate to enter into body. These glyphosate compounds can lead to oxidative stress, nitrosative stress, apoptosis and necrosis of the renal tissue; leading to glomerular sclerosis, glomerular collapse, proximal tubular damage and tubulointerstitial damage. This evidenced by the elevated excretion of As, Cd, heavy metals, glyphosate and AMPA in urine of healthy individuals, whilst patients with CKDu have significantly lower levels of these compound excreted in urine. Although glyphosate alone might not be the cause of CKDu, it is arguable that the raised levels of glyphosate in endemic regions, coupled with localized geo environmental factors and nephrotoxic substances causes renal damage, which may lead to CKDu 29. 3. 2. 9. Bioaccumulation Most CKDu endemic areas are around tanks and reservoirs. The big tanks are usually home to many plants and aquatic animals. The bioaccumulation of pesticide residues, toxins and heavy metals in these organisms is a major area of concern. Both the Mahaweli Irrigation system and the Minneriya Irrigation System both exist in the dry zone, namely NCP. Water travels through hills, tanks and eventually the fields, and has an elevated level of hardness of water, along with pesticide residues, toxins and heavy metals. 3. 2. 10. Smoking There was a significantly increased risk of ESRD in renal disease when compared to nonsmokers, in Multiple Risk Factor Intervention Trial. This difference was independent of other factors such as age, gender, diabetes mellitus hypertension, ethnicity etc. 31. In diabetic individuals, smoking is known to increase the risk of nephropathy. Smoking was identified as a known risk factor for microalbuminuria. Microalbuminuria is recognized to be a marker of renal damage and hence CKD. There is a five times more likely chance of microalbuminuria in the subjects who have a history of smoking when compared to subjects with no history of smoking.
----------------------------------------------------------------------


======================================================================
CHUNK 36 of 647
======================================================================
ID: 1803.11253v1_9
Content Type: reference
Words: 441
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
Microalbuminuria is recognized to be a marker of renal damage and hence CKD. There is a five times more likely chance of microalbuminuria in the subjects who have a history of smoking when compared to subjects with no history of smoking. The findings of the study postulate that groundwater, along with cigarette consumption are probable sources of environmental toxin that may lead to CKDu 25. Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 3. 2. 11. Cyanobacterial toxin All the regions that are known to have a high prevalence of the CKD, is clustered around tanks and reservoirs of the irrigation system. A lower prevalence was observed in the communities that used water from natural springs for consumption. The water sampled from these natural springs, showed an absence of cyanobacteria and algae. The water contained very low levels of fluoride, nitrogen, phosphate and potassium. The analysis of the water from the reservoirs showed the presence of cyanobacterial blooms that are capable of producing hepatotoxic effects and carcinogenic effects. The regions that are endemic to CKD are seen to have many reservoirs which could explain the high prevalence of the disease (Athuraliya et al. , 2009). 3. 2. 12. Drinking well water One study found that in male farmers in PadaviSripura, who spray glyphosate have an increased risk of CKDu coupled with consumption of well water and have a history of consumption from an abandoned well for a period of more than 5 years. Univariable analysis found that consumption of water from an abandoned well increased the risk of contracting CKDu by 7 times. The abandonment of wells that were previously used for drinking water is a commonly observed phenomenon in CKDu endemic areas. The reasoning provided by the locals is that the water is not palatable and therefore unsuitable for drinking or cooking purposes, due to the increase in hardness of water. This leads to the locals having to travel further to obtain water, however more and more wells are being abandoned due to the progression of hard water. Therefore drinking water from a well and from abandoned wells, are used as significant predictors of CKDu 22. 3. 2. 13. Dehydration Due to the increasing hardness of water in wells of the PadaviSripura area, the locals need to travel further to obtain water for consumption. This scarcity of water, may lead to less consumption of water leading to dehydration. Dehydration further causes complications to the kidneys, resulting in renal tissue damage, which invariably leads to CKD. There are more suggested hypotheses put forward in relation to the etiology of CKDu in Sri Lanka.
----------------------------------------------------------------------


======================================================================
CHUNK 37 of 647
======================================================================
ID: 1803.11253v1_10
Content Type: evidence
Words: 496
Medical Entities: CKD
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
This scarcity of water, may lead to less consumption of water leading to dehydration. Dehydration further causes complications to the kidneys, resulting in renal tissue damage, which invariably leads to CKD. There are more suggested hypotheses put forward in relation to the etiology of CKDu in Sri Lanka. This includes maternal malnutrition, consumption of untreated water from the fields, low intake of calcium, ionic species in water, oxidative stress on renal tissue due to multifactorial origin, genetic predisposition, low BMI, chronic undernutrition, organophosphates, synergy of As and CD, used of NSAIDs, the use of synthetic fertilizers, history of snake bites, consumption of water directly from reservoirs, fungal and bacterial toxins 9. IV. CONCLUSION The Ministry of Health and the World Health Organization estimate that around 15% of the population found in endemic areas are susceptible to develop CKDu. This greatly increases the national socioeconomic burden on the public healthcare system. The specific etiologic causative agent behind CKDu is still unknown. However the suggested hypotheses discussed in this review provides insight for any further research to build on. V. ACKNOWLEDGEMENTS The authors wish to thank the International College of Business and Technology, Sri Lanka for the financial support. REFERENCES 1 Noble, A. , Amerasinghe, P. , Manthrithilake, H. and Arasalingam, S. , n. d. Review of Literature on Chronic Kidney Disease of Unknown Etiology (CKDu) in Sri Lanka. 2 Ene-Iordache, B. , Perico, N. , Bikbov, B. , Carminati, S. , Remuzzi, A. , Perna, A. , Islam, N. , Bravo, R. F. , Aleckovic-Halilovic, M. , Zou, H. , Zhang, L. , Gouda, Z. , Tchokhonelidze, I. , Abraham, G. , Mahdavi-Mazdeh, M. , Gallieni, M. , Codreanu, I. , Togtokh, A. , Sharma, S. K. , Koirala, P. , Uprety, S. , Ulasi, I. and Remuzzi, G. , 2016. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. The Lancet Global Health, 4(5), pp. e307e319. 3 Jayasinghe and Saroj, 2014. Redalyc. Chronic Kidney Disease of Unknown Etiology Should Be Renamed Chronic Agrochemical Nephropathy. MEDICC Review, 16(2), pp. 7274. Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 4 Nanayakkara, S. , Senevirathna, S. T. M. L. D. , Karunaratne, U. , Chandrajith, R. , Harada, K. H. , Hitomi, T. , Watanabe, T. , Abeysekera, T. , Aturaliya, T. N. C. and Koizumi, A. , 2012a. Evidence of tubular damage in the very early stage of chronic kidney disease of uncertain etiology in the North Central Province of Sri Lanka: A cross-sectional study. Environmental Health and Preventive Medicine. 5 Bandara, R. M. C. J. , Bandara, B. M. R. , Abeykoon, D. M. B. , Wickramasinghe, a, Wijesundara, D. S. a, Karunaratne, V. and Karunaratne, N. , 2011. Proceedings of the Peradeniya University Research Sessions, Sri Lanka, Vol. 16, 24. Proceedings of the Peradeniya University Research Sessions, 16(November), p. 156. 6 Cerdas, M. , 2005. Chronic kidney disease in Costa Rica.
----------------------------------------------------------------------


======================================================================
CHUNK 38 of 647
======================================================================
ID: 1803.11253v1_13
Content Type: evidence
Words: 497
Medical Entities: diabetes
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
Progression, remission, regression of chronic renal diseases. The Lancet, 357(9268), pp. 16011608. 8 Barsoum, R. S. , 2013. Burden of chronic kidney disease: North Africa. pp. 164166. 9 Ramirez-Rubio, O. , Brooks, D. R. , Amador, J. J. , Kaufman, J. S. , Weiner, D. E. and Scammell, M. K. , 2013. Chronic kidney disease in Nicaragua: A qualitative analysis of semi-structured interviews with physicians and pharmacists. BMC Public Health, 13(1). 10 Saboli, I. , 2006. Common mechanisms in nephropathy induced by toxic metals. Nephron Physiol. , 104(3), p107-14. 11 Nanayakkara, S. , Senevirathna, S. T. M. L. D. , Karunaratne, U. , Chandrajith, R. , Harada, K. H. , Hitomi, T. , Watanabe, T. , Abeysekera, T. , Aturaliya, T. N. C. and Koizumi, A. , 2012b. Evidence of tubular damage in the very early stage of chronic kidney disease of uncertain etiology in the North Central Province of Sri Lanka: A cross-sectional study. Environmental Health and Preventive Medicine, 17(2), pp. 109117. 12 Jayatilake, N. , Mendis, S. , Maheepala, P. and Mehta, F. R. , 2013. Chronic kidney disease of uncertain aetiology: Prevalence and causative factors in a developing country. BMC Nephrology. 13 Jayasumana, M. A. C. S. , Paranagama, P. A. , Amarasinghe, Wijewardane, K. M. R. C. , Dahanayake, K. S. , Fonseka, S. I. , Rajakaruna, K. D. L. M. P. , Mahamithawa, A. M. P. , Samarasinghe, U. D. and Senanayake, V. K. , 2013. Possible link of Chronic arsenic toxicity with Chronic Kidney Disease of unknown etiology in Sri Lanka. Journal of Natural Sciences Research www, 3(1), pp. 2225921. 14 Wickramarathna, S. , Balasooriya, S. , Diyabalanage, S. and Chandrajith, R. , 2017. Tracing environmental aetiological factors of chronic kidney diseases in the dry zone of Sri LankaA hydrogeochemical and isotope approach. Journal of Trace Elements in Medicine and Biology, 44, pp. 298306. 15 Cavanaugh, K. L. , n. d. Diabetes Management Issues for Patients With Chronic Kidney Disease. 16 Jayasekara, K. B. , Dissanayake, D. M. , Sivakanesan, R. , Ranasinghe, A. , Karunarathna, R. H. and Priyantha Kumara, G. W. G. , 2015. Epidemiology of Chronic Kidney Disease, With Special Emphasis on Chronic Kidney Disease of Uncertain Etiology, in the North Central Region of Sri Lanka. Journal of Epidemiology, 25(4), pp. 275280. 17 Athuraliya, N. T. C. , Abeysekera, T. D. J. , Amerasinghe, P. H. , Kumarasiri, R. , Bandara, P. , Karunaratne, U. , Milton, A. H. and Jones, A. L. , 2011. Uncertain etiologies of proteinuric-chronic kidney disease in rural Sri Lanka. Kidney International. 18 De Silva, P. M. C. S. , Mohammed Abdul, K. S. , Eakanayake, E. M. D. V. , Jayasinghe, S. S. , Jayasumana, C. , Asanthi, H. B. , Perera, H. S. D. , Chaminda, G. G. T. , Chandana, E. P. S. and Siribaddana, S. H. , 2016. Urinary Biomarkers KIM-1 and NGAL for Detection of Chronic Kidney Disease of Uncertain Etiology (CKDu) among Agricultural Communities in Sri Lanka.
----------------------------------------------------------------------


======================================================================
CHUNK 39 of 647
======================================================================
ID: 1803.11253v1_14
Content Type: evidence
Words: 489
Medical Entities: dialysis
Source: 1803.11253v1.pdf

----------------------------------------------------------------------
Urinary Biomarkers KIM-1 and NGAL for Detection of Chronic Kidney Disease of Uncertain Etiology (CKDu) among Agricultural Communities in Sri Lanka. PLoS Neglected Tropical Diseases, 10(9), pp. 117. Manuscript id. 631855358 www. ijstre. com A comprehensive review of Chronic Kidney Disease of Unknown Etiology 19 Johnson Savvy Soumya Misra Ramakant Sahu Poornima Saxena CONSULTANTS B Mathur H C Agarwal, S. H. , 2012. Environmental contamination and its association with Chronic Kidney Disease of Unknown Etiology in North Central Region of Sri Lanka INVESTIGATORS. 20 Ranasinghe, H. and Ranasinghe, M. , 2015. Status, Gaps and Way Forward in Addressing the Chronic Kidney Disease Unidentified ( CKDu ) in Sri Lanka. Journal of Environmental Professionals Sri Lanka, 4(2), pp. 5868. 21 Chandrajith, R. , Nanayakkara, S. , Itai, K. et al. Environ Geochem Health (2011) 33: 267. 22 Jayasumana, C. , Paranagama, P. , Agampodi, S. , Wijewardane, C. , Gunatilake, S. and Siribaddana, S. , 2015c. Drinking well water and occupational exposure to Herbicides is associated with chronic kidney disease, in Padavi-Sripura, Sri Lanka. Environmental health: a global access science source. 23 Redmon, J. H. , Elledge, M. F. , Womack, D. S. , Wickremashinghe, R. , Wanigasuriya, K. P. , Peiris-John, R. J. , Lunyera, J. , Smith, K. , Raymer, J. H. and Levine, K. E. , 2014. Additional perspectives on chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka - Lessons learned from the WHO CKDu population prevalence study. BMC Nephrology. 24 Jayasumana, C. , Fonseka, S. , Fernando, A. , Jayalath, K. , Amarasinghe, M. , Siribaddana, S. , Gunatilake, S. and Paranagama, P. , 2015a. Phosphate fertilizer is a main source of arsenic in areas affected with chronic kidney disease of unknown etiology in Sri Lanka. SpringerPlus. 25 Wanigasuriya, K. P. , Peiris-John, R. J. and Wickremasinghe, R. , 2011. Chronic kidney disease of unknown aetiology in Sri Lanka: Is cadmium a likely cause? BMC Nephrology. 26 Jayasumana, C. , Fonseka, S. , Fernando, A. , Jayalath, K. , Amarasinghe, M. , Siribaddana, S. , Gunatilake, S. and Paranagama, P. , 2015b. Phosphate fertilizer is a main source of arsenic in areas affected with chronic kidney disease of unknown etiology in Sri Lanka. SpringerPlus, 4(1), pp. 18. 27 Ludlow, M. , Luxton, G. and Mathew, T. , 2007. Effects of fluoridation of community water supplies for people with chronic kidney disease. Nephrology Dialysis Transplantation. 28 Wimalawansa, S. A. and Wimalawansa, S. J. , 2014. Agrochemical-Related Environmental Pollution: Effects on Human Health. Global Journal of Biology, Agriculture Health Sciences, 3(3), pp. 7283. 29 Jayasumana, C. , Gunatilake, S. and Senanayake, P. , 2014. Glyphosate, hard water and nephrotoxic metals: Are they the culprits behind the epidemic of chronic kidney disease of unknown etiology in Sri Lanka? International Journal of Environmental Research and Public Health. 30 Elledge, M. , Hoponick Redmon, J. , Levine, K. , Wickremasinghe, R. , Wanigasariya, K. and Peiris-John, R. , 2014.
----------------------------------------------------------------------


======================================================================
CHUNK 40 of 647
======================================================================
ID: 1_0
Content Type: recommendation
Words: 497
Section: Healthy Eating for Adults with Chronic Kidney Disease In this section:
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Healthy Eating for Adults with Chronic Kidney Disease In this section: Why is healthy eating important for adults with CKD? What aspects of nutrition are important for adults with CKD? How can I eat healthy with CKD? What is medical nutrition therapy? Clinical Trials for Healthy Eating for Adults with CKD Why is healthy eating important for adults with CKD? Healthy kidneys balance salts and minerals in the blood. When you have chronic kidney disease (CKD), the kidneys cant filter your blood the way they should. What you eat and drink can help your kidneys maintain a healthy balance of salts and minerals in your body and help you feel better. Choosing healthy foods and beveragesand avoiding foods high in sodium, potassium, and phosphorusmay prevent or delay some health problems from CKD. What you eat and drink may also affect how well your kidney disease treatments work. Understanding how different nutrients and liquids affect the body is important for people with CKD. As CKD advances, nutritional needs change. Your health care professional may recommend you choose foods more carefully and may suggest you work with a registered dietitian, if possible, to create an eating plan for your individual needs. You can find a registered dietitian External link who specializes in kidney disease through the Academy of Nutrition and Dietetics online or through your health care professional. The nutritional needs for children with CKD are different than for adults. Learn more. What aspects of nutrition are important for adults with CKD? Calories The foods and beverages you eat and drink give your body energy. The energy is measured in calories. If you consume fewer calories than your body uses, you may lose weight. Losing too much weight can make you sicker. Fat Fat gives your body energy, helps control your cholesterol and blood pressure levels, and helps your body absorb vitamins. Fat also provides nutrients your body needs and is an important part of a healthy eating plan. Everyone needs some fat in their diet, but too much fat or choosing foods higher in saturated fat or trans fat may cause buildup in your blood vessels, heart, and kidneys. People with CKD have a higher risk of developing heart and blood vessel disease NIH external link and should focus on consuming healthier unsaturated fats while limiting saturated and trans fats. Liquids Your body needs liquids to function properly. However, people with CKD may need to limit how much liquid they consume because damaged kidneys cant remove extra fluid. Talk with your health care professional about how much liquid you should have each day. Phosphorus Damaged kidneys cant remove phosphorus from the blood as well as healthy kidneys can. Phosphorus can build up in the blood in people with CKD. Too much phosphorus in your blood can harm your blood vessels and make your bones thin, weak, and more likely to break. High levels of phosphorus in your blood can also cause itchy skin and bone and joint pain.
----------------------------------------------------------------------


======================================================================
CHUNK 41 of 647
======================================================================
ID: 1_1
Content Type: recommendation
Words: 477
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Phosphorus can build up in the blood in people with CKD. Too much phosphorus in your blood can harm your blood vessels and make your bones thin, weak, and more likely to break. High levels of phosphorus in your blood can also cause itchy skin and bone and joint pain. Potassium CKD can make it harder for the kidneys to remove potassium from the blood, and the potassium levels in the blood can become very high. Having too little or too much potassium in your blood can cause heart and muscle problems. For this reason, its important to work with a dietitian or health care professional to help find the right amount of potassium for you. Protein Protein helps build and maintain muscle, bone, skin, connective tissue, internal organs, and blood. Protein also helps fight disease and heal wounds. As your body uses protein, the protein breaks down into waste. Your kidneys remove this waste from the blood. Some people with CKD may need to consume moderate amounts of protein so waste doesnt build up in the blood. However, too little protein may lead to malnutrition, a condition that occurs when your body doesnt get enough nutrients. Work with a dietitian or health care professional to find the right balance of protein to make sure you are properly nourished without causing strain to your kidneys. Sodium Sodium is a mineral that helps control the amount of fluids in your body. Sodium is found in table salt and in many processed foods. Too much sodium causes your blood to retainor hold on tofluids. When your body retains fluids, it can cause high blood pressure and swelling, putting stress on your kidneys and heart. Be aware of the amount of sodium in the foods and beverages you consume and work with your dietitian or health care professional to determine your sodium limit. A smiling woman holding a grocery bag of food in her kitchen. Eating healthy with CKD can help your kidneys maintain a healthy balance of salts and minerals in your body and can help you feel better. How can I eat healthy with CKD? There is no single meal plan for everyone with CKD. In the early stages of CKD, you may have few limits to what you can eat and drink. As your CKD advances and your nutritional needs change, you may need to make more changes to your diet. Talk with your health care team about challenges you may have finding healthy food. A health care professional, dietitian, or social worker may be able to recommend resources that can help you. The U. S. Department of Agriculture also has a list of resources External link for finding and affording healthy food. Pay attention to calories People with CKD may avoid eating because they dont feel hungry or because foods or beverages dont taste the same.
----------------------------------------------------------------------


======================================================================
CHUNK 42 of 647
======================================================================
ID: 1_2
Content Type: reference
Words: 496
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
The U. S. Department of Agriculture also has a list of resources External link for finding and affording healthy food. Pay attention to calories People with CKD may avoid eating because they dont feel hungry or because foods or beverages dont taste the same. If you find that you dont feel like eating, talk with a dietitian or health care professional to make sure you are getting enough calories and that the calories are from nutritious sources. Your dietitian or health care professional can help you find healthy ways to get the calories your body needs. Choose heart-healthy foods You may protect your heart health and lower your chance of developing heart and blood vessel disease by replacing saturated fats and trans fats in your diet with healthier unsaturated fats, which include monounsaturated fats and polyunsaturated fats. Monounsaturated fats and polyunsaturated fatsfound in foods such as canola oil, safflower oil, avocados, nuts, and seedsare healthy alternatives to saturated fats and trans fats. Saturated fats and trans fats can raise cholesterol levels and clog blood vessels. Saturated fats, which are found in animal products such as red meat, poultry, and butter, are usually solid at room temperature. Trans fats can be found in fast foods, fried foods, commercially produced baked goods, and other foods cooked with partially hydrogenated or hydrogenated oil or shortening. Tips for following a heart-healthy diet include Choose heart-healthy foods NIH external link, including plenty of fruits and vegetables. Grill, broil, bake, roast, air-fry, or stir-fry foods, instead of deep-frying. Cook with nonstick cooking spray or a small amount of olive oil instead of butter. Trim fat from meat and remove skin from poultry before eating. Limit saturated and trans fats. Look for the amount of saturated fat External link and trans fat External link on the Nutrition Facts label. Limit alcohol. Ask your health care professional how much alcohol is safe for you. Talk with your dietitian or health care professional about healthy ways you can include fat in your diet External link. Track your liquids You may need to adjust how much liquid you have each day, depending on your kidney function. A dietitian or health care professional can work with you to determine how much liquid you should have each day. Contact your health care professional if you notice any swelling in your face, arms, legs, or abdomen. Choose foods and drinks with less phosphorus Phosphorus is found naturally in foods that are rich in protein, such as meat, dairy products, and beans. Phosphorus is also added to many foods. Phosphorus additives are the primary source of phosphorus for many people. Tips to reduce phosphorus in your diet include Limit or avoid packaged and processed foods and drinks that have added phosphorus, such as deli meats, flavored drinks, and other processed foods. Check Nutrition Facts labels External link for added phosphorus. Look for phosphorus or words with PHOS, such as phosphoric acid, disodium phosphate, and monosodium phosphate on the ingredient list.
----------------------------------------------------------------------


======================================================================
CHUNK 43 of 647
======================================================================
ID: 1_3
Content Type: recommendation
Words: 499
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Check Nutrition Facts labels External link for added phosphorus. Look for phosphorus or words with PHOS, such as phosphoric acid, disodium phosphate, and monosodium phosphate on the ingredient list. Eat larger portions of fruits and vegetables, which are naturally low in phosphorus, and smaller portions of foods high in phosphorus. Keep in mind, your body absorbs more phosphorus from animal-based foods, such as meat and poultry, than from plant-based foods, such as beans and seeds. Some packaged meats and poultry have added phosphorus. Ask someone who works in the meat department to show you which meats do not have added phosphorus. A health care professional can check your blood phosphorus level using a blood test NIH external link. Foods and drinks with added phosphorus may cause your blood phosphorus level to go up more than foods and drinks that naturally contain phosphorus. Your dietitian or health care professional may suggest changes to what you eat and drink to help keep your phosphorus level in a healthy range. As kidney disease advances, you may need to take a phosphate binder with meals to lower the amount of phosphorus in your blood. A phosphate binder is a medicine that acts like a sponge to soak up, or bind, phosphorus while it is in the stomach. Because it is bound, the phosphorus does not get into your blood. Instead, your body removes the phosphorus through your stool. Choose foods that help keep your potassium level in the goal range Your food and drink choices can help you keep your potassium level in a healthy range. If your potassium level is high, your health care professional may recommend you Limit serving sizes of foods that contain potassium. Keep in mind that a large serving of a lower-potassium food may have more potassium than a small serving of a higher-potassium food. Use spices and herbs instead of salt substitutes, which can be high in potassium. Limit foods with potassium chloride on the ingredient list. Potassium chloride is sometimes used in place of salt in some packaged foods. Drain canned fruits and vegetables and throw out the liquid, which is often high in potassium. Use food preparation and cooking methods, such as boiling and leaching, that can lower the amount of potassium in certain vegetables. If you have diabetes and your blood glucose levelalso called blood sugar levelgets low, choose apple, grape, or cranberry juice instead of other fruit juices that are higher in potassium, such as orange juice. A health care professional can check your potassium level using a blood test NIH external link. Talk with your dietitian or health care professional about ways you can adjust your food and drink choices to meet your potassium goal. Your health care professional may suggest you take a potassium binder to lower the amount of potassium in your blood. Similar to phosphate binders, potassium binders are medicines that prevent some potassium from getting into the blood. The potassium is removed from the body through your stool.
----------------------------------------------------------------------


======================================================================
CHUNK 44 of 647
======================================================================
ID: 1_4
Content Type: recommendation
Words: 497
Medical Entities: CKD,dialysis
Source: 1.txt

----------------------------------------------------------------------
Your health care professional may suggest you take a potassium binder to lower the amount of potassium in your blood. Similar to phosphate binders, potassium binders are medicines that prevent some potassium from getting into the blood. The potassium is removed from the body through your stool. Taking certain medicines, as well as skipping dialysis treatments, can also raise your potassium level. Your health care professional may adjust the medicines you take if your potassium level is too high. If you receive dialysis treatments, be sure to attend all dialysis sessions to help prevent potassium from building up in your blood. A grandfather has dinner with his daughter and granddaughter. Talk with your dietitian or health care professional about changes you can make to what you eat and drink if your CKD gets worse. Choose the amount and types of protein your body needs Protein is in many foods you eat, including foods from plants and animals. You may need to adjust the amount of protein in your diet to help keep your kidneys healthier longer. Your protein needs may also change over time. Work with your dietitian or health care professional to find the amount and sources of protein External link you should include in your diet. Your health care professional may recommend you limit how much meat and dairy foods you consume get the rest of your protein from plant-based foods choose lean, or low-fat, meats that also are low in phosphorus If you dont eat animal products, eat a variety of plant-based proteins to meet your bodys protein needs. People with CKD who are on dialysis may need to eat more protein because the dialysis treatment removes protein from the blood. The amount of protein removed from the blood depends on the type of dialysis treatment. For example, peritoneal dialysis removes more protein than hemodialysis. A variety of animaland plant-based proteins on a cutting board. Talk with your dietitian or health care professional about the amount and sources of protein you should include in your diet. Choose and prepare foods with less salt and sodium Most Americans consume more sodium than they should. Much of this sodium comes from packaged, prepared, and restaurant foods, not from a saltshaker. Even foods that dont taste salty can be high in sodium. Canned foods, some frozen foods, and most processed meats contain large amounts of salt. Snack foods such as chips and crackers are also high in salt. Table salt, some seasonings, ketchup, mustard, and certain sauces such as barbecue, soy, and teriyaki sauces are high in sodium. The 20202025 Dietary Guidelines for Americans External link recommends adults limit their sodium to no more than 2, 300 milligrams per day. 1 Many people with CKD need to limit their sodium even more. Your health care professional can determine your sodium limit, based on your kidney health. Tips to reduce sodium in your diet External link include Limit the amount of prepared, packaged, and fast foods you eat.
----------------------------------------------------------------------


======================================================================
CHUNK 45 of 647
======================================================================
ID: 1_5
Content Type: reference
Words: 490
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
1 Many people with CKD need to limit their sodium even more. Your health care professional can determine your sodium limit, based on your kidney health. Tips to reduce sodium in your diet External link include Limit the amount of prepared, packaged, and fast foods you eat. Choose unprocessed meats instead of processed meats. Check for sodium on the Nutrition Facts label External link of food packages. A % Daily Value External link of 20% or more means the food is high in sodium, and a value of 5% or less means the food is low in sodium. Look for foods labeled sodium free, salt free, very low sodium, low sodium, reduced or less sodium, no salt added, unsalted, or lightly salted. Eat more fresh, frozen, and canned fruits and vegetables without added sauce, seasonings, sodium, or salt. Drain and rinse canned vegetables, beans, meats, and fish with water to remove extra salt. Cook foods from scratch. When you prepare your own food, you control what goes into it. Use spices, herbs, and sodium-free seasonings in place of salt. Use alternative seasonings, such as lemon juice, herbs, and hot peppers. Try slowly reducing the amount of sodium in your diet over time. Your taste buds will gradually adjust, and you wont notice the change in flavor. A Nutrition Facts label highlighting serving size, number of servings, and percent daily value for sodium. There may be more than one serving in the package, so be sure to check serving size. Percent daily value for sodium tells you how much sodium in one serving contributes to a daily diet of 2, 000 calories. Look for the serving size and sodium on the Nutrition Facts label. A label showing % Daily Value (%DV) of 5% or less per serving is considered low in sodium. What is medical nutrition therapy? Medical nutrition therapy (MNT) is nutrition counseling from a registered dietitian to help meet your medical or health goals. MNT can help delay CKD progression, prevent or treat complications, and improve your quality of life. Medicare and insurance coverage for MNT If you are enrolled in Medicare and have CKD, Medicare will cover MNT services External link. You will need a written referral from a doctor, and the MNT must be provided by a registered dietitian. If you have health insurance, check your insurance companys website or call customer service to find out if your insurance will pay for some or all MNT. If you dont have insurance or Medicare, ask a health care professional about the cost of a dietitians services. A health care professional may be able to connect you with organizations that can help cover the cost of nutrition counseling. Clinical Trials for Healthy Eating for Adults with CKD NIDDK conducts and supports clinical trials in many diseases and conditions, including kidney disease. The trials look to find new ways to prevent, detect, or treat disease and improve quality of life.
----------------------------------------------------------------------


======================================================================
CHUNK 46 of 647
======================================================================
ID: 1_6
Content Type: evidence
Words: 500
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Clinical Trials for Healthy Eating for Adults with CKD NIDDK conducts and supports clinical trials in many diseases and conditions, including kidney disease. The trials look to find new ways to prevent, detect, or treat disease and improve quality of life. What are clinical trials for healthy eating for adults with CKD? Clinical trialsand other types of clinical studies NIH external linkare part of medical research and involve people like you. When you volunteer to take part in a clinical study, you help doctors and researchers learn more about disease and improve health care for people in the future. Researchers are studying many aspects of healthy eating for adults with CKD, such as the impact of MNT on CKD progression how anti-inflammatory diets affect patients with CKD the relationship between protein intake and CKD progression Find out if clinical studies are right for you NIH external link. Watch a video of NIDDK Director Dr. Griffin P. Rodgers explaining the importance of participating in clinical trials. The 20 Best Foods for People with Kidney Disease Diet and kidney disease Foods to help kidneys Cauliflower Blueberries Sea bass Red grapes Egg white Garlic Buckwheat Olive oil Bulgur Cabbage Chicken Peppers Onions Arugula Macadamia nuts Radish Turnips Pineapple Cranberries Mushrooms FAQ Bottom line If you have kidney disease, you may need to follow a special diet. While this diet may not completely heal your kidneys, it may help protect them from further damage. When your kidneys arent working properly, waste builds up in the blood, including waste products from food. People with kidney disease can benefit from following a special diet known as a renal diet. Here, we look at 20 of the best foods for people with kidney disease. Diet and kidney disease Dietary restrictions vary depending on the level of kidney damage. People with later-stage kidney disease will have different limitsTrusted Source from those with early kidney disease. The diet will need to boost kidney function at any stage while lowering the riskTrusted Source of further damage. While dietary restrictions vary, people with kidney disease typically need to restrict the following nutrients. The kidneys may have difficulty removing or processing these nutrients, and high levels can cause damage to the body. Nutrient Amount sodium, the key ingredient in salt under 2. 3 gramsTrusted Source per day potassium adjust dietary potassium intake to maintain serum potassium within normal range phosphorus adjust dietary phosphorus intake to maintain serum phosphate levels in the normal range protein restrictions will depend on stage of kidney disease Since kidney disease is closely linked to heart disease, its best to combine these choices with a heart-healthy diet one that contains plenty of fresh, plant-based foods and is low in saturated fats. Individuals with kidney disease have a unique experience, so its important to talk with a doctor about your specific dietary needs. ADVERTISEMENT Build an understanding of your nutritional intake Labcorp OnDemands Micronutrient Test may help you uncover nutritional deficiencies and make informed decisions about what you eat.
----------------------------------------------------------------------


======================================================================
CHUNK 47 of 647
======================================================================
ID: 1_7
Content Type: recommendation
Words: 500
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Individuals with kidney disease have a unique experience, so its important to talk with a doctor about your specific dietary needs. ADVERTISEMENT Build an understanding of your nutritional intake Labcorp OnDemands Micronutrient Test may help you uncover nutritional deficiencies and make informed decisions about what you eat. Clinics 5 miles away (95% of the U. S. ) HSA/FSA Payments Accepted Walk-ins Welcome 4. 8 s on App Store What foods help kidneys repair? Here are 20 foods that may improve kidney health or prevent it from worsening: 1. Cauliflower Cauliflower provides many nutrients, including vitamin K, folate, and fiber. It also containsTrusted Source antioxidants and anti-inflammatory compounds. Try mashed cauliflower in place of potato for a low potassium side dish. One-half cup or about 62 grams (g) of boiled cauliflower without salt containsTrusted Source: sodium: 9. 3 milligrams (mg) potassium: 88 mg phosphorus: 20 mg protein: 1 g 2. Blueberries Blueberries are rich in nutrients and antioxidants known as anthocyanins, which may protectTrusted Source against heart disease, diabetes, and other diseases. Theyre also low in sodium, phosphorus, and potassium. One cup (148 g) of fresh blueberries containsTrusted Source: sodium: 1. 5 mg potassium: 114 mg phosphorus: 18 mg protein: 1 g 3. Sea bass Sea bass is a fish option that provides high quality protein. It also contains healthy fats called omega-3s. Omega-3s may helpTrusted Source prevent a range of diseases and boost the health of those living with long-term conditions. Three ounces (85 g) of cooked sea bass containsTrusted Source: sodium: 74 mg potassium: 279 mg phosphorus: 211 mg protein: 20 g However, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Trusted Source recommends eating small portions of meat or fish, as high protein levels can make the kidneys work harder. One portion is 23 ounces of chicken, fish, or meat, or a piece around the size of a deck of cards. 4. Red grapes Red grapes are a good sourceTrusted Source of antioxidants called flavonoids, which may help reduceTrusted Source inflammation and protect against heart disease, diabetes, and other health conditions. One half-cup (75 g) of red grapes containsTrusted Source: sodium: 1. 5 mg potassium: 144 mg phosphorus: 15 mg protein: 0. 5 g 5. Egg whites Egg whites provide a high quality, kidney-friendly source of protein that is low in phosphorus. Egg whites may be a better choice than whole eggs for people on a renal diet, as egg yolks can be highTrusted Source in phosphorus. Two large, raw egg whites (66 g) containTrusted Source: sodium: 110 mg potassium: 108 mg phosphorus: 10 mg protein: 7 g 6. Garlic Garlic provides a tasty alternative to salt, adding flavor to dishes while also providing nutritional benefits. Its a good source of manganese and vitamin B6. It also contains sulfur compounds with anti-inflammatory properties. Three cloves (9 g) of garlic containTrusted Source: sodium: 1. 5 mg potassium: 36 mg phosphorus: 14 mg protein: 0. 5 g 7. Buckwheat Buckwheat is a whole grain thats low in potassium.
----------------------------------------------------------------------


======================================================================
CHUNK 48 of 647
======================================================================
ID: 1_10
Content Type: recommendation
Words: 490
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
One cup (165 g) of pineapple chunks containsTrusted Source: sodium: 2 mg potassium: 180 mg phosphorus: 13 mg protein: 1 g How to cut a pineapple 19. Cranberries Cranberries contain phytonutrients called A-type proanthocyanidins. These are antioxidants that may prevent urinary tract infections by reducingTrusted Source bacteria levels in urine. Cranberries are also low in potassium, phosphorus, and sodium. There are close links between urinary tract infections (UTIs) and kidney infections, and a UTI can lead toTrusted Source kidney complications. You can eat cranberries dried, cooked, fresh, or as a juice. One cup (100 g) of whole, fresh cranberries containsTrusted Source: sodium: 2 mg potassium: 80 mg phosphorus: 11 mg protein: 0. 5 g 20. Shiitake mushrooms Shiitake mushrooms are a savory ingredient that you can use as a plant-based meat substitute. Theyre suitable for people with kidney disease who follow a plant-based diet and anyone on a renal diet who needs to limit their protein intake. Theyre an excellent source of B vitamins, copper, manganese, and selenium. They also provide a good amount of plant-based protein and dietary fiber. Shiitake mushrooms are lower in potassium, sodium, and phosphorus than portabellaTrusted Source and white button mushroomsTrusted Source, making them a good choice for a renal diet. One cup (145 g) of cooked shiitake mushroom pieces without added salt containsTrusted Source: sodium: 6 mg potassium: 170 mg phosphorus: 42 mg protein: 2 g Frequently asked questions What is the best diet for kidney disease and kidney failure? It may not be possible to heal your kidneys, but according to the NIDDKTrusted Source, it may be possible to manage your kidney disease with dietary changes such as: avoiding too much salt and sodium getting enough, but not too much protein following a heart-healthy diet limiting alcohol consumption avoiding foods and drinks with too much phosphorus and potassium How can I make my kidneys stronger again? The National Kidney Foundation recommends the following to help keep your kidneys healthy: manage high blood pressure levels maintain ideal blood sugar levels avoid eating too much protein lower your salt intake avoid nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen (Advil, Motrin), aspirin, and naproxen (Naprosyn) get your annual flu shot What is the best drink for healthy kidneys? Water is the best option as it flushes out the kidneys without adding potassium or phosphorus. Unsweetened cranberry juice is also a good option, as it contains antioxidants that may protect against urinary tract infections. You might also try rice milk thats not enriched with potassium or phosphorus. Limit or avoid alcohol, as this can increase your chances of developing several health problems. What are 10 foods that are bad for the kidneys? Foods to avoid if you have kidney disease are mainly those that are high in sodium, phosphorus, or both. Individual dietary choices will depend on your stage of kidney disease and blood tests. Ultimately, people with CKD need to consult with a dietitian for personalized advice.
----------------------------------------------------------------------


======================================================================
CHUNK 49 of 647
======================================================================
ID: 1_11
Content Type: reference
Words: 491
Medical Entities: CKD,dialysis,diabetes
Source: 1.txt

----------------------------------------------------------------------
Foods to avoid if you have kidney disease are mainly those that are high in sodium, phosphorus, or both. Individual dietary choices will depend on your stage of kidney disease and blood tests. Ultimately, people with CKD need to consult with a dietitian for personalized advice. Here are some items you may want to avoid or limit: processed foods or premade meals, which tend to have added sodium canned foods with added salt opt for salt-free or rinse them before using them large portions of protein foods, such as meat or dairy foods alcohol deli meats Learn more about which foods to avoid if you have kidney disease. The bottom line People with kidney disease have to manage their intake of phosphorus, salt, and potassium. At certain stages, they may also need to limit their protein intake. As nutritional needs and restrictions change during the course of the disease, its best to speak with a doctor or registered dietitian before making any dietary changes. They will help you work out a diet suitable for you. Suitable options may include chicken, shiitake mushrooms, cranberries, macadamia nuts, and a wide range of other tasty and nutritious foods. Diabetes and Kidney Disease: What to Eat? What to know About 1 in 3 American adults with diabetes also has chronic kidney disease (CKD). Figuring out what to eat can be a major challenge. Diabetes and CKD diets share many of the same foods, but there are some important differences. Read on for the basics. Woman eating edamame Diabetes diet A healthy diabetes diet looks pretty much like a healthy diet for anyone. Eat lots of fruits, veggies, healthy fats, and lean protein. Eat less salt, sugar, and foods high in refined carbs (cookies, crackers, and soda, just to name a few). Your individual carb goal is based on your age, activity level, any medicines you take, and other factors. Following your meal plan will help keep blood sugar levels in your target range. This will also prevent more damage to your kidneys. Kidney diet With a CKD diet, youll avoid or limit certain foods to protect your kidneys. Youll include other foods to give you energy and keep you nourished. Your specific diet will depend on whether youre in early-stage or late-stage CKD or if youre on dialysis. Foods to limit Eat less salt/sodium. Over time, your kidneys lose the ability to control your sodium-water balance. Less sodium in your diet will help lower blood pressure. It will also decrease fluid buildup in your body, which is common in kidney disease. Focus on fresh, homemade food to better control the amount of sodium in your food. Eat only small amounts of restaurant food and packaged food, which usually have lots of sodium. Look for low sodium (5% or less) on food labels. In a week or two, youll get used to less salt in your food. Add flavor with herbs, spices, mustard, and flavored vinegars.
----------------------------------------------------------------------


======================================================================
CHUNK 50 of 647
======================================================================
ID: 1_12
Content Type: reference
Words: 498
Medical Entities: CKD,dialysis,diabetes
Source: 1.txt

----------------------------------------------------------------------
Eat only small amounts of restaurant food and packaged food, which usually have lots of sodium. Look for low sodium (5% or less) on food labels. In a week or two, youll get used to less salt in your food. Add flavor with herbs, spices, mustard, and flavored vinegars. But dont use salt substitutes unless your doctor or dietitian says you can. Many are very high in potassium, which you may need to limit. Depending on your kidney disease stage, you may also need to reduce the potassium, phosphorus, and protein in your diet. Many foods that are part of a typical healthy diet may not be right for a CKD diet. Phosphorus is a mineral that keeps your bones strong and other parts of your body healthy. Your kidneys cant remove extra phosphorus from your blood very well. Too much weakens bones and can damage your blood vessels, eyes, and heart. Meat, dairy, beans, nuts, whole-grain bread, and dark-colored sodas are high in phosphorus. Phosphorus is also added to lots of packaged foods. The right level of potassium keeps your nerves and muscles working well. With CKD, too much potassium can build up in your blood and cause serious heart problems. Oranges, potatoes, tomatoes, whole-grain bread, and many other foods are high in potassium. Apples, carrots, and white bread are lower in potassium. Your doctor may prescribe a potassium binder, a medicine that helps your body get rid of extra potassium. Eat the right amount of protein. More protein than you need makes your kidneys work harder and may make CKD worse. But too little isnt healthy either. Both animal and plant foods have protein. Your dietitian can help you figure out the right combination and amount of protein to eat. Say no to herbal supplements Herbal supplements arent safe if you have kidney disease. Some can hurt your kidneys and even make kidney disease worse. Some vitamins can cause kidney problems too and should also be avoided. Always talk to your doctor before taking any supplements or vitamins. Diabetes and CKD foods Below are just a few examples of foods a person with both diabetes and CKD can eat. Your dietitian can give you more suggestions and help you find recipes for tasty meals: Fruits: berries, grapes, cherries, apples, plums Veggies: cauliflower, onions, eggplant, turnips Proteins: lean meats (poultry, fish), eggs, unsalted seafood Carbs: white bread, bagels, sandwich buns, unsalted crackers, pasta Drinks: water, clear diet sodas, unsweetened tea Heres one way your CKD diet and diabetes diet can work together. If you drink orange juice to treat low blood sugar, switch to kidney-friendly apple or grape juice. Youll get the same blood-sugar boost with a lot less potassium. Late-stage CKD Your nutrition needs will change with late-stage CKD. If youre on dialysis, you may need to eat more, especially more protein. Your appetite can change because food tastes different. Dialysis filters your blood like kidneys do, but it doesnt work as well as healthy kidneys.
----------------------------------------------------------------------


======================================================================
CHUNK 51 of 647
======================================================================
ID: 1_13
Content Type: general
Words: 484
Medical Entities: CKD,dialysis,diabetes
Source: 1.txt

----------------------------------------------------------------------
Late-stage CKD Your nutrition needs will change with late-stage CKD. If youre on dialysis, you may need to eat more, especially more protein. Your appetite can change because food tastes different. Dialysis filters your blood like kidneys do, but it doesnt work as well as healthy kidneys. Fluid can build up in your body between treatments. You may need to limit how much fluid you drink. Youll need to watch for swelling around your eyes or in your legs, arms, or belly. Your blood sugar levels can actually get better with late-stage CKD. This may happen because of changes in how your body uses insulin. But when youre on dialysis, your blood sugar can increase. This is because the fluid used to filter your blood is high in glucose (sugar). Your need for insulin and other diabetes medicines will be hard to predict, so your doctor will monitor you closely. When you have kidney disease, it is important to watch what you eat and drink because your kidneys cannot remove waste products as well as they should. A kidney-friendly eating plan can help you stay healthier and slow down damage to your kidneys. This webpage is for people who have Stages 1 to 4 of chronic kidney disease (CKD) and are not on dialysis. Everyone is different and has different nutritional needs. Use this information as a guide. Work with a dietitian to create a kidney-friendly eating plan that is right for you. What is a kidney-friendly eating plan? A kidney-friendly eating plan is a way of eating that helps you stay healthy and can slow down damage to your kidneys. It includes foods that are easy on your kidneys and limits other foods and fluids so certain minerals in those foods, like potassium, do not build up to high levels in your body. How can I create a kidney-friendly eating plan that is right for me? Ask your doctor to refer you to a dietitian (someone with special training in food and nutrition to know which foods are right for people with kidney disease). You can talk to a dietitian about the foods you enjoy or any special requirements you have (for example, you are vegetarian or have food allergies) and they will help you create a kidney-friendly eating plan that is right for you and includes the foods you enjoy. Always talk to a dietitian before increasing or decreasing your daily intake of certain foods or nutrients. Medicare and many private insurance plans pay for a certain number of visits with a dietitian each year. Call your insurance company to ask if your plan covers medical nutrition therapy (MNT) with a dietitian. MNT is an approach to treat kidney disease through a tailored nutrition plan. As part of MNT, a dietitian will review your current eating habits, create a healthy eating plan, that includes your preferences, and help you overcome eating challenges.
----------------------------------------------------------------------


======================================================================
CHUNK 52 of 647
======================================================================
ID: 1_14
Content Type: general
Words: 490
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
MNT is an approach to treat kidney disease through a tailored nutrition plan. As part of MNT, a dietitian will review your current eating habits, create a healthy eating plan, that includes your preferences, and help you overcome eating challenges. Learn more about working with a dietitian to create and following a kidney-friendly eating plan Why is a kidney-friendly eating plan important? A kidney-friendly eating plan helps you manage your kidney disease and slow down damage to your kidneys. It does this by preventing certain minerals from building up in your body, which is important because your kidneys do not work as well to remove waste products from your body. A kidney-friendly eating plan can also help prevent other serious health problems and controls high blood pressure and diabetes, which can prevent kidney disease from getting worse. It also ensures that you get the right balance of nutrients to help you: Have energy to do your daily tasks Prevent infection Build muscle Stay at a healthy weight How can I follow a kidney-friendly eating plan? Your kidney-friendly eating plan may change over time but will always give you the right amount of key nutrients. Protein: One of the nutrients that gives you energy. Your body needs protein to grow, build muscles, heal and stay healthy. Fat: Fat is another one of the nutrients that gives you energy. Your body needs fat to carry out many jobs, such as using vitamins from your food and keep your body at the right temperature. Carbohydrates or carbs: Your bodys main source of energy. Your body can more easily convert carbs into energy than protein and fat. Work with your dietitian to follow the steps below for a kidney-friendly eating plan. Eat the right amount and the right types of protein Having too little protein can cause your skin, hair and nails to be weak. But having too much protein can make your kidneys work harder and cause more damage. This happens because when your body uses protein, it makes waste products that your kidneys must filter. To stay healthy and help you feel your best, you may need to adjust how much protein you eat. The amount of protein you should eat depends on your body size, activity level and health. Your doctor and dietitian may have you limit protein or change the type of protein you eat. For example, you may need to eat more lean proteins, which are foods that are high in protein and low in fat, such as whole eggs and skinless chicken and turkey. Ask your doctor and dietitian how much protein you should eat and what the best types of protein are for you. Choose the right types of fat Fat gives you energy and helps you use some of the vitamins in your food. You need some fat in your eating plan to stay healthy. Too much fat can lead to weight gain and heart disease.
----------------------------------------------------------------------


======================================================================
CHUNK 53 of 647
======================================================================
ID: 1_15
Content Type: reference
Words: 488
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Choose the right types of fat Fat gives you energy and helps you use some of the vitamins in your food. You need some fat in your eating plan to stay healthy. Too much fat can lead to weight gain and heart disease. Limit fat in your meal plan, and choose healthier fats when you can, such as olive oil. Choosing the right types of fat is also part of a heart-healthy eating plan called DASH. Choose whole grain carbohydrates Eating too many carbs can lead to weight gain. When you have kidney disease, it is best to choose whole grains and healthy carbs such as fruits and vegetables. Unhealthy carbs include sugar, honey, hard candies, soft drinks and other sugary drinks. If you have diabetes, you may also need to carefully track how many carbs you take in. Your dietitian can help you learn more about the carbs in your eating plan and how they affect your blood sugar. The ketogenic diet or keto diet is a type of low-carb diet that focuses on eating very low carbs, high fats and moderate protein amounts, so your body uses stored fat for energy instead of carbs. This diet may not be a healthy option for you because it limits your options, and you may miss out on some key nutrients. If you have questions about a specific diet, ask your dietitian. Eat the right amount of calories Calories are like fuel and give your body energy. Calories come from the protein, fat and carbs in your food and fluid plan. How many calories you need depends on your age, gender, body size and activity level. You may need to adjust how many calories you eat to stay at a healthy weight. Some people will need to limit the calories they eat. Others may need to have more calories. Your doctor and dietitian can help you figure out how many calories you should have each day. Choose and prepare foods with less sodium (salt) Sodium (salt) is a mineral found in almost all foods. It has many important roles in the way your body works. The amount of sodium found naturally in foods is enough to keep a healthy level in your body. But eating packaged foods and adding salt to foods can lead to eating too much sodium. Too much sodium can make you thirsty and make your body hold onto water, which can lead to swelling and raise your blood pressure. This can damage your kidneys more and make your heart work harder. One of the best things you can do is to limit how much sodium you eat. Here are some tips to limit sodium: Use herbs and spices for flavor while cooking. Do not add salt to your food when cooking or eating. Choose fresh or frozen vegetables instead of canned vegetables. If you use canned vegetables, drain and rinse them to remove extra salt.
----------------------------------------------------------------------


======================================================================
CHUNK 54 of 647
======================================================================
ID: 1_16
Content Type: recommendation
Words: 489
Section: Here are some tips to limit sodium:
Medical Entities: CKD,dialysis
Source: 1.txt

----------------------------------------------------------------------
Here are some tips to limit sodium: Use herbs and spices for flavor while cooking. Do not add salt to your food when cooking or eating. Choose fresh or frozen vegetables instead of canned vegetables. If you use canned vegetables, drain and rinse them to remove extra salt. When eating out, ask your server to have the chef not add salt to your dish. Work with your dietitian to find foods that are low in sodium. Healthy eating can look different depending on your stage of kidney disease. Learn more about healthy eating for your specific stage: Stages 1 and 2 Stages 3, 4 and 5 (not on dialysis) Kidney failure (on dialysis) Kidney transplant Find delicious kidney-friendly recipes Kidney Kitchen is home to hundreds of kidney-friendly recipes that cover a wide variety of tastes, cuisines and dietary preferen Start cooking How to control portion sizes? Good portion control or watching how much you eat is important in a kidney-friendly eating plan, because you may need to limit how much of certain things you eat and drink. To help control your portion sizes: Read the nutrition label to learn the serving size and how much of each nutrient is in one serving. Many packages have more than one serving. For example, a 20-ounce bottle of soda is two-and-a-half servings. For foods that do not have nutrition labels, such as fruits and vegetables, ask your dietitian for a list of nutrition facts to measure the right portions. Eat slowly and stop eating when you are full. It takes about 20 minutes for your stomach to tell your brain that you are full. If you eat too quickly, you may eat more than you need. Avoid eating while doing something else, such as watching TV or driving. When you are distracted, you may not realize how much you have eaten. Will my kidney-friendly eating plan change based on my stage of CKD? Yes, how strict your eating plan should be depends on your stage of kidney disease. When you are in the early stages of CKD (Stages 1 and 2), you will have less limits on what you can eat. As your kidney disease gets worse (Stages 3, 4 and 5), your doctor may recommend that you limit: Potassium: A mineral found in foods that your body needs to make your muscles work. Phosphorus: A mineral found in foods that works with calcium and vitamin D to keep your bones healthy. Fluids: Anything that turns to liquid at room temperature, not just water. Choose foods with the right amount of potassium When your kidneys are not working well, your potassium level may be too high or too low. Having too much or too little potassium can cause muscle cramps, problems with the way your heart beats and muscle weakness. If you have kidney disease, your doctor or dietitian may tell you to lower the amount of potassium in your eating plan.
----------------------------------------------------------------------


======================================================================
CHUNK 55 of 647
======================================================================
ID: 1_17
Content Type: reference
Words: 498
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Having too much or too little potassium can cause muscle cramps, problems with the way your heart beats and muscle weakness. If you have kidney disease, your doctor or dietitian may tell you to lower the amount of potassium in your eating plan. Use the lists below to learn about foods that are low or high in potassium. Foods low in potassium Apples, cranberries, grapes, pineapples and strawberries Cauliflower, onions, peppers, radishes, summer squash and lettuce Pita, tortillas and white breads Beef and chicken White rice Foods high in potassium Avocados, bananas, melons, oranges, prunes and raisins Artichokes, winter squash, plantains, spinach, potatoes and tomatoes Bran products and granola Beans (baked, black, pinto, etc. ) Brown or wild rice Limit phosphorus Healthy kidneys keep the right amount of phosphorus in your body. When your kidneys are not working well, phosphorus can build up in your blood. Too much phosphorus in your blood can lead to weak bones that break easily. Ask your doctor and dietitian if you need to limit phosphorus. They may also prescribe a medicine called a phosphate binder, which prevents your body from absorbing phosphorus from foods you eat. Use the lists below to learn how to replace high phosphorus foods with low phosphorus alternatives. Eat these low phosphorus foods Italian, French or sourdough bread Corn or rice cereals and cream of wheat Unsalted popcorn Some light-colored sodas and lemonade Avoid these high phosphorus foods Whole-grain bread Bran cereals and oatmeal Nuts and sunflower seeds Dark-colored colas Limit fluid When you have kidney disease, you may need to limit water and fluids. This is because damaged kidneys do not get rid of extra fluid as well as they should. Too much fluid in your body can cause high blood pressure, swelling and heart failure. To limit fluids, you will need to cut back on how much you drink and limit eating some foods that contain a lot of water, such as soups, ice cream, gelatin and many fruits and vegetables. If you need to limit fluids, here are some tips: Measure your fluids Drink from small cups to help you keep track of how much you had to drink Limit sodium (salt) to help you feel less thirsty When you feel thirsty: Chew gum Rinse your mouth with water and spit it out Suck on a piece of ice, mints or sugar-free hard candy Will my eating plan be different if I have diabetes? If you have diabetes, you need to control your blood sugar to prevent more damage to your kidneys. Your doctor and dietitian can help you create an eating plan that helps you control your blood sugar, while also limiting sodium, phosphorus, potassium and fluids. You can also ask your doctor to refer you to a diabetes educator who can work with you to better manage your diabetes. Will I get enough vitamins on a kidney-friendly eating plan? Your doctor and dietitian can help you find vitamins that are right for you.
----------------------------------------------------------------------


======================================================================
CHUNK 56 of 647
======================================================================
ID: 1_18
Content Type: reference
Words: 499
Medical Entities: CKD,diabetes
Source: 1.txt

----------------------------------------------------------------------
You can also ask your doctor to refer you to a diabetes educator who can work with you to better manage your diabetes. Will I get enough vitamins on a kidney-friendly eating plan? Your doctor and dietitian can help you find vitamins that are right for you. To help you get the right amounts of vitamins and minerals, your dietitian may suggest you take: A special supplement made for people with kidney disease. A special kind of vitamin D, folic acid or iron pill, to help prevent some common side effects of kidney disease, such as bone disease and anemia. Regular multi-vitamins may not be healthy for you if you have kidney disease. Tell your doctor and dietitian about any vitamins, supplements or over-the-counter medicines you are taking. Some can cause more damage to your kidneys or cause other health problems. Healthy eating for people with chronic kidney disease (CKD) Stages 1 to 3 What is CKD Chronic Kidney disease is a long term condition where the kidneys do not work well. It does not usually cause symptoms until later stages. CKD is normally found at earlier stages by blood and urine tests. Your GP can tell you what stage of kidney disease you have. This information is for people who have early-stage CKD. If you have late CKD you will see a specialist kidney (nephrology) team with a kidney Dietitian. More information about CKD can be found here: How does a healthy diet help my kidneys? Healthy eating is good for everyone. Some aspects are especially important for people with early-stage CKD. One of our kidneys jobs is to get rid of the waste products from food breakdown. When you have CKD, your kidneys are not able to do this well. A healthy diet makes less waste and puts less stress on the kidneys. Healthy eating can help manage diabetes, obesity, and high blood pressure. Controlling these conditions can help protect the kidneys too. The information in this leaflet is suitable for you if you are living with diabetes, obesity or high blood pressure. Read more to find out how to eat well for your kidneys and overall health. What is a healthy diet? A healthy diet has a good balance of different foods and nutrients each day to keep you healthy and well. Healthy eating is not about restricting your intake. It is about choosing a variety of different foods each day; in the amounts you need to keep you well. The Eatwell Guide helps to explain what a healthy diet looks like. You can find more information about the Eatwell Guide here: Eat more of these: Fruit and vegetables are a key part of healthy eating. They provide vitamins, minerals and fibre to keep you and your kidneys well. Aim to enjoy 5 portions of fruit and vegetables a day, or more if you can. Choose a variety to ensure you get different vitamins. This can be from fresh, frozen, dried or canned fruit and vegetables.
----------------------------------------------------------------------


======================================================================
CHUNK 57 of 647
======================================================================
ID: 1_19
Content Type: reference
Words: 499
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
They provide vitamins, minerals and fibre to keep you and your kidneys well. Aim to enjoy 5 portions of fruit and vegetables a day, or more if you can. Choose a variety to ensure you get different vitamins. This can be from fresh, frozen, dried or canned fruit and vegetables. One portion is approximately one handful Starchy foods like bread, potatoes, pasta, rice and other grains are part of a healthy diet. These foods are a key source of energy for the body. If you can, choose wholegrain products like wholemeal bread, brown rice, wholewheat pasta, oats and potatoes with skins on to ensure you get more fibre, and vitamins. Beans, lentils, chickpeas and other pulses provide protein. They are also high in fibre and low in less healthy fats. Regularly replacing some of your meat with these pulses may help to slow the loss of kidney function. Eat some of these: Animal protein foods like fish, eggs, meat, milk, yoghurt and cheese provide a range of vitamins and minerals. They can be part of a healthy diet when eaten in moderate amounts. However, it is best to eat more plant sources of protein such as lentils, pulses, legumes, tofu or nuts and less meat, especially red meat. Oily fish like salmon, mackerel or sardines provide a source of omega-3 (a healthy fat). Enjoy one portion of fish per week. Or you can obtain Omega-3 from rapeseed oil, walnuts or seeds (hemp, chia or flax/linseeds). Dairy foods provide protein, calcium, B vitamins and iodine. It is best to go for lower fat and lower sugar versions (for example natural yoghurt) most of the time. If you use a plant-based-dairy alternative, choose one that is fortified with calcium. It is best to limit plant milks and dairy alternatives (such as yoghurt) to 300 ml (half a pint) a day if they have phosphate additives listed in the ingredients. Eat small amounts of these: We need fats and oils in small amounts. It is best to choose fats like olive oil, nut, seed or healthy vegetable oils, such as rape seed oil. Limit less healthy fats such as coconut and palm oil, butter, lard and ghee. If you can, it is best to keep processed foods to a minimum. Foods that are pre-packed, or have added fat, salt, sugar and / or additives are processed. Ready meals are processed. This also includes meats or fish that are salted, cured, smoked, coated, breaded or battered. Eat less of these: Food or drinks that are high in less healthy fats, salt and sugar are best eaten only occasionally. These items include chocolate, cakes, biscuits, pastry, crisps, fried chips and sugary drinks. Try to keep portion sizes small. Note: it is advisable to avoid star fruit. Star fruit has a toxin that can build-up in the body and become harmful to those with kidney disease. Reducing salt: Reducing salt is helpful for everyone with CKD. Most of us eat more salt than we should.
----------------------------------------------------------------------


======================================================================
CHUNK 58 of 647
======================================================================
ID: 1_20
Content Type: recommendation
Words: 491
Section: Note:
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Note: it is advisable to avoid star fruit. Star fruit has a toxin that can build-up in the body and become harmful to those with kidney disease. Reducing salt: Reducing salt is helpful for everyone with CKD. Most of us eat more salt than we should. Salt is added to many foods before we buy them as part of the food manufacturing process, Eating salt and salty foods increases your blood pressure. Limiting the amount of salty foods, you can eat can help keep blood pressure under control and reduce further damage to kidneys. Salt can also make you thirsty and makes fluid retention worse. It is recommended to have less than 5g (one teaspoon) salt per day. Most of this salt is likely to be naturally occurring in the foods you eat. Your taste buds will adapt to less salt, but this may take about 3 weeks. Tips to reduce salt include: If you can, limit processed or convenience foods and takeaways. If you do eat these, check labels and choose versions that are lower in salt. Cook meals from scratch wherever possible Try not to add salt in cooking or at the table. This includes all types of salt, e. g. Lo Salt or other lower sodium salts, rock salt, sea salt, Himalayan pink salt, garlic and kosher salts etc. Salt substitutes such as Lo-salt or other low sodium salts contain a lot of potassium and are not always suitable for people with kidney disease. Use reduced salt stock cubes in your cooking, rather than standard cubes. These are available in most supermarkets. Flavour food using a variety of fresh or dried herbs, spices, garlic, ginger, onions, vinegars, lemon or lime juice. Be careful with seasoning mixes as these can contain a lot of salt. Understanding food labels: Reading and understanding food labels can look complicated and time consuming, but gets easier with practice. If you shop online, this information is available on the supermarket websites. Having less salt: Some foods may be labelled reduced salt but could still be quite high in salt. Remember to look at the Traffic Light Symbol on the front of the packaging. It will look something like this. Choose foods that are green or amber for salt. Have less of these that are coloured red. If there is no traffic light symbol, check the nutritional information on the back of food packaging. This may tell you the amount of salt per 100 g of the product, or per portion. If the label provides the salt per 100 g, compare with the table below Per 100g Low Medium High Salt 0-0. 3g 0. 3-1. 5g More than 1. 5g If the food label only says how much is in a portion, consider how much of that food you are planning to eat. The manufacturers portion size might be different from yours. Check the portion size on the label and compare it to your own.
----------------------------------------------------------------------


======================================================================
CHUNK 59 of 647
======================================================================
ID: 1_21
Content Type: general
Words: 498
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
5g More than 1. 5g If the food label only says how much is in a portion, consider how much of that food you are planning to eat. The manufacturers portion size might be different from yours. Check the portion size on the label and compare it to your own. Picking a larger or smaller portion can have a big impact on the amount of salt you consume. Phosphate: Avoiding phosphate additives in your food can be helpful if you have CKD. Too much phosphate from additives can be harmful to your heart, kidneys, and bones. Many processed foods contain phosphate additives. The good news is you can usually find a similar product without these additives. You can check in the ingredients list on the label. Most people find the easiest way is to look for phosp as part of a word on the list. However, sometimes a label only shows E numbers. Here is a list of E numbers to watch out for. Some people find it useful to carry a credit card-sized list while shopping, or you can save the numbers on your phone. Cooking from scratch more often will help to reduce the amount of additives you eat. Note: You can enjoy foods that naturally contain phosphates unless your kidney care team tells you otherwise. Our bodies dont absorb natural phosphates as easily as phosphate additives. If you need guidance on your diet, a kidney Dietitian will assist you in choosing the right foods, including those without additives. E338 Phosphoric acid E339 Sodium phosphates E340 Potassium phosphates E341 Calcium phosphates E343 Magnesium phosphates E450 Diphosphates E451 Triphosphates E452 Polyphosphates Special Diets Many people with CKD wont need to follow special diets. However, those with more advanced CKD may be advised to make changes to their potassium, phosphates, protein, or fluid intake. The advice you receive about limiting these nutrients will depend on your CKD stage, blood results, medications, and how you like to eat. If youve been told to make dietary changes, a kidney Dietitian can help you create a healthy, balanced and enjoyable diet while taking your condition in to account. You should not restrict your diet unless you have been advised by your Kidney Doctor or Dietitian to do so. Poor Appetite If youre in the advanced stages of CKD and find yourself often not feeling hungry, its a good idea to speak with to a kidney Dietitian. They can provide assistance for issues like not wanting to eat much, changes in taste, feeling sick, vomiting or losing weight without meaning to. Vitamin and mineral supplements If you are eating well and enjoying a varied diet, there is no need to take a vitamin and mineral supplement. If you do want to take a supplement or herbal remedy, discuss this with your kidney Doctor first. They can help to ensure it is safe to take. Other lifestyle guidance Alcohol General guidance is to try not to exceed 14 units of alcohol each week.
----------------------------------------------------------------------


======================================================================
CHUNK 60 of 647
======================================================================
ID: 1_22
Content Type: reference
Words: 484
Medical Entities: CKD,diabetes
Source: 1.txt

----------------------------------------------------------------------
If you do want to take a supplement or herbal remedy, discuss this with your kidney Doctor first. They can help to ensure it is safe to take. Other lifestyle guidance Alcohol General guidance is to try not to exceed 14 units of alcohol each week. If you do drink, spread your drinking evenly over three or more days and have several alcohol-free days per week (always check alcohol consumption is safe with your medication). Exercise Staying active is key to staying healthy. Exercise not only strengthens your bones and muscles but also helps you manage your weight, blood pressure, and diabetes. Aim to do 150 minutes of moderate intensity aerobic activity each week. For example, you can take a 30-minute walk five times a week. However, any exercise is better than none at all. Start slowly and gradually increase your activity based on your current fitness. Smoking If you currently smoke, then it is advisable to stop. There are special services to help you stop smoking. You can find out more about this at your GP practice. Summary Enjoy a varied healthy diet, rich in vegetables, fruits, wholegrains and pulses each day. Eat regularly and try not to miss meals. Eat less salt, foods that are high in salt and processed foods. Check food labels to cut down your intake of phosphate additives. Good control of blood pressure, diabetes and keeping to a wealthy weight are helpful to slow the progression of your CKD down. Discuss any over the counter supplements with your kidney Doctor before taking them. Only follow a special diet for your kidneys if you have been advised to by your kidney Doctor or Dietitian. Superfoods En Espaol Back to Top Prevention, daily life, and wellbeing Diet and nutrition Food and cooking Food and drink Last Updated: December 06, 2023 Medically reviewed by NKF Patient Education Team Explore kidney-friendly superfoods: discover new recipes, enjoy healthy twists on favorites, and make every meal nutritious for your kidney health. Table of Contents Fruits Vegetables Nuts/Seeds Animal Proteins Plant-based Proteins Oils/Fats Seasonings You may have heard that superfoods are super important for people with kidney disease. While the idea of completely managing kidney disease by eating certain foods is appealing the reality is not quite that simple. Many people think superfoods are foods that have special, almost magical, qualities. While some foods are certainly more nutritious than others, no food is the magic answer for good health. Eating a well-balanced diet of nutritious foods low-sodium foods packed with vitamins and the right minerals is one of the best things you can do to help stop or slow the progression of kidney disease. The nutritious foods we are spotlighting in this section were selected because they are super healthy choices, especially for people living with kidney disease. We are eager to introduce you to some foods and recipes that may be new to you.
----------------------------------------------------------------------


======================================================================
CHUNK 61 of 647
======================================================================
ID: 1_26
Content Type: reference
Words: 500
Medical Entities: CKD,dialysis,diabetes
Source: 1.txt

----------------------------------------------------------------------
Learn more about healthy oils and fats. Seasonings Spices Spices Spices enhance the flavor and smell of food without adding salt. They are rich in vitamins, minerals, and antioxidants. Learn more about spices. Herbs Herbs Herbs give flavor to food without the addition of salt. Nutrition and Kidney Disease, Stages 1-5 (Not on Dialysis) Back to Top Diseases and conditions Diet and nutrition Kidney diseases and conditions Early stage kidney disease Last Updated: March 18, 2024 Medically reviewed by NKF Patient Education Team Good nutrition helps people with kidney disease stay healthy. If your kidneys are not working so well, some changes in the diet help you feel better. Table of Contents Importance of Good Nutrition for People with Chronic Kidney Disease The Basics of Good Nutrition Changes to My Diet Registered dietitians and kidney disease Nutrients to manage in chronic kidney disease Fluids Calories Vitamins and Minerals Questions for your healthcare team Resources Importance of Good Nutrition for People with Chronic Kidney Disease Making healthy food choices is important to us all, and especially if you have chronic kidney disease (CKD). Good nutrition helps: Slow down the progression of kidney disease Provide energy to do your daily tasks Prevent infection Maintain muscle mass and strength Maintain a healthy weight The Basics of Good Nutrition A well-balanced diet gives you the right amounts of protein, calories, vitamins, and minerals each day. Eating a healthy diet, staying physically active, and taking all your medicines as prescribed are all important parts to keeping you healthy and feeling well. There is not only one correct eating plan for everyone with kidney disease. What you can or cannot eat may change over time, depending on your kidney function and other factors. Find more information and about kidney disease and nutrition: NKF Nutrition Hub Changes to My Diet Your kidneys help keep the right balance of nutrients and minerals in your body. But if you have kidney disease, your kidneys may not do this job very well. You may need to make some changes to your diet. There is not only one correct eating plan for everyone with kidney disease. What you can or cannot eat may change over time, depending on your kidney function and other factors. If you are following a certain eating plan for diabetes or heart disease, you will continue to do so. What is good for your diabetes and heart is good for your kidney. A kidney dietitian will help you combine these eating plans. Registered dietitians and kidney disease Ask your doctor about meeting with a Registered Dietitian with special training in kidney disease. A dietitian can: Teach you to make the best food choices based on your lifestyle and lab tests Help to make changes in your diet to help you better control diabetes and high blood pressure Help you to keep your kidney disease from getting worse Meeting with a dietitian is a service covered by Medicare and may also be covered by other types of insurance.
----------------------------------------------------------------------


======================================================================
CHUNK 62 of 647
======================================================================
ID: 1_27
Content Type: general
Words: 490
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
You may need to call your insurance provider to see if your plan covers meeting with a dietitian. Are you looking for nutrition guidance? Contact a CKD dietitian in your area. CKD Kidney Dietitian Directory Nutrients to manage in chronic kidney disease People with CKD may need to control the amount or type of one or more nutrients: Sodium Potassium Phosphorus Calcium Protein Eating the right amount or type of one or more of these nutrients may help control the buildup of waste and fluid in your blood. This means your kidneys do not have to work as hard to remove the extra waste and fluid. If your kidney disease gets worse, you may need to limit other nutrients as well. Your dietitian or healthcare provider will tell you if you need to do this based on your blood test results. Sodium and your CKD Diet: How to Spice Up Your Cooking Healthy kidneys control how much sodium is in your body. If your kidneys do not work well, too much sodium can cause fluid buildup, swelling, higher blood pressure, and strain on your heart. Your dietitian or healthcare provider can tell you the right amount of sodium you should have each day. Potassium Potassium is important for muscle function, including the heart muscle. Too much or too little potassium in the blood can be very dangerous. The amount of potassium you need is based on how well your kidneys are working and your medications. Your dietitian or healthcare provider can tell you about foods with potassium and the right amount for you to eat each day. Potassium from animal foods is absorbed at a higher rate than potassium from plants. Elevated blood sugars can also increase potassium levels. Some high-potassium foods include milk, meat, bananas, oranges and orange juice, cantaloupe, dried fruits, winter squash and salt substitutes. Phosphorus and Your Diet As kidney function gets lower, extra phosphorus can start building up in the blood. High phosphorus levels can cause bones to get weaker. Your dietitian or healthcare provider can tell you if you need to limit goods that are high in phosphorus. High phosphorus foods include dairy products, organ meats, colas, deli meats, and processed foods with phosphate additives. Avoid processed foods that have additives with PHOS like disodium PHOSphate. You can find these additives in the ingredients list on food labels. Calcium Foods that are good sources of calcium are often high in phosphorus. Your dietitian or healthcare provider will tell you if you need to limit calcium. Before taking any over-the-counter vitamin D or calcium supplements, talk to your healthcare provider. Protein Your body needs protein to help build muscle, repair tissue, and fight infection. Plant-based protein like beans and nuts are easier on the kidneys than animal proteins like meat and dairy products. This is because plant proteins produce less acid in the body than meat proteins. More acid in body can damage the kidneys.
----------------------------------------------------------------------


======================================================================
CHUNK 63 of 647
======================================================================
ID: 1_28
Content Type: general
Words: 488
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Plant-based protein like beans and nuts are easier on the kidneys than animal proteins like meat and dairy products. This is because plant proteins produce less acid in the body than meat proteins. More acid in body can damage the kidneys. Having very large amounts of protein, especially in the form of unnecessary supplements, can be stressful on the kidneys. But if protein intake is too low, you can lose muscle mass, become weak, and increase the bodys acid load, so it is important to eat the right amount each day. The amount of protein you need is based on: Your weight Your age growing children and adolescents, and older people, need more protein The amount of protein in your urine, and depending on your type of kidney disease Your dietitian or healthcare provider can tell you how much protein you should eat. Fluids The Dos and Donts of Fluid Management in Chronic Kidney Disease Most people in the early stages of kidney disease do not need to limit how much fluid they drink. If you do not know your stage of kidney disease, ask your healthcare provider. If your kidney disease worsens, your dietitian or healthcare provider can let you know if you need to limit fluids and how much to drink each day. Fluids may need to be limited based on how much urine you make each day, and if fluid build-up in your body is causing swelling or stress on your heart or lungs. Fluids include any food that is liquid at room temperature such as beverages, soups, gelatin, frozen desserts, and ice. Calories Every person is different in terms of the calories they need each day. Calories are like fuel. If you dont eat enough, your body will take protein from the muscles for energy. Its important to make sure you get the right number of calories. If you dont, you may get weak and damage your kidneys. Eating the right number of calories will: Help you stay at a healthy weight Give you the energy to do your daily tasks Help your body use the protein in food to build muscle and tissues Too many calories can cause extra weight gain, which can burden the kidneys. If you are overweight, some weight loss may be helpful. If weight loss is desired or you have diabetes, you should meet with a dietitian to set up a plan based on your kidney blood tests, current food choices, and daily activities. Vitamins and Minerals Vitamins and Minerals in Chronic Kidney Disease Most people get enough vitamins and minerals to stay healthy by eating a variety of foods each day. But kidney patients may need to limit some of these foods. If so, you may need to take special vitamin or mineral supplements, but only if a dietitian or healthcare provider tells you to. Some vitamins or mineral supplements may be harmful to people with kidney disease.
----------------------------------------------------------------------


======================================================================
CHUNK 64 of 647
======================================================================
ID: 1_29
Content Type: general
Words: 495
Medical Entities: CKD,hypertension,diabetes
Source: 1.txt

----------------------------------------------------------------------
But kidney patients may need to limit some of these foods. If so, you may need to take special vitamin or mineral supplements, but only if a dietitian or healthcare provider tells you to. Some vitamins or mineral supplements may be harmful to people with kidney disease. You should check with your healthcare provider before taking any medications you can buy without a prescription. Some supplements may be harmful to people with kidney disease. Over the counter vitamin and mineral supplements may contain too much phosphorous and potassium. You should also avoid taking herbal supplements. Good Fruits for Kidney Disease Managing Your CKD Diet Most fruits make for great additions to your kidney-friendly lifestyle because they are delicious, rich in fiber, low in sodium, and contain essential nutrients. The specific dietary needs for someone with chronic kidney disease (CKD) depend on multiple factors, so its important to have an idea of what fruits are good for people with kidney disease. As always, check with your doctor or dietitian about your specific needs. The Benefits of Fruits in a Kidney Disease Diet Fruits contain fiber, which has many health benefits, including improved gastrointestinal health. Additionally, people who consume high amounts of fiber tend to be at a lower risk for stroke, hypertension, coronary heart disease, obesity, and certain gastrointestinal diseases. 1 8 Great Fruits for Kidney Disease Diets Every fruit has a special set of qualitiesthey look and taste unique and offer different nutritional benefits. Understanding what each type of fruit provides will help you plan your kidney-friendly meals. Note that portion size is key for a kidney-friendly diet and, in general, a serving of fruit is equal to about one-half cup of raw fruit. Here are 8 tasty fruits to consider working into your CKD diet: Berries (all types): Low in potassium and high in antioxidants, fiber, and vitamin C, berries are low in sugar when they are consumed in modest portions, which can be beneficial for people with diabetes. Suggested recipe: Creamy Blueberry-Pecan Overnight Oatmeal Lemons and limes: Low in potassium and high in vitamin C, lemons and limes have a lower sugar content when consumed in a modest amount. They can be used in cooking instead of salt to bring out the natural flavors of a dish. Suggested recipe: Lemon Orzo Spring Salad Pineapples: Low in potassium, pineapples contain bromelain, a plant enzyme that has anti-inflammatory properties and may reduce swelling and pain in your joints. Suggested recipe: Vegan Smoothie Bowl Apples: Low in potassium and rich in fiber and vitamin C, apples also contain plant polyphenols, which are disease-fighting compounds found in plants. Suggested recipe: Apple and Cheddar with Jalapeo Slices Cherries: High in fiber and vitamin C and rich in antioxidants and anti-inflammatory compounds, cherries may also lessen the symptoms of gout, which can be a concern for people with CKD. 2 Grapes: High in vitamin K, grapes are also a good source of B vitamins like thiamine, riboflavin, and B6.
----------------------------------------------------------------------


======================================================================
CHUNK 65 of 647
======================================================================
ID: 1_30
Content Type: general
Words: 496
Medical Entities: CKD,dialysis
Source: 1.txt

----------------------------------------------------------------------
2 Grapes: High in vitamin K, grapes are also a good source of B vitamins like thiamine, riboflavin, and B6. B vitamins can increase your energy. Watermelon: While most melons are high in potassium, watermelon is a low-potassium fruit. It is also high in vitamins A and C, magnesium, and lycopene, a powerful antioxidant. Watermelon can contribute a significant amount of natural sugar and fluid to your diet, so stick to a 1/2 cup serving if you are watching your fluid. Suggested recipe: Watermelon, Cucumber and Feta Salad Avocados: Although high in fiber, magnesium, and healthy monounsaturated fatswhich lower LDL cholesterolavocados should only be eaten in small portions because theyre high in potassium. Suggested Recipe: Egg Salad Avocado Toast The one fruit you should avoid is star fruitit contains a neurotoxin that can cause neurological problems and toxicity for people on dialysis. 3 Managing Potassium in Fruit Fruits sometimes get a bad rap because of their potassium content, which some people living with CKD have to limit. While some fruits do have high potassium, you can still enjoy many of them in small portions so you can benefit from their nutrients while keeping your potassium level under control. Your own potassium level will determine if you need to be more careful when selecting the best fruits for you. Incorporate Tasty Fruits Regularly into Your Diet Fruits make for healthy, tasty snacks and side dishes; they are an excellent source of fiber, vitamins, antioxidants, and nutrients, and should be included in your kidney-friendly meal plan. In addition to fruits, there are a number of great food choices that will help you feel your best. As with most foods, remain aware of your portions. Knowing how to balance your fruit intake will further allow you to experience their many health benefits. Talk to your renal dietitian or nephrologist for guidance on the right balance of fruit for your current diagnosis and treatment modality. Health A-Z Diseases Conditions Procedures Tests Drugs Medications RX Drugs Medications Health Living Diet Weight Management Exercise Fitness Nutrition and Healthy Living Prevention Wellness Media Slideshows Quizzes Images Privacy Other Trust Info Privacy Policy About Us Contact Us Terms of Use Advertising Policy Subscribe health centersdigestion center What Fruit Is Good for Kidneys? Medical Author: Karthik Kumar, MBBS Medical Reviewer: Shaziya Allarakha, MD Disease and Condition: Kidney Failure 17 Kidney Friendly FruitsDaily IntakeFruits to AvoidHigh Potassium Foods Which fruit is best for kidneys? fruit for kidney health A variety of fruits can be beneficial for kidney health, such as the following. Eating a diet rich in antioxidants, vitamins, and other nutrients can help promote kidney health. If you have kidney disease, a variety of fruits can be beneficial to include in your diet as long as they dont contain excessive amounts of potassium and phosphorus. 17 Fruits for kidney health benefits Strawberries Contain two types of phenols, anthocyanins, and ellagitannins, which improve kidney function. Rich in antioxidants, which help protect the body from oxidative damage.
----------------------------------------------------------------------


======================================================================
CHUNK 66 of 647
======================================================================
ID: 1_31
Content Type: recommendation
Words: 487
Medical Entities: dialysis
Source: 1.txt

----------------------------------------------------------------------
17 Fruits for kidney health benefits Strawberries Contain two types of phenols, anthocyanins, and ellagitannins, which improve kidney function. Rich in antioxidants, which help protect the body from oxidative damage. Great source of vitamin C, manganese, and fiber. Contain anticancer and anti-inflammatory properties that promote overall good health. Cranberries Loaded with anti-inflammatory and antibacterial properties, which are beneficial for people suffering from kidney ailments or UTIs. Blueberries 1 cup of blueberries contains 114 grams of potassium and 18 milligrams of phosphorus. High in antioxidants and phytonutrients called anthocyanidins, which reduce inflammation and promote renal and kidney health. Good source of vitamin C and manganese, which are good for bones and skin and help reduce signs of aging. Raspberries Enriched with phytonutrients called ellagic acid, which help neutralize free radicals in the body and prevent cell damage. Contain flavonoids, which are good for improving kidney function and can reduce the growth of cancer cells. Excellent source of manganese, vitamin B and C, fiber, and folate. Apples 1 medium-sized apple has 195 milligrams of potassium and 20 milligrams of phosphorus. May help lower cholesterol and blood sugar levels and ease constipation. Anti-inflammatory properties and high fiber content, help improve kidney function. Grapes 1 cup of grapes contains 288 milligrams of potassium and 30 milligrams of phosphorus Good source of vitamins C and K (low levels of these vitamins are linked to kidney disease). High in fiber and contains small amounts of minerals like copper, manganese, and magnesium. Pineapples Low-potassium food option that helps lower blood pressure, which is a common complication of severe kidney disease. Contains bromelain, a digestive enzyme that helps dissolve kidney stones in the body. High in fiber and supports heart health (heart complications are common in people undergoing dialysis). Good source of vitamin C boost, which helps boost the immune system. Citrus fruits The more vitamin C in your diet, the better for your kidneys. Oranges, lemons, and other citrus fruits contain vitamin C in abundance. Consuming dilute lemon juice daily may help decrease the risk of kidney stone formation. Other fruits good for kidney health Other fruits that may be recommended for promoting kidney health include: Pears Peaches Clementines Nectarines Mandarins Plums Satsumas Watermelon Cherries How much fruit should you include in your diet? Since appropriate portion sizes vary from person to person, talk to your doctor or dietitian for recommendations on how much fruit to include in your diet to avoid consuming excessive amounts of these minerals. Which fruits are bad for the kidneys? When it comes to kidney health, fruits are on both sides of the fence. A person with renal illness should avoid high-potassium fruits. Bananas Bananas are high in potassium, with about 422 mg per medium-sized banana. As a result, if this fruit is a daily mainstay for people with chronic renal disease, maintaining a daily potassium intake of less than 2, 000 to 2, 500 mg may be difficult.
----------------------------------------------------------------------


======================================================================
CHUNK 67 of 647
======================================================================
ID: 1_32
Content Type: recommendation
Words: 488
Medical Entities: diabetes
Source: 1.txt

----------------------------------------------------------------------
Bananas Bananas are high in potassium, with about 422 mg per medium-sized banana. As a result, if this fruit is a daily mainstay for people with chronic renal disease, maintaining a daily potassium intake of less than 2, 000 to 2, 500 mg may be difficult. Oranges Although oranges and orange juice are loaded with antioxidants, they are high in potassium. Oranges and orange juice should be avoided or limited on a renal diet due to their high potassium level although they are best recognized for their vitamin C content. Grapes, apples, and cranberries are all suitable replacements for oranges. Dried fruits Dried fruits are not recommended for people with renal disease or diabetes because they contain a lot of sugar and minerals such as potassium. In reality, half a cup (65 grams) of dried apricots contains about 755 milligrams of potassium. Dried fruits are strong in fast-digesting sugar, which is undesirable if you have diabetes. Avocados Avocados are high in potassium. One avocado weighing about 200 grams contains 975 mg of potassium, almost half of the daily recommended amount for people with kidney disease. Kiwi Because kiwifruit contains a lot of oxalates, people who have kidney stones should avoid eating it. Furthermore, kiwifruits are high in potassium, which may be problematic for people with renal problems. Other fruits to avoid or limit for people with kidney disease Cantaloupe Honeydew Mangos Papaya Prune juice SLIDESHOW Kidney Stones: Symptoms, Causes, and Treatment See Slideshow Why should you avoid high potassium food with kidney disease? Potassium levels are not well-regulated in kidney disease. Both the disease and some medications used to treat kidney disease may cause potassium buildup in the body. Hence, potassium intake should be reduced in a kidney disease diet. Many fruits, including melons, bananas, oranges, prunes, and tomatoes, are high in potassium. Fruit punches, canned and bottled fruit juices, and iced tea are harmful in people with kidney disease. Apples, grapes, and strawberries are low-potassium foods that are considered healthy options. High vs low-potassium foods list Low-potassium foods Apples Berries Fruit cocktail Grapes Lemon Peaches Canned pears Pineapple Plums Watermelon High-potassium fruits Avocados Bananas Cantaloupe Dried fruits Honeydew Kiwi Mangos Oranges and orange juice Papaya Prune juice Further tips Instead of bananas, oranges or kiwis, choose apples, berries, or grapes. Instead of cantaloupe or honeydew, choose watermelon. Instead of nectarines, mangos, or papaya, eat peaches, plums, or pineapple. Instead of raisins or other dried fruit, use dried cranberries. Instead of orange or prune juice, try apple, cranberry, or grape juice. Health News GLP-1 Drugs Help Protect Against Sleep Apnea, Study Says New 1. 3B Lawsuit Accuses Johnson Johnson of Hiding Baby Powder Cancer Risk GI Problems Common In Menopause, Study Says Diabetes Drugs Might Counter Brain Decline In Early Alzheimers Patients Bedside Lawyers Help Hospitalized Violence Victims XML More Health News References Top What Fruit Is Good for Kidneys? Related Articles Can Drinking Water Stop Kidney Failure?
----------------------------------------------------------------------


======================================================================
CHUNK 68 of 647
======================================================================
ID: 1_33
Content Type: evidence
Words: 497
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Related Articles Can Drinking Water Stop Kidney Failure? While drinking more water can help boost kidney function, there is no evidence that suggests that it can prevent the progress of kidney failure. Can You Live With Stage I Kidney Disease? Because you can halt further kidney damage with diet modification and supportive treatment, patients can live an extra 30 years following their stage I CKD diagnosis. High-Sugar Fruits Sugar content in fruit varies. High-sugar fruits include mangoes, pears, grapes, cherries, bananas, figs, and watermelon. Low-sugar fruits include avocados, guava, raspberries, cantaloupe, papayas, Potassium Foods It turns out lots of things have more potassium than a banana! Heres a guide to the tastiest choices. How Long Does It Take a UTI to Turn Into a Kidney Infection? Failing to treat a urinary tract infection can lead to serious health problems, including kidney infections. If you have lingering symptoms, or recurrent UTIs, it is important to see your medical Kidney Disease Quiz Kidney disease is common. Take this kidney disease quiz to test your knowledge and learn the symptoms, causes and types of kidney disease and what foods to eat and avoid! Kidney Failure Kidney failure can occur from an acute event or a chronic condition or disease. Prerenal kidney failure is caused by blood loss, dehydration, or medication. Some of the renal causes of kidney failure Kidney Pain Kidney pain has a variety of causes and symptoms. Infection, injury, trauma, bleeding disorders, kidney stones, and less common conditions may lead to kidney pain. Symptoms associated with kidney Kidney Stone Slideshow What causes kidney stones? Where is kidney stone pain located on your body? Learn the symptoms and signs of kidney stone pain. Explore kidney stone treatment and how to prevent kidney stones. Kidneys Picture The kidneys are a pair of organs located in the back of the abdomen. See a picture of the Kidneys and learn more about the health topic. Ways to Keep Your Kidneys Healthy You might know that more than a drink or two a day is bad for your health. But in some cases, any alcohol at all may not be a great idea. What Are the Most Common Kidney Diseases? The most common type of kidney disease is chronic kidney disease (CKD). Other diseases include acute kidney injury, stones, infections, cysts, and cancer. What Foods Help Repair Kidneys? If you have chronic kidney disease, it is crucial to track food and fluid intake because diseased kidneys cant remove waste products from the body like healthy kidneys can. Good foods that help What Happens if Uric Acid Is High? A high uric acid level may occur when your kidneys dont eliminate uric acid efficiently and may result in the following health issues. Which Fruits Are High in Potassium? Potassium is an important mineral that plays a vital role in the body. Fruits that are high in potassium include bananas, cantaloupe, oranges, avocados, grapefruit, apricots, honeydew, guava and kiwi. Which Fruits Have the Highest Protein?
----------------------------------------------------------------------


======================================================================
CHUNK 69 of 647
======================================================================
ID: 1_34
Content Type: recommendation
Words: 477
Medical Entities: CKD,diabetes
Source: 1.txt

----------------------------------------------------------------------
Which Fruits Are High in Potassium? Potassium is an important mineral that plays a vital role in the body. Fruits that are high in potassium include bananas, cantaloupe, oranges, avocados, grapefruit, apricots, honeydew, guava and kiwi. Which Fruits Have the Highest Protein? The recommended daily allowance of protein for adults is 0. 36 grams per pound of bodyweight. The fruits that have the highest protein content include avocados and guava. Featured Slideshows Hepatitis C (Hep C) Transmission, Symptoms, Treatment and Prevention Breast Cancer A Visual Guide to Breast Cancer What Is COPD? Learn About This Progressive Lung Disease Health Categories Medical Slideshows Diseases Conditions Procedures Tests Medications Healthy Living Image Collection Quizzes Popular Health Centers Allergies Arthritis Blood Pressure Cancer Chronic Pain Cold Flu Depression Diabetes Digestion Health Living Healthy Kids Hearing Ear Heart HIV/AIDS Infectious Disease Mens Health Mental Health Neurology Pregnancy Sexual Health Skin Thyroid Womens Health More MedicineNet Privacy Policy About Us Contact Us TRUSTe 1996-2025 MedicineNet, Inc. An Internet Brands company. All rights reserved. Terms of Use. MedicineNet does not provide medical advice, diagnosis or treatment. See additional information. What fruits are good for stage 3 kidney disease? - Rebecca G, NJ All fruits and vegetables fit in a stage 3 CKD eating pattern. Usually, you have not been placed on a potassium restriction in stage 3. For meals its recommended that you have at least  your plate be vegetables and some fruits,  of your plate whole grains and  lean protein. For snacks: 1 small fruit with a small portion of protein (such as cheese, peanut butter, yogurt) to help keep you feeling full. Fruits are full of lots of different vitamins and minerals and eating a wide variety is important to help you get that benefit. We encourage fresh or frozen (not in syrup) fruits vs juice. By eating whole fruits, you also get the fiber which is missing in juice. It is easy to go a bit overboard with smaller fruits (grapes, tangerines, cut fruit) and juice. While you may eat too many calories when eating a larger portion of fruits, it still contains fiber and helps slow down the carbohydrate absorption vs drinking juice which doesnt have the fiber and could cause a spike in blood sugar. Also juice doesnt leave you feeling full as a piece of fruit, possibly you will end up eating something in addition which would add to your daily calorie intake. Some people need to avoid grapefruit and its juice because of medication if that is the case continue to avoid grapefruit. 10 Antioxidant Foods for the Kidney Diet Fresh, colorful and kidney-friendly fruits and vegetables arent just good; theyre good for people with chronic kidney disease (CKD). Powerful compounds called antioxidants found in certain foods may help protect you against other diseases such as cancer, heart disease, Alzheimers and Parkinsons disease.
----------------------------------------------------------------------


======================================================================
CHUNK 70 of 647
======================================================================
ID: 1_35
Content Type: recommendation
Words: 487
Medical Entities: CKD,dialysis
Source: 1.txt

----------------------------------------------------------------------
10 Antioxidant Foods for the Kidney Diet Fresh, colorful and kidney-friendly fruits and vegetables arent just good; theyre good for people with chronic kidney disease (CKD). Powerful compounds called antioxidants found in certain foods may help protect you against other diseases such as cancer, heart disease, Alzheimers and Parkinsons disease. Antioxidants neutralize harmful molecules in your body called free radicals, the normal yet damaging byproducts created when your body produces energy, fights infection or is exposed to toxins. Antioxidant vitamins A, C and E available in supplement form can be harmful to people on dialysis, though many take a renal vitamin supplement that contains 60-100 mg of vitamin C per day as recommended by their doctor. One of the best ways to get antioxidants is through food. Dietitians use colors in fruits and vegetables to identify antioxidants, which include: Red/Purple Anthocyanins, polyphenols, resveratrol Red Lycopene Orange Beta-carotene Orange/Yellow Cryptoxanthin, flavonoids Yellow/Green Lutein, zeaxanthin Green Indoles, sulforaphanes, lutein White/Green Allyl sulphides, quercetin Here are 10 colorful, high-antioxidant foods for the kidney diet. 1. Cranberries Cranberries add a distinctive zing to sweet breads, muffins and other recipes like Easy Cranberry Salad. Enjoy dried cranberries sprinkled on a salad or on their own as a snack. You can also drink cranberry juice or cranberry juice cocktail. 1/2 cup serving of raw cranberries 1 mg sodium, 40 mg potassium, 6 mg phosphorus 1/2 cup serving cranberry juice cocktail 3 mg sodium, 22 mg potassium, 3 mg phosphorus 1/2 cup serving dried cranberries 2 mg sodium, 24 mg potassium and 5 mg phosphorus 2. Plums Black plums are higher in antioxidants than red. Look for plums that have a fairly firm to slightly soft feel. Pit and freeze plums and add them to smoothies, pure them for Quick Fruit Sorbet or try Old-Fashioned Plum Cake. 1 medium plum 0 mg sodium, 104 mg potassium, 11 mg phosphorus 3. Blueberries Blueberries are classic additions to pancakes and blueberry muffins. Buy them frozen to use in smoothies or in a Blueberry Peach Crisp. When theyre in season, enjoy a bowl of fresh blueberries. 1/2 cup serving fresh blueberries 4 mg sodium, 65 mg potassium, 7 mg phosphorus 4. Blackberries/raspberries Sprinkle fresh berries on your cereal or oatmeal, use frozen ones in smoothies or bake them into pies such as More Mommas Blackberry Mountain Pie. Use berries in unexpected ways to bring out the flavor of meats, including this recipe for Raspberry Wings. 1/2 cup serving blackberries 1 mg sodium, 117 mg potassium, 16 mg phosphorus 1/2 cup serving raspberries 0 mg sodium, 93 mg potassium, 17 mg phosphorus 5. Garlic This tiny antioxidant powerhouse is available in fresh, bottled, minced or powdered form to use in Garlic Chicken with Balsamic Vinegar or another savory dish. Roasting a head of garlic mellows its flavor and makes a soft, delicious spread for bread. 1 clove garlic 1 mg sodium, 12 mg potassium, 4 mg phosphorus 6.
----------------------------------------------------------------------


======================================================================
CHUNK 71 of 647
======================================================================
ID: 1_43
Content Type: recommendation
Words: 477
Medical Entities: dialysis
Source: 1.txt

----------------------------------------------------------------------
Whats more, if chips are made from potatoes, theyll contain a significant amount of potassium as well (47Trusted Source). Summary Pretzels, chips, and crackers are easily consumed in large portions and tend to contain high amounts of salt. Additionally, chips made from potatoes provide a considerable amount of potassium. Kidney-friendly recipes Following a kidney-friendly diet requires limiting several foods, which can be challenging. However, there are many nutritious and delicious recipes that you can still enjoy as part of a balanced kidney diet. Here are a few tasty options available from the National Kidney Foundation: Chicken and Zucchini Quiche Pumpkin Pancakes Mexican-Style Stuffed Peppers Be sure to make adjustments as needed, depending on your specific needs and preferences. A renal dietitian can also recommend kidney-friendly recipes to help round out your diet. Summary There are many nutritious recipes available that can easily fit into a renal diet. You can also adjust recipes based on your needs and preferences. How are dietary restrictions for kidney disease determined? Your specific dietary restrictions will depend on your stage of kidney disease. For instance, people with early stages of chronic kidney disease will have different dietary restrictions than those with end-stage renal (kidney) disease or kidney failure. Those with end-stage kidney disease who require dialysis also have varying dietary restrictions. Dialysis is a type of treatment that removes extra water and filters waste (4Trusted Source). Most of those with late or end-stage kidney disease need to follow a kidney-friendly diet to avoid a buildup of certain chemicals or nutrients in the blood (5Trusted Source). In those with chronic kidney disease, the kidneys cannot adequately remove excess sodium, potassium, or phosphorus. As a result, theyre at a higher risk of elevated blood levels of these minerals (5Trusted Source). A kidney-friendly diet, or renal diet, usually limits sodium to under 2, 300 milligrams (mg) per day, as well as your potassium and phosphorus intake (5Trusted Source). The National Kidney Foundations most recent Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines dont set specific limits on potassium or phosphorus (6). Potassium and phosphorus are still a concern for people with kidney disease. Still, they should work closely with a doctor or dietitian to determine their personal limits for these nutrients, which are usually based on lab results. Damaged kidneys may also have trouble filtering the waste products of protein metabolism. Therefore, individuals with chronic kidney disease of all stages, especially stage 35, should limit the amount of protein in their diets unless theyre on dialysis (6, 7Trusted Source). However, those with end-stage kidney disease undergoing dialysis have an increased protein requirement (8Trusted Source). Frequently asked questions What foods help your kidneys work better? The best thing you can do to help your kidneys work better is to eat a well-balanced diet full of nutritious, vitamin-rich foods that are low in sodium, potassium, and phosphorus (53).
----------------------------------------------------------------------


======================================================================
CHUNK 72 of 647
======================================================================
ID: 1_44
Content Type: recommendation
Words: 500
Medical Entities: dialysis
Source: 1.txt

----------------------------------------------------------------------
Frequently asked questions What foods help your kidneys work better? The best thing you can do to help your kidneys work better is to eat a well-balanced diet full of nutritious, vitamin-rich foods that are low in sodium, potassium, and phosphorus (53). Some examples include: tofu cheese thats low in phosphorus (such as goat cheese, grated parmesan, mozzarella, Monterey Jack, Swiss cheese, and Brie) milk alternatives (such as oat, soy, or rice) healthy cooking oils (such as olive oil, safflower oil, or sesame oil) fish fresh fruit (like strawberries, blueberries, apples, pomegranates) beans Is peanut butter good for the kidneys? Peanut butter is a good source of plant-based protein. Its naturally low in carbohydrates, and has plenty of fiber to aid digestion. Its a good substitute for meat in a kidney diet plan. However, its worth noting that 2 tablespoons of peanut butter also has 65 milligrams of oxalate, and high amounts of oxalate can contribute to kidney stones (54, 55). Talk with your doctor if youre prone to kidney stones, as you may want avoid or reduce your peanut butter consumption. Also, when purchasing peanut butter, be sure to look for brands that dont add extra salt and sugar. Is chocolate bad for the kidneys? Dark chocolate is rich in antioxidants and has actually been shown to reduce certain markers of inflammation in people undergoing dialysis (50Trusted Source, 51Trusted Source). Still, chocolate is high in calories and added sugar and contains some phosphorus and potassium. Therefore, its best to enjoy it in moderation as part of a well-rounded diet, especially if you have kidney disease (52Trusted Source). Are eggs bad for the kidneys? Eggs are highly nutritious and can often fit into a balanced renal diet. However, people following a low protein diet may need to moderate their intake, depending on the amount of protein that they are allotted each day (48Trusted Source). Is coffee bad for the kidneys? Enjoying the occasional cup of coffee is typically fine on a renal diet and is unlikely to affect kidney health. However, drinking 34 cups (473710 mL) daily or adding large amounts of milk, creamer, or flavored syrup may increase potassium or phosphorus levels. Additionally, drinking multiple cups is not recommended if youve been advised to restrict your fluid intake (49). The bottom line If you have kidney disease, reducing your potassium, phosphorus, and sodium intake can be an important aspect of managing the disease. The high sodium, potassium, and phosphorus foods listed above are likely best limited or avoided. Dietary restrictions and nutrient intake recommendations will vary based on the severity of your kidney damage. Following a renal diet can seem daunting and a bit restrictive at times. However, working with a healthcare professional and renal dietitian can help you design a renal diet specific to your individual needs. What foods are bad for kidneys? Renal diet Foods to avoid Other foods Summary People with kidney disease typically need to follow a diet low in sodium, protein, potassium, and phosphorus.
----------------------------------------------------------------------


======================================================================
CHUNK 73 of 647
======================================================================
ID: 1_45
Content Type: recommendation
Words: 499
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
What foods are bad for kidneys? Renal diet Foods to avoid Other foods Summary People with kidney disease typically need to follow a diet low in sodium, protein, potassium, and phosphorus. This means limiting or avoiding foods such as avocados, brown rice, and chips. The kidneys perform many crucial functionsTrusted Source for health, including filtering waste products and excess fluid from the body and removing it through urine. They also regulate the bodys mineral balance and produce a hormone that stimulates red blood cell production. When a person has kidney disease, waste products can build up in their blood. A doctor may recommend dietary changes to help manage the condition and support kidney function. This article explains which foods to avoid or limit with kidney disease. It also provides an overview of the renal (or kidney-friendly) diet. Renal diet Bojan89/Getty Images A specialist kidney dietitian will typically work with people with kidney disease to tailor a diet to their needs. A kidney-friendly diet, also called a renal diet, may vary slightly depending on the stage of a persons kidney disease. For example, those in the early stages of chronic kidney disease (CKD) should limit their sodium and possibly protein intake. In the later stagesTrusted Source of CKD, known as kidney failure, an individual should follow a diet that limits sodium, potassium, and phosphorus. Learn about the link between kidney disease and potassium. Foods to avoid A dietitian may ask that individuals following a renal diet avoid the following foods: 1. Canned foods Sodium, a main ingredient of salt, is a natural mineral often found in canned foods in high quantities. Manufacturers typically addTrusted Source sodium to canned items to increase shelf life and enhance taste. With CKD, the kidneys cannot eliminate excess sodium as they should. This means people with CKD should avoid or limit eating canned goods such as soup, vegetables, and beans. Choosing canned foods labeled low sodium and draining the contents can help reduce the amount of sodium a person consumes. 2. Whole wheat bread A buildup of phosphorus and potassium can causeTrusted Source problems for people with CKD. Due to the highTrusted Source content of these minerals in whole wheat bread, people with CKD should instead choose white bread. For example, one slice of whole wheat bread contains 76. 3 mgTrusted Source of phosphorus and 90 mg of potassium. White bread, on the other hand, contains 31. 6 mgTrusted Source of phosphorus and 32. 8 mg of potassium. If a person does not wish to stop eating whole wheat bread entirely, they could instead consider reducing the amount they eat. For example, they could eat just one slice with a meal rather than two. 3. Dark-colored drinks Many manufacturers of dark-colored drinks add phosphorus to their products to enhance flavor, prolong shelf life, and prevent discoloration. Phosphorus in its additive form, found in dark cola and beer, is highly absorbable by the human body and is not recommendedTrusted Source for those following a renal diet.
----------------------------------------------------------------------


======================================================================
CHUNK 74 of 647
======================================================================
ID: 1_46
Content Type: recommendation
Words: 497
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Dark-colored drinks Many manufacturers of dark-colored drinks add phosphorus to their products to enhance flavor, prolong shelf life, and prevent discoloration. Phosphorus in its additive form, found in dark cola and beer, is highly absorbable by the human body and is not recommendedTrusted Source for those following a renal diet. However, root beer is an exception to this as it contains no phosphorusTrusted Source. 4. Avocados While healthcare professionals generally consider avocados a beneficial addition to a persons diet, people with renal problems may wish to avoid or limit them. This is because they are high in potassium, with one avocado weighing around 200 g containing 975 mgTrusted Source of potassium. According to the National Kidney Foundation, anything that exceeds 200 mg of potassium per serving is high in potassium. If needed, a person can still include avocados in their diet, but they should drastically reduce their portion size. 5. Bananas A large banana contains 487 mgTrusted Source of potassium, meaning a person with CKD should avoid or limit eating this fruit. Many other tropical fruits also have high potassium content. Pineapples may be a suitable alternative as they contain a much smaller amountTrusted Source of potassium compared with other tropical fruits. 6. Oranges and orange juice Oranges and orange juice are a potassium-rich food and drink. A small orange contains 174 mgTrusted Source of potassium, while 250 gTrusted Source of orange juice contains as much as 441 mg of potassium. Alternative fruits that are lower in potassium include grapes, apples, and cranberries. 7. Dried fruits Dried fruits are concentrated sources of many of the nutrients found in fresh fruits. This means it can be easier to exceed recommended daily intakes from them. People following a renal diet should avoid apricots, dates, prunes, and raisins, which are all high in potassium. 8. Tomatoes Tomatoes are another high potassium fruit that a person following a renal diet should limit. For reference, a cup (245 g) of tomato sauce contains 728 mgTrusted Source of potassium. 9. Brown rice While it is nutritious, brown rice has a higherTrusted Source phosphorus and potassium content than white rice. A cup (155 g) of cooked brown rice contains 149 mgTrusted Source of phosphorus and 94. 6 mg of potassium, while a cup (186 g) of cooked white rice contains 68. 8 mgTrusted Source of phosphorus and 53. 9 mg of potassium. Bulgur, buckwheat, and couscous are also alternatives to brown rice. 10. Dairy Despite dairy and milk traditionally being promoted for bone health, for people with CKD, consuming too much can be detrimental to bone health. The reason for this is that dairy is a natural source of phosphorus and potassium. A cup (244 g) of whole milk contains 205 mgTrusted Source of phosphorus and 322 mg of potassium. Kidney damage can cause an excess of phosphorus to build up in the blood (known as hyperphosphatemia). This condition can cause the body to pull calcium from the bones, resulting in thin, weak bones.
----------------------------------------------------------------------


======================================================================
CHUNK 75 of 647
======================================================================
ID: 1_47
Content Type: recommendation
Words: 473
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Kidney damage can cause an excess of phosphorus to build up in the blood (known as hyperphosphatemia). This condition can cause the body to pull calcium from the bones, resulting in thin, weak bones. It is important for people following a renal diet to limit dairy products to avoid this buildup of protein waste in the blood. Coconut milk may be a favorable substitute for people with CKD based onTrusted Source its low potassium, sodium, and oxalate content. 11. Processed meats Processed meats are meats that manufacturers have salted, dried, cured, or canned. Some examples include hot dogs, bacon, and pepperoni. To improve their taste and preserve flavor, they often contain lots ofTrusted Source salt. If a person regularly eats highly processed foods, keeping their sodium intake to 2, 300 mg per day (the amount recommended by the National Kidney Foundation) may be difficult. 12. Pickles, olives, and relish Pickles, processed olives, and relish are all examples of cured or pickled foods. During the curing or pickling process, manufacturers typically add saltTrusted Source to the food. For reference, five green pickled olives (considered a small serving) equates to almost 10%Trusted Source of the daily recommended amount of sodium. 13. Bran cereals, oatmeal, and granola Many cereals contain a mixture of potassium, phosphorus, and sodium. A person following a renal diet should avoid all of these. For example, a 30 gTrusted Source serving of bran flakes contains 160 mg of potassium, 135 mg of phosphorus, and 162 mg of sodium. A 100 gTrusted Source serving of granola contains 539 mg of potassium. 14. Potatoes Potatoes, including sweet potatoes, are potassium-rich vegetables. A medium-sized baked potato contains around 610 mgTrusted Source of potassium, and a medium-sized sweet potato contains 542 mgTrusted Source of potassium. Leaching is one way a person can reduce the high potassium content in potatoes. This method essentially involves soaking or boiling potatoes in water before cooking, which, according to older research, reduces the original potassium content by at least 50%Trusted Source. 15. Processed foods Processed foods include pizza, instant noodles, and convenience meals designed for the microwave. These foods typically contain high levels of salt, sugar, and fat. As mentioned above, the National Kidney Foundation recommends keeping sodium intake to 2, 300 mg per day. This may prove difficult if a person is eating highly processed foods regularly. 16. Pretzels, chips, and crackers Foods such as pretzels, chips, and crackers are typically high in sodium and lacking in nutrients. Because chips come from potatoes, they are also high in potassium. A small bag of potato chips contains around 148 mgTrusted Source of sodium and 336 mg of potassium, and 60 g of pretzels contain roughly 744 mgTrusted Source of sodium and 134 mg of potassium. The portion sizes of these snacks can often lead to greater salt intake than intended. 17.
----------------------------------------------------------------------


======================================================================
CHUNK 76 of 647
======================================================================
ID: 1_48
Content Type: recommendation
Words: 488
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
The portion sizes of these snacks can often lead to greater salt intake than intended. 17. Swiss chard, spinach, and beet greens There are many green, leafy vegetables that people following a renal diet may need to avoid or limit due to their high potassium content. This is the case for Swiss chard, spinach, and beet greens. For example, a cup of raw Swiss chard contains 136 mgTrusted Source of potassium. As with spinach, this vegetable shrinks when boiled, meaning a person may eat more than they would raw. A person with CKD should consider this as it will, in turn, increase their intake of potassium. Kidney-friendly foods Although an individual with CKD must adapt their diet, there are still many suitable options for them to try. People should choose foods with lower levels of sodium, potassium, and phosphorus. These include: Fruit: Options include apples, cranberries, grapes, pineapple, and strawberries. Vegetables: Options include cauliflower, lettuce, onions, peppers, and radishes. Baked goods: Options include pita, tortillas, and sourdough bread. Protein: Options include beef and chicken. Carbohydrates: Options include white rice and unsalted popcorn. Learn about other foods that are good for the kidneys. Summary If an individual has CKD, doctors typically recommend reducing their intake of potassium, phosphorus, and sodium to help manage the condition. The dietary restrictions depend on the stage of the disease. Although there is a long list of foods that are best to avoid on a renal diet, there is also a wide range of foods that people can eat without affecting their kidney health. An individual may work with a renal dietitian to find the most suitable diet for them. When you have kidney problems, diet becomes more important than ever. Our kidneys remove toxins from our bodies. When you have chronic kidney disease (CKD), your bodys ability to remove waste is compromised. Making conscious food choices and having a well-balanced diet becomes an important part in managing your disease progression. Ms Lynette Goh, Principal Dietitian, and Ms Ng Su Yi, Senior Dietitian at the National University Polyclinics (NUP) has answers to some of the common questions from patients with CKD. Why is diet important in managing my CKD? The kidneys work to maintain a good balance of fluids, salts and minerals in the blood. When kidneys no longer work as they used to, there is a need to change ones diet to prevent excess waste and fluids from building up in the body. A kidney-friendly diet can also help preserve kidney function or delay progression to kidney failure. What is an appropriate diet differs from person to person, and very much depends on their level of kidney function. What nutrients should I be concerned about if I have CKD? Protein, sodium and potassium are the main nutrients to watch closely. The required intake of these nutrients will differ according to the patients age, body size, physical activity levels and stage of kidney disease.
----------------------------------------------------------------------


======================================================================
CHUNK 77 of 647
======================================================================
ID: 1_49
Content Type: reference
Words: 483
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
What nutrients should I be concerned about if I have CKD? Protein, sodium and potassium are the main nutrients to watch closely. The required intake of these nutrients will differ according to the patients age, body size, physical activity levels and stage of kidney disease. Since theres so much variation, the best thing to do would be to consult your dietitian for a personalised diet plan. Sodium A patient with CKD should cut down on sodium, which is commonly found in salt as well as processed and canned foods. Sodium is known to cause retention of fluids in the body. Fluid retention in the body increases blood pressure and worsens CKD. However, it should be noted that the body does need some sodium and so it cannot be cut out entirely. Potassium Potassium is generally a good mineral for most people because it helps maintain a regular heartbeat and proper functioning of the nerves and muscles in the body. However, when the kidneys are not working as well, potassium may build up to dangerous levels in the body and this can affect the proper functioning of the heart. Potassium is found in fruits and vegetables, but dont be afraid to include them in your diet. Tips on avoiding those with higher sources and preparing them in the right way can help you maintain a safe potassium level, shared Ms Goh. Try these tips to maintain a healthy potassium level: 1. Replace fruits and vegetables with high potassium content with those of low or moderate potassium content High potassium content Moderate to low potassium content Fruits Banana, melons, dates, kiwi, plums, dried fruits. Apple, pear, orange, guava, lychee, mango, rambutan, papaya, watermelon, grapes Vegetables Bitter gourd, cabbage, Chinese kale (kai lan), mustard greens (chye sim), spinach, potato, tapioca. Bean sprouts (tau geh) cabbage, French beans, hairy cucumber, lady fingers/ okra, lettuce. 2. Keep to 2 servings of fruits and 2 servings of vegetables per day Example of 1 serving of fruit Example of 1 serving of vegetables 1 small apple/orange/pear (130g), 1 slices of papaya/watermelon (130g), 10 grapes (50g)  cup of cooked vegetables (100g), 100g raw non-leafy vegetables, 150g raw leafy vegetables 3. Eat whole fruits and vegetables instead of having fruit or vegetable juices, or dried fruit 4. Cut fresh vegetables into small pieces, and soak them in water for 1-2 hours prior to cooking to remove the potassium. Discard the water and rinse the vegetables before cooking. 5. Drain all juice or syrups from canned fruits and vegetables. Protein When we eat food that contains protein, the body breaks down the protein in order to absorb and use it. However, this process produces waste products, which require the kidneys to work. One misconception that CKD patients have is to cut out protein entirely, however the downside of such over-restriction is that your body does not get enough nutrients to function properly.
----------------------------------------------------------------------


======================================================================
CHUNK 78 of 647
======================================================================
ID: 1_50
Content Type: reference
Words: 445
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
However, this process produces waste products, which require the kidneys to work. One misconception that CKD patients have is to cut out protein entirely, however the downside of such over-restriction is that your body does not get enough nutrients to function properly. Protein is needed for building and maintaining muscles, healing wounds, and supporting your immune system, explained Ms Ng. She added that there is no standard diet or amount prescribed to patients. Each individuals dietary needs are different and changes depending on their kidney function. Food tastes bland now that I have to limit my sodium intake. How do I add flavour to my cooking? Food will likely taste bland at first as your taste buds are not used to it. Give yourself six weeks to adjust to a lower sodium diet. You can also have fun with herbs and spices to give your food an extra boost of flavour, shared Ms Goh. When adapting to a new diet, its easier to make changes gradually. You can start by reducing salt and processed sauces by half and using more natural seasonings such as lime, lemon juice, fresh chillies, onions, garlic and ginger. Herbs such as parsley, coriander, basil, and mint and spices such as pepper, cinnamon, cardamom, cumin and curry powder may also be used to flavour food. Just remember to choose fresh foods instead of canned or processed ones which usually contain high levels of sodium. Also, always taste your food before adding more salt or sauces, and avoid adding extra salt and sauces when youre eating. I dont have time to cook but its so difficult to eat out with my diet restrictions! Any advice or tips for eating out? Eating out can be challenging as most meals are high in salt intake. Here are four simple ways to cut down on salt when eating out: When having dishes with soup, such as noodles, ask to have the dish dry (i. e. leave the soup out) as the soup often contains high levels of salt. Request your dish to be cooked with less sauce and gravy wherever possible. If you prefer spicy food, ask for fresh-cut chilli instead of sambal or other spicy sauces. Choose meals prepared with fresh vegetables and lean meat, poultry or fish instead of processed foods such as canned or processed meat (e. g. fishballs, fishcake, and sausages). Im vegetarian. How do I ensure Im getting enough protein? It is important to plan your meals instead of eating what turns up to ensure youre getting enough and the right nutrients, including protein. A good guiding principle is to consciously include plant-based protein in every meal, said Ms Ng.
----------------------------------------------------------------------


======================================================================
CHUNK 79 of 647
======================================================================
ID: 1_51
Content Type: reference
Words: 481
Medical Entities: CKD
Source: 1.txt

----------------------------------------------------------------------
Im vegetarian. How do I ensure Im getting enough protein? It is important to plan your meals instead of eating what turns up to ensure youre getting enough and the right nutrients, including protein. A good guiding principle is to consciously include plant-based protein in every meal, said Ms Ng. Good sources of plant-based protein include: Soya and soya products such as tofu, tempeh, and soya milk Meat alternatives such as non-fried soy meat and plant-based burger patties that may include soy protein, beans, and/or lentils Dried beans, peas, and lentils Grains (e. g. quinoa, brown rice and oatmeal) Nuts, nut butter (e. g. hazelnut and almond butter) and seeds (e. g. sesame and sunflower seeds) If you are lacto-ovo-vegetarian, you may also wish to consider dairy products such as low-fat milk, low-fat yoghurt, cheese, and eggs in your diet as these too are good sources of protein. Changing your diet may not be as hard as you think! Whether or not you suffer from CKD, a good diet maintains a healthy body and well-functioning kidneys. In consultation with Ms Lynette Goh, Principal Dietitian and Ms Ng Su Yi, Senior Dietitian, NUP Lifestyle Dietetics National University Polyclinics Can Kidney Patients eat fruit and vegetables Can kidney patients eat fruit and vegetables? Tips on making low potassium choices when eating fruit and vegetables. Contrary to popular belief, patients with kidney disease CAN include fruit and vegetables, even with the dreaded potassium restrictions. Fruit and vegetables are an important part of a healthy, balanced diet and provide many vitamins and minerals, fibre and taste. When your kidney function starts to decline, the potassium levels in your blood may start to increase and you may be advised to follow a low potassium diet in order to help reduce it to a safe level. Not all renal patients need to follow a low potassium diet and it is important not to restrict yourself unless you have been advised by a qualified health professional. Your renal dietician can advise you how to follow a low potassium diet while making sure your diet stays balanced, nutritious and tasty. Fruit and vegetables are a known high source of potassium, however the types chosen and how they are prepared and cooked can impact on their potassium content. Even with a potassium restriction, two portions of fruit, such as an apple and an orange and two portions of vegetables, such as two heaped tablespoons each of carrots and broccoli, are allowed daily. Avoiding known higher sources and preparing them in the right way, helps you to maintain a safe potassium level within your blood. Tips on making low potassium choices when eating fruit and vegetables: Boil potatoes and vegetables in a large amount of water. Three egg sized potatoes are a suitable portion if following a low potassium diet. Make sure they are well cooked, double boiling is NOT necessary.
----------------------------------------------------------------------


======================================================================
CHUNK 80 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_0
Content Type: general
Words: 483
Medical Entities: CKD,dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
STAGE 5 Dialysis and You What you need to know Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Get support and hear from others who have experience with dialysis, transplant, living donation, and being a parent or care partneryou never know when youll inspire someone else! Join today at kidney. org/online-communities 2 NATIONAL KIDNEY FOUNDATION Contents Kidney Failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Dialysis Care Team. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Adjusting to DialysisYour New Normal. . . . . . . . . . . 13 Nutrition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Financial Resources. . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Living Well on Dialysis. . . . . . . . . . . . . . . . . . . . . . . . . . 23 Additional Resources. . . . . . . . . . . . . . . . . . . . . . . . . . 26 KIDNEY. ORG 3 Kidney Failure Stage 5 chronic kidney disease, also known as kidney failure, means your kidneys are functioning at less than 15% of a healthy kidney. For most, loss of kidney function is a slow process that can take many years. Since early chronic kidney disease (CKD) does not usually have any symptoms, many people learn they have CKD when their kidney function is very low. Healthy kidneys are responsible for: Removing waste products and extra fluid from the body Filtering about 190 quarts of blood to produce about two quarts of urine (pee) every 24 hours Making enzymes, called renin, that work with hormones to control blood pressure 4 NATIONAL KIDNEY FOUNDATION Releasing a hormone called erythropoietin, that tells the bone marrow (a spongy substance that is inside bones) to make more red blood cells Creating an active form of vitamin D to keep calcium at steady levels Removing excess phosphorus in the blood Keeping important chemicals well-balanced in the body When you have kidney failure, you will need either dialysis or a kidney transplant to survive. DIALYSIS Dialysis (hemodialysis and peritoneal dialysis) is a treatment that does some of the work that is normally done by healthy kidneys. Dialysis is needed when your own kidneys can no longer take care of your bodys needs.
----------------------------------------------------------------------


======================================================================
CHUNK 81 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_1
Content Type: general
Words: 500
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
DIALYSIS Dialysis (hemodialysis and peritoneal dialysis) is a treatment that does some of the work that is normally done by healthy kidneys. Dialysis is needed when your own kidneys can no longer take care of your bodys needs. Dialysis allows your body to: Remove waste and extra water to prevent them from building up Keep a safe level of certain chemicals in your blood such as potassium, sodium, and bicarbonate Help to regulate blood pressure HEMODIALYSIS Hemodialysis is a life-saving treatment for people with kidney failure. A hemodialysis machine works as an artificial kidney by removing wastes and extra fluid from your blood. KIDNEY. ORG 5 During hemodialysis, your blood is pumped through soft tubes to a hemodialysis machine where it goes through a special filter called a dialyzer. As your blood is filtered, it is returned to your bloodstream. Only a small amount of blood is out of your body at any time. A vascular access, which is an opening made in your skin and into a blood vessel, is the way you are connected to the hemodialysis machine. A surgeon creates a vascular access during a short surgical procedure. When you have dialysis, your blood flows out of the access through soft tubes and into a hemodialysis machine. After your blood is filtered in the machine, it goes through a soft tube to the access and back into your body. 6 NATIONAL KIDNEY FOUNDATION Hemodialysis can be done at a hospital, a dialysis center, or at home. Hemodialysis treatments at a dialysis center are usually done 3 times a week and each treatment takes 3 to 4 hours to complete. Home hemodialysis treatments may be performed more frequently, usually 5 to 6 days a week. You and your healthcare provider should work together to decide the best location for your hemodialysis treatment. PERITONEAL DIALYSIS There are two kinds of peritoneal dialysis (PD) -- continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). The basic treatment for CAPD and APD is the same. However, the number of treatments and the way the treatments are done make each method different. CAPD is a continuous, machine-free treatment and it is done while you go about your normal activities such as working, attending school, or traveling. With CAPD, about two quarts of cleansing fluid flows through a tube that goes into your belly and then draining the fluid through a second tube. This process is called an exchange (putting in and taking out the fluid). With CAPD, you raise the plastic bag of cleansing fluid to shoulder level, which allows the fluid to flow into your belly. When empty, the plastic bag is removed and thrown away. KIDNEY. ORG 7 When an exchange is finished, the fluid (which now has wastes removed from your blood) is drained from your belly (into another plastic bag) and thrown away. Each exchange takes about 30 to 40 minutes and is usually done three to five times in a 24-hour period while you are awake.
----------------------------------------------------------------------


======================================================================
CHUNK 82 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_2
Content Type: general
Words: 494
Medical Entities: CKD,dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
Each exchange takes about 30 to 40 minutes and is usually done three to five times in a 24-hour period while you are awake. Some patients like to do their exchanges at mealtimes and before going to bed. APD differs from CAPD in that a machine (cycler) delivers and then drains the cleansing fluid for you. This treatment is usually is done at night while you sleep. TRANSPLANTATION Transplantation is when a healthy kidney from a donor (living or deceased) is surgically placed inside your body. Kidney transplant surgery usually lasts 3 to 4 hours. A kidney transplant is not a cure for kidney failure, it is a treatment. 8 NATIONAL KIDNEY FOUNDATION When you have a kidney transplant, the new kidney functions as a normal kidney. Usually, your damaged kidneys are left in place and not removed. Only one donor kidney is transplanted, and it is placed in the lower part of the abdomen. For the rest of your life, you will need to take immunosuppressant medication, which lowers the risk of your body rejecting the transplanted kidney. Side effects of immunosuppressant medication can include weight gain, acne, upset stomach, and facial hair. Long-term side effects of immunosuppressant medication include a weak immune system. CONSERVATIVE MANAGEMENT Conservative management focuses on your quality of life and managing symptoms without dialysis or a kidney transplant. Conservative management is also called comfort care, non-dialytic care, supportive care, or comprehensive conservative care. The goals of conservative management are to: Preserve kidney function for as long as possible Manage symptoms (nausea, loss of appetite, and depression) and other kidney-failureassociated problems, such as anemia Maintain a good quality of life for as long as possible Prepare for end-of-life care KIDNEY. ORG 9 Dialysis Care Team The dialysis care team consists of your doctor (nephrologist) or advanced practitioner, nephrology nurse, kidney dietitian, nephrology social worker, and dialysis technician. NEPHROLOGIST The team leaders in many clinics are doctors called nephrologistsor kidney doctors. They have advanced training in treating kidney disease. They are responsible for your care during dialysis treatments. Nephrologists also may take care of patients before and after a kidney transplant. ADVANCED PRACTITIONER Your team may also include advanced practitioners. nurse practitioners (NP) and physician assistants (PA) collaborate with the doctors in caring for kidney patients both in medical offices or in the dialysis unit. 10 NATIONAL KIDNEY FOUNDATION NEPHROLOGY NURSE Nephrology nurses are registered nurses (RNs) or licensed nurses (LVNs/LPNs) with education, training, and experience in caring for people at all stages of CKD, including stage 5 or kidney failure. They follow the rules, guidelines, and regulations set forth by the State Board of Nursing and described in the State Nurse Practice Act. Medicare requires that each dialysis center have a full-time RN with experience in dialysis. The RN is responsible for nursing services and home training programs for patients. REGISTERED KIDNEY (RENAL) DIETITIAN Registered kidney dietitians can help you plan healthy meals based on your personal lab reports.
----------------------------------------------------------------------


======================================================================
CHUNK 83 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_3
Content Type: recommendation
Words: 498
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
Medicare requires that each dialysis center have a full-time RN with experience in dialysis. The RN is responsible for nursing services and home training programs for patients. REGISTERED KIDNEY (RENAL) DIETITIAN Registered kidney dietitians can help you plan healthy meals based on your personal lab reports. Your kidney dietitian will review your monthly labs and show you how different foods can affect how you are feeling. They can also recommend the best types of supplements to prevent and treat malnutrition, bone problems, and anemia. KIDNEY. ORG 11 NEPHROLOGY SOCIAL WORKER Nephrology social workers provide emotional support as you adjust to your dialysis routine. They are also available to assist with travel arrangements so you can get to your treatments and make sure that you have access to your medications, appropriate housing, and help you to fully understand all your treatment options. PATIENT CARE AND BIOMEDICAL TECHNICIANS There are two kinds of technicians in your dialysis centerpatient care technicians (PCTs) and biomedical technicians. Both work under the guidance of the nephrology nurse or nephrologist. PCTs perform your dialysis treatment. In many dialysis centers, they are responsible for starting and ending each treatment and for monitoring you before, during, and after treatments. PCTs complete an in-depth training program. Some states require that they have state or national certification. Biomedical technicians are responsible for maintaining dialysis machines and water quality in your center. They order dialysis supplies and reprocess dialyzers for reuse. 12 NATIONAL KIDNEY FOUNDATION Adjusting to DialysisYour New Normal Getting used to the routines of dialysis will likely take some getting used to. There are a number of things you will need to learn and many new experiences to adjust to in the first few weeks. EMOTIONAL HEALTH Dialysis is a life-changing process and learning how to cope is important. Many people on dialysis say that fear and confusion are two very common feelings when they first started. Others felt odd seeing their blood going through the dialysis machine. Just remember, whatever you are feeling, there are people on your dialysis team who can answer questions and help support you when you are anxious. KIDNEY. ORG 13 Almost everyone gets past their initial fears of being on dialysis. Most say they are now doing fine and are comfortable with dialysis. Becoming more knowledgeable and more experiencedknowing what to expectoften helps a person cope better. Dialysis is not only new for youbut also for those closest to you, your family and friends will also want to support you. In addition, your loved ones may have questions about kidney failure and dialysis treatment. Its best to be honest and transparent with them. You will feel better and they will be in a better position to help and support you. Tell them when you need help with transportation, driving your kids to school, or going to doctor appointments. 14 NATIONAL KIDNEY FOUNDATION PHYSICAL HEALTH People on dialysis are much more likely to develop heart and blood vessel disease (also called cardiovascular disease).
----------------------------------------------------------------------


======================================================================
CHUNK 84 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_4
Content Type: reference
Words: 489
Medical Entities: dialysis,diabetes
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
Tell them when you need help with transportation, driving your kids to school, or going to doctor appointments. 14 NATIONAL KIDNEY FOUNDATION PHYSICAL HEALTH People on dialysis are much more likely to develop heart and blood vessel disease (also called cardiovascular disease). This higher risk is due to other health problems that often accompany kidney failure, such as diabetes and high blood pressure. It is very important that you do what you can to prevent or manage heart and blood vessel problems. Some of the ways to stay healthy while on dialysis include: Stay on your dialysis treatment Follow the prescribed diet as much as possible Plan out meals with a kidney dietitian Take all of your medications exactly as prescribed Exercise regularly Manage your stress Socialize with family and friends Speak to a nephrology social worker about support groups for people on dialysis Seek help to stop smoking In addition, after a dialysis treatment, you may have low blood pressure (hypotension) if too much fluid is removed from your body. Muscle cramps can also occur if too much fluid is removed or if the fluid is removed too fast. If your blood pressure drops, you may experience nausea and/or dizziness due to low blood pressure. KIDNEY. ORG 15 Nutrition Your diet is an important part of your treatment. Your kidneys cannot get rid of enough waste products and fluids from your blood so you may need to limit fluids and change certain foods in your diet. You may need to: Eat more high-protein foods Eat less high-salt, -potassium, and -phosphorus foods Change the amount of fluid you drink (including coffee, tea, water, and any food that is liquid at room temperature). Your kidney dietitian at your dialysis center will help you plan a healthy diet. 16 NATIONAL KIDNEY FOUNDATION PROTEIN People on dialysis need to eat more protein. Protein can help keep healthy blood protein levels and improve health. Protein also helps keep your muscles strong, heal wounds faster, strengthen your immune system, and helps improve overall health. Eat a high-protein food (meat, fish, poultry, fresh pork, or eggs) at every meal, or about 810 ounces of highprotein foods every day. Here are some examples of portion sizes: 3 ounces the size of a deck of cards: a medium pork chop, a  pound hamburger patty,  chicken breast, or a medium fish fillet 1 ounce 1 egg or -cup egg substitute, -cup tuna, -cup ricotta cheese, 1 slice of low sodium lunchmeat, 1 tablespoon peanut butter,  ounce of nuts or seeds Note: Highly processed foods should be avoided because of their high phosphorus and sodium content. Whole plant-based foods such as nuts and beans can be high in phosphorus but they are less absorbed than phosphorus amounts in processed foods. POTASSIUM Potassium is a mineral that is found in dairy products and fruits and vegetables. The muscles and nerves in your body use potassium to function.
----------------------------------------------------------------------


======================================================================
CHUNK 85 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_5
Content Type: recommendation
Words: 489
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
Whole plant-based foods such as nuts and beans can be high in phosphorus but they are less absorbed than phosphorus amounts in processed foods. POTASSIUM Potassium is a mineral that is found in dairy products and fruits and vegetables. The muscles and nerves in your body use potassium to function. Too much or too little potassium can prevent your heart muscle from working properly. Your kidney dietitian can let you know the appropriate amounts of potassium you should eat. KIDNEY. ORG 17 PHOSPHORUS Phosphorus is a mineral found in many foods that you eat every day. It is important for strong bones and healthy blood vessels. However, if your phosphorus levels are too high, it can cause weak, brittle bones and heart problems. SODIUM Salt is made up of sodium and chloride, and just 1 teaspoon of salt has the daily recommended amount of sodium. About 80% of the sodium is in the food we eat. Most fast foods, foods found in convenience stores, and processed foods are very high in sodium. When you have high levels of sodium in your blood, excess fluids start building up in your body. Having too much fluid in your body can increase blood pressure, and cause breathing trouble, heart damage, and higher fluid weight gains between dialysis treatments. People on dialysis are encouraged to buy snacks that are low in sodium, to cook with and use less table salt at home, and to eat fewer salty foods when out. Instead, replace salt with herbs, spices, and low-salt flavor enhancers. Also, avoid salt substitutes made with potassium. MANAGING FLUIDS Healthy kidneys remove extra fluids from the body. Dialysis also removes excess fluids that build up in your body, but not all of the excess fluids. This is the reason why people on dialysis have frequent lab tests. 18 NATIONAL KIDNEY FOUNDATION The lab results let you and your dialysis team know if you should increase or limit how much fluid you consume. Its important for your dialysis team to measure your dry weight and know whether you are still urinating. Gaining large amounts of fluid weight between dialysis treatments is unhealthy. Having too much fluid in your body can cause swelling, high blood pressure, and congestive heart failure. Removing large amounts of fluid during dialysis can cause cramping, low blood pressure, headaches, and nausea. SUPPLEMENTS Typically, people on dialysis take prescription kidney vitamins to replace nutrients and minerals lost during dialysis. Some nephrologists recommend other kinds of nutritional supplements to meet individual needs. Any over-the-counter supplements you may want to take should be discussed with your dialysis team before starting. KIDNEY. ORG 19 Financial Resources EMPLOYER GROUP HEALTH INSURANCE PROGRAM (EGHP): If you already have commercial health insurance, you can keep it. If you are no longer able to work, you may be able to keep your benefits through COBRA. MEDICARE Medicare is not just for people who are age 65 and older.
----------------------------------------------------------------------


======================================================================
CHUNK 86 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_6
Content Type: general
Words: 483
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
If you are no longer able to work, you may be able to keep your benefits through COBRA. MEDICARE Medicare is not just for people who are age 65 and older. The government program also helps US citizens and legal residents of all ages who need dialysis or a kidney transplant. Over 90% of Americans with kidney failure, which Medicare calls End-Stage Renal Disease or ESRD, have Medicare. If you (or your spouse or parent) have worked long enough to qualify for Medicare, it will pay most of your treatment costs, plus some or all of the costs for hospital stays, visits to doctors, and other services. 20 NATIONAL KIDNEY FOUNDATION If you have insurance through your or your spouses employer (Employee Group Health Plan), you can still apply for Medicare. Please call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email us at nkfcareskidney. org to learn more. When someone first enrolls in Medicare with a diagnosis of kidney failure (ESRD), Medicare coverage usually starts: On the fourth month of dialysis treatment Medicare coverage can start as early as the first month of dialysis if: You enroll in a home dialysis training program You start home dialysis training before the third month of dialysis; and are expected to finish home dialysis training and do dialysis at home. KIDNEY. ORG 21 MEDICAID Medicaid is a federal, government-sponsored insurance program, which is available to people who meet income requirements. Usually, eligibility for Medicaid benefits is the same as those used for Federal Poverty Guidelines. There are many levels of Medicaid insurance. In addition to federal Medicaid insurance, you may be eligible for additional coverage issued by your state and county. Some counties offer assistance with transportation and may help you qualify for Supplemental Nutrition Assistance Program (SNAP, formerly called the Food Stamp Program). SOCIAL SECURITY DISABILITY (SSD) Usually, 20 work credits earned in the last 10 years are needed to qualify. However, younger workers may be eligible for disability benefits with fewer work credits. If you are disabled before the age of 24, you will need 6 earned credits in the three years prior to the start of your disability. If you do not have enough work credits but have a long-term or permanent disability, you may be able to qualify for Supplemental Security Insurance benefits without any earned work credits. 22 NATIONAL KIDNEY FOUNDATION Living Well on Dialysis Starting dialysis can affect many parts of your day-to-day life. Many people find comfort in keeping their routines as close as possible to their alreadyestablished lifestyle. Others may prefer to focus on their dialysis treatment and adjusting to their routine. And, there are also those who feel kidney transplantation is their best treatment option. There are no right or wrong feelings. Always remember, choosing to have dialysis is a personal choice and the decision is always yours. KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 87 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_7
Content Type: reference
Words: 493
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
And, there are also those who feel kidney transplantation is their best treatment option. There are no right or wrong feelings. Always remember, choosing to have dialysis is a personal choice and the decision is always yours. KIDNEY. ORG 23 TRAVEL Most patients who receive dialysis can travel safely and continue their treatment while away from home. You should always consult your doctor before planning to travel. Most doctors encourage travel if your health is good. Traveling can give a big boost to your morale and sense of well-being. Many dialysis centers have a staff member who is experienced in arranging dialysis treatments away from home (transient dialysis). Some centers will help patients make travel arrangements. Ask your social worker or nephrology nurse to assist you. In addition, dialysisfinder. com is a website that has listings and contact information for dialysis centers across the US and around the world. Your Medicare and commercial insurance will likely pay the same amount as it would at your home center. Medicaid benefits usually have limited coverage outside of your home state. When you book travel, contact the agency so you know the amount of your financial responsibility. HOME HEMODIALYSIS People who are on home hemodialysis can travel but may want to make plans for in-center treatments while away. Some people prefer to travel with their machine, supplies, and portable water treatment equipment. 24 NATIONAL KIDNEY FOUNDATION PERITONEAL DIALYSIS People on peritoneal dialysis (PD) should plan ahead and arrange for back-up medical care while traveling. Contact a dialysis center thats near where you will be staying and see if you could go there if you have an emergency. The center may request a copy of medical records in advance. You should always carry a copy of your records with you. EMPLOYMENT Many people who are receiving dialysis treatment can go back to work after they have gotten used to their dialysis routine. However, if your job requires a lot of physical labor (heavy lifting, digging, etc), you may be unable to continue working. You should work out your dialysis schedule with your employer. Most employers are flexible about your need for dialysis. It is also important to understand your rights under the federal Americans with Disabilities Act (ADA). For example, working out your employment schedule with your dialysis schedule is a reasonable accommodation that employers are required to make under the ADA, unless they can prove it is an unnecessary hardship. Ask your nephrology social worker for more information. KIDNEY. ORG 25 Additional Resources NKF PATIENT AND FAMILY RESOURCES The National Kidney Foundation (NKF) has compiled a list of resources that you may find helpful. While we try to keep this list current, we cannot ensure the accuracy of information found on other websites. kidney. org/patients/resources NKF CARES Our Patient Information Help Line, NKF Cares, offers support for people affected by kidney disease, organ donation or transplantation. Its designed just for patients, family members and care partners.
----------------------------------------------------------------------


======================================================================
CHUNK 88 of 647
======================================================================
ID: 441_9378_2305_patbro_dialysisandyou_t2_8
Content Type: recommendation
Words: 290
Medical Entities: dialysis
Source: 441-9378_2305_patbro_dialysisandyou_t2.pdf

----------------------------------------------------------------------
kidney. org/patients/resources NKF CARES Our Patient Information Help Line, NKF Cares, offers support for people affected by kidney disease, organ donation or transplantation. Its designed just for patients, family members and care partners. Connect with a trained specialist who will answer your questions and listen to your concerns. Call toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org NKF PEERS Connect with a trained peer mentor who can share their experiences about dialysis, transplant, or living kidney donation with you. Call 855. NKF. PEER (855. 653. 7337) or go online kidney. org/patients/peers 26 NATIONAL KIDNEY FOUNDATION Setting a Standard for Care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 27 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 441-9378_2305
----------------------------------------------------------------------


======================================================================
CHUNK 89 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_0
Content Type: general
Words: 499
Medical Entities: CKD,dialysis,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
STAGES 1-5 Chronic Kidney Disease Are you at risk? Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Get support and hear from others who have experience with dialysis, transplant, living donation, and being a parent or care partneryou never know when youll inspire someone else! Join today at kidney. org/online-communities 2 NATIONAL KIDNEY FOUNDATION Contents About Chronic Kidney Disease 4 CKD Risk Factors 5 Diabetes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 High Blood Pressure. . . . . . . . . . . . . . . . . . . . . . . . . 6 Age. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Obesity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Heart Disease/Heart Failure. . . . . . . . . . . . . . . . . . . 12 Family History of CKD. . . . . . . . . . . . . . . . . . . . . . . 14 Social Determinants of Health 15 CKD and Race 18 CKD Prevention 19 Stop CKD in its Tracks. . . . . . . . . . . . . . . . . . . . . . 20 We Are Here To Help. . . . . . . . . . . . . . . . . . . . . . . . 25 Notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 KIDNEY. ORG 3 About Chronic Kidney Disease Chronic kidney disease (CKD) is a condition that develops when your kidneys arent working as well as they should. This means your kidneys cannot get rid of extra fluids and waste products in your blood. When the body cannot get rid of excess fluid and waste products serious problems, such as heart disease and stroke, can occur. If you have CKD and it gets worse, then the waste products and fluids continue to build up in your blood and you will probably start to feel very unwell. Its also likely you may notice other problemssymptoms may include things like high blood pressure and anemia, a condition in which there is a short supply of red blood cells in the body. Bottom lineanemia makes people feel tired and typically, they have very little energy.
----------------------------------------------------------------------


======================================================================
CHUNK 90 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_1
Content Type: general
Words: 476
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
Its also likely you may notice other problemssymptoms may include things like high blood pressure and anemia, a condition in which there is a short supply of red blood cells in the body. Bottom lineanemia makes people feel tired and typically, they have very little energy. CKD also increases your risk of worsening heart and blood vessel disease. CKD may progress slowly over a long time. Many people dont even know they have CKD until it is very bad. If it is found and treated early, 4 NATIONAL KIDNEY FOUNDATION CKD may often be slowed or stopped. If it worsens, however, CKD can lead to kidney failure. People with kidney failure are coping with a very serious disease. When you have a diagnosis of kidney failurethat means your kidneys no longer work well enough to keep you alive, and you need to go on dialysis or have a kidney transplant. CKD Risk Factors Anyone can have CKDat any age. However, some people are more likely than others to develop CKD. The 2 most common CKD risk factors are diabetes and/or high blood pressure (hypertension) You may have an increased risk for developing CKD if you have obesity, over 60 years of age, have heart disease or heart failure, and/or have family members who have had CKD or kidney failure. Diabetes Diabetes (also called sugar diabetes or sugar disease) is a disease that causes your blood sugar levels to be too high. Blood sugar is your bodys main source of energy. It comes from your food and is carried in your blood to your cells. When you have diabetes, your body either doesnt produce enough insulin or doesnt use insulin properly. Insulin is a hormone that helps your body use blood sugar for energy. KIDNEY. ORG 5 DIABETES AND CKD: Diabetes damages the kidneys by making them work harder to filter blood. This can cause the kidneys to scar and lose their ability to filter waste products from the blood. High blood sugar can also damage your blood vessels in the kidneys, further reducing kidney function. In the United States, about 37 million people have diabetes, and about 1 in 3 will develop CKD. PREVENTION: There is no cure for diabetes, but it can be managed with diet, exercise, and medication. By managing your diabetes, you can lower your risk of developing CKD. If you have diabetes, it is important to have your kidneys checked regularly by a doctor. High Blood Pressure High blood pressure (hypertension) is a health problem that makes your blood pressure too high. This can hurt your kidneys over time and cause CKD. H3 HIGH BLOOD PRESSURE AND CKD: High blood pressure makes your kidneys work harder. This can cause scarring of the kidneys making them unable to filter blood well. High blood pressure can also damage the blood vessels in the kidneys.
----------------------------------------------------------------------


======================================================================
CHUNK 91 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_2
Content Type: general
Words: 497
Medical Entities: CKD,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
This can hurt your kidneys over time and cause CKD. H3 HIGH BLOOD PRESSURE AND CKD: High blood pressure makes your kidneys work harder. This can cause scarring of the kidneys making them unable to filter blood well. High blood pressure can also damage the blood vessels in the kidneys. 6 NATIONAL KIDNEY FOUNDATION In the United States, about 1 in 2 adults have high blood pressure and about 1 in 5 adults with high blood pressure will develop CKD. PREVENTION: There is no cure for high blood pressure, but it can be treated. By treating your high blood pressure, you can lower your risk of developing CKD. This includes taking your medications as prescribed, eating a healthy diet, exercising regularly, and losing weight if you have obesity. If you have high blood pressure, it is important to have your kidneys checked regularly by a doctor. KIDNEY. ORG 7 Age As people age, kidneys are less able to filter waste products from the blood than in younger people. This is because kidneys naturally decline in function over time. AGE AND CKD: The exact cause of age-related CKD is not fully understood, but it is thought to be due to a combination of factors, including: Natural aging process: Kidneys naturally decline in function over time Pre-existing conditions: People with other health conditions, such as high blood pressure, diabetes, obesity, and heart disease or heart failure, are at an increased risk of developing CKD Exposure to toxins: Certain toxins, such as lead and mercury, can damage the kidneys and increase a persons risk of developing CKD After the age of 40, it is normal to have a decline in your kidney filtration rates. 8 NATIONAL KIDNEY FOUNDATION PREVENTION: While you cannot prevent getting older, there are steps you can take to prevent developing CKD as you age. These are some ways to keep your kidneys as healthy as possible as you are getting older: 1. Eat less salt: Many seniors dont realize just how much salt theyre consuming on a daily basis. Eating too much salt can increase blood pressure. Salt can also increase the chances of developing kidney stones, which can hurt your kidneys. 2. Keep diabetes well-controlled: CKD is considered a secondary disease. This is because developing CKD is often the direct result of other conditions, such as diabetes. If you do not have well-managed diabetes, you may be placing a lot of strain on your kidneys. 3. Stay well-hydrated: A key purpose of the kidneys is to filter toxins out of the blood and then get rid of the wastes through your urine (pee). If you dont drink enough water every KIDNEY. ORG 9 day, your body may not be able to fully remove the wastes from your body. If you are not wellhydrated, you increase the chances that you may develop kidney stones and CKD. Its a good idea to check with your healthcare professional to see how much fluid you should drink daily. 4.
----------------------------------------------------------------------


======================================================================
CHUNK 92 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_3
Content Type: general
Words: 487
Medical Entities: CKD,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
If you are not wellhydrated, you increase the chances that you may develop kidney stones and CKD. Its a good idea to check with your healthcare professional to see how much fluid you should drink daily. 4. Reduce alcohol and caffeine: The liquids you drink go through your body, pass through your kidneys, and leave your body in your urine. Drinking too much alcohol can dehydrate you and stress your kidneys, while too much caffeine can increase your blood pressure and also make your kidneys work harder. Plain water is the best liquid to drink. 5. Limit using painkillers: Be careful with pain medicine, some prescription and over-thecounter pain medicines can hurt your kidneys if you take them a lot. If you need to take pain medicine, talk to your doctor about the best ones for you. 6. Treat urinary tract infections: Urinary tract infections (UTIs) are germs that spread up the urethra (a duct, or tube that lets urine pee leave your body) and into the kidneys. When germs get into your kidneys, longterm damage can happen, so its important to treat UTIs as soon as possible. If it hurts when you urinate or if your pee looks cloudy, tell a doctor so you can get better. Antibiotic therapy can stop UTIs before the infection gets to your kidneys. 10 NATIONAL KIDNEY FOUNDATION Obesity Obesity is a condition in which a person has excess body fat. There are a number of ways to measure obesity, including body mass index (BMI), body fat percentage, and waist circumference: BMI is a measure of body fat based on height and weight, but it does not take into account factors such as muscle mass and body fat distribution. Body fat percentage is a more accurate measure of obesity than BMI. It is the percentage of body weight that is made up of fat. Waist circumference is another measure of obesity. It is the circumference of the waist at the level of the navel. A healthy waist circumference for adults ranges from under 40 inches for men and less than 35 inches for women. KIDNEY. ORG 11 Rising rates of obesity and diabetes in the United States are linked to increased risks of high blood pressure and are projected to cause an 11% to 18% surge in kidney failure by 2030. OBESITY AND CKD: Obesity is a major risk factor for CKD and it can lead to high blood pressure, which is the second leading cause of CKD. High blood pressure can damage the blood vessels in the kidneys, making it difficult for the kidneys to filter waste products from the blood. Obesity can also lead to insulin resistance, which is a condition in which the bodys cells do not respond normally to insulin (a hormone that helps the body use glucose for energy). When cells are resistant to insulin, glucose builds up in the blood, which can damage the kidneys.
----------------------------------------------------------------------


======================================================================
CHUNK 93 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_4
Content Type: general
Words: 487
Medical Entities: CKD,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
Obesity can also lead to insulin resistance, which is a condition in which the bodys cells do not respond normally to insulin (a hormone that helps the body use glucose for energy). When cells are resistant to insulin, glucose builds up in the blood, which can damage the kidneys. PREVENTION: Obesity is a chronic disease, but it can be prevented or managed with a healthy diet, regular exercise, and a healthy weight. If you have obsity, it is important to talk to your doctor about how to lose weight and manage your risk of CKD. Heart Disease/Heart Failure Heart disease and heart failure are two major conditions that affect the heart. Heart disease is a group of conditions that damage the heart and blood vessels. 12 NATIONAL KIDNEY FOUNDATION The most common cause of death in people with CKD is heart disease. It can cause narrowed or blocked blood vessels and lead to a heart attack. Heart failure occurs when the heart cannot pump enough blood to meet the bodys needs. HEART DISEASE/HEART FAILURE AND CKD: Both heart disease and heart failure are risk factors for developing CKD because both conditions can damage the kidneys. The main causes of heart disease are the same as CKD, which are diabetes and high blood pressure. If you already have CKD, you are at higher risk for developing heart disease. PREVENTION: You can help prevent heart disease by eating healthy foods, exercising, and not smoking. Its also important to keep your blood pressure and cholesterol levels in check. If you have diabetes, its important to manage it well. Taking these steps can help keep your heart healthy and strong. KIDNEY. ORG 13 Family History of CKD Some diseases are said to run in the family when more than one person has the same illness. Its true that some diseases and conditions, such as sickle cell anemia, that can affect multiple family members are caused by gene variants (also known as mutations) and can be inherited (passed down from parent to child). Since CKD affects some families more than others understanding the factors that can lead to the disease is important so that you can prevent CKD from developing. Also, if you know you are at risk for CKD, then you can take the right stepsright awayto slow down or stop the disease from getting worse. 14 NATIONAL KIDNEY FOUNDATION Social Determinants of Health People develop CKD for a number of reasons, and many factors can increase your chances of getting it. Some of these things are medical, like having high blood pressure or diabetes. However, environmental factors can also play a part. For example, breathing in dirty air can hurt our lungs, while while drinking contaminated water can cause stomach infections. In addition, there are social factors, which are things like how much money we have, our education level, and our relationships with family and friends can affect our health.
----------------------------------------------------------------------


======================================================================
CHUNK 94 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_5
Content Type: general
Words: 491
Medical Entities: CKD,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
For example, breathing in dirty air can hurt our lungs, while while drinking contaminated water can cause stomach infections. In addition, there are social factors, which are things like how much money we have, our education level, and our relationships with family and friends can affect our health. Discrimination and not having access to healthcare can also increase the risk of developing CKD. According to the US Department of Health and Human Services, Office of Disease Prevention and Health Promotion report, Healthy People 2030, these social factors are called Social Determinants of Health, (SDoH), and they are the conditions in the environments, such as where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. For example, if you are not able to buy healthy food at a store near you, then it will be hard for you to eat well. People who cannot eat healthy foods are more likely to develop serious health conditions like heart disease, diabetes, obesity, and CKD. KIDNEY. ORG 15 SDoH can contribute to developing serious long-term diseases such as high blood pressure, diabetes, lupus nephritis, and obesityall conditions that increase your risk of developing CKD. In addition, your genetics or having family members with CKD may also play a role. Its not always easy to be healthy or have a healthy lifestyle. And why is that? Wellthe short answer is that many people, especially people living, working, and learning in under-resourced communities, simply do not have access to the very basics that are needed, such as open and green spaces like parks, reliable public transportation, healthy foods to eat, and access to appropriate medical care. All of Us Research Program, National Institutes of Health, US Department of Health Human services, Social determinants of health, Twitter, June 1, 2022. Accessed May 10, 2023. twitter. com/AllofUsResearch/status/1532106012576063488 16 NATIONAL KIDNEY FOUNDATION Other reasons include not having health insurance, not having a regular doctor who knows you and your medical history, and local healthcare and policy issues, which may not provide a clear path for patients to follow. For example, if you are pregnant and unable to get good prenatal care, you can develop eclampsia (a type of high blood pressure that can occur during pregnancy and cause seizureswhich can be lifethreatening to both baby and mom) and other conditions. Eclampsia can also lead to long-term kidney damage. KIDNEY. ORG 17 CKD and Race Over 37 million adults in the United States have CKD and the people who are most at risk self-identify their race as: Black/African American Hispanic/Latino American Indian/Alaska Native Asian American Native Hawaiian/Other Pacific Islander Biracial Multiracial The reason why some people are at higher risk of developing CKD is due to the SDoH, which has been caused by race-based social, economic, and political decisions that were made decades ago. These unfair decisions have impacted many urban and rural areas throughout the US.
----------------------------------------------------------------------


======================================================================
CHUNK 95 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_6
Content Type: general
Words: 489
Medical Entities: CKD,GFR,hypertension,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
These unfair decisions have impacted many urban and rural areas throughout the US. Some racial groups have a higher risk of developing CKD than othersbut their increased risk is not due to their race. 18 NATIONAL KIDNEY FOUNDATION CKD Prevention While many are at risk for developing CKD, not everyone does. There are usually a number of factors that come together to cause the disease. Remember, knowing the risk factors lets you take charge of your health. If you have any risk factors, you should: Get tested for CKD with 2 simple tests: A urine (pee) test (urine albumin/creatinine ratioalso known as uACR) checks to see if you have protein in your urine. Your body needs protein. But it should only be in the blood, not your urine. A small amount of protein in your urine may mean your kidneys are not filtering your blood well enough, which can be an early sign of CKD. A blood test (estimated glomerular filtration rateeGFR) measures how well your kidneys work. Labs calculate eGFR using creatinine levels (a normal waste product in the blood), along with your age and gender. Get tested for diabetes, high blood pressure, and heart disease. If you dont know if you have diabetes, high blood pressure, or heart disease, its important for you to find out. KIDNEY. ORG 19 Stop CKD in its Tracks And, if you already have CKD, these tips can help you to slow down or stop CKD from getting worse. SEE YOUR HEALTHCARE PROVIDER AT LEAST ONCE A YEAR You take your car in for a tune-up to make sure it runs smoothly, and you should take the same care of your body. Your doctor can check for kidney disease with 2 simple tests: a urine test and a blood test. Make sure to get tested at least once a year. CONTROL BLOOD PRESSURE High blood pressure can damage your kidneys. If your blood pressure remains high, your doctor may have you take medicine. Simple tweaks to your lifestyle, such as cutting back on salt and alcohol, losing excess weight, and exercising can help keep your blood pressure in check. 20 NATIONAL KIDNEY FOUNDATION MANAGE BLOOD SUGAR Blood sugar levels can be influenced by several factors, including those out of a persons control such as hormones, illness, or stress. Over time, high blood sugar levels can cause blood vessels inside the kidney to become narrow and clogged which can damage blood vessels and harm the kidneys. If you have diabetes, the best way to protect your kidneys is to manage blood sugar levels as best as possible. Your treatment plan may include changes to your diet, exercise, and medicine to lower your blood sugar levels. EAT A HEALTHY DIET A healthy diet plan, such as the Mediterranean Diet and the DASH (Dietary Approaches to Stop Hypertension) Diet, can help lower blood pressure and the amount of blood lipids (fat in the blood). KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 96 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_7
Content Type: recommendation
Words: 484
Medical Entities: hypertension,diabetes
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
EAT A HEALTHY DIET A healthy diet plan, such as the Mediterranean Diet and the DASH (Dietary Approaches to Stop Hypertension) Diet, can help lower blood pressure and the amount of blood lipids (fat in the blood). KIDNEY. ORG 21 These meals include fresh fruits and vegetables, fatfree or low-fat milk and milk products, whole grains, fish, poultry, beans, seeds, and nuts. They also have less salt, sugars, fats, and red meats. KEEP ACTIVE Youve heard it before! But its important to repeat exercise can help you: Maintain a healthy weight Control your blood pressure and cholesterol Build strength and endurance Lower your chances of getting diabetes, heart disease, and kidney disease 22 NATIONAL KIDNEY FOUNDATION Many types of exercises can help you stay healthy including walking, household chores, playing a sport, or aerobic exercise (jogging, swimming, biking, climbing stairs, or hiking). STOP SMOKING Everyone is well aware of the dangers associated with smoking. Smoking causes diseases in every organ of the body, including the kidneys. If you cannot quit smoking on your own, ask your doctor about treatment options. You can also visit smokefree. gov for free help and support to stop smoking. LIMIT OVER-THE-COUNTER PAIN MEDICATIONS Over-the-counter pain medications can cause kidney damage. These medications are called NSAIDs (nonsteroidal anti-inflammatory drugs) and include products like Advil (ibuprofen) and Aleve (naproxen). They are typically used to lower fevers like when someone has the flu and to reduce aches and pains due to inflammation like when we have a minor muscle ache from playing sports. KIDNEY. ORG 23 Studies have found that NSAIDs may increase the risk of developing kidney disease. Long-term use of NSAIDs, especially at high doses, reduces the blood flow to the kidney which can cause harm to kidney tissue. Its important to know that Tylenol (acetaminophen) is not an NSAID and is an appropriate medication to use to lower fevers and reduce minor aches and pains associated with inflammation. If you are taking NSAIDs, you should ask your doctor about other medicines to manage pain, such as acetaminophen. 24 NATIONAL KIDNEY FOUNDATION We Are Here To Help There are two ways to learn about the many free resources available to you: Call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Learn more at kidney. org KIDNEY. ORG 25 Notes: 26 NATIONAL KIDNEY FOUNDATION Setting a Standard for Care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management.
----------------------------------------------------------------------


======================================================================
CHUNK 97 of 647
======================================================================
ID: 441_9471_2307_patbro_riskfactors_t3_002_8
Content Type: recommendation
Words: 152
Medical Entities: dialysis
Source: 441-9471_2307_patbro_riskfactors_t3_002.pdf

----------------------------------------------------------------------
The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 27 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 443-9471_2307
----------------------------------------------------------------------


======================================================================
CHUNK 98 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_0
Content Type: general
Words: 491
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
HIGH BLOOD PRESSURE AND CHRONIC KIDNEY DISEASE Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Get support and hear from others who have experience with dialysis, transplant, living donation, and being a parent or care partneryou never know when youll inspire someone else! Join today at kidney. org/online-communities 2 NATIONAL KIDNEY FOUNDATION Contents High Blood Pressure and Chronic Kidney Disease. . 4 High blood pressure is the second leading cause of CKD? . . . . . . . . . . . . . . . . . . . 5 High Blood Pressure and Kidney Damage. . . . . . . . . . 6 Protecting Your Kidneys When You Have High Blood Pressure. . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Tests for High Blood Pressure and CKD. . . . . . . . . . . 9 Cholesterol, Fats, High Blood Pressure, and CKD. 12 Pregnancy, High Blood Pressure, and CKD 13 Key Points To Remember 16 We Are Here To Help. . . . . . . . . . . . . . . . . . . . . . . . . . . 17 KIDNEY. ORG 3 High Blood Pressure and Chronic Kidney Disease Blood pressure is an important measurement of your health. It tells you how hard your blood is pushing against the walls of your arteries. This measurement provides valuable information about your bodys functioning. When your blood pressure is at the right level, your body gets the oxygen and nutrients it needs. Keeping your blood pressure in a healthy range is important for your overall health and well-being. High blood pressure, or hypertension, happens when blood pushes against your artery walls too hard and for too long. Many things can cause high blood pressure, including: Getting older Having a family history of high blood pressure Being overweight Not physically active Using tobacco Eating too much salt 4 NATIONAL KIDNEY FOUNDATION Drinking too much alcohol Having too much stress High blood pressure can cause problems in your body. It makes your heart work too hard, can damage your arteries, and increase the risk of heart disease, stroke, and chronic kidney disease. High blood pressure and chronic kidney disease (CKD) are closely linked. Approximately 1 in 5 people have high blood pressure, and many are at risk of developing CKD due to the harmful effects of long-term high blood pressure on the kidneys. When blood pushes too hard in your kidneys, it can lead to CKD over time. ? Did you know High blood pressure is the second leading cause of CKD? Diabetes is the first. KIDNEY. ORG 5 Likewise, CKD can contribute to high blood pressure. When your kidneys dont work well, they struggle to keep salt and water balanced in your body, causing high blood pressure.
----------------------------------------------------------------------


======================================================================
CHUNK 99 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_1
Content Type: reference
Words: 486
Medical Entities: CKD,diabetes
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
? Did you know High blood pressure is the second leading cause of CKD? Diabetes is the first. KIDNEY. ORG 5 Likewise, CKD can contribute to high blood pressure. When your kidneys dont work well, they struggle to keep salt and water balanced in your body, causing high blood pressure. Its a two-way relationship, which is why its so important both conditions are managed well. High Blood Pressure and Kidney Damage High blood pressure can hurt your kidneys in two ways: Damage blood vessels in the kidneys: High blood pressure can harm blood vessels in the kidneys, making them less able to clean your blood Makes the kidneys work too hard: High blood pressure forces the kidneys to work harder and clean more blood than normal which can cause kidney damage 6 NATIONAL KIDNEY FOUNDATION Protecting Your Kidneys When You Have High Blood Pressure Having high blood pressure doesnt mean youll definitely get CKD. There are steps you can take to lower your risk such as: Eat a healthy diet: Eat various fruits, vegetables, whole grains, and lean proteins. Limit your intake of saturated and trans fats, cholesterolrich foods, and processed foods. Take prescribed medications: If your healthcare provider has prescribed cholesterol-lowering or blood pressure medications, take them as directed. These medications can help control blood pressure and reduce the strain on your kidneys. KIDNEY. ORG 7 Be active: Regular physical activity can help to maintain a healthy weight, improve blood circulation, and manage your blood pressure. Aim for at least 150 minutes of moderateintensity aerobic exercise per week. Manage your weight: Maintaining a healthy weight is a key step for people with high blood pressure. If you are overweight, losing even a small amount of weight can make a big difference in your overall health. Avoid smoking: Smoking damages your blood vessels and increases the risk of developing high blood pressure and CKD. Quitting smoking can significantly improve your heart health and protect your kidneys. Drink less alcohol: Drinking too much can raise your blood pressure. 8 NATIONAL KIDNEY FOUNDATION Tests for High Blood Pressure and CKD You cant take care of something if you dont know its there. Regular testing can help keep high blood pressure and CKD under control. These are some of the common tests used to screen and monitor high blood pressure and CKD: High blood pressure: Home blood pressure machines Electrocardiograms (EKGs), which measure and record electrical activity in the heart Calculate your body mass index (BMI) by comparing your weight to your height Regularly checking the levels of fat in your blood A1C to screen and manage prediabetes and diabetes KIDNEY. ORG 9 STEP 4: Get 4 Easy Tests TYPE OF TEST WHY ITS IMPORTANT TARGET GOAL Blood Pressure High blood pressure can damage small Good 140/90 or lower blood vessels (glomeruli) in the kidneys. It is Better 130/80 or lower the second-leading cause of kidney failure after diabetes.
----------------------------------------------------------------------


======================================================================
CHUNK 100 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_2
Content Type: general
Words: 487
Medical Entities: GFR,proteinuria,albuminuria,diabetes
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
ORG 9 STEP 4: Get 4 Easy Tests TYPE OF TEST WHY ITS IMPORTANT TARGET GOAL Blood Pressure High blood pressure can damage small Good 140/90 or lower blood vessels (glomeruli) in the kidneys. It is Better 130/80 or lower the second-leading cause of kidney failure after diabetes. Best 120/80 or lower Check with your healthcare team to see if your blood pressure is at the right level for you. A1C A blood test that measures the percentage of Normal 5. 7% or lower (hemoglobin A1C) glucose, or sugar, thats in your blood. The test Prediabetes Between 5. 7% and 6. 4% is used to diagnose prediabetes and diabetes. Diabetes 6. 5% or over ACR Traces of a type of protein called albumin in Under 30 mg of albumin per gram of urinary (albumin-tothe urine (albuminuria) may be an early sign of creatinine (a normal waste product) creatinine ratio) kidney disease. Increased amounts of albumin and other proteins in the urine (proteinuria) indicate kidney damage. eGFR Test is used to measure how well the kidneys Over 90 is good (estimated are working by checking creatinine levels in 60-89 should be monitored glomerular blood and using a calculation to find out your filtration rate) glomerular filtration rate (GFR). Less than 60 for 3 months indicates kidney disease ST ECPK D5: : Stay Healthy STEP 6: Learn More Estimated glomerular filtration rate (eGFR) 6 THINGS PEOPLE WITH KIDNEY DISEASE RESOURCES: sees how well your kidneys are working SHOULD DO: National Kidney Foundation. kidney. org Low eUrr ihnieg ahl bbulomoindtpor-ecsresuatrienine ration (uACR) Are you at risk for kidney disease? Take the Mancahgeec bkslo foodr psruogteairn l einv eyolsur pee, which may Kidney Risk Quiz. MinuteForYourKidneys. org Redu b c e e a s s a ig lt n i n o t f a k k i e dney damage Centers for Disease Control and Prevention Avo iUdl torvaseor-uthnde -ocro CunT tsecra nno snhsotwerso aid picture of (CDC) Chronic Kidney Disease Basics. antiinyofluarm kmidanteoyrsy a dnrdu ugrsin (aNrSy AsIyDstse) msu. cThh easse cdc. gov/kidneydisease/basics aspirpinic t(uerge, s B sahyoewr t, h Beu sfifzeer ionf y), o iubru kpidronfeeyns. National Institute of Diabetes and Digestive (eg, TAudmvoilrs, , M kiodtnrieny )s, t oanneds, n oarp croysxtesn c (aeng a, lAsole ve) and Kidney Diseases (NIDDK) Kidney Disease. Modbeera steee pnr oonte ain s ccaonn sumption niddk. nih. gov/health-information/ Get an annual flu shot kidney-disease 10 9 THINGS EVERNYATOIONNEAL S KHIDONEUY LFODU NDDOAT: ION Exercise regularly Control weight Follow a well-balanced diet Quit smoking Drink only in moderation For more information, contact the Stay hydrated National Kidney Foundation Monitor cholesterol levels Get an annual physical and kidney tests Toll-free help line: 855. NKF. CARES Know your family medical history or email: nkfcareskidney. org KIDNEY. ORG This content is provided for informational use only and is not intended as medical advice or as a substitute for the medical advice of a healthcare professional.
----------------------------------------------------------------------


======================================================================
CHUNK 101 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_3
Content Type: general
Words: 475
Medical Entities: CKD,GFR,proteinuria,albuminuria,diabetes
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
NKF. CARES Know your family medical history or email: nkfcareskidney. org KIDNEY. ORG This content is provided for informational use only and is not intended as medical advice or as a substitute for the medical advice of a healthcare professional. 2021 National Kidney Foundation, Inc. 441-9040_2102 STEP 4: Get 4 Easy Tests TYPE OF TEST WHY ITS IMPORTANT TARGET GOAL Blood Pressure High blood pressure can damage small Good 140/90 or lower blood vessels (glomeruli) in the kidneys. It is Better 130/80 or lower the second-leading cause of kidney failure after diabetes. Best 120/80 or lower Check with your healthcare team to see if your blood pressure is at the right level for you. A1C A blood test that measures the percentage of Normal 5. 7% or lower (hemoglobin A1C) glucose, or sugar, thats in your blood. The test Prediabetes Between 5. 7% and 6. 4% is used to diagnose prediabetes and diabetes. Diabetes 6. 5% or over ACR Traces of a type of protein called albumin in Under 30 mg of albumin per gram of urinary (albumin-tothe urine (albuminuria) may be an early sign of creatinine (a normal waste product) creatinine ratio) kidney disease. Increased amounts of albumin and other proteins in the urine (proteinuria) indicate kidney damage. eGFR Test is used to measure how well the kidneys Over 90 is good (estimated are working by checking creatinine levels in 60-89 should be monitored glomerular blood and using a calculation to find out your filtration rate) glomerular filtration rate (GFR). Less than 60 for 3 months indicates kidney disease STEP 5: Stay Healthy STEP 6: Learn More 6 THINGS PEOPLE WITH KIDNEY DISEASE RESOURCES: SHOULD DO: National Kidney? FoundatiDoind. ykoidun keny. oowrg Lower high blood pressure Are you at risk for kidneyP deoispelaes we? h oT ahkaev et hreeceived a kidney Manage blood sugar levels Kidney Risk Quiz. MinutetFraonrsYpoluanrKt icdanne dyesv. oerlogp CKD and Reduce salt intake Centers for Disease Cont h r i o g l h a b n l d o o P d r e p v r e e n ss ti u o r n e? Avoid over-the-counter nonsteroid (CDC) Chronic Kidney Disease Basics. Regular check-ups and living a antiinflammatory drugs (NSAIDs) such as cdc. gov/kidneydisease/basics healthy lifestyle can help protect aspirin (eg, Bayer, Bufferin), ibuprofen National Institute of Diabyeotuers naenwd kDidigneesyt! i v e (eg, Advil, Motrin), and naproxen (eg, Aleve) and Kidney Diseases (NIDDK) Kidney Disease. Moderate protein consumption niddk. nih. gov/health-information/ Get an annual flu shot kidney-disease 9 THINGS EVERYONE SHOULD DO: KIDNEY. ORG 11 Exercise regularly Control weight Follow a well-balanced diet Quit smoking Drink only in moderation For more information, contact the Stay hydrated National Kidney Foundation Monitor cholesterol levels Get an annual physical and kidney tests Toll-free help line: 855. NKF. CARES Know your family medical history or email: nkfcareskidney. org KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 102 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_4
Content Type: recommendation
Words: 499
Medical Entities: CKD,hypertension
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
NKF. CARES Know your family medical history or email: nkfcareskidney. org KIDNEY. ORG This content is provided for informational use only and is not intended as medical advice or as a substitute for the medical advice of a healthcare professional. 2021 National Kidney Foundation, Inc. 441-9040_2102 Cholesterol, Fats, High Blood Pressure, and CKD When it comes to cholesterol and fats in your blood, its important to keep them in check. Just like hard butter can clog your arteries, high cholesterol levels, and other fats in your blood can lead to health problems and can contribute to the development of high blood pressure and cause harm to your kidneys. High blood pressure can be caused and get worse by eating an unhealthy diet high in cholesterol and unhealthy fats. These substances can build up in your blood vessels, making them narrower and less flexible. As a result, your heart has to work harder to pump blood through these narrowed vessels, leading to an increase in blood pressure. High cholesterol and fats in your blood can also harm your kidneys. When your blood vessels become damaged or narrowed, it affects the blood flow to your kidneys. This can reduce their ability to effectively filter waste and excess fluids from your blood. Over time, this can lead to kidney damage and increase the risk of developing CKD. By making healthy lifestyle choices and following your healthcare providers recommendations, you can help manage your cholesterol and fat levels, reduce your risk of high blood pressure, and safeguard the health of your kidneys. Remember, even small steps towards a healthier lifestyle can lead to big improvements in your overall well-being. 12 NATIONAL KIDNEY FOUNDATION Pregnancy, High Blood Pressure, and CKD Pregnancy can have several risks for women with CKD and high blood pressure. Here are the important things to be aware of: Pre-eclampsia: This is when a pregnant woman has high blood pressure and has signs that some of her organs, like her kidneys and liver, may not be working normally. It usually starts after the 20th week of pregnancy in women whose blood pressure had been normal. Pre-eclampsia can be dangerous for the mother and the baby if not treated. It can stop the baby from getting enough blood and oxygen. It can also cause harm to the moms kidneys and liver. KIDNEY. ORG 13 Eclampsia: This is a more severe form of preeclampsia and it can lead to seizures in the mother. If not treated, it can cause coma and even death for both the mother and the baby. Gestational hypertension: High blood pressure that starts after the 20th week of pregnancy can lead to gestational hypertension. This condition differs from pre-eclampsia because there are no signs of organ injury. Gestational hypertension may increase the likelihood of preterm birth, low birth weight, and placental abruption (when the placenta becomes detached from the uterus before delivery). Worsening kidney function: Pregnancy places extra stress on the kidneys, especially for women who already have CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 103 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_5
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,dialysis,hypertension
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
Gestational hypertension may increase the likelihood of preterm birth, low birth weight, and placental abruption (when the placenta becomes detached from the uterus before delivery). Worsening kidney function: Pregnancy places extra stress on the kidneys, especially for women who already have CKD. Depending on the severity of kidney function loss, additional treatments such as dialysis, may be needed. 14 NATIONAL KIDNEY FOUNDATION Acute kidney injury (AKI): A sudden loss of kidney function and women with high blood pressure and CKD are at increased risk. AKI can occur during pregnancy and poses risks to both the mother and the baby. It is important to seek medical attention immediately to treat an AKI. Premature birth: Women with CKD and high blood pressure have an increased risk of delivering their baby prematurely, before 37 weeks of pregnancy. Premature infants may require specialized care due to potential health complications. Fetal growth restriction: Having both CKD and high blood pressure during pregnancy may impact the babys growth, leading to fetal growth restriction (when a baby in the uterus does not grow to normal weight during pregnancy). This can result in a low-birthweight baby with a higher risk of having medical problems. Increased risk of cesarean delivery: Women with CKD and high blood pressure may have a higher likelihood of needing a cesarean section (C-section) for delivery. Regular checks with a healthcare provider during pregnancy can find these problems early. Your healthcare provider can then work with you to make sure your pregnancy is as safe as possible. KIDNEY. ORG 15 Key Points To Remember Understanding the link between high blood pressure and CKD is important for overall health. High blood pressure can harm your kidneys over time, leading to CKD. On the other hand, CKD can also contribute to high blood pressure. Its a two-way relationship. To prevent CKD, its necessary to manage your high blood pressure effectively. This includes making healthy lifestyle choices and following your healthcare providers advice. By reducing your salt intake, being physically active, maintaining a healthy weight, and limiting alcohol, you can lower your risk of developing CKD. Taking prescribed medications as directed is also important for controlling blood pressure and protecting your kidneys. High blood pressure damages the blood vessels in your kidneys, making it harder for them to filter waste and maintain a proper balance of fluids. Regular monitoring through recommended tests, such as EKG, BMI assessments, and lipid profiles for high blood pressure, as well as eGFR and uACR tests for CKD, can help catch issues early. Remember, small steps can make a big difference in keeping your blood pressure under control and maintaining kidney health. If you have questions, speak with your healthcare team. They know you and can answer questions about you. 16 NATIONAL KIDNEY FOUNDATION We Are Here To Help There are two ways to learn about the many free resources available to you: Call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney.
----------------------------------------------------------------------


======================================================================
CHUNK 104 of 647
======================================================================
ID: 443_9484_2307_patbro_hbpandckd_t3_0_6
Content Type: recommendation
Words: 247
Medical Entities: dialysis
Source: 443-9484_2307_patbro_hbpandckd_t3_0.pdf

----------------------------------------------------------------------
16 NATIONAL KIDNEY FOUNDATION We Are Here To Help There are two ways to learn about the many free resources available to you: Call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Learn more at kidney. org KIDNEY. ORG 17 Setting a Standard for Care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. 18 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 19 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 443-9484_2307
----------------------------------------------------------------------


======================================================================
CHUNK 105 of 647
======================================================================
ID: about living donation_patient brochure_11_24_0
Content Type: general
Words: 496
Medical Entities: dialysis
Source: About Living Donation-Patient Brochure_11_24.pdf

----------------------------------------------------------------------
About Living Kidney Donation Contents About Living Donation. . . . . . . . . . . . . . . . . . . . . . . . . . 4 The Evaluation Process. . . . . . . . . . . . . . . . . . . . . . . . . . 8 Surgery and Recovery. . . . . . . . . . . . . . . . . . . . . . . . . 20 After Donation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Making an Informed Decision. . . . . . . . . . . . . . . . . . . . 24 More Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 The Sound of Change. Change starts with you. A nationwide community of people affected by kidney disease is coming together to create change and you can help. Join Voices for Kidney Health, a community of patient and health professional advocates working with elected officials and public leaders to create big solutions to help everyone facing the challenges of kidney disease. Protect living donors Expand access to home dialysis Advance healthcare equity Spur investment in prevention and research Join us voices. kidney. org 2 KIDNEY. ORG 3 About Living Donation What is living kidney donation? Living donation is when a living person donates an organ (or part of an organ) to another person. A healthy person who has two kidneys can donate one to someone in need. A living donor may donate to someone they know, like a family member, friend, or spouse, or a stranger who theyve never met. A potential donor is someone who is thinking about donating. A recipient is someone with kidney failure who needs a kidney transplant. Who can be a living kidney donor? To donate a kidney, the person must be in good physical and mental health. Living donors must be at least 18 years old to donate at a transplant center in the United States. Some centers require a donor to be 21 or even a little older. There are some medical conditions that could prevent someone from being a living donor, including having uncontrolled high blood pressure or cancer. 4 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 5 Each transplant center is different, so always let the Are there different types of living donation? transplant center decide who would be a good donor. THERE ARE TWO MAIN TYPES OF LIVING DONATION: If someone is not approved as a living donor at one transplant center, they may be able to get evaluated Directed Donation is when the donor names at other centers.
----------------------------------------------------------------------


======================================================================
CHUNK 106 of 647
======================================================================
ID: about living donation_patient brochure_11_24_5
Content Type: recommendation
Words: 459
Medical Entities: dialysis
Source: About Living Donation-Patient Brochure_11_24.pdf

----------------------------------------------------------------------
Talk to the transplant team about returning to work and other physical activities, like playing sports. 20 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 21 AFTER DONATION What can I expect after donation? Living donors generally rate their experience as What are the long-term risks of donation? positive. Studies show that between 8090% of donors say that after theyve donated, they would Research has shown that living donors can live a still make the decision to donate. Some donors have normal, healthy life with one kidney. In fact, when one reported feeling anxious or depressed after donation. kidney is removed, the other kidney will grow to take The process of getting through the evaluation and over the work the donated kidney was doing. This is surgery while hoping to give someone a kidney called compensatory growth. Studies show that after can bring a lot of different emotions. Feelings of donation, a donors total kidney function (how well the depression among living donors for a short time after kidney works) returns to roughly 70% within 10 to 11 donation are not uncommon, even when both donor days, and about 70 to 80% at long-term follow-up. and recipient are doing well. Donors will have a slightly higher than average risk of Donors should talk to the transplant team to let developing high blood pressure in the long term. Its them know how they are feeling both physically and important to eat a healthy diet and get back to regular emotionally during follow-up visits because emotional physical activity after recovery to stay healthy. This is health is important, too. For donors that are struggling especially important for female donors who may want with mixed emotions at any time during the process or to become pregnant after donation. after donation, NKF recommends: There is also a slightly higher risk of developing Talking to the living donor social worker or kidney failure after donation compared to the average Independent Living Donor Advocate (ILDA) for person. Research so far has shown this occurs in support and guidance. less than 1% of people who donate. Less than 1% of Talk with and hear from other living donors people who have donated end up needing dialysis or who have had similar experiences. You can a transplant, themselves, which is only slightly higher call 855. 653. 2273 or visit kidney. org/peers than the average risk of someone who hasnt donated. to learn more. The small number of donors who have problems with their kidney later in life are able to get a higher place on the waitlist because they have donated a kidney. 22 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 23 MAKING AN INFORMED DECISION If you are thinking about donating a kidney Donating a kidney is a very personal decision.
----------------------------------------------------------------------


======================================================================
CHUNK 107 of 647
======================================================================
ID: about living donation_patient brochure_11_24_7
Content Type: reference
Words: 165
Medical Entities: dialysis
Source: About Living Donation-Patient Brochure_11_24.pdf

----------------------------------------------------------------------
listen to concerns. 855. 653. 2273 NKFCareskidney. org You can also find free educational material and other resources by calling, emailing, or visiting the website. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2024 National Kidney Foundation, Inc. 11-10-7051_2407
----------------------------------------------------------------------


======================================================================
CHUNK 108 of 647
======================================================================
ID: advance_directives_0
Content Type: general
Words: 497
Medical Entities: dialysis
Source: advance_directives.pdf

----------------------------------------------------------------------
Advance Directives A guide for patients and their loved ones Contents Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 What is the Patient Self-Determination Act? . . . . . . . . . 5 What is an advance directive? . . . . . . . . . . . . . . . . . . . 6 Are there different kinds of advance directives? . . . . 6 Why is an advance directive important to me? . . . . . . . 7 What types of decisions can I make? . . . . . . . . . . . . . . . 8 Which treatments can I include in my advance directive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Can an advance directive state the conditions under which dialysis could be stopped or continued? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Am I required by law to have an advance directive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Do I need to see a lawyer to make an advance directive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Where can I get advance directives forms? . . . . . . . . 12 Do advance directives forms have to be witnessed? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Should I speak to my doctor before making an advance directive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 2 NATIONAL KIDNEY FOUNDATION How will people know if I have an advance directive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Do organized religions object to the use of advance directives? . . . . . . . . . . . . . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 109 of 647
======================================================================
ID: advance_directives_2
Content Type: general
Words: 498
Medical Entities: dialysis
Source: advance_directives.pdf

----------------------------------------------------------------------
Often, doctors and loved ones are asked to make difficult treatment decisions. In some cases, the courts have been called on to make life or death decisions. This booklet contains information about decisions you can make before a medical crisis occurs. With this information, you can choose to prepare a legal document to guide loved ones, your doctor, and other healthcare providers in caring for you. Making these decisions in advance helps your loved ones, and spares them the burden of making decisions for you in a medical crisis. 4 NATIONAL KIDNEY FOUNDATION What is the Patient Self-Determination Act? The Patient Self-Determination Act, which went into effect in December 1991, gives adults with the capability to make medical decisions for themselves, the right to make decisions today about healthcare treatment they would want to receive in the future if they could not communicate what they want at that time. This law requires that hospitals, nursing homes and other health agencies give all patients information about their right to have a legal document called an advance directive. New regulations for dialysis units require that patients be informed about advance directives and the right to refuse treatment. KIDNEY. ORG 5 What is an advance directive? An advance directive is a legal document that informs doctors and healthcare providers of medical decisions you have made for future crisis care if you cannot communicate these decisions for yourself. If you have an advance directive in your medical record, your doctor and other healthcare providers can take care of you according to your wishes as stated in the advance directive. Are there different kinds of advance directives? There are two basic kinds of advance directives. A living will, the most common type of advance directive, tells your doctor or healthcare provider in writing what type of medical care you want or 6 NATIONAL KIDNEY FOUNDATION do not want if you should become unable to make these decisions for yourself. Another type of advance directive is called a durable power of attorney for healthcare decisions or a healthcare proxy. This document allows you to name someone, such as a family member or close friend, to act on your behalf to make medical decisions for you if you are unable to make these decisions for yourself. The person who acts on your behalf is called your surrogate. It is important to ask this person if they are willing to act as your agent and to talk about which treatments you would and would not want as well as your shortand long-term goals and values. Your states laws typically allow you to have both a living will and a durable power of attorney or to combine them in a single form. You may want to speak to a lawyer or contact your state or local bar association about your states laws concerning advance directives. You may also want to speak to a social worker at your dialysis unit. Why is an advance directive important to me?
----------------------------------------------------------------------


======================================================================
CHUNK 110 of 647
======================================================================
ID: advance_directives_3
Content Type: recommendation
Words: 465
Medical Entities: dialysis
Source: advance_directives.pdf

----------------------------------------------------------------------
You may want to speak to a lawyer or contact your state or local bar association about your states laws concerning advance directives. You may also want to speak to a social worker at your dialysis unit. Why is an advance directive important to me? An advance directive is important for two reasons. First, it lets you make your own decisions about your future healthcare, even if you are not able to make decisions, such as whether to continue or stop certain treatments, at the time these decisions are needed. Second, it tells your doctor and loved ones which treatments you want and do not want if you are not able to communicate your wishes. Knowing your wishes helps your doctor and loved ones feel more comfortable making healthcare decisions for you. KIDNEY. ORG 7 What types of decisions can I make? With an advance directive, you may be able to: accept all treatments recommended by a healthcare provider accept some treatments and refuse others refuse all recommended treatments Some states may limit your ability to delegate the authority to refuse one or more types of treatment to someone else, for example, providing artificial nutrition or water. Some states may require that treatment be continued once it is accepted by your surrogate. It is important to speak with a lawyer or a social worker at your hospital or dialysis unit, or get a copy of your states advance directive forms. (See Where can I get advance directives forms? on. ) 8 NATIONAL KIDNEY FOUNDATION Which treatments can I include in my advance directive? You can choose to receive pain medicine for comfort, even if you refuse other treatments. You may be able to accept or refuse additional treatments, such as: Cardiopulmonary resuscitation (CPR) to attempt to revive a heart that has stopped beating. (CPR includes heart massage, drugs, electric shocks, and artificial breathing machines. ) Tube feedings, including giving food, water or both through a tube into a vein or the stomach. Artificial respiration, which is a machine (ventilator or respirator) that breathes for a person through a tube in the throat. Antibiotics to fight infection. Dialysis, either hemodialysis or peritoneal for kidney failure. Surgery such as heart bypass, gall bladder removal, etc. Blood transfusions or blood products, including specifying whether you would want blood only from your family members or friends. KIDNEY. ORG 9 Can an advance directive state the conditions under which dialysis could be stopped or continued? Yes. An advance directive enables you to tell your doctor and loved ones your feelings and wishes for continued treatment if and when you are no longer able to make this decision for yourself. You may tell your surrogate to stop dialysis if you: Develop severe brain damage (caused by stroke, Alzheimers disease, etc. )
----------------------------------------------------------------------


======================================================================
CHUNK 111 of 647
======================================================================
ID: advance_directives_4
Content Type: general
Words: 490
Section: You may tell your surrogate to stop dialysis if you:
Medical Entities: dialysis
Source: advance_directives.pdf

----------------------------------------------------------------------
You may tell your surrogate to stop dialysis if you: Develop severe brain damage (caused by stroke, Alzheimers disease, etc. ) and that you do not know or understand what is happening around you Cannot move independently (due to a stroke, paralysis, etc) Need to totally depend on others You may also state that you want to continue dialysis until: you die from another cause your doctor advises your surrogate that continued treatment is not medically reasonable Am I required by law to have an advance directive? No. The federal law and various state laws and regulations permit patients to sign advance directives but do not require you to sign them. A dialysis unit or hospital cannot require you to sign an advance directive. 10 NATIONAL KIDNEY FOUNDATION Do I need to see a lawyer to make an advance directive? You do not need to see a lawyer to make an advance directive. Usually, a social worker at your dialysis unit or hospital can help you. To find out more about the laws in your state, you may want to speak to a lawyer, a social worker at your treatment center or senior citizen center, or contact your state or local bar association. Also, see the resources listed starting on. KIDNEY. ORG 11 Where can I get advance directives forms? You can get copies of forms from your state or local bar association, most senior citizen centers, and those healthcare providers who are required to give information. You can also get your state forms on the Internet from state health department websites or from the National Hospice and Palliative Care Organization (call or write for forms at the address or phone number listed on ). You can list the treatments you would or would not want without using a form, but a court or medical provider may not accept it. It is best to complete an advance directive on a state-approved form. 12 NATIONAL KIDNEY FOUNDATION Do advance directives forms have to be witnessed? Advance directives must comply with your states laws and regulations. State laws may require that these forms be witnessed or notarized. Banks and many other businesses have notaries who will notarize these forms. In some states, doctors and other healthcare providers are not permitted to witness advance directives. Should I speak to my doctor before making an advance directive? Yes. Your doctor can help explain treatment options to help you fill out the form. Also, you can let your doctor know what you would want under an advance directive and find out whether he or she would object to carrying one out. If so, you may want to find a doctor who will agree to treat you the way you want. How will people know if I have an advance directive? The only way your loved ones, friends, doctor or other healthcare providers will know that you have an advance directive is if you tell them.
----------------------------------------------------------------------


======================================================================
CHUNK 112 of 647
======================================================================
ID: advance_directives_6
Content Type: reference
Words: 491
Medical Entities: dialysis
Source: advance_directives.pdf

----------------------------------------------------------------------
Yes. You can donate organs or tissues by stating your wishes in an advance directive. However, it is important to tell your loved ones about your wishes concerning organ donation so they will carry them out. You may also want to speak to your lawyer about having a special provision in your living will stating that ventilators may be used to the extent needed to preserve your organs until the donation can be made. If your state allows you to designate your organ donation wishes in your drivers license, you should do so to ensure that your wishes are respected. Where can I get more information? Talk to members of your healthcare team or any healthcare provider. Healthcare professionals are obliged to give you information about advance directives. Talk with your lawyer, your local bar association, or the Legal Aid Society in your community or your senior citizen center. Also, see the list of resources starting on. KIDNEY. ORG 17 Topics to discuss with your loved ones Dealing with life and death issues can be difficult for many people. Yet, it is important that you decide how you feel about these things and what you would want if you should ever become unable to make your own decisions or communicate them to others. Talking over the following questions with a loved one may help. What is the poorest quality of life that would be acceptable for you? Under what circumstances, if any, would you want to stop dialysis? How do you feel about death and dying? How important is it to you being independent and making your own decisions? Do you have any health problems now? How would you describe them? Would your religious beliefs affect how you feel about life-sustaining treatments? If you were terminally ill with no hope of recovery, would you want any of the following life-sustaining treatments to continue? : comfort care (use of medicine to lessen pain) cardiopulmonary resuscitation (CPR) tube feeding of food, water, or both mechanical or artificial respiration using a machine that breathes for you 18 NATIONAL KIDNEY FOUNDATION antibiotics to fight infection dialysis surgery blood transfusions or blood products If you had severe and permanent brain damage, would you want any of the above life-sustaining treatments to continue? If so, which ones? If you were in a permanent coma, would you want any of these life-sustaining treatments to continue? If so, which ones? Do you think your family and friends would support you in your decisions about future medical care? Who would you want to state your decisions for you if you were unable to express them yourself? Would this person be agreeable to doing this? Would you want to donate any organs or tissue (heart, kidneys, liver, eyes, bone) to someone else at the time of your death? Specify which organs or tissues, if any, you would want to donate. Have you ever had to make a healthcare decision for someone?
----------------------------------------------------------------------


======================================================================
CHUNK 113 of 647
======================================================================
ID: choosing_a_treatment_0
Content Type: reference
Words: 496
Medical Entities: CKD,GFR,dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
STAGE 5 Choosing a Treatment for Kidney Failure Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your Kidney Failure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a Kidney Transplant. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 lab test that measures the amount of blood your Hemodialysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Peritoneal Dialysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Living With Your Treatment Choice. . . . . . . . . . . . . . . 21 STAGES OF KIDNEY DISEASE Comfort Care: Choosing Not to Start Dialysis. . . . . . 31 ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 3 Kidney Failure What happens when your kidneys fail? Your kidneys normally remove wastes and extra fluid from your blood. When your kidneys fail because of disease or injury, wastes and extra fluid can build up in your blood and make you sick. Some of the symptoms of kidney failure include: nausea trouble sleeping poor appetite fatigue hiccups dry, itchy skin Introduction weight loss If your healthcare professional said you may need muscle cramping at night dialysis or a kidney transplant soon, you are probably wondering how to decide on the best choice for you. abnormal bleeding or bruising easily This booklet has general information to help you and swelling of your feet or ankles your family make this decision.
----------------------------------------------------------------------


======================================================================
CHUNK 114 of 647
======================================================================
ID: choosing_a_treatment_1
Content Type: general
Words: 480
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
abnormal bleeding or bruising easily This booklet has general information to help you and swelling of your feet or ankles your family make this decision. You should talk about puffiness around your eyes the pros and cons of each treatment option with your anemia (low red blood cell count) family, and healthcare professionals. They will help you decide which treatment is best for you. trouble breathing or feeling short of breath 4 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 5 When is treatment needed? How do I know which treatment is best for me? Your healthcare professional will help you decide The two treatments for kidney failure are dialysis and when you need to start treatment. This decision kidney transplantation. Two different kinds of dialysis is based on: can be donehemodialysis and peritoneal dialysis. Both types of treatment has pros and cons. You can your symptoms also choose not to do dialysis or have a transplant, other health problems you have or you may decide to have comfort care only. As how much kidney function you have left you learn more about each one, speaking with your your nutritional health healthcare professional and your family can help you decide which treatment is best for you. Your decision should be based on many things: medical condition lifestyle personal preference No matter which treatment you choose, you need to make a commitment to follow your treatment plan. This involves: following your treatment schedule following your special diet taking all your medicines as instructed Following your treatment plan will help you live longer and feel better. 6 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 7 Kidney Transplant Can I get a transplant before going on dialysis? Yes. In fact there are long-term benefits to having a What is a kidney transplant? transplant without having dialysis first. Your healthcare professional can refer you to a transplant center for A kidney transplant is an operation that places a tests. Or you can contact a local transplant center healthy kidney from another person into your body. directly. For help finding a local transplant center, call The kidney may come from someone who has died NKF CARES 855. 653. 2273. or from a living person who may be a close relative, spouse, or friend. It can even come from someone who wishes to donate a kidney to anyone in need of Types of kidney transplants a transplant. Your new kidney will be placed in your If a family member or friend is willing to donate a lower abdomen and connected to your bladder and kidney, the tests can be started right away. If there is a blood vessels. match, surgery can be scheduled. The transplant operation takes about 3 hours and you Sometimes a loved one may want to donate a kidney will be in the hospital for about 5 to 7 days. After the but their blood type is incompatible.
----------------------------------------------------------------------


======================================================================
CHUNK 115 of 647
======================================================================
ID: choosing_a_treatment_2
Content Type: reference
Words: 493
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
If there is a blood vessels. match, surgery can be scheduled. The transplant operation takes about 3 hours and you Sometimes a loved one may want to donate a kidney will be in the hospital for about 5 to 7 days. After the but their blood type is incompatible. Some transplant transplant, you will need to take special medications centers will help incompatible pairs of recipient/ to prevent your body from rejecting the new kidney. donors through a process called paired exchange, You will have to take these medications for as long which involves two living donors and two recipients. as you have the transplant. Many patients prefer a transplant over dialysis because it gives them more If the recipient from one pair is compatible with freedom, allows for a less restricted diet, and may the donor from the other pair, and vice versa the improve their quality and length of life. transplant center may arrange for a swapfor two simultaneous transplants to take place. This allows A kidney transplant is a treatment, not a cure. A two transplant candidates to receive organs and two person with a kidney transplant still has kidney donors to give organs though the original recipient/ disease, and may need some of the other medicines donor pairs were unable to do so with each other. they took before the transplant. 8 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 9 Figure 1: Paired Exchange Hemodialysis What is hemodialysis? Hemodialysis is a treatment that removes wastes and extra fluid from your blood. During hemodialysis, your blood is pumped through soft tubes to a dialysis machine where it goes through a special filter called a dialyzer (also called an artificial kidney). As your blood is filtered, it is returned to your bloodstream. Only a small amount of blood is out of your body at any time. In order to be connected to the dialysis machine, you need to have an access, or entrance, to your bloodstream. (See, What is a hemodialysis access? ) Treatments are usually done 3 times a week. Each treatment lasts about 3 to 5 hours. In paired exchange, an incompatible donor/ recipient pair (such as a mother and son that dont have compatible blood types) are matched with another incompatible donor/recipient pair for a swap. Each donor gives a kidney to the other persons intended recipient. However, if you do not have a living donor, you will need to be on a waiting list until a kidney from a suitably matched deceased donor becomes available. In the meantime, you can have dialysis treatments. 10 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 11 Where can I have hemodialysis treatment? Are there different types of home hemodialysis? Hemodialysis treatments can be done at home or With home hemodialysis, you will have 3 different in a dialysis center. Dialysis centers may be located types of treatment options to choose from: within a hospital or in a separate facility. You and your Conventional home hemodialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 116 of 647
======================================================================
ID: choosing_a_treatment_3
Content Type: general
Words: 481
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
Hemodialysis treatments can be done at home or With home hemodialysis, you will have 3 different in a dialysis center. Dialysis centers may be located types of treatment options to choose from: within a hospital or in a separate facility. You and your Conventional home hemodialysis. Treatments healthcare provider will decide which place is best, are usually done 3 times a week, and each based on your medical condition and your wishes. treatment lasts about 3 to 5 hours. Short daily home hemodialysis. This involves How does hemodialysis at home work? more treatments each week for shorter periods. Home hemodialysis is a great option for many patients For example, you might do 6 treatments a week with kidney failure. Your home must have room for the (compared with the usual 3). Each treatment equipment and enough water drainage and electrical would last about 1 to 2 hours. Many people power to operate the dialysis machine and water feel that their quality of life improves with this purification unit. Medicare may help cover the cost of method of dialysis because they sleep better minor changes to your home for home hemodialysis. and have better control of blood phosphorus levels, blood pressure and anemia (low red Some home dialysis setups need you to have a dialysis blood cell count). care partner. Usually this is a family member or friend, Nocturnal (nighttime) home hemodialysis. but may also be someone you hire to assist you. You This involves long, slower treatments, which and your partner will be trained to do hemodialysis at are done during the sleep hours, usually for home. There are also home dialysis options that do 6 to 8 hours. Many people sleep better and not require a treatment partner. This type of dialysis is have better control of blood phosphorus levels, called solo-, selfor independent-home dialysis. blood pressure, and anemia with this method of dialysis. 12 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 13 Comparing Hemodialysis: At Home Versus in a Center HOME HEMODIALYSIS IN DIALYSIS CENTER ADVANTAGES DISADVANTAGES ADVANTAGES: DISADVANTAGES: Dialysis is done Space in the home needs Trained staff performs Treatment days and in the comfort of to be dedicated to the all aspects of treatment. times are scheduled by your own home. machine, water system (if (You may be able to do the center. You do not need to travel needed) and supplies. some things yourself, like You must travel to the inserting the needles. ) to a dialysis center. center at least three Since other people are times weekly. You have more flexibility to choose a time of day dialyzing at same time, Other people are doing friendships may develop. to do dialysis. dialysis at same time, so you have less privacy. You and your dialysis partner learn how to do Loved ones may worry treatments independent if they cant be with you of the center staff. during treatment.
----------------------------------------------------------------------


======================================================================
CHUNK 117 of 647
======================================================================
ID: choosing_a_treatment_4
Content Type: recommendation
Words: 495
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
to do dialysis. dialysis at same time, so you have less privacy. You and your dialysis partner learn how to do Loved ones may worry treatments independent if they cant be with you of the center staff. during treatment. There is a greater sense There may be rules of control from having against eating and independence with the drinking while on dialysis. treatment schedule in relation to your life and work schedule. 14 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 15 What is a hemodialysis access? GRAFT If your blood vessels are not If you choose hemodialysis, you need to have a suitable for a fistula, a graft may permanent access, or entrance, to your bloodstream. be used. This involves joining an This is done with minor surgery, usually to your arm. artery and nearby vein with a Vein There are three different types of access: small, soft tube made of synthetic Artery material. The graft is placed FISTULA entirely beneath your skin. A fistula is the recommended Graft choice for an access. It is made by joining an artery to a nearby vein under your skin to make a Artery CATHETER bigger blood vessel. This type of The third type of access, Fistula access is recommended because called a catheter, is inserted it has fewer problems and lasts Vein into a large vein in your longer. You should be looked at neck or chest. The ends of by a special healthcare the tubes sit on your skin professional, called a vascular surgeon, at least 6 outside your body. This type months before you will need to start dialysis. Your of access is generally used kidney healthcare professional or surgeon may order Catheter Tubes when you need dialysis for a an ultrasound evaluation of your blood vessels to see short period of time. which ones will work best for the fistula. This is called However, catheters are also used as a permanent vessel mapping. A fistula should be placed early access when a fistula or a graft cannot be placed. (several months before starting dialysis), so it has plenty of time to heal and will be ready for use by the What happens after the fistula or graft heals? time you begin hemodialysis. After the fistula or graft has healed and dialysis is started, two needles will be placedone in the artery side and one in the vein side of the access every time you have treatment. The needles are then connected to soft plastic tubes. One tube carries your blood from the needle to the dialyzer (the artificial kidney) where it is cleaned. The cleaned blood is returned to you through the other tubing. 16 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 17 Peritoneal Dialysis TIPS Peritoneal dialysis might be a good choice if you: What is peritoneal dialysis? live far from a clinic or have no reliable In peritoneal dialysis (PD), your blood is cleaned inside transportation to a dialysis center your body, not outside your body.
----------------------------------------------------------------------


======================================================================
CHUNK 118 of 647
======================================================================
ID: choosing_a_treatment_5
Content Type: general
Words: 481
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
ORG 17 Peritoneal Dialysis TIPS Peritoneal dialysis might be a good choice if you: What is peritoneal dialysis? live far from a clinic or have no reliable In peritoneal dialysis (PD), your blood is cleaned inside transportation to a dialysis center your body, not outside your body. The lining of your are working or are in school abdomen (the peritoneum) acts as a natural filter. like to travel A cleansing solution, called dialysate, flows into your prefer to be in control of your treatment abdomen (your belly) through a soft tube called a fear needles PD catheter. The PD catheter is placed during minor surgery. Wastes and extra fluid pass from your blood are soon expecting a transplant into the cleansing solution. After several hours, you drain the used solution from your abdomen and refill with fresh cleansing solution to begin the process again. Removing the used solution and adding fresh solution takes about a half hour and is called an exchange. Peritoneal dialysis can be done at home, at work, at school, or even during travel. Peritoneal dialysis is a home-based treatment. Many people who choose peritoneal dialysis feel it allows them greater flexibility and independence. 18 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 19 Are there different types of peritoneal dialysis? Living With Your Treatment Choice Yes. The most common ones are: Continuous Ambulatory Peritoneal Dialysis Will I feel better after I start treatment? (CAPD). With CAPD, you do the exchanges Once you get used to your treatment, you should yourself 4 to 6 times a day. begin to feel better. The dialysis treatments or Automated Peritoneal Dialysis (APD). With APD, transplanted kidney will take over some of the work of a machine called a cycler does the exchanges your damaged kidneys and remove wastes and extra automatically once you have set up the fluid from your body. This will make many of your equipment. APD can be done while you sleep. symptoms better. However, if you do APD, you may also need to do 1 or 2 exchanges yourself during the day to Will I be able to change to make sure enough wastes and extra fluid are another treatment type? being cleared from your blood. If you start on one type of treatment but feel you would like to try something else, you can speak to your healthcare professional. For example, if you choose hemodialysis, it doesnt mean you cant ask to switch to peritoneal dialysis at a later date. Even if you choose to have a kidney transplant, you may need a period of dialysis until you can be transplanted with a new kidney. It is not uncommon for people who have had kidney failure for many years to have had more than one type of treatment in that time. 20 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 21 Will I need to take special medications? Vitamin and mineral supplements.
----------------------------------------------------------------------


======================================================================
CHUNK 119 of 647
======================================================================
ID: choosing_a_treatment_6
Content Type: general
Words: 477
Medical Entities: dialysis,diabetes
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
It is not uncommon for people who have had kidney failure for many years to have had more than one type of treatment in that time. 20 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 21 Will I need to take special medications? Vitamin and mineral supplements. You may need to take some vitamins and minerals You may need to take: that you are not getting in your diet, or that Phosphate binders. These medicines keep your are lost during dialysis. Your healthcare bones strong by helping your body balance two provider or kidney dietitian will tell you which important mineralscalcium and phosphorus. ones you need. A special prescription form of vitamin D. This Other medicines. You may need to take medicine also helps to keep your bones healthy. medicines for other health conditions such as Drugs called ESAs (erythropoiesis-stimulating to lower high blood pressure, high cholesterol, agents). ESAs act like a natural hormone made or diabetes. by your kidneys called erythropoietin. This If you have a transplant, you will also need to take: hormone tells your body to make red blood cells. Not having enough of it can cause anemia Anti-rejection medicines. These medicines (low red blood cell count). Treatment with an help keep your body from rejecting the ESA can help your body make red blood cells. new kidney. Extra iron. Your body also needs iron to make red blood cells, especially if you are receiving ESAs. Without enough iron, your ESA treatment will not work as well. TIP Part of the reason you feel so tired may be due to anemia (low red blood cell count). Treatment to correct anemia will help you feel stronger and have more energy. 22 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 23 Will my diet need to change? Yes. The type of diet you follow will depend on the treatment you receive. Your dialysis or transplant center will have a kidney dietitian who will help you plan your food choices to make sure you are getting the right amount of protein, calories, vitamins, minerals and fluids. The dietitian will help you with creating a nutrition plan so you can continue enjoying your favorite foods and be as healthy as possible. Can exercise help me? Yes. Exercise can help you feel stronger and improve Can I work if I am on dialysis your overall well-being. Walking is good way to or have a transplant? exercise. You should speak to your healthcare Yes. It is possible to work with dialysis or after a professional about an exercise program that is transplant. Returning to work may help you feel more right for you. positive and independent. If you get in-center dialysis, the staff may be able to arrange your treatments to fit How long can I live on dialysis? your work schedule. If you do home dialysis, you can fit your treatments into your own schedule.
----------------------------------------------------------------------


======================================================================
CHUNK 120 of 647
======================================================================
ID: choosing_a_treatment_7
Content Type: general
Words: 491
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
positive and independent. If you get in-center dialysis, the staff may be able to arrange your treatments to fit How long can I live on dialysis? your work schedule. If you do home dialysis, you can fit your treatments into your own schedule. Now that we know more about how to care for people with kidney failure, they live longer, feel better, and have more active lives. Your overall health and how TIP well you follow your treatment plan are important in To learn more about treatment choices for kidney how well you do. If you choose dialysis, it is important failure, speak to your healthcare professional or to get the right dose of dialysis. Studies have shown other members of your healthcare team. Ask them that dialysis patients do better and live longer when to arrange for you to meet with a person who is they get enough treatment. Your dialysis care team on dialysis or who has had a kidney transplant. If can measure how much dialysis you receive. This information seminars are available, try to attend should be done on a regular basis to make sure and take a family member or close friend. treatments are cleaning enough wastes out of your blood. 24 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 25 When does Medicare begin to pay? Medicare will begin to cover dialysis treatments or a kidney transplant when: You start your third full month of in-center hemodialysis You start a home dialysis training course at a Medicare-approved facility within the first three months of treatment, and you plan to do home dialysis You are admitted to a Medicare-approved hospital for a transplant, or up to two months What insurance coverage is available? before admittance if pre-transplant healthcare and testing are started Many of the costs of dialysis and kidney transplant are covered by the federal government through Medicare. You are already on Medicare Medicare is not just for people who are 65 and older. The program also helps Americans and legal residents How much will Medicare cover? of all ages who need dialysis or a kidney transplant Medicare may pay up to 80% of the costs associated and who qualify for coverage. with dialysis and kidney transplant. But Medicare People with kidney failure can enroll in Medicare alone is not enough. Many other sources of coverage at their local Social Security office, or by calling are available to help pay for what Medicare does not 800. 772. 1213 and making an appointment to enroll. cover, including: Before signing up, your dialysis clinic or transplant Employer health insurance, private health program must complete a form and have it signed insurance, COBRA by your healthcare professional, verifying you have State programs such as Medicaid and high-risk started dialysis or received a kidney transplant. insurance pools To find your local office, look for Social Security Administration in the government pages of your phone Veteran benefits book or go to socialsecurity. gov/locator.
----------------------------------------------------------------------


======================================================================
CHUNK 121 of 647
======================================================================
ID: choosing_a_treatment_8
Content Type: general
Words: 497
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
insurance pools To find your local office, look for Social Security Administration in the government pages of your phone Veteran benefits book or go to socialsecurity. gov/locator. State kidney programs Medigap (Medicare supplemental health insurance) 26 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 27 To learn more about all your options for insurance and members of the healthcare team. Social workers coverage, you can speak to: at dialysis centers are trained to provide counseling to help people make the transition to dialysis or Your state insurance commissioner and ask transplantation. what options are available to you where you live An independent insurance broker Some of the biggest changes are: The NKF Cares Patient Help Line toll-free at 855. getting used to a new routine with peritoneal NKF. CARES (855. 653. 2273) or email nkfcares dialysis or hemodialysis kidney. org following your diet and nutrition plan A financial aid coordinator at your dialysis taking all your medicines exactly as instructed center or transplant center by your healthcare professional (including anti- Your county or state social service department rejection medicines if you have a transplant) or Medicaid office continuing with your work, studies, school, family commitments, and hobbies Does Medicare pay for home hemodialysis? The healthcare team (social workers, dietitians, The federal governments Medicare program covers healthcare professionals, nurses, technicians, and the cost of home hemodialysis, just as they do other staff) are trained to help you make these for dialysis in a hospital or other treatment center. changes and to help you understand all areas of However, Medicare will not cover the cost of a home your care. health aide if you have no one who can be a care partner for you. How can my family and I cope with kidney failure? You and your family may have difficulty accepting the changes in your lives caused by kidney failure, which can be a lot to handle. You may have feelings of frustration, guilt, denial, anger and depression. You and your family may find it helpful to share your questions and concerns with each other and with people who are willing to offer support. These can include close friends 28 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 29 Is it normal to have fears about beginning treatment? Yes. It is normal to have concerns about how you will feel, whether the treatment will hurt, what the staff and other patients will think of you, and how long you can live with kidney failure. The following steps can help you cope with your feelings: Ask your healthcare provider if you can Comfort Care: Choosing Not to Start Dialysis visit a dialysis center. Visiting the center can help you make decisions. If you are interested in a kidney What if I do not want to do dialysis transplant, ask your healthcare provider or have a transplant? for a referral to a transplant center. Set You have the right to decide whether or not to start up an appointment to visit with the staff dialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 122 of 647
======================================================================
ID: choosing_a_treatment_9
Content Type: reference
Words: 500
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
for a referral to a transplant center. Set You have the right to decide whether or not to start up an appointment to visit with the staff dialysis. Some people feel that the burdens outweigh and get answers to your questions. the benefits for them. Often this is due to other health Speak to others who have been through conditions. If you are eligible for a transplant, you also the same experience. have the right to decide if this is the right option for you. You should discuss your thoughts carefully with Discuss all your concerns with the people you trust and seek advice from your healthcare healthcare team at the treatment center. provider, family member(s), and others who have your Call your local National Kidney best interests at heart. Foundation (NKF) office for information and a list of the programs and services What will happen if I dont start dialysis? available. Find your local NKF office by visiting the NKF website at kidney. Choosing not to start dialysis once your healthcare org or by calling the NKF Cares Patient provider has determined you need dialysis means that Help Line toll-free at 855. NKF. CARES you are choosing to let your kidney failure take its (855. 653. 2273) or emailing nkfcares natural course. This will ultimately lead to your death. kidney. org 30 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 31 How long will I live if I choose Will my healthcare team continue to help me? not to start dialysis? Yes. Your healthcare professional, advanced People with kidney failure may survive for a few days practitioner, social worker, nurse, and other healthcare to several weeks without dialysis, depending on the team members should be available to you and your amount of kidney function they have, how severe their family to discuss your concerns and advise you about symptoms are, and their overall medical condition. the type of care you might need. Your healthcare team will help arrange the necessary referrals or consultations for your circumstances. Supportive What if Im not sure if dialysis could help me? care or palliative care can assist you to make sure you Sometimes it may not be clear if the benefits of are comfortable. Many people choose to remain at dialysis outweigh the burdens. Each persons situation home, and services are available to support you and is different. If you are uncertain, you may be able to your family. start treatment for a trial periodfor example, one to three months. During and after the trial period, your How do I discuss this decision healthcare professional and the other members of with my family and friends? your dialysis team will talk with you about how you are feeling and coping with the treatment routine. Many people find it difficult to talk about whether Ask as many questions as you need to help with or not to start treatment, and they worry about how your decision to continue or to stop treatment. Its others will feel and react.
----------------------------------------------------------------------


======================================================================
CHUNK 123 of 647
======================================================================
ID: choosing_a_treatment_10
Content Type: recommendation
Words: 393
Medical Entities: dialysis
Source: choosing_a_treatment.pdf

----------------------------------------------------------------------
Many people find it difficult to talk about whether Ask as many questions as you need to help with or not to start treatment, and they worry about how your decision to continue or to stop treatment. Its others will feel and react. The best approach is to important to note that you always have the right to discuss your feelings openly with your loved ones. stop dialysis at any time. Your family will most likely feel very emotional too, and may have questions. You may wish to consult with your religious or spiritual advisor, social worker, healthcare professional, or other healthcare worker before making a decision. 32 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 33 Where can I learn more? Setting a standard for care There are many things to consider when choosing The National Kidney Foundation, through its Kidney comfort care only. The National Kidney Foundation has Disease Outcomes Quality Initiative (KDOQI), defines a brochure called If You Choose Not to Start Dialysis stages of kidney disease and offers guidelines that Treatment, which is specifically dedicated to this help your healthcare professional and healthcare topic; call the NKF CARES Patient Help Line toll-free at team make important decisions about your medical 855. NKF. CARES (855. 653. 2273) or email nkfcares treatment. kidney. org to request your free copy. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. 34 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 35 Fueled by passion and urgency, the National Kidney Foundation (NKF) is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, we focus on the whole patient through the lens of kidney health. Relentess in our work, we enhance lives through action, education, and accelerating change. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG KIDNEY. ORG 2022 National Kidney Foundation, Inc. 11-10-0352_2204
----------------------------------------------------------------------


======================================================================
CHUNK 124 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_0
Content Type: general
Words: 427
Medical Entities: CKD,GFR,dialysis,albuminuria
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Racial and ethnic minorities are also more likely to progress from CKD to end-stage renal disease (ESRD)also known as end-stage kidney disease (ESKD)and are less likely to have been under the care of a nephrologist before starting dialysis. These disparities are related to patient, clinician, clinical and system factors. Patient factors include genetic predisposition (e. g. , APOL1 risk variants), barriers to accessing care, low health literacy, cultural and attitudinal beliefs, such as mistrust of health care providers and language barriers. Clinician factors include limited knowledge of CKD, discomfort with its clinical complexity, and communication challenges. Clinical factors include conflicting guidance about screening for CKD and the complexity of treating patients with multiple comorbid conditions. System factors include limited access to care and lack of clinical decision support tools. Primary care practice teams can help reduce disparities in care for CKD through early identification, treatment, monitoring progression, collaborating with nephrologists and other specialists, building care teams and engaging patients. This educational guide is intended to foster the development of primary care practice teams in order to enhance care for vulnerable patients who are at risk of CKD or who have CKD and are at risk of progression of disease or complications. This guide addresses three aspects of care: identification of CKD; treatment and monitoring progression; and delivering patient-centered care. It is meant to inform readers about disparities in the care of patients with CKD, present potential actions that may improve care and suggest other available resources that may be used by primary care practice teams in caring for vulnerable patients. About Chronic Kidney Disease CKD is progressive loss of renal function, beginning with asymptomatic kidney damage and potentially ending in near total kidney failureESRDwhich requires renal replacement therapy for ongoing survival. According to the Centers for Disease Control and Prevention (CDC), 37 million adults in the US have CKD and most of them are unaware of their condition. The clinical stages of CKD are defined by declining glomerular filtration rates (GFR) and albuminuria categories indicating increasing damage to kidney function. Equations for estimating GFR include adjustments for race, because non-Hispanic blacks have higher GFR than non-Hispanic whites at the same level of serum creatinine. Similarly, males have higher GFR than females and younger people have higher GFR than older people at the same levels of creatinine. of 19 April 2021 Introduction While CKD is typically progressive, it does not affect all patients at the same rate. Racial minorities have a greater risk of progressing from CKD to ESRD and progress more rapidly than their non-Hispanic white counterparts.
----------------------------------------------------------------------


======================================================================
CHUNK 125 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_1
Content Type: general
Words: 472
Medical Entities: CKD,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
of 19 April 2021 Introduction While CKD is typically progressive, it does not affect all patients at the same rate. Racial minorities have a greater risk of progressing from CKD to ESRD and progress more rapidly than their non-Hispanic white counterparts. Progression of CKD of 19 April 2021 tnemtaerT egatS DKC seigetartS SC N o rm G F R c r e e n K D R F a c to a l fo r is k rs (e. g. , a n e m ia d is e a s e, m In c re a s e d C K D R is k C K D R is k R e d u c tio n; S C r e e n in g C o m p lic a tio n s, h y p e rte n s io n, h y p o g ly c e m ia, c a rd io v a s c u in e ra l a n d b o n e d is tu rb a n c e s, m a ln u tritio n d e p re s s io n ) K id n e y D e c re a s in g D a m a g e G F R D ia g n o s is T re a t T re a tm e n t; C o m p lic a tio n s, E s tim a te C K D S lo w P r o g re s s io n P ro g re s s io n la, r R eb T K id n e y F a ilu re p la c e m e n t y D ia ly s is o r r a n s p la n t D e a th Source: Adapted from Eckardt, K. U. , Coresh, J. , Devuyst, O. , Johnson, R. J. , Kottgen, A. , Levey, A. S. (2013). Evolving Importance of Kidney Disease: From Subspecialty to Global Health Burden. Global Kidney Disease. 382; 9887: 158-169. Available at It is also true that the vast majority of patients with CKD do not ever progress to kidney failure. CKD is considered a disease multiplier because it often occurs with other conditions such as diabetes, hypertension or heart disease. Notably, CKD patients have a heightened risk of cardiovascular disease and death at every stage of CKD. The two conditions are linked: CKD and heart disease share risk factors such as diabetes and hypertension, and each condition can lead to or worsen the other. CKD is diagnosed through a blood test measuring serum creatinine and a urine test to assess albumin. CKD is staged using both results over a 3-month time period.
----------------------------------------------------------------------


======================================================================
CHUNK 126 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_2
Content Type: general
Words: 494
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
CKD is diagnosed through a blood test measuring serum creatinine and a urine test to assess albumin. CKD is staged using both results over a 3-month time period. In the early stages of CKD (Stages 13), the focus of care is on slowing or preventing progression and treating complications; in the later stages (Stages 45), the focus of care shifts to planning for kidney failure. The KDIGO Heat Map displays the risk of progression for each GFR category. Progression of CKD is related to control of comorbidities, (diabetes, hypertension, cardiovascular disease), prevention of additional damage (acute kidney injury, nephrotoxic agents), optimizing health consequences (anemia, proteinuria), and recognition of population-based risk (race/ethnicity, age, family history). Early diagnosis and appropriate treatment can prevent or delay progression to later-stage CKD, resulting in decreased morbidity, mortality and costs. Introduction KDIGO Heat Map (KDIGO, 2017) Source: Kidney Disease Improving Global Outcomes (KDIGO). (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). Available at Primary Care Is Key to Reducing Disparities in Chronic Kidney Disease Interventions that can slow progression of CKD include early identification, controlling blood pressure, controlling blood glucose, reducing albuminuria, eating a healthy diet and maintaining a healthy lifestyle. Primary care practice teams have an opportunity to apply population health strategies that may improve identification of individuals with CKD, improve care for patients with CKD and slow progression of the disease. As the front line of health care, primary care is especially important for conditions such as CKD, which may not cause symptoms until the late stages of disease. By increasing awareness of known racial, ethnic and economic disparities in care for CKD, this guide encourages primary care professionals to adopt strategies that can improve health care and health for vulnerable populations. of 19 April 2021 Introduction Example: Indian Health Service Improvements in Care for Chronic Kidney Disease The Indian Health Service (IHS) cut the rate of kidney failure in half for Rates of Kidney Failure from Diabetes by Race and Ethnicity: 1996 and 2013 Native Americans with diabetes by (Cases per 100, 000 people) applying population health approaches to patients with noted 60 socioeconomic disparities. In 1996, 50 American Indians and Alaska Natives 40 30 had the highest rates of diabetes20 related ESRD incidence, compared 10 with other racial and ethnic groups in 0 the US. By 2013, the incidence of Native Asians Blacks Whites Hispanics diabetes-related ESRD had Americans decreased from 57. 3 percent in 1996 1996 2013 to 26. 5 percent in 2013 (Bullock et al. , 2017). The decrease coincided with incorporating the assessment and treatment of CKD into IHS standards for managing diabetes. While the IHS had previously adopted systematic approaches to controlling diabetes, including multidisciplinary team-based care, patient education, community outreach, and tracking process and outcome data, the revised standards included: Routine laboratory reporting of GFR in the electronic medical record. Annual monitoring of urine albumin excretion.
----------------------------------------------------------------------


======================================================================
CHUNK 127 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_3
Content Type: general
Words: 493
Medical Entities: CKD,GFR,dialysis,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
While the IHS had previously adopted systematic approaches to controlling diabetes, including multidisciplinary team-based care, patient education, community outreach, and tracking process and outcome data, the revised standards included: Routine laboratory reporting of GFR in the electronic medical record. Annual monitoring of urine albumin excretion. Prescription of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB). To improve diabetes care, IHS also developed clinical education programs and tools, culturally relevant patient education materials and electronic medical record-based population management tools. With these efforts, the IHS was able to achieve a 54 percent decrease in age-adjusted incidence of diabetes-related ESRD for patients with well-documented socioeconomic disparities, including poverty, limited health care resources and disproportionate burden of comorbidities (Bullock et al. , 2017). How This Guide Is Organized This guide is written for primary care practice teams and is intended to raise awareness of disparities in CKD and improve the care of vulnerable patients with CKD, and suggests possible approaches to improve the care of vulnerable patients with CKD. It is divided into the following sections: Summary. Approaches to Identifying Chronic Kidney Disease. Approaches to Treatment and Monitoring of CKD Progression. Approaches to Centering Care on the Patient. of 19 April 2021 Introduction Each of the topical sections in the guide explains the importance of the issue and describes potential interventions that primary care practice teams can take to address disparities in care. The Suggested Steps and Resources sections include links to available resources. Existing resources are paired with suggested action steps and are categorized by type (informational materials, practical tools, training materials) and format (CKD tracking tool, letter template, mobile app, online calculator, pamphlet/handout, reference material, referral form, video, webpage). Clinicians and their teams can use this guide to educate themselves, encourage the development and use of protocols to identify people with CKD, monitor progress, connect patients to appropriate resources and refer those who need specialty care. of 19 April 2021 Approaches to Identifying Chronic Kidney Disease Approaches to Identifying Chronic Kidney Disease Why Is It Important to Identify Chronic Kidney Disease? Why Is It Important to Identify Chronic Kidney Disease? Racial and ethnic minorities are more likely to progress from CKD to renal failure than their non-Hispanic white counterparts. Beyond kidney failure, CKD progression has other consequences, such as anemia, hypertension, hypoglycemia, mineral and bone disturbances, cardiovascular disease, polypharmacy, medication side effects and death. Most CKD is a long-term consequence of difficult-to-control diabetes and hypertension, conditions that are more common among racial minorities and low-income populations. Early identification and intervention can slow or prevent CKD progression. CKD may have no symptoms in most stages, so many people are unaware of their CKD status until late-stage disease. In addition, limited provider awareness of CKD risk factors and surveillance guidelines can contribute to low patient awareness. Improving identification allows earlier treatment of CKD, which may reduce the number of people who progress to later-stage CKD, require transplant or dialysis or experience secondary consequences.
----------------------------------------------------------------------


======================================================================
CHUNK 128 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_4
Content Type: general
Words: 498
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
In addition, limited provider awareness of CKD risk factors and surveillance guidelines can contribute to low patient awareness. Improving identification allows earlier treatment of CKD, which may reduce the number of people who progress to later-stage CKD, require transplant or dialysis or experience secondary consequences. Identification of CKD typically includes screening at-risk individuals, determining the stage of disease and communicating results and next steps to patients. There are multiple challenges to improving disparities in identification of CKD: Clinical care teams and people at risk need to understand more about CKD, including its causes, stages and consequences. Primary care practice teams need protocols for detecting CKD. Most guidelines agree that people with diabetes or hypertension should be screened. Research shows that older individuals, non-Hispanic blacks, Native Americans and Hispanics should also be considered for CKD screening. Screening for CKD may be conducted by community-based organizations that are not coordinated with primary care teams. Addressing these challenges can improve identification of CKD in vulnerable populations, which has the potential to slow or prevent the progression of disease. Improving Identification of CKD: Suggested Steps of 19 April 2021 Approaches to Identifying Chronic Kidney Disease Improving Identification of CKD: Suggested Steps Resources Informational Materials Develop and implement a CKD detection protocol that defines the population Practical Tools at risk Training Materials Leverage health information systems to identify and track at-risk patients and prompt the clinical care team of the need for Practical Tools CKD detection Develop scripts for the care team to explain the risks of CKD and how it is detected Promote CKD detection at every opportunity Include CKD detection during preventive or well-care visits Informational Materials Integrate CKD detection into care management programs (e. g. , diabetes, hypertension, heart disease) Practical Tools Coordinate with community-based CKD screening activities that outreach to racial and ethnic minorities and low-income populations Use two tests to detect CKD over a 3-month period Spot urine for albumin-to-creatinine ratio (ACR) to detect albuminuria Informational Materials Blood test for serum creatinine to estimate GFR Practical Tools Repeat positive tests over a 3-month period Determine risk or stage of CKD and inform patient Use culturally and linguistically appropriate materials Informational Materials Have information available in various formats (written, visual, video, apps) Practical Tools Address emotional response Consider health literacy levels Measure, track and improve CKD detection rates Informational Materials Examine differences based on race, ethnicity, other risk factors Training Materials Review with the clinical care team of 19 April 2021 Approaches to Treatment and Monitoring of CKD Progression Approaches to Treatment and Monitoring of CKD Progression Why Is It Important to Treat and Monitor Progression? Why Is It Important to Treat and Monitor CKD Progression? Although the prevalence of CKD is relatively similar across racial and ethnic groups, minorities are more likely to progress from CKD to ESRD, and progress more rapidly than non-Hispanic whites. Clinical and system-wide interventions for slowing the progression of CKD largely consist of controlling risk factors, developing treatment plans and encouraging lifestyle changes.
----------------------------------------------------------------------


======================================================================
CHUNK 129 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_5
Content Type: general
Words: 346
Medical Entities: CKD,proteinuria,albuminuria,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Clinical and system-wide interventions for slowing the progression of CKD largely consist of controlling risk factors, developing treatment plans and encouraging lifestyle changes. Accordingly, management of CKD often coexists with control of conditions such as diabetes, hypertension and cardiovascular disease. Care for CKD consists of treating the risk factors for progression, including diabetes, hypertension, use of nephrotoxic medications, history of acute kidney injury, proteinuria and albuminuria, and treating the consequences of CKD, including anemia, electrolyte abnormalities and mineral bone disorders. The main interventions usually include: Medical treatment (e. g. , control blood pressure and glucose, manage cardiovascular disease, reduce albuminuria). Prevention (administer vaccinations, avoid nephrotoxic medications, including NSAIDS such as ibuprofen or naproxen). Nutritional guidance (e. g. , limit sodium intake). Lifestyle modifications (e. g. , exercise, quit smoking). Although interventions to slow progression or treat consequences of CKD are known, research suggests that many patients do not receive appropriate education about CKD and controlling risk factors, and minority patients are least likely to receive the information. Recent studies have shown that CKD registries have the potential to improve care for diverse populations in the areas of albuminuria monitoring, prescriptions for ACE inhibitors/ARBs, nephrotoxic medication use, hepatitis B immunizations, outpatient nephrology visits, vascular access placement and referral to transplant (Tuot et al. , 2018, Mendu et al. , 2019). Challenges to improving disparities in CKD treatment and fostering collaboration between primary care teams and specialists include: Clinical care teams need guidance on treating CKD in the context of comorbid conditions such as diabetes, hypertension and cardiovascular disease. Clinical care teams need tools that address multifaceted and complex health care needs, coupled with other life challenges that can impact the progression of disease in minority and underserved populations. Although electronic health records have the potential to support CKD care, they must be incorporated into the daily workflow and need additional functionality and customization to track clinical factors. Limited access to nephrologists for consultation. Addressing these barriers can improve CKD management in vulnerable populations, which has the potential to reduce disparities and the risk of progression to ESRD.
----------------------------------------------------------------------


======================================================================
CHUNK 130 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_6
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Limited access to nephrologists for consultation. Addressing these barriers can improve CKD management in vulnerable populations, which has the potential to reduce disparities and the risk of progression to ESRD. of 19 April 2021 Approaches to Treatment and Monitoring of CKD Progression Improving Treatment and Monitoring of CKD Progression: Suggested Steps Improving Treatment and Monitoring of CKD Progression: Suggested Steps Resources Integrate CKD guidelines into the control of diabetes, hypertension and cardiovascular conditions Control blood pressure: Set target goals and consider prescribing angiotensin receptor blockers (ARB)/angiotensin converting enzyme (ACE) inhibitors for patients with Informational Materials elevated blood pressure Practical Tools Control diabetes: Determine HbA1c targets, consider SGLT2 inhibitors for appropriate Training Materials patients Reduce albuminuria through RAAS therapy and blood pressure control Consider statin therapy for appropriate patients Educate patients about health behaviors that may affect progression of CKD Promote healthy eating and monitoring of fluid intake: Consider referral for dietary counseling Informational Materials Encourage exercise and weight control Practical Tools Discourage smoking, illegal drug use, excessive alcohol consumption Training Materials Advise patients regarding use of over-the-counter nephrotoxic medications (e. g. , NSAIDs, protein-pump inhibitors, supplements) Address emotional response to diagnosis and recommendations to change behaviors Monitor CKD progression Determine testing interval for monitoring GFR and albuminuria based on stage of CKD and risk of progression Monitor medications that require dose adjustment based on level of kidney function Practical Tools and adjust as necessary Use health information systems to prompt clinicians of the need for CKD monitoring and further follow-up when progression is identified (e. g. , automated urine albumin testing reminders) Establish relationships with nephrologists and other specialists Establish consulting relationships with nephrologists Informational Materials Identify triggers for referral to nephrology. Consider: level of complexity, GFR Practical Tools threshold, rapidity of decline in GFR and preparation for renal replacement therapy Consider eConsults for patients with potential delays in specialty referral of 19 April 2021 Approaches to Centering Care on the Patient Approaches to Centering Care on the Patient? Why Is It Important to Center Care on the Patient Why Is It Important to Center Care on the Patient? The Institute of Medicine defines patient centered care as care that is respectful of, and responsive to, individual patient preferences, needs and values and ensuring that patient values guide all clinical decisions (IOM, 2001). The Commonwealth Fund identified the following characteristics of a patient-centered primary care practice: superb access to care; patient engagement in care; clinical information systems that support high-quality care, practice-based learning and improvement; care coordination; integrated, comprehensive care and smooth information transfer across the provider team; ongoing, routine patient feedback; publicly available information on practices (Davis et al. , 2005). Treatment for CKD may be complicated by other health conditions and by socioeconomic challenges such as poverty, lack of health insurance, low health literacy, language barriers, inadequate access to healthy food, financial barriers to obtaining medications, limited transportation and environmental or safety concerns. Challenges to treating vulnerable CKD patients in primary care include: Limited time during clinic visits.
----------------------------------------------------------------------


======================================================================
CHUNK 131 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_7
Content Type: reference
Words: 495
Section: Challenges to treating vulnerable CKD patients in primary care include:
Medical Entities: CKD
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Challenges to treating vulnerable CKD patients in primary care include: Limited time during clinic visits. It takes time to educate patients about the causes, stages and consequences of CKD and how to manage it. A diagnosis of CKD can evoke an emotional response that can negatively affect the patients ability to learn how to manage it. Patients might have limited health literacy in CKD-related topics. Living conditions can significantly affect an individuals health status. Complex social determinants such as unstable housing, food insecurity, poverty, lack of education, unsafe neighborhoods and access to transportation contribute to disparities in CKD. Social Determinants of Health Health professionals are increasingly aware of the importance of nonmedical factors on health. Where and how a person lives can have a greater impact on health than medical care delivered by the health care system (Healthy People, 2019b). Organizations are working to develop tools for practices to address social determinants of health; for example, materials that educate teams about health disparities and health equity, assess implicit bias or offer guidance on collecting population data or building relationships with community-based organizations. These resources can help primary care practices evolve their care processes to meet patient needs more effectively. Delivering patient-centered care, forming multidisciplinary care teams (e. g. , pharmacists, community health workers, dieticians, social workers) and assessing social determinants of health can help address disparities in care for CKD. Improving Patient-Centered Care: Suggested Steps of 19 April 2021 Approaches to Centering Care on the Patient Improving Patient-Centered Care: Suggested Steps Resources Assemble a multidisciplinary care team with defined roles and responsibilities Identify multidisciplinary care team members (e. g. , pharmacists, community health workers, Informational dieticians, social workers) Materials Consider creating care coordination agreements with specialists and team members to formally specify responsibilities Develop a strategy for educating patients about CKD Determine the basic components of CKD education and adapt available resources of CKD education to your practice Review and refer patients to CKD resources that include a variety of formats and platforms such as written materials, podcasts, videos, appsto address variability in learning styles and Informational level of health literacy Materials Connect patients to CKD educational resources that are culturally and linguistically appropriate Training Consider community health workers, patient navigators and group educational efforts Materials Compile a list of community-based CKD resources and initiatives to share with patients and caregivers Refer patients to benefits available through Medicare (e. g. , medical nutrition therapy services, CKD education benefit) Understand and address the patients social determinants of health Ask patients about social determinants of health (e. g. , ability to pay for medications) Informational Incorporate CKD detection into the practice workflow Materials Practical Tools Identify community resources that can address social determinants of health Connect patients with resources that can meet their needs Include family, caregivers and the patients community in treatment Informational and educational efforts Materials Incorporate patient and family/caregiver preferences (e. g. , cultural, religious, personal values) Training into treatment plans and educational efforts.
----------------------------------------------------------------------


======================================================================
CHUNK 132 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_8
Content Type: evidence
Words: 500
Medical Entities: CKD,GFR,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Materials Periodically reassess the patients understanding of their diagnosis and treatment plan, Informational to encourage opportunities to iteratively address identified patient-centered barriers Materials of 19 April 2021 References References 1. Acre, C. M. , Mitani, A. A. , Goldstein, B. A. , Winkelmayer, W. C. (2012). Hispanic Ethnicity and Vascular Access Use in Patients Initiating Hemodialysis in the United States Clin J Am Soc Nephrol, 7(2), 289-296. Available at 2. American Diabetes Association (ADA). (2018). Statistics About Diabetes. Available at 3. Bullock, A. , Rios Burrows, N. , Narva, A. , Sheff, K. , Hora, I. , Lekiachvili, A. , Cain, H. , Espey, D. (2017). Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease Among American Indians/Alaska Natives United States, 1996-2013. MMWR Morb Mortal Wkly Rep. 66(1): 26-32. Available at 4. Centers for Disease Control and Prevention (CDC). (2019). Chronic Kidney Disease in the United States, 2019. Available at : : textCKD%20Is%20Common%20Among%20US%20AdultstextMore%20than%201%20in%207, are%20estimated%20to%20 have%20CKD 5. Centers for Disease Control and Prevention (CDC). (2017). Hypertension Prevalence and Control Among Adults: United States, 2015-2016. Retrieved March 7, 2019. Available at 6. Davis, K. , Schoenbaum, S. C. , Audet, A. (2005). A 2020 Vision of Patient-Centered Primary Care. J Gen Intern Med. 20(10): 953-957. Available at 7. Derose, S. F. , Rutkowski, M. P. , Crooks, P. W. , Shi, J. M. , Wang, J. Q. , Kalantar-Zadeh, K. , Kovesdy, C. P. , Levin, N. W. , Jacobsen, S. J. (2013). Racial Differences in Estimated GFR Decline, ESRD, and Mortality in an Integrated System. Am J. Kidney Dis. 62(2): 236-44. Available at 8. Eckardt, K. U. , Coresh, J. , Devuyst, O. , Johnson, R. J. , Kottgen, A. , Levey, A. S. (2013). Evolving Importance of Kidney Disease: From Subspecialty to Global Health Burden. Global Kidney Disease. 382; 9887: 158-169. Available at 9. Fischer, M. J. , Hsu, J. Y. , Lora, C. M. , Ricardo, A. C. , Anderson, A. H. , Bazzano, L. , Cuevas, M. M. , Hsu, C. , Kusek, J. W. , Renteria, A. , Ojo, A. O. , Raj, D. S. , Rosas, S. E. , Pan, Q. , Yaffe, K. , Go, A. S. , Lash, J. P. , Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. (2016). CKD Progression and Mortality Among Hispanics and Non-Hispanics. JASN. 27(11): 3488-3497. Available at 0WT. MC_IDTMD0 10. Healthy People 2020. (2019a). Disparities. Available at 11. Healthy People 2020. (2019b). Social Determinants of Health. Available at 12. Institute of Medicine (IOM). (2001). Crossing the Quality Chasm: A New Health System for the 21st Century. Available at 13. iStock. (2019). Kidney Pictures, Images, and Stock Photos. Available at 14. Kidney Disease Improving Global Outcomes (KDIGO). (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). Available at 15. Kidney Failure Risk Equation (KFRE). (2019). Kidney Failure Risk Equation. Available at 16. Medicare Payment Advisory Commission (MedPAC). (2019). Report to the Congress: Medicare Payment Policy.
----------------------------------------------------------------------


======================================================================
CHUNK 133 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_9
Content Type: evidence
Words: 454
Medical Entities: CKD,dialysis
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Available at 15. Kidney Failure Risk Equation (KFRE). (2019). Kidney Failure Risk Equation. Available at 16. Medicare Payment Advisory Commission (MedPAC). (2019). Report to the Congress: Medicare Payment Policy. Available at 17. Mendu, M. L. , Ahmed, S. , Maron, J. K. , Rao, S. K. , Chaguturu, S. K. , May, M. F. , Mutter, W. P. , Burdge, K. A. , Steele, D. J. R. , Mount, D. B. , Waikar, S. S. , Weilburg, J. B. , Sequist, T. D. (2019). Development of an Electronic Health Record-Based Chronic Kidney Disease Registry to Promote Population Health Management. BMC Nephrol. 20: 72. Available at 18. Molnar, A. O. , Hiremath, S. , Brown, P. A. , Akbari, A. (2016). Risk Factors for Unplanned and Crash Dialysis Starts: A Protocol for a Systematic Review and Meta-Analysis. 5: 117. Available at 19. Narva, A. S. , Norton, J. M. , Boulware, L. E. (2016). Educating Patients about CKD: The Path to Self-Management and Patient-Centered Care. Clin J Am Soc Nephrol, 11(4), 694-703. Available at 20. Nee, R. , Yuan, C. M. , Hurst, F. P. , Jindal, R. M. , Agodoa, L. Y. , Abbott, K. C. (2016). Impact of Poverty on Race and Pre-End-Stage Renal Disease Care Among Dialysis Patients in the United States Clin Kidney J. Available at 21. Tuot, D. S. , McCulloch, C. E. , Velasquez, A. , Schillinger, D. , Hsu, C. , Handley, N. , Powe, N. R. (2018). Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial. Am J Kidney Dis. 72(2): 168-177. Available at 22. Waterman, A. D. , Browne, T. , Waterman, B. M. , Gladstone, E. H. , Hostetter, T. (2008). Attitudes and Behaviors of African Americans Regarding Early Detection of Kidney Disease. Am J Kidney Dis. 51: 554-562. of 19 April 2021 Comprehensive Resource List Comprehensive Resource List Informational Practical Training Patient - Alternative Resource Material Tool Material Focused Languages of 19 April 2021 DKC gniyfitnedI rof secruoseR detsegguS 1. Develop and implement a CKD detection protocol that defines the population at-risk NKFMinorities and Kidney Disease (Webpage) BernsScreening in Asymptomatic Adults (Reference Material) NKFLaboratory Engagement Plan (Reference Material) NKFCritical Care Algorithm: How to Manage Your CKD Patients (Reference Material) AAKPField Ambassadors (Webpage) NKFA Primary Care Approach to CKD Management (Reference Material) 2. Leverage health information systems to identify and track at-risk patients and prompt clinical care team of the need for CKD detection RPAPatient Identification Assessment Evaluation Tool (CKD Tracking Tool) RPAPatient Identification Assessment Instructions (CKD Tracking Tool) 3. Promote detection at every opportunity NKFKEEP Screening Events (Webpage) NKDEPKidney Sundays: A ToolkitGuide for Faith-Based Communities on Making the Kidney Connection (Reference Material) 4.
----------------------------------------------------------------------


======================================================================
CHUNK 134 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_10
Content Type: reference
Words: 347
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Promote detection at every opportunity NKFKEEP Screening Events (Webpage) NKDEPKidney Sundays: A ToolkitGuide for Faith-Based Communities on Making the Kidney Connection (Reference Material) 4. Use two tests to detect CKD over a 3-month period NKDEPMaking Sense of CKD: A Concise Guide for Managing CKD in Primary Care (Reference Material) NKDEPUACR In Evaluating Patients with Diabetes for Kidney Disease (Reference Material) NKFFrequently Asked Questions About GFR Estimates (Reference Material) NKFeGFR Calculator (Mobile App) NKDEPGFR Calculators (Online Calculator) NKFGFR Calculators (2) (Online Calculator) NKFScreening for Albuminuria in Patients with Diabetes (Reference Material) 5. Determine stage of CKD and inform patient ANNACKD Fact Sheet (Reference Material) MEICKD: Take Charge of Your Health (Pamphlet/Handout) () NKDEPCommunicating Difficult Messages to Patients (Webpage) NKFKidney Disease Can Be TreatedPrintable Stages Chart (Pamphlet/Handout) NKFQuick Reference Guide on Kidney Disease Screening (Reference Material) NKDEPExplaining Your Kidney Test Results: A Tear-Off Pad for Clinical Use (Pamphlet/Handout) (Chinese, French, Spanish, Vietnamese) NKDEPYour Kidney Test Results (Pamphlet/Handout) (Spanish) NKFCKD Risk Assessment Tool (Reference Material) 6. Measure, track, and improve CKD detection rates NKFCKD Change Package (Reference Material) CDCCKD Surveillance System (Reference Material) Kirwan InstituteImplicit Bias Module Series (Reference Material) AAFPAddressing Implicit Bias in Health Care Delivery (Reference Material) Comprehensive Resource List of 19 April 2021 noissergorP DKC fo gnirotinoM dna tnemtaerT rof secruoseR detsegguS Informational Practical Training Patient - Alternative Resource Material Tool Material Focused Languages 1. Integrate CKD guidelines into the control of diabetes, hypertension and cardiovascular conditions Upstate NY Practice-Based Research NetworkCKD Quick Reference Guide for the Primary Care Clinician (Reference Material) NKFCholesterol and Kidney Disease: What Your Need to Know (Pamphlet/Handout) NKDEPMaking Sense of CKD: A Concise Guide for Managing CKD in the Primary Care Setting (Reference Material) NKFHypertension and Antihypertensive Agents in CKD (Reference Material) NKFCardiovascular Disease in CKD (Reference Material) NKFHeart Failure and CKD: What Your Need to Know (Pamphlet/Handout) University of BuffaloAn Algorithm for Managing CKD in the Primary Care Setting (Reference Material) NKFCritical Care Algorithm: How to Manage Your CKD Patients (Reference Material) SelectHealth and Intermountain HealthcareManagement of CKD: Care Process Model (Reference Material) NKDEPCKD Training Program for Diabetes Educators (Video) 2.
----------------------------------------------------------------------


======================================================================
CHUNK 135 of 647
======================================================================
ID: chronic kidney disease disparities _ educational guide for primary care _ 508 _ april 2021_11
Content Type: general
Words: 496
Section: Educate patients about health behaviors that may affect progression of CKD NKDEPCKD and Diet:
Medical Entities: CKD,hypertension
Source: Chronic Kidney Disease Disparities - Educational Guide for Primary Care - 508 - April 2021.pdf

----------------------------------------------------------------------
Educate patients about health behaviors that may affect progression of CKD NKDEPCKD and Diet: Assessment, Management, and Treatment (Reference Material) NKDEPCollaborate with a Registered Dietician (Webpage) UnknownDietary Approaches to Stop Hypertension (DASH) Diet Modified for Adults with CKD (Reference Material) NKDEPEating Right for Kidney Health (Pamphlet/Handout) (Spanish) NKDEPNutrition Tips for People with CKD (Sodium, Protein, Phosphorus, Potassium, Food Label Reading) (SpanishSodium, (Pamphlet/Handout) Protein, Phosphorus, Potassium, Food Label Reading) ProsciaMyPlate for Healthy Eating with CKD (Reference Material) NKDEPKeeping Kidneys Safe: Smart Choices About Medicines (Webpage) NKFPhosphorus and Your Kidney Diet (Pamphlet/Handout) NKFCKD: Know the Risks of Medications and Imaging Studies (Safety Card for Patient Care) (Reference Material) AAKPUnderstanding Depression in Kidney Disease (Pamphlet/Handout) NKDEPCKD Diet Counseling (Medical Nutrition Therapy) Referral Form (Referral Form) NKFCRN Pocket Guide to Nutrition Assessment in the Patient with CKD Mobile App (Mobile App) AAKPNutrition Counter: A Reference for the Kidney Patient (Reference Material) (Spanish) NKDEPCKD and Nutrition for Dietetic EducatorsCKD 101: Nutrition Educators (Reference Material) NKDEPCKD Nutrition Management Training Program (Video) NKDEPKeeping Kidneys Safe: Pharmacists Role in Counseling High-Risk Patients on NSAID Use to Prevent Kidney Injury (Video) 3. Monitor CKD progression RPAPatient Management Assessment and Evaluation Tools and Instruction Document (CKD Tracking Tool) Comprehensive Resource List Resources current as of April 2021; Cost associated with resource of 19 April 2021 tnemtaerT rof secruoseR detsegguS noissergorP DKC fo gnirotinoM dna Informational Practical Training Patient - Alternative Resource Material Tool Material Focused Languages RPAAdvanced CKD Management Flow Sheet (CKD Tracking Tool) Kidney Failure Risk Equation (Online Calculator) 4. Establish relationships with nephrologists and other specialists NKDEPCollaborate with a Nephrologist (Webpage) RPAAwareness Letter (Letter Template) RPACKD Post-Consult Letter (Letter Template) RPAReferring Physician Fax-Back Form (Referral Form) NKFRelative Risk, Monitoring and Referral in Patients with CKD (Mobile App) NKDEPNephrology Referral Form (Referral Form) NKDEPCKD Diet Counseling (Medical Nutrition Therapy) Referral Form (Referral Form) Ontario Renal NetworkOutpatient Nephrology Form for Primary Care Providers (Referral Form) tneitaP eht no eraC gniretneC rof secruoseR detsegguS 1. Assemble a multidisciplinary care team with defined roles and responsibilities NKDEPCollaborate with a Registered Dietician (Webpage) NKDEPCollaborate with a Nephrologist (Webpage) 2. Develop a strategy for educating patients about CKD NKDEPKidney Disease Education Lesson Builder (Webpage) TuotAssessment of CKD Patient Educational Materials (Reference Material) CDCChronic Kidney Disease in the United States (Pamphlet/Handout) AAKPKidney Beginnings: A Patients Guide to Living with Reduced Kidney Function (Reference Material) () AAKPPocket Guide to Managing Kidney Disease (Pamphlet/Handout) 3. Understand and address the patients social determinants of health (SDOH) NACHCPRAPARE Implementation and Action Toolkit (Reference Material) AAFPAddressing Social Determinants of Health in Primary Care (Reference Material) AAFPThe EveryONE Project Toolkit (Reference Material) BanerjeeFood Insecurity and CKD (Reference Material) AAFPSocial Determinants of Health Screening Tools (Screening Form) (Spanish, Chinese, French, Korean, Tagalog, Vietnamese) 4. Include family, caregivers and the patients community in treatment and educational efforts NKDEPCommunicating Difficult Messages to Patients (Webpage) NKDEPFamily Reunion Health Guide (Reference Material) NKDEPKidney Sundays: A ToolkitGuide for Faith-Based Communities on Making the Kidney Connection (Reference Material) AAKPKidneyWorks Employment Resources (Reference Material) 5.
----------------------------------------------------------------------


======================================================================
CHUNK 136 of 647
======================================================================
ID: coping_0
Content Type: general
Words: 499
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
STAGE 5 Coping Managing kidney failure Contents Dealing with Emotions Why me? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 How does kidney failure affect patients and their families? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Is it normal to feel afraid? . . . . . . . . . . . . . . . . . . . . . . . 6 Is it normal to have mood swings? . . . . . . . . . . . . . . . . 6 Who can help my family and me adjust? . . . . . . . . . . . . 8 When should I seek professional counseling? . . . . . . . 8 Is it normal for people on dialysis to feel upset sometimes with the staff at a dialysis center? . . . . . . 9 Is it normal to feel anxious while waiting for a kidney transplant? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 What else should I understand about my emotions? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Your Family and Relationships Can people with kidney failure still enjoy sex? . . . . . . 11 What if I lose interest in sex? . . . . . . . . . . . . . . . . . . . . 12 Can men with kidney failure father children? . . . . . . . 13 Can a woman with kidney failure have a baby? . . . . . 14 Can a woman who has had a transplant have a baby? . . . . . . . . . . . . . . . . . . . . . . . . 14 2 NATIONAL KIDNEY FOUNDATION Adjusting to a New Lifestyle How important is social activity? . . . . . . . . . . . . . . . . . 15 Can I work or go to school? . . . . . . . . . . . . . . . . . . . . . 16 Can I travel? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 137 of 647
======================================================================
ID: coping_1
Content Type: general
Words: 499
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
. . . . . . . . . . . . 16 Can I travel? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Can I exercise? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Will my diet have to change? . . . . . . . . . . . . . . . . . . . . 21 Your Finances and Insurance How will I pay for my treatments? . . . . . . . . . . . . . . . . 22 Does Medicare pay for home hemodialysis and peritoneal dialysis? . . . . . . . . . . . . . . . . . . . . . . . . . 23 How much will Medicare cover? . . . . . . . . . . . . . . . . . 23 More Information Where can I find more information? . . . . . . . . . . . . . 26 KIDNEY. ORG 3 Dealing with Emotions Why me? Anyone can get kidney failure, regardless of who you are, where you live, how old you are, or what type of work you do. Having kidney failure is a lot to handle. It requires lifestyle changesnot only for you, but for your family, too. This brochure can help you and your loved ones learn how to cope with kidney failure. 4 NATIONAL KIDNEY FOUNDATION How does kidney failure affect patients and their families? In time, many patients accept the fact that they have kidney failure and will need treatment for the rest of their lives. Others have trouble with all the changes in their lives that the disease brings. Its important to understand that the stresses and frustrations of kidney failure are real. At times, it may be difficult for both you and your family to cope. You may feel like your world is caving in. Your family members may feel that way too, especially if they havent faced a major crisis before, or if the diagnosis was not expected. They may feel helpless because they cannot do anything about your illness. They may be angry that kidney failure has happened to their family or friend. They may fear that you may die. They may feel guilty if they did not realize the serious nature of your illness earlier. A period of confusion and tension may follow as everyone tries to cope with the demands of the illness, the anxiety of treatment, and the disruption of everyday life. You and your family will need time to adjust. Remembering that can help. KIDNEY. ORG 5 Is it normal to feel afraid?
----------------------------------------------------------------------


======================================================================
CHUNK 138 of 647
======================================================================
ID: coping_2
Content Type: reference
Words: 496
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
You and your family will need time to adjust. Remembering that can help. KIDNEY. ORG 5 Is it normal to feel afraid? You and your family will have many emotions as you learn to live with kidney failure. You may feel sad, confused, anxious, fearful, angry, or even guilty. At times, your feelings may shift from disbelief and denial to acceptance or grief. The goal is to understand, cope with, and even accept your feelings, rather than ignore them or pretend they dont exist. Understanding that other people, like you, share many of your feelings can help. What youre going through is normal. It is part of getting used to your diagnosis, and to living with kidney failure. It can also be helpful to share your feelings with others, to ask for help, and to tell others what you need. Even your closest family members cannot read your mind. Its important to tell them how you feel. In addition to loved ones, other people can provide emotional support, including friends, clergy, support groups, chat rooms, professional counselors, and of course, your healthcare team. Is it normal to have mood swings? Moodiness is common among people with kidney failure. It can be caused by: Waste products. The buildup of waste products in the blood (called uremia), which can irritate the nervous system. Medicines. Some medicines may cause moodiness or make you feel depressed. 6 NATIONAL KIDNEY FOUNDATION The stress caused by chronic illness. The problems caused by your illness can make you irritable, angry, frustrated, and much more. Mood swings can come from feeling hopeless or helpless about having a lifethreatening disease. Your family members and friends might feel confused by your mood swings. It may help to talk with them about it openly and honestly. If they understand that being irritable and moody can be part of having kidney failure, they may find it easier to cope. You and your family may want to discuss ways for everyone to relax when tensions are high. Or you may want to consider family counseling. KIDNEY. ORG 7 Who can help my family and me adjust? All dialysis units and transplant centers have clinical social workers on staff who are trained to help with the nonmedical issues you and your family are facing. They can answer many of your questions or direct you to others who can help. Social workers are important members of your healthcare team. They can help to make kidney-failure treatment a more manageable part of your life. Inspiration and support can also come from other patients with kidney failure. Ask your social worker about support groups in your area. TIP If you would like to connect with another patient, the National Kidney Foundation can help. Contact us and ask about the Peers Lending Support Program. Call toll-free 855. NKF. PEERS (855. 653. 7337) or email nkfpeerskidney. org. When should I seek professional counseling? Feeling sad or upset on occasion is a normal part of life.
----------------------------------------------------------------------


======================================================================
CHUNK 139 of 647
======================================================================
ID: coping_3
Content Type: reference
Words: 494
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
Contact us and ask about the Peers Lending Support Program. Call toll-free 855. NKF. PEERS (855. 653. 7337) or email nkfpeerskidney. org. When should I seek professional counseling? Feeling sad or upset on occasion is a normal part of life. However, there are times when you may need help coping with these feelings. Asking for help is not a sign of weakness, but of your desire to do well. Many people need help with their emotions as they learn to cope with kidney failure. 8 NATIONAL KIDNEY FOUNDATION If you find yourself feeling overly sad, irritable, isolated, overwhelmed, unable to face each day, crying too much, or feeling like you want to give up, you may have depression. Its important to know that depression is a medical condition. It can be treated. You do not need to suffer from it, or be embarrassed about it. Studies show that 20% to 40% of people with kidney failure have depression. Your social worker can help you figure out if what youre feeling is depression, and can help you get treatment for it. Treatment may include medicine, counseling, or other kinds of support. Is it normal for people on dialysis to feel upset sometimes with the staff at a dialysis center? Yes. A dialysis center is different from any other healthcare setting. It can start to feel like the staff members are a second family because you spend so much time there. It is normal to feel frustrated and angry with them sometimes. It is important that you discuss your feelings openly with the staff. Keeping your feelings bottled up inside can affect your treatment, health, and emotional adjustment. Is it normal to feel anxious while waiting for a kidney transplant? Waiting for a suitable kidney can be stressful. If you have a living donor, your wait for a transplant should be fairly short. If you are waiting for a kidney from someone who has died, you may have to wait a long KIDNEY. ORG 9 timeperhaps even years. Using this time to learn as much as you can about a kidney transplant can help. Talk to others who have had a transplant and discuss your concerns openly with your healthcare team. The more you learn, the less anxious youll feel. What else should I understand about my emotions? Its important to understand that your emotions and physical health are connected. A healthy emotional life will help you to live longer and feel better. Your emotional health means many thingshow you cope, how you live, what you do to stay involved in the world around you, and how you relate to others. Its more than feelings or emotions. It means having a sense of purpose, experiencing joy, having hope, keeping active, and so much more. Set reasonable goals for yourself. Be flexible. Allow for mistakes. Try to keep a positive attitude. Spend time with people who make you laugh. All these things can help you stay healthy.
----------------------------------------------------------------------


======================================================================
CHUNK 140 of 647
======================================================================
ID: coping_4
Content Type: general
Words: 496
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
It means having a sense of purpose, experiencing joy, having hope, keeping active, and so much more. Set reasonable goals for yourself. Be flexible. Allow for mistakes. Try to keep a positive attitude. Spend time with people who make you laugh. All these things can help you stay healthy. 10 NATIONAL KIDNEY FOUNDATION Your Family and Relationships Can people with kidney failure still enjoy sex? Many people think that sexuality refers only to sexual intercourse. But sexuality includes many things, like intimacy, touching, hugging, and kissing. It includes how you feel about yourself, how well you communicate, and how willing you are to be close to someone else. There are many things that can affect your sexuality if you have kidney failurehormones, nerves, energy levels, even medicine. But there are also things you and your healthcare team can do to deal with these changes. Dont be afraid to ask questions or get help from a healthcare professional. KIDNEY. ORG 11 Its important to remember that people with kidney failure can have healthy marriages and intimate relationships. They can fall in love, care for families, and be sexual. Staying emotionally and physically close with those you love is important. And, its something everyone wants and needs. What if I lose interest in sex? Your interest in sex may change when you have kidney failure. At first, you may have less interest in sex. This can happen because you need a lot of energy to cope with the physical and emotional changes brought on by your illness. In time, your interest may return. Some men may find it more difficult to have or keep an erection. This is very common with kidney failure. It can result from the side effects of medicine, having a buildup of toxic wastes in the blood that may not 12 NATIONAL KIDNEY FOUNDATION be fully removed by dialysis, or other things. Many of these problems can be treated. Dont be afraid to ask questions or get help from a healthcare professional. Emotions can also affect sexual functioning. This includes stress, depression, nerves, fear of disability or death, marriage problems, and much more. People with a kidney transplant usually have fewer sexual problems related to kidney disease. After the transplant, sexual functioning should return to normal. Can men with kidney failure father children? Yes. Men, who are on dialysis or are a kidney transplant recipient can have children. If youve been trying to have a child for a year or more without success, talk with your healthcare professional. KIDNEY. ORG 13 Can a woman with kidney failure have a baby? Some changes in your body may make it hard to get pregnant. For example, most women on dialysis have anemia (a low red blood cell count) and hormone changes. This may cause irregular periods. Women with kidney failure are usually advised against becoming pregnant. The risk to the mother and developing baby can be higher than in women who do not have kidney failure.
----------------------------------------------------------------------


======================================================================
CHUNK 141 of 647
======================================================================
ID: coping_5
Content Type: recommendation
Words: 499
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
This may cause irregular periods. Women with kidney failure are usually advised against becoming pregnant. The risk to the mother and developing baby can be higher than in women who do not have kidney failure. If you are thinking about becoming pregnant, talk to your healthcare professional. If you become pregnant, you will need close medical supervision, which may include changes in medicine, and more dialysis to have a healthy baby. Can a woman who has had a transplant have a baby? Yes. If you have a kidney transplant, you are likely to have regular periods and good general health, so getting pregnant and having a baby is possible. However, its recommended that you do not become pregnant for at least one year after your transplant, even if you have stable kidney function. In some cases, pregnancy may not be recommended. This may be due to a high risk to your life or possible loss of the transplant. Talk with your healthcare professional if you have a transplant and are thinking about getting pregnant. 14 NATIONAL KIDNEY FOUNDATION Adjusting to a New Lifestyle How important is social activity? Being involved in the world around you and staying close to others is very important. Social support is something we all need, but its especially important for someone with a chronic illness. It may be helpful to find activities you enjoy that also provide social support, like walking clubs, volunteer work, babysitting, or taking classes. Your social worker can help you find groups and activities to join. Participating in hobbies, clubs, community action groups, sports, and spirituality can have a positive effect on your health. Dont forget that you are also a valuable friend and partner to others. Remember that your loved ones may need your support as well. On days that you feel well, ask what you can do for them. If you are feeling isolated or alone, talk to your social worker. There are support groups, patient mentors, and outreach services designed for people like you! KIDNEY. ORG 15 Can I work or go to school? Many people with kidney failure work or go to school full-time or part-time. Many people who start dialysis or have a transplant want to return to work or school quickly. It can help them to feel better and get their lives back to normal. Some people take a little time off from work when they first start dialysis, while others take a longer leave of absence to get used to dialysis or to recover from surgery. You should talk to your healthcare professional about when would be a good time for you to return to work or school. At first, returning to your daily routine, in addition to your treatment schedule, may be tiring. You may need support and encouragement at home and from your healthcare team. If you are thinking of giving up your job or education, you may want to consider taking sick leave or a brief leave of absence instead.
----------------------------------------------------------------------


======================================================================
CHUNK 142 of 647
======================================================================
ID: coping_6
Content Type: reference
Words: 492
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
You may need support and encouragement at home and from your healthcare team. If you are thinking of giving up your job or education, you may want to consider taking sick leave or a brief leave of absence instead. Discuss your condition openly with your employer or school administrator if you think it will affect your ability to do the job, or to finish your degree. Answer 16 NATIONAL KIDNEY FOUNDATION any questions or concerns they might have. Talk about any special needs you might have. For example, you might need to start work earlier in the day in order to go to dialysis. As you return to work or school, you should keep several things in mind: If you are on peritoneal dialysis and need to do an exchange during the day, you will need to ask your employer or school administrator for a clean, private place to do your exchange. A letter from your doctor may be requested. This letter should state that you are medically stable to return to work or school, and describe any limitations you may have. If you dialyze in a clinic, talk to your dialysis team about changing your dialysis schedule to better meet your needs. Most dialysis clinics will try to schedule a convenient shift for patients who are employed or in school. You may also wish to consider home dialysis options. This will give you more flexibility in your schedule. If you receive Social Security Disability Insurance (SSDI) or Social Security Income (SSI), the local Division of Vocational Rehabilitation Office may assist you in returning to a job or retraining you for a new job. For more information on the Social Security Administrations Ticket to Work program and other employment initiatives, go to ssa. gov/work or call 800. 772. 1213. KIDNEY. ORG 17 People facing dialysis treatment or a transplant may worry that their treatment could cause them to lose their job. The Americans with Disabilities Act is a law that was passed in 1990 that does not allow discrimination because of disabilities. If you are concerned about discrimination, contact an attorney, the Equal Employment Opportunity Commission (EEOC) or the Department of Labor. For information about filing a claim, call toll-free 800. 669. 4000. Can I travel? Yes, most people can travel safely and get dialysis treatments while away from home. Of course, you should always talk to your healthcare professional before travelling. Most healthcare professionals support travel if your overall health and kidney function is stable. If you like to travel, it may be a big boost to your spirits and sense of well-being. Its important to remember to bring more of the medications you may need, just in case there are any emergencies and you are not be able to return home as planned. Sometimes plans change due to poor weather, staffing problems, or other issues that can make travelling difficult and unpredictable. Also, check with your insurance company about coverage.
----------------------------------------------------------------------


======================================================================
CHUNK 143 of 647
======================================================================
ID: coping_7
Content Type: reference
Words: 486
Medical Entities: dialysis,diabetes
Source: coping.pdf

----------------------------------------------------------------------
Sometimes plans change due to poor weather, staffing problems, or other issues that can make travelling difficult and unpredictable. Also, check with your insurance company about coverage. Medicare covers 80% of dialysis treatments in the United States. But in most cases, it does not cover dialysis treatments outside the United States. 18 NATIONAL KIDNEY FOUNDATION When planning a trip: If you are on hemodialysis: You should make plans with a dialysis clinic in the area you wish to visit at least six to eight weeks in advance. You may need to plan even further in advance during popular tourist seasons. This is because some dialysis clinics may be full and less able to take in unscheduled patients. Many dialysis centers have a staff member who can help arrange treatments for you while you are away from home or help you make your own arrangements. If you are on peritoneal dialysis: You will need to make plans for back-up medical care if you are going to be out of town for any length of time. Your nurse or healthcare professional can give you a referral to a peritoneal dialysis program in the area you are visiting and make sure the right records are sent ahead of your visit. If you are on a transplant waiting list: Tell the staff how they can reach you at all times. If you are traveling somewhere you cannot be reached, you should change your status to on hold until you return. KIDNEY. ORG 19 Can I exercise? Yes. Physical activity will give you energy, reduce stress, and help you stay more independent. It can also improve depression and overall mood. Its important to talk to your healthcare professional before you begin an exercise program. You may have new limitations due to your dialysis access or protecting your transplanted kidney. Physical activity should not be confused with heavy exercise. If your ability to exercise is less than it was before, do not be discouraged. Any form of body movement helpswalking, gardening, dancing, even grocery shopping. The key is finding something you enjoy. Your energy will increase with activity, and, in time, youll be able to do more. 20 NATIONAL KIDNEY FOUNDATION Will my diet have to change? Yes. The type of diet you follow will depend on the treatment you receive. Your dialysis or transplant center will have a staff dietitian who can help you plan your meals to make sure you are getting the right amount of protein, calories, vitamins, minerals, and fluids. A dietitian can also work with you to develop a nutrition plan that allows you to enjoy your favorite foods and stay as healthy as possible. If you are on dialysis: You will need to eat less salt, avoid foods high in potassium and phosphorus, and limit fluids. If you have other health problems, such as diabetes or heart issues, you may have other food restrictions as well.
----------------------------------------------------------------------


======================================================================
CHUNK 144 of 647
======================================================================
ID: coping_8
Content Type: general
Words: 496
Section: If you are on dialysis:
Medical Entities: dialysis,diabetes
Source: coping.pdf

----------------------------------------------------------------------
If you are on dialysis: You will need to eat less salt, avoid foods high in potassium and phosphorus, and limit fluids. If you have other health problems, such as diabetes or heart issues, you may have other food restrictions as well. If you have a kidney transplant: Some medicines can interact with certain foods and can cause harm to your new kidney. Talk to your healthcare professional because you may need to change your diet to protect your transplanted kidney. If you have other health problems, such as diabetes, high blood pressure, or weight gain, you may need to make other changes as well. Otherwise, you may not have many food restrictions. Remember, good nutrition and maintaining a healthy weight will go a long way in keeping your new kidney working well for as long as possible. KIDNEY. ORG 21 Your Finances and Insurance How will I pay for my treatments? Many costs for dialysis and kidney transplant are covered by the federal government through Medicare. Medicare is not just for people who are 65 and older. The program also includes many people who need dialysis or a kidney transplant. People with kidney failure can find out more about Medicare enrollment at their local Social Security office, or by calling 800. 772. 1213. Talk to staff at your dialysis clinic or transplant center for more information. 22 NATIONAL KIDNEY FOUNDATION Does Medicare pay for home hemodialysis and peritoneal dialysis? The federal governments Medicare program covers 80% of the cost of home hemodialysis and peritoneal dialysis, just as they do for dialysis in a hospital or other treatment center. However, Medicare will not cover the cost of a home health aide if you have no one who can be a care partner for you. How much will Medicare cover? Medicare may pay up to 80% of the costs associated with dialysis and kidney transplant. But Medicare alone may not be enough. There are many other kinds of coverage that can help pay for what Medicare does not cover, including: State programs such as Medicaid and high-risk insurance pools TRICARE (if you are active in or retired from military service) Veterans benefits Employer health insurance, private health insurance, COBRA Medigap (Medicare supplemental health insurance) State kidney programs (where available) KIDNEY. ORG 23 To learn more about these options: Medicare: Contact Social Security at 800. 772. 1213 or check Medicares website at medicare. gov. You can also ask for a free copy of a handbook explaining Medicare coverage for dialysis and transplant services. State Medicaid: Contact your states welfare department (Department of Social Services) or visit medicaid. gov. TRICARE and veterans benefits: Contact your local Veterans Affairs office or check TRICAREs Web site at tricare. mil. Employer or private health insurance: Read your policy carefully and talk with your insurance agent or company benefits counselor. If you are 65 or older, you may be able to get counseling about health insurance benefits at your local senior citizens center.
----------------------------------------------------------------------


======================================================================
CHUNK 145 of 647
======================================================================
ID: coping_9
Content Type: recommendation
Words: 495
Medical Entities: dialysis
Source: coping.pdf

----------------------------------------------------------------------
mil. Employer or private health insurance: Read your policy carefully and talk with your insurance agent or company benefits counselor. If you are 65 or older, you may be able to get counseling about health insurance benefits at your local senior citizens center. Talk to your social worker if you are having difficulty paying for your medications. Many drug companies have programs to help people who cannot afford to pay for their prescription medications. 24 NATIONAL KIDNEY FOUNDATION Lets Review Its important to understand that the stresses and frustrations of kidney failure are very real, and at times very difficult. The following steps may help: Discuss your concerns with your healthcare team. Write down questions ahead of time. Remember, youre an important member of the team, and taking an interest in your own care will help you live better and longer. Share your feelings with family, close friends, fellow patients, and others you trust. Allow them to share their feelings with you. Together, you can learn how to help each other. Seek help and information from a social worker at the dialysis center or transplant clinic, or from an outside counselor. Stay close to others who are important you. Having healthy relationships with people is important for everyone, and its especially important for someone living with a chronic illness. Stay involved in the pleasures, activities, and responsibilities of daily living. Follow an exercise program approved by your healthcare professional. Try not to focus on your problems, but instead, on the good things that may be happening in your life. Be patient and set realistic goals. Get involved in your own care by finding out as much as possible about kidney failure and its treatment. Your treatment center, healthcare team, and the National Kidney Foundation can help. KIDNEY. ORG 25 More Information Where can I find more information? There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. Becoming an educated patient is very important to being healthy! 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 146 of 647
======================================================================
ID: dialysis_patients_bill_of_rights_0
Content Type: general
Words: 500
Medical Entities: dialysis
Source: dialysis_patients_bill_of_rights.pdf

----------------------------------------------------------------------
DIALYSIS PATIENTS BILL OF RIGHTS AND RESPONSIBILITIES www. kidney. org Your Rights 1. Quality Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2. Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3. Individual Treatment. . . . . . . . . . . . . . . . . . . . 4 4. Privacy and Confidentiality. . . . . . . . . . . . . . . 4 5. Services Without Discrimination. . . . . . . . . . 4 6. Treatment Options. . . . . . . . . . . . . . . . . . . . . . . 5 7. Emergency Care. . . . . . . . . . . . . . . . . . . . . . . 6 8. Dietary Counseling. . . . . . . . . . . . . . . . . . . . . 6 9. Social Work Services. . . . . . . . . . . . . . . . . . . 6 10. Facility Management. . . . . . . . . . . . . . . . . . . . . 7 11. Formal Complaint Process. . . . . . . . . . . . . . . . 7 12. Refusal, Advance Directives, and End-of-Life Care. . . . . . . . . . . . . . . . . . . . . . . . . 7 13. Medical Consultation. . . . . . . . . . . . . . . . . . . . . 8 14. Research Programs. . . . . . . . . . . . . . . . . . . . . . 8 15. Treatment Costs. . . . . . . . . . . . . . . . . . . . . . . . 9 Your Responsibilities 1. Be Informed. . . . . . . . . . . . . . . . . . . . . . . . . . . 10 2. Plan and Follow a Treatment Program. . . . . . 10 3. Be On Time. . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 4. Follow Facility Policies. . . . . . . . . . . . . . . . . . . 10 5. Be Considerate. . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 147 of 647
======================================================================
ID: dialysis_patients_bill_of_rights_1
Content Type: general
Words: 485
Medical Entities: dialysis
Source: dialysis_patients_bill_of_rights.pdf

----------------------------------------------------------------------
. . . . . . . 10 4. Follow Facility Policies. . . . . . . . . . . . . . . . . . . 10 5. Be Considerate. . . . . . . . . . . . . . . . . . . . . . . . . 11 6. Fulfill Financial Obligations. . . . . . . . . . . . . . . 11 2 NATIONAL KIDNEY FOUNDATION Your Rights 1. Quality Care You have the right to: Receive high-quality healthcare that meets recognized professional goals. Be part of the healthcare team, along with a social worker, nurse, doctor, and dietitian. Expect that staff members in training will be directly supervised. 2. Information You have the right to: Receive information from your nephrologist (kidney doctor) in words that you can understand. This should include information about your medical conditions, treatment choices, test results, and possible problems. If this information cannot be given to you directly, the doctor should speak to your family or the person acting on your behalf. Be informed about current dialysis treatments for kidney disease. Receive a complete review of any test results and treatment from your doctor or a member of the healthcare team. Be informed of any possible side effects of medications you are taking. WWW. KIDNEY. ORG 3 3. Individual Treatment You have the right to: Be treated with dignity, respect, and consideration. Suggest a change in the type of treatment. Expect your kidney doctor and other members of your healthcare team to listen to you when you suggest changes in your dialysis treatment. Expect that treatment will be tailored to your individual health needs. Expect that the patient-to-staff ratio at your facility conforms to state regulations. 4. Privacy and Confidentiality You have the right to: Expect privacy when receiving medical care. Expect examinations and discussions about your care to be held in private. Expect that your personal medical information will be kept confidential. 5. Services Without Discrimination You have the right to: Expect medical care without regard to your race, color, gender, sexual preference, religion, or national origin. 4 NATIONAL KIDNEY FOUNDATION 6. Treatment Options You have the right to: Receive a full explanation of all treatment options for kidney disease, including their advantages and disadvantages. Receive a full explanation of the kidney transplant process, including all transplant options. Select the transplant center at which you desire to have a transplant evaluation after consultation with the nephrologist. Be informed of new advances in home care and have the opportunity to make a change to that treatment option. Receive educational materials about new procedures in home care. Receive follow-up care by dietary, social work, and nursing services. Receive information about dialysis facilities that offer home dialysis. WWW. KIDNEY. ORG 5 7. Emergency Care You have the right to: Receive emergency medical care without unnecessary delay.
----------------------------------------------------------------------


======================================================================
CHUNK 148 of 647
======================================================================
ID: dialysis_patients_bill_of_rights_2
Content Type: reference
Words: 496
Medical Entities: dialysis
Source: dialysis_patients_bill_of_rights.pdf

----------------------------------------------------------------------
Receive educational materials about new procedures in home care. Receive follow-up care by dietary, social work, and nursing services. Receive information about dialysis facilities that offer home dialysis. WWW. KIDNEY. ORG 5 7. Emergency Care You have the right to: Receive emergency medical care without unnecessary delay. Be informed by the dialysis facility about their emergency plan in case of a disaster (e. g. , snow storm, fire, loss of power). Be informed of the facilitys plan of action in case of medical/health emergencies. 8. Dietary Counseling You have the right to: Receive counseling from a qualified dietitian according to federal and state law. Receive nutritional educational material and instruction. Receive care and counseling on a regular basis. 9. Social Work Services You have the right to: Receive counseling from a qualified social worker according to federal and state law. Receive an evaluation and follow-up care, including a vocational rehabilitation review. Receive referrals to community services when needed. 6 NATIONAL KIDNEY FOUNDATION 10. Facility Management You have the right to: Expect the dialysis facility to employ skilled staff and provide safe, clean, comfortable, and professional surroundings. Expect the facility to make every effort to make you comfortable and give you your treatment on time, according to a schedule that meets your special needs whenever possible. Expect the facility to monitor the quality of treatment and equipment according to regulations. 11. Formal Complaint Process You have the right to: Make a complaint to your facility management and request that they try to resolve a problem. Ask and be instructed on your dialysis facilitys grievance process. File a complaint with the End-Stage Renal Disease Network in the region and/or your state health department in an attempt to resolve a problem. 12. Refusal, Advance Directives, and End-of-Life Care You have the right to: Make decisions about your healthcare based on information given to you by your kidney doctor. Complete an advance directive stating your wishes. Be informed by your kidney doctor of the possible results of refusing drugs, treatments, or procedures. WWW. KIDNEY. ORG 7 Be informed of how the facility handles end-of-life needs. Refuse any drugs, treatments, or procedures offered to you. Indicate your refusal in writing. Accept full responsibility for the medical outcomes of your refusal. 13. Medical Consultation You have the right to: Request consultation with another doctor for any kidneyor non-kidney-related medical problem. Know that payment for consultation may not be covered under Medicare or other healthcare coverage, and you may be responsible for payment. 14. Research Programs You have the right to: Receive a full explanation of any research program in which you may be able to participate. Know that the study will not be conducted without your informed consent or the consent of the person acting on your behalf. Refuse or withdraw from the research study at any time. 8 NATIONAL KIDNEY FOUNDATION 15. Treatment Costs You have the right to: Receive a full explanation of all charges by the facility and doctor.
----------------------------------------------------------------------


======================================================================
CHUNK 149 of 647
======================================================================
ID: dialysis_patients_bill_of_rights_3
Content Type: recommendation
Words: 415
Medical Entities: dialysis
Source: dialysis_patients_bill_of_rights.pdf

----------------------------------------------------------------------
Refuse or withdraw from the research study at any time. 8 NATIONAL KIDNEY FOUNDATION 15. Treatment Costs You have the right to: Receive a full explanation of all charges by the facility and doctor. Be informed about your financial responsibilities after Medicare or Medicaid and/or other healthcare insurance coverage prior to receiving treatment. Obtain assistance with completing insurance forms. Get information about how you can pay your bill and about programs available to help you. WWW. KIDNEY. ORG 9 Your Responsibilities 1. Be Informed It is your responsibility to: Learn as much as you can about your kidney disease and how it is treated. Talk to your healthcare team about your concerns regarding your treatment. 2. Plan and Follow a Treatment Program It is your responsibility to: Supply all information about your health that is needed to plan and carry out a treatment program that will give you the best results. Find out about the other services and referrals that are recommended by your healthcare team. 3. Be On Time It is your responsibility to: Make every effort to be on time for your scheduled dialysis. Tell the dialysis facility ahead of time if you are unable to attend your next treatment date. Understand that your treatment time may be shortened if you arrive late. 4. Follow Facility Policies It is your responsibility to: Follow the facility policies and procedures that have been developed to provide safety and quality of care for all patients. 10 NATIONAL KIDNEY FOUNDATION 5. Be Considerate It is your responsibility to: Treat other patients and staff members with respect, dignity and consideration. Never threaten others, act in a violent manner, or cause any physical harm. 6. Fulfill Financial Obligations It is your responsibility to: Make every effort to pay your bills for care from the dialysis facility and doctor(s). Obtain Medicare Part B coverage or co-insurance through a private carrier. Inform the facility business office of all health insurance programs and policies from which you receive direct payment for services in the treatment of kidney disease. Pay the dialysis facility and doctor when you receive payments from your health insurance company or medical policies. WWW. KIDNEY. ORG 11 The National Kidney Foundation is the leading organization in the U. S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Help fight kidney disease. Learn more at www. kidney.
----------------------------------------------------------------------


======================================================================
CHUNK 150 of 647
======================================================================
ID: dialysis_patients_bill_of_rights_4
Content Type: general
Words: 172
Medical Entities: dialysis
Source: dialysis_patients_bill_of_rights.pdf

----------------------------------------------------------------------
Help fight kidney disease. Learn more at www. kidney. org Many thanks to the following organizations for their role in assisting with the development of the Dialysis Patients Bill of Rights and Responsibilities American Society of Transplantation NKF Council on Renal Nutrition Centers for Medicare NKF Council of Nephrology Medicaid Services Nurses and Technicians ESRD Network 4 NKF Patient Family Council ESRD Network 7 National Renal Administrators ESRD Network 8 Association ESRD Network 13 Renal Physicians Association ESRD Network 18 TransPacific Renal Network NKF Council of Nephrology Social Workers 30 East 33rd Street New York, NY 10016 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 2013 National Kidney Foundation, Inc. 11-65-1639_FBE Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org
----------------------------------------------------------------------


======================================================================
CHUNK 151 of 647
======================================================================
ID: dining_out_with_confidence_1_2_0
Content Type: reference
Words: 500
Medical Entities: CKD,GFR
Source: dining_out_with_confidence_1_2.pdf

----------------------------------------------------------------------
STAGES 15 Dining Out with Confidence A Guide for People with Kidney Disease Stages of chronic kidney disease There are 5 stages of chronic kidney disease (CKD) as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of chronic kidney disease (CKD) as shown in the table below. Your healthcare provider will Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 tell you the stage of kidney disease, based on how Guidelines for Specific Meals or Courses. . . . . . . . . . . 7 well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number Breakfast: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 comes from a lab test that measures the amount of Beverages: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Salads and Salad Bars: . . . . . . . . . . . . . . . . . . . . . . . . . 9 Appetizers: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 STAGES OF KIDNEY DISEASE Entres: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 ESTIMATED Side Dishes: . .
----------------------------------------------------------------------


======================================================================
CHUNK 152 of 647
======================================================================
ID: dining_out_with_confidence_1_2_1
Content Type: general
Words: 500
Medical Entities: GFR
Source: dining_out_with_confidence_1_2.pdf

----------------------------------------------------------------------
11 STAGES OF KIDNEY DISEASE Entres: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 ESTIMATED Side Dishes: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Desserts: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% Specialized or Ethnic Restaurants: . . . . . . . . . . . . . . . . 18 kidney function Fast Foods: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Where can you get more information? . . . . . . . . . . . 26 Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 3 Introduction Most people enjoy eating out. This guide gives ideas for making your dining experience fun. Start by asking your kidney dietitian for any tips or advice. If you have sodium, potassium, phosphorus, protein, or fluid restrictions, this booklet will help you make good decisions. Your specific dietary needs will depend on your level of kidney function and other health conditions. PLAN AHEAD If you will be eating out for dinner, plan breakfast and lunch at home accordingly. Cut back on serving sizes and foods high in sodium and potassium during the day. Moderation is key. Call ahead to learn more 4 NATIONAL KIDNEY FOUNDATION about the menu and how the food is prepared. Many restaurants now have websites where they list their menus. Many apps also provide nutrition information. Choose a restaurant where it will be easiest to select foods best suited for you. Restaurants where food is made to order are the best choice. Restaurant staff are used to special food requests or methods of preparation. However, some may require that you call at least 24 hours in advance to make arrangements. MAKING YOUR SELECTIONS Look over the menu carefully. Ask your server for more details about anything you do not understand. Practice making requests about the way your food is prepared or served.
----------------------------------------------------------------------


======================================================================
CHUNK 153 of 647
======================================================================
ID: dining_out_with_confidence_1_2_9
Content Type: recommendation
Words: 481
Medical Entities: CKD,dialysis,diabetes
Source: dining_out_with_confidence_1_2.pdf

----------------------------------------------------------------------
Yams and sweet potato pie are high in potassium. Best meal choices might include fried chicken (with skin removed), corn, string beans or okra, wilted lettuce, corn bread, butter, and banana cake, apple cake or peach cobbler for dessert. Enjoy, and dont forget your phosphate binders. 24 NATIONAL KIDNEY FOUNDATION Fast Foods: Eating at fast-food restaurants is not totally out of the question. It does, however, take some thought and planning. While many fast-food items are pre-salted, there may be some items that are prepared without salt. You can also avoid high-sodium condiments, such as BBQ or soy sauce, and limit others, such as catsup, to one package. Many fast-food restaurants provide nutrition information, so you can check the sodium and potassium content. Your dietitian can also provide this information and tell you the specific amounts of sodium and potassium allowed in your diet. FAST FOODS Better Choices Poor Choices Regular or junior-size Large, superor king-size hamburgers hamburgers or cheeseburgers Roast beef or turkey sandwiches Sandwiches with bacon, sauces or cheese Grilled or broiled chicken Fried or breaded chicken sandwiches, tuna or chicken sandwiches, chicken nuggets salad or strips Unsalted onion rings French fries, Tater Tots, potato chips, baked potatoes, potato salad, baked beans Lettuce salads, coleslaw, High-potassium foods from macaroni salad, fresh tomato the salad bar or pickles slice Non-cola soda, lemonade, tea Milk shakes and cola sodas and coffee, water KIDNEY. ORG 25 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions. If you want to read more about chronic kidney disease (CKD), the National Kidney Foundation has more than 50 other publications that cover many subjects such as: CKD risk factors, like high blood pressure and diabetes. Complications of CKD, such as heart disease, anemia, or bone problems. Nutrition for people with CKD, with information about carbohydrates, protein, sodium, phosphorus, and potassium. Treating kidney disease early. Treating kidney failure with transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. All publications are free, but there is a limit of five per person. Becoming an educated patient is very important to being healthy 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management.
----------------------------------------------------------------------


======================================================================
CHUNK 154 of 647
======================================================================
ID: dining_out_with_confidence_1_0
Content Type: reference
Words: 500
Medical Entities: CKD,GFR
Source: dining_out_with_confidence_1.pdf

----------------------------------------------------------------------
STAGES 15 Dining Out with Confidence A Guide for People with Kidney Disease Stages of chronic kidney disease There are 5 stages of chronic kidney disease (CKD) as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of chronic kidney disease (CKD) as shown in the table below. Your healthcare provider will Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 tell you the stage of kidney disease, based on how Guidelines for Specific Meals or Courses. . . . . . . . . . . 7 well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number Breakfast: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 comes from a lab test that measures the amount of Beverages: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Salads and Salad Bars: . . . . . . . . . . . . . . . . . . . . . . . . . 9 Appetizers: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 STAGES OF KIDNEY DISEASE Entres: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 ESTIMATED Side Dishes: . .
----------------------------------------------------------------------


======================================================================
CHUNK 155 of 647
======================================================================
ID: dining_out_with_confidence_1_1
Content Type: general
Words: 500
Medical Entities: GFR
Source: dining_out_with_confidence_1.pdf

----------------------------------------------------------------------
11 STAGES OF KIDNEY DISEASE Entres: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 ESTIMATED Side Dishes: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Desserts: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% Specialized or Ethnic Restaurants: . . . . . . . . . . . . . . . . 18 kidney function Fast Foods: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Where can you get more information? . . . . . . . . . . . 26 Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 3 Introduction Most people enjoy eating out. This guide gives ideas for making your dining experience fun. Start by asking your kidney dietitian for any tips or advice. If you have sodium, potassium, phosphorus, protein, or fluid restrictions, this booklet will help you make good decisions. Your specific dietary needs will depend on your level of kidney function and other health conditions. PLAN AHEAD If you will be eating out for dinner, plan breakfast and lunch at home accordingly. Cut back on serving sizes and foods high in sodium and potassium during the day. Moderation is key. Call ahead to learn more 4 NATIONAL KIDNEY FOUNDATION about the menu and how the food is prepared. Many restaurants now have websites where they list their menus. Many apps also provide nutrition information. Choose a restaurant where it will be easiest to select foods best suited for you. Restaurants where food is made to order are the best choice. Restaurant staff are used to special food requests or methods of preparation. However, some may require that you call at least 24 hours in advance to make arrangements. MAKING YOUR SELECTIONS Look over the menu carefully. Ask your server for more details about anything you do not understand. Practice making requests about the way your food is prepared or served.
----------------------------------------------------------------------


======================================================================
CHUNK 156 of 647
======================================================================
ID: dining_out_with_confidence_1_9
Content Type: recommendation
Words: 481
Medical Entities: CKD,dialysis,diabetes
Source: dining_out_with_confidence_1.pdf

----------------------------------------------------------------------
Yams and sweet potato pie are high in potassium. Best meal choices might include fried chicken (with skin removed), corn, string beans or okra, wilted lettuce, corn bread, butter, and banana cake, apple cake or peach cobbler for dessert. Enjoy, and dont forget your phosphate binders. 24 NATIONAL KIDNEY FOUNDATION Fast Foods: Eating at fast-food restaurants is not totally out of the question. It does, however, take some thought and planning. While many fast-food items are pre-salted, there may be some items that are prepared without salt. You can also avoid high-sodium condiments, such as BBQ or soy sauce, and limit others, such as catsup, to one package. Many fast-food restaurants provide nutrition information, so you can check the sodium and potassium content. Your dietitian can also provide this information and tell you the specific amounts of sodium and potassium allowed in your diet. FAST FOODS Better Choices Poor Choices Regular or junior-size Large, superor king-size hamburgers hamburgers or cheeseburgers Roast beef or turkey sandwiches Sandwiches with bacon, sauces or cheese Grilled or broiled chicken Fried or breaded chicken sandwiches, tuna or chicken sandwiches, chicken nuggets salad or strips Unsalted onion rings French fries, Tater Tots, potato chips, baked potatoes, potato salad, baked beans Lettuce salads, coleslaw, High-potassium foods from macaroni salad, fresh tomato the salad bar or pickles slice Non-cola soda, lemonade, tea Milk shakes and cola sodas and coffee, water KIDNEY. ORG 25 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions. If you want to read more about chronic kidney disease (CKD), the National Kidney Foundation has more than 50 other publications that cover many subjects such as: CKD risk factors, like high blood pressure and diabetes. Complications of CKD, such as heart disease, anemia, or bone problems. Nutrition for people with CKD, with information about carbohydrates, protein, sodium, phosphorus, and potassium. Treating kidney disease early. Treating kidney failure with transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. All publications are free, but there is a limit of five per person. Becoming an educated patient is very important to being healthy 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management.
----------------------------------------------------------------------


======================================================================
CHUNK 157 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_0
Content Type: evidence
Words: 485
Medical Entities: CKD,hypertension,diabetes
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
Saudi J Kidney Dis Transpl 2011; 22(6): 1289-1293 Saudi Journal 2011 Saudi Center for Organ Transplantation of Kidney Diseases and Transplantation Renal Data from Asia-Africa Epidemiology of Chronic Kidney Disease in a Sri Lankan Population: Experience of a Tertiary Care Center Eranga S. Wijewickrama1, Dinushi Weerasinghe2, Pubudu S. Sumathipala2, Charith Horadagoda1, Rushika D. Lanarolle2, Rezvi MH. Sheriff2 University Medical Unit1, National Hospital of Sri Lanka, Department of Clinical Medicine2, Faculty of Medicine, Colombo, Sri Lanka ABSTRACT. Chronic kidney disease (CKD) is a growing problem in Sri Lanka. Diabetes and hypertension are the main contributors to the disease burden. A new form of CKD of uncertain etiology (CKD-u) is the predominant form of CKD in certain parts of Sri Lanka, threatening to reach epidemic proportions. A cross-sectional descriptive study was carried out over a three-month period at the National Hospital of Sri Lanka to identify the underlying etiologic factors for the disease in a cohort of patients with CKD. A total of 200 patients were studied with a mean age of 50. 57 years. Of them, 108 (54%) were in CKD stage V. Majority of the patients were from the western province (137, 68. 5%) with only five (2. 5%) from provinces with high prevalence of CKD-u. The most common underlying causes of CKD were diabetes (88, 44%) and hypertension (34, 17%). However, in patients younger than 40 years of age the most common cause was glomerulonephritis (20, 42. 6%). Diabetes was the most common cause of CKD among patients from the western province (74, 54%). The prevalence of CKD-u was twice as high in patients from areas outside the western province compared with patients from this province (P 0. 05). The low prevalence of CKD-u in the study population could be the result of poor representation of patients from provinces with high prevalence of CKD-u. Introduction stage renal disease (ESRD), there are more than 200 with overt CKD (stage III or IV) and Chronic kidney disease (CKD) is fast becoalmost 5000 with covert disease (stage I or II). 2 ming a global epidemic. 1 Data from the United Unfortunately, such data are not available for States suggest that for every patient with endmost of the developing countries, including Sri Correspondence to: Lanka. CKD is a growing problem in Sri Lanka. HosDr. Eranga Sanjeewa Wijewickrama, pital admissions due to diseases of the genitoUniversity Medical Unit, urinary system have nearly doubled during the National Hospital of Sri Lanka, period between 1990 and 2007. 3 During the same Colombo, Sri Lanka period, hospital deaths due to diseases of the E-mail: erangaswgmail. com genitourinary system has risen from 2. 6 to 9. 1 1290 Wijewickrama ES, Weerasinghe D, Sumathipala PS, et al per 100, 000 population. 3 CKD has been the preof CKD, were considered as having CKD. dominant contributor to this rise in inhospital An interviewer-administered questionnaire was morbidity and mortality. used to gather information related to CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 158 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_1
Content Type: evidence
Words: 491
Medical Entities: CKD,GFR,hypertension,diabetes
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
6 to 9. 1 1290 Wijewickrama ES, Weerasinghe D, Sumathipala PS, et al per 100, 000 population. 3 CKD has been the preof CKD, were considered as having CKD. dominant contributor to this rise in inhospital An interviewer-administered questionnaire was morbidity and mortality. used to gather information related to CKD. The increased incidence of CKD is mainly Additional information was gathered from the attributed to the rise in prevalence of type-2 bed head tickets of the patients and from their diabetes mellitus and hypertension among the follow-up notes and clinic records. Sri Lankans. 4, 5 Additionally, an apparently new Diabetes was considered the presumptive unform of CKD of uncertain etiology (CKD-u) derlying cause of CKD if a patient had clinihas recently emerged from certain parts of Sri cally and biochemically confirmed diabetes melLanka. This entity is the chief contributor to the litus and one of the following criteria in the increasing number of CKD patients origiabsence of indicators of any other etiologies: nating from north and north central provinces long duration of diabetes before the onset of of the country. 6 The observation that diseases of CKD (minimum of five years) or the presence the genitourinary system are the leading cause of diabetic retinopathy on fundus examination. of inhospital deaths in Anuradhapura and the Hypertension was considered the presumptive second leading cause in Polonnaruwa and underlying cause if a patient with CKD had Vavuniya, in comparison to them being the hypertension associated with any of the folninth leading cause of inhospital deaths overall lowing criteria in the absence of indicators of in Sri Lanka, highlights the impact of CKD-u in any other etiologies: long duration of hyperthese provinces. 3 tension (at least five years), presence of conDiabetes and hypertension are considered to centric left ventricular hypertrophy, or the prebe the chief causes of CKD in areas outside the sence of hypertensive retinopathy at the time of CKD-u provinces. However, with the recent diagnosis of CKD. liberation of the northern territory from the A diagnosis of glomerulonephritis was made clutches of civil war, more and more patients based on renal biopsy findings. Other etiologic from these areas are seeking treatment from factors were diagnosed on the basis of renal tertiary care centers in Colombo and Kandy imaging and biopsy findings. (which are situated outside these CKD-u The stage of CKD was established based on provinces). the estimated glomerular filtration rate (GFR) Therefore, the epidemiology of CKD in these according to the Kidney Disease Outcomes nonCKD-u areas is also changing. Hence, Quality Initiative (K/DOQI) guidelines. 7 The research on CKD should be extended to all estimated GFR was calculated using the parts of the country without confining only to abbreviated MDRD equation. 8 the CKD-u areas. Differences in patient characteristics between the two groups for categorical variables were Subjects and Methods assessed by the Chi-square test. For continuous variables, a t test for independent samples was A cross-sectional descriptive study was carried done.
----------------------------------------------------------------------


======================================================================
CHUNK 159 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_2
Content Type: reference
Words: 496
Medical Entities: CKD,hypertension,diabetes
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
8 the CKD-u areas. Differences in patient characteristics between the two groups for categorical variables were Subjects and Methods assessed by the Chi-square test. For continuous variables, a t test for independent samples was A cross-sectional descriptive study was carried done. The level of significance was set at P out in the medical wards and the renal clinic of 0. 05. All analyses were done with the SPSS the university medical unit of the National Hos16. 0 statistical software. pital of Sri Lanka. Consecutive consenting patients with CKD who were admitted to the wards Results and all patients with CKD who attended the clinic and who gave consent were recruited over a A total of 200 patients were included in the period of three months. study with male to female ratio of 2. 1: 1. The Patients with serum creatinine more than 120 mean age was 50. 57 years with a range from 10 mol/L, either persisting for more than three to 85 years. A total of 108 patients (54%) had months or associated with ultrasound evidence CKD stage V, whereas 42 (21%) and 26 (13%) Chronic kidney disease in a Sri Lankan population 1291 Table 1. Relationship of age groups with different etiologies of chronic kidney disease. Overall number Over 40 years Under 40 years Etiology P value n (%) n (%) n (%) Diabetes 88 (44) 83 (54. 2) 5 (10. 6) 0. 0001 Hypertension 34 (17) 30 (19. 6) 4 (8. 5) 0. 076 Glomerulonephritis 24 (12) 4 (2. 6) 20 (42. 6) 0. 0001 Chronic pyelonephritis 1 (0. 5) 1 (2. 1) Obstructive uropathy 11 (5. 5) 8 (5. 2) 3 (6. 4) ns Polycystic kidney disease 12 (6) 9 (5. 9) 3 (6. 4) ns Hereditary 9 (4. 5) 5 (3. 3) 4 (8. 5) ns Miscellaneous 2 (1) 2 (4. 3) Uncertain 19 (9. 5) 14 (9. 2) 5 (10. 6) ns Total 200 153 47 patients had CKD stage IV and III, respectively. was the cause of CKD in 18 patients (28. 6%) The common underlying causes for CKD infrom areas outside the western province comcluded diabetes, seen in 88 patients (44%) folpared with only 16 (11. 7%) from the western lowed by hypertension, seen in 34 (17%) (Table province. Both these differences were statisti1). However, the most common cause for CKD cally significant. in patients younger than 40 years was glomeThe prevalence of CKD without any apparent rulonephritis, seen in 20 patients (42. 6%). The cause was only 19 (9. 5%) in the population difference in the prevalence of CKD due to studied. The prevalence of this entity was almost diabetes between the older and younger age twice as high in patients who were from areas groups was statistically significant (54. 2 vs outside the western province compared with 10. 6%, P 0. 05). Similarly, the difference in the patients who were from this province (9, 14. 3% prevalence of CKD due to glomerulonephritis vs 10, 7. 3%).
----------------------------------------------------------------------


======================================================================
CHUNK 160 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_3
Content Type: reference
Words: 473
Medical Entities: CKD,hypertension,diabetes
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
2 vs outside the western province compared with 10. 6%, P 0. 05). Similarly, the difference in the patients who were from this province (9, 14. 3% prevalence of CKD due to glomerulonephritis vs 10, 7. 3%). However, this difference was between the two groups was statistically not statistically significant. significant (2. 6 vs 42. 6%, P 0. 05). Majority of the patients, numbering 137 (68. 5%), were from Discussion the western province. Only five patients (2. 5%) were from north and north central provinces CKD is reaching epidemic proportions in Sri where CKD-u has a high prevalence. Diabetes Lanka. In this background, knowledge of the was the cause of CKD in 74 patients (54%) from etiologic factors for CKD in Sri Lanka is the western province compared with only 14 important. Diabetes and hypertension are on (22. 2%) from elsewhere (Table 2). Hypertension the rise in Sri Lanka in line with other Asian Table 2. Comparison of etiology of chronic kidney disease between patients from the western province and elsewhere. Western province Outside western Etiology P value n (%) province n (%) Diabetes 74 (54%) 14 (22. 2%) 0. 001 Hypertension 16 (11. 7%) 18 (28. 6%). 006 Glomerulonephritis 12 (8. 8%) 12 (19%) ns Chronic pyelonephritis 1 (0. 7%) - - Obstructive uropathy 10 (7. 3%) 1 (1. 6%) ns Polycystic kidney disease 6 (4. 4%) 6 (9. 5%) ns Hereditary 7 (5. 1%) 2 (3. 1%) ns Miscellaneous 1 (0. 7%) 1 (1. 6%) ns Uncertain 10 (7. 3%) 9 (14. 3%) ns Total 137 63 1292 Wijewickrama ES, Weerasinghe D, Sumathipala PS, et al hereditary causes, glomerulonephritis). CKD of uncertain or unknown etiology is an entity described in certain provinces of Sri Lanka. The geographic distribution of CKD-u appears to be based toward the northern regions of the country in which the north central, part of north western, and part of Uva provinces are included. The population at risk are scattered in the north central region with high prevalence observed at Medawachchiya, Padaviya, Dehiattakandiya, Girandurukotte, Medirigiriya and recently Nikawewa (Figure 1). This entity was discovered when several studies failed to identify a specific cause for CKD in the vast majority of the patients from these areas. For example, a recent study which was carried Figure 1. Map of Sri Lanka showing areas with out among CKD patients attending the outpatient high prevalence of chronic kidney disease of clinics of Kandy and Anuradhapura hospitals, unknown etiology. which provide services for most of these CKD-u countries. 4, 5 This observation is further highareas, revealed that 54% and 82% of patients, respectively, were not identified to have a spelighted in our study. These findings were sicific cause for the disease. 6 This is in contrast to milar to the results of the previous study conducted three years earlier in the same institute.
----------------------------------------------------------------------


======================================================================
CHUNK 161 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_4
Content Type: reference
Words: 494
Medical Entities: CKD,dialysis,hypertension
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
These findings were sicific cause for the disease. 6 This is in contrast to milar to the results of the previous study conducted three years earlier in the same institute. 9 the reported prevalence of CKD of uncertain etiology in other parts of the world, which ranges In that study, conducted by Gooneratne et al, at from 6. 2% to 14. 7%. 10 The majority of the the National hospital of Sri Lanka in 2006, affected patients were young males engaged in diabetic nephropathy was the leading cause of paddy farming who belonged to low socioCKD with a prevalence of 30. 6%. Prevalence of economic communities. hypertension as a cause of CKD was 13. 2%. The presence of high levels of fluoride, However, there are significant differences in widespread use of agrochemicals, presence of the results between the two studies. The preheavy metals, such as cadmium, lead, and uravalence of diabetic nephropathy had risen by nium in soil and water could be postulated as almost 50% from 30. 6% to 44% during the 3contributory factors. As demonstrated in some year period. There had been a smaller rise in the studies, mycotoxins, use of herbal/ayurvedic meprevalence of hypertensive nephrosclerosis dicines, smoking, and a history of snake bite are (13. 2%17%). some other factors to be considered. 11 The prevalence of CKD of uncertain etiology However, no convincing evidence for a spein our study population was only 9. 5%. This was cific cause for this entity has yet been found. A much lower than the figure three years back, study funded by the World Health Organization which was 25. 6%. Several factors could have is currently underway in Sri Lanka in order to contributed to this. Firstly, our study contained resolve this issue. a higher number of patients from the western Our study was conducted at the National province compared with the previous study Hospital of Sri Lanka, which is the largest (western to elsewhere ratio of 2. 2: 1 vs 1. 4: 1). hospital in the country, situated in the capital Secondly, only five patients (2. 5%) were from Colombo, mainly functioning as a referral center provinces with high prevalence of CKD-u. for specialized care of patients. It also provides Thirdly, better diagnostic work-up might have general medical services for a large proportion resulted in a higher number being diagnosed as of inhabitants of Colombo and a similar number having a specific cause for their disease (eg, Chronic kidney disease in a Sri Lankan population 1293 visiting the city on a daily basis. It has eight References general medical units, including our unit. In addition, our unit functions as a specialized 1. Nahas AM, Belle AK. Chronic kidney disease: nephrology, dialysis, and transplant unit. We The global challenge. Lancet 2005; 365: 331-40. provide inpatient care, outpatient care, and referral 2. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-9. services. 3. Annual Health Statistics of Sri Lanka, 2007.
----------------------------------------------------------------------


======================================================================
CHUNK 162 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_5
Content Type: evidence
Words: 488
Section: Chronic kidney disease:
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
Chronic kidney disease: nephrology, dialysis, and transplant unit. We The global challenge. Lancet 2005; 365: 331-40. provide inpatient care, outpatient care, and referral 2. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-9. services. 3. Annual Health Statistics of Sri Lanka, 2007. The specialized nature of our nephrology ser4. Katulanda P, Sheriff MH, Mathews DR. The vices resulted in majority of the study patients diabetic epidemic in Sri Lanka: a growing belonging to advanced CKD. In addition, cerproblem. Ceylon Med J 2006; 51: 26-8. tain etiologic factors, such as glomeruloneph5. Katulanda P, Constantine GR, Mahesh JG, et al. ritis and hereditary diseases may have been Prevalence and projections of diabetes and over-represented in the study population, espeprediabetes in adults in Sri Lanka: Sri Lanka cially among the young. Diabetes, Cardiovascular Study (SLDCS). Diabet Since the study was institution-based, other Med 2008; 25(9): 1062-9. variables such as the health-seeking behavioral 6. Athuraliya TN, Abeysekera DT, Amerasinghe PH, Kumarasiri PV, Dissanayake V. Prevalence of patterns of the patients, the distance to the chronic kidney disease in two tertiary care hoshospital, the socioeconomic status of the patients, pitals: high proportion of cases with uncertain and the ability to afford travel, would have aetiology. Ceylon Med J 2009; 54: 23-5. affected the results. Therefore, these results may 7. National Kidney Foundation: K/DOQI Clinical not represent the true epidemiologic pattern of practice guidelines for chronic kidney disease: the CKD in the area concerned. evaluation, classification and stratification. Am J We used the inclusion criterion of serum Kidney Dis 2002; 39(Suppl): S1-266. creatinine value of 120 mol/L while selecting 8. Levey AS, Greene T, Kusek JW, et al. A simpatients for the study. Thus, we might have plified equation to predict glomerular filtration missed patients with early stages of CKD and rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828. would have confined our study only to patients 9. Gooneratne IK, Ranaweera AK, Liyanarchchi with advanced CKD. This is a limitation in our NP, Gunawardane N, Lanarolle RD. Epidemiostudy. In conclusion, diabetes and hypertension logy of chronic kidney disease in a Sri Lankan are the leading causes for the CKD in the wespopulation. Int J Diab Dev Ctries 2008; 28: 60-4. tern province of Sri Lanka. Post-War changes 10. Wing AJ. Causes of end-stage renal failure. In: in population demographics do not seem to Davison MA, Cameron JS, Grunfeld JP, Ponticelli have influenced the epidemiology of CKD in C, Ritz E, Winearls EG, eds. The Oxford Textareas outside the CKD-u provinces. Larger mulbook of Clinical Nephrology 1st edition. ticenter studies involving units caring for CKD 11. Wanigasuriya KP, Peiris-John RJ, Wickremapatients in both CKD-u and nonCKD-u prosinghe R, Hittarage A. Chronic renal failure in North Central Province of Sri Lanka: an envivinces should be carried out in order to undersronmentally induced disease. Trans Royal Soc tand the true burden of the disease in Sri Lanka.
----------------------------------------------------------------------


======================================================================
CHUNK 163 of 647
======================================================================
ID: epidemiology_of_chronic_kidney_disease_in_a_sri.41_6
Content Type: evidence
Words: 85
Medical Entities: CKD
Source: epidemiology_of_chronic_kidney_disease_in_a_sri.41.pdf

----------------------------------------------------------------------
Wanigasuriya KP, Peiris-John RJ, Wickremapatients in both CKD-u and nonCKD-u prosinghe R, Hittarage A. Chronic renal failure in North Central Province of Sri Lanka: an envivinces should be carried out in order to undersronmentally induced disease. Trans Royal Soc tand the true burden of the disease in Sri Lanka. Trop Med Hyg 2007; 101(10): 1013-7 Acknowledgment We thank the staff of wards and clinics of University Medical Unit and Faculty of Medicine for their support and all my colleagues who helped me during the study.
----------------------------------------------------------------------


======================================================================
CHUNK 164 of 647
======================================================================
ID: gfr_a_key_to_understanding_0
Content Type: general
Words: 494
Medical Entities: CKD,GFR
Source: gfr_a_key_to_understanding.pdf

----------------------------------------------------------------------
STAGES 15 Estimated Glomerular Filtration Rate (eGFR) A key to understanding how well your kidneys are working 2 NATIONAL KIDNEY FOUNDATION Contents How do doctors check for kidney disease? 4 Wouldnt I know if something was wrong with my kidneys? 4 What is estimated glomerular filtration rate (eGFR)? 5 How is eGFR checked? 5 Do you know what your eGFR is? 5 Stages of chronic kidney disease 6 What is a normal eGFR number? 7 Does age affect eGFR? 8 If my eGFR is low, what are the next steps? 9 Am I at increased risk for kidney disease? 10 If the tests find kidney disease, what does it mean for my health? 10 Can treatment keep kidney disease from getting worse? 11 Where can I get more information? 14 KIDNEY. ORG 3 Most people are aware that their blood pressure and cholesterol numbers are important in knowing their risk for heart and blood vessel diseases. Yet few know about estimated glomerular filtration rate (eGFR), one of the numbers that measures the health of their kidneys. This brochure explains what eGFR is, how it is measured, and why it is important in understanding chronic kidney disease (CKD). How do doctors check for kidney disease? Kidney disease can be found with two simple tests: A urine test for protein (uACR) A blood test for creatinine (eGFR) Even if these tests are normal now, they should be repeated in the future, especially if you are at increased risk for kidney disease. Wouldnt I know if something was wrong with my kidneys? Not always. Early kidney disease can be silent, without pain or other symptoms. Most people do not know that they have early kidney disease. When kidney disease gets worse, some people do notice problems such as swelling around the ankles, puffiness around the eyes, high blood pressure, nausea, poor appetite, or vomiting. 4 NATIONAL KIDNEY FOUNDATION What is estimated glomerular filtration rate (eGFR)? Your eGFR tells a lot about how well your kidneys are working. Your kidneys are important. They keep you healthy. They filter out waste and extra fluid from your blood, help make red blood cells, and keep your bones strong. When kidneys arent working well, wastes build up in your blood. Your bones can become weak. You may not have enough red blood cells for your bodys needs. Your eGFR number is a calculated measurement of how well your kidneys are working. If your eGFR number is low, your kidneys may not be working as well as they should. Its important to find this out early. Early treatment may help keep kidney disease from getting worse. How is eGFR checked? Having a simple blood test for creatinine is the first step in checking your eGFR. Creatinine is a waste product made by your bodys muscles. Your kidneys usually keep the level of creatinine just right. The level of creatinine in your blood, your age, and gender are used to calculate your eGFR.
----------------------------------------------------------------------


======================================================================
CHUNK 165 of 647
======================================================================
ID: gfr_a_key_to_understanding_1
Content Type: reference
Words: 472
Medical Entities: CKD,GFR
Source: gfr_a_key_to_understanding.pdf

----------------------------------------------------------------------
Creatinine is a waste product made by your bodys muscles. Your kidneys usually keep the level of creatinine just right. The level of creatinine in your blood, your age, and gender are used to calculate your eGFR. Do you know what your eGFR is? Your healthcare professional or testing lab usually calculates your eGFR number. Be sure to talk with your doctor about the result. KIDNEY. ORG 5 Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 6 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease What is a normal eGFR number? There are 5 stages of kidney disease as shown in the In adults, the normal eGFR number is more than 90. table below. Your healthcare provider will tell you the IF YOUR eGFR IS BETWEEN 60 AND 89 stage of kidney disease, based on how well your People with mildly low eGFR (between 60 and 89) kidneys are working and your estimated glomerular may not have kidney disease if there is no sign of filtration rate (eGFR). The eGFR number comes from a kidney damage, such as protein in their urine. These lab test that measures the amount of blood your people should have their eGFR checked often. They kidneys are filtering each minute. As CKD gets worse, may be asked to avoid medications that can damage the eGFR number goes down. the kidneys (such as ibuprofen) or reduce the dose of medicines that are removed by the kidneys. STAGES OF KIDNEY DISEASE If there is kidney damage, such as protein in the urine, a result between 60 and 89 may mean early ESTIMATED GLOMERULAR kidney disease. Even an eGFR over 90 with protein FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION in the urine is a sign of kidney disease. eGFR must Kidney damage (e. g. , protein remain low for three months for kidney disease to be 1 in the urine) with normal 90 or above 90100% diagnosed.
----------------------------------------------------------------------


======================================================================
CHUNK 166 of 647
======================================================================
ID: gfr_a_key_to_understanding_2
Content Type: general
Words: 498
Medical Entities: GFR,dialysis,diabetes
Source: gfr_a_key_to_understanding.pdf

----------------------------------------------------------------------
eGFR must Kidney damage (e. g. , protein remain low for three months for kidney disease to be 1 in the urine) with normal 90 or above 90100% diagnosed. kidney function Kidney damage with mild IF YOUR eGFR IS BELOW 60 2 60 to 89 loss of kidney function 6089% When eGFR is below 60 for more than three months, it usually means you have moderate-to-severe kidney Mild to moderate loss of 3a 45 to 59 disease. You may be referred to a nephrologist (kidney kidney function 4559% doctor) for evaluation and treatment. Moderate to severe loss of 3b 30 to 44 IF YOUR eGFR IS BELOW 15 kidney function 3044% An eGFR below 15 means kidney failure. If kidney failure occurs, dialysis or a kidney transplant will be Severe loss of kidney 4 15 to 29 function 1529% needed to stay alive. 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 7 Does age affect eGFR? Yes. eGFR gets lower with age, even in people without kidney disease. The older you are, the lower your eGFR. For this reason, the eGFR calculation takes age in to account. At any age, an eGFR below 60 for three months or more indicates kidney disease. eGFR Declines with Age (even in people without kidney disease) Age (years) Average eGFR 2029 116 3039 107 4049 99 5059 93 6069 85 70 75 8 NATIONAL KIDNEY FOUNDATION If my eGFR is low, what are the next steps? More tests should be done to understand why it is low. The results of these tests may provide clues about what is happening with your kidneys. Examples of tests that might be ordered are: Urine tests that look for: The type and amount of protein in your urine (a sign of kidney damage) Red blood cells (a sign of bleeding in the urinary system) White blood cells (a sign of infection) Ultrasound or CT scan to get a picture of your kidneys and urinary system. These pictures show the size of your kidneys and if tumors, kidney stones, or cysts are present. A biopsy to remove a tiny piece of the kidney for evaluation. The sample is studied under a microscope to see what kind of kidney damage is may be present. KIDNEY. ORG 9 Am I at increased risk for kidney disease? Some people are more likely than others to develop kidney disease. You may be at increased risk for kidney disease if you: Have diabetes Have high blood pressure Have a family history of kidney disease or kidney failure Are age 60 or older Are overweight or obese If the tests find kidney disease, what does it mean for my health? If you have kidney disease, your kidneys have lost some of their ability to keep you healthy. They arent able to do their full jobs: filter your blood, help make red blood cells, and keep bones strong. The most common causes of kidney disease are diabetes and high blood pressure.
----------------------------------------------------------------------


======================================================================
CHUNK 167 of 647
======================================================================
ID: gfr_a_key_to_understanding_3
Content Type: recommendation
Words: 494
Medical Entities: GFR,dialysis,diabetes
Source: gfr_a_key_to_understanding.pdf

----------------------------------------------------------------------
If you have kidney disease, your kidneys have lost some of their ability to keep you healthy. They arent able to do their full jobs: filter your blood, help make red blood cells, and keep bones strong. The most common causes of kidney disease are diabetes and high blood pressure. There are also other problems caused by kidney disease like high blood pressure, poor nutrition, and heart disease. 10 NATIONAL KIDNEY FOUNDATION Can treatment keep kidney disease from getting worse? The earlier your kidney disease is found, the better. If it is found and treated early, you may be able to keep it from getting worse. That is why it is so important for people with risk factors to be tested for kidney disease. Heart and blood vessel problems Poor nutritional health High blood pressure Anemia Bone problems Kidney disease affects many areas of the body. KIDNEY. ORG 11 The success of treatment depends on a number of things: Your stage of kidney disease when you start treatment. The earlier you start, the better you are likely to do. How carefully you follow your treatment plan. Learn all you can about kidney disease and its treatment. Talk to your doctor about what you can do. What caused your kidney disease. Some kidney diseases are more difficult to control. 12 NATIONAL KIDNEY FOUNDATION Key Points to Remember: Two simple tests will find chronic kidney disease: A urine test for protein (uACR) A blood test for creatinine (eGFR) Get a blood pressure measurement. eGFR is an important number that estimates how much kidney function you have. If you have kidney disease, a treatment plan will be developed especially for you. It will be based on your eGFR, the cause of your kidney disease, and other health factors. Your doctor will monitor your stage of kidney disease using your eGFR. You should keep track of it, too. You can keep kidney disease from getting worse by following your treatment plan carefully. If kidney disease progresses to kidney failure, dialysis or a kidney transplant will be needed. KIDNEY. ORG 13 Where can I get more information? If you have questions, speak with your healthcare team. They know you and can answer questions. You can also call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org. A trained professional will listen to your concerns and answer your questions. 14 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management.
----------------------------------------------------------------------


======================================================================
CHUNK 168 of 647
======================================================================
ID: hemodialysis_0_0
Content Type: reference
Words: 495
Medical Entities: CKD,GFR,dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
STAGE 5 Hemodialysis What you need to know Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Contents Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 When will I need to start treatment for kidney failure? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 How does hemodialysis help people with kidney failure? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 How does hemodialysis work? . . . . . . . . . . . . . . . . . . . 6 How does the dialyzer clean my blood? . . . . . . . . . . . . 8 Where is hemodialysis done? . . . . . . . . . . . . . . . . . . . . 9 How long will each hemodialysis treatment last? . . . . 9 How do I know if I am getting the right amount of dialysis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Can hemodialysis be done at home? . . . . . . . . . . . . . . 12 Home hemodialysis versus in a center. . . . . . . . . . . . 14 Can dialysis cure my kidney disease? . . . . . . . . . . . . . 16 Will I need to follow a special diet? . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 169 of 647
======================================================================
ID: hemodialysis_0_1
Content Type: recommendation
Words: 487
Medical Entities: CKD,GFR,dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
. . . . . . 14 Can dialysis cure my kidney disease? . . . . . . . . . . . . . 16 Will I need to follow a special diet? . . . . . . . . . . . . . . . 18 What insurance coverage is available for dialysis? . . 20 Will dialysis change my lifestyle? . . . . . . . . . . . . . . . . 20 Can people on dialysis travel? . . . . . . . . . . . . . . . . . . . 21 Can people on dialysis continue to work? . . . . . . . . . . 22 Understanding your lab values. . . . . . . . . . . . . . . . . . . 23 Where can you get more information? . . . . . . . . . . . . 25 KIDNEY. ORG 3 Introduction Healthy kidneys clean your blood and remove extra fluid in the form of urine. They also make hormones your body needs for some important functions. When kidney failure occurs, treatment is needed to replace some of the important jobs your kidneys do. The treatments for kidney failure are hemodialysis, peritoneal dialysis, and kidney transplant. Learn all you can and speak to your healthcare professional to find best choice for you. This booklet is written for people who may be getting ready to start treatment for kidney failure as well as for those who are already on hemodialysis. Information is based on recommendations from the National Kidney Foundations Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Clinical Practice Guidelines. 4 NATIONAL KIDNEY FOUNDATION When will I need to start treatment for kidney failure? Treatment is needed when someone has stage 5 chronic kidney disease (CKD), which is also called kidney failure. Your healthcare professional can tell your stage of kidney disease by checking your estimated glomerular filtration rate (eGFR). Your eGFR is a calculation from the results of a blood test for creatinine, a waste product from muscle activity. If your eGFR falls below 15, you have kidney failure (CKD stage 5), and you will need to have a kidney transplant or dialysis treatment to replace the function of your kidneys. If your eGFR is less than 30 (CKD stage 4), your healthcare provider should talk to you about the different treatments for kidney failure. Ask about information classes in your area so you can learn more about kidney failure treatment options. How does hemodialysis help people with kidney failure? Hemodialysis is a life-saving treatment for people with kidney failure. A hemodialysis machine works as an artificial kidney by: Removing wastes and extra fluids in your body to prevent them from building up in your blood Helping to regulate blood pressure KIDNEY. ORG 5 How does hemodialysis work?
----------------------------------------------------------------------


======================================================================
CHUNK 170 of 647
======================================================================
ID: hemodialysis_0_2
Content Type: reference
Words: 498
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
Hemodialysis is a life-saving treatment for people with kidney failure. A hemodialysis machine works as an artificial kidney by: Removing wastes and extra fluids in your body to prevent them from building up in your blood Helping to regulate blood pressure KIDNEY. ORG 5 How does hemodialysis work? A hemodialysis machine has a special filter called a dialyzer to clean your blood. To get your blood to the dialyzer, a surgeon will make an opening into one of your blood vessels. This opening is called an access, this is done with minor surgery, usually in your arm. Fistulas and grafts are two types of accesses that are used. A fistula is the first choice for an access. It is made by joining an artery to a nearby vein under your skin to make a bigger blood vessel. This type of access is preferred because it has fewer problems and lasts longer. You should be evaluated by a special doctor called a vascular surgeon at least six months before you will need to start dialysis. A fistula should be placed early (several months before starting dialysis) so it has plenty of time to heal and be ready by the time you start treatment. If your blood vessels are not suitable for a fistula, a graft may be done. This involves joining an artery and a nearby vein with a small, soft tube made of synthetic material that is placed under your skin. After the fistula or graft has fully healed, it can be used for dialysis. During dialysis, two needles will be placed into your access. Each needle is connected to a plastic tube. One tube carries your blood to the dialyzer where it is cleaned and the other tube returns the cleaned blood back to your body. 6 NATIONAL KIDNEY FOUNDATION There is a third type of access, called a catheter, which is a soft tube that is placed into a large vein in your neck or chest. This type of access is generally used only when you need dialysis for a short period of time. Catheters can be used as a permanent access when a fistula or a graft cannot be placed. Catheters can be connected directly to the dialysis tubes and needles are not used. Catheters have more health complications than other types of access. KIDNEY. ORG 7 How does the dialyzer clean my blood? Inside the dialyzer, or filter, there are two sidesone for your blood and the other for a fluid called dialysate. A thin film, called a membrane, separates these two sides. Blood cells, proteins, and types of cells remain in your blood because they are too big to pass through the membrane. Smaller waste products, such as urea and creatinine, and extra fluid, move from your blood through the mem brane, and are removed. The composition of the dialysate, or cleansing fluid, is made for your special needs according to your healthcare professionals prescription. 8 NATIONAL KIDNEY FOUNDATION Where is hemodialysis done?
----------------------------------------------------------------------


======================================================================
CHUNK 171 of 647
======================================================================
ID: hemodialysis_0_3
Content Type: recommendation
Words: 441
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
Smaller waste products, such as urea and creatinine, and extra fluid, move from your blood through the mem brane, and are removed. The composition of the dialysate, or cleansing fluid, is made for your special needs according to your healthcare professionals prescription. 8 NATIONAL KIDNEY FOUNDATION Where is hemodialysis done? Hemodialysis can be done at a hospital, a dialysis center or even at home. You and your healthcare professional should work together to decide where it would be best for you to have your hemodialysis treatment. How long will each hemodialysis treatment last? Hemodialysis treatments are usually done three times a week. Each treatment lasts about four hours, but you may need more time to make sure that enough wastes and fluids are removed. Just how often you should get dialysis depends on: How well your kidneys are working The amount of fluid you retain between treatments The amount of waste products you have in your blood The kind of dialyzer you are using Your healthcare professional will recommend and write a dialysis prescription that is best for you. Studies have shown that getting the right amount of dialysis improves your overall health, makes you feel better, keeps you out of the hospital, and may help you to live longer. KIDNEY. ORG 9 How do I know if I am getting the right amount of dialysis? Your healthcare professional will develop a special dialysis prescription for you. This will help to make sure that you get the right treatment. In addition, your dialysis care team will monitor your treatment with monthly lab tests to measure the amount of dialysis you receive (your dose of dialysis). The most accurate way to measure this is called urea kinetic modeling. The number that tells how well your blood is being cleaned by dialysis is your Kt/V (sounds like kay tee over vee). Your goal Kt/V number may change depending on how often you have dialysis and on how well your kidneys are working. For example, many dialysis patients who have treatments 3 times a week, should have a Kt/V of at least 1. 2 for each treatment. There are other ways to measure the dialysis dose that is delivered. One is called the urea reduction ratio (URR). If this ratio is used to measure your delivered dose of dialysis, your URR should be at least 65% for each treatment. 10 NATIONAL KIDNEY FOUNDATION Tips Know your dose of dialysis Ask your dialysis care team which test they are using to determine your dose of dialysis. Ask what your number is. If you are not pleased with your number, ask how it can be improved.
----------------------------------------------------------------------


======================================================================
CHUNK 172 of 647
======================================================================
ID: hemodialysis_0_4
Content Type: general
Words: 456
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
10 NATIONAL KIDNEY FOUNDATION Tips Know your dose of dialysis Ask your dialysis care team which test they are using to determine your dose of dialysis. Ask what your number is. If you are not pleased with your number, ask how it can be improved. Your dialysis care team is available to help you make sure your: Access is working well Dialyzer is working well Blood flow and the flow rate of the dialysate fluid (cleansing fluid) are working well during dialysis Blood samples are taken correctly You can also help to make sure you are receiving the right dialysis dose by: Keeping all your appointments Completing your full treatment Taking care of your access KIDNEY. ORG 11 Can hemodialysis be done at home? Many patients have their hemodialysis treatments at home. If you and your healthcare professional decide home hemodialysis is a good choice for you, then you will be trained how to do hemodialysis at home. Home hemodialysis allows you to schedule your treatments to fit your routine. Your home must have enough space for the equipment and enough water drainage and electric power to operate the dialysis machine and water purification unit. Medicare covers up to 80% of the cost of home hemodialysis, just as they do for dialysis in a hospital or other treatment center. Medicare may help cover the cost of minor plumbing or electrical modifications to your home for home hemodialysis. There are three types of home hemodialysisconventional, short daily, and nocturnal. Conventional home hemodialysis is usually done 3 times a week for 3-5 hours. Short daily home hemodialysis involves more treatments per week for shorter periods. Nocturnal hemodialysis involves longer, slower treatments, which are done while you sleep, usually for 6 to 8 hours. 12 NATIONAL KIDNEY FOUNDATION Research shows that people who use short daily and nocturnal home hemodialysis: Take less medication to control high blood pressure and anemia Take less medication to keep high blood phosphorus under control Have improvements in blood pressure, nerve damage, and symptoms of restless leg syndrome Feel better during dialysis and less washed out after dialysis Have fewer limits on their diet and fluid intake Have more energy Sleep better Have fewer and shorter hospital stays Have a better quality of life Live longer With daily home hemodialysis, you dont have the swings in your blood chemistries and fluids like you do when you dont dialyze every day, so you feel a lot better. Home dialysis is for people who want to be in control of the process and be at home. David J. , patient on daily home hemodialysis KIDNEY. ORG 13 Home hemodialysis versus in a center Home hemodialysis has some important pros and cons when compared with in-center hemodialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 173 of 647
======================================================================
ID: hemodialysis_0_5
Content Type: reference
Words: 487
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
Home dialysis is for people who want to be in control of the process and be at home. David J. , patient on daily home hemodialysis KIDNEY. ORG 13 Home hemodialysis versus in a center Home hemodialysis has some important pros and cons when compared with in-center hemodialysis. PROS of Home Hemodialysis CONS of Home Hemodialysis Easier to fit into your daily schedule Initial fears about duties and caring for the dialysis machine Easier to keep working if you have a job or you wish Training for home hemodialysis is not offered by all to return to work or school dialysis centers The convenience and cost savings of not having to More space is needed in your home for equipment travel to a dialysis center three times a week and supplies Independence and being in control of your own Training may take three to eight weeks or longer, treatments with threeto five-hour training sessions per week The comfort and privacy of being in your own home Some plumbing and wiring changes in your home during treatment may be necessary, but newer machines use standard household outlets Having greater access to telephone, family Electric, gas, and water bills may increase slightly members, and visitors during treatment Being able to eat and drink when you choose Some new machines are portable, but you will have to find a dialysis center for support when traveling Less social interaction compared with going to the dialysis center 14 NATIONAL KIDNEY FOUNDATION Home hemodialysis versus in a center Home hemodialysis has some important pros and cons when compared with in-center hemodialysis. PROS of Home Hemodialysis CONS of Home Hemodialysis Easier to fit into your daily schedule Initial fears about duties and caring for the dialysis machine Easier to keep working if you have a job or you wish Training for home hemodialysis is not offered by all to return to work or school dialysis centers The convenience and cost savings of not having to More space is needed in your home for equipment travel to a dialysis center three times a week and supplies Independence and being in control of your own Training may take three to eight weeks or longer, treatments with threeto five-hour training sessions per week The comfort and privacy of being in your own home Some plumbing and wiring changes in your home during treatment may be necessary, but newer machines use standard household outlets Having greater access to telephone, family Electric, gas, and water bills may increase slightly members, and visitors during treatment Being able to eat and drink when you choose Some new machines are portable, but you will have to find a dialysis center for support when traveling Less social interaction compared with going to the dialysis center KIDNEY. ORG 15 Tips Protect your remaining kidney function Studies show that maintaining as much kidney function as possible, leads to greater overall satisfaction in people on dialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 174 of 647
======================================================================
ID: hemodialysis_0_6
Content Type: reference
Words: 480
Medical Entities: dialysis,diabetes
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
ORG 15 Tips Protect your remaining kidney function Studies show that maintaining as much kidney function as possible, leads to greater overall satisfaction in people on dialysis. Ask your dialysis care team about the steps you can take to help keep your kidney working as well as possible, such as: Take blood pressure medicines, if needed, as instructed by your healthcare professional. Studies show that some blood pressure medicines may help protect kidneys from further damage. Avoid medicines that can harm your kidneys, such as some pain relievers called nonsteroidal anti-inflammatory drugs (NSAIDs), and certain antibiotics. Ask your healthcare provider about taking diuretics (water pills) to help remove salt and water from your blood. Make sure conditions like diabetes and high blood pressure are well-controlled. Can dialysis cure my kidney disease? In some cases of sudden (also called acute) kidney failure, dialysis may only be needed for a short time until the kidneys get better. However, when kidney disease progresses slowly over time to kidney failure, your kidneys do not get better. You will need dialysis for the rest of your life, unless you are able to receive a kidney transplant. 16 NATIONAL KIDNEY FOUNDATION Tips Staying comfortable on dialysis If you experience symptoms like cramps, headaches, nausea, or dizziness during dialysis, ask your dialysis care team if any of the following steps could help you: Slow down your fluid removal, which could increase your dialysis time. Check the dose and timing of your blood pressure medications. Adjust your dry weight or target weight. Lower the temperature of the dialysate a little. Ask your healthcare provider if it would help to change to a different type of dialyzer. You can help yourself by carefully following your sodium (salt) and fluid limits between treatments to decrease fluid buildup in your body. KIDNEY. ORG 17 Will I need to follow a special diet? Yes. Your diet will be different from the one you followed before starting dialysis. Although certain foods may be limited, you need to get the right amount of protein and calories to maintain good health. The registered dietitian at your center will help you develop a meal plan that meets your needs. Its important to keep to your fluid and sodium (salt) limits so you dont build up too much fluid in your body between treatments. This buildup may lead to needing more fluid removal (ultrafiltration) during your dialysis treatment. Ultrafiltration may cause some discomfort during your treatment. Excess fluid buildup can also increase your blood pressure. 18 NATIONAL KIDNEY FOUNDATION To help prevent fluid buildup between treatments, your daily diet should not include over 2, 000 mg of sodium (salt). Your dietitian can help you plan a low sodium diet. You may also need to limit the amount of potassium and phosphorous in your diet. Review your monthly labs with your dietitian and discuss your individual diet needs.
----------------------------------------------------------------------


======================================================================
CHUNK 175 of 647
======================================================================
ID: hemodialysis_0_7
Content Type: general
Words: 492
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
Your dietitian can help you plan a low sodium diet. You may also need to limit the amount of potassium and phosphorous in your diet. Review your monthly labs with your dietitian and discuss your individual diet needs. Tips Keep sodium levels under control Limit the amount of sodium in your diet and help prevent too much fluid buildup by trying the following: Cook with herbs and spices instead of salt. Read food labels; choose foods low in sodium. When eating out, order meat or fish without salt. Ask for gravy or sauce on the side because these may contain large amounts of salt and should be used in small amounts. Limit use of canned, processed, and frozen foods. Avoid salt substitutes and specialty low-sodium foods made with salt substitutes because these are high in potassium. Speak to your dietitian if you have any questions or want more tips. KIDNEY. ORG 19 What insurance coverage is available for dialysis? The federal governments Medicare program covers 80 percent of all dialysis costs for most patients. If you are not already on Medicare when you start dialysis, your coverage will start on the 1st day of the 4th month. If you begin a home training program within your first 90 days of treatment, then coverage will be retroactive, which means you will be covered starting back on day 1. Private insurance or state Medicaid programs may also help with the costs. Ask your social worker or financial coordinator about your insurance options. Dialysis centers also have billing personnel who can answer your questions about insurance coverage and billing. Will dialysis change my lifestyle? You and your family need time to get used to dialysis and your treatment schedule. The social worker at your dialysis center can provide support and help you and your family adjust to changes in your lifestyle. Once you get used to your treatment, you should feel a lot better. In fact, you may feel more like doing some of the activities you enjoyed before you developed kidney disease. Medications are available to treat anemia and also help keep your bones healthy so you can feel stronger and less tired. 20 NATIONAL KIDNEY FOUNDATION Can people on dialysis travel? Yes. Dialysis centers are located in every part of the United States and in many other countries. Before you travel, you must make an appointment for dialysis treatment at another dialysis center. The staff at your dialysis center may be able to help you arrange the appointment. KIDNEY. ORG 21 Can people on dialysis continue to work? Yes. Many people on dialysis work when they are on dialysis. If your job requires a lot of physical labor (heavy lifting, digging, etc. ), you may need to change your duties. Tips Improve your quality of life Ask your healthcare provider about an exercise program that is right for you. Regular exercise can make you feel stronger. Learn all you can about your treatment.
----------------------------------------------------------------------


======================================================================
CHUNK 176 of 647
======================================================================
ID: hemodialysis_0_8
Content Type: general
Words: 494
Medical Entities: GFR,dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
), you may need to change your duties. Tips Improve your quality of life Ask your healthcare provider about an exercise program that is right for you. Regular exercise can make you feel stronger. Learn all you can about your treatment. Speak to your dialysis care team if you have any questions. They are there to help you do well on your treatment. Spend time with loved ones doing things you enjoy. 22 NATIONAL KIDNEY FOUNDATION Understanding your lab values Albumin and normalized protein nitrogen appearance (nPNA) are measures of your nutritional health. The test results show if you are getting enough protein and calories from your diet. Average daily weight gain is the amount of fluid weight you gain each day between dialysis treatments. If you do not follow your fluid and salt limits between treatments, you may gain too much fluid weight. Calcium and phosphorus are two minerals that are important for bone health. Having too much or too little amounts of these minerals in your blood can lead to loss of calcium from the bones and increased risk of heart and blood vessel disease. Estimated glomerular filtration rate (eGFR) is a calculation that measures how well your kidneys are working. Your eGFR can be calculated using the results of your blood creatinine test, your age, and gender. Hemoglobin is the part of red blood cells that carries oxygen to your tissues. If your number is too low, you have anemia, and you will need to take one or more medicines to raise the red blood cell level in your body. Kt/V and URR are measures of your dose of dialysis. They tell whether you are receiving the right amount of dialysis. KIDNEY. ORG 23 Parathyroid hormone (PTH) is made by four small parathyroid glands, which are located in your neck. If these glands make too much PTH, you may lose calcium from your bones. Over time, this can weaken your bones and cause them to break more easily. Pre-dialysis and post-dialysis blood pressure should be taken each time you receive dialysis. Your blood pressure goes down when excess fluid and salt are removed from your blood by your dialysis treatment. Potassium is a mineral that is important for a healthy heart. High or low levels of potassium in your blood may be harmful for your heart. Target weight (or dry weight) is how much you should weigh after dialysis removes excess fluid from your body. Transferrin saturation (TSAT) and serum ferritin are measures of iron stored in your body. Iron is needed to make red blood cells. You may need extra iron if you have anemia (low iron). 24 NATIONAL KIDNEY FOUNDATION Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to learn more about kidney disease: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273).
----------------------------------------------------------------------


======================================================================
CHUNK 177 of 647
======================================================================
ID: hemodialysis_0_9
Content Type: recommendation
Words: 302
Medical Entities: dialysis
Source: hemodialysis_0.pdf

----------------------------------------------------------------------
If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to learn more about kidney disease: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. Becoming an educated patient is very important to being healthy! KIDNEY. ORG 25 IMPORTANT NAMES AND PHONE NUMBERS KIDNEY DOCTOR: name: phone: NURSE: name: phone: DIALYSIS TECHNICIAN: name: phone: DIETITIAN: name: phone: SOCIAL WORKER: name: phone: 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 27 Fueled by passion and urgency, the National Kidney Foundation (NKF) is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, we focus on the whole patient through the lens of kidney health. Relentless in our work, we enhance lives through action, education, and accelerating change. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG KIDNEY. ORG 2023 National Kidney Foundation, Inc. 11-50-0214_2212
----------------------------------------------------------------------


======================================================================
CHUNK 178 of 647
======================================================================
ID: hemodialysis_access_0
Content Type: general
Words: 489
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
STAGE 5 Hemodialysis Access What you need to know Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Connect with others affected by kidney disease. Get support and share your experiences you never know when youll inspire someone else! JOIN TODAY AT kidney. org/online-communities KIDNEY DISEASE DIALYSIS TRANSPLANT LIVING DONATION Contents Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 What is a hemodialysis access? . . . . . . . . . . . . . . . . . . . 5 Are different types of access available? . . . . . . . . . . . . 5 Pros and Cons of different access types. . . . . . . . . . . 9 Caring for your access after surgery. . . . . . . . . . . . . . 12 What happens when I start dialysis? . . . . . . . . . . . . . . 14 What happens if my access is not working well? . . . . 15 Will my dialysis care team check my access? . . . . . . . 15 Caring for your AV fistula or graft. . . . . . . . . . . . . . . . 16 Protecting your AV fistula or graft. . . . . . . . . . . . . . . . 17 Preventing catheter-related infections. . . . . . . . . . . . 18 Access problems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 What kinds of access problems can happen? How are they treated? . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Warning signs of access problems. . . . . . . . . . . . . . 20 Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Key points to remember. . . . . . . . . . . . . . . . . . . . . . . . 22 Where can I find more information? . . . . . . . . . . . . . . 24 KIDNEY. ORG 3 Introduction Whether you are already on hemodialysis treatment or you will soon be starting dialysis, this booklet will help you better understand the ways hemodialysis machines reach (access) your blood for filtering.
----------------------------------------------------------------------


======================================================================
CHUNK 179 of 647
======================================================================
ID: hemodialysis_access_1
Content Type: general
Words: 486
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
. . . . . . . . . . . . . . 24 KIDNEY. ORG 3 Introduction Whether you are already on hemodialysis treatment or you will soon be starting dialysis, this booklet will help you better understand the ways hemodialysis machines reach (access) your blood for filtering. Some of the covered topics include: Choosing the best access for you Pros and cons of different access types Your access is important for best results from hemodialysis treatment Access care Maintaining your access 4 NATIONAL KIDNEY FOUNDATION What is a hemodialysis access? A hemodialysis access, sometimes called a vascular access, is an opening made in your skin and blood vessel during a short surgical procedure. When you have dialysis, your blood flows out of the access through soft tubes and into a hemodialysis machine. After your blood is filtered in the machine, it goes through a soft tube to the access and back into your body. Are different types of access available? Yes, there are three types of accesses that are used for hemodialysis. Your doctor should teach you about the pros and cons of each one. Your doctor should refer you to a special surgeon with hemodialysis access experience at least six months before you need to start treatment. A surgeon can evaluate you and help you choose the type of access that is best for you. When your doctor tells you that you will need dialysis in the near future, you should protect the arm where the surgery will be done. Dont allow anyone to draw blood or give you an injection in this arm. Also, never let anyone use a cuff to take your blood pressure from this arm. You should wear a medical alert bracelet to inform hospital staff about your arm. KIDNEY. ORG 5 AV FISTULA Vein (V) Artery (A) AV Fistula An AV (artery-vein) fistula is the best choice for hemodialysis. It is preferred because it: Usually lasts longer Has fewer problems like clotting and infections A fistula should be placed several months before you need to start dialysis. This allows the fistula enough time to fully heal before starting dialysis. Minor surgery is needed to create the fistula. It is made by connecting a vein to a nearby artery, usually in your arm. This creates a large blood vessel that has a fast flow of blood. Your lower forearm (between the wrist and elbow) is the preferred location for your fistula. A fistula usually takes one to four months to mature, which means the vein becomes larger due to increased blood flow. Once the access has matured, dialysis treatments can start. Ask your healthcare provider when you can start doing exercises, such as squeezing a rubber ball, to help your fistula mature Fistulas usually last for many years. 6 NATIONAL KIDNEY FOUNDATION AV GRAFT Vein Artery An AV (artery-vein) graft is usually the second choice for an access.
----------------------------------------------------------------------


======================================================================
CHUNK 180 of 647
======================================================================
ID: hemodialysis_access_2
Content Type: general
Words: 452
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
Ask your healthcare provider when you can start doing exercises, such as squeezing a rubber ball, to help your fistula mature Fistulas usually last for many years. 6 NATIONAL KIDNEY FOUNDATION AV GRAFT Vein Artery An AV (artery-vein) graft is usually the second choice for an access. Minor surgery is done using an artificial tube between a vein and a nearby artery. The AV graft generally needs to be in place at least two weeks after surgery before they can be used. CATHETER A catheter is most often used for a temporary access. For example, it is sometimes used for a short time in people who get an AV fistula and need to fully healed before it can be used. KIDNEY. ORG 7 Sometimes a catheter is used over a long period of time because a fistula or graft is not possible. Catheters are made of soft plastic tubing. There are two parts, one for removing your blood and the other for returning the cleaned blood to your body. A catheter is typically placed only when you need to start dialysis immediately. It is put in a large vein, usually in your neck but sometimes in your upper chest. Catheters have more problems (like clotting and infections) than fistulas or grafts. They may not allow for enough blood flow for good dialysis treatment. 8 NATIONAL KIDNEY FOUNDATION Pros and Cons of different access types AV Fistula Pros and Cons PROS: Lasts longer Not prone to infection Provides excellent blood flow once it is ready to use Less likely to develop blood clots and become blocked You can take showers once the access heals after surgery CONS: Needs to mature, which takes one to four months, before it can be used Needles are used to connect to the dialysis machine KIDNEY. ORG 9 AV Graft Pros and Cons PROS: Provides excellent blood flow once it is ready to use You can take showers once the access heals after surgery CONS: Does not last as long as an AV fistula More prone to infection than an AV fistula Needs at least two weeks before it can be used Clotting can be a problem that may require surgery or other treatment to correct Needles are used to connect to the dialysis machine 10 NATIONAL KIDNEY FOUNDATION Catheter Pros and Cons PROS: Can be used right away No needles are needed to connect to the machine. CONS: Usually a temporary access Most prone to infection May not have enough blood flow for best dialysis results Blood clots can form that block blood flow through the catheter Can cause narrowing of major blood vessels Check with your care team to see if showering is an permitted KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 181 of 647
======================================================================
ID: hemodialysis_access_4
Content Type: recommendation
Words: 463
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
This tells them if enough fluids and waste products are being removed from your blood. Your delivered dose of dialysis will be checked by doing a blood test to measure your Kt/V (pronounced kay tee over vee). If you are getting the right amount of dialysis, your Kt/V should be 1. 2 or more. Another test that measures your delivered dose is called urea reduction ratio (URR). Your URR result should be 65% or more. If your Kt/V or URR numbers are too low, your access may not be working well. Will my dialysis care team check my access? Yes, you should have a complete physical exam of your access before every dialysis treatment. KIDNEY. ORG 15 Caring for your AV fistula or graft Ask your dialysis care team to teach you how to prevent infection and keep your fistula or graft working well Wash your access site every day with an antibacterial soap (ask your dialysis care team to recommend a good soap to use) Wash your access site before every dialysis treatment (your dialysis center has hand washing sinks and antibacterial soap) Do not scratch your access (your fingernails can be a source of infection) Your nurse or technician should clean your access site with an antiseptic before putting the needles in (do not touch your access area after it has been disinfected) Your nurse or technician should wear a surgical mask, a face shield, and clean gloves when working near your access 16 NATIONAL KIDNEY FOUNDATION Avoid coughing or sneezing on your access site during treatment Always wear a clean glove or use a clean gauze pad if you are holding your own access site after the needles are removed Apply only gentle pressure to stop bleeding after the needles are removed (press only where the needle was placed and just below never press above where the needle was) Call your dialysis care team at once if the area of the access is sore, swollen, red, or feels hot this could be a sign of infection Protecting your AV fistula or graft Do not let anyone measure your blood pressure on your access arm (your other arm should be used instead) Do not let anyone take blood from your access arm when you are not on dialysis If the vibration (thrill) or sound (bruit) of your access is absent or seems different, call your dialysis care team at once because your access may not be working well Ask your dialysis care team how to make your needle sticks as comfortable as possible. Different sites for the needles can be used for each dialysis People who have a fistula can ask to use a button hole technique, which is a less painful way to use same site for each dialysis KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 182 of 647
======================================================================
ID: hemodialysis_access_5
Content Type: general
Words: 494
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
Different sites for the needles can be used for each dialysis People who have a fistula can ask to use a button hole technique, which is a less painful way to use same site for each dialysis KIDNEY. ORG 17 Preventing catheter-related infections Ask your dialysis care team to teach you how to prevent infections and keep your catheter working well Be sure your catheter has a clean, dry dressing during and after every dialysis (make sure your nurse or technician checks your catheter for signs of infection at every dialysis) Make sure you wear a surgical mask when you are being connected to or disconnected from the dialysis machine Make sure your nurse or technician wears a surgical mask, face shield, and clean gloves when working near your catheter Use a protective cover for your catheter when showering (ask your dialysis care team how to get one of these covers) Ask your nurse or technician to teach you how to change the dressing Keep extra dressing supplies in your home in case you need to replace your dressing Contact your care team is you see or feel anything unusual with your access 18 NATIONAL KIDNEY FOUNDATION Access problems What kinds of access problems can happen? How are they treated? Sometimes, even when you take the best care of your access, you may have problems. If an infection occurs, your doctor will order antibiotics for you. If your access develops a clot, it needs to be treated with special medications. Sometimes this medication can be given in the dialysis unit. Other times, you may need to go to the hospital for treatment. Sometimes surgery is needed to remove a clot or repair an access. Angioplasty may be needed to widen a narrowed fistula or graft. Your dialysis care team will check your access for problems. You, too, can help spot possible problems. Learn the warning signs listed on pages 20-21. Contact your doctor or dialysis center right away if you notice any of them. KIDNEY. ORG 19 Warning signs of access problems INFECTION Warning signs: Redness, swelling, soreness, and/or a feeling of warmth around your access site; fever, chills, and/or achy feeling. Steps to take: Call your doctor or dialysis care team at once. Youll need to take antibiotic medicine prescribed by your doctor. CLOTTING OR POOR BLOOD FLOW IN YOUR ACCESS Warning signs: Absence of the vibration (thrill) or sound (bruit) at your fistula or graft site; swelling of your arm; lower skin temperature around the access site; a decrease in your delivered dose of dialysis (Kt/V or URR); or changes in other lab values. 20 NATIONAL KIDNEY FOUNDATION Steps to take: Call your doctor or dialysis center. Keep a record of your Kt/V or URR and other labs. Speak to your dialysis care team when there are changes. BLEEDING FROM YOUR ACCESS Warning signs: Bleeding from a fistula or graft that lasts more than 20 minutes after your dialysis treatment is over.
----------------------------------------------------------------------


======================================================================
CHUNK 183 of 647
======================================================================
ID: hemodialysis_access_6
Content Type: general
Words: 498
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
Keep a record of your Kt/V or URR and other labs. Speak to your dialysis care team when there are changes. BLEEDING FROM YOUR ACCESS Warning signs: Bleeding from a fistula or graft that lasts more than 20 minutes after your dialysis treatment is over. Any bleeding from a catheter site or catheter tube. Steps to take: For bleeding from a fistula or graft, gently press your access with a clean gauze pad to stop the blood; if bleeding lasts more than 20 minutes, call your doctor or dialysis center at once. For bleeding from a catheter site or tube, call your doctor or dialysis center at once, or go to the emergency room at your local hospital. DECREASED CIRCULATION IN YOUR ACCESS ARM Warning signs: Feelings of numbness, tingling, coldness, or weakness in your arm; blue fingers or sores at the tips of your fingers. Steps to take: Call your doctor or dialysis center right away (this must be treated at once to prevent nerve damage in your access arm). KIDNEY. ORG 21 Summary Key points to remember Keeping your access working well will help you get the most from hemodialysis and help you feel your best. If your access is not working well, it can decrease the amount of dialysis you receive, which may affect your overall health and how long you live on dialysis. A fistula is the preferred type of access. If you are already receiving hemodialysis and you do not have a fistula, ask your doctor or dialysis care team if you are a candidate for a fistula. Make sure your dialysis care team checks your access often. They should do some special tests to make sure it is working well. 22 NATIONAL KIDNEY FOUNDATION Do not let anyone measure your blood pressure on your access arm, or take blood from your access arm when you are not getting dialysis. Your other arm should be used to measure blood pressure and do blood tests. Ask your dialysis care team to teach you the steps for good access care to prevent infection and keep your access working well. Know the warning signs for problems with your access. Track your important test results, such as your Kt/V and your URR. Ask your dialysis care team if you have any questions about your access or any other aspects of your hemodialysis care. KIDNEY. ORG 23 Where can I find more information? If you have questions, speak to your doctor and other members of your healthcare team. You may also call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org NKF CARES The National Kidney Foundation offers a toll-free patient help line for people affected by kidney disease, organ donation, or kidney transplant. Patients, families, and caregivers can speak with a trained specialist who will help answer questions and listen to concerns. You can also find free publications and other resources by calling, emailing, or visiting the website.
----------------------------------------------------------------------


======================================================================
CHUNK 184 of 647
======================================================================
ID: hemodialysis_access_7
Content Type: recommendation
Words: 404
Medical Entities: dialysis
Source: hemodialysis_access.pdf

----------------------------------------------------------------------
Patients, families, and caregivers can speak with a trained specialist who will help answer questions and listen to concerns. You can also find free publications and other resources by calling, emailing, or visiting the website. NKF PEERS Preparing for and having a kidney transplant is associated with a range of questions and emotions. You can talk to a peer mentor who has been in a similar situation by contacting NKF Peers. Call 855. NKF. PEER (855. 653. 7337) or email nkfpeerskidney. org to find out more. If you are considering donating a kidney, you can be connected with a living donor. THE BIG ASK: THE BIG GIVE A free, educational initiative that teaches kidney patients in need of a transplant how to ask their friends and loved ones to consider living organ donation. It provides factual, unbiased information that addresses many common concerns, and offers support to those who are making a decision about living kidney donation. Contact NKF or visit kidney. org/livingdonation for more information. 24 NATIONAL KIDNEY FOUNDATION Important names and phone numbers KIDNEY DOCTOR: name: phone: NURSE PRACTITIONER/PHYSICIAN ASSISTANT name: phone: PRIMARY CARE NURSE name: phone: DIETITIAN: name: phone: SOCIAL WORKER name: phone: PATIENT CARE TECHNICIAN name: phone: ACCESS SURGEON: name: phone: KIDNEY. ORG 25 NOTES 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 27 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 11-50-0216_2212
----------------------------------------------------------------------


======================================================================
CHUNK 185 of 647
======================================================================
ID: hfhs_ckd_v6_0
Content Type: recommendation
Words: 430
Medical Entities: CKD,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
DIVISIONS OF NEPHROLOGY HYPERTENSION AND GENERAL INTERNAL MEDICINE Chronic Kidney Disease (CKD) Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers A Collaborative Approach (Edition 6. 0) Delicate durability describes the human body, and nowhere is this more apparent than in the urinary tract. If the liver is all bulk and Delicate durability describes the human body, thunder, the heart fist and thrust and piston, and nowhere is this more apparent than in the and the brain a foamy paste of insubstantial urinary tract. If the liver is all bulk and electricity, the parts of the urinary tract thunder, the heart fist and thrust and piston, namely the kidneys, ureters, and bladder are and the brain a foamy paste of insubstantial a tracery of tubules and ducts of such a fineness electricity, the parts of the urinary tract as would lay mad a master plumber, more, namely the kidneys, ureters, and bladder are a Venetian glassblower. a tracery of tubules and ducts of such a fineness as would lay mad a master plumber, more, RICHARD SELZER (1996) a Venetian glassblower. RICHARD SELZER (1996) D ISCLAIMER. Final treatment recommendations are the responsibility of the prescribing healthcare p rovider and are in no manner considered the responsibility of Henry Ford Health System, its a gents, providers, or the authors. DISCLAIMER. Final treatment recommendations are the responsibility of the prescribing healthcare CprOoPvYidReIrG HanT d a2r0e0 i2n, 2n0o0 3m, 2a0n0n4e, r 2c0o0n6s, i 2d0er0e7d, AtNheD 2re0s1p1o. n HsiEbNilRitYy FoOf RHDe HnrEyA LFToHrd S YHSTeEaMlth. System, its aAglel nrtigs, h ptsr orveisdeervrse, d o. rN tho ep aaurtt hoofr sth. is publication may be reproduced, transmitted, transcribed, stored in a retrieval system, or translated into any language in any form or by any means without written C peOrPmYiRssIiGoHnT o f H 20 en 0 r 2 y, 2 F 0 o 0 rd 3, H 2 e 0 a 0 l 4 th, 2 S 0 y 0 st 6 e, m 20. 07, AND 2011. HENRY FORD HEALTH SYSTEM. All rights reserved. No part of this publication may be reproduced, transmitted, transcribed, stored in a retrieval system, or translated into any language in any form or by any means without written permission of Henry Ford Health System. CONTENTS FOREWORD 2 CHRONIC KIDNEY DISEASE STAGING AND PROGRESSION 4 CONSULTATION 11 DIABETIC KIDNEY DISEASE 15 HYPERTENSION IN CHRONIC KIDNEY DISEASE 19 PROTEINURIA IN CHRONIC KIDNEY DISEASE 24 Delicate durability describes the human body, ANEMIA OF CHRONIC KIDNEY DISEASE 28 and nowhere is this more apparent than in the CKD-MINERAL AND BONE DISORDER 31 urinary tract.
----------------------------------------------------------------------


======================================================================
CHUNK 186 of 647
======================================================================
ID: hfhs_ckd_v6_1
Content Type: recommendation
Words: 447
Medical Entities: CKD,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
If the liver is all bulk and Delicate durability describes the human body, DYSLIPIDEMIA OF CHRONIC KIDNEY DISEASE 40 thunder, the heart fist and thrust and piston, a a n n d d t n h o e w b h r e a r i e n i a s t fo h a is m m y o p r a e s a t p e p o a f r i e n n s t u t b h s a ta n n i t n i a t l h e NUTRITION IN CHRONIC KIDNEY DISEASE 43 urinary tract. If the liver is all bulk and electricity, the parts of the urinary tract IMMUNIZATIONS IN CHRONIC KIDNEY DISEASE 45 thunder, the heart fist and thrust and piston, n a a n m d t e h ly e t b h r e a i k n i d a n f e o y a s m, u y r e p t a e s r t s e, a o n f d in b s l u a b d s d ta er n t ia a l re KIDNEY REPLACEMENT THERAPY 48 a tracery of tubules and ducts of such a fineness electricity, the parts of the urinary tract MEDICATION-RELATED PROBLEMS 51 as would lay mad a master plumber, more, a n a V m en el e y t i t a h n e g k l i a d s n s e b y lo s, w u e r r e. t ers, and bladder are SELECTED AGENTS 56 a tracery of tubules and ducts of such a fineness DIAGNOSTIC CODING PRINCIPLES 63 as would lay mad a master plumber, more, a Venetian glassblow e r R. I CHARD SELZER (1996) CHRONIC KIDNEY DISEASE DIAGNOSTIC CODES 66 CKD WEBSITES OF INTEREST 69 RICHARD SELZER (1996) COMMENTS TO AUTHORS 69 WEBSITE MANAGEMENT 70 PURCHASING INFORMATION 70 CHRONIC KIDNEY DISEASE CHECKLIST 71 PLAN OF CARE ACTION PLAN 36 DIAGRAMS Consultation 14 D ISCLAIMER. Final treatment recommendations are the responsibility of the prescribing healthcare p rovider and are in no manner considered the responsibility of Henry Ford Health System, its Approach to Hypertension Treatment in CKD 23 a gents, providers, or the authors. CKD Proteinuria Evaluation 27 DISCLAIMER. Final treatment recommendations are the responsibility of the prescribing healthcare CprOoPvYidReIrG HanT d a2r0e0 i2n, 2n0o0 3m, 2a0n0n4e, r 2c0o0n6s, i 2d0er0e7d, AtNheD 2re0s1p1o. n HsiEbNilRitYy FoOf RHDe HnrEyA LFToHrd S YHSTeEaMlth. System, its Management of Mineral-Bone Disease in CKD 39 aAglel nrtigs, h ptsr orveisdeervrse, d o. rN tho ep aaurtt hoofr sth.
----------------------------------------------------------------------


======================================================================
CHUNK 187 of 647
======================================================================
ID: hfhs_ckd_v6_2
Content Type: recommendation
Words: 474
Medical Entities: CKD,GFR
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
n HsiEbNilRitYy FoOf RHDe HnrEyA LFToHrd S YHSTeEaMlth. System, its Management of Mineral-Bone Disease in CKD 39 aAglel nrtigs, h ptsr orveisdeervrse, d o. rN tho ep aaurtt hoofr sth. is publication may be reproduced, transmitted, transcribed, stored CKD Dyslipidemia Treatment 42 in a retrieval system, or translated into any language in any form or by any means without written C peOrPmYiRssIiGoHnT o f H 20 en 0 r 2 y, 2 F 0 o 0 rd 3, H 2 e 0 a 0 l 4 th, 2 S 0 y 0 st 6 e, m 20. 07, AND 2011. HENRY FORD HEALTH SYSTEM. (cid: 1) All rights reserved. No part of this publication may be reproduced, transmitted, transcribed, stored in a retrieval system, or translated into any language in any form or by any means without written (cid: 1) permission of Henry Ford Health System. Foreword K IDNEY disease, some acute but mostly chronic remains the core of this SIXTH EDITION of CHRONIC KIDNEY DISEASE (CKD): CLINICAL PRACTICE RECOMMENDATIONS FOR PRIMARY CARE PHYSICIANS AND HEALTHCARE PROVIDERS A COLLABORATIVE APPROACH by Editors Jerry Yee Gregory D. Krol. This edition represents a significant departure from Editions 15. It is now multi-authored, underscoring the complexity of Chronic Kidney Disease, better known in the vernacular as CKD a disease domain complex that is highly associated with a progressive cardiovascular disease burden. Aside from the multi-authorship of the SIXTH EDITION, this work provides exciting illustrations by Dunham Design and immaculate print quality by Dynamic Marketing. As with prior editions, the writing remains consistently concise, precise, and decisive. I NTERESTINGLY, the booklet was originally conceived and written for the Henry Ford Health System. However, like the automotive industry of the City of Detroit, it has significantly transcended its local borders. All told, more than 30, 000 copies have been distributed within the United States, Puerto Rico, Mexico, and Canada since its original publication. From the first edition that provided textually based nuts and bolts management of CKD through its fifth edition, the booklet has gained in quality and size, while providing up-to-date information. The first edition brought to the fore the importance of the eGFR in the screening of this under-recognized entity, CKD. The second and third editions amplified the importance of the cardiovascular complications of CKD. The fourth and fifth editions emphasized evidence-based practice across the continuum of CKD care and provided colorful easy-to-read diagrams. Essentially, it is not a textbook steeped in information that is outdated by the time of printing, but a periodical that reliably informs Primary Care Physicians about CKD essentials. Overall, the content is current and crystallized, ready for translation into clinical practice. D EDICATED readings of the HENRY FORD CKD BOOKLET as it is known outside of the Henry Ford Health System are suggested in order to fully comprehend the complexity of CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 188 of 647
======================================================================
ID: hfhs_ckd_v6_3
Content Type: recommendation
Words: 474
Medical Entities: CKD,GFR,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Overall, the content is current and crystallized, ready for translation into clinical practice. D EDICATED readings of the HENRY FORD CKD BOOKLET as it is known outside of the Henry Ford Health System are suggested in order to fully comprehend the complexity of CKD. It should be on the must have list of Internal Medicine housestaff and Nephrology fellows-intraining as it continues to remain popular among the younger generation of physicians, nurses, and mid-level providers. Its Internet presence accounted for 1, 000 downloads in 2010. Translation into other languages is under consideration and there is clamor for mobile device distribution. Most importantly, the booklet has received plaudits from national organizations and societies, and its format and content have been adapted by multiple agencies, including the Michigan Quality Initiative Consortium (MQIC) and the National Kidney Foundations of Michigan and Illinois. 2 N EW information regarding the eGFR is highlighted in the SIXTH EDITION. As the underpinning of the stages of CKD, knowledge regarding the functionality of the eGFR has matured, with validation across more populations. Standardization of the serum creatinine by isotope dilution mass spectrometry is occurring increasingly across clinical laboratories in the United States. This recalibration lowers the eGFR by 6%. Notwithstanding this improvement in eGFR reporting, combining this parameter with proteinuria more clearly delineates the risk category of a CKD patient. Principally, proteinuria of (cid: 1)2 on dipstick analysis or within the macro-albuminuric range portends a poorer renal outcome. Lastly, this edition prominently features an international perspective on CKD-Mineral and Bone Disorder. E XPERT and representation of the respective clinical disease domains of CKD distinguishes and enhances this version. Now, this mini-compendium renders an even broader perspective to CKD with the following contributions: DIABETIC KIDNEY DISEASE by Susanne Nicholas (UCLA) HYPERTENSION by Debbie Cohen and Raymond Townsend (Univ. of Penn) PROTEINURIA by Julie Lin (Brigham and Womens Hospital) ANEMIA OF CKD by Anatole Besarab (Henry Ford Hospital) NUTRITION IN CKD by M. Cristina Kilates (Henry Ford Hospital) CKD-MINERAL AND BONE DISORDER by L. Tammy Ho (Univ. of Chicago) MEDICATION-RELATED PROBLEMS SELECTED AGENTS by Carol Moore (Henry Ford Hospital) KIDNEY REPLACEMENT THERAPY by Jariatul Karim Lalathaksha Kumbar (Henry Ford Hospital) WEBSITE MANAGEMENT by Gerard Zasuwa (Henry Ford Hospital) Each chapter follows the outlines of the previous versions: brief introduction, evidence base, pathophysiology, and guidelineor expert consensus-based diagnosis and therapy. THE PLAN OF CARE ACTION PLAN and the CHECKLIST remain outstandingly simple, informative, and efficient formats to present a large body of information into digestible learnings. These two invaluable components of the SIXTH EDITION distill numerous guidelines and consensus-based recommendations by level of evidence and grade of quality to improve our practices. Y ES! is the feeling that I had upon completing the SIXTH EDITION. You, the reader should review it, digest it, practice it, and also, enjoy it. I certainly did and still do.
----------------------------------------------------------------------


======================================================================
CHUNK 189 of 647
======================================================================
ID: hfhs_ckd_v6_4
Content Type: definition
Words: 499
Medical Entities: CKD,GFR,dialysis,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Y ES! is the feeling that I had upon completing the SIXTH EDITION. You, the reader should review it, digest it, practice it, and also, enjoy it. I certainly did and still do. KAMYAR KALANTAR-ZADEH, MD, MPH, PHD UNIVERSITY OF CALIFORNIA, LOS ANGELES 3 CHRONIC KIDNEY DISEASE STAGING AND PROGRESSION by Gregory D. Krol Introduction Optimal management of patients with chronic kidney disease (CKD) requires appropriate interpretation and use of the markers and stages of CKD, early disease recognition, and collaboration between primary care physicians and nephrologists. Because multiple terms have been applied to chronic kidney disease (CKD), eg, chronic renal insufficiency, chronic renal disease, and chronic renal failure, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) has defined the all-encompassing term, CKD. Using kidney rather than renal improves understanding by patients, families, healthcare workers, and the lay public. This term includes the continuum of kidney dysfunction from mild kidney damage to kidney failure, and it also includes the term, end-stage renal disease (ESRD). Definition and Interpretation Management of CKD requires the clear understanding of its definition as proposed by the National Kidney Foundation (NKF). An informed interpretation of the estimated glomerular filtration rate (eGFR) is required, since the GFR is still considered the best overall index of kidney function in stable, non-hospitalized patients. Kidney damage is defined by any one of the following findings: a) pathologic kidney abnormalities b) persistent proteinuria c) other urine abnormalities, eg, renal hematuria d) imaging abnormalities e) eGFR 60 mL/min/1. 73 m2 on two occasions separated by (cid: 1)90 days and that is not associated with a transient, reversible condition such as volume depletion. The 5 stages of CKD are based on eGFR (see TABLE). CLASSIFICATION OF CHRONIC KIDNEY DISEASE Estimated GFR Stage Comment (mL/min/1. 73 m2) 1 90 Normal GFR w/ proteinuria 2 6089 Age-related decline in GFR w/proteinuria 3A 3059 Low risk of progression to kidney failure 3B 4 1529 High risk of progression to kidney failure 5 5D 15 Kidney failure 5T Because of greater cardiovascular disease risk and risk of disease progression at lower eGFRs, CKD Stage 3 is sub-divided into Stages 3A (4559 mL/min/1. 73 m2) and 3B (3044 mL/min/1. 73 m2. CKD Stage 5 includes patients that may require or are undergoing kidney replacement therapy. Designations 5D and 5T indicate end-stage renal disease patients who undergo chronic dialysis (5D) treatment or have undergone kidney transplantation (5T). 4 The eGFR is primarily determined by serum creatinine (SCr), and the preferred method for estimating GFR is the body surface area-normalized, 4-variable, Modification of Diet in Renal Disease Study (MDRD) Equation based on SCr, age, gender, and ethnicity. eGFR (mL/min/1. 73 m2) 186 (SCr)1. 154 (Age)0. 203 (0. 742, if female) (1. 212, if African American) Replace the constant 186 with 175, if the laboratory uses a standardized SCr (IDMS method). This reduces eGFR by 6%. eGFRs based solely on BUN and creatinine or by 24-h endogenous creatinine clearances, are not required for routine screening of CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 190 of 647
======================================================================
ID: hfhs_ckd_v6_5
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
742, if female) (1. 212, if African American) Replace the constant 186 with 175, if the laboratory uses a standardized SCr (IDMS method). This reduces eGFR by 6%. eGFRs based solely on BUN and creatinine or by 24-h endogenous creatinine clearances, are not required for routine screening of CKD. As with all tests, the eGFR has limitations. eGFR calculations may be inaccurate in the following circumstances: acute hospitalizations, acute kidney injury (AKI)/acute renal failure (ARF), malnutrition, major limb amputation, cirrhosis, severe obesity, and at the extremes of age. It is not recommended to use eGFR in lieu of SCr during AKI/ARF. Improved eGFR equations, CKD-EPI and Cystatin-C equations, remain as research tools, and the 4-parameter MDRD eGFR remains the current gold standard. Regardless of the measure, most cases require appropriate appreciation of kidney function and must include an assessment of retrospective and prospective markers of kidney function aside from eGFR, including BUN and urinary protein excretion, in order to more completely assess etiology, stability, progression, or improvement in renal function, and to guide therapy. Normal physiologic age-related changes in kidney function often lower GFRs to 6090 mL/min/1. 73 m2. The age-related decline in GFR is 1 mL/min/1. 73 m2/yr, beginning after 3040 y. o. In addition and paradoxically, the reduction of muscle mass associated with aging may overestimate the GFR and potentially mislead the healthcare provider. Notably, the majority of CKD Stage 3 or 4 patients will not develop CKD Stage 5/kidney failure (1% risk). However, if other evidence of kidney disease is present, eg, proteinuria; imaging study revealing small (9 cm by ultrasonography) or echogenic kidney(s), cysts or stones; resistant hypertension (HTN); or rapid or acute elevations of BUN and SCr, an etiology of CKD must be established and aggressive therapy is warranted. Generally, a kidney-specific imaging study (renal ultrasonogram, CT scan) is not required in the following clinical setting: eGFR 60 mL/min/1. 73 m2 with no proteinuria because the overwhelming majority of such studies are normal. Epidemiology Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. The prevalence of CKD Stages 25 has continued to increase since 1988 as have the prevalences of diabetes and hypertension, which are respectively etiologic in approximately 40% and 25% of CKD cases. The current estimate is that 26 million US persons 20 y. o. have CKD. However, 15. 2 % is the more recent CKD prevalence estimate, based on 20032006 NHANES data of U. S. adults aged (cid: 1)20 y. o. , a decrease from the 15. 9% cited in the NHANES data collected from 19992002. This decrease was reflected in CKD Stage 1 as Stage 3 increased to 6. 5% from 20032006. The prevalence of CKD Stages 4 and 5 has doubled since 19881999, but has remained stable since 2002 at 0. 6%. 5 CKD stage prevalence from NHANES 20032006 by the CKD-EPI equation are Stage 1, 4. 1%; Stage 2, 3. 2%; Stage 3, 6. 5%; and Stages 4 and 5 combined, 0. 6%.
----------------------------------------------------------------------


======================================================================
CHUNK 191 of 647
======================================================================
ID: hfhs_ckd_v6_6
Content Type: evidence
Words: 490
Medical Entities: CKD,GFR,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
6%. 5 CKD stage prevalence from NHANES 20032006 by the CKD-EPI equation are Stage 1, 4. 1%; Stage 2, 3. 2%; Stage 3, 6. 5%; and Stages 4 and 5 combined, 0. 6%. Stratified by age, all CKD stages were more prevalent in persons aged (cid: 1)60 y. o. (39. 4%) than in those aged 4059 y. o. (12. 6%) or 2039 y. o. (8. 5%). By educational level, CKD at any stage was more prevalent among persons with less than a high school education (22. 1%) than in persons with at least a high school education (15. 7%). CKD prevalence was greater among non-Hispanic blacks (15. 6%), nonHispanic whites (14. 5%), and among other ethnicities (13. 1%). The prevalences of diabetes and HTN in African Americans with CKD were 60. 6% and 96%, respectively, compared to Caucasian prevalences of 45. 7% and 90. 7%, respectively (United States Renal Data Survey, 2010). Also, CKD prevalence was higher in diabetics than non-diabetics (40. 2% v 15. 4%), in those with cardiovascular disease (CVD) than in those without it (28. 2% v 15. 4%), and in those with HTN than in those without it (24. 6% v 12. 5%). For 2010, the estimated cost of ESRD is 28 billion, and projected as 54 billion by 2020. In the last quarter of 2009, the prevalence of ESRD (N572, 569, includes kidney-transplanted patients) was greater than in 2005 (N485, 012). In terms of incidence or newly-initiated ESRD patients, diabetes was etiologic in 37. 5%, HTN 24. 4%, glomerulonephritis 14. 8%, cystic disease 4. 7%, and others 18. 6%. African American patients are 3. 7 times more susceptible for development of ESRD, and Native Americans and Asians are 1. 9and 1. 3 times more likely to develop ESRD. Recognition, Screening and Stratification of CKD Only 5% and 10% of the general Medicare population undergoes a screening urinalysis or a SCr, respectively. The NKF KEEP (Kidney Early Evaluation Program) screening program is a free community-based survey that identified individuals with CKD over the past 10 years. Since its inception, KEEP has screened 150, 000 at-risk individuals with diabetes and/or HTN or those with a first-order relative with known kidney disease, diabetes, or HTN. Urine was evaluated for hematuria, pyuria and microalbuminuria. The KEEP population was better educated, had more insurance, and a higher prevalence of HTN, obesity, and diabetes than the NHANES cohort. Specifying CKD as a low estimated GFR and/or presence of microalbuminuria, 26% of KEEP/high risk participants had CKD nearly twice that noted in the general population NHANES study. Strikingly, only 2. 0% of these high risk patients self-reported a history of kidney disease. These consistent findings over the past decade underscore the lack of recognition and education regarding CKD and the missed opportunities to better manage, prevent, and reduce CKDs associated premature and increased comorbidties, mortality, and high healthcare costs. Stratification of CKD into 5 stages focuses the clinician on CKD management aspects.
----------------------------------------------------------------------


======================================================================
CHUNK 192 of 647
======================================================================
ID: hfhs_ckd_v6_7
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
These consistent findings over the past decade underscore the lack of recognition and education regarding CKD and the missed opportunities to better manage, prevent, and reduce CKDs associated premature and increased comorbidties, mortality, and high healthcare costs. Stratification of CKD into 5 stages focuses the clinician on CKD management aspects. The metabolic abnormalities of CKD evolve in a fairly well established pattern. Anemia of CKD and CKD-Mineral and Bone Disorder (CKD-MBD) often begin during Stage 3. Hypertension is aggravated in CKD Stages 35 and acid-base balance, dyslipidemia, and glucose homeostasis become deranged later. During Stages 35, reductions in medication dosages may be required because of a lower eGFR. The disease domains of HTN, proteinuria, and hyperlipidemia may appear at any stage and therapy must be targeted to specific levels. Lastly, screening for metabolic complications of CKD is typically not recommended in persons with eGFR 60 mL/min/1. 73 m2 and no albuminuria, unless a genetic disorder with a high degree of penetrance is present (autosomal dominant polycystic kidney disease). The development of CKD multiplies the mortality risk associated with CVD, particularly in CKD Stages 4 and 5. CKD increases CVD morbidity and mortality risks in diabetics by 2to 4-fold and 6 in patients with HTN and diabetes by 4to 8-fold. Further, CKD-attributable CVD risk increases rapidly through CKD Stages 35 by several-fold. At-Risk Groups CKD carries a 3-fold higher risk of death. Therefore, clinical risk factors for the initiation and/or progression of CKD should be ascertained during routine healthcare encounters and periodically, thereafter. Individuals at increased risk for CKD must be tested for kidney damage and have their eGFRs evaluated more frequently. In addition, aggressive risk factor reduction should be carried out in individuals at increased risk for CKD even when CKD is not clinically apparent. A CKD risk factor classification, based on a cardiovascular scheme follows (see Table, p. 9). Hypertension (prevalence 74. 5 million) and diabetes (prevalence 23. 6 million) are the two most important CKD risk factors. Overall, diabetes is prevalent in 44% of the ESRD population and in HTN 28%. Together, these two disorders constitute 72% of the causes of ESRD. Recently, insulin resistance, obesity, and the metabolic syndrome have been implicated as risk factors. A family history of kidney disease is a risk factor for CKD. Nearly 24% of ESRD patients have an afflicted first-degree relative, an association that is much stronger in African Americans than whites. Other CKD risk factors include the following: a prior history of AKI/ARF, urinary tract obstruction, stones, reduced kidney mass (solitary kidney), nephrotoxins (analgesics, aminoglycosides, amphotericin, radiocontrast), autoimmunity (SLE), low birth weight, preeclampsia, sociodemographics (older age, male gender, reduced access to healthcare, low income/education level, hazardous chemical or environmental exposures), and certain ethnicities: African American, Native American, Hispanic, and Asian. Acute Kidney Injury (AKI)/Acute Renal Failure (ARF) The term ARF is being increasingly supplanted by the term AKI, but precise and consensus-based definitions of AKI have only recently been introduced.
----------------------------------------------------------------------


======================================================================
CHUNK 193 of 647
======================================================================
ID: hfhs_ckd_v6_8
Content Type: definition
Words: 487
Medical Entities: CKD,GFR
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Acute Kidney Injury (AKI)/Acute Renal Failure (ARF) The term ARF is being increasingly supplanted by the term AKI, but precise and consensus-based definitions of AKI have only recently been introduced. AKI is common and occurs at a rate of 522 cases/100, 000 pt-yr. Thus far, AKI staging systems that define renal risk, injury, and failure have not consistently predicted renal or morbid outcomes due to select patient-specific demographics, preexisting CKD and comorbidities (see TABLE, P. 8). Such systems require further refinement. AKI often complicates CKD, particularly in Stages 35. Persons with or without preexistent kidney disease may incur permanent decrements in kidney function after single or repeated episodes of AKI/ARF. The optimal method of establishing CKD is by examining medical records; renal imaging is the next best method, eg, kidney ultrasonography (US) or CT scan. By US, normal, adult kidney sizes are 1012 cm in the sagittal plane; however, size discrepancies up to 37% may be found. AKI represents a substantial risk factor for progressive CKD. A single episode of AKI may generate a steeper decline in renal function than normally expected from aging alone. Therefore, patients who develop severe AKI or recover slowly from AKI must be closely monitored, even when the eGFR returns to baseline. Rapid recovery of AKI (7 d) generally requires minimal follow-up, unless there was pre-existing CKD. AKI is categorized as prerenal, parenchymal, and postrenal etiologies. To eliminate the latter from the differential diagnosis, always rule out urinary outlet obstruction when establishing an etiology for AKI/ARF, particularly in males with clinically undiagnosed prostatic hyperplasia. AKI continues to occur with increasing frequency and constitutes 70% of Nephrology inpatient 7 consultations. The increased utilization of pharmaceuticals has increased the frequency of immune-mediated (allergic) tubulointerstitial nephritis, particularly from antibiotics. When challenged by sodium (volume) depletion, CKD patients often develop AKI more rapidly than normal individuals. The consequent prerenal azotemia, from absolute (vomiting, overdiuresis) or relative volume depletion (cirrhosis, nephrosis or heart failure) accounts for nearly 40% of cases of hospital-acquired AKI. Administration of pharmaceuticals such as NSAIDs, antibiotics (aminoglycosides), or iodinated radiocontrast media can induce AKI/ARF. Lastly, volume depleted patients are more susceptible to radiocontrast-induced nephropathy. This disorder accounts for 317% cases of hospital-acquired ARF, and this is often preventable (see MEDICATION-RELATED PROBLEMS IN CKD, P. 51). CLASSIFICATION OF ACUTE KIDNEY INJURY / ACUTE RENAL FAILURE Stage Serum Creatinine Urine Output 1 SCr(cid: 1) of 0. 3 mg/dL 0. 5 mL/kg/h for 6 h Risk SCr (cid: 1) of 1. 5-2. 0-fold 2 SCr (cid: 1) of 2. 03. 0-fold 0. 5 mL/kg/h for 12 h Injury 3 SCr (cid: 1) of 0. 3 mg/dL or 3-fold from baseline 0. 3 mL/kg/h for 24 h Failure SCr 4. 0 mg/dL with acute (cid: 1) 0. 5 mg/dL Anuria for 12 h CKD patients undergoing cardiothoracic and/or other emergent surgical procedures that occur with blood loss, sepsis and/or radiocontrast administration have highly increased risk for AKI/ARF.
----------------------------------------------------------------------


======================================================================
CHUNK 194 of 647
======================================================================
ID: hfhs_ckd_v6_9
Content Type: reference
Words: 483
Medical Entities: CKD,GFR,proteinuria,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
3 mL/kg/h for 24 h Failure SCr 4. 0 mg/dL with acute (cid: 1) 0. 5 mg/dL Anuria for 12 h CKD patients undergoing cardiothoracic and/or other emergent surgical procedures that occur with blood loss, sepsis and/or radiocontrast administration have highly increased risk for AKI/ARF. In these circumstances, the GFR cannot be reliably determined since it depends on steady-state creatinine generation and elimination. CKD patients treated with anti-RAAS medications commonly develop elevations of BUN and SCr. The potential benefits of chronic anti-RAAS treatment likely outweigh a mild stable decline of GFR from ACEI and ARB use. Generally, increases in SCr of up to 30% and serum K levels of 5. 5 mEq/L can be tolerated. However, unless moderate hyperkalemia (K 5. 5 mEq/L), oliguria, relative hypotension, or a substantial GFR reduction occurs, these agents should generally be continued. Progression of Chronic Kidney Disease (CKD) Fortunately, most patients do not progress from CKD Stage 3 to 5, but 17% of CKD Stage 4 patients will progress to Stage 5 and 1% of CKD Stage 3 patients will. However, the transition to CKD Stage 4 is often insidious and under-recognized. Importantly, this transition represents a clinical event similar to a stroke or acute myocardial infarction because CKD Stage 4 is marked by a major increase in cardiovascular mortality and progression to CKD Stage 5. During CKD Stage 4, death is a competing risk for progression to ESRD. Comprehensive systems targeting early recognition, prevention and management, and treatment by primary care physicians and physician extenders are required at this critical stage in collaboration with nephrologists. 8 Aside from uncontrolled HTN, one of the strongest prognosticators for declining kidney function is proteinuria. A spot urine protein-to-creatinine ratio (UPC) or urine albumin-to-creatinine ratio (UACR) quantifies proteinuria. Generally, UPCs 0. 51 g protein per g creatinine predict a more favorable prognosis, while UPCs 1 predict more rapid functional decline and more intensive evaluation, ie, kidney biopsy. Modifiable risk factors for CKD progression are HTN, diabetes, morbid obesity, metabolic syndrome, hypercholesterolemia, heavy consumption of non-narcotic analgesic preparations, anemia, and cigarette smoking. Perhaps the best prognosticator for CKD progression is the rate of decline of GFR. Rates of decline 4 mL/min/1. 73 m2 per year are associated with greater progression risk. In diabetics, annual eGFR rates of decline (cid: 1)1012 mL/min/1. 73 m2 may occur. In heart failure, eGFR declines (cid: 1)15 mL/min/1. 73 m2 per year are associated with worse anemia and progression to CKD Stage 5. African American ethnicity is a major risk factor for progressive CKD from type 2 diabetic kidney disease, HTN (nephrosclerosis), and HIV. In general, Native Americans, Hispanics, and Asians have increased risk for type 2 diabetic CKD. Cigarette smoking aggravates CKD. Risk factors that promote the accelerated atherosclerosis of CKD include elevated angiotensin II levels, proteinuria, secondary hyperparathyroidism, dysregulated calcium and phosphate metabolism, ECF volume expansion, and the intrinsic chronic inflammatory state of CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 195 of 647
======================================================================
ID: hfhs_ckd_v6_11
Content Type: recommendation
Words: 494
Medical Entities: CKD,GFR,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Int J Clin Pract 64(13): 1784, 2010 10 CONSULTATION by Jerry Yee Introduction In a survey, family medicine physicians (N89), general internists (N89), and nephrologists (N129) evaluated a case of progressive CKD. Family medicine and internal medicine doctors recognized and recommended subspecialist care for progressive CKD less frequently than nephrologists. Their opinions also differed from nephrologists regarding evaluations by and expectations of nephrologists. The survey recommended the following: a) greater dissemination of existing clinical practice guidelines b) targeted CKD-specific education c) consensus-building and guideline development by family medicine physicians, internists, and nephrologists. Data from dedicated CKD clinics corroborate these findings. Currently, there is a concerted effort from many nephrology societies, including AMA, AHRQ, and ABIM to improve CKD education for those who must engage and practice it. Timely consultation by the nephrologist in CKD promotes improved clinical outcomes and reduces the total cost of care for the patient and the public. It has been estimated that healthcare savings of 18. 5 to 60. 6 billion would accrue by reducing the CKD progression rate by 1030% over the next decade. The optimal time for consultation is during CKD Stages 34. As eGFR falls below 45 mL/min/1. 73 m2 (CKD Stage 3B), there is a significant increase in CVD risk. Crossing this eGFR threshold is equivalent to experiencing a major cardiovascular event. This risk is worsened at any CKD stage by the presence of persistent proteinuria. Estimating the GFR is important because this process not only optimizes the time of referral, but also delineates the progression rate of CKD. Urinary abnormalities, electrolyte imbalances, uncontrolled HTN, or metabolic abnormalities constitute reasons to initiate nephrological consultation. Certain conditions such as malignancy, dementia, multiple comorbidities, or an advanced directive may preclude referral to a nephrologist. Glomerular Filtration Rate (GFR) MDRD Study GFR 60 mL/min/1. 73 m2 Cockroft-Gault CrCl 60 mL/min/1. 73 m2 Serum Creatinine (SCr) Males (cid: 1)1. 51. 7 mg/dL on two separate occasions, separated by at least 2 wk, unless AKI/ARF is established Females (cid: 1)1. 11. 3 mg/dL on two separate occasions, separated by at least 2 wk, unless AKI/ARF is established 11 COMMENTS Normal age-related decline in GFR is 1 mL/min/1. 73 m2/yr after age 3040 y. o. However, there is significant normal variation. Trend analysis at the individual level is key. An unexplained, non-reversible rapid decline in GFR is considered to be (cid: 1)4 mL/min/1. 73 m2/yr and should prompt a nephrology consultation. GFR is the principal but not the only determinant of SCr levels. Hypercatabolic states or muscle injury may increase the SCr as can increased creatine ingestion (supplement). Cimetidine, trimethoprim, corticosteroids, pyrimethamine, phenacemide, salicylates, and vitamin D metabolites can elevate SCr, but do not reduce GFR. Cimetidine, trimethoprim, pyrimethamine, probenecid, triamterene, amiloride, and salicylates inhibit tubular creatinine secretion. Cephalexin, flucytosine and nitrofurantoin interfere with the creatinine assay and increases the plasma measured level ex vivo. Tetracycline (anti-anabolic), GI bleeding, and glucocorticoid steroids increase protein catabolism and increase BUN but not SCr levels.
----------------------------------------------------------------------


======================================================================
CHUNK 196 of 647
======================================================================
ID: hfhs_ckd_v6_14
Content Type: recommendation
Words: 488
Medical Entities: CKD,GFR,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Microvascular disease is much more prevalent in type 1 DKD than in type 2 DKD. Specifically, retinopathy marked by the development of new retinal vessels is present in almost all type 1 DKD and 60% of type 2 DKD. Therefore, the absence of retinopathy or the presence of small kidneys by ultrasound in the latter group should prompt a search for a different etiology of CKD since other primary renal disorders such as focal and segmental glomerulosclerosis and minimal change disease, among others, may exist in patients with DM. In addition, IgA nephropathy, and membranous nephropathy may co-exist with DKD. In some series, diabetic nephropathy may be accompanied by another non-hypertension-related kidney disorder in 515% of cases. In the United States, it is estimated that 50% of diabetic patients will develop DKD. In type 2 DM, there is an incidence of 3%/yr for the development of nephropathy (overt proteinuria) after 1020 yr of poorly controlled disease. In general, the key markers of CKD are increased urine albuminto-creatinine ratio (UACR) and increased SCr estimates of GFR (eGFR), 60 ml/min/1. 73 m2, 15 from 2 abnormal readings at least 3 months apart. Microalbuminuria (30300 mg/24 h; UACR 3-30 mg/g) is the earliest clinical sign of DKD and is typically present in 2030% of type 1 diabetics 15 yr after the onset of DM. Progression to macroalbuminuria (300 mg/24 h; UACR 30 mg/g) is associated with increased progression of CKD and possibly, ESRD. The level of proteinuria 2g/24-h may be identified qualitatively by (cid: 1)3 urine dipstick or followed quantitatively by the urine protein-to-creatinine ratio (UPC; normal 0. 2 g/g), or a 24-h urine collection. The 24-h urine protein is considered the gold standard of urine protein determination as protein excretion may vary with the circadian rhythm, particularly in patients with glomerular disease. Afternoon (after 1600 h) UPC testing may significantly underestimate the morning UPC or 24-h urine protein. Proteinuria 3. 5g/24-h is considered nephrotic range proteinuria. A spot morning (08001200 hours) UPC has been shown to correlate well with the 24-h urine collection in patients with DKD, and therefore is also a good screening test for DKD and for monitoring patients on a stable treatment regimen. Benign proteinuria that occurs due to fever, intense exercise, postural changes, volume depletion, or acute illnesses should be reevaluated during stable conditions. The typical annual rates of progression of DKD from the diagnosis of DM to microalbuminuria, macroalbuminuria, and then to advanced CKD or ESRD are 2. 0%, 2. 8%, and 2. 3%, respectively. DM and microalbuminuria represent independent risk factors for CVD. In addition, nearly 7080% of diabetic CKD patients are hypertensive. Thus, routine screening for DKD is recommended for diabetic patients as follows: a) annual testing of urinary albumin excretion by spot UACR and eGFR in type 1 diabetic patients with (cid: 1)5 yr duration of DM and b) annual testing of all type 2 diabetic patients from the time of diagnosis.
----------------------------------------------------------------------


======================================================================
CHUNK 197 of 647
======================================================================
ID: hfhs_ckd_v6_15
Content Type: reference
Words: 490
Medical Entities: CKD,GFR,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Because several factors may cause transient increases in microalbuminuria, the diagnosis requires at least 2 serial first-morning urine specimens over 23 weeks. Occasionally, proteinuria in DM may herald other possible causes of CKD, particularly glomerular disorders as described above. Suspect other causes when one or more of the following is present: a) absence of diabetic retinopathy or neuropathy b) presence of low or rapidly decreasing GFR c) presence of rapidly increasing proteinuria or nephrotic syndrome d) refractory hypertension e) active (blood and protein) urinary sediment f) manifestations of other systemic disease g) presence of 30% reduction in GFR within 23 months of the initiation of anti-reninangiotensinaldosterone system (RAAS) therapy. The rate of improvement in renal function following this initial expected physiologic decline in eGFR will depend on several patient-related factors, such as disease severity and ethnicity. For example, African Americans typically display earlier and more rapid declines in renal function. The presence of one or more of these clinical scenarios should prompt urgent patient referral to a nephrologist for confirmatory and/or additional diagnoses. Clinical remission of renal disease has taken place when proteinuria declines to 1 g/24-h, and regression is defined by a decline in proteinuria to 0. 3 g/24-h. 16 Treatment Considerations Due to increased CVD risk in diabetic patients, prompt treatment of DKD and other CV risk factors is critical. Therefore, treatment of DKD toward therapeutic targets (eg, HbA1C, BP, lipids, BMI) involves risk factor reduction to prevent DKD progression and a multimodal approach that addresses lifestyle modification. Such modifications include a DASH (Dietary Approach to Stop Hypertension), restricted dietary sodium intake at 1. 5 g/24 h, smoking cessation, restricted dietary intake of saturated fat and cholesterol (200 mg/24-h), and regular aerobic exercise. Spontaneous remission of microalbuminuria may occur in some patients with types 1 and 2 DM. This may be attributable to improved BP control and/or glycemic control. The strongest predictors of progressive DKD are the presence of poor glycemic control, hypertension, and glomerular hyperfiltration. Importantly, as DKD progresses, the requirements for insulin to maintain glycemic control diminish as renal metabolism and excretion of insulin concomitantly and progressively decreases. A reduction in insulin and/or other antihyperglycemiant medications (not metformin) may be required to prevent hypoglycemia. Thus, the three mainstays of optimal DKD treatment are: a) strict glycemic control b) tight BP control c) maximal proteinuria reduction with an ACEI or ARB, singly or in combination. There are multiple, well-conducted clinical studies which indicate that these strategies retard the progression of DKD. The non-dihydropyridine calcium channel blockers (eg, diltiazem and verapamil) are anti-proteinuric and may potentiate the anti-proteinuric effects of anti-RAAS treatment(s). Even greater inhibition of the RAAS by the addition of a direct renin inhibitor (eg, aliskiren) or an aldosterone receptor antagonist (eg, aldosterone or eplerenone) may achieve improved anti-proteinuric effects. New research has uncovered an antioxidant drug, bardoxolone methyl that induces genes that suppress inflammatory mediators as a potential anti-proteinuric agent in the treatment of DKD.
----------------------------------------------------------------------


======================================================================
CHUNK 198 of 647
======================================================================
ID: hfhs_ckd_v6_17
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
At-Risk Groups African Americans develop hypertensive CKD (nephrosclerosis) much more frequently than Caucasians. Genetic susceptibility to hypertensive nephropathy associated with genetic polymorphisms (eg, APOL1, MYH9) in African Americans may contribute to this risk. In addition, hypertensive kidney disease in African Americans may not always be attributable to high BP and may reflect an underlying glomerular disorder. Suspect these in non-diabetic individuals diagnosed with hypertensive nephropathy when their UPCs are 1 or UACRs are 300 mg/g. African Americans also tend to respond less well than Caucasian patients to monotherapy with beta blockers (BBs), ACEIs (angiotensin-convertingenzyme inhibitors) and/or ARBs (angiotensinreceptor blockers). However, ethnicity-related differences in therapeutic response are usually nullified by concomitant diuretic therapy. For example, the response to combined thiazide diuretic-ACEI/ARB therapy is equivalent among the various ethnicities. Therefore, no particular agent should be avoided in patients of African American ethnicity. Since non-diabetic CKD patients have equivalent or greater risk for the development of CVD as diabetic patients without CKD, cardiovascular protective measures in addition to antihypertensive therapy must always be considered. Since a given individuals BP response to high sodium intake (salt sensitivity) is not predictable, sodium restriction should generally be enforced in all CKD patients, ie, 1500 mg sodium (65 mEq Na) per day. Blood Pressure Profile Hypertension in CKD is considered by default as resistant HTN, ie, treatment requires 3 or more antihypertensive agents at maximally tolerated doses and one of which must be a diuretic. The typical BP profile is a SBP greatly exceeding DBP, manifested as an elevated pulse pressure (55 mmHg). Either the SBP or pulse pressure may be increased in hypervolemic/edematous individuals who must often be treated with diuretics. Proteinuria Evaluation for and quantitation of albuminuria/proteinuria is recommended when there is a family history of CKD or the eGFR is 60 mL/min/1. 73 m2. Achievement of target BP goals, particularly for the more important systolic pressure, will require two or more antihypertensive medications in most cases, if the initial SBP is (cid: 1)150 mmHg, two antihypertensive agents should be initiated, an anti-reninangiotensinaldosterone system (RAAS) drug such as an ACEI or ARB and either a diuretic (eg, thiazide or loop diuretic, the latter predicated by the GFR) or CCB (calcium channel blocker). Lastly, non-dihydropyridine calcium channel blockers (NDHPCCBs: diltiazem, 19 verapamil) are preferred in proteinuric CKD, with appropriate caution during concomitant beta blocker therapy, or with contraindication due to bradycardia. Proteinuria accelerates the rate of decline of GFR in hypertensive, diabetic, and non-diabetic individuals. Hypertension exacerbates proteinuria and promotes tubulointerstitial inflammation, fibrosis, and tubular atrophy, further elevating BP. Also, proteinuria, more specifically, albuminuria is an independent risk factor for stroke, LVH, and death. In the presence of 12 g/d proteinuria, the risk for progressive CKD rises steeply after SBP (cid: 2)130 mmHg. All of the antireninangiotensinaldosterone system (anti-RAAS) agents are anti-fibrogenic, including aldosterone receptor antagonists (ARAs). Patients with a SBP of 115130 mmHg and proteinuria 1 g/d have a relatively lower risk of progression.
----------------------------------------------------------------------


======================================================================
CHUNK 199 of 647
======================================================================
ID: hfhs_ckd_v6_18
Content Type: recommendation
Words: 485
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
All of the antireninangiotensinaldosterone system (anti-RAAS) agents are anti-fibrogenic, including aldosterone receptor antagonists (ARAs). Patients with a SBP of 115130 mmHg and proteinuria 1 g/d have a relatively lower risk of progression. However, a SBP of 120130 mmHg may be considered optimal for patients with HTN and proteinuria since SBPs (cid: 1)120 have been associated with an enhanced risk of adverse cardiovascular events in proteinuric CKD patients, particularly those with stroke or heart failure. Treatment The Seventh Report of the Joint National Committee (JNC 7) issued a set of Compelling Indications (see TABLE) for the treatment of HTN, which should also be followed in CKD patients. Modification of lifestyle and dietary interventions should always be enforced in hypertensive CKD patients. Sodium restriction can produce substantial BP reductions, and primarily entails reducing the intake of salty processed foods. Currently, there is insufficient evidence to support a SBP goal 130 mmHg in CKD with urine protein-to-creatinine ratio 0. 22. In patients with CKD and proteinuria that is 1 g/d, a SBP of 120130 mmHg is recommended. Overall, HTN control in CKD patients is suboptimal with less than one-half of patients achieving target BP levels. In the majority of such cases, the blood pressure regimen can be improved. JNC 7 COMPELLING INDICATIONS HYPERTENSION TREATMENT Indication Treatment Chronic kidney disease ACEI, ARB Diabetes mellitus ACEI, ARB, BB, CCB Heart failure ACEI, ARB, BB, ARA, thiazide High CAD risk ACEI, thiazide, BB, CCB Post-MI ACEI, BB, ARA Primary stroke prevention ARB (losartan, LIFE Trial) Secondary stroke prevention ACEI Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker; ARA, aldosterone receptor antagonist (epleronone, spironolactone). Selection of a non-dihydropyridine CCB is preferred in CKD patients with proteinuria. 20 Therapeutic Targets BP 130/80 mmHg CKD without proteinuria BP 120129/7579 mmHg CKD with proteinuria First-line Agents GFR 20 mL/min/1. 73 m2 ACEI or ARB Most CKD patients with HTN require 2 or more antihypertensive medications Second and Third Line Agents GFR (cid: 2)40 mL/min/1. 73 m2 Add thiazide and/or CCB, if anti-RAAS agent is first-line GFR 40 mL/min/1. 73 m2 Add loop agent, eg, bumetanide or furosemide (twice-daily dosing) or torsemide (once-daily dosing) and/or CCB, if anti-RAAS agent started as first-line therapy Fourth-line Agents HR 80 bpm Beta blocker or alpha/beta blocker HR (cid: 1)80 bpm Consider adding ARA (spironolactone or eplerenone), if proteinuria present Specific Clinical Situations Diabetes ACEI or ARB for type 1 diabetes ARB or ACEI for type 2 diabetes CAD Beta blocker, CCB, alpha/beta blocker, eg, labetalol BPH Alpha-1 blocker, eg, prazosin, terazosin, doxazosin Thiazide-resistant HTN Amiloride or ARA Primary aldosteronism ARA Orthostatic hypotension Target 2-min standing SBP (120 mmHg) Stage 2 Hypertension (uncontrolled) SBP (cid: 2)150 mmHg on (cid: 2)2 occasions, separated by (cid: 2)2 d DBP (cid: 2)90 mmHg on (cid: 2)2 occasions, separated by (cid: 2)2 d COMMENTS Anti-RAAS therapy: SCr increases are common and can often be tolerated.
----------------------------------------------------------------------


======================================================================
CHUNK 200 of 647
======================================================================
ID: hfhs_ckd_v6_20
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Using UACR more reliably classifies individuals with higher risk CKD (ie, those who might develop progressive disease) who have been stratified into CKD Stages 3 and 4 by the MDRD 4variable eGFR equation. Using the combination of eGFR 60 mL/min/1. 73 m2 and proteinuria by UACR reduces the prevalence of CKD Stages 3 and 4 patients by 76%, from 16. 3 million to 3. 9 million. Note that UPC testing is not nationally standardized due to variation in laboratory methodology; however, UACR testing is standardized. The presence of even small amounts of albuminuria (10 mg/g) is associated with adverse cardiovascular outcomes. While ACEI (angiotensin-convertingenzyme inhibitor) and/or ARB (angiotensin-receptor blocker) therapies reduce albuminuria and are associated with reduced risk for developing ESRD (especially in diabetes and hypertension), they are underutilized. Ideally, 70% or more of patients should be treated with these drugs. Types of Proteinuria Traditionally, normal urinary protein excretion is considered to be 150 mg/24-h; total urinary proteins measured are comprised of immunoglobulins, assorted globulins, and Tamm-Horsfall mucoprotein. Persistently elevated total urinary protein signifies: a) defect(s) in the glomerular basement membrane b) impaired tubular protein reabsorption, eg, tubulointerstitial nephritis c) increased filtration of low molecular weight protein(s), ie, overflow proteinuria as may occur with light chains. Persistent proteinuria is defined as two or more positive quantitative tests of protein excretion, separated by at least 2 weeks. Common, benign sources of albuminuria/proteinuria include orthostatic proteinuria, intense activity/exercise, and fever. Serious causes of proteinuria include glomerular disorders and myeloma. False positive albuminuria results by urine dipstick include highly alkaline urine, concentrated urine, gross hematuria and the presence of mucus, semen or white cells. Individuals at increased risk for CKD should undergo testing for proteinuria. The urinalysis dipstick may not register proteinuria when the urine is highly dilute, (ie, specific gravity (cid: 1)1. 015). In addition, the dipstick preferentially detects albumin, which is the major urinary protein excreted in proteinuric CKD disorders, eg, diabetes, glomerular disorders. 24 Evaluation of Proteinuria Early or first morning spot UPC ratio (urine protein and urine creatinine expressed as mg/dL) correlates with the daily protein excretion rate (g/24-h). A UPC 2 correlates with 2 g of proteinuria per 24-h and approximates the 24-h urine total protein collection, a collection fraught with error(s). Since the majority of protein excretion in glomerular disease is albumin, albuminspecific tests have been devised, eg, albumin-specific dipsticks and the UACR, traditionally classified as normal (30 mg/g), microalbuminuria (30300 mg/g) and macroalbuminuria (300 mg/g). Notably, a new classification system that eschews the terms microand macroalbuminuria may be established in the near future. Quantitative urinary protein (principally albuminuria) testing by UPC or UACR is recommended within 3 months of documentation of (cid: 1)1 proteinuria by dipstick analysis. Two or more positive quantitative tests, preferably on first morning urine specimens, should be documented before diagnosing persistent proteinuria (see CKD PROTEINURIA EVALUATION, P. 27). The urine dipstick favors albumin detection and is relatively insensitive for tubular proteinuria, eg, immunoglobulin light chains.
----------------------------------------------------------------------


======================================================================
CHUNK 201 of 647
======================================================================
ID: hfhs_ckd_v6_21
Content Type: recommendation
Words: 448
Medical Entities: CKD,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Two or more positive quantitative tests, preferably on first morning urine specimens, should be documented before diagnosing persistent proteinuria (see CKD PROTEINURIA EVALUATION, P. 27). The urine dipstick favors albumin detection and is relatively insensitive for tubular proteinuria, eg, immunoglobulin light chains. If tubular proteinuria is suspected, specific qualitative and quantitative examinations may be required, eg, serum free light chain analysis (Freelite) and serum and urine immunofixation. For screening purposes, a 24-h urine is unnecessary, but if a serum monoclonal protein is detected, a 24-h urine collection for immunofixation is indicated. Consultation with a clinical laboratory expert is advised to optimize diagnostic yield in such cases. Anti-Proteinuric Therapy Anti-proteinuric therapy reduces tubulointerstitial fibrosis and thus, progression of CKD. Patients with stable, persistent proteinuria of 1 g/24-h have a very small risk of progression to kidney failure compared to individuals with greater proteinuria. However, glomerular proteinuria in the nephrotic range (2 g/m2/d; 3. 03. 5 g/24-h in adults) has an ominous prognosis and is associated with edema, hypercholesterolemia, hypoalbuminemia, anemia, lipiduria, vitamin D deficiency, and greater risk for progression to ESRD. Irrespective of the degree of proteinuria, all therapies that reduce proteinuria should be optimized for BP control of 130/80 mmHg as tolerated. Anti-renin angiotensinaldosterone (RAAS) agents, ACEIs and ARBs, represent first-line anti-proteinuric drugs and should be utilized whenever possible. These agents are indicated in the treatment of diabetic and non-diabetic proteinuric CKD. Antihypertensive regimens that include anti-RAAS therapy are more efficacious than regimens that do not include ACEIs or ARBs, and their benefit is maximized in CKD patients that manifest either 0. 5 g/d of proteinuria, UPCs 0. 22, or microalbuminuria by UACR. The anti-RAAS therapies exert differential, beneficial effects on glomerular structural proteins, intraglomerular pressures, local and systemic sympathetic nervous systems, inflammatory pathways, and the systemic blood pressure. Notably, no specific agent reduces tubular proteinuria. Recently, aldosterone receptor antagonists (ARAs) and direct renin inhibitors (DRIs) have demonstrated anti-proteinuric properties. Non-dihydropyridine CCB (calcium channel blockers), diltiazem and verapamil, also reduce proteinuria and complement the anti-RAAS agents. Combinations of such agents (ACEI ARB) frequently reduce proteinuria by an additional 25 40%. However, dual-agent anti-RAAS therapies involving ACEIs or ARBs (VA NEPHRON-D) with other antiproteinuric agents, eg, (ACEI or ARB) ARA or (ACEI or ARB) DRI (ALTITUDE) should be initiated and monitored by a nephrologist. The goal of attaining target BP supersedes additional use of antiproteinuric agents. Recent data suggest that pentoxifylline and HMG-Co synthetase inhibitors, simvastatin and atorvastatin, may reduce proteinuria. 25 Finally, high sodium intake and poor glycemic control may retard BP-lowering and proteinuriareducing effects of antihypertensive agents. Sodium intake of (cid: 1)1500 mg daily is recommended for patients with CKD. Therapeutic Targets for Proteinuria Reduction UPC 0.
----------------------------------------------------------------------


======================================================================
CHUNK 202 of 647
======================================================================
ID: hfhs_ckd_v6_23
Content Type: recommendation
Words: 494
Medical Entities: CKD,dialysis,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Anemia of CKD usually begins during CKD Stage 3, ie, GFRs 60 mL/min/1. 73 m2. Anemia occurs in 42%, 54% and 76% of CKD Stage 3, 4 and 5 patients, respectively, and is more severe in diabetics. Anemia multiplies the mortality risks of diabetes, heart failure, and CKD. Treatment of anemia of CKD is associated with improved vitality and socialization, but has not been shown to decrease LVH or cardiovascular or all-cause mortality. Iron deficiency should be corrected before administration of any ESA (erythropoiesis stimulating agent). The KDOQI CLINICAL PRACTICE GUIDELINE AND CLINICAL PRACTICE RECOMMENDATIONS FOR ANEMIA IN CHRONIC KIDNEY DISEASE: 2007 UPDATE OF HEMOGLOBIN TARGET states a Clinical Practice Recommendation for a Hb target of 11. 0 to 12. 0 g/dL and a top-level Hb of 13. 0 g/dL in CKD. To obtain reimbursement for ESA therapy, the Hb must be 10 g/dL on the date that an ESA is first prescribed, and reimbursement is dependent upon payors coverage policies. Lastly, an attestation of medical necessity for ESA treatment may be required for reimbursement by third party payors. Pathophysiology The primary reason for anemia in CKD is an absolute or relative deficiency of renal erythropoietin (EPO) synthesis. Individual sensitivity and responsiveness to an ESA is highly variable and dosing requirements are heterogeneous. Occult causes of blood loss and iron deficiency must be ruled out in all patients as a cause of hyporesponsivenss to ESA treatment. Less commonly, vitamin deficiencies, eg, B and folate, and inflammatory causes of ESA resistance should be ruled out 12 secondarily. Inflammation upregulates hepcidin, a liver-synthesized protein that reduces gut iron absorption and impedes iron release from the reticuloendothelial system to the developing erythron. Finally, effective iron delivery is required for optimal ESA-stimulated production of fully hemoglobinized red blood cells. Iron Deficiency Iron deficiency is common in CKD. CKD patients should be iron replete before initiating ESAs. To correct iron deficiency, oral iron should always be tried initially, and multiple iron salt preparations are available. However, to achieve iron repletion, parenteral iron may be required in non-dialysis CKD patients. Multiple studies attest to the safety of several parenteral iron preparations, including iron sucrose FDA-approved, ferumoxytol FDA-approved, and low molecular weight iron dextran used off label. 28 Safety During anemia treatment, Hb elevations of 12 g/dL per month are generally well tolerated. More rapid increments are not advised. Recent clinical trials describe an increased risk of blood clots, strokes, and heart attacks in CKD and dialysis patients, in association with treatment to Hb levels of 13 g/dL, particularly at high doses of ESA. FDA and ESA manufacturers have agreed to revised product labelings that include a black box warning with an FDA-approved target Hb of 1012 g/dL (see below). However, the heterogeneity of responses to ESA/iron-based anemia therapy among patients and even over time in the same patient makes the targeting of an exact Hb difficult. Lastly, ESA dosing has been extended to once monthly intervals in several clinical trials.
----------------------------------------------------------------------


======================================================================
CHUNK 203 of 647
======================================================================
ID: hfhs_ckd_v6_24
Content Type: reference
Words: 493
Medical Entities: CKD,dialysis
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
However, the heterogeneity of responses to ESA/iron-based anemia therapy among patients and even over time in the same patient makes the targeting of an exact Hb difficult. Lastly, ESA dosing has been extended to once monthly intervals in several clinical trials. Therapeutic Targets Hb 1012 g/dL (do not exceed Hb 13 g/dL) TSAT 20% but 50% Ferritin 100 ng/mL CHr 32 pg/cell Therapeutic phlebotomy should not be undertaken, if the Hb is 1318 g/dL, in the absence of ESA therapy, unless symptoms are present, eg, headache. Ferritin 800 ng/mL is not a contraindication to the use oral or parenteral iron; interpretation of clinical context and trend analysis of iron utilization is required, particularly with inflammation. CHr (mean cellular hemoglobin content of reticulocytes); utility of this parameter has only been validated in hemodialysis-dependent ESRD patients. Evaluation CBC, absolute reticulocyte ct, TSAT, ferritin, vitamin B, and folate levels. Always rule out other 12 causes of anemia, eg, malignancy, inflammatory conditions, vitamin D deficiency, and iron deficiency before starting an ESA. Monitor iron parameters and CBC twice monthly after initiating therapy or until Hb stabilizes within the target range, then monthly. Use the absolute reticulocyte count to assess efficacy. Treatment Iron Ferrous sulfate: 200 mg elemental iron/24-h (alternative, ferrous fumarate) Iron dextran (INFeD): 5001000 mg iv infusions of low molecular wt iron dextran Iron sucrose (Venofer): 100200 mg iv infusions in non-dialysis-dependent CKD Ferumoxytol (Feraheme): 5001000 mg iv in non-dialysis-dependent CKD Iron dextran, iv, high molecular weight (Dexferrum), is a distinct and separate product from INFeD (see above). Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (Procrit or Epogen): 1040, 000 Units, subcutaneously, q14 wk; begin therapy at Hb 10 g/dL at starting dose, 100 Units/kg/wk. Darbepoetin alfa (Aranesp): 40300 mcg, subcutaneously, q24 wk or q1 mo; begin therapy at Hb 10 g/dL at starting dose, 0. 9 mcg/kg/q2 wk (equivalent to package insert dose, 0. 45 mcg/kg/wk) NB: ESA therapy entails informed consent at each administration. In hemodialysis patients, administration of vitamin D may reduce ESA utilization. 29 COMMENTS Ascorbic acid (vitamin C) should be co-administered with iron in achlorhydric patients (250 mg per iron tablet), during H antagonist or PPI therapy, or after gastric ulcer surgery (eg, 2 Billroth II surgery). Ca-based P-binders bind iron salts. Consult a nephrologist before initiating ESA treatment, if oral iron therapy does not achieve Hb (cid: 1)10 g/dL or if parenteral iron is considered. Dose conversion ratio of epoetin alfa to darbepoetin alfa is 225260 to 1. EPO levels should not be measured as part of a routine anemia evaluation. ESAs are contraindicated during acute blood loss. Iron salts should only be ingested on an empty stomach. Iron salts bind fluoroquinolones, tetracyclines, Ca-based P-binders, and levothyroxine. Administer thyroid hormones separately from iron. Parenteral iron is contraindicated during active infection. REFERENCES 1. A Besarab, et al. J Am Soc Nephrol 10: 2029, 1999 2. T Ganz. Blood 102(3): 783, 2003 3. Toto RD, et al. Am J Nephrol 24: 453, 2004 4.
----------------------------------------------------------------------


======================================================================
CHUNK 204 of 647
======================================================================
ID: hfhs_ckd_v6_26
Content Type: recommendation
Words: 482
Medical Entities: CKD,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Ca, P, Parathyroid Hormone (PTH), and Vitamin D Physiology Total serum calcium is 40% ionized (free), 50% albumin-bound and 10% complexed to P and organic anions. Ionized Ca regulates the parathyroid gland (PTG) Ca-sensing receptor (CaR), vitamin D, and PTH. Low ionized Ca levels reduce CaR stimulation and increase PTH secretion, elevating ionized Ca and renal P excretion and calcitriol synthesis. An average daily dietary P intake is 8001400 mg, 80% of which is renally excreted via PTH action. In an individual with normal renal function, low P stimulates calcitriol independently leading to decreased PTH and increased gut absorption of P. Progressive CKD leads to progressive elevation in P; low P levels in a patient with significant CKD should lead to consideration of other additional underlying issues such as malnutrition. High P levels raise PTH and are associated with greater CVD and all-cause mortality. The traditional thought has been that increased P is one inciting factor in the development of SHPT and CKD-MBD, and goals of therapy have debated the maintenance of a 31 normal P range versus reduction to the normal range. Dietary P restriction is beneficial in early CKD, and renal dietary consultation may be sought at any CKD Stage. As CKD progresses, diet alone is likely to be an ineffective intervention to prevent or correct hyperphosphatemia. Currently, P binders remain a mainstay of therapy in patients with elevated levels. SHPT may develop in late CKD Stage 2. PTH levels are elevated in nearly one-third of CKD Stage 3 patients and may be increased despite normal Ca and P levels. Vitamin D as 25(OH)D deficiency is frequent in CKD and may further elevate PTH. In CKD Stage 4, hyperphosphatemia from renal P retention occurs. To prevent progressive PTG growth and PTH secretion as CKD worsens, screen for and begin treatment of SHPT early. Please note the developing story of Fibroblast Growth Factor 23 (FGF23). Bone-derived FGF23 is one of an undefined number of circulating peptides known as phosphatonins. FGF23 acts on kidney proximal tubular cells and decreases P reabsorption, thereby increasing urinary P excretion. FGF-23 apparently directly suppresses PTH and decreases calcitriol synthesis by inhibiting proximal tubular 1-OHase inhibition. FGF-23 is significantly elevated in CKD and is the subject of much current research aimed at determining its significance as a CKD biomarker or parameter of successful therapy, with other phosphatonins. Metabolic acidosis defined as a serum HCO 3 22 mEq/L that is not generated by respiratory alkalosis is under-recognized. Acidosis potentiates bone-lytic PTH effects, thereby increasing Ca and P bone resorption. It also increases SNS activity, aggravating hypertension, induces insulin resistance, and promotes muscle-protein catabolism. Treatment with sodium bicarbonate generally does not produce ECF volume expansion (eg, edema) or worsen HTN. If edema or BP elevation occurs, loop diuretic therapy is recommended. Once established, the treatment of metabolic acidosis should always be initiated with sodium bicarbonate (NaHCO) or another alkali.
----------------------------------------------------------------------


======================================================================
CHUNK 205 of 647
======================================================================
ID: hfhs_ckd_v6_27
Content Type: recommendation
Words: 483
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Treatment with sodium bicarbonate generally does not produce ECF volume expansion (eg, edema) or worsen HTN. If edema or BP elevation occurs, loop diuretic therapy is recommended. Once established, the treatment of metabolic acidosis should always be initiated with sodium bicarbonate (NaHCO) or another alkali. 3 CALCIUM, PHOSPHORUS, PARATHYROID HORMONE, AND VITAMIN D ACTIONS Compound Source/Distribution Action Bone mineralization, (cid: 1)Ionized Ca Diet, bone resorption CaR activation (cid: 1)CaR stimulation Kidney, PTG, other (cid: 2) SHPT, (cid: 2) PTG growth Diet, renal P retention, bone (cid: 1)P (cid: 1) PTH, complexes Ca, (cid: 1)FGF23 resorption (cid: 1) ionized Ca, (cid: 1) P excretion (cid: 1)PTH PTG (cid: 1) calcitriol synthesis (cid: 1)PTH receptor Bone (osteoblast), kidney See PTH stimulation Endogenous synthesis; (cid: 2) SHPT, (cid: 1) gut Ca/P absorption (cid: 1)Vitamin D exogenous administration (cid: 1) kidney Ca absorption Bone, kidney, PTG, gut and other (cid: 1)VDR stimulation (cid: 2) PTH gene activity tissues Abbreviations: CaR, calcium-sensing receptor; PTG, parathyroid gland; SHPT, secondary hyperparathyroidism; P, serum phosphorus; VDR, vitamin D receptor. Vitamin D includes vitamins D2 and D3and three active D sterols, calcitriol, and two synthetic vitamin D2 compounds. Renal synthesis of calcitriol is tightly regulated. Its level does not reflect vitamin D sufficiency, which correlates better with 25(OH)D levels. Vitamin D receptor (VDR) stimulation by active vitamin D sterols suppresses PTH secretion, enhances gut Ca and P 32 absorption, and increases renal Ca reabsorption. As CKD worsens parathyroid VDR and CaR densities are reduced, aggravating SHPT (see TABLE). VITAMIN D STEROLS AND ANALOGS Compound Chemical Name Source Pro-vitamin D2 Ergosterol Diet Pro-vitamin D3 7-Dehydrocholesterol Cholesterol Vitamin D2 (Calciferol, Drisdol) Ergocalciferol UV light ergosterol UV light Vitamin D3 Cholecalciferol 7-dehydrocholesterol 25(OH)-cholecalciferol; Calcidiol 25-OHn D3 (liver) 25(OH)D3 Calcitriol (Rocaltrol) 1, 25(OH) 2 -cholecalciferol; 1-OHn 25(OH)D3 1-25(OH) 2 -D3 (kidney) Doxercalciferol (Hectorol) 1-(OH)D2 Synthetic D2 prohormone Paricalcitol (Zemplar) 19-nor-1-25(OH) 2 -D2 Synthetic D2 analog Active vitamin D sterol Management and Therapeutic Options Nutritional vitamin D, ergocalciferol (plant sources) or cholecalciferol (animal sources), can be used as treatment for hypovitaminosis D at any CKD stage. Currently, 25(OH)D levels 30 ng/mL represent vitamin D insufficiency. However, these agents may not sufficiently suppress PTH elevations in CKD Stages 35, despite replenishing vitamin D stores. Consequently, active vitamin D sterols may be required to suppress PTH to target levels. Any of these compounds can be used concomitantly with vitamin D2 or D3. Oral vitamin D is recommended in CKD Stages 3 and 4, and active vitamin D sterols are recommended to prevent and treat early SHPT and CKD-MBD. Treatment (with active vitamin D sterols) is indicated when 25(OH)D levels are 30 ng/mL; Corrected calcium (Corr Ca) is 9. 5 mg/dL; P 4. 6 mg/dL; and PTH levels are elevated and continue to rise with time. The optimal PTH levels in CKD are unknown and likely vary with a number of factors, not limited to stage of CKD and race.
----------------------------------------------------------------------


======================================================================
CHUNK 206 of 647
======================================================================
ID: hfhs_ckd_v6_28
Content Type: recommendation
Words: 495
Medical Entities: CKD,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
5 mg/dL; P 4. 6 mg/dL; and PTH levels are elevated and continue to rise with time. The optimal PTH levels in CKD are unknown and likely vary with a number of factors, not limited to stage of CKD and race. An iPTH range that is 29 (cid: 1) ULN (130600 pg/mL) may be acceptable, with the growing acceptance that therapy of mineral metabolism should be individualized, ie, trend analysis of the above parameters is favored over absolute values. Corr Ca (mg/dL) Total serum Ca 0. 8 (4 Albumin) Doxercalciferol, a vitamin D2 prohormone, requires hepatic hydroxylation for activation. Paricalcitol, a calcitriol analog, is active upon administration and does not require in vivo activation. Doxercalciferol and paricalcitol exert vitamin D-like actions and are less prone to induce hypercalcemia than calcitriol. Ca-based P-binders are recommended in CKD Stages 3 and 4 for P 4. 6 mg/dL when the corrected Ca is 10. 2 mg/dL and there is no evidence of coronary, peripheral vascular/cardiac valvular calcification. During Ca-based P-binder therapy, the total daily elemental Ca intake (dietary prescribed) should not exceed 2000 mg daily. This limit is imposed to prevent excessive Ca loading and extraskeletal calcification and dystrophic medial arterial calcification that occur earlier 33 in diabetes and CKD. Sevelamer hydrochloride, a non-metal anion exchange resin, and lanthanum carbonate are non-Ca-based P-binders. These agents may be used as initial P-binder therapy, if arterial/cardiac vascular calcification is present or, if the corrected Ca is 10. 2 mg/dL. These drugs do not alter Ca or PTH levels and do not affect treatment by vitamin D or its analogs. Sevelamer typically reduces LDL-C by 30% and raises HDL-C. Lastly, the Ca (cid: 2) P product as a therapeutic parameter is no longer used. KDIGO TARGETS FOR CKD-MINERAL AND BONE DISORDER CKD Ca P iPTH HCO 3 Stage (mg/dL) (mg/dL) (pg/mL) (mEq/L) 3 NL range NL range 29 (cid: 1) ULN 2226 4 NL range NL Range 29 (cid: 1) ULN 2226 Lower toward NL Lower toward NL 5 29 (cid: 1) ULN 2226 range range KDIGO: Kidney Disease: Improving Global Outcomes, 2006. Trend analysis of each parameter is preferred over treatment(s) directed at absolute parameter levels. PTH levels of 130600 pg/mL roughly equal 29 (cid: 1) ULN. Serum calcium corrected to serum albumin of 4. 0 g/dL. Trend analysis of Ca, P, and intact PTH is recommended rather than treatment of isolated values. Evaluation Ca, P, iPTH Every 2 wk initially in CKD Stages 34 until normalized, then every 312 mo depending on stage and trends Serum HCO Every 14 mo, depending on degree of metabolic acidosis 3 25(OH)D 30 ng/mL at initial evaluation; begin therapy, then repeat level every 3 mo until (cid: 1)30 ng/mL; subsequent levels are evaluated depending on CKD stage and levels. Vitamin D and Active Vitamin D Sterols Vitamin D Ergocalciferol (D2) 25(OH)D 15 ng/mL: 50, 000 IU q1 wk 4, then every 1 mo 8, unless corrected Ca 9. 5 g/dL and/or P 4.
----------------------------------------------------------------------


======================================================================
CHUNK 207 of 647
======================================================================
ID: hfhs_ckd_v6_29
Content Type: recommendation
Words: 481
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Vitamin D and Active Vitamin D Sterols Vitamin D Ergocalciferol (D2) 25(OH)D 15 ng/mL: 50, 000 IU q1 wk 4, then every 1 mo 8, unless corrected Ca 9. 5 g/dL and/or P 4. 6 mg/dL (new) 25(OH)D 1530 ng/mL: 50, 000 IU q1 mo 6, unless Corr Ca 9. 5 g/dL and/or P 4. 6 mg/dL Please note, often longer durations of weekly therapy may be required. Monitor levels every 3 mo and continue weekly or monthly dosing, accordingly. Cholecalciferol (D3) 25(OH)D 30 ng/mL: 1, 750 IU once daily (new) Active Vitamin D Sterols Calcitriol Initial dose for CKD Stages 34: 0. 250. 50 mcg once daily Doxercalciferol Initial dose for CKD Stages 34: 1. 0 mcg once daily (see COMMENTS) Paricalcitol Initial dose for CKD Stages 34: 1. 0 mcg once daily or 2. 0 mcg, 3 times weekly (see COMMENTS) 34 COMMENTS Active vitamin D sterols: therapeutic choices at CKD Stages 35 include calcitriol, doxercalciferol or paricalcitol. Treatment plan includes periodic monitoring of Ca, P, albumin and PTH (see ACTION PLAN) and rarely induces Ca or P elevations that warrant their discontinuation. Active vitamin D sterols: may co-administer with ergocalciferol, if SHPT is present because ergocalciferol rarely suppresses PTH to target levels. Active vitamin D sterols: initiate during CKD Stages 34, if Ca 9. 5 mg/dL, P 4. 6 mg/dL, and PTH greater than target range. Ergocalciferol: consider in CKD Stages 3 and 4, if corrected Ca 9. 5 mg/dL, P 4. 6 mg/dL, PTH elevated, and 25(OH)D 30 ng/mL. Refer to the MEDICATION RELATED PROBLEMS IN CKD section for FDA-regulated labeling of the recommended doses of these agents in CKD. The lack of evidence supporting a definitive goal PTH and a clearcut therapeutic regimen makes this area controversial. Consequently, drug manufacturer labeling may differ from recommendations from consensus organizations such as KDIGO and from the practices of experts in the field. Recommended guidelines should not substitute for clinical judgment. Due to the absence of definitive evidence, any treatment plan should include periodic monitoring of Ca, P, albumin, and PTH (see ACTION PLAN), with therapy based on trend analysis. Only rarely should a single abnormal value of Ca or P warrant discontinuation of active vitamin D sterols. Phosphorus Binders (always taken with meals) Calcium acetate 1. 01. 5 g elemental Ca daily for P 4. 6 mg/dL (PhosLo) and Ca 8. 810. 2 mg/dL; 667 mg of Ca acetate contains 167 mg elemental Ca (25%) Calcium 1. 01. 5 g elemental Ca daily for P 4. 6 mg/dL Carbonate and Ca 8. 810. 2 mg/dL; CaCO3 dose is 40% elemental Ca Not FDA-approved at any CKD stage Sevelamer HCl 8002400 mg 3 times daily for P 4. 6 mg/dL and (Renagel) Ca 10. 2 mg/dL (Ca-based P-binder contraindicated) FDA-approved for CKD Stage 5 Sevelamer 8002400 mg 3 times daily for P 4. 6 mg/dL and Carbonate Ca 10.
----------------------------------------------------------------------


======================================================================
CHUNK 208 of 647
======================================================================
ID: hfhs_ckd_v6_30
Content Type: general
Words: 494
Medical Entities: CKD,GFR,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
6 mg/dL and (Renagel) Ca 10. 2 mg/dL (Ca-based P-binder contraindicated) FDA-approved for CKD Stage 5 Sevelamer 8002400 mg 3 times daily for P 4. 6 mg/dL and Carbonate Ca 10. 2 mg/dL (Ca-based P-binder contraindicated) (Renvela) FDA-approved for CKD Stage 5 Lanthanum 5001000 mg 3 times daily for P 4. 6 mg/dL and Carbonate Ca 10. 2 mg/dL (Ca-based P-binder contraindicated) (Fosrenol) FDA-approved for ESRD Metabolic Acidosis NaHCO 0. 52. 0 mEq/kg daily; target HCO 2226 mEq/L 3 3 35 PLAN OF CARE AND ACTION PLAN FOR CHRONIC KIDNEY DISEASE STAGES 14 Stage GFR Description Action Clinical Testing Treatment Considerations Normal RISK factors: age 60 years, obesity, SCREEN for general and specific BP monitoring: every 12 mo SMOKING cessation autoimmune disorders, DM, HTN, conditions FASTING lipid profile: every 12 mo WEIGHT reduction 90 kidney stones, ADPKD, prior SCREEN for CKD w/ eGFR LYTES, Glucose, BUN, SCr: DAILY aspirin: 81 mg once daily mL/min/1. 73 m2 AKI/ARF, UTIs, toxic drug exposures, INITIATE CKD risk reduction / eGFR every 12 mo TARGETS and FH of CKD intervention strategies UA for hematuria or proteinuria BP: 130/80 mmHg microscopic exam LIPIDS: LDL-C 70100 and TG 150 mg/dL GLUCOSE: FBS 130 mg/dL, HbA1C 7% 1 KIDNEY damage with normal GFR ESTABLISH etiology of CKD BP monitoring: every 12 mo CONSULT Nephrology if eGFR declines by 4 mL/min/yr (urinary, imaging or histologic DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, TARGETS 90 abnormalities) and comorbid conditions eGFR: every 12 mo BP: 130/80 mmHg mL/min/1. 73 m2 LIPID profile: every 12 mo LIPIDs: LDL-C 70100, TG 150 mg/dL; UA with microscopic evaluation non-HDL-C130 mg/dL UPC if non-diabetic: every 12 mo PROTEINURIA: UPC 0. 2; UACR 30 mg/g; UACR if diabetic: every 12 mo anti-proteinuric therapy with ACEI and/or ARB 2 KIDNEY damage with mild GFR ESTIMATE CKD progression rate BP monitoring: every 312 mo AVOID nephrotoxins; rule out AKI/ARF, eg, obstruction decrease (urinary, imaging or DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, TARGETS 60 89 histologic abnormalities) and comorbid conditions eGFR: every 612 mo BP: 130/80 mmHg mL/min/1. 73 m2 MOST lower GFRs in this range are CBC, reticulocyte ct, TSAT, LDL-C: 70100, TG 150, and non-HDL-C 130 mg/dL due to age-related GFR decline and ferritin if Hb 1012 g/dL: every 12 mo Hb: 1012 g/dL, TSAT 20%, and ferritin 100 ng/mL do not require evaluation, if no CONSIDER Ca / P / PTH / 25(OH)D UACR: 30 mg/g or UPC 0. 2 with anti-RAAS drug proteinuria is present evaluations UACR or UPC: every 312 mo 3A MODERATE decline of GFR ESTIMATE CKD progression rate BP monitoring: every 312 mo AVOID nephrotoxins; rule out ARF (eg, obstruction) COMPLICATIONS more frequent at DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, NUTRITIONAL assessment at any time during CKD Stages 35 45 59 CKD Stage 3B as GFR (cid: 1) and comorbid conditions eGFR: every 312 mo TARGETS mL/min/1. 73 m2 to 45 mL/min/1. 73 m2.
----------------------------------------------------------------------


======================================================================
CHUNK 209 of 647
======================================================================
ID: hfhs_ckd_v6_31
Content Type: evidence
Words: 480
Medical Entities: CKD,GFR,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
73 m2 to 45 mL/min/1. 73 m2. KIDNEY imaging study, eg, US or CT CBC: Hb 10 g/dL every 13 mo until Hb Hb: 1012 g/dL, TSAT 20%, ferritin 100 ng/mL with oral PROTEINURIA is a serious CV risk CONSIDER Nephrology CONSULTATION 1012 g/dL; then every 36 mo and/or iv iron and/or erythropoiesis stimulating agent 3B factor and has prognostic TSAT and ferritin if Hb 13 g/dL (males) Ca P: to normal range with P-binders importance for progression of CKD or 12 g/dL (females) and after therapy (no Ca-based P-binders if vascular / valvular calcification) 30 44 BASELINE Ca / P / PTH / Alk Phos / 25(OH)D 25(OH)D: 30 ng/mL with vitamin D2 / D3 mL/min/1. 73 m2 Ca / P / PTH / Alk Phos, depending on iPTH: 130600 pg/mL with calcitriol or vitamin D analogs baseline and CKD progression if iPTH progressively increases 25(OH)D, depending on baseline and NaHCO3: 2226 mEq/L and titrate NaHCO3 therapy response to treatment UPC: 0. 2 or UACR 30 mg/g with anti-RAAS drug EVALUATE for extraskeletal calcification UPC or UACR: every 612 mo 4 SEVERE decline of GFR NEPHROLOGY consultation with transition BP monitoring: every 36 mo CKD-specific education: kidney replacement therapy modality MAJOR increase in CVD risk, of management and care LYTES, Glucose, BUN, SCr, eGFR every IMMUNIZATIONS: TIV, PPV-23, and HBV (consider Tdap, VZ) 15 29 ie, CKD Stage 4 should be INITIATE decisions regarding 312 mo REINFORCE dietary prescription mL/min/1. 73 m2 considered equivalent kidney replacement therapy, CBC, TSAT, ferritin: every 36 mo RENAL-formulated MVI to a major CVD clinical event vascular access, and kidney BASELINE Ca / P / PTH / Alk Phos / PROTECT dominant (handwriting) arm transplant 25(OH)D; then repeat levels every VASCULAR access surgery evaluation DIAGNOSE and treat CVD risk 612 mo TARGETS factors and comorbid conditions EVALUATE for extraskeletal calcification Hb: 1012 g/dL, TSAT 20%, ferritin 100 ng/mL with oral ADJUST drug dosing for CKD stage UPC or UACR: every 312 mo and/or iv iron and/or ESA (darbepoetin or epoetin) Ca P: to normal range with P-binders (no Ca-based P-binders if vascular / valvular calcification) 25(OH)D: 30 ng/mL with vitamin D2 / D3 iPTH: to 130600 pg/mL with calcitriol or vitamin D analogs, if iPTH progressively increases NaHCO3: 2226 mEq/L with NaHCO3 therapy UPC: 0. 2 or UACR 30 mg/g with anti-RAAS therapy (consider stopping anti-RAAS therapy if GFR 20) HBV Ab titer: 10 mIU/mL COMMENTS EEaarrllyy r reeccooggnnitiitoionn, e, veavlaulautaiotino, na, n adn tdre tartematemnte onft CoKf DC KinD a i nm au lmtiduilstcidipislicniaprlyin faasryh ifoans, h dioencr, edaescerse masoersb imdiotyrb, idity, mortality, and healthcare costs. mortality, and healthcare costs. eGFRs 45 mL/min/1. 73 m2 in older persons (age 65 yo) may not require Nephrology evaluation in all cases, unless there is heavy proteinuria (UACR 0. 5 or UPC 0. 51. 0) or a progressive decline in eGFR ( 4 mL/min/1. 73 m2).
----------------------------------------------------------------------


======================================================================
CHUNK 210 of 647
======================================================================
ID: hfhs_ckd_v6_32
Content Type: general
Words: 460
Medical Entities: CKD,GFR,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
mortality, and healthcare costs. eGFRs 45 mL/min/1. 73 m2 in older persons (age 65 yo) may not require Nephrology evaluation in all cases, unless there is heavy proteinuria (UACR 0. 5 or UPC 0. 51. 0) or a progressive decline in eGFR ( 4 mL/min/1. 73 m2). PLAN OF CARE AND ACTION PLAN FOR CHRONIC KIDNEY DISEASE STAGES 14 Stage GFR Description Action Clinical Testing Treatment Considerations Normal RISK factors: age 60 years, obesity, SCREEN for general and specific BP monitoring: every 12 mo SMOKING cessation autoimmune disorders, DM, HTN, conditions FASTING lipid profile: every 12 mo WEIGHT reduction 90 kidney stones, ADPKD, prior SCREEN for CKD w/ eGFR LYTES, Glucose, BUN, SCr: DAILY aspirin: 81 mg once daily mL/min/1. 73 m2 AKI/ARF, UTIs, toxic drug exposures, INITIATE CKD risk reduction / eGFR every 12 mo TARGETS and FH of CKD intervention strategies UA for hematuria or proteinuria BP: 130/80 mmHg microscopic exam LIPIDS: LDL-C 70100 and TG 150 mg/dL GLUCOSE: FBS 130 mg/dL, HbA1C 7% 1 KIDNEY damage with normal GFR ESTABLISH etiology of CKD BP monitoring: every 12 mo CONSULT Nephrology if eGFR declines by 4 mL/min/yr (urinary, imaging or histologic DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, TARGETS 90 abnormalities) and comorbid conditions eGFR: every 12 mo BP: 130/80 mmHg mL/min/1. 73 m2 LIPID profile: every 12 mo LIPIDs: LDL-C 70100, TG 150 mg/dL; UA with microscopic evaluation non-HDL-C130 mg/dL UPC if non-diabetic: every 12 mo PROTEINURIA: UPC 0. 2; UACR 30 mg/g; UACR if diabetic: every 12 mo anti-proteinuric therapy with ACEI and/or ARB 2 KIDNEY damage with mild GFR ESTIMATE CKD progression rate BP monitoring: every 312 mo AVOID nephrotoxins; rule out AKI/ARF, eg, obstruction decrease (urinary, imaging or DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, TARGETS 60 89 histologic abnormalities) and comorbid conditions eGFR: every 612 mo BP: 130/80 mmHg mL/min/1. 73 m2 MOST lower GFRs in this range are CBC, reticulocyte ct, TSAT, LDL-C: 70100, TG 150, and non-HDL-C 130 mg/dL due to age-related GFR decline and ferritin if Hb 1012 g/dL: every 12 mo Hb: 1012 g/dL, TSAT 20%, and ferritin 100 ng/mL do not require evaluation, if no CONSIDER Ca / P / PTH / 25(OH)D UACR: 30 mg/g or UPC 0. 2 with anti-RAAS drug proteinuria is present evaluations UACR or UPC: every 312 mo 3A MODERATE decline of GFR ESTIMATE CKD progression rate BP monitoring: every 312 mo AVOID nephrotoxins; rule out ARF (eg, obstruction) COMPLICATIONS more frequent at DIAGNOSE and treat CVD risk factors LYTES, Glucose, BUN, SCr, NUTRITIONAL assessment at any time during CKD Stages 35 45 59 CKD Stage 3B as GFR (cid: 1) and comorbid conditions eGFR: every 312 mo TARGETS mL/min/1. 73 m2 to 45 mL/min/1. 73 m2.
----------------------------------------------------------------------


======================================================================
CHUNK 211 of 647
======================================================================
ID: hfhs_ckd_v6_33
Content Type: evidence
Words: 491
Medical Entities: CKD,GFR,proteinuria
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
73 m2 to 45 mL/min/1. 73 m2. KIDNEY imaging study, eg, US or CT CBC: Hb 10 g/dL every 13 mo until Hb Hb: 1012 g/dL, TSAT 20%, ferritin 100 ng/mL with oral PROTEINURIA is a serious CV risk CONSIDER Nephrology CONSULTATION 1012 g/dL; then every 36 mo and/or iv iron and/or erythropoiesis stimulating agent 3B factor and has prognostic TSAT and ferritin if Hb 13 g/dL (males) Ca P: to normal range with P-binders importance for progression of CKD or 12 g/dL (females) and after therapy (no Ca-based P-binders if vascular / valvular calcification) 30 44 BASELINE Ca / P / PTH / Alk Phos / 25(OH)D 25(OH)D: 30 ng/mL with vitamin D2 / D3 mL/min/1. 73 m2 Ca / P / PTH / Alk Phos, depending on iPTH: 130600 pg/mL with calcitriol or vitamin D analogs baseline and CKD progression if iPTH progressively increases 25(OH)D, depending on baseline and NaHCO3: 2226 mEq/L and titrate NaHCO3 therapy response to treatment UPC: 0. 2 or UACR 30 mg/g with anti-RAAS drug EVALUATE for extraskeletal calcification UPC or UACR: every 612 mo 4 SEVERE decline of GFR NEPHROLOGY consultation with transition BP monitoring: every 36 mo CKD-specific education: kidney replacement therapy modality MAJOR increase in CVD risk, of management and care LYTES, Glucose, BUN, SCr, eGFR every IMMUNIZATIONS: TIV, PPV-23, and HBV (consider Tdap, VZ) 15 29 ie, CKD Stage 4 should be INITIATE decisions regarding 312 mo REINFORCE dietary prescription mL/min/1. 73 m2 considered equivalent kidney replacement therapy, CBC, TSAT, ferritin: every 36 mo RENAL-formulated MVI to a major CVD clinical event vascular access, and kidney BASELINE Ca / P / PTH / Alk Phos / PROTECT dominant (handwriting) arm transplant 25(OH)D; then repeat levels every VASCULAR access surgery evaluation DIAGNOSE and treat CVD risk 612 mo TARGETS factors and comorbid conditions EVALUATE for extraskeletal calcification Hb: 1012 g/dL, TSAT 20%, ferritin 100 ng/mL with oral ADJUST drug dosing for CKD stage UPC or UACR: every 312 mo and/or iv iron and/or ESA (darbepoetin or epoetin) Ca P: to normal range with P-binders (no Ca-based P-binders if vascular / valvular calcification) 25(OH)D: 30 ng/mL with vitamin D2 / D3 iPTH: to 130600 pg/mL with calcitriol or vitamin D analogs, if iPTH progressively increases NaHCO3: 2226 mEq/L with NaHCO3 therapy UPC: 0. 2 or UACR 30 mg/g with anti-RAAS therapy (consider stopping anti-RAAS therapy if GFR 20) HBV Ab titer: 10 mIU/mL COMMENTS Early recognition, evaluation, and treatment of CKD in a multidisciplinary fashion, decreases morbidity, mortality, and healthc Aarlwe acyoss ctso. n sider reversible etiologies of acute kidney injury (AKI)/acute renal failure (ARF) at any stage of CKD, eg, urinary tract outlet obstruction, volume depletion, and adverse drug reactions. CKD Stage 5 patients require management by a nephrologist COMMENTS Baking soda is essentially NaHCO 3. It can be used to treat metabolic acidosis when NaHCO 3 is unavailable. 1 tsp of baking soda is equivalent to 23 mEq Na and HCO.
----------------------------------------------------------------------


======================================================================
CHUNK 212 of 647
======================================================================
ID: hfhs_ckd_v6_35
Content Type: recommendation
Words: 478
Medical Entities: CKD,GFR,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Two large trials (4D and AURORA) in ESRD patients demonstrated no cardiovascular or mortality benefits. A recent large, randomized controlled trial (SHARP) of CKD patients treated by simvastatin/ezetimibe demonstrated a positive effect of LDL-Clowering therapy in non-dialysisdependent CKD (eGFR, 27 mL/min/1. 73 m2) and ESRD patients. Major atherosclerotic events (combination of non-fatal MI, coronary death, ischemic stroke, or any revascularization event) were reduced by 17% compared to placebo. There was no effect on reducing the progression of CKD. Lipid-Lowering Strategies Lipid-lowering therapy in CKD is recommended, if TGs 200 mg/dL and/or LDL-C 100 mg/dL after 3 months of therapeutic lifestyle changes (TLC). Lipid evaluation should be conducted at initial evaluation, 23 months after treatment changes, and at least, annually afterward. Treatment goals are equivalent to ATP III criteria for CHD and/or diabetes. LDL-C should be lowered to 100 mg/dL, with an optional, more aggressive goal of 70 mg/dL. Statins are first-line therapy in CKD patients with elevated LDL-C, but there is no preferred agent. Ezetimibe may be added to statin therapy. Bile acid sequestrants and niacin may be used, if statins cannot be used. Lastly, the target for combined dyslipidemia in CKD (TGs 200 mg/dL; non-HDL-C (cid: 1)130 mg/dL) is a nonHDL-C 130 mg/dL (see CKD DYSLIPIDEMIA TREATMENT). Gemfibrozil is considered the fibric acid derivative (fibrates) of choice for CKD patients with elevated TGs. Fibrates must be administered cautiously with statins in CKD to avoid hepatic toxicity or myopathy. However, there is no evidence that statins induce a greater incidence of rhabdomyolysis in CKD patients, compared to the general population. Muscle pain from statin therapy is genetically predisposed and is not an effect of CKD. 40 Therapeutic Targets TG 150 mg/dL LDL-C 70100 mg/dL (diabetes: optional goal is 70 mg/dL) Non-HDL-C (cid: 1)130 mg/dL ( Total-C HDL-C) Evaluation TG, LDL-C Every 23 mo until treatment goal achieved, then every 612 mo Non-HDL-C Every 23 mo until treatment goal achieved, then every 612 mo Treatment Statin Dose that reduces LDL-C to (cid: 1)70100 mg/dL Gemfibrozil Limit to 300 mg twice daily for GFR 50 mL/min/1. 73 m2 COMMENTS Baseline hepatic transaminase levels should be determined before initiating statin therapy, after 23 months of treatment and periodically afterward. Bile acid sequestrants are contraindicated, if TGs are 400mg/dl. CKD dose adjustments: atorvastatin and pravastatin do not require dose adjustments. It is unknown, if dose adjustments are required for simvastatin and fluvastatin. Lovastatin: a 50% dose reduction recommended, if GFR 60 mL/min/1. 73 m2. Ezetimibe (Zetia): a cholesterol absorption inhibitor may be substituted, if statin therapy is not tolerated. Ezetimibe requires no dose adjustment at any level of CKD. Ezetimibe or colesevelam may be used to reduce statin doses, ie, potential benefit from using multiple low doses of drugs instead of a single high dose in CKD. Colesevelam is contraindicated, if TGs are increased. Non-HDL-C may be evaluated in the non-fasting state.
----------------------------------------------------------------------


======================================================================
CHUNK 213 of 647
======================================================================
ID: hfhs_ckd_v6_36
Content Type: recommendation
Words: 494
Medical Entities: CKD,proteinuria,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Ezetimibe or colesevelam may be used to reduce statin doses, ie, potential benefit from using multiple low doses of drugs instead of a single high dose in CKD. Colesevelam is contraindicated, if TGs are increased. Non-HDL-C may be evaluated in the non-fasting state. Renal dietitian consultation, if fasting TGs (cid: 2)500 mg/dL and/or elevated LDL-C. Triglycerides: if TGs (cid: 2)200 mg/dL, non-HDL-C is the therapeutic target. REFERENCES 1. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41(Suppl 3): S1, 2003 2. 4D Study: C Wanner, et al. N Engl J Med 353: 238, 2005 (4D Study) 3. BC Kwan, et al. J Am Soc Nephrol 18: 1246, 2007 4. AURORA: BC Fellstrm, et al. N Engl J Med 360: 1395, 2009 5. SHARP: Study of Heart and Renal Protection: Available at URL: sharp/; Accessed 12/31/2010 41 42 NUTRITION IN CHRONIC KIDNEY DISEASE by M. Cristina Kilates Introduction Malnutrition evolves during the progression of CKD with electrolyte abnormalities, muscle mass reduction, and depressed immunological function. These problems are compounded by anorexia that often accompanies advanced CKD and poor food choice(s), ie, lack of high biological value protein. Hypoalbuminemia and related nutritional disorders, including vitamin and mineral deficiencies are common. Preventing malnutrition through periodic visits to a trained renal nutritionist for nutrition surveillance is recommended and may avert complications. Protein Intake High biological value protein intake should be maintained, while sodium, potassium, and phosphorus intake are restricted. Protein targets vary depending on CKD Stage (see NUTRITIONAL TARGETS FOR CKD). A controlled protein diet slows the decline of kidney function more than one with more liberal protein intake. Fluid restriction should only be instituted, if hyponatremia is present. The reduction of sodium and phosphate intake is much more important than restricting fluid intake, unless there is hyponatremia (S Na 130 mEq/L). Monitoring A 24-h urine collection for sodium (goal 100 mEq Na per 24-h), urea nitrogen and creatinine is highly informative regarding the level of compliance with a dietary prescription. To preserve lean body mass, a supervised exercise regimen should be considered in conjunction with dietary recommendations. Patients with high BP are advised to follow a DASH (Dietary Approaches to Stop Hypertension) diet, which has proven efficacy. Modification of a DASH diet will be required in CKD patients because of its high potassium and phosphate contents. Lastly, patients with proteinuria at any stage of CKD should be referred to a Renal Dietitian/Nutritionist. NUTRITIONAL TARGETS FOR CKD STAGES 35 CKD Calories Na K P Protein Stage (kcal/kg/d) (mEq/d) (mEq/d) (mg/d) (g/kg/d) 3 3035 65 6001000 0. 75 4 3035 65 4060 6001000 0. 60. 8 5 Per dietitian 65 4060 6001000 0. 60. 8 General recommendation Renal-Formulated Multivitamins (MVIs) Nephplex Rx 1 tablet once daily Nephrocaps 1 capsule once daily Nephro-Vite Rx 100 1 tablet once daily Nephron FA 1 tablet twice daily (65 mg iron per tablet) 43 HIGH POTASSIUM-CONTAINING FOODS Avocado K-salt substitutes, eg, Lite Salt.
----------------------------------------------------------------------


======================================================================
CHUNK 214 of 647
======================================================================
ID: hfhs_ckd_v6_37
Content Type: recommendation
Words: 491
Medical Entities: CKD,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
60. 8 General recommendation Renal-Formulated Multivitamins (MVIs) Nephplex Rx 1 tablet once daily Nephrocaps 1 capsule once daily Nephro-Vite Rx 100 1 tablet once daily Nephron FA 1 tablet twice daily (65 mg iron per tablet) 43 HIGH POTASSIUM-CONTAINING FOODS Avocado K-salt substitutes, eg, Lite Salt. Baked beans Fresh peaches Bananas Mangoes Blenderized fruits and vegetables Milk Brans Nuts Broccoli Oranges, nectarines Brussels sprouts Papaya, pomegranate Cantaloupe Spinach Chocolate Tomatoes Dried beans, legumes, peas Sweet potatoes, white potatoes, yams Dried fruits Winter squashes (acorn, butternut, hubbard) HIGH PHOSPHORUS-CONTAINING FOODS Baked beans Nuts, nut butters Bran Organ meats Brown rice, wild rice Pizza Cheese Pancakes, waffles, biscuits Chocolate and chocolate drinks Processed meats: hot dogs, sausage, turkey Cola Sardines Ice cream Seeds Milk, milk mixes Whole grain breads Milk-based coffees and puddings Yogurt Food preservatives often contain unlabeled and unknown quantities of phosphate-rich preservatives and may contribute to hyperphosphatemia. COMMENTS Caution is advised during administration of combination drugs with K-sparing diuretics: amiloride, triamterene, ACEIs, ARBs, and ARAs. Renal nutritionist consultation is recommended at any stage or CKD. Renal-formulated MVIs may be combined with iron salts. REFERENCES 1. DASH: Available at URL: Accessed 12/31/2010 2. Nutritional management in diabetes and CKD: Available at URL: Accessed 12/31/2010 3. Dietary Potassium (K): Available at URL: Accessed 12/31/2010 4. L Murphy-Gutekunst. J Renal Nutr 20(1): e1, 2010 44 IMMUNIZATIONS IN CHRONIC KIDNEY DISEASE by Jerry Yee Introduction CKD patients are immunocompromised in CKD Stage 5 and ESRD; however, the degree of immunocompromise is less certain and documented in earlier stages. Nonetheless, CKD patients are immunized less frequently against influenza virus and S. pneumoniae than the general population. Influenza and pneumococcal vaccines may be co-administered. CKD patients should receive the following immunizations: a) Trivalent, inactivated influenza A/B (TIV) vaccine b) 23-valent polysaccharide pneumococcal (Pneumovax, PPV23) vaccine c) Hepatitis B virus (HBV) vaccine Hepatitis B Virus HBV vaccination is advised in patients with progressive CKD, and immunization in CKD Stage 4, pre-ESRD, is recommended because late Stage 5 vaccination produces lesser rates of seroconversion. In CKD Stage 5, antigen presenting cell and CD4 cell defects occur. HBVantibody responses to HBV are less intense and less durable. Immunocompetence, measured by achievement of an antibody titer 10 mIU/mL, occurs in just 5070% of ESRD patients. Hepatitis C virus (HCV) positive patients can be safely immunized against HBV. Lastly, booster vaccinations with tetanus toxoid, diphtheria, and acellular pertussis vaccines (Tdap) may be administered alone or co-administered with any of the vaccines listed below. HEPATITIS B VACCINES: DOSES AND SCHEDULES Group Recombivax HB Engerix B Dose Vol Schedule Dose Vol Schedule Age/CKD Stage (mcg) (mL) (mo) (mcg) (mL) (mo) 20 y. o. 3 doses: 4 doses: 10 IM 1. 0 20 1. 0 Stages 14 0, 1 6 0, 1, 2 6 2 1. 0 20 y. o. 3 doses: 4 doses: 40 IM 1. 0 40 at Stage 5 0, 1 6 0, 1, 2 6 1 site Abbreviations: IM, intramuscular.
----------------------------------------------------------------------


======================================================================
CHUNK 215 of 647
======================================================================
ID: hfhs_ckd_v6_38
Content Type: recommendation
Words: 466
Medical Entities: CKD,dialysis
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
3 doses: 4 doses: 10 IM 1. 0 20 1. 0 Stages 14 0, 1 6 0, 1, 2 6 2 1. 0 20 y. o. 3 doses: 4 doses: 40 IM 1. 0 40 at Stage 5 0, 1 6 0, 1, 2 6 1 site Abbreviations: IM, intramuscular. Special formulation (Recombivax HB Dialysis Formulation) COMMENTS HBV immunization: evaluate antibody titer 2 mo after last dose. If antibody titer 10 mIU/mL, repeat entire dosing series and determine antibody response after 14 mo. Combined hepatitis A/B vaccine (Twinrix) may be administered as a 3-dose series: 0, 1, and 6 mo. Healthcare workers who demonstrate an initial response to HBV immunization may be considered for a single booster dose after 5 years (Not FDA or NKF guideline). 45 Influenza Virus United States Renal Data System data revealed that Medicare patients with chronic kidney disease (CKD) were 5. 4 times more likely to receive an influenza vaccine versus employer group health plan patients with CKD (43% v 8%). The Agency for Healthcare Research and Quality advocates that CKD patients be vaccinated yearly in order to decrease morbidity and mortality related to influenza. TIV immunization is now comprised of 2 A one is H1N1 and 1 B virus strains and may be co-administered with pneumococcal vaccine. CKD/ESRD patients at risk for hepatitis A (eg, chronic liver disease, HCV, HIV, multiple sexual partners, homosexual males, and iv drug users) should be vaccinated with Hepatitis A vaccines (Havrix and Zaqta). Varicella zoster Varicella zoster (VZ) re-activation or infection may be precipitated by the immunosuppression that follows organ transplantation. VZ immunization is available as two live, attenuated virus vaccines (Zostavax, Varivax). These may be administered in CKD patients. Patients undergoing consideration as organ transplant recipients should, where applicable, receive VZ immunizations pre-transplantation. Vaccines FDA-approved vaccines that are commonly administered to CKD patients are briefly described below. S. pneumoniae Pneumovax 23 Single 0. 5-mL (25 mcg) IM (deltoid) injection. Alternative: subcutaneous injection is permitted. Revaccination with a single dose may be considered 5 years after the last dose in persons (cid: 1)65 y. o. who were 65 y. o. at the time of initial vaccination. Tetanus, diphtheria (Td); Tetanus, diphtheria and pertussis (Tdap) Td Dose 1 of initial series: 0. 5-mL IM injection, upper arm Doses 2 and 3: 48 wk between doses 1 and 2 and 612 mo between doses 2 and 3 Booster doses: 0. 5-mL IM injection every 10 years after initial series Tdap One dose is recommended for ages 1964 y. o. Trivalent Inactivated Influenza Vaccine TIV Single annual dose IM 46 COMMENTS Intranasal live, attenuated influenza virus vaccine (FluMist) is not FDA-approved for CKD patients. Oseltamivir phosphate (Tamiflu) and zanamivir (Relenza) neuraminidase inhibitors are not FDA-approved for CKD patients. HBV vaccines are contraindicated in persons with yeast allergy.
----------------------------------------------------------------------


======================================================================
CHUNK 216 of 647
======================================================================
ID: hfhs_ckd_v6_39
Content Type: recommendation
Words: 491
Medical Entities: CKD,GFR,dialysis
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Oseltamivir phosphate (Tamiflu) and zanamivir (Relenza) neuraminidase inhibitors are not FDA-approved for CKD patients. HBV vaccines are contraindicated in persons with yeast allergy. Pneumococcal polysaccharide vaccine (Pneumovax23): persons without CKD and (cid: 1)65 y. o. should receive a 1-time revaccination, if 65 y. o. at time of the initial vaccination and not revaccinated during the previous 5 years. REFERENCES 1. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): Available at URL: Accessed 01/15/2011 2. M Dinits-Pensy, et al. Am J Kidney Dis 46: 997, 2005 3. AT Kausz, et al. Adv Chronic Kidney Dis 13: 209, 2006 4. TJ Vachharajani. Semin Dial 17: 320, 2004 5. ACIP: Available at URL: 6. ACIP: 7. KDIGO Guideline: Available at URL: Accessed 01/08/2011 47 KIDNEY REPLACEMENT THERAPY by Jariatul Karim Lalathaksha Kumbar Introduction Anticipation of the need to initiate kidney replacement therapy (KRT) is paramount. Nearly 43% of CKD Stage5/ESRD patients have no pre-ESRD evaluation by a nephrologist and often begin KRT in-hospital via a hemodialysis (HD) catheter. In these cases, healthcare expenditures during the initial 3 months of ESRD therapy increase by an average of 30, 000 per patient. To prevent this untoward clinical scenario, advanced CKD Stage 4 patients should be referred to a vascular access surgeon at eGFR 20 mL/min/1. 73 m2 for timely planning of appropriate HD vascular access or peritoneal dialysis (PD) catheter placement. In the US, lack of timely (early) vascular access planning, type of medical care prior to onset of ESRD, and socioeconomic factors result in a disproportionately high proportion of patients beginning KRT with in-hospital HD via temporary, non-tunneled, non-cuffed HD catheters that are associated with significant and costly morbidity (infections, venous stenosis) and mortality. To offset this trend, in 1997 the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) Clinical Practice Guidelines recommended earlier referral of CKD patients to nephrologists to facilitate vascular access evaluation and construction to optimize clinical outcomes and costs. Timing of Kidney Replacement Therapy The decision to treat patients with CKD by KRT as kidney transplantation, peritoneal dialysis, or hemodialysis should be made collaboratively by patients and their healthcare team. KRT is an expensive government entitlement program: minimum annual per patient cost, 36, 000; annual average cost 77, 000. Recent data reveal that starting KRT early does not increase patient survival. Although CKD Stage 5 begins at eGFR 15 mL/min/1. 73 m2, KRT does not have to begin then, if the patient is well. The number of comorbidities that a patient has must be taken into consideration before initiating KRT. Patients 75 y. o. , particularly, if male, with multiple comorbidities managed conservatively fare just as well as those on dialysis because death versus dialysis is a competing survival risk. Therefore, conservative management, when chosen, focuses the shift from simply attempting to prolong life to providing quality of life and alleviation of symptoms. This includes optimization of all parameters associated with CKD care (see CHECKLIST).
----------------------------------------------------------------------


======================================================================
CHUNK 217 of 647
======================================================================
ID: hfhs_ckd_v6_40
Content Type: general
Words: 472
Medical Entities: CKD,dialysis
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Therefore, conservative management, when chosen, focuses the shift from simply attempting to prolong life to providing quality of life and alleviation of symptoms. This includes optimization of all parameters associated with CKD care (see CHECKLIST). Education An informed patient fares better than the non-informed one. CKD education entails information of various kidney replacement therapies: transplantation, PD, in-center HD, and home HD. Physical conditions such as vision and manual dexterity, motivational level to actively participate in care, and family/social circumstances all play roles in the decision-making process. CKD educational materials are widely distributed over the Internet. Patient advocacy groups have authored numerous, helpful informational materials written at an appropriate reading level (see CKD WEBSITES OF INTEREST). When adequately informed about ESRD modalities, 38% of CKD Stage 5 patients choose PD in comparison to 5% of patients who had not received more intensive ESRDmodality training. The provision of dedicated CKD education classes for patients and families, in conjunction with CKD clinics, has resulted in improved clinical outcomes, particularly in ESRD-modality training, vascular access placement, BP control, and anemia of CKD. 48 Peritoneal Dialysis Peritoneal dialysis (PD) is a viable option for most ESRD patients; however, it was chosen by just 10. 9% of ESRD patients who began ESRD care between 2005 and 2007. Peritoneal dialysis as a modality option was discussed with 61% of patients before initiation of dialysis. Instillation of a hypertonic glucose-containing solution via a trans-abdominal PD catheter provides uremic solute (diffusion) and excess sodium and water removal (convection). PD catheters should be implanted at least 4 weeks prior to the date of their anticipated use. BP and P control are superior with PD compared to conventional HD. PD involves diffusion of uremic solutes and electrolytes from capillaries lining the peritoneal membranes into the externally infused dialysate. The continual nature of PD is suited for heart failure patients and/or volume-dependent HTN. Contraindications to PD include extreme obesity, multiple abdominal surgeries, and recurrent peritonitis. Complications of PD catheters include peritonitis, catheter malfunction, and failure of PD due to membrane loss/fibrosis. Peritonitis can be treated with intra-peritoneal or iv antibiotics and may require catheter exchange. Catheter removal is absolutely indicated when pseudomonal, MRSA, or fungal peritonitis occurs. Hemodialysis About 92% of the incident dialysis patients in the United States undergo conventional HD, typically carried out thrice-weekly in a designated HD unit, ie, in-center dialysis, with typical treatment times of 34 h. Some centers offer nocturnal HD where patients sleep during treatment by slow, low-efficiency dialysis. Home HD is conducted in the home environment, 56 sessions weekly for 2. 53 h. Control of BP and phosphorus are superior with PD, nocturnal PD, and home HD compared to conventional thrice-weekly HD. Optimal HD requires a well-functioning vascular access and this can be provided via an autogenous AVF (arteriovenous fistulas), bioprosthetic AVG (arteriovenous grafts), or HD catheters.
----------------------------------------------------------------------


======================================================================
CHUNK 218 of 647
======================================================================
ID: hfhs_ckd_v6_42
Content Type: recommendation
Words: 486
Medical Entities: CKD,GFR,proteinuria,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Such adverse effects may occur in the context of AKI/ARF or in CKD. Caution is warranted when using any of the listed agents in CKD. Alternative therapies should be explored in each clinical circumstance and the risk-to-benefit ratio of any agent must be determined by the prescribing individual. The clinician is advised to determine all medications that require dose adjustments based upon GFR in steady-state conditions. Pharmacy consultation is advised to optimize drug dosing, particularly in cases of acute kidney injury. Acute Kidney Injury / Acute Renal Failure Azotemia: exenatide (Byetta) has been associated with AKI. Crystalluric tubular damage: acyclovir (Zovirax), indinavir (Crixivan), sulfadiazine, triamterene, triamterene/HCTZ combinations (Dyazide, Maxzide), topiramate (Topamax), and orlistat (Xenical). Decreased creatinine secretion: trimethoprim (Proloprim, Bactrim, Septra, Sulfatrim, Polyprim), probenecid (Benemid), spironolactone (Aldactone), amiloride (Midamor), triamterene (Dyrenium), pyrimethamine (Daraprim), salicylates, and cimetidine (Tagamet). GFR is not reduced, although eGFR will be lowered; BUN does not change. Decreased GFR: ACEIs and ARBs reduce efferent arteriolar resistance. ARBs produce less SCr elevations than ACEIs. Intratubular CaP precipitation: oral sodium phosphate solutions (OSPS) may induce AKI in CKD patients via intratubular calcium-phosphate precipitation with nephrocalcinosis and are contraindicated in CKD patients. OSPS include Visicoland Osmo-Prep. Intrarenal vasoconstriction with decreased GFR: NSAIDs, COX-1/-2, selective COX-2 inhibitors, and calcineurin inhibitors (CNIs, eg, cyclosporine, tacrolimus) may reduce GFR, promote sodium retention (edema), and aggravate hyperkalemia. Long-term use of CNIs can result in nephrotoxicity in 2560% of patients and is often associated with elevated blood concentrations underscoring the importance of monitoring CNI blood levels. Tubulointerstitial nephritis (Interstitial nephritis): This disorder may represent 917% of cases of in-hospital ARF and is often the etiology of AKI/ARF of unknown origin. The most common sign of acute tubulointerstitial nephritis is hematuria, although classically, leukocyte casts are associated with this disorder. Microscopic evaluation of the urine should be used to confirm this often missed disorder. Allergic antibiotic-associated interstitial nephritis is common. Lithium (Eskalith, Lithobid) is associated with tubulointerstitial nephritis and in some cases, nephrotic syndrome. Idiosyncratic reactions to NSAIDs may induce immune-mediated acute or chronic interstitial nephritis. 51 Idiosyncratic reactions to NSAIDs may induce interstitial nephritis, typically in association with minimal change disease and heavy proteinuria (see above). Acute interstitial nephritis that has not improved within 24 weeks, following withdrawal of the offending agent, may be empirically treated with a 30-d course of glucocorticoid steroids. Contrast-induced nephropathy (CIN): prophylactic volume expansion with sodium chlorideor sodium bicarbonate-based solutions reduces the incidence of AKI in non-edematous, stable CKD patients. Stage 35 patients (GFR 60 mL/min/1. 73 m2), with or without diabetes. Saline: Isotonic (normal) saline or isotonic sodium bicarbonate prophylaxis is recommended for non-diabetic and diabetic CKD patients. Hospitalized, non-edematous, hemodynamically stable CKD patients should receive an infusion of isotonic sodium bicarbonate or 0. 9% saline at 1 mL/kg bodyweight for up to 12 h before, during and 12 h after contrast administration. Drugs: stop diuretics (if feasible), NSAIDs, and metformin 48 h pre-contrast delivery.
----------------------------------------------------------------------


======================================================================
CHUNK 219 of 647
======================================================================
ID: hfhs_ckd_v6_43
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,dialysis,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Hospitalized, non-edematous, hemodynamically stable CKD patients should receive an infusion of isotonic sodium bicarbonate or 0. 9% saline at 1 mL/kg bodyweight for up to 12 h before, during and 12 h after contrast administration. Drugs: stop diuretics (if feasible), NSAIDs, and metformin 48 h pre-contrast delivery. Radiocontrast medium: isosmolal radiocontrast (iodixanol, Visipaque, 290 mOsm/kg) has reduced the risk of AKI/ARF in higher risk patients, ie, diabetes. Diabetes: glycemic control should be achieved prior to acute contrast delivery, eg, serum glucose 150 mg/dL. N-acetylcysteine (NAC): this agent has not been definitively proven to reduce the risk of developing radiocontrast-induced nephropathy. If used, administer 1200 mg po q-12 h for 4 doses: 1200 mg 13 h pre-contrast administration, 1200 mg 1 h pre-contrast and 1200 mg twice daily following contrast administration. Dialysis: dialysis/hemofiltration is not recommended as prophylaxis. ACEI or ARB therapy: withdrawal pre-contrast administration may be beneficial. Gadolinium (Gd): Gd-based contrast agent (GABCA) procedures, eg, MRI/MRA, are rarely associated with AKI. However, Gd-chelates used for MRI contrast enhancement, are associated with a fibrotic skin disorder, nephrogenic systemic fibrosis (NSF) that may also involve visceral organs. The risk of developing NSF is estimated at 14% in advanced CKD. Alternatives to Gdbased imaging studies should be aggressively sought in CKD Stages 4 and 5 and ESRD patients. Three GBCA, gadopentetate dimeglumine (Magnevist), gadodiamide (Omniscan), and gadoversetamide (Optimark) are contraindicated for patients with acute kidney injury (AKI) or severe CKD because NSF risk is deemed higher in these individuals. 4 GBCAs that are approved for MRIs carry new labeling explicitly warning of the risk of NSF associated with GBCA: gadofosveset trisodium (Ablavar, Vasovist); gadoxetate disodium (Eovist); gadobenate dimeglumine (Multihance); and gadoteridol (Prohance). Clinicians are advised to screen for AKI or severe CKD before GBCA administration and to monitor kidney function post-receipt of Gd-chelates. Serial hemodialyses to remove GBCA rapidly may be required in CKD Stages 4 and 5 patients and ESRD patients. NB: Gadodiamide and gadoversetamide may cause spurious hypocalcemia by interfering with total serum calcium assays. Avoid Ca measurements for several hours post-GBCA administration. 52 Hyperkalemia Decreased cellular K uptake: / blockers, eg, labetalol (Trandate, Normodyne) and nonselective -adrenergic blocking agents, eg, propranolol (Inderal, Inderal LA). Decreased renal K secretion: Anti-RAAS therapy with ACEIs and ARBs: ARBs produce less severe K elevations and reduce GFR less than ACEIs. Decreased distal nephron K secretion: Amiloride (Midamor), pentamidine (Pentam-300, Pentacarinat), triamterene (Dyrenium) and triamterene/HCTZ combinations (Dyazide, Maxzide), trimethoprim (Proloprim) and trimethoprim/sulfamethoxazole combinations (Bactrim, Septra, Sulfatrim, Polyprim). Interference with prostaglandin metabolism: NSAIDs, COX-1/-2 and selective COX-2 inhibitors decrease renal K secretion by interfering with prostaglandin metabolism, which produces intrarenal vasoconstriction. ARAs: Spironolactone (Aldactone) and epleronone (Inspra). High K-containing foods: Patients should be counseled on the avoidance of high-K containing foods (see NUTRITION IN CKD). COMMENTS Renal dietary consultation is advised for persistent hyperkalemia (K 5. 5 mEq/L) and/or when polystyrene sulfonate (Kayexelate) is considered for treatment of hyperkalemia. The routine use of polystyrene sulfonate is not recommended.
----------------------------------------------------------------------


======================================================================
CHUNK 220 of 647
======================================================================
ID: hfhs_ckd_v6_44
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
COMMENTS Renal dietary consultation is advised for persistent hyperkalemia (K 5. 5 mEq/L) and/or when polystyrene sulfonate (Kayexelate) is considered for treatment of hyperkalemia. The routine use of polystyrene sulfonate is not recommended. Rule out pseudohyperkalemia from elevated platelet counts, eg, 750, 000 plt/mm3, severe leukocytosis, eg, 50, 000 WBC/mm3, or most commonly, prolonged tourniquet time, before treating hyperkalemia. Consult Nephrology prior to initiating hyperkalemia therapy with polystyrene sulfonate (this compound may cause bowel perforation/necrosis). Mild hyperkalemia (K, 5. 05. 5 mEq/L) usually requires no treatment, and dietary potassium restriction is the primary therapy. Diabetic Kidney Disease Hypoglycemia: CKD decreases renal elimination of the active moiety or metabolite(s) of certain agents, thereby increasing the risk for hypoglycemia. The following agents may require dose reductions. Insulin is eliminated/metabolized by the kidney often requiring a dose reduction of insulin of 2550%. Meglitinides: nateglinide (Starlix) requires no dose adjustment in CKD, but repaglinide (Prandin) does require dose adjustment in CKD. Sulfonylureas: glipizide (Glucotrol), glyburide (Diabeta, Micronase); Glipizide is preferred in CKD as it lacks active metabolites (glyburide has active renally eliminated metabolites). Other: sulfonamide antibiotics, quinine, disopyramide, and gabapentin (Neurontin). 53 Fluid retention/Heart failure exacerbation: thiazolidinediones, eg, pioglitazone (Actos), rosiglitazone (Avandia) should be used cautiously in CKD. Other: DPP-IV inhibitors, eg, sitagliptin (Januvia) and saxagliptin (Onglyza) have a low-risk for hypoglycemia. Sitagliptin requires dose-adjustment in CKD. Metformin is generally contraindicated in moderate to severe CKD (see below). COMMENTS (cid: 1)-glucosidase inhibitors: acarbose (Precose) and miglitol (Glyset) do not cause hypoglycemia, but are not recommended for eGFR 25 mL/min/1. 73 m2 GLP-1 receptor agonists: exenatide (Byetta) is contraindicated for eGFR 30 mL/min/1. 73 m2; liraglutide (Victoza) may be preferred as it requires no dose adjustment in CKD. Metabolic Acidosis Bicarbonate loss in urine: Carbonic anhydrase inhibitors, eg, glaucoma therapy drugs: dorzolamide (Trusopt), dorzolamide/timolol (Cosopt), and brinzolamide (Azopt). Acetazolamide (Diamox) and methazolamide (Neptazane) dosages should be reduced in CKD and are ineffective at GFR 10 mL/min/1. 73 m2. Lactic acidosis: metformin hydrochloride (Glucophage XR, Fortamet, Riomet), and metformin-containing drug combinations: glyburide/metformin (Glucovance), glipizide/metformin (Metaglip), rosiglitazone/metformin (Avandamet), saxigliptin/metformin (Kombiglyze XR). Metformin is contraindicated, if GFR 50 mL/min/1. 73 m2, ie, SCr (cid: 1)1. 5 mg/dL in males or 1. 4 mg/dL in females in CKD or AKI. Stop metformin before iodinated radiocontrast delivery and hold for 48 h post-procedure. Restart drug after kidney function returns to baseline. Mitochondrial damage: nucleoside analogs, eg, zalcitabine (ddC, Hivid), didanosine (ddI, Videx), stavudine (d4T, Zerit), lamivudine (3TC, Epivir), abacavir (Ziagen), and tenofovir (TDF, Viread), alone or in combination with other anti-HIV drugs. 54 Neurotoxicity Extrapyramidal side effects: metoclopramide (Reglan) should be reduced by 2550% in CKD Stages 35 and only used short-term. Mental status changes/Neurotoxicity/Seizures: Acyclovir (Zovirax) and valacyclovir (Valtrex) should undergo total daily dose reductions of 5075% in CKD Stages 35. Cefipime (Maxipime): reduce total daily dose by 50% in CKD Stages 4 and 5. Meperidine hydrochloride (Demerol) metabolite, nor-meperidine, accumulates and can induce seizures; contraindicated in advanced CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 221 of 647
======================================================================
ID: hfhs_ckd_v6_45
Content Type: reference
Words: 492
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Mental status changes/Neurotoxicity/Seizures: Acyclovir (Zovirax) and valacyclovir (Valtrex) should undergo total daily dose reductions of 5075% in CKD Stages 35. Cefipime (Maxipime): reduce total daily dose by 50% in CKD Stages 4 and 5. Meperidine hydrochloride (Demerol) metabolite, nor-meperidine, accumulates and can induce seizures; contraindicated in advanced CKD. Neuropathy: Colchicine (Colcrys): relatively contraindicated in CKD and may induce myopathy and/or neuropathy. Use no more than 0. 6 mg daily in CKD Stages 4 and 5. Limit duration of use to 6 consecutive months. Nitrofurantoin (Macrodantin): absolute contraindication in CKD Stages 4 and 5 due to risk of irreversible peripheral neuropathy. Hepatotoxicity Hypersensitivity (DRESS syndrome): This syndrome usually develops 24 weeks after initiation of treatment with allopurinol when standard dosages (20400 mg/day) are administered to patients with CKD. Allopurinol (Zyloprim) should generally not be administered at total daily doses exceeding 200 mg in CKD Stages 35. Drug Rash with Eosinophilia and Systemic Symptoms 55 SELECTED AGENTS by Carol Moore Introduction A list of agents commonly used in CKD care follows, grouped by drug class. Alkali (Base) Therapy Sodium bicarbonate Indication: Alkali replacement therapy in CKD to prevent protein wasting, decrease bone demineralization, and increase vitamin D synthesis. Tablet: 325 mg (3. 87 mEq HCO) and 650 mg (179 mg Na; 7. 74 mEq HCO). 3 3 Initiate therapy, if HCO 3 22 mEq/L on two occasions, separated by (cid: 1)2 wk. CKD: 2346 mEq/d in 23 divided doses to provide 0. 52. 0 mEq HCO /kg/d to attain target 3 serum HCO 2226 mEq/L. 3 Do not co-administer with Ca-based P-binders or iron salts. Consult Nephrology, if HCO 3 22 mEq/L or NaHCO 3 therapy 46 mEq/d. Baking Soda Indication: Alkali replacement therapy in CKD to prevent protein wasting, decrease bone demineralization, and increase vitamin D synthesis. 1 tsp: 500 mg Na, 23 mEq HCO (3, 650-mg NaHCO tablets) 3 3 Initiate therapy, if HCO 3 22 mEq/L on two occasions, separated by (cid: 1)2 wk. CKD: 23 divided doses totaling 0. 52. 0 mEq HCO/kg/d to attain target HCO of 2226 mEq/L. 3 3 Do not co-administer with Ca-based P-binders or iron salts. Consult Nephrology, if HCO 3 22 mEq/L or NaHCO 3 therapy 46 mEq/d. Erythropoiesis-Stimulating Agents (ESAs) Begin ESA treatment of Anemia of CKD at Hb 10 g/dL, if there is no iron deficiency. The FDA target Hb range is 1012 g/dL. Iron stores should be replenished prior to initiation of therapy with an ESA. Consult a nephrologist for assistance in ESA dosing. The conversion rate of epoetin alfa to darbepoetin is 225260 Units of epoetin alfa to 1 mcg darbepoetin alfa. Darbepoetin alfa (Aranesp) Indication: Anemia of CKD; begin therapy at Hb 10 g/dL Single-dose vial: 25, 40, 60, 100, 150, 200, 300, and 500 mcg CKD: 40100 mcg subcutaneously every 14 wk (0. 45 mcg/kg/q wk) Therapy is initiated weekly and may be extended to longer intervals when Hb is stabilized. Consult nephrologist for assistance in appropriate dosing.
----------------------------------------------------------------------


======================================================================
CHUNK 222 of 647
======================================================================
ID: hfhs_ckd_v6_46
Content Type: reference
Words: 499
Medical Entities: CKD,dialysis
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
45 mcg/kg/q wk) Therapy is initiated weekly and may be extended to longer intervals when Hb is stabilized. Consult nephrologist for assistance in appropriate dosing. PACKAGE INSERT: Epoetin alfa (recombinant human erythropoietin; Epogen) Indication: Anemia of CKD; begin therapy at Hb 10 g/dL Single-dose vial: 2000, 3000, 4000, 10, 000, and 40, 000 Units Multi-dose vial: 20, 000 units (20, 000 Units per 1 or 2 mL) CKD: 10, 00040, 000 units subcutaneously every 14 wk (50100 Units/kg/wk) Consult nephrologist for assistance in appropriate dosing. PACKAGE INSERT: 56 Iron Therapy (on empty stomach) Iron therapy may be initiated at any level of hemoglobin. The degree and mode of replenishment depend on the degree of deficiency and tolerability of the patient to oral iron or iv iron therapies. Iron should be administered to replenish and maintain iron stores to the following levels: TSAT 20% and ferritin 100 ng/mL in CKD Stages 35 (ESRD: 200 ng/mL). Consult a nephrologist for assistance in appropriate dosing of parenteral iron and ESAs, which should not be initiated until the Hb is 10 g/dL. Oral formulations These agents should only be taken on an empty stomach. Take oral iron 2 h before or 4 h after antacids and at least 1 h after thyroid hormone. When effective at replenishing and maintaining iron stores, oral iron formulations are preferred in non-dialysis CKD patients. However, oral iron agents are tolerated poorly by many patients and also, the dose required to replenish iron stores is often greater than can be delivered in a timely fashion, thus necessitating parenteral iron. ESRD patients on chronic HD receive iv iron at HD and should not receive concomitant oral iron products. Any iron preparation, oral or iv, may be concurrently administered with an ESA. Ferrous sulfate Indication: Iron replacement and repletion therapy in CKD. Oral and liquid preparations with 100325 mg ferrous sulfate (20% elemental iron). CKD: typical dose is 12, 325 mg ferrous sulfate tablets, 3 times daily. Ferrous fumarate Indication: Iron replacement and repletion therapy in CKD. Oral and liquid preparations with 90324 mg ferrous fumarate (33% iron). CKD: typical dose is 12, 325 mg ferrous fumarate tablets, 3 times daily. Intravenous formulations Iron dextran, low molecular wt. (INFeD) Indication: Iron replacement and iron repletion therapy in CKD. Single-dose vial: 50 mg iron per 1 mL in 2or 10-mL vials CKD: 5001000 mg iron as 2 separate doses of 250500-mg iv, as required to replenish/maintain iron stores. Standard dilution: 5001000 mg iron in 2501000 mL of normal saline. Only FDA-approved as a 100-mg iv dose, following a 25-mg iv test dose. Anaphylactoid reaction rate is 0. 7%. PACKAGE INSERT: 57 Ferric gluconate (Ferrlecit) Indication: Iron replacement and iron repletion therapy in CKD Single-dose ampule: 62. 5 mg iron per 5 mL (12. 5 mg/mL) CKD: 5001000 mg iron as 125-mg dose infusions, as required to replenish/maintain iron stores. Undiluted, slow iv push: 125 mg iron over 10 min. Standard dilution for infusion is 125mg iron in 100 mL normal saline.
----------------------------------------------------------------------


======================================================================
CHUNK 223 of 647
======================================================================
ID: hfhs_ckd_v6_47
Content Type: reference
Words: 496
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
5 mg iron per 5 mL (12. 5 mg/mL) CKD: 5001000 mg iron as 125-mg dose infusions, as required to replenish/maintain iron stores. Undiluted, slow iv push: 125 mg iron over 10 min. Standard dilution for infusion is 125mg iron in 100 mL normal saline. Delivery rate not to exceed 250 mg iron over 60 min. Product is FDA approved in ESRD as a 125-mg dose iv. PACKAGE INSERT: Iron sucrose (Venofer) Indication: Iron replacement and iron repletion therapy in CKD. Single-dose vial: 100 mg iron per 5 mL (20 mg/mL) CKD: 5001000 mg iron as 100300-mg infusions, as required to replete/maintain iron stores. Undiluted slow iv push: 100200 mg over 25 min Standard dilution for infusion is 100 mg iron in 100 mL normal saline Delivery rate not to exceed 150 mg iron over 60 min, ie, 300 mg/2-h Product is FDA-approved for CKD Stages 35, including ESRD PACKAGE INSERT: venofer. com/VenoferHCP/images/IN2340%20Rev%2010_05. pdf Ferumoxytol (Feraheme) Indication: Iron replacement and iron repletion therapy in CKD Single-dose vial: 510 mg iron per 17 mL (30 mg/mL) CKD: 510 mg iron IV with a second 510mg dose IV 3-8 days later, as required to replete/maintain iron stores. No test dose is required. Undiluted slow iv push: 510 mg in (cid: 1)17 seconds. Delivery rate not to exceed 30 mg per second. Product is FDA-approved for CKD Stages 35, including ESRD. Ferumoxytol may affect the diagnostic ability of MRI for up to 3 mo. Gd-based studies should be conducted prior to ferumoxytol administration PACKAGE INSERT: Phosphorus Binders (always taken with meals) Calcium acetate (PhosLo) Indication: P-binder therapy in CKD GelCap or tablet: 667 mg (25% elemental Ca/169 mg elemental Ca) CKD: 13 capsules taken with meals up to 3 times daily. Consult Nephrology, if daily dose exceeds 9 GelCaps. FDA approved for CKD Stage 5 58 Calcium carbonate (Tums and others) Indication: P-binder therapy in CKD Multiple preparations: 4001250 mg (40% is elemental Ca) per unit dose CKD: 500 mg elemental Ca taken with meals up to 3 times daily. Sevelamer hydrochloride (Renagel) Sevelamer carbonate (Renvela) Indication: P-binder therapy in CKD Renagel Tablet: 400 mg or 800 mg tablets Renvela Tablet: 800 mg tablet or Renvela Powder: 0. 8 g or 2. 4 g packets CKD: 8002400 mg taken with meals up to 3 times daily. Consult Nephrology, if daily sevelamer hydrochloride dose is 4800 mg. PACKAGE INSERT: renagel. com/docs/renagel_pi. pdf PACKAGE INSERT: renvela. com/docs/renvela_PI. pdf FDA-approved for CKD Stage 5. Lanthanum carbonate (Fosrenol) Indication: P-binder therapy in CKD Tablet: 500, 750, and 1000 mg tablets CKD: 5001000 mg taken with meals up to 3 times daily. Consult Nephrology, if daily lanthanum carbonate dose is 3750 mg. PACKAGE INSERT: FDA-approved for CKD Stage 5. COMMENTS Do not take Ca-based P-binders with iron salts or NaHCO 3. Calcium carbonate is not FDA-approved for use as a P-binder. Dietary and prescribed elemental Ca should not exceed 2000 mg daily. Ca-based binders should not be initiated in those with a Ca 10.
----------------------------------------------------------------------


======================================================================
CHUNK 224 of 647
======================================================================
ID: hfhs_ckd_v6_48
Content Type: recommendation
Words: 497
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
COMMENTS Do not take Ca-based P-binders with iron salts or NaHCO 3. Calcium carbonate is not FDA-approved for use as a P-binder. Dietary and prescribed elemental Ca should not exceed 2000 mg daily. Ca-based binders should not be initiated in those with a Ca 10. 2 mg/dl or where there is evidence of vascular calcification. Consult Nephrology, if prescribed elemental Ca 1500 mg, Corr Ca 10. 2 mg/dL, or P 4. 6 mg/dL. Vitamin D Rationale for vitamin D treatment in CKD is to replenish vitamin D stores, not to suppress PTH. Ergocalciferol (D2 Calciferol, Drisdol); Indication: Nutritional vitamin D deficiency, eg, 25(OH)D level 30 ng/mL Softgel: 1. 25 mg (50, 000 IU) CKD: 50, 000 IU once weekly 4 and once monthly 8, if 25(OH)D 15 ng/mL and 50, 000 IU once monthly 6, if 25(OH)D is 1530 ng/mL unless Corr Ca is 9. 5 g/dL and/or P 4. 6 mg/dL. Note, longer durations of weekly vitamin D therapy may be required. Monitor levels every 3 mo, then continue once weekly or monthly dosing as determined by clinical circumstances and vitamin D levels. 59 Cholecalciferol (D3) Indication: Nutritional vitamin D deficiency, eg, 25(OH)D level 30 ng/mL, Tablet: 1000 IU, 2000 IU, 1750 IU or Softgel: 1000 IU, 2000 IU, and 5000 IU, Renally formulated vitamin preparation (Vital-D-Rx) contains 1750 IU cholecalciferol. CKD: 17505000 IU once daily. Vitamin D3 1750 IU once daily (cid: 1) Vitamin D2 50, 000 IU monthly). Active Vitamin D Sterols Active vitamin D sterols should only be initiated when 25(OH)D level is 30 ng/mL, with elevated iPTH. Consult nephrologist, if PTH remains elevated after 3 months of therapy. In CKD, vitamin D has rarely caused hypercalcemia at recommended doses. ESRD patients generally receive active vitamin D sterols (see Comments, p. 35). Calcitriol 1, 25(OH) 2 D3; Rocaltrol Indication: Prevention and treatment of SHPT in CKD Stages 35. Capsule: 0. 25 and 0. 5 mcg. Intravenous Solution: 1 mcg/mL or 2 mcg/mL vial. CKD Stage 3: PTH 70 pg/mL: 0. 25-0. 5 mcg once daily with monitoring of Corr Ca and P every 2 wk initially. CKD Stage 4: PTH 110 pg/mL: 0. 250. 50 mcg once daily with monitoring of serum Corr Ca and P every 2 wk initially. CKD Stage 5: If PTH 150 pg/mL: Initiate 0. 5 mcg per HD (titrated to goal PTH, maximal ESRD dose, 2 mcg/HD) with monitoring of serum Corr Ca and P every 2 wk initially. PACKAGE INSERT: rocheusa. com/products/rocaltrol/pi. pdf Doxercalciferol 1(OH)D2; Hectorol Indication: Prevention and treatment of SHPT in CKD Stages 35. Capsule: 0. 5, 1. 0, and 2. 5 mcg capsule. Intravenous Solution: 2 mcg/mL vial. Maximum daily dose in CKD Stage 3 or 4: 3. 5 mg. CKD Stage 3: iPTH 70 pg/mL: 1. 0 mcg once daily with increases of 0. 5 mcg and monitoring of serum Corr Ca and P every 2 wk initially. CKD Stage 4: iPTH 110 pg/mL: 1. 0 mcg once daily with increases of 0.
----------------------------------------------------------------------


======================================================================
CHUNK 225 of 647
======================================================================
ID: hfhs_ckd_v6_49
Content Type: reference
Words: 499
Medical Entities: CKD
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
5 mg. CKD Stage 3: iPTH 70 pg/mL: 1. 0 mcg once daily with increases of 0. 5 mcg and monitoring of serum Corr Ca and P every 2 wk initially. CKD Stage 4: iPTH 110 pg/mL: 1. 0 mcg once daily with increases of 0. 5 mcg and monitoring of serum Corr Ca and P every 2 wk initially. CKD Stage 5: iPTH 150 pg/mL: Initiate 12 mcg per HD (titrated to goal PTH, ESRD maximum dose, 8 mcg per HD treatment) with monitoring of serum Corr Ca and P every 2 wk initially. PACKAGE INSERT: hectorol. com//media/Files/HectorolUS/Hectorol%20Capsule%20PI%20 Text_2006-01. pdf 60 Paricalcitol 19-nor-1-OH 2 D2; Zemplar Indication: Prevention and treatment of SHPT in CKD Stages 35. Capsule: 1. 0, 2. 0, and 4. 0 mcg capsule. Intravenous Solution: 2 mcg/mL and 5 mcg/mL vial. CKD Stages 34: iPTH (cid: 1)500 pg/mL: 1. 0 mcg once daily or 2. 0 mcg 3 times weekly, with dose increases of 1. 0 mcg daily and monitoring of serum Corr Ca and P every 2 wk. iPTH 500 pg/mL: 2. 0 mcg once daily or 4. 0 mcg 3 times weekly, with dose increases of 1. 0 mcg daily and monitoring of serum Corr Ca and P every 2 wk. CKD Stage 5: If iPTH 150 pg/mL: Initiate 12 mcg per HD (titrated to goal iPTH, ESRD maximum dose 15 mcg per HD treatment) with monitoring of serum Corr Ca and P every 2 wk, initially. PACKAGE INSERT: rxabbott. com/pdf/Zemplarcappi. pdf Calcimimetics Cinacalcet (Sensipar) Indication: Treatment of SHPT in ESRD. Tablet: 30, 60, and 90 mg tablet. Maximum daily dose: 180 mg. CKD Stage 5: Initiate 30 mg once daily (titrated every 24 wk to goal PTH) with ESRD monitoring of serum Corr Ca and P every 2 wk. a) Initiate cautiously in patients with Ca 8. 4 mg/dL. b) Monitor frequently for hypocalcemia during therapy. c) PTH should only be drawn 8 h after dose is taken. PACKAGE INSERT: pi. amgen. com/united_states/sensipar/sensipar_pi_hcp_english. pdf Renal-Formulated Multivitamins (MVIs) Non-iron containing formulations: ESRD patients should be prescribed non-iron containing formulations as they receive iv iron at HD. ESRD patients should take their vitamin in the evening. Renal Softgels, NephPlex Rx, Nephrocaps Nephro-Vite Rx: 1 tablet once daily. Indication: Vitamin supplementation in CKD Stages 35. Tablet/Softgel: B vitamins, vitamin C 4060 mg and folic acid 1 mg. Renal Vital-Rx for CKD: 1 tablet once daily. Indication: Vitamin supplementation in CKD Stages 35, with vitamin D. Tablet: 1750 IU cholecalciferol (D3), B vitamins, and folic acid 1 mg. 61 Iron-containing formulations Nephron FA for CKD: 1 tablet twice daily. Indication: Vitamin supplementation in CKD Stages 35, with iron deficiency. Tablet: B vitamins, vitamin C 40 mg, folic acid 1 mg, sodium docusate 75 mg, and ferrous fumarate 200 mg (66 mg elemental iron). Niferex for CKD: 1 capsule once daily. Indication: Vitamin supplementation in CKD Stages 35, with iron deficiency. Tablet: B 25 mcg, folic acid 1 mg, and iron polysaccharide complex (150 mg elemental iron).
----------------------------------------------------------------------


======================================================================
CHUNK 226 of 647
======================================================================
ID: hfhs_ckd_v6_51
Content Type: reference
Words: 487
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Coding should be applied as specifically as possible, with appropriate utilization of 4th and 5th digits. For example, codes are specific for types 1 and 2 diabetes and their complications. Diabetic complications are assigned 4th digits (250. x), and the degree of glycemic control is assigned a 5th digit (250. xx). Diagnoses of electrolyte disorders should be completely spelled out, ie, hyponatremia and hyperkalemia must not be documented with shorthand forms or symbols: hyponatremia must be used instead of Na and hyperkalemia must be used instead of K. Lastly, symptoms and signs of CKD also have specific codes, eg, dysuria, hematuria, nocturia, tenesmus, etc. 63 CKD Codes ICD-9-CM codes for CKD have been reclassified and parallel clinical stratification of CKD. Before 3 months, use the ARF code. After 3 months of kidney disease, a CKD Stage-specific code should be used. The invalid Code 585 has been replaced by CKD Stage-specific codes, 585. 1585. 6 and 585. 9 (see Tables). Specifically, code 585. 5 denotes CKD Stage 5, but not ESRD (585. 6) or CKD, unspecified (585. 9). If CKD results from systemic illness, that disorder is coded first. For example, a hypertensive SLE patient with diffuse proliferative glomerulonephritis of 5 months duration and laboratory findings: SCr 2. 5 mg/dL, GFR 43 mL/min/1. 73 m2, BP 153/90 mmHg, iPTH 220 pg/mL, 25(OH)D 18 ng/mL, Hct 29%, and UPC 5. 3, is coded as follows. Systemic disorder: SLE (710. 0); Etiology, proliferative glomerulonephritis (581. 0) and CKD Stage 3 (585. 3). Complications: benign HTN of CKD (403. 1x), secondary hyperparathyroidism of renal origin (588. 81), hypovitaminosis D, unspecified (268. 9), anemia of CKD (285. 21), and proteinuria (791. 0). Hypertension Codes Codes for HTN are grouped as 401405. When documenting HTN, the adjective benign or malignant should always precede the diagnosis of HTN. Primary (essential or benign) HTN without CKD is coded 401. 9. However, if high BP is the cause of CKD, benign HTN of CKD often termed hypertensive nephrosclerosis (403. 1x) is coded first followed by a CKD Stagespecific code. For example, an individual with HTN for 20 years, GFR 50 mL/min/1. 73 m2, and microalbuminuria should be assigned codes 403. 10, 585. 3, and 791. 0. If HTN follows the onset of diabetic CKD and is not malignant (asymptomatic, not requiring hospitalization or associated with acute target organ damage), then the code for benign hypertension associated with CKD Stages 15 but not ESRD (403. 10) should follow coding of the primary disorder with a CKD Stage code (eg, 250. 40, 403. 10, and 585. x). In this case, the diabetic nephropathy code (250. 4x) is followed by the benign HTN of CKD code (403. 10), and the CKD stage code (585. x). Hypertensive nephrosclerosis cannot be coded concurrent with primary hypertension (401. 9) or secondary hypertension (405. 0405. 9). Generalized or regional atherosclerosis often accompanies hypertension and these disorders can also be coded when actively managed.
----------------------------------------------------------------------


======================================================================
CHUNK 227 of 647
======================================================================
ID: hfhs_ckd_v6_52
Content Type: recommendation
Words: 492
Medical Entities: CKD,proteinuria,albuminuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
10), and the CKD stage code (585. x). Hypertensive nephrosclerosis cannot be coded concurrent with primary hypertension (401. 9) or secondary hypertension (405. 0405. 9). Generalized or regional atherosclerosis often accompanies hypertension and these disorders can also be coded when actively managed. However, coding here may be more appropriately coded as unspecified hypertension, with CKD (403. 90, 403. 91). CKD Complication Codes This section describes under-coding of CKD-associated complications. Mineral, electrolyte and acid-base disturbances of CKD are often diagnosed and managed, but not coded. Hypotonicity/hyponatremia, hypertonicity/hypernatremia, dyskalemias, dyscalcemias, phosphorus disorders, and acid-base disturbances should be coded when present, appropriately documented and addressed in the treatment plan (see above). Hyperuricemia is coded as abnormal blood chemistry (790. 6) and is frequent in CKD, but it does not define gout (274. 0274. 9) or uric acid stone disease (274. 11). 64 CKD Code Omissions Coding omissions are frequent in CKD. For example, the codes for hypertensive heart and CKD (404. x) are underutilized. In addition, all UTIs (599. 0) should be coded concurrently with organism-specific codes (eg, E. coli 482. 2). Lastly, parenchymal abnormalities such as cysts (acquired 593. 2; congenital 753. 10, 753. 11; ADPKD 753. 13) or agenesis/dysgenesis (753. 0) and dysplasia (753. 15) have specific codes, but are often not coded at all. COMMENTS Evaluation and Management coding of CKD should be internally reviewed at each institution and with respective healthcare payors. ICD-9-CM will eventually be phased out in the United States. ICD-10-CM is a more complicated system that is substantially more robust in its descriptive capabilities. The codes described in this section will no longer be applicable at the time of ICD-10-CM implementation. REFERENCES H Quan, et al. Med Care 43: 1130, 2005 65 CHRONIC KIDNEY DISEASE DIAGNOSTIC CODES Disorder Code Comment Acute Renal Failure (ARF, AKI) 584. 9 Excludes any CKD Code CKD, Stages 15 585. x x 15 for CKD Stages 15 Chronic kidney replacement therapy CKD at end-stage renal disease 585. 6 initiated, eg, HD, CAPD, kidney (ESRD) transplantation (add V42. 0) CKD, w/o established etiology. CKD, UNSP 585. 9 Excludes ARF (584. 9) Kidney failure, UNSP (not from Acuity/chronicity and etiology of kidney 586 pregnancy, HTN) failure are unknown Renal sclerosis, UNSP 587 Implies small kidneys Impaired kidney function, NOS 588. 9 See kidney failure, UNSP (586) Small kidney, unilateral 589. 0 By confirmatory imaging study Small kidneys, bilateral 589. 1 By confirmatory imaging study Small kidney, NOS 589. 9 By confirmatory imaging study Anemia of CKD 285. 21 EPO Level Not Recommended Excludes anemia of CKD (285. 21) and anemia Anemia of other chronic disease 285. 29 of malignancy (285. 22) In CKD, iron deficiency is TSAT 20% and/or Anemia, iron deficiency 280. 9 ferritin 100 ng/mL Nephrotic s. (nephrosis), from Code first underlying disease, eg, 581. 81 systemic disorder type 2 diabetes mellitus (250. 4 x) Albuminuria/proteinuria, Nephrotic s. (nephrosis), NOS 581. 9 hypercholesterolemia and edema CKD-MBD manifested as osteitis, Renal osteodystrophy (ROD) 588.
----------------------------------------------------------------------


======================================================================
CHUNK 228 of 647
======================================================================
ID: hfhs_ckd_v6_53
Content Type: evidence
Words: 498
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
9 ferritin 100 ng/mL Nephrotic s. (nephrosis), from Code first underlying disease, eg, 581. 81 systemic disorder type 2 diabetes mellitus (250. 4 x) Albuminuria/proteinuria, Nephrotic s. (nephrosis), NOS 581. 9 hypercholesterolemia and edema CKD-MBD manifested as osteitis, Renal osteodystrophy (ROD) 588. 0 osteomalacia, osteoporosis, sclerosis Secondary HPT, renal origin 588. 81 iPTH 70 pg/mL at any CKD Stage Other specified disorder 588. 89 Result of impaired function Vitamin D deficiency, UNSP 268. 9 25(OH)D level 30 ng/mL Diabetes, Type 1 w/ CKD, 250. 41 Add CKD Stage-specific code (585. x) Controlled glycemia DM, Type 1 w/ CKD and 250. 43 Add CKD Stage-specific code (585. x) uncontrolled glycemia DM, Type 2 w/ CKD and 250. 40 Add CKD Stage-specific code (585. x) controlled glycemia DM, Type 2 w/ CKD and 250. 42 Add CKD Stage-specific code (585. x) uncontrolled glycemia x 0 cholesterol; 1 triglyceride; Dyslipidemia 272. x 2 mixed (cholesterol and triglyceride) x 1 fasting glucose; 9 non-fasting glucose, Glucose, elevation; hyperglycemia 790. 2 x NOS Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; HTN, hypertension; PKD, polycystic kidney disease; NOS, not otherwise specified; ULN, upper limit normal; UNSP, unspecified. 66 CHRONIC KIDNEY DISEASE DIAGNOSTIC CODES Disorder Code Comment Normal GFR w/ No Proteinuria and No Benign/Essential HTN w/ No CKD 401. 9 Hematuria Malignant HTN CKD, Stages 14 or 403. 00 Add CKD Stage-specific code (585. x) UNSP Malignant HTN CKD, Stage 5 or 403. 01 Add CKD Stage-specific code (585. x) ESRD Benign HTN CKD, Stages 14 or 403. 10 Add CKD Stage-specific code (585. x) UNSP Benign HTN CKD Stage 5 or ESRD 403. 11 Add CKD Stage-specific code (585. x) Add CKD Stage-specific code (585. x); UNSP HTN CKD, Stages 14 403. 90 unknown, if malignant or benign Add CKD Stage-specific code (585. x); UNSP HTN CKD, Stage 5 or ESRD 403. 91 unknown, if malignant or benign Hypertensive heart and kidney Add CKD Stage-specific code (585. x); refer 404. xx disease to ICD-9-CM (Section 404) Diagnosis established by imaging study. Benign renovascular HTN 405. 11 Excludes 405. 19. UNSP HTN, secondary 405. 9 Excludes essential HTN (401. 9) Include with diabetes and CKD Stages 15 Benign HTN, secondary, not 405. 19 and ESRD, Excludes 403. xx. renovascular Excludes renovascular origin (405. 11). Hyperaldosteronism, UNSP 255. 10 HTN, w/o a formal, prior diagnosis Incidental or transient finding; use for 796. 2 of HTN white coat HTN Infectious Pyelonephritis 590. x x 0 chronic disorder; 1 acute Other specified pathological Glomerulonephritis or interstitial nephritis 583. 89 kidney lesion/abnormality not specified elsewhere Cystic kidney disease, acquired 593. 2 Excludes codes 753. 1, 753. 13 Cystic kidney disease, NOS 753. 10 Excludes codes 593. 2, 753. 13 ADPKD, PKD 753. 13 Excludes codes 593. 2, 753. 10 Calculus (Stone), Kidney; Excludes stone in bladder, pelvis and/or 592. 0 Nephrolithiasis ureters Calculus, ureter 592. 1 Includes stone in pelvis or ureter Calculus, uric acid 274. 11 Excludes 592. 0 Renal colic 788. 0 Symptom code Hyperuricemia 790.
----------------------------------------------------------------------


======================================================================
CHUNK 229 of 647
======================================================================
ID: hfhs_ckd_v6_54
Content Type: recommendation
Words: 495
Medical Entities: CKD,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
13 ADPKD, PKD 753. 13 Excludes codes 593. 2, 753. 10 Calculus (Stone), Kidney; Excludes stone in bladder, pelvis and/or 592. 0 Nephrolithiasis ureters Calculus, ureter 592. 1 Includes stone in pelvis or ureter Calculus, uric acid 274. 11 Excludes 592. 0 Renal colic 788. 0 Symptom code Hyperuricemia 790. 6 Abnormal blood chemistry Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; HTN, hypertension; PKD, polycystic kidney disease; NOS, not otherwise specified; ULN, upper limit normal; UNSP, unspecified. 67 CHRONIC KIDNEY DISEASE DIAGNOSTIC CODES DISORDER CODE COMMENT DISORDER OF MAGNESIUM 275. 2 HYPOOR HYPERMAGNESEMIA Phosphorus/phosphate 275. 3 Hypoor hyperphosphatemia Calcium 275. 4x x 1 hypocalcemia; 2 hypercalcemia Potassium 276. x x 7 hyperkalemia; 8 hypokalemia Sodium 276. x x 0 hypernatremia; 1 hyponatremia Chloride 276. 9 Hypoor hyperchloremia Acidosis 276. 2 Metabolic and/or respiratory Alkalosis 276. 3 Metabolic and/or respiratory Acid-Base disorder, mixed 276. 4 Acidosis and/or alkalosis Salt and/or water Loss, Volume depletion, UNSP 276. 50 w/ or w/o dehydration Dehydration Perform orthostatic vital signs for (complication/comorbid 276. 51 payment; see volume depletion (276. 50, condition) 276. 52) Hypovolemia, volume depletion 276. 52 Volume depletion w/ or w/o dehydration Edema, renal origin without heart Excludes edema from heartand/or liver 276. 6 failure disorder, eg, cirrhosis (782. 3) Edema, non-renal origin 782. 3 Edema from heart failure or cirrhosis Hypotension, orthostatic 458. 0 Excludes hypotension (458. 9) Hypotension, low BP 458. 9 Excludes volume depletion (276. 50) UTI UNSP; 599. 0 Clinical or Lab Diagnosis Non-Candida species Code 599. 6 is invalid; Excludes BPH w/ Urinary tract obstruction, UNSP 599. 60 obstruction (600. 01) Hematuria, UNSP 599. 70 Symptom, positive dipstick Hematuria, gross 599. 71 Patient-related symptom Hematuria, microscopic 599. 72 Hematuria confirmed by microscopy Urinary retention, NOS 788. 20 Symptom code Incomplete bladder emptying 788. 21 Symptom code x 1 frequency; 2 polyuria; Urinary symptoms 788. 4x 3 nocturia x 0 protein; 2 hemoglobinuria; Urinalysis, abnormal dipstick or 791. x 5 glucose; 6 ketones; and 7 cells or casts; microscopic evaluation Excludes hematuria (599. 7) Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; HTN, hypertension; PKD, polycystic kidney disease; NOS, not otherwise specified; ULN, upper limit normal; UNSP, unspecified. 68 CKD WEBSITES OF INTEREST American Association of Kidney Patients: American Kidney Fund: American Society of Nephrology: American Society of Hypertension: American Society of Pediatric Nephrology: Centers for Medicare and Medicaid Services: Dietary Approaches to Stop Hypertension (DASH): Greenfield Health Systems: Hypertension Online: Immunizations: International Society of Nephrology: Kidney Disease: Improving Global Outcomes (KDIGO): National Anemia Action Council: National Kidney Disease Education Program: National Kidney Foundation: National Kidney Foundation: National Kidney Foundation of Michigan: Nephron Information Center: Renal Physicians Association: United States Renal Data System Coordinating Center: COMMENTS TO AUTHORS Please direct comments regarding this publication to The Editors by Email: Jerry Yee (JYee1Hfhs. Org) Gregory Krol (GKrol1Hfhs. Org) 69 WEBSITE MANAGEMENT by Gerard Zasuwa Updated editions of CHRONIC KIDNEY DISEASE (CKD): CLINICAL PRACTICE RECOMMENDATIONS FOR PRIMARY CARE PHYSICIANS AND HEALTHCARE PROVIDERS A COLLABORATIVE APPROACH (EDITION 6.
----------------------------------------------------------------------


======================================================================
CHUNK 230 of 647
======================================================================
ID: hfhs_ckd_v6_55
Content Type: recommendation
Words: 456
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
Org) Gregory Krol (GKrol1Hfhs. Org) 69 WEBSITE MANAGEMENT by Gerard Zasuwa Updated editions of CHRONIC KIDNEY DISEASE (CKD): CLINICAL PRACTICE RECOMMENDATIONS FOR PRIMARY CARE PHYSICIANS AND HEALTHCARE PROVIDERS A COLLABORATIVE APPROACH (EDITION 6. 0) can be obtained from the Greenfield Health Systems website in Adobe portable document format (pdf). GHSRENAL. COM/CKD/HFHS_CKD_GUIDELINES_V6. 0. PDF (Webmaster: Gerard Zasuwa) PURCHASING INFORMATION JERRY YEE, MD HENRY FORD HOSPITAL DIVISION OF NEPHROLOGY AND HYPERTENSION 2799 WEST GRAND BLVD. , CFP-514 DETROIT, MI 482022689 EMAIL: JYEE1HFHS. ORG Glomerulus III: Architecture Pedro Cortes IF LOST, PLEASE RETURN TO THE OWNER: the ghosts of dead patients that haunt us do not ask why we did not employ the latest fad of clinical investigation. They ask us, why did you not test my urine? SIR ROBERT GRIEVE HUTCHISON (18711960) 70 CHRONIC KIDNEY DISEASE CHECKLIST CKD IDENTIFICATION RISK ASSESSMENT RULE OUT AKI/ARF (cid: 1) MDRD GFR 60 mL/min (cid: 1) Hypertension (cid: 1) R/O obstruction (cid: 1) UPC 0. 2 (cid: 1) Diabetes (cid: 1) R/O hypovolemia (cid: 1) UACR 30 mg/g (cid: 1) Metabolic syndrome (cid: 1) Heart failure (cid: 1) Hematuria (cid: 1) Morbid obesity (cid: 1) Hypotension (cid: 1) Kidney stones (cid: 1) Elevated LDL-C (cid: 1) Nephrotoxic drug (cid: 1) Structural defect (cid: 1) Heart failure (cid: 1) NSAID, COX-1/2 (cid: 1) Small kidney sizes (cid: 1) Family History of CKD (cid: 1) Rhabdomyolysis (cid: 1) Ethnicity (cid: 1) Radiocontrast agent CVD RISK REDUCTION (cid: 1) Autoimmunity (cid: 1) Phosphate cathartic (cid: 1) Aspirin (cid: 1) Environmental toxin (cid: 1) Beta blocker (cid: 1) Nephrotoxic drug DYSLIPIDEMIA (cid: 1) Smoking cessation (cid: 1) Cigarette smoking (cid: 1) LDL-C 100 (cid: 1) Weight reduction (cid: 1) Preeclampsia (cid: 1) Non-HDL-C 130 mg/dL (cid: 1) Recurrent UTIs (cid: 1) TG 150 mg/dL DIABETES (cid: 1) Prior Hx of AKI/ARF (cid: 1) (cid: 1) LDL-C (cid: 2) statin (cid: 1) BP 130/80 mmHg (cid: 1) (cid: 1) TG (cid: 2) gemfibrozil (cid: 1) ACEI or ARB PROTEINURIA RENAL NUTRITION (cid: 1) HbA1C 7% (eAG, 154) (cid: 1) ACEI or ARB (cid: 1) Protein restriction (cid: 1) UACR 30 mg/g (cid: 1) DRI or ARA (cid: 1) Na K restriction (cid: 1) Glipizide preferred (cid: 1) BP optimized (cid: 1) P Restriction (cid: 1) NDHPCCB (cid: 1) Renal MVI HYPERTENSION (cid: 1) ACEI ARB (cid: 1) Caloric restriction (cid: 1) BP 130/80 mmHg (cid: 1) Pentoxifylline (cid: 1) Renal nutritionist (cid: 1) Diuretic IMMUNIZATIONS (cid: 1) ACEI or ARB CKD-MBD (cid: 1) HBV (cid: 1) JNV 7 Compelling (cid: 1) Ca P in normal range (cid: 1) HBV Ab titer 10 IU/mL Indication(s) (at any iPTH level) (cid: 1) U 100 mEq/24-h (cid: 1) PTH 130600 pg/mL (cid: 1) TIV, annual Na (cid: 1) UPC 0.
----------------------------------------------------------------------


======================================================================
CHUNK 231 of 647
======================================================================
ID: hfhs_ckd_v6_56
Content Type: general
Words: 192
Medical Entities: CKD,hypertension
Source: HFHS_CKD_V6.pdf

----------------------------------------------------------------------
2 (cid: 1) Trend Alk Phos (cid: 1) Pneumovax, initial (cid: 1) Extraskeletal calcn (cid: 1) Pneumovax, booster ANEMIA OF CKD (cid: 1) 25(OH)D 30 (cid: 1) Tdap, booster (cid: 1) Hb 1012 g/dL (cid: 1) Vitamin D2 or D3 LATE-STAGE CKD (cid: 1) R/O blood loss (cid: 1) Active Vitamin D (cid: 1) Patient education (cid: 1) TSAT 20% (cid: 1) P-binder Rx (cid: 1) Modality choice (cid: 1) Ferritin 100 ng/mL (cid: 1) Reconcile meds (cid: 1) Vit B 12 Folate METABOLIC ACIDOSIS (cid: 1) Adjust drug dose(s) (cid: 1) Iron therapy: po / iv (cid: 1) HCO3 2226 mEq/L (cid: 1) Protect access arm (cid: 1) Inflammation (cid: 1) NaHCO3 Rx (cid: 1) Access evaluation (cid: 1) ESA treatment (cid: 1) Protein restriction (cid: 1) Consider transplant Abbreviations: Alk Phos, alkaline phosphatase; ARA, aldosterone receptor antagonist; DRI, direct renin inhibitor; eAG, estimated average glucose; ESA, erythropoiesis-stimulating agent; UACR, urine albumin-to-creatinine ratio; UPC, urine protein-to-creatinine ratio; TSAT, transferrin saturation; NDHPCCB, non-dihydropyridine calcium channel blocker; TIV, trivalent inactivated influenza vaccine. NEPHROLOGY CONSULTATION MAY BE CONSIDERED AT ANY STAGE OF CKD 71 Notes DIVISIONS OF NEPHROLOGY HYPERTENSION AND GENERAL INTERNAL MEDICINE 74
----------------------------------------------------------------------


======================================================================
CHUNK 232 of 647
======================================================================
ID: home_hemo_0
Content Type: general
Words: 489
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
STAGE 5 Home Hemodialysis A Guide for Patients and Their Families 2 NATIONAL KIDNEY FOUNDATION Contents Introduction How hemodialysis works. . . . . . . . . . . . . . . . . . . . . . . . . 5 Home hemodialysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 A brief history of home hemodialysis. . . . . . . . . . . . . 6 Pros and cons of home hemodialysis. . . . . . . . . . . . . . 8 Different schedules of home hemodialysis. . . . . . . . . 10 Added benefits of short daily and nocturnal home hemodialysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Deciding if home hemodialysis is right for you Questions to consider. . . . . . . . . . . . . . . . . . . . . . . . . . 13 New technology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Finding a center that offers home hemodialysis. . . . 17 Staying in touch with your dialysis center. . . . . . . . . . 18 Preparing for home hemodialysis Getting an access. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Paying for home hemodialysis Insurance coverage. . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Summary Key points to remember. . . . . . . . . . . . . . . . . . . . . . . . 24 For more information Other resourses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 True or false quiz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 KIDNEY. ORG 3 Introduction When you are told that you have kidney failure and need treatment to stay alive, it can be a difficult and challenging time in your life. You may have many concerns. These concerns can be physical, emotional, and financial. If your kidney disease diagnosis is recent, you may feel overwhelmed, confused, and angry.
----------------------------------------------------------------------


======================================================================
CHUNK 233 of 647
======================================================================
ID: home_hemo_1
Content Type: recommendation
Words: 492
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
You may have many concerns. These concerns can be physical, emotional, and financial. If your kidney disease diagnosis is recent, you may feel overwhelmed, confused, and angry. You may worry about how kidney failure and dialysis will change your future and your quality of life. But there are some important things you can do to help yourself. Learn all you can about your treatment options. Take an active role in decisions about your care. 4 NATIONAL KIDNEY FOUNDATION Kidney failure can be treated with hemodialysis, peritoneal dialysis, or kidney transplantation. Reviewing the pros and cons of each of these options can help you and your healthcare professional decide what is best for you. This booklet is about a special type of hemodialysis hemodialysis done at home, or home hemodialysis. See for a list of resources on the other treatment options. How hemodialysis works Hemodialysis is a treatment that replaces some of the work of your own kidneys. Hemodialysis clears wastes and extra fluid from your blood. Your blood is cleaned by a part of the dialysis machine called the artificial kidney or dialyzer. For blood to flow through the dialysis machine, you need to have an access, or entrance, to your bloodstream. This is created by minor surgery, usually to an arm. (See Getting an access on. ) At each dialysis treatment, two needles are placed into the dialysis access site in your arm; one needle carries your blood through sterile tubing to the artificial kidney (dialyzer), and your cleaned blood is returned to your body through the second needle. Home hemodialysis Hemodialysis can be done at home. When you do home hemodialysis, you may be better able to fit your treatments into your daily schedule. If you work, home hemodialysis may make your treatments easier to plan. KIDNEY. ORG 5 Studies show that the more you know about your treatment and the more you do on your own, the better you are likely to feel on dialysis. If your doctor recommended hemodialysis as the best treatment option for you, hemodialysis at home may be a good choice. A brief history of home hemodialysis Home hemodialysis began in the United States in 1964. By 1973, when Medicare first covered dialysis costs, 40 percent of patients received their hemodialysis at home. With the start of Medicare payments for dialysis, more centers began to open. In 2008, new regulations were established by the Centers for Medicare and Medicaid Services (CMS), the government agency responsible for Medicare. Now, dialysis centers are required to inform patients about the option of home dialysis. Your dialysis team members must provide you with a list of places that will train you how to do home hemodialysis. The regulations require that people with severe kidney disease and kidney failure receive information about all possible treatment options. Medicare covers up to 80% of the cost of home hemodialysis, just as they do for dialysis in a hospital or other treatment center.
----------------------------------------------------------------------


======================================================================
CHUNK 234 of 647
======================================================================
ID: home_hemo_2
Content Type: reference
Words: 315
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
The regulations require that people with severe kidney disease and kidney failure receive information about all possible treatment options. Medicare covers up to 80% of the cost of home hemodialysis, just as they do for dialysis in a hospital or other treatment center. Medicare may help cover the cost of minor plumbing or electrical modifications to your home for home hemodialysis. 6 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 7 Pros and cons of home hemodialysis Different ways of scheduling home hemodialysis treatments are possible (see ). All share some important pros and cons compared with in-center hemodialysis: PROS of Home Hemodialysis CONS of Home Hemodialysis Easier to fit into your daily schedule Initial fears about duties and caring for the dialysis machine Easier to keep working or attend school Training for home hemodialysis is not offered by all dialysis centers Convenience and cost savings of not having to More space is needed in your home for equipment travel to a dialysis center three times a week and supplies Independence and being in control of your Training may take three to eight weeks or longer, treatments with threeto five-hour training sessions per week Likelihood of a better health outcome over time Some plumbing and wiring changes in your home may be necessary, but newer machines use standard household outlets Comfort and privacy of being in your own home Electric, gas, and water bills may increase slightly during treatment Having access to telephone, family members, and Some new machines are portable, but you will have visitors during treatment to find a dialysis center for support when traveling Being able to eat and drink if you choose Less social interaction compared with going to the dialysis center Your access may last longer. (See Getting an access on. ) 8 NATIONAL KIDNEY FOUNDATION Pros and cons of home hemodialysis Different ways of scheduling home hemodialysis treatments are possible (see ).
----------------------------------------------------------------------


======================================================================
CHUNK 235 of 647
======================================================================
ID: home_hemo_3
Content Type: recommendation
Words: 490
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
(See Getting an access on. ) 8 NATIONAL KIDNEY FOUNDATION Pros and cons of home hemodialysis Different ways of scheduling home hemodialysis treatments are possible (see ). All share some important pros and cons compared with in-center hemodialysis: PROS of Home Hemodialysis CONS of Home Hemodialysis Easier to fit into your daily schedule Initial fears about duties and caring for the dialysis machine Easier to keep working or attend school Training for home hemodialysis is not offered by all dialysis centers Convenience and cost savings of not having to More space is needed in your home for equipment travel to a dialysis center three times a week and supplies Independence and being in control of your Training may take three to eight weeks or longer, treatments with threeto five-hour training sessions per week Likelihood of a better health outcome over time Some plumbing and wiring changes in your home may be necessary, but newer machines use standard household outlets Comfort and privacy of being in your own home Electric, gas, and water bills may increase slightly during treatment Having access to telephone, family members, and Some new machines are portable, but you will have visitors during treatment to find a dialysis center for support when traveling Being able to eat and drink if you choose Less social interaction compared with going to the dialysis center Your access may last longer. (See Getting an access on. ) KIDNEY. ORG 9 Different schedules of home hemodialysis You can do hemodialysis at home using one of three types of schedules. Whichever schedule you choose, you will be trained to perform dialysis safely and to handle any problems that may arise. Everyone is different and training time differs between people, but usually takes three to eight weeks. 1. Conventional home hemodialysis: You perform hemodialysis three times a week for three to four hours or longer each time. 2. Short daily home hemodialysis: This schedule calls for hemodialysis five to seven times a week, using machines designed for short, daily home treatment. Treatments usually last about two hours each. Because you are receiving dialysis more often, less fluid needs to be removed from 10 NATIONAL KIDNEY FOUNDATION your blood each time. This reduces recovery symptoms like headaches, nausea, cramping, and feeling washed out after your treatment. 3. Nocturnal (nighttime) home hemodialysis: These are longer, slower treatments done at night while you sleep. You may receive this kind of dialysis six nights a week or every other night. It depends on what your doctor recommends for you. Treatments usually last about six to eight hours. Some centers monitor your treatments by having information from your dialysis machine sent to a staffed location via telephone modem or the Internet. More hours of dialysis each week can increase waste removal from your blood. Its also possible to combine daily and nocturnal home hemodialysis. Whether you can combine treatments depends on your needs, your health, and your dialysis machine.
----------------------------------------------------------------------


======================================================================
CHUNK 236 of 647
======================================================================
ID: home_hemo_4
Content Type: general
Words: 494
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
More hours of dialysis each week can increase waste removal from your blood. Its also possible to combine daily and nocturnal home hemodialysis. Whether you can combine treatments depends on your needs, your health, and your dialysis machine. Whatever treatment schedule you choose, its important to know if you are receiving the right amount of dialysis. Blood tests are done regularly during the year to check on the amount of dialysis you receive and to help decide if any adjustments to your treatment plan are needed. For more information on how the amount of dialysis is measured, speak with your doctor and your dialysis care team. KIDNEY. ORG 11 Added benefits of short daily and nocturnal home hemodialysis Having frequent dialysis is closer to how your kidneys functioned when they were healthy. Many reports indicate that people who use short daily and nocturnal home hemodialysis: Take less medication to control high blood pressure and anemia (low red blood cell count) Take less medication to keep high blood phosphorus under control Have improved blood pressure, nerve damage, and symptoms of restless leg syndrome Feel better during dialysis and less washed out after dialysis Have fewer limits on what they can eat and drink Have more energy Sleep better Have fewer and shorter hospital stays Have a better quality of life Live longer With daily home hemodialysis, you dont have the swings in your blood chemistries and fluids like you do when you dont dialyze every day, so you feel a lot better. Home dialysis is for people who want to be in control of the process and be at home. David J. , patient on daily home hemodialysis 12 NATIONAL KIDNEY FOUNDATION Deciding if home hemodialysis is right for you Home hemodialysis is not a good fit for everyone. You will need to find a dialysis center that offers training and support in home hemodialysis. You must also be willing to be responsible for your own treatment. The following are questions you may want to discuss with your doctor, your employer, and healthcare team. Questions to consider YOUR JOB: Can I keep my job and do home hemodialysis? Can I get paid time off to train for home hemodialysis? If I quit working, how long can I keep my health insurance? Can I get other health insurance? How will this change affect my family and me? KIDNEY. ORG 13 FINDING A HOME HEMODIALYSIS PROGRAM Does my local dialysis center offer home hemodialysis training? If not, where is the closest center with training? Am I willing to change centers, or even doctors, to get home hemodialysis? How far would I be willing to go for training that takes several weeks and for clinic visits every four to six weeks? How long does training take? What is the training schedule? How will I learn to put the needles in my arm for hemodialysis? Who will be my trainer? Can I make an appointment to talk with them?
----------------------------------------------------------------------


======================================================================
CHUNK 237 of 647
======================================================================
ID: home_hemo_5
Content Type: general
Words: 498
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
How long does training take? What is the training schedule? How will I learn to put the needles in my arm for hemodialysis? Who will be my trainer? Can I make an appointment to talk with them? 14 NATIONAL KIDNEY FOUNDATION CHANGES AT HOME What will it take to install a dialysis machine in my house? Will my landlord allow me to put a dialysis machine in my apartment? Where can I put the equipment and supplies? What are the rules about the disposal of medical waste in my area? How much will my insurance pay for training and home hemodialysis supplies? COSTS What out-of-pocket costs will I need to pay? Will insurance pay for any necessary changes in my home? How much will my electric, gas, and water bills increase? WORKING WITH THE DIALYSIS CENTER How will the dialysis center staff support me once Im doing treatment at home? Who repairs my machine when it breaks? How long do repairs usually take? Where can I get dialysis if my machine is broken? How often do I need to come back to the center for clinic visits? Is transportation assistance available if I need a ride to the clinic? Can I see my local doctor monthly, so I wont have to come to the clinic as often? KIDNEY. ORG 15 LONG-TERM CONCERNS: What treatment does my kidney doctor believe is best? Why? Will I do better long-term with home hemodialysis? New technology More user-friendly dialysis machines are being developed for home use. These machines are easier to set up, clean, and disinfect and have easy-to-use alarms to alert you to a problem. With some newer machines, there are fewer supplies to store. If you and your doctor think home hemodialysis is a good choice for you, ask your dialysis training staff about the best equipment for you. With daily dialysis, Ive noticed that I have increased energy, better sleep, and improved concentration at work. People shouldnt have to live to dialyze. Daily home hemodialysis on your own schedule makes it possible to live life as best you can. Bill P. , a patient on daily home hemodialysis 16 NATIONAL KIDNEY FOUNDATION Finding a center that offers home hemodialysis Your healthcare professional will help you find a dialysis center that has a home hemodialysis program certified by CMS. If your center does not offer home hemodialysis, see for websites that can help you find centers that offer home hemodialysis. Visit the center. Talk with the home training nurse and other staff. Ask to speak to patients who do home dialysis. Two things will ensure your success: 1. a dialysis center and nurse willing to train you and follow your care; and 2. your commitment to learn and do hemodialysis at home. KIDNEY. ORG 17 Staying in touch with your dialysis center You will need to visit your dialysis center about once a month for a check-up, lab tests, and to see your kidney doctor, nurse, dietitian, and social worker.
----------------------------------------------------------------------


======================================================================
CHUNK 238 of 647
======================================================================
ID: home_hemo_6
Content Type: reference
Words: 490
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
KIDNEY. ORG 17 Staying in touch with your dialysis center You will need to visit your dialysis center about once a month for a check-up, lab tests, and to see your kidney doctor, nurse, dietitian, and social worker. You may also need to receive some of your medicines, such as intravenous iron, at your center. Between visits to the center, your healthcare team is there to help. If you have a question about your diet or treatment, call your center. When you go home after your training, your center will give you phone numbers that you can call if you have questions. Some centers monitor care over the Internet. Keep a list of important phone numbers in a handy place (see ). You can use the chart at the end of this booklet to get started. 18 NATIONAL KIDNEY FOUNDATION Preparing for home hemodialysis Getting an access To do any type of hemodialysis, you need to have a way to gain access to your bloodstream. Your access is created by a doctor called a vascular surgeon. There are three types of access: Fistula: This is the first choice for an access for most people. It has fewer problems and lasts the longest, especially if you are the only person inserting the needles. A fistula involves surgery to connect an artery and a nearby vein, usually in your arm. Have your fistula created early, so it has time to heal and is ready to use when you need to start treatment. KIDNEY. ORG 19 Graft: If the surgeon evaluates your blood vessels and a fistula is not possible, a graft is the second best access choice for hemodialysis. A graft also requires surgery. It is made by connecting an artery and nearby vein with a small, soft tube made of synthetic material. However, a graft is more prone to infection and clotting than a fistula. If that happens, you may need treatment or more surgery to fix or replace the graft. Catheter: Another way to access your bloodstream is to have a plastic tube called a catheter put into a large vein in your neck or chest. Catheters are only used long-term if no other access can be made. Catheters are more prone to infections and clots. If you have a catheter, you must follow strict catheter care instructions to stay healthy. You will learn how to: Set up your equipment in your home Insert and remove your needles Figure out how much fluid to remove from your blood during dialysis Use and care for your dialysis machine and water system (if needed) Notice and handle medical and equipment problems that may occur Store and order your supplies Check your blood pressure 20 NATIONAL KIDNEY FOUNDATION Paying for home hemodialysis Insurance coverage The social worker at your dialysis center should give you information about coverage for home hemodialysis and other costs that may be related to receiving your treatment at home.
----------------------------------------------------------------------


======================================================================
CHUNK 239 of 647
======================================================================
ID: home_hemo_7
Content Type: recommendation
Words: 499
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
Medicare pays for part of the cost of home hemodialysis and training. Medicare is not just for people who are 65 and older. The program also helps Americans and legal residents of all ages who need dialysis or a kidney transplant and qualify for coverage. Other sources that help pay for dialysis include: Private insurance Some managed care organizations Medicaid Veterans Administration Indian Health Service (IHS) KIDNEY. ORG 21 If you have an employer group health plan, it will be the primary coverage for the first 30 months of your treatment, with Medicare as your secondary insurer. After those first 30 months, Medicare will become your primary insurance. Your home training nurse will tell you if your home will need plumbing or wiring changes for home hemodialysis. Some of these costs may be covered by private insurance or your center. You may be given the option of receiving your dialysis supplies from your dialysis center or dealing directly with a supply company. You can expect your monthly water and electric bills to increase a little. Speak to your social worker if you have additional questions or concerns about coverage for home hemodialysis. 22 NATIONAL KIDNEY FOUNDATION I started feeling stronger and more energetic. I had less bone pain, so I was able to walk more and started exercising regularly. I stopped taking some medications and I generally feel good. With home dialysis, you do everything from setting up the machine, connecting and disconnecting yourself to the machine, and disinfecting the machine afterwards. But taken as a whole, the positives far outweigh the negatives. Henry E. , a patient on nocturnal home hemodialysis KIDNEY. ORG 23 Summary Key points to remember Pros of home hemodialysis Its easier to fit into your daily or weekly schedule. There are fewer restrictions on what you can eat and drink, especially for those doing daily or nocturnal treatment. You are in control of your own treatment and have more independence. Your health over time is likely to be better. Many patients say they feel better and have more energy. Three basic types of hemodialysis can be performed at home: Conventionalthree times a week for three to four hours or longer each time Short dailyfive to seven times a week for about two hours each time Nocturnalthree to six nights a week for six to eight hours each time. Talk to your healthcare practitioner about whether home hemodialysis would be a good treatment choice for you. They can also help you choose the best type of home hemodialysis for your needs. To perform hemodialysis, you will need to have a permanent access to your blood created. Doctors recommend a fistula for most patients. 24 NATIONAL KIDNEY FOUNDATION Both you and a care partner (in most cases) will need to be trained to do home hemodialysis. Your care partner may be a family member, friend, or a healthcare worker whom you hire to assist you. Medicare, private insurance, and several other sources pay for home hemodialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 240 of 647
======================================================================
ID: home_hemo_8
Content Type: general
Words: 467
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
Your care partner may be a family member, friend, or a healthcare worker whom you hire to assist you. Medicare, private insurance, and several other sources pay for home hemodialysis. Speak to your social worker if you have any questions. Even though you will be at home, you still need to keep in touch with your dialysis center for monthly checkups, questions, and in case of problems. KIDNEY. ORG 25 For more information If you have questions, speak to your doctor and other members of your healthcare team. You may also call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Other resourses DIALYSIS FACILITY COMPARE Find information about dialysis centers that offer home hemodialysis training programs. medicare. gov HOME DIALYSIS CENTRAL Learn about home dialysis options, talk to other patients, find out if a dialysis center near you offers a home hemodialysis program. homedialysis. org MEDICARE Read a patient booklet about coverage for kidney failure treatment. medicare. gov/publications/pubs/pdf/10128. pdf ESRD NETWORKS Find out who oversees dialysis quality and collects data, and learn about your own Network at the Forum of ESRD Networks website. esrdnetworks. org AMERICAN ASSOCIATION OF KIDNEY PATIENTS (AAKP) Learn about kidney disease and treatment. aakp. org 26 NATIONAL KIDNEY FOUNDATION U. S. NATIONAL KIDNEY AND UROLOGIC DISEASES INFORMATION CLEARINGHOUSE Download or order booklets on kidney disease. kidney. niddk. nih. gov/kudiseases/pubs/kidneyfailure/ index. htm RENALWEB Find resources on home hemodialysis. renalweb. com/topics/homedialysis/homedialysis. htm THE NATIONAL KIDNEY FOUNDATIONS PATIENT FAMILY COUNCIL Join the National Kidney Foundations Patient Family Council, the largest patient organization dedicated to issues affecting patients with chronic kidney disease and their families. Membership in the Council is free. kidney. org/patients or call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273). KIDNEY. ORG 27 True or false quiz Take this quiz and see how much you learned. Check your answers at the end. 1. Conventional home hemodialysis is done every day. True False 2. Daily home hemodialysis treatments last about two hours each. True False 3. Nocturnal home hemodialysis is done while you sleep. True False 4. With home hemodialysis, your diet may be more restricted. True False 5. Training for home hemodialysis takes about a year. True False 28 NATIONAL KIDNEY FOUNDATION 6. A fistula is the preferred type of access for hemodialysis. True False 7. In hemodialysis, wastes and excess fluid are removed from your blood by a filter, called a dialyzer. True False 8. People on home hemodialysis visit the dialysis center once every six months for a checkup. True False 9. With home hemodialysis, your electric and water bills will probably be lower. True False Answers F 9 F 8 T 7 T 6 F 5 F 4 T 3 T 2 F 1 KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 241 of 647
======================================================================
ID: home_hemo_9
Content Type: recommendation
Words: 267
Medical Entities: dialysis
Source: home_hemo.pdf

----------------------------------------------------------------------
True False 9. With home hemodialysis, your electric and water bills will probably be lower. True False Answers F 9 F 8 T 7 T 6 F 5 F 4 T 3 T 2 F 1 KIDNEY. ORG 29 IMPORTANT NAMES AND PHONE NUMBERS KIDNEY DOCTOR: name: phone: HOME TRAINING NURSE: name: phone: SOCIAL WORKER: name: phone: DIETITIAN: name: phone: MACHINE TECHNICIAN: name: phone: SUPPLY COMPANY: name: phone: 24-HOUR CONTACT: name: phone: 30 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 31 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 11-10-0329_2212
----------------------------------------------------------------------


======================================================================
CHUNK 242 of 647
======================================================================
ID: hyperkalemia_1
Content Type: general
Words: 485
Medical Entities: diabetes
Source: hyperkalemia.pdf

----------------------------------------------------------------------
But too much potassium in your blood can be dangerous. It can cause serious heart problems. 4 NATIONAL KIDNEY FOUNDATION What causes hyperkalemia? The most common causes include: Kidney disease. Hyperkalemia can happen if your kidneys do not work well. It is the job of the kidneys to balance the amount of potassium taken in with the amount lost in urine. Potassium is taken in through the foods you eat and liquids you drink. It is filtered by the kidneys, and lost through urine. Healthy kidneys can make up for high potassium by removing more. In the early stages of kidney disease, the kidneys can often make up for high potassium. But as kidney function gets worse, they may not be able to remove enough potassium from your body. Advanced kidney disease is a common cause of hyperkalemia. Common causes of kidney disease include diabetes and high blood pressure. A diet high in potassium. Eating too much food that is high in potassium can also cause hyperkalemia, especially in people with advanced kidney disease. Foods such as melons, orange juice, and bananas are high in potassium. (See ) Drugs that prevent the kidneys from losing enough potassium. Some drugs can keep your kidneys from removing enough potassium. This can cause your potassium levels to rise. (See ) Other (less common) causes include: Taking extra potassium, such as a salt substitute or certain supplements. A disorder called Addisons disease, which can occur if your body does not make enough of certain hormones. Hormones are chemicals produced by different glands WWW. KIDNEY. ORG 5 and organs, including the kidneys, to trigger certain responses in your body. Burns or other severe injuries. Poorly controlled diabetes. What are the symptoms of hyperkalemia? Many people have few, if any, symptoms. If symptoms do appear, they are usually mild and non-specific. You may feel some muscle weakness, numbness, tingling, nausea, or other unusual feelings. Hyperkalemia is common in people with kidney disease. It usually develops slowly over many weeks or months, and is most often mild. It can recur. If hyperkalemia comes on suddenly and you have very high levels of potassium, you may feel heart palpitations, shortness of breath, chest pain, nausea, or vomiting. Sudden or severe hyperkalemia is a life-threatening condition. It requires immediate medical care. Call 911 or go to the emergency room. How do I know if I have hyperkalemia? A blood test can find the level of potassium in your blood. High potassium is usually found by chance during a routine blood test. Your healthcare provider will also give you a complete physical checkup. You will be asked about your medical history, your diet, and the medicines you take. This will help find out what caused your hyperkalemia and plan your treatment. It is important that you tell your healthcare provider about all the medicines you take, even over-thecounter products such as herbals and other supplements.
----------------------------------------------------------------------


======================================================================
CHUNK 243 of 647
======================================================================
ID: hyperkalemia_2
Content Type: general
Words: 485
Medical Entities: diabetes
Source: hyperkalemia.pdf

----------------------------------------------------------------------
This will help find out what caused your hyperkalemia and plan your treatment. It is important that you tell your healthcare provider about all the medicines you take, even over-thecounter products such as herbals and other supplements. 6 NATIONAL KIDNEY FOUNDATION Many herbal remedies, supplements, salt substitutes, and over-the counter products have high amounts of potassium. Treatment for Hyperkalemia Can hyperkalemia be treated? Yes. You may need to follow a low-potassium diet. Your healthcare provider will tell you if any changes in your medicines are needed. You should not take salt substitutes, which are high in potassium. A dietitian can help you create a meal plan that is low in potassium. Some people may also need special medicine to help remove extra potassium from the body and keep it from coming back. This may include: Water pills (diuretics) help rid your body of extra potassium. They work by making your kidney create more urine. Potassium is normally removed through urine. Potassium binders often come in the form of a powder. They are mixed with a small amount of water and taken with food. When swallowed, they bind to the extra potassium in the bowels and remove it. Some potassium binders can also be taken by the rectum (an enema). You must follow the instructions carefully when taking potassium binders. For example, potassium binders may interfere with how other drugs work if you take them at the same time. Potassium binders are not for use in children. For sudden or severe hyperkalemia, you will need immediate medical care. If you have heart palpitations, shortness of breath, chest pain, nausea, vomiting, or muscle paralysis, call 911 or go to the emergency room. These could be signs of a serious heart problem. WWW. KIDNEY. ORG 7 What is a normal level of potassium in blood? For most people, the level of potassium in your blood should be between 3. 5 and 5. 0, depending on the laboratory that is used. Ask your healthcare provider what your potassium level is. If I have hyperkalemia, should I stop taking my medicines? Do not stop taking your prescribed medicines unless your healthcare provider tells you to, especially if you have a medical condition such as diabetes, heart disease, high blood pressure, or kidney disease. Call your healthcare provider if you have any questions about the medicines you take. 8 NATIONAL KIDNEY FOUNDATION What kinds of medicines can cause hyperkalemia? Tell your healthcare provider about all the medicines you take, even herbal supplements or over-the-counter drugs. This is very important. Some examples of medicines that can raise your potassium levels are described here. This list does not contain all medicines that can raise your potassium levels. Keep an updated list of all the medicines you take. Have it with you during your healthcare visits. ACE inhibitors, ARBS, and beta-blockers (blood pressure medicines). Blood pressure medicines are used to help lower blood pressure.
----------------------------------------------------------------------


======================================================================
CHUNK 244 of 647
======================================================================
ID: hyperkalemia_4
Content Type: reference
Words: 494
Medical Entities: dialysis
Source: hyperkalemia.pdf

----------------------------------------------------------------------
The table on the following page will help you choose fruits, vegetables, and other foods that are lower in potassium. WWW. KIDNEY. ORG 11 What are some high-potassium foods? Fruits Bananas, melons, oranges, nectarines, kiwi, mango, papaya, prunes, pomegranate Dates, dried fruits, dried figs Vegetables Avocados, broccoli, brussel sprouts, sweet potatoes, parsnips, pumpkin, vegetable juices, white potatoes, winter squash Tomato and tomato-based products Deep-colored and leafy green vegetables (such as spinach or swiss chard) Dried beans and peas, black beans, refried beans, baked beans, lentils, legumes Other Milk, yogurt Nuts and seeds Bran and bran products Chocolate, granola, molasses, peanut butter Salt substitutes 12 NATIONAL KIDNEY FOUNDATION What are some lower-potassium foods? Fruits Apple, blueberries, cranberries, grapes, grapefruit, pears, pineapple, raspberries, strawberries Vegetables Asparagus, cabbage, carrots, celery, corn, cucumber, eggplant, green or wax beans, green peas or beans, lettuce (iceberg), onions, radishes, turnips, water chestnuts Other Rice, noodles, pasta, bread and bread products (not whole grains) Angel cake, yellow cake, pies without chocolate or high-potassium fruit, cookies without nuts or chocolate WWW. KIDNEY. ORG 13 What else can I do to keep potassium levels from getting too high? Eat a variety of foods, but in moderation. Remember, almost all foods have some potassium. The size of the serving and how the food is prepared is very important. Drain canned fruits, vegetables, and meats carefully before serving. Do not drink or use the liquid. If you want to include some high-potassium vegetables in your diet, eat smaller portions or leach them before using. If you are on dialysis, do not skip or shorten your dialysis treatments. How do I leach vegetables? Peel and place vegetables such as potatoes, sweet potatoes, carrots, beets, winter squash and rutabagas in cold water so they wont darken. Slice the vegetable 1/8th inch thick. Rinse in warm water for a few seconds. Soak for a minimum of two hours in warm water. Use ten times the amount of water to the amount of vegetables. If soaking longer, change the water every four hours. Rinse under warm water again for a few seconds. Cook vegetables with five times the amount of water to the amount of vegetable. 14 NATIONAL KIDNEY FOUNDATION Points to remember: Hyperkalemia can happen if your kidneys do not work well. A simple blood test can determine the level of potassium in your blood. In most people, hyperkalemia develops slowly over weeks or months and is usually mild. Many people can control high potassium by following a low-potassium diet, and reducing or avoiding certain medicines, at the direction of their healthcare provider. Others may need to take water pills or potassium binders to help control high potassium. Sudden or severe hyperkalemia can be life-threatening and requires immediate medical care. Call 911 or go to the emergency room if you experience heart palpitations, shortness of breath, chest pain, nausea, or vomiting. WWW. KIDNEY. ORG 15 Where can I get more information? If you have questions, ask your healthcare team.
----------------------------------------------------------------------


======================================================================
CHUNK 245 of 647
======================================================================
ID: hyperkalemia_5
Content Type: general
Words: 248
Medical Entities: GFR,diabetes
Source: hyperkalemia.pdf

----------------------------------------------------------------------
Call 911 or go to the emergency room if you experience heart palpitations, shortness of breath, chest pain, nausea, or vomiting. WWW. KIDNEY. ORG 15 Where can I get more information? If you have questions, ask your healthcare team. You can also call the National Kidney Foundation Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org. A trained professional will listen to your concerns and help answer your questions. The National Kidney Foundation does not provide medical advice. Your healthcare provider is the single best source of information regarding your health. If you want to learn more about kidney disease, the National Kidney Foundation has many other publications that cover many subjects: What kidney disease is and who is at risk for getting it GFR (glomerular filtration rate) Nutrition and diet Diabetes and your kidneys High blood pressure and your kidneys Lifestyle issues for people with kidney disease, including: Staying fit Coping with kidney disease 16 NATIONAL KIDNEY FOUNDATION Notes WWW. KIDNEY. ORG 17 Notes 18 NATIONAL KIDNEY FOUNDATION Notes WWW. KIDNEY. ORG 19 The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding, patient centric organization dedicated to the awareness, prevention and treatment of kidney disease in the US. Help us fight kidney disease. Learn more at kidney. org This publication has been sponsored and developed in collaboration with Relypsa, Inc. 30 East 33rd Street New York, NY 10016 800. 622. 9010 2017 National Kidney Foundation, Inc. 01-10-7269_DBH
----------------------------------------------------------------------


======================================================================
CHUNK 246 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_0
Content Type: general
Words: 484
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
IF YOU CHOOSE NOT TO START DIALYSIS TREATMENT www. kidney. org For many people with kidney failure, dialysis helps them live longer and improves their quality of life. But for some people, the improvement they feel may be a lot more limited often because of their serious health problems. It is important to know that in such a situation, you have the right to decide not to start dialysis. Before making a decision, however, you should discuss your thoughts carefully with people you trust and seek advice from your doctor or other healthcare provider, family member(s), your lawyer or others who have your best interests at heart. This booklet has been written to answer some general questions you may have about the choice not to start dialysis. Can I really decide not to start dialysis treatment? Yes. You have the right to decide not to start dialysis if you feel that the burdens outweigh the benefits to you. If you are not able to make this kind of decision, someone (such as a family member, lawyer, etc. ) can make this decision on your behalf. The person you name to make such decisions is called your surrogate. (See next question. ) 2 NATIONAL KIDNEY FOUNDATION How do I go about naming someone to be my surrogate? A surrogate is someone you choose to make decisions for you if you are not able to make them yourself. Naming a surrogate is done by filling out a form known as an advance directive, a healthcare proxy, or a durable healthcare power of attorney. It is important to make sure the person you name is willing to act on your behalf. It is also very important that you tell the person about your wishes and values so that he or she can make the decisions you would make if you were not able to speak for yourself. It will be helpful to your surrogate if you give clear directions on your advance directive form about dialysis and/or other medical treatments you would want or not want. WWW. KIDNEY. ORG 3 The role and responsibilities of the surrogate, as well as the types of decisions the surrogate may make, vary from state to state, depending on the laws of each state. Generally, the surrogate must follow your wishes. For more information about naming a surrogate and about the laws in your state, you may want to speak with an attorney or your local or state bar association. You may also obtain copies of the forms used in your state by calling or writing to the: National Hospice and Palliative Care Organization, 1731 King Street, Suite 100, Alexandria, VA, 22314; phone: 800. 646. 6460 or 703. 837. 1500; www. nhpco. org. (Also see the National Kidney Foundation booklet Advance Directives: A Guide for Patients and Their Families. ) Will my doctor help me decide whether to start treatment? Yes.
----------------------------------------------------------------------


======================================================================
CHUNK 247 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_1
Content Type: evidence
Words: 488
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
646. 6460 or 703. 837. 1500; www. nhpco. org. (Also see the National Kidney Foundation booklet Advance Directives: A Guide for Patients and Their Families. ) Will my doctor help me decide whether to start treatment? Yes. Your doctor will speak with you about what dialysis treatment involves and what deciding not to start dialysis would mean for you. While you try to make this decision, you may also want to get advice from people who provide emotional support to you and your loved ones and other trained professionals, such as your social 4 NATIONAL KIDNEY FOUNDATION worker. However, the final decision about starting or not starting treatment remains with you or your surrogate. Suppose I am not sure whether dialysis could help me? Sometimes it may not be clear whether the benefits of dialysis outweigh the burdens. Each persons situation is different. If you are uncertain, you may be able to start treatment for a trial periodfor example, one to three months. During and after the trial period, your doctor and the other members of your dialysis team will talk with you about how you are feeling and coping with the treatment routine. Ask as many questions as you need to help with your decision to continue or to stop treatment. How do I discuss this decision with my family and friends? Many people find it difficult to talk about whether or not to start treatment, and they worry about how others will feel and react. Although you may find it hard at first, the best approach is to discuss your feelings openly with your loved ones. Your family will most likely feel very emotional too, and may have questions. You may wish to include, other people WWW. KIDNEY. ORG 5 in this discussion whose advice you value, such as your religious or spiritual advisor, social worker, doctor or other healthcare worker. Will I be asked to speak to a mental health professional? If your doctor is concerned that you may not want to start dialysis for an emotional reason, such as depression, he or she may ask you to speak with a psychiatrist, social worker or other counseling professional. Depression may be treated successfully with counseling, medicine or a combination of both. Your doctor may also want you to speak with a mental health professional to make sure you understand the full impact of choosing not to start dialysis. How long will I live if I choose not to start dialysis? There is no certain answer to this question. It varies, because everybody is different. Each persons medical status is unique. People with kidney failure may survive days to weeks without dialysis, depending on the amount of kidney function they have, how severe their symptoms are, and their overall medical condition. 6 NATIONAL KIDNEY FOUNDATION Is death from kidney failure painful? Not usually. If you do feel any discomfort, pain medication may be prescribed for you.
----------------------------------------------------------------------


======================================================================
CHUNK 248 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_2
Content Type: recommendation
Words: 489
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
6 NATIONAL KIDNEY FOUNDATION Is death from kidney failure painful? Not usually. If you do feel any discomfort, pain medication may be prescribed for you. Without treatment for kidney failure, toxins, and fluid will build up in your body, making you feel increasingly tired, nauseous and itchy. These symptoms can be controlled with medication and other supportive measures to make you more comfortable and lessen your anxiety. The fluid build-up can make it more difficult for you to breathe. Your doctor can prescribe medication or a treatment called ultrafiltration to remove fluid and make breathing easier for you. Your doctor may also recommend that you limit your intake of salt and fluids to reduce fluid weight gain. Is deciding not to start dialysis considered suicide? Many religions believe people have the right to refuse medical treatment, including dialysis, if they feel it will not help them and will be burdensome. You may wish to speak with your religious or spiritual advisor if you have concerns about this. WWW. KIDNEY. ORG 7 What type of food and drink could I have? Typically, there is no reason for you to continue to follow your kidney diet once you choose end-of-life care. In fact, favorite foods and beverages are usually encouraged. Your doctor, nurse, and dietitian can answer other specific questions you may have about food and fluid intake. If I make this decision, will my doctor continue to help me? Yes. Your doctor should be available to you and your family to discuss your concerns and advise you about the type of care you might need. Your doctor should work with members of your healthcare team to arrange the necessary referrals or consultations for your circumstances. Other professionals, such as the social worker or nurse who has been part of your healthcare team should also remain available to you. Do I have a choice of where I die? Your wishes about where you want to die will be honored as much as possible. Many people choose to die at home, where they feel more comfortable in familiar surroundings. If you choose this option, a hospice 8 NATIONAL KIDNEY FOUNDATION or home health agency may assist you and your loved ones in making any special arrangements for your care at home. A nursing home may be an option for some people. Admission to the hospital may not be a consideration, depending on your insurance coverage and overall medical condition. Could I get hospice care? If you choose not to start dialysis, you require end-of-life care and you are eligible for hospice services. The type of hospice care available may be either a home hospice program or a hospice facility. A social worker, a visiting nurse service or home care agency may be able to help you and your loved ones make arrangements for hospice care. Hospice services usually include some visits from a nurse, a home health aid, and a social worker.
----------------------------------------------------------------------


======================================================================
CHUNK 249 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_3
Content Type: general
Words: 485
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
A social worker, a visiting nurse service or home care agency may be able to help you and your loved ones make arrangements for hospice care. Hospice services usually include some visits from a nurse, a home health aid, and a social worker. For more information about hospice programs in your community, speak with your doctor, nurse or social worker. You may also be able to get information from your religious community, or from friends and neighbors who have had experience with hospice care. If you are a senior citizen, you can contact a local senior WWW. KIDNEY. ORG 9 center or the local or state Office on Aging. Also check your local yellow pages and Internet resources such as www. hospicedirectory. org If I choose to die at home, can I get a home healthcare worker to help my family care for me? The types of services covered at home will depend on your insurance. If you are in a home hospice program, a home health aide may be available to assist. If your insurance does not cover a home health aide, and you and your loved ones wish to pay privately for these services, you can do so. There may also be government programs to help with costs. Ask your doctor, social worker, and community or government agencies about available and affordable home services. Will I still be covered by Medicare and/or my private medical insurance if I stop treatment? Your Medicare coverage will not end, even if you decide to stop dialysis. It is important that you and your family speak with your doctor about the type of care you will need. Once this is decided, you can check on whether or not Medicare and/or private insurance will cover this care. 10 NATIONAL KIDNEY FOUNDATION If I change my mind, can I go back on dialysis? You may start or return to dialysis if you change your mind. If you have missed several treatments, you may have some discomfort when you first start dialysis again. You will require vascular access if you do not already have a working dialysis fistula. You should discuss the possibility of returning to dialysis with your doctor. WWW. KIDNEY. ORG 11 Is there anything else I should know about not starting dialysis? If you decide not to start treatment, you or your surrogate may want to make sure the following items are in order: Signed Advance Directives documents that comply with your state law. Advance Directives refer to documenting your health and medical treatment wishes and designating a surrogate. You do not need a lawyer to complete advance directives. There are usually three types of advance directives: Living Will: This specifies what kind of medical treatment you want if you become unable to make decisions yourselffor example, the use of life-sustaining therapies or equipment like CPR (cardiopulmonary resuscitation) and ventilators, feeding and other treatments like pain medication.
----------------------------------------------------------------------


======================================================================
CHUNK 250 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_4
Content Type: general
Words: 482
Section: There are usually three types of advance directives:
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
There are usually three types of advance directives: Living Will: This specifies what kind of medical treatment you want if you become unable to make decisions yourselffor example, the use of life-sustaining therapies or equipment like CPR (cardiopulmonary resuscitation) and ventilators, feeding and other treatments like pain medication. Healthcare Proxy: This specifies who you choose to make healthcare decisions for you if and when you become unable to make them yourself. Durable Healthcare Power of Attorney: This provides power of attorney to someone you choose to make decisions on your behalf on all matters other than medical (e. g. , legal, financial, banking and business matters), if and when 12 NATIONAL KIDNEY FOUNDATION you become unable to make decisions yourself. This document allows the person you choose to make bank transactions, pay bills, and take care of other important matters, if and when you are not able to take care of them yourself. An inventory, including the location of your bank, brokerage and other financial accounts, stock and bond holdings, real estate and business records, medical and other insurance policies, pension plans and other legal papers The names, addresses and telephone numbers of your attorney, accountant, family members and other loved ones, friends and business associates who should be notified of your death or who may have information that will be helpful in dealing with your estate A statement about your preference for funeral/memorial services, burial or cremation instructions, and decisions about organ and tissue donation A written, videoor audio-taped message to family members and other loved ones, business associates and friends, if you choose WWW. KIDNEY. ORG 13 If you provide care for loved ones, a plan for how their care will be provided for after your death. Additional information about advance directives, living wills, healthcare proxies or durable healthcare powers of attorney may be obtained from your lawyer, if you have one, or your local or state bar association. These forms are downloadable from the Internet. You may also obtain copies of the forms used in your state by contacting the National Hospice and Palliative Care Organization (see for contact information), or by visiting your local library. 14 NATIONAL KIDNEY FOUNDATION What if I have more questions? If you have more questions about medical concerns, speak with your doctor, social worker, nurse or other people whose advice you trust. Other Resources Call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org Coalition for the Supportive Care of Kidney Patients: www. kidneysupportivecare. org The following free NKF booklets may be helpful: Advance Directives: A Guide for Patients and Their Families Order 11-10-0803, www. kidney. org/ atoz/pdf/AdvanceDirect. pdf Choosing a Treatment for Kidney Failure Order 11-10-0352, www. kidney. org/ ATOZ/pdf/choosing_treat. pdf When Stopping Dialysis Treatment Is Your Choice Order 11-10-0331, www. kidney. org/atoz/pdf/ StopDialysis. pdf Learn more at www. kidney. org WWW. KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 251 of 647
======================================================================
ID: if_you_choose_not_to_start_dialysis_treatment_5
Content Type: general
Words: 111
Medical Entities: dialysis
Source: if_you_choose_not_to_start_dialysis_treatment.pdf

----------------------------------------------------------------------
kidney. org/ atoz/pdf/AdvanceDirect. pdf Choosing a Treatment for Kidney Failure Order 11-10-0352, www. kidney. org/ ATOZ/pdf/choosing_treat. pdf When Stopping Dialysis Treatment Is Your Choice Order 11-10-0331, www. kidney. org/atoz/pdf/ StopDialysis. pdf Learn more at www. kidney. org WWW. KIDNEY. ORG 15 The National Kidney Foundation is the leading organization in the U. S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Help fight kidney disease. Learn more at www. kidney. org 30 East 33rd Street New York, NY 10016 800. 622. 9010 2008 National Kidney Foundation, Inc. 11-10-0330_IBD
----------------------------------------------------------------------


======================================================================
CHUNK 252 of 647
======================================================================
ID: j_krcp_23_194_0
Content Type: evidence
Words: 494
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Review Article Kidney Res Clin Pract 2025; 44(3): 411-433 pISSN: 2211-9132 eISSN: 2211-9140 The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions Afiatin Makmun1, Bancha Satirapoj2, Do Gia Tuyen3, Marjorie W. Y. Foo4, Romina Danguilan5, Sanjeev Gulati6, 7, Sejoong Kim8, Sunita Bavanandan9, Yi-Wen Chiu10, Sydney C. W. Tang11 1Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia 2Division of Nephrology, Department of Medicine, Phramongkutkloa Hospital, Bangkok, Thailand 3Division of Nephrology, Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam 4Department of Renal Medicine, Singapore General Hospital, Duke-NUS Medical School, Singapore 5National Kidney and Transplant Institute, Quezon, the Philippines 6Nephrology and Kidney Transplant Fortis Group of Hospitals, New Delhi, India and Manipal University, India 7Department of Nephrology, Manipal University, Manipal, India 8Division of Nephrology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea 9Department of Nephrology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia 10Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 11 Division of Nephrology, Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China The disease burden of chronic kidney disease (CKD) and its impact on healthcare systems has been poorly studied in Asia, a socioeconomically diverse region with wide variations in availability, access, and quality of CKD care. The high CKD burden in this region is predominantly driven by an increased prevalence of risk factors including diabetes mellitus, hypertension, obesity, and use of traditional medicines and is further aggravated by challenges associated with effective implementation of population-based screening and surveillance systems in early detection and intervention of CKD. The Asian continent mostly comprised of lowand middle-income countries with resource restraints lacks robust population-based CKD registries resulting in a paucity of data on CKD incidence and prevalence, various treatment modalities, uptake of current guidelines, and the overall impact of implementation of developmental programs. There is an urgent need for a collaborative action plan between the healthcare community and governments in this region to detect CKD in its early stages and prevent its complications including kidney failure, cardiovascular disease, and death. Research-based evidence on the impact of early detection, sustainable treatment options, quality of life, delay or avoidance of dialysis, and related cost analysis is the need of the hour. We highlight successful implementation of strategic and policy-sharing programs adopted in a few countries; also, consolidate available region-specific data, quantify estimates of CKD burden and propose strategies with a multidisciplinary approach involving patients, the healthcare community and governmental bodies to combat CKD and its complications. Keywords: Asia, Chronic renal insufficiency, Prevalence, Risk factors Received: July 28, 2023; Revised: April 12, 2024; Accepted: May 7, 2024 Correspondence: Sydney C. W. Tang Division of Nephrology, Department of Medicine, Queen Mary Hospital, School of Clinical Medicine, The University of Hong Kong, Room 407 Professorial Block, 102 Pokfulam Road, Hong Kong. E-mail: scwtanghku.
----------------------------------------------------------------------


======================================================================
CHUNK 253 of 647
======================================================================
ID: j_krcp_23_194_1
Content Type: definition
Words: 480
Medical Entities: CKD,GFR,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
E-mail: scwtanghku. hk ORCID: 2025 by The Korean Society of Nephrology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial and No Derivatives License (https: // creativecommons. org/licenses/by-nc-nd/4. 0/) which permits unrestricted non-commercial use, distribution of the material without any modifications, and reproduction in any medium, provided the original works properly cited. Kidney Res Clin Pract 2025; 44(3): 411-433 Introduction Methodology Chronic kidney disease (CKD) with a global prevalence of A three-step process was implemented for preparing a 13. 4%, is a major contributor to morbidity and mortality comprehensive review on the burden of CKD in Asia (Fig. due to noncommunicable diseases 1. It is the 12th lead1). A comprehensive and extensive literature review was ing cause of death worldwide and is projected to be the 5th conducted to consolidate data as available in the public leading cause of death by 2040 24. CKD is an independomain on CKD prevalence and disease burden in Asia dent predictor of premature mortality, increased hospital- (defined as countries in Eastern, Southern, and Southeastization, economic burden on patients, payers, healthcare ern Asia, Asia Pacific excluding Australasian countries). infrastructure, and reduced quality of life 5, 6. In 2016, an In November 2022, a steering committee meeting conestimated 1. 2 million persons died due to CKD, and it is sisting of 10 experts from Hong Kong, India, Indonesia, forecasted that approximately 2. 2 to 4. 0 million lives will Republic of Korea, Malaysia, the Philippines, Singapore, be lost to CKD by 2040 7. The change in the burden of Taiwan, Thailand, and Vietnam, was convened to review CKD from 1990 to 2016 in terms of incidence, prevalence, the regional burden, evaluate the role of risk factors on death, and disability-adjusted life years (DALYs) showed incidence and progression of CKD, and the unmet needs an alarming rise with CKD incidence increasing by 89%, and challenges unique to Asia. The committee aimed to prevalence by 87%, death due to CKD by 98%, and DALYs outline region-specific guidance strategies in the early by 62% 8. This trend is driven by increased incidences of type 2 diabetes mellitus (T2DM), hypertension (HTN), and obesity in an increasing age population worldwide. CKD is defined as abnormalities of kidney structure Comprehensive literature review to compile and analyze available or function, present for 3 months, with implications for data on the prevalence of CKD and its impact in the Asia region health. Glomerular filtration rate (GFR) is a gold standard marker for kidney function. Decreased GFR (60 mL/ min/1. 73 m2) for 3 months indicates CKD while renal failFirst Steering Committee Meeting (November 2022)a Expert panel discussion on the regional burden, risk factors, ure is defined as GFR 15 mL/min/1. 73 m2. CKD is associand unmet needs and challenges in CKD management unique to ated with an elevated risk of developing cardiovascular disAsia region ease (CVD) 6.
----------------------------------------------------------------------


======================================================================
CHUNK 254 of 647
======================================================================
ID: j_krcp_23_194_2
Content Type: recommendation
Words: 479
Medical Entities: CKD,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
73 m2. CKD is associand unmet needs and challenges in CKD management unique to ated with an elevated risk of developing cardiovascular disAsia region ease (CVD) 6. Asia has one of the highest CKD prevalence rates worldwide and is currently witnessing an exponential rise in the incidence of diabetes mellitus (DM) and HTN Initial draft reviewed by the Steering Committee 9. The Asian continent mostly consists of lowand middle-income countries that have resource restraints with a lack of robust population-based CKD registries resulting in Second Steering Committee Meeting (February 2023) was convened to further deliberate and finalize the manuscript content a paucity of data on CKD prevalence, disease burden, and the overall impact of implementation of developmental programs. Final manuscript (outcome of a synthesis of literature review This review aims to provide a comprehensive updated findings, insights gathered from expert panel discussion, and the overview of the region-specific prevalence and disease resulting consensus recommendations) burden of CKD in Asia. It also describes the challenges and unmet medical needs unique to this region with diverse Figure 1. Steering Committee composition and methodology socioeconomic and cultural backgrounds. It also aims to for the development of manuscript. CKD, chronic kidney disease. provide strategies and guidance for CKD management aSteering Committee comprised of 10 nephrology specialists repamidst diversity of the region, providing a platform for reresenting a diverse array of countries including Hong Kong, India, gional policy makers to bring healthcare improvement in Indonesia, Malaysia, the Philippines, Republic of Korea, Singapatients with CKD. pore, Taiwan, Thailand, and Vietnam. 412 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia detection of CKD and retardation of its progression by imRegional prevalence and disease burden of chronic plementing effective screening, surveillance programs, and kidney disease across Asia guideline-driven management. The expert panel provided an update on the current CKD screening, surveillance, and There is a substantial variation in the prevalence of CKD management practices and discussed the successful implebetween countries in the Asia region that ranges between mentation of strategic programs adopted in their respective 7. 0% and 34. 3% 10. An estimated 434 million people have countries. These strategies incorporated current evidence CKD across Eastern, Southern, and Southeastern Asia of and adapted to the local healthcare framework. which 65 million are in advanced stages of CKD (stages Comprehensive nonsystematic literature search of the 45) 10 between 1990 and 2019; all-age incident cases MEDLINE and EMBASE databases using combinations of and CKD death counts more than doubled from 3. 7 milthe key terms: chronic kidney disease, CKD, prevalence lion (range, 3. 4 million4. 0 million) to 9. 8 million (range, and disease burden, Asia, Asia Pacific, diabetic kidney 9. 0 million10. 6 million) and 340, 636 (316, 106365, 632) disease, risk factors was done. Articles published before to 763, 024 (696, 050823, 829), respectively (Table 1) 9. the year 2000 were excluded.
----------------------------------------------------------------------


======================================================================
CHUNK 255 of 647
======================================================================
ID: j_krcp_23_194_3
Content Type: reference
Words: 496
Medical Entities: CKD,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
0 million) to 9. 8 million (range, and disease burden, Asia, Asia Pacific, diabetic kidney 9. 0 million10. 6 million) and 340, 636 (316, 106365, 632) disease, risk factors was done. Articles published before to 763, 024 (696, 050823, 829), respectively (Table 1) 9. the year 2000 were excluded. The panel critically reviewed The years lived with disability ranged from 60 to 180 per the published literature and provided a country-specific 100, 000, with the highest in Thailand, Malaysia, Singapore, update on factors impacting the care continuum of CKD in and the Philippines. However, the years of life lost (YLLs) their countries such as commonly used screening methwere similar in most of the countries in Asia region (400 odologies, identification of target population for screening to 600 per 100, 000), with the exception of the Philippines and monitoring, availability of dialysis resources, newer with a YLL rate between 1, 000 and 1, 200 per 100, 000 (Suptherapeutic agents, healthcare reimbursement policies plementary Fig. 1, available online) 11. Most countries in and patient education strategies and programs. Although Asia reported an increase of 100% or more in the absolute mainland China and Japan were included in the evidence count of CKD incidents, prevalent cases, deaths, and DAreview, the disease burden data reported in this manuLYs between 1990 and 2019 9. script and the strategies and future directions suggested There is a preponderance of CKD in younger age groups by the panel are specific to the 10 countries represented by in Asian countries with more than 50% of prevalent cases the participating experts. seen in those below the age of 50 years 12, 13. The Indian Chronic Kidney Disease (ICKD) study, an ongoing compreTable 1. The country-wide burden of chronic kidney disease Country Prevalencea Incidence Death DALYsa China 150. 5 (138. 6162. 3) 3. 1 (2. 83. 4) 0. 2 (0. 20. 2)a 5. 8 (5. 06. 6) India 115. 2 (106. 6124. 2) 2. 2 (2. 02. 4) 0. 2 (0. 20. 3)a 7. 5 (6. 68. 5) Indonesia 25. 9 (23. 828. 0) 0. 4 (0. 40. 4) 0. 04 (0. 030. 05)a 1. 6 (1. 41. 9) Japan 24. 7 (23. 126. 4) 1. 0 (0. 91. 1) 0. 04 (0. 030. 05)a 0. 8 (0. 70. 9) Thailand 11. 3 (10. 512. 1) 0. 3 (0. 30. 3) 0. 03 (0. 020. 03)a 0. 7 (0. 60. 9) Philippines 10. 2 (9. 511. 1) 0. 2 (0. 20. 3) 0. 03 (0. 030. 04)a 1. 1 (0. 91. 3) Vietnam 10. 0 (9. 210. 8) 0. 2 (0. 20. 2) 0. 02 (0. 020. 02)a 0. 6 (0. 50. 7) Republic of Korea 5. 5 (5. 25. 8) 0. 2 (0. 20. 2) 7, 979 (6, 9318, 864) 0. 2 (0. 20. 2) Taiwan 3. 7 (3. 53. 9) 0. 1 (0. 10. 1) 8, 248 (6, 51210, 329) 0. 2 (0. 20. 3) Malaysia 3. 1 (2. 93. 4) 0. 1 (0. 10.
----------------------------------------------------------------------


======================================================================
CHUNK 256 of 647
======================================================================
ID: j_krcp_23_194_4
Content Type: reference
Words: 486
Medical Entities: CKD,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
5 (5. 25. 8) 0. 2 (0. 20. 2) 7, 979 (6, 9318, 864) 0. 2 (0. 20. 2) Taiwan 3. 7 (3. 53. 9) 0. 1 (0. 10. 1) 8, 248 (6, 51210, 329) 0. 2 (0. 20. 3) Malaysia 3. 1 (2. 93. 4) 0. 1 (0. 10. 1) 6, 105 (4, 8677, 450) 0. 2 (0. 20. 2) Singapore 0. 7 (0. 70. 70) 0. 02 (0. 020. 02) 758 (656830) 0. 02 (0. 020. 02) Hong Kong NA Data are expressed as mean (range). Countries are listed in descending order of prevalence. DALYs, disability-adjusted life years; NA, not applicable. aData presented in millions. Reused from the article of Aashima et al. (Nephrology Carlton 2022; 27: 610620) 9 with original copyright holders permission. www. krcp-ksn. org 413 hensive evaluation of a nationwide cohort of patients with 23, 24. mild-to-moderate CKD found the cohort to be younger as The incidence of treated kidney failure in Asian countries compared to Western cohorts by 5 to 20 years. This trend ranged from 525 per million population (pmp) (Taiwan) to is seen in other Asian cohorts as well with the exception 116 pmp (mainland China) 2528 (Fig. 2). of Japan 13. Asia has a high population of patients with Although most countries in Asia provide all three moadvanced CKD as the majority of patients with early stages dalities of KRTHD, peritoneal dialysis (PD), and kidney remain undetected 1419. transplantation, there remains considerable variability in the availability and costs of treatment (Fig. 3A). A number Burden of renal replacement therapy on patients, caregivof the countries have adequate access to KRT and compreers, and healthcare system hensive KRT registries except a few lowand low-to-middle income countries (Fig. 3B) 17. The cost implications of CKD results in an increased economic burden on the KRT are significant, for both patients and healthcare syspatient, attributable to multiple ambulatory visits, more tems. PD is a cost-effective option in this region and can be frequent and longer hospitalizations, and higher treatment as low as one-third that of HD and thus has been promoted costs as a result of associated comorbidities. The health-reas the preferred choice in Hong Kong 17, 29. Countries lated quality of life is significantly impacted in CKD palike Japan, Republic of Korea, Hong Kong, and Taiwan have tients and is inversely proportional to the stage of CKD, full coverage for KRT via national health insurance while age, and socioeconomic profile of the patients 20, 21. others provide partial coverage with assistance from NGOs. Several estimates forecast the use of kidney replacement In China, there were approximately one million kidney therapy (KRT) to more than double by 2030, with the largfailure patients in 2017 with only 52% on KRT 30. HD is est increase seen in Asia 22. The demography of the popthe predominant KRT modality, accounting for approxulation requiring hemodialysis (HD) in Asia region differs imately 86% of dialysis patients 31.
----------------------------------------------------------------------


======================================================================
CHUNK 257 of 647
======================================================================
ID: j_krcp_23_194_5
Content Type: definition
Words: 483
Medical Entities: CKD,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
HD is est increase seen in Asia 22. The demography of the popthe predominant KRT modality, accounting for approxulation requiring hemodialysis (HD) in Asia region differs imately 86% of dialysis patients 31. From 2018 to 2021, from the west in two aspects namely the relatively younger overall kidney failure incidence and prevalence rates have age and the higher prevalence of CKD of unknown etiology increased from 164 to 197 pmp and 1, 388 to 1, 499 pmp, Mainland China Hong Kong India Malaysia Japan Thailand Republic of Korea Singapore Taiwan Kidney failure incidence (per million population) Figure 2. Incidence of kidney failure in the Asian region. The figure offers a comparative overview of the incidence of kidney failure (defined as glomerular filtration rate 15 mL/min/1. 73 m2), highlighting the variation across Asian countries. Data as of 2022; data unavailable from Indonesia, the Philippines, and Vietnam. Reused from the United States Renal Data System ( 25. noigeR/seirtnuoC Kidney Res Clin Pract 2025; 44(3): 411-433 116 173 232 292 307 339 355 376 525 0 100 200 300 400 500 600 414 www. krcp-ksn. org Thailand Taiwan Singapore Malaysia Indonesia Hong Kong China Singapore Taiwan Hong Kong Thailand Malaysia Figure 3. Trend in the utilization of kidney replacement modalities by country among patients with kidney failure. (A) Hemodialysis (HD) and peritoneal dialysis (PD). (B) Kidney transplantation. Most Asian countries showed a higher utilization of HD spanning from 84% to 93%. Notably, Hong Kong exhibited a greater preference for PD (68%). Data as of 2022; data unavailable from Republic of Korea, the Philippines, India, and Vietnam. Reused from the United States Renal Data System ( 25. respectively. In the Philippines, although a PD-first policy however, initiatives are underway to increase the uptake was implemented, it was less successful and HD continues of PD to reduce costs 34. In Malaysia, there is a PD-first to be the most common modality of KRT 32. In Vietnam, policy within the Ministry of Health centers but overall in though there is a paucity of data on the number of patients the country, 85. 2% of kidney failure patients are on HD and with kidney failure in need of dialysis, it is estimated to only 11. 2% on PD 19. A population-based study in India be over 100, 000 persons with approximately 30% on HD reported the crudeand age-adjusted kidney failure inci- 33. In Indonesia, HD continues to be the KRT of choice, dence rates as 151 and 232 pmp, respectively 35, 36. HowyrtnuoC yrtnuoC Makmun, et al. Burden of chronic kidney disease in Asia A 84 16 92 8 87 13 88 12 93 7 32 68 86 14 0 10 20 30 20 40 50 60 70 80 90 100 Patient composition (%) HD PD B 18 15 10 6 2 0 2 4 6 8 10 12 14 16 18 20 Kidney transplantation (per million population) www. krcp-ksn.
----------------------------------------------------------------------


======================================================================
CHUNK 258 of 647
======================================================================
ID: j_krcp_23_194_6
Content Type: reference
Words: 500
Medical Entities: CKD,dialysis,albuminuria,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
krcp-ksn. org 415 Kidney Res Clin Pract 2025; 44(3): 411-433 ever, only 175, 000 and 8, 500 people were receiving HD and parity PPP) in 2010 to USD 785 million (PPP) in 2016 48. PD, respectively, as per a survey conducted in 2018 37, 38. Since most of the HD facilities are located in urban regions, Risk factors for chronic kidney disease and its home-based PD that can be self-administered by patients progression in Asia or caregivers is being advocated to be included as the first option KRT in policies in several Asian countries such as The risk factors associated with CKD can be classified as India, Indonesia, and Vietnam. Cost-utility and budget imsusceptibility factors that increase an individuals susceptipact analyses from Thailand, China, Indonesia, Singapore, bility to renal damage, initiating factors that directly initiate and Malaysia using real-practice dialysis data show PD as a renal damage, and progression factors that worsen renal cost-effective and sustainable form of initial treatment reldamage resulting in rapid decline of renal function (Fig. 4) ative to HD from both governmental and patient perspec- 49. tives 3942. DM and HTN are the more common risk factors of CKD In Thailand, over 0. 1 million patients require dialysis in developed countries, whereas glomerulonephritis and 18, 43, 44 and 20, 000 people with kidney failure need unknown causes account for higher incidence of CKD in treatment with HD or PD every year. Its PD-first policy developing countries 23, 50. The prevalence of kidney has saved the lives of nearly 50, 000 kidney failure patients failure is higher among men, despite a higher prevalence under the universal coverage scheme 45. The economic of CKD in women 5153. With considerable variation in burden of CKD is available for Singapore where the annuCKD etiology, chronic glomerulonephritis (e. g. , immunoal expenditure for dialysis accounts for USD 230 million globulin A IgA nephropathy) continues to be the leading 46, 47 and Malaysia where the total annual expenditure on cause of CKD in several countries like Japan, China, and kidney failure by the public sector has grown 94% within a Thailand while infectious disease-related CKD or CKD of span of 7 years, from USD 405 million (purchasing power unknown origin (CKDu) are highly prevalent in certain Risk factors Susceptibility factors Initiating factors Progression factors Ethnicity Autoimmune diseases Acute kidney injury Family history Diabetes mellitus Cardiovascular disease Lower socioeconomic status Drug toxicity and pesticide use Dyslipidemia Low birth weight Glomerulonepharitis Hyperkalemia, Male sex Hypertension hyperphostaemia, anemia Older age Nephrolithiasis High-dietary protein intake Obesity Nephrotoxins Higher level albuminuria NSAIDS and herbal medicines Higher blood pressure level Polycystic kidney disease Metabolic acidosis Systemic infections Obesity Tropical infections Poor glycemic control in diabetics Urinary tract infections or obstructions Smoking Figure 4. Risk factors for chronic kidney disease initiation and progression. Figure depicts the risk factors associated with the initiation and progression of chronic kidney disease that lead to exacerbation of kidney damage leading to a rapid decline in kidney function. NSAIDs, nonsteroidal anti-inflammatory drugs. 416 www.
----------------------------------------------------------------------


======================================================================
CHUNK 259 of 647
======================================================================
ID: j_krcp_23_194_7
Content Type: reference
Words: 496
Medical Entities: CKD,GFR,dialysis,proteinuria,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Risk factors for chronic kidney disease initiation and progression. Figure depicts the risk factors associated with the initiation and progression of chronic kidney disease that lead to exacerbation of kidney damage leading to a rapid decline in kidney function. NSAIDs, nonsteroidal anti-inflammatory drugs. 416 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia other parts of the region such as India 5456. CKD and subsequent kidney failure with a poor prognosis 54, 55. Patients of Asian descent diagnosed with Diabetes mellitus IgA nephropathy tend to have a poorer prognosis and an increased risk of progression to kidney failure 76. In The Global Burden of Disease Study of 2019 showed DM to a registry-based study on patients of Pacific Asian oribe the cause of the majority of CKD incidence worldwide gin in North America with biopsy-proven idiopathic IgA with Asia accounting for the highest prevalence of DMnephropathy, the risk of renal failure (end-stage renal CKD, especially in South and Eastern regions 57. The disease) was approximately 1. 5 times higher along with a prevalence of CKD in patients with DM ranged from 25% to faster decline in estimated GFR (eGFR). The most common 53% 19, 5865. Though the prevalence of CKD in patients form of glomerulonephritis in Singapore is membranous with DM is not reported, a high proportion of CKD has glomerulonephritis; however, there is a rising prevalence been reported in Philippines (35. 9%) 66. In Singapore, of focal segmental glomerulosclerosis as well, similar to DM remains the leading cause of kidney failure in new Malaysia, Thailand, and China 56. In Indonesia, primary patients starting dialysis, accounting for 68. 2% of cases in glomerulopathy (comprised of 8% of CKD patients) and 2019 67. Based on the recent 2021 registry data, diabetic autoimmune diseases (around 1% of CKD patients have nephropathy accounts for 66. 9% of incident dialysis and systemic lupus erythematosus) are some of the significant 56. 3% of prevalent dialysis in the Singaporean population risk factors for CKD 14. According to the CKD registry of 28. the Indian Society of Nephrology, glomerulonephritis is the second most common cause of CKD in India 13. Hypertension Lifestyle and environmental factors Patients with CKD and HTN are at a higher risk of kidney failure than patients with blood pressure (BP) within norLifestyle factors, i. e. , diet, physical inactivity, alcohol conmal limits 68. A recent systematic review reports the oversumption, tobacco smoking, a higher salt intake, and obesiall prevalence estimate of HTN in the Southeast Asian urty are major drivers for CKD. Numerous population-based ban population as 33. 82% 69. In a narrative review by Teo studies have shown an association between obesity and et al. 70, it was found that HTN-associated CKD, particudevelopment of proteinuria, decreased eGFR, and rapid larly in the Asia region, accounts for the largest proportion progression of CKD 77, 78. Asia has seen an alarming of CKD burden. The prevalence of HTN in the general poprise in obesity 79, 80.
----------------------------------------------------------------------


======================================================================
CHUNK 260 of 647
======================================================================
ID: j_krcp_23_194_8
Content Type: reference
Words: 484
Medical Entities: CKD,GFR,proteinuria
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
70, it was found that HTN-associated CKD, particudevelopment of proteinuria, decreased eGFR, and rapid larly in the Asia region, accounts for the largest proportion progression of CKD 77, 78. Asia has seen an alarming of CKD burden. The prevalence of HTN in the general poprise in obesity 79, 80. High sodium diet is linked with an ulation and in CKD patients are tabulated for Asian counincreased risk of acid reflux, high BP, and resistance to the tries as available (Supplementary Table 1, available online) effects of renin-angiotensin system (RAS) blockers which 14, 19, 43, 7075. The overall prevalence of HTN among the may contribute to kidney failure 81. adult population in 2013 was 25. 2% in males from 29% in Epidemiological studies suggest a plausible link between 2008, and 19. 3% in females from 22%, while the prevalence exposure to ambient fine particulate matter PM and kid2. 5 of DM increased to 5. 6% from 4% in males, and 5. 3% from ney disease 82. 5. 5% in females. With the current population of the Philippines at 100 million, this represents a substantial populaTropical diseases tion at risk for CKD. Notably, HTN is decreasing while DM is significantly increasing from 3% in 2003 to 5. 4% in 2014. Certain tropical diseases and conditions endemic to Asia can cause severe renal injury and complicate preexisting Glomerulonephritis and immunoglobulin A nephropathy renal disease. Tropical infections such as malaria, leishmaniasis, leptospirosis, and dengue can involve the kidIgA nephropathy, the most common form of primary neys, varying from transient urinary abnormalities to seglomerulonephritis (30%40%) worldwide, is highly prevvere acute kidney injury (AKI) 83, 84. It has been reported alent in the Asian population and is the leading cause of that a significant proportion of patients with no preexisting www. krcp-ksn. org 417 Kidney Res Clin Pract 2025; 44(3): 411-433 kidney disease who recover from AKI develop CKD and 92. Similarly, metabolic acidosis occurs in about 20% of patients with preexisting kidney disease suffer progression patients with CKD and contributes to CKD progression. 85. Early intervention and correction of metabolic acidosis can In Indonesia, Weils disease and infections such as leptoimpede the progression of CKD 95. spirosis are known to contribute to CKD progression 86. Acute kidney injury Indigenous medicines and chronic kidney disease of unknown origin AKI is a critical risk factor for CKD 96. In a meta-analysis on the global burden of AKI, the incidence of AKI in the In South Asian countries such as Sri Lanka, Thailand, and hospitalized population ranged from 11. 6% to 31. 0% 97 India, CKDu is suspected to be due to the presence of 99. The high prevalence of AKI in Asia is mostly due to the environmental toxins (heavy metals, pesticides) in combiuse of nephrotoxic medicines, exposure to environmental nation with factors such as heat stress, and underground nephrotoxins, drug-induced AKI, and infections. water with high fluoride levels 87, 88.
----------------------------------------------------------------------


======================================================================
CHUNK 261 of 647
======================================================================
ID: j_krcp_23_194_9
Content Type: general
Words: 448
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
The high prevalence of AKI in Asia is mostly due to the environmental toxins (heavy metals, pesticides) in combiuse of nephrotoxic medicines, exposure to environmental nation with factors such as heat stress, and underground nephrotoxins, drug-induced AKI, and infections. water with high fluoride levels 87, 88. CKDu is distinct in the clinicopathologic characteristics with lower age group Existing framework for diagnosis and being commonly affected with minimal to no proteinuria. management of chronic kidney disease in Asia The disease progresses rapidly leading to stage 5 CKD needing KRT over a span of several months 87. Regular Early detection of CKD is crucial for initiating timely therause of certain herbal medicines has also been a documentpeutic interventions, thereby delaying further progression ed cause of CKD in certain Asian populations. The use of and subsequently limiting the risk of long-term morbidity aristolochic acid-containing herbs is responsible for the and mortality associated with the disease 51. Despite the high prevalence of CKD in Taiwan 89. Heavy metals (merenormous health burden of CKD in Asian countries, only cury) contained in traditional medicines can cause chronic a few accepted guidelines are available for implementing poisoning, which can cause membranous nephropathy effective screening and surveillance programs facilitating 90. early identification of CKD in high-risk populations in this region. Anemia and electrolyte disturbances in chronic kidney Persistently elevated serum creatinine and albuminuria disease are important diagnostic and prognostic biomarkers of CKD. For initial assessment, measurement of eGFR using Anemia is a common complication that contributes to the serum creatinine is considered the gold standard because disease burden of CKD 91. It significantly increases the of its affordability, easy accessibility, and long history of risk of morbidity and mortality in CKD patients particularly clinical use. Estimating equations for eGFR measurement those with comorbidities of DM and/or HTN. The develsuch as Chronic Kidney Disease Epidemiology Collaboraopment of anemia in CKD patients is due to an absolute or tion (CKD EPI) and Modification of Diet in Renal Disease relative deficiency of erythropoietin. Prevalence of anemia (MDRD) are widely accepted across the Asian region in is higher in uncontrolled HTN than in well-controlled, routine clinical practice 100. However, these equations suggesting that HTN is independently associated with have been mainly derived and validated in the Western increased anemia risk 92. Hyperkalemia is a common population and are associated with inherent inaccuracies finding in CKD which is associated with decreased renal in GFR estimation due to racial variation, which limits their ion excretion, as well as the use of some medications for general use across diverse Asian ethnicities. In an attempt CKD or DM and heart failure 93. Hyperphosphatemia to improve eGFR, some investigators proposed modificais common in CKD 94.
----------------------------------------------------------------------


======================================================================
CHUNK 262 of 647
======================================================================
ID: j_krcp_23_194_10
Content Type: recommendation
Words: 484
Medical Entities: CKD,GFR,albuminuria
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
In an attempt CKD or DM and heart failure 93. Hyperphosphatemia to improve eGFR, some investigators proposed modificais common in CKD 94. It has a significant effect on vastions in the original CKD-EPI equation allowing adjustcular calcifications, and the onset of the complex mineral ment for racial differences, which resulted in more accurate and bone disorders associated with CKD, together with eGFR estimations in Asian, Taiwanese, and Chinese CKD hypocalcemia and decreased 1-25(OH) vitamin D levels patients 61, 101103. It can be challenging to establish the 2 418 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia best GFR estimating equation for a population, due to a tin C is limited by less availability and high cost, compared lack of evidence supporting its application to a particular to serum creatinine 111. setting or racial ethnicity 104. Kidney Disease: Improving Persistent albuminuria is a definite marker of impaired Global Outcomes (KDIGO) 2012 guidelines recommend renal function, irrespective of eGFR 105. Measurement using the 2009 CKD-EPI creatinine equation in adults for of albuminuria by a spot urine sample using either albuinitial and subsequent eGFR estimation unless an alternamin-specific dipsticks or urine albumin-to-creatinine ratio tive modified equation has been validated in the local pop- (UACR) is most accepted by physicians and nephrologists. ulation 105. Recently, the Task Force from the National KDIGO preferentially recommends using UACR, followed Kidney Foundation and American Society of Nephrology by urine protein-to-creatinine ratio over total protein urirecommended the implementation of a new 2021 CKD-EPI nalysis strips (either automated or manual) in assessing equation for calculating eGFR without racial co-efficient albuminuria in CKD diagnosis and follow-up. Although to improve generalizability across different populations; quantitative assessment of albuminuria using UACR is however, studies validating its performance in Asian popufavored and recommended by the guidelines, it is unaflation are warranted 106. fordable in certain developing Asian countries and dipCystatin C is recommended by KDIGO 2012 guidelines stick screening is considered acceptable to be followed by as a reliable biomarker of kidney function which is less inappropriate confirmatory testing 112. Commonly used fluenced by racial differences, compared to creatinine. Indiagnostic tests used in countries across Asia are listed in creased cystatin C levels have been found to be associated Table 2. with a higher risk of developing CKD, CVD, kidney failure, and mortality 107109. Staging of CKD mainly based on Definition and classification of chronic kidney disease serum creatinine might lead to misclassification of patients due to false positives and therefore, the use of equations The definition and indications of CKD have been described involving both serum cystatin C and creatinine have been in current KDIGO guidelines. Classification of CKD is suggested to improve diagnostic accuracy, risk stratificabased on the cause, GFR category, and albuminuria catetion assessment for CKD and reduced requirement of folgory (Supplementary Tables 2 and 3, available online). low-up testing 105, 110. However, the use of serum cystaTable 2.
----------------------------------------------------------------------


======================================================================
CHUNK 263 of 647
======================================================================
ID: j_krcp_23_194_11
Content Type: recommendation
Words: 471
Medical Entities: CKD,GFR,dialysis,albuminuria,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Classification of CKD is suggested to improve diagnostic accuracy, risk stratificabased on the cause, GFR category, and albuminuria catetion assessment for CKD and reduced requirement of folgory (Supplementary Tables 2 and 3, available online). low-up testing 105, 110. However, the use of serum cystaTable 2. Commonly used diagnostic tests across Asia Test Country Blood pressure eGFR UACR Dipstick Serum creatinine China No Yes (CKD-EPI) Yes Yes No Hong Kong No Yes Yes Yes No India No Yes Yes (or UPCR) Yes No Indonesia No Yes (CKD-EPI) Yes (or UPCR) Yes No Japan No No No Yes Yes Singapore No Yes (calculated) Yes No Yes Malaysia No Yes (CKD-EPI) Yes (for DM patients if Yes No dipstick is negative) Philippines No Yes Yes No No Republic of Korea Yes Yes (calculated) Yes (or UPCR) Yes No Taiwan No Yes (MDRD) Yes No Thailand No Yes (CKD-EPI) Yes (only in CKD patients) Yes (for screening) No Vietnam No Yes Yes Yes No Countries are listed in alphabetical order. CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; UACR, urinary albumin-to-creatinine ratio; UPCR, urine protein-to-creatinine ratio. www. krcp-ksn. org 419 Kidney Res Clin Pract 2025; 44(3): 411-433 Existing chronic kidney disease management strategies treating kidney failure to preventing its development in the first place. Effective prevention, early detection, conservaBoth KDIGO and Asian Pacific Society of Nephrology tive management, an appropriate combination of dialysis clinical practice guidelines advocate annual screening modalities, and optimizing the availability of kidney transof patients with T2DM for CKD, starting from the time plantation form the cornerstone of CKD care strategies. of diagnosis and beginning 5 years after the diagnosis of Asia region is faced with unique challenges such as wide type 1 DM 113, 114. A comprehensive multidisciplinary disparities in the socioeconomic profiles, burden of CKD, management approach is recommended to target these culture, ethnicity, and political landscape. A collaborative risk factors with lifestyle modifications such as proper effort among the government and policymakers of each nutrition, regular physical activity, weight control, and country to achieve better integrated CKD/kidney failure abstinence from smoking, with regular risk factor assesscare will improve kidney care of patients in the region. ment every 3 to 6 months. As per the latest KDIGO 2022 Developmental programs aimed at improving clinical outguidelines, sodium-glucose cotransport 2 inhibitors can comes and optimizing healthcare costs associated with be initiated as first-line therapy in patients with T2DM and CKD management are undertaken by several countries CKD with eGFR 20 mL/min/1. 73 m2 (updated from 30 (Table 3 119124). Several screening strategies aimed at mL/min/1. 73 m2 in the 2020 guidelines) and continued the general and high-risk population are currently undertill the initiation of dialysis or KRT. This recommendation taken at national levels (Table 4).
----------------------------------------------------------------------


======================================================================
CHUNK 264 of 647
======================================================================
ID: j_krcp_23_194_12
Content Type: recommendation
Words: 488
Medical Entities: CKD,GFR,dialysis,albuminuria
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
73 m2 (updated from 30 (Table 3 119124). Several screening strategies aimed at mL/min/1. 73 m2 in the 2020 guidelines) and continued the general and high-risk population are currently undertill the initiation of dialysis or KRT. This recommendation taken at national levels (Table 4). is strongly based on findings from recent clinical trials, which have clearly demonstrated the efficacy and safety Unmet needs and challenges unique to Asia of dapagliflozin in patients with eGFR 5 mL/min/1. 73 m2 and albumin-to-creatinine ratio 200 to 5, 000 mg/g Limited screening and surveillance systems impacting (DAPA CKD trial) and empagliflozin among patients with chronic kidney disease prevention eGFR 20 mL/min/1. 73 m2 and heart failure (EMPEROR and EMPA Kidney trial) 115117. Additionally, hyperFour of the 10 International Society of Nephrology world parathyroidism (HPT) has been linked to adverse renal regions are located in the Asia sector, ie, North and East, and cardiovascular outcomes in patients with CKD. In Oceania and South-East Asia South Asia, and the Middle 2021, KDIGO recommended the use of standardized BP East 125. The region is socioeconomically, culturally, measurement, treated with a target systolic BP 120 mmHg and ethnically diverse. As per the World Bank, China, 118. Treatment with antihypertensive medications such India, Thailand, Vietnam, Indonesia, Malaysia, and the as RAS inhibitors (angiotensin-converting enzyme inhibiPhilippines are middle-income economies, whereas Hong tor ACEi or angiotensin receptor blocker ARB) is the recKong, Singapore, Republic of Korea, Taiwan, and Japan are ommended first-line therapy for patients with HPT, CKD, high-income economies. CKD screening and targeted early and moderate to severe albuminuria (G1G4, A2A3), with identification while asymptomatic or at an early stage can or without DM. These recommendations discourage using enable effective interventions that can delay disease proany combination of ACEi, ARB, and direct renin inhibitors gression and reduce the incidence of associated compliin patients with severe kidney impairment (Supplementary cations such as cardiovascular risk, dyslipidemia, anemia, Fig. 2, available online). and bone and mineral disease (Fig. 5) 4, 126. Multiple barriers prove to be hindrances in the impleSuccessful chronic kidney disease care strategies mentation of screening programs in Asia attributable to or policy-sharing programs across Asia patient-related factors or the health system in general. Social risk factors, such as limited financial resources and low Worldwide the nephrology community recognizes the health literacy are significant patient-level barriers. Educacompelling need for a strategic plan to effectively address tional materials may be unavailable in the local vernacular the growing incidence of CKD and an integrated approach which may be an obstacle in the rural areas of Asian counfor its management. The mindset has transitioned from tries. Lack of regional data leads to the application of West420 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia Table 3. Developmental programs and initiatives for CKD screening Country Developmental programs Taiwan The national kidney care program has resulted in improved clinical outcomes along with a reduction in health care system costs.
----------------------------------------------------------------------


======================================================================
CHUNK 265 of 647
======================================================================
ID: j_krcp_23_194_13
Content Type: reference
Words: 481
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia Table 3. Developmental programs and initiatives for CKD screening Country Developmental programs Taiwan The national kidney care program has resulted in improved clinical outcomes along with a reduction in health care system costs. The Department of Health made CKD prevention and care a major public health priority and an integrated CKD care program was initiated to promote the screening of high-risk populations, patient education, and multidisciplinary team care. Nephrotoxic Chinese herbs containing aristolochic acid were prohibited through public health legislation in 2003. National pay-for-performance programs for CKD were implemented as part of health care improvement projects, along with diabetes mellitus and cardiovascular disease care in 2006 (pre-ESKD program) and 2011 (early CKD program) 119. The Taiwan model has been proposed for adoption by the Indonesian Ministry of Health as well. Republic of Korea The Korean National Health Screening Program for CKD was implemented in 2002 with biannual screening starting at the age of 40 years for CKD by proteinuria (dipstick) and eGFR testing. Korean organ transplantation policies have ensured an increase in the availability of donor transplants, the Korean Society for Transplantation established a webbased registry, the Korean Organ Transplantation Registry to educate patients, donor families, and healthcare professionals. Philippines The Philippines national insurance covers kidney transplantation as a single largest payment for any surgical procedure. Thailand The Chronic Kidney Disease Prevention in the Northeast Thailand (CKDNET) is an initiative to reduce the CKD burden in the region. Pamphlets, posters, brochures, and other media are distributed for CKD education and awareness at the community level. Locally suitable practice guidelines have been formulated 120. Hong Kong The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program is an effective screening program at the primary care level that identified potential subjects for further evaluation and aided in educating the public about the significance of following up even asymptomatic renal diseases 121. Singapore The HALT-CKD program was started in 2017, the Holistic Approach in Lowering and Tracking Chronic Kidney Disease (HALT-CKD) program concentrates on a concerted effort for timely detection and delaying the progression of CKD in primary care settings through an integrated and multi-faceted approach. The program focuses on a series of lifestyle modifications (low-salt diet, physical activity, smoking cessation) and medical interventions such as optimization of RAASi, MRA, and SGLT2i government has also authorized subsidies and reimbursements to reduce the financial burden in CKD patients 122. Malaysia Under the Strategic Action Plan for Healthy Kidneys (ACT-KID) 2018-2025 there are various initiatives utilizing multisectoral collaborations to promote public and healthcare practitioner awareness of CKD which emphasize the need for screening and early detection, as well as guideline-directed CKD management 123. Indonesia The government NHIS launched a noncommunicable and chronic disease management program named Indonesian Chronic Disease Management Program (PROLANIS) in 2014 with T2DM and hypertension as the main focus.
----------------------------------------------------------------------


======================================================================
CHUNK 266 of 647
======================================================================
ID: j_krcp_23_194_14
Content Type: reference
Words: 331
Medical Entities: CKD,GFR,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Indonesia The government NHIS launched a noncommunicable and chronic disease management program named Indonesian Chronic Disease Management Program (PROLANIS) in 2014 with T2DM and hypertension as the main focus. It is specifically designed to be implemented at the primary care level (government-owned community healthcare centers, primary care clinics, or private doctors). As an integrated health service program, it controls the clinical and laboratory outcomes, prevents disease complications and improves patients quality of life 124. This program gives additional benefits to its participants through monthly regular meetings for medical consultation, peer group education by healthcare professionals, healthcare visit reminders, peer club activities, and home visits. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; MRA, mineralocorticoid receptor antagonists; NHIS, National Health Insurance System; RAASi, renin-angiotensin-aldosterone system inhibitors; SGLT2i, sodium glucose cotransporter-2 inhibitor; T2DM, type 2 diabetes mellitus. ern guidelines in a population that is markedly different in countries like India. There is a dearth of key strategies for racial, ethnic, and sociocultural profile. Patient adherence screening and early detection of CKD at a community level to follow-up is a major challenge as patients are apprehenand sensitizing primary care clinicians on its importance. sive of fear of repercussions at the workplace and do not Sparse educational initiatives for patients, inadequate paavail of medical reimbursements and insurance schemes. tient follow-up routines, and lack of multidisciplinary care In Indonesia for example, the National Health Insurance are barriers that are attributable to the healthcare system. reported low screening uptake among patients with DM and HTN for CKD screening despite the screening program Lack of adequate healthcare resources and policies on being covered by national insurance. Rampant practice of chronic kidney disease impacting effective chronic kidney self medications and use of alternative medicines that are disease management potentially nephrotoxic also hinder preventive efforts 89. There are no national-level screening programs in some There are considerable gaps in health care capacity, workwww. krcp-ksn. org 421 Kidney Res Clin Pract 2025; 44(3): 411-433 Table 4.
----------------------------------------------------------------------


======================================================================
CHUNK 267 of 647
======================================================================
ID: j_krcp_23_194_15
Content Type: recommendation
Words: 476
Medical Entities: CKD,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
There are no national-level screening programs in some There are considerable gaps in health care capacity, workwww. krcp-ksn. org 421 Kidney Res Clin Pract 2025; 44(3): 411-433 Table 4. Strategies for regular screening in diabetic/hypertensive populations Campaigns/strategies for regular screening Country General population High-risk population CKD population Hong Kong None Diabetic patients annual complications Covered in regular clinic visits screening India None Physician-directed Indonesia PROLANIS under NHS Republic of Korea World kidney day campaign annually by KSN Campaign for shared decision-making for choosing renal replacement therapy Big walk for kidney campaign by KSN (SDM-ART) in CKD patients School Urine Screening Program for all elementary, middle, and high school students annually (urinalysis) Conscription examination for 19-year-old men (including urinalysis) NHI checkup Local household, workplace subscriber, family members of 40 years old or older, and dependents Conducted once every 2 years, and every year for non-office workers 40and 66-years-old people are subject to a life-changing period of health checkups Employment and recruitment physical examination (including urinalysis) Malaysia Under Skim Peduli Kesihatan untuk Kumpulan B40 (PeKa B40), Malaysian citizens aged 40 years and with household incomes in the bottom 40% are eligible for free health screening in private primary care clinics which includes renal function tests and urine full and microscopic examination Government health clinics (Klinik Kesihatan) in Malaysia provide free health screening for NCDs for Malaysians aged 40 years and above through walk-in or online appointments at selected locations The Social Security Organization (SOCSO) offers free health screening to active SOCSO contributors for more than 12 months who are aged 40 years and above, or between ages 30 to 39 years with NCD health risks Screening for high-risk populations is recommended by local clinical practice guidelines for management of CKD, and the Malaysian Society of Nephrology has organized a structured webinar training program for primary care doctors on CKD prevention, early detection, and management Philippines Tests included in the primary health benefit of the NHI program Annual tests included for all government employees, private corporations Local government units use different strategies for their constituentsthey can have the laboratory tests during annual vaccination programscoincide the tests with other annual programs like community meetings or religious occasions Singapore National Diabetes Workgroup set up to screen and improve care and care delivery for diabetic patients working with primary care teams and setting up of registry HALT-CKD workgroup targets on screening of high-risk groups maximizing treatment for kidney retardation and lifestyle change with collaboration between community and healthcare institution physicians Upcoming Healthier SG program will incorporate approaches for healthier lifestyles for the nation starting with prevention with an emphasis on a community approach ACE Workgroup (ACE clinical guidelines) at the national level to provide objective and credible healthcare guidance, enabling stakeholders to make better-informed choices through evidence-based practice Taiwan Several national programs cover students, 1. N HI reimburses all high-risk groups 1.
----------------------------------------------------------------------


======================================================================
CHUNK 268 of 647
======================================================================
ID: j_krcp_23_194_16
Content Type: definition
Words: 490
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
N HI reimburses all high-risk groups 1. N HI reimburses all the CKD popmilitary personnel, pregnant women, for CKD screening using eGFR and ulation for regular renal function employees, and any adult 45 years ACR follow-up for regular CKD screening using eGFR and 2. E xtra incentives for regular CKD 2. E xtra incentives for CKD regular urine dipstick test screenings in the DM population (pay follow-ups (pay by performance in by performance in DM program) early CKD and pre-ESKD program) Thailand None DM, hypertension, autoimmune disease, renal stone, aging, cardiovascular disease, genetic disease, strong family history of CKD Vietnam Not regularly Screening for CKD done in high-risk population ACE, Agency for Care Effectiveness; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HALT, Holistic Approach in Lowering and Tracking; KSN, Korean Society of Nephrology; NCD, noncommunicable diseases; NHI, National Health Insurance; NHS, National Health Service; PROLANIS, Indonesian Chronic Disease Management Program. 422 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia Indications for referral to specialist GFR 30 mL/min/1. 73 m2 (GFR categories G4G5) Persistent significant albuminuria (ACR 300 mg/g) CKD progression defined as decline in GFR category with at least 25% reduction in eGFR from baseline OR persistent decline in eGFR 5 mL/min/1. 73 m2 annually CKD with hypertension not managed with 4 or more antihypertensive medications Persistent serum potassium derangement Recurring or extensive kidney stones Urinary red call casts (RBC 20/high power field) Categories Measure Normal to mildly Moderately increased Severely increased increased (A1) (A2) (A3) AER (mg/24 hours) 30 30300 300 PER (mg/24 hours) 150 150500 500 ACR (mg/mmol) 3 330 30 (mg/g) 30 30300 300 PCR (mg/mmol) 15 1550 50 (mg/g) 150 150500 500 Protein reagent strip Negative to trace Trace to or greater Figure 5. Indications requiring referral to kidney specialists. Referral indications based on CKD staging and specific conditions warranting comprehensive evaluation and management are elaborated. These indications emphasize the importance of specialized assessment and intervention by kidney specialists to optimize patient care and outcomes in CKD management. Albuminuria and proteinuria can be measured using excretion rates in timed urine collections, the ratio of concentrations to creatinine concentration in spot urine samples, and using reagent strips in spot urine samples. Relationships among measurement methods within a category are not exact. For example, the relationships between AER and ACR and between PER and PCR are based on the assumption that average creatinine excretion rate is approximately 1. 0 g/day or 10 mmol/day. The conversions are rounded for pragmatic reasons (for an exact conversion from mg/g of creatinine to mg/mmol of creatinine, multiply by 0. 113). Creatinine excretion varies with age, sex, race, and diet; therefore, the relationship among these categories is approximate only. ACR 10 mg/g (1 mg/mmol) is considered normal; ACR 1030 mg/g (13 mg/mmol) is considered high normal. ACR 2, 200 mg/g (220 mg/mmol) is considered nephrotic range.
----------------------------------------------------------------------


======================================================================
CHUNK 269 of 647
======================================================================
ID: j_krcp_23_194_17
Content Type: recommendation
Words: 449
Medical Entities: CKD,GFR
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
113). Creatinine excretion varies with age, sex, race, and diet; therefore, the relationship among these categories is approximate only. ACR 10 mg/g (1 mg/mmol) is considered normal; ACR 1030 mg/g (13 mg/mmol) is considered high normal. ACR 2, 200 mg/g (220 mg/mmol) is considered nephrotic range. The relationship between urine reagent strip results and other measures depends on urine concentration. ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCR, protein-to-creatinine ratio; PER, protein excretion rate; RBC, red blood cell. force limitations, and quality of care in Asia. tact in almost all cases of CKD and play a vital role in the detection and management of early-stage CKD, lack the Work force limitations competencies and understanding of current guidelines Primary care physicians who are the first clinical conin the diagnosis and management of CKD. There is a perwww. krcp-ksn. org 423 Kidney Res Clin Pract 2025; 44(3): 411-433 sistence of traditional, less accurate diagnostic procedures level that includes demographics, current treatment, and and limited availability and affordability of tests for more clinical outcomes 129. There are wide variations between reliable biomarkers of CKD such as eGFR and UACR 127. the registries as well with a few being very specific capThere is uncertainty regarding the right time to refer to a turing granular details such as ethnic differences, while nephrologist causing a delay in timely intervention. Referothers lack basic data. Most countries also do not maintain rals are further adversely impacted by patient-level barriers a systematic repository of data consisting of disease, occursuch as nonavailability of appointments and referral cenrence, prevalence, clinical outcomes, demographic data, ters being too far. The role of community health workers is and cost of treatments (Fig. 6). Although a few registries paramount especially in rural communities and there is a were developed, the data collection was manual with limgeneral lack of understanding and low risk perception reitations in data quality and quantity. The use of technology garding CKD within this group resulting in delayed diagnomay aid in more granular data collection. sis at a primary care level. Continuous in-service training is crucial in the management of CKD patients and has not Emerging research and future actionable been successfully implemented across Asia. directions in chronic kidney disease detection and management in Asia: consensus Inadequate reimbursement systems recommendations The availability of specialist nephrologists (ratio of nephrologists per patient and ratio of nephrologists per patient on Early stages of CKD and the subsequent transition to adKRT) shows a significant disparity in Asian countries, as vanced stages and finally to kidney failure, both pose high this is driven by policies specific to the country. Availability clinical risks and carry substantial healthcare-related costs.
----------------------------------------------------------------------


======================================================================
CHUNK 270 of 647
======================================================================
ID: j_krcp_23_194_18
Content Type: reference
Words: 416
Medical Entities: CKD,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Availability clinical risks and carry substantial healthcare-related costs. of KRT shows significant disparity with some Asian counResearch-based evidence about the impact of early detectries such as Singapore, Thailand, Taiwan, Hong Kong, and tion, sustainable treatment options, quality of life, delay or Malaysia having adequate KRT facilities and the treatment complete avoidance of dialysis, and related cost analysis being mostly publicly funded; whereas, in other countries, is the need of the hour. Initiatives directed at effective deKRT facilities are limited with inadequate or nonexistent tection and management of CKD can be categorized into reimbursement policies such as India where patients bear three levels: patient, physician and medical societies, and the expenses of KRT. KRT reimbursement policies of counpolicy makers and government. tries in Asia are listed below (Table 5). Patient advocacy groups for increasing CKD awareness and eliminating negative perceptions about the disease Lack of adequate data, policies, and programs among CKD patients have been particularly beneficial in India as primary care physicians are often busy in hospiThere is a lack of exact estimates of CKD burden in Asia tals and have limited time for such activities. In Republic with limited screening and surveillance systems. Current of Korea, short educational videos engage the younger data collection efforts are focused on KRT through dialysis population with access to the internet and smartphones and transplantation registries; however, systematic assessand create CKD awareness. This is similar to the situation ment of CKD in its early stages is critical as well 128. Kidin Malaysia, where social media platforms such as internet ney failure registries are currently maintained in Taiwan websites are managed by nephrologists to provide public (Taiwan Renal Data System), Hong Kong (Renal Registry of and patient information, and patient chat groups have Hong Kong), Malaysia (Malaysian Dialysis and Transplant been established to provide support and counteract health Registry), Indonesia (Indonesian Renal Registry), Japan misinformation. At the physician and medical society level, (Japan Kidney Disease Registry), Thailand (Thailand Reappropriate management of co-morbid metabolic diseases nal Replacement Therapy Registry), Singapore (Singapore and risk factors especially cardiovascular events can be Renal Registry), and Republic of Korea (Korean Renal Data prioritized. Appropriate and timely transition of care for System). However, there is a definite gap in the quality of younger patients with DM and CKD to pediatricians who data collected in the registries; especially at the patient often follow their patients into early adulthood is crucial. At 424 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia Table 5.
----------------------------------------------------------------------


======================================================================
CHUNK 271 of 647
======================================================================
ID: j_krcp_23_194_19
Content Type: reference
Words: 490
Medical Entities: CKD,GFR,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
At 424 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia Table 5. KRT reimbursement policies in Asia Type of reimbursement for HD and PD Key expenses PD-first policy HD to PD reimSpecific eligibility Country excluded in (year of HD PD coveragea bursement ratio criteria implementation) Hong Kong Complete Complete Transportation 32%: 68% None Yes (1985) India Complete Complete Income criteria No specified for government reimbursement Indonesia Yes Yes Yes 80%: 100% based No PD policy preNo on hospital poliferred cies Republic of 90% 90% All drugs have Similar PD homecare No Korea their own strict management criteria for coverpilot project age launched for PD penetration Malaysia Complete/near-complete Transportation Overall None Yes for MOH serfor MOH, Public Service 88. 3%: 11. 7% vices Department, and Social HD: PD utilizaSecurity Services-funded tion but within patients. The government MOH the ratio provides subsidies to 59. 4%: 40. 6% for NGOs (e. g. , NKF) and now, respectively various religious organizations also provide charity KRT services Philippines Partial Complete for 3 4: 3 All diagnosed For some hospitals exchanges daily kidney failure and the national patients eligible health insurance program Singapore Public and private healthSubsidy frameTransportation Similar Eligibility for VWO No PD preferred care schemes. Additionwork similar to is based on ally, subsidies available HD means testing from the government and that is reviewed VWOs e. g. , NKF, KDF on regular basis EPO is reimbursed up to 80% with a maximum cap Blood tests are covered as part of dialysis package Taiwan Complete Complete Full coverage 1. 07: 1 No No Thailand Yes Yes Transportation 80: 20 No Yes (2008) Vietnam 80% 80% EPO, drugs, blood Equal Based on health No tests insurance In Taiwan, the policy encourages PD, in Indonesia the MOH target for PD: HD is 10: 90, in the Philippines, the national health insurance program is considering increasing coverage to of HD to 156 sessions/yr. PD (increase to 4 exchanges/day) when indicated, cover icodextrin and cycler therapy to make the benefit higher than HD. In Singapore, PD is encouraged. There is the provision of a national home visit program, to empower and handhold in the initial phase of therapy, followed by regular review in the latter phases. EPO, erythropoietin; KDF, Kidney Dialysis Foundation; KRT, kidney replacement therapy; HD, hemodialysis; MOH, Ministry of Health; NGO, nongovernment organization; NKF, National Kidney Foundation; PD, peritoneal dialysis; VWO, voluntary welfare organization. ae. g. , EPO, drugs, blood tests, transportation. the government level, policies to ensure the screening of atment of serum creatinine and eGFR levels can enable risk populations and universal coverage of CKD diagnostic healthcare professionals to diagnose and institute approtests would aid in the early detection and management of priate care earlier. Patient access to POCT to monitor their CKD. serum creatinine and eGFR values, similar to diabetics who Point of care testing (POCT) that allows rapid measureroutinely record their blood glucose results would promote www. krcp-ksn.
----------------------------------------------------------------------


======================================================================
CHUNK 272 of 647
======================================================================
ID: j_krcp_23_194_20
Content Type: reference
Words: 497
Medical Entities: CKD,GFR,dialysis,hypertension,diabetes
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Patient access to POCT to monitor their CKD. serum creatinine and eGFR values, similar to diabetics who Point of care testing (POCT) that allows rapid measureroutinely record their blood glucose results would promote www. krcp-ksn. org 425 Kidney Res Clin Pract 2025; 44(3): 411-433 A Mass awareness programs targeted at specific population and their familes through Patient engagement strategies social media, schools, workplaces etc for Support groups, social media chat disemination of information groups etc. Educate individuals about adhering to follow-up protocol Capture patient-reported outcome through wearable Low healthcare literacy and No educational initiatives or technologies such as fit-bits awareness of high risk factors advocacy groups for CKD and fitness bands of CKD among patients, healthcare givers community healthworkers Limited availability of routine Fragmented CKD educational CKD screening and detection programs programs in high-risk groups Educate patient on the across the region due to Standardized, attractive availability and importance restricted funding individualized programs of CKD screening for different population/age groups (adapted to societal culture and religous norm) B Promote appropriate lifestyle changes Mass awareness programs targeted Risk factor optimization at specific populations and their families Information on access to healthcare Provision of easy access to information reimbursement in the community (e. g. , community centers, religious places, work places) No specific program for CKD management Significant treatment gaps (on dietary suggestion, associated with CKD and its medication, follow-up); low major risk factors such as adoption rate; unaffordable diabetes and hypertension Shortage of medicines, lack of multidisciplinary Fragmented referral team for CKD care pathways Constituting a multidisciplinary team (nephrologists, dieticians, Self medication and Standardized of primary physicians, dialysis nurses) and traditional medicines management algorithms/ counsellors, allied health healthcare reimbursement referral pathways for workers and physicians schemes and poor access CKD prevention and to existing schemes management The use of physician extenders with training in specific area of focus Figure 6. Unmet challenges and proposed mitigation strategies targeted at (A) individual, (B) community, and (C) national levels. AI, artificial intelligence; CKD, chronic kidney disease; KRT, kidney replacement therapy. (Continued to the next page) 426 www. krcp-ksn. org Makmun, et al. Burden of chronic kidney disease in Asia C In countries with exisiting registries, future Set up registries and population epidemiological researches: algorithm, based databases and country use of AI for CKD progression predictor specific strategies to address unique challenges Moderate use of registries and Lack of demographic Quality of data in registry is and treatment line data suboptimal No registries maintained for Limited data on follow-up of kidney failure patients early stage CKDs Registry for CKD KRT Digitalization of existing Real world evidence studies records and well developed and registry studies to systems for data capture on establish treatment patterns incidence and management and associated outcomes outcome over time will provide data for effective intervention Figure 6. Continued patient empowerment, encouraging patients to take stock be increased. Finally, CKD research capacity needs to be of their own health and wellbeing. enhanced by the nephrology community through a multidisciplinary approach.
----------------------------------------------------------------------


======================================================================
CHUNK 273 of 647
======================================================================
ID: j_krcp_23_194_21
Content Type: evidence
Words: 496
Medical Entities: CKD,dialysis
Source: j-krcp-23-194.pdf

----------------------------------------------------------------------
Continued patient empowerment, encouraging patients to take stock be increased. Finally, CKD research capacity needs to be of their own health and wellbeing. enhanced by the nephrology community through a multidisciplinary approach. Conclusion Conflicts of interest Asia is a vast and diverse region comprising highly populated countries with unique features and challenges. Each ST reports receiving honoraria from Boehringer Ingelheim, countrys socioeconomic situation, geographic location, GlaxoSmithKline, AstraZeneca, Novartis, Baxter, and Bayer, and governmental funding structure for CKD detection is the President (20222024) of the Asian Pacific Society and management have an impact on the availability, acof Nephrology and an executive member (20202023) of cess, and quality of CKD care. There is an urgent need for KDIGO. RD reports receiving honoraria from AstraZeneca, a collaborative action plan between the healthcare comNovartis, Bayer, Boehringer Ingelheim, Astellas Pharma, munity and governments in this region to detect CKD in its Corbridge, and Philippine Council for Health Research early stages and prevent its complications including kidney and Development and travel support from AstraZeneca, failure, CVD, and death. Individual countries should be Boehringer Ingelheim, Corbridge, and Macro Pharma, and encouraged to develop strategies for effective prevention, is part of Maria Corazon Torres Y Javier (MCTJ) Foundation early identification, and timely intervention. Initiatives and Transplantation Society of the Philippines. SK reports for preventive interventions to decrease the incidence of receiving research grant support from the National EviCKD and kidney failure should be undertaken. Patient and dence-based Healthcare Collaborating Agency and Korea physician awareness of kidney disease as a complication Evaluation Institute of Industrial Technology and serves of other chronic diseases should be reinforced. Governon the advisory board of the Korean Society of Nephrology. ment spending on CKD-focused healthcare needs should YWC reports receiving honoraria from AstraZeneca, Baxwww. krcp-ksn. org 427 Kidney Res Clin Pract 2025; 44(3): 411-433 ter, Kyowa Kirin, and Panion BF Biotech Inc. AM reports ORCID receiving honoraria from Zullig Pharma, Fresenius Kabi, Wellesta, Fresenius Medical care, Sinar Roda Utama, EtaAfiatin Makmun, na Biotechnologies, and travel support from Pfizer, Sanbe Bancha Satirapoj, Pharma, Kalbe Fima, Sinar Roda Utama, Dexa Medica, Do Gia Tuyen, Baxter and serves on the advisory board of Astra Zeneca, Marjorie W. Y. Foo, Renalmed, Zullig Pharma and serves as the chief of InRomina Danguilan, donesian Renal Registry, National Coordinator of CAPD Sanjeev Gulati, program, Board of fellow nephrologist curriculum. SB reSejoong Kim, ports receiving Boehringer Ingelheim, Astra Zeneca, and Sunita Bavanandan, Baxter as a speaker, is a member of the Board of Directors Yi-Wen Chiu, for National Kidney Foundation Malaysia, Regional Board Sydney C. W. Tang, chair for Oceania and Southeast Asia, International Society of Nephrology, and reports receiving donations to dialysis References unit from patients relatives, private organizations and National Kidney Foundation, all of which were approved by 1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic Ministry of Health. DGT, BS, MWY, SG declare no conflict kidney disease: a systematic review and meta-analysis. PLoS of interest. One 2016; 11: e0158765. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 274 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_0
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
S U P P L E M E N T TO KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease VOLUME 105 ISSUE 4S APRIL 2024 www. kidney-international. org KDIGO 2024 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE KidneyInternational(2024)105(Suppl4S), S117S314 S117 contents www. kidney-international. org VOL 105 ISSUE 4S APRIL 2024 KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease S118 Tables, figures, and supplementary material S124 KDIGO Executive Committee S125 Reference keys S126 CKD nomenclature S127 Conversion factors S128 Abbreviations and acronyms S129 Notice S130 Foreword S131 Work Group membership S133 Abstract S134 Patient foreword S135 Introduction, qualifying statements, and key concepts S141 Special considerations S144 SummaryofrelativeandabsoluterisksrelevanttoCKDfrommeta-analysisof large multinational population studies in the CKD Prognosis Consortium (CKD-PC) S149 Summary of recommendation statements and practice points S169 Chapter 1: Evaluation of CKD S196 Chapter 2: Risk assessment in people with CKD S205 Chapter 3: Delaying CKD progression and managing its complications S246 Chapter 4: Medication management and drug stewardship in CKD S255 Chapter 5: Optimal models of care S270 Chapter 6: Research recommendations S274 Methods for guideline development S283 Biographic and disclosure information S294 Acknowledgments S295 References This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources. Because of the differences between in vitro and in vivo systems and between laboratoryanimalmodelsandclinicaldatainhumans, invitroandanimaldatadonotnecessarilycorrelatewithclinicalresults. S118 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org contents TABLES S137 Table 1. Criteria for chronic kidney disease S137 Table 2. GFR categories in CKD S137 Table 3. Albuminuria categories in chronic kidney disease (CKD) S169 Table 4. Use of GFR and albuminuria S171 Table 5. Risk factors for CKD S174 Table 6. Guidance for selection of additional tests for evaluation of cause S178 Table 7. Description of initial and supportive tests for evaluation of GFR S179 Table 8. Indications for use of cystatin C S180 Table 9. Comparison of estimated GFR and measured GFR S181 Table 10. Indications for measured GFR S184 Table11. Implementationstandards to ensure accuracyand reliabilityof GFR assessments using creatinine and cystatin C S184 Table 12. Reported examples of substances that may cause analytical interferences in creatinine assays S187 Table 13. Criteria for a validated GFR estimating equation S189 Table 14. Validated GFR estimating equations S190 Table 15. Criteria for equation comparison for comparison of candidate equations to another (i. e. , how to determine validity) S191 Table 16. Factors causing biological variation in urine albumin or urine protein S193 Table 17. Implementation standards to ensure accuracy and reliability of urine samples S198 Table 18.
----------------------------------------------------------------------


======================================================================
CHUNK 275 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_1
Content Type: recommendation
Words: 496
Medical Entities: CKD,GFR,dialysis,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Criteria for equation comparison for comparison of candidate equations to another (i. e. , how to determine validity) S191 Table 16. Factors causing biological variation in urine albumin or urine protein S193 Table 17. Implementation standards to ensure accuracy and reliability of urine samples S198 Table 18. Impact of albuminuria/proteinuria on CKD progression in pediatrics S199 Table 19. Externally validated risk equations for predicting kidney failure in the general (CKD G3G5) population S203 Table 20. Externally validated risk equations for predicting a 40% decline in GFR S209 Table 21. Impact of plant-based foods in people with CKD S212 Table 22. Age-based sodium intake recommendations S222 Table23. Variationoflaboratoryvaluesinalargepopulationdatabasebyagegroup, sex, andeGFR; bicarbonate, mmol/l, mean (SD), n 3, 990, 898 S223 Table24. Variationoflaboratoryvaluesinalargepopulationdatabasebyagegroup, sex, andeGFR; potassium, mmol/l, mean (SD), n 4, 278, 600 S225 Table 25. Factors and mechanisms that impact on potassium measurements S226 Table 26. Medications associated with increased risk of hyperkalemia S227 Table 27. A comparison of potassium exchange agents S227 Table 28. Suggested action in the event of moderate and severe hyperkalemia S229 Table29. Variationoflaboratoryvaluesinalargepopulationdatabasebyagegroup, sex, andeGFR; hemoglobin, g/dl, mean (SD), n 3, 561, 622 S233 Table 30. Randomized controlled trials in the treatment of asymptomatic hyperuricemia in people with CKD S247 Table31. Keyexamplesofcommonmedicationswithdocumentednephrotoxicityand, whereavailable, selected non-nephrotoxic alternatives S252 Table 32. Medications that should be considered for temporary discontinuation before elective surgeries and potential perioperative adverse events associated with their continued use S253 Table 33. Potential risk factors for contrast-associated acute kidney injury S256 Table 34. Benefits and consequences of early versus late referral S257 Table 35. Factors associated with late referral for kidney replacement therapy planning S257 Table 36. Outcomes examined in a systematic review by Smart et al. S258 Table 37. Recommended patient-reported outcome measurement tools for use in people with CKD KidneyInternational(2024)105(Suppl4S), S117S314 S119 contents www. kidney-international. org S259 Table 38. Management strategies for common symptoms in CKD S261 Table 39. List of validated assessment tools for malnutrition S262 Table 40. Key features of existing CKD care models S266 Table 41. Indications for the initiation of dialysis S267 Table 42. Studies examining the timing of dialysis in people with CKD S268 Table 43. People with kidney failure who receive comprehensive conservative care S275 Table 44. Clinical questions and systematic review topics in PICOS format S280 Table 45. Classification for certainty of evidence S280 Table 46. GRADE system for grading the certainty of evidence S281 Table 47. KDIGO nomenclature and description for grading recommendations S281 Table 48. Determinants of the strength of recommendation FIGURES S136 Figure 1. Associations of chronic kidney disease (CKD) staging by estimated glomerular filtration rate by creatinine and cystatin C (eGFRcr-cys) and albumin-to-creatinine ratio (ACR) categories and risks for 10 common complications by age in multivariable-adjusted analyses S138 Figure2. Age-standardizedchronickidneydiseasedisability-adjustedlife-year(DALY)ratesforeachlocationby sociodemographic index, both sexes combined, 2019 S139 Figure 3. Screening algorithm for diagnosis and staging of chronic kidney disease (CKD) in adults S141 Figure 4. Special considerations for chronic kidney disease (CKD) care across the lifespan S145 Figure 5.
----------------------------------------------------------------------


======================================================================
CHUNK 276 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_2
Content Type: reference
Words: 497
Medical Entities: CKD,GFR,dialysis,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Age-standardizedchronickidneydiseasedisability-adjustedlife-year(DALY)ratesforeachlocationby sociodemographic index, both sexes combined, 2019 S139 Figure 3. Screening algorithm for diagnosis and staging of chronic kidney disease (CKD) in adults S141 Figure 4. Special considerations for chronic kidney disease (CKD) care across the lifespan S145 Figure 5. Associations of chronic kidney disease (CKD) staging by estimated glomerular filtration rate by creatinine (eGFRcr) and albumin-to-creatinine ratio (ACR) categories and risks for 10 common complications in multivariable-adjusted analyses S146 Figure 6. Associations of chronic kidney disease (CKD) staging by estimated glomerular filtration rate by creatinine and cystatin C (eGFRcr-cys) and albumin-to-creatinine ratio categories and risks for 10 common complications in multivariable-adjusted analyses S147 Figure7. Hazardratiosforadverseoutcomesusingthecontinuousmodelofestimatedglomerularfiltrationrate (eGFR), comparison of the shape of associations between creatinine-based eGFR (eGFRcr) and creatinine and cystatin Cbased eGFR (eGFRcr-cys) in the population with cystatin C (eGFRcr-cys population) S173 Figure 8. Evaluation of cause of chronic kidney disease (CKD) S174 Figure 9. Actionable genes in kidney disease S175 Figure 10. Proposed organization for implementing genetics in nephrology S177 Figure 11. Approach to glomerular filtration rate (GFR) evaluation using initial and supportive tests S182 Figure12. Sourcesandmagnitudeoferroraroundmeasuredglomerularfiltrationrate(mGFR)andestimatedGFR (eGFR) S197 Figure 13. Frequency of monitoring glomerular filtration rate (GFR) and albuminuria in people with chronic kidney disease (CKD) S199 Figure14. (a)Predictedriskofkidneyfailureand(b)40%declineinestimatedglomerularfiltrationrate(eGFR) by chronic kidney disease (CKD) eGFR (G1G5) and albumin-to-creatinine ratio (ACR) (A1A3) categories in Optum Labs Data Warehouse S201 Figure 15. Transition from an estimated glomerular filtration rate (eGFR)-based to a risk-based approach to chronic kidney disease care S202 Figure 16. Comparison of risk of chronic kidney disease (CKD) progression (5-year probability of estimated glomerularfiltrationrateeGFR60ml/minper1. 73m2)versuskidneyfailureinadultswithCKDG1 G2 calculated from the risk equation available at S205 Figure 17. Chronic kidney disease (CKD) treatment and risk modification S206 Figure 18. Holistic approach to chronic kidney disease (CKD) treatment and risk modification S208 Figure 19. Protein guideline for adults with chronic kidney disease not treated with dialysis S120 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org contents S209 Figure 20. Average protein content of foods in grams S214 Figure21. Algorithmformonitoringofpotassiumandestimatedglomerularfiltrationrate(eGFR)aftertheinitiation of renin-angiotensin system inhibitors S215 Figure22. Effectofsodium-glucosecotransporter-2inhibitors(SGLT2i)withkidneydiseaseoutcomesbydiabetes status S216 Figure 23. Effects of sodium-glucose cotransporter-2 (SGLT2) inhibition versus placebo on cardiovascular and mortality outcomes by diabetes status and trial population S217 Figure24. Effectsofsodium-glucosecotransporter-2(SGLT2)inhibitionversusplaceboonkidneyfailure(chronic kidney disease CKD trials) S219 Figure25. Effectsofempagliflozinversusplaceboonannualrateofchangeinestimatedglomerularfiltrationrate (GFR) by key subgroups in the Study of Heart and Kidney Protection With Empagliflozin (EMPAKIDNEY) S220 Figure 26. Serum potassium monitoring during treatment with a nonsteroidal mineralocorticoid receptor antagonist (MRA) (finerenone) S221 Figure27. Effectoffinerenoneversusplaceboonkidneyandcardiovascularoutcomesinpooledanalysesfromthe FinerenoneinReducing KidneyFailureandDiseaseProgression inDiabeticKidneyDisease(FIDELIODKD)andFinerenoneinReducingCardiovascularMortalityandMorbidityinDiabeticKidneyDisease (FIGARO-DKD trials) S222 Figure 28. Association between estimated glomerular filtration rate (eGFR) with serum bicarbonate concentration in general population and high-risk cohorts from the Chronic Kidney Disease Prognosis Consortium, by level of albuminuria (A1A3) S224 Figure29. Distributionofbloodpotassiumingeneralpopulationandhigh-riskcohortsfromtheChronicKidney Disease Prognosis Consortium, by estimated glomerular filtration rate (eGFR) S224 Figure 30. Meta-analyzed adjusted prevalence ofhyperkalemia (25th and 75thpercentile cohort)ingeneral populationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium, bydiabetes status S225 Figure 31. Serum potassium concentration and confounder-adjusted risk of death by presence or absence of diabetes, heart failure (HF), or chronic kidney disease (CKD) S228 Figure 32. Actions to manage hyperkalemia (potassium 5.
----------------------------------------------------------------------


======================================================================
CHUNK 277 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_3
Content Type: reference
Words: 498
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Meta-analyzed adjusted prevalence ofhyperkalemia (25th and 75thpercentile cohort)ingeneral populationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium, bydiabetes status S225 Figure 31. Serum potassium concentration and confounder-adjusted risk of death by presence or absence of diabetes, heart failure (HF), or chronic kidney disease (CKD) S228 Figure 32. Actions to manage hyperkalemia (potassium 5. 5 mmol/l) in chronic kidney disease S228 Figure 33. Potassium absorption rates of plant-based, animal-based, and processed foods S229 Figure34. Associationbetweenestimatedglomerularfiltrationrate(eGFR)andhemoglobinconcentrationfrom generalpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium, by diabetes status S230 Figure 35. Association between estimated glomerular filtration rate (eGFR) with serum concentrations of parathyroid hormone, phosphate, and serum calcium in general population and high-risk cohorts from the Chronic Kidney Disease Prognosis Consortium, by level of albuminuria (A1A3) S233 Figure36. Riskofall-causeandcardiovascularmortalitybyestimatedglomerularfiltrationrate(eGFR)andlevelof albuminuria from general population cohorts contributing to the Chronic Kidney Disease Prognosis Consortium S235 Figure 37. Effect of lowering low-density lipoprotein (LDL) cholesterol per 1. 0 mmol/l on risk of major vascular events by level of estimated glomerular filtration rate (eGFR) at recruitment S237 Figure 38. Predicted 5-year absolute benefits and harms of allocation to aspirin (A) versus control (C) using a secondary or primary prevention strategy, by different levels of risk (based on age and sex) S240 Figure39. Meta-analyzedadjustedprevalenceofatrialfibrillationfromcohortscontributingtotheChronicKidney Disease Prognosis Consortium, by diabetes status S241 Figure 40. Strategies forthe diagnosisand managementofatrial fibrillation S242 Figure 41. Pooled hazard ratio (HR) comparing nonvitamin K antagonist oral anticoagulants (NOACs) with warfarin among people with chronic kidney disease in terms of stroke S243 Figure 42. Pooled hazard ratio (HR) comparing nonvitamin K antagonist oral anticoagulants (NOACs) with warfarin among people with chronic kidney disease in terms of bleeding S244 Figure43. Evidencefrom(a)randomizedcontrolledtrials(RCTs)regardingtherapeuticanticoagulationdoseby glomerular filtration rate (GFR) and (b) in areas where RCTs are lacking S245 Figure 44. Advice on when to discontinue nonvitamin K antagonist oral anticoagulants (NOACs) before procedures (low vs. high risk) KidneyInternational(2024)105(Suppl4S), S117S314 S121 contents www. kidney-international. org S248 Figure45. Selectedherbalremediesanddietarysupplementswithevidenceofpotentialnephrotoxicity, grouped by the continent from where the reports first came S250 Figure 46. Suggested steps in the process of medication review and reconciliation S251 Figure 47. Essential steps for appropriate sick day rule implementation S255 Figure 48. Circumstances for referral to specialist kidney care services and goals of the referral S258 Figure 49. Common symptoms, prevalence, and severity in people with chronic kidney disease S261 Figure 50. Optimal care model by increasing severity of chronic kidney disease (CKD) S262 Figure 51. The chronic care model S262 Figure 52. Specific components of the chronic kidney disease model of care S263 Figure 53. Strategy for effective patient education programs for people with chronic kidney disease (CKD) S264 Figure 54. Telehealth technologies for people with chronic kidney disease (CKD) S265 Figure 55. The process of transition from pediatric to adult care in chronic kidney disease (CKD) S269 Figure 56. Relationship between supportive care, comprehensive conservative care, and end-of-life care S279 Figure 57. Search yield and study flow diagram SUPPLEMENTARY MATERIAL Supplementary File (PDF) Appendix A. Search strategies Table S1. Search strategies for systematic review topics Appendix B. Concurrence with Institute of Medicine (IOM) standards for guideline development Table S2.
----------------------------------------------------------------------


======================================================================
CHUNK 278 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_4
Content Type: reference
Words: 496
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Relationship between supportive care, comprehensive conservative care, and end-of-life care S279 Figure 57. Search yield and study flow diagram SUPPLEMENTARY MATERIAL Supplementary File (PDF) Appendix A. Search strategies Table S1. Search strategies for systematic review topics Appendix B. Concurrence with Institute of Medicine (IOM) standards for guideline development Table S2. Guideline development checklist IOM standards for development of trustworthy clinical practice guidelines Appendix C. Data supplement - Summary of findings (SoF) tables cited in the guideline text Chapter 1. Evaluation of CKD TableS3. AdultsandchildrenwithorwithoutCKD, estimatedGFR(eGFR)basedonmeasurementsofcystatinC (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys) versus measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker) TableS4. AdultsandchildrenwithsuspectedordiagnosedCKD, nativekidneybiopsyversusclinicalorstandard diagnosis or prognosis for studies evaluating diagnostic or prognostic benefit; no comparator for studies evaluating safety TableS5. Adultsandchildren, machine-readquantitativeorsemiquantitativeproteinoralbuminurinedipstick testsversuslaboratory-basedmethodsformeasuringurinaryproteinoralbumin(e. g. , 24-hoururinary sample, spot urine protein-to-creatinine ratio PCR, or albumin-to-creatinine ratio ACR) Chapter 2. Risk assessment in people with CKD Table S6. Adults, children, and young people with CKD G1G5, C-statistics of kidney failure risk equations for predicting progression (e. g. , Tangri equation KFRE) Table S7. Adults, children, and young people with CKD G1G5, Brier scores of kidney failure risk equations for predicting progression (e. g. , Tangri equation KFRE) Table S8. Adults, children, and young people with CKD G1G5, R2 statistics of kidney failure risk equations for predicting progression (e. g. , Tangri equation KFRE) Table S9. Adults, children, and young people with CKD G1G5, sensitivity and specificity to start kidney replacement therapy (KRT) for kidney failure risk equations for predicting progression (e. g. , Tangri equation KFRE) Chapter 3. Delaying CKD progression and managing its complications Table S10. Adults and children with CKD, sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus placebo or usual care; active comparator (e. g. , another glucose-lowering agent) Table S11. Adults and children with CKD and symptomatic hyperuricemia, uric acidlowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad) versus active comparator, placebo, or usual care Table S12. Adults and children with CKD and asymptomatic hyperuricemia, uric acidlowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad) versus active comparator, placebo, or usual care TableS13. Adults andchildren withCKD andischemic heartdisease, angiography orcoronaryrevascularization versus medical treatment S122 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org contents Table S14. Adults and children with CKD and atrial fibrillation, nonvitamin K antagonist oral anticoagulant (NOAC) with warfarin or NOAC alone versus medical treatmentstroke outcomes Table S15. Adults and children with CKD and atrial fibrillation, nonvitamin K antagonist oral anticoagulant (NOAC) with warfarin or NOAC alone versus medical treatmentbleeding outcomes Appendix D Data supplement - Summary of findings (SoF) tables not cited in the guideline text Chapter 3. Delaying CKD progression and managing its complications Table S16. AdultsandchildrenwithCKDbutnottype 2diabetes, steroidalmineralocorticoidreceptoragonists (MRAs; canrenone, eplerenone, spironolactone)ornon-steroidalMRAs(finerenone, esaxerenone)versus activecomparator, placebo, orusualcare Table S17. Adults and children with CKD at risk for cardiovascular disease (CVD), aspirin versus placebo Appendix E PRISMA diagrams Chapter 1. Evaluation of CKD Figure S1. PRISMA diagramfortheclinicalquestionWhatisthe diagnosticandprognosticbenefitandsafetyof kidney biopsyamongpeoplewith CKD? Figure S2.
----------------------------------------------------------------------


======================================================================
CHUNK 279 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_5
Content Type: reference
Words: 348
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
AdultsandchildrenwithCKDbutnottype 2diabetes, steroidalmineralocorticoidreceptoragonists (MRAs; canrenone, eplerenone, spironolactone)ornon-steroidalMRAs(finerenone, esaxerenone)versus activecomparator, placebo, orusualcare Table S17. Adults and children with CKD at risk for cardiovascular disease (CVD), aspirin versus placebo Appendix E PRISMA diagrams Chapter 1. Evaluation of CKD Figure S1. PRISMA diagramfortheclinicalquestionWhatisthe diagnosticandprognosticbenefitandsafetyof kidney biopsyamongpeoplewith CKD? Figure S2. PRISMA diagram for the clinical question What is the diagnostic accuracy of eGFR based on measurementsofcystatinC, creatinine, ortheircombinationcomparedtomGFRamongpeoplewith and without CKD? FigureS3. PRISMAdiagramfortheclinicalquestionInchildrenandyoungadultswithsuspectedordiagnosed CKD, what is the accuracy of ACR and PCR compared to 24-hour excretion of albumin or protein? FigureS4. PRISMAdiagramfortheclinicalquestionWhatisthediagnosticaccuracyandreproducibilityofPOC blood creatinine compared to laboratory-based tests among people with suspected or diagnosed CKD? Figure S5. PRISMA diagram for the clinical question What is the diagnostic accuracy of quantitative and semiquantitative protein or albumin urine dipstick tests compared to laboratory-based tests among people with suspected or diagnosed CKD? Chapter 3. Delaying CKD progression and managing its complications FigureS6. PRISMAdiagramfortheclinicalquestionWhatistheeffectofSGLT2icomparedwithplacebo, usual care, or an active comparator among people with CKD in terms of mortality, progression of CKD, complications of CKD, and adverse events? Figure S7. PRISMA diagram for the clinical question What is the effect of MRAs compared with placebo, usual care, oranactivecomparatoramongpeoplewithCKDbutnottype2diabetesintermsofmortality, progression of CKD, complications of CKD, and adverse events? Figure S8. PRISMA diagram for the clinical question What is the effect of glucagon-like peptide-1 (GLP-1) receptor agonists compared with placebo, usual care, or an active comparator among people with CKD but not type 2 diabetes in terms of mortality, progression of CKD, complications of CKD, and adverse events? FigureS9. PRISMAdiagramfortheclinicalquestionWhatistheeffectofuricacidloweringtherapycompared withplacebo, usualcare, oranactivecomparatoramongpeoplewithCKDandhyperuricemiainterms of mortality, progression of CKD, complications of CKD, and adverse events? FigureS10. PRISMAdiagramfortheclinicalquestionWhatistheeffectofaspirincomparedtoplacebointermsof the primarypreventionof cardiovascular disease (CVD)andsafetyamongpeople with CKD? Figure S11. PRISMA diagram for the clinical question What are the effects of angiography or coronary revascularizationcomparedtomedicaltreatmentamongpeoplewithCKDandischemicheartdisease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)? Figure S12. PRISMA diagram for the clinical question What are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks? KidneyInternational(2024)105(Suppl4S), S117S314 S123 KDIGO executive committee www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 280 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_6
Content Type: recommendation
Words: 477
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Figure S12. PRISMA diagram for the clinical question What are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks? KidneyInternational(2024)105(Suppl4S), S117S314 S123 KDIGO executive committee www. kidney-international. org KDIGO EXECUTIVE COMMITTEE Garabed Eknoyan, MD Norbert Lameire, MD, PhD Founding KDIGO Co-Chairs Wolfgang C. Winkelmayer, MD, MPH, ScD Immediate Past Co-Chair Michel Jadoul, MD Morgan E. Grams, MD, PhD, MHS KDIGO Co-Chair KDIGO Co-Chair Gloria E. Ashuntantang, MD Michelle M. OShaughnessy, MB, BCh, BAO, MS, MD Sunita Bavanandan, MBBS Patrick Rossignol, MD, PhD Irene de Lourdes Noronha, MD, PhD Paul E. Stevens, MB, FRCP Michelle R. Denburg, MD, MSCE Rita S. Suri, MD, MSc Joachim H. Ix, MD, MAS Irma Tchokhonelidze, MD Vivekanand Jha, MD, DM, FRCP, FAMS Marc G. Vervloet, MD, PhD, FERA Holly Kramer, MD, MPH Wolfgang C. Winkelmayer, MD, MPH, ScD Adrian Liew, MD, MBBS, MRCP, FAMS, FASN, FRCP, MClinEpid Motoko Yanagita, MD, PhD Reem A. Mustafa, MD, PhD, MPH KDIGO Staff John Davis, Chief Executive Officer Danielle Green, Executive Director Melissa Thompson, Chief Operating Officer Michael Cheung, Chief Scientific Officer Amy Earley, Guideline Development Director Jennifer King, Director of Medical Writing Tanya Green, Events Director Coral Cyzewski, Events Coordinator Kathleen Conn, Director of Communications S124 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org reference keys Reference keys NOMENCLATURE ANDDESCRIPTIONFORRATING GUIDELINERECOMMENDATIONS Withineachrecommendation, thestrengthofrecommendationisindicatedasLevel1orLevel2, andthecertaintyofthesupporting evidenceisshown asA, B, C, orD. Implications Grade Patients Clinicians Policy Level1 Mostpeopleinyoursituationwould Mostpatientsshouldreceivethe Therecommendationcanbeevaluated Werecommend wanttherecommendedcourseof recommendedcourseofaction. asacandidatefordevelopingapolicy action, andonlyasmallproportion oraperformancemeasure. wouldnot. Level2 Themajorityofpeopleinyoursituation Differentchoiceswillbeappropriatefor Therecommendationislikelytorequire Wesuggest wouldwanttherecommendedcourse differentpatients. Eachpatientneeds substantialdebateandinvolvementof ofaction, butmanywouldnot. helptoarriveatamanagement stakeholdersbeforepolicycanbe decisionconsistentwiththeirvalues determined. andpreferences. Grade Certaintyofevidence Meaning A High Weareconfidentthatthetrueeffectisclosetotheestimateoftheeffect. B Moderate Thetrueeffectislikelytobeclosetotheestimateoftheeffect, butthereisapossibilitythatitissubstantiallydifferent. C Low Thetrueeffectmaybesubstantiallydifferentfromtheestimateoftheeffect. D Verylow Theestimateofeffectisveryuncertain, andoften, itwillbefarfromthetrueeffect. Practicepointsareconsensus-basedstatementsrepresentingtheexpertjudgmentoftheWorkGroupandarenotgraded. Theyareissuedwhena clinicalquestiondidnothaveasystematicreviewperformed, tohelpreadersimplementtheguidancefromgradedrecommendation(e. g. , frequency ofmonitoring, provisionofstandardcaresuchasregularclinicvisits, referraltospecialistcare, etc. ), orforissuinggoodpracticestatementswhen thealternativeisconsideredtobeabsurd. Usersshouldconsiderthepracticepointasexpertguidanceanduseitastheyseefittoinformthecareof patients. Althoughthesestatementsaredevelopedbasedonadifferentmethodology, theyshouldnotbeseenaslessimportantoradowngrade fromgradedrecommendations. KidneyInternational(2024)105(Suppl4S), S117S314 S125 CURRENTCHRONICKIDNEY DISEASE(CKD) NOMENCLATUREUSEDBYKDIGO CKDisdefinedasabnormalitiesofkidneystructureorfunction, presentforaminimumof3months, withimplicationsforhealth. CKDis classifiedbasedonCause, Glomerularfiltrationrate(GFR)category(G1G5), andAlbuminuriacategory(A1A3), abbreviatedasCGA. Persistent albuminuria categories Description and range )2m 37. 1/nim/lm( seirogetac RFG egnar dna noitpircseD CKD nomenclature www. kidney-international. org A1 A2 A3 KDIGO: Prognosis of CKD by GFR Normal to mildly Moderately Severely and albuminuria categories increased increased increased 30 mg/g 30300 mg/g 300 mg/g 3 mg/mmol 330 mg/mmol 30 mg/mmol G1 Normal or high 90 G2 Mildly decreased 6089 Mildly to G3a 4559 moderately decreased Moderately to G3b 3044 severely decreased G4 Severely decreased 1529 G5 Kidney failure 15 Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red: very high risk. GFR, glomerular filtration rate. S126 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org conversion factors CONVERSIONFACTORS OFCONVENTIONAL UNITSTOSIUNITS Conventionalunit Conversionfactor SIunit Albumin-to-creatinineratio(ACR) mg/g 0. 113 mg/mmol Calcium mg/dl 0. 2495 mmol/l Creatinine mg/dl 88. 4 mmol/l Protein-to-creatinineratio(PCR) mg/g 0. 113 mg/mmol Phosphate mg/dl 0. 3229 mmol/l Urate mg/dl 59. 48 mmol/l SI, InternationalSystemofUnits. Note: Conventionalunit(cid: 1)conversionfactorSIunit.
----------------------------------------------------------------------


======================================================================
CHUNK 281 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_7
Content Type: evidence
Words: 481
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
S126 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org conversion factors CONVERSIONFACTORS OFCONVENTIONAL UNITSTOSIUNITS Conventionalunit Conversionfactor SIunit Albumin-to-creatinineratio(ACR) mg/g 0. 113 mg/mmol Calcium mg/dl 0. 2495 mmol/l Creatinine mg/dl 88. 4 mmol/l Protein-to-creatinineratio(PCR) mg/g 0. 113 mg/mmol Phosphate mg/dl 0. 3229 mmol/l Urate mg/dl 59. 48 mmol/l SI, InternationalSystemofUnits. Note: Conventionalunit(cid: 1)conversionfactorSIunit. EQUIVALENT ALBUMINURIACATEGORIES INCKD ACR(approximateequivalent) Category AER(mg/24h) (mg/mmol) (mg/g) Terms A1 30 3 30 Normaltomildlyincreased A2 30300 330 30300 Moderatelyincreaseda A3 300 30 300 Severelyincreased ACR, albumin-creatinineratio; AER, albuminexcretionrate; CKD, chronickidneydisease. aRelativetotheyoungadultlevel. KidneyInternational(2024)105(Suppl4S), S117S314 S127 abbreviations and acronyms www. kidney-international. org Abbreviations and acronyms ACEi angiotensin-converting enzyme inhibitor(s) IgG immunoglobulin G ACR albumin-to-creatinine ratio IQR interquartile range ADA American Diabetes Association i. v. intravenous ADPKD autosomaldominantpolycystickidneydisease KDIGO Kidney Disease: Improving Global AER albumin excretion rate Outcomes AIDS acquired immune deficiency syndrome KDOQI KidneyDiseaseOutcomesQuality Initiative AKD acute kidney disease KFRE Kidney Failure Risk Equation AKI acute kidney injury KRT kidney replacement therapy ARB angiotensin II receptor blocker LDL low-density lipoprotein ASCVD atherosclerotic cardiovascular disease LMIC lowand middle-income countries BMI body mass index MACE major adverse cardiovascular events BP blood pressure MDRD Modification of Diet in Renal Disease BSA body surface area mGFR measured glomerular filtration rate CI confidence interval MRA mineralocorticoid receptor antagonist(s) CKD chronic kidney disease mTOR mammalian target of rapamycin CKD-EPI Chronic Kidney Disease Epidemiology NICE National Institute for Health and Care Collaboration Excellence CKiD Chronic Kidney Disease in Children NIHR National Institute for Health and Care CKD-MBD chronic kidney disease-mineral and bone Research disorder NOAC nonvitamin K antagonist oral CKD-PC Chronic Kidney Disease Prognosis anticoagulant Consortium NSAIDs nonsteroidal anti-inflammatory drugs CrCl creatinine clearance OR odds ratio CT computed tomography OTC over-the-counter CVD cardiovascular disease PCR protein-to-creatinine ratio DALY disability-adjusted life-year PCSK-9 proproteinconvertasesubtilisin/kexintype-9 eGFR estimated glomerular filtration rate PICOS population, intervention, comparator, eGFRcr creatinine-based estimated glomerular outcomes, study design filtration rate POCT point-of-care testing eGFRcr-cys creatinine and cystatin Cbased estimated PROM patient-reported outcome measure glomerular filtration rate QoL quality of life eGFRcys cystatin Cbased estimated glomerular RAS(i) renin-angiotensin system (inhibitor) filtration rate RAAS(i) renin-angiotensin-aldosterone system EKFC European Kidney Function Consortium (inhibitor) EMA European Medicines Agency RBC red blood cell EMR electronic medical record RCT randomized controlled trial ERT Evidence Review Team RR relative risk FDA Food and Drug Administration SCr serum creatinine GBD Global Burden of Disease SBP systolic blood pressure GFR glomerular filtration rate SES socioeconomic status GLP-1 RA glucagon-like peptide-1 receptor agonist(s) SGLT2i sodium-glucose cotransporter-2 GN glomerulonephritis inhibitor(s) HBV hepatitis B virus T1D Type 1 diabetes HCV hepatitis C virus T2D Type 2 diabetes HDL high-density lipoprotein UK United Kingdom HIV human immunodeficiency virus US United States HR hazard ratio USRDS United States Renal Data System HRQoL health-related quality of life WHO World Health Organization S128 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org notice Notice SECTIONI: USEOFTHECLINICAL PRACTICEGUIDELINE ThisClinicalPracticeGuidelinedocumentisbaseduponliteraturesearchesconductedfromJuly2022throughApril2023and updatedinJuly2023. Itisdesignedtoassistdecision-making. Itisnotintendedtodefineastandardofcareandshouldnotbe interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur whencliniciansconsidertheneedsofindividualpatients, availableresources, andlimitationsuniquetoaninstitutionortypeof practice.
----------------------------------------------------------------------


======================================================================
CHUNK 282 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_8
Content Type: recommendation
Words: 500
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org notice Notice SECTIONI: USEOFTHECLINICAL PRACTICEGUIDELINE ThisClinicalPracticeGuidelinedocumentisbaseduponliteraturesearchesconductedfromJuly2022throughApril2023and updatedinJuly2023. Itisdesignedtoassistdecision-making. Itisnotintendedtodefineastandardofcareandshouldnotbe interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur whencliniciansconsidertheneedsofindividualpatients, availableresources, andlimitationsuniquetoaninstitutionortypeof practice. Healthcare providers using the statements in this document (both practice points and recommendations) should decide how to apply them to their own clinical practice. SECTIONII: DISCLOSURE KidneyDisease: ImprovingGlobalOutcomes(KDIGO)makeseveryefforttoavoidanyactualorreasonablyperceivedconflicts ofinterestthatmayarisefromanoutsiderelationshiporapersonal, professional, orbusinessinterestofamemberoftheWork Group. AllmembersoftheWorkGrouparerequiredtocomplete, sign, andsubmitadisclosureandattestationformshowing all such relationships that might be perceived as or are actual conflicts of interest. This document is updated annually, and information is adjusted accordingly. All reported information is published in its entirety at the end of this document in the Work Group members Disclosure section and is kept on file at KDIGO. Copyright (cid: 1) 2023, Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http: // creativecommons. org/licenses/by-nc-nd/4. 0/). Single copies may be made for personal use as allowed by national copyright laws. Special rates are available for educational institutions that wish to make photocopies for nonprofit educational use. No part of this publication may be reproduced, amended, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without explicitpermissioninwritingfromKDIGO. Detailsonhowtoseekreprints, permissionforreproductionortranslation, and furtherinformationaboutKDIGOspermissionspoliciescanbeobtainedbycontactingMelissaThompson, ChiefOperating Officer, at melissa. thompsonkdigo. org. Neither KDIGO, Kidney International, the Publisher, nor the authors, contributors, or editors shall have or assume any liability for anydirect, indirect, incidental, special, exemplary, orconsequential damages (including withoutlimitation lost profits) or any injury and/or damage to persons or property, however caused and on any theory of liability, whether in contract, strict liability, or tort (including product liability, negligence or otherwise) arising in any way out of the use or operation of any methods, products, instructions, or ideas contained in the material herein. KidneyInternational(2024)105(Suppl4S), S117S314 S129 foreword www. kidney-international. org Foreword KidneyInternational(2024)105(Suppl4S), S117S314; Copyright2023, KidneyDisease: ImprovingGlobalOutcomes(KDIGO). PublishedbyElsevierInc. onbehalfoftheInternationalSocietyofNephrology. Thisisanopenaccess articleundertheCCBY-NC-NDlicense( The Kidney Disease: Improving Global Outcomes (KDIGO) theevidencereviewsfromtheEvidenceReviewTeam. Practice organization was established in 2003 with the mission to points provide guidance on clinical questions that were not, improve the care and outcomes of people living with kidney and largely could not be, studied by the Evidence Review disease worldwide. The development and implementation of Team. global clinical practice guidelines is central to the many acWe view the current guideline as a dynamic, evolving tivitiesofKDIGOtofulfillitsmission. Twentyyearslater, we resourceratherthanastaticdocument. Wearedelightedbythe are excited to present this update of the KDIGO Clinical recentpaceofclinicaldiscoverythatsubstantiallyincreasedthe Practice Guideline for the Evaluation and Management of scientific basis of optimal CKD diagnosis and management, Chronic Kidney Disease (CKD) to complement the existing andweremaincommittedtoupdatingrecommendationsand 12 guidelines that address various other facets of kidney practice points as important evidence emerges. We hope that disease management. the guideline will serve as a useful tool for clinicians in their OuraspirationisthattheKDIGOCKDGuidelineservesas daily practice, providingclearinsightintotheevidence-based a comprehensive reference for evidence-based practices, ofrecommendations while highlighting areas requiring further fering clear and valuable guidance for the optimal diagnosis research.
----------------------------------------------------------------------


======================================================================
CHUNK 283 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_9
Content Type: recommendation
Words: 373
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
We hope that disease management. the guideline will serve as a useful tool for clinicians in their OuraspirationisthattheKDIGOCKDGuidelineservesas daily practice, providingclearinsightintotheevidence-based a comprehensive reference for evidence-based practices, ofrecommendations while highlighting areas requiring further fering clear and valuable guidance for the optimal diagnosis research. Ultimately, ouraimistofacilitatemoreeffectiveand andtreatmentofCKD. Theupdatedguidelineistheresultof consistent care to patients with CKD worldwide, and the a rigorous process, extensively detailed in the KDIGO publicationoftheCKDGuidelinewillprovidethefoundation Methods Manual. To promote objectivity and transparency, of many dissemination and implementation activities to inwe screen Guideline Co-Chairs and Work Group members creasetheoutreachandusefulnessofthiswork. (which include clinicians, researchers, and patients) for conWe extend our heartfelt gratitude for all those who have flicts of interest. Over a span of 23 years, these individuals contributed to the CKD Guideline. First, to the members of volunteer their time, starting with the creation of a Scope of the Methods Committee, particularly Dr. Marcello Tonelli, Work that undergoes an open public review to engage all MD, SM, MSc, ChairoftheCommittee, andAmyEarley, BS, stakeholders. This document is then adapted into a Request KDIGO Guideline Development Director, for setting the forProposal, whichisusedtoenlistanindependentEvidence expectation of rigor, balance, and transparency throughout Review Team. the process. Next, to the Evidence Review Team at Johns TheEvidenceReviewTeamconductsasystematicreviewof Hopkins University, for their meticulous work in reviewing existing literature, extracting studies with appropriate design the existing literature. Third, to the Work Group members, and outcomes deemed important by both people with CKD led by the indefatigable Drs. Adeera Levin, MD, and Paul and clinicians. All work is meticulously graded on study Stevens, MB, for their diligence and innumerable hours volquality and potential bias, forming the basis for quantifying unteeredtoshepherdtheguidelinetopublication. Fourth, to the overall certainty of the evidence using the Grading of the many individuals who provided comments during the Recommendations Assessment, Development, and Evaluarounds of public review. Finally, to the whole KDIGO staff, tion (GRADE) approach. The penultimate version of the for their steadfast, behind the scenes commitment to excelguideline also undergoes public review to capture additional lence in patient care. perspectives. Thus, guidelinesaretheresultofarigorousand objective assessment of available evidence, enriched by the Sincerely, collective expertise of healthcare providers, researchers, and Morgan E. Grams, MD, PhD, MHS patients alike. Guideline statements (We recommend or Michel Jadoul, MD Wesuggest)reflectclinicalquestionsthatwereaddressedby KDIGO Co-Chairs S130 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 284 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_10
Content Type: recommendation
Words: 499
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
perspectives. Thus, guidelinesaretheresultofarigorousand objective assessment of available evidence, enriched by the Sincerely, collective expertise of healthcare providers, researchers, and Morgan E. Grams, MD, PhD, MHS patients alike. Guideline statements (We recommend or Michel Jadoul, MD Wesuggest)reflectclinicalquestionsthatwereaddressedby KDIGO Co-Chairs S130 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org Work Group membership Work Group membership WORKGROUPCO-CHAIRS Paul E. Stevens, MB, FRCP, RCPathME Adeera Levin, MD, FRCPC East Kent Hospitals University University of British Columbia NHS Foundation Trust Vancouver, Canada Canterbury, United Kingdom WORKGROUP Sofia B. Ahmed, MD, MMSc, FRCPC Magdalena Madero, MD University of Alberta Instituto Nacional de Cardiologa Ignacio Chavz Edmonton, Alberta, Canada Mexico City, Mexico Juan Jesus Carrero, Pharm, PhD Pharm, PhD Med, Natasha McIntyre, PhD MBA, FNKF, FERA Western University Karolinska Institutet London Health Sciences Centre-Victoria Hospital Stockholm, Sweden London, Ontario, Canada Bethany Foster, MD, MSCE Kelly Morrow, MS, RDN, CD, FAND McGill University Bastyr University, Osher Center for Integrative Montreal, Quebec, Canada Medicine University of Washington Kenmore, Washington, USA Anna Francis, MBBS, FRACP, CF, MMed, PhD Glenda Roberts Queensland Childrens Hospital UWCenter for Dialysis Innovation Brisbane, Australia Kidney Research Institute Seattle, Washington, USA Rasheeda K. Hall, MD, MBA, MHS Duke School of Medicine Dharshana Sabanayagam, MD, FRACP Durham, North Carolina, USA University of Sydney Sydney, Australia Will G. Herrington, MA, MBBS, MD, FRCP University of Oxford Elke Schaeffner, MD, MSc Oxford, United Kingdom Charit Universittsmedizin Berlin Berlin, Germany Guy Hill Manchester, United Kingdom Michael Shlipak, MD, MPH University of California, San Francisco Lesley A. Inker, MD, MS, FRCP(C) San Francisco, California, USA Tufts Medical Center Boston, Massachusetts, USA Rukshana Shroff, MD, FRCPCH, PhD Rmeyza Kazanco(cid: 1)glu, MD UCL Great Ormond Street Hospital Institute of Child Health, London, United Kingdom Bezmialem Vakif University Istanbul, Turkey Navdeep Tangri, MD, PhD, FRCP(C) University of Manitoba Edmund Lamb, PhD, FRCPath Winnipeg, Manitoba, Canada East Kent Hospitals University NHS Foundation Trust Teerawat Thanachayanont, MD, MSc Canterbury, United Kingdom Bhumirajanagarindra Kidney Institute Bangkok, Thailand Peter Lin, MD, CCFP Canadian Heart Research Center Ifeoma Ulasi, MBBS, FWACP, PGD, MSc Toronto, Ontario, Canada University of Nigeria, Ituku-Ozalla Campus Enugu, Nigeria KidneyInternational(2024)105(Suppl4S), S117S314 S131 Work Group membership www. kidney-international. org Germaine Wong, MD, PhD Luxia Zhang, MD, MPH University of Sydney Peking University First Hospital Sydney, Australia Beijing, China Chih-Wei Yang, MD Chang Gung University Taoyuan, Taiwan METHODSCOMMITTEEREPRESENTATIVE Bertram L. Kasiske, MD, FACP Hennepin County Medical Center University of Minnesota Minneapolis, MN, USA EVIDENCE REVIEWTEAM The Johns Hopkins University Evidence-based Practice Center Karen A. Robinson, PhD, Professor of Medicine Lisa Wilson, ScM, Research Associate Renee F. Wilson, MS, Research Associate Dipal M. Patel, MD, PhD, Assistant Professor of Medicine Troy Gharibani, BS, BA, Research Assistant Xuhao Yang, MSPH, Research Assistant Verna Lazar, MBBS, MPH, Research Assistant Jeongmin Hana Kim, PharmD, MSc, Research Assistant S132 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org abstract Abstract The KidneyDisease: ImprovingGlobalOutcomes(KDIGO) 2024ClinicalPracticeGuideline for the Evaluation and Management of Chronic Kidney Disease (CKD) is an update to the KDIGO 2012 guideline on the topic. The aim is to assist clinicians caring for people with CKD, both adultsandchildren.
----------------------------------------------------------------------


======================================================================
CHUNK 285 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_11
Content Type: recommendation
Words: 488
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org abstract Abstract The KidneyDisease: ImprovingGlobalOutcomes(KDIGO) 2024ClinicalPracticeGuideline for the Evaluation and Management of Chronic Kidney Disease (CKD) is an update to the KDIGO 2012 guideline on the topic. The aim is to assist clinicians caring for people with CKD, both adultsandchildren. Peoplereceivingdialysisandkidneytransplantrecipientsarenotthefocusof thisguideline. ThescopeincludeschaptersdedicatedtotheevaluationofCKD, riskassessmentin peoplewithCKD, managementtodelayCKDprogressionandmanageitscomplications, medical management and drug stewardship in CKD, and optimal models of CKD care. In addition, this guideline includes a comprehensive introduction from the guideline Co-Chairs, a patient foreword, a discussion of special population considerations, a presentation of the relative and absolute risks associated with specific outcomes from the CKD Prognosis Consortium (CKDPC), andanextensivesectiondedicatedtoresearchrecommendationsbasedonthecurrentgaps inevidence. Thegoaloftheguidelineistogenerateausefulresourceforcliniciansandpatientsby providing actionable recommendations based on a rigorous formal evidence review, practice points that serve to direct clinical care or activities for which a systematic review was not conducted, and useful infographics. The guideline targets a broad audience of healthcare providers involved in the care of people with CKD as well as people with CKD themselves while being mindfulofimplicationsfor policyandpayment. Developmentofthisguideline updatefollowed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendationsarebasedonsystematicreviewsofrelevantstudies, andappraisalofthecertainty of the evidence and the strength of recommendations followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented. Keywords: chronic kidney disease; CKD; evaluation; guideline; KDIGO; management CITATION In citing this document, the following format should be used: Kidney Disease: Improving GlobalOutcomes(KDIGO) CKDWorkGroup. KDIGO 2024ClinicalPracticeGuidelinefor the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105(4S): S117S314. KidneyInternational(2024)105(Suppl4S), S117S314 S133 patient foreword www. kidney-international. org Patient foreword The identification of chronic kidney disease (CKD) begins a medical intervention, and may well lead to issues over longjourney forany patientthatwillhaveadirectimpacton adherence. their lifestyle and future health outcomes. This guideline A controlled, managed CKD decline is so beneficial to identifies the suitability of medical interventions that can patientswhohavesomanysocialissuestocontendwith, beit improveordelaytheseriousnessofCKDandpossiblekidney diet, tiredness, liquid control, pill overload, and a deep dive failure. into the very mechanics of how we eat and drink to survive Inacomplicatedworldofhealthprovision, havingasetof and excrete excesses. evidential recommendations and practice points provides In an ever-increasingly busy world of medical care, as pakidney service providers with the targets for a quality CKD tients, webelievethatthebestapproachisforanyphysicianto serviceforpeoplewithkidneydisease. However, ifthestarting aim to achieve a partnership of knowledge with the patient point for many peopleis ignoranceof what akidney actually regardingtheirCKDcare. Thiswillbuildpatientconfidenceand does, thenwithoutaholisticapproachtopatientcare, muchof self-awareness, withtheaimthatanypatientwhosadlyarrivesat the potential effectiveness of medical interventions can be possibledialysisisintherightstateofmind, whichiscriticalfora diluted because of patient circumstances and psychological consideredapproachtothenextstageofapatientsjourney. challenges. Acceptance of the seriousness of CKD can take a lot Guy Hill longer for a person to process, to the possible detriment of CKD Work Group Member S134 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org introduction, qualifying statements, and key concepts Introduction, qualifying statements, and key concepts This 2024 update of the KDIGO Clinical Practice Guideline cardiovascular disease (CVD), mortality (all-cause and carfor the Evaluation and Management of Chronic Kidney Disdiovascular), kidney failure, and acute kidney injury (AKI).
----------------------------------------------------------------------


======================================================================
CHUNK 286 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_12
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org introduction, qualifying statements, and key concepts Introduction, qualifying statements, and key concepts This 2024 update of the KDIGO Clinical Practice Guideline cardiovascular disease (CVD), mortality (all-cause and carfor the Evaluation and Management of Chronic Kidney Disdiovascular), kidney failure, and acute kidney injury (AKI). ease (CKD)1 is an evidence-based guideline that provides The development of risk-prediction tools has refined monirecommendations and practice points for clinical toring and referral to specialist nephrology and has aided in management activities. the estimation of prognosis. 6, 810 Although there remains The past 10 years have provided new hope for improved ongoing discussion about application of the same thresholds treatmentofCKD. Agreaterunderstandingofhealthylifestyle to define disease in older adults, 11 it is still clear that even and lifestyle modifications together with new medications in older populations, risk of adverse outcomes increases andtechnologiesfurnishimprovedoptionsfortreatmentand with higher CKD stages (Figure 1). 12 In any field of monitoring of CKD. People with CKD, healthcare providers, medicine, although data from large population studies and health systems are eager to implement these advances in inform clinical practice guidelines and associated the most effective and evidence-based manner. This requires recommendations for care, it is critically important to integration of new therapies with lifestyle management and consider the individual in front of you, their preferences, existing medications using approaches that engage patients and their individual risks and benefits. We recognize that andoptimizeapplicationofhealthresources. Thegoalofthis the threshold GFR 60 ml/min per 1. 73 m2 (GFR guidelinedocumentistoprovidesuchguidance. Themajority categories G3aG5) for 3 months to indicate a diagnosis of statements from the 2012 guideline have been updated of CKD is well below the average in young adult men and based on current knowledge and practice. Only 6 statements women, 13 but because a significant GFR reduction in were retained in their original form in 2012. younger people is also usually associated with other markers As Co-Chairs, we would like to recognize the outstanding of kidney disease, the diagnosis of CKD would be captured. effortsoftheWorkGroup, theEvidenceReviewTeam(ERT), Similarly, we recognize that there is an average ageand Kidney Disease: Improving Global Outcomes (KDIGO) associated GFR decline observed in longitudinal and crossstaff. The Work Group was diverse, multinational, multidissectional studies, 14 but with substantial variation among ciplinary, experienced, thoughtful, and dedicated. Notably, individuals within the population, 15 such that not all the Work Group included 2 members who have CKD who individuals will have a significant GFR decline with age. 12 contributed actively as peers to keep the guideline relevant This guideline is not intended to be a textbook, and thus and patient-centered. We are indebted to each and every instatements regarding prevention and screening for CKD, dividual who contributed to this process. We hope that the althoughimportanttopics, arenotaddressedindepthbutare guidance provided here will help improve the care of people briefly discussed below in the context of the global burden of with CKD worldwide. CKDandinChapter1. Foramoredetaileddiscussionofthese The KDIGO 2012 CKD guideline was built on the United issues, we refer readers to existing textbooks and reviews.
----------------------------------------------------------------------


======================================================================
CHUNK 287 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_13
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
CKDandinChapter1. Foramoredetaileddiscussionofthese The KDIGO 2012 CKD guideline was built on the United issues, we refer readers to existing textbooks and reviews. 1618 States(US)-basedKidneyDiseaseOutcomesQualityInitiative Prevention and screening for CKD should be conducted (KDOQI) 2002 Guideline on Definition, Classification, and mostly by healthcare providers in primary care and in other Evaluation of CKD, 2 accepted by the international specialties, such as endocrinology, cardiology, and oncology, community in 2005. It reinforced the definition of CKD rather than restricted to nephrologists. We strongly support incorporating a persistent reduction in glomerular filtration efforts aimed at the early detection and treatment of CKD rate (GFR) and markers of kidney damage and modified the among people at high risk for CKD, including those with staging and classification system to include elements that hypertension, diabetes, and CVD. Screening efforts in these had begun to be appreciated by the clinical community. 3 and other populations should include assessments of GFR Specifically, the 2012 guideline introduced the concept of a (estimated or in certain situations measured see Section 1. 2 CGA classification of CKD based on cause (C), level of and albuminuria or surrogate, see Section 1. 3). kidney function determined by GFR (G), and degree of Theintendedstarting pointfor thisupdateoftheKDIGO albuminuria (A). The CGA classification laid a foundation 2012 CKD guideline is an established diagnosis of CKD, upon which management, treatment, research, and risk thoughtherearesomepracticepointstoclarifytheevaluation assessment of CKD have since been based. of CKD and the ascertainment of chronicity. The care of The definition, staging, and classification of CKD propeoplewithCKDismultifacetedandcomplex. Severalcritical posed by the KDIGO 2012 CKD guideline have been widely aspects of this comprehensive care, such as blood pressure accepted and implemented worldwide. Research has since (BP), diabetes, andlipidmanagement, havebeenaddressedin highlighted that higher specific stages or categories of CKD, other KDIGO guidelines. These topics were not reviewed for characterizedbylevelofGFRandalbuminuriaindependently, the current guideline, but recommendations have been portend greater relative risk (RR) for adverse outcomes. 47 incorporated where relevant and we refer readers to those These include, but are not limited to, CKD progression, specific KDIGO guidelines and their updates. 1923 KidneyInternational(2024)105(Suppl4S), S117S314 S135 introduction, qualifying statements, and key concepts www. kidney-international. org Age 65 ACR, mg/g ACR, mg/g Age 65 ACR, mg/g ACR, mg/g eGFRcr-cys 10 1029 30299 300 10 1029 30299 300 eGFRcr-cys 10 1029 30299 300 10 1029 30299 300 All-cause mortality Myocardial infarction All-cause mortality Myocardial infarction 105 0. 99 1. 2 1. 5 2. 4 0. 93 1. 0 1. 1 2. 6 105 1. 2 1. 4 1. 9 3. 5 0. 97 1. 4 2. 0 19 90104 ref 1. 3 1. 5 2. 5 ref 1. 2 1. 3 1. 9 90104 ref 1. 2 1. 4 2. 0 ref 1. 2 1. 1 1. 9 6089 1. 2 1. 6 2. 0 2. 9 1. 3 1. 4 1. 6 2. 1 6089 1. 2 1. 5 1. 8 2. 3 1. 1 1. 4 1. 5 1. 9 4559 2. 1 2. 7 2. 9 4. 5 1. 8 2.
----------------------------------------------------------------------


======================================================================
CHUNK 288 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_14
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
5 1. 4 7. 6 18 16 30 1. 9 1. 9 2. 0 2. 6 8. 4 4. 1 5. 9 10 Figure1Associationsofchronickidneydisease(CKD)stagingbyestimatedglomerularfiltrationratebycreatinineandcystatinC (eGFRcr-cys)andalbumin-to-creatinineratio(ACR)categoriesandrisksfor10commoncomplicationsbyageinmultivariable-adjusted analyses. Numbersreflecttheadjustedhazardratiocomparedwiththereferencecell. Adjustmentvariablesincludedage, sex, smokingstatus (current, former, ornever), systolicbloodpressure, totalcholesterol, high-densitylipoproteincholesterol, bodymassindex, useof antihypertensivemedications, andamedicalhistoryofdiabetes, coronaryheartdisease, stroke, heartfailure, atrialfibrillation, peripheralartery disease, cancer, andchronicobstructivepulmonarydisease, whererelevant. Thecolorsweredeterminedforeachoutcomeseparatelyusingthe followingrule: thepercentileshadedthedarkestgreencolorcorrespondstotheproportionofcellsinthegridwithoutCKD(e. g. , 6of24cells), andthepercentileshadedthedarkestredcolorcorrespondstoproportionexpectedtobeathighestrisk(e. g. , 5of24cells). Inthismanner, the numbersofgreenandredcellsareconsistentacrossoutcomes, butthepatternsareallowedtodiffer. ref, referencecell. Reproducedwith permissionfromJAMA, WritingGroupfortheCKDPrognosisConsortium; GramsME, CoreshJ, MatsushitaK, etal. Estimatedglomerularfiltration rate, albuminuria, andadverseoutcomes: anindividual-participantdatameta-analysis. JAMA. 2023; 330(13): 12661277. 12Copyright2023 AmericanMedicalAssociation. Allrightsreserved. Thisclinicalpracticeguidelineincludes2differenttypesof published. These include refinement of evaluation of GFR, statements: gradedrecommendations, whicharesupportedby population and individual risk prediction, and novel treatsystematicreviews(i. e. , denovoreviewsconductedbytheinments which have all positively influenced the prognosis for dependentERTorexistinghigh-qualityreviewsthathavebeen people with CKD. The Work Group has aimed to generate a systematicallyidentified), andungradedpracticepoints, which guideline that is both rigorouslydevoted to new and existing servetodirectclinicalcareoractivitiesforwhichasystematic evidence, and clinically useful. review was not conducted for various reasons (e. g. , lack of a Research recommendations are presented in a separate sufficient evidence base or randomized controlled trials sectionattheendofthisdocumentandareintendedtoguide RCTs would be impractical/unethical). Both recommendathe next set of important research questions to inform and tions and practice points are intended to help guide clinical improve outcomes of people living with CKD. The research practiceandaidindecision-making; thus, theycollectivelyare recommendationsarenotexhaustivebutareintendedtohelp the guidance statements. They are clearly articulated and focus the clinical and research communities on unanswered presented together so that all guideline statements can be questions including improving diagnostic tools and evaluaimplemented. The distinction between them is based on the tion of kidney function, development and testing of risk processbywhichtheyarederived, thatprocessisbasedonthe prediction equations in clinical and research settings, evaluframework methodology from the KDIGO Methods Comation of different therapies to delay progression in various mittee and aligns with other international guideline groups combinations, improved medication management, and utilizing the Grading of Recommendations Assessment, optimal models of care. We specifically urge the community Development, andEvaluation(GRADE)methodology. to be inclusive of people across the lifecycle and include sex Several exciting developments have been introduced into andgender, andetiologyofCKD, asimportantvariablesinall clinical practice since the KDIGO 2012 CKD guideline was studies. S136 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org introduction, qualifying statements, and key concepts Definition andclassificationofCKD Table2GFRcategoriesin CKD DefiningCKD. CKDisdefined asabnormalities ofkidney GFR GFR(ml/min structureorfunction, presentforaminimumof3months, category per1. 73m2) Terms with implications for health (Table 1). 1 Classifying CKD. CKD is classified based on Cause, GFR G G 2 1 6 0 9 8 0 9 N M o il r d m ly al d o ec r r h e i a g s h eda category (G1G5), and Albuminuria category (A1A3), G3a 4559 Mildlytomoderatelydecreased abbreviated as CGA. 1 These 3 components of the G3b 3044 Moderatelytoseverelydecreased classification system are each critical in the assessment of G4 1529 Severelydecreased G5 15 Kidneyfailure people with CKD and help enable determination of severity CKD, chronickidneydisease; GFR, glomerularfiltrationrate. and risk. Listed below are reference tables describing each aRelativetotheyoungadultlevel. Intheabsenceofevidenceofkidneydamage, component. Note that while the definition of CKD includes neitherG1norG2fulfillsthecriteriaforCKD.
----------------------------------------------------------------------


======================================================================
CHUNK 289 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_15
Content Type: definition
Words: 499
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
and risk. Listed below are reference tables describing each aRelativetotheyoungadultlevel. Intheabsenceofevidenceofkidneydamage, component. Note that while the definition of CKD includes neitherG1norG2fulfillsthecriteriaforCKD. many different markers of kidney damage and is not confined to decreased GFR and albumin-to-creatinine ratio (ACR) 30 mg/g 3 mg/mmol, the classification system financial cost, mortality, morbidity, or other indicators and is based on the 2 dimensions of GFR and degree of can be measured by combining 2 indicators to describe the albuminuria (Tables 2 and 3). This nuance is often missed disability-adjusted life-years (DALYs): the number of years by healthcare providers and students. of life lost to disease and the number of years lived with Itis well established that patient advocates with CKD and disability due to disease. healthcare providers prefer the more clinically useful and Globally, in 2017, a systematic analysis from the all-age generally understood assessment of GFR resulting from the GBD project found 697. 5 million (95% uncertainty interval use of GFR estimating equations compared with serum UI: 649. 2752. 0) cases of all-stage CKD, for a global prevacreatinine(SCr)alone. Globally, althoughstillnotuniversally lenceof9. 1%(8. 5%9. 8%). 25By2021, ajointstatementfrom available in all countries, SCr is measured routinely and the the American Society of Nephrology, European Renal approachtoassessmentofGFRisthereforetouseSCrandan Association, and International Society of Nephrology estimating equation for initial assessment of GFR. The indicated that more than 850 million people suffer from approach to evaluation of GFR using initial and supportive some form of kidney disease, roughly double the number of tests is described in greater detail in Chapter 1. people who live with diabetes (422 million) and 20 times Etiology of CKD should be sought, and there are more than the prevalence of cancer worldwide (42 million) numerous systems for grouping various etiologies, some of or people living with AIDS/HIV (36. 7 million). These whichareevolvingwithnewknowledgeanddiagnostictools. estimates derive from aggregation of studies worldwide, There are congenital and genetic causes of CKD, some assowhich have applied a variety of definitions of CKD; ciatedwithsystemicdiseases, andothersthatareprimary. Itis nevertheless, they furnish the best guide about global CKD beyond our remit to suggest a specific approach, but we prevalence. highlight the importance of establishing a cause to individIn 2017, CKD was estimated to account for 35. 8 million ualize management of CKD. (95% UI: 33. 7e38. 0) DALYs, and 1. 2 million people died from CKD. Most of the burden of CKD was concentrated in Theglobalburden ofCKD the 3 lowest quintiles of sociodemographic index (SDI). In The Global Burden of Disease, Injuries, and Risk Factors 2019, CKD was responsible for 41. 5 million (95% UI: 38. 3 Study (GBD) pulls together data on premature death and 45. 0)DALYs, and1. 43millionpeoplediedfromCKD. 24Agedisability from more than 350 diseases and injuries in 204 standardized DALY rates (Figure 224) were highest in central countries, byageandsex, from1990tothepresent. 24Disease and Andean Latin America, at 1348. 1 (1203. 61521. 6) and burden is the impact of a health problem as measured by 836. 3 (704. 2981. 6) per 100, 000, respectively (global rate was 514. 9 474. 9558. 9).
----------------------------------------------------------------------


======================================================================
CHUNK 290 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_16
Content Type: reference
Words: 476
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
24Disease and Andean Latin America, at 1348. 1 (1203. 61521. 6) and burden is the impact of a health problem as measured by 836. 3 (704. 2981. 6) per 100, 000, respectively (global rate was 514. 9 474. 9558. 9). In 2017, CKD in diabetes represented a third of all DALYs, and there were 1. 4 million Table1Criteriaforchronickidneydisease (eitherofthe following presentforaminimumof3months) Markersofkidney Albuminuria(ACR30mg/g3mg/mmol) Table3Albuminuria categoriesin chronickidneydisease damage(1ormore) Urinesedimentabnormalities Persistenthematuria ACR(approximately Electrolyteandotherabnormalitiesdueto equivalent) AER tubulardisorders Category (mg/24h) (mg/mmol) (mg/g) Terms Abnormalitiesdetectedbyhistology Structuralabnormalitiesdetectedbyimaging A1 30 3 30 Normaltomildly Historyofkidneytransplantation increased A2 30300 330 30300 Moderatelyincreaseda DecreasedGFR GFR60ml/minper1. 73m2 A3 300 30 300 Severelyincreased (GFRcategoriesG3aG5) ACR, albumin-to-creatinineratio; AER, albuminexcretionrate. ACR, albumin-to-creatinineratio; GFR, glomerularfiltrationrate. aRelativetotheyoungadultlevel. KidneyInternational(2024)105(Suppl4S), S117S314 S137 2500 2000 1500 1000 500 0 0 10 20 30 40 50 60 70 80 90 100 SDI (95% UI: 1. 21. 6) CVD-related deaths in people with CKD; glucose cotransporter-2 inhibitors (SGLT2i) recently 25. 3 (22. 228. 9) million CVD DALYs were attributable to concluded that screening adults for albuminuria to identify impaired kidney function. Overall, CKD and its effect on CKD could be cost-effective in the United States. 27 CVD resulted in 2. 6 million (95% UI: 2. 42. 8) deaths in This evidence aligns with the KDIGO Controversies Con2017 and CKD has risen from 19th to 11th in rank among ference on Early Detection and Intervention in CKD, which leading causes of death between 1990 and 2019 due to concluded that early identification of CKD in people at risk, aging and an increasing burden of risk factors for CKD whoareusuallyasymptomatic, wouldlikelybebeneficialinthe (including diabetes and hypertension) that, together, community and primary care settings if the programs are contribute to more than half of the deaths from CKD. interwoven with risk stratification and treatment. 17 A community program must be able to provide treatment to Screening andprevention the high-risk group of patients with newly detected CKD to DespitetheincreasingrecognitionofthetrueburdenofCKD, justify systematic early detection strategies. An additional there remains controversy and lack of consensus as to the conclusion was that screening and treatment programs for utility of population screening for CKD26 or targeted CKD should be implemented based on risk stratification to screening programs, 18 due to the complexity of the prioritize people, particularly in settings with limited underlying sociopolitical and resource environment. Public economic resources. Although globally people with health policy has a role to play in identifying and hypertension, diabetes, or CVD are at high risk for CKD, addressing risk factors to prevent CKD, to identify CKD other high-risk people may be identified through genetic risk early, and to delay its progression and associated adverse factors or by varying exposure to environmental pollution, outcomes. Education of both health personnel and the pesticides, water, and nephrotoxic medications including populations at risk, implementation of early kidney disease significant analgesic use and herbal medications, depending detection programs, and incorporation of evidence-based on geographical region.
----------------------------------------------------------------------


======================================================================
CHUNK 291 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_17
Content Type: recommendation
Words: 479
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Education of both health personnel and the pesticides, water, and nephrotoxic medications including populations at risk, implementation of early kidney disease significant analgesic use and herbal medications, depending detection programs, and incorporation of evidence-based on geographical region. Frameworks in which to consider treatment of CKD and its associated conditions, such as BP specific regional factors have been offered to facilitate and diabetes, are all essential components of a strategy to discussionaboutthevalueandcontextofscreeningforCKD. 26 address this burden. A systematic review suggested that Currently, kidney disease awareness remains low, and screening for CKD is cost-effective in people with diabetes worldwideonly6%ofthegeneralpopulationand10%ofthe and hypertension, the 2 most common causes of CKD high-risk population are aware of their CKD status. Imporworldwide. 16 However, clinical trials have not been tanttonoteisthatpatientadvocateswithCKDstronglyargue conducted to determine whether or not an intervention to forearlierCKDscreeninganddiagnosis. 17Theyalsoadvocate detect, risk-stratify, and treat CKD would improve the for CKD detection to be integrated with patient and family health outcomes for the targeted population. Nevertheless, education and engagement to improve accessing appropriate cost-effective analysis of population-wide screening for CKD healthcare and knowledge and adherence to recommended incorporating evidence-based treatment with sodiumlifestyle modification and medications. )000, 001 rep( etar YLAD introduction, qualifying statements, and key concepts www. kidney-international. org GBD super-region High income Central Europe, eastern Europe, and central Asia South Asia Southeast Asia, east Asia, and Oceania Sub-Saharan Africa Latin America and Caribbean North Africa and Middle East Figure2Age-standardizedchronickidneydiseasedisability-adjustedlife-year(DALY)ratesforeachlocationbysociodemographic index(SDI), bothsexescombined, 2019. GBD, globalburdenofdisease. ReproducedfromGlobalBurdenofDisease2019: GBDcauseandrisk summarieschronickidneydisease. Lancet. 2020; 396: S152S153. 242020TheAuthor(s). PublishedbyElsevierLtd. ThisisanOpenAccessarticle undertheCCBY4. 0license. S138 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org introduction, qualifying statements, and key concepts Identify adults at risk for CKD Test for GFR and ACR  other markers of kidney damage GFR 60 ml/min per 1. 73 m2 or ACR 30 mg/g 3 mg/mmol and/or other markers of kidney damage present Test for GFR or ACR if not performed and exclude AKI/AKD GFR 60 ml/min per 1. 73 m2 and/or AKI/AKD present: GFR 60 ml/min per 1. 73 m2 and ACR 30 mg/g 3 mg/mmol after 3 months follow AKI/AKD guidance ACR 30 mg/g 3 mg/mmol or earlier if evidence of chronicity and no other markers of kidney damage present Measure eGFRcr-cys if not performed and available CKD not present Timing of retesting based on individual characteristics such Stage according to GFR and ACR as risk of progression Establish underlying cause Estimate risk of progression Initiate treatment Figure3Screeningalgorithmfordiagnosisandstagingofchronickidneydisease(CKD)inadults. Riskfactorconditionsarelistedin Table5. Forrecommendedmethodstoestimateglomerularfiltrationrate(eGFR), seeSection1. 2. Markersofkidneydamageotherthan albuminuriamayalsobeusedtodiagnoseCKD, butalbumin-to-creatinineratio(ACR)andGFRarestillrequiredtodeterminestageand estimateriskofprogression. Acutekidneydisease(AKD)isdefinedbytheabnormalitiesofkidneyfunctionand/orstructurewithimplications forhealthandwithadurationof3months. 28TheorangeboxesindicateactionsinpeopleatriskforCKDandinwhomtestingshouldbe performed. Theblueboxesindicatetestingsteps. ThegreenboxesindicatetheidentificationofCKDanditsstagesandtheinitiationof treatment. ThepurpleboxindicatestheidentificationofAKD/acutekidneyinjury(AKI). PleasealsoseetheKidneyDisease: ImprovingGlobal Outcomes(KDIGO)ClinicalPracticeGuidelineforAcuteKidneyInjury. 97 Use of a simple algorithm such as that shown above in Internationalconsiderations settings such as primary care, cardiology, and endocrinology In lowand middle-income regions of the world and in the could significantly improve the early identification and lowersociodemographicquintiles, thereisalargegapbetween treatment of CKD (Figure 3). 28 CKD burden and provision of adequate healthcare. There is There are no current evidence-based recommendations limitedaccesstokidneyreplacementtherapy(KRT)combined regardingthefrequencyofscreeninginpeopleatriskofCKD.
----------------------------------------------------------------------


======================================================================
CHUNK 292 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_18
Content Type: recommendation
Words: 491
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
28 CKD burden and provision of adequate healthcare. There is There are no current evidence-based recommendations limitedaccesstokidneyreplacementtherapy(KRT)combined regardingthefrequencyofscreeninginpeopleatriskofCKD. with the rising prevalence of diabetes and hypertension and In the setting of diabetes, a consensus report from the Amerevidence of substantial sex and gender disparities in access to ican Diabetes Association (ADA) and KDIGO recommends CKDtreatment. Thesefactorshighlighttheimportanceofearly annual screening of people with diabetes for CKD. 29 CKD identification and treatment of risk factors in primary care. screening should start at diagnosis of type 2 diabetes (T2D) However, the majority of the worlds populationwith CKD is because evidence of CKD is often already apparent at this inlow-andmiddle-incomecountries(LMIC) wherethereare time. For type 1 diabetes (T1D), screening is recommended disparities in access to laboratory diagnostic services, kidney commencing 5 years after diagnosis. The overall costs of a biopsy, and imaging services, in availability of appropriately screening program are largely driven by the frequency of skilled healthcare providers and the availability and affordrepeat screening, so the timing of repeated testing should be abilityofmedications. TheInternationalSocietyofNephrology guided by CKD risk. There are risk equations available to survey assessing global kidney healthcare resources reported estimate the interval risk of developing CKD, and this risk thatfewerthan1in4surveyedcountrieshadfacilitiesavailable stratification could guide repeat testing intervals. 30 for routine measurements of SCr or proteinuria. 31 KidneyInternational(2024)105(Suppl4S), S117S314 S139 introduction, qualifying statements, and key concepts www. kidney-international. org Importantly, slowing CKD progression at early stages available. Therefore, this guidance document includes should provide economic benefits and prevent the developstandards for laboratory tests. The International ment of kidney failure and cardiovascular complications. A Consortium for Harmonization of Clinical Laboratory systematic review of care models in LMIC found that those Results (ICHLR) was established to create a pathway for supporting primary care providers or allied health workers harmonization and aid implementation of clinical guidelines achieved effectiveness in slowing GFR decline, as opposed to recommending the use of laboratory tests in the diagnosis interventions centered on specialtycare alone. 32 Where there and management of disease, 33 ensuring that both reference areresourcelimitations, itislogicaltodeployresourceswhere materials and test methodology are harmonized. The they will be most cost-effective, for example, to higher-risk, ICHLR aimed to prioritize measurands by medical preventable stages. importance and both coordinate and stimulate development of technical and regulatory processes to achieve Standardization/accuracy oftesting toolsincluding harmonization of those measurands. 34 Although this has assays/equipment been achieved for SCr, the current status of other key The KDIGO 2012 CKD guideline built on recommendations measurands such as cystatin C and urinary albumin is not made to clinical laboratories in the earlier KDOQI 2002 yet sufficiently clear. guidance. Clinical laboratories were specifically charged with The foundations for this 2024 guideline have been develmeasuring SCr and serum cystatin C using assays with caliopedoverthelast20years, galvanizingthecollaborativework bration traceable to the international standard reference of researchers, healthcare providers, laboratory physicians, materials recommending that, for SCr, there should be patients, andcarers. Thecurrentupdatedguidelinedocument minimal bias compared with isotope-dilution mass specreinforces methods for accurate diagnosis of CKD and pretrometry.
----------------------------------------------------------------------


======================================================================
CHUNK 293 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_19
Content Type: recommendation
Words: 471
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Thecurrentupdatedguidelinedocument minimal bias compared with isotope-dilution mass specreinforces methods for accurate diagnosis of CKD and pretrometry. 1Recommendationswere also made with respect to diction, incorporates novel treatment strategies and apmeasurement and reporting of albumin and protein in the proachestomanaging peoplelivingwithCKD, andidentifies urine. Although some of the recommendations have further areas for research. Importantly, as the field is rapidly become part of routine practice, the effective use of clinical changing, we commit to updating relevant sections of this guidelines and therefore effective patient care, including documentasnewevidencebecomesavailable, toensuremore accurate diagnosis and referral prioritization, clinical timely updates than have previously been possible. research, and public health prioritization, require comparability of laboratory results independent of time, place, and measurement procedure. Key to this is Adeera Levin, MD, FRCPC establishing precision and between-laboratory agreement Paul E. Stevens, MB, FRCP with traceability to accepted reference standards wherever CKD Guideline Co-Chairs S140 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org special considerations Special considerations TheWorkGrouprecognizesthatkidneydiseasesaffectpeople 1019 years old). When there are altered care recommendaatdifferenttimesandwithdifferentimpactsacrossthewhole tionsandpracticepointsduetotheuniqueneedsofchildren lifespan. Thus, enablingapersonalizedapproach, considering or the lack of data to inform recommendations and practice age, sex, and gender for diagnosis, risk assessment, and points, theseconsiderationsarediscussedwithinthePediatric treatment is critical. At the extremes of agethe very young considerations sections of the guideline. and the very olddiagnostic procedures, treatment aims, The management of children and adolescents with CKD treatment modalities, and decision-making differ due to difneedsspecialconsideration(Figure4). Childrenandadultshave ferences in prognosis, treatment options, and prioritization. differentetiologiesofCKD. Upto40%50%ofchildhoodCKD Inyoung and middle-aged adults, treatment approaches may isduetocongenitalanomaliesofthekidneysandurinarytract differ due to specific circumstances, such as pregnancy or (CAKUT); the younger the CKD population, the greater the menopause. Sex (biological attributes) and gender (socioproportion with CAKUT as the cause. 35, 36 CAKUT is cultural factors), as well as other important intersectional characterized by slower progression to kidney failure and a factors including but not limited to geographical location, higherlikelihoodofpolyuriathantheconditionscausingCKD socioeconomic status (SES), and race and ethnicity, play inadults. PediatricCKDhasseveraluniqueaspects: important roles in kidney health and disease. Deliveryofcare. Pediatrichealthcareprovidersengagewith Hereweintroduceconceptsastowhyage, sex, andgender not only the person with CKD but also their carers and sibshould be considered in the context of diagnosis, treatment, lings. Age-appropriate care and education, understood by and care planning in people with CKD. In addition, the both the child and their carers, is necessary. Holistic considspecific guideline chapters incorporate statements where eration of the needs and capabilities of the family unit is special considerations regarding age, sex, and gender are important in ensuring effective CKD care. Engagement with relevant to clinical practice and understanding. patients and families must change over the course of childhood from being entirelycarer-directed for infants, changing Considerations inchildren andadolescents to include the whole family unit in childhood, and then When the guideline refers to people with CKD, this includes leaning toward the young person to ensure successful tranchildren (people 10 years old) and adolescents (people sition to adult-oriented care.
----------------------------------------------------------------------


======================================================================
CHUNK 294 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_20
Content Type: recommendation
Words: 487
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Sex Child/adolescent Menopause Growth Contraception Nutrition Weight/BSA-based drug dosing Neurocognitive development of risk factors and Supporting education complications Transition to adult care Holistic approach to care for the whole family unit Older adults Multidimensionality of chronic conditions/ multimorbidity Frailty (including sarcopenia) Cognitive function Polypharmacy Prioritization Pregnancy/lactation End-of-life care Gender Drug pharmacokinetics Gender identity and pharmacodynamics Gender roles Drug teratogenicity Gender relations Risk of CKD progression Institutionalized Increased risk of pregnancy complications, preterm birth gender and small for gestational age babies Fertility Figure4Specialconsiderationsforchronickidneydisease(CKD)careacrossthelifespan. BSA, bodysurfacearea. KidneyInternational(2024)105(Suppl4S), S117S314 S141 special considerations www. kidney-international. org Growth, puberty, and young adulthood. Childhood and among others. Often, several of these features coexist espeadolescence are characterized by physical growth and develcially in older adults with CKD. opment. All CKD care aims to optimize these physiological Implications for aging adults with CKD are important in processes, whicharecommonlydisruptedbyCKD. Pubertyis both diagnosis and treatment. The interpretation of laboraa time of rapid somatic growth with an increase in muscle tory results (specifically SCr) used in the staging system bulk and therefore constitutes a high-risk period for CKD should factor in an older adults habitus given the frequency progressionascompromisedkidneysmaynothypertrophyto of sarcopenia. A creatinine-based eGFR (eGFRcr) will overadapt to the larger body size. Adolescence and emerging estimate GFR in the elderly (and others) with sarcopenia adulthood bring individuation and exploration of sexuality leading to drug overdosing. Urine ACR at the same time will and adult behaviors, and kidney disease care must recognize be falsely high due to the falsely low creatinine in the deand adapt to these changes. nominator. Furthermore, the presence of frailty may alter Kidney development and long-term assessment of kidney treatment targets recommended for younger people with risks. Althoughnephronformationiscompleteby36weeksof CKD, as they may not necessarily be transferable to older gestation, kidney function continues to develop throughout adults. Strict BP-lowering, for example, may come with the early childhood, with nephron growth and maturation prorisk of dizziness, falls, and fractures in older adults, many of gressing particularly rapidly in the first yearof life. An actual whom are on anticoagulants risking severe hemorrhage. increaseinGFRoverthecourseofthefirst12yearsoflife, and Themultidimensionalityofcomorbiditiesinoldageposes evenupto4yearsofage, isexpected. Atrajectoryofincreasing challenges, as it demands a sophisticated integrated and GFRininfancyandveryearlychildhoodfollowedbyaperiodof complex multidisciplinary care and treatment approach, relative stability and a subsequent progression in CKD in which may not be available in every healthcare system. Life adolescenceoradulthood iscommon. Giventhelong life exexpectancy in old age is naturally limited compared with pectancy of children, follow-upplans must takeinto account younger people. Perspectives and treatment goals shift over the risk of late CKD or kidney failure. Healthy children and the life course, and recognizing these in very old adults, as adolescentsshouldhaveexcellentkidneyfunction, soanestidifferent from those in middle-aged or younger adults with mated eGFR under 90 ml/min per 1. 73 m2 (CKD G2G5) CKD, iscriticaltothedevelopmentofmorepersonalizedcare representsdecreasedkidneyfunctionintheseagegroups. Early plansandgoals. Specifically, puresurvivalmaybecomelessof assessmentandinterventionofchildrenwithCKDiscrucialto a priority for an older individual, whereas maintaining an maximizeoverallhealthacrossthelifespan. acceptable, good quality of life (QoL) may be more imporNeurodevelopment and education. A primary goal of peditant.
----------------------------------------------------------------------


======================================================================
CHUNK 295 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_21
Content Type: recommendation
Words: 436
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
73 m2 (CKD G2G5) CKD, iscriticaltothedevelopmentofmorepersonalizedcare representsdecreasedkidneyfunctionintheseagegroups. Early plansandgoals. Specifically, puresurvivalmaybecomelessof assessmentandinterventionofchildrenwithCKDiscrucialto a priority for an older individual, whereas maintaining an maximizeoverallhealthacrossthelifespan. acceptable, good quality of life (QoL) may be more imporNeurodevelopment and education. A primary goal of peditant. The context of a persons situation and own values and atric CKD care is to optimize neurodevelopmental gains. preferences may modify the prioritization for testing, treatCKD can affect development, cognition, school attendance, ment types, and treatment goals. For example, the decisionvocational outcomes, and future employment. Mitigating making between KRTand conservative care should be made thesedeficitsthrougheffective, individualizedcareisessential on the basis of the persons priorities, medical needs, and to give children with CKD the best possible future. informed decision as to benefits and harms of various options. Theseinformeddecisionsrequiregoodcommunication Considerations inolderadults between caregivers, people with CKD, and their relatives/ Older adults constitute a substantial and steadily growing carers; they require time, room, adequate understandable proportion of people under nephrology and medical care language, patience, trust, and commitment. Repeated conglobally, especially in Western industrialized countries. versationsarecritical, giventhehigherprevalenceofcognitive Longevity in many parts of the world is increasing, and thus deficits in older adults with CKD. These cognitive issues theprevalenceofCKDinthosepeopleisalsoincreasing. The accompany both aging and CKD and frequently remain un2022 US Renal Data System (USRDS) annual data report recognized, thus, impeding shared decision-making and highlights that the number of individuals initiating KRT is advance care planning in this group. continuously ascending with increasing age. In Taiwan, for In summary, older adults constitute the largest group example, KRT incidence in those aged 75 was 2858 per among all people with advanced CKD. Although every single million population (pmp) compared with 1583 pmp among person needs individual care, the multidimensional medical peopleaged6574years, 530pmpamong peopleaged4564 complexity inherent in very old age is challenging. Where years, and 97 pmp among people aged 2044 years. The specific recommendations or practice points require special pattern is very similar across the globe with the majority of consideration in the elderly, we make clear statements in the people initiating dialysis over the age of 75, which puts special considerations section and encourage clinicians to emphasisonagroupofpeoplewhoarenotjustold, butvery individualize therapies and goals of care in all patients, with old, and incorporates more and more people over the age of special attention to those of advanced age. 80. Octoand nonagenarians often demonstrate distinct patterns of disease complexity. These features include multiConsiderations regardingsexandgender morbidity often accompanied by polypharmacy, frailty, It is increasingly recognized that sex (biological attributes) cognitive impairment, and gerontopsychiatric disorders and gender (sociocultural factors) factors across individuals S142 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org special considerations contribute to differences in kidney health and disease.
----------------------------------------------------------------------


======================================================================
CHUNK 296 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_22
Content Type: recommendation
Words: 476
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
These features include multiConsiderations regardingsexandgender morbidity often accompanied by polypharmacy, frailty, It is increasingly recognized that sex (biological attributes) cognitive impairment, and gerontopsychiatric disorders and gender (sociocultural factors) factors across individuals S142 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org special considerations contribute to differences in kidney health and disease. 3739 and is perceived by others, e. g. , woman, man, girl, boy, Sex-basedvariationingenetics, physiology, immunology, and and gender-diverse), roles (social expectations and norms anatomy, aswellasgender factorssuchasidentity, roles, and typically associated with a given gender, e. g. , primary relations in addition to institutionalized gender, influences household earner and caregiver), relations (interactions kidney disease pathophysiology, presentation, response to with and treatment by others based on an individuals therapy, complications, and outcomes, highlighting the need perceived and/or expressed gender identity), and to take these factors into consideration in the care of the institutionalized gender (e. g. , distribution of power and person living with kidney disease. resources in society). 37 Globally, the prevalence of CKD not being treated with A small but increasing proportion of the worlds populadialysis defined by level of eGFR is greater in women than tion identifies as transgender, gender-diverse, or nonbinary men. 40 Progression of CKD has been reported as more rapid where sex assigned at birth differs from gender identity, in men, 41, 42inwomen, 43or nodifferencebysexorgender. 44 highlighting the urgent need to build transgender cultural These incongruities are likely a reflection of differences in safety within all aspects of kidney disease management and cause of kidney disease and definitions of outcomes (e. g. , care. 49 loss of eGFR or receipt of KRT). Taking sex and gender considerations into account is Thereissubstantialliteraturedemonstratingthatbothsexcritical to optimize the care of the individual with kidney and gender-related factors (e. g. , puberty, menstrual patterns, disease. Althoughthereisincreasing literaturetoinformsexhormonal contraception, pregnancy and pregnancy-related and gender-specific recommendations in nephrology, signifcomplications, menopause, menopausal hormone therapy, icantknowledgegapsremain, underscoringtheimportanceof testosterone levels, and gender-affirming hormone therapy) a person-centered approach in kidney care. play important roles in the risk, progression, complications, and treatment of kidney disease. 45 Considerations regardingfertilityandpregnancy These factors will play prominent roles in progression of Neither fertility nor pregnancy in people with CKD was part kidney disease across different stages of the life cycle. For of the scope of work for this guideline update, but there will example, theuseofsomerecommended medicationshasnot be special consideration relating to fertility and pregnancy been studied in pregnant populations, highlighting the requiring specific reference in relevant sections of the importance of contraceptive counseling in accordance with a guideline. persons values and preferences. In other instances, preconFertility. CKDisassociatedwithdecreasedfemaleandmale ception counseling, changing medications to nonteratogenic fertility. 50, 51 Progressively impaired function of the options and a multidisciplinary approach, is required to hypothalamic-pituitary-gonadal axis appears to play a key optimizetheoutcomesofapotentialpregnancyinthesetting role in the pathophysiology, although multiple factors of CKD. Sex-based differences in pharmacokinetics and contribute to the reduction in fertility in this population.
----------------------------------------------------------------------


======================================================================
CHUNK 297 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_23
Content Type: recommendation
Words: 496
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
50, 51 Progressively impaired function of the options and a multidisciplinary approach, is required to hypothalamic-pituitary-gonadal axis appears to play a key optimizetheoutcomesofapotentialpregnancyinthesetting role in the pathophysiology, although multiple factors of CKD. Sex-based differences in pharmacokinetics and contribute to the reduction in fertility in this population. In pharmacodynamics that are accentuated with increasing age conjunction with the decreased fertility associated in CKD and changing hormonal status may alter the response to and the uncertainty of the impact of assisted reproductive different therapies for the treatment of kidney disease. For technologies on kidney function, ongoing discussion of example, women are more likely to report adverse reactions family planning potential between the person with CKD toangiotensin-convertingenzymeinhibitors (ACEi), 46which and their healthcare provider is essential. play a role in adherence and failure to reach guidelinePregnancy. People with CKD are at risk for adverse pregrecommended target doses. nancy-associated outcomes, including progression of their There are differences between women and men in the underlying CKD, a flare of their kidney disease, and adverse detection, recognition, monitoring, referrals, and managepregnancy complications including pre-eclampsia, preterm ment of CKD. 47, 48 Although the reasons behind these delivery, andsmallforgestationalageinfant. 52, 53Theseverity disparities are unclear, access to kidney care may be limited of CKD is associated with risk of adverse pregnancy by familial and other caregiving responsibilities, as well as outcomes. A multidisciplinary approach to preconception financial challenges, occupational obligations, and time counseling and management of pregnancy is necessary to constraints, which are influenced by gender identity (how achieve optimal outcomes for both the person with CKD an individual self-identifies, behaves, expresses their gender, and the infant. 54 KidneyInternational(2024)105(Suppl4S), S117S314 S143 relative and absolute risks associated with CKD www. kidney-international. org Summary of relative and absolute risks relevant to CKD from meta-analysis of large multinational population studies in the CKD Prognosis Consortium (CKD-PC) OutcomesrelevanttoCKD, andtheprognosticimportanceof kidney specific (kidney failure and AKI), and 2 general CKDcategories outcomes (all-cause mortality and all-cause The most highly evaluated endpoints in epidemiological hospitalization). studies have been all-cause mortality, cardiovascular events (iv) Additional analyses have been conducted using the 2021 (myocardialinfarction, stroke, andheartfailure), andkidneyCKD-EPI combined eGFR equation that incorporates specific outcomes (progression to kidney failure and AKI), bothcreatinineandcystatinC. Althoughthesamplesize although additional outcomes such as all-cause hospitalizafor these subsequent analyses is much smaller (n  tion and incident atrial fibrillation have been studied more 720, 736), it does permit better differentiation of associrecently. Inthissection, wehighlightnewerdataderivedfrom ations of eGFR and risk and allows validation of CKD the CKD Prognosis Consortium (CKD-PC). 12 We describe thresholds across populations. the associations of CKD categories with 10 of these important outcomes and demonstrate the importance of CKDstagingbyeGFRcrandACRandassociationwithadverse different methods of estimating GFR (i. e. , using creatinineevents or cystatin Cbased equations) on these risk gradients. Figure 512 presents the RRs for all eGFR/ACR combinations Healthcare providers, researchers, and policy makers for the 10 identified outcomes. should understand the association of CKD parameters (ACR The RRs presented have all been adjusted for age, sex, and eGFR) in populations.
----------------------------------------------------------------------


======================================================================
CHUNK 298 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_24
Content Type: reference
Words: 493
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
3 1. 5 2. 0 4559 3. 9 4. 7 5. 5 7. 5 1. 3 1. 6 1. 8 2. 2 3044 5. 8 7. 0 8. 4 10 1. 6 2. 0 2. 2 2. 5 30 11 12 12 21 2. 0 2. 0 2. 7 4. 4 Hospitalization: 3 cohorts Peripheral artery disease: 6 cohorts 630 489 participants; 464 894 events 642 624 participants; 3943 events 105 1. 0 1. 1 1. 1 1. 6 0. 9 1. 9 1. 8 2. 9 90104 ref 1. 1 1. 3 1. 4 ref 1. 5 2. 0 3. 2 6089 1. 1 1. 2 1. 3 1. 6 1. 3 1. 8 2. 1 3. 9 4559 1. 3 1. 4 1. 5 1. 7 2. 5 3. 7 3. 3 4. 0 3044 1. 5 1. 5 1. 6 2. 1 4. 0 3. 7 4. 5 6. 9 30 1. 8 2. 0 2. 1 3. 0 7. 8 4. 5 9. 0 12 Figure6Associationsofchronickidneydisease(CKD)stagingbyestimatedglomerularfiltrationratebycreatinineandcystatinC (eGFRcr-cys)andalbumin-to-creatinineratiocategoriesandrisksfor10commoncomplicationsinmultivariable-adjustedanalyses. Numbersreflecttheadjustedhazardratiocomparedwiththereferencecell. Adjustmentvariablesincludedage, sex, smokingstatus(current, former, ornever), systolicbloodpressure, totalcholesterol, high-densitylipoproteincholesterol, bodymassindex, useofantihypertensive medications, andamedicalhistoryofdiabetes, coronaryheartdisease, stroke, heartfailure, atrialfibrillation, peripheralarterydisease, cancer, andchronicobstructivepulmonarydisease, whererelevant. Thecolorsweredeterminedforeachoutcomeseparatelyusingthefollowingrule: thepercentileshadedthedarkestgreencolorcorrespondstotheproportionofcellsinthegridwithoutCKD(e. g. , 6of24cells), andthe percentileshadedthedarkestredcolorcorrespondstoproportionexpectedtobeathighestrisk(e. g. , 5of24cells). Inthismanner, thenumbers ofgreenandredcellsareconsistentacrossoutcomes, butthepatternsareallowedtodiffer. ref, referencecell. Reproducedwithpermission fromJAMA, WritingGroupfortheCKDPrognosisConsortium; GramsME, CoreshJ, MatsushitaK, etal. Estimatedglomerularfiltrationrate, albuminuria, andadverseoutcomes: anindividual-participantdatameta-analysis. JAMA. 2023; 330(13): 12661277. 12Copyright2023American MedicalAssociation. Allrightsreserved. CKDstaging byeGFRcr-cysandACR andriskforadverse andACR. ThereplacementofeGFRcrwitheGFRcr-cysinthe events heatmapledtoseveralchangesintheriskdistributions. Most Within the CKD-PC collaboration, 720, 736 individuals had notably, the groups with eGFR category 4559 ml/min per measures of blood cystatin C in addition to having eGFRcr 1. 73 m2 and ACR 10 mg/g 1 mg/mmol were moved to S146 KidneyInternational(2024)105(Suppl4S), S117S314 4 3 2 1. 5 1 0. 7 higher risk for all 10 outcomes, and this cell was no longer Efforts should be directed at people with higher risk with labeled green for any of the complications (Figure 6). The GFR levels 60 ml/min per 1. 73 m2 to prevent the distinction in these risk relationships was further explored incidence of CKD or further reductions in GFR. using spline analyses to depict the risk relationships of Among older adults, the findings of consistently elevated eGFRcr and eGFRcr-cys with all the 10 complications. For RRforolderadultswithCKDG3a, A1, asdefinedbyeGFRcrthe 8 outcomes that are not influenced by changes in cys, support the inclusion of this large group in the CKD creatinine (all except kidney failure and AKI), eGFRcr population. TheseelevatedRRstellushowmuchmorelikely exhibited a J-shaped association such that risk increased theoutcomeiscomparedwiththereferencegroup(eGFR90 with eGFR values over 105 ml/min per 1. 73 m2 104 ml/min per 1. 73 m2 and ACR 10 mg/g 1 mg/ (Figure 712). In contrast, eGFRcr-cys demonstrated much mmol). Crucially, they do not tell us what the overall likemore linear associations with each of these complications lihoodoftheoutcome, theabsoluterisk, is. Theabsoluterisk throughout its distribution. forimportantCKDcomplicationsishigheramongolderthan Based upon the risk relationships of eGFRcr-cys and younger adults at nearly every stage, particularly for CVD, ACR categories with all complications, the existing CKD heartfailure, andmortality.
----------------------------------------------------------------------


======================================================================
CHUNK 299 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_25
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Theabsoluterisk throughout its distribution. forimportantCKDcomplicationsishigheramongolderthan Based upon the risk relationships of eGFRcr-cys and younger adults at nearly every stage, particularly for CVD, ACR categories with all complications, the existing CKD heartfailure, andmortality. Therefore, thispopulationisalso staging is appropriate among both younger and older likely to benefit from having their CKD diagnosed, staged, adults. and treated. Some authors have suggested that the GFR threshold for CKDof60ml/minper1. 73m2shouldberaisedto75ml/min RationaleforusingcystatinCcontaining equationsforCKD per1. 73m2foryoungeradultsandloweredto45ml/minper staging 1. 73m2forolderadults. 55Inyoungeradults, thepurposeofa The rationale for using cystatin C versus SCr, or a combihigher GFR threshold reflects the longer risk horizon for nationofboth, ineGFRequationsisthatcreatinine, whichis younger people, which could lead to higher lifetime CKD directlylinkedtomusclemass, maybemisleadingatextremes progression risks for a given GFR stage. However, the ofbodyhabitus, orinspecificconditions(spinalcordinjuries higher lifetime progression risks in younger adults with and sarcopenia), and that cystatin C is impacted by different GFR 6089 ml/min per 1. 73 m2 can be addressed in their variables (steroid use, thyroid disease, and cancer). Thus, management without changing the definition of CKD. because neither is a perfect marker to use for estimating oitar drazaH 4 3 2 1. 5 1 0. 7 oitar drazaH www. kidney-international. org relative and absolute risks associated with CKD a b 15 30 45 60 75 90 105 120 15 30 45 60 75 90 105 120 eGFRcr, ml/min/1. 73 m2 eGFRcr-cys, ml/min/1. 73 m2 All-cause mortality, 721394 participants; 102910 events Heart failure, 674255 participants; 28530 events Cardiovascular mortality, 719987 participants; 27051 events All-cause hospitalization, 676519 participants; 7862 events Peripheral artery disease, 660412 participants; 4458 events Myocardial infarction, 711478 participants; 18659 events Kidney failure with replacement therapy, 637387 participants; 24342 events Stroke, 711293 participants; 17609 events Acute kidney injury, 632452 participants; 466201 events Figure7Hazardratiosforadverseoutcomesusingthecontinuousmodelofestimatedglomerularfiltrationrate(eGFR), comparison oftheshapeofassociationsbetweencreatinine-basedeGFR(eGFRcr)andcreatinineandcystatinCbasedeGFR(eGFRcr-cys)inthe populationwithcystatinC(eGFRcr-cyspopulation). (a)AssociationsofeGFRbasedoncreatininealonewithall-causemortality, cardiovascularmortality, all-causehospitalizations, myocardialinfarction, stroke, heartfailure, atrialfibrillation, andperipheralarterydisease; (b) AssociationsofeGFRbasedoncreatinineandcystatinCwithall-causemortality, cardiovascularmortality, all-causehospitalizations, myocardial infarction, stroke, heartfailure, atrialfibrillation, andperipheralarterydisease. ReproducedwithpermissionfromJAMA, WritingGroupforthe CKDPrognosisConsortium; GramsME, CoreshJ, MatsushitaK, etal. Estimatedglomerularfiltrationrate, albuminuria, andadverseoutcomes: an individual-participantdatameta-analysis. JAMA. 2023; 330(13): 12661277. 12Copyright2023AmericanMedicalAssociation. Allrightsreserved. KidneyInternational(2024)105(Suppl4S), S117S314 S147 relative and absolute risks associated with CKD www. kidney-international. org clearance, the combination of the 2 compounds gives more 1. 73 m2. These limitations are not observed when risk is accurate estimates of GFR when compared with measured estimated using eGFRcr-cys or cystatin Cbased eGFR values. (eGFRcys) (Figure 7). Very low levels of SCr often represent poor health status, When comparing GFR estimates using these 2 filtration such as frailty or sarcopenia, which limits the production of markers, risk gradients are consistently stronger for most creatinine. This biological feature of creatinine (i. e. , relation outcomesforeGFRcysincomparisonwitheGFRcr. Therefore, to muscle mass) has limited its prognostic utility and results for the purpose of evaluating the association of eGFR with in reducing the risk associations for eGFRcr 4560 ml/min outcomes(i. e. , projectingprognosisforpeoplewithCKD), the per1. 73m2andelevating risksforeGFRcr110ml/minper eGFRcysoreGFRcr-cyscanbeconsideredmoreaccurate. S148 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Summary of recommendation statements and practice points Chapter 1: Evaluation of CKD 1. 1 Detection and evaluation of CKD 1. 1. 1 Detection of CKD Practice Point 1. 1. 1.
----------------------------------------------------------------------


======================================================================
CHUNK 300 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_26
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
73m2andelevating risksforeGFRcr110ml/minper eGFRcysoreGFRcr-cyscanbeconsideredmoreaccurate. S148 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Summary of recommendation statements and practice points Chapter 1: Evaluation of CKD 1. 1 Detection and evaluation of CKD 1. 1. 1 Detection of CKD Practice Point 1. 1. 1. 1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR). Practice Point 1. 1. 1. 2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD. 1. 1. 2 Methods for staging of CKD Recommendation 1. 1. 2. 1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimatedfromthecombinationofcreatinineandcystatinC(creatinineandcystatin Cbased estimated glomerular filtration rate eGFRcr-cys) (1B). 1. 1. 3 Evaluation of chronicity Practice Point 1. 1. 3. 1: Proof of chronicity (duration of a minimum of 3 months) can be established by: (i) review of past measurements/estimations of GFR; (ii) review of past measurements of albuminuria or proteinuria and urine microscopic examinations; (iii)imaging findings such as reduced kidney size and reduction in cortical thickness; (iv) kidney pathological findings such as fibrosis and atrophy; (v) medical history, especially conditions known to cause or contribute to CKD; (vi) repeat measurements within and beyond the 3-month point. Practice Point 1. 1. 3. 2: Do not assume chronicity based upon a single abnormal level for eGFR and ACR, as the finding could be the result of a recent acute kidney injury (AKI) event or acute kidney disease (AKD). PracticePoint1. 1. 3. 3: ConsiderinitiationoftreatmentsforCKDatfirstpresentationofdecreasedGFRorelevatedACR if CKD is deemed likely due to presence of other clinical indicators. 1. 1. 4 Evaluation of cause Practice Point 1. 1. 4. 1: Establish the cause of CKD using clinical context, personal and family history, social and environmental factors, medications, physical examination, laboratory measures, imaging, and genetic and pathologic diagnosis (Figure 8). KidneyInternational(2024)105(Suppl4S), S117S314 S149 summary of recommendation statements and practice points www. kidney-international. org Physical exam Symptoms and signs Nephrotoxic of urinary tract medications abnormalities Social and Medical environmental history history Obtain careful family history Symptoms and signs for possible genetic causes, of systemic diseases including family pedigree for CKD Laboratory tests, imaging, and tissue sample, such as: Urinalysis and urine sediment Urine albumin-to-creatinine ratio Serologic tests Ultrasound Kidney biopsy Genetic testing Figure8Evaluationofcauseofchronickidneydisease(CKD). Practice Point 1. 1. 4. 2: Use tests to establish a cause based on resources available (Table 622, 98-100). Table6Guidancefortheselectionofadditional testsforevaluation ofcause Testcategory Examples Commentorkeyreferences Imaging Ultrasound, intravenousurography, CTkidneys Assesskidneystructure(i. e. , kidneyshape, size, symmetry, andevidenceof uretersbladder, nuclearmedicinestudies, MRI obstruction)forcysticdiseaseandrefluxdisease. Evolvingroleofadditionaltechnologies(e. g. , 3Dultrasound) Kidneybiopsy Ultrasound-guidedpercutaneous Usuallyexaminedbylightmicroscopy, immunofluorescence, andelectron microscopy, and, insomesituations, mayincludemoleculardiagnostics Usedforexactdiagnosis, planningtreatment, assessingactivityand chronicityofdisease, andlikelihoodoftreatmentresponse; mayalsobe usedtoassessgeneticdisease Laboratorytests: Chemistryincludingacid-baseandelectrolytes, RefertoKDIGO2021ClinicalPracticeGuidelinefortheManagementof serologic, urine serologictestssuchasanti-PLA2R, ANCA, anti-GBM GlomerularDiseases22 tests antibodies Increasingrecognitionoftheroleoflightchainsinkidneydiseaseevenin Serum-freelightchains, serum, andurineprotein theabsenceofmultiplemyeloma(monoclonalgammopathyofrenal electrophoresis/immunofixation significanceMGRS)98 Urinalysisandurinesedimentexamination Presenceofpersistenthematuriaoralbuminuriaiscriticalindetermining differentialdiagnosis Genetictesting APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, Evolvingasatoolfordiagnosis, increasedutilizationisexpected.
----------------------------------------------------------------------


======================================================================
CHUNK 301 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_27
Content Type: recommendation
Words: 498
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Evolvingroleofadditionaltechnologies(e. g. , 3Dultrasound) Kidneybiopsy Ultrasound-guidedpercutaneous Usuallyexaminedbylightmicroscopy, immunofluorescence, andelectron microscopy, and, insomesituations, mayincludemoleculardiagnostics Usedforexactdiagnosis, planningtreatment, assessingactivityand chronicityofdisease, andlikelihoodoftreatmentresponse; mayalsobe usedtoassessgeneticdisease Laboratorytests: Chemistryincludingacid-baseandelectrolytes, RefertoKDIGO2021ClinicalPracticeGuidelinefortheManagementof serologic, urine serologictestssuchasanti-PLA2R, ANCA, anti-GBM GlomerularDiseases22 tests antibodies Increasingrecognitionoftheroleoflightchainsinkidneydiseaseevenin Serum-freelightchains, serum, andurineprotein theabsenceofmultiplemyeloma(monoclonalgammopathyofrenal electrophoresis/immunofixation significanceMGRS)98 Urinalysisandurinesedimentexamination Presenceofpersistenthematuriaoralbuminuriaiscriticalindetermining differentialdiagnosis Genetictesting APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, Evolvingasatoolfordiagnosis, increasedutilizationisexpected. HNF1B, PKD1, PKD2 Recognitionthatgeneticcausesaremorecommonandmaypresent withoutclassicfamilyhistory99, 100 ANCA, antineutrophilcytoplasmicantibody; APOL1, apolipoprotein1; COL4A, typeIVcollagenalphachain; CT, computedtomography; GBM, glomerularbasementmembrane; HNF1B, hepatocytenuclearfactor1B; MRI, magneticresonanceimaging; NPHS1, congenitalnephroticsyndrome; PKD1, polycystickidneydisease-1; PKD2, polycystickidney disease-2; PLA2R, M-typephospholipaseA2receptor; UMOD, uromodulin. Recommendation 1. 1. 4. 1: We suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate (2D). 1. 2 Evaluation of GFR 1. 2. 1 Other functions of kidneys besides GFR PracticePoint1. 2. 1. 1: UsethetermGFRwhenreferringtothespecifickidneyfunctionofglomerularfiltration. Usethe more general term kidney function(s) when dealing with the totality of functions of the kidney. S150 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points 1. 2. 2 Guidance to physicians and other healthcare providers Practice Point 1. 2. 2. 1: Use serum creatinine (SCr) and an estimating equation for initial assessment of GFR (Figure 11). Initial test eGFRcr Consider sources of error and need for more accurate assessment. Is eGFR thought to be accurate? Yes No Measure Use eGFRcr cystatin C Consider potential sources of error in eGFRcr-cys and need for an even more accurate assessment. Is a more accurate assessment needed? No Yes Use Measure GFRcr-cys GFR Evaluation of GFR for clinical application 15 30 45 60 90 120 Figure11Approachtoglomerularfiltrationrate(GFR)evaluationusinginitialandsupportivetests. Thealgorithmdescribesthe approachtotheevaluationofGFR. TheapproachusesinitialandsupportivetestingtodevelopafinalassessmentoftrueGFRandtoapplyitin individualdecision-making. TheinitialtestfortheevaluationofGFRiscreatinine-basedestimatedGFR(eGFRcr), whichwillbeavailableformost peoplebecausecreatinineismeasuredroutinelyaspartofthebasicmetabolicpanel. IfeGFRcrisexpectedtobeinaccurate, orifamore accurateassessmentofGFRisneededforclinicaldecision-making, suchasdiagnosisorstagingofchronickidneydiseaseordrugdosing, then, ifavailable, cystatinCshouldbemeasured, andcreatinineandcystatinCbasedestimatedGFR(eGFRcr-cys)shouldbeestimated. IfeGFRcr-cys isexpectedtobeinaccurate, orifanevenmoreaccurateassessmentofGFRisneededforclinicaldecision-making, then, ifavailable, GFRshould bemeasuredusingplasmaorurinaryclearanceofexogenousfiltrationmarkers. InitialtestmaybeestimatedGFRbycystatinC(eGFRcysor eGFRcr-cys)inotherwisehealthypopulationswithchangesincreatininegenerationduetonon-GFRdeterminantssuchaschangesinmuscle massorcreatininesecretionorextrarenaleliminationduetotheuseofspecificmedications. SourcesoferrorineGFRcr-cysincludeverylow musclemassorveryhighlevelsofinflammation, highcatabolicstates, orexogenoussteroiduse. ConsidereGFRcysratherthaneGFRcr-cysin otherwisehealthypopulationswithdecreasedcreatininegenerationduetoreducedmusclemassordecreasedcreatininesecretionor extrarenaleliminationduetotheuseofspecificmedications. Recommendation 1. 2. 2. 1: We recommend using eGFRcr-cys in clinical situations when eGFRcr is less accurate and GFR affects clinical decision-making (Table 8127-142) (1C). Practice Point 1. 2. 2. 2: Where more accurate ascertainment of GFR will impact treatment decisions, measure GFR using plasma or urinary clearance of an exogenous filtration marker (Table 9). PracticePoint1. 2. 2. 3: UnderstandthevalueandlimitationsinbotheGFRandmeasuredglomerularfiltrationrate(mGFR) as well as the variability and factors that influence SCr and cystatin C measurements. Practice Point 1. 2. 2. 4: Interpretation of SCr level requires consideration of dietary intake. KidneyInternational(2024)105(Suppl4S), S117S314 S151 summary of recommendation statements and practice points www. kidney-international. org Table8Indicationsforuseofcystatin C Domain Specificclinicalcondition Causeofdecreasedaccuracy CommentsonGFRevaluation Bodyhabitusandchanges Eatingdisorders127 Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifnocomorbidillness inmusclemass otherthanreductioninmusclemass. Extremesport/exercise/ Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifanincreaseinmuscle bodybuilder massistheonlyabnormality. Above-kneeamputation128 Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateinthosewithoutother comorbidconditions. SuggesteGFRcr-cysin thosewithcomorbidillness. Spinalcordinjurywith Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateinthosewithoutother paraplegia/paraparesisor comorbidillness. SuggesteGFRcr-cysinthose quadriplegia/quadriparesis withcomorbidillness. ClassIIIobesitya, b Non-GFRdeterminantsofSCr eGFRcr-cysdemonstratedtobemostaccurate. andSCys Lifestyle Smoking129-131 Non-GFRdeterminantsofSCys Minimaldata, suggesteGFRcrifnochangestononGFRdeterminantsofSCrorcomorbidillness. Diet Low-proteindiet Non-GFRdeterminantsofSCr Ketodiets Non-GFRdeterminantsofSCr Minimaldata, suggesteGFRcrmaybeappropriateif Vegetarian Non-GFRdeterminantsofSCr nochangestonon-GFRdeterminantsofSCrorno High-proteindiets Non-GFRdeterminantsofSCr comorbidillness. andcreatinesupplements IllnessotherthanCKD Malnutrition Chronicillness, presumed eGFRcr-cysmaybelessaccuratebecauseof impactonnon-GFR coexistenceofmalnutritionandinflammation. determinantsofSCrandSCys SuggestusingmGFRfortreatmentdecisions basedonthelevelofGFR. Cancera, 132-137 Chronicillness, presumed eGFRcr-cysdemonstratedtobemostaccuratein impactonnon-GFR populationsstudiedbutlikelihoodoflesser determinantsofSCrandSCys accuracyinmorefrailpeopleorincancerswith highcellturnover. SuggestusingmGFRfor treatmentdecisionsbasedonthelevelofGFR. Heartfailurea, 138, 139 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Cirrhosisa, 79, 140, 141 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Catabolicconsuming Chronicillness, presumed MinimaldatabuteGFRcr-cysmaybeinaccurate.
----------------------------------------------------------------------


======================================================================
CHUNK 302 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_28
Content Type: recommendation
Words: 499
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
determinantsofSCrandSCys SuggestusingmGFRfortreatmentdecisions basedonthelevelofGFR. Cancera, 132-137 Chronicillness, presumed eGFRcr-cysdemonstratedtobemostaccuratein impactonnon-GFR populationsstudiedbutlikelihoodoflesser determinantsofSCrandSCys accuracyinmorefrailpeopleorincancerswith highcellturnover. SuggestusingmGFRfor treatmentdecisionsbasedonthelevelofGFR. Heartfailurea, 138, 139 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Cirrhosisa, 79, 140, 141 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Catabolicconsuming Chronicillness, presumed MinimaldatabuteGFRcr-cysmaybeinaccurate. diseasesc impactonnon-GFR SuggestusingeGFRcr-cysvs. eGFRcrforroutine determinantsofSCrandSCys GFRevaluation. SuggestusingmGFRfortreatment decisionsbasedonthelevelofGFR. Musclewastingdiseases142 Chronicillness, presumed Minimaldata. Onestudyshowslargebiasforboth impactonnon-GFR eGFRcrandeGFRcys. SuggestusingeGFRcr-cys determinantsofSCrandSCys forroutineGFRevaluation. SuggestusingmGFR fortreatmentdecisionsbasedonthelevelofGFR. Medicationeffects Steroids(anabolic, hormone) Non-GFRdeterminantsofSCr. PhysiologicaleffectonSCysunknown, suggest EffectonSCysnotknown eGFRcr-cys. Decreasesintubularsecretion Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly creatinineandnocomorbidillness. Suggestusing mGFRfortreatmentdecisionsbasedonthelevel ofGFR. Broadspectrumantibiotics Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly thatdecreaseextrarenal creatinineandnocomorbidillness. Suggestusing elimination mGFRfortreatmentdecisionsbasedonthelevel ofGFR. eGFR, estimatedglomerularfiltrationrate; eGFRcr, creatinine-basedestimatedGFR; eGFRcr-cys, creatinineandcystatinCbasedestimatedGFR; GFR, glomerularfiltrationrate; mGFR, measuredglomerularfiltrationrate; SCr, serumcreatinine; SCys, serumcystatinC. aDatasummarizedinAdingwupuetal. 149 bObesityclassIIIvariesbyregionbutcommonlybodymassindex40or35kg/m2. cCatabolicconsumingdiseasemayincludetuberculosis, AIDS, hematologicmalignancies, andsevereskindiseases. Therearenodatawithmeasuredglomerularfiltrationrate (mGFR)toevaluatethisdirectly. S152 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Table9Comparisonofestimated GFRandmeasuredGFR EstimatedGFRbySCrand/orcystatinC MeasuredGFR Inexpensiveandeasytoimplement Moreexpensive, moretime-consuming, andinvasive Widelyavailableandmayalsobeused Onlyavailableincertaincenters atpointofcare, easilyrepeatable Methodstomeasurethatdonotrequireurinecollectionsareavailable(i. e. , plasmaclearance) Mostprotocolsrequirerepeatbloodsamplespotentiallyoveralongduration Microsamplingtestsbyfingerpickenablepoint-of-caretesting. Testinghasbeendescribed, butnotroutinelyperformed Notsufficientlyaccurateandprecise AccurateforGFRinallsituationsandacrosstheGFRrange. Requiresindividualizedprotocols forallclinicalsituations LagsbehindchangesinGFR AbletoidentifyearlychangesinGFR Subjecttonon-GFRdeterminantconfounding Lessinfluencedbynon-GFRdeterminants GFR, glomerularfiltrationrate; SCr, serumcreatinine. Practice Point 1. 2. 2. 5: Assess the potential for error in eGFR when assessing a change in GFR over time. PracticePoint1. 2. 2. 6: ConsidertheuseofcystatinCbasedestimatedglomerularfiltrationrate(eGFRcys)insomespecific circumstances. Practice Point 1. 2. 2. 7: Understand the implications of differences between eGFRcr and eGFRcys, as these may be informative, in both direction and magnitude of those differences. Practice Point 1. 2. 2. 8: Consider timed urine collections for measured creatinine clearance if mGFR is not available and eGFRcr-cys is thought to be inaccurate. 1. 2. 3 Guidance to clinical laboratories PracticePoint1. 2. 3. 1: ImplementthelaboratorystandardsofcareoutlinedinTable11toensureaccuracyandreliability when assessing GFR using creatinine and cystatin C. Table11Implementation standardsto ensureaccuracy andreliability ofGFRassessmentsusingcreatinineandcystatinC (cid: 3) ReporteGFRinadditiontotheserumconcentrationsoffiltrationmarkersusingvalidatedequations. (cid: 3) ReporteGFRroundedtothenearestwholenumberandrelativetoabodysurfacearea(BSA)of1. 73m2inadultsusingtheunitsml/minper1. 73m2. (cid: 3) ReportedeGFRlevels60ml/minper1. 73m2shouldbeflaggedasbeinglow. (cid: 3) Whenreportinglevelsoffiltrationmarkers, report: (i) SCrconcentrationroundedtothenearestwholenumberwhenexpressedasstandardinternationalunits(mmol/l)androundedtothenearest 100thofawholenumberwhenexpressedasconventionalunits(mg/dl); (ii) serumcystatinCconcentrationroundedtothenearest100thofawholenumberwhenexpressedasconventionalunits(mg/l). (cid: 3) Measurefiltrationmarkersusingaspecific, precise(coefficientofvariationCV2. 3%forcreatinineand2. 0%forcystatinC)assaywithcalibration traceabletotheinternationalstandardreferencematerialsanddesirablebias(3. 7%forcreatinineand3. 2%forcystatinC)comparedwithreference methodology(orappropriateinternationalstandardreferencemethodgrouptargetinexternalqualityassessmentEQAforcystatinC). (cid: 3) Useanenzymaticmethodtoassaycreatinine, wherepossible. (cid: 3) Separateserum/plasmafromredbloodcellsbycentrifugationwithin12hoursofvenipuncture. (cid: 3) WhencystatinCismeasured, measurecreatinineonthesamesampletoenablecalculationofeGFRcr-cys. eGFR, estimatedglomerularfiltrationrate; eGFRcr-cys, estimatedglomerularfiltrationratebasedoncreatinineandcystatinC; GFR, glomerularfiltrationrate; SCr, serum creatinine. PracticePoint1. 2. 3. 2: Givenavailableresources, clinicallaboratoriesmayconsiderthepossibilityofmeasurementofboth creatinine and cystatin either as an in-house test or as a referred test. Specialconsiderations Pediatricconsiderations. Practice Point 1. 2. 3. 3: Laboratories measuring creatinine in infants or small children must ensure their quality control process include the lowest end of the expected range of values for the group of interest. Practice Point 1. 2. 3. 4: Consider the consistent use of enzymatic creatinine assays in children, given the higher relative contribution of non-creatinine chromogens to measured creatinine in children when using the Jaffe assay, and the high prevalence of icteric and hemolyzed samples in the neonatal period. PracticePoint1. 2. 3. 5: AneGFRcrlevel90ml/minper1. 73m2canbeflaggedaslowinchildrenandadolescentsoverthe age of 2 years. KidneyInternational(2024)105(Suppl4S), S117S314 S153 summary of recommendation statements and practice points www. kidney-international. org 1. 2. 4 Selection of GFR estimating equations Recommendation 1. 2. 4. 1: WerecommendusingavalidatedGFRestimatingequationtoderiveGFRfromserum filtrationmarkers(eGFR)ratherthanrelyingontheserumfiltrationmarkersalone(1D). Practice Point 1. 2. 4. 1: Use the same equation within geographical regions (as defined locally e. g. , continent, country, regionandaslargeaspossible). Withinsuchregions, equationsmaydifferforadultsandchildren. Practice Point 1. 2. 4. 2: Use of race in the computation of eGFR should be avoided.
----------------------------------------------------------------------


======================================================================
CHUNK 303 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_29
Content Type: recommendation
Words: 484
Medical Entities: GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
2. 4. 1: WerecommendusingavalidatedGFRestimatingequationtoderiveGFRfromserum filtrationmarkers(eGFR)ratherthanrelyingontheserumfiltrationmarkersalone(1D). Practice Point 1. 2. 4. 1: Use the same equation within geographical regions (as defined locally e. g. , continent, country, regionandaslargeaspossible). Withinsuchregions, equationsmaydifferforadultsandchildren. Practice Point 1. 2. 4. 2: Use of race in the computation of eGFR should be avoided. Specialconsiderations Pediatricconsiderations. Practice Point 1. 2. 4. 3: Estimate GFR in children using validated equations that have been developed or validated in comparable populations. 1. 3 Evaluation of albuminuria 1. 3. 1 Guidance for physicians and other healthcare providers Practice Point 1. 3. 1. 1: Use the following measurements for initial testing of albuminuria (in descending order of preference). In all cases, a first void in the morning midstream sample is preferred in adults and children. (i) urine ACR, or (ii) reagent strip urinalysis for albumin and ACR with automated reading. If measuring urine protein, use the following measurements: (i) urine protein-to-creatinine ratio (PCR), (ii) reagent strip urinalysis for total protein with automated reading, or (iii) reagent strip urinalysis for total protein with manual reading. Practice Point 1. 3. 1. 2: Use more accurate methods when albuminuria is detected using less accurate methods. (cid: 3) Confirm reagent strip positive albuminuria and/or proteinuria by quantitative laboratory measurement and express as a ratio to urine creatinine wherever possible (i. e. , quantify the ACR or PCR if initial semiquantitative tests are positive). (cid: 3) Confirm ACR 30mg/g (3mg/mmol) on a random untimed urine with a subsequent first morning void in the morning midstream urine sample. Practice Point 1. 3. 1. 3: Understand factors that may affect interpretation of measurements of urine albumin and urine creatinine and order confirmatory tests as indicated (Table 16). Table16Factors causingbiological variation inurine albuminorurineprotein Factor FalselyelevatedACRorPCR FalsedecreaseinACRorPCR Variabilityinurine albuminorprotein Hematuria Increasesalbuminandproteinintheurine Menstruation Increasesalbuminandproteinintheurine Exercise259 Increasesalbuminandproteinintheurine Infection260, 261 Symptomaticurinaryinfectioncancause productionofproteinfromtheorganism Nonalbuminproteins Otherproteinsmaybemissedbyalbuminreagentstrips Variabilityinurinary creatinineconcentration Biologicalsex Femaleshavelowerurinarycreatinineexcretion, Maleshavehigherurinarycreatinineexcretion, thereforehigherACRandPCR thereforelowerACRandPCR Weight73, 160 Lowurinarycreatinineexcretionconsistentwithlow Highurinarycreatinineexcretionconsistentwithhighweight weightcancausehighACRorPCRrelativeto cancauselowACRorPCRrelativetotimedexcretion timedexcretion Changesincreatinine LowerurinarycreatinineexcretionwithAKI Highurinarycreatinineexcretionwithhigh-proteinintake excretion orlow-proteinintake orexercise ACR, albumin-to-creatinineratio; AKI, acutekidneyinjury; PCR, protein-to-creatinineratio. S154 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Specialconsiderations Pediatricconsiderations. Practice Point 1. 3. 1. 4: In children, obtain a first morning urine sample for initial testing of albuminuria and proteinuria (in descending order of preference): (i) Both urine PCR and urine ACR, (ii) Reagent strip urinalysis for total protein and for albumin with automated reading, or (iii)Reagent strip urinalysis for total protein and for albumin with manual reading. 1. 3. 2 Guidance to clinical laboratories PracticePoint1. 3. 2. 1: ImplementthelaboratoryreportingandhandlingstandardsoutlinedinTable17toensureaccuracy and reliability of the findings when assessing urine samples. Table17Implementation standardsto ensureaccuracy andreliability ofurine samples (cid: 3) Samplesforalbuminmeasurementanalyzedfreshorstoredat4(cid: 4)Cforupto7days (cid: 3) Samplesforalbuminmeasurementshouldnotbestoredfrozenat(cid: 5)20(cid: 4)C (cid: 3) ReportACRinuntimedurinesamplesinadditiontourinealbuminconcentrationratherthantheconcentrationsalone (cid: 3) Reportingto1decimalplaceforACRwhethermg/mmolormg/g (cid: 3) AnalyticalCVofmethodstomeasureurinealbuminshouldbe15%. ACR, albumin-to-creatinineratio; CV, coefficientofvariation. Practice Point 1. 3. 2. 2: Implementation of an external quality assessment scheme/program for urine albumin and creatinine, including calculation of the ACR, is a preferred practice for laboratories. 1. 4 Point-of-care testing Recommendation 1. 4.
----------------------------------------------------------------------


======================================================================
CHUNK 304 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_30
Content Type: recommendation
Words: 482
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
ACR, albumin-to-creatinineratio; CV, coefficientofvariation. Practice Point 1. 3. 2. 2: Implementation of an external quality assessment scheme/program for urine albumin and creatinine, including calculation of the ACR, is a preferred practice for laboratories. 1. 4 Point-of-care testing Recommendation 1. 4. 1: We suggest that point-of-care testing (POCT) may be used for creatinine and urine albuminmeasurementwhereaccesstoalaboratoryislimitedorprovidingatestatthe point-of-care facilitates the clinical pathway (2C). Practice Point 1. 4. 1: Whenever a POCT device is used for creatinine and urine albumin testing, ensure that the same preanalytical, analytical, and postanalytical quality criteria relating to the specimen collection and performance ofthedevice, includingexternal qualityassessment, andthe interpretationofthe resultisused. Practice Point 1. 4. 2: Where a POCT device for creatinine testing is being used, generate an estimate of GFR. Use the equation consistent with that used within the region. Practice Point 1. 4. 3: Where a POCT device is being used for albuminuria testing, the capability of also analyzing creatinine and producing an ACR is important. Assess the ability of the POCT ACR devices to produceapositiveresultin85%ofpeoplewithsignificantalbuminuria(ACR30mg/gor3mg/ mmol), as part of the evaluation and consideration of using the device. Chapter 2: Risk assessment in people with CKD 2. 1 Overview on monitoring for progression of CKD based upon GFR and ACR categories Practice Point 2. 1. 1: Assess albuminuria in adults, or albuminuria/proteinuria in children, and GFR at least annually in people with CKD. Practice Point 2. 1. 2: Assess albuminuria and GFR more often for individuals at higher risk of CKD progression when measurement will impact therapeutic decisions. Practice Point 2. 1. 3: For people with CKD, a change in eGFR of 20% on a subsequent test exceeds the expected variability and warrants evaluation. Practice Point 2. 1. 4: Among people with CKD who initiate hemodynamically active therapies, GFR reductions of 30% on subsequent testing exceed the expected variability and warrant evaluation. Practice Point 2. 1. 5: For albuminuria monitoring of people with CKD, a doubling of the ACR on a subsequent test exceeds laboratory variability and warrants evaluation. KidneyInternational(2024)105(Suppl4S), S117S314 S155 summary of recommendation statements and practice points www. kidney-international. org 2. 2 Risk prediction in people with CKD Recommendation2. 2. 1: InpeoplewithCKDG3G5, werecommendusinganexternallyvalidatedriskequation to estimate the absolute risk of kidney failure (1A). Practice Point 2. 2. 1: A 5-year kidney failure risk of 3%5% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations. Practice Point 2. 2. 2: A 2-year kidney failure risk of 10% can be used to determine the timing of multidisciplinary care in addition to eGFR-based criteria and other clinical considerations. Practice Point 2. 2. 3: A 2-year kidney failure risk threshold of 40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations. Practice Point 2. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 305 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_31
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 2. 2. 3: A 2-year kidney failure risk threshold of 40% can be used to determine the modality education, timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for transplantation, in addition to eGFR-based criteria and other clinical considerations. Practice Point 2. 2. 4: Note that risk prediction equations developed for use in people with CKD G3G5, may not be valid for use in those with CKD G1G2. Practice Point 2. 2. 5: Use disease-specific, externally validated prediction equations in people with immunoglobulin A nephropathy (IgAN) and autosomal dominant polycystic kidney disease (ADPKD). 2. 3 Prediction of cardiovascular risk in people with CKD Practice Point 2. 3. 1: For cardiovascular risk prediction to guide preventive therapies in people with CKD, use externally validated models that are either developed within CKD populations or that incorporate eGFR and albuminuria. Practice Point 2. 3. 2: For mortality risk prediction to guide discussions about goals of care, use externally validated models that predict all-cause mortality specifically developed in the CKD population. Chapter 3: Delaying CKD progression and managing its complications 3. 1 CKD treatment and risk modification Practice Point 3. 1. 1: Treat people with CKD with a comprehensive treatment strategy to reduce risks of progression of CKD and its associated complications (Figure 17). Impact on CKD pathophysiology CKD manifestations CKD outcomes Prevention and treatment of clinical symptoms and signs (including blood pressure) Minimize risk of progression to kidney failure Maximize health-related quality of life, physical function, Manage risk and appropriate treatment of capacity to work, and ability to socialize complications, including cardiovascular diseases, Appropriate monitoring and treatment of laboratory hospitalization, gout, infections, etc. abnormalities of CKD associated with implications for health (e. g. , anemia, CKD-MBD, potassium disorders, acidosis) Modification of the natural course of CKD and its symptoms Figure17Chronickidneydisease(CKD)treatmentandriskmodification. CKD-MBD, chronickidneydisease-mineralandbonedisorders. 3. 2 Lifestyle factors Practice Point 3. 2. 1: Encourage people with CKD to undertake physical activity compatible with cardiovascular health, tolerance, andleveloffrailty; achieveanoptimalbodymassindex(BMI); andnottouse tobacco products. Referral to providers and programs (e. g. , psychologists, renal dietitians or accredited nutrition providers, pharmacists, physical and occupational therapy, and smoking cessation programs) should be offered where indicated and available. 3. 2. 1 Avoiding use of tobacco products No specific recommendations or practice points S156 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points 3. 2. 2 Physical activity and optimum weight TheWorkGroupconcurswithalltherecommendationandpracticepointsrelatingtophysicalactivityfromtheKDIGO2022 ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease23andconsidersthattheyshouldextendtoall adults with CKD. We draw attention to the following statements: Recommendation 3. 2. 2. 1: We recommend that people with CKD be advised to undertake moderate-intensity physical activity for a cumulative durationofat least 150minutesper week, or to a level compatible with their cardiovascular and physical tolerance (1D). Practice Point 3. 2. 2. 1: Recommendations for physical activity should consider age, ethnic background, presence of other comorbidities, and access to resources. Practice Point 3. 2. 2. 2: People with CKD should be advised to avoid sedentary behavior. PracticePoint3. 2. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 306 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_32
Content Type: recommendation
Words: 496
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 2. 2. 1: Recommendations for physical activity should consider age, ethnic background, presence of other comorbidities, and access to resources. Practice Point 3. 2. 2. 2: People with CKD should be advised to avoid sedentary behavior. PracticePoint3. 2. 2. 3: Forpeopleathigherriskoffalls, healthcareprovidersshouldprovideadviceontheintensityofphysical activity (low, moderate, or vigorous) and the type of exercises (aerobic vs. resistance, or both). Practice Point 3. 2. 2. 4: Physicians should consider advising/encouraging people with obesity and CKD to lose weight. Specialconsiderations Pediatricconsiderations. Practice Point 3. 2. 2. 5: Encourage children with CKD to undertake physical activity aiming for World Health Organization (WHO)-advised levels (i. e. , 60 minutes daily) and to achieve a healthy weight. 3. 3 Diet Practice Point 3. 3. 1: AdvisepeoplewithCKDtoadopthealthyanddiversedietswithahigherconsumptionofplant-based foods compared to animal-based foods and a lower consumption of ultraprocessed foods. Practice Point 3. 3. 2: Use renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions. 3. 3. 1 Protein intake Recommendation 3. 3. 1. 1: We suggest maintaining a protein intake of 0. 8 g/kg body weight/d in adults with CKD G3G5 (2C). Practice Point 3. 3. 1. 1: Avoid high protein intake (1. 3 g/kg body weight/d) in adults with CKD at risk of progression. Practice Point 3. 3. 1. 2: In adults with CKD who are willing and able, and who are at risk of kidney failure, consider prescribing, under close supervision, a very lowprotein diet (0. 30. 4 g/kg body weight/d) supplemented with essential amino acids or ketoacid analogs (up to 0. 6 g/kg body weight/d). Practice Point 3. 3. 1. 3: Do not prescribe lowor very lowprotein diets in metabolically unstable people with CKD. Specialconsiderations Pediatricconsiderations. Practice Point 3. 3. 1. 4: Do not restrict protein intake in children with CKD due to the risk of growth impairment. The target protein and energy intake in children with CKD G2G5 should be at the upper end of the normal range for healthy children to promote optimal growth. Olderadults. Practice Point3. 3. 1. 5: Inolderadultswithunderlyingconditionssuchasfrailtyandsarcopenia, considerhigherprotein and calorie dietary targets. 3. 3. 2 Sodium intake The Work Group concurs with the following recommendation from KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease23 and the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 21 Recommendation3. 3. 2. 1: Wesuggest thatsodium intakebe2gofsodium perday(or90mmolofsodium per day, or 5 g of sodium chloride per day) in people with CKD (2C). KidneyInternational(2024)105(Suppl4S), S117S314 S157 summary of recommendation statements and practice points www. kidney-international. org PracticePoint3. 3. 2. 1: Dietarysodiumrestrictionisusuallynotappropriateforpatientswithsodium-wastingnephropathy Specialconsiderations Pediatricconsiderations. PracticePoint3. 3. 2. 2: Followage-basedRecommendedDailyIntakewhencounselingaboutsodiumintakeforchildrenwith CKD who have systolic and/or diastolic blood pressure 90th percentile for age, sex, and height. 3. 4 Blood pressure control TheWorkGroupconcurswiththeKDIGO2021ClinicalPracticeGuidelinefortheManagementofBloodPressureinChronic KidneyDisease, whichencouragesindividualizedBPtargetsandtheuseofagentsaccordingtoage, coexistentCVD, andother comorbidities; risk of progression of CKD; and tolerance to treatments. 21 We highlight the following guidance: Recommendation3. 4.
----------------------------------------------------------------------


======================================================================
CHUNK 307 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_33
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
PracticePoint3. 3. 2. 2: Followage-basedRecommendedDailyIntakewhencounselingaboutsodiumintakeforchildrenwith CKD who have systolic and/or diastolic blood pressure 90th percentile for age, sex, and height. 3. 4 Blood pressure control TheWorkGroupconcurswiththeKDIGO2021ClinicalPracticeGuidelinefortheManagementofBloodPressureinChronic KidneyDisease, whichencouragesindividualizedBPtargetsandtheuseofagentsaccordingtoage, coexistentCVD, andother comorbidities; risk of progression of CKD; and tolerance to treatments. 21 We highlight the following guidance: Recommendation3. 4. 1: WesuggestthatadultswithhighBPandCKDbetreatedwithatargetsystolicbloodpressure (SBP)of120mmHg, whentolerated, usingstandardizedofficeBPmeasurement(2B). Practice Point 3. 4. 1: Consider less intensive BP-lowering therapy in people with frailty, high risk of falls and fractures, very limited life expectancy, or symptomatic postural hypotension. Specialconsiderations Pediatricconsiderations. TheWorkGroupconcurswiththeKDIGO2021ClinicalPracticeGuidelinefortheManagementofBloodPressureinChronic Kidney Disease, and we highlight the following guidance21: Recommendation 3. 4. 2: We suggest that in children with CKD, 24-hour mean arterial pressure (MAP) by ambulatorybloodpressuremonitoring(ABPM)shouldbeloweredto50thpercentile for age, sex, and height (2C). Practice Point 3. 4. 2: Monitor BP once a year with ABPM and every 36 months with standardized auscultatory office BP in children with CKD. Practice Point 3. 4. 3: In children with CKD, when ABPM is not available, it is reasonable to target manual auscultatory officeSBP, obtainedinaprotocol-drivenstandardizedsetting, of50th75thpercentileforage, sex, and height unless achieving this target is limited by signs or symptoms of hypotension. 3. 5 Glycemic control Please refer to the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease for specific recommendations, practice points, and research recommendations. 3. 6 Renin-angiotensin system inhibitors TheWorkGrouphighlightsrecommendationsfromtheKDIGO2021ClinicalPracticeGuidelinefortheManagementofBlood Pressure in Chronic Kidney Disease and selected practice points for treatment with RASi from the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease21 and the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 23 The Work Group considers several recommendations to apply even in the absence of high BP and has adapted the recommendations from the BP guideline to remove this requirement. Key recommendations and practice points are highlighted: Recommendation 3. 6. 1: We recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor ACEi or angiotensin II receptor blocker ARB) for people with CKD and severely increased albuminuria (G1G4, A3) without diabetes (1B). Recommendation3. 6. 2: WesuggeststartingRASi(ACEiorARB)forpeoplewithCKDandmoderatelyincreased albuminuria (G1G4, A2) without diabetes (2C). Recommendation 3. 6. 3: We recommend starting RASi (ACEi or ARB) for people with CKD and moderately-toseverely increased albuminuria (G1G4, A2 and A3) with diabetes (1B). Recommendation 3. 6. 4: We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in people with CKD, with or without diabetes (1B). S158 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Practice Point 3. 6. 1: RASi (ACEi or ARB) should be administered using the highest approved dose that is tolerated to achieve thebenefitsdescribedbecausetheproven benefitswere achievedintrials using thesedoses. Practice Point 3. 6. 2: Changes in BP, serum creatinine, and serum potassium should be checked within 24 weeks of initiation or increase in the dose of a RASi, depending on the current GFR and serum potassium. Practice Point 3. 6. 3: Hyperkalemia associated with use of RASi can often be managed by measures to reduce the serum potassium levels rather than decreasing the dose or stopping RASi.
----------------------------------------------------------------------


======================================================================
CHUNK 308 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_34
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 6. 3: Hyperkalemia associated with use of RASi can often be managed by measures to reduce the serum potassium levels rather than decreasing the dose or stopping RASi. Practice Point 3. 6. 4: Continue ACEi or ARB therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation of treatment or an increase in dose. Practice Point 3. 6. 5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate eGFR 15 ml/min per 1. 73 m2). PracticePoint3. 6. 6: ConsiderstartingpeoplewithCKDwithnormaltomildlyincreasedalbuminuria(A1)onRASi(ACEior ARB) for specific indications (e. g. , to treat hypertension or heart failure with low ejection fraction). Practice Point 3. 6. 7: ContinueACEiorARB in peoplewithCKD even when the eGFR falls below 30 ml/min per 1. 73 m2. 3. 7 Sodium-glucose cotransporter-2 inhibitors (SGLT2i) The Work Group concurs with the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, which stated: We recommend treating patients with type 2 diabetes (T2D), CKD, and an eGFR 20 ml/min per 1. 73m2withanSGLT2i(1A). 23However, inthepresentguideline, weofferamoregeneral1Arecommendationforadultswith CKD. WealsohighlightpracticepointsfromtheKDIGODiabetesguideline fordiabetesmanagementinCKD, whicharealso relevant for people with CKD without diabetes: Recommendation3. 7. 1: Werecommendtreatingpatientswithtype2diabetes(T2D), CKD, andaneGFR20ml/ min per 1. 73 m2 with an SGLT2i (1A). Practice Point 3. 7. 1: Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1. 73 m2, unless it is not tolerated or KRT is initiated. Practice Point 3. 7. 2: It is reasonable to withhold SGLT2i during times of prolonged fasting, surgery, or critical medical illness (when people may be at greater risk for ketosis). Recommendation 3. 7. 2: We recommend treating adults with CKD with an SGLT2i for the following (1A): (cid: 3) eGFR 20 ml/min per 1. 73 m2 with urine ACR 200 mg/g (20 mg/mmol), or (cid: 3) heart failure, irrespective of level of albuminuria. Practice Point 3. 7. 3: SGLT2i initiation or use does not necessitate alteration of frequency of CKD monitoring and the reversible decrease in eGFR on initiation is generally not an indication to discontinue therapy. Recommendation 3. 7. 3: We suggest treating adults with eGFR 20 to 45 ml/min per 1. 73 m2 with urine ACR 200 mg/g (20 mg/mmol) with an SGLT2i (2B). 3. 8 Mineralocorticoid receptor antagonists (MRA) TheWorkGrouphighlightsakey recommendation andpracticepointsfromtheKDIGO2022ClinicalPracticeGuidelinefor Diabetes Management in Chronic Kidney Disease. 23 Recommendation 3. 8. 1: We suggest a nonsteroidal mineralocorticoid receptor antagonist with proven kidney orcardiovascularbenefitforadultswithT2D, aneGFR25ml/minper1. 73m2, normal serum potassium concentration, and albuminuria (30 mg/g 3 mg/mmol) despite maximum tolerated dose of RAS inhibitor (RASi) (2A). Practice Point 3. 8. 1: NonsteroidalMRAaremostappropriateforadultswithT2DwhoareathighriskofCKDprogression and cardiovascular events, as demonstrated by persistent albuminuria despite other standard-of-care therapies. KidneyInternational(2024)105(Suppl4S), S117S314 S159 summary of recommendation statements and practice points www. kidney-international. org Practice Point 3. 8. 2: AnonsteroidalMRAmaybeaddedtoaRASiandanSGLT2ifortreatmentofT2DandCKDinadults. Practice Point 3. 8.
----------------------------------------------------------------------


======================================================================
CHUNK 309 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_35
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 8. 1: NonsteroidalMRAaremostappropriateforadultswithT2DwhoareathighriskofCKDprogression and cardiovascular events, as demonstrated by persistent albuminuria despite other standard-of-care therapies. KidneyInternational(2024)105(Suppl4S), S117S314 S159 summary of recommendation statements and practice points www. kidney-international. org Practice Point 3. 8. 2: AnonsteroidalMRAmaybeaddedtoaRASiandanSGLT2ifortreatmentofT2DandCKDinadults. Practice Point 3. 8. 3: To mitigate risk of hyperkalemia, select people with consistently normal serum potassium concentration and monitor serumpotassium regularly after initiation of a nonsteroidal MRA (Figure 26). K 4. 8 mmol/l K 4. 95. 5 mmol/l K 5. 5 mmol/l Initiate finerenone Continue finerenone 10 mg or 20 mg Hold finerenone - 10 mg daily if eGFR 2559 ml/min/1. 73 m2 Monitor K every 4 months Consider adjustments to diet or concomitant - 20 mg daily if eGFR 60 ml/min/1. 73 m2 medications to mitigate hyperkalemia Monitor K at 1 month after initiation and then every 4 Recheck K months Consider reinitiation if/when K 5. 0 mmol/l Increase dose to 20 mg daily, if on 10 mg daily Restart 10 mg daily if previously held for hyperkalemia and K now 5. 0 mmol/l Figure26Serumpotassiummonitoringduringtreatmentwithanonsteroidalmineralocorticoidreceptorantagonist(MRA) (finerenone). AdaptedfromtheprotocolsofFinerenoneinReducingKidneyFailureandDiseaseProgressioninDiabeticKidneyDisease(FIDELIODKD)andFinerenoneinReducingCardiovascularMortalityandMorbidityinDiabeticKidneyDisease(FIGARO-DKD). TheWorkGroupconsiders thesepotassiumthresholdstobeconservative, anditmaybeconsideredappropriatetocontinueMRAsinpeoplewithpotassiumof5. 56. 0mmol/ l. ThisalgorithmcouldbeusedforsteroidalMRA. TheUSFoodandDrugAdministration(FDA)hasapprovedinitiationofK5. 0mmol/l. This figureisguidedbytrialdesignandtheFDAlabelandmaybedifferentinothercountries. Serumcreatinine/estimatedglomerularfiltrationrate (eGFR)shouldbemonitoredconcurrentlywithserumpotassium. ReproducedfromKidneyDisease: ImprovingGlobalOutcomesDiabetesWork Group. KDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23 Practice Point 3. 8. 4: The choice of a nonsteroidal MRA should prioritize agents with documented kidney or cardiovascular benefits. Practice Point 3. 8. 5: A steroidal MRA may be used for treatment of heart failure, hyperaldosteronism, or refractory hypertension, butmaycausehyperkalemiaorareversibledeclineinglomerularfiltration, particularly amongpeople with a low GFR. 3. 9 Glucagon-like peptide-1 receptor agonists (GLP-1 RA) The Work Group highlights a key recommendation and practice point from the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 23 Recommendation 3. 9. 1: In adults with T2D and CKD who have not achieved individualized glycemic targets despite use of metformin and SGLT2 inhibitor treatment, or who are unable to use those medications, we recommend a long-acting GLP-1 RA (1B). Practice Point 3. 9. 1: The choice of GLP-1 RA should prioritize agents with documented cardiovascular benefits. 3. 10 Metabolic acidosis Practice Point 3. 10. 1: In people with CKD, consider use of pharmacological treatment with or without dietary intervention to prevent development of acidosis with potential clinical implications (e. g. , serum bicarbonate 18 mmol/l in adults). Practice Point 3. 10. 2: Monitor treatment for metabolic acidosis to ensure it does not result in serum bicarbonate concentrations exceeding the upper limit of normal and does not adversely affect BP control, serum potassium, or fluid status. 3. 11 Hyperkalemia in CKD 3. 11. 1 Awareness of factors impacting on potassium measurement Practice Point 3. 11. 1. 1: Be aware of the variability of potassium laboratory measurements as well as factors and mechanisms that may influence potassium measurement including diurnal and seasonal variation, plasma versus serum samples, and the actions of medications. 3. 11. 2 Potassium exchange agents Practice Point 3. 11. 2. 1: Be aware of local availability or formulary restrictions with regard to the pharmacologic management of nonemergent hyperkalemia. 3. 11.
----------------------------------------------------------------------


======================================================================
CHUNK 310 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_36
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
3. 11. 2 Potassium exchange agents Practice Point 3. 11. 2. 1: Be aware of local availability or formulary restrictions with regard to the pharmacologic management of nonemergent hyperkalemia. 3. 11. 3 Timing to recheck potassium after identifying moderate and severe hyperkalemia in adults No recommendations and practice points S160 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points 3. 11. 4 Managing hyperkalemia No recommendations and practice points 3. 11. 5 Dietary considerations PracticePoint3. 11. 5. 1: ImplementanindividualizedapproachinpeoplewithCKDG3G5andemergenthyperkalemiathat includes dietary and pharmacologic interventions and takes into consideration associated comorbiditiesandqualityoflife(QoL). Assessmentandeducationthrougharenaldietitianoranaccredited nutrition provider are advised. PracticePoint3. 11. 5. 2: Provideadvicetolimittheintakeoffoodsrichinbioavailablepotassium(e. g. , processedfoods) for people with CKD G3G5 who have a history of hyperkalemia or as a prevention strategy during disease periods in which hyperkalemia risk may be a concern. 3. 12 Anemia The KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease will be updated in 2024. 437 3. 13 CKD-Mineral Bone Disorder (CKD-MBD) TheWorkGrouphighlightstheKDIGO2017ClinicalPracticeGuidelineUpdatefortheDiagnosis, Evaluation, Prevention, and Treatment of ChronicKidney DiseaseMineral and Bone Disorder (CKD-MBD). 20Please refer to this publication for specific recommendations, selection, dosing of specific therapeutic agents, and research recommendations. 3. 14 Hyperuricemia Recommendation3. 14. 1: We recommendpeoplewith CKDandsymptomatichyperuricemiashouldbeoffered uric acidlowering intervention (1C). PracticePoint3. 14. 1: ConsiderinitiatinguricacidloweringtherapyforpeoplewithCKDaftertheirfirstepisodeofgout (particularly where there isnoavoidable precipitant or serum uric acidconcentration is 9 mg/dl m 535 mol/l). Practice Point 3. 14. 2: Prescribe xanthine oxidase inhibitors in preference to uricosuric agents in people with CKD and symptomatic hyperuricemia. Practice Point 3. 14. 3: For symptomatic treatment of acute gout in CKD, low-dose colchicine or intra-articular/oral glucocorticoids are preferable to nonsteroidal anti-inflammatory drugs (NSAIDs). Dietaryapproaches. PracticePoint3. 14. 4: Nonpharmacologicalinterventionswhichmayhelppreventgoutincludelimitingalcohol, meats, and high-fructose corn syrup intake. Recommendation 3. 14. 2: We suggest not using agents to lower serum uric acid in people with CKD and asymptomatic hyperuricemia to delay CKD progression (2D). 3. 15 Cardiovascular disease (CVD) and additional specific interventions to modify risk 3. 15. 1 Lipid management ThebenefitsofloweringLDLcholesterolusingstatin-basedtherapiesontheriskofASCVDarewellestablishedinpeoplewith andwithoutCKD. ThereareclearrecommendationsonwhentoinitiatesuchtherapiessetoutintheKDIGOClinicalPractice GuidelineforLipidManagementinChronicKidneyDisease. 19TheWorkGroupconcurswithalltherecommendationsinthis guideline. In particular, we draw attention to: KidneyInternational(2024)105(Suppl4S), S117S314 S161 summary of recommendation statements and practice points www. kidney-international. org Recommendation 3. 15. 1. 1: In adults aged 50 years with eGFR 60 ml/min per 1. 73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3aG5), we recommend treatment with a statin or statin/ezetimibe combination (1A). Recommendation 3. 15. 1. 2: In adults aged 50 years with CKD and eGFR 60 ml/min per 1. 73 m2 (GFR categories G1G2), we recommend treatment with a statin (1B). Recommendation3. 15. 1. 3: Inadultsaged1849yearswithCKDbutnottreatedwithchronicdialysisorkidney transplantation, we suggest statin treatment in people with one or more of the following (2A): (cid: 3) known coronary disease (myocardial infarction or coronary revascularization), (cid: 3) diabetes mellitus, (cid: 3) prior ischemic stroke, or (cid: 3) estimated 10-year incidence of coronary death or nonfatal myocardial infarction 10%. Practice Point 3. 15. 1. 1: Estimate 10-year cardiovascular risk using a validated risk tool. Practice Point 3. 15. 1.
----------------------------------------------------------------------


======================================================================
CHUNK 311 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_37
Content Type: recommendation
Words: 496
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 15. 1. 1: Estimate 10-year cardiovascular risk using a validated risk tool. Practice Point 3. 15. 1. 2: In people with CKD, choose statin-based regimens to maximize the absolute reduction in lowdensity lipoprotein (LDL) cholesterol to achieve the largest treatment benefits. PracticePoint3. 15. 1. 3: InadultswithCKDaged1849, alower(i. e. , 10%)estimated10-yearincidenceofcoronarydeath or nonfatal myocardial infarction may also be appropriate thresholds for initiation of statin-based therapy. Practice Point 3. 15. 1. 4: Considerprescribing proprotein convertase subtilisin/kexin type 9 (PCSK-9)inhibitorsto people with CKD who have an indication for their use. Dietaryapproaches. PracticePoint3. 15. 1. 5: Consideraplant-basedMediterranean-styledietinadditiontolipid-modifyingtherapytoreduce cardiovascular risk. 3. 15. 2 Use of antiplatelet therapy Recommendation 3. 15. 2. 1: We recommend oral low-dose aspirin for prevention of recurrent ischemic cardiovascular disease events (i. e. , secondary prevention) in people with CKD and established ischemic cardiovascular disease (1C). Practice Point 3. 15. 2. 1: Consider other antiplatelet therapy (e. g. , P2Y inhibitors) when there is aspirin intolerance. 12 3. 15. 3 Invasive versus intensive medical therapy for coronary artery disease Recommendation 3. 15. 3. 1: We suggest that in stable stress-test confirmed ischemic heart disease, an initial conservative approach using intensive medical therapy is an appropriate alternative to an initial invasive strategy (2D). Practice Point 3. 15. 3. 1: Initial management with an invasive strategy may still be preferable for people with CKD with acuteorunstablecoronarydisease, unacceptablelevelsofangina(e. g. , patientdissatisfaction), left ventricular systolic dysfunction attributable to ischemia, or left main disease. S162 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points 3. 16 CKD and atrial fibrillation Practice Point 3. 16. 1: Follow established strategies for the diagnosis and management of atrial fibrillation (Figure 40). In people with CKD, use opportunistic pulse-based screening (e. g. , taking at when measuring BP), followed by a Step 1 Diagnosis wearable device or Holter ECG testing Step 2 (they are likely to have an increased CHADS-VASc risk factor for stroke and are at high risk even with a score of 01) Prophylaxis against 2 2 stroke and systemic managed (e. g. , alcohol advice, use of a proton pump inhibitor) thromboembolism Use medical therapy (e. g. , beta blockade) to control ventricular rate to less than about 90 bpm at rest to decrease Step 3 symptoms and related complications Rate/rhythm control For people with persistent symptoms despite adequate rate control, consider rhythm control with cardioversion, antiarrhythmic therapy and/or catheter ablation Figure40Strategiesforthediagnosisandmanagementofatrialfibrillation. Considerdoseadjustmentsnecessaryinpeoplewith chronickidneydisease(CKD). Thefollowinghasbeenrecommendedasastandardpackagefordiagnosticevaluationofnewatrialfibrillation: (i)a12-leadelectrocardiogram(ECG)toestablishthediagnosis, assessventricularrate, andcheckforthepresenceofconductiondefects, ischemia, orstructuralheartdisease; (ii)laboratorytestingforthyroidandkidneyfunction, serumelectrolytes, andfullbloodcount; and(iii) transthoracicechocardiographytoassessleftventricularsizeandfunction, leftatrialsize, forvalvulardisease, andrightheartsizeandfunction. BP, bloodpressure; CHA DS -VASc, Congestiveheartfailure, Hypertension, Age75(doubled), Diabetes, Stroke(doubled), Vasculardisease, 2 2 Age65to74, andSexcategory(female); HAS-BLED, Hypertension, Abnormalliver/kidneyfunction, Strokehistory, Bleedinghistoryor predisposition, Labileinternationalnormalizedratio(INR), Elderly, Drug/alcoholusage. Recommendation 3. 16. 1: We recommend use of nonvitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e. g. , warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1G4 (1C). Practice Point 3. 16. 2: NOAC dose adjustment for GFR is required, with caution needed at CKD G4G5. PracticePoint3. 16.
----------------------------------------------------------------------


======================================================================
CHUNK 312 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_38
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 16. 2: NOAC dose adjustment for GFR is required, with caution needed at CKD G4G5. PracticePoint3. 16. 3: DurationofNOACdiscontinuationbeforeelectiveproceduresneedstoconsiderproceduralbleeding risk, NOAC prescribed, and level of GFR (Figure 44). KidneyInternational(2024)105(Suppl4S), S117S314 S163 summary of recommendation statements and practice points www. kidney-international. org Dabigatran ApixabanEdoxabanRivaroxaban No important bleeding risk and/or adequate local hemostasis possible: perform at trough level (i. e. , 12 or 24 h after last intake) Low risk High risk Low risk High risk CrCl 80 ml/min 24 h 48 h 24 h 48 h CrCl 5080 ml/min 36 h 72 h 24 h 48 h CrCl 3050 ml/mina 48 h 96 h 24 h 48 h CrCl 1530 ml/mina No official indication No official indication 36 h 48 h CrCl 15 ml/min No official indication for use There is no need for bridging with LMWH/UFH Figure44AdviceonwhentodiscontinuenonvitaminKantagonistoralanticoagulants(NOACs)beforeprocedures(lowvs. highrisk). Theboldvaluesdeviatefromthecommonstoppingruleof24-hourlowrisk, 48-hourhighrisk. Lowriskisdefinedasalowfrequencyof bleedingand/orminorimpactofableed. Highriskisdefinedasahighfrequencyofbleedingand/orimportantclinicalimpact. Adaptedfrom HeidbuchelH, VerhammeP, AlingsM, etal. UpdatedEuropeanHeartRhythmAssociationpracticalguideontheuseofnonvitamin-K antagonistanticoagulantsinpatientswithnon-valvularatrialfibrillation: executivesummary. EurHeartJ. 2017; 38: 21372149. 724aManyofthese peoplemaybeonlowerdoseofdabigatran(110mgtwiceperdayb. i. d. )orapixaban(2. 5mgb. i. d. ), orhavetobeonthelowerdoseof rivaroxaban(15mgQD)oredoxaban(30mgQD). Dabigatran110mgb. i. d. hasnotbeenapprovedforusebytheUSFoodandDrug Administration. CrCl, creatinineclearance, LMWH, low-molecular-weightheparin; UFH, unfractionatedheparin. ReproducedfromTurakhiaMP, BlankestijnPJ, CarreroJJ, etal. Chronickidneydiseaseandarrhythmias: conclusionsfromaKidneyDisease: ImprovingGlobalOutcomes (KDIGO)ControversiesConference. EurHeartJ. 2018; 39: 23142325. 710TheAuthor(s)2018. PublishedbyOxfordUniversityPressonbehalfof theEuropeanSocietyofCardiology. ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNonCommercialLicense( Chapter 4: Medication management and drug stewardship in CKD 4. 1 Medication choices and monitoring for safety PracticePoint4. 1. 1: PeoplewithCKDmaybemoresusceptibletothenephrotoxiceffectsofmedications. Whenprescribing such medications to people with CKD, always consider the benefits versus potential harms. Practice Point 4. 1. 2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receivingmedicationswithnarrowtherapeuticwindows, potentialadverseeffects, ornephrotoxicity, both in outpatient practice and in hospital settings. PracticePoint4. 1. 3: Reviewandlimittheuseofover-the-countermedicinesanddietaryorherbalremediesthatmaybe harmful for people with CKD. Medicationsandpregnancy. PracticePoint4. 1. 4: WhenprescribingmedicationstopeoplewithCKDwhoareofchild-bearingpotential, alwaysreview teratogenicitypotentialandprovideregularreproductiveandcontraceptivecounselinginaccordance with the values and preferences of the person with CKD. 4. 2 Dose adjustments by level of GFR Practice Point 4. 2. 1: Consider GFR when dosing medications cleared by the kidneys. Practice Point 4. 2. 2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing. Practice Point 4. 2. 3: Where more accuracy is required for drug-related decision-making (e. g. , dosing due to narrow therapeuticortoxicrange), drugtoxicity, orclinicalsituationswhereeGFRcrestimatesmaybeunreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated. S164 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org summary of recommendation statements and practice points Practice Point 4. 2. 4: In people with extremes of body weight, eGFR nonindexed for body surface area (BSA) may be indicated, especially for medications with a narrow therapeutic range or requiring a minimum concentration to be effective. Practice Point 4. 2. 5: Consider and adapt drug dosing in people where GFR, non-GFR determinants of the filtration markers, or volume of distribution are not in a steady state. 4. 3 Polypharmacy and drug stewardship Practice Point 4. 3. 1: Perform thorough medication review periodically and at transitions of care to assess adherence, continued indication, and potential drug interactions because people with CKD often have complex medication regimens and are seen by multiple specialists. Practice Point 4. 3.
----------------------------------------------------------------------


======================================================================
CHUNK 313 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_39
Content Type: recommendation
Words: 412
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
4. 3 Polypharmacy and drug stewardship Practice Point 4. 3. 1: Perform thorough medication review periodically and at transitions of care to assess adherence, continued indication, and potential drug interactions because people with CKD often have complex medication regimens and are seen by multiple specialists. Practice Point 4. 3. 2: Ifmedicationsarediscontinuedduringanacuteillness, communicateaclearplanofwhentorestart the discontinued medications to the affected person and healthcare providers, and ensure documentation in the medical record. Practice Point 4. 3. 3: Considerplanneddiscontinuationofmedications(suchasmetformin, ACEi, ARBs, andSGLT2i)in the 4872 hours prior to elective surgery or during the acute management of adverse effects as a precautionary measure to prevent complications. However, note that failure to restart these medications after the event or procedure may lead to unintentional harm (see Practice Point 4. 3. 2). 4. 3. 1 Strategies to promote drug stewardship Practice Point 4. 3. 1. 1: Educate and inform people with CKD regarding the expected benefits and possible risks of medications so that they can identify and report adverse events that can be managed. Practice Point 4. 3. 1. 2: Establish collaborative relationships with other healthcare providers and pharmacists and/or usetoolstoensureandimprovedrugstewardshipinpeoplewithCKDtoenhancemanagement of their complex medication regimens. 4. 4 Imaging studies Practice Point 4. 4. 1: Consider the indication for imaging studies in accordance with general population indications. Risks and benefits of imaging studies should be determined on an individual basis in the context of their CKD. 4. 4. 1 Radiocontrast: intra-arterial and intravenous dye studies Practice Point 4. 4. 1. 1: Assess the risk for AKI in people with CKD receiving intra-arterial contrast for cardiac procedures using validated tools. Practice Point 4. 4. 1. 2: The intravenous administration of radiocontrast media can be managed in accordance with consensusstatementsfromtheradiologysocietiesinpeoplewithAKIorGFR60ml/minper1. 73 m2 (CKD G3aG5) undergoing elective investigation. 4. 4. 2 Gadolinium-containing contrast media PracticePoint4. 4. 2. 1: ForpeoplewithGFR30ml/minper1. 73m2(CKDG4G5)whorequiregadolinium-containing contrast media, preferentially offer them American College of Radiology group II and III gadolinium-based contrast agents. KidneyInternational(2024)105(Suppl4S), S117S314 S165 summary of recommendation statements and practice points www. kidney-international. org Chapter 5: Optimal models of care 5. 1 Referral to specialist kidney care services Practice Point 5. 1. 1: Refer adults with CKD to specialist kidney care services in the circumstances listed in Figure 48. Circumstances category Circumstance examples Actions Cause of CKD is uncertain Further evaluation and Causes Hereditary kidney disease specialist management Recurrent extensive nephrolithiasis based on diagnosis A 3%5% 5-year risk of requiring KRT measured using a validated risk equation Planning and preparation eGFR/risk of KRT eGFR 30 ml/min per 1.
----------------------------------------------------------------------


======================================================================
CHUNK 314 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_40
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Circumstances category Circumstance examples Actions Cause of CKD is uncertain Further evaluation and Causes Hereditary kidney disease specialist management Recurrent extensive nephrolithiasis based on diagnosis A 3%5% 5-year risk of requiring KRT measured using a validated risk equation Planning and preparation eGFR/risk of KRT eGFR 30 ml/min per 1. 73 m2 for kidney replacement A sustained fall in GFR of 20% or 30% in those therapy people initiating hemodynamically active therapies Consistent finding of significant albuminuria Diagnosis of CKD (ACR 300 mg/g 30 mg/mmol or AER 300 mg/24 hours, approximately equivalent to PCR 500 mg/g 50 mg/mmol Albuminuria or PER 500 mg/24 h) in combination with hematuria Further evaluation and microscopic 2-fold increase in albuminuria in people with significant and management hematuria albuminuria undergoing monitoring A consistent finding of ACR 700 mg/g 70 mg/mmol Urinary red cell casts, RBC 20 per high power field sustained and not readily explained CKD and hypertension refractory to treatment 4 antihypertensive agents Persistent abnormalities of serum potassium Others Acidosis Management of CKD Anemia complications Bone disease Malnutrition Figure48Circumstancesforreferraltospecialistkidneycareservicesandgoalsofthereferral. ACR, albumin-to-creatinineratio; AER, albuminexcretionrate; CKD, chronickidneydisease; eGFR, estimatedglomerularfiltrationrate; KRT, kidneyreplacementtherapy; PCR, proteincreatinineratio; PER, proteinexcretionrate; RBC, redbloodcells. Specialconsiderations Pediatricconsiderations. Practice Point 5. 1. 2: Refer children and adolescents to specialist kidney care services in the following circumstances: (cid: 3) an ACR of 30 mg/g (3 mg/mmol) or a PCR of 200 mg/g (20 mg/mmol) or more, confirmed on a repeat first morning void sample, when well and not during menstruation, (cid: 3) persistent hematuria, (cid: 3) any sustained decrease in eGFR, (cid: 3) hypertension, (cid: 3) kidney outflow obstruction or anomalies of the kidney and urinary tract, (cid: 3) known or suspected CKD, or (cid: 3) recurrent urinary tract infection. 5. 2 Symptoms in CKD 5. 2. 1 Prevalence and severity of symptoms No recommendations and practice points 5. 2. 2 Identification and assessment of symptoms PracticePoint5. 2. 2. 1: AskpeoplewithprogressiveCKDabouturemicsymptoms(e. g. , reducedappetite, nausea, andlevel of fatigue/lethargy) at each consultation using a standardized validated assessment of uremic symptoms tool. S166 KidneyInternational(2024)105(Suppl4S), S117S314 5. 2. 3 Management of common symptoms for people with CKD PracticePoint5. 2. 3. 1: Useevidence-informedmanagementstrategiestosupportpeopletolivewellwithCKDandimprove their health-related quality of life. Practice Point 5. 2. 3. 2: Screen people with CKD G4G5, aged 65, poor growth (pediatrics), or symptoms such as involuntary weight loss, frailty, or poor appetite twice annually for malnutrition using a validated assessment tool. Practice Point 5. 2. 3. 3: Enable availability of appropriate medical nutrition therapy for people withsigns of malnutrition, ideally under the supervision of renal dietitians or accredited nutrition providers if not available. 5. 3 Team-based integrated care Practice Point 5. 3. 1: Enable access to a patient-centered multidisciplinary care team consisting of dietary counseling, medication management, education, and counseling about different KRT modalities, transplant options, dialysis access surgery, and ethical, psychological, and social care for people with CKD. Practice Point 5. 3. 2: Education programs that also involve care partners where indicated are important to promote informed, activated people with CKD. Practice Point 5. 3.
----------------------------------------------------------------------


======================================================================
CHUNK 315 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_41
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 5. 3. 2: Education programs that also involve care partners where indicated are important to promote informed, activated people with CKD. Practice Point 5. 3. 3: Consider the use of telehealth technologies including web-based, mobile applications, virtual visiting, and wearable devices in the delivery of education and care. Specialconsiderations Pediatric considerations. 5. 3. 1 Transition from pediatric to adult care 5. 3. 1. 1 Pediatric providers PracticePoint5. 3. 1. 1. 1: Prepareadolescentsandtheirfamiliesfortransfertoadult-orientedcarestartingat1114yearsofage by using checklists to assess readiness and guide preparation, and by conducting part of each visit without the parent/guardian present (Figure 55). Preparation for transfer Preparation for regular adult care Transition Transition Pediatric care Joint pediatric-adult care Regular or adult care Young adult care PracticePoint5. 3. 1. 1. 2: Provideacomprehensivewrittentransfersummary, andideallyanoralhandover, tothereceiving healthcare providers including all relevant medical information as well as information about the young persons cognitive abilities and social support (Figure 55). PracticePoint5. 3. 1. 1. 3: Transfer young people to adult care during times of medical and social stability where possible. 5. 3. 1. 2 Adult providers PracticePoint5. 3. 1. 2. 1: Recognizethatyoungpeopleunder25yearsofagewithCKDareauniquepopulationathighriskfor adverse outcomes at least in part due to physiologic incomplete brain maturation. PracticePoint5. 3. 1. 2. 2: Encourageyoung people to informally visit the adult care clinic to which they will be transferred before the first appointment (Figure 55). elbats nehw refsnarT www. kidney-international. org summary of recommendation statements and practice points Start early (1114 yr) Use checklists to assess readiness and guide preparation Allow young people to visit the clinic before transfer See young person alone for Recognize that emerging adulthood is a period of at least part of each visit high risk for adverse outcomes See emerging adults more frequently than older adults Comprehensive written with same stage of CKD summary and verbal Include caregivers or significant others in patient visits, handover, including with permission of patient cognitive ability and social support Follow-up after transfer 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Age (years) Figure55Theprocessoftransitionfrompediatrictoadultcareinchronickidneydisease(CKD). KidneyInternational(2024)105(Suppl4S), S117S314 S167 summary of recommendation statements and practice points www. kidney-international. org PracticePoint5. 3. 1. 2. 3: AssessyoungpeoplewithCKDmorefrequentlythanolderpeoplewiththesamestageofCKDand, with the agreement of the young person, include the caregivers or significant other of the young personintheircare, atleastinthefirst13yearsfollowingtransferfrompediatriccare(Figure55). 5. 4 Timing the initiation of dialysis Practice Point 5. 4. 1: Initiate dialysis based on a composite assessment of a persons symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities. Practice Point 5. 4. 2: Initiate dialysis if the presence of one or more of the following situations is evident (Table 41). This often but not invariably occurs in the GFR range between 5 and 10 ml/min per 1. 73 m2. Table41Indicationsforthe initiation ofdialysis Symptomsorsignsattributabletokidneyfailure(e. g. , neurologicalsignsandsymptomsattributabletouremia, pericarditis, anorexia, medicallyresistant acid-basedorelectrolyteabnormalities, intractablepruritus, serositis, andacid-baseorelectrolyteabnormalities) Inabilitytocontrolvolumestatusorbloodpressure Progressivedeteriorationinnutritionalstatusrefractorytodietaryintervention, orcognitiveimpairment Practice Point 5. 4. 3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is 1520 ml/min per 1. 73 m2 or risk of KRT is 40% over 2 years. Specialconsiderations Pediatricconsiderations.
----------------------------------------------------------------------


======================================================================
CHUNK 316 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_42
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,dialysis,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
4. 3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is 1520 ml/min per 1. 73 m2 or risk of KRT is 40% over 2 years. Specialconsiderations Pediatricconsiderations. Practice Point 5. 4. 4: In children, in addition to the adult indications for dialysis, poor growth refractory to optimized nutrition, growth hormone, and medical management is an indication for initiating KRT. Practice Point 5. 4. 5: Pursue living or deceased donor preemptive kidney transplantation as the treatment of choice for children in whom there is evidence of progressive and irreversible CKD. The eGFR at which preemptivetransplantationshouldbeundertakenwilldependonmultiplefactorsincludingtheageand sizeofthechildandtherateofprogressionofkidneyfailurebutwillusuallybebetween515ml/min per 1. 73 m2. 5. 5 Structure and process of supportive care and comprehensive conservative management Practice Point 5. 5. 1: Inform people with CKD about the options for KRT and comprehensive conservative care. Practice Point 5. 5. 2: Support comprehensive conservative management as an option for people who choose not to pursue KRT. Practice Point 5. 5. 3: Provide access to resources that enable the delivery of advanced care planning for people with a recognized need for end-of-life care, including those people undergoing comprehensive conservative care. S168 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Chapter 1: Evaluation of CKD 1. 1 Detection and evaluation of CKD Early detection of any chronic disease, including CKD, provides greater opportunities to reduce morbidity as treatBoth decreased GFR and increased albuminuria or other ments can be initiated earlier in the disease course. Because markersofkidneydamageareoftensilentandnotapparentto treatmentsforCKDprovidebenefitsinreducingriskforboth the person at risk of CKD or the healthcare provider unless CVD and CKD progression, strategies that promote early laboratorytestsareperformed. ThecauseofthedecreasedGFR detection of CKD should improve kidney and nonkidneyor increased albuminuria may also not be apparent. In the relatedoutcomes. Evenifmedicaltreatmentsarenotavailable decade since the publication of the previous KDIGO Clinical orindicatedforanindividual, therearerecommendedlifestyle Practice Guideline for the Evaluation and Management of changesthatcouldbeimplementedafterthediagnosisofCKD ChronicKidney Disease, 1 there have been substantial advances (Chapter3). InterviewswithpeoplewhohaveCKDhaveproin treatment for CKD of all causes (Chapter 3), targeted therapies for specific causes of CKD (e. g. , KDIGO 2021 vided evidence that many would alter their lifestyle if they received a diagnosis of CKD. 17 Knowledge of level of Clinical Practice Guideline for the Management of albuminuria and GFR also helps guide clinical decisions Glomerular Diseases22), as well as understanding of and beyond initiating treatments specifically for CKD (Table 4). methods to determine the etiology of CKD. All together, these Eachoftheseisconsideredingreaterdepthinthesubsequent advances have the potential to slow and possibly prevent the chapters. Finally, if a familial form of kidney disease is progression of kidney disease. Thus, in this section of Chapter suspected, the diagnosis of the disease in one person may 1, we emphasize the importance of detecting CKD, and allowdetectioninotherfamilymembers. Thus, initialtesting considerations for the optimal methods for staging of CKD, of blood and urine to detect CKD is important, with and how to establish chronicity and etiology. confirmatorytestingifinitialfindingsindicatethepresenceof abnormalitiesofcreatinine/eGFRoralbuminuria. 1. 1. 1DetectionofCKD From a societal perspective, early identification of and intervention for CKD could have a positive impact on health PracticePoint1. 1. 1.
----------------------------------------------------------------------


======================================================================
CHUNK 317 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_43
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
confirmatorytestingifinitialfindingsindicatethepresenceof abnormalitiesofcreatinine/eGFRoralbuminuria. 1. 1. 1DetectionofCKD From a societal perspective, early identification of and intervention for CKD could have a positive impact on health PracticePoint1. 1. 1. 1: Testpeopleatriskforandwithchronic disparities. Inmanycountries, thereisahigherincidenceofCKD kidneydisease(CKD)usingbothurinealbuminmeasurement amongpeoplewithlowerSES, andthesepeoplearemorelikely andassessmentofglomerularfiltrationrate(GFR). toprogresstokidneyfailureandhavelessaccesstoKRT(dialysis Table4UseofGFRandalbuminuria Currentlevel Clinicaldecisions GFR Albuminuria ChangeinthelevelofGFR Diagnosisand (cid: 3) DetectionofCKD (cid: 3) DetectionofCKD (cid: 3) DetectionofAKIandAKD staging (cid: 3) Evaluationforkidneydonation (cid: 3) DetectionofCKDprogression Treatment (cid: 3) Referraltonephrologists (cid: 3) Referraltonephrologists (cid: 3) TreatmentofAKI (cid: 3) PatientandfamilyeducationaboutCKD (cid: 3) Patientandfamilyeducationabout (cid: 3) Monitoringdrugtoxicity andbenefitoflifestylechanges CKDandbenefitoflifestylechanges (cid: 3) Re-evaluateCKDtreatment (cid: 3) MonitorprogressionofGFRdecline (cid: 3) MonitorprogressionofGFRdecline strategies (cid: 3) Referralforkidneytransplantation (cid: 3) Eligibilityforclinicaltrials (cid: 3) Placementofdialysisaccess (cid: 3) Dosageandmonitoringformedications clearedbythekidney (cid: 3) Determinesafetyofdiagnostictestsorprocedures (cid: 3) Eligibilityforclinicaltrials Riskassessment (cid: 3) RiskofCKDcomplications (cid: 3) RiskforCKDprogression (cid: 3) Riskforkidneyfailure (cid: 3) RiskforCKDprogression (cid: 3) RiskforCVD (cid: 3) RiskforCVD, HF, andmortality (cid: 3) RiskofCVD (cid: 3) Riskformortality (cid: 3) Riskforadversepregnancy (cid: 3) Riskformedicationerrors (cid: 3) Fertilityandriskofcomplications outcome (cid: 3) Riskforperioperativecomplications ofpregnancy (cid: 3) Riskformortality (cid: 3) Fertilityandriskofcomplications ofpregnancy AKD, acutekidneydisease; AKI, acutekidneyinjury; CKD, chronickidneydisease; CVD, cardiovasculardisease; GFR, glomerularfiltrationrate; HF, heartfailure. KidneyInternational(2024)105(Suppl4S), S117S314 S169 chapter 1 www. kidney-international. org andtransplantation). 56ApublichealthapproachtowardCKD and subsequently allowing for treatment initiation. Primary detectionandtreatmentcouldreduceinequitiesintheburden care physicians or other medical specialists who care for of kidney failure by slowing the rate of progression and the people with risk factors for CKD, such as endocrinology, riskofCVDforeveryone. 57 cardiology, or rheumatology, are ideal settings for an The possible harm of early detection of CKD is that the intervention that targets people with undetected CKD. newdiagnosismaycauseanxietyinsomepeople, particularly Implementing an early detection intervention would be if the testing is not discussed in advance of the results. Disfacilitated by integrated healthcare systems and the use of cussionsarounddiseasedetectionarecommonintheprimary electronic health records. These structures would facilitate care setting, and shared decision-making is an established the linkage between risk stratification and treatment to have practice through which people may agree to the testing, the desired effect of slowing the progression of CKD. confirmthattheywouldliketobetested, andprepareforthe The highest priority conditions for CKD detection are range of possible results and their implications. 5860 Early hypertension, diabetes, andCVD, includingheartfailure. For detection increases burden and costs associated with physidiabetes, theADAandKDIGOrecommendannualscreening cian visits or treatments, and this may not be balanced by of people with diabetes for CKD. 29 CKD screening should savings from averting adverse outcomes. start at diagnosis of T2D because evidence of CKD is often CKDfitstheWorldHealthOrganization(WHO)criteriafor already apparent at this time. For T1D, screening is an early detection program. 6163 Given that chronic disease recommended commencing 5 years after diagnosis. A detection and prevention frameworks have been deployed for second important group includes people with recent AKI or other disease and risk factor conditions, in our view, CKD acute kidney disease (AKD), particularly multiple episodes detectionstrategiesshouldbeimplementedforhigh-riskpeople. of AKI, and those who have been partially diagnosed with A framework has beendeveloped forcommunitiestoalign CKD by either eGFR or albuminuria but cannot be fully CKD detection and treatment strategies within their broader staged. Other groups who might be considered for CKD publichealthprioritiestoensurethatthegoalsoftheinterventesting are shown in Table 5.
----------------------------------------------------------------------


======================================================================
CHUNK 318 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_44
Content Type: reference
Words: 493
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
of AKI, and those who have been partially diagnosed with A framework has beendeveloped forcommunitiestoalign CKD by either eGFR or albuminuria but cannot be fully CKD detection and treatment strategies within their broader staged. Other groups who might be considered for CKD publichealthprioritiestoensurethatthegoalsoftheinterventesting are shown in Table 5. This list is not exhaustive and tionareachievedwithoutcompromisingother valuablehealth may be modified by local epidemiological considerations. As initiatives. 26Boththeefficacyandthecost-effectivenessofCKD per above, 2023 analyses suggest that population screening detection and treatment interventions will depend upon the may in fact be cost-effective, obviating the need for specific strategies that are employed in the healthcare system. selecting and addressing an ever-changing list of at risk Therefore, results from future clinical trials should be groups. 27 evaluated within their unique context and may not generalize Testing for CKD without regard to age generates controtoallCKDdetectionefforts. versy. Those in older age groups experience the greatest MostpeoplewithoratriskforCKD, healthcareproviders, and burden of CKD and are also at the highest risk for cardiopolicymakerswouldwishtoidentifyCKD. Mostpeoplewhoare vascularcomplications. Aswithotherdetectionprogramslike already receiving medical care wouldchoose case-finding stracancer detection, CKD detection efforts should be individutegiestoenableearlierriskstratificationandtreatmentforpre- alized based on the persons goals of care and suitability for viously undiagnosed CKD. 17, 64 Thus, the application of earlier treatment. treatmenttodelay CKDprogressioninpeoplewithCKDisof a higher priority than the lack of clinical trial evidence that Practice Point 1. 1. 1. 2: Following incidental detection of case-findingstrategiesthemselvesimproveoutcomes. elevated urinary albumin-to-creatinine ratio (ACR), heThis practice point promoting CKD detection efforts may maturia, or low estimated GFR (eGFR), repeat tests to have implications for health equity, because CKD disproconfirm presence of CKD. portionatelyaffectspeoplefromminoritizedpopulationsand Thereisknownbiologicalandanalyticalvariability inSCr those who have lower SES. The increasing availability and and in urine albumin or urine protein not related to their evidencesupportingseveraltreatmentsforCKDadvocatesfor properties as markers of kidney disease. In people without early disease detection. Given the asymptomatic progression risk factors for CKD, there is a low pretest probability for of CKD, systematic testing of people with risk factors for CKD. Thus, any unexpected results should be verified before CKD is the only method that would detect CKD at early diagnosing a person as having CKD. In people with risk stages and allow the initiation of appropriate treatments. factors for CKD, thereis ahigher probability that the person CKD detection could reduce the proportion of people with doeshaveCKDevenwithanunexpectedfinding. Subsequent CKD who will experience the morbidity of CKD G4G5. testing should be performed to confirm the diagnosis and to Cost-effectiveness analyses, performed in the new era of complete the evaluation, as is required. Timing of the repeat effectivedisease-modifyingtherapies, describeamorepositive sample should be determined based on clinical setting view of population-wide screening. 27 including risk factors for CKD as well as concern for AKI/ Figure 328 provides an algorithm for the identification of AKD. people at risk for CKD testing in those at risk, further Hematuria is common and associated with risk for subtesting in those identified as having CKD to confirm stages, sequent development of CKD. 65 There are several causes of S170 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 319 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_45
Content Type: recommendation
Words: 486
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
people at risk for CKD testing in those at risk, further Hematuria is common and associated with risk for subtesting in those identified as having CKD to confirm stages, sequent development of CKD. 65 There are several causes of S170 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table5RiskfactorsforCKD Domains Exampleconditions Commonriskfactors Hypertension Diabetes Cardiovasculardisease(includingheartfailure) PriorAKI/AKD Peoplewholiveingeographicalareaswith AreaswithendemicCKDu highprevalenceofCKD AreaswiththehighprevalenceofAPOL1geneticvariants Environmentalexposures Genitourinarydisorders Structuralurinarytractdisease Recurrentkidneycalculi Multisystemdiseases/chronicinflammatory Systemiclupuserythematosus conditions Vasculitis HIV Iatrogenic(relatedtodrugtreatmentsandprocedures) Drug-inducednephrotoxicityandradiationnephritis Familyhistoryorknowngeneticvariant Kidneyfailure, regardlessofidentifiedcause associatedwithCKD Kidneydiseaserecognizedtobeassociatedwithgeneticabnormality(e. g. , PKD, APOL1-mediatedkidneydisease, andAlportsyndrome) Gestationalconditions Pretermbirth Smallgestationalsize Pre-eclampsia/eclampsia OccupationalexposuresthatpromoteCKDrisk Cadmium, lead, andmercuryexposure Polycyclichydrocarbons Pesticides AKD, acutekidneydisease; AKI, acutekidneyinjury; APOL1, apolipoproteinL1; CKD, chronickidneydisease; CKDu, chronickidneydiseaseofundeterminedorigin; PKD, polycystickidneydisease. transient hematuria. Persistent hematuria may indicate equations using both creatinine and cystatin C afford greater glomerular disease, other kidney diseases, or urologic accuracy incomparisonwitheitherfiltrationmarkeralone. The disease including genitourinary malignancy. Thus, persistent recommendationplacesalower valueontheresourceutilization hematuria should prompt further investigation. 66, 67 and cost associated with the assessment of eGFRcr-cys. Specialconsiderations Keyinformation Pediatric considerations. People who are born preterm, Balance of benefits and harms. In the CKD-PC collaboraespeciallyifalsosmallforgestationalage, areatincreasedrisk tion, 720, 736peoplehadmeasuresofbloodcystatinCinaddifor CKD and kidney failure. This is largely related to tiontohavingeGFRcrandACR. 12Replacingtheassessmentof decreasednephronnumber. 6870Additionalinsultsafterbirth eGFRcr with eGFRcr-cys in the matrix of GFR categories led such as neonatal AKI and childhood obesity can further into several changes in the risk distributions. Most notably, the crease the risk of CKD. 71, 72 groupwithan eGFR category 4559 ml/min per1. 73m2 and ACR10mg/g(1 mg/mmol) was movedtohigher riskfor 1. 1. 2MethodsforstagingofCKD all 10 outcomes, and this category was no longer labeled as being low-risk (green) for any of the complications Recommendation 1. 1. 2. 1: In adults at risk for CKD, (Figure 612). For the 8 outcomes that are not influenced by we recommend using creatinine-based estimated changes in creatinine (i. e. all except kidney failure and AKI), glomerular filtration rate (eGFRcr). If cystatin C is eGFRcr exhibited a J-shaped association such that risk available, the GFR category should be estimated increased with eGFR values 105 ml/min per 1. 73 m2 from the combination of creatinine and cystatin C (Figure 712). In contrast eGFRcr-cys demonstrated much (creatinine and cystatin Cbased estimated glomermore linear associations with each of these complications ular filtration rate eGFRcr-cys) (1B). throughout its distribution. These data demonstrate that the combined eGFRcr-cys equation is superior for distinguishing For the diagnosis and staging of CKD by GFR, this recomGFRriskstagescomparedwitheGFRcr. mendation puts a high value on data suggesting that the most Certainty of evidence. This recommendation is based on 2 accurate method of estimating GFR is by using 2 biomarkers broadlydifferenttypesofdatadatacomparingtheaccuracy (cystatinCandcreatinine), aseachhaslimitationsandbenefits (P ) of equations from a combination of creatinine and 30 as filtration markers. As compared with mGFR, estimating cystatin C as filtration markers and creatinine and cystatin C KidneyInternational(2024)105(Suppl4S), S117S314 S171 chapter 1 www. kidney-international. org alone and data from the CKD-PC examining the risk of 1. 1. 3Evaluation ofchronicity outcome by GFR stage assessed by eGFRcr compared with eGFRcr-cys. Ascomparedwithequationsbasedoncreatinine Practice Point 1. 1. 3.
----------------------------------------------------------------------


======================================================================
CHUNK 320 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_46
Content Type: recommendation
Words: 481
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org alone and data from the CKD-PC examining the risk of 1. 1. 3Evaluation ofchronicity outcome by GFR stage assessed by eGFRcr compared with eGFRcr-cys. Ascomparedwithequationsbasedoncreatinine Practice Point 1. 1. 3. 1: Proof of chronicity (duration of a and cystatin C alone, the equation using both creatinine and minimum of 3 months) can be established by: cystatin C comes closest to mGFR most consistently (i) review of past measurements/estimations of GFR; (Supplementary Table S37396). The CKD-PC data were an (ii) review of past measurements of albuminuria or individual-level data analysis of 27, 503, 140 participants proteinuria and urine microscopic examinations; from 114 global cohorts (eGFRcr) and 720, 736 participants (iii) imaging findings such as reduced kidney size and from 20 cohorts (eGFRcr-cys) and 9, 067, 753 participants reduction in cortical thickness; from 114 cohorts (albuminuria) from 1980 to 2021 from (iv) kidney pathological findings such as fibrosis and around the world conveying a high degree of robustness in atrophy; the association of CKD stage with a broad range of adverse (v) medical history, especially conditions known to outcomes. Based on the totality and consistency of the cause or contribute to CKD; CKD-PC data, the overall certainty of the evidence was (vi) repeat measurements within and beyond the 3rated as moderate. month point. Valuesandpreferences. Thisrecommendationplacesahigh value on the need for the most accurate assessment of GFR. Practice Point 1. 1. 3. 2: Do not assume chronicity based The Work Group judged that many people at risk for CKD upon a single abnormal level for eGFR and ACR, as the would prefer an accurate measurement when confirming the finding could be the result of a recent acute kidney injury diagnosis of CKD and its staging. For this reason, the Work (AKI) event or acute kidney disease (AKD). Group prioritized eGFRcr-cys over eGFRcr or eGFRcys for PracticePoint1. 1. 3. 3: Considerinitiationoftreatmentsfor themostaccuratemeasurement. Therecommendationputsa CKD at first presentation of decreased GFR or elevated low value on the availability and cost of an assessment of ACR if CKD is deemed likely due to presence of other eGFRcr-cys suggesting that people at risk of CKD would opt clinical indicators. for the more accurate assessment. Kidney diseases may be acute or chronic. 1, 97 We explicitly Resource use andcosts. The costs and resource use associyetarbitrarilydefinethedurationofaminimumof3months ated with eGFRcr-cys are currently greater than those of (90 days) as delineating chronic kidney disease. The eGFRcr; however, theneedforanaccuratemeasurementmay rationale for defining chronicity is to differentiate CKD offset these expenses. In addition, accuratediagnosis of CKD from AKDs (such as acute glomerulonephritis GN), asearlyaspossiblemayleadtolowerresourceutilizationand including AKI, which may require different timelines for healthcarespending thanif diagnosed inlaterstages ofCKD. initiation of treatments, different interventions, and have FormoreinformationonthecostsassociatedwithcystatinC different etiologies and outcomes. The duration of kidney assessments, please refer to Section 1. 2. 2. disease may be documented or inferred based on the Considerationsforimplementation. Thebiggestconsideration clinical context. For example, a person with decreased GFR forimplementationistheavailabilityofcystatinCmeasurement.
----------------------------------------------------------------------


======================================================================
CHUNK 321 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_47
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
initiation of treatments, different interventions, and have FormoreinformationonthecostsassociatedwithcystatinC different etiologies and outcomes. The duration of kidney assessments, please refer to Section 1. 2. 2. disease may be documented or inferred based on the Considerationsforimplementation. Thebiggestconsideration clinical context. For example, a person with decreased GFR forimplementationistheavailabilityofcystatinCmeasurement. or kidney damage during an acute illness, without prior Forthisreason, therecommendationincludesthealternativefor documentation of kidney disease, may be inferred to have eGFRcrinsuchcasestakingintoconsiderationthelimitations AKD. Resolution over days to weeks would confirm the anddrawbacksofcreatinine-basedmeasurements. diagnosis of AKI from a variety of different causes. A Rationale person with similar findings in the absence of an acute The KDIGO CKD staging system based on 2 dimensions, illness may be inferred to have CKD, and if followed over GFR and albuminuria, was created largely to reflect the astime, would be confirmed to have CKD. In both cases, sociation of outcomes of people with CKD, relative to the repeat ascertainment of GFR and kidney damage is earlierstagingsystemsbasedsolelyonGFRstages. Assessment recommended for accurate diagnosis and staging. The of GFR stage is ideally performed using accurate assessment timing of the evaluation depends on clinical judgment, with ofGFRandACRandisusedtobestcapturetheprognosisfor earlier evaluation for those suspected of having AKI and people with CKD with regard to outcomes such as kidney later evaluation for those suspected of having CKD. failure, CVD, and mortality risk. There is now a large eviFor people with risk factors for CKD, delaying diagdence base demonstrating that the use of eGFRcr-cys reclasnosis for the sake of confirming chronicity can delay sifiesalarge proportionof thepopulation into different GFR care. Many people may not recognize the importance of stages and the new stages better reflect their risk associaa repeat visit if treatment had not been initiated. Thus, tions. For that reason, where available, cystatin C should be initiating treatment both allows for earlier intervention added to creatinine for the purpose of estimating GFR for and also indicates to people the importance of the CKD diagnosis and staging. disease. S172 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Specialconsiderations informative: (i)highprevalenceofmonogenicsubtypeswithinthe Pediatric considerations. Newbornswhoclearlyhavekidney clinicalcategory, (ii)earlyageofonsetofCKD, (iii)syndromic/ disease(e. g. , severecongenitalmalformationsofthekidneyand multisystemfeatures, (iv)consanguinity, (v)possibilityofidenurinarytract)donotneedtowait3monthstoconfirmCKD. tifyingaconditionamenabletotargetedtreatment, and(vi)CKD/ kidneyfailureofunknownetiologywhenkidneybiopsywouldnot 1. 1. 4Evaluationofcause beinformativeduetoadvanceddisease. 100 Practice Point 1. 1. 4. 1: Establish the cause of CKD using The KDIGO Controversies Conference also highlighted clinical context, personal and family history, social and the importance of an educated workforce with expertise in environmental factors, medications, physical examination, kidney genetics, genomics, and computational research for laboratory measures, imaging, and genetic and pathologic appropriate use and interpretation of these tests (Figure diagnosis (Figure 8). 10100). Access to genetic counseling and medical genetics is important for psychosocial support, appropriate use of Practice Point 1. 1. 4. 2: Use tests to establish a cause based genetic testing, and to limit costs. 102 on resources available (Table 622, 98-100). Most people with a new diagnosis of CKD and their In evaluation of cause, healthcare providers should select healthcareproviderswouldprefertoundertakeevaluationfor specific diagnostic tests based on the pretest probability of a the underlying cause to ensure that the best possible care is specificdiagnosisinformed byclinicalpresentation.
----------------------------------------------------------------------


======================================================================
CHUNK 322 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_48
Content Type: recommendation
Words: 499
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
102 on resources available (Table 622, 98-100). Most people with a new diagnosis of CKD and their In evaluation of cause, healthcare providers should select healthcareproviderswouldprefertoundertakeevaluationfor specific diagnostic tests based on the pretest probability of a the underlying cause to ensure that the best possible care is specificdiagnosisinformed byclinicalpresentation. Identificaprovided. Although some people identified as having CKD tionofcauseconfersbenefitfortargetingtherapytoslow promay prefer not to undergo the (sometimes invasive) progression to kidney failure, understanding contributing factors, cedurestoevaluatecause, establishingcauseenablesthemost and prognosis. In addition, identification of cause can help appropriate management strategy to be implemented. people communicate information about a genetic or familial Resources available for evaluation of cause will vary causetorelatives, improveunderstandingoftheirconditionin worldwide. Peoplemaynotbeabletopayforsomediagnostic thecontextofself-caremanagement, andimprovehealthliteracy. tests. Therefore, healthcare providers should tailor the evalGenetic testing is emerging as a valuable component for uation of cause based on these resource constraints (e. g. , evaluation of cause. In some studies, 10% of people with urine protein reagent strip testing instead of ACR). CKD, regardless of family history, were observed to carry EducationonthevalueofestablishingadiagnosisofCKD genetic pathogenic and likely pathogenic variant(s) that is critical. This can be done through local, national, and inrepresentaplausible molecularcause for the development or ternational kidney societies and within healthcare training progression of CKD. 101103 In some cases, identification of programs (Chapter 5). Additional resources may be required actionable genes through genetic testing can impact the to support wider scale implementation of diagnostic tests, clinicalmanagementofpeoplewithCKD(Figure9100). 104, 105 especially genetic testing, availability of biopsies, and the The prevalence of genetic causes to CKD is expected to support required for implementation. increase in future years through increased recognition. Identification of cause is often achieved by standard clinArecentKDIGOControversiesConferencelistedthefollowing icalmethods(i. e. , historyandexamination), knowledgeofthe recommendations for when genetic testing can be particularly causesofCKDandtheirmanifestations(i. e. , levelofGFRand specific marker of kidney damage such as hematuria, urine Physical albumin, or cysts), together with specialized investigations exam (Figure 8). Not all evaluations of cause are required in all Symptoms and signs people. Information from the clinical context and initial Nephrotoxic of urinary tract medications tests may lead to further evaluations (Table 6), which are abnormalities likely to be conducted as part of specialized kidney care services and dependent on resources (Chapter 5). Social and Medical environmental history Recommendation 1. 1. 4. 1: We suggest performing a history kidneybiopsyasanacceptable, safe, diagnostictest to evaluate cause and guide treatment decisions Symptoms and signs Obtain careful family history when clinically appropriate (2D). for possible genetic causes, of systemic diseases including family pedigree for CKD Thisrecommendationplacesahighvalueonanacceptablesafety Laboratory tests, imaging, and tissue sample, such as: profile of kidney biopsies when used to evaluate the cause of Urinalysis and urine sediment CKD and to plan appropriate treatment. Urine albumin-to-creatinine ratio Serologic tests Ultrasound Keyinformation Kidney biopsy Balance of benefits and harms. The benefits of kidney bi- Genetic testing opsy in terms of diagnosis, prognosis, and planning approFigure8Evaluationofcauseofchronickidneydisease(CKD). priatetreatmentforboththepersonwithCKDandhealthcare KidneyInternational(2024)105(Suppl4S), S117S314 S173 chapter 1 www. kidney-international. org Table6Guidancefortheselectionofadditional testsforevaluation ofcause Testcategory Examples Commentorkeyreferences Imaging Ultrasound, intravenousurography, CTkidneys Assesskidneystructure(i. e. , kidneyshape, size, symmetry, andevidenceof uretersbladder, nuclearmedicinestudies, MRI obstruction)forcysticdiseaseandrefluxdisease.
----------------------------------------------------------------------


======================================================================
CHUNK 323 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_49
Content Type: recommendation
Words: 493
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The benefits of kidney bi- Genetic testing opsy in terms of diagnosis, prognosis, and planning approFigure8Evaluationofcauseofchronickidneydisease(CKD). priatetreatmentforboththepersonwithCKDandhealthcare KidneyInternational(2024)105(Suppl4S), S117S314 S173 chapter 1 www. kidney-international. org Table6Guidancefortheselectionofadditional testsforevaluation ofcause Testcategory Examples Commentorkeyreferences Imaging Ultrasound, intravenousurography, CTkidneys Assesskidneystructure(i. e. , kidneyshape, size, symmetry, andevidenceof uretersbladder, nuclearmedicinestudies, MRI obstruction)forcysticdiseaseandrefluxdisease. Evolvingroleofadditionaltechnologies(e. g. , 3Dultrasound) Kidneybiopsy Ultrasound-guidedpercutaneous Usuallyexaminedbylightmicroscopy, immunofluorescence, andelectron microscopy, and, insomesituations, mayincludemoleculardiagnostics Usedforexactdiagnosis, planningtreatment, assessingactivityand chronicityofdisease, andlikelihoodoftreatmentresponse; mayalsobe usedtoassessgeneticdisease Laboratorytests: Chemistryincludingacid-baseandelectrolytes, RefertoKDIGO2021ClinicalPracticeGuidelinefortheManagementof serologic, urine serologictestssuchasanti-PLA2R, ANCA, anti-GBM GlomerularDiseases22 tests antibodies Increasingrecognitionoftheroleoflightchainsinkidneydiseaseevenin Serum-freelightchains, serum, andurineprotein theabsenceofmultiplemyeloma(monoclonalgammopathyofrenal electrophoresis/immunofixation significanceMGRS)98 Urinalysisandurinesedimentexamination Presenceofpersistenthematuriaoralbuminuriaiscriticalindetermining differentialdiagnosis Genetictesting APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, Evolvingasatoolfordiagnosis, increasedutilizationisexpected. HNF1B, PKD1, PKD2 Recognitionthatgeneticcausesaremorecommonandmaypresent withoutclassicfamilyhistory99, 100 ANCA, antineutrophilcytoplasmicantibody; APOL1, apolipoprotein1; COL4A, typeIVcollagenalphachain; CT, computedtomography; GBM, glomerularbasementmembrane; HNF1B, hepatocytenuclearfactor1B; MRI, magneticresonanceimaging; NPHS1, congenitalnephroticsyndrome; PKD1, polycystickidneydisease-1; PKD2, polycystickidney disease-2; PLA2R, M-typephospholipaseA2receptor; UMOD, uromodulin. providers are through improved understanding of the idenmortalityafternativekidneybiopsy inpeoplewith suspected tifieddiseasestateandtheextentofactiveandchroniclesions. or diagnosed CKD was low. Across the 15 studies that reThe harms include the possibility of complications of the portedonmortalityafteranativekidneybiopsy, therewere3 procedure (bleeding risk/pain), the obtaining of a nonreported deaths. The rate of perirenal hematoma across 14 diagnostic or insufficient sample (wasted resource), and the studies was estimated to be 16% (95% confidence interval anxiety induced while awaiting the results. CI: 12%22%). No studies reported on retroperitoneal ThesystematicreviewperformedbytheERTidentified37 hemorrhage (Supplementary Table S4106126). studies assessing the prognostic benefit and safety of kidney Certainty of evidence. The overall certainty of evidence for biopsy among people with CKD. Ten studies examined the kidneybiopsyandoutcomesofharmsisverylow(Supplementary diagnostic and/or prognostic benefit of kidney biopsy or inTableS4106126). Thecriticaloutcomes, mortalityandperirenal fluence of biopsy results on management decisions. The hematomas, were primarily assessed in observational studies diagnostic findings were heterogeneous and variable, which without a comparison group. Because of the potential for did not lend themselves to further synthesis. The rate of confounding, theERTconsideredthebodyofevidencetohave Conditions amenable Conditions amenable Avoidance of Conditions at risk for Conditions amenable Conditions for which to specific diseaseto nonspecific prolonged recurrence after to specific screening genetic testing is modifying therapies renoprotective immunosuppressive kidney transplantation for extrarenal relevant for reproductive strategies therapies manifestations counseling Examples: Example: Example: Examples: Examples: Example: GLA (Fabry) COL4A3/4/5 (Alport) Glomerular disease (CFH/CFI/C3): aHUS HNF1B: diabetes Prenatal/preimplantation AGXT (primary and RAAS blockade due to mutations in (AGXT, GRHPR, PKD1/PKD2 diagnosis hyperoxaluria (PH)) Alport genes HOGA): primary (ADPKD): intracranial CoQ10 genes (SRNS) (COL4A3/4/5) hyperoxaluria (PH) aneurysms CTNS (cystinosis) Adenine phosphoribo- FLCN: renal cell Tubulopathies syltransferase deficiency carcinoma, etc. (Na, K etc. ) (APRT) Figure9Actionablegenesinkidneydisease. Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecificclinicalactions frompreventionortreatmentofacondition, supportedbyrecommendationsbasedonevidence. ADPKD, autosomaldominantpolycystic kidneydisease; aHUS, atypicalhemolyticuremicsyndrome, CKD, chronickidneydisease; RAAS, renin-angiotensin-aldosteronesystem, SRNS, steroid-resistantnephroticsyndrome. ReproducedfromKDIGOConferenceParticipants. Geneticsinchronickidneydisease: conclusionsfroma KidneyDisease: ImprovingGlobalOutcomes(KDIGO)ControversiesConference. KidneyInt. 2022; 101: 11261141. 100Copyright2022, Kidney Disease: ImprovingGlobalOutcomes(KDIGO). PublishedbyElsevierInc. onbehalfoftheInternationalSocietyofNephrology. Thisisanopen accessarticleundertheCCBY-NC-NDlicense( S174 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Clinic type Number of nephrologists Knowledge level Source of knowledge Centers of expertise Advanced training and Few High (multidisciplinary teams) subspecialties and extensive clinical experience Connections with geneticists As many CME courses, workshops Medium and genetic counselors as possible and heuristically based All nephrology Medical school/ clinics All Basic fellowships/licensing Figure10Proposedorganizationforimplementinggeneticsinnephrology. Withinahealthsystem, multiplecentertypes, provider specialties, andeducationstrategiesareneededforoptimalimplementationofgeneticsinnephrology.
----------------------------------------------------------------------


======================================================================
CHUNK 324 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_50
Content Type: evidence
Words: 499
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Withinahealthsystem, multiplecentertypes, provider specialties, andeducationstrategiesareneededforoptimalimplementationofgeneticsinnephrology. A3-tieredorganizationmodelincludes thefollowing: (i)abasic, commonlevelofknowledgeingeneticsamongallnephrologists; (ii)clinicalconnectionsbetweennephrologistsand geneticistsandgeneticcounselors; and(iii)centersofexpertisewherenephrologistswithgeneticexpertisecollaboratewithgeneticistsand geneticcounselors. CME, continuingmedicaleducation. ReproducedfromKDIGOConferenceParticipants. Geneticsinchronickidneydisease: conclusionsfromaKidneyDisease: ImprovingGlobalOutcomes(KDIGO)ControversiesConference. KidneyInt. 2022; 101: 11261141. 100 Copyright2022, KidneyDisease: ImprovingGlobalOutcomes(KDIGO). PublishedbyElsevierInc. onbehalfoftheInternationalSocietyof Nephrology. ThisisanopenaccessarticleundertheCCBY-NC-NDlicense( serious study limitations. The certainty of the evidence for Considerationsforimplementation. To optimize benefit and mortality was further downgraded because there were few safety, a standardized approach for kidney biopsy with a events reported. The certainty of the evidence for perirenal vettedandstandardizedoperatingprotocoldesignedforlocal hematomas was downgraded because there was significant implementation is warranted. Of note, most studies reported statistical heterogeneity in the results across studies. The ERT using ultrasound-guided biopsies and older literature sugdid not identify any studies that reported on the critical gesting higher bleeding rates were conducted in the absence outcomeofretroperitonealhemorrhage. of guided biopsies; thus, we might infer that there is a poValuesandpreferences. TheWorkGroupjudgedthatmany tentialforhigherrateofharmsinblind/unguidedbiopsies. people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and Rationale potentially offer prognostic information. Thus, this recomKidney biopsy is an important part of the investigations for mendation puts a high value on the specificity of a kidney thecauseofCKD. Itisoftendeferredbecauseofthepotential biopsy for the evaluation of cause as well as the very low for harm or lack of recognition of potential utility. The evicertainty evidence demonstrating a low risk of complications dence to support safety of biopsy is heterogeneous and associated with kidney biopsy. Because the potential that the therefore uncertain, but in the studies evaluated, appears to information gleaned from the biopsy may not directly or confer low risk of harm, supporting our suggestion that immediately benefitthe person, the Work Groupjudged that kidney biopsies should be considered when it is thought that some people may prefer to decline a kidney biopsy. The dethey can provide information to identify cause, facilitate cision to pursue biopsy should be a shared decision and be prognostication, and inform treatment strategies. informed by probability of and utility of the information obtained on both diagnostic and prognostic fronts. Specialconsiderations Resource use and costs. Resources available for evaluation Pediatric considerations. Children and young people with of cause will vary worldwide and is dependent on the kidney failurearemorelikely to havea genetic cause of their healthcare systems. People with CKD maynot be able to pay disease than adults. In some healthcare settings, genetic for biopsy or afford the time away from work for the protesting may be pursued first, obviating the need for kidney cedure. Resources in specific countries may not permit biopsy and the associated risks, which may be different in appropriateanalysisoftheobtainedsamples. Thus, healthcare children than adults. providers decisions to perform a kidney biopsy in the presence of limited resources may therefore be influenced based 1. 2 Evaluation of GFR on expected yield for that individual and the perceived value The kidney has many functions, including excretory, endoof the extra information gained. crine, and metabolic functions. GFR is one component of KidneyInternational(2024)105(Suppl4S), S117S314 S175 chapter 1 www. kidney-international. org excretory function but is widely accepted as the best overall or albuminuria.
----------------------------------------------------------------------


======================================================================
CHUNK 325 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_51
Content Type: recommendation
Words: 494
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
crine, and metabolic functions. GFR is one component of KidneyInternational(2024)105(Suppl4S), S117S314 S175 chapter 1 www. kidney-international. org excretory function but is widely accepted as the best overall or albuminuria. These primarily result in polyuria and/or indexof kidney function because it is generally reduced after electrolyte disturbances and may or may not progress to widespread structural damage and most other kidney funcreducedGFRorkidneyfailure. Thus, theexclusiveuseofGFR tions decline in parallel with GFR in CKD. in diagnosing CKD would not be of value in children, highIn this section, we describe the overall approach for the lighting the importance of appreciating different markers evaluation of GFR. As in the previous KDIGO Clinical linked to different kidney functions. Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 1 the first method to evaluate GFR 1. 2. 2Guidance tophysicians andotherhealthcare providers should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests We describe a framework for evaluation of GFR beginning from either the more accurate eGFRcr-cys or measurement withaninitialtestandfollowedbyadditionalsupportivetests of GFR using urinary or plasma clearance of exogenous (Figure 11, Tables 7 and 8127142). filtration markers. In contrast to the previous guideline, we Figure11depictsanalgorithmforevaluationofGFRfrom emphasize the use of eGFRcr-cys based on accumulating initial test using eGFRcr, followed by decisions for when to evidence for its greater accuracy across populations and the perform supportive tests such as cystatin C or mGFR use of mGFR given the known residual errors in all (Tables 7 and 8). Healthcare providers should consider both estimating equations. We also describe laboratory potential sources of error in eGFR as well as whether the techniques and standards that satisfy the requirements for clinical decision requires a highly accurate GFR when robust result reporting. We encourage healthcare providers considering the need for additional tests. The level of to have a clear understanding of the value and limitations accuracy that is needed for a clinical decision for the use of of both filtration markers and mGFR, the importance of potentially toxic medications, a medication with a narrow standardization of assays for creatinine and cystatin C, and therapeutic window, or for other therapies with potential quality control procedures for exogenous markers. Finally, for adverse events, may exceed the capability of any eGFR we describe currently available, validated estimating equation, and in such cases, mGFR should be performed. equations that can be used for the reporting of GFR by This assessment would ideally be performed every time a clinical laboratories. GFR value is used to make a clinical decision. 1. 2. 1OtherfunctionsofkidneysbesidesGFR Practice Point 1. 2. 2. 1: Use serum creatinine (SCr) and an estimating equation for initial assessment of GFR Practice Point 1. 2. 1. 1: Use the term GFR when referring (Figure 11). tothespecifickidneyfunctionofglomerularfiltration. Use There are no RCTs to quantify the impact for the use of the more general term kidney function(s) when dealing less accurate methods versus more accurate methods of with the totality of functions of the kidney. assessment of GFR.
----------------------------------------------------------------------


======================================================================
CHUNK 326 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_52
Content Type: recommendation
Words: 496
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
1: Use the term GFR when referring (Figure 11). tothespecifickidneyfunctionofglomerularfiltration. Use There are no RCTs to quantify the impact for the use of the more general term kidney function(s) when dealing less accurate methods versus more accurate methods of with the totality of functions of the kidney. assessment of GFR. For most clinical circumstances, estiThe kidneys play several roles in the body, including mating GFR from SCr is appropriate for diagnosis, staging, metabolism and excretion of substances, volume and BP and monitoring the progression of CKD, and observational regulation, erythropoietin production, and regulation of datadocumentedanincreaseinCKDrecognitionandreferral electrolytes, acid-base status, and mineral homeostasis. tonephrologistsshortlyaftertheimplementationofreporting Glomerular filtration is oneof many functionsof the kidney. of eGFR by clinical laboratories, especially for females and GFR is considered the best overall assessment of kidney elderly people. 143145 GFR is used in many routine and functions as, in general, losses of these other functions complex clinical decisions as an assessment of excretory correlate with the loss of GFR. The term kidney function kidney function(Table4)todetectandstageAKDandCKD, reflects the entirety of different and complex physiological determine CKD progression, dose medications, determine functionsofthekidney; thus, kidneyfunctionshouldnotbea appropriate use of diagnostic tests, and guide treatment term used interchangeably with GFR. decisions around KRT therapies. Equations are available Assessment of the overall functions of the kidney is a that estimate GFR using SCr and adjusting for sex and age, complextask. GFRisusedastheprimarytooltoassesskidney and professional societies throughout the world have function in practice. Loss of other kidney functions are recommended that GFR estimates should be used in known as complications of CKD and are addressed in association with SCr reporting. Sources of error in GFR Chapter3. ThissectionfocusesonhowGFRcanbeevaluated estimation from SCr concentration include nonsteady-state using both mGFR and eGFR. conditions, non-GFR determinants of SCr, measurement error at higher GFR, and interferences with the creatinine Specialconsiderations assays. GFR estimates are less precise at higher GFR levels Pediatric considerations. There are numerous kidney disthan at lower levels, and healthcare providers should remain ordersin children that may present with tubulardysfunction aware of caveats for any estimating equation that may (e. g. , Bartters and Dent disease) rather than decreased GFR influence the accuracy in an individual person. S176 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Initial test eGFRcr Consider sources of error and need for more accurate assessment. Is eGFR thought to be accurate? Yes No Measure Use eGFRcr cystatin C Consider potential sources of error in eGFRcr-cys and need for an even more accurate assessment. Is a more accurate assessment needed? No Yes Use Measure GFRcr-cys GFR Evaluation of GFR for clinical application 15 30 45 60 90 120 Figure11Approachtoglomerularfiltrationrate(GFR)evaluationusinginitialandsupportivetests. Thealgorithmdescribesthe approachtotheevaluationofGFR. TheapproachusesinitialandsupportivetestingtodevelopafinalassessmentoftrueGFRandtoapplyitin individualdecision-making. TheinitialtestfortheevaluationofGFRiscreatinine-basedestimatedGFR(eGFRcr), whichwillbeavailableformost peoplebecausecreatinineismeasuredroutinelyaspartofthebasicmetabolicpanel. IfeGFRcrisexpectedtobeinaccurate, orifamore accurateassessmentofGFRisneededforclinicaldecision-making, suchasdiagnosisorstagingofchronickidneydiseaseordrugdosing, then, ifavailable, cystatinCshouldbemeasured, andcreatinineandcystatinCbasedestimatedGFR(eGFRcr-cys)shouldbeestimated. IfeGFRcr-cys isexpectedtobeinaccurate, orifanevenmoreaccurateassessmentofGFRisneededforclinicaldecision-making, then, ifavailable, GFRshould bemeasuredusingplasmaorurinaryclearanceofexogenousfiltrationmarkers. InitialtestmaybeestimatedGFRbycystatinC(eGFRcysor eGFRcr-cys)inotherwisehealthypopulationswithchangesincreatininegenerationduetonon-GFRdeterminantssuchaschangesinmuscle massorcreatininesecretionorextrarenaleliminationduetotheuseofspecificmedications. SourcesoferrorineGFRcr-cysincludeverylow musclemassorveryhighlevelsofinflammation, highcatabolicstates, orexogenoussteroiduse. ConsidereGFRcysratherthaneGFRcr-cysin otherwisehealthypopulationswithdecreasedcreatininegenerationduetoreducedmusclemassordecreasedcreatininesecretionor extrarenaleliminationduetotheuseofspecificmedications. MostpeoplewithCKDandtheirhealthcareproviderswould Recommendation 1. 2. 2. 1: We recommend using preferthemoreaccurateassessmentofkidneyfunctionresulting eGFRcr-cys in clinical situations when eGFRcr is less fromthe use of GFRestimating equations compared with SCr accurate and GFR affects clinical decision-making alone.
----------------------------------------------------------------------


======================================================================
CHUNK 327 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_53
Content Type: recommendation
Words: 490
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
IfeGFRcr-cys isexpectedtobeinaccurate, orifanevenmoreaccurateassessmentofGFRisneededforclinicaldecision-making, then, ifavailable, GFRshould bemeasuredusingplasmaorurinaryclearanceofexogenousfiltrationmarkers. InitialtestmaybeestimatedGFRbycystatinC(eGFRcysor eGFRcr-cys)inotherwisehealthypopulationswithchangesincreatininegenerationduetonon-GFRdeterminantssuchaschangesinmuscle massorcreatininesecretionorextrarenaleliminationduetotheuseofspecificmedications. SourcesoferrorineGFRcr-cysincludeverylow musclemassorveryhighlevelsofinflammation, highcatabolicstates, orexogenoussteroiduse. ConsidereGFRcysratherthaneGFRcr-cysin otherwisehealthypopulationswithdecreasedcreatininegenerationduetoreducedmusclemassordecreasedcreatininesecretionor extrarenaleliminationduetotheuseofspecificmedications. MostpeoplewithCKDandtheirhealthcareproviderswould Recommendation 1. 2. 2. 1: We recommend using preferthemoreaccurateassessmentofkidneyfunctionresulting eGFRcr-cys in clinical situations when eGFRcr is less fromthe use of GFRestimating equations compared with SCr accurate and GFR affects clinical decision-making alone. Minimal cost or resources issues are expected because (Table 8127-142) (1C). creatinineisavailableinhealthcaresettingsglobally, andevaluating GFR with the use of creatinine in the form of GFR estimatingequationshasbeenrecommendedfor20years. This recommendation places a high value on using estimates of eGFRfromcreatinineiswidelyused. Attentionisrequired GFRderivedfromacombinationofcreatinineandcystatinCin to implement and ensure the quality of eGFR reporting by clinical situations where eGFRcr is an unreliable or inadequate clinical laboratories and ensure coordination with the elecassessmentofGFR. ThereisconsistentevidencethateGFRcr-cys tronic medical record (EMR), including those eGFR reports provides more accurate estimates of mGFR than eGFRcr and from point-of-care settings (Section 1. 2. 2). eGFRcys in ambulatory people. KidneyInternational(2024)105(Suppl4S), S117S314 S177 chapter 1 www. kidney-international. org Table7Descriptionofinitial andsupportivetestsforthe evaluationofGFR GFRassessmentmethod Specifictests Guidanceforuseandimplementation EstimatedGFR Creatinine(eGFRcr) MostusedmethodtoassessGFR. Inmostcases, initialtestfortheevaluationofGFR. Standardizedassayrequiredtodecreasebetween-center analyticalvariation CystatinC(eGFRcr-cys, eGFRcys) UsedinselectedcircumstancesaslistedinTable8 Standardizedassayrequiredtodecreasebetween-center analyticalvariation mGFR Goldstandard. Urinaryorplasmaclearanceofexogenous UsedinselectedcircumstancesaslistedinTable8 markers(e. g. , iohexol, iothalamate, 51Cr-EDTA, and99mTc-DTPA) Standardprotocolsforclearancemethodsandforthe standardizedassay Timedurineclearance Creatinine Highlypronetoerrorsandrecommendedonlywhen nootheroptionsforsupportivetestsforGFRevaluation; performanceundersupervisedconditionsmaydecreaseerror Nuclearmedicine Imagingofthekidneysafterinjectionoftracercleared Highlypronetoerrors; notrecommended imaging bythekidneys(e. g. , 99mTc-DTPAscintigraphy) 51Cr-EDTA, chromium 51-labeled ethylenediaminetetraacetic acid; 99mTc-DTPA, technetium 99m-labeled diethylenetriamine pentaacetate; eGFRcr, creatinine-based estimatedGFR; eGFRcr-cys, creatinineandcystatinCbasedestimatedGFR; eGFRcys, cystatinCestimatedGFR; GFR, glomerularfiltrationrate; mGFR, measuredglomerular filtrationrate. Keyinformation chronic illnesses, and low in other populations due to inBalance of benefits and harms. Please see Practice Point consistencies and imprecision in the studies currently avail1. 2. 2. 1regardingthebenefitofaccurateassessmentofGFRfor able in the literature. Most of the studies used in the clinical decision-making. In clinical practice, there may be developmentandinitialexternalvalidationoftheseequations situations where the estimation of GFR from SCr alone may wereperformed in ambulatory people whowereneither frail be a source of error, for example, muscle wasting/loss, or norhadacuteorchronicillnesses. Thereremainsapaucityof where greater accuracy of GFR estimation is required for studies examining the accuracy of eGFR in such popclinical decision-making (e. g. , drug dosing). In most of these ulations. 142 Many studies that have been performed in such situations, estimating GFR using a combined creatinine and populations are small, increasing risk for analytical cystatin C equation provides the required degree of accuracy variability, and show inconsistent results among the studies and obviates the need for expensive and time-consuming even within the same disease. Some reports in populations measurement of GFR using an approved gold standard with cancer, HIV, or obesity demonstrate greater accuracy methodology. GFRestimatingequationsthatincorporateboth for eGFRcr-cys than either eGFRcr or eGFRcys. 132135, 155157 creatinine and cystatin C have particular benefit in terms of Consistent with these findings, a large study of people living improved accuracy in relation to mGFR compared with in Stockholm, Sweden referred for an mGFR test who had equivalentequationsusingonlyoneofthesemarkers. 91, 92, 146149 diagnoses for heart failure, liver failure, cancer, CVD, or In 2 large-scale studies in pooled cohorts of general popdiabetes found eGFRcr-cys to be the most accurate and ulation cohorts and clinical populations in North America least biased.
----------------------------------------------------------------------


======================================================================
CHUNK 328 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_54
Content Type: definition
Words: 488
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
91, 92, 146149 diagnoses for heart failure, liver failure, cancer, CVD, or In 2 large-scale studies in pooled cohorts of general popdiabetes found eGFRcr-cys to be the most accurate and ulation cohorts and clinical populations in North America least biased. 82 In other studies of sick or frail people, such and Europe, the P (defined as the percentage of the eGFR as very advanced liver or heart failure or those admitted to 30 values within (cid: 6)30% of mGFR) using eGFRcr-cys is in the the intensive care unit, all eGFR tests demonstrated very range of 90%, 91, 147 which is considered optimal. 1 Greater low levels of accuracy. 73, 137, 158161 accuracy of eGFRcr-cys compared with eGFRcr or eGFRcys There are insufficient data to indicate the accuracy of is also observed in studies evaluating GFR estimating eGFRcr, eGFRcys, or eGFRcr-cys for many diseases. For equations compared with mGFR in other countries such as example, inpeoplewithhighcellturnoversuchashematologic Brazil, Congo, Pakistan, Singapore, Japan, and China, with cancers, we expect that cystatin C would provide highly inacP estimated between 80% and 90%, 77, 78, 83, 88, 93, 136, 150154 curateestimatesduetotheincreaseincystatinCbecauseofcell 30 which is considered adequate for most decision-making. 1 turnover rather than decreased GFR disease. 162165 However, Potential harms include increased costs, as described therearenodatatoevaluatethathypothesis. Importantly, even below, and greater complexity in the interpretation of GFR for people from populations where eGFRcr-cys has been with discrepant results between eGFRcr, eGFRcys, and demonstratedtobemoreaccurate, healthcareprovidersshould eGFRcr-cys. Thisinturnmayleadtoanincreasednumberof assessthepotentialsourcesoferrorineGFRandtheneedfora nephrology consults, especially initially as healthcare prohighly accurate level of GFR. Among people who are frail or viders may be unfamiliar with these new tests. with multiple comorbid illnesses, eGFRcr-cys may be insuffiCertainty of evidence. The Work Group considered the ciently accurate due to large contributions from non-GFR overall certainty of the evidence to be moderate to high in determinants of creatinine, cystatin C, or both markers. ambulatory people who were neither frail nor had acute or Conversely, in otherwise healthy populations with decreased S178 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table8Indicationsforuseofcystatin C Domain Specificclinicalcondition Causeofdecreasedaccuracy CommentsonGFRevaluation Bodyhabitusandchanges Eatingdisorders127 Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifnocomorbidillness inmusclemass otherthanreductioninmusclemass. Extremesport/exercise/ Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifanincreaseinmuscle bodybuilder massistheonlyabnormality. Above-kneeamputation128 Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateinthosewithoutother comorbidconditions. SuggesteGFRcr-cysin thosewithcomorbidillness. Spinalcordinjurywith Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateinthosewithoutother paraplegia/paraparesisor comorbidillness. SuggesteGFRcr-cysinthose quadriplegia/quadriparesis withcomorbidillness. ClassIIIobesitya, b Non-GFRdeterminantsofSCr eGFRcr-cysdemonstratedtobemostaccurate. andSCys Lifestyle Smoking129-131 Non-GFRdeterminantsofSCys Minimaldata, suggesteGFRcrifnochangestononGFRdeterminantsofSCrorcomorbidillness. Diet Low-proteindiet Non-GFRdeterminantsofSCr Ketodiets Non-GFRdeterminantsofSCr Minimaldata, suggesteGFRcrmaybeappropriateif Vegetarian Non-GFRdeterminantsofSCr nochangestonon-GFRdeterminantsofSCrorno High-proteindiets Non-GFRdeterminantsofSCr comorbidillness. andcreatinesupplements IllnessotherthanCKD Malnutrition Chronicillness, presumed eGFRcr-cysmaybelessaccuratebecauseof impactonnon-GFR coexistenceofmalnutritionandinflammation. determinantsofSCrandSCys SuggestusingmGFRfortreatmentdecisions basedonthelevelofGFR. Cancera, 132-137 Chronicillness, presumed eGFRcr-cysdemonstratedtobemostaccuratein impactonnon-GFR populationsstudiedbutlikelihoodoflesser determinantsofSCrandSCys accuracyinmorefrailpeopleorincancerswith highcellturnover. SuggestusingmGFRfor treatmentdecisionsbasedonthelevelofGFR. Heartfailurea, 138, 139 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Cirrhosisa, 79, 140, 141 Chronicillness, presumed Althoughlimiteddata, eGFRcysappearslessbiased impactonnon-GFR butallhavelowaccuracy. SuggestusingeGFRcrdeterminantsofSCrandSCys cysoreGFRcysforroutineGFRevaluation. Suggest usingmGFRfortreatmentdecisionsbasedonthe levelofGFR. Catabolicconsuming Chronicillness, presumed MinimaldatabuteGFRcr-cysmaybeinaccurate. diseasesc impactonnon-GFR SuggestusingeGFRcr-cysvs. eGFRcrforroutine determinantsofSCrandSCys GFRevaluation. SuggestusingmGFRfortreatment decisionsbasedonthelevelofGFR. Musclewastingdiseases142 Chronicillness, presumed Minimaldata. Onestudyshowslargebiasforboth impactonnon-GFR eGFRcrandeGFRcys. SuggestusingeGFRcr-cys determinantsofSCrandSCys forroutineGFRevaluation. SuggestusingmGFR fortreatmentdecisionsbasedonthelevelofGFR. Medicationeffects Steroids(anabolic, hormone) Non-GFRdeterminantsofSCr. PhysiologicaleffectonSCysunknown, suggest EffectonSCysnotknown eGFRcr-cys. Decreasesintubularsecretion Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly creatinineandnocomorbidillness. Suggestusing mGFRfortreatmentdecisionsbasedonthelevel ofGFR. Broadspectrumantibiotics Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly thatdecreaseextrarenal creatinineandnocomorbidillness. Suggestusing elimination mGFRfortreatmentdecisionsbasedonthelevel ofGFR.
----------------------------------------------------------------------


======================================================================
CHUNK 329 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_55
Content Type: recommendation
Words: 488
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Catabolicconsuming Chronicillness, presumed MinimaldatabuteGFRcr-cysmaybeinaccurate. diseasesc impactonnon-GFR SuggestusingeGFRcr-cysvs. eGFRcrforroutine determinantsofSCrandSCys GFRevaluation. SuggestusingmGFRfortreatment decisionsbasedonthelevelofGFR. Musclewastingdiseases142 Chronicillness, presumed Minimaldata. Onestudyshowslargebiasforboth impactonnon-GFR eGFRcrandeGFRcys. SuggestusingeGFRcr-cys determinantsofSCrandSCys forroutineGFRevaluation. SuggestusingmGFR fortreatmentdecisionsbasedonthelevelofGFR. Medicationeffects Steroids(anabolic, hormone) Non-GFRdeterminantsofSCr. PhysiologicaleffectonSCysunknown, suggest EffectonSCysnotknown eGFRcr-cys. Decreasesintubularsecretion Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly creatinineandnocomorbidillness. Suggestusing mGFRfortreatmentdecisionsbasedonthelevel ofGFR. Broadspectrumantibiotics Non-GFRdeterminantsofSCr eGFRcysmaybeappropriateifmedicationaffectsonly thatdecreaseextrarenal creatinineandnocomorbidillness. Suggestusing elimination mGFRfortreatmentdecisionsbasedonthelevel ofGFR. eGFR, estimatedglomerularfiltrationrate; eGFRcr, creatinine-basedestimatedGFR; eGFRcr-cys, creatinineandcystatinCbasedestimatedGFR; GFR, glomerularfiltrationrate; mGFR, measuredglomerularfiltrationrate; SCr, serumcreatinine; SCys, serumcystatinC. aDatasummarizedinAdingwupuetal. 149 bObesityclassIIIvariesbyregionbutcommonlybodymassindex40or35kg/m2. cCatabolicconsumingdiseasemayincludetuberculosis, AIDS, hematologicmalignancies, andsevereskindiseases. Therearenodatawithmeasuredglomerularfiltrationrate (mGFR)toevaluatethisdirectly. KidneyInternational(2024)105(Suppl4S), S117S314 S179 chapter 1 www. kidney-international. org creatininegenerationduetoreducedmusclemassordecreased Rationale creatininesecretionorextrarenaleliminationduetotheuseof WedescribeaframeworkfortheevaluationofGFRbeginning specific medications, it is possible that eGFRcys rather than with an initial test and followed by additional supportive tests eGFRcr-cys would be preferred. (Figure 11, Table 7). Cystatin C is an alternative endogenous Valuesandpreferences. TheWorkGroupjudgedthatmost filtration marker that is now increasingly available. Its assay people and most healthcare providers would want to use the canbeputonautoanalyzers, andthereforeitsutilizationcould most accurate assessment of GFR available to them and be increased with clinical demand. eGFRcr-cys provides the would, therefore, wish to estimate GFR from a combination most accurate estimate and is recommended as the primary of creatinine and cystatin C, when available. However, they supportive test for people in whom there are concerns about wouldalsobalanceadditionalcostsassociatedwithcystatinC eGFRcr accuracy (Table 8127142). However, there remain against the potential benefits. residualerrorswithsomegroupsofpeoplehavingaveryhigh Differences between eGFRcr and eGFRcys may prompt level of errors. In such people, we advocate using mGFR. We recognitionthatbothareestimatesofGFRandbothareassoanticipatethatsuchconsiderationsbemadeateveryencounter ciated with error, requiring interpretation as to the best estiwhereGFRisbeingusedforaclinicaldecision. mateofGFR. Inourview, thisisdesirable, anduncertaintyasto thelevelofGFRisanindicationfornephrologyreferral. Practice Point 1. 2. 2. 2: Where more accurate ascertainment Resource use and costs. Costs for the higher frequency of ofGFRwillimpacttreatmentdecisions, measureGFRusing cystatinCtestingincludeone-timecostsassociatedwithinitiplasma or urinary clearance of an exogenous filtration ationoftheassaywithinalaboratory, whichincludebuilding marker (Table 9). theinformationtechnologyinfrastructureandmethodverifiGiven the benefit of accurate assessment of GFR for clincation studies, and continuous costs associated with mainical decision-making, there is a need to appreciate the value tainingtheassay, whichincludereagents, dailyqualitycontrol, and circumstances in which directly mGFR is required. The requirements for calibration verification, and proficiency greatest benefit of mGFR is that it is less influenced by nontesting. Reagent costs are currently more expensive than GFR determinants, in contrast to eGFR. GFR is measured creatininebutarelowercomparedwithothercommonlyused using exogenous filtration markers and urinary or plasma biomarkers. IfcystatinCisperformedinanoutsidelaboratory, clearance. The precision of mGFR can be determined from othercosts, aswithanylaboratorytest, mayensue. Additional variabilitywithrepeatedmeasures. Time-to-timevariabilityis costs may also be a result of the increased referrals to nethe method used to assess error. phrologiststoassisttheinterpretationofpotentiallydiscordant One systematic review summarizing the available data results between eGFRcr and eGFRcys. Ideally, these decrease comparing current GFR measurement methods to each other overtimewithincreasedutilization. andtotheclassicgoldstandardofinulinurinaryclearancerecConsiderations for implementation. We recognize that for ommended the use of iothalamate, iohexol, ethylthese recommendations to be implemented, cystatin C needs enediaminetetraacetic acid (EDTA), and diethylenetriamine to be widely available. Wherever possible, access to both pentaacetate (DTPA) as exogenous markers of choice. 166 A creatinine and cystatin C measurements should be made subsequent study recommended against plasma 99mTc-DTPA, available when evaluating GFR. Education for healthcare especially when clearances are performed over 24 hours.
----------------------------------------------------------------------


======================================================================
CHUNK 330 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_56
Content Type: recommendation
Words: 477
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Wherever possible, access to both pentaacetate (DTPA) as exogenous markers of choice. 166 A creatinine and cystatin C measurements should be made subsequent study recommended against plasma 99mTc-DTPA, available when evaluating GFR. Education for healthcare especially when clearances are performed over 24 hours. 167 providers and people with CKD for optimal use and interSeveral studies demonstrate that the method by which the pretationofthesetestsisrequired. SeeSection1. 2. 3fordetails clearance of exogenous markers is measured may impact regarding the measurement of creatinine and cystatin C by accuracy. For example, for people with lower GFRs, delayed clinical laboratories. blood sampling is most accurate, whereas for people with Table9Comparisonofestimated GFRandmeasuredGFR EstimatedGFRbySCrand/orcystatinC MeasuredGFR Inexpensiveandeasytoimplement Moreexpensive, moretime-consuming, andinvasive Widelyavailableandmayalsobeused Onlyavailableincertaincenters atpointofcare, easilyrepeatable Methodstomeasurethatdonotrequireurinecollectionsareavailable(i. e. , plasmaclearance) Mostprotocolsrequirerepeatbloodsamplespotentiallyoveralongduration Microsamplingtestsbyfingerpickenablepoint-of-caretesting. Testinghasbeendescribed, butnotroutinelyperformed Notsufficientlyaccurateandprecise AccurateforGFRinallsituationsandacrosstheGFRrange. Requiresindividualizedprotocols forallclinicalsituations LagsbehindchangesinGFR AbletoidentifyearlychangesinGFR Subjecttonon-GFRdeterminantconfounding Lessinfluencedbynon-GFRdeterminants GFR, glomerularfiltrationrate; SCr, serumcreatinine. S180 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table10Indicationsformeasured GFR ClinicalconditionsinwhicheGFRcr-cysisinaccurateoruncertainduetopotentialnon-GFRdeterminantsofcreatinineandcystatinC. Thismayinclude catabolicstates, suchasseriousinfectionsorinflammatorystates, highcellturnoverasinsomecancers, advancedcirrhosisorheartfailure, useofhighdosesteroids, ortheveryfrail. SeeFigure12forapproachtoindividualdecision-making. ClinicalsettingsinwhichgreateraccuracyisneededthanisachievedwitheGFRcr-cys. Forexample, decisionsaboutsimultaneouskidneytransplantat thetimeofothersolidorgantransplant, kidneydonorcandidacy, anddrugdosingifthereisanarrowtherapeuticindexorserioustoxicity(e. g. , chemotherapiesthatareclearedbythekidney). eGFRcr-cys, estimatedGFRbycreatinineandcystatinC; GFR, glomerularfiltrationrate. better-preservedGFRs, earlierbloodsamplingismostaccurate, European Kidney FunctionConsortium(EKFC) together with andinpeoplewithextensiveedemaorascites, plasmaclearance theEuropeanFederationofClinicalChemistryandLaboratory protocols are very inaccurate and not recommended; instead, MedicineiscurrentlyharmonizingmGFRprotocolsforiohexol urinary clearance protocols are recommended. 167 Finally, it is plasma clearance to deliver standardized operating procedures well recognized that assessing GFR using the imaging of forGFRmeasurementsinthenearfuture. nuclear tracers is less accurate than eGFR, and we do not Decisions to measure GFR should be made by both nerecommenditasamethodtomeasureGFR. 168 phrologists and other physicians using the framework sugThe evaluation of time-to-time variability of plasma gestedinFigure11. Physiciansshoulddeterminehowaccurate clearance of iohexol and eGFR found a within-subject biothe GFR needs to be for a specificclinical decision. If greater logical coefficient of variation (CV) for mGFRof 6. 7% (95% accuracy is needed than can be achieved using eGFR, mGFR CI: 5. 6%8. 2%), whereas CVs for eGFRcr, eGFRcys, and is recommended. Greater accuracy may be required due to eGFRcr-cys were approximately 5. 0%. 169 Other studies have inaccuracy of eGFR in the individual person due to the observed CV for this same mGFR method ranging from presenceofnon-GFRdeterminantsorduetotherequirement approximately 5% to 10%. 169, 170 There are less data for of the clinical setting. Table 10 lists indications for when one other methods; for urinary clearance of iothalamate, mightconsidermGFRasopposedtoeGFRcr-cys. estimated CVs were 6. 3% and 16. 6% across 2 studies. 171173 WedescribeaframeworkfortheevaluationofGFRbeginning The Work Group judged that there will be some clinical with an initial test and followed by additional supportive tests situations where estimating GFR from both creatinine and (Figure 11, Table 7). mGFR is recommended when there are cystatin C will be insufficiently reliable or precise, and the concerns about the accuracy of eGFRcr-cys (Table 8127-142) or greatestbenefitandleastharmwillbeachievedbymeasuring where an accurate level of GFR is required for optimal GFR with the appropriate standardized methods. decision-making, asdescribedinTable10. Costs for mGFR are variable and harder to quantify. The infrastructure required is greater, as testing requires both PracticePoint1. 2. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 331 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_57
Content Type: recommendation
Words: 497
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
decision-making, asdescribedinTable10. Costs for mGFR are variable and harder to quantify. The infrastructure required is greater, as testing requires both PracticePoint1. 2. 2. 3: Understandthevalueandlimitations patient and personnel time for inserting a peripheral intrain both eGFR and measured glomerular filtration rate venous catheter, administering the exogenous marker, col- (mGFR)aswellasthevariabilityandfactorsthatinfluence lecting serial blood specimens over several hours (depending SCr and cystatin C measurements. on the protocol), and the associated materials for the All studies evaluating the performanceof eGFR compared collection and measuring blood levels by high-performance with mGFR observe error in any GFR estimate. Even in liquid chromatography or mass spectrometry. Utilization of populations wherethereisahighaccuracy(i. e. , P of 90%), 30 mGFR may require input from a nephrologist in some set10% of the population would have errors 30% relative to tings, which would also add to the costs of testing. mGFR. Withinthesestudies, errorratesarelikelytobehigher All nephrologists ideally should therefore have access to at insomesubgroupsandlowerinothers. Acriticalcomponent least1methodtomeasureGFRusingplasmaorurinaryclearance of the recommended approach to evaluation of GFR (Figure ofexogenousmarkers. Toensurehighlyaccuratemeasurements, 11) is that physicians have a clear understanding of the these clearance methods should be performed using standard value and limitations of eGFR and mGFR, which defines operatingprocedures. Externalqualityassessment(EQA)should when a person requires one or another supportive test. beused forassaysoftheexogenousmarkers. Special considerThesourceoferrorineGFRmayberelatedtoerrorsineGFR ationsinclearancemethodsarerequiredforsomepopulationsto orinmGFR(Figure12174). Themostimportantsourcesoferror obtain a high level of accuracy (e. g. , later sampling time for arenon-GFRdeterminantsofeithercreatinineorcystatinC. The peoplewithlowGFRorurinary, insteadofplasmaclearancefor non-GFRdeterminantsofcreatinineincludegenerationbydiet edematous people). GFR centers, under the direction of a and muscle mass, tubular secretion, and extrarenal nephrologist champion or laboratory director, analogous to elimination. 130, 175 The non-GFR determinants of cystatin C cardiacimaging, arelikelytohelpbothincreaseutilizationand are less well understood but thought to be higher adiposity, ensurehighqualityresults. Therewillbeadditionalrequirements smoking, hypoand hyperthyroidism, glucocorticoid excess, forstorage, administration, and disposal if radionuclide methand chronic inflammation (as indicated by insulin resistance, odologiesareadopted. Nationalkidneysocietiescanworkwith higher levels of C-reactive protein and tumor necrosis factor, payers to support reimbursement for mGFR procedures. The orlowerlevelsofserumalbumin). 129, 130, 176185 KidneyInternational(2024)105(Suppl4S), S117S314 S181 chapter 1 www. kidney-international. org eGFR P 90% 30  30%  30% 2139 4278 15 30 45 60 90 120  15%  15% 2635 5169 mGFR P 90% 15 Biological variability Analytical variability mGFR Measurement error in the Non ideal properties of clearance procedure Measurement error in the assay of eGFR Measurement error in the assay determinants of serum concentrations of endogenous Figure12Sourcesandmagnitudeoferroraroundmeasuredglomerularfiltrationrate(mGFR)andestimatedGFR(eGFR). Itis importanttodeterminehowaccuratetheassessmentofGFRneedstobeforclinicaldecision-making. P foreGFRreferstothepercentof 30 eGFRsthatarewithin30%ofmGFR. Ifaccuracywithin30%isacceptable(P 80%)oroptimal(P 90%), eGFRmaybesufficient, provided 30 30 thattherearenotlargedeviationsinnon-GFRdeterminantsofcreatinineorcystatinC. Ifgreateraccuracyisneeded, mGFRisadvised. The accuracyformGFRisbasedontime-to-timevariability. P formGFRreferstothepercentofonemGFRthatwaswithin15%ofthesecond. Ata 15 GFRof60ml/minper1. 73m2, 30%accuracyforeGFRcorrespondsto42to78ml/minper1. 73m2and15%accuracyformGFRcorrespondsto 51to69ml/minper1. 73m2. AtaGFRof30ml/minper1. 73m2, 30%accuracyforeGFRcorrespondsto21to39ml/minper1. 73m2and15% accuracyformGFRcorrespondsto26to35ml/minper1. 73m2. Non-GFRdeterminantsofendogenousfiltrationmarkersincludegeneration, tubularhandling, andextrarenalelimination. Nonidealpropertiesofexogenousfiltrationmarkersincludetabularhandlingandextrarenal elimination. ReproducedfromKidneyInternational, volume96, issue2, InkerLA, LeveyAS. KnowingyourGFRwhenisthenumbernot(exactly) thenumber? Pages280282. 174Copyright2019, withpermissionfromtheInternationalSocietyofNephrology. PublishedbyElsevierInc. All rightsreserved. mGFRalsodiffersfromthetruephysiologicalGFR, which documented the impact of a cooked meat or fish meal on itself cannot be directly measured. Errors may be related to creatinine concentrations. 187 For example, one study m analytical errors in the assay or the clearance procedure. For demonstrates increase in SCr of approximately 20 mol/l example, theoverestimationofGFRisseeniflatesamplesare (0. 23mg/dl)whichinthestudy populationwasequivalentto not taken for people with low GFR.
----------------------------------------------------------------------


======================================================================
CHUNK 332 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_58
Content Type: reference
Words: 477
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Errors may be related to creatinine concentrations. 187 For example, one study m analytical errors in the assay or the clearance procedure. For demonstrates increase in SCr of approximately 20 mol/l example, theoverestimationofGFRisseeniflatesamplesare (0. 23mg/dl)whichinthestudy populationwasequivalentto not taken for people with low GFR. 167, 186 Urinary clearances decrease in eGFR of approximately 20 ml/min per 1. 73 m2. are preferred to plasma clearance methods in people with Maximumpostprandialeffectswerereachedinsomesubjects extensive third spacing of fluid. 169173 In the absence of by 2 hours and others by 4 hours. Waiting for at least 12 changes related to disease progression, a change in mGFR hours before the measurement of SCr, after meat or fish from time to time may occur due to preanalytical (e. g. , intake, bestavoidsthiseffect. Werecognizethatthisapproach patient preparation and time of day), analytical (laboratory maybechallengingtoimplementintheclinicalenvironment. measurement variability), and biological (changes in true physiological GFR) variability, as is the case for eGFR. This Practice Point 1. 2. 2. 5: Assess the potential for error in does not detract from the advantage of mGFR as being free eGFR when assessing a change in GFR over time. from non-GFR determinants. It is important for WhenevaluatingachangeineGFRovertime, thequestion nephrologists to appreciate and understand these errors and is whether the true GFR is changing. However as described nuances to appropriately order the right tests in specific above, thereareseveralotherpotentialcausesforachangein circumstances. observedeGFR, otherthanAKI, suchaschangesinnon-GFR determinants of the filtration markers or analytical errors in Practice Point 1. 2. 2. 4: Interpretation of SCr level requires the assays. Healthcare providers should consider whether consideration of dietary intake. there has been a change in non-GFR determinants (e. g. , a Most studies measuring GFR for clinical or research purrecent meat meal nowor at the first measurement or change posesareperformedinthemorningafteraperiodoffastingor in muscle mass or extreme activity). The impact of the moderateproteinintake. Ideally, optimalapplicationofeGFR combined effect of analytical and biological variation on would simulate these conditions. Several studies have eGFR in determining progression is discussed in Chapter 2. S182 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 When evaluating a change in GFR using mGFR, the comcontrast, when there is discordance, eGFRcr-cys is more bined effect of changes in biological and analytical variation accurate than either eGFRcr or eGFRcys. This suggests that should be considered as part of the interpretation of the rewhen eGFRcr and eGFRcys are discordant, it is reasonable sults (Figure 12174). 169 to continue to measure cystatin C serially in addition to creatinine in those settings where GFR will affect clinical PracticePoint1. 2. 2. 6: ConsidertheuseofcystatinCbased decisions. It is also reasonable to consider performing/ estimated glomerular filtration rate (eGFRcys) in some conducting mGFR when using medications with narrow specific circumstances. therapeutic index or high toxicity or to inform critical ThecombinationofeGFRcrandeGFRcystogetherismore treatment decisions (Chapter 4). accurate than eGFRcr or eGFRcys alone. 91, 147 The greater accuracy is due to the fact that the non-GFR determinants Practice Point 1. 2. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 333 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_59
Content Type: evidence
Words: 499
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
therapeutic index or high toxicity or to inform critical ThecombinationofeGFRcrandeGFRcystogetherismore treatment decisions (Chapter 4). accurate than eGFRcr or eGFRcys alone. 91, 147 The greater accuracy is due to the fact that the non-GFR determinants Practice Point 1. 2. 2. 8: Consider timed urinecollections for for each marker are different, and therefore using both measuredcreatinineclearanceifmGFRisnotavailableand leads to convergence on the estimate of GFR and minimizes eGFRcr-cys is thought to be inaccurate. the effect of either marker. 188 mGFR is not available everywhere. In these settings, it In individuals where non-GFR determinants of creatinine might be reasonable to consider measured urinary creatinine or cystatin C are substantially greater than for the other clearance (CrCl). It is widely available and therefore marker, eGFRcr-cys would not provide the more accurate commonlyusedbutishighlypronetoerrorduetounder-or estimate. This imbalance is more likely to occur for creatiovercollection. AsystematicreviewofGFRmethodsobserved nine, given its association with diet and muscle mass, which a mean bias of 25% across 23 studies, and as such, did not canvarygreatlyacrossvariouspeople. Insuchcases, itwould find this method to reach sufficient accuracy. 166 The errors be reasonable to use eGFRcys. occur in both directions and thus do not appear solely due The non-GFR determinants for cystatin C are less well to the presence of tubular secretion of creatinine, which studied, andit iserroneoustoassumethateGFRcys provides would be expected to overestimate mGFR. For example, in the more accurate estimate in all circumstances. We, therethe pilot study for the African American Study of Kidney fore, advise limiting this strategy to selected clinical settings Disease (AASK), 25% of participants had a 24-hour where people are otherwise healthy with known changes in measured CrCl that was at least 18% lower than the mGFR, non-GFRdeterminantsofcreatinine. Forexample, in1study and another 25% had measured CrCl at least 23% greater that compared eGFRcr and eGFRcys before and after amputhan the GFR. Of note, measured CrCl had substantially tation in otherwise healthy military veterans, there was a better correlation with mGFR when it was measured during sizable change in eGFRcr as would be expected with the loss an mGFR procedure191; therefore, if measured CrCl is to be of a limb and loss of mobility, but no change in eGFRcys. 128 performed, then it should ideally be supervised given the In another study of people with anorexia, serum levels of high risk of inaccuracy with urine collection. cystatin C were more strongly correlated with mGFR than were levels of SCr, but this has not been further evaluated Specialconsiderations using eGFR and standardized assays. 127 Other situations Sex and gender considerations. It is unclear how best to may be where there are medications that inhibit tubular estimate GFR in people who are transgender, gender-diverse, secretion of creatinine, although there are no studies to or nonbinary, where a persons gender identity is different provide evidence to drive guidance. from their sex assigned at birth. Gender-affirming testosterone therapy is associated with an increase in SCr concenPractice Point 1. 2. 2. 7: Understand the implications of diftration, 192 with less certainty for the impact of estrogen.
----------------------------------------------------------------------


======================================================================
CHUNK 334 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_60
Content Type: reference
Words: 481
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
from their sex assigned at birth. Gender-affirming testosterone therapy is associated with an increase in SCr concenPractice Point 1. 2. 2. 7: Understand the implications of diftration, 192 with less certainty for the impact of estrogen. ferences between eGFRcr and eGFRcys, as these may be Gender-affirming testosterone therapy is associated with an informative, in both direction and magnitude of those increase in serum cystatin C and gender-affirming estradiol, differences. and antiandrogen therapy is associated with a decrease in For people who have simultaneous SCr and cystatin C serum cystatin C. 193 The impact of gender-affirming values, the agreement or discrepancy between eGFRcr and hormone therapy, if any, on true GFR is unknown. In eGFRcys may help to guide further actions. Several studies keeping with guidance from the American Association of havedemonstratedthat25%30%ofpeoplehavediscordance Clinical Chemistry and the National Kidney Foundation, 194 betweeneGFRcrandeGFRcysaslargeasorlargerthan15ml/ evaluation of eGFR should use a shared decision-making min per 1. 73 m2 or 20%. 82, 138, 189 One study demonstrated approach with the person with CKD, taking into account that factors associated with higher values for eGFRcr muscle mass, sex hormone milieu, sex assigned at birth, compared with eGFRcys included older age, female sex, and gender identity. We also note that the new EKFC nonBlack race, higher eGFR, higher BMI, weight loss, and cystatin equation does not include a variable for sex. current smoking. 190 Two recent studies demonstrate that Pediatric considerations. There are currently insufficient when there is concordance between eGFRcr and eGFRcys, externallyvalidateddatatoassessifcombiningcreatinineand there is high and similar accuracy for eGFRcr, eGFRcys, and cystatin improves the performance of pediatric eGFR equaeGFRcr-cys with estimated P of 87%91%. 82, 138, 189 In tions. Internal analysis of the Chronic Kidney Disease in 30 KidneyInternational(2024)105(Suppl4S), S117S314 S183 chapter 1 www. kidney-international. org Table11Implementation standardsto ensureaccuracy andreliability ofGFRassessmentsusingcreatinineandcystatinC (cid: 3) ReporteGFRinadditiontotheserumconcentrationsoffiltrationmarkersusingvalidatedequations. (cid: 3) ReporteGFRroundedtothenearestwholenumberandrelativetoabodysurfacearea(BSA)of1. 73m2inadultsusingtheunitsml/minper1. 73m2. (cid: 3) ReportedeGFRlevels60ml/minper1. 73m2shouldbeflaggedasbeinglow. (cid: 3) Whenreportinglevelsoffiltrationmarkers, report: (i) SCrconcentrationroundedtothenearestwholenumberwhenexpressedasstandardinternationalunits(mmol/l)androundedtothenearest 100thofawholenumberwhenexpressedasconventionalunits(mg/dl); (ii) serumcystatinCconcentrationroundedtothenearest100thofawholenumberwhenexpressedasconventionalunits(mg/l). (cid: 3) Measurefiltrationmarkersusingaspecific, precise(coefficientofvariationCV2. 3%forcreatinineand2. 0%forcystatinC)assaywithcalibration traceabletotheinternationalstandardreferencematerialsanddesirablebias(3. 7%forcreatinineand3. 2%forcystatinC)comparedwithreference methodology(orappropriateinternationalstandardreferencemethodgrouptargetinexternalqualityassessmentEQAforcystatinC). (cid: 3) Useanenzymaticmethodtoassaycreatinine, wherepossible. (cid: 3) Separateserum/plasmafromredbloodcellsbycentrifugationwithin12hoursofvenipuncture. (cid: 3) WhencystatinCismeasured, measurecreatinineonthesamesampletoenablecalculationofeGFRcr-cys. eGFR, estimatedglomerularfiltrationrate; eGFRcr-cys, estimatedglomerularfiltrationratebasedoncreatinineandcystatinC; GFR, glomerularfiltrationrate; SCr, serum creatinine. Children (CKiD) cohort revealed that averaging the eGFRcr typically comprising some 20% of the measured substance and eGFRcys reduced mean bias in people who are Black, reported as creatinine in adults at physiological creatinine White, and other race. Likewise, averaging eGFRs derived concentrations. Enzymatic assays are available that are more from the equations improved accuracy to 89%91% (as specific for creatinine and less susceptible to chemical and assessed by P ) across race groups. This has not been chromogenic (e. g. , icterus and hemolysis) interferences. 30 externally validated. 195 Although enzymatic methods are not totally immune to the interferences affecting the Jaffe method and may be suscep1. 2. 3Guidancetoclinicallaboratories tibletootherinterferencesspecifictotheenzymaticapproach, in the majority of people, use of an enzymatic method will Practice Point 1. 2. 3. 1: Implement the laboratory standards reducethepossibilityofinterference(Table12127, 196215).
----------------------------------------------------------------------


======================================================================
CHUNK 335 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_61
Content Type: reference
Words: 495
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
30 externally validated. 195 Although enzymatic methods are not totally immune to the interferences affecting the Jaffe method and may be suscep1. 2. 3Guidancetoclinicallaboratories tibletootherinterferencesspecifictotheenzymaticapproach, in the majority of people, use of an enzymatic method will Practice Point 1. 2. 3. 1: Implement the laboratory standards reducethepossibilityofinterference(Table12127, 196215). Itis of care outlined in Table 11 to ensure accuracy and likelythatcystatinCmeasurementswillbelesssusceptibleto reliability when assessing GFR using creatinine and chemicalandspectralinterferencesaffectingcreatinineassays, cystatin C. but inevitably, interferences will surface with more extensive clinical experience, for example, those due to circulating Practice Point 1. 2. 3. 2: Given available resources, clinical antibodies that are seen with other immunoassays. 216218 laboratories may consider the possibility of measurement After venipuncture, in unseparated samples, there is a ofbothcreatinineandcystatineitherasanin-housetestor gradual increase in measured SCr over time when the Jaffe as a referred test. assayisused. Thiseffectisnotseenwhenenzymaticassaysare Consistency, standardization, and comparability of laboratorymeasuresofcreatinineandcystatinC; thereportingof results and of GFR estimates; and the flagging of reported Table12Reportedexamplesofsubstancesthat maycause results where indicated are of paramount importance. The analyticalinterferences increatinineassays assays used should have the required specificity for the anaJaffemethods Enzymaticmethods lyte, and the calibration of assays is essential for the interAcetaminophen196 Bilirubin211 pretation of kidney function measures. Results should be Aspirin196 Lidocainemetabolites212 traceable to reference materials and methods listed on the Ascorbicacid197 Metamizole196 Joint Committee for Traceability in Laboratory Medicine Bacterialcontamination198 N-acetylcysteine213 Bilirubin199, 200 Prolinestabilizers, presentin (JCTLM) database. Blood-substituteproducts201 intravenousimmunoglobulin Estimation of GFR improves identification of CKD. Cephalosporins202, 203 preparations214 Adoption of the laboratory standards described here will Fluorescein204 Phenindione215 ensure that healthcare providers receive eGFR reports in a Glucose205 HemoglobinF206 consistent style and with assurance regarding the accuracy Ketones/ketoacids207 and reliability of the result. Flagging decreased values for Lipids208 eGFR can alert healthcare providers to the possibility of Metamizoleprotein206-209 kidney disease and may indicate the need for additional Pyruvate, includingthatarising fromdelayedsampleprocessing143 evaluation or adjustment of doses of medications that are Streptomycin210 excreted by the kidney. Thenatureofinterference(magnitudeanddirectionofbias)fromthelistedcomGlobally, most creatinine measurements are undertaken poundsisdependentontheprecisereactionconditionsinuse, inrelationtotiming using a colorimetric method (Jaffe). This method also reacts ofspectrophotometricreadingsandchemicalcompositionofthereagent: different versionsoftheJaffeandenzymaticmethodsusedbydifferentmanufacturerswill with avariety of substances that are not creatinine (so-called respond in variable ways to interferences. Further information may be found in non-creatininechromogens, e. g. , glucoseandacetoacetate), Myersetal. 205 S184 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 used. 219 We therefore advise that serum should be removed the local laboratory or alternatively as a referred test in from the red blood cells within 12 hours of venipuncture centralized laboratories. A range of commercially available when the Jaffe assay is being used. routine clinical biochemistry analyzers from a variety of AsdescribedinSection1. 2, eGFRisanimperfectestimate manufacturers can support cystatin C assays and will allow of mGFR. At best, 90% of eGFR will fall within 30% of turnaround time for results as rapid as that for routine mGFR. As shown in Figure 12, one of the sources of error electrolytes and creatinine when provided locally. Timeliness is analytical variability in measurement of the filtration will affect utilization (i. e. , if results are available on the same markers.
----------------------------------------------------------------------


======================================================================
CHUNK 336 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_62
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
As shown in Figure 12, one of the sources of error electrolytes and creatinine when provided locally. Timeliness is analytical variability in measurement of the filtration will affect utilization (i. e. , if results are available on the same markers. Optimization of laboratory measurements of day), then the test is more likely to be useful for routine or creatinine and cystatin C can help to reduce the uncertainty urgent decisions, and this may increase the pressure on labinherent in GFR estimation. The components of oratories to provide this test locally. measurement error that laboratories must address are Estimated GFR. Implementation and modification (e. g. , a accuracy (trueness of the result), imprecision (analytical change in equation) of GFR estimation require close variability of the result, commonly expressed as a CV), and communicationbetweenthelaboratoryandarangeofclinical specificity (reduction of interferences in the measurement). users, including primary and secondary care healthcare proThe availability of international reference standards for both viders, pharmacists, dietitians, and people with CKD. 223 creatinine220 and cystatin C221 and demonstration that the Laboratories should only use GFR estimating equations that laboratory results have minimal bias compared with these have been sufficiently validated in the population to which help to ensure the accuracy of results. Imprecision targets they are being applied and that are appropriate for the are commonly based on the known biological variability of creatinine and cystatin C assays in use (Section 1. 2. 4). 223 biomarkers ( Analytical They should also ensure that their end-to-end reporting variability that is less than half the within-person biological processes, including calculations embedded within the variability is generally considered desirable. 222 The target laboratory information system, are subject to regular EQA. CVs proposed here for creatinine and cystatin C should be Laboratory reports for computed values should indicate the achievable by automated laboratory methods. Achieving the filtration marker (i. e. , eGFRcr, eGFRcys, and eGFRcr-cys). target precision and bias goals proposed will ensure that Documentation should indicate which equation was used. laboratory error contributes to a less than 10% increase in To aid clarity in reporting across and within healthcare root mean square error when estimating GFR. 205 systems, and to provide guidance regarding the number of Most people with CKD, healthcare providers, and policy meaningful digits in a result, a standardized approach in makers would want laboratories to implement calibrated asrelation to reporting units of GFR, creatinine, and cystatin C says for creatinine and cystatin C that comply with internashould be implemented. Input age maybe rounded towhole tionalstandardsandusereagentsforanalysisthatconformto numbers or as a fractional year because the influence on internationally approved reference materials. Compliance eGFR is small. To adjust GFR for differences in body size, withtherecommendedstandardswouldensureconfidencein mGFR is commonly adjusted for body surface area (BSA), the results and in clinical decisions and any changes in withapopulationaverageBSAvalueof1. 73m2beingused. In management and treatment made as a consequence. practice, eGFR values derived using most equations are Globally, mostGFRestimatesarecurrentlyproducedusing alreadyadjustedforBSA, becauseBSAwastakenintoaccount creatinine results generated by Jaffe assays, which are relawhen the equations were originally developed using regrestively inexpensive.
----------------------------------------------------------------------


======================================================================
CHUNK 337 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_63
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
73m2beingused. In management and treatment made as a consequence. practice, eGFR values derived using most equations are Globally, mostGFRestimatesarecurrentlyproducedusing alreadyadjustedforBSA, becauseBSAwastakenintoaccount creatinine results generated by Jaffe assays, which are relawhen the equations were originally developed using regrestively inexpensive. Use of more specific enzymatic creatinine sion modeling against BSA-adjusted mGFR. assays can improve the estimation of GFR. However, enzyeGFR is mostlycomputed using the information recorded matic creatinine assays are more expensive than Jaffe assays. inthesexvariableinEMRs. SomeEMRsincludelegalsex, sex Use of cystatin C in combined creatinine-cystatin C GFR assignedatbirth, andgenderidentity, whereasothersinclude equations can also further improve GFR estimation, but onlyonevariable. Insomecases, thisvariablemaybemissing cystatin C measurement adds significantly to the cost. or reportedasnonbinary. Inthesecases, eGFR valuescannot Althoughtheper-patientcostincreaseofenzymaticcreatinine be computed and will be displayed as a missing value. Laband cystatin C measurement is relatively small, the impleoratories should add a comment directing healthcare promentationofthesemoreexpensiveapproacheshassignificant vidersandpeoplewithCKDtoonlinecalculatorstofacilitate cost implications across entire healthcare systems. a shared decision-making approach to the personwith CKD. Implementation considerations include the following: ThecommentmayalsoincludeasuggestiontousecystatinC Creatinine. Resource limitations that may restrict access to as there is less difference between eGFRcys values for males enzymatic creatinine should not be seen as a barrier to andfemalesandwherethereisnowanoptionforcomputing implementation of a GFR reporting program based on Jaffe eGFR without the use of sex. creatinine measurement. Together, the set of statements allow for a consistent Cystatin C. Ideally, cystatin C will be available for timely approach to the measurement and reporting of serum filtrasame-day results, which requires either measurement within tion markers and eGFR in clinical practice. KidneyInternational(2024)105(Suppl4S), S117S314 S185 chapter 1 www. kidney-international. org Specialconsiderations 1. 2. 4Selection ofGFRestimating equations Pediatricconsiderations. PracticePoint1. 2. 3. 3: Laboratoriesmeasuringcreatininein Recommendation 1. 2. 4. 1: We recommend using a infants or small children must ensure their quality control validated GFR estimating equation to derive GFR from serum filtration markers (eGFR) rather than process include the lowest end of the expected range of relying on the serum filtration markers alone (1D). values for the group of interest. Practice Point 1. 2. 3. 4: Consider the consistent use of Practice Point 1. 2. 4. 1: Use the same equation within enzymatic creatinine assays in children, given the higher geographical regions (as defined locally e. g. , continent, relative contribution of non-creatinine chromogens to country, andregionandaslargeaspossible). Withinsuch measuredcreatinineinchildrenwhenusingtheJaffeassay, regions, equations may differ for adults and children. and the high prevalence of icteric and hemolyzed samples The recommendation places a high value on the use of an in the neonatal period. estimating equation for GFR that has been validated in the Practice Point 1. 2. 3. 5: An eGFRcr level 90ml/min per population of interest and which has been shown to be most 1. 73m2canbeflaggedaslowinchildrenandadolescents accurate in comparison with mGFR and a low value on the comparison of performance characteristics across different over the age of 2 years. equations. The key points are to use an equation validated in In the KDIGO 2012 Clinical Practice Guideline for the and most suited to the population of interest.
----------------------------------------------------------------------


======================================================================
CHUNK 338 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_64
Content Type: recommendation
Words: 488
Medical Entities: CKD,GFR,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
equations. The key points are to use an equation validated in In the KDIGO 2012 Clinical Practice Guideline for the and most suited to the population of interest. Evaluation and Management of Chronic Kidney Disease, 1 a cutoff of 60 ml/min per 1. 73 m2 was chosen to define low Keyinformation GFR for children. In this update, we advise increasing the Balance of benefits and harms. This recommendation reccutoffto90ml/minper 1. 73m2forchildrenandadolescents. ognizes that there are now a number of validated GFR estiIn children and adolescents, a reduced GFR is likely to mating equations available. They have differing performance deteriorate further and, therefore, warrants closer monitoring characteristics, whichmaydifferdependingonthepopulation andearlyintervention. Childrenwithlower-than-normalGFR of interest. The intention of suggesting the use of the same oftenexperiencedeteriorationinGFRduring periodsofrapid equation within a region is to reduce clinical confusion if growth in adolescence. 224 Those with subnormal GFR during people with CKD go to different laboratories withina region adolescence are more likely to eventually experience clinically and to enable appropriate population comparisons. Use of important low GFR later in life. Even mild decreases in different equations (and thus different eGFR values for the eGFR (i. e. , CKD G2) are associated with poor kidney same person) may lead to confusion for both the individual outcomes. In a US study of over 7 million children captured person and their healthcare providers. by electronic health record data, 8600 had CKD G2. At 10 The Work Group judgedthatthere is potential for harm if years from cohort entry, the rate of reaching kidney failure people get different eGFR values when receiving care in or a 50% decline in eGFR ranged from around 10% different settings. As described in Section 1. 2. 2, there are (nonglomerular CKD) to around 40% (glomerular CKD). 225 several sources of variability in eGFR. Differences between Furthermore, eGFR between 60 and 90 ml/min per 1. 73 m2 valid equations are often substantially less than these sources is sometimes associated with impaired linear growth and of variability, but that might not be understood by most with hyperparathyroidism in children and adolescents. 226, 227 healthcare providers or people, leading to excessive anxiety A higher cutoff defining low GFR for children and adoand repeated testing for small changes in GFR as related to lescents also reflects their longer life expectancy. Early interthe use of a different GFR estimating equation. Using the vention may have profound protection of GFR. CKD G2 has same equation within the same geographical region can long been considered to reflect decreased GFR in children, eliminate the source of variation that is related to the specific reflected by the inclusion of children and adolescents with parameters of the GFRestimating equation. CKDG2inpediatricCKDtrialsandcohortstudies, including Thereisbenefittoclinicalcare, research, andpublichealth EffectofStrictBloodPressureControlandACEInhibitionon with the use of validated equations such that decisions, the Progression of CRF in Pediatric Patients (ESCAPE), 228 researchfindings, andpublicpolicyareinformedbyaccurate Hypertension Optimal Treatment in Children with Chronic estimates of CKD. Kidney Disease (HOT-KIDS; United Kingdom), 229 CKiD Certainty of evidence.
----------------------------------------------------------------------


======================================================================
CHUNK 339 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_65
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
CKDG2inpediatricCKDtrialsandcohortstudies, including Thereisbenefittoclinicalcare, research, andpublichealth EffectofStrictBloodPressureControlandACEInhibitionon with the use of validated equations such that decisions, the Progression of CRF in Pediatric Patients (ESCAPE), 228 researchfindings, andpublicpolicyareinformedbyaccurate Hypertension Optimal Treatment in Children with Chronic estimates of CKD. Kidney Disease (HOT-KIDS; United Kingdom), 229 CKiD Certainty of evidence. This recommendation is based on (North America), 230 KoreaN cohort study for outcomes in WorkGroupconsensusregardinggoodclinicalpracticetouse people with pediatric CKD (KNOW-PedCKD; South a GFR estimating equation validated in the population of Korea), 231 and the Kids with CKD (KCAD; Australia and interest. Table 13 lists criteria for validated equations. New Zealand). 232 The definition of CKD remains Thecriteriaweredevelopedbyaccumulatedevidencefrom unchanged; the flagging of GFR 90 ml/min per 1. 73 m2 as assessment of the performance of eGFR versus mGFR across low for children and adolescents reflects the need for closer equations and populations. For example, use of equations assessment for evidence of kidney damage and monitoring. developed using assays that are not traceable to reference S186 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table13CriteriaforavalidatedGFRestimating equation Criteria Consideration DevelopedusingrigorousmeasuredGFR(mGFR)methods; ideallyusingcomparablemeasurementsfor Developmentmethods allindividualsinthedevelopmentpopulations Developedusingassaysforfiltrationmarkerstraceabletoreferencematerialswithacceptableaccuracy Developmentmethods andimprecision Developedwithsufficientsamplesizeforthepopulation Developmentpopulation StudypopulationswithawiderangeofclinicalcharacteristicsandGFR, wherepossiblerepresentative Developmentpopulation oftheclinicalpopulationsinwhichequationsaretobeapplied, includingrepresentativesamples ofgeneralpopulationandpeoplewithkidneydisease Performancevs. mGFRevaluatedinseparatepopulationsfromthatinwhichitwasdeveloped Accuracy (i. e. , externalvalidation, notrandomsplitofdevelopmentdata) Performanceshowscertainthresholdsforperformancecomparedwithotherequations(seeTable15) Accuracy Canbereportedbylaboratories(i. e. , noothervariablesrequiredforcomputationthatare Implementationbyclinicallaboratories notreadilyavailable) GFR, glomerularfiltrationrate. materials cannot be applied to settings with differences in CKD, and other healthcare providers is also required, which assays, 233 or use of equations developed in one population incursbothdirectandindirectcosts. Therewillbecosts, both may not perform well in other populations with very humanresourceandmeetingscosts, associatedwithdecisiondifferent characteristics. 153, 234, 235 makingaroundwhichequationtouse. Additionalcostswillbe Values and preferences. There are now several valid equaaccruedifvalidationandimpactstudiesarerequired. tions that can be reasonably used in local settings. The Work Considerationsforimplementation. Eachregionshouldhave Group recognizes that different values and preferences may a mechanism for review and selection of equations for lead to different decisions in selection among validated GFR implementation by laboratories. For most countries, this estimating equations. Thus, instead of being prescriptive, we might be through the national kidney society working in list a set of criteria that defines a valid equation, a set of collaboration with laboratory physician organizations or equationsconsideredvalidatthistime, andalistofmetricsto regional laboratory groups, as has occurred in the United define better versus worse performance as evaluated in the StatesandEurope, respectively. 236, 237Decisionsatthislevelby localarea. ItisofvaluethatGFRthresholdsfordefinitionand continental or national organizations are likely to minimize stagingbestandardizedusingvalidequationsoptimizedfora the likelihood that decisions for equation use will be made specific region helps to ensure this occurs. Where possible, within small geographical areas or governed by local inclusion of representation from key constituents in the decisions, leading to greater variation in eGFR and population in the development of the equation and ensuring uncertainty by people with CKD and healthcare providers. that it remains valid in those populations is also of value. Considerations in decisions about implementation will Using validated eGFR equations improves the accuracy of reflect the balance of the criteria listed in Table 13. assessment of true GFR but remains imperfect, and no single There are likely to be tradeoffs between optimal accuracy equationperformsconsistentlyacrossallpopulations. TheWork in local regions versus uniformity.
----------------------------------------------------------------------


======================================================================
CHUNK 340 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_66
Content Type: recommendation
Words: 485
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Considerations in decisions about implementation will Using validated eGFR equations improves the accuracy of reflect the balance of the criteria listed in Table 13. assessment of true GFR but remains imperfect, and no single There are likely to be tradeoffs between optimal accuracy equationperformsconsistentlyacrossallpopulations. TheWork in local regions versus uniformity. Equations optimized for a GroupjudgedthatpeoplewithCKDandtheirhealthcareprospecificregioncanhelptoensurethattheGFRthresholdsfor viderswouldwantGFRestimatedusingtheequationproviding disease definition, classification, and risk estimation have the the greatest accuracy in the population of their geographical same implications across regions. However, it would lead to region. TheWorkGrouprecognizesthatacrosstheworldthereis barriers to implementation, as it will not be possible for all significant variation in the sociodemographic and ethnic regions to conduct a sufficiently large and representative makeupofpopulationsandthatevenwell-validatedequations study to evaluate these equations and develop modifications. developedindifferentpopulationsmaynotperformaswellas If not possible, or in the interim, we advise using equations othersdevelopedandvalidatedinthepopulationofinterest. that were developed in populations most similar to the Resource use and costs. Thereareanumberofinitialcosts available populations. For example, until more accurate reincludinghumanresourcecostsassociatedwithtakingthetime gion-specific equations are available in countries within to decide on which equation, then time and technical inforCentralorSouthAmerica, itmaybereasonable touseCKDmationresourcestobeconsideredtochangethecomputation, EPIgiventheinclusion ofBlackandHispanicparticipantsin and the laboratory and nephrology teams to test the new thedevelopmentofequation, andwithinAfricancountries, to equation and inform the clinical partners on the change. In use the EKFC equations using the Q-values, the median SCr addition, education for primary care providers, people with concentrationinacohortdevelopedin2Africancountries. 234 KidneyInternational(2024)105(Suppl4S), S117S314 S187 chapter 1 www. kidney-international. org However, other considerations may also be relevant for the creatinine equation had a Q-value developed from Belgium regional organization making these decisions. We also note and Sweden but was validated in 7 European studies and is that if cystatin C is available, then using eGFRcr-cys would recommended for use in White Europeans. 240 They have simplify the selection of the equation as the performance of recently published Q-values for Black Europeans developed eGFRcr-cys computed from the different equations is more from a cohort of 90 kidney donors in Paris and for Black similar than that of eGFRcr. Africans developed from 2 cohorts in Rpublique Dmocratique de Congo Cote DIvoire. The EKFC cystatin C Rationale equation includes only age and cystatin C, that is, it does not The KDIGO 2012 Clinical Practice Guideline for the Evaluinclude sexor race. The Q-value forcystatin C was developed ation and Management of Chronic Kidney Disease recomin a White cohort in Uppsala, Sweden. The cystatin Cbased mendedtoreporteGFRcrinadultsusingthe2009CKD-EPI EKFC equation has beenvalidated in White Europeans, Black creatinine equation. An alternative creatinine-based GFR Europeans, White Americans, and Black Africans. To increase estimating equation is acceptable if it has been shown to accuracy and precision, EKFC recommends averaging improve accuracy of GFR estimates compared to the 2009 creatinine and cystatin C to obtain an estimate of GFR that CKD-EPI creatinine equation. We are updating this recomincludes both filtration markers. eGFRcr-cys (the average of mendation to accommodate the availability of alternative the EKFC creatinine and EKFC cystatin C) also provides the equations that also have high levels of accuracy.
----------------------------------------------------------------------


======================================================================
CHUNK 341 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_67
Content Type: recommendation
Words: 481
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
We are updating this recomincludes both filtration markers. eGFRcr-cys (the average of mendation to accommodate the availability of alternative the EKFC creatinine and EKFC cystatin C) also provides the equations that also have high levels of accuracy. Since the mostaccurate estimates, consistentwith the findings ofCKDpublication of the KDIGO 2012 Clinical Practice Guideline EPIeGFRcr-cys. for the Evaluation and Management of Chronic Kidney DisIn both the CKD-EPI and EKFC external validation dataease1 for GFR estimation in adults, there have been 3 main sets, thereareconsistentfindingsthattheeGFRcr-cysprovides sources of validated equations: those developed by the improved performance in estimating mGFR compared with CKD-EPI, those developed by EKFC, and modifications of the respective creatinineor cystatin-only equations. This reeach for use in specific regions (Table 1483, 91, 147, 148, 235, 238 inforcestherecommendationinSection1. 2. 1emphasizingthe 243). Table 15 lists thresholds for key performance metrics greater use of eGFRcr-cys for decisions that require GFR. that can be used to guide comparison between equations. There have been several modifications to the CKD-EPI The CKD-EPI Research Group developed equations for equationsforuseinindividualcountries, includingChina, Japan, estimatingGFRfromcreatinine, cystatinC, andthecombination andPakistan. 83, 153, 235Weexpectcountry-specificmodifications of both, with and without inclusion of a coefficient for Black ofbothCKD-EPIandEKFCtocontinuetobedeveloped. One race. TheconcernsaboutthecontinueduseofraceinGFRthat recent study in China reported no clinically meaningful led to the removal of the race coefficient are described in the difference in the performance of the Asian-modified CKD-EPI rationalethatfollowsPracticePoint1. 2. 4. 2. The2009CKD-EPI andEKFCequationscomparedwithmGFR. 244 creatinineequationincludescreatinine, age, race, andsex. 238The Studies vary in their consistency and precision. Direct 2021CKD-EPIcreatinineequationwasrefittedwithoutraceand comparisons of available estimating equationsin populations includes creatinine, age, and sex. 147 As a consequence of not with worldwide applicability are lacking, and so too are including the Black race coefficient, the 2021 CKD-EPI validation studies comparing equations against mGFR in all creatinine equation leads to a small overestimate of GFR in populationsofinterest. Theoverallcertaintyoftheevidenceis non-Black individuals and a small underestimate in Black therefore low but where the performance characteristics of individuals. The 2009 CKD-EPI creatinine equation is more GFR estimating equations in the population of interest are accurate than the 2021 CKD-EPI creatinine equation in the known, therearedatatosupporttheuseofoneequationover non-Blackracegroup, asindicatedbythepercentageofeGFRs another for improved accuracy of GFR reporting. within30%ofmGFR(P ), althoughthechangeinthelevelof 30 accuracy is small compared with the known variability in Practice Point 1. 2. 4. 2: Use of race in the computation of mGFRandeGFR, andP remainsatthelevelconsistentwith eGFR should be avoided. 30 recommended targets as indicated in prior CKD guidelines Estimating equations for GFR have historically incorpo- (Table 1483, 91, 147, 148, 235, 238243 Section 1. 2. 2, Figure 12174). 1, 147 rated demographic variables of age, sex, and race to explain The 2021 CKD-EPI eGFR creatinine-cystatin C equation that variation in serum concentrations of endogenous filtration includes both filtration markers but does not include a term markers that are unrelated to GFR, thereby minimizing sysforBlackraceleadstoimprovedaccuracyinbothracegroups, tematic errors in subgroups defined by these variables and with less difference between race groups in all metrics. The systematic differences between groups.
----------------------------------------------------------------------


======================================================================
CHUNK 342 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_68
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The systematic differences between groups. EKFCdevelopedequationsforestimatingGFRfromcreatinine Age, sex, and race variables were included in the 2009 and cystatin C. 91, 240 Before implementation in other regions, CKD-EPI equation as previous studies indicated higher the authors recommended that local regions specify averageSCrforthesamemGFRlevelinpeoplewhoareolder population-specific Q-values for the creatinine-based EKFC versus younger, males versus females, and people who are equation, whichisthenormallevelofcreatinineinthatregion. Black versus non-Black. Incorporation of these variables TomaketheSCr-basedEKFCequationapplicableforchildren, minimized systematic errors in groups and systematic difage-adjusted Q-values were defined. The original EKFC ferences between groups. 147, 245 Similarly, subsequent to the S188 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table14Validated GFRestimating equations Equationnameand Marker year Age Variables Developmentpopulations Creatinine CKD-EPI2009238 18; modification DevelopedusingA, S, Rbut 8254BlackandNBindividualsfrom10studies CKD-EPI40for reportednotusingtheBlack intheUnitedStatesandEuropea pediatricavailable racecoefficient, A, S, R(NB) CKiDU252021239 125 A, S, height 928childrenwithCKDintheUnitedStatesand Canada CKD-EPI2021147 18 A, S 8254BlackandNBindividualsfrom10studies intheUnitedStatesandEuropea EKFC2021240 2100 A, S, EuropeanBlackandNB mGFRvs. SCr(11, 251participantsin7studies specificQ-value; separate inEuropeand1studyfromtheUnitedStates) Q-valuesforAfricavs. Europe NormalGFRfrom5482participantsin12studies ofkidneydonorcandidates(100%Caucasian) EuropeanNBQfrom83, 157laboratorysamples (age240years)in3Europeanhospitalclinical laboratories; EuropeanBlackQ-value(N90 livingkidneydonorsfromParis); AfricanBlack Q-value(N470healthyindividualsfrom RpubliqueDmocratiquedeCongo); All Q-valuesdevelopedincohortsindependent forEKFCdevelopmentandvalidation LundMalmRevised A, S 3495GFRexaminationsfrom2847adultsfrom 2014241 SwedenreferredformeasurementofGFR CKD-EPI2009 18 A, S 589peoplewithdiabetesfromtheThirdAffiliated Modifiedfor HospitalofSunYat-senUniversity, China China2014b, 242 CKD-EPI2009 18 A, S 413hospitalizedJapanesepeoplein80medical Modifiedfor centers Japan2016b, 83 CKD-EPI2009 18 A, S 542randomlyselectedlow-tomiddle-income Modifiedfor communitiesinKarachiand39peoplefrom Pakistan2013b, 235 thekidneyclinic CystatinC CKD-EPI2012148 18 A, S 5352BlackandNBindividualsfrom13studies intheUnitedStatesandEurope EKFC202391 18100 A mGFRvs. SCys(assumedtobethesameas mGFRvs. SCr) NormalGFR(sameasfortheSCrequation) Qfromlaboratorysamplesfrom227, 643(42% female)laboratorysamplesfromUppsala UniversityHospital, Sweden CAPA2014243 A, S 4690individualswithinlargesubpopulationsof childrenandAsianandCaucasianadults CreatinineCKD-EPI2012148 18 DevelopedusingA, S, Rbut 5352BlackandNBindividualsfrom13studies cystatinC reportednotusingtheBlack intheUnitedStatesandEurope racecoefficient, A, S, R(NB) CKD-EPI2021147 18 A, S 5352BlackandNBindividualsfrom13studiesin theUnitedStatesandEurope AverageofEKFCcr 2 A, S, Europeanracespecific SeeaboveforEKFCcreatinineandcystatinC andcys240 Q-value; separateQ-values forAfricavs. Europe A, age; CAPA, CaucasianandAsianpediatricandadultsubjects; CKD, chronickidneydisease; CKD-EPI, ChronicKidneyDiseaseEpidemiologyCollaboration; CKiD, chronic kidneydiseaseinchildren; cr, creatinine; cys, cystatinC; EKFC, EuropeanKidneyFunctionConsortium; GFR, glomerularfiltrationrate; mGFR, measuredglomerularfiltration rate; NB, non-Black; Qvalues, medianlevelofserumcreatinineorcystatinCinagivenpopulationwithoutchronickidneydisease; R, race; S, sex; SCr, serumcreatinine; SCys, serumcystatinC; U25, under25yearsold. aAlsoincluded100Asiansand353HispanicorNativeAmericans. bModifiedfromCKD-EPIorMDRD; modificationsmayreflectsystematicdifferencesinmeasurementofcreatinineandmGFRaswellaspopulationdifferencesinnon-GFR determinantsofcreatinine. KidneyInternational(2024)105(Suppl4S), S117S314 S189 chapter 1 www. kidney-international. org Table15Criteriaforequationcomparisonforcomparisonof ExamplesofvalidatedequationsincludetheCKiDunder25 candidateequations toanother(i. e. , howtodetermine years old (U25) 2021 eGFRcr equation, the EKFC, and the validity) CKD-EPI40. The Work Group judged that many healthcare Criteria Consideration providerswouldchoosetheCKiDU252021eGFRcrequation given it was derived in a multiracial cohort of children with Systematicerror(bias): absolutemagnitude Small5 oftheabsolutevalueofthemedian Moderate510 CKDandhasbeenexternallyvalidatedincohortswithreduced differencemedian(eGFRmGFR) Large10 and normal GFR. The performance of the CKiD U25 2021 eGFRcrequationisuncertainintheveryyoung, thosewithvery Precision: IQRofthedifferencebetween Small10 eGFRandmGFR Moderate1020 low GFR, or in populations outside of Europe and North Large20 America. 257 An alternative height/sex/age/creatinine-based GFRestimatingequationisacceptableifithasbeenshownto Accuracy: P 30 (percentageofestimates Optimal90 improve accuracy of GFR estimates in the population of within30%ofmGFR) A Po cc o e r p ta 8 b 0 le8090 interest (Table 1483, 91, 147, 148, 235, 238243). The EKFC equation has beenvalidated in a large cohort of European children (N eGFR, estimatedglomerularfiltrationrate; IQR, interquartilerange; mGFR, measured glomerularfiltrationrate.  1254), as well as in adults. 240 Of interest, the EKFC Unitsforsystematicerror(bias)andIQRareml/minper1. 73m2andforunitsforP30 equation in children is the same as in adults. Thus, both arepercentages. Equationsthathavelargeerror(bias)orIQR, orlowP30havepoor CKiD U25 and EKFC allow a GFR estimation for children performance. with CKD without changes in calculated eGFR at the initial publication, the EKFC equation also included as transition between adolescence and young adulthood.
----------------------------------------------------------------------


======================================================================
CHUNK 343 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_69
Content Type: recommendation
Words: 482
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
73m2andforunitsforP30 equation in children is the same as in adults. Thus, both arepercentages. Equationsthathavelargeerror(bias)orIQR, orlowP30havepoor CKiD U25 and EKFC allow a GFR estimation for children performance. with CKD without changes in calculated eGFR at the initial publication, the EKFC equation also included as transition between adolescence and young adulthood. In separate Q-values, the median SCr concentration for Black childrenwithneurologicaldisorders, muscle wasting, or who Europeans from Paris and Africans from Cote DIvoire and have metabolic disorders and are on a very lowprotein diet, Democratic Republic of the Congo. 91 acystatinCbasedequationislikelymoreappropriate. Racediffersfromageandsex, asrace(andethnicity)isdy1. 3 Evaluation of albuminuria namic, shapedbygeographic, cultural, andsociopoliticalforces, and thus the definition canchange across geography andover Albuminuria refers to abnormal loss of albumin in the urine time. 246, 247 Consistent with this, in the past several years, (urineACR30mg/gor3mg/mmol). Albuminisonetype inclusion of race in GFR estimating equations, along with of plasma protein found in the urine in normal subjects and other algorithms in medicine, faced increasing scrutiny, inlargerquantityinpeoplewithkidneydisease. IntheKDIGO particularly in the United States but also elsewhere in the 2012 Clinical Practice Guideline for the Evaluation and world. 248254Concernsincluded, first, raceisasocialandnota ManagementofChronicKidneyDisease, 1clinicalterminology biologicalconstruct, andthus thedefinitionofaracegroup is was changed to focus on albuminuria rather than proteinuria subjecttochangeovertime. Second, usingabinaryvariableto as albumin is the principal component of urinary protein in assignracegroupsignoressocialandbiologicaldiversitywithin mostkidneydiseases. Epidemiologicdatademonstrateastrong and among people with similar racial background groups. relationship between the quantity of urine albumin with both Third, there are differences across countries and regions in kidney and CVD risk and observed CVD even at very low self-reported race and ethnicity, thus leading to uncertainty as levels, and assays to measure albumin are more precise and tohowtoapplytheterm, andblanketusecanleadtoerror. sensitive than assays to measure urine protein. We refer to Thus, even though the inclusion of an indicator for race albuminuria or urine albumin when discussing general group leads to improved accuracy compared with mGFR in conceptsandwillrefereithertototalprotein, albumin, orother somestudies, theseconcernsandotherconsiderationsledtothe specificproteinswhendiscussingthatparameterspecifically. 2021recommendationforitnottobeusedinthecomputation of eGFR in the United States. 255 Other countries have also 1. 3. 1Guidance forphysicians andother healthcareproviders recognized that race should not be included in computation and elected to use the CKD-EPI 2009 age, sex, racenonPractice Point 1. 3. 1. 1: Use the following measurements for Black, as the population of people who are Black was initialtestingofalbuminuria(indescendingorderofprefersufficiently small to not warranterror forother groups. 236, 256 ence). In all cases, a first void in the morning midstream We recognize that specific countries or regions (e. g. , Japan sampleispreferredinadultsandchildren. and Thailand) have developed region-specific equations. 153 (i) urine ACR, or Weadvocateformodifyingequationsbasedonthepopulation (ii) reagent strip urinalysis for albumin and ACR with beingtested. automated reading. Ifmeasuringurineprotein, usethefollowingmeasurements: Specialconsiderations (i) urine protein-to-creatinine ratio (PCR), Pediatricconsiderations. (ii) reagent strip urinalysis for total protein with autoPractice Point 1. 2. 4. 3: Estimate GFR in children using mated reading, or validated equations that have been developed or validated (iii) reagent strip urinalysis for total protein with in comparable populations. manual reading. S190 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 344 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_70
Content Type: reference
Words: 495
Medical Entities: GFR,proteinuria,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
(ii) reagent strip urinalysis for total protein with autoPractice Point 1. 2. 4. 3: Estimate GFR in children using mated reading, or validated equations that have been developed or validated (iii) reagent strip urinalysis for total protein with in comparable populations. manual reading. S190 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 Table16Factors causingbiological variation inurine albuminorurineprotein Factor FalselyelevatedACRorPCR FalsedecreaseinACRorPCR Variabilityinurine albuminorprotein Hematuria Increasesalbuminandproteinintheurine Menstruation Increasesalbuminandproteinintheurine Exercise259 Increasesalbuminandproteinintheurine Infection260, 261 Symptomaticurinaryinfectioncancause productionofproteinfromtheorganism Nonalbuminproteins Otherproteinsmaybemissedbyalbuminreagentstrips Variabilityinurinary creatinineconcentration Biologicalsex Femaleshavelowerurinarycreatinineexcretion, Maleshavehigherurinarycreatinineexcretion, thereforehigherACRandPCR thereforelowerACRandPCR Weight73, 160 Lowurinarycreatinineexcretionconsistentwithlow Highurinarycreatinineexcretionconsistentwithhighweight weightcancausehighACRorPCRrelativeto cancauselowACRorPCRrelativetotimedexcretion timedexcretion Changesincreatinine LowerurinarycreatinineexcretionwithAKI Highurinarycreatinineexcretionwithhigh-proteinintake excretion orlow-proteinintake orexercise ACR, albumin-to-creatinineratio; AKI, acutekidneyinjury; PCR, protein-to-creatinineratio. Practice Point 1. 3. 1. 2: Use more accurate methods when (effectively tubular and overproduction) proteinuria to be albuminuria is detected using less accurate methods. missed. The significance of this issue is thought to be low in (cid: 3) Confirm reagent strip positive albuminuria and/or proadults. 258261 teinuria by quantitative laboratory measurement and Inhealth, relativelysmallamountsofalbumin(30mg/24 express as a ratio to urine creatinine wherever possible hours) are lost in the urine. Urine albumin measurement (i. e. , quantify the ACR or PCR if initial semiquantitative provides a more specific and sensitive measure of changes in tests are positive). glomerular permeability than urinary total protein. 262264 (cid: 3) Confirm ACR 30 mg/g (3 mg/mmol) on a random Thereisevidencethaturinaryalbuminisamoresensitivetest untimed urine with a subsequent first morning void in to enable the detection of glomerular pathology associated the morning midstream urine sample. with some other systemic diseases including diabetes, hypertension, and systemic sclerosis. 265268 Practice Point 1. 3. 1. 3: Understand factors that may affect Total protein measurement is problematic in urine due to interpretation of measurements of urine albumin and imprecision and insensitivity at low concentrationsrelatively urine creatinine and order confirmatory tests as indicated largeincreasesinurinealbuminlosscanoccurwithoutcausinga (Table 16). significantmeasurableincreaseinurinarytotalprotein, 264large The practice point advocating for the use of spot samples sample-to-samplevariationintheamountandcompositionof measuring albumin or protein greatly facilitates its incorpoproteins, high and variable concentrations of nonprotein ration into clinical practice by avoiding the need for timed interfering substances relative to the protein concentration, urine collections. Such spot samples can overor underestiand high inorganic ion content. Most laboratories currently mate urine albumin duetovariationin dilution. Use of ACR use either turbidimetry or colorimetry269 to measure total or protein-to-creatinine ratio (PCR) in spot urine samples protein. Thesemethodsdonotgiveequalanalyticalspecificity can decrease this error. ACR is an estimate of total urine aland sensitivity for all proteins, with a tendency269271 to react bumin loss. The creatinine excretion rate varies substantially more strongly with albumin than with globulin and other betweenpeople. ACRorPCRwilloverestimateurinealbumin non-albumin proteins, 272275 and many have significant loss in people with low creatinine excretion and will underinterferences causing falsely high results. 275277 There is no estimate urine albumin or protein loss in people with very reference measurement procedure and no standardized high creatinine excretion. reference material for urinary total protein measurement ThedecisionbypriorguidelineWorkGroupsnottohavea ( The variety of methods and calibrants in sex-specific threshold and to use easy-to-remember values use means that there is inevitably significant betweenregardlessofunitsmayalsoleadtosomemisclassification. On laboratoryvariation.
----------------------------------------------------------------------


======================================================================
CHUNK 345 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_71
Content Type: reference
Words: 500
Medical Entities: CKD,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
reference material for urinary total protein measurement ThedecisionbypriorguidelineWorkGroupsnottohavea ( The variety of methods and calibrants in sex-specific threshold and to use easy-to-remember values use means that there is inevitably significant betweenregardlessofunitsmayalsoleadtosomemisclassification. On laboratoryvariation. 278280 balance, the current Work Group agrees with this approach Studies examining the diagnostic accuracy of tests to giventhe continued underutilization of urine albumin in the quantify urine albumin and other proteins usually compare assessment of CKD. tests with laboratory quantification from 24-hour urine colItis possible that replacing urinary total protein measurelections. Itisgenerallyrecognizedthata24-hoursampleisthe mentwithalbuminmeasurementmaycausenonalbuminuric definitive means of demonstrating the presence of KidneyInternational(2024)105(Suppl4S), S117S314 S191 chapter 1 www. kidney-international. org albuminuria. However, timedsamplesareoftencollectedwith Althoughthereferencepointremainstheaccuratelytimed error. Overnight, firstvoidinthemorning, secondvoidinthe 24-hour specimen, it is widely accepted that this is adifficult morning, or random sample collections are therefore recproceduretocontroleffectivelyandthatinaccuraciesinurinary ommended as first-line tests. 281, 282 Because creatinine collection may contribute to errors in estimation of albumin excretion in the urine is fairly constant throughout the 24and/orproteinlosses. Inpractice, untimedurinesamplesarea hour period, the measurement of ACR (or PCR) allows reasonable first test for ascertainment of albuminuria. A first correction for variations in urinary concentration. 283, 284 morningvoidsampleispreferredbecauseitcorrelateswellwith ACR is a suitable alternative to timed measurement of urine 24-hour albumin and/or protein excretion, has relatively low albumin loss. 285290 PCR on random or early morning intraindividual variability, and is required to exclude the untimed samples shows good diagnostic performance and diagnosisoforthostatic(postural)proteinuria. Arandomurine correlation with 24-hour collection. 281, 291298 sampleisacceptableifnofirstmorningvoidsampleisavailable. We acknowledge that reagent strip devices can have a role Theconcentrationofalbuminorproteininaurinesamplewill insettings whereaccesstolaboratoryservicesmaybelimited be affected by hydration (i. e. , how diluted or concentrated a (see Section 1. 4). urinesampleis), andreportingthealbuminorproteintothe Implementation of first morning voids will be difficult to creatinine ratio will correct for urinary concentration and obtain in most healthcare settings. Nephrology offices could reduceintraindividualvariability. 205, 261, 301, 302 develop protocols to send people with CKD home with a Thereis biological and analytical variability in urine albuurinecollectioncontainerandinstructiononhowtoobtaina minandurineproteinloss. Thereareseveralbiologicalfactors clean catch, which the person brings back before their next thataffecturinealbuminorproteinloss, separatefromkidney visit. Alternatively, obtainingbloodandurinetestsbeforethe disease(Table16). 259Allofthesecanleadtofalsedetectionof next visit can facilitate first morning voids. However, in the CKD or its progression. Thus, positive tests should be absenceofafirstmorningvoid, arandomsamplemaystillbe confirmed, especially inpeoplewithoutrisk factorsforCKD. used. Negative findings in people at high risk for CKD, for Largechangeswouldberepeatedtoconfirmincreasingurine example, wheretheurinesampleisdiluted, canbeconfirmed albumin and urine protein. Chapter 2 discusses the with a subsequent first morning void. Positive findings in magnitudeofchangetobeconsideredarealchangegiventhe peopleatlowriskforCKD, wheretheACRlevelisjustabove knownbiologicalandanalyticalvariability. the threshold where the urine samples are concentrated, can There is also biological variability in urine creatinine also be confirmed with a first morning void. excretion. Changeincreatinineconcentrationintheurinecan The numeric equivalence of ACR in mg/g (mg/mmol) to alsoleadtoobservedchanges inACRorPCR, independently approximately g/d is based on the simple assumption that of changes in protein loss. In general, urine creatinine meacreatinine excretion rate (CER) approximates 1 gram/d (10 surements are less susceptible to factors that interfere with mmol/d). Tobetterestimateurinealbumininindividualswith SCr assays. If a more accurate quantification of albuminuria creatininegenerationthatisverydifferentfromtheaverage, one or total proteinuria is required, measure urine albumin or mightconsidermeasuringatimedurinecollectionifthevalue total protein in a timed collection under supervised condiwouldaffectclinicaldecisions.
----------------------------------------------------------------------


======================================================================
CHUNK 346 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_72
Content Type: recommendation
Words: 499
Medical Entities: proteinuria,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Tobetterestimateurinealbumininindividualswith SCr assays. If a more accurate quantification of albuminuria creatininegenerationthatisverydifferentfromtheaverage, one or total proteinuria is required, measure urine albumin or mightconsidermeasuringatimedurinecollectionifthevalue total protein in a timed collection under supervised condiwouldaffectclinicaldecisions. AswithassessmentofGFRusing tions as recommended above. measuredCrCl, usesupervisedurinecollections. Alternatively, equationsareavailablethatestimatecreatininegenerationfrom Specialconsiderations predictionequationsandthenmultiplythatvaluebytheACRto Pediatricconsiderations. compute an estimated albumin excretion rate (AER) that acPractice Point 1. 3. 1. 4: In children, obtain a first morning commodatesthelowerorhigherlevelofCER. 299, 300 urine sample for initial testing of albuminuria and proMeasurementofurinaryalbuminisrecommendedbecause teinuria (in descending order of preference): it is relatively standardized and because it is the single most (i) Both urine PCR and urine ACR, important protein lost in the urine in most CKDs. Use of (ii) Reagent strip urinalysis for total protein and for urinary albumin measurement as the preferred test for proalbumin with automated reading, or teinuria detection will improve the sensitivity, quality, and (iii) Reagent strip urinalysis for total protein and for consistency of approach to the early detection and managealbumin with manual reading. ment of kidney disease. Consistent with the KDIGO 2012 Clinical Practice Commonly used reagent strip devices measuring total Guideline for the Evaluation and Management of Chronic protein are insufficiently sensitive for the reliable detection of Kidney Disease, 1 PCR is advised and preferred as initial proteinuria, do not adjust for urinary concentration, and are screening for children as the majority of children have onlysemiquantitative. Furthermore, thereisnostandardization underlying developmental abnormalities often referred to as between manufacturers. The use of such strips should be CAKUT and a much higher proportion of children than discouraged in favor of quantitative laboratory measurements adults have tubular pathology. 303 Testing for ACR may miss of albuminuria or proteinuria, or validated point-of-care detubular proteinuria. However, testing exclusively for vicesforurinealbumin/ACR(Section1. 4). Whenused, reagent proteinuria does not allow characterization of the source. If strip results should be confirmed by laboratory testing. urine PCR is used, urine ACR should also be measured to S192 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 better characterize proteinuria. Significant albuminuria ensurethathealthcareprovidersreceiveurineACRreportsin generally reflects glomerular damage. 304 Importantly, in the a consistent style and with assurance regarding the accuracy context of screening for children with diabetes, ACR and reliability of the result. remains the standard, in line with adult guidelines. Measurementofurinealbuminforthedetectionofkidney The same considerations of using first morning samples disease as with any analyte should be with methodology (because of orthostatic proteinuria) and considering trantraceabletointernationalstandardsusingastandardreference siently increased proteinuria during intercurrent illness or material. This is currently not the case, and results may vary after exercise apply to children as well as adults. Orthostatic by greater than 40% between laboratories depending on the proteinuria is estimated to affect 2%5% of adolescents. 305 methodology used with attendant impact on the interpretaAgeandbodysizeareimportantforinterpretingproteinuria tion of reported results. and albuminuria. In term and preterm neonates, PCR is high The type of urine collection and the analytical method (PCR 10003000 mg/g 100300 mg/mmol) in the first days influence result interpretation. Twenty-four-hour urine colandweeksoflife, andisrelatedtoglomerularandtubularlosses lections present problems in terms of completeness of ofproteinfromimmaturenephrons, aswellasverylowcreaticollection, specimen storage, and timing accuracy.
----------------------------------------------------------------------


======================================================================
CHUNK 347 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_73
Content Type: recommendation
Words: 499
Medical Entities: albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
and albuminuria. In term and preterm neonates, PCR is high The type of urine collection and the analytical method (PCR 10003000 mg/g 100300 mg/mmol) in the first days influence result interpretation. Twenty-four-hour urine colandweeksoflife, andisrelatedtoglomerularandtubularlosses lections present problems in terms of completeness of ofproteinfromimmaturenephrons, aswellasverylowcreaticollection, specimen storage, and timing accuracy. Therefore, ninefromlowmusclemass. Recentstudiesoutlineproteinuria the assessment of ACR from a single void is a common and rangesforneonates, includingforpretermandlow-birth-weight convenient clinical practice. The ACR accounts for hydration neonates. Asthetubulesmature, proteinuriaslowlydeclines. In and has similar diagnostic performance to 24-hour urine general, a PCRof 500 mg/g (50 mg/mmol) (or a 24-hour AER. The collection method should remain consistent, prefproteinof150mg/m2/d)isconsiderednormalforinfantsaged erably using the first morning void specimen. 6monthsto2years. Forchildrenover2years, afirstmorning If specimens are being stored for future analysis, careful urinePCRof200mg/g(20mg/mmol)protein, or150mg/ attention must be paid to the storage conditions to avoid m2/d, orafirstmorningurineACR30mg/g(3mg/mmol)is degradationofalbuminleadingtoquantificationerror. Thereusuallyconsiderednormal. 83, 306309Morecomprehensivevalues portedeffectsoffrozenstorageonurinealbuminaresomewhat canbefoundinPediatricNephrology. 310 inconsistent. Albuminisgenerallystableinurinestoredat2 (cid: 4) C8 (cid: 4) C for 7 days. However, lossesof albuminhave beenreported 1. 3. 2Guidancetoclinicallaboratories whenurineisstoredfrozenattemperatureshigherthan(cid: 5)80 (cid: 4) C. Precipitates often form when urine is stored refrigerated or The following comments are focused on the laboratory frozen but can be redissolved onwarming: samples should be assessmentofalbuminuria, ratherthantotalproteinuria, given warmed to room temperature and mixed before analysis. 290 albuminmeasurementisthepreferredapproachtoproteinuria Albumin losses may beaffectedby factors including period of evaluation (Section 1. 3. 1. ) However, some of these practice storage, sample albumin concentration, and individual points (sample type and storage, reporting as a PCR) would variation. 311 It should be possible to provide refrigerated apply equally to total protein measurement practices. storage and process samples for albumin measurement in a laboratorywithin7daysinmosthealthcaresettings. Practice Point 1. 3. 2. 1: Implement the laboratory reporting The internationally accepted laboratory quality standards and handling standards outlined in Table 17 to ensure are variably met worldwide, and laboratories are at different accuracy and reliability of the findings when assessing levelswithrespecttoquality. However, theWorkGroupplaced urine samples. ahighvalueontheaccuracyandreliabilityofquantificationof albuminuriaandjudgedthatpeoplewithCKD, theirhealthcare Practice Point 1. 3. 2. 2: Implementation of an external providers, and policy makers would want laboratories to achqualityassessmentscheme/programforurinealbuminand ieve these reporting and handling standards. creatinine, including calculation of the ACR, is a preferred Thedirectcostsoftotalproteinmeasurementinurineare practice for laboratories. lower than those of urine albumin. However, total protein Adoption of the reporting and handling standards for measurement lacks sensitivity for the detection of low but assessment of urine samples is of paramount importance to clinicallysignificantlevelsofalbuminuria. Forthis, andother reasonsdiscussedinSection1. 3. 1, themeasurementofACRis Table17Implementation standardsto ensureaccuracy and preferred to that of PCR. reliability ofurinesamples Urine albumin should be measured using immunological assays capable of specifically and precisely quantifying albu- (cid: 3) Samplesforalbuminmeasurementanalyzedfreshorstoredat4(cid: 4)Cfor upto7days min at low concentrations and of producing quantitative re- (cid: 3) Samplesforalbuminmeasurementshouldnotbestoredfrozen sults over the clinically relevant range. The biological at(cid: 5)20(cid: 4)C variation of urine albumin exceeds 60%. Target analytical (cid: 3) ReportACRinuntimedurinesamplesinadditiontourinealbumin variation (CV) should be based on anoptimal levelof 0. 25 concentrationratherthantheconcentrationsalone (cid: 3) Reportingto1decimalplaceforACRwhethermg/mmolormg/g biological variation, approximately 15%. This is in keeping (cid: 3) AnalyticalCVofmethodstomeasureurinealbuminshouldbe15%. with good practice recommendations from the National ACR, albumin-to-creatinineratio; CV, coefficientofvariation.
----------------------------------------------------------------------


======================================================================
CHUNK 348 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_74
Content Type: recommendation
Words: 479
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Target analytical (cid: 3) ReportACRinuntimedurinesamplesinadditiontourinealbumin variation (CV) should be based on anoptimal levelof 0. 25 concentrationratherthantheconcentrationsalone (cid: 3) Reportingto1decimalplaceforACRwhethermg/mmolormg/g biological variation, approximately 15%. This is in keeping (cid: 3) AnalyticalCVofmethodstomeasureurinealbuminshouldbe15%. with good practice recommendations from the National ACR, albumin-to-creatinineratio; CV, coefficientofvariation. Academy of Clinical Biochemistry. 312 KidneyInternational(2024)105(Suppl4S), S117S314 S193 chapter 1 www. kidney-international. org Significant progress has been made in developing a certiThis recommendation places a high value on the advantages fied reference material for urine albumin and a reference of POCTs including convenience, elimination of sample transmeasurement procedure. 313, 314 However, current portation to the central laboratory, minimal sample processing, commercially available assays for urine albumin are not simple analytic process, minimal sample requirement, and imstandardized against this reference material. Laboratories mediate availability of results. It places a lower value on the should ensure that they are enrolled and demonstrate limited and heterogeneous data related to their diagnostic satisfactory performance in, an EQA scheme for urine accuracy. albumin, creatinine, and ACR. Urine albumin (and protein) concentrations in urine Keyinformation should be reported as a ratio to creatinineACR (or PCR). Balance of benefits and harms. POCTs for both creatinine Reporting as a ratio to creatinine corrects for variations in andurinealbuminhaveseveralpotentialbenefits. POCTmay urinary flow rate and enables reporting on untimed, spot lead to earlier diagnosis, and as a result, earlier treatment of samples, obviating the need for timed, including 24-hour, CKD. They may also be used to monitor CKD progression, collections, which are prone to collection error and tedious which enables more timely treatment decisions. The rapid for people to undertake. Reporting albumin as a ratio to reporting, low cost, and convenience to people with CKD creatinine reduces the intraindividual variability in albumincompared with central laboratory testing are also important uriacomparedwithreportingasalbuminconcentrationalone benefitsofPOCTs. However, itsprovisioncanraisechallenges (mg/mmol or mg/g). 315 in relation to maintenance of analytical and diagnostic perTo aid clarity in reporting across and within healthcare formance, and governance arrangements. In addition, these systems, and to provide guidance regarding the number of tests maybe less accuratethan laboratory testing, which may meaningful digitsinaresult, astandardizedapproachshould lead to misdiagnosis, misclassification, overtreatment, or be used in relation to reporting units of ACR and PCR. ACR undertreatment. The balance of benefits and harms needs results should be expressed to one decimal place (mg/mmol) rigorous evaluation specific to each clinical situation. or whole numbers (mg/g). Both enzymatic and Jaffe assays Forcreatinine, theERTidentifiedasystematicreviewfrom are generally suitable for the measurement of creatinine in the National Institute for Health and Care Excellent (NICE)/ urine, although high concentrations of glucose can interfere National Institute for Health Research (NIHR) diagnostic in Jaffe urine creatinine measurement and produce clinically guidelinethatevaluatedpoint-of-carecreatinineteststoassess meaningful errors in ACR. GFR before computed tomography (CT) scanning with contrast media. 316 The ERTalso updated the findings of this 1. 4 Point-of-care testing systematic review. The review from NICE/NIHR identified and qualitatively synthesized data from 54 studies on Recommendation 1. 4.
----------------------------------------------------------------------


======================================================================
CHUNK 349 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_75
Content Type: recommendation
Words: 484
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
GFR before computed tomography (CT) scanning with contrast media. 316 The ERTalso updated the findings of this 1. 4 Point-of-care testing systematic review. The review from NICE/NIHR identified and qualitatively synthesized data from 54 studies on Recommendation 1. 4. 1: We suggest that point-ofdiagnostic accuracy: eGFR diagnostic accuracy (n  12), care testing (POCT) may be used for creatinine and SCr diagnostic accuracy (n  7), and correlation and bias urine albumin measurement where access to a labof POC creatinine tests compared with laboratory-based oratoryislimitedorprovidingatestatthepoint-oftests (n  50). One study317 was identified in the update of care facilitates the clinical pathway (2C). the NICE/NIHR review assessing POC creatinine test compared with laboratory standards in a pediatric Practice Point 1. 4. 1: Whenever a POCT device is used for population with malaria in Uganda. creatinineand urine albumin testing, ensurethat thesame These studies covered 3 types of devices: StatSensor, ipreanalytical, analytical, and postanalytical quality criteria STAT, andABLdevices. Ingeneral, all3devicesdemonstrated relating to the specimen collection and performance ofthe acceptableaccuracyatlowerlevelsofeGFR(30ml/minper device, including external quality assessment, and the 1. 73m2). 316Resultsshowedthati-STATandABLdevicesmay interpretation of the result is used. havehigherprobabilitiesofcorrectlyclassifyingpeopleinthe same eGFR categories as the laboratory reference than Practice Point 1. 4. 2: Where a POCT device for creatinine StatSensor devices. testing isbeing used, generate an estimate of GFR. Use the For albumin, the ERT identified a systematic review pubequation consistent with that used within the region. lished in 2014, by McTaggart et al. , 318 that evaluated the diagnostic accuracy of quantitative and semiquantitative PracticePoint1. 4. 3: WhereaPOCTdeviceisbeingusedfor protein or albumin urine dipstick tests compared with albuminuria testing, the capability of also analyzing laboratory-based tests among people with suspected or creatinine and producing an ACR is important. Assess the diagnosed CKD. The ERT included relevant studies from ability of the POCT ACR devices to produce a positive this review and conducted an update. result in85% of people with significant albuminuria (ACR Sixty-five studies (in 66 articles)319344, 345368, 369384 eval- 30 mg/g or 3 mg/mmol), as part of the evaluation and uated the accuracy of quantitative and semiquantitative proconsideration of using the device. tein or albumin dipstick tests in a general population not on S194 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 1 KRT or receiving end-of-life care. Studies addressed the pathway, for example, through more rapid disease detection following critical outcomes: measurement bias (n  1), or avoidance of hospital referral. analytical variability (n  5), analytical sensitivity (n  2), Considerations for implementation. POCTs may not be and analytic specificity (n  63) (Supplementary Table available everywhere. Support from the local laboratory serS5336, 347, 363, 372, 373, 377, 382384). Specificity ranged from 17. 5 to vice should be sought to guide the purchase, evaluation, 99. 5 when evaluative ACR 30 mg/g (3 mg/mmol) and implementation, governance, and ongoing quality assurance 30. 098. 7 when evaluative ACR 300 mg/g (30 mg/ ofPOCT. Theabilitytotestcreatinineinapersonshomemay mmol). For PCR, specificity ranged from 80. 896.
----------------------------------------------------------------------


======================================================================
CHUNK 350 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_76
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
5 to vice should be sought to guide the purchase, evaluation, 99. 5 when evaluative ACR 30 mg/g (3 mg/mmol) and implementation, governance, and ongoing quality assurance 30. 098. 7 when evaluative ACR 300 mg/g (30 mg/ ofPOCT. Theabilitytotestcreatinineinapersonshomemay mmol). For PCR, specificity ranged from 80. 896. 9 when have applicability to virtual ward settings (hospital at evaluative PCR 200 mg/g (20 mg/mmol) and 75. 695. 2 home). when evaluative PCR 500 mg/g (50 mg/mol). It is worth noting that for albuminuria testing, the NaThe evidence regarding the performance of POCT for tional Academy of Clinical Biochemistry has proposed that creatinine and urine albumin is heterogeneous limiting the devices should have 95% sensitivity for the detection of determination of overall findings across these critical outalbuminuria. 312ThisisnotalwaysachievedbyPOCTdevices, comes. However, given the cost-effectiveness benefits, availespecially those that produce semiquantitative results. 318 abilityofthetestintheabsenceoflaboratorystudies, andthe acceptable test performance, the Work Group judged that in specific clinical scenarios, POCTshould be used. Rationale POCTcanbecarriedoutinawiderangeofsettingsincluding Certainty of evidence. The certainty of evidence for POCT primary care, community clinics, rural communities, and for creatinine testing was rated as low due to consistent secondary care supporting timely diagnosis, monitoring, and reporting of reference standards across all outcomes, with some concerns regarding patient selection and flow and treatment. Importantly, inlocationswherelaboratoryservices may be limited or nonexistent (e. g. , rural and remote comtiming and directness of the evidence. The certainty of evimunities), the ability to test versus not testing blood and dence regarding performance of all POCT for urine albumin urine was important. Advantages of POCT include convewas very low based on the Quality Assessment of Diagnostic nience, elimination of sample transportation to the central Accuracy Studies (QUADAS-2) assessment of individual studies due to sparse data, heterogeneous findings, and conlaboratory, minimalsampleprocessingbecausetheanalysisis of whole blood/urine, simple analytic process, minimal cerns about patient selection, index tests, and unclear sample requirement, and immediate availability of results. reporting of the reference standards. However, thesetestsmaybepronetoerrorsandinaccuracies. Values and preferences. The recommendation suggested For these reasons, the recommendation suggests the use of thatthemajorityofpeoplewithCKDwhohavelimitedaccess thesetestsbasedonthespecificclinicalneedorgeographical/ to laboratories would choose to use POCT. These tests may social circumstances. facilitate people with CKD being seen at home or in remote UseofPOCTmayfacilitateaccesstoearlierdiagnosisand, settings. Many people with CKD will value the immediate thus, care and can be implemented in rural and remote loresultsavailablewithPOCTversuswaitingforthetestsfroma cations. The value of POCT for currently underserved poplab. In addition, some people with CKD will place a higher ulationscannotbeoverstatedandshouldincludethecapacity valueonavoidingexpensivelabteststhatmaynotbecovered by their insurance, difficult travel to central healthcare facilfor generating creatinine-based eGFR equations. The POCT devicesusedwouldideallymeasurebothbloodcreatinineand ities, and exposureto infection risk in hospital. These people urine for albumin and creatinine to measure ACR and be with CKD may also place a lower value on the potential standardized and calibrated with similar rigor as is recominaccuracies associated with POCTs compared with in-center mended for laboratory tests. laboratory testing. Resource use and costs. For people with CKD, the use of Specialconsiderations POCTs may be less expensive than tests conducted in a Pediatric considerations.
----------------------------------------------------------------------


======================================================================
CHUNK 351 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_77
Content Type: recommendation
Words: 461
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
laboratory testing. Resource use and costs. For people with CKD, the use of Specialconsiderations POCTs may be less expensive than tests conducted in a Pediatric considerations. The ability to use a small sample clinical laboratory. In areas with limited access to healthcare volume, fingerprick sample asopposedtovenipuncture, may andinsurance, thesetestsmaybecostsavingandincreasethe detection for CKD. 385, 386 For the healthcare system, some have applicability to testing in children. direct reagent and staff costs of POCT tend to be higher on For research recommendations, please see Chapter a per test basis than those of centralized laboratory testing, 6: Research recommendations. but these costs may be offset by other savings in the clinical KidneyInternational(2024)105(Suppl4S), S117S314 S195 chapter 2 www. kidney-international. org Chapter 2: Risk assessment in people with CKD 2. 1 Overview on monitoring for progression of CKD individualized, and informed by the severity of CKD, stage of based upon GFR and ACR categories puberty, and observed recent rate of progression. Practice Point 2. 1. 1: Assess albuminuria in adults, or Practice Point 2. 1. 2: Assess albuminuria and GFR more albuminuria/proteinuria in children, and GFR at least often for individuals at higher risk of CKD progression annually in people with CKD. when measurement will impact therapeutic decisions. Monitoring CKD through the surveillance of albuminuria Previousguidelineshavesuggestedtheroutinemonitoring and GFR serves to update staging for prognosis, identify of albuminuria and GFR. Prior guidelines have suggested timing of intervention strategies, and assess the effectiveness annual monitoring for those with CKD G1G2, every 6 of specific treatments. No clear threshold defines a clinically monthsforthosewithCKDG3, every3monthsforCKDG4, relevant change in GFR or albuminuria, as any worsening andevery6weeksforCKDG5disease. Giventhegreaterrisk could reflect deterioration in kidney health. However, overof disease progression, those with higher risk of disease interpretationofsmallchangesinthesemeasuresmayleadto progression should undergo more frequent monitoring unnecessary changes in clinical management that could be (Figure1329). Morefrequentmonitoringmaybeindicatedin unhelpful or even deleterious. Education for healthcare propeople with changing clinical status, intercurrent events, and viders and people with CKD about the variability of specific after therapeutic interventions to assess response and laboratory measurements in kidney disease is important to adherence and ensure safety. In addition, progression risk facilitate understanding and to mitigate inappropriate may vary by the etiology of CKD within a specific stage changesintreatmentstrategiesduetononclinicallysignificant based on GFR and albuminuria or proteinuria. fluctuations in either positive or negative directions. There is an expected variability in GFR caused by both Practice Point 2. 1. 3: For people with CKD, a change in biological and analytical factors of the biomarkers used eGFR of 20% on a subsequent test exceeds the expected (Figure 12). We have chosen to consider the 95% CI of test variability and warrants evaluation. reproducibility for both eGFR and ACR as an important Within-subject variation in measured and eGFR is well factor for determining thresholds for clinical evaluation. described(Figure12).
----------------------------------------------------------------------


======================================================================
CHUNK 352 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_78
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
We have chosen to consider the 95% CI of test variability and warrants evaluation. reproducibility for both eGFR and ACR as an important Within-subject variation in measured and eGFR is well factor for determining thresholds for clinical evaluation. described(Figure12). Thus, theabilitytodistinguishbetween The initial evaluation of an observed change in either eGFR biological and analytical versus pathological variation in the or ACR should be to repeat the test(s) so as to determine if mGFR and eGFR is important for healthcare providers and the observed change is clinically significant progression of people with CKD. Studies show that intraindividual CKD or is within biological and analytical variability of the biological variation in eGFR is similar across eGFR test. equations: CKD-EPI-creatinine (5. 3% 4. 5%6. 4%), CKDEPI-cystatin C (5. 3% 4. 5%6. 5%), and CKD-EPISpecialconsiderations creatinine-cystatin C (5. 0% 4. 3%6. 2%). The reference Pediatric considerations. Monitoring of children in the perchange value (RCV) is defined as the threshold of change ipubescent phase should be undertaken more frequently than that differs from the individuals prior value with 95% CI; the CKD stagebased recommended frequency of monitoring in a cohort of people with CKD, eGFRcr and eGFRcys had as puberty is a period of high risk of progression. 387 Reasons RCVs ranging from 14%20% in the positive and negative for this are incompletely understood, but potential directions. Although attention to progressive loss of eGFR is mechanisms include inability of diseased kidneys to undergo important, smaller changes in GFR may not be related to the hypertrophy needed to accompany the rapid somatic true changes in kidney health, especially if transient and growth that characterizes puberty and the negative effect of require cautious interpretation. increased levels of sex steroids. 388 A study of over 900 ThresholdsforCKDprogressionusedinclinicaltrialsand children with CKD due to CAKUT showed a decline that epidemiological studiesaredifferent than those suggestedfor was 10 times faster in creatinine-based eGFR after the monitoring of people with CKD. In research studies, 30% period of peak growth than before that period. 388 The CKiD 40%declinesinGFRhavebeenassociatedwithincreasedrisk study (including children with CKD of any cause) showed for kidney failure, and treatment effects on these endpoints more rapid declines in both eGFR (creatinineand cystatin have been associated with changes in risk for kidney failure. Cbased) and mGFR after the period of peak growth velocity Becausetheseareevaluatedatthegrouplevel, smallerrorsin than before. 387 Frequency of monitoring should be individual people with CKD are minimized. S196 KidneyInternational(2024)105(Suppl4S), S117S314 Albuminuria categories Description and range Practice Point 2. 1. 4: Among people with CKD who initiate nondipper who received SGLT2i, except in unusual cases hemodynamically active therapies, GFR reductions of whentheacutedipineGFRwas30%frombaseline. 389, 390 30%onsubsequenttestingexceedtheexpectedvariability Thesefindingswereconsistentacrossallsubgroups. and warrant evaluation. A significant drop in eGFR (30%) while initiating antiAcute eGFR decline after intensive BP control has been hypertensive agents, renin-angiotensin system inhibitors observed in people with CKD, with reductions of 10%20% (RASi), mineralocorticoid receptor antagonists (MRA), or being typical within the first 3 months of treatment. These SGLT2i should prompt a review into other causes and wardeclines in eGFR are hemodynamically mediated, representrantsclosemonitoring.
----------------------------------------------------------------------


======================================================================
CHUNK 353 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_79
Content Type: reference
Words: 458
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
These SGLT2i should prompt a review into other causes and wardeclines in eGFR are hemodynamically mediated, representrantsclosemonitoring. However, healthcareprovidersshould ing a response to BP falling below the lower threshold of a avoid the urge to stop these kidney-protective agents, persons autoregulatory response. For many, this initial particularlybecausetheseearlierdipsaretypicallyreversible decline in eGFR is transient and will stabilize or resolve over and not an indication of drug toxicity. time, asresettingoftheautoregulatoryfunctionoccurs. Thus, acute rises in SCr (or declines in eGFR) of 20%30% are PracticePoint2. 1. 5: Foralbuminuriamonitoringofpeople expected and do not warrant changes in therapeutic agents, with CKD, a doubling of the ACR on a subsequent test which may be important for cardioand kidney-protective exceeds laboratory variability and warrants evaluation. effects in the long term. This phenomenon is especially Small fluctuations in albuminuria or proteinuria levels common when using ACEi/angiotensin II receptor blockers may not indicate disease progression. Appreciation of factors (ARBs), as they both lower BP and alter arteriolar flow that impact albuminuria and changes in the measure is through the glomeruli, and SGLT2i through similar hemoimportant for healthcare providers. Routine surveillance usdynamic mechanisms. ingACRorPCRiswarrantedinhigherriskpeoplewithCKD, PosthocanalysesoftrialsofSGLT2itreatmentinpeoplewith as changes in urine ACR are associated with kidney failure. diabetes, heart failure, and CKD suggested that participants Specifically, in large population studies, a doubling of the with10%initialdropineGFRhavesimilareGFRtrajectories ACRwithina2-yeardurationisassociatedwithanincreasein and kidney benefits from SGLT2i compared with the theriskofprogressiontokidney failureby50%100%. 391, 392 )2m 37. 1/nim/lm( seirogetac RFG egnar dna noitpircseD www. kidney-international. org chapter 2 A1 A2 A3 CKD is classified based on: Normal to mildly Moderately Severely (cid: 129)Cause (C) increased increased increased (cid: 129)GFR (G) 30 mg/g 30299 mg/g 300 mg/g (cid: 129) Albuminuria (A) 3 mg/mmol 329 mg/mmol 30 mg/mmol Screen Treat Treat G1 Normal or high 90 1 1 3 Screen Treat Treat G2 Mildly decreased 6089 1 1 3 Mildly to Treat Treat Treat G3a 4559 moderately decreased 1 2 3 Moderately to Treat Treat Treat G3b 3044 severely decreased 2 3 3 Treat Treat Treat G4 Severely decreased 1529 3 3 4 Treat Treat Treat G5 Kidney failure 15 4 4 4 Low risk (if no other markers of kidney disease, no CKD) High risk Moderately increased risk Very high risk Figure13Frequencyofmonitoringglomerularfiltrationrate(GFR)andalbuminuriainpeoplewithchronickidneydisease(CKD). AlbuminuriaandGFRgridreflectstheriskofprogressionbyintensityofcoloring(green, yellow, orange, red, anddeepred). Thenumbersinthe boxesareaguidetothefrequencyofmonitoring(numberoftimesperyear). ReproducedfromdeBoerIH, KhuntiK, SaduskyT, etal. Diabetes managementinchronickidneydisease: aconsensusreportbytheAmericanDiabetesAssociation(ADA)andKidneyDisease: ImprovingGlobal Outcomes(KDIGO). KidneyInt. 2022; 102: 974989. 29Copyright2022, InternationalSocietyofNephrology, AmericanDiabetesAssociation, and KDIGO. PublishedbyElsevierInc. andAmericanDiabetesAssociation. Allrightsreserved. KidneyInternational(2024)105(Suppl4S), S117S314 S197 chapter 2 www. kidney-international. org Table18Impactofalbuminuria/proteinuria onCKDprogression inpediatrics Study Impactofalbuminuria/proteinuria ESCAPE228 A50%reductionofproteinuriawithinthefirst2monthsoftreatmentinitiationmorethanhalvedtheriskofprogressionofkidney diseaseover5years. Glucketal. 225 Inacohortofover7millionchildren, 0. 1%hadCKDG2orhigher. TherelativeriskofCKDprogression, definedasreachingCKDG5or havinga50%declineineGFR, wasdoubledforthosewhohad1proteinuriaondipstickwithouthypertensionandwas quadrupledforthosewithproteinuriaandhypertensionoveramedianfollow-upof5years. CKiD393 ACRof300mg/g(30mg/mmol)wasassociatedwithan84%higherriskofdiseaseprogressionoveramedianfollow-upof3years comparedwithanACRof30mg/g(3mg/mmol). PCRof630mg/g(71mg/mmol)wasassociatedwithan87%higherriskof diseaseprogressioncomparedwithaPCRof140mg/g(16mg/mmol). 4C EachloghighervalueofACRwasassociatedwitha50%higherriskofkidneyfailureora50%declineineGFRoveramedian study394, 395 follow-upof3years. A115%increaseinalbuminuriawasassociatedwithfasterdiseaseprogressionaftercessationofRASiinchildren withadvancedCKD. ItalKids396 SignificantlyslowerdeclineincreatinineclearanceinpeoplewithbaselinePCRsof200mg/g(23mg/mmol)and200900mg/g (23102mg/mmol)whencomparedwiththosewithaPCRof900mg/g(102mg/mmol). Thistranslatedtohigherratesofkidney survivalover5yearsinthelowerproteinuriagroups: 97%and94%vs. 45%. Indian CKDprogressionriskwithin2yearswastripledforthosewithproteinuria2000mg/g(226mg/mmol). cohort397 Japanese RiskofCKDprogressionwas7timesashighforthosewithproteinuria2000mg/g(226mg/mmol)comparedwiththosewith cohort398 lowerproteinuriaconcentrationsafteradjustmentforCKDstage, hypertension, sex, andage. ACR, albumin-to-creatinineratio; CKD, chronickidneydisease; CKiD, chronickidneydiseaseinchildren; eGFR, estimatedglomerularfiltrationrate; ESCAPE, EffectofStrictBlood PressureControlandACEInhibitionontheProgressionofCRFinPediatricPatients; PCR, protein-to-creatinineratio; RASi, renin-angiotensin-systeminhibitors.
----------------------------------------------------------------------


======================================================================
CHUNK 354 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_80
Content Type: reference
Words: 468
Medical Entities: CKD,GFR,proteinuria,albuminuria,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
1%hadCKDG2orhigher. TherelativeriskofCKDprogression, definedasreachingCKDG5or havinga50%declineineGFR, wasdoubledforthosewhohad1proteinuriaondipstickwithouthypertensionandwas quadrupledforthosewithproteinuriaandhypertensionoveramedianfollow-upof5years. CKiD393 ACRof300mg/g(30mg/mmol)wasassociatedwithan84%higherriskofdiseaseprogressionoveramedianfollow-upof3years comparedwithanACRof30mg/g(3mg/mmol). PCRof630mg/g(71mg/mmol)wasassociatedwithan87%higherriskof diseaseprogressioncomparedwithaPCRof140mg/g(16mg/mmol). 4C EachloghighervalueofACRwasassociatedwitha50%higherriskofkidneyfailureora50%declineineGFRoveramedian study394, 395 follow-upof3years. A115%increaseinalbuminuriawasassociatedwithfasterdiseaseprogressionaftercessationofRASiinchildren withadvancedCKD. ItalKids396 SignificantlyslowerdeclineincreatinineclearanceinpeoplewithbaselinePCRsof200mg/g(23mg/mmol)and200900mg/g (23102mg/mmol)whencomparedwiththosewithaPCRof900mg/g(102mg/mmol). Thistranslatedtohigherratesofkidney survivalover5yearsinthelowerproteinuriagroups: 97%and94%vs. 45%. Indian CKDprogressionriskwithin2yearswastripledforthosewithproteinuria2000mg/g(226mg/mmol). cohort397 Japanese RiskofCKDprogressionwas7timesashighforthosewithproteinuria2000mg/g(226mg/mmol)comparedwiththosewith cohort398 lowerproteinuriaconcentrationsafteradjustmentforCKDstage, hypertension, sex, andage. ACR, albumin-to-creatinineratio; CKD, chronickidneydisease; CKiD, chronickidneydiseaseinchildren; eGFR, estimatedglomerularfiltrationrate; ESCAPE, EffectofStrictBlood PressureControlandACEInhibitionontheProgressionofCRFinPediatricPatients; PCR, protein-to-creatinineratio; RASi, renin-angiotensin-systeminhibitors. However, changes in albuminuria within an individual have emphasizestheRRofadverseoutcomesbylevelsofeGFRand substantial variability, with large fluctuations expected given albuminuria in populations, and encourages healthcare that the 95% CI around repeat ACR testing is providers to classify those people with CKD as high risk for approximately 50%. For this reason, the Work Group has kidney, cardiovascular, andotheradverseeventsbasedonthose defined a doubling in albuminuria or more as exceeding the 2 parameters. 400 The heatmaps also reinforce the importance expected variability and warranting evaluation if replicated to all of using both eGFR and ACR for assessing severity and upon repeat testing. Conversely, reductions of the ACR by prognosisofCKDandarecolor-codedtoindicatethoseRRsin up to 50% are also consistent with random fluctuation. populationsbutdonotenableindividualriskprediction. However, thepeoplewithinaspecificcellonthegridor Specialconsiderations within an eGFR/ACR category have awide range of absolute Pediatric considerations. Increases in albuminuria and risks for each of the adverse outcomes of interest. An indiproteinuria are also associated with increased risk of disease vidual persons risk for each outcome is influenced by their progression in pediatric populations. A number of studies in underlying etiology of CKD, demographic characteristics, pediatric subjects detailed in Table 18225, 228, 393398 highlight comorbid conditions, and other factors including lifestyle, the value of measurement of albuminuria/proteinuria. SES, nutrition, andintercurrentevents. Thus, theRRsshown Considerations in older adults. Urine ACR in older adult in the heatmap tables can be crudely interpreted as a multipopulation may be elevated due to the loss of muscle mass plier superimposed upon the aforementioned other characleading to lower SCr and lower urinary CrCl. In older adults teristics. There can be substantial variability and overlap, up orpeoplewithfrailty, theinterpretationofurineACRshould to8000%intheriskofCKDprogressionor4000%intherisk take into consideration age-related changes in muscle mass of kidney failure, for 2 people in the same heatmap category and/or sarcopenia. or CKD stage (Figure 14401, 402)402; therefore, individual risk prediction using accurate and externally validated risk 2. 2 Risk prediction in people with CKD equations is important in the personalization of care and The CKD staging heatmaps reflect RRs for each CKD catecan be used to inform absolute risk for individual people. gory compared with persons who do not have CKD at a The corollary to individualizing absolute risks versus RRs population level; however, a persons absolute risk for each isappreciatingtheabsoluteversusrelativebenefitsofdiseaseoutcomerequiresthe use of riskprediction equationsfor the modifying therapies. Although the relative benefits of medispecific adverse event. cations such asSGLT2i mayappear similar acrosssubgroups, Individual-level risk prediction can inform key clinical dethe actual benefit on specific outcomes is highest among cisions, improve the patient-healthcare provider dialogue, and people who have the higher absolute risks for that enablepersonalizedcareforpersonswithCKD. 399Theheatmap outcome.
----------------------------------------------------------------------


======================================================================
CHUNK 355 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_81
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Although the relative benefits of medispecific adverse event. cations such asSGLT2i mayappear similar acrosssubgroups, Individual-level risk prediction can inform key clinical dethe actual benefit on specific outcomes is highest among cisions, improve the patient-healthcare provider dialogue, and people who have the higher absolute risks for that enablepersonalizedcareforpersonswithCKD. 399Theheatmap outcome. 403 Risk prediction equations can be used to better concept introduced in the KDIGO 2012 CKD guideline identify these people and perform better than healthcare S198 KidneyInternational(2024)105(Suppl4S), S117S314 a b Kidney failure replacement therapy risk among patients Risk of 40% decline in eGFR among patients with eGFR 60 ml/min/1. 73 m2 (N350, 232) with eGFR 15 ml/min/1. 73 m2 (N1, 365, 272) CKD G3aA1G3bA1 G4A1 G5A1 G3aA2G3bA2 G4A2 G5A2 G3aA3G3bA3 G4A3 G5A3 G1A1G2A1G3aA1G3bA1G4A1G1A2G2A2G3aA2G3bA2G4A2G1A3G2A3G3aA3G3bA3G4A3 stage CKD categories substantially overlapping multiple risk ranges Nearly all CKD categories substantially overlap multiple risk ranges provider subjective estimation of risk. 404 Several risk This recommendation places a high value on the need and poprediction tools have been developed specifically for people tential benefits for individual risk prediction to deliver personwith CKD, and when implemented, allow healthcare alizedcareforpeoplewithCKD. Therecommendationisworded providers to more precisely estimate risk for individual to encourage healthcare providers, patients, researchers, and people for specific outcomes, which supports a deeper policy makers to go beyond broad categories of RR for populapersonalization of CKD management. 405, 406 Besides tion and to estimate the absolute risk of outcomes for each inimproving individual risk prediction, these tools may be dividual. The recommendation also places a high value on used to more effectively use specialized and often scarce, externally validated prediction equations that can be applied in nephrology resources, identify people for earlier use of diverse healthcare settings and the need for implementation disease-modifying therapy, or enable personalized science in laboratory information systems and EMRs to enable discussions of overall goals of care. Importantly, some of the delivery of risk-based care for people with CKD. the developed prediction models have been externally validated in multiple populations, have high discrimination Keyinformation performance (C-statistics 0. 8 or higher), and are easily Balance of benefits and harms. There is a large body of used via online calculators (Table 199, 10, 407411). evidencetosupporttheuseofthevalidatedriskequationsto estimate the absolute risk of kidney failure requiring dialysis Recommendation 2. 2. 1: In people with CKD G3G5, or transplant in people with CKD G3G5. Risk equations we recommend using an externally validated risk usingroutinelycollecteddatahavebeendeveloped, externally equation to estimate the absolute risk of kidney validated, and implemented in labs, EMRs, and health failure (1A). systems. 408, 412, 413 )%( ERFK fo ksir raey-2 100 90 80 70 60 50 40 30 20 10 0 )%( enilced %04 RFGe fo ksiR www. kidney-international. org chapter 2 80 Referral thresholds 70 Thresholds 20%40%: dialysis access/transplant 10%: maximize therapy 10%: multidisciplinary care 60 5%: consider multiple medications 2%: nephrology 50 1%: optimize medications 40 30 20 10 0 Figure14(a)Predictedriskofkidneyfailureand(b)40%declineinestimatedglomerularfiltrationrate(eGFR)bychronickidney disease(CKD)eGFR(G1G5)andalbumin-to-creatinineratio(ACR)(A1A3)categoriesinOptumLabsDataWarehouse. Thelinesshow potentialthresholdsforclinicaldecisions. KFRE, KidneyFailureRiskEquation. Reproducedfrom(a)ChenTK, HoenigMP, NitschD, etal. Advancesinthemanagementofchronickidneydisease. BMJ. 2023; 383: 074216401; (b)GramsM, SangY, BallewS, etal. TH-PO890. Risk prediction: CKDstagingisthebeginning, nottheend. JAmSocNephrol.
----------------------------------------------------------------------


======================================================================
CHUNK 356 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_82
Content Type: reference
Words: 492
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Thelinesshow potentialthresholdsforclinicaldecisions. KFRE, KidneyFailureRiskEquation. Reproducedfrom(a)ChenTK, HoenigMP, NitschD, etal. Advancesinthemanagementofchronickidneydisease. BMJ. 2023; 383: 074216401; (b)GramsM, SangY, BallewS, etal. TH-PO890. Risk prediction: CKDstagingisthebeginning, nottheend. JAmSocNephrol. 2022; 33: 301. 402 Table19Externally validatedriskequationsforpredictingkidney failureinthegeneral(CKDG3G5)population Outcome Discrimination Equation Variable Population (timehorizon) andcalibration Usability KFRE9, 10, 407, 408 Age, sex, eGFR, ACR(4variable) 1millionpatients, 100, 000 Treatedkidney 0. 880. 91/  www. kidneyfailurerisk. com calcium, phosphate, bicarbonate, eventsfrommorethan failure(25yr) www. ckdpc. org/riskandalbumin(8variables) 30countries models. html KPNW410 Age, sex, eGFR, albuminuria, 39, 013patients, 1097events Kidneyfailure 0. 95/  systolicBP, antihypertensiveuse, fromtheKaiserPermanente (5yr) diabetes, anddiabetes HealthSystem(UnitedStates) complications Landrayetal. 411 Sex, SCr, albuminuria, and 595patients, 190eventsfrom Kidneyfailure 0. 91/ phosphate theCRIBandEastKentcohorts intheUnitedKingdom Z6score409 SCr, albumin, cystatinC, urea, 7978patients, 870eventsdeveloped Kidneyfailure 0. 890. 92/ hemoglobin, andACR intheGermanCKDstudy, validated (5yr) in3additionalEuropeancohorts ACR, albumin-to-creatinineratio; BP, bloodpressure; CKD, chronickidneydisease; CRIB, chronicrenalimpairmentinBirmingham; eGFR, estimatedglomerularfiltrationrate; KFRE, KidneyFailureRiskEquation; KPNW, KaiserPermanenteNorthwest; SCr, serumcreatinine. KidneyInternational(2024)105(Suppl4S), S117S314 S199 chapter 2 www. kidney-international. org Multiplesystematicreviewsandqualityassessmentsofrisk of AKI or AKD or in younger individuals with CKD G1G2 predictionequationshavebeenperformedinthelast10years, whomaybeathighriskofprogressionbutlowriskofkidney withthemostrecentreviewpublishedin2020. 405Thisreview failure in the next 5 years. In these people, more proximal included 35 development studies and 17 external validation outcomes such as 40% decline in GFR or lifetime risk were studies, and described the variables included in the judged to be more appropriate (i. e. , establishing a validated prediction models and provided a decision aid for selecting riskequationfortheappropriateoutcomeofinterest, derived the best model for the prediction horizon and the from the population of interest). As described above, underlying etiology of kidney disease. More recently, an healthcare providers should be cognizant of the impact of additional externally validated model using serum cystatin biologicalandanalyticalvariability inalbuminuriaandeGFR C has also been developed in Germany and externally valuesandthesubsequentimpactoncalculationofpredicted validated in 3 European cohorts. 409 A summary of riskofkidneyfailure. externally validated models for kidney failure is provided Certaintyoftheevidence. Toassessthecertaintyofevidence, below and in Table 19. 9, 10, 407411 theERTexamined2existingsystematicreviewsaddressingthe We highlight here 3 validated models, The Kidney Failure question of the ability of risk prediction models to predict RiskEquation(KFRE), theVeteransAffairsmodel, andtheZ6 kidney failure (see Supplementary Table S6). 406, 415 The 2021 Score model. All of these use routinely collected data from review fromNICEintheUnitedKingdom(UK)assessedthe labs or EMRs and have been validated in different popcertainty of evidence for a variety of risk-based equations to ulations, both in North America and internationally to predict kidney failure and concluded that there was highvarying degrees. Detailed review of all existing prediction quality evidence to state that the chosen risk prediction models is beyond the scope of this document. equationsaccuratelypredictkidneyfailure. 415Therewashigh TheKFREwasdevelopedandinitiallyvalidatedin8391adults certainty of the evidence (C-statistics were high, and the CIs from 2 Canadian provinces, and subsequently validated in were narrow). The Tangri 2013 review did not assess the 721, 357 individuals from more than 30 countries spanning 4 certainty of evidence as part of the review (Supplementary continents. 9, 10 In this large validation study, cohorts from both TablesS6S99, 85, 89, 94, 96, 408, 416). 406 general populations and nephrology clinic settings were The Work Group agreed with the NICE assessment and included. Discriminationwasexcellent(C-statistic0.
----------------------------------------------------------------------


======================================================================
CHUNK 357 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_83
Content Type: reference
Words: 485
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
9, 10 In this large validation study, cohorts from both TablesS6S99, 85, 89, 94, 96, 408, 416). 406 general populations and nephrology clinic settings were The Work Group agreed with the NICE assessment and included. Discriminationwasexcellent(C-statistic0. 80in28/ considered evidence from other systematic reviews and 30 cohorts), and the use of a calibration factor improved recently published validation studies. The certainty of evicalibration for some regions outside of North America; the dencewasbasedontheestablishedandgrowingevidencebase validation populations now exceed 2 million individuals in for clinical validation and clinical utility as well as feasibility more than 60 cohorts from nearly every continent. 407, 408 The for validated risk prediction equations that predict kidney KFREisconsistentlyhighlyaccurateandhasnotbeenimproved failure. bytheadditionoflongitudinalslopesorvariabilityofeGFRand Values and preferences. The Work Group judged that the urineACR, orbyaddingcardiovascularcomorbidities. 407 accurate prediction of kidney failure was of importance to A further 2 externally validated models from large US people with CKD, their families, and healthcare providers, health systems (Kaiser Permanente North West and Veterans and that most people with CKD would choose to receive Affairs) also use routinely collected data and predict kidney prognostic information about their individual risk of kidney failurewithhighaccuracywithina5-yearhorizon. 410, 414Only failureaspartofroutinecare. Foraglobalguideline, theWork 1 externally validated model for kidney failure has been Group focused on prediction equations that were externally developed using serum cystatin C (Z6 model), and although validated, had a low risk of bias, and included variables that it is highly accurate in 4 European cohorts, it has not been were routinely available in most healthcare settings. validated in other continents. 409 Resource use and costs. Most externally validated risk TheWorkGroupjudgedthatthepublishedexternallyvaliequationsforpredictingkidneyfailureuseroutinelycollected dated models (delineated in Table 199, 10, 407411) all had data including laboratory variables such as eGFR, albuminsufficient accuracy to be used in clinical settings. Given the uria, and serum albumin, phosphate, calcium, or hemoglopotential benefits and utility of knowing the risk of kidney bin, or information on demographics and comorbid failure, patients and healthcare providers should be conditionsthat can be easilyobtained. As such, these models encouraged to use these tools. Assessing risk of progression canbeeasilyimplementedatlowcosttohealthsystems. Only can aid in optimizing healthcare delivery services, facilitate 1 externally validated model (Z6 Score) used cystatin C, and the earlier identification of individuals for disease-modifying its usability in global health will depend on the potential therapy, help with planning for modality education, and increased routine availability of cystatin C in laboratories identify goals of care planning. There are limited but worldwide. supportive studies describing the better prediction of Considerations for implementation. Given the potential outcomeswhenusingriskequationscomparedwithcarethat value of risk prediction models for planning and care deis delivered according to isolated eGFR values and clinical cisions, healthcareprovidersshouldconsiderhowtointegrate judgment. Potential harms from the use of prediction risk prediction models into clinical practice, either in EMRs, equations could result from inappropriate use in the settings laboratory information systems, or using other mechanisms S200 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 2 (mobile apps). These should aid clinical workflow and decikidney. org/professionals/kdoqi/gfr_calculatorPedRiskCalc). 417 sion-makingandevenpatientunderstanding.
----------------------------------------------------------------------


======================================================================
CHUNK 358 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_84
Content Type: recommendation
Words: 485
Medical Entities: CKD,GFR,proteinuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org chapter 2 (mobile apps). These should aid clinical workflow and decikidney. org/professionals/kdoqi/gfr_calculatorPedRiskCalc). 417 sion-makingandevenpatientunderstanding. Wherepossible, Further analyses combining the CKiD datawith that from the laboratories should report the results from a validated risk ESCAPE trial (of BP control in CKD progression in children) equation specific to the region automatically for individuals resulted in a risk calculator that uses diagnosis, eGFR and with CKD G3G5 when the required variables are available. proteinuria, and can be accessed at www. ckdprognosis. Simpler equations can be implemented and reported when com. 418 The 4-value KFRE has been validated in the CKiD minimal data are available and more complex equations, cohort with good discrimination. 416 However, further requiring additional variables, can be implemented if the evaluation of the calibration in the cohort revealed required data are present. incongruence between predicted and observed outcomes in The reporting of risk in the laboratory reports and EMRs those with higher predicted risks of kidney failure (who had should be standardized with appropriate guidance on risk lower observed risks). 419 thresholds, when available. Local validation studies can be Considerations regarding sex and gender. There is uncerperformed to determine optimal calibration of the specific taintyaroundwhethersexassignedatbirthorgenderidentity risk prediction equations before implementation. Impleistobeusedinriskequations. Atpresent, aholisticapproach mentation of risk equations that are externally validated and should be used that takes into account sex assigned at birth, use routinely collected data should be prioritized for health sex hormone milieu, and gender identity with shared deciequity and global health considerations. sion-making with the person with CKD. Rationale PracticePoint2. 2. 1: A5-yearkidneyfailureriskof3%5% Risk prediction equations that are externally validated, and can be used to determine need for nephrology referral in locallycalibrated, whenpossible, canleadtoimprovementin additiontocriteriabasedoneGFRorurineACR, andother the delivery of CKD care. These equations should be used as clinical considerations. they can further personalize care plans for people with CKD In most developing and developed countries, there are and enable discussions about the benefits and harms of disinsufficient nephrology care resources to manage all people ease-modifying therapy. with CKD. Using an objective tool to appropriately triage This is a strong recommendation, as the Work Group thosemostlikelytobenefitfromreferralmayhelptomanage judged that the evidence supporting both the clinical validity thosenephrologyresourcesinanevidence-informedmanner. andclinicalutilityofriskpredictionequationswassufficiently Because only a small fraction of the CKD population is at strongtorecommendwidespreadadoption. TheWorkGroup high risk for progression to kidney failure, those people with judged that most externally validated equations rely on lowerrisksofprogressiontokidneyfailuremaybeeffectively routinely collected data and could therefore be implemented managed in primary care settings with guideline-based equallyinlow-resourcesettings. TheWorkGroupalsojudged treatments to delay CKD progression (Figure 15). Referral that the majority of physicians will be comfortable in calcucriteria for nephrology services that include a risk threshold lating the risk of kidney failure and discussing the risk and of 3%5% over 5 years have been examined retrospectively related treatment decisions with patients and caregivers. and have also been implemented prospectively in several healthcare settings. 420, 421 Specialconsiderations In settings within Canada and the UK, retrospective Pediatricconsiderations.
----------------------------------------------------------------------


======================================================================
CHUNK 359 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_85
Content Type: recommendation
Words: 465
Medical Entities: CKD,GFR,dialysis,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
and have also been implemented prospectively in several healthcare settings. 420, 421 Specialconsiderations In settings within Canada and the UK, retrospective Pediatricconsiderations. WorkfromtheCKiDgroup(2015) studies have found that the use of these risk thresholds has providesariskcalculatorfordiseaseprogression, usingage, sex, avoided harms from nonreferral or delayed referral of those glomerular versus nonglomerular disease, eGFR, hypertension progressing to kidney failure. 412 In addition, prospective andlaboratory parameters(calculatoravailableat evaluation has demonstrated a reduction in nephrology eGFR-based criteria eGFR 3060 eGFR 30 eGFR 20 Transition from Transition from Access and primary care to nephrology care to transplant nephrology care interprofessional care planning Kidney eGFR 90 60 30 20 10 failure KF risk 3%5% KF risk 10% KF risk 40% Risk-based criteria 5 years 2 years 2 years Figure15Transitionfromanestimatedglomerularfiltrationrate(eGFR)-basedtoarisk-basedapproachtochronickidneydisease care. KF, kidneyfailure. KidneyInternational(2024)105(Suppl4S), S117S314 S201 referral wait times, particularly for high-risk individuals. In andfoundacceptablespecificityandpositivepredictivevalues other clinical settings with relatively scarce access to for the risk-based threshold criteria as compared with eGFR nephrology care, these thresholds should be adjusted to alone. The Work Group noted that the KDOQI vascular acensure that wait times are acceptable for local standards. 421 cess guideline (2019) currently recommend a risk-based Discussion of risk should also consider the individual threshold 50% or eGFR 15 ml/min per 1. 73 m2 for person, their comorbidities, and their risk of death from initiation of vascular access planning, while acknowledging other causes. that access to surgeons and primary failure to maturation rates may vary by patient and by center. 423 Practice Point 2. 2. 2: A 2-year kidney failure risk of 10% Basedoncurrentevidence, athresholdof40%riskoran can be used to determine the timing of multidisciplinary eGFR of 15 ml/min per 1. 73 m2 is acceptable to use for care in addition to eGFR-based criteria and other clinical initiating vascular access referral. Lower risk thresholds, such considerations. as 20%, can optimize sensitivity, can be used to initiate People with CKD G4G5 are more likely to develop conmodality education, and may be appropriate for presurgical current complications of CKD including anemia, hypervascular access planning or referral for transplantation in kalemia, bone mineral disorders, and/or metabolic acidosis centers with longer wait times. and protein-energy wasting. In addition, they remain at high riskforadverseeventsincludingAKI, emergencydepartment Practice Point 2. 2. 4: Note that risk prediction equations visits, and hospitalizations. As such, in many countries and developed for use in people with CKD G3G5, may not be healthcare settings, these people may be enrolled in intervalid for use in those with CKD G1G2. disciplinarycareclinicsorreceivecaremanagementresources The Work Group recognizes that the progression of CKD to reduce morbidity and healthcare costs, and to avoid uncanoccuratallseverities, and that in earlier stages of disease planned dialysis initiation. (G1G3), large declines in eGFR can occur in 2to 5-year A risk threshold risk of 10% over 2 years has been time frames without reaching kidney failure (Figure 16424).
----------------------------------------------------------------------


======================================================================
CHUNK 360 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_86
Content Type: reference
Words: 497
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
(G1G3), large declines in eGFR can occur in 2to 5-year A risk threshold risk of 10% over 2 years has been time frames without reaching kidney failure (Figure 16424). studied and implemented in some jurisdictions in Canada as Riskpredictionmodelsdevelopedinpopulationswithlater the key eligibility criteria for access to interdisciplinary care stages of CKD are not accurate in CKD G1G2, whereas thatincludesanurse, pharmacist, renaldietitianoraccredited alternative, accurate, externally validated risk prediction nutrition provider, and other allied health support. This equationshavebeendeveloped for predicting40% decline in practice point is based on results from these studies, which eGFR or kidney failure at all stages of CKD. For this demonstrate acceptance and preference of a risk-based criteria by patients and providers. 422 Given the costs associated with delivery of care management resources and interdisciplinary models, risk-based thresholds offer a useful Patient profile: guide to the selection of the ideal target patient population 50-year-old male with diabetes, eGFR 80 ml/min per 1. 73 m2, urine ACR 1 g/g to derive most benefit from the highly specialized team. It Kidney failure risk: 0. 07% over 2 years, 0. 23% over 5 years CKD progression risk: 10. 4% over 3 years is important to note that people with CKD at earlier stages or those at lower risk of progression may benefit from an 12 individual allied health resource (e. g. , pharmacist or dietitian); however, risk-based thresholds provide a guide to 10 identify people with CKD who benefit most from an entire multidisciplinary team. 8 6 Practice Point 2. 2. 3: A 2-year kidney failure risk threshold of40%canbeusedtodeterminethemodalityeducation, 4 timing of preparation for kidney replacement therapy (KRT) including vascular access planning or referral for 2 transplantation, in addition to eGFR-based criteria and other clinical considerations. 0 The appropriate timing for modality education, timing of vascular access planning, or referral for transplantation in a personwith lowor declining GFR can be difficult to predict. Vascular access planning in all adults with CKD G4 would leadtotheunnecessaryplacementoffistulae, whereaswaiting until eGFR falls below 15 ml/min per 1. 73 m2 may lead to inappropriate overuse of central venous catheters at dialysis initiation. Studies have described the potential utilityof riskbased thresholds in planning for dialysis access specifically )%( ksiR chapter 2 www. kidney-international. org CKD progression 10. 4% Kidney failure 0. 07% 2 years 3 years Figure16Comparisonofriskofchronickidneydisease(CKD) progression(5-yearprobabilityofestimatedglomerularfiltration rateeGFR60ml/minper1. 73m2)versuskidneyfailurein adultswithCKDG1G2calculatedfromtheriskequation availableat failureriskcalculatedfromKidneyFailureRiskEquation(KFRE). ACR, albumin-to-creatinineratio. CKDprogressionriskfromGramsME, BrunskillNJ, BallewSH, etal. Developmentandvalidationof predictionmodelsofadversekidneyoutcomesinthepopulationwith andwithoutdiabetes. DiabetesCare. 2022; 45: 20552063. 424 S202 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 2 Table20Externally validatedriskmodelsforpredictinga40%declinein GFR Time Discrimination Variables Population/events horizon(yr) andcalibration CKD-PC424 16variablesincludingdemography, CVD 1. 6millionadultswithorat 5 0. 740. 77 riskfactors, clinicalandlaboratoryvariable riskforCKD Klinrisk8 20laboratoryvariablesderivedfromCBC, 177, 196adultswithCKDG1G4 15 0. 840. 88 chemistrypanel, andurine oratriskforCKD KidneyIntelx425 3proprietarybiomarkers, 5additional 1146adultswithCKDG1G3 5 0. 77 clinicalvariablesincludingalbuminuria, BP anddiabetes BP, bloodpressure; CBC, completebloodcount; CKD, chronickidneydisease; CKD-PC, ChronicKidneyDiseasePrognosisConsortium; GFR, glomerularfiltrationrate. intermediate CKD progression outcome, 3 recent publica2. 3 Prediction of cardiovascular risk in people with tions present models for people with or without diabetes, CKD using both regression and machine learningbased methods, with or without biomarkers (Table 20).
----------------------------------------------------------------------


======================================================================
CHUNK 361 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_87
Content Type: reference
Words: 482
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
intermediate CKD progression outcome, 3 recent publica2. 3 Prediction of cardiovascular risk in people with tions present models for people with or without diabetes, CKD using both regression and machine learningbased methods, with or without biomarkers (Table 20). 8, 424, 425 Given the Practice Point 2. 3. 1: For cardiovascular risk prediction to potential utility of these new models to identify high-risk guidepreventivetherapiesinpeoplewithCKD, useexternally people for early intervention, they should be used to predict validated models that are either developed within CKD disease progression in people with CKD G1G2 and may populationsorthatincorporateeGFRandalbuminuria. supplement established risk equations among people with Cardiovascular morbidity and mortality disproportionCKD G3. People with CKD identified as intermediate risk ately affect people with CKD, and risk prediction tools (e. g. , 1% per year) with these tools may benefit from the developed in the general (non-CKD) population may unearlier initiation of therapy and closer follow-up, and those derestimate the risk of atherosclerotic CVD (ASCVD) or identified as high risk (e. g. , 5% per year) may have the heart failure in CKD populations. Absolute risk is used to largest benefit from multidrug therapy to slow progression. determine eligibility for disease-modifying pharmacological therapy in CVD guidelines, and underestimation of risk may Practice Point 2. 2. 5: Use disease-specific, externally valilead to suboptimal treatment of people with CKD, perpetudatedpredictionequationsinpeoplewithimmunoglobulin ating biases (renalism) that have existed for more than 2 Anephropathy(IgAN)andautosomaldominantpolycystic decades. Newmodelsthathavebeendevelopedspecificallyin kidney disease (ADPKD). adults with CKD (QRISK3430) and severe CKD (ckdpc. org), 6 Risk predictionmodelsforspecificetiologies ofCKDhave and modifications to existing CVD models (pooled cohort also been developed, are externally validated, and used in equations PCE/Systematic COronary Risk Evaluation healthcaresettingstoguideclinicalcare. Forautosomaldomi- SCORE431) that include eGFR and albuminuria should be nant polycystic kidney disease (ADPKD), 2 equations can be used to predict cardiovascular events in individuals with usefulindeterminingthelonger-termriskofkidneyfailureand CKD. 390393, 427, 428, 430, 431, 432 In the case of the PCE, the may guide therapy with tolvaptanthe Mayo Clinic ClassifiCKD patch significantly improves the calibration of ASCVD cation tool and the Predicting Renal Outcome in Polycystic risk, and the eGFR patch improves the prediction of CVD Kidney Disease (PROPKD) score, 426, 427 which incorporates mortality using SCORE. Recently, the American Heart geneticdata. Of these, theMayoClinic Classification toolhas Association Predicting Risk of CVD EVENTs (PREVENT(cid: 3), beenshowntobeaccurateinexternalvalidation. pending) equations were developed in over 6 million US In people with IgAN, 2 externally validated prediction adults aged 3079 years without known CVD with tools (clinical or clinical  histology) have been developed outcomes of incident ASCVD and HF (combined and usinglargeinternationalcohortstudies. Modelsthatincluded separately). 433, 434 These equations included eGFR in the the mesangial hypercellularity (M), endocapillary hyperprimary model and included ACR in an add-on model, so cellularity, segmental glomerulosclerosis (S), and tubular atthey may be particularly appropriate for people with CKD. rophy/interstitial fibrosis (T) (MEST) histological score were more accurate (C-statistic: 0. 810. 82 vs. 0. 78) and showed Practice Point 2. 3.
----------------------------------------------------------------------


======================================================================
CHUNK 362 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_88
Content Type: recommendation
Words: 499
Medical Entities: CKD,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
rophy/interstitial fibrosis (T) (MEST) histological score were more accurate (C-statistic: 0. 810. 82 vs. 0. 78) and showed Practice Point 2. 3. 2: For mortality risk prediction to guide improved reclassification in development and external validiscussions about goals of care, use externally validated dation datasets. 428, 429 Given the availability of accurate models that predict all-cause mortality specifically develexternally validated models, these should be preferentially oped in the CKD population. used over more general CKD models in people with an People with CKD are at high risk of all-cause mortality, established diagnosis of IgAN or ADPKD. It is important to and the competing risk of death can affect clinical decisionnote that the clinical presentation of IgAN can include making, particularly forolderadultswithCKDG4, whomay rapidly progressive disease, and people with rapidly simultaneously be at high risk of kidney failure requiring progressive GN may not have been well represented in the dialysis. All-causemortalitycanbechallengingtopredictdue cohorts used to develop existing prediction tools. to the multiple biological pathways and differences in KidneyInternational(2024)105(Suppl4S), S117S314 S203 chapter 2 www. kidney-international. org personal preferences and goals of care that are not captured approximately 0. 70). These may be more appropriate to byriskpredictionmodels. ModelsdevelopedbytheCKD-PC identify high-risk groups, where earlier discussions about formultipleoutcomesinCKDG4predicttheriskofdeath, conservative care pathways or alternative goals of care may nonfatal CVD event, or kidney failure in adults at 2 and 4 have been helpful. These models should not be used to years and were developed using multinational data. 6, 434 determine the futility of initiating KRT. A 5-year mortality model was also developed in the Cardiovascular Health Study in older adults from the United For research recommendations, please see Chapter States, where the majority of people had CKD G3. 434 Both 6: Research recommendations. models have modest discrimination (C-statistics S204 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Chapter 3: Delaying CKD progression and managing its complications 3. 1 CKD treatment and risk modification therapies that achieve CKD treatment and risk modification and to minimize limitations to access for people with CKD Practice Point 3. 1. 1: Treat people with CKD with a as their disease can substantially impact on QoL and comprehensive treatment strategy to reduce risks of healthcare system resources. A key goal for healthcare progression of CKD and its associated complications providers should be to identify people at risk and to start (Figure 17). such treatments early in the course of CKD to maximize Risk factors associated with CKD progression, CVD, and potential benefits. other CKD complications are highly interrelated, 435 and This chapter provides evidence-based guidelines to suphence so is their management. We use the term CKD port holistic management of the risks associated with CKD treatment and risk modification to encompass the aim of (Figure 18). Previously published KDIGO clinical practice CKD treatment, which is to impart meaningful beneficial guidelines for the management of BP, diabetes, lipids, effects on CKD manifestations and on CKD outcomes anemia, and CKD-MBD in CKD are available and support (Figure 17). CKD manifestations include symptoms and our statements.
----------------------------------------------------------------------


======================================================================
CHUNK 363 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_89
Content Type: reference
Words: 485
Medical Entities: CKD,GFR,dialysis,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Previously published KDIGO clinical practice CKD treatment, which is to impart meaningful beneficial guidelines for the management of BP, diabetes, lipids, effects on CKD manifestations and on CKD outcomes anemia, and CKD-MBD in CKD are available and support (Figure 17). CKD manifestations include symptoms and our statements. 1921, 23, 436 This chapter also describes certain clinical/laboratory abnormalities associated with CKD, laboratory abnormalities including bicarbonate, potassium, which confer health implications. These include increased and uric acid, together with a summary of the observed BP, anemia, dyslipidemia, CKD-mineral and bone disorder ranges associated with different stages of CKD (CKD-MBD), potassium disorders, severe acidosis, decreased fertility, and increased risk of complications of 3. 2 Lifestyle factors pregnancy. CKD outcomes refer to progression to kidney failure and CKD-associated morbidity and mortality. These Practice Point 3. 2. 1: Encourage people with CKD to underare wide ranging and include several CVDs, hospitalization, takephysicalactivitycompatiblewithcardiovascularhealth, infections, and gout. Reducing the risk of CKD progression tolerance, andleveloffrailty; achieveanoptimalbodymass by targeting its underlying pathophysiology may have index (BMI); and not to use tobacco products. Referral to beneficial effects on a range of CKD manifestations and providers and programs(e. g. , psychologists, renal dietitians CKD-associated outcomes, although some complications oraccreditednutritionproviders, pharmacists, physicaland may need specific targeted interventions. Healthcare systems occupational therapy, and smoking cessation programs) should aim to provide safe and proven cost-effective should be offered where indicated and available. Impact on CKD pathophysiology CKD manifestations CKD outcomes Prevention and treatment of clinical symptoms and signs (including blood pressure) Minimize risk of progression to kidney failure Maximize health-related quality of life, physical function, Manage risk and appropriate treatment of capacity to work, and ability to socialize complications, including cardiovascular diseases, Appropriate monitoring and treatment of laboratory hospitalization, gout, infections, etc. abnormalities of CKD associated with implications for health (e. g. , anemia, CKD-MBD, potassium disorders, acidosis) Modification of the natural course of CKD and its symptoms Figure17Chronickidneydisease(CKD)treatmentandriskmodification. CKD-MBD, chronickidneydisease-mineralandbonedisorders. KidneyInternational(2024)105(Suppl4S), S117S314 S205 chapter 3 www. kidney-international. org Regular risk factor Lifestyle reassessment Stop use of (every 36 Healthy diet Physical activity tobacco products Weight management months) SGLT2i Aim for SBP 120 mm Hg Statin-based therapy continue until dialysis RAS inhibitor at maximum moderateor First-line or transplant tolerated dose (if HTN) high-intensity statin drug therapy for most patients ASCVD risk, lipids BP Manage hyperglycemia Use ns-MRA in Dihydropyridine CCB Antiplatelet Manage anemia, as per the KDIGO people with diabetes and/or diuretic if agent for CKD-MBD, acidosis, Targeted therapies Diabetes Guideline, and an indication needed to achieve clinical ASCVD and potassium for complications including use of for use individualized abnormalities, GLP-1 RA where indicated BP target where indicated Steroidal MRA if needed Ezetimibe, PCSK9i for resistant hypertension indicated based on if eGFR 45 ASCVD risk and lipids Use the same principles to diagnose and manage ASCVD and atrial fibrillation as in people without CKD Figure18Holisticapproachtochronickidneydisease(CKD)treatmentandriskmodification. Angiotensin-convertingenzymeinhibitor orangiotensinIIreceptorblockershouldbefirst-linetherapyforbloodpressure(BP)controlwhenalbuminuriaispresent; otherwise dihydropyridinecalciumchannelblocker(CCB)ordiureticcanalsobeconsidered. All3classesareoftenneededtoattainBPtargets. Icons presentedindicatethefollowingbenefits: bloodpressurecuffbloodpressurelowering; glucometerglucose-lowering; heartheart protection; kidneykidneyprotection; scaleweightmanagement.
----------------------------------------------------------------------


======================================================================
CHUNK 364 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_90
Content Type: recommendation
Words: 474
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Angiotensin-convertingenzymeinhibitor orangiotensinIIreceptorblockershouldbefirst-linetherapyforbloodpressure(BP)controlwhenalbuminuriaispresent; otherwise dihydropyridinecalciumchannelblocker(CCB)ordiureticcanalsobeconsidered. All3classesareoftenneededtoattainBPtargets. Icons presentedindicatethefollowingbenefits: bloodpressurecuffbloodpressurelowering; glucometerglucose-lowering; heartheart protection; kidneykidneyprotection; scaleweightmanagement. ASCVD, atheroscleroticcardiovasculardisease; CKD-MBD, chronickidney disease-mineralandbonedisorder; eGFR, estimatedglomerularfiltrationrate; GLP-1RA, glucagon-likepeptide-1receptoragonist; HTN, hypertension; KDIGO, KidneyDisease: ImprovingGlobalOutcomes; MRA, mineralocorticoidreceptorantagonist; ns-MRA, nonsteroidal mineralocorticoidreceptorantagonist; PCSK9i, proproteinconvertasesubtilisin/kexintype9inhibitor; RAS, renin-angiotensinsystem; SBP, systolicbloodpressure; SGLT2i, sodium-glucosecotransporter-2inhibitor. ModifiedfromKidneyDisease: ImprovingGlobalOutcomesDiabetes WorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23 Copyright2022, KDIGO: KidneyDiseaseImprovingGlobalOutcomes. PublishedbyElsevierInc. onbehalfoftheInternationalSocietyof Nephrology. ThisisanopenaccessarticleundertheCCBY-NC-NDlicense( Thispracticepointcallsouttheneedforacomprehensive tobaccotoquitusingtobaccoproducts23andextendsthatadvice and integrated approach to lifestyle modification and recogtoallpeoplewithCKDwhousetobaccoproductstoreducethe nizes that in some circumstances, there is value in referring riskofassociatedprematuremortalityfromCVD, aswellasrisk peopletoprofessionalsorprogramswithexpertiseinlifestyle of respiratory diseases and cancer. 437 Intensive nurse-led modification. We also appreciate that different healthcare programs appear effective at supporting smoking abstinence systems and regions will have variable access to such andcanbecombinedwithpharmacologicalintervention(e. g. , specialized services or teams, and thus availability may be an nicotine replacement therapy of nicotine-receptor partial issue. agonists)toimprovesmokingabstinenceover16weeks. 438See the KDIGO 2021 Clinical Practice Guideline for the 3. 2. 1Avoidinguseoftobaccoproducts Management of Blood Pressure in Chronic Kidney Disease21 The Work Group concurs with the previous KDIGO recomand KDIGO 2022 Clinical Practice Guideline for Diabetes mendations to advise people with diabetes and CKD who use ManagementinChronicKidneyDisease23forfulldetails. S206 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 3. 2. 2Physicalactivityandoptimumweight this age group should not be restrained (i. e. , in a stroller or The Work Group concurs with all the recommendation and carrier) for 60 minutes at a time. Only 13. 4% of 224 practice points relating to physical activity from the KDIGO participants of the CKiD study aged 12 years (median: 15 2022 Clinical Practice Guideline for Diabetes Management years) met these WHO targets, 240, 257, 303, 305, 446 compared with in Chronic Kidney Disease23 and considers that they should 25% of general population children ofcomparable age. 447 Less extend to all adults with CKD. We draw attention to the than 2% of CKiD participants met screen time following statements: recommendations (2 hours per day on school days) comparedwith27%ofthegeneralpopulation. Physicalactivity Recommendation 3. 2. 2. 1: We recommend that peohas numerous benefits for cardiovascular, mental, and social ple with CKD be advised to undertake moderatehealth. Given that children with CKD are at higher risk for intensity physical activity for a cumulative duration problemsinall theseareas, physicalactivity maybeevenmore of at least 150 minutes per week, or to a level importantintheCKDpopulation. compatible with their cardiovascular and physical tolerance (1D). 3. 3 Diet Practice Point 3. 2. 2. 1: Recommendations for physical acPractice Point 3. 3. 1: Advise people with CKD to adopt tivity should consider age, ethnic background, presence of healthy and diverse diets with a higher consumption of other comorbidities, and access to resources. plant-based foods compared to animal-based foods and a lower consumption of ultraprocessed foods. Practice Point 3. 2. 2. 2: People with CKD should be advised to avoid sedentary behavior. Practice Point 3. 3. 2: Use renal dietitians or accredited nutrition providers to educate people with CKD about diPractice Point 3. 2. 2.
----------------------------------------------------------------------


======================================================================
CHUNK 365 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_91
Content Type: recommendation
Words: 497
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Practice Point 3. 2. 2. 2: People with CKD should be advised to avoid sedentary behavior. Practice Point 3. 3. 2: Use renal dietitians or accredited nutrition providers to educate people with CKD about diPractice Point 3. 2. 2. 3: For people at higher risk of falls, etary adaptations regarding sodium, phosphorus, potashealthcareprovidersshouldprovideadviceontheintensity sium, andproteinintake, tailoredtotheirindividualneeds, of physical activity (low, moderate, or vigorous) and the and severity of CKD and other comorbid conditions. type of exercises (aerobic vs. resistance, or both). Plant-baseddietsuseproportionatelymoreplant-basedfood choices, and animal-based food is consumed in moderation. PracticePoint3. 2. 2. 4: Physiciansshouldconsideradvising/ Diets such as Dietary Approaches to Stop Hypertension encouraging people with obesity and CKD to lose weight. (DASH)arerichinfruits, vegetables, wholegrains, andlow-fat BMIrelatestolevelsofadiposityonapopulationscale(though dairy foods. A Mediterranean diet pattern is built around imperfectly), andaBMIofover25kg/m2inadults(i. e. , overweight vegetables, fruits, herbs, nuts, beans, wholegrains, andseafood orobese)isassociatedwithanincreasedriskofmultiplechronic but also includes moderate amounts of dairy, meat, and eggs. diseases including development of CKD. 439, 440 Such adiposityBy definition, vegan and vegetarian diets are plant-based. A CKD associations appear to be causal. 441, 442 BMI can whole-food, plant-based diet low in animal-based and ultraoverestimate risk in people with high muscle mass, 443 and risk processedfoodsmaybehelpfultoslowtheprogressionofCKD for a given BMI may vary by ethnicity (with Asians being at anddelayneedfordialysisviareductionofcardiometabolicrisk higher risk of metabolic disorders at lower BMIs than factorssuchashypertension, CVD, diabetes, andobesity. 448, 449 Europeans). 443, 444Nevertheless, itisimportanttoprovidepeople Ultraprocessed foods such as sugar-sweetened beverages, fast with CKD advice about their weight using BMI in conjunction foods, frozen meals, chips, candy, and pastries are high in with other information, including ethnicity, diet, comorbidity, salt, sugar, and fat, and low in nutritional value, and they physicalactivitylevels, riskoffalls, andlaboratoryvalues. promote inflammation, which may contribute to worsening kidney function. A plant-based diet is rich in antiSpecialconsiderations inflammatory nutrients, fiber, and phytochemicals, and has Pediatricconsiderations. been shown to reduce proteinuria and decrease metabolic Practice Point 3. 2. 2. 5: Encourage children with CKD to acidosis. 448, 449 The probiotic nature of plant-based foods may undertake physical activity aiming for World Health Oralso support the microbiome and reduce inflammation and ganization (WHO)advised levels (i. e. , 60 minutes daily) intestinal production of uremic toxins. 450 A recent systematic and to achieve a healthy weight. review evaluated the association of dietary patterns and TheWHOrecommends60minutesofmoderate-to-vigorous kidney-related outcomes. 451, 452 Dietary patterns that include physicalactivitydailyforchildren517yearsold, includingaermore plant-based unprocessed protein have been obic activities as well as activities that strengthen muscle and demonstrated, in cohort studies and small RCTs, to slow the bone. 445Limitsonsedentary time, particularlyscreentime, are trajectory of eGFR decline, reduce the risk of kidney failure, alsorecommended. Forchildren15yearsofage, 180minutes reduce risk of mortality, and improve scores in some QoL perdayofphysicalactivityisrecommended; youngchildrenin domains (e. g. , DASH and Mediterranean diet). KidneyInternational(2024)105(Suppl4S), S117S314 S207 chapter 3 www. kidney-international. org 3. 3. 1Proteinintake of the amount of protein in grams that would be recommended based on body weight. Clinicians should Recommendation3. 3. 1. 1: Wesuggestmaintaininga advise people with CKD not to confuse grams of protein per protein intake of 0.
----------------------------------------------------------------------


======================================================================
CHUNK 366 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_92
Content Type: recommendation
Words: 468
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
KidneyInternational(2024)105(Suppl4S), S117S314 S207 chapter 3 www. kidney-international. org 3. 3. 1Proteinintake of the amount of protein in grams that would be recommended based on body weight. Clinicians should Recommendation3. 3. 1. 1: Wesuggestmaintaininga advise people with CKD not to confuse grams of protein per protein intake of 0. 8 g/kg body weight/d in adults day with the weight of food in grams (i. e. , 100 g of meat with CKD G3G5 (2C). containsonlyapproximately25gofprotein; Figure2023). Unlike carbohydrates and fats, excess dietary proteins PracticePoint3. 3. 1. 1: Avoidhighproteinintake(1. 3g/kg cannot be stored in the body and are catabolized, leading to accumulation of protein waste products such as urea and body weight/d) in adults with CKD at risk of progression. other uremic toxins. As CKD progresses, these byproducts accumulate and affect organ function. High-protein intake Practice Point 3. 3. 1. 2: In adults with CKD who are willing also contributes to increased intraglomerular pressure and and able, and who are at risk of kidney failure, consider prescribing, under close supervision, a very lowprotein glomerular hyperfiltration, which, in turn, may lead to glodiet (0. 30. 4 g/kg body weight/d) supplemented with merulosclerosis and tubulointerstitial injury. 458, 459 Progressive decline in kidney function is also associated essential amino acids or ketoacid analogs (up to 0. 6 g/kg with a spontaneous loss of appetite potentially leading to body weight/d). inadequate protein and energy intake. 460 The Work Group Practice Point 3. 3. 1. 3: Do not prescribe lowor very low therefore encourages maintaining protein intake in adults with CKD within the recommended range around 0. 8 g/kg protein diets in metabolically unstable people with CKD. body weight/d, and particularly avoiding excess protein This recommendation places a higher value on slowing the intakes (1. 3 g/kg of body weight/d), which may be rate of GFR decline without the challenges associated with harmful for the kidney. 455 There is observational evidence adherence to lower-protein diets, potential adverse effects, and suggesting that excess protein intake may accelerate kidney the contraindications in people with sarcopenia, cachexia, or functional decline. 461463 undernutrition. The Work Group judged that many wellThe protein type, not only the quantity, may also be informed people with CKD G3G5 would choose to implement relevant. Table 21 briefly summarizes the impact of plantthis recommendation. based diets in people with CKD. 464470 In another cohort study of older subjects (N  291, mean age 76 years) with Keyinformation eGFR 60 ml/min per 1. 73 m2, there was no significant Balanceofbenefitsandharms. TheWorkGroupconsidered association between vegetable protein intake and change in thatmaintainingaproteinintakeof0. 8g/kgbodyweightper eGFR. 460 Observational studies452, 464, 465 and an RCT466 day in adults in the absence of indications for a higher or have associated a higher plant-based protein relative to lower protein intake was congruent with a persons culture animal-based protein consumption or adherence to plantandQoL.
----------------------------------------------------------------------


======================================================================
CHUNK 367 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_93
Content Type: recommendation
Words: 488
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
8g/kgbodyweightper eGFR. 460 Observational studies452, 464, 465 and an RCT466 day in adults in the absence of indications for a higher or have associated a higher plant-based protein relative to lower protein intake was congruent with a persons culture animal-based protein consumption or adherence to plantandQoL. Considerationsforproteinrestrictioninthecontext based protein dominant diets with slower eGFR decline of individual preferences, true impact on CKD progression over time and lower risk of death; no study so far has based on etiology, and other factors need to be considered assessed the measures of patient preferences. 471 It is unclear and weighed against any potential adverse impacts, such as whether the associations are attributed to plant-based malnutrition. protein intake per se or to other nutrients or lifestyle habits In many societies, most adults and older adults consume that accompany the plant-based protein intervention; moreproteinthanrecommended, withaverageproteinintakes however, there is biological plausibility. A crossover study of of 1. 2 g/kg/d. 453, 454 There is general agreement that, in the 10 healthy individuals fed for 3 weeks evaluated the effect absence of intercurrent disease, the protein requirements for of a plant-based protein diet versus an animal-based protein people with CKD are not different from those of healthy diet on kidney function parameters. Both diets provided the subjects. 455 The Work Group thus suggests maintaining a same amount of total protein per day. Compared with protein intake of 0. 8 g/kg body weight/d, a target consistent animal-based protein, a plant-based protein diet reduced with the WHO Recommended Dietary Allowances for the renal plasma flow, increased renal vascular resistance, and general population. 456, 457 Figure 1923 shows some examples lowered the fractional clearance of albumin. 472, 473 Body weight (kg) 35 40 50 55 60 65 70 75 80 85 90 95 100 Grams of protein per 28 32 40 44 48 52 56 60 64 68 72 76 80 day (wt 0. 8 g/kg) Figure19Proteinguidelineforadultswithchronickidneydiseasenottreatedwithdialysis. wt, bodyweightinkg. Reproducedfrom KidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronic KidneyDisease. KidneyInt. 2022; 102: S1S127. 23Copyright2022, KDIGO: KidneyDiseaseImprovingGlobalOutcomes. PublishedbyElsevier Inc. onbehalfoftheInternationalSocietyofNephrology. ThisisanopenaccessarticleundertheCCBY-NC-NDlicense( org/licenses/by-nc-nd/4. 0/). S208 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Animal proteins Plant proteins Meat, poultry, fish, seafood, eggs: Legumes, dried beans, nuts, seeds: 28 g (1 oz) 68 g protein 100 g (0. 5 cup) cooked 710 g protein 1 egg 68 g protein Whole grains, cereals: Dairy, milk, yogurt, cheese: 250 100 g (0. 5 cup) cooked 36 g protein ml (8 oz) 810 g protein 28 g (1 oz) cheese 68 g protein Starchy vegetables, breads: 24 g protein Figure20Averageproteincontentoffoodsingrams. ReproducedfromKidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23Copyright2022, KDIGO: KidneyDiseaseImprovingGlobalOutcomes. PublishedbyElsevierInc. onbehalfoftheInternationalSocietyofNephrology. Thisisan openaccessarticleundertheCCBY-NC-NDlicense( A low-protein intake (0. 8 g/kg body weight/d) reduces decline and little or no difference in the number of uremia and uremic toxin generation and improves kidney participants who reached kidney failure (6 studies, 1814 hemodynamics by constricting the glomerular afferent arteparticipants: RR, 1. 05; 95% CI: 0. 731. 53). Similar null rioles and lowering intraglomerular pressure.
----------------------------------------------------------------------


======================================================================
CHUNK 368 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_94
Content Type: recommendation
Words: 480
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
05; 95% CI: 0. 731. 53). Similar null rioles and lowering intraglomerular pressure. 458, 474, 475 Lowassociations were observed in a meta-analysis of 8 studies protein diets and very lowprotein diets have been used for involvingpeoplewithdiabetesandCKD. 478 almost a century as a strategy to reduce clinical symptoms However, thereissomeevidencethatverylowproteindiets and postpone the need to start maintenance dialysis (i. e. , 0. 30. 4 g/kg of body weight/d) under strict supervision treatment. They may also reduce uremic complications and can favorably impact kidney outcomes. A meta-analysis of symptoms, suchasmetabolicacidosisandphosphateload. 476 studies including people with CKD G4G5 without diabetes TheWorkGroupconsidersthattheevidencedoesnotsupreportedthatverylowproteindietscomparedwithlow-proportarecommendationtofollowlow-proteindietsalone(i. e. , tein diet or normal-protein diet may reduce the number of 0. 40. 6 g/kg of body weight/d) as a strategy to slow the propeoplewhoreachkidneyfailure(10studies, 1010participants: gressionofCKD. Inameta-analysisofpeoplewithCKDwithout RR, 0. 65; 95%CI: 0. 490. 85). 477Dataonadverseeffects, such diabetes, 477alow-proteindietcomparedwithanormal-protein as weight loss and malnutrition, and on QoL were limited. dietinparticipantswithCKDG3aandG3b(9studies)orCKD Thereislimitedevidenceontheuseofverylowproteindiets G4(1study)foundlittleornodifferenceinmortalityoreGFR inpeoplewithCKDanddiabetes. 23 Table21Impactofplant-basedfoods inpeoplewithCKD Study(N); studydesign CKDstageorGFR Intervention(follow-up) Outcome CRIC467(N2403); 2070ml/minper1. 73m2 HighDASHvs. lowDASH(14yr) CKDprogression: HR: 0. 83; 95%CI: 0. 690. 99 observational Mortality: HR: 0. 75; 95%CI: 0. 620. 90 NHANES468(N1110); 3059ml/minper1. 73m2 DASHbyquintiles(7. 8yr) Kidneyfailurerelativehazard(RH)compared observational withquintile5: quintile1: RH: 1. 7; 95%CI: 1. 12. 7; quintile2: RH: 2. 2; 95%CI: 1. 14. 1 CORDIOPREV466 60ml/minper1. 73m2 Mediterraneandietvs. DeclineinGFR(cid: 5)3. 72ml/minper1. 73m2 (N53); RCT low-fatdiet(5yr) vs. (cid: 5)5. 4ml/minper1. 73m2, P0. 03 CKDQLD469(N145); CKDG3G4 Highvegetableandnutintake Compositeall-causemortality, kidneyfailure, observational (median36mo) ordoublingofSCr: HR: 0. 61, 95%CI: 0. 390. 94 REGARDS470(N3972); 60ml/minper1. 73m2 Plant-baseddiet(6yr) All-causemortality: HR: 0. 77; 95%CI: 0. 610. 97 observational NHANESIII465(N5346); 60ml/minper1. 73m2 Increasingplant-to-protein All-causemortalityforevery33%increase: observational ratio(8. 4yr) HR: 0. 77, 95%CI: 0. 610. 96 Longitudinalstudyofaging Baseline65. 6(cid: 6)13. 1ml/min Highervs. lowerintakeof Each10ghigherintakeofplant-basedprotein women464(N1374); per1. 73m2 plant-basedprotein(10yr) reducedadeclineinGFRby0. 12ml/min observational per1. 73m2peryear CI, confidenceinterval; CKD, chronickidneydisease; CKDQLD, ChronicKidneyDiseaseinQueensland; CORDIOPREV, CORonaryDietInterventionwithOliveoilandcardiovascularPREVentionstudy; CRIC, ChronicRenalInsufficiencyCohort; DASH, DietaryApproachestoStopHypertension; GFR, glomerularfiltrationrate; HR, hazardratio; NHANES, NationalHealthandNutritionExaminationSurvey; RCT, randomizedcontrolledtrial; REGARDS, ReasonsforGeographicandRacialDifferencesinStroke; SCr, serum creatinine. KidneyInternational(2024)105(Suppl4S), S117S314 S209 chapter 3 www. kidney-international. org Verylowproteindietsareusuallyvegetarianorvegandiets all-causedeathandkidneyfailurepreventionwhencomparing and may risk deficiencies of some essential amino acids. A verylowproteintolow-ornormal-proteindiets, andmoderate strategy to counteract this is the addition of supplements of that there was some benefit to the critical outcome of kidney essentialaminoacidsorprecursorsofessentialaminoacids(i. e. , failureforthecomparisonofverylowproteindietswithlow-or ketoacidanalogs). Bylackingtheaminogroup, ketoacidanalogs normal-proteindietsasdemonstratedbythewideCIsforthese serveassubstratesforproteinsynthesiswithouttheproduction outcomesincludingpotentialforimportantbenefitsandharms. of toxic nitrogenous waste products. Limitations of ketoacid Inaddition, therewasimportantandunexplainedheterogeneity analogs are, however, high pill burden and high cost. Fifteen present. Itisuncertainwhetherlow-orverylowproteindiets monthsofstrictadherencetovegetarianverylowproteindiets impactachangeinGFR. of0. 3g/kgbodyweight/dsupplementedwith0. 125g/kgbody Thecertaintyofevidencewasverylowwhencomparinglowweight/dofketoacidsinpeoplewithanaverageeGFRof18ml/ proteintonormal-proteindietsforachangeinGFRandlowwhen min per 1. 73 m2 at baseline slowed the decline in eGFR, comparingverylowproteintolow-ornormal-proteindiets. This increased bicarbonate levels, and reduced the need for KRT isbecausetheCIsincludedpotentialforimportantbenefitsand comparedwithacontrolgroupthatateamixed-proteindietof harms. There was important and unexplained heterogeneity 0. 6g/kgbodyweight/d. 479Arecentpragmatictrialwasnotable present; theoutcomewasreportedasasurrogateoutcome; and to reproduce this finding, 480 potentially attributed by the therewasunclearallocationconcealmentin4studies. authorstochallengesinpatientcompliancewiththetreatment. The overall certainty of evidence for the remaining outThereisconcernthatlow-proteinandverylowproteindiets comes was very low because of increased risk of bias and may result in malnutrition. However, in the meta-analysis by small studies with wide CIs. In addition, many studies were Hahnetal.
----------------------------------------------------------------------


======================================================================
CHUNK 369 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_95
Content Type: recommendation
Words: 500
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
authorstochallengesinpatientcompliancewiththetreatment. The overall certainty of evidence for the remaining outThereisconcernthatlow-proteinandverylowproteindiets comes was very low because of increased risk of bias and may result in malnutrition. However, in the meta-analysis by small studies with wide CIs. In addition, many studies were Hahnetal. , 47712studiesreportednoevidenceofmalnutrition unclear about allocation concealment/random sequence in their study participants, whereas 3 studies reported small generation, and had significant, unexplained heterogeneity, numbers of participants in each arm with worsening wide CIs for important benefits and harms, and use of surnutritional status. The estimated average requirement for rogate outcomes. protein intake in adults is approximately 0. 50. 6 g/kg body Valuesandpreferences. TheWorkGroupjudgedthatsome weight/d, which corresponds to the amount of protein clinically suitable people would choose to implement a diet required to avoid negative nitrogen balance. 456 Thus under with protein of 0. 8 g/kg body weight/d unless there are correct supervision, these diets may not lead to malnutrition. conditions that contraindicate such as sarcopenia, cachexia, Malnutrition may arise if the reduction in protein is followed or undernutrition. In addition, the Work Group judged that by a reduction in energy intake. This may be preventable by proteinrestrictionwouldbeimplementedbymany peopleas adequate patient education on food choices and close a way of managing their kidney disease. It will also have an supervision by renal dietitians or accredited nutrition impact on overall QoL with the adoption of a more plantspecialists. A patient-centered approach involves a shared based diet; however, there may be challenges with impleunderstanding oftreatmentgoals, effective communicationto menting and adhering to these changes. alleviate anxieties around food or food misconceptions, Resource use and costs. The risks, benefits, resource use, individualized advice that matches cultural values and and costs of dietary protein interventions should be considpreferences, and assistance with implementation of dietetic ered when treating people with CKD. The Work Group adviceinthefaceofalargesymptomburden. consideredthatplant-basedproteinscouldhaveacost-benefit Some of the trials on low-protein diets were conducted effect compared with animal-based protein, but evidence in before treatment with RASi was introduced, and all of them this topic remains limited. before the SGLT2i era. Because the mechanism of action of Considerations for implementation. Protein restriction these medications and that of low-protein and very low without support and advice from renal dietitians or other protein diets are complementary, it has been postulated that accredited nutrition providers may result in low dietary dithese strategies may synergize and maximize their combined versity and limited food choices, adversely impacting QoL effect on delaying CKD progression. 475, 481, 482 Studies are and altering fundamental components of a persons culture needed to demonstrate this hypothesis. anddailylife. Theuseofculturallyappropriatefoodsthatare Low-orverylowproteindietsarenotindicatedinpeople morefamiliartopeople, nutritionalstatus, goalsofcare, QoL, whoaremetabolicallyunstableorduringperiodsofmetabolic and patient preferences should be considered in the impleinstability. This includes conditions that may exacerbate the mentation of these recommendations and practice points. riskofmalnutritioninthecontextoflow-proteinintake, such as sarcopenia, cachexia, active inflammatory or infectious Rationale diseases, periods of hospitalization or the early postoperative TheWorkGroupsuggestsdietaryproteininterventionsbased period, poorlycontrolleddiabetes, consumptivediseasessuch onconsiderationofthepossiblebenefitsofplant-basedfoods, as cancer, treatment of antibiotic or immunosuppressive kidney protection, and avoidance of adverse effect of unsumedications, and significant short-term loss of body weight. pervisedproteinrestriction. PeoplewithCKDnotondialysis Certainty ofevidence.
----------------------------------------------------------------------


======================================================================
CHUNK 370 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_96
Content Type: recommendation
Words: 469
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
riskofmalnutritioninthecontextoflow-proteinintake, such as sarcopenia, cachexia, active inflammatory or infectious Rationale diseases, periods of hospitalization or the early postoperative TheWorkGroupsuggestsdietaryproteininterventionsbased period, poorlycontrolleddiabetes, consumptivediseasessuch onconsiderationofthepossiblebenefitsofplant-basedfoods, as cancer, treatment of antibiotic or immunosuppressive kidney protection, and avoidance of adverse effect of unsumedications, and significant short-term loss of body weight. pervisedproteinrestriction. PeoplewithCKDnotondialysis Certainty ofevidence. Thecertaintyofevidencewasmoderwith or without diabetes may opt for some degree of dietary atethattherewaslittletonodifferenceinthecriticaloutcomeof protein moderation, especially as control of dietary intake S210 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 empowers people with CKD and supports self-care manage3. 3. 2Sodium intake ment. People put a large value on diet, cultural preferences, The Work Group concurs with the following recommendaand QoL; however, adherence to a low-protein diet remains tion from the KDIGO 2022 Clinical Practice Guideline for challenging, may impact social and psychological well-being, Diabetes Management in Chronic Kidney Disease23 and the and given that most of the trials for protein restriction were KDIGO 2021 Clinical Practice Guideline for the conducted before RASi and SGLT2i were implemented, may Managementof BloodPressureinChronicKidneyDisease. 21 not be worth the sacrifice/change in lifestyle. The impact of protein restriction and the use of nonanimal-based protein Recommendation 3. 3. 2. 1: We suggest that sodium diets should be evaluated in the context of new care paraintake be 2 g of sodium per day (or 90 mmol of sodiumperday, or5gofsodiumchlorideperday) digms to ascertain the incremental gain of these strategies in people with CKD (2C). relative to the efforts and costs. Specialconsiderations PracticePoint3. 3. 2. 1: Dietarysodiumrestrictionisusually Pediatricconsiderations. not appropriate for patients with sodium-wasting Practice Point 3. 3. 1. 4: Do not restrict protein intake in nephropathy. children with CKD due to the risk of growth impairment. Global average sodium intake is estimated to be 4310 mg/ ThetargetproteinandenergyintakeinchildrenwithCKD G2G5shouldbeattheupperendofthenormalrangefor d(10. 78gofsaltperday), whichfarexceedsthephysiological requirementandismorethandoubletheWHOrecommendahealthy children to promote optimal growth. tionof2gofsodium(equivalentto5gofsalt)perday in Children with CKD likely have similar resting energy adults. 491 This perhaps reflects the pervasive use of sodium in expenditure to healthy children and should have total energy requirements in the normal range. 483 As in adults, protein many commercial food products, which makes achieving WHO targets challenging to meet for many people. There are restriction was considered for children with CKD in the past. large-scale RCTs quantifying the benefits of restricted salt Two RCTs have compared low-protein versus normal-protein diets in children with CKD. 484, 485 One found poorer growth intake (e. g. , using 75% sodium and 25% potassium chloride salt substitutes) to lower BP and reduce the risk of for those on a low-protein diet, and the other found no cardiovascular events in the general population. 492 In RCTs difference in eGFR between the groups. A 2007 Cochrane withupto36weeksoffollow-up, reductionindietarysodium meta-analysis concluded that there was uncertainty over the hasalso beenshown to lower BPandlevels ofalbuminuria in possible harm of strict low-protein diets on growth in young infants. 486The2009KDOQIguidelinesandthe2020Pediatric peoplewithCKD.
----------------------------------------------------------------------


======================================================================
CHUNK 371 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_97
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
492 In RCTs difference in eGFR between the groups. A 2007 Cochrane withupto36weeksoffollow-up, reductionindietarysodium meta-analysis concluded that there was uncertainty over the hasalso beenshown to lower BPandlevels ofalbuminuria in possible harm of strict low-protein diets on growth in young infants. 486The2009KDOQIguidelinesandthe2020Pediatric peoplewithCKD. 492494Althoughpresumedtoreducetherisk of CKD progression and CVD, longer term trials have not Renal Nutrition Taskforce suggest maintaining an intake of dietary protein at 100%140% of the dietary reference intake beenconductedtoconfirmtheseeffectstranslateintoreduced risk of clinical outcomes in CKD. 493 Given the effects of (DRI)or the SDI for ideal body weight inchildrenwith CKD G3 and at100%120% ofthe DRI/SDIin childrenwith CKD sodium restriction on BP, it is reasonable to recommend G4G5. 487, 488 sodium restriction to people with CKD in combination with pharmacological strategies to minimize the risk of kidney and Olderadults. CVDs. PeoplewithCKDmayhavesalt-wastingkidneydisease, Practice Point 3. 3. 1. 5: In older adults with underlying malnutrition, or be exposed to extremely hot climatic conditions such as frailty and sarcopenia, consider higher conditions. In such scenarios, this recommendation may not protein and calorie dietary targets. apply. InolderadultswithCKD, nutritionalmanagementshould consider potential challenges stemming from simultaneous Specialconsiderations and potentially conflicting risks of CKD progression and Pediatricconsiderations. malnutrition/protein-energy wasting. In older adults, protein Practice Point 3. 3. 2. 2: Follow age-based Recommended targets should be set after careful individual assessment to Daily Intake when counseling about sodium intake for identify the most urgent clinical challenge. childrenwithCKDwhohavesystolicand/ordiastolicblood Geriatricguidelinesrecommendproteinintakesof1. 01. 2g/ pressure 90th percentile for age, sex, and height. kgbodyweight/dtopreventage-relatedmalnutritionandpreTheWHOrecommendsthatthemaximumintakeof2g/d ventsarcopenia. 489Suchproteinintakesmaybeappropriatein sodium (5 g/d salt) in adults should be adjusted downward some people with stable or slowly progressing CKD, whose based on the energy requirements of children relative to those clinical picture is dominated by old age and related challenges of adults (Table 22495). Children born with low birth weight to their nutritional and functional status. On the other hand, (2. 5 kg) are at increased risk for CKD in later life and may protein restriction may be appropriate in older adults whose also be at higher risk for hypertension and increased salt primaryclinicalchallengeisCKDwithsignificantprogression, sensitivity. Salt sensitivity is a physiological trait by which BP provided they are metabolically stable. 490Thecourse ofaction in some people exhibits changes parallel to changes in salt should consider patient preferences and when necessary, intake. Children born with low birth weight may have a 37% involvefamilymembersandcaregivers. increased salt sensitivity (defined as an increase in mean BP KidneyInternational(2024)105(Suppl4S), S117S314 S211 chapter 3 www. kidney-international. org Table22Age-basedsodium intakerecommendations495 cardiovascular events (MACE) by one-quarter (hazard ratio HR: 0. 75; 95% CI: 0. 640. 89), and that relative benefit was Age Recommendedadequatesodiumintake(g/d) similar in people with and without CKD. The SPRINT trial 0 7 6 12 m m o o 0 0. . 1 3 1 7 0 0 excluded people with diabetes, but cardiovascular benefits of 13yr 0. 370 intensive BP lowering on risk of stroke and heart failure are 48yr 1. 0 clearly apparent in people with diabetes in individual patient 913yr 1. 2 level data meta-analysis of intensive versus standard BP1470yr 1. 5 lowering trials.
----------------------------------------------------------------------


======================================================================
CHUNK 372 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_98
Content Type: recommendation
Words: 498
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
370 intensive BP lowering on risk of stroke and heart failure are 48yr 1. 0 clearly apparent in people with diabetes in individual patient 913yr 1. 2 level data meta-analysis of intensive versus standard BP1470yr 1. 5 lowering trials. 499 StandardizedBPmonitoringcanbechallengingtoofferina 3 mm Hg over 24 hours while on a high salt diet, when clinic setting due to the time required500; however, it is compared with a controlled salt diet). That sensitivity may considered potentially hazardous to apply the recommended increase further in those who are small for gestational age. 496 SBPtargetof120mmHgtoBPmeasurementsobtainedina Children with CKD often have underlying tubular condinonstandardizedmanner. 500Apractical solutionto ensurethe tions that predispose them to numerous electrolyte losses, identification of high BP is by using home-based monitoring including sodium. For these children, a supplemented rather (or telemonitoring). Trials have shown that 2 morning and than restricted sodium intake will be required. For nonsalteveningBPmeasurementstakenduringthefirstweekofevery wasting children, salt intake should be limited to the agemonth can be used to titrate antihypertensive medication and based Recommended Daily Intake. reduceBPmorethanusualcareapproaches. 501 Peoplewhoarefrail, havelimitedlifeexpectancy, orhavea 3. 4 Blood pressure control history of falls and fractures may have increased risk of additional events if BP targets of 120 are achieved. Postural The Work Group concurs with the KDIGO 2021 Clinical hypotension in these people is associated with adverse outPractice Guideline for the Management of Blood Pressure in comes, and thus weighing the benefits of some attenuation of Chronic Kidney Disease, which encourages individualized BP eGFRdeclineversusthelife-changingimpactoffalls, fractures, targetsanduseofagentsaccordingtoage, coexistentCVD, and and other events should be considered in choosing specific othercomorbidities; riskofprogressionofCKD; andtolerance targets. to treatments. 21 We highlight the following guidance: Specialconsiderations Recommendation 3. 4. 1: We suggest that adults Pediatricconsiderations. TheWorkGroupconcurswiththe with high BP and CKD be treated with a target KDIGO2021ClinicalPracticeGuidelinefortheManagement systolic blood pressure (SBP) of 120 mm Hg, of Blood Pressure in Chronic Kidney Disease, and we highwhen tolerated, using standardized office BP light the following guidance21: measurement (2B). Recommendation 3. 4. 2: We suggest that in children with CKD, 24-hour mean arterial pressure (MAP) by Practice Point 3. 4. 1: Consider less intensive BP-lowering ambulatory blood pressure monitoring (ABPM) therapy in people with frailty, high risk of falls and fracshould be lowered to 50th percentile for age, sex, tures, verylimitedlifeexpectancy, orsymptomaticpostural and height (2C). hypotension. RCTs have not demonstrated that intensive BP-lowering results in meaningful reductions in the risk of kidney failure, Practice Point 3. 4. 2: Monitor BP once a year with ABPM but the RCT evidence supporting important cardiovascular andevery36monthswithstandardizedauscultatoryoffice benefitsshouldencouragesuchastrategy. ByaimingforanSBP BP in children with CKD. 120 mm Hg, more adults with CKD will achieve an SBP 130 mm Hg, even if they do not meet the 120 mm Hg Practice Point 3. 4. 3: In children withCKD, when ABPM is target. Observationally, onaverage, each20mmHghigherthan notavailable, itisreasonabletotargetmanualauscultatory usualSBPand10mmHghigherdiastolicBPisassociatedwith office SBP, obtained in a protocol-driven standardized an approximate doubling ofcardiovascular risk, with no lower setting, of 50th75th percentile for age, sex, and height limitdowntoatleast115/75mmHg. 497DatafromtheSystolic unlessachievingthistargetislimitedbysignsorsymptoms Blood Pressure Intervention Trial (SPRINT) support the SBP of hypotension.
----------------------------------------------------------------------


======================================================================
CHUNK 373 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_99
Content Type: recommendation
Words: 494
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Observationally, onaverage, each20mmHghigherthan notavailable, itisreasonabletotargetmanualauscultatory usualSBPand10mmHghigherdiastolicBPisassociatedwith office SBP, obtained in a protocol-driven standardized an approximate doubling ofcardiovascular risk, with no lower setting, of 50th75th percentile for age, sex, and height limitdowntoatleast115/75mmHg. 497DatafromtheSystolic unlessachievingthistargetislimitedbysignsorsymptoms Blood Pressure Intervention Trial (SPRINT) support the SBP of hypotension. target of 120 mm Hg (when measured using a standardized These statements with respect to children are generally office BP measurement) to reduce cardiovascular risk in worded to maintain consistency with the KDIGO 2021 adults aged 75 years, or aged 50 years with 1 or more of Clinical Practice Guideline for the Management of Blood the following risk factors: clinical or subclinical CVD (other PressureinChronicKidneyDisease, 21wherethefullrationale than stroke), eGFR 2060 ml/min per 1. 73 m2, or 15% 10and evidence behind the statements are available. However, year cardiovascular risk. 498 Compared with a target of 140 the suggestion to target auscultatory office SBP at the 50th mm Hg, this approach reduces the risk of major adverse 75th percentile when ABPM is not available departs from S212 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 the BP guideline (the previous guideline suggested a target PracticePoint3. 6. 1: RASi(ACEiorARB)shouldbe 90th percentile). Although office BP may be higher than administeredusingthehighestapproveddosethatis BP measured by ABPM, this is not universally the case. toleratedtoachievethebenefitsdescribedbecausethe Given the evidence that intensive BP control may slow CKD provenbenefitswereachievedintrialsusingthesedoses. progression together with the very low risk of adverse effects of intensive BP lowering in children, 228 we consider Practice Point 3. 6. 2: Changes in BP, serum creatinine, and serum potassium should be checked within 24 that more intensive BP lowering targeting around the 50th weeks of initiation or increase in the dose of a RASi, percentile is reasonable. However, a target even lower than depending on the current GFR and serum potassium. the 50th percentile has not been shown to offer additional benefits. Recent trial data found that using a target of office Practice Point 3. 6. 3: Hyperkalemia associated with use auscultatory SBP at 50th to 75th percentile versus intensive ofRASicanoftenbemanagedbymeasurestoreducethe control to below the 40th percentile did not result in serum potassium levels rather than decreasing the dose significant differences in left ventricular mass index. 229 or stopping RASi. Practice Point 3. 6. 4: Continue ACEi or ARB therapy 3. 5 Glycemic control unless serum creatinine rises by more than 30% within 4 weeks following initiation of treatmentor an increase Please refer to the KDIGO 2022 Clinical Practice Guideline in dose. for Diabetes Management in Chronic Kidney Disease for specific recommendations, practice points, and research PracticePoint3. 6. 5: Considerreducingthedoseordisrecommendations. continuingACEiorARBinthesettingofeithersymptomatichypotensionoruncontrolledhyperkalemia 3. 6 Renin-angiotensin system inhibitors despitemedicaltreatment, ortoreduceuremicsymptoms whiletreatingkidneyfailure(estimatedglomerularfiltrationrateeGFR15ml/minper1. 73m2). The Work Group highlights recommendations from the KDIGO2021Clinical PracticeGuideline for theManagement of Blood Pressure in Chronic Kidney Disease and selected Practice Point 3. 6. 6: Consider starting people with CKD practicepointsfortreatmentwithRASifromtheKDIGO2021 withnormaltomildlyincreasedalbuminuria(A1)onRASi Clinical Practice Guideline for the Management of Blood (ACEi or ARB) for specific indications (e. g. , to treat hyperPressure in Chronic Kidney Disease21 and the KDIGO 2022 tensionorheartfailurewithlowejectionfraction).
----------------------------------------------------------------------


======================================================================
CHUNK 374 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_100
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
6. 6: Consider starting people with CKD practicepointsfortreatmentwithRASifromtheKDIGO2021 withnormaltomildlyincreasedalbuminuria(A1)onRASi Clinical Practice Guideline for the Management of Blood (ACEi or ARB) for specific indications (e. g. , to treat hyperPressure in Chronic Kidney Disease21 and the KDIGO 2022 tensionorheartfailurewithlowejectionfraction). Clinical Practice Guideline for Diabetes Management in TheroleofRASi(specificallyACEiorARB)inthemanageChronic Kidney Disease. 23 The Work Group considers mentofBPandpeoplewithCKD, diabetes, and/orhighBPhave several recommendations to apply even in the absence of been specifically considered in recent KDIGO guidelines. 21, 23 high BP and has adapted the recommendations from the BP AlthoughtemporarilystoppingRASimaybeavalidtreatment guideline to remove this requirement. Key recommendations strategy for emergent hyperkalemia, we advise to ensure the and practice points are highlighted: reinitiationoftreatmentsoncetheadverseeventisresolved, so that people are not deprivedof a needed medication (Practice Point 4. 3. 3). 502506 The Work Group offers the new Practice Recommendation 3. 6. 1: We recommend starting renin-angiotensin-system inhibitors (RASi) (angioPoint 3. 6. 6 and a revised algorithm for initiation of RASi tensin-converting enzyme inhibitor ACEi or (Figure 21). 23 The algorithm has been updated to suggest a angiotensin II receptor blocker ARB) for people 30% decrease in eGFR (rather than increase in creatinine) with CKD and severely increased albuminuria (G1 should be a trigger to investigate for an underlying other G4, A3) without diabetes (1B). condition. This represents a threshold above which the eGFR change is greater than would be expected from natural Recommendation3. 6. 2: WesuggeststartingRASi(ACEi variation. Lastly, it should be noted that restricting salt intake orARB)forpeoplewithCKDandmoderatelyincreased albuminuria(G1G4, A2)withoutdiabetes(2C). mayhelpensuremaximaleffectsofRASi. Recommendation 3. 6. 3: We recommend starting Practice Point 3. 6. 7: Continue ACEi or ARB in people RASi (ACEi or ARB) for people with CKD and with CKD even when the eGFR falls below 30 ml/min per moderately-to-severely increased albuminuria 1. 73 m2. (G1G4, A2 and A3) with diabetes (1B). InarecentSTOP-ACEitrialof411participantswithmean eGFR of 13 ml/min per 1. 73 m2, a policy of discontinuing Recommendation 3. 6. 4: We recommend avoiding RASi in CKD G4G5 did not result in any kidney or carany combination of ACEi, ARB, and direct renin indiovascular benefits. 507 Two observational studies have also hibitor (DRI) therapy in people with CKD, with or without diabetes (1B). found that associations suggesting outcomes were worse among participants who stopped RASi after reaching an KidneyInternational(2024)105(Suppl4S), S117S314 S213 chapter 3 www. kidney-international. org Initiate ACEi or ARB Monitor serum creatinine and potassium (within 24 weeks after starting or changing dose) Normokalemia Hyperkalemia 30% decrease in eGFR 30% decrease in eGFR Increase dose of ACEi or ARB Review concurrent drugs Review for causes of AKI or continue on maximally Moderate dietary potassium Correct volume depletion tolerated dose intake Reassess concomitant medications Consider: (e. g. , diuretics, NSAIDs) - diuretics Consider renal artery stenosis - sodium bicarbonate - potassium binders Reduce dose or stop ACEi or ARB if mitigation strategies ineffective Figure21Algorithmformonitoringofpotassiumandestimatedglomerularfiltrationrate(eGFR)aftertheinitiationofreninangiotensinsysteminhibitors. ACEi, angiotensin-convertingenzymeinhibitor; AKI, acutekidneyinjury; ARB, angiotensinIIreceptorblocker; NSAID, nonsteroidalanti-inflammatorydrug. ModifiedfromKidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022 ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23Copyright2022, KDIGO: KidneyDiseaseImprovingGlobalOutcomes. PublishedbyElsevierInc. onbehalfoftheInternationalSocietyofNephrology. Thisisanopen accessarticleundertheCCBY-NC-NDlicense( eGFR 30 ml/min per 1. 73 m2, compared with those who PracticePoint3. 7. 2: ItisreasonabletowithholdSGLT2i continue.
----------------------------------------------------------------------


======================================================================
CHUNK 375 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_101
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
ACEi, angiotensin-convertingenzymeinhibitor; AKI, acutekidneyinjury; ARB, angiotensinIIreceptorblocker; NSAID, nonsteroidalanti-inflammatorydrug. ModifiedfromKidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022 ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23Copyright2022, KDIGO: KidneyDiseaseImprovingGlobalOutcomes. PublishedbyElsevierInc. onbehalfoftheInternationalSocietyofNephrology. Thisisanopen accessarticleundertheCCBY-NC-NDlicense( eGFR 30 ml/min per 1. 73 m2, compared with those who PracticePoint3. 7. 2: ItisreasonabletowithholdSGLT2i continue. 508, 509 In addition, a recent individual patient level during times of prolonged fasting, surgery, or critical data meta-analysis demonstrated a benefit in delaying KRT medical illness (when people may be at greater risk for in patients with eGFR 30 ml/min per 1. 73 m2. 510 ketosis). 3. 7 Sodium-glucose cotransporter-2 inhibitors Recommendation 3. 7. 2: We recommend treating (SGLT2i) adults with CKD with an SGLT2i for the following (1A): The Work Group concurs with the KDIGO 2022 Clinical (cid: 3) eGFR20ml/minper1. 73m2withurineACR200 Practice Guideline for Diabetes Management in Chronic mg/g (20 mg/mmol), or Kidney Disease, which stated: We recommend treating pa- (cid: 3) heart failure, irrespective of level of albuminuria. tientswithtype2diabetes(T2D), CKD, andaneGFR20ml/ min per 1. 73 m2 with an SGLT2i (1A). 23 However, in this Practice Point 3. 7. 3: SGLT2i initiation or use does not guideline, we offer a more general 1A recommendation for necessitatealterationoffrequencyofCKDmonitoringand adults with CKD. We also highlight practice points from the reversible decrease in eGFR on initiation is generally the KDIGO Diabetes guideline for diabetes management in not an indication to discontinue therapy. CKD, which are also relevant for people with CKD without UseofSGLT2iinpeoplewithT2Disrecommendedinprevious diabetes: guidelines irrespective of level of albuminuria. This new recommendation(3. 7. 2)placeshighvalueontheimportanceofreducing riskofkidneyfailure, cardiovascularmortality, andheartfailure Recommendation 3. 7. 1: We recommend treating patients with type 2 diabetes (T2D), CKD, and an inpeoplewithCKDandhighvalueonthelargerelativereductions eGFR 20 ml/min per 1. 73 m2 with an SGLT2i (1A). inriskforkidneydiseaseprogressioninaseriesoflarge, placebocontrolled RCTs. Italso placesmoderate valueon thebenefits of Practice Point 3. 7. 1: Once an SGLT2i is initiated, it is SGLT2i on risk of AKI, hospitalization for heart failure and reasonabletocontinueanSGLT2ieveniftheeGFRfalls myocardial infarction, risk of hospitalization from any cause, below 20 ml/min per 1. 73 m2, unless it is not tolerated and high value on the demonstrable net absolute benefits or KRT is initiated. versusabsoluteharmsinpeoplewithCKD(particularlyinthose S214 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Kidney disease progression Acute kidney injury Mean Events/participants Event rate per RR Events/participants Event rate per RR baseline eGFR, 1000 patient-years (95% CI) 1000 patient-years (95% CI) ml/min per SGLT2 Placebo SGLT2 Placebo SGLT2 Placebo SGLT2 Placebo 1. 73 m2 inhibitor inhibitor inhibitor inhibitor Diabetes DECLARETIMI 58 85 56/8582 102/8578 1. 6 3. 0 0. 55 (0. 390. 76) 125/8574 175/8569 3. 5 4. 9 0. 69 (0. 550. 87) CANVAS Program 77 80/5795 81/4347 3. 6 5. 8 0. 61 (0. 450. 83) 30/5790 28/4344 1. 6 2. 5 0. 66 (0. 391. 11) VERTIS CV 76 49/5499 32/2747 2. 6 3. 4 0. 76 (0. 491. 19) 42/5493 22/2745 2. 5 2. 7 0. 95 (0. 571. 59) EMPAREG OUTCOME 74 51/4645 47/2323 4. 0 7. 6 0. 51 (0. 350. 76) 45/4687 37/2333 2. 5 6. 2 0. 41 (0. 270. 63) DAPAHF 63 18/1075 24/1064 12 16 0. 73 (0.
----------------------------------------------------------------------


======================================================================
CHUNK 376 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_102
Content Type: reference
Words: 497
Medical Entities: GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
76 (0. 491. 19) 42/5493 22/2745 2. 5 2. 7 0. 95 (0. 571. 59) EMPAREG OUTCOME 74 51/4645 47/2323 4. 0 7. 6 0. 51 (0. 350. 76) 45/4687 37/2333 2. 5 6. 2 0. 41 (0. 270. 63) DAPAHF 63 18/1075 24/1064 12 16 0. 73 (0. 391. 34) 31/1073 39/1063 19 24 0. 79 (0. 501. 25) EMPERORREDUCED 61 13/927 23/929 13 24 0. 52 (0. 261. 03) 26/927 33/929 21 27 0. 77 (0. 461. 28) EMPERORPRESERVED 60 38/1466 44/1472 15 18 0. 82 (0. 531. 27) 60/1466 84/1472 20 28 0. 69 (0. 500. 97) DELIVER 60 33/1578 37/1572 9. 5 11 0. 87 (0. 541. 39) 59/1578 52/1572 17 15 1. 13 (0. 781. 63) CREDENCE 56 153/2202 230/2199 27 41 0. 64 (0. 520. 79) 86/2200 98/2197 17 20 0. 85 (0. 641. 13) SOLOISTWHF 51 NA/NA NA/NA. . . . . . 25/605 27/611 55 59 0. 94 (0. 551. 59) SCORED 44 37/5292 52/5292 5. 0 7. 0 0. 71 (0. 461. 08) 116/5291 111/5286 16 16 1. 04 (0. 811. 35) DAPACKD 44 103/1455 173/1451 35 60 0. 57 (0. 450. 73) 48/1455 69/1451 15 22 0. 66 (0. 460. 96) EMPAKIDNEY 36 108/1525 175/1515 36 59 0. 55 (0. 440. 71) 73/1525 81/1515 24 27 0. 88 (0. 641. 20) Subtotal: diabetes 67 739/40, 041 1020/33, 489. . . . 0. 62 (0. 560. 68) 766/40, 664 856/34, 087. . . . 0. 79 (0. 720. 88) No diabetes DAPAHF 68 10/1298 15/1307 5. 0 8. 0 0. 67 (0. 301. 49) 18/1295 30/1305 9. 9 16 0. 60 (0. 341. 08) EMPERORREDUCED 63 5/936 10/938 5. 2 10 0. 50 (0. 171. 48) 20/936 34/938 16 28 0. 56 (0. 320. 98) DELIVER 63 17/1551 17/1557 5. 0 4. 9 1. 01 (0. 511. 97) 30/1551 47/1558 8. 8 14 0. 64 (0. 411. 02) EMPERORPRESERVED 62 12/1531 18/1519 4. 5 6. 9 0. 68 (0. 331. 40) 37/1531 47/1519 12 15 0. 80 (0. 521. 23) DAPACKD 42 39/697 70/701 29 53 0. 51 (0. 340. 75) 16/697 21/701 11 15 0. 75 (0. 391. 43) EMPAKIDNEY 39 119/1779 157/1790 35 47 0. 74 (0. 590. 95) 34/1779 54/1790 10 16 0. 63 (0. 410. 97) Subtotal: no diabetes 56 202/7792 287/7812. . . . 0. 69 (0. 570. 82) 155/7789 233/7811. . . . 0. 66 (0. 540. 81) Total: overall 65 941/47, 833 1307/41, 301. . . . 0. 63 (0. 580. 69) 921/48, 453 1089/41, 898. . . . 0. 77 (0. 700. 84) 0. 25 0. 5 0. 751. 00 1. 50 0. 25 0. 5 0. 751. 00 1. 50 Trend across trials sorted by eGFR: Favors SGLT2 inhibitor Favors placebo Trend across trials sorted by eGFR: Favors SGLT2 inhibitor Favors placebo Diabetes P0. 87; Diabetes P0. 02; No diabetes P0. 86; No diabetes P0. 66; Heterogeneity by diabetes status: P0. 31 Heterogeneity by diabetes status: P0. 12 Figure22Effectofsodium-glucosecotransporter-2inhibitors(SGLT2i)withkidneydiseaseoutcomesbydiabetesstatus.
----------------------------------------------------------------------


======================================================================
CHUNK 377 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_103
Content Type: recommendation
Words: 494
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
50 Trend across trials sorted by eGFR: Favors SGLT2 inhibitor Favors placebo Trend across trials sorted by eGFR: Favors SGLT2 inhibitor Favors placebo Diabetes P0. 87; Diabetes P0. 02; No diabetes P0. 86; No diabetes P0. 66; Heterogeneity by diabetes status: P0. 31 Heterogeneity by diabetes status: P0. 12 Figure22Effectofsodium-glucosecotransporter-2inhibitors(SGLT2i)withkidneydiseaseoutcomesbydiabetesstatus. ACR, albuminto-creatinineratio; CI, confidenceinterval; eGFR, estimatedglomerularfiltrationrate; NA, notapplicable; RR, relativerisk. ReproducedfromNuffield DepartmentofPopulationHealthRenalStudiesGroup, SGLTInhibitorMeta-AnalysisCardio-RenalTrialistsConsortium. Impactofdiabetesonthe effectsofsodiumglucoseco-transporter-2inhibitorsonkidneyoutcomes: collaborativemeta-analysisoflargeplacebo-controlledtrials. Lancet. 2022; 400: 17881801. 5112022TheAuthor(s). PublishedbyElsevierLtd. ThisisanOpenAccessarticleundertheCCBY4. 0license. withoutdiabeteswhoareatverylowriskofketoacidosis). SGLT2i progression. 403, 513 Key differences between the 2 trials were alsofavorablyreduceBP, uricacidlevels, measuresoffluidoverthe inclusion of a large number of causes of kidney disease load, theriskofserioushyperkalemia, anddonotincreaseriskof not related to diabetes, lower eGFR, and lower levels of hypoglycemia. The recommendation is consistent with but exACR in The Study of Heart and Kidney Protection With pandsonRecommendation1. 3. 1fromtheKDIGO2022Clinical Empagliflozin (EMPA-KIDNEY) compared with the PracticeGuidelineforDiabetesManagementinChronicKidDapagliflozin and Prevention of Adverse Outcomes in neyDiseasetoincludepeoplewithcausesofCKDnotrelatedto Chronic Kidney Disease (DAPA-CKD) trial. diabetes. In a collaborative metanalysis including those 2 and 11 other trials (13 trials with just over 90, 000 randomized parKeyinformation ticipants) in comparison with placebo, those allocated to an Balance of benefits and harms. Benefits. Several large, plaSGLT2i experienced a 37% reduction in the risk of kidney cebo-controlled RCTs have provided clear demonstrations of disease progression and a 23% reduction in the risk of AKI the efficacy of SGLT2i, which substantially reduce the risk of irrespective of diabetes status (Figure 22). 511 kidney failure, AKI, and hospitalization for heart failure, and The same meta-analysis showed that, compared with plaalso moderately reduce the risk of cardiovascular death and cebo, allocation to an SGLT2i reduced the risk of the commyocardialinfarctioninpeoplewithandwithoutCKD. These posite of cardiovascular death or hospitalization for heart benefits appear to be irrespective of diabetes status, cause of failure by 23% irrespective of diabetes status (Figure 23511), kidney disease, or level of GFR. 511, 512 The benefits of SGLT2i although there were limited numbers of cardiovascular inpeoplewithdiabetesandCKDhavebeenfullydescribedin events in people with CKD without diabetes. SGLT2i also the KDIGO 2022 Clinical Practice Guideline for Diabetes afford an approximate 10% RR reduction in MACE, Management in Chronic Kidney Disease. 23 primarily from reduced risk of cardiovascular death and Two large RCTs using 2 different SGLT2i recruited 10, 913 myocardial infarction with no clear effect on stroke. 511, 512 participants and focused on CKD populations at risk of Furthermore, SGLT2i also importantly reduce the risk of progression, reporting benefits in terms of kidney disease hospitalization from any cause, 403 reduce BP, 403, 513, 514 uric KidneyInternational(2024)105(Suppl4S), S117S314 S215 chapter 3 www. kidney-international. org Cardiovascular death or hospitalization for heart failure Cardiovascular death Mean Events/participants RR Events/participants RR baseline eGFR, (95% CI) (95% CI) ml/min per 1. 73 m2 SGLT2 inhibitor Placebo SGLT2 inhibitor Placebo Diabetes High atherosclerotic cardiovascular risk trials 80 1490/24, 563 1232/18, 005 0. 80 (0. 740. 86) 1026/24, 563 755/18, 005 0. 86 (0. 780. 95) Stable heart failure trials 61 923/5046 1154/5037 0. 77 (0. 710. 84) 468/5046 527/5037 0. 88 (0. 780.
----------------------------------------------------------------------


======================================================================
CHUNK 378 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_104
Content Type: reference
Words: 487
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
80 (0. 740. 86) 1026/24, 563 755/18, 005 0. 86 (0. 780. 95) Stable heart failure trials 61 923/5046 1154/5037 0. 77 (0. 710. 84) 468/5046 527/5037 0. 88 (0. 780. 99) Chronic kidney disease trials 45 643/10, 474 847/10, 457 0. 74 (0. 660. 82) 363/10, 474 434/10, 457 0. 83 (0. 720. 95) Subtotal: diabetes 67 3056/40, 691 3233/34, 113 0. 77 (0. 730. 81) 1908/40, 691 1774/34, 113 0. 86 (0. 800. 92) No diabetes Stable heart failure trials 64 710/5316 890/5322 0. 78 (0. 700. 86) 396/5316 452/5322 0. 88 (0. 771. 00) Chronic kidney disease trials 40 50/2476 53/2491 0. 95 (0. 651. 40) 26/2476 25/2491 1. 04 (0. 591. 83) Subtotal: no diabetes 56 760/7792 943/7813 0. 79 (0. 720. 87) 422/7792 477/7813 0. 88 (0. 781. 01) Total: overall 65 3816/48, 483 4176/41, 926 0. 77 (0. 740. 81) 2330/48, 483 2251/41, 926 0. 86 (0. 810. 92) Heterogeneity by diabetes status: P0. 67 Heterogeneity by diabetes status: P0. 68 Noncardiovascular death All-cause death Diabetes High atherosclerotic cardiovascular risk trials 80 572/24, 557 461/18, 003 0. 88 (0. 781. 00) 1671/24, 563 1299/18, 005 0. 87 (0. 810. 94) Stable heart failure trials 61 317/5046 316/5037 1. 00 (0. 861. 16) 785/5046 843/5037 0. 93 (0. 841. 02) Chronic kidney disease trials 45 230/10, 474 240/10, 457 0. 94 (0. 791. 12) 599/10, 474 683/10, 457 0. 87 (0. 780. 97) Subtotal: diabetes 67 1133/40, 685 1035/34, 111 0. 93 (0. 851. 01) 3120/40, 691 2901/34, 113 0. 88 (0. 840. 93) No diabetes Stable heart failure trials 64 263/5316 251/5322 1. 05 (0. 881. 24) 659/5316 703/5322 0. 94 (0. 851. 05) Chronic kidney disease trials 40 38/2476 52/2491 0. 74 (0. 491. 14) 64/2476 77/2491 0. 84 (0. 601. 18) Subtotal: no diabetes 56 301/7792 303/7813 1. 00 (0. 851. 17) 723/7792 780/7813 0. 93 (0. 841. 03) Total: overall 65 1434/48, 477 1338/41, 924 0. 94 (0. 881. 02) 3843/48, 483 3681/41, 926 0. 89 (0. 850. 94) Heterogeneity by diabetes status: P0. 43 Heterogeneity by diabetes status: P0. 36 0. 5 0. 75 1. 001. 251. 50 0. 5 0. 75 1. 001. 251. 50 SGLT2 inhibitor Favors placebo SGLT2 inhibitor Favors placebo Figure23Effectsofsodium-glucosecotransporter-2(SGLT2)inhibitionversusplacebooncardiovascularandmortalityoutcomesby diabetesstatusandtrialpopulation. Collaborativemeta-analysisofdatafrom13largeplacebocontroltrialsofSGLT2inhibitors. Datafrom EffectofSotagliflozinonCardiovascularEventsinPatientswithType2DiabetesPostWorseningHeartFailure(SOLOIST-WHF)areincludedin totalsbutexcludedfromthestableheartfailuretrialsgroupasthetrialincludedpatientswithrecentacutedecompensatedheartfailure. CI, confidenceinterval; eGFR, estimatedglomerularfiltrationrate; RR, relativerisk. ReproducedfromNuffieldDepartmentofPopulationHealth RenalStudiesGroup, SGLTInhibitorMeta-AnalysisCardio-RenalTrialistsConsortium. Impactofdiabetesontheeffectsofsodiumglucosecotransporter-2inhibitorsonkidneyoutcomes: collaborativemeta-analysisoflargeplacebo-controlledtrials. Lancet. 2022; 400: 17881801. 511 2022TheAuthor(s). PublishedbyElsevierLtd. ThisisanOpenAccessarticleundertheCCBY4. 0license. acidlevels, 515weight/fluidoverload, 516andtheriskofserious are not caused by SGLT2 inhibition, and there is no hyperkalemia. 517 increased risk of hypoglycemia. There is an increased risk of Harms. SGLT2i are well tolerated with high levels of mycotic genital infections (in men and women), but these adherence in the RCTs in CKD. 403, 513, 514 In the studied are generally mild and treating these infections with lowpopulations, any risk of ketoacidosis or lower-limb cost topical agents should help treatment adherence. amputation resulting from SGLT2i use was substantially Certainty of evidence.
----------------------------------------------------------------------


======================================================================
CHUNK 379 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_105
Content Type: reference
Words: 476
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
403, 513, 514 In the studied are generally mild and treating these infections with lowpopulations, any risk of ketoacidosis or lower-limb cost topical agents should help treatment adherence. amputation resulting from SGLT2i use was substantially Certainty of evidence. SGLT2i have been studied in a lower than the potential absolute benefits and generally series of large trials with consistent effects observed berestricted to people with diabetes. Meta-analysis estimates of tween trials, using different agents in the class. The trials absolute benefits and harms for each 1000 people with have robust double-blind designs that minimize risk of CKD and T2D treated for 1 year with an SGLT2i were 11 bias, and they have provided precise estimates of effect fewer cardiovascular deaths or hospitalizations for heart with no risk of publication bias due to the Nuffield failure, for approximately 1 episode of ketoacidosis and Department of Public Health (NDPH) Renal Studies approximately 1 lower-limb amputation, respectively (and Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal also 11 fewer people developing kidney disease progression Trialists Consortium (SMART) collaboration, which and 4 fewer people with AKI). The corresponding benefits brought together all the trialists that have conducted the in people with CKD without diabetes were 15 fewer people relevant large trials. The totality of the evidence provides with kidney disease progression, 5 fewer with AKI, and 2 high levels of certainty of efficacy, with larger effect sizes fewer cardiovascular deaths or hospitalizations for heart observed in many populations. Relative effects on kidney failure per 1000 patient-years of treatment with no excess disease progression appeared to be larger among people risk of ketoacidosis or amputation observed. 511 The vast with higher levels of albuminuria who are at highest abmajority of urinary tract infections in people taking SGLT2i solute risk of progression. The size of RR reductions S216 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Mean Events/participants Rate per 1000 Relative risk Trend across baseline patient-years (95% CI) trials sorted eGFR (ml/min/ by eGFR 1. 73 m2) SGLT2i Placebo SGLT2i Placebo Diabetes CREDENCE 56 116/2202 165/2199 20 29 0. 68 (0. 54, 0. 86) SCORED 44 NA/NA NA/NA 26 37 DAPA-CKD 44 77/1455 109/1451 24 39 0. 69 (0. 51, 0. 92) P0. 48 EMPA-KIDNEY 36 74/1525 116/1515 0. 59 (0. 44, 0. 79) Subtotal: DIABETES 47 267/5182 390/5165 0. 66 (0. 56, 0. 77) No diabetes DAPA-CKD 42 32/697 52/701 24 39 0. 56 (0. 36, 0. 87) EMPA-KIDNEY 39 83/1779 105/1790 25 31 0. 80 (0. 60, 1. 07) P0. 19 Subtotal: NO DIABETES 40 115/2476 157/2491 0. 72 (0. 56, 0. 91) TOTAL: OVERALL 45 382/7658 547/7656 0. 67 (0. 59, 0. 77) 0. 5 0. 75 1. 001. 251. 50 SGLT2i better Placebo better Heterogeneity by diabetes status: P0. 54 Figure24Effectsofsodium-glucosecotransporter-2(SGLT2)inhibitionversusplaceboonkidneyfailure(chronickidneydisease CKDtrials). Kidneyfailuredefinedasacompositeofsustainedestimatedglomerularfiltrationrate(eGFR)15ml/minper1. 73m2(or eGFR10ml/minper1. 73m2inTheStudyofHeartandKidneyProtectionWithEmpagliflozinEMPA-KIDNEY), maintenancedialysis, orkidney transplantation. DataforkidneyfailurenotavailableforEffectofSotagliflozinonCardiovascularandRenalEventsinPatientswithType2 DiabetesandModerateRenalImpairmentWhoAreatCardiovascularRisk(SCORED). 518CI, confidenceinterval; CREDENCE, Canagliflozinand RenalEndpointsinDiabeteswithEstablishedNephropathyClinicalEvaluation; DAPA-CKD, DapagliflozinandPreventionofAdverseOutcomes inChronicKidneyDisease; NA, notapplicable.
----------------------------------------------------------------------


======================================================================
CHUNK 380 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_106
Content Type: recommendation
Words: 434
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
67 (0. 59, 0. 77) 0. 5 0. 75 1. 001. 251. 50 SGLT2i better Placebo better Heterogeneity by diabetes status: P0. 54 Figure24Effectsofsodium-glucosecotransporter-2(SGLT2)inhibitionversusplaceboonkidneyfailure(chronickidneydisease CKDtrials). Kidneyfailuredefinedasacompositeofsustainedestimatedglomerularfiltrationrate(eGFR)15ml/minper1. 73m2(or eGFR10ml/minper1. 73m2inTheStudyofHeartandKidneyProtectionWithEmpagliflozinEMPA-KIDNEY), maintenancedialysis, orkidney transplantation. DataforkidneyfailurenotavailableforEffectofSotagliflozinonCardiovascularandRenalEventsinPatientswithType2 DiabetesandModerateRenalImpairmentWhoAreatCardiovascularRisk(SCORED). 518CI, confidenceinterval; CREDENCE, Canagliflozinand RenalEndpointsinDiabeteswithEstablishedNephropathyClinicalEvaluation; DAPA-CKD, DapagliflozinandPreventionofAdverseOutcomes inChronicKidneyDisease; NA, notapplicable. appears to be irrespective of the level of GFR, with no the reduced risk of hospitalization and serious hyperevidence of a threshold level of eGFR below which benkalemia and uric acid levels, all of which are common efits start to attenuate. CKD complications. For the 1A recommendation (3. 7. 1), also see the 2022 Resource use and costs. Because of the high cost of KRT, update to theKDIGO Clinical PracticeGuideline in Diabetes SGLT2i havebeenfoundtobe cost-saving in thepeople with Managementfordetailsofthecertaintyoftheevidence. 23Our CKD and diabetes recruited in the completed trials. 519 ERTspecificallyalsoundertookasystematicreviewlimitedto Generic SGLT2i are already available in some countries. people with CKD and no diabetes and considered the From a healthcare system perspective, reducing the cost certainty of the effect in this subgroup to be moderate. The burden of hospitalizations and dialysis is highly desirable, ERT identified the collaborative meta-analysis, 511 which and QoL may be preserved longer from their avoidance. included data from 2 RCTs evaluating an SGLT2i among Specifics as to whether people bear the costs of these adults with CKD without diabetes. 403, 513 Both RCTs were medications will be country-dependent. considered to have a low risk of bias. The collaborative Considerations for implementation. The Work Group meta-analysis harmonized the definition of CKD considered it safe to continue or even initiate an SGLT2i progression among the trials. The certainty of the evidence when the eGFR falls below 20 ml/min per 1. 73 m2 and for CKD progression was graded as high (no concerns continue their use until the time KRT is initiated (as was regarding the risk of bias of the studies or the consistency, the approach used in the large CKD population directness, and precision of the results). The certainty of the RCTs403, 513, 514). We also considered that initiating SGLT2i evidence for the kidney failure outcome in people with does not necessitate alteration of frequency of laboratory CKD without diabetes was downgraded to moderate due to monitoring. It is not routinely necessary to recheck blood imprecision (although clear benefits are demonstrated in tests after initiating an SGLT2i in adults with CKD (see the CKD trials: Figure 24518). Neither RCTreported on the Practice Point 3. 7. 3). 403 critical outcome of hospitalizations for any cause in the Reduced glomerular hyperfiltration resulting from subgroup without diabetes. SGLT2i can result in a dip in eGFR which is reversible. Valuesandpreferences.
----------------------------------------------------------------------


======================================================================
CHUNK 381 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_107
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Neither RCTreported on the Practice Point 3. 7. 3). 403 critical outcome of hospitalizations for any cause in the Reduced glomerular hyperfiltration resulting from subgroup without diabetes. SGLT2i can result in a dip in eGFR which is reversible. Valuesandpreferences. The Work Group judged that fully None of the large trials demonstrated an increased risk of informed people with CKD with an indication for an AKI in people treated with SGLT2i (Figure 22), and the SGLT2i would choose to receive SGLT2i for their proven intervention does not induce hyperkalemia (an important benefits on risk of CKD progression, AKI, and a range of difference compared with inhibitors of the renincardiovascular outcomes, their generally good safety profile, angiotensin-aldosterone pathway, which generally require and simplicity to implement (assuming local availability additional monitoring after initiation Figure 21). and insurance coverage if required). SGLT2i also confer Note that adults with polycystic kidney disease were health benefits that may motivate people with CKD due to excluded from the large CKD trials testing SGLT2i. KidneyInternational(2024)105(Suppl4S), S117S314 S217 chapter 3 www. kidney-international. org Rationale follow-upintheA2andA3groupswereconsideredseparately Largetrialsindividuallyandwhencombinedinmeta-analysis (Figure25403). demonstrate clear net benefits of SGLT2i, with net benefits Certainty of evidence. The overall certainty of evidence for particularlylargeinpeoplewithoutdiabetesduetoalmostno theefficacyofSGLT2itodelayCKDprogressioninpeoplewith risk of serious harm from ketoacidosis or lower-limb ampuCKD without diabetes is moderate (see Supplementary Table tation. S1023, 403, 511, 518, 521524). The ERT identified an individual participant data (IPD) meta-analysis, 511 which included data Recommendation 3. 7. 3: We suggest treating adults from 2 RCTs evaluating an SGLT2 inhibitor among adults with eGFR 20 to 45 ml/min per 1. 73 m2 with urine withCKDbutnotdiabetes. 403, 513BothRCTswereconsidered ACR 200 mg/g (20 mg/mmol) with an SGLT2i tohavealowriskofbias. TheIPDmeta-analysisharmonized (2B). the definition of CKD progression among the trials. The certainty of the evidence for CKD progression was graded as Thisrecommendationplaceshighvalueonthepotentialforlonghigh as there were no concerns regarding the risk of bias of termuse ofSGLT2iin people withoutdiabetes who haveasubthestudiesortheconsistency, directness, andprecisionofthe stantiallydecreasedGFRto reduce theriskofkidney failurebut results. The certainty of the evidence for kidney failure was recognizes remaining uncertainty in this population due to the downgradedtomoderateduetoimprecision. shortfollow-upintheRCTs. Italsoplacesmoderatevalueonthe Values and preferences. The Work Group judged that fully benefits of SGLT2i on risk of AKI, cardiovascular death and informedadultswithoutdiabetesandlowlevelsofalbuminuria myocardialinfarction, andriskofhospitalizationfromanycause. (urineACR200mg/g20mg/mmol)whohaveestablished SGLT2ialsofavorablyreduceBP, uricacidlevels, fluidoverload, CKD and an eGFR of 2045 ml/min per 1. 73 m2 may be andtheriskofserioushyperkalemia. NotethatapersonwithCKD particularlymotivatedtotakeSGLT2iforthebenefitsidentified andheartfailurehasaclear indicationfor theuseofSGLT2ito on rate of decline in GFR as they already have substantially reduce risk of cardiovascular death or hospitalization for heart reducedGFR. AdultswithestablishedCKDarehighlylikelyto failureirrespectiveoflevelofalbuminuria(Figure 24). wanttostarttreatmentearlytomaximizebenefits. ExtrapolationofthefindingsfromeGFRslopeanalyses(Figure25)could Keyinformation mean substantial delays in any future requirement for KRT. Benefits and harms. Several large placebo-controlled RCTs People with CKD may also be motivated by the potential for have provided clear demonstrations of the efficacy of SGLT2i, SGLT2i to reduce risk of AKI, hospitalization, serious whichsubstantiallyreducetheriskofkidneydiseaseprogression hyperkalemia, fluidoverload, anduricacidlevels, allofwhich and kidney failure (Figures 22 and 24) as well as moderately arecommonCKDcomplications. reduce the riskof CVD events (Figure 23) inpeoplewith and Resource use and costs. Health economic analyses are without CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 382 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_108
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
reduce the riskof CVD events (Figure 23) inpeoplewith and Resource use and costs. Health economic analyses are without CKD. Furthermore, a meta-analysis of the kidney requiredinpeoplewithCKDwithoutdiabetesandlowlevels disease progression outcome subdivided by primary kidney of albuminuria to establish their level of cost-effectiveness. diagnosisdemonstratedthattherewasnosignificantsubgroup From a healthcare system perspective, reducing the cost interaction by primary kidney diagnosis, and SGLT2i reduced burdenofhospitalizationsanddialysisishighlydesirable, and the risk of AKI by 23% in people with or without diabetes QoL maybe preservedlonger fromtheir avoidance. Specifics (Figure 22). 511 SGLT2i also reduce the risk of hospitalization as to whether people bear the costs of these medications will for any cause in people with CKD. 403, 520 Some uncertainty be country-dependent. remains about the effects on kidney disease progression in Considerations for implementation. . The considerations for peoplewithoutdiabeteswithurineACR200mg/g(20mg/ implementation in people with CKD and low levels of albummol), which led to a different grading of the minuria are no different to people with albuminuria (see recommendationforthatpopulation. EMPA-KIDNEYwasthe above for details). key trial to assess effects in people with CKD at risk of progressionwithurineACR200mg/g(20mg/mmol)and Rationale found evidence of significant interaction by ACRstatus for its Large trials considered individually and combined in metaprimaryoutcome(trendP0. 02). Relativeeffectsappearedto analysis demonstrate clear net benefits of SGLT2i, but evbelargerinpeoplewithhigherlevelsofalbuminuria. Theslow idence for benefits on CKD progression in people without rate of progression and small number of outcomes in the A1 diabetes and with low levels of albuminuria is limited to subgroup limited the power for EMPA-KIDNEY to assess eGFR slope analyses in heart failure trials and one CKD effects on the primary outcome in this subgroup. There were, trial all with relatively short follow-up periods. However, however, important effects on the chronic (i. e. , long-term) extrapolation of these eGFR slope results suggests that slope in all albuminuria subgroups, and significant reductions important benefits would accrue for such people if treated in progression using total slope analyses over the 2 years of long term. S218 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Mean annual rate of change in estimated GFR (ml/min per 1. 73 m2 per year) Subgroup Empagliflozin Placebo Absolute difference (95% CI) Total slope Diabetes Present 2. 01 (0. 11) 2. 91 (0. 11) 0. 90 (0. 59, 1. 21) Absent 2. 30 (0. 10) 2. 92 (0. 10) 0. 62 (0. 33, 0. 91) Estimated GFR (ml/min per 1. 73 m2) 30 2. 12 (0. 13) 2. 64 (0. 13) 0. 51 (0. 15, 0. 87) 30 45 1. 86 (0. 11) 2. 59 (0. 11) 0. 73 (0. 42, 1. 05) 45 2. 83 (0. 16) 4. 04 (0. 17) 1. 21 (0. 76, 1. 67) Urinary albumin-to-creatinine ratio (mg/g) 30 0. 72 (0. 16) 0. 88 (0. 16) 0. 17 (0. 27, 0. 60) 30 300 1. 19 (0. 13) 1. 64 (0. 13) 0. 46 (0. 09, 0. 83) 300 3. 22 (0. 10) 4. 42 (0. 10) 1. 19 (0. 92, 1. 47) All participants 2. 16 (0. 08) 2. 92 (0. 08) 0. 75 (0. 54, 0.
----------------------------------------------------------------------


======================================================================
CHUNK 383 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_109
Content Type: recommendation
Words: 491
Medical Entities: CKD,GFR,proteinuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
27, 0. 60) 30 300 1. 19 (0. 13) 1. 64 (0. 13) 0. 46 (0. 09, 0. 83) 300 3. 22 (0. 10) 4. 42 (0. 10) 1. 19 (0. 92, 1. 47) All participants 2. 16 (0. 08) 2. 92 (0. 08) 0. 75 (0. 54, 0. 96) Long-term slope Diabetes Present 1. 05 (0. 12) 2. 73 (0. 12) 1. 68 (1. 36, 2. 00) Absent 1. 66 (0. 11) 2. 75 (0. 11) 1. 09 (0. 79, 1. 39) Estimated GFR (ml/min per 1. 73 m2) 30 1. 84 (0. 14) 2. 85 (0. 14) 1. 01 (0. 63, 1. 39) 3045 1. 18 (0. 12) 2. 50 (0. 12) 1. 32 (0. 99, 1. 65) 45 1. 58 (0. 17) 3. 60 (0. 17) 2. 01 (1. 53, 2. 49) Urinary albumin-to-creatinine ratio (mg/g) 30 0. 11 (0. 17) 0. 89 (0. 16) 0. 78 (0. 32, 1. 23) 30 300 0. 49 (0. 14) 1. 69 (0. 14) 1. 20 (0. 81, 1. 59) 300 2. 35 (0. 11) 4. 11 (0. 11) 1. 76 (1. 46, 2. 05) All participants 1. 37 (0. 08) 2. 75 (0. 08) 1. 37 (1. 16, 1. 59) 1 0. 5 0 0. 5 1 1. 5 2 Placebo better Empagliflozin better Figure25Effectsofempagliflozinversusplaceboonannualrateofchangeinestimatedglomerularfiltrationrate(GFR)bykey subgroupsintheStudyofHeartandKidneyProtectionWithEmpagliflozin(EMPA-KIDNEY). CI, confidenceinterval. ReproducedfromThe NewEnglandJournalofMedicine, TheEMPA-KIDNEYCollaborativeGroup, HerringtonWG, StaplinN, WannerC, etal. Empagliflozininpatients withchronickidneydisease, volume388, issue2, Copyright2023MassachusettsMedicalSociety. Reprintedwithpermissionfrom MassachusettsMedicalSociety. 403 Specialconsiderations There is limited research on kidney effects of SGLT2i in Pediatric considerations. SGLT2i have not been tested in children. One study of 8 childrenwith CKD and proteinuria clinical trials on children with kidney disease. Limited foundareductionin24-hoururineproteinfromameanof2. 1 observational data and phase II trial data exist for children g/d to a mean of 1. 5 g/d over 12 weeks. 530 Theoretically, the with and without kidney disease. Four studies (99 children glycosuric effect of SGLT2i may lead to a negative calorie and youngadults with diabetesand normal GFR) found that balance, interfering with optimal growth, especially in small pharmacokinetics and pharmacodynamics were likely to be childrenwithunderlyinggrowthretardation. Clinicaltrialsin the same in children and adults. 525528 Recent workmodeled the pediatric population are suggested, including in those pediatric dapagliflozin dosing for smaller children based on with specific etiologies and at different age groups (i. e. , known pharmacokinetics and pharmacodynamics. 483 Side prepubescent, peripubescent, andpostpubescent). effects reported from the prior studies included an increase in glycosuria and infrequent reporting of nausea, genital 3. 8 Mineralocorticoid receptor antagonists (MRA) infection, dehydration, and abdominal pain. In an RCT, there were no episodes of diabetic ketoacidosis and similar TheWorkGrouphighlightsakeyrecommendationandpractice numbers of hypoglycemia between placebo and points from the KDIGO 2022 Clinical Practice Guideline for dapagliflozin, mostly occurring in those on insulin. 529 DiabetesManagementinChronicKidneyDisease. 23 KidneyInternational(2024)105(Suppl4S), S117S314 S219 chapter 3 www. kidney-international. org K 4. 8 mmol/l K 4. 95. 5 mmol/l K 5. 5 mmol/l Initiate finerenone Continue finerenone 10 mg or 20 mg Hold finerenone - 10 mg daily if eGFR 2559 ml/min/1.
----------------------------------------------------------------------


======================================================================
CHUNK 384 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_110
Content Type: recommendation
Words: 477
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
529 DiabetesManagementinChronicKidneyDisease. 23 KidneyInternational(2024)105(Suppl4S), S117S314 S219 chapter 3 www. kidney-international. org K 4. 8 mmol/l K 4. 95. 5 mmol/l K 5. 5 mmol/l Initiate finerenone Continue finerenone 10 mg or 20 mg Hold finerenone - 10 mg daily if eGFR 2559 ml/min/1. 73 m2 Monitor K every 4 months Consider adjustments to diet or concomitant - 20 mg daily if eGFR 60 ml/min/1. 73 m2 medications to mitigate hyperkalemia Monitor K at 1 month after initiation and then every 4 Recheck K months Consider reinitiation if/when K 5. 0 mmol/l Increase dose to 20 mg daily, if on 10 mg daily Restart 10 mg daily if previously held for hyperkalemia and K now 5. 0 mmol/l Figure26Serumpotassiummonitoringduringtreatmentwithanonsteroidalmineralocorticoidreceptorantagonist(MRA) (finerenone). AdaptedfromtheprotocolsofFinerenoneinReducingKidneyFailureandDiseaseProgressioninDiabeticKidneyDisease(FIDELIODKD)andFinerenoneinReducingCardiovascularMortalityandMorbidityinDiabeticKidneyDisease(FIGARO-DKD). TheWorkGroupconsiders thesepotassiumthresholdstobeconservative, anditmaybeconsideredappropriatetocontinueMRAsinpeoplewithpotassiumof5. 56. 0mmol/ l. ThisalgorithmcouldbeusedforsteroidalMRA. TheUSFoodandDrugAdministration(FDA)hasapprovedinitiationofK5. 0mmol/l. This figureisguidedbytrialdesignandtheFDAlabelandmaybedifferentinothercountries. Serumcreatinine/estimatedglomerularfiltrationrate (eGFR)shouldbemonitoredconcurrentlywithserumpotassium. ReproducedfromKidneyDisease: ImprovingGlobalOutcomesDiabetesWork Group. KDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease. KidneyInt. 2022; 102: S1S127. 23 Recommendation 3. 8. 1: We suggest a nonsteroidal the nonsteroidal MRA (ns-MRA) finerenone reduced mineralocorticoid receptor antagonist with proven cardiovascular risk in people with CKD and T2D (HR: 0. 86; kidneyorcardiovascularbenefitforadultswithT2D, 95% CI: 0. 780. 95). The benefit was in large part due to a an eGFR 25 ml/min per 1. 73 m2, normal serum 22% reduction in the risk of hospitalization for heart failure potassiumconcentration, andalbuminuria(30mg/ (HR: 0. 78; 95% CI: 0. 660. 92), with no clear effect on stroke g 3 mg/mmol) despite maximum tolerated dose of RAS inhibitor (RASi) (2A). (Figure 27). 535 These trials have some limitations on their generalizability to all people with CKD at risk of progression, Practice Point 3. 8. 1: Nonsteroidal MRA are most given that study participants had an eGFR of 25 ml/min appropriateforadultswithT2Dwhoareathighriskof per 1. 73 m2 and an ACR of 30 mg/g (3 mg/mmol), and CKD progression and cardiovascular events, as that people without diabetes were excluded. demonstrated by persistent albuminuria despite other Whetherbasedonlaboratorydataorinvestigatorreports, standard-of-care therapies. finerenone approximately doubled the RR of hyperkalemia compared with controls. However, risks were generally low Practice Point 3. 8. 2: A nonsteroidal MRA may be added andaverageincreaseinserumpotassiumwasapproximately toaRASiandanSGLT2ifortreatmentofT2DandCKD 0. 20. 3mEqfrombaselinevalues. Thelowabsolutebaseline in adults. risk of hyperkalemia may be due to the selection of particPractice Point 3. 8. 3: To mitigate risk of hyperipants with serum potassium 4. 8 mmol/l and careful kalemia, select people with consistently normal serum algorithmic monitoring of potassium during follow-up. potassiumconcentrationandmonitorserumpotassium Specific analyses of FIDELIO-DKD reported that 2. 3% and regularly after initiation of a nonsteroidal MRA 11. 0% of participants in the finerenone group withdrew or (Figure 26). interrupted treatment due to hyperkalemia (defined as serum potassium 5. 5 mmol/l), respectively, versus Practice Point 3. 8. 4: The choice of a nonsteroidal MRA 0. 9% and 5. 2% for the placebo group. 535 Overall, in should prioritize agents with documented kidney or cardiovascular benefits. FIDELITY, permanent treatment withdrawal for hyperkalemia was 1. 7% versus 0. 6%. Hospitalization for Practice Point 3. 8.
----------------------------------------------------------------------


======================================================================
CHUNK 385 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_111
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
8. 4: The choice of a nonsteroidal MRA 0. 9% and 5. 2% for the placebo group. 535 Overall, in should prioritize agents with documented kidney or cardiovascular benefits. FIDELITY, permanent treatment withdrawal for hyperkalemia was 1. 7% versus 0. 6%. Hospitalization for Practice Point 3. 8. 5: A steroidal MRA may be used for serious hyperkalemia was relatively rare with a 1% excess treatment of heart failure, hyperaldosteronism, or rerisk over 3 years. 536 Finerenone was also otherwise fractoryhypertension, butmaycausehyperkalemiaora generally well-tolerated with no excess risk for serious AKI reversible decline in glomerular filtration, particularly identified in the 2 large trials. Further details are available among people with a low GFR. in the KDIGO 2022 Clinical Practice Guideline for MRAs reduce BP and albuminuria in people with CKD531 Diabetes Management in Chronic Kidney Disease. 23 and are part of recommended care for heart failure with Trials assessing the effect of combining an SGLT2i and reduced ejection fraction. 532 The large Finerenone in finerenone compared with either alone are ongoing (ClinReducing Kidney Failure and Disease Progression in Diabetic icalTrials. gov Identifier: NCT05254002). Adequately powKidney Disease (FIDELIO-DKD)533 and Finerenone in ered, large-scale, clinical outcome, placebo-controlled trials Reducing Cardiovascular Mortality and Morbidity in Diabetic of steroidal and ns-MRAs have not been conducted in Kidney Disease (FIGARO-DKD)534 placebo-controlled trials people with causes of CKD not related to diabetes, but are and their pooled analysis (FIDELITY)535 demonstrated that ongoing. 537 S220 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Outcome Finerenone (n 6519) Placebo (n 6507) Hazard ratio P valuea (95% CI) Number of Number of Number of Number of patients patients with patients patients with with event event per 100 with event event per 100 (%) patient-years (%) patient-years Composite cardiovascular outcomeb 825 (12. 7) 4. 34 939 (14. 4) 5. 01 0. 86 (0. 780. 95) 0. 0018 Death from cardiovascular causes 322 (4. 9) 1. 61 364 (5. 6) 1. 84 0. 88 (0. 761. 02) 0. 092 Nonfatal myocardial infarction 173 (2. 7) 0. 88 189 (2. 9) 0. 97 0. 91(0. 741. 12) 0. 36 Nonfatal stroke 198 (3. 0) 1. 01 198 (3. 0) 1. 02 0. 99 (0. 821. 21) 0. 95 Hospitalization for heart failure 256 (3. 9) 1. 31 325 (5. 0) 1. 68 0. 78 (0. 660. 92) 0. 0030 eGFR 57% composite kidney outcomec 360 (5. 5) 1. 96 465 (7. 1) 2. 55 0. 77 (0. 670. 88) 0. 0002 Kidney failure 254 (3. 9) 1. 38 297 (4. 6) 1. 62 0. 84 (0. 710. 99) 0. 039 End-stage kidney diseased 151 (2. 3) 0. 76 188 (2. 9) 0. 96 0. 80 (0. 640. 99) 0. 040e Sustained decrease in eGFR to 15 ml/min/1. 73 m2 195 (3. 0) 1. 06 237 (3. 6) 1. 29 0. 81(0. 670. 98) 0. 026e Sustained 57% decrease in eGFR from baseline 257 (3. 9) 1. 40 361 (5. 5) 4. 03 0. 70 (0. 600. 83) 0. 0001 Renal death 2 (0.
----------------------------------------------------------------------


======================================================================
CHUNK 386 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_112
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
73 m2 195 (3. 0) 1. 06 237 (3. 6) 1. 29 0. 81(0. 670. 98) 0. 026e Sustained 57% decrease in eGFR from baseline 257 (3. 9) 1. 40 361 (5. 5) 4. 03 0. 70 (0. 600. 83) 0. 0001 Renal death 2 (0. 1) 0. 01 4 (0. 1) 0. 02 0. 53 (0. 102. 91) 0. 46e eGFR 40% composite kidney outcomef 854 (13. 1) 4. 81 995 (15. 3) 5. 64 0. 85 (0. 770. 93) 0. 0004 Sustained 40% decrease in eGFR from baseline 817 (12. 5) 4. 60 962 (14. 8) 5. 45 0. 84 (0. 760. 92) 0. 0002 Death from any cause 552 (8. 5) 2. 76 614 (9. 4) 3. 10 0. 89 (0. 791. 00g) 0. 051e Hospitalization for any cause 2836 (43. 5) 19. 04 2926 (45. 0) 19. 91 0. 96 (0. 911. 01) 0. 087e 0. 5 1. 0 2. 0 Favors finerenone Favors placebo Figure27EffectoffinerenoneversusplaceboonkidneyandcardiovascularoutcomesinpooledanalysesfromtheFinerenonein ReducingKidneyFailureandDiseaseProgressioninDiabeticKidneyDisease(FIDELIO-DKD)andFinerenoneinReducing CardiovascularMortalityandMorbidityinDiabeticKidneyDisease(FIGARO-DKDtrials). CI, confidenceinterval; eGFR, estimated glomerularfiltrationrate. aStatisticaltestswherePvaluesareprovidedwereexploratoryinnature; therefore, noadjustmentformultiplicitywas performed. bThecompositeoftimetofirstonsetofcardiovasculardeath, nonfatalmyocardialinfarction, nonfatalstroke, orhospitalizationfor heartfailure. cThecompositeoftimetofirstonsetofkidneyfailure, sustained57%decreaseinestimatedglomerularfiltrationratefrom baselineover4weeks, orrenaldeath. dInitiationofchronicdialysisfor90daysorkidneytransplantation. eAnalysesforPvaluesnot prespecified. fThecompositeoftimetofirstonsetofkidneyfailure, sustained40%decreaseinestimatedglomerularfiltrationratefrom baselineover4weeks, orrenaldeath. gP1. 001to3decimalplaces. ReproducedfromAgarwalR, FilippatosG, PittB, etal. Cardiovascular andkidneyoutcomeswithfinerenoneinpatientswithtype2diabetesandchronickidneydisease: theFIDELITYpooledanalysis. EurHeartJ. 2022; 43: 474484. 535TheAuthor(s)2021. PublishedbyOxfordUniversityPressonbehalfoftheEuropeanSocietyofCardiology. Thisisan OpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttribution-NonCommercialLicense( licenses/by-nc/4. 0/). Specialconsiderations ResultsoftheFLOWtrialassessingeffectsofGLP-1RAin Pediatricconsiderations. No relevant studies to inform this a dedicated CKD population are awaited. It is a definitive guideline have been completed in children. assessment of semaglutide on kidney outcomes in 3534 people with CKD, albuminuria, and T2D. 537a Nevertheless, 3. 9 Glucagon-like peptide-1 receptor agonists extrapolating current evidence from trials in people with (GLP-1 RA) T2D where kidney function was generally preserved suggests GLP-1 RA safely improve glycemic control and TheWorkGrouphighlightsakeyrecommendationandpractice may reduce weight and risk of CVD in people with point from the KDIGO 2022 Clinical Practice Guideline for CKD. 23, 538 Meta-analysis of these large, placebo-controlled DiabetesManagementinChronicKidneyDisease. 23 cardiovascular outcome GLP-1 RA trials has shown reduced MACE in people with prior CVD or at high risk. 538 The Recommendation 3. 9. 1: In adults with T2D and CKD size of RR reductions on cardiovascular risk appears similar who have not achieved individualized glycemic in people with or without decreased GFR. 538 Once targets despite use of metformin and SGLT2 inhibaggregated, GLP-1 RAs were shown to have modestly itor treatment, or who are unable to use those reduced risk of hospitalization for heart failure (HR: 0. 89; medications, werecommendalong-actingGLP-1RA 95% CI: 0. 820. 92) and separately reduced risk of death (1B). from any cause (HR: 0. 88; 95% CI: 0. 820. 94). 538 The KDIGO 2022 Clinical Practice Guideline for Diabetes Practice Point 3. 9. 1: The choice of GLP-1 RA should Management in Chronic Kidney Disease has recommended prioritize agents with documented cardiovascular benefits. that long-acting GLP-1 RAs are prioritized ahead of insulin in people with T2D and CKD. GLP-1 RAs with proven KidneyInternational(2024)105(Suppl4S), S117S314 S221 1 per 1. 73 m2 with reductions most evident in CKD stages G4 G5 (Figure 28, 541 Table 23).
----------------------------------------------------------------------


======================================================================
CHUNK 387 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_113
Content Type: recommendation
Words: 487
Medical Entities: CKD,GFR,proteinuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
that long-acting GLP-1 RAs are prioritized ahead of insulin in people with T2D and CKD. GLP-1 RAs with proven KidneyInternational(2024)105(Suppl4S), S117S314 S221 1 per 1. 73 m2 with reductions most evident in CKD stages G4 G5 (Figure 28, 541 Table 23). The adjusted adult prevalence of 0 serum bicarbonate 22 mmol/l was 7. 7% and 6. 7% in those with and without diabetes at stage G3, A1, respectively, increasing to 38. 3% and 35. 9% by CKD stage G5, A3. 1 Practice Point 3. 10. 1: In people with CKD, consider use of 2 pharmacological treatment with or without dietary intervention to prevent development of acidosis with potential 3 clinical implications (e. g. , serum bicarbonate 18 mmol/l in adults). 4 Practice Point 3. 10. 2: Monitor treatment for metabolic 5 acidosis to ensure it does not result in serum bicarbonate 15 30 45 60 75 90 105 120 concentrations exceeding the upper limit of normal and eGFR, ml/min/1. 73 m2 does not adversely affect BP control, serum potassium, or fluid status. The Work Group has not provided a graded recommendationforthetreatmentofacidosisduetoalackoflarge-scale RCTs supporting its use. In 2012, a 2B recommendation was justified because alkali supplementation may be a promising low-cost, high-benefitadjuncttreatmentforpeoplewithCKD andmaybeaccessibletoallpopulations. Thiswasbasedonan RCT that had suggested potential kidney disease progression and nutritional benefits with no important increase in BPor heart failure complications. 1 However, since 2012, a number of trials testing the hypothesis that sodium bicarbonate cardiovascular benefitthatdonotrequiredoseadjustmentin therapy would slow kidney disease progression have been CKD include liraglutide, semaglutide (injectable), and reported, including several employing placebo control. A dulaglutide. 23 2021 systematic review identified 15 trials with 3 months of follow-up in people with CKD (eGFR 60 ml/min per 3. 10 Metabolic acidosis 1. 73 m2 and/or proteinuria) comparing the effects of oral sodium bicarbonate versus placebo or versus no study As GFR decreases, the kidneys ability to excrete hydrogen medication on kidney outcomes. Of the 15 trials (2445 ions and generate bicarbonate decreases, resulting in the participants, median follow-up 12 months), 11 were development of chronic metabolic acidosis. Metabolic published since 2012. The totality of the evidence remains acidosis is observationally associated with increased risk of limited by a low number of outcomes, and meta-analysis protein catabolism, muscle wasting, inflammation, and other restricted to the placebo-controlled trials does not confirm complications such as impaired cardiac function and morany important modifying effect of oral sodium bicarbonate tality thatarealsoassociatedwithdecreasedeGFR. 539, 540The versus placebo on risk of kidney failure (HR: 0. 81; 95% CI: causality of such associations remains to be demonstrated. 0. 541. 22). 542 The largest placebo-controlled trial of oral Definitionandprevalence. Serumbicarbonateconcentration sodium bicarbonate was conducted by the Clinical and begins to fall progressively once eGFR falls below 60 ml/min cost-effectiveness of oral sodium bicarbonate therapy for l/lomm, etanobracib mureS chapter 3 www. kidney-international. org A1 A2 A3 Figure28Associationbetweenestimatedglomerularfiltration rate(eGFR)withserumbicarbonateconcentrationingeneral populationandhigh-riskcohortsfromtheChronicKidney DiseasePrognosisConsortium, bylevelofalbuminuria(A1A3). Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthe meanadjustedvalueataneGFRof80ml/minper1. 73m2and albuminexcretion30mg/g(3mg/mmol). Reproducedfrom AmericanJournalofKidneyDiseases, volume73, issue2, InkerLA, GramsME, LeveyAS, etal.
----------------------------------------------------------------------


======================================================================
CHUNK 388 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_114
Content Type: recommendation
Words: 497
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org A1 A2 A3 Figure28Associationbetweenestimatedglomerularfiltration rate(eGFR)withserumbicarbonateconcentrationingeneral populationandhigh-riskcohortsfromtheChronicKidney DiseasePrognosisConsortium, bylevelofalbuminuria(A1A3). Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthe meanadjustedvalueataneGFRof80ml/minper1. 73m2and albuminexcretion30mg/g(3mg/mmol). Reproducedfrom AmericanJournalofKidneyDiseases, volume73, issue2, InkerLA, GramsME, LeveyAS, etal. RelationshipofestimatedGFRand albuminuriatoconcurrentlaboratoryabnormalities: anindividual participantdatameta-analysisinaGlobalConsortium, pages206 217, Copyright2018, withpermissionfromtheNationalKidney Foundation, Inc. 541 Table23Variation oflaboratoryvalues inalarge populationdatabaseabyagegroup, sex, andeGFR; bicarbonate, mmol/l, mean(SD), andn3, 990, 898 GFRcategory(ml/minper1. 73m2) Measure, mean(SD) Age(yr) Sex 105D 90104 7589 6074 4559 3044 1529 014 Serumbicarbonate 65 Female 27. 4(4. 1) 27. 1(2. 9) 26. 9(2. 9) 26. 8(2. 9) 26. 5(3. 1) 25. 9(3. 5) 24. 8(4. 0) 24. 0(4. 8) Male 27. 1(3. 9) 26. 6(2. 9) 26. 7(2. 9) 26. 5(2. 9) 26. 1(3. 1) 25. 3(3. 8) 24. 1(4. 0) 24. 2(4. 8) 65 Female 25. 2(2. 8) 26. 1(2. 8) 26. 3(2. 8) 26. 4(2. 9) 26. 2(3. 2) 25. 1(3. 6) 23. 6(4. 2) 24. 0(5. 0) Male 26. 4(2. 8) 26. 5(3. 0) 26. 6(2. 7) 26. 5(2. 9) 25. 9(3. 2) 24. 8(4. 4) 23. 5(4. 1) 24. 4(4. 7) eGFR, estimatedglomerularfiltrationrate; GFR, glomerularfiltrationrate. aDatafromtheOptumLabsDataWarehouse, alongitudinal, real-worlddataassetwithdeidentifiedadministrativeclaimsandelectronichealthrecorddata. Thedatabase containslongitudinalhealthinformationonenrolleesandpatients, representingthediversityofgeographicalregionsacrosstheUnitedStates. S222 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 older people with chronic kidney disease and low-grade alkaline-rich plant-based diets in adults with CKD acidosis (BiCARB) Study Group. 543 It contributed 33 of 152 demonstrate a comparable benefit to oral sodium versus 33 of 148 kidney failure outcomes to the metabicarbonate in controlling metabolic acidosis. 548551 analysis in its bicarbonate versus placebo arms, respectively (HR: 0. 97; 95% CI: 0. 641. 49). Importantly, the BiCARB Specialconsiderations trial, which studied people with CKD G3G4 aged 60 Pediatric considerations. As in adults, children with CKD years and sodium bicarbonate concentration 22 mmol/l, often have metabolic acidosis. In the CKiD and the Cardioalso found no evidence of benefit on nonkidney outcomes vascularComorbidityinChildrenwithChronicKidneyDisease to support oral sodium bicarbonate supplementation (the Study(4C)studies, 38%60%ofchildrenhadaserumbicarprimary outcome was based on the Short Physical bonate of22mmol/l, varyingbyCKD category. Low bicarPerformance Battery at 12 months, and secondary outcomes bonate was associated with increased risk of disease included generic and disease-specific QoL assessments, progression. 395, 552 It should also be noted that for younger anthropometry, kidney function, walk distance, BP, and children, the normal range for sodium bicarbonate is as low bone and vascular health markers). Allocation to oral as 17 mmol/l. In children, metabolic acidosis is also likely to sodium bicarbonate was associated with higher costs and cause growth retardation. Data from the observational CKiD lower European Quality of Life 5 Dimensions 3 Level study revealed that prepubertal children with acidosis who Version (EQ-5D-3L) assessed QoL over 1 year. 543 were treated with alkali had improved growth. 553 In children Licensed non-alkali oral interventions may be an alternawith normal GFR but renal tubular acidosis, prolonged tivetooralsodiumbicarbonatetotreatmetabolicacidosisbut acidosis can also result in poor growth. The KDOQI have not been shown to have particular advantages. 544, 545 guideline on bone metabolism for children with CKD Although placebo-controlled trials have found no good recommends the prevention of acidosis in children to evidence that correcting sodium bicarbonate levels has optimizegrowth.
----------------------------------------------------------------------


======================================================================
CHUNK 389 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_115
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The KDOQI have not been shown to have particular advantages. 544, 545 guideline on bone metabolism for children with CKD Although placebo-controlled trials have found no good recommends the prevention of acidosis in children to evidence that correcting sodium bicarbonate levels has optimizegrowth. 554Therehavenotbeenanytrialsexamining important effects on clinical outcomes, the Work Group the effect of bicarbonate supplementation on CKD concluded that the intervention is clearly effective at progressionorgrowthinchildren. increasing serum bicarbonate concentration and is a suitable treatment to avoid more severe acidosis with 3. 11 Hyperkalemia in CKD potential for clinical implications. The Work Group suggests that a serum bicarbonate of 18 mmol/l in adults is Definition and prevalence. Potassium is key to cell memdesirable to avoid, but large RCTs are required to determine brane electrophysiology, with abnormalities predisposing to a precise threshold whereby the treatment of low serum abnormal cardiac conduction and arrhythmias. The kidneys bicarbonate levels leads to improvements in clinical playakeyroleinpotassiumhomeostasiswithdecreasedGFR outcome. As correction of bicarbonate to the normal range generally associated with increased potassium concentration has not been demonstrated to reduce the risk of kidney (Table 24; Figure 29555). The definition of hyperkalemia is failure, lower thresholds to initiate therapy than 18 mmol/l based on the distribution of potassium values in the general could be considered (see Research Recommendations). population. Hyperkalemia is uncommon when the eGFR is Dietary approaches. Dietary modifications that limit the 60 ml/min per 1. 73 m2 and increases with lower GFR. consumption of acid-rich foods and/or increase the intake of AdultswithCKDG3, A1inthegeneralandhigh-riskpopalkaline-richfoodsreducethenetendogenousacidproduction ulationcohorts, contributingtotheCKD-PC, hadanadjusted and can serve as an additional strategy to control metabolic prevalence of hyperkalemia (defined as a serum potassium acidosisinpeoplewithCKD. 546, 547Suchdietsaregenerallylow 5. 0 mmol/l) of 8. 8% and 4. 5% in those with and without inanimalproteinorhaveahigherconsumptionofplant-based diabetes, respectively, increasingto34. 4%and23. 7%byCKD foodsoveranimal-basedfoods(i. e. , plant-dominantdietssuch G5, A3 (Figure 30). 541 Note that there is variability in the as Mediterranean or vegetarian diets). Four small RCTs of prevalence of hyperkalemia, and it is not inevitable at lower Table24Variationoflaboratoryvaluesinalargepopulationdatabaseabyagegroup, sex, andeGFR; potassium, mmol/l, mean (SD), andn4, 278, 600 GFRcategory(ml/minper1. 73m2) Measure, mean(SD) Age(yr) Sex 105D 90104 7589 6074 4559 3044 1529 014 Serumpotassium 65 Female 4. 1(0. 5) 4. 2(1. 3) 4. 2(0. 5) 4. 3(0. 5) 4. 3(1. 3) 4. 4(0. 5) 4. 5(1. 0) 4. 5(2. 0) Male 4. 2(0. 5) 4. 3(0. 6) 4. 3(1. 1) 4. 4(0. 6) 4. 4(0. 7) 4. 5(1. 1) 4. 6(0. 6) 4. 6(1. 6) 65 Female 4. 1(0. 7) 4. 2(1. 3) 4. 3(17. 0) 4. 2(1. 0) 4. 3(0. 5) 4. 3(0. 6) 4. 4(0. 6) 4. 5(1. 1) Male 4. 2(0. 4) 4. 3(0. 5) 4. 3(0. 6) 4. 3(0. 4) 4. 4(0. 5) 4. 5(0. 6) 4. 5(0. 7) 4. 6(0. 7) eGFR, estimatedglomerularfiltrationrate; GFR, glomerularfiltrationrate. aDatafromtheOptumLabsDataWarehouse, alongitudinal, real-worlddataassetwithdeidentifiedadministrativeclaimsandelectronichealthrecorddata. Thedatabase containslongitudinalhealthinformationonenrolleesandpatients, representingthediversityofgeographicalregionsacrosstheUnitedStates. KidneyInternational(2024)105(Suppl4S), S117S314 S223 ACR and prior diabetes, hyperglycemia, constipation, RASi, 557 and MRA. 536 Note that SGLT2i do not appear to 1 increase serum potassium values.
----------------------------------------------------------------------


======================================================================
CHUNK 390 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_116
Content Type: reference
Words: 499
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
3(0. 4) 4. 4(0. 5) 4. 5(0. 6) 4. 5(0. 7) 4. 6(0. 7) eGFR, estimatedglomerularfiltrationrate; GFR, glomerularfiltrationrate. aDatafromtheOptumLabsDataWarehouse, alongitudinal, real-worlddataassetwithdeidentifiedadministrativeclaimsandelectronichealthrecorddata. Thedatabase containslongitudinalhealthinformationonenrolleesandpatients, representingthediversityofgeographicalregionsacrosstheUnitedStates. KidneyInternational(2024)105(Suppl4S), S117S314 S223 ACR and prior diabetes, hyperglycemia, constipation, RASi, 557 and MRA. 536 Note that SGLT2i do not appear to 1 increase serum potassium values. 403, 517 Studies have demonstrated a continuous U-shaped rela0. 8 tionship between serum potassium and all-cause mortality in a range of different populations (Figure 31). 555, 558 It has 0. 6 also been associated with worse kidney prognosis. 559 Observationally, the risk of death from the same degree of 0. 4 hyperkalemia is lower in more advanced CKD stages. 560564 This may suggest that there are adaptive mechanisms that 0. 2 render better tolerance to elevated levels of potassium in circulation. 561, 565568 0 3. 11. 1Awareness offactorsimpactingonpotassium measurement There are several factors and mechanisms that may impact on potassium measurements, including the actions of medications thatcanincreasetheriskofdevelopinghyperkalemia. Theseare summarizedinTables25556, 569575and26. 23, 576 Practice Point 3. 11. 1. 1: Be aware of the variability of potassium laboratory measurements as well as factors and mechanisms that may influence potassium measurement including diurnal and seasonal variation, plasma versus serum samples, and the actions of medications. TheWorkGroupwouldliketohighlightFigure26forthe monitoring of serum potassium during treatment with a levelsofGFR, thusunderstandingpotassiumphysiologyandits nonsteroidal MRA (finerenone) from the KDIGO 2022 impactingfactorsareimportantineffectivepatientcare. Clinical Practice Guideline for Diabetes Management in Hyperkalemia in people with preserved GFR is less prevChronic Kidney Disease. 23 alent. Anacuteepisodeofhyperkalemiaisapotassiumresult Hyperkalemiahasbeenassociatedwiththerapeuticactions above the upper limit of normal that is not known to be ofeitherreducingorstoppingRASi. 577580Stepscanbetaken chronic. At the current time, there is no consensus on the to mitigate the risk of hyperkalemia and improve potassium magnitude, duration, and frequency of elevated potassium controlthatcouldincreasetheuseofRASi inpeoplewithan values that define chronicity. 556 In addition to decreased evidenced indication. For details on how to manage hypereGFR, other risk factors for hyperkalemia included higher kalemia associated with the use of RASi and associated No diabetes Diabetes Hyperkalemia Hyperkalemia eGFR A1 A2 A3 eGFR A1 A2 A3 90 1. 5% (0. 4, 4. 6) 1. 1% (0. 3, 3. 2) 1. 4% (0. 4, 4. 4) 90 1. 8% (0. 5, 5. 5) 3. 6% (1. 1, 10. 5) 1. 0% (0. 3, 3. 0) 7589 1. 7% (0. 5, 5. 1) 1. 6% (0. 5, 4. 8) 1. 5% (0. 5, 4. 7) 7589 2. 8% (0. 8, 8. 3) 4. 0% (1. 2, 11. 6) 4. 6% (1. 4, 13. 0) 6074 2. 3% (0. 7, 7. 0) 2. 0% (0. 6, 6. 0) 2. 3% (0. 7, 7. 0) 6074 3. 9% (1. 2, 11. 2) 5. 0% (1. 5, 14. 2) 6. 6% (1. 8, 17. 4) 4559 4. 5% (1. 4, 12. 8) 3. 5% (1. 1, 10. 3) 5. 2% (1. 6, 14. 6) 4559 8. 8% (2. 7, 23. 3) 9. 9% (3. 1, 25. 5) 11. 4% (3. 6, 28. 8) 3044 9. 5% (3. 0, 24. 8) 10. 5% (3. 3, 26. 9) 11.
----------------------------------------------------------------------


======================================================================
CHUNK 391 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_117
Content Type: reference
Words: 471
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
5% (1. 4, 12. 8) 3. 5% (1. 1, 10. 3) 5. 2% (1. 6, 14. 6) 4559 8. 8% (2. 7, 23. 3) 9. 9% (3. 1, 25. 5) 11. 4% (3. 6, 28. 8) 3044 9. 5% (3. 0, 24. 8) 10. 5% (3. 3, 26. 9) 11. 3% (3. 6, 28. 5) 3044 12. 8% (4. 1, 31. 5) 18. 7% (6. 3, 41. 9) 87. 5% (67. 1, 95. 6) 1529 16. 1% (5. 3, 37. 5) 19. 0% (6. 4, 42. 5) 23. 7% (8. 3, 49. 4) 1529 24. 7% (8. 8, 50. 8) 31. 5% (11. 9, 59. 1) 34. 4% (13. 3, 62. 2) Figure30Meta-analyzedadjustedprevalenceofhyperkalemia(25thand75thpercentilecohort)ingeneralpopulationandhigh-risk cohortsfromtheChronicKidneyDiseasePrognosisConsortium, bydiabetesstatus. Hyperkalemiaisdefinedaspotassium5mmol/l. The adjustedprevalenceofhyperkalemiaateachestimatedglomerularfiltrationrate(eGFR)andalbuminuriastagewascomputedasfollows: first, therandom-effectsweightedadjustedmeanoddsatthereferencepoint(eGFR50ml/minper1. 73m2)wasconvertedintoaprevalence estimate. Tothereferenceestimate, themeta-analyzedoddsratiosforhyperkalemiawereappliedtoobtainprevalenceestimatesateGFR95, 80, 65, 35, and20ml/minper1. 73m2foreachstageofalbuminuria. Theprevalenceestimateswereadjustedto60yearsold, halfmale, nonBlack, 20%historyofCVD, 40%eversmoker, andbodymassindex30kg/m2. The25thand75thpercentilesforpredictedprevalencewerethe estimatesfromindividualcohortsinthecorrespondingpercentilesoftherandom-effectsweighteddistributionofadjustedodds. A1, albuminuria30mg/g(3mg/mmol); A2, albuminuria30300mg/g(330mg/mmol); A3, 300mg/g(30mg/mmol). Reproducedfrom AmericanJournalofKidneyDiseases, volume73, issue2, InkerLA, GramsME, LeveyAS, etal. RelationshipofestimatedGFRandalbuminuriato concurrentlaboratoryabnormalities: anindividualparticipantdatameta-analysisinaGlobalConsortium, pages206217, Copyright2018, withpermissionfromtheNationalKidneyFoundation, Inc. 541 ytisneD chapter 3 www. kidney-international. org eGFR 60 eGFR 3059 eGFR 30 2. 5 3 3. 5 4 4. 5 5 5. 5 6 6. 5 Potassium, mmol/ Figure29Distributionofbloodpotassiumingeneralpopulation andhigh-riskcohortsfromtheChronicKidneyDiseasePrognosis Consortium, byestimatedglomerularfiltrationrate(eGFR). Densityreferstotheproportionofthepopulationexperiencing serumpotassiumlevel(e. g. , 0. 08ofthepopulationwithaGFR60 haveapotassiumof3. 8; conversely, 0. 2ofthepopulationwitha GFR30haveapotassiumof5. 5). ReproducedfromKovesdyCP, MatsushitaK, SangY, etal. Serumpotassiumandadverseoutcomes acrosstherangeofkidneyfunction: aCKDPrognosisConsortium meta-analysis. EuropeanHeartJournal2018; 39: 15351542by permissionofOxfordUniversityPressonbehalfoftheEuropean SocietyofCardiology. 555Allrightsreserved. TheAuthor(s)2018. InclusionunderaCreativeCommonslicenseisprohibited. org/10. 1093/eurheartj/ehy100 S224 KidneyInternational(2024)105(Suppl4S), S117S314 1. 0 0. 9 0. 8 0. 7 0. 6 0. 5 0. 4 0. 3 0. 2 0. 1 0 2. 5 3. 0 3. 5 4. 0 4. 5 5. 0 5. 5 6. 0 6. 5 7. 0 7. 5 8. 0 Baseline serum potassium level, mEq/l Table25Factors andmechanismsthatimpact onpotassiummeasurements556, 569-575 Factor/mechanism Possiblecause/clinicalimplication Pseudohyperkalemiainvivoserumpotassiumisnormaland (cid: 3) Tighttourniquet commonlyGFRpreserved, butduringtheprocessof (cid: 3) Hand/armexercisingorclenchingatthetimeofblooddraw drawingbloodorclotting, therehasbeenareleaseof (cid: 3) Hemolysisduetovigorousshakingofbloodvial/inappropriateblooddraw intracellularpotassium equipment/inappropriatestorageofsamples (cid: 3) Ifsuspected, bloodshouldberetakenandanalyzedintheappropriate mannerandtimeframe556, 569 (cid: 3) Presenceofthrombocytosis/leukocytosis (cid: 3) Ifsuspected, takeplasmapotassiumasserumpotassiummaybefalsely increased570 Hyperkalemiaduetodisruptioninthemechanismofshifting (cid: 3) Increaseinplasmaosmolarity(e. g. , dehydrationandhyperglycemia) potassiumoutofcells (cid: 3) Massivetissuebreakdown(e. g. , rhabdomyolysisandtumorlysissyndrome) (cid: 3) b-adrenergicblockade, especiallyduringandimmediatelyafterexercise569 (cid: 3) Insulindeficiency (cid: 3) Aldosteroneblockade (cid: 3) Nonorganicacidosis Hyperkalemiaduetodisruptioninthemechanismofmoving (cid: 3) Disruptioninthereleaseofinsulininresponsetoraisedserumpotassium(e. g. , in potassiumintocells uncontrolleddiabetes) (cid: 3) Disruptiontothereleaseofaldosteroneinresponsetoaraisedserumpotassium569 Hyperkalemiaduetothedecreasedabilitytoexcrete (cid: 3) AdvancingCKDresultingininabilitytoexcreteexcessivepotassium potassium (cid: 3) Constipation: inadvancingCKD, thegutassumesamuchmoreimportantrolein maintainingpotassiumbalancebyincreasingtheexcretionofpotassium571, 572 (cid: 3) Medications: blockingtheRAASpathwayandothermedicationresultinginthe inabilitytoexcreteexcessivepotassium(Table26)569, 573 Diurnalvariationinpotassiumexcretionwithmostexcretion (cid: 3) Circadianexcretionofkidneyelectrolyteshavebeenwelldocumented. 574Clinical inhumansoccurringclosetonoon relevanceisyettobeunderstood (cid: 3) Notethe0. 240. 73mmol/lvariationinKvalueswithinindividualsovera 24-hourperiod Plasmavs. serumpotassiumvalues (cid: 3) Potassiumvaluesdifferbetweenserumandplasmavalueswithserumvaluesbeing typicallyhigher. Healthcareprovidersneedtobeawareoftherightreference valuesforthesample570 Postprandialhyperkalemia (cid: 3) AskidneyfunctiondeclinesinCKD, thereisacorrespondingdeclineintheabilityof thekidneystoincreasekaliuresispostprandially, eventuallybecoming insufficienttomaintainexternalpotassiumbalance575 CKD, chronickidneydisease; GFR, glomerularfiltrationrate; K, potassium; RAAS, renin-angiotensin-aldosteronesystem. ytilatrom fo ytilibaborp detciderP www. kidney-international. org chapter 3 HF, CKD, and DM CKD HF DM Control group Figure31Serumpotassiumconcentrationandconfounder-adjustedriskofdeathbythepresenceorabsenceofdiabetes, heart failure(HF), orchronickidneydisease(CKD). ReproducedfromCollinsAJ, PittB, ReavenN, etal. Associationofserumpotassiumwithallcausemortalityinpatientswithandwithoutheartfailure, chronickidneydisease, and/ordiabetes. AmJNephrol. 2017; 46: 213221. 5582017 TheAuthor(s)PublishedbyS. KargerAG, Basel. ThisarticleislicensedundertheCreativeCommonsAttribution-NonCommercial-NoDerivatives 4. 0InternationalLicense(CCBY-NC-ND)( KidneyInternational(2024)105(Suppl4S), S117S314 S225 chapter 3 www. kidney-international. org Table26Medicationsassociated withincreased riskofhyperkalemia Class Mechanism Example ACEi InhibitconversionofangiotensinItoangiotensinII Captopril, lisinopril, perindopril, etc. ARB InhibitactivationofangiotensinIreceptorbyangiotensinII Losartan, irbesartan, candesartan, etc.
----------------------------------------------------------------------


======================================================================
CHUNK 392 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_118
Content Type: reference
Words: 483
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
ReproducedfromCollinsAJ, PittB, ReavenN, etal. Associationofserumpotassiumwithallcausemortalityinpatientswithandwithoutheartfailure, chronickidneydisease, and/ordiabetes. AmJNephrol. 2017; 46: 213221. 5582017 TheAuthor(s)PublishedbyS. KargerAG, Basel. ThisarticleislicensedundertheCreativeCommonsAttribution-NonCommercial-NoDerivatives 4. 0InternationalLicense(CCBY-NC-ND)( KidneyInternational(2024)105(Suppl4S), S117S314 S225 chapter 3 www. kidney-international. org Table26Medicationsassociated withincreased riskofhyperkalemia Class Mechanism Example ACEi InhibitconversionofangiotensinItoangiotensinII Captopril, lisinopril, perindopril, etc. ARB InhibitactivationofangiotensinIreceptorbyangiotensinII Losartan, irbesartan, candesartan, etc. Aldosteroneantagonist Blockaldosteronereceptoractivation Spironolactone, eplerenone, andfinerenone b-Adrenergicreceptor Inhibitreninrelease Propranolol, metoprolol, andatenolol blocker Digitalisglycoside InhibitNa-K-ATPase, necessaryforcollectingductKsecretion Digoxin Heparin Reducedproductionofaldosterone Heparinsodium Potassium-sparing BlockcollectingductapicalNachannel, decreasinggradientforKsecretion Amilorideandtriamterene diuretic NSAIDs InhibitsynthesisofprostaglandinEandprostacyclin, inhibitingreninrelease Ibuprofen, naproxen, diclofenac, etc. CNI InhibitNa-K-ATPase, necessaryforcollectingductKsecretion Cyclosporineandtacrolimus ns-MRA BlockMR-mediatedNareabsorption Finerenone Other BlockcollectingductapicalNachannel, decreasinggradientforKsecretion Trimethoprimandpentamidine ACEi, angiotensin-convertingenzymeinhibitor; ARB, angiotensinIIreceptorblocker; ATP, adenosinetriphosphate; CNI, calcineurininhibitor; K, potassium; Na, sodium; NSAID, nonsteroidalanti-inflammatorydrug; ns-MRA, nonsteroidalmineralocorticoidreceptorantagonist. DatafromWeineretal. 576andKidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. 23 monitoring, pleaserefertoFigure21. SeeSection4. 3formore 3. 11. 4Managinghyperkalemia information on continuing RASi after hyperkalemia events. In people with CKD and the management of nonemergent hyperkalemia, a systematic approach of treating correctable factors (e. g. , correction of severe metabolic acidosis) and 3. 11. 2Potassium exchange agents understandingtheroleofdietandmedicationsmayprovide a pragmatic framework. Figure 32 shows a stepwise Practice Point 3. 11. 2. 1: Be aware of local availability or practical approach to the management of hyperkalemia in formulary restrictions with regard to the pharmacologic CKD. management of nonemergent hyperkalemia. The pharmacologic management of nonemergent hyperkalemia has a number of clinical tools with the increased 3. 11. 5Dietary considerations number of licensed potassium exchange agents. These medIn early stages of CKD, high intake of foods naturally rich in ications have differing mechanisms of action, onsets of clinpotassium appears to be protective against disease progresical effects, and potential medication and disease-state sion, and dietary restriction of foods naturally containing interactions (Table 27581, 582). Although the classic potassium potassium, such as fruits and vegetables, may be harmful to exchange agents have had tolerability issues, the newer ones cardiac health; therefore, such restriction is not endorsed. 587 appear to have fewer such issues and appear relatively safe when used long term. 575, 583, 584 Use of these newer exchange Practice Point 3. 11. 5. 1: Implement an individualized agents may help facilitate essential use of RASi/MRA. approach in people with CKD G3G5 and emergent However, it is important that the healthcare provider be hyperkalemia that includes dietary and pharmacologic inaware of clinical nuances and local availability or formulary terventions and takes into consideration associated restrictions in determining therapy selection. 583 A comorbidities and quality of life (QoL). Assessment and comparison of available potassium exchange agents can be education through a renal dietitian or an accredited found in Table 27. nutrition provider are advised. 3. 11. 3Timingto recheck potassiumafteridentifying moderPracticePoint3. 11. 5. 2: Provideadvicetolimittheintakeof ateandsevere hyperkalemiain adults foodsrichinbioavailablepotassium(e. g. , processedfoods) Think Kidneys and the UK Kidney Association have profor people with CKD G3G5 who have a history of vided a practical guide, whichwe have adapted (Table 28) for hyperkalemia or as a prevention strategy during disease repeat testing after a hyperkalemic episode. 585 The timing of periods in which hyperkalemia risk may be a concern.
----------------------------------------------------------------------


======================================================================
CHUNK 393 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_119
Content Type: reference
Words: 454
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
585 The timing of periods in which hyperkalemia risk may be a concern. repeat testing is guided by the level of hyperkalemia and the Diet may increase serum potassium postprandially, 575, 588 clinical context. 586 but other conditions such as the use of potassium-sparing S226 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Table27Acomparison ofpotassiumexchange agents (Polystyrenesulfonates)sodiumorcalcium Patiromer Sodiumzirconiumcyclosilicate(SZC) Mechanismof Sodium-potassiumexchangeresin(SPS)or Calcium-potassiumexchangepolymer CrystallinecompoundthattrapsKin action calcium-potassiumexchangeresin(CPS) exchangeforhydrogenandsodium cations Counterion SPS: Suspensioncontains65mmol/60ml(15g) 1600mgofcalciumper8. 4gof Approximately400mgofsodiumper content ofsodiumandpowderapproximately4. 1 patiromer 5gofSZC mmol/gofsodium. CPS: 1. 62. 4mmol/gofcalcium. Cationsbound Potassium, magnesium, andcalcium Potassium, magnesium, andphosphate Potassium (boundbycalciumrelease)582 Formulation Powderforreconstitution(oral), suspension Powderforreconstitution(oral) Powderforreconstitution(oral ofrouteof (oral), andenema(rectal) suspension) administration Dosageand Oral: 1560g/d(upto4timesperday) Initial: 8. 4gorallyonceperday Initial: 10gorally3timesperdayfor titration Rectal: 30g/d(forSPSuptoamaximum (maximum25. 2gorallyonceper upto48hours of50g/d) day); dosecanbeincreasedby8. 4g incrementsat1-weekintervals Maintenance 1560g/dorallyperdaydependingon 8. 425. 2gorallyonceperday 5geveryseconddayto10gonce dosing potassiumlevelandleveloftolerability perday Onsetofeffect Variable, hourstodays 47hours Startstoreducepotassiumwithin 1hourwithnormokalemiatypically at2448hours Duration Variable, 624hours 24hours Notstudied; notsystematically ofeffect absorbedandexcretedfecally Administration Separatefromoralmedicationsbyatleast Separatefromoralmedicationsbyat Nodoseadjustmentsorseparationof pearls 3hoursbeforeor3hoursafter least3hoursbeforeor3hoursafter timeofdosingisrequiredforany administration; ifgastroparesis, separate administrationexceptforthose medicationthatdoesnothavepHothermedicationsby6hours drugstonothaveaclinically dependentbioavailability. However, importantinteraction SZCshouldbeadministeredatleast 2hoursbeforeor2hoursafteroral medicinalproductswithclinically meaningfulgastricpH-dependent bioavailability Adverseeffects GIevents(nausea, vomiting, diarrhea, GIevents(nausea, diarrhea, and Hypokalemiaandedemaeventsarethe constipation), electrolytedisturbances flatulence), electrolytedisturbances mostcommon. MilderreportsofGI (hypokalemia, hypocalcemia, and (hypokalemia, hypercalcemia, and events(nausea, diarrhea, and hypomagnesemia), edema, andpotentially hypomagnesemia) constipation) seriousGIadverseevents(intestinal Insufficientpostmarketingsurveillance Insufficientpostmarketingsurveillance necrosis, bleeding, ischemiccolitis, and atpresenttoevaluatelong-term/ atpresenttoevaluatelong-term/ perforation) rareevents rareevents GI, gastrointestinal. ModifiedfromBridgemanMB, ShahM, FooteE. Potassium-loweringagentsforthetreatmentofnonemergenthyperkalemia: pharmacology, dosingandcomparativeefficacy. NephrologyDialysisTransplantation, Volume34, Supplement3, pagesiii45iii50. 581TheAuthor(s)2019. PublishedbyOxfordUniversityPressonbehalfofERA-EDTA. All rightsreserved. medications, metabolic acidosis, hyperosmosis due to Table28Suggestedaction intheeventofmoderate and hyperglycemia, hypernatremia or uremia, and constipation severehyperkalemia are more likely to explain plasma potassium abnormalities Severityof than diet. 545, 556, 572, 589 Although short-term dietary hyperkalemia ClinicallyunwellorAKI Unexpectedresult restriction of the foods highest in potassium is a valid Moderate Assessandtreat Repeatwithin strategy to treat acute hyperkalemia, restriction of foods K6. 06. 4mmol/l inhospital 24hours highest in bioavailable potassium may be a supportive Severe Takeimmediateactiontoassessandtreat. prevention strategy for people with a history of K6. 5mmol/l Assessmentwillincludebloodtestingand hyperkalemia or during periods in which hyperkalemia risk electrocardiogrammonitoring is a concern. 590 Increased efforts toward education on AKI, acutekidneyinjury; K, potassium. potassium content in foods can serve to improve diet DatafromThink Kidneys, the Renal Association and theBritish Society for Heart Failure. 585 quality and diversity for many people with CKD where this KidneyInternational(2024)105(Suppl4S), S117S314 S227 chapter 3 www. kidney-international. org 1st line: Review non-RASi medications (e. g. NSAIDs, trimethoprim) Address correctable factors Assess dietary potassium intake (dietary referral) and consider appropriate moderation of dietary potassium intake 2nd line: Consider: Medications Appropriate use of diuretics Optimize serum bicarbonate levels Licensed potassium exchange agents 3rd line: Reduce dose or discontinue RASi/MRA Last resort (Discontinuation is associated with increased cardiovascular events. Review and restart RASi or MRA at a later date if patient condition allows. ) Figure32Actionstomanagehyperkalemia(potassium5. 5mmol/l)inchronickidneydisease. MRA, mineralocorticoidreceptor antagonists; NSAID, nonsteroidalanti-inflammatorydrug; RASi, renin-angiotensinsysteminhibitors. restriction may not be needed.
----------------------------------------------------------------------


======================================================================
CHUNK 394 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_120
Content Type: reference
Words: 485
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Review and restart RASi or MRA at a later date if patient condition allows. ) Figure32Actionstomanagehyperkalemia(potassium5. 5mmol/l)inchronickidneydisease. MRA, mineralocorticoidreceptor antagonists; NSAID, nonsteroidalanti-inflammatorydrug; RASi, renin-angiotensinsysteminhibitors. restriction may not be needed. 546, 556, 591 Although guidelines with CKD and healthcare providers, using clear messaging, and available information to people with CKD have heavily on dietary approaches to potassium management is emphasized plant-based foods as potential causes of needed ( hyperkalemia in CKD, 592 other healthy nutrients in plant- 1684867542809-330edb79-52b4), as well as a policy to based foods affect potassium absorption and improve food labeling by detailing the added potassium used distribution588, 593, 594; therefore, the net bioavailable in processing. potassium from plant-based foods may be lower than appreciated. 595 Highly processed foods (rich in potassium Specialconsiderations additives), meats, dairy products, juices, and salt substitutes International considerations. For people with CKD and made with potassium chloride are actually higher in severe recurrent hyperkalemia (potassium 6 mmol/l), the absorbable potassium than many plant-based fresh foods balance to be considered is between the additional cost of (Figure 33592). 596598 the number needed to treat with potassium exchange agents Teaching materials for people with CKD should place a to prevent additional costs of hyperkalemia over and above greater focus on highly processed versus unprocessed food CKD management costs. If the price for potassium-lowering restriction for hyperkalemia management. 592 An example of therapy is lower than the reduction of inpatient and a patient resource for potassium management can be outpatient costs due to prevented hyperkalemia, the costfound at: benefit ratio will be favorable because in addition to the Potassium_Management_in_Kidney_Disease. pdf. health benefits, there is a net saving of healthcare costs Cooking methodssuchassoakingfoods for510minutes resulting from potassium-lowering treatment. The key is to in previously boiled water can effectively reduce the potasimplement a successful affordable strategy for hyperkalemia sium by half for some foods. 599 Thus, educating people management that allows the maintenance of other therapies Plant-based foods Animal-based foods Processed foods Absorption rate Absorption rate Absorption rate 50%60% 70%90% 90% Plant-based foods may have Animal-based protein has higher Potassium salts (often found in processed foods) absorption rate and carbohydrate content encourages K in higher amounts of K remaining has been reported to be 90% shifts into intracellular space, minimizing in serum impacts on serum K Figure33Potassiumabsorptionratesofplant-based, animal-based, andprocessedfoods. DatafromPicardK, GriffithsM, MagerDR, RichardC. Handoutsforlow-potassiumdietsdisproportionatelyrestrictfruitsandvegetables. JRenNutr. 2021; 31: 210214. 592 S228 KidneyInternational(2024)105(Suppl4S), S117S314 directed at reducing both progression of CKD and reduction 1. 5 in MACE. Pediatricconsiderations. AsdescribedforadultswithCKD, 1 abnormal serum potassium levels are also commonly seen in 0. 5 children with advanced stages of CKD, as well as those with 0 glomerular disorders, metabolic acidosis, and those on RASi. 600Inaddition, asmallgroupofchildrenwithCKDcan 0. 5 havepersistenthypokalemia, usuallyasaresultofinheritedor 1 acquired renal tubular disorders. 1. 5 In children with CKD, discontinuation of RASi was associated with an acceleration of kidney function decline 2 compared with a matched control cohort of children in 2. 5 whom RASi were continued.
----------------------------------------------------------------------


======================================================================
CHUNK 395 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_121
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
600Inaddition, asmallgroupofchildrenwithCKDcan 0. 5 havepersistenthypokalemia, usuallyasaresultofinheritedor 1 acquired renal tubular disorders. 1. 5 In children with CKD, discontinuation of RASi was associated with an acceleration of kidney function decline 2 compared with a matched control cohort of children in 2. 5 whom RASi were continued. 395 In children with CKD, the dietary management of potassiumcanposeuniquechallengesastheprovisionofadequate energy, protein, and micronutrients for growth cannot be compromised, and specialized low potassium nutritional formulas may not be widely available or palatable. 601 An example of a patient resource (for children and their caregivers) for potassium management can be found at: Nutrition taskforceEuropean Society for Paediatric Nephrology ( 3. 12 Anemia The KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease will be updated in 2024. 436 Mean hemoglobin is, on average, lower in both men and women with an eGFR 60 ml/min per 1. 73 m2 compared 3. 13 CKD-Mineral Bone Disorder (CKD-MBD) withhealthadultsandprogressivelyfallswithdecreasingGFR (Table 29; Figure 34541). For example, adults with CKD G3, TheWorkGrouphighlightstheKDIGO2017ClinicalPractice A1 in the general and high-risk population cohorts Guideline Update for the Diagnosis, Evaluation, Prevention, contributing to the CKD-PC had an adjusted prevalence of andTreatmentofChronicKidneyDiseaseMineralandBone anemia (hemoglobin 12 g/dl in men; 11 g/dl in women) Disorder (CKD-MBD). 20 Please refer to this publication for of 14. 9% and 11. 5% in those with and without diabetes, specific recommendations, selection, dosing of specific respectively, and this prevalence increased to 60. 7% and therapeuticagents, andresearchrecommendations. 57. 4% by CKD G5, A3. Note that a drop in Hb is expected Changes in bone mineral metabolism and alterations in in pregnancy (physiologic anemia) and may not warrant calciumandphosphatehomeostasisoccurearlyinthecourse treatment (although the cutoff at which treatment is of CKD and progress as eGFR declines (Figure 35541). These desirable is unclear and requires clinical judgment). Please are detectable as abnormalities of serum calcium, phosphate, refer to the KDIGO Clinical Practice Guideline for Anemia vitamin D metabolites, and circulating hormones (i. e. , in Chronic Kidney Disease publications for specific parathyroid hormone PTH and fibroblast growth factorrecommendations, selection, and dosing of specific 23). These changes are grouped under the umbrella term therapeutic agents, as well as research recommendations. CKD-MBD, which also includes renal osteodystrophy and Table29Variationoflaboratoryvaluesinalargepopulationdatabaseabyagegroup, sex, andeGFR; hemoglobin, g/dl, mean (SD), andn3, 561, 622 GFRcategory(ml/minper1. 73m2) Measure, mean(SD) Age(yr) Sex 105D 90104 7589 6074 4559 3044 1529 014 Hemoglobin 65 Female 12. 2(2. 0) 13. 2(4. 6) 13. 2(1. 7) 13. 2(1. 5) 12. 8(1. 6) 12. 1(1. 7) 11. 2(1. 8) 10. 3(1. 7) Male 12. 9(2. 4) 14. 2(1. 8) 14. 2(1. 7) 14. 1(1. 8) 13. 5(1. 9) 12. 7(2. 0) 11. 5(2. 0) 10. 5(2. 0) 65 Female 13. 0(1. 4) 13. 3(1. 3) 13. 4(2. 0) 13. 4(1. 4) 13. 0(1. 6) 12. 1(1. 8) 11. 0(1. 9) 10. 6(2. 5) Male 14. 9(1. 5) 15. 0(3. 1) 15. 0(1. 4) 14. 9(1. 6) 14. 1(2. 0) 12. 9(2. 2) 11. 7(2. 2) 10. 9(2. 0) eGFR, estimatedglomerularfiltrationrate; GFR, glomerularfiltrationrate. aDatafromtheOptumLabsDataWarehouse, alongitudinal, real-worlddataassetwithdeidentifiedadministrativeclaimsandelectronichealthrecorddata. Thedatabase containslongitudinalhealthinformationonenrolleesandpatients, representingthediversityofgeographicalregionsacrosstheUnitedStates.
----------------------------------------------------------------------


======================================================================
CHUNK 396 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_122
Content Type: recommendation
Words: 478
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
4(1. 4) 13. 0(1. 6) 12. 1(1. 8) 11. 0(1. 9) 10. 6(2. 5) Male 14. 9(1. 5) 15. 0(3. 1) 15. 0(1. 4) 14. 9(1. 6) 14. 1(2. 0) 12. 9(2. 2) 11. 7(2. 2) 10. 9(2. 0) eGFR, estimatedglomerularfiltrationrate; GFR, glomerularfiltrationrate. aDatafromtheOptumLabsDataWarehouse, alongitudinal, real-worlddataassetwithdeidentifiedadministrativeclaimsandelectronichealthrecorddata. Thedatabase containslongitudinalhealthinformationonenrolleesandpatients, representingthediversityofgeographicalregionsacrosstheUnitedStates. d/g, nibolgomeH www. kidney-international. org chapter 3 Female Male 15 30 45 60 75 90 105 120 eGFR, ml/min/1. 73 m2 Figure34Associationbetweenestimatedglomerularfiltration rate(eGFR)andhemoglobinconcentrationfromgeneral populationandhigh-riskcohortsfromtheChronicKidneyDisease PrognosisConsortium, bydiabetesstatus. Theyaxisrepresents themeta-analyzedabsolutedifferencefromthemeanadjustedvalue ataneGFRof80ml/minper1. 73m2andalbuminexcretion30mg/g (3mg/mmol). ReproducedfromAmericanJournalofKidneyDiseases, volume73, issue2, InkerLA, GramsME, LeveyAS, etal. Relationshipof estimatedGFRandalbuminuriatoconcurrentlaboratoryabnormalities: anindividualparticipantdatameta-analysisinaGlobalConsortium, pages206217, Copyright2018, withpermissionfromtheNational KidneyFoundation, Inc. 541 KidneyInternational(2024)105(Suppl4S), S117S314 S229 180 160 140 120 100 80 60 40 20 0 20 extraskeletal (i. e. , vascular) calcification related to these Recommendation 3. 14. 1: We recommend people abnormalities of metabolism. It has been recommended withCKDandsymptomatichyperuricemiashouldbe that in people with CKD G3aG5, treatments of CKD-MBD offered uric acidlowering intervention (1C). should be based on serial assessments of phosphate, calcium, and PTH levels considered together. 20 The Work Group placed high value on avoiding the unHigher serum phosphate concentrations are associated with mortality, 602andexperimentaldatasuggestthatserumphosphate pleasant symptoms of acute gout and preventing long-term complications of recurrent gout among people with CKD. concentration is directly related to bone disease, vascular calcification, 603, 604 and CVD. Low-phosphorus diets and There are well-tolerated and low-cost oral medications that can effectively lower blood uric acid concentration in people binders are used to help lower serum phosphate to reduce the with CKD. long-term complications of CKD-MBD, although more research is needed to fully understand the disease-modifying impact of these interventions. 605 Similarly, despite evidence Keyinformation suggesting no benefit on clinical outcomes, 606 vitamin D Balance of benefits and harms. Systematic review of the replacement and calcimimetics to control PTH levels and to management of gout by the American College of Rheumaintain calcium within the normal range are also common matology found strong evidence for uric acid lowering in strategies. Forrecommendationsregardingselectionanddosing people with tophaceous gout, radiographic damage due to with specific therapeutic agents and research, please see the gout, or frequent gout flares; some of whom also had KDIGO 2017 Clinical Practice Guideline Update for the CKD. 607 Diagnosis, Evaluation, Prevention, and Treatment of Chronic The ERTassessed the safety of uric acidlowering therapy KidneyDiseaseMineralandBoneDisorder(CKD-MBD). 20 and found that uric acid lowering did not increase adverse events among people with CKD and particularly focused on 3. 14 Hyperuricemia risk of cutaneous reactions and hypersensitivity (pooled RR: Definitionandprevalence. Uricacidistheendproductofthe 1. 00; 95% CI: 0. 601. 65) and hepatotoxicity (pooled RR: metabolism of purine compounds, and both increased urate 0. 92; 95%CI: 0. 372. 30). Uricacidloweringtherapywasalso productionanddecreasedkidneyexcretionofuricacidcanlead found not to modify the risk of cardiovascular events or allto hyperuricemia. The American College of Rheumatology causemortalityinpeoplewithCKD. 150, 609, 610Thisreassuring defines hyperuricemia as a serum uric acid concentration of cardiovascular safety profile is consistent with general 6. 8mg/dl(approximately400 m mol/l). 607 population data.
----------------------------------------------------------------------


======================================================================
CHUNK 397 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_123
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
372. 30). Uricacidloweringtherapywasalso productionanddecreasedkidneyexcretionofuricacidcanlead found not to modify the risk of cardiovascular events or allto hyperuricemia. The American College of Rheumatology causemortalityinpeoplewithCKD. 150, 609, 610Thisreassuring defines hyperuricemia as a serum uric acid concentration of cardiovascular safety profile is consistent with general 6. 8mg/dl(approximately400 m mol/l). 607 population data. In the open-label Allopurinol and Data from the US National Health and Nutrition ExamiCardiovascular Outcomes in Patients With Ischemic Heart nation Survey (NHANES) 20152016 found that the crude Disease (ALL-HEART) randomized trial, 5721 people aged adult prevalence of gout (defined as self-reported, doctor 60 years with ischemic heart disease but no history of diagnosis, oruricacidloweringtherapyuse)was3. 9%witha gout were included. Allopurinol did not modify higherprevalenceinmenthanwomen(5. 2%vs. 2. 7%). After cardiovascular risk compared with standard care (HR for adjustmentforageandsex, aneGFRconsistentwithCKDG3 the composite primary outcome of nonfatal myocardial was associated with about twicethe prevalenceof gout(odds infarction, nonfatal stroke, or cardiovascular death: 1. 04; ratio: 1. 96; 95% CI: 1. 053. 66). 608 95% CI: 0. 891. 21). Findings were similar when 540 people m/gp, enomroh dioryhtaraP 1. 2 0. 3 1. 0 0. 2 0. 8 0. 1 0. 6 0 0. 4 0. 1 0. 2 0 0. 2 0. 2 0. 3 15 30 45 60 75 90 105 120 15 30 45 60 75 90 105 120 d/gm, surohpsohp mureS nimubla( muiclac mureS d/gm, )detcerroc chapter 3 www. kidney-international. org A1 A2 A3 15 30 45 60 75 90 105 120 eGFR, ml/min/1. 73 m2 eGFR, ml/min/1. 73 m2 eGFR, ml/min/1. 73 m2 Figure35Associationbetweenestimatedglomerularfiltrationrate(eGFR)withserumconcentrationsofparathyroidhormone, phosphate, andserumcalciumingeneralpopulationandhigh-riskcohortsfromtheChronicKidneyDiseasePrognosisConsortium, by levelofalbuminuria(A1A3). Theyaxisrepresentsthemeta-analyzedabsolutedifferencefromthemeanadjustedvalueataneGFRof80ml/ minper1. 73m2andalbuminexcretion30mg/g(3mg/mmol). A1, albuminuria30mg/g(3mg/mmol); A2, albuminuria30300mg/g (330mg/mmol); A3, 300mg/g(30mg/mmol). ReproducedfromAmericanJournalofKidneyDiseases, volume73, issue2, InkerLA, Grams ME, LeveyAS, etal. RelationshipofestimatedGFRandalbuminuriatoconcurrentlaboratoryabnormalities: anindividualparticipantdatametaanalysisinaGlobalConsortium, pages206217, Copyright2018, withpermissionfromtheNationalKidneyFoundation, Inc. 541 S230 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 withaneGFRof60ml/minper1. 73m2atbaseline(among PracticePoint3. 14. 1: Considerinitiatinguricacidlowering whom 71 primary outcomes accrued) were compared with therapyforpeoplewithCKDaftertheirfirstepisodeofgout the 5181 people with an eGFR of 60 ml/min per 1. 73 m2 (particularlywherethereisnoavoidableprecipitantorserum (568 outcomes). 611 uricacidconcentrationis9mg/dl535 m mol/l). Certaintyofevidence. The overall certainty of the evidence Although the initiation of uric acidlowering therapy in for uric acidlowering therapy among people with CKD and people with a first gouty arthritis episode and no tophi was hyperuricemia is very low (see Supplementary Table notrecommendedbytheAmericanCollegeofRheumatology, S11150, 612614). The critical outcome of delaying progression uric acidlowering therapy use was suggested to be initiated of CKD was addressed by 7 RCTs. 150, 612, 615619 The 2 largest in people with CKD G3G5, serum uric acid concentration RCTs were considered to have a low risk of bias. 615, 616 The 9 mg/dl (535 m mol/l), or urolithiasis at the time of their certainty of the evidence was downgraded for inconsistency first episode of gout. This was justified by the higher risk of because there was substantial statistical heterogeneity gout progression and development of clinical tophi in detected in the meta-analysis (I2  50%) and the estimated CKD. 607 The ERTevidence review identified that uric acid RRs ranged from 0. 05 to 2. 96.
----------------------------------------------------------------------


======================================================================
CHUNK 398 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_124
Content Type: recommendation
Words: 498
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
This was justified by the higher risk of because there was substantial statistical heterogeneity gout progression and development of clinical tophi in detected in the meta-analysis (I2  50%) and the estimated CKD. 607 The ERTevidence review identified that uric acid RRs ranged from 0. 05 to 2. 96. The certainty of the evidence lowering therapy results in an increased risk of a gout flare was further downgraded because of very serious during the first 3 months after initiation in people with imprecision. There were 81 kidney failure events among the CKD. This is an expected short-term risk of uric acid participants in the 7 trials. lowering that people should be counseled about when The overall certainty of the evidence for delaying proinitiating such therapy. Two relatively small randomized gression is very low, and the certainty for the critical harm trials have suggested that starting uric acidlowering outcomes, such as cutaneous reactions, hypersensitivity, and therapy during a gout flare does not appear to extend flare hepatotoxicity, was graded as low. However, the certainty of duration. 620, 621 Once initiated, the American College of evidence for uric acidlowering interventions in reducing Rheumatology suggests continuing uric acidlowering frequencyandseverityofgoutattack, andlimitingtophaceous therapy indefinitely. 607 deposition is consistently high, so the recommendation is given an overall grade of level C. PracticePoint3. 14. 2: Prescribexanthineoxidaseinhibitors Values and preferences. People with gout have reported inpreferenceto uricosuric agents inpeoplewith CKDand that they were initially hesitant to start uric acidlowering symptomatic hyperuricemia. therapy, but that after experiencing improved control of Xanthine oxidase inhibitors (e. g. , allopurinol and inflammatory symptoms and tophi, they became strong febuxostat)reduceserumuricacidconcentrationbyreducing advocates for its earlier institution. 607 purine metabolism into uric acid. Uricosuric agents enhance Resource use and costs. There are several generic xanthine its urinary excretion (probenecid is an example), but their oxidase inhibitors that arewell tolerated and widely available effectisbluntedinthecontextofreducedGFR. Notethatthe at low cost. Cardiovascular Safety of Febuxostat and Allopurinol in ParConsiderations for implementation. In most countries, the ticipants With Gout and Cardiovascular Comorbidities cost and availability of uric acidlowering therapies make (CARES)double-blindrandomizedtrialofallopurinolversus the medications very accessible. The risk of serious adverse febuxostat in 6190 people with gout and prior CVD found events (e. g. , Stevens-Johnson syndrome) is related to the thatthese2interventionswerenoninferiorwithrespecttothe presence of specific human leukocyte antigen (HLA) compositeprimarycardiovascularoutcome. However, overall B5801, which is more common in those of Han Chinese, mortality and cardiovascular mortality were higher in the Korean, Thai, and African descent. In specific regions, febuxostatgroupthanintheallopurinolgroup(HRfordeath assessment of the HLA type is recommended before from any cause: 1. 22; 95% CI: 1. 011. 47 and HR for carcommencing the drug; where testing is not available, close diovasculardeath: 1. 34; 95%CI: 1. 031. 73). 622Inpeoplewith monitoring at initiation of the medication should be unT2D, post hocanalysesfrom2large, placebo-controlled RCTs dertaken. At the current time, there is no indication to have reported that SGLT2i reduce serum uric acid commence medication for high serum uric acid levels in concentration and appeared to reduce gout adverse event the absence of symptoms.
----------------------------------------------------------------------


======================================================================
CHUNK 399 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_125
Content Type: recommendation
Words: 492
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
At the current time, there is no indication to have reported that SGLT2i reduce serum uric acid commence medication for high serum uric acid levels in concentration and appeared to reduce gout adverse event the absence of symptoms. reports or initiations of uric acidlowering therapy. 515, 623 Observational studies suggest that diuretics (thiazide and Rationale loop) increase serum uric acid concentration. 624 The effect Uric acidlowering therapy reduces uric acid levels and their is mediated through multiple potential kidney-centered associatedsymptomaticjointandskincomplications, andare mechanisms, which are summarized in a review of druggenerally safe to use. induced hyperuricemia. 625 KidneyInternational(2024)105(Suppl4S), S117S314 S231 chapter 3 www. kidney-international. org Practice Point 3. 14. 3: For symptomatic treatment of acute skin cutaneous reactions if theycarry the HLA-B5801 allele. gout in CKD, low-dose colchicine or intra-articular/oral It has been suggested that HLA-B5801 allele screening may glucocorticoids are preferable to nonsteroidal anti-inflambe considered in people who will be treated with allopurinol matory drugs (NSAIDs). (although there is uncertainty that screening would be costTheAmericanCollegeofRheumatologyrecommendedthat effective). 634 colchicine, NSAIDs, or glucocorticoids are preferred first-line therapiesforacutegouttreatmentbasedondemonstratedhigh Recommendation 3. 14. 2: We suggest not using levels of evidence for efficacy, low cost, and tolerability. 607 agents to lower serum uric acid in people with CKD and asymptomatic hyperuricemia to delay CKD Administration early after symptom onset is encouraged. For progression (2D). colchicine, the US Food and Drug Administration (FDA)- approved dosing (1. 2 mg immediately followed by 0. 6 mg an hour later, with ongoing anti-inflammatory therapy until the The Work Group judged that most well-informed people with flare resolves) was highlighted. 607 Dose adjustment should be CKD would prefer to optimize medical therapies that have considered for CKD G5. Anti-inflammatory treatment may be proven benefit for CKD progression, and that the evidence does useful as prophylaxis against a symptomatic flare when notsupporttreatmentofasymptomatichyperuricemiatomodify initiating uric acidlowering therapy and may sometimes be risk of CKD progression. required long term (without diarrhea). We have advised that low-dose colchicine is preferable to NSAIDs given the safety and tolerability profile and may also reduce risk of Keyinformation cardiovascularevents. 626Incontrast, NSAIDscancausetoxicity Balance of benefits and harms. On balance, despite obserin CKD and need to be used cautiously. 627 Short courses of vationalstudiesimplicatingelevated serumuricacidlevelsin glucocorticoids titrated to symptoms response (e. g. , 30 mg theprogressionofCKD, thedatafromsystematicreviewsand prednisoloneorallyfor35days)couldbeusedasanalternative. multiple RCTs do not support treatment in the absence of symptoms. Given the pill burden and lack of data, there is Dietaryapproaches. little support for the use of uric acidlowering agents. Practice Point 3. 14. 4: Nonpharmacological interventions Observational data that implicate elevated serum uric acid which may help prevent gout include limiting alcohol, levels in the progression of CKD have not been shown to meats, and high-fructose corn syrup intake. reflect causal associations, 635, 636 as RCTs evaluating uric acid Highalcoholintake, highpurineintake, andconsumption lowering on progression of CKD do not demonstrate clear of carbonated drinks are associated with higher levels of benefit on progression, including data summarized in a serum uric acid.
----------------------------------------------------------------------


======================================================================
CHUNK 400 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_126
Content Type: reference
Words: 500
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
reflect causal associations, 635, 636 as RCTs evaluating uric acid Highalcoholintake, highpurineintake, andconsumption lowering on progression of CKD do not demonstrate clear of carbonated drinks are associated with higher levels of benefit on progression, including data summarized in a serum uric acid. Consumption of these products in higher Cochrane systematic review comprising 12 RCTs that had amounts is associated with both higher levels and gout randomized 1187 participants. 609 Since the 2017 Cochrane symptoms. Incontrast, dietsthatarelowinfatanddairy, and review, 3 large, important RCTs with negative results have high fiber, plant-based diets are associated with lower incibeen conducted in people with CKD and asymptomatic dence of gout. Thus, diet modification may be of value in hyperuricemia (Table 30). 615, 616, 637 people with CKD, high uric acid, and gout. TheERTreviewidentified25studies(26publications)that Serumuricacidlevelsamongpeoplewithahistoryofgout compared a uric acidlowering therapy with placebo, usual are higher in those with higher versus moderate levels of care, oranotheruricacidloweringtherapyamongpeoplewith alcohol intake (30 units/wk vs. 20 units/wk), asis the risk CKD and hyperuricemia. 150, 612619, 622, 637652 Twenty-two of recurrence. 624, 628 The odds of gout also appear higher studies(23publications)150, 612619, 622, 637652werenewstudies among those with higher median purine intake (850 mg publishedsincetheCochranerevieworwerenotcapturedby vs. 850 mg estimated purine intake in the last 24 hours). 624 the Cochrane 2017 review. 609 We did not include 9 studies Experimentally, 2 hours after ingestion of 1 g/kg of body from the Sampson et al. 609 review because they did not weight of fructose, serum uric acid concentration increases include a separate analysis among people with CKD or by 12 mg/dl (59. 5119 m mol/l), 629 and its consumption in because the study was reported as a meeting abstract only. carbonated drinks is observationally associated with higher Among people with CKD and hyperuricemia, the effects of serum uric acid concentration levels, 630, 631 and incident gout uric acidlowering therapy compared with placebo or usual (whereas diet versions of these drinks are not). 632 Foods care were unclear in terms of progression of kidney failure associated with a low incidence of gout include low-fat dairy, (pooled RR: 0. 92; 95% CI: 0. 431. 98 for studies ranged in and high-fiber and plant-based diets. 633 follow-up from 3 months to 7 years), cutaneous reactions and hypersensitivity (pooled RR: 1. 00; 95% CI: 0. 601. 65), Specialconsiderations and hepatotoxicity (pooled RR: 0. 92; 95% CI: 0. 372. 30). Pediatric considerations. There are no uric acidlowering Lastly, within the various therapies among people with CKD trials in children. and hyperuricemia, the effects of febuxostat compared with International considerations. Asian (as opposed to African benzbromarone on cutaneous reactions and hypersensitivity and Caucasian) ethnicities may be at higher risk of serious wereunclear(RR: 0. 20; 95%CI: 0. 014. 01). S232 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Table30Randomized controlledtrialsin thetreatment ofasymptomatic hyperuricemiain peoplewithCKD Intervention Study(N) CKDpopulation (follow-up) Outcome CKD-FIX615(N369) CKDG3G4, meanACR717mg/g(81mg/mmol), Allopurinolvs. NosignificantdifferenceineGFRdecline, meanurate8. 2mg/dl(490mmol/l) placebo(104wk) (cid: 5)3. 33vs. (cid: 5)3. 23ml/minper1. 73m2/yr PERLStudygroup616 eGFR4099. 9ml/minper1. 73m2 Allopurinolvs. NosignificantdifferenceinmGFRdecline, (N530) andtype1diabetes placebo(3yr) (cid: 5)3. 0vs. (cid: 5)2. 5ml/minper1. 73m2/yr FEATHERStudy637 CKDG3 Febuxostatvs.
----------------------------------------------------------------------


======================================================================
CHUNK 401 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_127
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org chapter 3 Table30Randomized controlledtrialsin thetreatment ofasymptomatic hyperuricemiain peoplewithCKD Intervention Study(N) CKDpopulation (follow-up) Outcome CKD-FIX615(N369) CKDG3G4, meanACR717mg/g(81mg/mmol), Allopurinolvs. NosignificantdifferenceineGFRdecline, meanurate8. 2mg/dl(490mmol/l) placebo(104wk) (cid: 5)3. 33vs. (cid: 5)3. 23ml/minper1. 73m2/yr PERLStudygroup616 eGFR4099. 9ml/minper1. 73m2 Allopurinolvs. NosignificantdifferenceinmGFRdecline, (N530) andtype1diabetes placebo(3yr) (cid: 5)3. 0vs. (cid: 5)2. 5ml/minper1. 73m2/yr FEATHERStudy637 CKDG3 Febuxostatvs. NosignificantdifferenceineGFRslope (N467) placebo(108wk) 0. 23(cid: 6)5. 26vs. (cid: 5)0. 47(cid: 6)4. 4. 8ml/minper 1. 73m2 ACR, albumin-to-creatinineratio; CKD, chronickidneydisease; CKD-FIX, ControlledTrialofSlowingofKidneyDiseaseProgressionfromtheInhibitionofXanthineOxidase; eGFR, estimatedglomerularfiltrationrate; FEATHER, Febuxostatvs. PlaceboRandomizedControlledTrialRegardingReducedRenalFunctioninPatientsWithHyperuricemia ComplicatedbyChronicKidneyDiseaseStage3; PERL, PreventingEarlyRenalLossinDiabetes. Certainty of the evidence. The overall certainty of the eviRationale denceforuricacidloweringtherapyamongpeoplewithCKD There is insufficient evidence to recommend the use of uric andhyperuricemiaisverylow. Thecriticaloutcomeofdelaying acidlowering therapies in asymptomatic hyperuricemia for theprogressionofCKDwasaddressedby7RCTs. 150, 612, 615619 the specific purpose of delaying CKD progression. We make The certainty of the evidence was downgraded for therecommendationnotgivinguricacidloweringtherapyin inconsistency because there was some statistical heterogeneity asymptomatic hyperuricemia for slowing of kidney disease detected in our meta-analysis (Supplementary Table S12 based on the current evidence that suggests unclear benefits. 615619, 637, 638, 640, 642, 651, 653). The certainty of the evidence was We judge that it is best practice not to expose people to further downgraded because of very serious imprecision, as medications that provide little benefit. there were few events in the trials. Valuesandpreferences. TheWorkGroupjudgedthatmost 3. 15 Cardiovascular disease (CVD) and additional well-informed people with CKD would prefer to optimize specific interventions to modify risk medical therapies that have proven benefit for CKD progression, and that there is little evidence to support the Prevalenceanddiagnosis. PeoplewithCKDareatincreased treatment of asymptomatic hyperuricemia to modify the risk risk of CVD, 654, 655 a key feature of which is structural heart of CKD progression. disease, heart failure, and sudden death. 656658 Increased risk Resource use and costs. There are no cost considerations, of atherosclerotic disease also accompanies CKD. 654 These beyond cost-savings, in our recommendation not to use uric risks increase progressively as eGFR declines (Figure 3612). 4 acidlowering agents. Risk of death from CVD exceeds the risk of progression to Considerations for implementation. There are no implekidney failure for the majority of people with CKD. mentation considerations in our recommendation not to use The diagnosis of cardiac disease can be more complex and uric acidlowering agents. challenging in CKD, with many standard tests needing careful Overall ACR (mg/g) Overall ACR (mg/g) eGFRcr 10 1029 30299 300999 1000 eGFRcr 10 1029 30299 300999 1000 105 1. 6 2. 2 2. 9 4. 3 5. 8 105 1. 4 2. 0 3. 0 4. 1 5. 4 90104 Ref 1. 3 1. 8 2. 6 3. 1 90104 Ref 1. 3 1. 9 2. 7 3. 6 6089 1. 0 1. 3 1. 7 2. 2 2. 8 6089 1. 0 1. 4 1. 7 2. 4 3. 2 4559 1. 3 1. 6 2. 0 2. 4 3. 1 4559 1. 4 1. 7 2. 2 2. 8 3. 8 3044 1. 8 2. 0 2. 5 3. 2 3. 9 3044 2. 0 2. 3 2. 8 3. 7 4. 6 1529 2.
----------------------------------------------------------------------


======================================================================
CHUNK 402 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_128
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
4 3. 2 4559 1. 3 1. 6 2. 0 2. 4 3. 1 4559 1. 4 1. 7 2. 2 2. 8 3. 8 3044 1. 8 2. 0 2. 5 3. 2 3. 9 3044 2. 0 2. 3 2. 8 3. 7 4. 6 1529 2. 8 2. 8 3. 3 4. 1 5. 6 1529 3. 2 3. 1 3. 5 5. 0 6. 5 15 4. 6 5. 0 5. 3 6. 0 7. 0 15 6. 1 6. 4 6. 4 7. 3 8. 2 All-cause mortality: 82 cohorts Cardiovascular mortality: 76 cohorts Study size 26, 444, 384; events 2, 604, 028 Study size 26, 022, 346; events 776, 441 Figure36Riskofall-causeandcardiovascularmortalitybyestimatedglomerularfiltrationrate(eGFR)andlevelofalbuminuriafrom generalpopulationcohortscontributingtotheChronicKidneyDiseasePrognosisConsortium. ACR, albumin-to-creatinineratio; eGFRcr, creatinine-basedestimatedglomerularfiltrationrate. ReproducedwithpermissionfromJAMA, WritingGroupfortheCKDPrognosis Consortium; GramsME, CoreshJ, MatsushitaK, etal. Estimatedglomerularfiltrationrate, albuminuria, andadverseoutcomes: anindividualparticipantdatameta-analysis. JAMA. 2023; 330(13): 12661277. 12Copyright2023AmericanMedicalAssociation. Allrightsreserved. KidneyInternational(2024)105(Suppl4S), S117S314 S233 chapter 3 www. kidney-international. org considerationinpeoplewithCKD. 659, 660Forexample, exercise recommendations on when to initiate such therapies set out electrocardiography may be limited through inability to in the KDIGO Clinical Practice Guideline for Lipid exercisetoadiagnosticworkload, orpresenceofmicrovascular Management in Chronic Kidney Disease. 19 The Work disease. Perceivedrisks ofcontrast agents may limitthe use of Group concurs with all the recommendations in this diagnosticimaging, thusimpactingtreatmentchoices; therisks guideline. In particular, we draw attention to: ofcontrastagentsmaylimittheuseofimaging. Inaddition, a strain pattern may mask diagnostic ST depression, and acute Recommendation 3. 15. 1. 1: In adults aged 50 years coronary syndrome is less likely to present with classical with eGFR 60 ml/min per 1. 73 m2 but not treated withchronicdialysis orkidney transplantation(GFR ischemic symptoms and electrocardiographic changes than in categories G3aG5), we recommend treatment with the general population, instead often manifesting as heart a statin or statin/ezetimibe combination (1A). failure symptoms or syncope. 659, 660 In people with GFR 60 ml/min per 1. 73 m2 (GFR categories G3aG5), KDIGO has Recommendation 3. 15. 1. 2: In adults aged 50 years previously recommended that serum concentrations of with CKD and eGFR 60 ml/min per 1. 73 m2 (GFR troponinbeinterpretedwithcautionwithrespecttodiagnosis categoriesG1G2), werecommendtreatmentwitha of acute coronary syndrome. 1 More sensitive troponin assays statin (1B). maintain high diagnostic accuracy in people with CKD, but higher assay-specific optimal cutoff levels may be Recommendation3. 15. 1. 3: Inadultsaged1849years considered. 661Regardlessofassay, carefulattentiontotrendsin withCKDbutnottreatedwithchronicdialysisorkidneytransplantation, wesuggeststatintreatmentin troponin concentration over time is required through serial peoplewithoneormoreofthefollowing(2A): measurement. 662 (cid: 3) known coronary disease (myocardial infarction or Management. In people with CKD, the same principles coronary revascularization), should be used to manage atherosclerotic risk as in people (cid: 3) diabetes mellitus, without CKD. The level of care for CVD offered to people (cid: 3) prior ischemic stroke, or with CKD should not be prejudiced by their GFR. Data (cid: 3) estimated 10-year incidence of coronary death or suggest the underuse of proven effective treatment in nonfatal myocardial infarction 10%. people with CKD presenting with acute coronary syndrome. 663 Prevention of ASCVD should consider pharmaceutical, The Work Group offers the following practice points to dietary, and lifestyle intervention, which target traditional support implementation of the recommendations above.
----------------------------------------------------------------------


======================================================================
CHUNK 403 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_129
Content Type: recommendation
Words: 484
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
people with CKD presenting with acute coronary syndrome. 663 Prevention of ASCVD should consider pharmaceutical, The Work Group offers the following practice points to dietary, and lifestyle intervention, which target traditional support implementation of the recommendations above. cardiovascular risk factors (e. g. , BP and dyslipidemias), as well as CKD-MBD, which accelerates vascular calcification PracticePoint3. 15. 1. 1Estimate10-yearcardiovascularrisk resulting in both vascular intima (resulting in increased using a validated risk tool. amounts of calcium in atherosclerotic plaques664) and Details of the Work Group recommendations on how to vascular media calcification (leading to increased vascular estimateriskareprovidedinChapter2, Section2. 3. Currently, stiffness). 604 the CKD patch for the Systematic Coronary Risk Evaluation (SCORE) tool and the American Heart Association 3. 15. 1Lipidmanagement PREVENT (cid: 3), pending equations are the only ones validated. Dyslipidemia in CKD is frequently characterized by high triglycerides, low HDL cholesterol, and an increased proportion PracticePoint3. 15. 1. 2: InpeoplewithCKD, choosestatinoflow-densitylipoprotein(LDL)particles, whicharesmalland basedregimenstomaximizetheabsolutereductioninlowoxidized. 665 In adults with newly identified CKD, it has been densitylipoprotein(LDL)cholesteroltoachievethelargest recommended to evaluate their lipid profile (total cholesterol, treatment benefits. LDL cholesterol, HDL cholesterol, and triglycerides), but Since 2013, published literature has continued to demonfollow-up lipid measurements are not required for the strate the general safety of statin-based therapies. 667 This majority of people (i. e. , a fire-and-forget policy is includesindividualparticipant-leveldatameta-analysisbythe recommended). 19 This is because treatment initiation is Cholesterol Treatment Trialists collaboration, showing that based on risk, and the benefits of statin-based therapy have statintherapycausesonlyasmallexcessofmildmusclepain, been shown to be independent of the level of cholesterol. For and most (90%) of all reports of muscle symptoms among those with a total cholesterol 7. 5 mmol/l (290 mg/dl) and users are not due to their statins. 668 In CKD, the Study of a personal or family history of premature ischemic heart Heart and Renal Protection (SHARP) demonstrated that an disease (e. g. , an event before the age of 60 years in an intensive statin-based regimen was safe and not associated individual or first-degree relative), it is important to consider with any serious nonvascular hazard. 669, 670 A Cholesterol familial disease and specialist referral. 666 Treatment Trialists collaboration meta-analysis combining The benefits of lowering LDL cholesterol using statinSHARP with the other large trials took into account the based therapies on the risk of ASCVD are well established in smaller reductions in LDL cholesterol achieved with statinpeople with and without CKD. There are clear based therapy in people with CKD G3G5. After S234 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 standardizationtoa1. 0mmol/l(38. 7mg/dl)LDLcholesterol 20 mg, 672 rosuvastatin 10 mg, 673 and simvastatin 20 mg difference, the RR reductions in major vascular events combinedwithezetimibe10mg. 669, 670 observed with statin-based treatment in the large statin trials were shown to become progressively smaller as eGFR Practice Point 3. 15. 1. 3: In adults with CKD aged 1849, a declines, with little evidence of benefit in people on dialysis lower(i. e. , 10%)estimated10-yearincidenceofcoronary (Figure 37).
----------------------------------------------------------------------


======================================================================
CHUNK 404 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_130
Content Type: reference
Words: 500
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
669, 670 observed with statin-based treatment in the large statin trials were shown to become progressively smaller as eGFR Practice Point 3. 15. 1. 3: In adults with CKD aged 1849, a declines, with little evidence of benefit in people on dialysis lower(i. e. , 10%)estimated10-yearincidenceofcoronary (Figure 37). 671 The corollary of this observation is that in death or nonfatal myocardial infarction may also be peoplewithCKD, statin-basedregimensshouldbechosento appropriate thresholds for initiation of statin-based maximize the absolute reduction in LDL cholesterol to therapy. achievethelargesttreatmentbenefits. Largetrialshaveshown The Work Group deems it appropriate to consider lower the following once-daily intensive statin-based regimens are thresholds for the initiation of statin-based therapy in adults safe in CKD (including people on dialysis): atorvastatin with CKD than suggested in the KDIGO 2013 Number of events (% per annum) RR (CI) per 1. 0 mmol/ P for reduction in LDL trend Statin or more Control or less cholesterol intensive regimen intensive regimen Major coronary event eGFR 60 m min per 1. 73 m2 3200 (1. 2%) 4178 (1. 6%) 0. 74 (0. 700. 79) 0. 01 eGFR 45 to 60 m/min per 1. 73 m2 1157 (1. 7%) 1479 (2. 2%) 0. 76 (0. 690. 84) eGFR 30 to 45 m/min per 1. 73 m2 457 (2. 3%) 567 (2. 8%) 0. 80 (0. 680. 95) eGFR 30 m/min per 1. 73 m2 not on dialysis 163 (1. 5%) 179 (1. 7%) 0. 87 (0. 681. 12) On dialysis 264 (2. 1%) 287 (2. 3%) 0. 89 (0. 701. 14) Total 5303 (1. 4%) 6761 (1. 8%) 0. 76 (0. 730. 79) Coronary revascularisation eGFR 60 m/min per 1. 73 m2 3943 (1. 5%) 4963 (1. 9%) 0. 76 (0. 710. 80) 0. 9 eGFR 45 to 60 m/min per 1. 73 m2 1039 (1. 5%) 1387 (2. 1%) 0. 71 (0. 640. 80) eGFR 30 to 45 m/min per 1. 73 m2 265 (1. 3%) 328 (1. 6%) 0. 81 (0. 641. 02) eGFR 30 m/min per 1. 73 m2 not on dialysis 99 (0. 9%) 123 (1. 2%) 0. 78 (0. 571. 05) On dialysis 183 (1. 5%) 224 (1. 8%) 0. 78 (0. 581. 05) Total 5618 (1. 5%) 7113 (1. 9%) 0. 75 (0. 730. 78) Stroke eGFR 60 m/min per 1. 73 m2 1408 (0. 5%) 1661 (0. 6%) 0. 83 (0. 760. 92) 0. 07 eGFR 45 to 60 m/min per 1. 73 m2 575 (0. 8%) 708 (1. 0%) 0. 81 (0. 700. 93) eGF 30 to 45 m/min per 1. 73 m2 263 (1. 3%) 284 (1. 4%) 0. 91 (0. 731. 13) eGFR 30 m min per 1. 73 m2 not on dialysis 116 (1. 1%) 137 (1. 3%) 0. 83 (0. 631. 10) On dialysis 213 (1. 7%) 199 (1. 6%) 1. 09 (0. 821. 44) Total 2591 (0. 7%) 3019 (0. 8%) 0. 84 (0. 800. 89) Major vascular event eGFR 60 m/min per 1. 73 m2 7348 (2. 9%) 8933 (3. 6%) 0. 78 (0. 750.
----------------------------------------------------------------------


======================================================================
CHUNK 405 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_131
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
83 (0. 631. 10) On dialysis 213 (1. 7%) 199 (1. 6%) 1. 09 (0. 821. 44) Total 2591 (0. 7%) 3019 (0. 8%) 0. 84 (0. 800. 89) Major vascular event eGFR 60 m/min per 1. 73 m2 7348 (2. 9%) 8933 (3. 6%) 0. 78 (0. 750. 82) 0. 008 eGFR 45 to 60 m/min per 1. 73 m2 2377 (3. 6%) 3013 (4. 6%) 0. 76 (0. 700. 81) eGFR 30 to 45 m/min per 1. 73 m2 863 (4. 5%) 1014 (5. 2%) 0. 85 (0. 750. 96) eGFR 30 m/min per 1. 73 m2 not on dialysis 320 (3. 0%) 364 (3. 5%) 0. 85 (0. 711. 02) On dialysis 571 (4. 7%) 599 (5. 0%) 0. 94 (0. 791. 11) Total 11, 617 (3. 2%) 14, 079 (3. 9%) 0. 79 (0. 770. 81) 0. 5 0. 75 1. 00 1. 50 99% or 95% CI LDL cholesterol LDL cholesterol lowering better lowering worse Figure37Effectofloweringlow-densitylipoprotein(LDL)cholesterolper1. 0mmol/lonriskofmajorvasculareventsbylevelof estimatedglomerularfiltrationrate(eGFR)atrecruitment. Meta-analysisof28largetrialsofstatin-basedtherapyusingindividual participantleveldata. Theblacksquaresandhorizontallinesrepresent99%confidenceintervals(CIs), withdiamondsrepresenting95%CI. RR, relativerisk. ReproducedfromHerringtonWG, EmbersonJ, MihaylovaB, etal. ImpactofrenalfunctionontheeffectsofLDLcholesterol loweringwithstatin-basedregimens: ameta-analysisofindividualparticipantdatafrom28randomisedtrials. LancetDiabetesEndocrinol. 2016; 4: 829839. 671TheAuthor(s). PublishedbyElsevierLtd. ThisisanOpenAccessarticleundertheCCBYlicense. KidneyInternational(2024)105(Suppl4S), S117S314 S235 chapter 3 www. kidney-international. org recommendations. There is good evidence for the safety of approximately 22%25%. 684 There is no large-scale CKDintensive LDL-cholesterol lowering, and statin-based therapy specific trial comparing these dietary interventions. combined with a fire-and-forget strategy is low cost. This approach is consistent with a more recent recommendation 3. 15. 2Useofantiplatelet therapy for primary prevention in CKD by the American College of Cardiology/American Heart Association (which recomRecommendation3. 15. 2. 1: Werecommendorallowmended 10-year thresholds of 7. 5%). 674 dose aspirin for prevention of recurrent ischemic cardiovascular disease events (i. e. , secondary prevention) in people with CKD and established Practice Point 3. 15. 1. 4: Consider prescribing proprotein ischemic cardiovascular disease (1C). convertase subtilisin/kexin type 9 (PCSK-9) inhibitors to people with CKD who have an indication for their use. Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inThis recommendation places high value on the importance of hibitors have been shown to safely reduce ASCVD risk when reducing recurrenceofmyocardialinfarction, ischemicstrokes, added to maximal tolerated statin-based regimens inpeople at or peripheral arterial disease complications in people with high coronary risk. 675, 676 Subgroup analyses suggest that their CKD and established ischemic CVD due to the mortality and safety profile and their biochemical and clinical efficacy are disability associated with such complications. In secondary similar when participants with CKD and without CKD are prevention, trials have clearly shown the absolute benefits of compared. These trials recruited down to an eGFR of 20 ml/ low-doseaspirinsubstantiallyexceedthepotentialforbleeding min per1. 73m2. 677, 678Currentexamplesofrecommendations complications, creating certainty about net benefits when for the use of PCSK-9 inhibitors from the cardiology treating this population. In people with CKD without prior community(andlicensedindications)includeasanadjunctto ischemic CVD, the balance of benefits and risks are uncertain dietandmaximallytoleratedstatintherapyforthetreatmentof and may be counterbalancedlarge RCTs are ongoing. adults with heterozygous familial hypercholesterolemia or for peoplewithclinicalASCVDwhorequireadditionalloweringof LDLcholesterol. 679, 680 Keyinformation Balance of benefits and harm. Based on a number of large Dietaryapproaches.
----------------------------------------------------------------------


======================================================================
CHUNK 406 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_132
Content Type: recommendation
Words: 497
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
In people with CKD without prior community(andlicensedindications)includeasanadjunctto ischemic CVD, the balance of benefits and risks are uncertain dietandmaximallytoleratedstatintherapyforthetreatmentof and may be counterbalancedlarge RCTs are ongoing. adults with heterozygous familial hypercholesterolemia or for peoplewithclinicalASCVDwhorequireadditionalloweringof LDLcholesterol. 679, 680 Keyinformation Balance of benefits and harm. Based on a number of large Dietaryapproaches. RCTs in populations that are likely to be largely free from Practice Point 3. 15. 1. 5: Consider a plant-based MediterCKD, lifelong use of low-dose aspirin (75100 mg) for the ranean-styledietinadditiontolipid-modifyingtherapyto preventionofrecurrenceofcomplicationsofischemicCVDis reduce cardiovascular risk. strongly recommended among people with known CVD (a Diet and lipids have been comprehensively reviewed by therapeutic approach referred to as secondary prevention). other clinical practice guidelines. 679, 681 In that work, the Conversely, it is not possible to provide definitive recomWork Groups highlighted that in general populations, mendationsonwhentouseaspirintopreventafirstischemic observational studies have associated plant-based diets that cardiovascular event (i. e. , primary prevention) in people at include higher consumption of fruit, vegetables, nuts, highrisk, andaresearchrecommendationisprovided. Thisis legumes, fish, olive oil, yogurt, and whole grains, with lower due to uncertainty of the net absolute value of such an risk of CVD. Diets associated with higher risk are those approach, as any reduction in the risk of atherosclerotic including high consumption of red and processed meats, cardiovascular events needs to be weighed against the risk of refined carbohydrates, and salt. Vegetable sources of fats majorbleeding. ItisimportanttoconsiderCKD-specificdata and polyunsaturated fatty acids (e. g. , in nuts, seeds, in the totality of the evidence. avocado, and olive oil) are also associated with a lower risk Key evidence from general populations is derived from a compared with animal fats, including dairy fat. 679 A 2009 meta-analysis by the Anti-thrombotic Treatment TriaMediterranean-style diet has an emphasis on extra virgin lists collaboration. The analyses included data on long-term olive oil and is high in unsaturated fat. RCTs have shown aspirin use versus control care in 16 secondary prevention that such diets have important effects on cardiovascular risk trials (approximately 17, 000 people at high average risk, in the long term despite only small effects on traditional approximately 43, 000 person-years, 3306 serious vascular markers of metabolic syndrome profile. 682685 In the large events defined as myocardial infarction, stroke, or cardioPrevencin con Dieta Mediterrnea (PREDIMED) primary vascular death), and 6 primary prevention trials (approxiprevention trial of 7447 adults, the Mediterranean diet rich mately 95, 000participantsatlowaverage risk, approximately in extra virgin olive oil reduced the risk of major 660, 000person-years, 3554seriousvascularevents). 685aInthe cardiovascular events by 31% (HR: 0. 69; 95% CI: 0. 53 secondary prevention trials, allocation to aspirin reduced the 0. 91). The Coronary Diet Intervention With Olive Oil and risk of both ischemic stroke and myocardial infarction by Cardiovascular Prevention (CORDIOPREV) trial found that about one-fifth, such that an overall RR reduction for any allocation to a Mediterranean diet rich in extra virgin olive serious vascular event was 19% compared with controls oil reduced the risk of the composite of MACE by (RR: 0. 81; 95% CI: 0. 750. 87).
----------------------------------------------------------------------


======================================================================
CHUNK 407 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_133
Content Type: reference
Words: 497
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
81; 95% CI: 0. 750. 87). This equated to a 1. 49% S236 KidneyInternational(2024)105(Suppl4S), S117S314 lower absolute risk of serious vascular events per year SomepeoplewithCKDhavebeen includedin antiplatelet compared with an estimated absolute risk of any major therapy trials. ArecentCochranecollaborationmeta-analysis bleeding, which was an order of magnitude smaller at of 40, 597 trial participants with CKD recruited into anti0. 03% per year. Note that this hazard of major bleeding was platelet versus placebo trials and 11, 805 recruited into antiextrapolated from the primary prevention trials as stroke platelet agent comparison trials found that allocation to causes and extracranial bleeds were generally not well antiplatelet therapy may reduce the RR of myocardial recorded in the relatively older secondary prevention trials infarction by approximately 12% (RR: 0. 88; 95% CI: 0. 79 (Figure 38685a). 0. 99). Therewasanexpectedincreasedriskofmajorbleeding, Female, entry age 5059 years Female, entry age 6574 years 60 50 40 38. 7% 30 25. 9% 21. 0% 20 A C A C 10 A C A C A C A C 3. 9% 4. 5% 0. 3% 0. 2% 0. 9% 0. 9% 0. 5% 0 Male, entry age 5059 years Male, entry age 6574 years 60 50 45. 2% 40 36. 7% 30 29. 7% A C 20 A C A C 10 A C 8. 0% A C A C 3. 4% 3. 9% 0. 5% 0. 3% 1. 2% 0. 7% 0 Primary Secondary )%( ksir raey-5 )%( ksir raey-5 www. kidney-international. org chapter 3 Vascular death Nonfatal MI/stroke Nonfatal GI or other extracranial bleed 47. 7% 1. 1% 55. 8% 9. 2% Primary Secondary Figure38Predicted5-yearabsolutebenefitsandharmsofallocationtoaspirin(A)versuscontrol(C)usingasecondaryorprimary preventionstrategy, bydifferentlevelsofrisk(basedonageandsex). GI, gastrointestinal; MI, myocardialinfarction. Reproducedwith permissionfromTheLancet, volume373, AntithromboticTrialists(ATT)Collaboration, Aspirinintheprimaryandsecondarypreventionof vasculardisease: collaborativemeta-analysisofindividualparticipantdatafromrandomisedtrials, pages18491860, Copyright2009Elsevier Ltd. 685a KidneyInternational(2024)105(Suppl4S), S117S314 S237 chapter 3 www. kidney-international. org but the magnitude of the RR was consistent with the data occasionally associated with an interstitial nephritis), and from general populations (RR: 1. 35; 95% CI: 1. 101. 65). 686 the Work Group considers that it is prudent to consider Note that these analyses did not distinguish between bleeding risk and offers PPIs when prescribing antiplatelet primary and secondary prevention settings. 686 The 2009 therapy or antithrombotic therapy, particularly when such Anti-thrombotic Treatment Trialists collaboration metatherapies are combined. 693 analysis and results from 3 more recent large trials (A Study of Cardiovascular Events in Diabetes ASCEND, 687 Aspirin Rationale in Reducing Events in the Elderly ASPREE, 688 and Aspirin Meta-analysis of trials has clearly established the cardioto Reduce Risk of Initial Vascular Events ARRIVE689) vascular benefits of low-dose aspirin in people who have assessing the effects of aspirin versus placebo for primary establishedASCVD. Anyharmofbleedingisfaroutweighed prevention in specific high-risk populations found that any bythebenefits(unlikethesituationforprimaryprevention, harm from major bleeding counterbalanced any benefit of where bleeding risk has been consistently identified in aspirin on cardiovascular risk (with ASPREE and ARRIVE large aspirin trials and cardiovascular benefits to date have both finding no significant effect on cardiovascular events not). in their studied populations of older adults or high-risk adults, respectively).
----------------------------------------------------------------------


======================================================================
CHUNK 408 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_134
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
in their studied populations of older adults or high-risk adults, respectively). 685a A dedicated large primary Practice Point 3. 15. 2. 1: Consider other antiplatelet therapy prevention aspirin trial in CKD is underway. 690 (e. g. , P2Y inhibitors) when there is aspirin intolerance. 12 Certaintyofevidence. The 2009 meta-analysis by the AntiBleeding from gastrointestinal mucosa with antiplatelet thrombotic Treatment Trialists collaboration on the effect of therapyislikelytobeduetotheireffectonhemostasisofpreaspirin compared with placebo in terms of the primary and existing mucosal lesions. This hypothesis is supported by secondary prevention of CVD and safety among people with P2Y inhibitors (e. g. , clopidogrelor ticagrelor)not reducing 12 andwithoutCKDwasassessedtohavehighriskofbiasusing theriskofbleedingintrialscomparingthemtoaspirin. 694, 695 the Risk of Bias Assessment Tool for Systematic Reviews However, ifpeopleareaspirinintolerant, aP2Y inhibitor is (ROBIS) checklist due to unclear identification and selection a noninferior alternative. Note that in 200 1 9 2, the FDA of studies, unclear data collection and study appraisal, and recommended that the coadministration of clopidogrel and high risk of bias for synthesis and findings (although we did omeprazole (a PPI) should be avoided because omeprazole not contact the authors to clarify these details). 685a This reduces the effectiveness of clopidogrel. There is uncertainty review did not report on the evidence or certainty of about the precise effect of omeprazole as pharmacokinetic evidence assessments directly in the report. Given the data are inconclusive, but PPIs with inhibition of CYP2C19 available evidence, the recommendation has a low certainty are preferred when using clopidogrel. 696 of evidence (Level C). Guidelines from the cardiology community provide recValues and preferences. Maintaining QoL by minimizing ommendations for the use of dual antiplatelet therapy for a risk of worsening of ischemic heart disease and recurrent period after acute coronary syndrome or percutaneous stroke-related disability is important to both people with coronary intervention. These guidelines recommend to CKD andcaregivers. 691TheWorkGroupconsideredthat the apply the same diagnostic and therapeutic strategies in risk of bleeding would be considered acceptable by most people with CKD. 663 CKD does not modify the benefits of people with CKD once the clear net benefits were explained ticagrelor, 697 and antiplatelet therapy doses do not need to and gastroprotection was offered. The Work Group be modified at decreased eGFR. Note that other considered that some people with CKD without prior antithrombotic therapy choices and doses may need to ischemic coronary, cerebrovascular, or peripheral arterial consider a persons GFR. disease but at increased risk (e. g. , due to diabetes) may still wish to consider using aspirin and accept the risk of major Specialconsiderations bleeding. 687 Some people with CKD may also have a kidney Internationalconsiderations. Giventheclinicaleffectiveness diagnosis that indirectly supports considering the use of oflow-doseaspirinanditslowcost, thereshouldnotbemany aspirin despite a lack of evidence (e. g. , presumed or proven barriers to accessing this medication in any setting. renovascular disease). The Work Group is not aware of any risk tools that could be used to help counsel such people with CKD as to their expected net absolute benefits and 3. 15.
----------------------------------------------------------------------


======================================================================
CHUNK 409 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_135
Content Type: recommendation
Words: 491
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
renovascular disease). The Work Group is not aware of any risk tools that could be used to help counsel such people with CKD as to their expected net absolute benefits and 3. 15. 3Invasiveversusintensivemedicaltherapyforcoronary risks based on risk factors of the person with CKD, arterydisease including any difference by sex. (Note that scores to predict Recommendation3. 15. 3. 1: Wesuggestthatinstable cardiovascular risk are considered in Chapter 2. ) stress-test confirmed ischemic heart disease, an Resourceuseandcosts. Low-doseaspirinisavailableatlow initial conservative approach using intensive medicost and does not require monitoring. caltherapyisanappropriatealternativetoaninitial Considerationsforimplementation. Proton-pumpinhibitors invasive strategy (2D). (PPIs) are generally effective, 692 safe, and low cost (although S238 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 This recommendation places high value on the finding from therapy among people with CKD not undergoing KRT and recent, large trials in both general and CKD populations that ischemic heart disease is very low (Supplementary Table havesuggestedthatintensivemedicaltherapyisasuitableinitial S13700704). Most of the RCTs reporting on the critical strategy for the management of stable stress-test confirmed outcomes (all-cause mortality, CVD mortality, CVD events, ischemic heart disease. It places value on the need for inkidney failure, and AKI) had some concerns regarding the terventions, which carry risk to people with CKD and subrisk of bias, particularly with lack of blinding for the stantial healthcare costs to demonstrate benefits on outcome assessors, participants crossing over to the other cardiovascularoutcomesbeforetheyareconsideredastandardof treatment group, and the selection of reporting. The care. Importantly, this recommendation should not apply to certainty of the evidence was downgraded for all outcomes those with severe angina symptoms, left ventricular dysfunction because of imprecision. The certainty of the evidence for (e. g. , ejection fraction 35%), or left main stem disease as they cardiovascular mortality was downgraded because were excluded from the definitive trials. It should be noted that publication bias was strongly suspected. trials in CKD have not ruled out antianginal benefits in people Values and preferences. Although this was not confirmed with CKD (despite negative findings). by ISCHEMIA-CKD, antianginal benefits of an invasive strategyareapparentingeneralpopulations, andpeoplewith Keyinformation symptoms may still elect for an initially invasive approach to Balance of benefits and harm. Benefits. Benefits should be manage stable stress-test confirmed coronary artery disease considered in the context of the totality of evidence in people after being counseled about the risks. with and without CKD regarding interventions. Comparisons Resourceuseandcosts. Itis not possible to formally assess between aggressive medical therapy alone and invasive inthe cost-effectiveness of intensive medical therapy versus an terventions do not support invasive strategies to reduce death initial invasive strategy due to mixed findings from the evior prevent myocardial infarction. 707, 707a However, those with dence in people with stable ischemic heart disease. However, frequent angina symptoms (at least weekly) gained invasive strategies will have higher cost implications to improvement with the invasive strategy707; thus, the benefit healthcare systems, people with CKD, or both. of an invasive strategy might be restricted to those with Considerations for implementation. Access and availability angina.
----------------------------------------------------------------------


======================================================================
CHUNK 410 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_136
Content Type: recommendation
Words: 496
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
However, frequent angina symptoms (at least weekly) gained invasive strategies will have higher cost implications to improvement with the invasive strategy707; thus, the benefit healthcare systems, people with CKD, or both. of an invasive strategy might be restricted to those with Considerations for implementation. Access and availability angina. The reason for a lack of clear antianginal effect of an of invasive therapies will vary in different healthcare sysinvasive strategy in International Study of Comparative tems, as might the availability of medications for maximal Health Effectiveness with Medical and Invasive Approaches medicaltherapy. Thekeytoimplementationistoencourage Chronic Kidney Disease (ISCHEMIA-CKD) needs some the understanding of the value of full therapy as compared consideration, and key reasons relating to insufficient power with invasive therapy so that healthcare providers and due to protocol differences have been proposed. 698 Although people with CKD understand the risks and benefits of low power to detect an effect on angina is a key potential invasive strategies. Given the costs of invasive strategies, explanation for differences in findings between the 2 trials, there may be additional value to implementing this CKD-MBD and coronary calcification in CKD, which makes recommendation. microvascular disease more common and increases the technical challenge of revascularization, may also have partly Rationale contributed to these differences. 699 Evidencesuggeststhatthekeyindicationforaninitialinvasive The ERTassessed the effects of angiography or coronary strategy to manage stable ischemic heart disease is based on intervention in people with CKD and ischemic heart disease symptoms, and intensive medical therapy is a suitable identified 4 other trials, but excluded mixed populations, approachifsymptomcontrolissatisfactoryinpeoplewithor including ISCHEMIA-CKD, which recruited some people on withoutCKD. InCKD, theantianginalbenefitsofaninitially dialysis and some people who have received a kidney transinvasive approach have not been demonstrated. plant. The review found no clear benefits on cardiovascular outcomes in 3 other trials and raised a hypothesis about Practice Point 3. 15. 3. 1: Initial management with an invabeneficial effects on mortality overall (Supplementary Table sive strategy may still be preferable for people with CKD S13700704). Such an effect has not been observed in the withacuteorunstablecoronarydisease, unacceptablelevels larger general population trials. of angina (e. g. , patient dissatisfaction), left ventricular Harms. The harms ofinvasivestrategiesincludetheriskof systolic dysfunction attributable to ischemia, or left main dialysis initiation, death, and stroke risk (stroke was interdisease. estingly not periprocedural). 707 The ISCHEMIA trial has been described as deeply disCertaintyofevidence. The ERTreview was limited to trials rupting prior attitudes regarding management strategies for only recruiting people with CKD (and did not include the people with stable coronary artery disease, 705 and clinical ISCHEMIA-CKDtrialdiscussedaboveduetotheinclusionof practice guidelines that predate the trial need updating. 706 somepeopleondialysisandsomepeoplewhohavereceiveda Despite the International Study of Comparative Health kidney transplant). The overall certainty of the evidence Effectiveness with Medical and Invasive Approaches comparing coronary revascularization with optimal medical (ISCHEMIA) and ISCHEMIA-CKD trial results, it is KidneyInternational(2024)105(Suppl4S), S117S314 S239 chapter 3 www. kidney-international. org considered that the well-established intervention of coronary Overall ACR (mg/g) revascularization will continue to have a key role in angina eGFRcr 10 1029 30299 300999 1000 relief.
----------------------------------------------------------------------


======================================================================
CHUNK 411 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_137
Content Type: recommendation
Words: 495
Medical Entities: CKD,albuminuria,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
kidney-international. org considered that the well-established intervention of coronary Overall ACR (mg/g) revascularization will continue to have a key role in angina eGFRcr 10 1029 30299 300999 1000 relief. 705 Importantly, this recommendation should not 105 1. 1 1. 3 1. 7 2. 4 3. 5 apply to those with unacceptably severe angina symptoms. 90104 Ref 1. 2 1. 5 1. 9 2. 3 It should also be noted that people with left ventricular 6089 1. 0 1. 2 1. 4 1. 7 2. 2 dysfunction (i. e. , ejection fraction 35%) or left main 4559 1. 2 1. 3 1. 5 1. 8 2. 4 disease were excluded from the definitive ISCHEMIA 3044 1. 4 1. 5 1. 7 2. 0 2. 4 trial. 707a The Work Group considers that certain design 1529 1. 9 1. 8 2. 0 2. 6 3. 0 features of the ISCHEMIA-CKD trial may have led to 15 2. 6 2. 5 3. 1 3. 6 4. 2 angina benefits not being detected, and the trial results Atrial fibrillation: 50 cohorts should not rule out angina benefits in people with CKD Study size 22, 886, 642; events 1, 068, 701 (see above). If an invasive strategy is pursued, there are Figure39Meta-analyzedadjustedprevalenceofatrial effective strategies to reduce the risk of contrast-induced fibrillationfromcohortscontributingtotheChronicKidney AKI (Chapter 4). 708 DiseasePrognosisConsortium, bydiabetesstatus. ACR, albuminThetotalityoftheevidencefromtheCKD-specifictrialsis t fi o lt - r c a r t e io at n in r e at r e a. t R io ep e r G o F d R u c c r e, d cr w ea it t h in p in e e r - m b i a s s s e io d n e f s r t o im m a J t A e M g A lo, m W e ri r t u in la g r Group consistent with no net difference between an initial conserfortheCKDPrognosisConsortium; GramsME, CoreshJ, MatsushitaK, vative approach using aggressive medical therapy versus an etal. Estimatedglomerularfiltrationrate, albuminuria, andadverse invasive strategy when treating stable stress-test confirmed outcomes: anindividual-participantdatameta-analysis. JAMA. 2023; 330(13): 12661277. 12Copyright2023AmericanMedical ischemic heart disease. This is consistent with the large genAssociation. Allrightsreserved. eral population-based ISCHEMIA trial. 707a 3. 16 CKD and atrial fibrillation simple to implement. Figure 40 outlines approaches to different diagnostic and management strategies. In CKD, the same principles to diagnose and manage atrial fibrillation should be used as in people without CKD. Practice Point 3. 16. 1: Follow established strategies for the Prevalence and consequences. Atrial fibrillation is the comdiagnosisandmanagementofatrialfibrillation(Figure40). monest sustained arrhythmia, with risk increasing steeply with Prophylaxis against stroke and systemic thromboembolism. increasing age (earlier in men than women). 709 There is a Recent cardiology guidelines recommend a risk factorbased particularly high prevalence in people with CKD. Crude approach to stroke thromboprophylaxis decisions in atrial prevalence ranging from 16% to 21% has been reported in fibrillation using the Congestive heart failure, Hypertension, people with CKD not requiring KRT.
----------------------------------------------------------------------


======================================================================
CHUNK 412 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_138
Content Type: recommendation
Words: 473
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
709 There is a Recent cardiology guidelines recommend a risk factorbased particularly high prevalence in people with CKD. Crude approach to stroke thromboprophylaxis decisions in atrial prevalence ranging from 16% to 21% has been reported in fibrillation using the Congestive heart failure, Hypertension, people with CKD not requiring KRT. 710 In the cohorts Age 75 (doubled), Diabetes, Stroke (doubled), Vascular contributing to the CKD-PC, adults with CKD G3, A1 had disease, Age 65 to 74, and Sex category (female) (CHA DS - 2 2 an adjusted risk of atrial fibrillation of 1. 21. 5, increasing to VASc)strokeriskscore. Theyrecommendthatonlypeopleat an adjusted risk of 4. 2 by CKD stages G5, A3 (Figure 3912). low stroke risk (CHA DS -VASc score  0 in men, or 1 in 2 2 Atrial fibrillation can directly cause thromboembolism women) should not be offered antithrombotic therapy. Oral (particularly stroke) and/or heart failure. It is also linked, anticoagulants should be considered for stroke prevention perhaps directly or through shared risk factors, with increased with a CHA DS -VASc score of 1 in men or 2 in women, 2 2 risk of death, hospitalization, vascular dementia, depression, considering net clinical benefit and values and preferences and reduced QoL. 709 Detailed clinical practice guidelines have of people with CKD. Oral anticoagulants are clearly recombeen formulated by the cardiology community describing mendedforstrokepreventioninpeoplewithatrialfibrillation definitions, classification, diagnosis, screening strategies, and and a CHA DS -VASc score 2 in men or 3 inwomen. 709 2 2 management. 709 It is beyond the scope of this KDIGO Our Work Group considered that oral anticoagulation for guideline to consider all aspects of the diagnosis and thromboprophylaxis should nearly always be considered for management of atrial fibrillation in people with CKD. The preventing stroke in people with decreased eGFR and atrial ERTreview focused on the role of nonvitamin K antagonist fibrillation (Figure 40). The presence of decreased GFR is a oral anticoagulants (NOACs) versus warfarin for risk for thromboembolic stroke in people with atrial thromboprophylaxis in CKD. fibrillation. 710712 It has been estimated that approximately Identification and management. Atrial fibrillation can be 95% of people with an eGFR of 60 ml/min per 1. 73 m2 asymptomaticbutsymptomsarenotaprerequisiteforriskof have a CHA DS -VASc score of 2, increasing to 2 2 complications. Astheprevalenceofatrialfibrillationishighin approximately 99% at an eGFR of 30 ml/min per 1. 73 peoplewithCKDandthereareeffectivestrategiestomanage m2. 711 Importantly, it has also been shown that in a group its associated complications, opportunistic pulse-based of people with a CHA DS -VASc score of 0 to 1 point (i. e. , 2 2 screening (e. g. , when taking BP), followed by a 12-lead a group where thromboprophylaxis may not be considered electrocardiogramifanirregularlyirregularpulseisidentified indicated), people with CKD within the group are at much should be considered. Such an approach is low cost and higher risk of cerebrovascular and other systemic S240 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 413 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_139
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Such an approach is low cost and higher risk of cerebrovascular and other systemic S240 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 In people with CKD, use opportunistic pulse-based screening (e. g. , taking at when measuring BP), followed by a Step 1 Diagnosis wearable device or Holter ECG testing Step 2 (they are likely to have an increased CHADS-VASc risk factor for stroke and are at high risk even with a score of 01) Prophylaxis against 2 2 stroke and systemic managed (e. g. , alcohol advice, use of a proton pump inhibitor) thromboembolism Use medical therapy (e. g. , beta blockade) to control ventricular rate to less than about 90 bpm at rest to decrease Step 3 symptoms and related complications Rate/rhythm control For people with persistent symptoms despite adequate rate control, consider rhythm control with cardioversion, antiarrhythmic therapy and/or catheter ablation Figure40Strategiesforthediagnosisandmanagementofatrialfibrillation. Considerdoseadjustmentsnecessaryinpeoplewith chronickidneydisease(CKD). Thefollowinghasbeenrecommendedasastandardpackagefordiagnosticevaluationofnewatrialfibrillation: (i)a12-leadelectrocardiogram(ECG)toestablishthediagnosis, assessventricularrate, andcheckforthepresenceofconductiondefects, ischemia, orstructuralheartdisease; (ii)laboratorytestingforthyroidandkidneyfunction, serumelectrolytes, andfullbloodcount; and(iii) transthoracicechocardiographytoassessleftventricularsizeandfunction, leftatrialsize, forvalvulardisease, andrightheartsizeandfunction. BP, bloodpressure; CHA DS -VASc, Congestiveheartfailure, Hypertension, Age75(doubled), Diabetes, Stroke(doubled), Vasculardisease, 2 2 Age65to74, andSexcategory(female); HAS-BLED, Hypertension, Abnormalliver/kidneyfunction, Strokehistory, Bleedinghistoryor predisposition, Labileinternationalnormalizedratio(INR), Elderly, Drug/alcoholusage. thromboembolic events, with an annual rate of 2. 9% Keyinformation compared with 0. 2% in people without CKD. 711 Balance of benefits and harms. Benefits. Data from 42, 411 Including GFR into atrial fibrillation risk scores has not participants who received NOACs and 29, 272 participants shownimportantincrementalbenefittoitsintroduction(e. g. , whoreceivedwarfarinin4phaseIIItrialsweremeta-analyzed adding 2 points for CrCl 60 ml/min to CHADS referred in2014. SuchtrialslargelyexcludedpeoplewithCKDG4G5 2 to as Renal Dysfunction, Congestive Heart Failure, Hyperbut did include large numbers of participants with earlier tension, Age, Diabetes, Stroke/Transient Ischemic Attack stages of CKD. Overall, NOACs significantly reducedthe risk R CHADS )improved net reclassification index but not of stroke or systemic embolic events by 19% compared with 2 2 the C-statistic. 710 However, as decreased GFR is associated warfarin (RR: 0. 81; 95% CI: 0. 730. 91). This benefit was a with age, diabetes, CVD, and so on, the incremental result largely from reduced risk of hemorrhagic strokes (RR: predictive advantage by adding a CKD parameter to the 0. 49; 95% CI: 0. 380. 64). There were large amounts of data CHA DS -VASc score, which already includes these on stroke in those with a CrCl of 50 ml/min, and the 2 2 parameters, would be expected to have little effect. There is relativebenefits wereconsistentand clearlyevident in people considerable scope to improve the predictive performance with CKD. There were also consistent effects in subgroup of thromboprophylaxis risk scores for use in CKD. 713 analysesbyage, sex, priordiabetes, priorstroke, andCHADS 2 score. 714Amorerecentmeta-analysispublishedin2021only Recommendation 3. 16. 1: We recommend use of focused on subgroups with CKD and included data from 7 nonvitamin K antagonist oral anticoagulants trials of NOACs versus warfarin in atrial fibrillation. It also (NOACs)inpreferencetovitaminKantagonists(e. g. , reported a 19% reduced risk of stroke/thromboembolic warfarin) for thromboprophylaxis in atrial fibrillacomplications in the NOAC group (HR: 0. 81; 95% CI: tion in people with CKD G1G4 (1C). 0. 690. 97).
----------------------------------------------------------------------


======================================================================
CHUNK 414 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_140
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
It also (NOACs)inpreferencetovitaminKantagonists(e. g. , reported a 19% reduced risk of stroke/thromboembolic warfarin) for thromboprophylaxis in atrial fibrillacomplications in the NOAC group (HR: 0. 81; 95% CI: tion in people with CKD G1G4 (1C). 0. 690. 97). 715 Data in CKD G5 on dialysis were limited to observational studies. 715 Our evidence review aimed to ThisrecommendationputshighvalueontheuseofNOACs, also collect information on subtypes of outcome from subgroup referred to as direct-acting oral anticoagulants or DOACs, in analyses reporting results specifically in people with CKD. people with CKD due to their simpler pharmacokinetic profile, Evidence of efficacy in the large trials is mainly for the dosing, and monitoring than vitamin Kantagonists and due to outcomes of stroke and hemorrhagic stroke, but our review their improved efficacy and relatively similar safety profile. only found data from 3 trials for these outcomes resulting Although people with CKD G4G5 have been understudied in in imprecise estimates of effect. The findings were RCTs, implementation in such groups can be achieved after qualitatively consistent with the totality of the evidence considering choice of NOAC and dosing. (Figure 41, Supplementary Table S14716721). KidneyInternational(2024)105(Suppl4S), S117S314 S241 chapter 3 www. kidney-international. org Kidney Follow-up Author, year function Country length Intervention Control HR (95% CI) Any stroke Bohula, 2016 CrCl 3050 46 countries 2. 8 yr Edoxaban 60 mg Warfarin 0. 91 (0. 67, 1. 24) Hori, 2013 CrCl 3049 Japan 2. 5 yr Rivaroxaban 10 mg Warfarin 0. 99 (0. 29, 3. 42) Fox, 2011 CrCl 3049 45 countries 707 d Rivaroxaban 20 mg Warfarin 0. 95 (0. 64, 1. 41) Subtotal (I20. 0%, P0. 980) 0. 93 (0. 73, 1. 18) Ischemic stroke Stanifer, 2020 eGFR 2550 39 countries 1. 8 yr Apixaban 2. 55 mg Warfarin 0. 86 (0. 54, 1. 35) Hijazi, 2018 eGFR 50 44 countries 1. 8 yr Dabigatran 150 mg Warfarin 0. 50 (0. 28, 0. 87) Bohula, 2016 CrCl 3050 46 countries 2. 8 yr Edoxaban 60 mg Warfarin 0. 99 (0. 70, 1. 40) Hori, 2013 CrCl 3049 Japan 2. 5 yr Rivaroxaban 10 mg Warfarin 0. 74 (0. 17, 3. 31) Fox, 2011 CrCl 3049 45 countries 707 d Rivaroxaban 20 mg Warfarin 1. 02 (0. 71, 1. 46) Subtotal (I219. 5%, P0. 291) 0. 87 (0. 69, 1. 10) Hemorrhagic stroke Bohula, 2016 CrCl 3050 46 countries 2. 8 yr Edoxaban 60 mg Warfarin 0. 58 (0. 30, 1. 12) Hori, 2013 CrCl 3049 Japan 2. 5 yr Rivaroxaban 10 mg Warfarin 1. 98 (0. 18, 21. 80) Fox, 2011 CrCl 3049 45 countries 707 d Rivaroxaban 20 mg Warfarin 0. 58 (0. 23, 1. 47) Subtotal (I20. 0%, P0. 619) 0. 62 (0. 36, 1. 04) NOTE: Weights are from random effects analysis 0. 2 0. 5 1 2 5 Weighted hazard ratio of stroke Favors NOAC Favors control Figure41Pooledhazardratio(HR)comparingnonvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeople withchronickidneydiseaseintermsofstroke. BohulaE, GiuglianoR, RuffC, etal. Impactofrenalfunctiononoutcomeswithedoxabanin theENGAGEAF-TIMI48trial. Circulation. 2016; 134: 2436716; FoxKA, PicciniJP, WojdylaD, etal. Preventionofstrokeandsystemicembolism withrivaroxabancomparedwithwarfarininpatientswithnon-valvularatrialfibrillationandmoderaterenalimpairment. EurHeartJ. 2011; 32: 23872394718; HijaziZ, HohnloserSH, OldgrenJ, etal. Efficacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrial fibrillationinrelationtorenalfunctionovertimeaRE-LYtrialanalysis. AmHeartJ.
----------------------------------------------------------------------


======================================================================
CHUNK 415 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_141
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
2 0. 5 1 2 5 Weighted hazard ratio of stroke Favors NOAC Favors control Figure41Pooledhazardratio(HR)comparingnonvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeople withchronickidneydiseaseintermsofstroke. BohulaE, GiuglianoR, RuffC, etal. Impactofrenalfunctiononoutcomeswithedoxabanin theENGAGEAF-TIMI48trial. Circulation. 2016; 134: 2436716; FoxKA, PicciniJP, WojdylaD, etal. Preventionofstrokeandsystemicembolism withrivaroxabancomparedwithwarfarininpatientswithnon-valvularatrialfibrillationandmoderaterenalimpairment. EurHeartJ. 2011; 32: 23872394718; HijaziZ, HohnloserSH, OldgrenJ, etal. Efficacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrial fibrillationinrelationtorenalfunctionovertimeaRE-LYtrialanalysis. AmHeartJ. 2018; 198: 169177719; HijaziZ, AlexanderJH, LiZ, etal. ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialfibrillationafteracutecoronary syndromeorpercutaneouscoronaryintervention: insightsfromtheAUGUSTUStrial. Circulation. 2021; 143: 12151223722; HoriM, MatsumotoM, TanahashiN, etal. SafetyandefficacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialfibrillation: subanalysisofJROCKETAFforpatientswithmoderaterenalimpairment. CircJ. 2013; 77: 632638720; StaniferJ, PokorneyS, ChertowG, etal. Apixabanversus warfarininpatientswithatrialfibrillationandadvancedchronickidneydisease. Circulation. 2020; 141: 13841392. 721CI, confidenceinterval; CrCl, creatinineclearance; eGFR, estimatedglomerularfiltrationrate. Harms. The 2014 meta-analysis of 4 large phase III trials and dosing. 714 The 2021 meta-analysis that focused on CKD found that NOACs reduced the risk of death from any subgroups from 7 trials found that bleeding events were also cause by 10%, confirming net safety (RR: 0. 90; 95% CI: not significantly different among those allocated NOACs 0. 850. 95). Compared with warfarin, NOACs reduced the versus warfarin (HR: 0. 83; 95% CI: 0. 581. 18). 715 Data in risk of intracranial hemorrhage (defined as hemorrhagic CKD G5 on dialysis were limited to observational studies. 715 stroke, epidural, subdural, and subarachnoid hemorrhage) Our evidence review was again limited to a small number of by about one-half (RR: 0. 48; 95% CI: 0. 390. 59), and the studies reporting subtypes of bleeding outcomes, and so risk of gastrointestinal bleeding was increased by about analyses found imprecise estimates of treatment effect. The one-quarter (RR: 1. 25; 95% CI: 1. 011. 55). Overall, there findings were qualitatively consistent with the totality of the was no clear effect on the combination of these 2 safety evidence (Figure 42, Supplementary Table S15716722). The outcomes referred to as major bleeding (RR: 0. 86; 95% CI: review raised a hypothesis that some NOACs may be more 0. 731. 00). 714 There were large amounts of data on major likely to reduce the risk of bleeding. However, given the bleeding in those with a CrCl of 50 ml/min, so evidenceofeffectmodificationbytimeintherapeuticrangein reassuring safety data clearly extended to people with the warfarin group, we have not provided specific CKD. There were also consistent safety data in subgroup recommendationstoprefercertainNOACs. analyses by age, sex, prior diabetes, prior stroke, and Certaintyofevidence. The overall certainty of the evidence CHADS score. There was a suggestion that major bleeding comparing NOACs with warfarin among people with CKD 2 was significantly reduced in people attending centers where andatrialfibrillationislow(SupplementaryTablesS14716721 timeintherapeuticinternationalnormalizedratio(INR)range and S15716722). Most of the RCTs evaluating the critical was 66% compared with centers with 66% time in range outcomes were considered to have a low risk of bias. The (interaction P  0. 02). This suggests that benefits of NOACs critical outcome of stroke was reported as any stroke, are in part a result of their simpler pharmacokinetic profile ischemic stroke, and/or hemorrhagic stroke. Because there S242 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Kidney Follow-up Author, year function Country length Intervention Control HR (95% CI) All clinically relevant bleeding Hijazi, 2021 CrCl 3050 33 countries 6 mos Apixaban 2.
----------------------------------------------------------------------


======================================================================
CHUNK 416 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_142
Content Type: reference
Words: 486
Medical Entities: GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Because there S242 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Kidney Follow-up Author, year function Country length Intervention Control HR (95% CI) All clinically relevant bleeding Hijazi, 2021 CrCl 3050 33 countries 6 mos Apixaban 2. 55 mg Warfarin 0. 59 (0. 41, 0. 84) Stanifer, 2020 eGFR 2550 39 countries 1. 8 yrs Apixaban 2. 55 mg Warfarin 0. 35 (0. 17, 0. 72) Hori, 2013 CrCl 3049 Japan 2. 5 yrs Rivaroxaban 10 mg Warfarin 1. 22 (0. 78, 1. 91) Fox, 2011 CrCl 3049 45 countries 707 dys Rivaroxaban 20 mg Warfarin 0. 98 (0. 85, 1. 15) Subtotal (I2 79. 9%, P0. 002) 0. 76 (0. 51, 1. 14) Fatal bleeding Bohula, 2016 CrCl 3050 46 countries 2. 8 yrs Edoxaban 60 mg Warfarin 0. 48 (0. 22, 1. 07) Hori, 2013 CrCl 3049 Japan 2. 5 yrs Rivaroxaban 10 mg Warfarin 1. 04 (0. 07, 16. 70) Subtotal (I2 0. 0%, P0. 595) 0. 51 (0. 24, 1. 09) Major bleeding Hijazi, 2021 CrCl 3050 33 countries 6 mos Apixaban 2. 55 mg Warfarin 0. 51 (0. 28, 0. 93) Stanifer, 2020 eGFR 2550 39 countries 1. 8 yrs Apixaban 2. 55 mg Warfarin 0. 59 (0. 45, 0. 77) Hijazi, 2018 eGFR 50 44 countries 1. 8 yrs Dabigatran 150 mg Warfarin 1. 11 (0. 87, 1. 14) Bohula, 2016 CrCl 3050 46 countries 2. 8 yrs Edoxaban 60 mg Warfarin 0. 76 (0. 58, 0. 98) Hori, 2013 CrCl 3049 Japan 2. 5 yrs Rivaroxaban 10 mg Warfarin 0. 89 (0. 36, 2. 18) Fox, 2011 CrCl 3049 45 countries 707 dys Rivaroxaban 20 mg Warfarin 0. 98 (0. 73, 1. 30) Subtotal (I2 79. 0%, P0. 000) 0. 80 (0. 61, 1. 05) Intracranial hemorrhage Bohula, 2016 CrCl 3050 46 countries 2. 8 yrs Edoxaban 60 mg Warfarin 0. 46 (0. 26, 0. 82) Fox, 2011 CrCl 3049 45 countries 707 dys Rivaroxaban 20 mg Warfarin 0. 82 (0. 41, 1. 60) Subtotal (I2 38. 2%, P0. 203) 0. 60 (0. 34, 1. 05) Clinically relevant nonmajor bleeding Hori, 2013 CrCl 3049 Japan 2. 5 yrs Rivaroxaban 10 mg Warfarin 1. 35 (0. 82, 2. 22) Fox, 2011 CrCl 3049 45 countries 707 dys Rivaroxaban 20 mg Warfarin 1. 01 (0. 85, 1. 20) Subtotal (I2 14. 1%, P0. 281) 1. 06 (0. 86, 1. 31) NOTE: Weights are from random effects analysis 0. 2 0. 5 1 2 5 Weighted hazard ratio of bleeding Favors NOAC Favors control Figure42Pooledhazardratio(HR)comparingnonvitaminKantagonistoralanticoagulants(NOACs)withwarfarinamongpeople withchronickidneydiseaseintermsofbleeding. BohulaE, GiuglianoR, RuffC, etal. Impactofrenalfunctiononoutcomeswithedoxabanin theENGAGEAF-TIMI48trial. Circulation. 2016; 134: 2436716; FoxKA, PicciniJP, WojdylaD, etal. Preventionofstrokeandsystemicembolism withrivaroxabancomparedwithwarfarininpatientswithnon-valvularatrialfibrillationandmoderaterenalimpairment. EurHeartJ. 2011; 32: 23872394718; HijaziZ, HohnloserSH, OldgrenJ, etal. Efficacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrial fibrillationinrelationtorenalfunctionovertimeaRE-LYtrialanalysis. AmHeartJ. 2018; 198: 169177719; HoriM, MatsumotoM, TanahashiN, etal. SafetyandefficacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialfibrillation: subanalysisofJ-ROCKETAFfor patientswithmoderaterenalimpairment. CircJ. 2013; 77: 632638720; StaniferJ, PokorneyS, ChertowG, etal. Apixabanversuswarfarinin patientswithatrialfibrillationandadvancedchronickidneydisease. Circulation. 2020; 141: 13841392721; HijaziZ, AlexanderJH, LiZ, etal. ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialfibrillationafteracutecoronary syndromeorpercutaneouscoronaryinterventioninsightsfromtheAUGUSTUStrial. Circulation. 2021; 143: 12151223. 722CI, confidenceinterval; CrCl, creatinineclearance; eGFR, estimatedglomerularfiltrationrate.
----------------------------------------------------------------------


======================================================================
CHUNK 417 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_143
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
2011; 32: 23872394718; HijaziZ, HohnloserSH, OldgrenJ, etal. Efficacyandsafetyofdabigatrancomparedwithwarfarininpatientswithatrial fibrillationinrelationtorenalfunctionovertimeaRE-LYtrialanalysis. AmHeartJ. 2018; 198: 169177719; HoriM, MatsumotoM, TanahashiN, etal. SafetyandefficacyofadjusteddoseofrivaroxabaninJapanesepatientswithnon-valvularatrialfibrillation: subanalysisofJ-ROCKETAFfor patientswithmoderaterenalimpairment. CircJ. 2013; 77: 632638720; StaniferJ, PokorneyS, ChertowG, etal. Apixabanversuswarfarinin patientswithatrialfibrillationandadvancedchronickidneydisease. Circulation. 2020; 141: 13841392721; HijaziZ, AlexanderJH, LiZ, etal. ApixabanorvitaminKantagonistsandaspirinorplaceboaccordingtokidneyfunctioninpatientswithatrialfibrillationafteracutecoronary syndromeorpercutaneouscoronaryinterventioninsightsfromtheAUGUSTUStrial. Circulation. 2021; 143: 12151223. 722CI, confidenceinterval; CrCl, creatinineclearance; eGFR, estimatedglomerularfiltrationrate. werefewstrokeeventsreportedacrosstheRCTs, thecertainty achieve fewer quality-adjusted life-years compared with of the evidence was downgraded for imprecision. NOACs. 723 Values and preferences. High value on the use of NOACs Considerations for implementation. A decision not to antiincluded the conclusion that the simple dosing and lack of coagulate for thromboembolic prophylaxis due to low risk INRmonitoringcomparedwithvitaminKantagonistswould wouldideallybere-evaluatedateachconsultationandatleast lead to a substantial reduction in burden for those with an every 6 months. When using antithrombotic therapy in indicationforanticoagulationandtheirhealthservices. There peoplewithCKD, itisprudenttotreatmodifiableriskfactors is also good evidence for improved efficacy and a relatively for bleeding (e. g. , alcohol intake) and use gastroprophylaxis similar safety profile. Most fully informed people with CKD with a PPI, particularly when combined with antiplatelet would be expected to select a NOAC over a vitamin K therapy. antagonist. Resource use and costs. NOACs have been shown to be Rationale cost-effective for stroke prevention in atrial fibrillation and A number of large RCTs demonstrated that NOACs reduce may even be cost-saving in people with CKD. Vitamin K theriskofintracranialbleedingcomparedwithwarfarinand, antagonist use may be associated with higher costs and overall, modestly reduce mortality in people with atrial KidneyInternational(2024)105(Suppl4S), S117S314 S243 chapter 3 www. kidney-international. org a eCrCl (ml/min)a Warfarin Apixabanb Dabigatran Edoxabanc Rivaroxaban 95 Adjusted dose (INR 23) 5 mg b. i. d. 150 mg b. i. d. 60 mg QDd 20 mg QD 5195 Adjusted dose (INR 23) 5 mg b. i. d. 150 mg b. i. d. 60 mg QD 20 mg QD 3150 Adjusted dose (INR 23) 5 mg b. i. d. 150 mg b. i. d. or 30 mg QD 15 mg QD 110 mg b. i. d. e b eCrCl (ml/min)a Warfarin Apixabanb Dabigatran Edoxaban Rivaroxaban 1530 Adjusted dose for INR 2. 5 mg PO b. i. d. Unknown 30 mg QDh 15 mg QD 23 could be considered could be considered (75 mg PO b. i. d. )f, g could be considered could be considered 15 not on dialysis Equipoise based on Unknown Not recommended Not recommended Unknown observational data (2. 5 mg PO b. i. d. )f (15 mg QD)f and meta-analysis 15 on dialysis Equipoise based on Unknown Not recommended Not recommended Unknown observational data (2. 5 mg PO b. i. d. )f (15 mg QD)f and meta-analysis Figure43Evidencefrom(a)randomizedcontrolledtrials(RCTs)regardingtherapeuticanticoagulationdosebyglomerularfiltration rate(GFR)and(b)inareaswhereRCTsarelacking. DosingofnonvitaminKantagonistoralanticoagulants(NOACs)basedsolelyon limitedpharmacokineticandpharmacodynamicdata(i. e. , therearenorandomizedefficacyorsafetytrialdataassessingclinicaloutcomes forstrokethromboprophylaxisinatrialfibrillationatchronickidneydiseaseCKDG4G5). aCockcroft-Gaultestimatedcreatinineclearance (eCrCl). bApixabandosemodificationfrom5mgtwiceperday(b. i. d. )to2. 5mgb. i. d. ifapersonhasany2ofthefollowing: serum creatinine1. 5mg/dl(133 m mol/l), age80years, orbodyweight60kg. cIntheEffectiveAnticoagulationWithFactorXaNextGeneration inAtrialFibrillationThrombolysisinMyocardialInfarction48(ENGAGE-AFTIMI48)study, thedosewashalvedifanyofthefollowing: eCrCl of3050ml/min, bodyweight60kg, orconcomitantuseofverapamilorquinidine(potentP-glycoproteininhibitors). dThisdosehasnot beenapprovedforusebytheUSFoodandDrugAdministration(FDA)inthiscategoryofGFR. eIncountrieswhere110mgb. i. d. isapproved, healthcareprovidersmaypreferthisdoseafterclinicalassessmentofthromboembolicversusbleedingrisk. Thisdosehasnotbeen approvedforusebytheUSFDA. fNOACdoseslistedinparenthesisaredosesthatdonotcurrentlyhaveanyclinicalorefficacydata. The dosesofNOACsapixaban5mgb. i. d. , brivaroxaban15mgeveryday, anddabigatran75mgb. i. d. areincludedintheUSFDAapproved labelingbasedonlimiteddosepharmacokineticandpharmacodynamicsdatawithnoclinicalsafetydata. Wesuggestconsiderationofthe lowerdoseofapixaban2. 5mgoralb. i. d. inCKDG5andG5Dtoreducebleedingriskuntilclinicalsafetydataareavailable. gDabigatran75 mgavailableonlyintheUnitedStates. hThedosewashalvedifanyofthefollowing: estimatedCrClof3050ml/min, bodyweightof60kg, orconcomitantuseofverapamilorquinidine(potentP-glycoproteininhibitors). INR, internationalnormalizedratio; QD, everyday. ReproducedfromTurakhiaMP, BlankestijnPJ, CarreroJJ, etal. Chronickidneydiseaseandarrhythmias: conclusionsfromaKidneyDisease: ImprovingGlobalOutcomes(KDIGO)ControversiesConference. EurHeartJ.
----------------------------------------------------------------------


======================================================================
CHUNK 418 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_144
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
dThisdosehasnot beenapprovedforusebytheUSFoodandDrugAdministration(FDA)inthiscategoryofGFR. eIncountrieswhere110mgb. i. d. isapproved, healthcareprovidersmaypreferthisdoseafterclinicalassessmentofthromboembolicversusbleedingrisk. Thisdosehasnotbeen approvedforusebytheUSFDA. fNOACdoseslistedinparenthesisaredosesthatdonotcurrentlyhaveanyclinicalorefficacydata. The dosesofNOACsapixaban5mgb. i. d. , brivaroxaban15mgeveryday, anddabigatran75mgb. i. d. areincludedintheUSFDAapproved labelingbasedonlimiteddosepharmacokineticandpharmacodynamicsdatawithnoclinicalsafetydata. Wesuggestconsiderationofthe lowerdoseofapixaban2. 5mgoralb. i. d. inCKDG5andG5Dtoreducebleedingriskuntilclinicalsafetydataareavailable. gDabigatran75 mgavailableonlyintheUnitedStates. hThedosewashalvedifanyofthefollowing: estimatedCrClof3050ml/min, bodyweightof60kg, orconcomitantuseofverapamilorquinidine(potentP-glycoproteininhibitors). INR, internationalnormalizedratio; QD, everyday. ReproducedfromTurakhiaMP, BlankestijnPJ, CarreroJJ, etal. Chronickidneydiseaseandarrhythmias: conclusionsfromaKidneyDisease: ImprovingGlobalOutcomes(KDIGO)ControversiesConference. EurHeartJ. 2018; 39: 23142325. 710TheAuthor(s)2018. Publishedby OxfordUniversityPressonbehalfoftheEuropeanSocietyofCardiology. ThisisanOpenAccessarticledistributedunderthetermsofthe CreativeCommonsAttributionNon-CommercialLicense( fibrillation. Theyofferbenefitsintermsofeaseofmonitoring. GFR of a person with CKD (Figure 43710). Consult the CKDdoesnotappeartoimportantlymodifythesebenefits, at relevant summaries of product characteristics for the latest least down to G4. information on dosing (Chapter 4). Practice Point 3. 16. 2: NOAC dose adjustment for GFR is Practice Point 3. 16. 3: Duration of NOAC discontinuation required, with caution needed at CKD G4G5. before elective procedures needs to consider procedural Doses of NOACs may need to be modified in people with bleeding risk, NOAC prescribed, and level of GFR decreasedGFRtakingintoconsiderationtheage, weight, and (Figure 44). 710, 724 S244 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 3 Dabigatran ApixabanEdoxabanRivaroxaban No important bleeding risk and/or adequate local hemostasis possible: perform at trough level (i. e. , 12 or 24 h after last intake) Low risk High risk Low risk High risk CrCl 80 ml/min 24 h 48 h 24 h 48 h CrCl 5080 ml/min 36 h 72 h 24 h 48 h CrCl 3050 ml/mina 48 h 96 h 24 h 48 h CrCl 1530 ml/mina No official indication No official indication 36 h 48 h CrCl 15 ml/min No official indication for use There is no need for bridging with LMWH/UFH Figure44AdviceonwhentodiscontinuenonvitaminKantagonistoralanticoagulants(NOACs)beforeprocedures(lowvs. highrisk). Theboldvaluesdeviatefromthecommonstoppingruleof24-hourlowrisk, 48-hourhighrisk. Lowriskisdefinedasalowfrequencyof bleedingand/orminorimpactofableed. Highriskisdefinedasahighfrequencyofbleedingand/orimportantclinicalimpact. Adaptedfrom HeidbuchelH, VerhammeP, AlingsM, etal. UpdatedEuropeanHeartRhythmAssociationpracticalguideontheuseofnonvitamin-K antagonistanticoagulantsinpatientswithnon-valvularatrialfibrillation: executivesummary. EurHeartJ. 2017; 38: 21372149. 724aManyofthese peoplemaybeonlowerdoseofdabigatran(110mgtwiceperdayb. i. d. )orapixaban(2. 5mgb. i. d. ), orhavetobeonthelowerdoseof rivaroxaban(15mgQD)oredoxaban(30mgQD). Dabigatran110mgb. i. d. hasnotbeenapprovedforusebytheUSFoodandDrug Administration. CrCl, creatinineclearance, LMWH, low-molecular-weightheparin; UFH, unfractionatedheparin. ReproducedfromTurakhiaMP, BlankestijnPJ, CarreroJJ, etal. Chronickidneydiseaseandarrhythmias: conclusionsfromaKidneyDisease: ImprovingGlobalOutcomes (KDIGO)ControversiesConference. EurHeartJ. 2018; 39: 23142325. 710TheAuthor(s)2018. PublishedbyOxfordUniversityPressonbehalfof theEuropeanSocietyofCardiology. ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNonCommercialLicense( For research recommendations, please see Chapter 6: Research recommendations. KidneyInternational(2024)105(Suppl4S), S117S314 S245 chapter 4 www. kidney-international. org Chapter 4: Medication management and drug stewardship in CKD Medication management is an important component of the As in all medical decision-making, healthcare providers care of people with CKD. Medications can be highly benefishould consider the indication, benefit-risk profile, and pocial, but some may be toxic, are excreted by the kidney, may tential nephrotoxicity while balancing accessibility, availabilhave narrow therapeutic windows, or may have no proven ity, local health policies, cultural practices, affordability, and clear evidence of benefit or indication in people with CKD. patient preferences. Where available, consultation with Drug stewardship refers to the effective, safe, and suspharmacists as part of the multidisciplinary team is encourtainable use of medications by all staff and physicians, aged to assure optimized comprehensive medication manencompassing the whole cycle of medication use. Medicaagement and to improve pharmacoequity. tions need to be prescribed responsibly, monitored for efficacy and safety, and when they do not or no longer serve Practice Point 4. 1. 1: People with CKD may be more sustheirintendedpurpose, discontinued. Thischapterdiscusses ceptible to the nephrotoxic effects of medications.
----------------------------------------------------------------------


======================================================================
CHUNK 419 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_145
Content Type: recommendation
Words: 497
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Medicaagement and to improve pharmacoequity. tions need to be prescribed responsibly, monitored for efficacy and safety, and when they do not or no longer serve Practice Point 4. 1. 1: People with CKD may be more sustheirintendedpurpose, discontinued. Thischapterdiscusses ceptible to the nephrotoxic effects of medications. When key concepts in the processes of drug stewardship in people prescribing such medications to people with CKD, always with CKD. It is beyond the scope of this guideline to list all consider the benefits versus potential harms. the medications that may have altered risks/benefits in Between 18%20% of people withCKD G3G5 receiveat people with CKD. Such information is widely available in least one potentially inappropriate nephrotoxic medication documents that may exist at local, regional, or national annually, primarily NSAIDs, nephrotoxic antivirals, and bodies (e. g. , British National Formulary: www. bnf. org) and bisphosphonates. 729 Nephrotoxic medications may be in textbooks of pharmacology. However, we describe case indicated in people with CKD if expected benefits exceed examples to highlight the key classes of commonly prepotential harms. 730 However, whenever possible, healthcare scribed medications in people with CKD. This guidance is providers should strive to use non-nephrotoxic alternatives. based on knowledge of pharmacology that has universal Common nephrotoxic medications to be aware of and relevance. Inmanycases, knowledgeofalteredrisks/benefits potential alternatives that could be prescribed instead are of medications comes, however, from observational studies listed in Table 31. 725, 731738 Although some nephrotoxic and case reports from routine care. medications have viable alternatives, the alternatives may be less potent or there is limited comparison data on clinical 4. 1 Medication choices and monitoring for safety outcomes, safety, and cost-effectiveness. Abnormal kidney function results in alteration in pharmaPractice Point 4. 1. 2: Monitor eGFR, electrolytes, and thercokineticsandpharmacodynamics, andforpeoplewithCKD, apeutic medication levels, when indicated, in people with asthe GFR worsens, so does theprevalenceof polypharmacy CKD receiving medications with narrow therapeutic winand comorbidities. 725 People with CKD are at increased risk dows, potential adverse effects, or nephrotoxicity, both in of medication errors and inappropriate prescribing (noted outpatient practice and in hospital settings. to be up to 37% in ambulatory outpatient studies and up Ensuring a safe use of medication requires careful monito 43% in long-term care studies726, 727). Thus, improved toringforadverseeffectsandefficacy. Akeyexampleincludes understanding and collaboration with pharmacists in the need to monitor potassium and creatinine during the developing care plans and medication review is strongly initialweeksoftreatmentwithACEiandARBs(Figure21). 23 recommended. Medications such as gentamicin and vancomycin have a People with CKD have reduced ability to excrete medicanarrow therapeutic range, with higher trough levels tions and/or their metabolites (which may increase adverse commonly associated with AKI, and so require close event risk or exaggerate/diminish efficacy) and increased monitoring of GFR and medication levels during prolonged sensitivity to medications (e. g. , those bound to albumin in treatment. 731 Other medications, such as lithium or hypoalbuminemic states such as nephrotic syndrome). methotrexate, require at least annual monitoring of Additional issues include nephrotoxicity, diminished tolercreatinine to evaluate potential risks of nephrotoxicity.
----------------------------------------------------------------------


======================================================================
CHUNK 420 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_146
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
731 Other medications, such as lithium or hypoalbuminemic states such as nephrotic syndrome). methotrexate, require at least annual monitoring of Additional issues include nephrotoxicity, diminished tolercreatinine to evaluate potential risks of nephrotoxicity. anceof side effects in the contextof coexistingcomorbidities or older age, and lack of adequate evidence for either benefit Practice Point 4. 1. 3: Review and limit the use of over-theorharmofspecificcompounds, duetohistoricalexclusionof countermedicinesanddietaryorherbalremediesthatmay people with (advanced) CKD from most clinical trials. 727, 728 be harmful for people with CKD. S246 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 4 Table31Keyexamples ofcommon medicationswithdocumented nephrotoxicity and, whereavailable, selected nonnephrotoxicalternatives Nephrotoxicmedication Potentialnon-nephrotoxicalternatives Analgesics NSAIDs: nephrotoxiceffectsincludeadecreaseinGFRthroughareductionin Acetaminophen prostaglandin-dependentkidneybloodflow, allergicinterstitialnephritis(AIN), andnephroticsyndrome725 Antimicrobials Aminoglycosides: accumulatesintheproximaltubularcellsanddisruptsphospholipid Cephalosporinsandcarbapenems metabolism, resultingincellapoptosisandacutetubularnecrosis(ATN)731, 732 Vancomycin: unclearcauseofnephrotoxicity, butlikelyrelatedtoATNandpossibleAIN731, 732 Linezolidanddaptomycin731 Sulfamethoxazole-trimethoprim: AIN, ATN, crystalluriawithinthedistalconvoluted Clindamycinprimaquine, pentamidine, tubuleandreversibleinhibitionoftubularcreatininesecretion731 andatovaquone Gastrointestinalmedications Protonpumpinhibitors: mayresultinAKIandCKDduetotubulointerstitialnephritis H2-receptorantagonists andAIN733, 734 Cardiovascularmedications Warfarin: glomerularhemorrhage, oxidativestresscausingkidneytubulardamage, and NonvitaminKantagonistoralanticoagulants directeffectsonkidneyvascularcalcificationbyvitaminKdependentalterations ofmatrixGlaprotein735, 736 Other Lithium: nephrogenicdiabetesinsipidusaswellasCKDfromchronictubulointerstitial Aripiprazole, lamotrigine, quetiapine, valproate nephropathy737 CKD, chronickidneydisease; GFR, glomerularfiltrationrate; NSAID, nonsteroidalanti-inflammatorydrug. Kidneydiseasecanbeinducedoracceleratedbytheuseof by coexisting volume depletion and by other illness or certain over-the-counter (OTC) medications, herbal remmedication use. edies, and other dietary supplements. One of the most used Dietary supplementsare readilyavailableinmostcountries class of OTC analgesic medications is NSAIDs. NSAIDs are around the world and are usually not classified as OTC medassociated with interstitial nephritis, analgesic nephropathy, ications. Becauseofthis, theirregulationforidentityandsafety andhypertension. 739IndiscriminatechronicOTCNSAIDuse can vary widely. Although laws pertaining to dietary supplehas been associated with a higher risks of kidney failure ment labeling prohibit specific claims for the treatment or compared with nonuse and should be discouraged. 740743 prevention of disease, these products are widely used as However, judicious NSAID use, under careful supervision of alternative or complementary therapy. Patients and proa nephrologist, may be preferred to other pain medications viders often assume that these products are at least safe and such as opioids that have stronger associations with adverse possibly effective. Their pharmacokinetics may be unknown events. 744, 745 PPIs are also common OTC medications in and potential toxicity unstudied. Classic examples include some countries that have been associated with AKI and creatine supplements used for body building that have been CKD due to tubulointerstitial nephritis and acute interstitial associated with allergic interstitial nephritis. 750, 751 Another nephritis. 733, 734 example is vitamin C (ascorbic acid) supplements, which in Theuse ofherbal compounds remainshighly prevalentin excesscanleadtotubularcalciumoxalatecrystaldeposition. 752 somecountriesandcultures. 746Theseproductsareoftenused Healthcare providers are encouraged to routinely inquire in an unmonitored setting without the input of healthcare about the use of herbal remedies and recommend stopping providers. Many of these remedies are composed of natural any unprescribed alternative remedy that may pose a threat compounds with complex active ingredients that have not for (kidney) health. Figure 45747, 753, 754 lists common herbal been evaluated in people with CKD and/or that may lead to remedies and dietary supplements arranged by the countries many different adverse effects. The frequency of CKD where the adverse effects were reported to increase associated with herbal remedy use is not known and is awareness and facilitate discussions.
----------------------------------------------------------------------


======================================================================
CHUNK 421 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_147
Content Type: recommendation
Words: 497
Medical Entities: CKD,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The frequency of CKD where the adverse effects were reported to increase associated with herbal remedy use is not known and is awareness and facilitate discussions. likely different in different parts of the world, depending on local availability and reasons for use. Examples include Specialconsiderations aristolochic acid nephropathy or nephrotoxicity due to Global access to medications. Access to medications varies alkaloid compounds often found in Chinese herbal globally. Approximately 30% of the world population lacks remedies. 747 However, cases of nephrotoxicity have been timely access to quality medications. The International Socireported for many other herbal remedies globally. 746, 748, 749 etyof Nephrology (ISN)reportsthat only 35% of patientsin The potential toxicity of herbal remedies may be enhanced low-resource settings have access to ACEi/ARBs, statins, and KidneyInternational(2024)105(Suppl4S), S117S314 S247 chapter 4 www. kidney-international. org Hemlock (Conium maculatum) Noni juice (Morinda citrifolia) Cyprinidae (grass carp, common carp, silver carp, Senna fruit tea (Sennae fructus angustifoliae) black shark fish, bony-lipped barb fish) Germanium Indian carp (Labeo rohita) Alfafa (Medicago sativa L. ) Hydrazine sulfate Mourning cypress (Cupressus funebris) Black cohosh (Actaea racemosa) Willow bark (Salix daphnoides) Snake gallbladder (Naja naja atra) Cone flower (Echinacea) Anatolian hawthorn (Crataegus orientalis) Star fruit (Averrhoa carambola) Chromium picolinate Tribulus terrestris Oduvan (Cleistanthus collinus) CKLS (colon, kidney, liver, spleen Yellow oleander (Thevetia peruviana) purifier contains Aloe vera, Cascara Djenkol beans, jering (Pithecolobium lobatum) sagrada, Larrea tridentata and Arctostaphylos uva-ursi) Tripterygium Creatine Chimonanthus Hemlock (Conium maculatum) Tetrandra Ma huang (Ephedra sinica) Menispermi Hydrazine sulfate Strychnos Noni juice (Morinda citrifolia) Wood veratry St. Johns wort (Hypericum perforatum) Aconitum Wormwood oil (Artemisia absinthium) Groundsel L-lysine Monkhood Chaparral (Larrea tridentata) Bee pollen Fish gallbladder Propolis Star fruit (Averrhoa carambola) Cats claw (Uncaria tomentosa) Cone flower (Echinacea) Worldwide: Wild wisteria, violet tree Spurge (Euphorbia matabelensis) Licorice (Glycyrrhiza glabra) (Securidaca longipedunculata) Khat leaf (Catha edulis) Mushrooms (Amanita phalloides, Cortinarius spp. ) Paraphenylene diamine (PPD) Cape aloe (Aloe capensis) Aristocholic acid-containing Chinese herbs Takaout roumia Impila, ox-eye daisy (Callilepis laureola) Sheep bile Potassium dichromate Bird flower (Crotalaria laburnifolia) Figure45Selectedherbalremediesanddietarysupplementswithevidenceofpotentialnephrotoxicity, groupedbythecontinent fromwherethereportsfirstcame. DatafromYangB, XieY, GuoM, etal. NephrotoxicityandChineseherbalmedicine. ClinJAmSocNephrol. 2018; 13: 16051611747; GabardiS, MunzK, UlbrichtC. Areviewofdietarysupplement-inducedrenaldysfunction. ClinJAmSocNephrol. 2007; 2: 757765753; PerazellaMA. Pharmacologybehindcommondrugnephrotoxicities. ClinJAmSocNephrol. 2018; 13: 18971908. 754 insulin. 755 There are also numerous barriers to additional BP and hypertension. 757 Nonoral hormonal contraceptives important medications for the management of CKD have a less clear impact on BP. 757 complications, such as erythropoietin analogs, iron infusion, Pregnancy may pose a risk of CKD progression for people and phosphate or potassium binders. withestablishedCKD. Inaddition, somerecommendedmediThere are growing concerns regarding the use of falsified cationstosloworpreventCKDprogressionareteratogenic(such and substandard medications in lowto lower-middleinas ACEi/ARBs or mammalian target of rapamycin inhibitors) come countries as they pose potential harm, particularly to anddiscontinuationduringpregnancyshouldbeconsidered. 758 those people at risk of and with CKD. Patients and their Some CKD-specific medications should be continued during familiesshouldbeawarethatmedicationfalsificationisoften pregnancies such as hydroxychloroquine, tacrolimus, associated with illicit internet supply. Many vulnerable comcyclosporin, eculizumab, prednisone, azathioprine, colchicine, munities and people with low health literacy and those in and intravenous immunoglobulin.
----------------------------------------------------------------------


======================================================================
CHUNK 422 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_148
Content Type: reference
Words: 482
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
758 those people at risk of and with CKD. Patients and their Some CKD-specific medications should be continued during familiesshouldbeawarethatmedicationfalsificationisoften pregnancies such as hydroxychloroquine, tacrolimus, associated with illicit internet supply. Many vulnerable comcyclosporin, eculizumab, prednisone, azathioprine, colchicine, munities and people with low health literacy and those in and intravenous immunoglobulin. A thorough medication countries with less rigorous regulatory systems are more at chart review is necessary to replace teratogenic medications risk of medication falsification. Therefore, increased global before conception, or whenever this is not possible, ensure a awareness is important, and people with CKD should be strictmonitoringplanwithcessationofpotentiallyteratogenic provided with appropriate education and follow-up with medications at conception. 759 A similar approach should be relevant support in accordance with local health policies. undertaken during lactation recognizing that some Medicationsandpregnancy. medications suitable for use during pregnancy may not be Practice Point 4. 1. 4: When prescribing medications to appropriate for lactation, and vice versa. 760 Multidisciplinary peoplewithCKDwhoareofchild-bearingpotential, always care with obstetrics and potentially other subspecialty care is review teratogenicity potential and provide regular reprorequired before conception and throughout pregnancy and ductive and contraceptive counseling in accordance with lactation. 54 the values and preferences of the person with CKD. Sex-specificaspectsofmedicationuseinCKD. Sexdifferences When pregnancy is not desired, we note that while the in medication safety and efficacy in people with CKD are effect of different forms of contraception on GFR is ununderstudied, 38, 761, 762 For example, sex differences in body known, 756 oral contraceptives are associated with increased weight and composition as well as physiological functions S248 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 4 may impact drug metabolism and response. Because drug There is now a recognition by major regulatory agencies dosages are often universal, women are more likely to that any contemporary, widely accepted, and clinically consume higher doses in relation to their body applicable estimating GFR equation is considered reasonable weight, 136, 763, 764 and this could be associated with more to assess GFR in pharmacokinetic studies. 770, 771 adverse events. 136 In people with heart failure with reduced ejection fraction, observational studies show improved Practice Point 4. 2. 4: In people with extremes of body survival in women with lower doses of renin-angiotensinweight, eGFRnonindexedforbodysurfacearea(BSA)may aldosterone system (RAAS)-blocking medications, whereas be indicated, especially for medications with a narrow men benefit from higher doses. 765, 766 This may be related to therapeutic range or requiring a minimum concentration lower RAAS activity in women compared with men. 767 to be effective. For assessment of CKD, itis relevantto comparetheGFR 4. 2 Dose adjustments by level of GFR according to a standard body size. For this reason, GFR estimatingequationshavebeendevelopedinunitsofml/min PracticePoint4. 2. 1: ConsiderGFRwhendosingmedications per 1. 73 m2. However, because drug clearance is more cleared by the kidneys. strongly associated with nonindexed eGFR (ml/min) than Many medications and/or their active metabolites are indexed eGFR (ml/min per 1. 73 m2), in very small or large excreted by the kidneys.
----------------------------------------------------------------------


======================================================================
CHUNK 423 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_149
Content Type: evidence
Words: 475
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
2. 1: ConsiderGFRwhendosingmedications per 1. 73 m2. However, because drug clearance is more cleared by the kidneys. strongly associated with nonindexed eGFR (ml/min) than Many medications and/or their active metabolites are indexed eGFR (ml/min per 1. 73 m2), in very small or large excreted by the kidneys. Failure to properly account for the individuals, this can result in overor underdosing, respeceffect of GFR when designing appropriate drug-dosing regitively, as well as noninitiation of certain medications. 772, 773 mens can predisposeapersonto treatmentfailureoradverse Nonindexed eGFR can be obtained by multiplying the events. 725, 728 Although guidelines for adjustment of the indexed eGFR results by the persons BSA and dividing by dosing regimen at varying severities of CKD provided by 1. 73 m2, or by using an appropriate online calculator. the manufacturer are widely available in pharmacopeias, textbooks, online references, or local procedures, there may Practice Point 4. 2. 5: Consider and adapt drug dosing in be significant differences in information provided by these people where GFR, non-GFRdeterminants ofthefiltration resources. 768 markers, orvolumeofdistributionarenotinasteadystate. In people with rapidly changing health status, it can be a Practice Point 4. 2. 2: For most people and clinical settings, challenge to estimate the GFR. Serum concentrations of validated eGFR equations using SCr are appropriate for filtrationmarkersmaybechangingbecauseofchangesintrue drug dosing. GFRand/orinnon-GFRdeterminantsofthemarker(Section 1. 2). Insuchsettingsforpeoplewhorequiremedicationsthat Practice Point 4. 2. 3: Where more accuracy is required for are impacted by or could impact GFR, healthcare providers drug-related decision-making (e. g. , dosing due to narrow should regularly assess risk, benefits, and value of the therapeutic or toxic range), drug toxicity, or clinical situmedication, and consider higher or lower doses than ations where eGFRcr estimates may be unreliable, use of indicated. Where possible, use medication level testing to equations that combine both creatinine and cystatin C, or guide dosing. 730, 774 measured GFR may be indicated. An assessment of GFR is important for guiding decisions Specialconsiderations related to the choice and dosing of medications. Section 1. 2 Dose adjustments in cancer. GFR plays a large role in addresses the accuracy of validated eGFR equations, as well determining anticancer therapy, including anticancer agent as indications for the use of eGFRcr-cys or mGFR. selection, dosing, and eligibility for investigational drugs and There is inconsistency between this guidance and those clinicaltrials. 775, 776Notwithstandingitslackofvalidationand found in the package inserts or classic source references for its relative inaccuracy compared with other validated eGFR drug dosing. Regulatory agencies have not universally equations, the Cockroft-Gault equation continues to be one required pharmacokinetics in abnormal kidney function for of the most commonly used eGFR methods for these medicationapproval. 769In addition, although theCockcroftpeople. 775, 776 An evaluation of eGFR equation performance GaultformulaforestimatingCrClhasbeenusedinmanypast against mGFR determined by plasma clearance of 51Crpharmacokinetic studies that serve as the basis for the drug EDTA in 1200 people with solid tumors observed the dosing, there are multiple concerns with that equation.
----------------------------------------------------------------------


======================================================================
CHUNK 424 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_150
Content Type: evidence
Words: 473
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
769In addition, although theCockcroftpeople. 775, 776 An evaluation of eGFR equation performance GaultformulaforestimatingCrClhasbeenusedinmanypast against mGFR determined by plasma clearance of 51Crpharmacokinetic studies that serve as the basis for the drug EDTA in 1200 people with solid tumors observed the dosing, there are multiple concerns with that equation. It eGFRcr (CKD-EPI) and the eGFRcr-cys (CKD-EPI) was developed in an era when the need for standardization predicted mGFR with greater accuracy than Cockroftof creatinine measurements was not appreciated, women Gault. 136 We advise that the same approach to GFR and individuals of Black race were not included, and there evaluation described in Section 1. 2 be adopted in oncology are concerns about use of weight, which can be impacted practice and clinical trials. 136, 764 BSA-adjusted eGFR may be by edema or obesity. 770 However, to date, few studies have indicated for selected specific situations like carboplatin been conducted to compare different equations for eGFR in dosing. It is important to consider that non-GFR the context of drug dosing/kinetics, etc. determinants of both creatinine and cystatin C may be KidneyInternational(2024)105(Suppl4S), S117S314 S249 chapter 4 www. kidney-international. org moreprofoundinpeoplewithcancer, andmGFRmaybethe in assessing medication appropriateness, number, dose, and preferredmethodtoguidetheinitialdosingforaselectgroup potential interactions. Drug stewardship promotes safe ofanticancerdrugsincluding, butnotlimitedto, carboplatin, medication use throughout the course of therapy. cisplatin, and methotrexate (Section 1. 2). Medications need to be prescribed responsibly, monitored Dose adjustment in children/neonates. In addition to the for efficacy and safety, and when no longer required, usual weight-based dosing for children, specific guidance on discontinued. drugdosing should befollowedforneonateswho havelower GFR than those outside the neonatal period. Practice Point 4. 3. 1: Perform thorough medication review Dose adjustment in pregnancy. Creatinine decreases physiperiodically and at transitions of care to assess adherence, ologically during pregnancy due to glomerular hypercontinued indication, and potential drug interactions filtration, and BSA varies. This creates challenges for using because people with CKD often have complex medication GFR or eGFR equations. 54 In such settings for people who regimens and are seen by multiple specialists. require medications that are impacted by or could impact Medication review is essential for minimizing the occurGFR, healthcare providers should regularly assess risk, rence of medication-related problems (e. g. , inappropriately benefit, and value of medications. highdosesanddruginteractions)thatcommonlyoccurinthe CKD population. 777 If a person no longer has an indication 4. 3 Polypharmacy and drug stewardship for a medication that may contribute to kidney injury (e. g. , PPIs), healthcare providers should recognize the People with CKD are particularly susceptible to polyopportunity to discontinue the medication. Medication pharmacy due to multiplicity of comorbidities and multiple review at each clinical encounter, especially care transitions, physician or health system encounters related to those. Most is an opportunity to review medication types, interval, and people with CKD not treated with dialysis receive 612 doses especially if the individual has experienced a decline different medications per day.
----------------------------------------------------------------------


======================================================================
CHUNK 425 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_151
Content Type: reference
Words: 474
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Most is an opportunity to review medication types, interval, and people with CKD not treated with dialysis receive 612 doses especially if the individual has experienced a decline different medications per day. 763 Polypharmacy leads to in GFR (e. g. , metformin) or physiologic changes that can increased pill burden and potential harm due to medication impact medication volume of distribution (e. g. , volume errors and drug-drug interactions. Thus, healthcare overload and sarcopenia). 778 Figure 46729 discusses key steps providers, including clinical pharmacists, should be diligent in the medication review process. Three studies have Medicationreview Assessing that the dosage and regimen are correct Evaluating whether each medication Reviewing the medication list is necessary or whether any other Optimizing Minimizing for interactions or adverse effects necessary medication is required the medicationmedication related Ensuring that proper Determining whether each impact CKD problem monitoring takes place medication is the preferred patient medication for its indication Assessing medication adherence and causes for nonadherence Resolving any discrepancies between the actual medication list Medication agreement Obtaining an accurate and the one in the medical record medication list Communication with other physicians M edicationreconciliation Medicationreview Figure46Suggestedstepsintheprocessofmedicationreviewandreconciliation. Bestpracticesformedicationreviewandreconciliation inpeoplewithchronickidneydisease(CKD)include8steps728andcanbesummarizedasfollows: (i)obtainanaccuratemedicationlistfromthe patient; (ii)evaluatewhetherallmedicationsaremedicallynecessaryorwhetheranyothermedicationsisrequired; (iii)assesswhethercurrent therapyrepresentsthedrugofchoiceforeachindication, individualizedforeachpatient; (iv)evaluatethemedicationdosageandregimen, takingintoconsiderationrelatedfactorssuchasliverdysfunction, patientsize, orweight(e. g. , amputation, musclewasting, andover-or underweight); (v)reviewthemedicationlistfordruginteractions, includingdrug-drug, drug-disease, drug-laboratory, anddrug-food interactions; (vi)ensurethatpropermonitoringtakesplace; (vii)determinewhetherthereareanybarrierstopatientadherence, andevaluate relevantlaboratoryvalues; and(viii)identifyandresolveanydiscrepanciesbetweenthemedicationslistandtheoneinthemedicalrecord; communicationofperformedchangesinthemedicationchartwithotherphysiciansisnecessarygiventheroleofmultipleprescribersinvolved inthecareofpatientswithCKD. 729 S250 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 4 evaluated medication review by clinical practices in people Practice Point 4. 3. 3: Consider planned discontinuation of with CKD, observing reductions in the use of inappropriate medications(suchasmetformin, ACEi, ARBs, andSGLT2i) medications and medication-related problems, both in in the 4872 hours prior to elective surgery or during the outpatient and inpatient settings. 765, 766 The most frequent acute management of adverse effects as a precautionary reviews involved altering dosage or dose interval and measure to prevent complications. However, note that discontinuing NSAIDs. More frequent medication reviews failure to restart these medications after the event or promay be needed in older adults with complex medication cedure may lead to unintentional harm (see Practice Point regimens compared with younger people with CKD. 4. 3. 2). In the context of good drug stewardship, healthcare proThe rationale for temporary discontinuation of certain vidersshouldbeawareoftheissueofprescribingcascade. A medications before elective surgery or procedures is to preprescribing cascade is a sequence of events that begins when vent perioperative AKI and other complications such as hyanadverseeventismisinterpretedasanewmedicalcondition potension or metabolic acidosis or hyperkalemia during the and a subsequent drug is prescribed to treat this adverse perioperative period. 735 Medications that should be event. 779 Before prescribing new medications to address discontinued before elective surgery due to potential newly reported symptoms, it is important to first assess if perioperative adverse effects are shown in Table 32. 735, 736 the symptoms represent a side effect from an existing There is consistent evidence that withholding RASi is medication.
----------------------------------------------------------------------


======================================================================
CHUNK 426 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_152
Content Type: recommendation
Words: 480
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
735, 736 the symptoms represent a side effect from an existing There is consistent evidence that withholding RASi is medication. An example of a prescribing cascade is as associated with lower risk of perioperative hypotension in follows: peripheral edema because of calcium channel various types of surgery and procedures (noncardiacsurgery, blocker may be managed by initiation of a new medication cardiac surgery, and coronary angiography). 737, 785, 786 The (i. e. , diuretic), which can lead to additional adverse evidence that withholding RASi would lower perioperative reactions (e. g. , hypokalemia and dizziness). AKI is less consistent as affected by fewer studies with low sample sizes. 787, 788 In the surgical context, PracticePoint4. 3. 2: Ifmedicationsarediscontinuedduring antihyperglycemic agents such as sulfonylureas, metformin, an acute illness, communicate a clear plan of when to and SGLT2i would be held because of fasting before the restartthediscontinuedmedicationstotheaffectedperson surgery. Case reports, case series, and a systematic review of andhealthcareproviders, andensuredocumentationinthe 47 cases739, 740, 789 support the current recommendations that medical record. SGLT2i should be withheld at least 34 days before the Sickdayruleshavebeenendorsedasusefulguidancetopeople elective surgery. 741, 742 withCKDinthesettingofacute, dehydratingillness. Specifically, Temporary discontinuation of medications to manage patients receive guidance to temporarily stop the following adverse events is indicated in most cases. However, fear for medications: sulfonylureas, ACEi, diuretics/direct renin inadverse event recurrence often results in failure to resume hibitors, metformin, ARBs, NSAIDs, andSGLT2i(oftendescribed treatments. InCKD, hyperkalemiaorAKIarenotuncommon withtheacronymSADMANS). 780However, thereisapaucityof adverseeffectsofRASitreatment, towhichclinicalguidelines evidence to support sick day rules to prevent AKI or other recommend discontinuation of RASi and therapy reinitiation clinically relevant outcomes. 781, 782 Instead, data suggest at low dosages when the event is resolved. 23, 29, 790, 791 Despite potential harm if people make mistakes in recognizing this advice, permanent discontinuation of RASi seems to be dehydrating illness or about which drugs to stop and when to the most common clinical reaction to occurrence of adverse restart. 783 Figure 47 shows the steps that must occur correctly events. 580, 792 Observational studies consistently show that for sick day rules to be implemented appropriately. The most withholding RASi medication compared with continuing reported problem is failure to restart the medication. 784 The treatment after these adverse events is associated with a plan to restart medications should be detailed in the medical lower recurrence of adverse events, but conversely a higher recordsandclearlycommunicatedtothepatients. Patientsmay risk of MACE and death, for which prevention is one of the additionallybenefitfrommedicationreviewwithinamonthto main indications for RASi. 502506 See Section 3. 11 on ensureappropriatemedicationsarerestarted. hyperkalemia management. Identifies Recalls or retrieves Identifies and Recovers and Sick dehydrating illness list of pills to stop stops pills resumes pills Figure47Essentialstepsforappropriatesickdayruleimplementation. KidneyInternational(2024)105(Suppl4S), S117S314 S251 chapter 4 www. kidney-international. org Table32Medicationsthat shouldbe considered for Under-recognition of CKD diagnoses in medical records is temporarydiscontinuation beforeelective surgeriesand associated with medication errors, including potentially potentialperioperative adverseevents associated withtheir inappropriate prescription of nephrotoxic medications. 729 continueduse Medications Potentialperioperativeadverseevents Practice Point 4. 3. 1.
----------------------------------------------------------------------


======================================================================
CHUNK 427 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_153
Content Type: reference
Words: 495
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
KidneyInternational(2024)105(Suppl4S), S117S314 S251 chapter 4 www. kidney-international. org Table32Medicationsthat shouldbe considered for Under-recognition of CKD diagnoses in medical records is temporarydiscontinuation beforeelective surgeriesand associated with medication errors, including potentially potentialperioperative adverseevents associated withtheir inappropriate prescription of nephrotoxic medications. 729 continueduse Medications Potentialperioperativeadverseevents Practice Point 4. 3. 1. 2: Establish collaborative relationships with other healthcare providers and pharmacists and/or ACEi/ARB Hypotension, AKI Diuretics Volumedepletion, AKI usetoolstoensureandimprovedrugstewardshipinpeople SGLT2i Ketoacidosis(starvationordiabetes) with CKD to enhance management of their complex Metformin LacticacidosisifAKIoccurs medication regimens. Aminoglycosides Acutetubularnecrosis/AKI Clinical pharmacists are highly qualified experts in mediNSAIDs AKI, acuteinterstitialnephritis(AIN) cines and, as part of the multidisciplinary team, can play a ACEi, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensinIIreceptorblocker; NSAID, nonsteroidalanti-inflammatorydrug; SGLT2i, pivotal role in improving the quality of care and ensuring sodiumglucosecotransporter-2inhibitor. patient safety in a range of ways. This includes carrying out structured medication reviews for people with CKD and associated health problems and improving patient safety, In all these situations, enhanced communication with the outcomes, andvaluethroughaperson-centeredapproach. 798 patients, andbetweeninpatientandoutpatientteams, isneces800 In addition and where clinical pharmacists are not availsarytoensureresumptionofmedicationsinatimelymanner. able, clinical decision support systems can optimize this Specialconsiderations process through automation and decision support integrated Pediatric considerations. ManychildrenwithCKDwithunintotheEMRs, supportingdrugstewardshipthroughalertsto derlying tubular disorders have an obligate urine output irrehealthcare providers on the need for dose adjustment to spectiveoftheirhydrationstatusandareatparticularlyhighrisk prevent adverse effects. In RCTs enrolling people with CKD, of hypotension and AKI during an acute dehydrating illness. electronic clinical decision support systems have demonTherefore, temporary discontinuation of medications such as stratedefficacyinreducingmedicationerrors, avoidingdrugdiuretics and RASi that may lead to serious complications of drug interactions, and improving dose adjustment of medivolume depletion, such as hypotension and AKI, should be cationsexcretedbythekidneys. 801806Recognizingthatmany considered during illnesses. If medications are discontinued of these tools may not be available in all communities, the duringanillness, aclearplanofwhentorestartthediscontinued conceptsofregularreviewandevaluationofmedicationsbya medicationsshouldbecommunicatedtopeoplewithCKDand knowledgeable healthcare provider are a critical component documentedinthemedicalrecord. of care for people with CKD. 4. 3. 1Strategiestopromotedrugstewardship Specialconsiderations Pediatric considerations. Parents and carers should be cenPractice Point 4. 3. 1. 1: Educate and inform people with tral to drug stewardship for children with CKD, with CKD regarding the expected benefits and possible risks of increasing involvement from the young person as they move medications so that they can identify and report adverse toward transition. events that can be managed. Peoplewithkidneydiseasehavearoleindrugstewardship, 4. 4 Imaging studies and given that they may receive medications from nonnephrologyhealthcareproviders, peoplewithCKDshouldbe Practice Point 4. 4. 1: Consider the indication for imaging encouragedtoinformthoseprescribersthattheyhavekidney studies in accordance with general population indications. disease to facilitate consideration of doses and potential side Risksandbenefitsofimagingstudiesshouldbedetermined effect of medications. Thus, education and information for on an individual basis in the context of their CKD. people with CKD inclusive for their population (i. e. , literacy The use of iodinated radiocontrast media has been assolevelandlanguages)areencouraged. Althoughbrochuresand ciatedwiththeoccurrenceofAKI, withvaryingratesreported conversations may be useful, interactive electronic health inobservationalstudiesdependingonthepopulationstudied, applicationshavebeenshowntobeacceptabletopatientsand the type, route and dose of agent being used, and the defimay lead them to apply the knowledge gained more effecnition of nephrotoxicity. The term contrast-induced AKI tively.
----------------------------------------------------------------------


======================================================================
CHUNK 428 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_154
Content Type: reference
Words: 492
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Althoughbrochuresand ciatedwiththeoccurrenceofAKI, withvaryingratesreported conversations may be useful, interactive electronic health inobservationalstudiesdependingonthepopulationstudied, applicationshavebeenshowntobeacceptabletopatientsand the type, route and dose of agent being used, and the defimay lead them to apply the knowledge gained more effecnition of nephrotoxicity. The term contrast-induced AKI tively. 793797 Practical implementation tips involve printing hasbeentraditionallycoinedtodescribethiscondition, 807but out the results of the most recent eGFR estimation for the subsequent research characterizing this entity suggests causal patienttobringalong infuturehealthcareconsultationsand/ linkstobeweak, 807809andthetermcontrast-associatedAKI or write down a list of ongoing medications to alert other (CA-AKI) has been suggested instead. healthcare providers of medication risks and benefits. Although there is potential risk for AKI with contrast Adiagnosis of CKD should always be reflected in medical administrationinpeoplewithCKDG4G5, cautionshouldbe records, as this will alert physicians on the need to consider exercised inwithholding contrast treatment orevaluation of a adjusting or avoiding certain medications or procedures. potentially fatal condition solely based on GFR. 810, 811 Harm S252 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 4 Table33Potentialriskfactorsforcontrast-associated acute (cid: 3) Useofminimumradiocontrastdosetoachieveadiagnostic kidneyinjury study Patient-associated Procedure-associated (cid: 3) Withdrawal of nonessential potentially nephrotoxic medications (e. g. , NSAIDs, diuretics, aminoglycosides, amphoReducedGFR, acuteorchronica High-osmolarcontrast Diabetesmellitusb Largevolumeofcontrast tericin, platins, zoledronate, and methotrexate) in people Reducedintravascularvolume Serialcontrastprocedures with AKI or eGFR 30 ml/min per 1. 73 m2 for 2448 Concomitantnephrotoxicmedications Intra-arterialprocedures hours before and 48 hours after radiocontrast exposure GFR, glomerularfiltrationrate. (cid: 3) InpeoplewitheGFR30ml/minper1. 73m2andwithout aDefinedasestimatedglomerularfiltrationrate45ml/minper1. 73m2withother evidence of AKI, metformin need not be stopped before riskfactorsoreGFR30ml/minper1. 73m2. bAugmentsriskinpeoplewithunderlyingkidneyfunctionimpairment. iodinated contrast media (ICM) administration, and there Reproduced from Cashion W, Weisbord SD. Radiographic contrast media and isnoneedfortestingtoevaluateGFRafterward. Forpeople p th a e ge k s id 1 n 2 e 3 y 4. C 1 li 2 n 4 ic 2 a. 8 l 1 J 3 o h u t r t n p a s l: / o /j f o t u h r e na A ls m. lw er w ica. c n om So / c c i j e a t s y n/ o f f ul N lt e e p x h t/ r 2 o 0 lo 2 g 2 y /, 0 v 8 o 0 l 0 u 0 m /r e ad 1 io 7, g i r s a s p u h e ic 8 _, with AKIor an eGFR 30 ml/min per 1. 73 m2, it remains contrast_media_and_the_kidney. 20. aspx. Copyright2022bytheAmericanSociety appropriatetostopmetforminatthetimeoforbeforeICM ofNephrology. TheCreativeCommonslicensedoesnotapplytothiscontent. Use injection and should not be restarted for at least 48 hours of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact permissionslww. com for andonlythenifGFRremainsstableandtheongoinguseof furtherinformation. metformin has been reassessed by the clinical team. 818 (cid: 3) Given the lack of strong evidence demonstrating that may be induced through delaying, not performing, or continuing RAASi is beneficial, referring healthcare proproviding suboptimal diagnostic/therapeutic imaging vidersshouldconsiderwithholdingRAASiinpeopleatrisk procedures due to fear of contrast-associated complications for 48 hours before elective contrast-enhanced CT to to people with reduced GFR.
----------------------------------------------------------------------


======================================================================
CHUNK 429 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_155
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,proteinuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
818 (cid: 3) Given the lack of strong evidence demonstrating that may be induced through delaying, not performing, or continuing RAASi is beneficial, referring healthcare proproviding suboptimal diagnostic/therapeutic imaging vidersshouldconsiderwithholdingRAASiinpeopleatrisk procedures due to fear of contrast-associated complications for 48 hours before elective contrast-enhanced CT to to people with reduced GFR. 811, 812 Table 33813 describes the potential causes of CA-AKI identified in available studies that avoid the potential for hypotension and hyperkalemia shouldCA-AKIdevelop. RAASimayberestartedifCA-AKI may suggest an approach to people with CKD. does not occur or after the return of GFR to baseline. 4. 4. 1Radiocontrast: intra-arterialandintravenous dyestudies (cid: 3) Consideration of avoiding dehydration for people not undergoingdialysisandwhohaveeGFR30ml/minper1. 73 Practice Point 4. 4. 1. 1: Assess the risk for AKI in people m2 or AKI and receiving intravenous contrast. 815, 819 with CKD receiving intra-arterial contrast for cardiac (cid: 3) Use of N-acetylcysteine, ascorbic acid, furosemide, dopaprocedures using validated tools. mine, fenoldopam, or calcium channel blockers as preThe reported risk of CA-AKI is higher with procedures ventative measures of CA-AKI has not been shown to be a involving arterial administration compared with venous consistent benefit. 813 administration of contrast. 814 This difference in risk may be (cid: 3) Prophylactic pericontrast hemodialysis has been shown to due to differences in patient populations (those who require be potentially harmful and is not recommended. 813 arterial contrast are likely to have comorbidities that increase the likelihood of AKI) or to differences in the Specialconsiderations nephrotoxicity of intra-arterial contrast material. Globalaccesstocontrastagents. Thepreferenceofcontrast Known risk factors for CA-AKI are advanced age, heart agent may depend on availability and cost, particularly in failure, the volume of contrast material, proteinuria, hyperlower-incomecountriesandlower-middleincomecountries. glycemia, and use of RASi. 815 The highest risk for AKI is associated with interventional (rather than diagnostic) 4. 4. 2Gadolinium-containing contrastmedia coronary angiography (particularly in the setting of acute Gadolinium chelates used during magnetic resonance imagmyocardial infarction). This may relate to the higher ing has previously been reported to cause nephrogenic sysvolume of contrast used in interventional procedures and temic fibrosis (NSF) before 2010, and the mechanisms have hemodynamic instability associated with the clinical been articulated. 820 Note that incidence of this condition has situation. 815817 notbeenreportedlaterthan2012, thusraisingthequestionas to the true risk of this condition. 821 Practice Point 4. 4. 1. 2: The intravenous administration of radiocontrast media can be managed in accordance with Practice Point 4. 4. 2. 1: For people with GFR 30 ml/min consensusstatementsfromtheradiologysocietiesinpeople per 1. 73 m2 (CKD G4G5) who require gadolinium-conwith AKI or GFR 60 ml/min per 1. 73 m2 (CKD G3aG5) taining contrast media, preferentially offer themAmerican undergoing elective investigation. College of Radiology group II and III gadolinium-based The Work Group refers the reader to the most recent contrast agents. radiologyguidelinesspecificallynotingthedifferencebetween PeoplewhoareatgreatestriskforNSFincludethosewith intravenous and intra-arterial radiocontrast: AKI, undergoing KRT, and those with CKD G4G5. Most (cid: 3) Use of low-osmolality contrast media and iso-osmolarity unconfounded cases have been associated with American contrast media College of Radiology group I gadolinium-based contrast KidneyInternational(2024)105(Suppl4S), S117S314 S253 chapter 4 www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 430 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_156
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,dialysis,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
radiologyguidelinesspecificallynotingthedifferencebetween PeoplewhoareatgreatestriskforNSFincludethosewith intravenous and intra-arterial radiocontrast: AKI, undergoing KRT, and those with CKD G4G5. Most (cid: 3) Use of low-osmolality contrast media and iso-osmolarity unconfounded cases have been associated with American contrast media College of Radiology group I gadolinium-based contrast KidneyInternational(2024)105(Suppl4S), S117S314 S253 chapter 4 www. kidney-international. org media (e. g. , gadodiamide, gadopentetate dimeglumine, and In recognition of the inability to accurately measure GFR gadoversetamide), and there is additional risk with repeated intheneonateand, byextension, theclearanceofcompounds doses. 822, 823 such as gadolinium, all nephrologists and radiologists must Hence, in people with GFR 30 ml/min per 1. 73 m2, the exercisecautionintermsofuseofgadolinium-basedcontrast use of newer linear and macrocyclic gadolinium-based media in this potentially high-risk population, and all other contrastmediasuchasgadobenatedimeglumine, gadobutrol, imagingmodalitiesshouldbeconsideredbeforechoosingone gadoteridol, gadoteratemeglumine, andgadoxetatedisodium requiring gadolinium exposure. Although not based on speshould be preferred. 824, 825 cificevidence, somehavesuggestedtheavoidanceofhigh-risk gadolinium agents in very young children (e. g. , neonates Specialconsiderations younger than 4 weeks of age). 826 Global access to gadolinium-contrast agents. There are cost Moreover because of kidney immaturity in fetuses, neoimplications in lower-income countries and lower-middle nates, and infants, this population (and consequently pregincome countries as the nonlinear-chelated preparations are nant women because of the risk to the fetus) is considered more expensive. potentiallyatriskforNSF. 827However, althoughthedataare Pediatricconsiderations. Considerationsspecifictotheuseof limited, thenumberofreportedcasesofNSFinthepediatric gadoliniumpreparationsinyoungchildrenandneonatesmust population is lower than in the adult population. 828 There alsobecontemplatedinadditiontothegeneraladmonishments is no convincing evidence that pediatric populations have againsttheiruseinsituationsofGFR30ml/minper1. 73m2. an increased risk compared with adults. The risk of NSF Inparticular, theFDAcurrentlydoesnotlicenseanygadolinin pediatric patients appears to be low, but data are ium-basedcontrastmediaproductforuseinchildren2years limited. 823 ofageand, likewise, theEuropeanMedicinesAgencycautions against the use of any gadolinium-based contrast agents in a For research recommendations, please see Chapter child1yearofage. TheriskofNSFinpediatricpopulations 6: Research recommendations. appearstobelow, butdataarelimited. 822, 823 S254 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 Chapter 5: Optimal models of care 5. 1 Referral to specialist kidney care services (cid: 3) Psychosocial support (cid: 3) Provision of conservative care and palliative care options Early identification and referral to specialist kidney care serwhere required. vicesfor people withCKD hasthepotential toreverse, delay, or prevent progression of disease and is a key focus of inPractice Point 5. 1. 1: Refer adults with CKD to specialist ternational initiatives in the context of the global epidemic kidney care services in the circumstances listed in ofkidneydisease. Thegoalsofearlyidentificationandreferral Figure 48: to specialistkidneycareservicesare several-fold and include: Thescopeofnephrologypracticeincludesawidevarietyof (cid: 3) Ensuring a specific diagnosis for CKD is sought, where conditions, notonlykidneyfailurebutalsoacuteandchronic appropriate primary and systemic diseases involving individual elements (cid: 3) Provision of specific therapy based on diagnosis of the kidney, resistant hypertension, and biochemical de- (cid: 3) Slowing/arresting CKD progression rangements. Thus, there are many potential benefits of (cid: 3) Evaluation and management of comorbid conditions nephrology referral in addition to those more commonly (cid: 3) Prevention and management of CVD recognizedsuchasidentificationofreversiblecausesofCKD, (cid: 3) Identification, prevention, and management of CKD-speprovision of treatment to slow progression of CKD, mancific complications (e. g. , malnutrition, anemia, bone disagement of the metabolic complications of CKD, and prepease, and acidosis) aration for dialysis and transplantation.
----------------------------------------------------------------------


======================================================================
CHUNK 431 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_157
Content Type: recommendation
Words: 481
Medical Entities: CKD,GFR,albuminuria,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
(cid: 3) PlanningandpreparationforKRT(e. g. , choiceofmodality, Central to achieving the best outcomes for people with access-placementandcare, andpreemptivetransplantation) CKD regardless of the reason for referral is timeliness. Circumstances category Circumstance examples Actions Cause of CKD is uncertain Further evaluation and Causes Hereditary kidney disease specialist management Recurrent extensive nephrolithiasis based on diagnosis A 3%5% 5-year risk of requiring KRT measured using a validated risk equation Planning and preparation eGFR/risk of KRT eGFR 30 ml/min per 1. 73 m2 for kidney replacement A sustained fall in GFR of 20% or 30% in those therapy people initiating hemodynamically active therapies Consistent finding of significant albuminuria Diagnosis of CKD (ACR 300 mg/g 30 mg/mmol or AER 300 mg/24 hours, approximately equivalent to PCR 500 mg/g 50 mg/mmol Albuminuria or PER 500 mg/24 h) in combination with hematuria Further evaluation and microscopic 2-fold increase in albuminuria in people with significant and management hematuria albuminuria undergoing monitoring A consistent finding of ACR 700 mg/g 70 mg/mmol Urinary red cell casts, RBC 20 per high power field sustained and not readily explained CKD and hypertension refractory to treatment 4 antihypertensive agents Persistent abnormalities of serum potassium Others Acidosis Management of CKD Anemia complications Bone disease Malnutrition Figure48Circumstancesforreferraltospecialistkidneycareservicesandgoalsofthereferral. ACR, albumin-to-creatinineratio; AER, albuminexcretionrate; CKD, chronickidneydisease; eGFR, estimatedglomerularfiltrationrate; KRT, kidneyreplacementtherapy; PCR, proteincreatinineratio; PER, proteinexcretionrate; RBC, redbloodcells. KidneyInternational(2024)105(Suppl4S), S117S314 S255 chapter 5 www. kidney-international. org Table34Benefitsandconsequencesofearlyversuslate referral Consequencesoflatereferral Benefitsofearlyreferral Severehypertensionandfluidoverload, andincreasedcardiovascular DelayrequirementforKRT, bettermanagementofCVD, and comorbidity comorbidconditions Lowprevalenceofpermanentaccess Reducedneedforurgentdialysisusingtemporaryaccess Delayedreferralfortransplant Greaterchoiceoftreatmentoptionsandpre-emptivetransplantation Higherinitialhospitalizationrate Reducedhospitallengthofstayandcosts Higher1-yearmortalityrate Lower1-yearmortalityrate LesschoiceofKRTmodality IncreasedinformedfreedomofchoiceofKRTmodality WorsepsychosocialadjustmentandincreaseinDALYs Earlyaccesstopsychosocialcounselingandsupportforcarepartners Malnutrition Improvednutritionalstatus CVD, cardiovasculardisease; DALY, disability-adjustedlife-year; KRT, kidneyreplacementtherapy. Referral to specialists for assessment does not necessarily responsible for late referral for KRTas shown in Table 35. 831 equate to access to or need for multidisciplinary care, and We encourage each nephrology program to explore factors differentiation of the value of each is important. Specialist associated with late referral to improve referral patterns referraltoaidinascertainmentofcauseandprognosiscanbe appropriately. seen as separate from care and support services targeted at Peoplewithkidneydiseasehaveneverbeenrandomizedto complications, and delay of, and preparation for progressive earlyorlatereferraltonephrologyservices, andthedefinitionof CKD. Applicationofriskpredictiontools(Chapter2)mayaid late referral in the published studies varies between 1 and 12 decision-making in terms of identifying those at risk of monthsbeforethestartofKRT. Threemonthsisprobablyless progression and determining action thresholds for multidisthan the absolute minimum amount of time required for ciplinary care and placement of access for KRTor referral to assessment, education, preparation for KRT, and creation of transplantation. Current recommendations to use validated access, but3monthsisthemostfrequentlyemployeddefinition. riskequationstoascertainthoseathighprobabilityofkidney Asystematicreviewof40studiesshowedthatearlyreferral failure within 2 years should prompt actions that align with was associated with better clinical and biochemical outcomes provision of appropriate education activities, review of unsuchasimprovementinmortalityat3and5years, decreasein derstanding, anddecision-making, andpromptingreferralsto hospitalizations, better access to vascular access and KRTwith other healthcare providers (e. g. , vascular access surgeons, peritonealdialysis, aswellasimprovementsinBP, hemoglobin, transplant teams, etc. ). and serum albumin (Table 36). 832 A retrospective study of Risk-based referral was compared with guideline referral 105, 219patients(earlyreferral21, 024patientsandlatereferral criteria in a cross-sectional study from the UK.
----------------------------------------------------------------------


======================================================================
CHUNK 432 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_158
Content Type: reference
Words: 465
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
). and serum albumin (Table 36). 832 A retrospective study of Risk-based referral was compared with guideline referral 105, 219patients(earlyreferral21, 024patientsandlatereferral criteria in a cross-sectional study from the UK. 829 Analysis 84, 195 patients) showed that early referral to nephrology care revealed that approximately 40% of patients classified as at wasassociatedwithslowerprogressionofCKDassignificantly highriskofprogressiontokidneyfailurebyKFRE(3%by5 morepatientsinearlyreferralgroupdidnotchangetheirCKD years) were missed by guideline referral criteria. Moreover, a stage(65%72. 9%vs. 52%64. 6%, P0. 05). 833 modelpredictingthetimingofclinicaloutcomes, validatedin Local practice and resources will dictate local referral a multicenter prospective cohort study of 1517 people aged practices. Regardless of the healthcare system, delay, or pre- 65 years with eGFR 1030 ml/min per 1. 73 m2, showed vention of progression of both CKD and its complications good performance for predicting the timing and occurrence will be of value to both individuals and healthcare systems. of KRT. Using this prediction model to guide referral for Local organizations will determine the best methods of vascular access preparation resulted in less unnecessary communication and interaction between people with CKD, arteriovenousfistulasurgeriesthanusingeGFRthresholds. 830 kidney care specialists, the multidisciplinary team, and priInthissection, weconsidertheevidencerelatingtotimely mary care physicians. referral for planning KRT in people with progressive CKD. Technology may be used to promote appropriate The literature concerning late referral has been remarkably nephrology referral. Embedding clinical practice guidelines consistent with both clinical studies and narrative reviews into clinical information systems may effectively create a identifying several adverse consequences of late referral and reminder system for primary care physicians. Clinical decirelated benefits of early referral (Table 34). sion support systems could also improve referral criteria Both individual and healthcare system factors are associadherence. The smartphone application, Nefroconsultor, ated with late referral for KRT planning. A systematic review whichusesKDIGOreferralcriteriawasshowntoincreasethe of 18 studies and physician surveys identified specific factors rate of appropriate referral by 28. 8%. 834 S256 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 Table35Factors associated withlate referralforkidney ChildrenwithknownorsuspectedCKDorwhoareatrisk replacementtherapy planning of CKD (as outlined above) should be referred to specialist Patient-relatedfactors Healthcaresystemrelatedfactors care. Thisallowsfortimelyinvestigationsanddiagnosis. Early integration of children with CKD into nephrology services Age Healthinsurancestatus will ensure optimal management of pediatric complications Race Typeofreferringphysician Comorbidillness Typeofreferringcenter of CKD (including growth restriction) and will promote acEtiologyofkidneydisease Healthsystemand/orphysicianrationing cess to preemptive transplantation (the KRTof choice). Noncomplianceor Distancetodialysiscenter nonadherence 5. 2 Symptoms in CKD Socioeconomicstatus 5. 2. 1Prevalenceandseverity ofsymptoms CKDconfersahigh burden ofuremic symptomsthatmay be under-recognized, underdiagnosed, and undertreated. 835 As Implementation of referral guidelines will inevitably lead kidney disease progresses, affected people experience an to an increased workload for specialist kidney care services. increasing burden of adverse uremic symptoms. These However, introductionoflocalinitiativesinconjunctionwith symptoms can impair their health-related QoL (HRQoL) by primary care providers can improve the appropriateness and interfering with social relationships, financial instability, and quality of the referral. A checklist for goal-directed care in contributing to overall poor well-being. 836 Patient-reported CKD should be considered.
----------------------------------------------------------------------


======================================================================
CHUNK 433 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_159
Content Type: reference
Words: 499
Medical Entities: CKD,GFR,dialysis,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
These However, introductionoflocalinitiativesinconjunctionwith symptoms can impair their health-related QoL (HRQoL) by primary care providers can improve the appropriateness and interfering with social relationships, financial instability, and quality of the referral. A checklist for goal-directed care in contributing to overall poor well-being. 836 Patient-reported CKD should be considered. Local initiatives combined with outcomes, including HRQoL and symptoms, are often national policy and practice changes can lead to an identified by people with CKD as more important to them improvement in the outcomes for people with CKD regardthan clinical outcomes, such as survival. 837, 838 A recent less of the level of resources available. systematic review of 126 patient-reported outcome studies involvingpeoplewithCKDG1G5, notonKRT, identifiedthe Specialconsiderations most common symptoms experienced in terms of prevalence Pediatricconsiderations. and severity in this population (Figure 49). 839 The most Practice Point 5. 1. 2: Refer children and adolescents to prevalent symptom reported in the CKD population not specialist kidney care services in the following on KRTwas fatigue at 70% (95% CI: 60%79%), whereas in circumstances: the identified control population without CKD, fatigue (cid: 3) an ACR of 30 mg/g (3 mg/mmol) or a PCR of 200 mg/g prevalence was 34% (95% CI: 0%70%). In terms of the (20 mg/mmol) or more, confirmed on a repeat first symptomsreportedasthemostsevere, sexualdysfunctionhad morning void sample, when well and not during the highest severity score. This review also looked at menstruation, populations receiving dialysis and/or transplantation, allowing (cid: 3) persistent hematuria, for the comparison of prevalence and severity across (cid: 3) any sustained decrease in eGFR, populations. Thisprovidesinsightintosymptomsthatmaybe (cid: 3) hypertension, attributable to changing or deteriorating kidney function and (cid: 3) kidney outflow obstruction or anomalies of the kidney may provide symptom targets for tracking in the care of and urinary tract, people with CKD, especially those with more advanced CKD, (cid: 3) known or suspected CKD, or suchasCKDG5. (cid: 3) recurrent urinary tract infection. 5. 2. 2Identificationandassessment ofsymptoms Table36Outcomes examinedinasystematic reviewby Practice Point 5. 2. 2. 1: Ask people with progressive CKD Smartetal. 832 abouturemicsymptoms(e. g. , reducedappetite, nausea, and level of fatigue/lethargy) at each consultation using a stanRelativeriskcomparingearly Outcomes vs. latereferral dardized validated assessment of uremic symptoms tool. The identification and assessment of symptoms in people Receivepermanentvascularaccess RR: 3. 22; 95%CI: 2. 923. 55 InitiationofKRTwithperitonealdialysis RR: 1. 74; 95%CI: 1. 641. 84 withprogressiveCKDareimportantforhighlightingchanges Three-monthmortality OR: 0. 61; 95%CI: 0. 550. 67 in clinical management, 840 redirecting treatment toward Five-monthmortality OR: 0. 66; 95%CI: 0. 600. 71 patient-centered management, and may lead to discussion Meandifferenceinearly about appropriate supportive care options. 838 Effective 2Outcomes vs. latereferral way communication and shared decision-making should be Initialhospitalization(d) (cid: 5)9. 1; 95%CI: (cid: 5)10. 92to(cid: 5)7. 32 key principles between healthcare providers and the people Systolicbloodpressure(mmHg) (cid: 5)3. 09; 95%CI: (cid: 5)5. 23to(cid: 5)0. 95 they treat, allowing them to work in partnership to identify Diastolicbloodpressure(mmHg) (cid: 5)1. 64; 95%CI: (cid: 5)2. 77to(cid: 5)0. 51 symptom burden, possible treatment strategies, and personHemoglobin(g/dl) 2. 76; 95%CI: 2. 53to2. 99 centered solutions. 835, 839, 841 Serumalbumin(g/dl) 1.
----------------------------------------------------------------------


======================================================================
CHUNK 434 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_160
Content Type: recommendation
Words: 500
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
09; 95%CI: (cid: 5)5. 23to(cid: 5)0. 95 they treat, allowing them to work in partnership to identify Diastolicbloodpressure(mmHg) (cid: 5)1. 64; 95%CI: (cid: 5)2. 77to(cid: 5)0. 51 symptom burden, possible treatment strategies, and personHemoglobin(g/dl) 2. 76; 95%CI: 2. 53to2. 99 centered solutions. 835, 839, 841 Serumalbumin(g/dl) 1. 92; 95%CI: 1. 83to2. 01 In the past, it had been challenging to find an accepted CI, confidenceinterval; KRT, kidneyreplacementtherapy; OR, oddsratio; RR, relative risk. standardized approach to assess and report outcomes for KidneyInternational(2024)105(Suppl4S), S117S314 S257 chapter 5 www. kidney-international. org Shortness of breath Fatigue Prevalence 42% Decreased appetite Prevalence 70% Severity score: 15 Prevalence 42% Severity score: 22. 8 Severity score: 19. 8 Poor mobility Leg swelling Prevalence 56% Prevalence 45% Severity score: 19 Severity score: no data Bone/joint pain Muscle cramps Prevalence 55% Prevalence 46% Severity score: no data Severity score: no data Drowsiness Heartburn Prevalence 53% Prevalence 46% Severity score: 22. 5 Severity score: no data Pain Itching Prevalence 53% Prevalence 46% Severity score: 22. 5 Poor sleep Sexual dysfunction Severity score: 25 Prevalence 49% Prevalence 48% Severity score: 23. 8 Severity score: 56. 4 Figure49Commonsymptoms, prevalence, andseverityinpeoplewithchronickidneydisease. Toaidcomparisonofsymptomseverity scoresacrossdifferentoutcomemeasures, allmeanseverityscoreswereconvertedtoa0100scale, whereahigherscoreindicatesgreater severity. AdaptedfromFletcherBR, DameryS, AiyegbusiOL, etal. Symptomburdenandhealth-relatedqualityoflifeinchronickidneydisease: aglobalsystematicreviewandmeta-analysis. PLoSMed. 2022; 19: e1003954. 839Copyright2022Fletcheretal. Thisisanopenaccessarticle distributedunderthetermsoftheCreativeCommonsAttributionLicense( thosewithCKD, and patient reportsoftheir HRQoL arestill reliability. 844846Furtherstudyisstillneededtoinvestigateits rarely routinely recorded, despite increasing recognition of optimal use in routine nephrology care. theirimportance. 841843Inaddition, manyoftheassessments developed have been for people on dialysis, with little vali5. 2. 3ManagementofcommonsymptomsforpeoplewithCKD dation in CKD populations not on KRT. In 2019, Verberne et al. 841 described an international standard set of outcome PracticePoint 5. 2. 3. 1: Useevidence-informedmanagement measures for people with CKD, developed in conjunction strategies to support people to live well with CKD and with people with very highrisk CKD G3G5. Within this improve their health-related quality of life. standardized set of outcome measures, there are 4 domains, The goal of effective symptom management in people with one of the domains targeting 6 patient-reported withCKD is to assist themto live better withkidneydisease, outcomes for HRQoL (fatigue, pain, general HRQoL, regardless of life expectancy, within a supportive care physical function, depression, and daily activity). To date, framework. 838 Unpleasant symptoms, such as CKDthere is no consensus on a single preferred patient-reported associated pruritis and emotional/psychological distress, outcome measure (PROM) instrument to be used to assess often occur within symptom clusters and treating one these symptoms. However, 3 generic tools have been symptom may potentially alleviate other symptoms. 835 recommended by the International Consortium for Health Developing treatment strategies can be challenging given Outcomes Measurement (ICHOM) (Table 37). the complexities of managing CKD in different populations The Patient-Reported Outcomes Measurement Informaand the variation in levels of evidence for managing the tion System (PROMIS) tool has been evaluatedin adultsand different symptoms experienced, with many strategies children with CKD, evidencing sufficient validity and extrapolated from studies of treatments in the general Table37Recommended patient-reported outcome measurementtoolsforusein peoplewithCKD PROMtool Comments SF-36version2 Widelyusedandwellvalidatedinmanypopulations. Requiresalicensefee. RAND-36 OlderversionoftheSF-36. Doesnotrequirealicensefee. OnlyavailableinEnglishandArabic. PROMISand Bothshortformsarebasedonextensiveitembanks. Availableinpaperandelectronicversions. Wellvalidatedingeneral PROMIS-29 populationwithvalidationinpeoplewithCKDshowinggoodreliabilityandsufficientvalidityinbothadultsandpediatric populations.
----------------------------------------------------------------------


======================================================================
CHUNK 435 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_161
Content Type: definition
Words: 492
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Requiresalicensefee. RAND-36 OlderversionoftheSF-36. Doesnotrequirealicensefee. OnlyavailableinEnglishandArabic. PROMISand Bothshortformsarebasedonextensiveitembanks. Availableinpaperandelectronicversions. Wellvalidatedingeneral PROMIS-29 populationwithvalidationinpeoplewithCKDshowinggoodreliabilityandsufficientvalidityinbothadultsandpediatric populations. CKD, chronickidneydisease; PROM, Patient-ReportedOutcomes; PROMIS, Patient-ReportedOutcomesMeasurementInformation; SF-36, 36-itemShortFormHealthSurvey. TabledevelopedwithdatafromVerberneetal. , 841Selewskietal. , 844andvanderWillikEM, vanBredaF, vanJaarsveldBC, etal. ValidityandreliabilityofPatient-Reported OutcomesMeasurementInformationSystem(PROMIS(cid: 4))usingcomputerizedadaptivetesting(CAT)inpatientswithadvancedchronickidneydisease. NephrolDialTransplant. 2022; 38: 11581169. 845 S258 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 population or people on hemodialysis. For example, sexual symptoms such as chronic pain and evaluation of dysfunction, a very common and one of the most severe management strategies. 848 Table 38838, 840, 849871 provides an symptoms described by people with CKD, is fraught with overview of the most common symptoms in CKD. barriers in terms of research from agreement of definitions, the stigma of sexual dysfunction, acknowledging the PracticePoint5. 2. 3. 2: ScreenpeoplewithCKDG4G5, aged distinction between sex and gender, discordance between 65, poor growth (pediatrics), or symptoms such as involresearch priorities and patient priorities, and understanding untary weight loss, frailty, or poor appetite twice annually that there are variable responses to treatment in people for malnutrition using a validated assessment tool. with CKD. 847 However, there has been some consensus that there is sufficient evidence to support guidance for Practice Point 5. 2. 3. 3: Enable availability of appropriate some symptoms such as uremic pruritis, sleep disturbances, medical nutrition therapy for people with signs of malnupain, depression, and restless leg syndrome, 838 but future trition, ideally under the supervision of renal dietitians or research is needed to understand the determinants of accredited nutrition providers if not available. Table38Managementstrategiesforcommon symptomsin CKD Managementstrategies Symptom Comment Lifestyle Pharmacological Other Pain Managementshouldbe Physiotherapy, exerciseand UseofanadaptedWorldHealth Referraltoaspecialistpain determinedbyetiologyand massagetherapy, andheat Organization(WHO)Analgesic clinicorpalliative/ severity formusculoskeletalpain. Ladderthattakesintoaccount supportivecareclinicmay pharmacokineticdataofanalgesics bebeneficialforthoseatrisk Considercomplementary inCKD. 850 ofaberrantbehaviors, therapiessuchas adverseoutcomes, orin acupuncture. 838, 840, 849 Beforestartingopioids, healthcare specialcircumstancessuch providersshouldassessriskof asendoflife. 849 substanceabuseandobtain informedconsentafteradiscussion aroundgoals, expectations, risks, andalternatives. Topicalanalgesicsmaybe effectivebutusedwithcaution toavoidadverseeventsdueto systemicabsorption. Thereare nostudiesonlong-termuseof anyanalgesicsinpeoplewith CKD; therefore, attentionshould bepaidtoissuesofefficacyand safety. Sleepdisorders Associatedwithfatigue, Managementofbasicsleep Melatonin851andsimple Cognitivebehavioral poorHRQoL. 838Maybe hygiene, exercise, optimal sedatives852, 853 therapy, 854addressing relatedtopruritus, pain, positioningwhensleeping, contributingfactorssuchas anemia, anxiety/depression, andremovalofdietaryor anemia, fluidretention, andshortnessofbreath. 840 otherstimulants838 mooddisorders, pain, and pruritus Restlessleg Associatedwithimpaired Managementofbasicsleep Cessationofmedicationsthat Correctionofcontributing syndrome sleepandHRQoL hygiene, exercise, optimal interferewiththedopamine factorssuchas positioningwhensleeping, pathway, ortrialswith hyperphosphatemiaand andremovalofdietaryor levodopa, nonergotdopamine irondeficiency/anemia otherstimulants838 antagonists, orlow-dose gabapentinoids855-857 Uremicpruritus Associatedwithdecreased Acupunture858 Gabapentinoidswithcontinued UltravioletBtherapy862 HRQoLandcontributesto assessmentofsymptomexperience othersymptoms, suchas andtitrationbyamedical Topicalcannabiscanbe poorsleep, fatigue, and provider859-861 considered863 depression838 Topicalagents(capsicum, rehydratingemollientsifconcurrent dryskin)861 (Continuedonfollowingpage) KidneyInternational(2024)105(Suppl4S), S117S314 S259 chapter 5 www. kidney-international. org Table38(Continued)Managementstrategiesforcommon symptomsin CKD Managementstrategies Symptom Comment Lifestyle Pharmacological Other Depression MayberelatedtoCKD Exercise864and Beforecommencing Cognitivebehavioral burdenandperception, loss acupuncture865 pharmacologicaltreatmentfor therapy870 ofcontrol, andmedication depression, healthcare effects. providersshouldbeawareofthe Socialsupport869 potentialnecessitytoadjust Addresscontributingfactors Associatedwithincreased dosage, andfollow-upwiththe (e. g. , pain, pruritusand morbidity, hospitalization, patient, duetoaltered mooddisorders) andmortality, andisintegral pharmacokineticsinCKD. 840In totheassessmentof somecircumstancesthismay HRQoL838 needtobedonein conjunctionwithspecialist psychiatricservices. Optionsmayinclude: (cid: 3) Serotoninreuptakeinhibitors (e. g. , citalopram, escitalopram, fluoxetine, paroxetine, and sertraline) (cid: 3) Serotonin-norepinephrinereuptakeinhibitors(e. g. , venlafaxine, duloxetine, andmirtazapine) (cid: 3) Atypicalantidepressants(e. g. , bupropion, trazodone, and nefazodone) (cid: 3) Tricyclicantidepressants(e. g. , amitriptyline)866-869 Poorappetiteand Associatedwithdepression, Increasedphysicalactivity Nodatatosupporttheuseof Addresscontributing anorexia malnutrition, poorHRQoL, mayincreaseappetite871 appetitestimulantsinpeoplewith factors(pain, heartburn, increasedhospitalization, CKDnotonKRT. mooddisorders, any andmortalityrates838 Managementhasnotbeenstudied dentalissues/mouth systematicallyinCKD.
----------------------------------------------------------------------


======================================================================
CHUNK 436 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_162
Content Type: reference
Words: 371
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
mooddisorders, any andmortalityrates838 Managementhasnotbeenstudied dentalissues/mouth systematicallyinCKD. 838 ulceration, constipation, socialandeconomic factors, andlackof physicalactivity) Dietaryassessmentbya dietitian Nauseaand Impacthasnotbeen Pharmacologicalmanagementhas Addresscontributing vomiting assessedsystematicallyin notbeensystematicallystudiedin factors(pain, heartburn, CKD. 838 CKD. 838 mooddisorders, any dentalissues/mouth ulceration, constipation, socialandeconomic factors, andlackof physicalactivity) Dietaryassessmentbya dietitian CKD, chronickidneydisease; HRQoL, health-relatedqualityoflife; G3, estimatedglomerularfiltrationrate(eGFR)3059ml/minper1. 73m2; G5, eGFR15ml/minper1. 73m2; KRT, kidneyreplacementtherapy. TableadaptedfromDavisonSN, LevinA, MossAH, etal. ExecutivesummaryoftheKDIGOControversiesConferenceonSupportiveCareinChronicKidneyDisease: developing aroadmaptoimprovingqualitycare. KidneyInt. 2015; 88: 447459. 8382015InternationalSocietyofNephrology. Indifferentworldregions, 11%50%ofadultsand20%45% as CKD progresses but is also influenced by comorbid ofchildrenwithCKDhavemalnutritioncharacterizedby proconditions such as diabetes, autoimmune diseases, and CVD. teinenergywasting(PEW). 872874InaEuropeancohortof1334 PEWisthoughttobedrivenbythedamagingeffectofuremic adults over the age of 65 years with CKD G4G5, 25% were toxinsonappetiteandchronicinflammation. 873875Giventhe foundtohavemoderatemalnutrition, andtheriskwasincreased impact on prognosis and QoL, nutritional assessment and with advancing age, female gender, and psychiatric disease. 875 intervention(ideallybyarenaldietitianoraccreditednutrition MalnutritioncanhappenatanystageofCKDandisassociated provider) using a validated assessment tool should be with a higher morbidity and mortality, loss of muscle mass, undertakenfor peoplewithCKDwhopresentwithfrailty, age and inflammation. It can also be associated with worse 65 years, weight loss, poor growth (pediatrics), poor outcomeswithkidneytransplant. 874TheriskofPEWincreases appetite, andallpeoplewithCKDG4andG5(Table39876878). S260 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 Table39Listofvalidated assessmenttools formalnutrition Validatedmalnutritionassessmenttool Attributes 7-PointSubjectiveGlobal Providesassessmentpointsonweightchange, dietaryintake, digestivefunction, functionalcapacity, Assessment(SGA)876 andmetabolicstress. Anutritionfocusedphysicalexaminationisalsoperformed. Thisupdatedversion oftheSGAismoresensitivetoshort-termnutritionchanges. Ascoreof12indicatesseveremalnutrition, 35ismildmalnutrition, and67indicatesnormalnutritionstatus. Malnutrition-InflammationScore877 Assessesmalnutritionandinflammationusing10parametersincludingdietaryintake, anthropometric measurements, laboratoryindices, andfunctionalcapacity. Thescorerangesfrom0(normal)to 30(severemalnutritionandinflammation). MiniNutritionAssessment878 Includesassessmentofdietaryintake, mobility, neuropsychology, andsomeanthropometricmeasurements, includingweightandcalfcircumference. Ascoreof1214pointsindicatesnormalnutritionstatus, 811indicatesatriskformalnutrition, and07pointsindicatesmalnutrition. 5. 3 Team-based integrated care component of the chronic care model is applied to the CKD care model. The specific components for CKD models of care are Practice Point 5. 3. 1: Enable access to a patient-centered presented in Figure 52 and include: multidisciplinary care team consisting of dietary coun- (i) Navigation system that leads to appropriate and seling, medicationmanagement, education, andcounseling timelyreferral. Thisreliesonagoodhealthcaresystem aboutdifferentKRTmodalities, transplantoptions, dialysis (ii) An education program that includes both general access surgery, and ethical, psychological, and social care CKD and KRT education, including conservative for people with CKD. management, where appropriate An optimal care model leads to the best outcomes for the (iii) Surveillance protocols for laboratory and clinic visits, individual, thepopulation, andthecommunity. Themodelof attention to cardiovascular comorbidities, and CKDcarevariesaccordingtoCKDseverityandriskofprogression associated comorbidities such as anemia, a vaccinato kidney failure, which will determine the target population tion program and goals (Figure 50). (iv) Management that includes self-care management CKD modelsof carefollow the same principles embodied in the chronicdisease model of care(Figure51879).
----------------------------------------------------------------------


======================================================================
CHUNK 437 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_163
Content Type: reference
Words: 499
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Themodelof attention to cardiovascular comorbidities, and CKDcarevariesaccordingtoCKDseverityandriskofprogression associated comorbidities such as anemia, a vaccinato kidney failure, which will determine the target population tion program and goals (Figure 50). (iv) Management that includes self-care management CKD modelsof carefollow the same principles embodied in the chronicdisease model of care(Figure51879). Each key particularly lifestyle modification including diet, KRT preparation team/ comprehensive conservative care team C K D N m Pr e u im p lt h a id r r o i y s l c o c i a g p r i l e s in t, ary care team I ncreasi n g seve  ri 3 t K % y i d o n f 5 C % ey K i D f n a  i K 5 1 l i u 0 d y % r n e e e a i n y r r  i s f K s 4 2 a k i 0 d i y % l n u e e a r in e y r s 2 f r a i y s il e k u a re rs risk Prep fo a K P D r r R i r K n i e s T R g c E G v T s o u d e e 5 p s u n l s t P f c t i - o r a i m o o o t n i f n m o s a c n n a o o a n t m g e C d e K p m m D lic a e G a n n 4 t a t io g n e s m C e K n D t G 3 C KD G 2 C KD G 1 3 K % id 5 n % ey i f n a 5 ilu y r e e a r r i s sk Iden C t V if y r i p sk a t r i e e d n u ts c t a i t o h n igh risk Figure50Optimalcaremodelbyincreasingseverityofchronickidneydisease(CKD). CV, cardiovascular; KRT, kidneyreplacement therapy. KidneyInternational(2024)105(Suppl4S), S117S314 S261 chapter 5 www. kidney-international. org Table40KeyfeaturesofexistingCKDcaremodels32, 880-882 Multidisciplinarycareteamcomposition CKD health systems Organization of CKD care (cid: 3) Nephrologist (cid: 3) Pharmacist (cid: 3) Endocrinologist, cardiologist, (cid: 3) Renaldietitianoraccredited Community SelfDelivery Clinical Decision transplantsurgeon, nutritionprovider Resources management system information support psychologist, etc. (cid: 3) Socialworker and policies support design systems (cid: 3) Nurse Interventions (cid: 3) BPmanagement (cid: 3) Educationondialysismodality (cid: 3) Diabeticmanagement selection (cid: 3) Cardiovascularmanagement (cid: 3) Vascularaccessplanning (cid: 3) Anemiamanagement (cid: 3) Transplantationeducationand Informed Productive Prepared proactive (cid: 3) Mineralandbonedisorder evaluation activated patient interactions multidisciplinary team management (cid: 3) Nutritionalanddietarycounseling (cid: 3) Conservativekidney (cid: 3) Medicationreconciliation management (cid: 3) Vaccinationprogram Improved outcomes Outcomes Figure51Thechroniccaremodel. Thechroniccaremodel (cid: 3) DelayprogressionofCKD (cid: 3) Improverateofoptimalmedication emphasizestheadditivebenefitsofdifferentcomponentsinthe (cid: 3) ImproveBPcontrol (cid: 3) Improvepatienteducation system, policy, provider, andpatientlevelsinimprovingclinical (cid: 3) ImproveCVDoutcomes outcomes. CKD, chronickidneydisease.
----------------------------------------------------------------------


======================================================================
CHUNK 438 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_164
Content Type: reference
Words: 491
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Thechroniccaremodel (cid: 3) DelayprogressionofCKD (cid: 3) Improverateofoptimalmedication emphasizestheadditivebenefitsofdifferentcomponentsinthe (cid: 3) ImproveBPcontrol (cid: 3) Improvepatienteducation system, policy, provider, andpatientlevelsinimprovingclinical (cid: 3) ImproveCVDoutcomes outcomes. CKD, chronickidneydisease. ReproducedfromEppingJordanJE, PruittSD, BengoaR, WagnerEH. Improvingthequalityof ACEi, angiotensin-convertingenzymeinhibitor; ARB, angiotensinIIreceptorblocker; BP, bloodpressure; CKD, chronickidneydisease; CVD, cardiovasculardisease. healthcareforchronicconditions. BMJQualitySafety, volume13, pages299305, Copyright2004, withpermissionfromBMJ PublishingGroupLtd. 879 Practice Point 5. 3. 2: Education programs that also involve care partners where indicated are important to promote exercise, and smoking cessation, as well as medicainformed, activated people with CKD. tions and psychosocial support for issues such as soAneffectivepatienteducationprogramisacriticalsuccess cial bereavement, depression, and anxiety factor of self-care management support strategies. Education (v) Three-way communication between people with should address 3 main issues: CKD, theirmultidisciplinaryspecialist careteam, and (i) standardized educational topics and resources, their primary care providers (ii) strategy to provide education effectively, and TherearevariousCKDcaremodelsaroundtheworld. The (iii) patient-centered concept. key features of existing CKD care models described in sysThe suggested components of effective patient education tematic reviews are shown in Table 40. 32, 880882 programsareillustratedinFigure53. Eachshouldbetailored Education Navigation To individual and family Disease triage About disease, diet, Transition lifestyle, and medications Healthcare system Surveillance Management Symptoms Blood tests Medications Urine tests Psychological support Other investigations Figure52Specificcomponentsofthechronickidneydiseasemodelofcare. S262 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 1. Create standardized educational material Cover pertinent information relevant to patient needs Use culturally and linguistically appropriate materials Available in various formats Suggested educational topics: Knowledge about CKD Knowledge about CKD management Treatment to slow progression of CKD Kidney anatomy and function Treatment of CKD complications Knowledge about Type of kidney failure Medication commonly used in people treatment options in kidney failure Etiology of CKD with CKD Signs and symptoms of CKD Medication safety in people with CKD Comprehensive conservative treatment Kidney tests Sick day rules Peritoneal dialysis Hemodialysis Lifestyle modification Kidney transplantation Nutritional therapy Understand how to prevent CKD progression Choose Improving Key objectives: and management of CKD complications appropriate CKD awareness Empower self-management KRT modality 2. Strategy to deliver educational session Multidisciplinary care team approach Community health care network Involving primary care physician Patient-to-patient discussion or peer support groups Focus on improvement of patients health literacy 3. Patient-centered Target high-risk people with CKD Triage patient to specific educational topics they need Engage family members and/or caregivers Target group: CKD G1G2 CKD G3G4 CKD G5 Figure53Strategyforeffectivepatienteducationprogramsforpeoplewithchronickidneydisease(CKD). Shouldbetailoredto individualneedsandwishes. KRT, kidneyreplacementtherapy. toindividualneeds, circumstances, andresources, seetextfor providers may be an effective strategy for providing patient/ details. carer education and empowering self-care management. 883 Standardized educational topics should cover 3 main Targeting education to people with CKD who are at high subject areas: knowledge about CKD, knowledge about risk of CKD progression might yield a better outcome than treatmenttoslowprogressionandcomplicationsofCKD, and routine care not only to the individual but also to the knowledge about the kidney failure management options. healthcare system. Engaging with family members or Educational material should be written and explained caregivers in a CKD education program will facilitate selfclearly with plain language. Customization of information to care management and psychosocial support.
----------------------------------------------------------------------


======================================================================
CHUNK 439 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_165
Content Type: recommendation
Words: 499
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
healthcare system. Engaging with family members or Educational material should be written and explained caregivers in a CKD education program will facilitate selfclearly with plain language. Customization of information to care management and psychosocial support. patient needs and literacy level, and sensitive to cultural norms and needs (i. e. , storytelling/videos vs. written matePractice Point 5. 3. 3: Consider the use of telehealth techrials). A multidisciplinary approach should be encouraged as nologies including web-based, mobile applications, virtual an effective strategy for providing education. Engaging comvisiting, and wearable devices in the delivery of education munity healthcare workers and other health education and care. KidneyInternational(2024)105(Suppl4S), S117S314 S263 chapter 5 www. kidney-international. org Telehealth has been used increasingly in medicine, telehealth technologies that were studied in people with including nephrology, during the COVID-19 pandemic. CKD are shown in Figure 54. Telehealth has the potential to augment patient care in CKD Standardized and culturally appropriate protocols should in many aspects such as improving access to CKD care in be considered. Although it is recognized that resources may outreach patients, increasing patient monitoring ability, vary across and within jurisdictions, the recommendations helping with healthcare provider shortage, and improving herearebasedonprinciplesofcare, whichshouldberelevant patient satisfaction. Telehealth in nephrology (Teleacross the globe. nephrology)canbecategorizedinto3mainareas: (i)remote CKDisacomplexconditionthatcoexistswithmanyother monitoring, (ii) providing education, and (iii) delivery of conditions. Therefore, models of care should be developed care. These have been implemented in 4 main platforms that integrate the complexity of the clinical conditions including internet web-based, smartphone applications, involved, patient-centered philosophies, and the healthcare interactive video conferencing, and wearable technology. environment. The principles of care are universal, but Remote monitoring technology has been designed to implementationmaybecustomizedtospecificcircumstances. promote self-care management through oversight of clinical parameters so people with CKD can monitor changes at Specialconsiderations home, suchasBP, bodyweight, orabnormalsymptoms. 884, 885 Pediatricconsiderations. This may encourage people with CKD to participate in the 5. 3. 1 Transitionfrompediatrictoadultcare management of CKD. 5. 3. 1. 1Pediatricproviders Telehealth technologies that enhance education in people with CKD have been reported in various forms. Web-based Practice Point 5. 3. 1. 1. 1: Prepare adolescents and their applications are probably the most popular platform used to familiesfortransfertoadult-orientedcarestartingat1114 provideeducationforpeoplewithCKDandtheirfamilies. 886 years of age by using checklists to assess readiness and Systematicreviewssuggestthatweb-basedCKDmaterialsare guide preparation, and by conducting part of each visit mostlyadequatebutnotwrittenatasuitableliteracylevelfor without the parent/guardian present (Figure 55). most people with CKD. 887, 888 Smart phone applications have been increasingly adopted Practice Point 5. 3. 1. 1. 2: Provide a comprehensive written for patient education in CKD. Educational material can be transfer summary, and ideally an oral handover, to the installed into smartphone applications as a tool for on-dereceiving healthcare providers including all relevant medmand knowledge. Moreover, smartphones applications that ical information as well as information about the young provide self-care management support for people with CKD persons cognitive abilities and social support (Figure 55). were reported in a pilot study. 889 The application targeted 4 key self-care management parameters: monitoring BP, PracticePoint5. 3. 1. 1. 3: Transferyoungpeopletoadultcare medication management, symptom assessment, and duringtimesofmedicalandsocialstabilitywherepossible.
----------------------------------------------------------------------


======================================================================
CHUNK 440 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_166
Content Type: recommendation
Words: 487
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
were reported in a pilot study. 889 The application targeted 4 key self-care management parameters: monitoring BP, PracticePoint5. 3. 1. 1. 3: Transferyoungpeopletoadultcare medication management, symptom assessment, and duringtimesofmedicalandsocialstabilitywherepossible. tracking laboratory results. Lastly, interactive video Althoughseveralorganizationshavemaderecommendations conferencing can provide patient education simultaneously abouttransitionfrompediatrictoadultcare, therehavebeenno with a virtual visit. 890, 891 This strategy should not be randomized trials to test the effectiveness of specific apintended to replace the clinic visit but would be helpful for proaches. 892894 Nevertheless, there is general agreement that dealing with any event that happens between follow-up preparationfortransfertoadultcareshouldstartasearlyas11 face-to-face visits, such as follow-up of clinical symptoms yearsofageandcertainlyby14yearswhenpossible. 895Anumber after starting or adjusting medication. Examples of oftoolsareavailabletoguidepreparation. Checkliststoassess CKD care aspects Domains Platforms Asynchronous Wearable technology Remote monitoring Synchronous Web-based with interactive application Asynchronous Web-based and smartphone applications Telehealth Education strategies Synchronous Interactive video conferencing Asynchronous Smartphone applications Delivery of care Synchronous Interactive video conferencing Figure54Telehealthtechnologiesforpeoplewithchronickidneydisease(CKD). S264 KidneyInternational(2024)105(Suppl4S), S117S314 Preparation for transfer Preparation for regular adult care Transition Transition Pediatric care Joint pediatric-adult care Regular or adult care Young adult care readiness (i. e. , TRxANSITION, Youth Quizfrom the On Trac 5. 3. 1. 2Adultproviders program, Transition Readiness Assessment Questionnaire (TRAQ), Readiness for Transition Questionnaire (RTQ), and PracticePoint5. 3. 1. 2. 1: Recognizethatyoungpeopleunder Got Transition tools are useful 25 years of age with CKD are a unique population at high to identify the areas of weakness. 896899 Young people should riskforadverseoutcomesatleastinpartduetophysiologic gradually be prepared for full autonomy with medical visits. incomplete brain maturation. Seeing the young person alone before inviting caregivers into the room allows young people to practice interacting with Practice Point 5. 3. 1. 2. 2: Encourage young people to inforhealthcare providers independently and provides privacy for mally visit the adult care clinic to which they will be thediscussionofsensitivetopics. transferred before the first appointment (Figure 55). Good communication between the transferring and receiving care teams is a cornerstone of successful transitions. Practice Point 5. 3. 1. 2. 3: Assess young people with CKD Acomprehensivewrittenmedicalsummarymustbeprovided; more frequently than older people with the same stage of a verbal handover is ideal. Because childhood CKD may be CKDand, withtheagreementoftheyoungperson, include associated with neurodevelopmental disabilities, a clear the caregivers or significant other of the young person in description of the young persons cognitive abilities, including their care, at least in the first 13 years following transfer strengths and weaknesses that may influence their ability for from pediatric care (Figure 55). self-care management, is critical. Information about social Evenforyoungpeoplewithoutchronicillness, theinterval support available to young people is also important. between 14 and 25 years of age is a period of change and Healthcare transitions are well known to be strongly increasing autonomy. Young people with CKD undergoing associatedwithadverseoutcomes, includinglosstofollow-up. transfer to adult care must navigate 2 transitions simultaTransferring during periods of instability is ill-advised and neously: the transition of care and the larger transition from may amplify the risk of poor outcomes. 894 To minimize the childhood to adulthood.
----------------------------------------------------------------------


======================================================================
CHUNK 441 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_167
Content Type: reference
Words: 498
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Young people with CKD undergoing associatedwithadverseoutcomes, includinglosstofollow-up. transfer to adult care must navigate 2 transitions simultaTransferring during periods of instability is ill-advised and neously: the transition of care and the larger transition from may amplify the risk of poor outcomes. 894 To minimize the childhood to adulthood. Development of the prefrontal corrisk of loss to follow-up, pediatric care providers should tex, responsible for planning, organization, and impulse follow-up with patients to ensure that they have engaged control, continues to approximately 25 years of age. Adult with the new care team. care providers must recognize that young adults constitute a Transition clinics may improve the outcomes of young high-risk population requiring special care. 903 Outcomes are people transitioning from pediatric to adult care. 900, 901 poorer during this interval than at other times of life. 904 Transition clinics may be staffed exclusively by pediatric Care must reflect the fact that this is a high-risk period. care providers and focus on preparation, or may be jointly An informal visit to the new clinic setting may help in staffed by pediatric and adult providers. 895, 902 Although reducing stress, improving engagement, and reducing loss to joint pediatric-adult clinics are viewed as ideal, their follow-up. 895 Intheinitial years after transfer, visits should be superiority has not been demonstrated in randomized trials. more frequent than for older adults with the same stage of Furthermore, feasibility may be limited by funding, CKDtoprovideanopportunity forcareproviderstoestablish geography, and staffing. Young people should have the arelationshipwiththeyoungperson, reducetheriskoflossto opportunity to visit the adult clinic before transfer. follow-up, improve adherence to medications, and provide elbats nehw refsnarT www. kidney-international. org chapter 5 Start early (1114 yr) Use checklists to assess readiness and guide preparation Allow young people to visit the clinic before transfer See young person alone for Recognize that emerging adulthood is a period of at least part of each visit high risk for adverse outcomes See emerging adults more frequently than older adults Comprehensive written with same stage of CKD summary and verbal Include caregivers or significant others in patient visits, handover, including with permission of patient cognitive ability and social support Follow-up after transfer 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Age (years) Figure55Theprocessoftransitionfrompediatrictoadultcareinchronickidneydisease(CKD). KidneyInternational(2024)105(Suppl4S), S117S314 S265 chapter 5 www. kidney-international. org enhanced monitoring of a group at high risk of adverse consistent with the IDEAL study and showed no benefits of outcomes. Although young adults must have an opportunity early-start dialysis compared with late-start dialysis in regard to meet their care providers alone, many will continue to tomortalityandhospitalizationrisk(Table42905909). desireandneedinvolvementofparentsorsignificantothersin Factorssuchasavailabilityofresources, reasonsforstarting theircare. This is a normal part of development, is associated dialysis, timing of dialysis initiation, patient education and withbetteroutcomes, andshouldbeencouraged. 895 preparedness, dialysis modality and access, as well as varied Multidisciplinary young adult clinics including youth country-specific factors significantly affect a persons expeworkers, social workers, pharmacists, and psychologists in riences and outcomes. As the burden of kidney failure addition to physicians and nurses may be beneficial.
----------------------------------------------------------------------


======================================================================
CHUNK 442 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_168
Content Type: recommendation
Words: 497
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
895 preparedness, dialysis modality and access, as well as varied Multidisciplinary young adult clinics including youth country-specific factors significantly affect a persons expeworkers, social workers, pharmacists, and psychologists in riences and outcomes. As the burden of kidney failure addition to physicians and nurses may be beneficial. 900 Peerhas increased globally, there has also been a growing recognisupport programs have also shown promise. 904 tion of the importance of patient involvement in determining the goals of care and decisions regarding treatment. It is 5. 4 Timing the initiation of dialysis importanttomoveawayfromaone-size-fits-allapproachto dialysis and provide more individualized or personalized care. Practice Point 5. 4. 1: Initiate dialysis based on a composite The availability of resources for formal multidisciplinary assessment of a persons symptoms, signs, QoL, preferteams, educationalmaterials, andaccesstospecializedcounseling ences, level of GFR, and laboratory abnormalities. for diet, advance directives, access planning, and preemptive transplantation varies around the world. These statements are Practice Point 5. 4. 2: Initiate dialysis if the presence of one proposedsothatbestpracticescanbedocumentedoraspired or more of the following situations is evident (Table 41). to. Theneedforeducation, planning, andappropriateexpertise This often but not invariably occurs in the GFR range for the management of this patient group is internationally between 5 and 10 ml/min per 1. 73 m2. relevant. Themethods, frequency, andtoolswithwhichthiscan beaccomplishedwillberegionspecific. Practice Point 5. 4. 3: Consider planning for preemptive Thereisaneedtofocusonregularsymptomassessmentas kidney transplantation and/or dialysis access in adults part of the CKD review in those with lower eGFR values. when the GFR is 1520 ml/min per 1. 73 m2 or risk of Individualassessmentandavailabilityofresourceswilldictate KRT is 40% over 2 years. specific timing of therapies. Healthcare providers should be Thesestatementsarewordedverypreciselytohighlightthe aware of the impact of early dialysis start on QoL before need to plan proactively for complex activities related to recommending this strategy to people with CKD. initiation of KRT. Also, there is a need to address symptoms Recognition that the planning of smooth transition to andtoavoidtheinstitutionofdialysistherapyatanarbitrary either dialysis or transplantation from advanced CKD renumber representing the degree of residual kidney function. quiresalignmentofmultipledifferentresourcesandactivities, Given the risks and benefits of KRT, as well as the potential as such the planning for these will be situation specific. It is imprecision of measurements, people with CKD need to be important to recognize that there is variability in the availtreated according to symptoms and signs, not simply based ability of vascular access services or peritoneal dialysis cathon laboratory values. Data from the Initiating Dialysis Early eter insertion for those who choose hemodialysis or and Late (IDEAL) RCTshow no survival advantage to early peritoneal dialysis, respectively, and access to preemptive start dialysis (i. e. , at higher levels of GFR). 905 Thus, the transplantation. The complexity of the decision-making and statement as written should help the healthcare provider to differentteamsandresourcesrequiredtoeffectivelytransition balancesymptomswithlaboratoryvaluesindecision-making. people often requires time, and thus the recommendation to SecondaryanalysesoftheIDEALstudyshowednosignifibegin planning of KRT is intentionally advised at a concantdifferenceinQoLorhealthcarerelatedcostbetweenearly servative time point. and late start dialysis groups. 905, 906 Moreover, subgroup analysis of the IDEAL study revealed no benefits on cardiac Specialconsiderations outcomein theearly-startdialysis group.
----------------------------------------------------------------------


======================================================================
CHUNK 443 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_169
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,dialysis,hypertension
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
people often requires time, and thus the recommendation to SecondaryanalysesoftheIDEALstudyshowednosignifibegin planning of KRT is intentionally advised at a concantdifferenceinQoLorhealthcarerelatedcostbetweenearly servative time point. and late start dialysis groups. 905, 906 Moreover, subgroup analysis of the IDEAL study revealed no benefits on cardiac Specialconsiderations outcomein theearly-startdialysis group. 907 Sincethe IDEAL Pediatricconsiderations. study, therewereanumberoflargesamplesizeobservational Practice Point 5. 4. 4: In children, in addition to the adult studies with an advanced statistical technique to reduce indications for dialysis, poor growth refractory to optipossible confounding factors and biases encountered in mized nutrition, growth hormone, and medical managepreviousobservationalstudies. 908910Theoverallresultswere ment is an indication for initiating KRT. Table41Indicationsforthe initiation ofdialysis Symptomsorsignsattributabletokidneyfailure(e. g. , neurologicalsignsandsymptomsattributabletouremia, pericarditis, anorexia, medicallyresistant acid-basedorelectrolyteabnormalities, intractablepruritus, serositis, andacid-baseorelectrolyteabnormalities) Inabilitytocontrolvolumestatusorbloodpressure Progressivedeteriorationinnutritionalstatusrefractorytodietaryintervention, orcognitiveimpairment S266 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 5 Table42Studiesexaminingthetimingofdialysisinpeople withCKD Study Studydesign Comparison/studypopulations Outcomes Results Cooperetal. RCT Latestartgroup(eGFR 57ml/min Mortality HRwithearlyinitiation, 1. 04; 95%CI: 0. 831. 30; CG 2010: IDEAL per1. 73m2) P0. 75 study905 Earlystartgroup(eGFR 1014ml/min CG per1. 73m2) Harrisetal. Posthocanalysis Latestartgroup(eGFR 57ml/min Cost Nostatisticaldifferencebetweenearlystartvs. CG 2011906 ofIDEALstudy per1. 73m2) Qualityoflife latestartgroup Earlystartgroup(eGFR 1014ml/min CG per1. 73m2) Whalleyetal. Posthocanalysis Latestartgroup(eGFR 57ml/min Changeincardiac Nostatisticallysignificantchangeincardiac CG 2013907 ofIDEALstudy per1. 73m2) structureand structureandfunctionover12-monthfollowfunction(LVMI, LVEF, up. Nostatisticallysignificantdifferencein Earlystartgroup(eGFR 1014ml/min LAVI)over12months cardiacstructureandfunctionbetweenthe2 CG per1. 73m2) andbetweengroups groups Rosanskyetal. Observational 81, 176subjectswithkidneyfailure 1-yearmortality Theunadjusted1-yearmortalitybyMDRD 2011910 study aged2064years, withoutdiabetes, eGFRatdialysisinitiationrangedfrom6. 8%in andwithnocomorbidityotherthan thereferencegroup(eGFR5. 0ml/minper hypertension 1. 73m2)to20. 1%inthehighesteGFRgroup (15. 0ml/minper1. 73m2). Nacaketal. Observational 35, 665subjectswithserumalbumin 1-yearmortality 1-yearmortalitywas4. 7%. Inthisgroup, the 2016909 study concentrationsof3. 5g/dlorhigher adjustedHRformortalitywas1. 27foreGFR beforehemodialysisinitiation 5. 09. 9ml/minper1. 73m2, 1. 53foreGFR 10. 014. 9ml/minper1. 73m2, and2. 18for GFR15. 0ml/minper1. 73m2comparedwith thereferencegroupofGFR5. 0ml/minper 1. 73m2. Fuetal. Observational 10, 290peoplewithCKDG4G5; 5-yearmortality Themaximum5-yearmortalityriskreductions 2021908 study comparedialysisinitiationstrategies were5. 1%(foreGFR vs. eGFR ), 15-16 6-7 witheGFRvaluesrangingbetween4 translatingintoabettersurvivalofonly1. 6 and19ml/minper1. 73m2andusean monthsovera5-yearperiodattheexpenseof eGFRbetween6and7ml/minper1. 73 startingdialysis4yearsearlier m2asthereferencegroup CG, Cockcroft-Gault; CI, confidenceinterval; CKD, chronickidneydisease; eGFR, estimatedglomerularfiltrationrate; HR, hazardratio; IDEAL, InitiatingDialysisEarlyandLate; LAVI, leftatrialvolumeindex; LVEF, leftventricularejectionfraction; LVMI, leftventricularmassindex; MDRD, ModificationofDietinRenalDisease; RCT, randomizedcontrolled trial. Practice Point 5. 4. 5: Pursue living or deceased donor pre- (e. g. , placement of dialysis access, dialysis modality emptive kidney transplantation as the treatment of choice selection, advance care planning, and assistance with home for children in whom there is evidence of progressive and therapies). irreversible CKD. The eGFR at which preemptive transInchildren, studiesfromtheUSRDS, theEuropeanSociety plantation should be undertaken will depend on multiple ofPaediatricNephrology(ESPN), andtheAustraliaandNew factors including the age and size of the child and the rate Zealand Dialysis and Transplant Registry (ANZDATA) found ofprogressionofkidneyfailurebutwillusuallybebetween no benefit from starting dialysis early. 911913 Of 15, 000 incieGFR 515 ml/min per 1. 73 m2. dentchildrenondialysisintheUSRDS, themortalityriskwas In children, poor growth can also be a reason to initiate 36% higher for those with eGFR 10 ml/min per 1. 73 m2 dialysis. The decision to start dialysis should be reached in comparedwiththosewithlowereGFRatdialysisinitiation. 912 discussionwiththechild(ifageappropriate), theircaregivers, Mortality risk increased in those starting dialysis with eGFR and their healthcare providers. Medical and psychosocial 5 and 12 ml/min per 1. 73 m2, with a greater risk in preparations for the initiation of dialysis should begin well people 6 years and older.
----------------------------------------------------------------------


======================================================================
CHUNK 444 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_170
Content Type: evidence
Words: 486
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
912 discussionwiththechild(ifageappropriate), theircaregivers, Mortality risk increased in those starting dialysis with eGFR and their healthcare providers. Medical and psychosocial 5 and 12 ml/min per 1. 73 m2, with a greater risk in preparations for the initiation of dialysis should begin well people 6 years and older. 914 A retrospective ESPN study of before dialysis is required. nearly 3000 children found that mortality did not differ Deferredinitiationshouldnotimplydeferredpreparation, when dialysis was started with an eGFR above or below 8 and early discussions regarding medical and psychosocial ml/min per 1. 73 m2. 911 These observational data may be preparationfortheinitiationofdialysisshouldnotbedelayed confounded by indication bias. KidneyInternational(2024)105(Suppl4S), S117S314 S267 chapter 5 www. kidney-international. org 5. 5 Structure and process of supportive care and (cid: 3) Interventions to delay progression and minimize risks comprehensive conservative management of adverse events or complications, but not including dialysis. Practice Point 5. 5. 1: Inform people with CKD about the Evaluating the prognosis of each personwith CKD is very options for KRT and comprehensive conservative care. important because each person has a different disease progression pattern. Patientprognosisis the key information for Practice Point 5. 5. 2: Support comprehensive conservative shareddecision-makinginCKDG5, whichrequiresunbiased management as an option for people who choose not to information on survival and person-centered outcomes pursue KRT. known to matter to people with CKD: QoL, symptom burden, and support from family and healthcare providers. PracticePoint5. 5. 3: Provideaccesstoresourcesthatenable Shared decision-making helps healthcare providers, people the delivery of advanced care planning for people with a with CKD, and family members to reach agreement on the recognizedneedforend-of-lifecare, includingthosepeople treatment direction that is appropriate with the persons undergoing comprehensive conservative care. values and preferences and family goals. This process should Thesestatementsareintendedtohighlighttheimportance be performed in a culturally appropriate way with considerof supportive care and the need for comprehensive conseration of appropriate health literacy. vativecareprocessesandresourcesinthecareofthiscomplex As CKD progresses, the person with CKD will experipatientgroup. Thetermsupportivecareinnephrologymeans ence more symptoms and complications related to CKD. carethatisfocusedonimprovingtheHRQoLforpeoplewith Therefore, active symptom assessment and management CKD at any severity or age and can be provided along with are the key components of comprehensive conservative therapies intended to prolong life, such as dialysis. 838 care in CKD G5. Assessing a persons symptoms on a Although typically considered in people with advanced regular basis helps redirect management toward a persons kidney disease, supportive care may be applicable to people values and preferences and family goals. There is limited in earlier CKD stages. Whereas comprehensive conservative evidence for selecting treatment strategies due to the management is usually referred to as active medical complexity of CKD and differences in people and the management in people with kidney failure who choose not considerable variation in the management strategies for to have KRT. There are 3 distinct groups of people with different symptoms. Intervention to delay progression of kidney failure who receive comprehensive conservative care CKD is still an important component of comprehensive because provision of supportive care differs for each.
----------------------------------------------------------------------


======================================================================
CHUNK 445 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_171
Content Type: recommendation
Words: 488
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
There are 3 distinct groups of people with different symptoms. Intervention to delay progression of kidney failure who receive comprehensive conservative care CKD is still an important component of comprehensive because provision of supportive care differs for each. 915 conservative care in both CKD-related aspects (maintain Descriptions of each group are shown in Table 43. residual kidney function and reduce cardiovascular Thereisincreasingrecognitionthatprovisionoforganized morbidity) and psychospiritual aspects (the person and caretothosewhoaredyingorchoosetonotpursueKRTisof their family members do not feel that active CKD treatvalue to people with CKD and their families. Healthcare ment is discontinued). providers involved in caring for these people should be alerAdvanced care planning (ACP) is a process under the ted to this need. comprehensive conservative care umbrella that involves unComprehensive conservative care is an alternative treatderstanding, communication, and discussion between a perment to KRT. This is planned, holistic, person-centered care sonwithCKD, thefamily, caregiver, andhealthcareproviders that includes the full integration of comprehensive conserfor the purpose of clarifying preferences for end-of-life care. vative care including the following: End-of-lifecareisthetreatmentduringthephasewheredeath (cid: 3) Detailed communication including estimating prognosis is inevitable. It focuses on QoL not quantity of lifetime. and advance care planning Functionalandcognitivedeclinethatmayhappenalongwith (cid: 3) Shared decision-making CKD progression results in difficult end-of-life conversations (cid: 3) Active symptom assessment and management involving people with CKD, families, and healthcare pro- (cid: 3) Psychological, social, family, cultural, and spiritual support viders. Therefore, an integrated approach to timely ACPand Table43People withkidney failurewhoreceive comprehensive conservative care Category Description Receivingconservativecare Conservativecarethatischosenormedicallyadvised. Choice-restrictedconservativecare ConservativecareforpersoninwhomresourceconstraintspreventorlimitaccesstoKRT; therefore, achoice forconservativecarecannotberecognized. UnrecognizedCKDG5 CKDispresentbuthasnotbeenrecognizedordiagnosed; therefore, achoiceforconservativecare cannotberecognized. CKD, chronickidneydisease; KRT, kidneyreplacementtherapy. S268 KidneyInternational(2024)105(Suppl4S), S117S314 Supportive care Comprehensive conservative care Physicians objective and subjective assessment of the dying process/medical futility Truthful, accurate, and comprehensive disclosure of the prognosis to family Obtain consensus and ensure consistency among all caregivers Shared decision-making and advance care planning Implementing the process of withholding or withdrawing life support Interventions to delay Deprescribing Active symptom Psychological, social, progression and minimize and reduce assessment and family, cultural, and to patient and appropriate support to the family complications of CKD monitoring management spiritual support End-of-life care Advanced stage CKD Clinicallydeteriorating Dying palliative care spanning the continuum of CKD care is prescriptive but rather to articulate the best practices in needed. End-of-life care is underused in the management of communities where resources may be available and to serve people with CKD G5 due to inadequate education during as a construct to review in those locations where resources nephrology training leading to poor end-of-life care discusare more limited. sionswiththeperson. Theoverallconceptofsupportivecare, ACP is thought to be a component of all comprehensive comprehensive conservative care, and end-of-life care is chronic disease management. Thus, ACP discussions are not shown in Figure 56. restricted only to those choosing supportive care. In different societies or cultural areas, the form and structure of this care may vary tremendously, and families For research recommendations, please see Chapter or religious organizations may be able to deliver suitable 6: Research recommendations. and sensitive care.
----------------------------------------------------------------------


======================================================================
CHUNK 446 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_172
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
In different societies or cultural areas, the form and structure of this care may vary tremendously, and families For research recommendations, please see Chapter or religious organizations may be able to deliver suitable 6: Research recommendations. and sensitive care. The details here are listed not to be erac evitroppuS Supportive care www. kidney-international. org chapter 5 Estimating prognosis Detailed communication Shared decision-making Figure56Relationshipbetweensupportivecare, comprehensiveconservativecare, andend-of-lifecare. Kidneysupportivecare emphasizeseffortstooptimizequalityoflifeandrelievesufferinginpeoplewithkidneydisease. Thisemphasisshouldbepresentforpeople undergoingcomprehensiveconservativecare, aswellasthosewhotransitiontoend-of-lifecare. CKD, chronickidneydisease KidneyInternational(2024)105(Suppl4S), S117S314 S269 chapter 6 www. kidney-international. org Chapter 6: Research recommendations The last 30 years have seen an exponential growth in the 4. For new equations predicting CVD and mortality literature relating to kidney disease. However, despite this risk as well as CKD progression, development and inclusionofpeoplewithCKDinprospectiveRCTs, thosewith implementationstudiesincludingvalidationindifferent lower GFR remain under-represented. Before the KDIGO populations (geographic and demographic) are 2012 CKD guideline, a low eGFR was an exclusion criterion required. foralmosteverylargecardiovascularandBPtrial. Asaresult, 5. Benefit-risk ratio assessments of old, new, and future we had a largely opinion-based literature. That is changing, medications should be performed by levels of GFR and and although still low, the proportion of the total CKD ACR and/or using validated risk equations. literature that is either an RCT, meta-analysis, or systematic 6. Drug studies evaluating pharmacodynamics should review has doubled from 3. 3% to 6. 5% of published articles consider using validated eGFR equations or mGFR for in the 5-year period ending December 2022. highly toxic drugs with a narrow therapeutic window, Several large international interventional studies have especially for those frequently used in CKD. As this may been completed in the last 8 years, either specifically tarbe prohibitively expensive for some medications, epidegeting people with CKD and other comorbidities (most miologicstudiesmayprovideinformationforrevisionsto notably diabetes or CVD), or with CKD defined by eGFR labels for some drugs. andACRcriteria(e. g. , CanagliflozinandRenalEndpointsin 7. Pharmacokinetic studies in people with CKD should not Diabetes with Established Nephropathy Clinical Evaluation automatically exclude GFR categories G4 and G5. CREDENCE, 514 DAPA-CKD, 513 EMPA-KIDNEY, 403 8. Studies should consider measurement of ACR in all coFIGARO-DKD, 534 and FIDELIO-DKD533). Interventional horts, whether specifically focused on CKD or not, given studies targeting specific pathways and diseases are additionalprognosticvalueofthisparameterforsomany increasing as well, though limited in scale due to rarity of outcomes. conditions (e. g. , IgAN, membranous nephropathy, and 9. All studies should ensure attention to etiology of CKD, systemic lupus erythematosus, etc. ). sex, gender, age, and SES considerations in design and There remain gaps in the evidence base to inform best analysis of results. diagnostic testing strategies, decision-making, and processes 10. Use of novel studydesigns (platform, registry-embedded, ofcare. Inaddition, sometherapiesofferingpromisehavenot andpragmatictrials), useoflargeadministrativedatasets, yet been adequately tested in people defined by specific and implementation science methodologies (e. g. , causal criteria with CKD (i. e. , people without diabetes, children, inference techniques) should be considered to enable the women, PKD, frail, elderly, etc. )andpeoplefromlow-income assessmentandevaluationofinterventions, processes, and and low-middle-income countries. We, therefore, begin this models of care. section detailing research recommendations with some gen11.
----------------------------------------------------------------------


======================================================================
CHUNK 447 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_173
Content Type: recommendation
Words: 466
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
)andpeoplefromlow-income assessmentandevaluationofinterventions, processes, and and low-middle-income countries. We, therefore, begin this models of care. section detailing research recommendations with some gen11. People living with CKD should be involved in clinical eralguidingprinciplesforthosedesigningstudiestoconsider studies throughout the research process from identificawhenaddressingkeyquestionsthatimpactpeoplelivingwith tion of knowledge gaps to knowledge mobilization and or at risk for CKD. study design. The following set of more specific research recommendaGuidingprinciples forresearch tions are organized according to chapter and are not exhaustive. They are generated in part from identifying gaps 1. To ensure that the evidence base is directly applicable to in knowledge during the evidence review and in part from all people with CKD, future studies should avoid autoclinical practice and patient perspectives. matic exclusion of older people, children, and young adults 18 years old, and give consideration to pregnant Screening and lactating people. The need for contraceptive requirementsfortrialparticipationshouldalsobereviewed. (cid: 3) Determinewhethereffortstosystematicallydetectandtreat 2. Decreased GFR should not be a reason for automatic CKDintargetedpopulationsinthecommunitysettingwill exclusion from research studies. reduce the incidence of CVD and CKD progression to 3. Estimatingequationsequallyapplicabletothosewithand kidney failure through earlier intervention of diseasewithout CKD are required for children and adolescents. modifying strategies. S270 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 6 Chapter 1. Evaluation of CKD: Improving the accuracy B DeterminewhethermoreefficientmethodsforGFR and sophistication of evaluation of kidney functions is measurement (POC, shorter protocols, and subcucritical to advancing the science and care of people with taneous administration) have adequate accuracy CKD. and precision to be considered a gold standard. (cid: 3) Imaging techniques B Identify barriers to the performance and impleB Determine which imaging techniques, or combimentation of mGFR in the nephrology diagnostic nation of imaging techniques, may be used to repertoire. assess kidney damage and evaluation of specific (cid: 3) Estimations of GFR causes of CKD. B Assess the diagnostic accuracy and utility of GFR B Develop more sophisticated imaging methods for estimatesusingendogenousfiltrationmarkerssuch assessment and follow-up to aid in noninvasive asSCrandcystatinCinchildrenandyoungadults evaluation of kidney functions (GFR, tubular, and and in frail, acute, or chronically ill populations; plasma clearance). obese and pregnant populations; transgender, (cid: 3) Genetic testing gender-diverse, and nonbinary populations; and B Determinetheadditionalvalueofgenetictestingin transplantrecipients. people with CKD, both with and without kidney B When reporting performance of eGFR in research biopsy, for determination of cause, prognosis, and studies, future studies should report P in addi15 treatment choices. tion to P, with expectation that improved equa30 (cid: 3) Kidney biopsy tions may achieve levels of accuracy approaching B Determinetheprevalenceofkidneybiopsyrelated that of mGFR. complications in different clinical circumstances B Assess the non-GFR determinants of endogenous (age, sizeofkidneys, acutevs. chronic, andcomorfiltration markers such as cystatin C. bidities) to inform risk estimates appropriate to B Assess the utility of changes in eGFRcr versus thoseinthecurrenteradependentonmethods(e. g. , eGFRcys versus eGFRcr-cys over time for clinical blind, ultrasound-guided, CT-guided, open, and decision-making, enrollment into clinical trials, transjugular)usedtoobtainkidneytissue. and so on.
----------------------------------------------------------------------


======================================================================
CHUNK 448 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_174
Content Type: evidence
Words: 495
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
chronic, andcomorfiltration markers such as cystatin C. bidities) to inform risk estimates appropriate to B Assess the utility of changes in eGFRcr versus thoseinthecurrenteradependentonmethods(e. g. , eGFRcys versus eGFRcr-cys over time for clinical blind, ultrasound-guided, CT-guided, open, and decision-making, enrollment into clinical trials, transjugular)usedtoobtainkidneytissue. and so on. (cid: 3) Novel urinary biomarkers B Examinetheeffectofsexhormonestatus(e. g. , puB Determinewhichnovelurinarybiomarkers, orcomberty, gonadectomy, or menopause), exogenous binationofbiomarkers, aidtheidentificationofCKD hormone use (e. g. , contraception, assisted reprocause (e. g. , interleukin IL-18, kidney injury moleductivetechnologies, menopausalhormonetherapy, cule KIM-1, neutrophil gelatinase-associated liptestosteronereplacementtherapy, orgender-affirmocalin NGAL, monocyte chemoattractant protein inghormonetherapy), orsexhormonedeprivation MCP-1, tissue inhibitor matrix metalloproteinase therapy(e. g. , antiandrogenorantiestrogentherapy) TIMP-1, alpha-1-microglobulin, uromodulin, onserumlevelsofcreatinineandcystatinCandtheir epidermalgrowthfactorEGF, andYKL-40). correspondingGFRestimatesandmGFR. B Determine how urine cytology may aid the idenB EvaluatetheaccuracyoftheCKiDU252021eGFRcr tification of CKD cause in specific circumstances. and EKFC equations in diverse cohorts outside of (cid: 3) Develop clinically robust and accessible tests for kidney NorthAmericaandEuropeinchildrenyoungerthan functional reserve 5years, inchildrenandadolescentswithobesity, and B Determinehowkidneyfunctionalreservevariesby inthosewitheGFR30ml/minper1. 73m2. demographiccharacteristicsincludingbirthweight, (cid: 3) Determine validity of different estimating equations for in people with and without CKD of different etiGFRinchildrenatdifferentpointsintime(25years, 510 ologies, inkidneydonors, andatdifferentlevelsof years, 1014 years, and 14 years). GFR and ACR. B Evaluate which estimating equations should be B Evaluate sex (e. g. , female, male, or intersex) difused for eGFR in young adults and what criteria ferences in GFR and kidney functional reserve at should be used to transition to adult eGFR equavarious hormonal stages such as puberty, mentions if not using EKFC equations. strual cycle, pregnancy, menopause, and gender (cid: 3) Evaluate the utility of total urine protein loss or PCR in differences (e. g. , identity, roles, or relations) in comparison with ACR in the evaluation of specific kidney people across the life cycle. diseases in both children and adults. B EvaluatechangesinkidneyfunctionalreserveafterAKI (cid: 3) Evaluate the role of detection and measurement of specific episodesirrespectiveofbaselineGFRandrecovery. tubular proteins to identify and quantify kidney damage (cid: 3) Develop better tests for tubular function. across the age, sex, and gender spectrum. (cid: 3) Measurement of GFR (cid: 3) Evaluate the clinical utility and diagnostic accuracy of B HarmonizeandstandardizeexistingmGFRprotocols cystatin C/eGFR in POCT devices using standardized anddeterminetheiraccuracyandcomparability. criteria. KidneyInternational(2024)105(Suppl4S), S117S314 S271 chapter 6 www. kidney-international. org (cid: 3) Evaluatethecost-effectivenessandcost-utilityofPOCTfor (cid: 3) Evaluatethebenefit-riskratioandimpactonQoLofdietary creatinine and urine albumin in specific situations (rural, restriction (i. e. , protein restriction vs. no protein restricremote, high risk, and children). tion) in people with CKD receiving optimal medical ther- (cid: 3) Define different clinical settings and specific circumstances apy (e. g. , ACEi/SGLT2i/ns-MRA). in which POCT would be valuable to patients, clinicians, B Does this vary by age, sex, ACR, initial eGFR, and and/or researchers. etiology of CKD? (cid: 3) Evaluatetheroleofsodiumrestrictionincombinationwith Chapter 2. Risk assessment in people with CKD: optimal medical therapy in prevention of progression of Improving the accuracy of risk assessment and demonCKD in people with CKD, including a range of baseline strating utility and usefulness of validated risk assessment BPs, ages, sex, and etiology of CKD. tools in clinical practice are critical to uptake.
----------------------------------------------------------------------


======================================================================
CHUNK 449 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_175
Content Type: evidence
Words: 472
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
tools in clinical practice are critical to uptake. (cid: 3) Examine the safety and efficacy of SGLT2i in the CKD (cid: 3) Determine whether persons who have a 30% decline in population subgroups understudied in completed large eGFRwhileusingRASi, SGLT2i, andMRAshavebetteroutRCTs (e. g. , people with PKD and T1D, children, young or comesiftheycontinueversusdiscontinuethesemedications. older adults, transgender, gender-diverse and nonbinary (cid: 3) Determinetheclinicalimportance/meaningofdivergenceof people, and women at different ages/hormonal status eGFRcys and eGFRcr in clinical practice, and whether the including pregnancy and lactation). divergencemagnitudeand/ordirectionvariesbydemography. (cid: 3) Evaluate the cost-effectiveness of strategies to prevent the (cid: 3) Evaluate the clinical and cost utilities of equations guiding progression of CKD in people with relatively low (e. g. , clinical decision-making in people with CKD including 5%)riskofkidneyfailurewithin5years, byetiology, age, children and young people, for individual people, clinisex, and gender. cians, and the healthcare system. (cid: 3) Evaluate and determine if additional clinically available (cid: 3) Develop implementation strategies and evaluation framebiomarkers predict outcomes in people with CKD without works to enable assessment of the potential barriers and diabetes and with lower ACR 30 mg/g (3 mg/mmol). facilitators of validated equations for CKD populations, (cid: 3) DeterminethesafetyandefficacyofSGLT2iforpreventionof including the new equations for CVD and mortality outprogressionofCKDinchildrenandyoungadultswithCKD. comes as well as for proximal CKD progression. (cid: 3) Do inhibitors of the aldosterone pathway have a role in (cid: 3) Riskscoresderivedfromvalidatedequationsshouldbetested prevention of progression of CKD and cardiovascular asbothinclusioncriteriaforenrichmentofstudycohortsas outcomes in people with CKD, including those with an wellaspotentialsurrogateendpointsinclinicaltrials. ACR 30 mg/g (3 mg/mmol), with and without T2D? (cid: 3) Evaluate the difference in performance characteristics of Whatarethenetbenefit-risksparticularlyathigherbaseline validatedriskequationsforeGFRusingendogenousfiltration serum potassium (e. g. , K  5. 0 mmol/l), and are effects markers such as cystatin C, creatinine, or both (eGFRcys, modified by concurrent use of an SGLT2i? eGFRcr, and eGFRcr-cys) for kidney failure, cardiovascular B Including youngadults, womenwithdifferenthorevents, andall-causemortality, andpregnancyandfetaloutmonalstatus/supplementation, andvaryingetiology. comesinavarietyofpopulations(i. e. , age, sex, andregion). (cid: 3) Evaluatethesafetyandefficacyofintroducingtherapywith an SGLT2i and an inhibitor of the aldosterone pathway Chapter3. DelayingCKDprogressionandmanagingits simultaneously as compared with sequentially in people complications: There is a paucity of well-designed studies with CKD. evaluating combination therapies and nutritional strategies (cid: 3) Evaluate the effects of GLP-1 RA on risk of adverse carin different populations with CKD and evaluating specific diovascular outcomes and kidney disease progression in target values for interventions in laboratory abnormalities, peoplewithvariousetiologiesofCKD. Trialsshouldinclude which generates uncertainty and confusion for both clinipeople without diabetes, particularly if they are overweight cians and patients. or obese. (cid: 3) Generate more evidence on the effect of nutritional thera- (cid: 3) Evaluate the impact of correction of metabolic acidosis, at pies (e. g. , varying levels of protein restriction with and differentlevelsofserumbicarbonatewithrespecttobenefits without supplementation e. g. , ketoanalogs) documenting intermsofCKDprogression, musclewasting, development, benefits (e. g. , delaying progression) versus potential harms or exacerbation of bone disease, protein malnutrition, (e. g. , patient intolerance and malnutrition). growth(inchildrenandadolescents), andmortality.
----------------------------------------------------------------------


======================================================================
CHUNK 450 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_176
Content Type: evidence
Words: 497
Medical Entities: CKD,GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
growth(inchildrenandadolescents), andmortality. (cid: 3) Evaluatedifferentnutritionregimensinlarger, longer-term (cid: 3) Evaluate the efficacy and safety of dietary interventions in RCTsthanthoseperformedtodateusingpragmaticdesigns specific groups of people with CKD (e. g. , diabetes vs. no to enable generalizability. diabetes). Outcomes should include PROMs and clinically (cid: 3) Evaluatetheeffectsofplant-basedproteindietsanddietssuch important cardiovascular and kidney outcomes, as well as as the Mediterranean, Okinawan, and DASH diets versus serum potassium concentration. animal-based protein diets on risk of CKD progression, (cid: 3) Evaluate the impact on kidney, cardiovascular, and safety metabolicacidosis, hyperphosphatemia, andhyperkalemia. outcomes by maintaining and optimizing RAASi despite S272 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org chapter 6 hyperkalemia in people with CKD stratified by grade of (cid: 3) Assess the non-GFR determinants of cystatin C and how heart failure, ACR, etiology of CKD, age, and sex. serum cystatin C concentration may be influenced by (cid: 3) Evaluate the impact on patient outcomes and resource medications. utilization of different strategies to address hyperkalemia (cid: 3) EvaluatetheroleofkineticeGFRtoinformandimprovedrug identified in outpatient populations with CKD. dosingandadministrationinpeopleinanonsteadystate. (cid: 3) Investigate best strategies to prevent hyperkalemia using (cid: 3) Evaluatetheutilityofendogenousfiltrationmarkerssuchas resource utilization outcomes such as reduction of hospicystatin C (eGFRcys) to inform drug dosing and talizations, emergency department presentations, and administration. additional investigations. (cid: 3) IdentifysettingsinwhichtheuseofeGFRcysoreGFRcr-cys can improve the safety and effectiveness of specific medi- (cid: 3) Evaluate the impact of low-potassium diets on serum pocations relative to eGFRcr. tassium, mortality, and QoL in patients with CKD, by age, sex, and etiology. (cid: 3) Evaluate different strategies (i. e. , consumer engagement, generic vs. specific reminders, etc. ) in people with CKD of (cid: 3) Large RCTs are needed to address effects of the use of podifferent ages, sex, gender, and etiology to ascertain the tassium exchange agents on clinical outcomes, such as impact on compliance and adherence. laboratory or hospital visits, cardiovascular outcomes, and (cid: 3) Evaluate the impact of electronic clinical decision support CKD progression. (cid: 3) Evaluate the value of uric acidlowering therapies on CKD systems to improve the medication management of people with CKD. andCVDoutcomesinpopulationsatriskofeitherorboth, (cid: 3) Evaluate the impact of deprescribing of nonessential/ ensuring representation of a range of ages, sex, and nonevidence-based medications on patient adherence and ethnicities. outcomes. (cid: 3) Whatdietarymodificationreducesserumuricacidandrisk (cid: 3) Evaluate the impact of newer agents (e. g. , SGLT2i and nsof gout in people with CKD? MRAs) in patients intolerant of ACEi/ARB. (cid: 3) What are the safety and efficacy of different symptomatic treatment strategies for acute gout in people with CKD Chapter 5. Optimal models ofcare: The key components (including a short course of NSAIDs as a potential of care models for different conditions have not been wellcomparator)? identified, butareknowntobemodifiedbyage, sex, gender, (cid: 3) RCTs are needed to assess the efficacy and safety of longand etiology. Implementation of known effective treatments term, low-dosecolchicineonriskofCVD, andgoutinCKD. lagsbehindtheevidence, anduseofimplementation science (cid: 3) Evaluate the clinical and cost-effectiveness of PCSK-9 intechniques is critical to ultimately enable clinicians and hibitors in people with CKD (vs. statins), by age, sex, and patientstobenefitfromadvancesincaremodeldevelopment etiology. and interventional studies.
----------------------------------------------------------------------


======================================================================
CHUNK 451 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_177
Content Type: recommendation
Words: 499
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Implementation of known effective treatments term, low-dosecolchicineonriskofCVD, andgoutinCKD. lagsbehindtheevidence, anduseofimplementation science (cid: 3) Evaluate the clinical and cost-effectiveness of PCSK-9 intechniques is critical to ultimately enable clinicians and hibitors in people with CKD (vs. statins), by age, sex, and patientstobenefitfromadvancesincaremodeldevelopment etiology. and interventional studies. (cid: 3) Assess effects of antiplatelet agents, such as low-dose (cid: 3) Evaluate the utility and barriers to using validated tools in aspirin, for primary prevention of CVD in people with clinical practice to assess the specific symptoms or outCKDinlargeRCTs, stratifiedbyage, sex, riskofevent, and comesofimportancetopeoplewithCKDofdifferentages, ethnicity. sex, gender, and ethnicity/region. (cid: 3) Develop and refine CKD-specific risk assessment tools for (cid: 3) Develop and evaluate/validate clinically relevant and reliCVD and major bleeding, so as to provide more individable tools for health literacy and workability for use in ualizeddecision-makingfortheuseofallagents(including different populations (i. e. , age, gender, and region). deprescribing). (cid: 3) Evaluate the burden, yield, variability, and stability of (cid: 3) Identify which people with CKD may particularly benefit routinescreeningforawiderangeofcommonsymptomsin frominvasivemanagementofischemicheartdiseaseversus people with CKD G3G5, irrespective of age, sex, gender, maximal medical therapy in people with CKD stratified by and etiology of CKD. age, sex, frailty, and etiology of CKD. (cid: 3) Quantitativeandqualitativemethodsshouldbedevelopedby (cid: 3) New thromboprophylaxis risk scores incorporating CKDwhich identification and classification of specific common specific predictors or ensemble modeling to combine symptomsexperiencedbypeoplewithCKDarecaptured. existing risk scores to improve risk prediction in people (cid: 3) Platform studies to evaluate the value of different inwith CKD are needed. terventions for common symptoms should be developed, enabling assessment of established and new therapies in a Chapter 4. Medication management and drug stewardrigorous manner. ship in CKD: Appropriate dosing of medications according (cid: 3) Using implementation science methods, evaluate best to different biological parameters in people with CKD is methodstoensureuptakeofproventherapiesforsymptom critical to evaluating benefits and risks; thus, studies tarmanagement into clinical care. geted at answering these questions will be valuable. (cid: 3) Determinethecomponentsessentialfortransitionclinicsto (cid: 3) Evaluate the effects of age, sex, body size, and etiology on have a positive impact on the outcomes of young people pharmacodynamics and pharmacokineticsofspecificdrugs with CKD, including cost-effectiveness and patient-rein people with CKD. ported outcomes. KidneyInternational(2024)105(Suppl4S), S117S314 S273 methods for guideline development www. kidney-international. org Methods for guideline development Aim searching, data extraction, risk-of-bias assessment, evidence The aim of this project was to update the KDIGO 2012 synthesis and meta-analysis, grading the certainty of the eviClinical Practice Guideline for the Evaluation and Managedence per critical outcome, and grading the overall certainty mentofChronicKidneyDisease. 1Theguidelinedevelopment of the evidence for the recommendations. The Work Group methods are described below. was responsible for writing the recommendations and the underlying rationale, grading the strength of the recomOverviewoftheprocess mendations, and developing practice points. This guideline adhered to international best practices for Defining scope and topics and formulating key clinical quesguideline development (Appendix B: Supplementary Table tions. The KDIGO 2012 CKD guideline was reviewed by the S2)916, 917 and have been reported in accordance with the Co-Chairs to identify topics to be included in the 2024 AGREE II reporting checklist.
----------------------------------------------------------------------


======================================================================
CHUNK 452 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_178
Content Type: recommendation
Words: 498
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The KDIGO 2012 CKD guideline was reviewed by the S2)916, 917 and have been reported in accordance with the Co-Chairs to identify topics to be included in the 2024 AGREE II reporting checklist. 918 The processes undertaken guideline. Scoping reviews of these topics were conducted by for the development of the KDIGO 2024 Clinical Practice theERTtoprovideanoverviewoftheavailableevidencebase Guideline for the Evaluation and Management of CKD are and to identify existing relevant systematic reviews. described below. The Risk of Bias in Systematic Reviews (ROBIS) tool was (cid: 3) Appointing Work Group members and the ERT used to assess the risk of bias of the existing reviews. When (cid: 3) Finalizing guideline development methodology high-quality systematic reviews were identified during the (cid: 3) Defining scope of the guideline scoping reviews, theERTconductedanupdatedsearchbased (cid: 3) Developingandregisteringprotocolsforsystematicreviews on the existing review and extracted information from the (cid: 3) Implementing literature search strategies to identify the newly identified studies. This information was added to the evidence base for the guideline existing review data and analyzed as appropriate. (cid: 3) Selecting studies according to predefined inclusion criteria For topics that did not map to current high-quality re- (cid: 3) Conducting data extraction and risk of bias assessment of views, denovo systematic reviewswereundertaken. Protocols included studies for each review were developed by the ERTand reviewed by (cid: 3) Conducting evidence syntheses, including meta-analysis the Work Group. Protocols were registered on PROSPERO where appropriate ( Systematic reviews (cid: 3) Assessing the certainty of the evidence for each critical were conducted in accordance with current standards, outcome including those from the Cochrane Handbook. 919 (cid: 3) Finalizing guideline recommendations and supporting Details of the Population, Intervention, Comparator, rationale Outcome andStudydesign (PICOS) ofthequestionsare pro- (cid: 3) Gradingthestrengthoftherecommendationsbasedonthe vided in Table 44. 23, 316, 318, 415, 511, 609, 920926 Information about overall certainty of the evidence and other considerations existingreviewsthatwereusedisincludedinthesetables. (cid: 3) Convening a public review of the guideline draft in July For some topics not predefined in the Scope of Work, the 2023 ERTextracted the certainty of evidence from existing high- (cid: 3) Updating systematic reviews quality systematic reviews, as available. Details of the PICOS (cid: 3) Amending the guideline based on the external review for these questions are also provided in Table 44. feedback and updated systematic reviews Literature searches and article selection. Searches for RCTs (cid: 3) Finalizing and publishing the guideline. were conducted on PubMed, Embase, and the Cochrane Commissioning of Work Group and ERT. KDIGO and the Central Register of Controlled Trials (CENTRAL), and Co-Chairs assembled and engaged a Work Group with searches for diagnosis/prognosis studies were conducted on expertise in pediatric, adult, and geriatric nephrology, PubMed, Embase, and CINAHL. For topics with available including both dialysis and transplant specialists; primary existing reviews, the review was used and an updated search care; internal medicine; dietetics; nursing; womens health; was conducted. The search strategies are provided in clinical trials; epidemiology; medical decision-making; and Appendix A: Supplementary Table S1. public health; as well as people living with CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 453 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_179
Content Type: reference
Words: 483
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The search strategies are provided in clinical trials; epidemiology; medical decision-making; and Appendix A: Supplementary Table S1. public health; as well as people living with CKD. Johns To improve efficiency and accuracy in the title/abstract Hopkins University, with expertise in nephrology, evidence screening process and to manage the process, search results synthesis, and guideline development, was contracted as the were uploaded to a web-based screening tool, PICO Portal ERT and was tasked with conducting the evidence reviews. (www. picoportal. net). PICO Portal uses machine learning to The ERT coordinated the methodological and analytical sortandpresentthosecitationsmostlikelytobepromotedto processes of guideline development, including literature full-textscreeningfirst. Thetitlesandabstractsresultingfrom S274 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org methods for guideline development Table44Clinical questionsandsystematicreviewtopicsin PICOSformat Chapter1 Evaluationofchronickidneydisease(CKD) Clinicalquestion WhatisthediagnosticandprognosticbenefitandsafetyofkidneybiopsyamongpeoplewithCKD? Population AdultsandchildrenwithsuspectedordiagnosedCKD Intervention(indextest) Nativekidneybiopsy Comparator Forstudiesevaluatingdiagnosticorprognosticbenefit, clinicalorstandarddiagnosis, orprognosis Forstudiesevaluatingsafety, nocomparator Outcomes Criticaloutcomes: mortality, perirenalhematoma(perinephrichematoma), andretroperitonealhemorrhage Otheroutcomes: diagnosticandprognosticbenefit, macroscopichematuria, transfusion, needforembolization, nephrectomy, AKI, andmajorcomplications Studydesign Noncomparativestudies, beforeandafterstudies Existingsystematicreview PoggioED, McClellandRL, BlankKN, etal. Systematicreviewandmeta-analysisofnativekidneybiopsycomplications. usedforhandsearching ClinJAmSocNephrol. 2020; 15: 1595602. 920 SoFtables SupplementaryTableS4 Searchdate March2023 Citationsscreened/included 1582/65 studies SupplementaryFigureS1 Clinicalquestion WhatisthediagnosticaccuracyofeGFRbasedonmeasurementsofcystatinC, creatinine, ortheircombination comparedwithmGFRamongpeoplewithandwithoutCKD? Population AdultsandchildrenwithorwithoutCKD Intervention(indextest) eGFRbasedonmeasurementsofcystatinC(eGFRcys), creatinine(eGFRcr), cystatinCandcreatinine(eGFRcr-cys) Comparator mGFR(usingurinaryorplasmaclearanceoftheexogenousfiltrationmarker) Outcomes Criticaloutcomes: measurementbias(eGFRmGFR), accuracy(P andP ) 30 15 Otheroutcomes: probabilityofbeingclassifiedineacheGFRcategory Studydesign Cross-sectional Existingsystematicreviews None SoFtables SupplementaryTableS3 Searchdate August2022 Citationsscreened/included 1848/47 studies SupplementaryFigureS2 Clinicalquestion InchildrenandyoungadultswithsuspectedordiagnosedCKD, whatistheaccuracyofthealbumin-tocreatinineratio(ACR)andprotein-to-creatinineratio(PCR)comparedwith24-hourexcretionofalbuminor protein? Population Childrenandyoungadults(age25years)withsuspectedordiagnosedCKD Intervention(indextest) ACRandPCR Comparator Albuminuriaorproteinuriadeterminedfrom24-hoururinecollection Outcomes Outcomes: median(IQR)ordifferencebetweeninterventionandcomparison, sensitivityandspecificityfordetection, anddiagnosisofsignificantproteinuria Studydesign Prospective, observationalstudies Existingsystematicreview NationalInstituteforHealthandCareExcellence(NICE). Evidencereviewfortheaccuracyofalbumin: creatinineratiovs. usedforhandsearching proteincreatinineratiomeasurementstoquantifyproteinuriainchildrenandyoungpeoplewithCKD. ChronicKidney Disease: EvidenceReviewB. NICE; 2021. 921 SoFtables Nosummaryoffindingstable Searchdate July2022 Citationsscreened/included 485/0 studies SupplementaryFigureS3 Clinicalquestion Whatisthediagnosticaccuracyandreproducibilityofpoint-of-care(POC)bloodcreatininecomparedwith laboratory-basedtestsamongpeoplewithsuspectedordiagnosedCKD? Population Adultsandchildren Intervention(indextest) QuantitativeinternationallystandardizedPOCcreatininetests Comparator Laboratory-basedmethodsformeasuringSCr Outcomes Criticaloutcomes: measurementbias, analyticalsensitivity(limitofdetection), andanalyticalvariability(coefficientof variation) Studydesign Cross-sectional Existingsystematicreviews NationalInstituteforHealthandCareExcellence. Point-of-carecreatininedevicestoassesskidneyfunctionbeforeCT usedforhandsearching imagingwithintravenouscontrast. NICEGuidelineNG37. NICE; 2019. 316 CorbettM, DuarteA, LlewellynA, etal. Point-of-carecreatinineteststoassesskidneyfunctionforoutpatientsrequiring contrast-enhancedCTimaging: systematicreviewsandeconomicevaluation. HealthTechnolAssess. 2020; 24: 1248. 922 SoFtables Nosummaryoffindingstable Searchdate January2023 Citationsscreened/included 986/55 studies SupplementaryFigureS4 Clinicalquestion Whatisthediagnosticaccuracyofquantitativeandsemiquantitativeproteinoralbuminurinedipsticktests comparedwithlaboratory-basedtestsamongpeoplewithsuspectedordiagnosedCKD? Population Adultsandchildren (Continuedonfollowingpage) KidneyInternational(2024)105(Suppl4S), S117S314 S275 methods for guideline development www. kidney-international. org Table44(Continued)Clinical questionsandsystematicreviewtopicsin PICOSformat Chapter1 Evaluationofchronickidneydisease(CKD) Intervention(indextest) Machine-readquantitativeorsemiquantitativeproteinoralbuminurinedipsticktests Comparator Laboratory-basedmethodsformeasuringurinaryproteinoralbumin(e. g. , 24-hoururinarysample, spoturineACR, or PCR) Outcomes Criticaloutcomes: measurementbias, analyticalsensitivity(limitofdetection), analyticalvariability(coefficientof variation), andanalyticspecificity(ornumberstocalculate) Otheroutcomes: probabilityofbeingclassifiedineachalbuminuriaorproteinuriastage Studydesign Cross-sectional Existingsystematicreviews McTaggartMP, NewallRG, HirstJA, etal. Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria: a forhandsearching systematicreviewandmeta-analysis. AnnIntMed. 2014; 160: 550557. 318 SoFtables SupplementaryTableS5 Searchdate July2022 Citationsscreened/included 2184/65 studies SupplementaryFigureS5 Chapter2 RiskassessmentinpeoplewithCKD Clinicalquestion Arekidneyfailurepredictionequationsgoodpredictorsofprogression, kidneyfailure, orend-stagerenal disease? Population Adults, children, andyoungpeoplewithCKDG1-G5 Predictor Kidneyfailureriskequations(e. g. , TangriequationKidneyFailureRiskEquation) Outcomes Prognosticperformance: Calibration(goodnessofmeasures, e. g. , R2, Brierscore, andHosmer-Lemeshowtest) Discrimination(e. g. , sensitivity/specificity; areaunderthecurveAUCfromreceiveroperatingcharacteristicROCand areaunderthereceiveroperatingcharacteristiccurveAUROC; C-statistic) Studydesign Systematicreview Existingsystematicreview NationalInstituteforHealthandCareExcellence. Evidencereviewforthebestcombinationofmeasurestoidentify increasedriskofprogressioninadults, childrenandyoungpeople. ChronicKidneyDisease: EvidenceReviewF. NICE EvidenceReviewsCollection; 2021. NICE. 415 SoFtables SupplementaryTablesS6S9 Searchdate N/A Chapter3 DelayingCKDprogressionandmanagingitscomplications Clinicalquestion Whatistheeffectofsodium-glucosecotransporter-2inhibitors(SGLT2i)comparedwithplacebo, usualcare, or anactivecomparatoramongpeoplewithCKDintermsofmortality, progressionofCKD, complicationsofCKD, andadverseevents? Population AdultsandchildrenwithCKD; subgroupofpeople(1)withtype2diabetes(T2D), (2)withoutT2D, (3)withheartfailure, and(4)withoutalbuminuria Intervention SGLT2i(canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, sotagliflozin, tofogliflozin) Comparator Activecomparator(e. g. , anotherglucose-loweringagent), placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailure(includingCKDprogression)andall-causehospitalizations Otheroutcomes: mortality, changeineGFR(includingacutechanges), complicationsofCKD, andadverseevents Studydesign Randomizedcontrolledtrials(RCTs) Existingsystematicreview KidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetes dataincluded ManagementinChronicKidneyDisease. KidneyInt. 2022; 102(5S): S1S127. 23 NuffieldDepartmentofPopulationHealthRenalStudiesGroup, SGLTInhibitorMeta-AnalysisCardio-RenalTrialists Consortium. Impactofdiabetesontheeffectsofsodiumglucoseco-transporter-2inhibitorsonkidneyoutcomes: collaborativemeta-analysisoflargeplacebo-controlledtrials. Lancet2022; 400: 17881801. 511 SoFtables SupplementaryTableS10 Searchdate NDPH2022: September2022; KDIGO2022: December2021; Updated: April2023 Citationsscreened/included 252/2 studies SupplementaryFigureS6 Clinicalquestion Whatistheeffectofmineralocorticoidreceptoragonists(MRAs)comparedwithplacebo, usualcare, oranactive comparatoramongpeoplewithCKDbutnotT2Dintermsofmortality, progressionofCKD, complicationsof CKD, andadverseevents?
----------------------------------------------------------------------


======================================================================
CHUNK 454 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_180
Content Type: reference
Words: 493
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
KDIGO2022ClinicalPracticeGuidelineforDiabetes dataincluded ManagementinChronicKidneyDisease. KidneyInt. 2022; 102(5S): S1S127. 23 NuffieldDepartmentofPopulationHealthRenalStudiesGroup, SGLTInhibitorMeta-AnalysisCardio-RenalTrialists Consortium. Impactofdiabetesontheeffectsofsodiumglucoseco-transporter-2inhibitorsonkidneyoutcomes: collaborativemeta-analysisoflargeplacebo-controlledtrials. Lancet2022; 400: 17881801. 511 SoFtables SupplementaryTableS10 Searchdate NDPH2022: September2022; KDIGO2022: December2021; Updated: April2023 Citationsscreened/included 252/2 studies SupplementaryFigureS6 Clinicalquestion Whatistheeffectofmineralocorticoidreceptoragonists(MRAs)comparedwithplacebo, usualcare, oranactive comparatoramongpeoplewithCKDbutnotT2Dintermsofmortality, progressionofCKD, complicationsof CKD, andadverseevents? Population AdultsandchildrenwithCKDbutnotdiabetes Intervention SteroidalMRAs(canrenone, eplerenone, spironolactone); nonsteroidalMRAs(esaxerenone, finerenone) Comparator Activecomparator, placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailureandall-causehospitalizations Otheroutcomes: mortality, progressionofCKD, complicationsofCKD, andadverseevents Studydesign RCTs Existingsystematicreview ChungEY, RuospoM, NataleP, etal. Aldosteroneantagonistsinadditiontoreninangiotensinsystemantagonistsfor usedforhandsearching preventingtheprogressionofchronickidneydisease. CochraneDatabaseSystRev. 2020; 10: Cd007004. 923 SoFtables SupplementaryTableS16 (Continuedonfollowingpage) S276 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org methods for guideline development Table44(Continued)Clinical questionsandsystematicreviewtopicsin PICOSformat Chapter3 DelayingCKDprogressionandmanagingitscomplications Searchdate January2020 Citationsscreened/included 106/19 studies SupplementaryFigureS7 Clinicalquestion WhatistheeffectofMRAscomparedwithplacebo, usualcare, oranactivecomparatoramongpeoplewithCKD andT2Dintermsofmortality, progressionofCKD, complicationsofCKD, andadverseevents? Population AdultsandchildrenwithCKDanddiabetesandsubgroupofpeoplewithheartfailure Intervention SteroidalMRAs(canrenone, eplerenone, andspironolactone)andnonsteroidalMRAs(esaxerenoneandfinerenone) Comparator Activecomparator, placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailureandall-causehospitalizations Studydesign RCTs Existingsystematicreviews KidneyDisease: ImprovingGlobalOutcomes(KDIGO)DiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelinefor DiabetesManagementinChronicKidneyDisease. KidneyInt. 2022Nov; 102(5S): S1S127. 23 SoFtables Nosummaryoffindingstable(seeKDIGODiabetesGuidelineDataSupplement) Searchdate December2021 Citationsscreened/included 106/44 studies Clinicalquestion Whatistheeffectofglucagon-likepeptide-1receptoragonists(GLP-1RA)comparedwithplacebo, usualcare, or anactivecomparatoramongpeoplewithCKDbutnotT2Dintermsofmortality, progressionofCKD, complicationsofCKD, andadverseevents? Population AdultsandchildrenwithCKDbutnotdiabetes Intervention GLP-1RA(albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, andtirzepatide) Comparator Activecomparator(e. g. , anotherglucose-loweringagent), placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailureandall-causehospitalizations Studydesign RCTs Existingsystematicreviews KamdarA, SykesR, MorrowA, etal. Cardiovascularoutcomesofglucoseloweringtherapyinchronickidneydisease usedforhandsearching patients: asystematicreviewwithmeta-analysis. RevCardiovascMed. 2021; 22: 14791490. 924 KidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetes ManagementinChronicKidneyDisease. KidneyInt. 2022; 102(5S): S1S127. 23 SoFtables Nosummaryoffindingstable Searchdate Kamdar2021: March2021; KDIGO2022: December2021 Citationsscreened/included 65/0 studies SupplementaryFigureS8 Clinicalquestion WhatistheeffectofGLP-1RAcomparedwithplacebo, usualcare, oranactivecomparatoramongpeoplewith CKDandT2Dintermsofmortality, progressionofCKD, complicationsofCKD, andadverseevents? Population AdultsandchildrenwithCKDanddiabetes; subgroupofpeoplewithheartfailure Intervention GLP-1RA(albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, andtirzepatide) Comparator Activecomparator(e. g. , anotherglucose-loweringagent), placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailureandall-causehospitalizations Studydesign RCTs Existingsystematicreviews KidneyDisease: ImprovingGlobalOutcomesDiabetesWorkGroup. KDIGO2022ClinicalPracticeGuidelineforDiabetes ManagementinChronicKidneyDisease. KidneyInt. 2022Nov; 102(5S): S1-S127. 23 SoFtables Nosummaryoffindingstable(seeKDIGODiabetesGuidelineDataSupplement) Searchdate December2021 Citationsscreened/included 154/19 studies Clinicalquestion Whatistheeffectofuricacidloweringtherapycomparedwithplacebo, usualcare, oranactivecomparator amongpeoplewithCKDandhyperuricemiaintermsofmortality, progressionofCKD, complicationsofCKD, andadverseevents? Population AdultsandchildrenwithCKDandhyperuricemiawithsubgroupsforsymptomaticandasymptomatichyperuricemia Intervention Allopurinol, benzbromarone, febuxostat, lesinurad, oxipurinol, pegloticase, probenecid, rasburicase, sulfinpyrazone, and topiroxostat Comparator Activecomparator(e. g. , anotheruricacidloweringtherapy), placebo, orusualcare Outcomes Criticaloutcomes: kidneyfailure, cutaneousreactions, hypersensitivity, andhepatotoxicity Otheroutcomes: all-causemortality, cardiovascularmortality, eGFR, ACR, cardiovascularevents, andgout Studydesign RCTs Existingsystematicreviews SampsonAL, SingerRF, WaltersGD. Uricacidloweringtherapiesforpreventingordelayingtheprogressionofchronic forhand-searchingand kidneydisease. CochraneDatabaseSysRev2017; 10: Cd009460. 609 updating SoFtables SupplementaryTablesS11andS12 Searchdate March2023 Citationsscreened/included 1859/30 studies SupplementaryFigureS9 (Continuedonfollowingpage) KidneyInternational(2024)105(Suppl4S), S117S314 S277 methods for guideline development www. kidney-international. org Table44(Continued)Clinical questionsandsystematicreviewtopicsin PICOSformat Chapter3 DelayingCKDprogressionandmanagingitscomplications Clinicalquestion Whatistheeffectofaspirincomparedwithplacebointermsoftheprimarypreventionofcardiovascular disease(CVD)andsafetyamongpeoplewithCKD? Population AdultsandchildrenwithCKDatriskforCVD(i. e. , peoplemustnothaveestablishedCVD) Intervention Aspirin Comparator Placebo Outcomes Criticaloutcomes: incidentCVDevents, bleeding(intracranialhemorrhage, majorextracranialhemorrhage, and clinicallyrelevantnonmajorbleeding) Studydesign RCTs Existingsystematicreviews PallikadavathS, AshtonL, BrunskillNJ, etal. Aspirinfortheprimarypreventionofcardiovasculardiseaseinindividuals updated withchronickidneydisease: asystematicreviewandmeta-analysis. EurJPrevCardiol. 2022; 28: 19531960. 925 SoFtables SupplementaryTableS17 Searchdate August2022 Citationsscreened/included 2293/5 studies SupplementaryFigureS10 Clinicalquestion Whataretheeffectsofangiographyorcoronaryrevascularizationcomparedwithmedicaltreatmentamong peoplewithCKDandischemicheartdiseaseintermsofmortality, CVDevents, kidneyfailure, andacutekidney injury(AKI)? Population AdultsandchildrenwithCKDandischemicheartdisease Intervention Angiographyorcoronaryrevascularization Comparator Medicaltreatment Outcomes Criticaloutcomes: all-causemortality, CVDmortality, CVDevents(includingcompositecardiovascularevents, myocardialinfarction, andheartfailure), kidneyfailure, andAKI Otheroutcomes: patient-reportedoutcomes Studydesign RCTs Existingsystematicreviews None SoFtables SupplementaryTableS13 Searchdate March2023 Citationsscreened/included 3521/5 studies SupplementaryFigureS11 Clinicalquestion WhataretheeffectsofnonvitaminKantagonistoralanticoagulants(NOACs)(alsoknownasdirect-actingoral anticoagulantsDOACs)withorwithoutwarfarincomparedwithplaceboorwarfarinaloneamongpeoplewith CKDandatrialfibrillationintermsofstrokeandbleedingrisks? Population AdultsandchildrenwithCKDandatrialfibrillation Intervention NOAC/DOAC(dabigatran, apixaban, edoxaban, rivaroxaban)withwarfarinandNOAC/DOACalone Comparator Warfarin, placebo Outcomes Criticaloutcomes: stroke(includingTIA), bleeding(includingintracranialhemorrhage, majorbleeding, andclinically relevantnonmajorbleeding) Studydesign RCTs Existingsystematicreviews KimachiM, FurukawaTA, KimachiK, etal. Directoralanticoagulantsversuswarfarinforpreventingstrokeandsystemic updated emboliceventsamongatrialfibrillationpatientswithchronickidneydisease. CochraneDatabaseSystRev. 2017; 11: CD011373. 926 SoFtables SupplementaryTablesS14andS15 Searchdate March2023 Citationsscreened/included 3340/7 studies SupplementaryFigureS12 ACR, albumin-to-creatinineratio; AKI, acutekidneyinjury; IQR, intraquartilerange; N/A, notapplicable; PICOS, Population, Intervention, Comparator, Outcomes, Studydesign; RCT, randomizedcontrolledtrial; SCr, serumcreatinine; SoF, summaryoffindings; TIA, transientischemicattack. the searches were initially screened independently by 2 Supplementary Figures S1S12 include PRISMA diagrams members of the ERT.
----------------------------------------------------------------------


======================================================================
CHUNK 455 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_181
Content Type: reference
Words: 468
Medical Entities: GFR,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
926 SoFtables SupplementaryTablesS14andS15 Searchdate March2023 Citationsscreened/included 3340/7 studies SupplementaryFigureS12 ACR, albumin-to-creatinineratio; AKI, acutekidneyinjury; IQR, intraquartilerange; N/A, notapplicable; PICOS, Population, Intervention, Comparator, Outcomes, Studydesign; RCT, randomizedcontrolledtrial; SCr, serumcreatinine; SoF, summaryoffindings; TIA, transientischemicattack. the searches were initially screened independently by 2 Supplementary Figures S1S12 include PRISMA diagrams members of the ERT. One screener was used when the recall for each systematic review. rate of citations promoted to full-text screening reached at A total of 30, 861 citations were screened. Of these, 145 least 90% and then title and abstract screening was stopped RCTs and 232 nonrandomized studies were included in the when the recall rate of citations promoted to full-text was at evidence review (Figure 57). least 95%. Citations deemed potentially eligible at the title Dataextraction. Data extraction, from studies and existing and abstract stage were screened independently by 2 ERT systematic reviews, was performed by a member of the ERT members at the full-text level. At both title/abstract and fulland confirmed by a second member of the ERT. Any differtextscreeningdisagreementsabouteligibilitywereresolvedby ences among members of the ERT were resolved through consensus, and, as necessary through discussion among the discussion. A third reviewer was included if consensus could ERTmembers. not be achieved. Search dates, number of citations that were screened, and Risk of bias of studies and systematic reviews. The majority number of eligible studies are included in Table 44. of reviews undertaken were intervention reviews that S278 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org methods for guideline development Randomized controlled trials identified from databases: Nonrandomized studies (cross-sectional, pre-post, PubMed: 7030 prospective observational, noncomparative): Embase: 5716 PubMed: 4944 Cochrane Central: 6999 Embase: 5196 KDIGO Diabetes 2022 GL: 393 CINAHL: 146 Other reviews: 153 Central: 82 Handsearching: 60 Other reviews: 68 Handsearching: 74 Included RCTs: Included nonrandomized studies: SGLT2: 79 RCTs (278 reports) Biopsy: 65 studies MRA (without type 2 diabetes): 19 RCTs (33 reports) eGFR: 47 studies (48 reports) GLP-1 (without type 2 diabetes): 0 RCTs ACR_PCR: 0 studies Uric acid: 30 studies (32 reports) POC creatinine: 55 studies Aspirin: 5 RCTs POC dipstick: 65 studies (66 reports) Angiography: 5 RCTs (7 reports) NOAC: 7 RCTs (13 reports) Included studies: RCTs: 145 (368 reports) Non-randomized: 232 studies (234 reports) 38 studies included in the analyses Figure57Searchyieldandstudyflowdiagram. ACR, albumin-to-creatinineratio; CINALL, CumulativeIndextoNursingandAlliedHealth Literature; eGFR, estimatedglomerularfiltrationrate; GLP-1, glucagon-likepeptide-1; KDIGO, KidneyDisease: ImprovingGlobalOutcomes; MRA, mineralocorticoidantagonists; NOAC, nonvitaminKantagonistoralanticoagulant; PCR, protein-to-creatinineratio; POC, pointofcare; RCT, randomizedcontrolledtrial; SGLT2, sodium-glucosecotransporter-2. includedRCTs. Forthesereviews, theCochraneRiskofBias2 Allrisk-of-biasassessmentswereconductedindependently tool was used to assess risk of bias for RCTs based on the by 2 members of the ERT, with disagreements resolved by randomization process, deviations from the intended ininternal discussion and consultation with a third ERTmemterventions, missing outcome data, measurement of the ber, as needed. outcome, and selection of the reported results. 927 Evidence synthesis and meta-analysis. Measures of treatment The Quality Assessment of Diagnostic Accuracy Studies effect.
----------------------------------------------------------------------


======================================================================
CHUNK 456 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_183
Content Type: recommendation
Words: 489
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Thegrading chance. Avalue greater than 50% was considered to indicate of the certainty of the evidence for each critical outcome is substantial heterogeneity. 933 also provided in these tables. The SoF tables are available in Grading the certainty of the evidence and the strength of a Appendix C and Appendix D of the Data Supplement guideline recommendation. The certainty of evidence for each published alongside the guideline or at critical outcome was assessed by the ERTusing the GRADE guidelines/ckd-evaluation-and-management/. approach. 934, 935 For outcomes based on data from RCTs, the Updating and developing the guideline stateinitial grade for the certaintyof the evidenceis considered to ments. Recommendations from the KDIGO 2012 Clinical behigh. Thecertaintyoftheevidenceisloweredintheevent Practice Guideline for the Evaluation and Management of of study limitations; important inconsistencies in results Chronic Kidney Disease were considered in the context of across studies; indirectness of the results, including newevidencebytheWorkGroupCo-ChairsandWorkGroup uncertainty about the population, intervention, outcomes members, and updated as appropriate. 1 Practice points were measured in trials, and their applicability to the clinical not yet proposed as a separate category in 2012, so the question of interest; imprecision in the evidence review KDIGO 2024 Work Group considered the following results; and concerns about publication bias. For options: where new evidence did not suggest a change to imprecision, data were benchmarked against optimal graded recommendations, the statements were retained as information size, 936 low event rates in either arm, CIs that graded recommendations; graded recommendations were indicate appreciable benefit and harm (25% decrease and updated where appropriate based on new evidence; existing 25% increase in the outcome of interest), and sparse data recommendations that fit the criteria for practice points (only 1 study), all indicating concerns about the precision were rewritten as practice points, and new guideline of the results. 936 The final grade for the certainty of the statements (both recommendations and practice points) evidence for an outcome could be high (A), moderate (B), were generated for new clinical questions from the 2024 low (C), or very low (D) (Tables 45 and 46). update. S280 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org methods for guideline development Table47KDIGOnomenclatureanddescription forgradingrecommendations Implications Grade Patients Clinicians Policy Level1 Mostpeopleinyoursituationwouldwant Mostpatientsshouldreceivethe Therecommendationcanbeevaluated Werecommend therecommendedcourseofaction, and recommendedcourseofaction. asacandidatefordevelopingapolicy onlyasmallproportionwouldnot. oraperformancemeasure. Level2 Themajorityofpeopleinyoursituation Differentchoiceswillbeappropriatefor Therecommendationislikelytorequire Wesuggest wouldwanttherecommendedcourse differentpatients. Eachpatientneeds substantialdebateandinvolvementof ofaction, butmanywouldnot. helptoarriveatamanagement stakeholdersbeforepolicycanbe decisionconsistentwiththeirvalues determined. andpreferences. KDIGO, KidneyDisease: ImprovingGlobalOutcomes. Grading the strength of the recommendations. The strength pathway, were considered in grading the strength of a ofarecommendationwasgradedbytheWorkGroupasLevel recommendation. 937 The following resources were 1orLevel2(Table47). Thestrengthofarecommendationwas considered: direct healthcare costs, nonhealthcare resources determined by the balance of benefits and harms across all (such as transportation and social services), informal critical and important outcomes, the grading of the overall caregiver resources (e. g. , time of family and caregivers), and certainty of the evidence, patient values and preferences, changes in productivity. No formal economic evaluations, resource use and costs, and other considerations (Table 48). including cost-effectiveness analysis, were conducted. Balanceofbenefitsandharms. TheWorkGroupdetermined Practice points.
----------------------------------------------------------------------


======================================================================
CHUNK 457 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_185
Content Type: reference
Words: 473
Medical Entities: CKD,GFR
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
As noted, although resource riences for the development of these guidelines. However, in implications were considered in the formulation of recomthedevelopmentoftheseguidelines, noscopingexercisewith mendations, no economic evaluations were undertaken. S282 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org biographic and disclosure information Biographic and disclosure information Adeera Levin, MD, FRCPC (Work Paul E. Stevens, MB, FRCP, RCPathME Group Co-Chair), is a professor of (Work Group Co-Chair), is consultant medicine, Head of the Division of nephrologist and medical examiner at Nephrology at the University of East Kent Hospitals University National British Columbia, and consultant Health Service (NHS) Foundation Trust, nephrologist at Providence Health Kent and Canterbury Hospital in the UK. Care/StPaulsHospital, inVancouver HewasappointedasConsultantPhysician Canada. and Nephrologist to the Royal Air Force She is the Executive Director of in 1990, returning to the NHS in April the BC Renal Agency, which oversees the care, planning, and 1995 as Clinical Director of the Kent Kidney Care Centre, budgets for kidney services in the province of British implementing a program of modernization and development Columbia. and establishing a predominantly clinical research program in She is active in international activities across the speckidney disease. He has served on several national and college trumofkidneyactivitiesandhasservedinleadershiprolesat committees, isaformer PresidentoftheBritishRenalSociety, theInternationalSocietyofNephrology(ISN), mostrecently andwasanadvisortotheDepartmentofHealthforbothkidney as President (20152017). She was one of the founding disease and national implementation of eGFR reporting. His members of the Declaration of Istanbul Custodian Group interest in guideline development began with commissioning (DICG) and served as one of the first Co-Chairs of that guidanceforthedevelopmentofkidneyservicesandthefirstUK group. She has been active in both ISN and DICG conCKDguidelinein2005. Heservedasclinicaladvisorandchairto cerning advocacy for patient rights for equitable access to severaloftheUKNationalInstituteforHealthandCareExcelcare, and in the prevention of exploitation of vulnerable lence (NICE) Clinical Guidelines, was a member of the UK populations. consensuspanelformanagementofAKI, andchairedtheNICE Her major research interests include nontraditional risk CKDtopicexpertreferencegroupandtheproductionofNICE factorsforCVDinpeoplewithCKDandprogressionofCKD Quality Standards in CKD. He is the current treasurer of the variability, as well as models of care. She has over 600 peerKidneyDisease: ImprovingGlobalOutcomes(KDIGO)Execureviewedpublicationsandnumerousbookchapters. Sheisthe tive Committee and was privileged to have co-chaired the Principal Investigator on a large national Strategy for PatientKDIGO2012ClinicalPracticeGuidelinefortheEvaluationand Oriented Research (SPOR) network grant Can-SOLVE CKD ManagementofChronicKidneyDisease. focusing on patient-oriented research. She collaborates with PES declared no competing interests. investigators across Canada and internationally. She has received numerous teaching and research awards SofiaB. Ahmed, MD, MMSc, FRCPC, fromCanadianSocietyofNephrology, KidneyFoundationof isaprofessorinthefacultyofmedicine Canada, andBritishColumbiaHealthResearchInstitute, and and dentistry at the University of was inducted as a fellow into the Canadian Academy of Alberta and the University of Alberta Health Sciences. For her contributions to the life of CanaChair inSex and Gender. Dr. Ahmed dians, she was awarded the highest civilian honor, the Order completedherMDandinternalmedof Canada in 2015. icine residency at the University of AL reports receiving consultancy fees from AstraZeneca, Toronto and a nephrology fellowship Bayer, Janssen, Novo Nordisk, OccuRx, and Otsuka; atBrighamandWomensandMassaresearch support from AstraZeneca, Boehringer Ingelheim, chusettsGeneralHospitalsinBoston. ShecompletedhermasCanadian Institutes of Health Research (CIHR), GlaxotersinmedicalsciencesatHarvardUniversity.
----------------------------------------------------------------------


======================================================================
CHUNK 458 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_186
Content Type: evidence
Words: 496
Medical Entities: CKD,hypertension,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
ShecompletedhermasCanadian Institutes of Health Research (CIHR), GlaxotersinmedicalsciencesatHarvardUniversity. Therecipientof SmithKline, National Institutes of Health (NIH), and the 2022 Hypertension Canada Senior Investigator Award, the Otsuka; speaker honoraria from AstraZeneca, Bayer, and 2021 Canadian Medical Association May Cohen Award for Boehringer Ingelheim; and funding for the development of WomenMentors, anda2020AmericanSocietyofNephrology educational presentations for AstraZeneca, Bayer, BoehDistinguishedMentorAward, Dr. Ahmedisstrongproponentof ringer Ingelheim, and Novo Nordisk. the importance of mentorship and fostering excellence in the Monies paid to institution. nextgenerationofresearchers. KidneyInternational(2024)105(Suppl4S), S117S314 S283 biographic and disclosure information www. kidney-international. org Dr. Ahmed is clinician-scientist with a focus on sex and andyoungadultswithkidneytransplants. Dr. Fosterhasbeen gender differences in human kidney and cardiovascular physfunded by CIHR and NIH to study immunosuppressive iologyandclinicaloutcomes. SheistheChairoftheCanadian medication adherence and graft outcomes in adolescent and Institutes of Health Research Institute of Gender and Health young adult kidney transplant recipients, whom she has Advisory Board, a member of the Canadian Medical Associaidentified to be at particularly high risk of graft loss. She has tionJournalGoverningCouncilandthePresident-Electforthe also highlighted important differences in kidney transplant Organization for the Study of Sex Differences. outcomes by recipient sex, the magnitude and direction of SBA reports receiving research support for CIHR, Heart and whichvary by recipient age and bydonor sex. Dr. Foster has Stroke Foundation, and NIH; being a member of the CIHR over 110 peer-reviewed publications and is an Associate EdInstitute of Gender and Health Advisory Board, the Canadian itor of the international journal Transplantation. She MedicalAssociationJournalGovernanceCouncil(volunteer), the contributed to the KDOQI Clinical Practice Guideline for Data Safety Monitoring Board Member for Adolescent Type 1 Nutrition in Children with CKD: 2008 Update and to the diabetes Treatment with SGLT2i for hyperglycEMia hyPerKDIGO 2020 Clinical Practice Guideline on the Evaluation filTrationTrial(ATTEMPT)trial(trialsponsoredbytheCIHR and Management of Candidates for Kidney Transplantation. andJuvenileDiabetesResearchFoundationCanada)(volunteer); She is also Chair of The Transplantation Societys Women in andservingasPresident-Elect, OrganizationfortheStudyofSex Transplantation initiative. Differences(volunteer). BFreportsreceivingresearchsupportfromCIHRandNIH, Monies paid to institution. and serves as Chair of the Women in Transplantation Initiative of The Transplantation Society. Monies paid to institution. Juan Jesus Carrero, Pharm, PhD Pharm, PhD Med, is a professor of cardio-renal epidemiology at KarAnna Francis, BSci, MBBS, FRACP, olinska Institutet. His research inCF, MMed, PhD, is a clinician volves the analysis of large routineresearcher at the University of care databases with the goal to Queensland and at Queensland improve the identification and manChildrens Hospital, Australia. She agement of people with CKD. has broad clinical experience in peJuan Jesus has published over 500 diatric nephrology and young adult original publications on various asCKDcarewithclinicalappointments pectsoftheepidemiologyofCKD, withemphasisonmodifiable at Queensland Childrens Hospital riskfactors: diet, lifestyle, processesofcare, andinappropriate andtheMaterYoungAdulthospital. Dr. Franciswasawarded use of medications. Juan Jesus has served in previous clinical a prestigious Churchill Fellowship, traveling to Germany, guidelinesfromKDIGO, KDOQI, andtheEuropeanSocietyfor England, and the US to explore transition programs to adult Clinical Nutrition and Metabolism (ESPEN) and currently careforyoungkidneytransplantrecipients; shehassetupthe servesasco-directoroftheeducationaloutreachprogramatthe pediatrickidneytransitionserviceandisco-leadintheyoung International Society of Renal Nutrition and Metabolism adult kidney transplant clinic in Queensland. Dr. Francis has (ISRNM). HehasreceivedtheResearchExcellenceAwardofthe publishedover50articlesonresearchareassuchasqualityof EuropeanRenalAssociation(ERA)andtheKoppleawardofthe life of children with CKD and long-term outcomes for chilUSNationalKidneyFoundation(NKF).
----------------------------------------------------------------------


======================================================================
CHUNK 459 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_187
Content Type: general
Words: 453
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Dr. Francis has (ISRNM). HehasreceivedtheResearchExcellenceAwardofthe publishedover50articlesonresearchareassuchasqualityof EuropeanRenalAssociation(ERA)andtheKoppleawardofthe life of children with CKD and long-term outcomes for chilUSNationalKidneyFoundation(NKF). dren with CKD, including transplantation outcomes and JJC reports receiving research support from Amgen, Astellas, survival. She is an associate editor at Kidney International AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme, Reports and is on the editorial board of Kidney International, NovoNordisk, andViforPharma; speakerhonorariafromAbbott, JournalofNephrology, andTransplantInternational. Shewasa Baxter, andFreseniusKabi; andservingasaboardmemberfor member of the inaugural ISN Emerging Leaders Program. AstraZeneca, Baxter, FreseniusKabi, andGlaxoSmithKline. AF declared no competing interests. Bethany Foster, MD, MSCE, is a Rasheeda K. Hall, MD, MBA, MHS, professor of pediatrics, Chair of the is an associate professor of medicine Department of Pediatrics at McGill in the Division of Nephrology at University and Pediatrician-in-Chief DukeUniversity School of Medicine, at the McGill University Health Durham, NC, USA. Dr. Hallreceived Centre. She is a pediatric nephroloa medical degree from Vanderbilt gist and a clinical epidemiologist University School of Medicine. She with a primary research interest in trained in internal medicine and the long-term outcomes of children nephrology at Duke University. She S284 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org biographic and disclosure information practices nephrology at the Durham Veterans Affairs adiposity and its related risk factors, and how these may Healthcare System, leading a geriatric nephrology clinic. interlink to also cause cardiovascular disease. He is also This innovative clinic incorporates geriatric assessment to focusing on how novel blood and urine biomarkers could inform CKD management and dialysis decision-making better assess effects of treatments on the kidney and predict conversations. Her research focuses on the integration of progression. geriatric principles into kidney care settings. Her research WGH reports receiving research support from Boehringer has also included observational cohort studies of physical Ingelheim and Eli Lilly, and serving on the Data Monifunction, frailty, and resilience; qualitative studies on toring Committee for Bayer (unpaid). quality of life and geriatric care, pharmacoepidemiology of Monies paid to institution. potentially inappropriate medications (PIMs), deprescribing intervention development, and geriatric models of care. She recently started the Kidney Disease Aging Research Guy Hill was diagnosed with IgAN Collaborative, a US-based initiative to lay the foundation in 1996 at the age of 35 and was in for collaboration across multiple institutions on geriatric kidney failure within 2 years. After a nephrology research. She also serves on the editorial board 2-year period of peritoneal dialysis, for American Journal of Kidney Diseases, Clinical Journal of he had a transplant in 2001. This the American Society of Nephrology, and Journal of the lasted until 2008 and then he did 4 American Geriatrics Society. years of home hemodialysis before a RKH reports receiving consultancy fees from Bayer and further transplant in 2012 that failed United Health Group; research support from American toworkforafurther9months.
----------------------------------------------------------------------


======================================================================
CHUNK 460 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_188
Content Type: evidence
Words: 456
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
This the American Society of Nephrology, and Journal of the lasted until 2008 and then he did 4 American Geriatrics Society. years of home hemodialysis before a RKH reports receiving consultancy fees from Bayer and further transplant in 2012 that failed United Health Group; research support from American toworkforafurther9months. Once Society of Nephrology Foundation for Kidney Research, awake, this transplant lasted until 2016 and then followed a National Institute on Aging, and Robert Wood Johnson further4yearsofhomehemodialysis, whichendedwithalive Foundation; and serving on the Advancing Kidney transplant from his brother in 2019, which is working sucHealth through Optimal Medication Management cessfully today. (AKHOMM). He has taken an active interest in patient advocacy and Monies paid to institution. support since 1999, mainly locally with his Manchester KidneyPatientAssociationofwhichheischair. Heisalsoonthe Patient Advisory Group for the National Kidney Charity, WilliamG. Herrington, MA, MBBS, Kidney Care UK. He has also been patient representative on MD, FRCP, is professorof trials and severalNICEassessmentsofnewdevicesanddrugsforpeople epidemiologyofkidneydiseaseatthe with CKD. Nuffield Department of Population He has attended a full range of kidney conferences and Health, University of Oxford and a professional discussion groups at a local, regional, and napracticing Honorary Consultant tional level on health service organizations that affect kidney Nephrologist atOxfordKidney Unit. patients. He jointly leads the Renal Studies His contact with many patients and professionals from all Group, which he joined in 2010 as a areas of the kidney service has given him a broad knowledge Clinical Research Fellow and trained on landmark kidney of all stages of kidney care and its challenges. trials (SHARP, 3C, and UKHARP3). GH declared no competing interests. He is Chief Investigator of the EMPA-KIDNEY trial, which tested the effects of empagliflozin 10 mg versus placebo on cardiorenal outcomes in 6609 people with CKD LesleyA. Inker, MD, MS, FRCP(C), with and without diabetes. He is on a number of clinical is professor of medicine at Tufts practice guideline working groups and co-chairs the UK University School of Medicine, and Kidney Association guideline group responsible for recan attending physician and Medical ommendations on the use of SGLT-2 inhibitors in adults Director of the Kidney and Blood with kidney disease. He is also interested in trial methodPressure Center in the Division of ology and has chaired the UK Renal Trials Network since Nephrology at Tufts Medical Center. 2020. Dr. Inkers primary research inHisepidemiologicalresearchaimstobetterunderstandthe terests are in kidney function meakey determinants of kidney disease development and prosurement and estimation, alternative endpoints for clinical gression(anditsassociatedcomplications)usingobservations trials of kidney disease progression, and epidemiology and from large blood-based prospective cohorts across a wide outcomes related to CKD. She is co-director of the Chronic range of different populations. He has a particular focus on Kidney Disease Epidemiology collaboration (CKD-EPI). Dr. KidneyInternational(2024)105(Suppl4S), S117S314 S285 biographic and disclosure information www. kidney-international.
----------------------------------------------------------------------


======================================================================
CHUNK 461 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_189
Content Type: evidence
Words: 491
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
She is co-director of the Chronic range of different populations. He has a particular focus on Kidney Disease Epidemiology collaboration (CKD-EPI). Dr. KidneyInternational(2024)105(Suppl4S), S117S314 S285 biographic and disclosure information www. kidney-international. org Inker has worked with NKF leadership on multiple public function using estimated GFR and cystatin C and the evaluhealthinitiativesforCKDcareintheUnitedStates, includinga ation of renal bone disease; he is coauthor of more than 100 member of the recent joint NKF-American Society of peer-reviewed papers in this area. He has been a member of Nephrology (ASN) task force on reassessing use of race in national and international guideline development groups diagnosisofCKD. Dr. Inkeristheinauguralchairofthesteering including NICE and KDIGO CKD guidelines and the committeefortheNKFPatientNetwork. Shehaschaired, orled Department of Health initiative to roll out eGFR across Enanalytical teams, for several scientific workshops related to gland. He is a former editor-in-chief of Annals of Clinical surrogateendpointsforCKDprogression. Sheisaninvestigator Biochemistry. on several trials of kidney disease progression. She has also ELreportsreceiving researchsupportfromNationalInstitute received many honors and awards, including the Garabed of Health Research. Eknoyan Award from the NKF, the ASN mid-career research Monies paid to institution. award, andtheMiltonO. andNatalieV. ZuckerPrize. LAI reports receiving consultancy fees from Diamtrix and PeterLin, MD, CCFP, isthedirector Tricida; and research support from Chinook, NIH, Naof primary care initiatives at the Cational Kidney Foundation, Otsuka and Reata. nadian Heart Research Centre. He Monies paid to institution. hasabusyfamilypracticeinToronto, Canada. He is also a contributing Rmeyza Kazanco(cid: 1)glu, MD, is the author to the Canadian Diabetes presidentandaprofessorofnephrology Guidelines 2013 and 2018 on the _ atBezmialemVakifUniversityIstanbul, vascular protection section and an Turkey. She received her medical associate editor for the Elsevier Web degreefromIstanbulUniversitySchool PortalPractice Update Primary Care. Dr. Lin has lectured _ ofMedicine, Istanbul. extensively on diabetes and its complications, especially She served as a council member of CKD, and he has worked with KDIGO to help improve care ISN as well as the chair of East and for people with CKD. He has also been tracking and Central Europe Regional Board. She providing information on COVID-19 to the public since the was also a member of the International Society of Peritoneal beginningofthepandemic. Hereachesouttothepublicwith DialysisMiddleEastchapterboard. ShecurrentlychairstheISN his role as a medical contributor to the Canadian BroadfellowshipcommitteeandisamemberofbothISNandTurkish castingCorporation(CBC)whichisthenationalnewsagency Society of Nephrologys Renal Disaster Preparedness Working in Canada. groups. She also serves as a member at board of councilors at PL reports receiving consultancy fees from AstraZeneca, DICG. Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, and Dr. Kazanco(cid: 1)glu isthe editor-in-chiefof Turkish Journalof Novo Nordisk; speaker honoraria from AstraZeneca, Bayer, Nephrology. Boehringer Ingelheim, Eli Lilly, Janssen, Merck, and Novo Her main areas of interest are glomerular disease, home Nordisk; funding for development of educational pretherapies especially peritoneal dialysis, and disaster/conflict sentations for AstraZeneca, Bayer, Boehringer Ingelheim, Eli medicine. She has participated in previous KDIGO ControLilly, Janssen, Merck, and Novo Nordisk; and serving as the versies Conferences. Associate Editor of Elsevier Online Practice Update Primary RK reports receiving speaker honoraria from Astellas and Care. Baxter Healthcare. Monies paid to institution.
----------------------------------------------------------------------


======================================================================
CHUNK 462 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_190
Content Type: general
Words: 470
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
She has participated in previous KDIGO ControLilly, Janssen, Merck, and Novo Nordisk; and serving as the versies Conferences. Associate Editor of Elsevier Online Practice Update Primary RK reports receiving speaker honoraria from Astellas and Care. Baxter Healthcare. Monies paid to institution. Magdalena Madero, MD, is a professor of medicine and the chief of Edmund Lamb, PhD, FRCPath, is nephrology at the National Heart consultant clinical scientist and clinInstitute in Mexico City. She was icaldirectorofpathologyatEastKent trained in Internal Medicine at St Hospitals University NHS Trust, ElisabethsMedicalCenterinBoston, Canterbury, Kent, UK. He has a MA, and then underwent her special interest in kidney disease and nephrology training at Tufts Medical undertook his PhD in kidney CenteralsoinBoston, MA. Shewent research at St Bartholomews HospibacktoMexicoCityin2007whereshejoinedthenephrology tal, London. His research interests staff at the National Heart Institute and became the Head of relate to the use of biochemical markers to diagnose and the Nephrology Division in 2011. Dr. Maderos research inmonitor kidney disease, including the assessment of kidney terests include CKD progression, complications, and S286 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org biographic and disclosure information outcomes, CKD of unknown origin and hemodialysis. She Morerecentlyshehasbeeninvolvedinthedevelopmentof has over 100 publications and 7000 citations. She was awarthe Centre for Quality, Innovation and Safety, in London, ded the Miguel Aleman award in 2015, given to the most Ontarioaswellasobtainingfundingtoresearchtheevolution outstanding young researcher in the country. As part of her ofvirtualhealthcareduringandafterpandemicandhow this educational activities, she runs the largest kidney fellowship may impact on future models of healthcare. programs in the country at the National Heart Institute NM declared no competing interests. (affiliatedtothemainNationalMexicanUniversityUNAM) in addition to teaching the nephrology course at the undergraduate Panamerican University medical school. She enjoys Kelly Morrow, MS, RDN, CD, patient care and is active in taking care of people with CKD. FAND, is a registered dietitian ShewastheformerPresidentofoneoftheMexicanSocieties nutritionist and fellow of the ofNephrology (IMIN) andservedasInternationalEditor for Academy of Nutrition and Dietetics. the American Journal of Kidney Diseases (20162021), as a Having autosomal dominant polymember of the KDIGO Executive Committee (20182021). cystic kidney disease as well as a SheservedastheChairfortheISNforLatinAmericaandthe kidney transplant has shaped her Caribbean (20192023) and is a council member for the interest in nutrition and commitSociety of Peritoneal Dialysis (20222024). She will become ment to providing compassionate an associate editor for Journal of the American Society of care for her kidney patients. She Nephrology in 2024. has been on the faculty at Bastyr University since 2002 MMreportsreceivingconsultancyfeesfromAstraZeneca, Bayer, where she has supervised clinical rotations in the UniandBoehringerIngelheim; researchsupportfromAstraZeneca, versitys community health clinic and taught in the DeBayer, BoehringerIngelheim, RenalResearchInstitute, and partments of Nutrition and Exercise Science, Naturopathic Tricida; speakerhonorariaandtravelfromAstraZeneca; and Medicine, Midwifery and Acupuncture and East Asian funding for expert testimony for AstraZeneca, Bayer, and Medicine. She is an affiliate dietitian with the Osher Center BoehringerIngelheim. for Integrative Medicine at the University of Washington Monies paid to institution.
----------------------------------------------------------------------


======================================================================
CHUNK 463 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_191
Content Type: evidence
Words: 494
Medical Entities: CKD,GFR,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
She is an affiliate dietitian with the Osher Center BoehringerIngelheim. for Integrative Medicine at the University of Washington Monies paid to institution. Department of Family Medicine, is a past Chair of Dietitians in Integrative and Functional Medicine through the Academy of Nutrition and Dietetics, and is a Co-Editor of Natasha McIntyre, PhD, is a cliniKrause and Mahans Food and the Nutrition Care Process cian scientist in London, Ontario. textbook. She has published and been an invited speaker She qualified as a nurse in 1991 in on topics related to integrative nutrition and dietary supLondon, UK, where she specialized plements and currently practices clinical nutrition in Seatinnephrologynursingandworkedin tle, Washington. theNHS, holdinganumberofsenior KM declared no competing interests. nursing leadership roles, until moving to Canada in 2014. Whilst in the UK, she completed Glenda Roberts was an information her PhD at the University of Nottingham, funded by a technology executive with 35 years researchfellowshipfromKidneyResearchUKandtheBritish of experience with the Global 100 Renal Society, focusing on people in primary care with CKD corporations, like Microsoft and G3, recruiting and following a cohort of 1741 people (the others before joining the University Renal Risk in Derby cohort study). Together with postof Washington (UW) in 2018 as the doctoral work, she has disseminated discoveries and coDirector of External Relations Paauthored scientific papers in a number of peer-reviewed tientEngagementfortheUWKidney nephrology journals. Research Institute and the UW Throughout her career she has been actively involved in Center for Dialysis Innovation (CDI); and the Chief Operaquality improvement for people with CKD or AKI and has tions and Strategy Officer for UWs Justice, Equity, Diversity experience of employing key quality improvement methand Inclusion Center for Transformative Research. odologies in healthcare settings on a local, national, and A passionate activist for research and people living with international scale; working with the NICE and the Nakidney diseases, she has received numerous awards and tional Patient Safety Agency in the UK and the Dialysis recognition for her work in kidney health. She was 1 of 2 Outcomes and Patient Patterns Study (DOPPS) global patients who served on the National Kidney Foundation research collaborative. (NKF)American Society of Nephrology (ASN) Task Force: KidneyInternational(2024)105(Suppl4S), S117S314 S287 biographic and disclosure information www. kidney-international. org Reassessing the Use of Race in Diagnosing Kidney Disease Elke Schaeffner, MD, MSc, is a that resulted in the removal of race from the estimated board-certified nephrologist and an glomerular filtration rate (eGFR) formula. Recently NKF epidemiologist at the Institute of announced that Glenda is the most recent recipient of the Public Health, CharitUniCeleste Lee Patient Engagement Award, the highest honor versittsmedizin Berlin where she given by NKF to a distinguished kidney patient who exemholdsaprofessorshipforNephrology plifies NKFs mission and Celestes legacy of putting patients and Health Care Research. She at the center of all aspects of healthcare through their studiedMedicineattheUniversityof involvementwithNKFandcommunitypartners. In2022, the Freiburg, Germany and obtained her ASN honored her with its highest award, the Presidents Master of Science in Epidemiology at the Harvard School of Medal.
----------------------------------------------------------------------


======================================================================
CHUNK 464 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_192
Content Type: reference
Words: 496
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
She at the center of all aspects of healthcare through their studiedMedicineattheUniversityof involvementwithNKFandcommunitypartners. In2022, the Freiburg, Germany and obtained her ASN honored her with its highest award, the Presidents Master of Science in Epidemiology at the Harvard School of Medal. She was the 2023 Accelerate Innovation spokesPublicHealth, Boston, USA. Dr. Schaeffnersprimaryfieldsof person for the Were United 4 Kidney Health campaign, research are renal epidemiology and aging, with a particular whichinviteshealthcareprofessionalstojointhemovement focus on CKD in an aging society as well as biomarkers for to shift their focus from kidney failure to kidney health. assessingkidneyfunction. Sheisprincipalinvestigator(PI)of With her CDI team, she won a KidneyX Redesign Dialysis the Berlin Initiative Studyapopulation-based cohortstudy Phase 1 prize for The Ambulatory Kidney to Improve investigating the epidemiology of CKD in persons aged 70 Vitality (AKTIV). The Kidney Week 2021 Celeste Castillo over the course of several years. Dr. Schaeffners engagement LeeMemorial Lecturer, GlendaalsoreceivedthePresidents in education has made her one of the leading figures in Volunteer Service Awards from President Donald J. Trump launching a new masters degree program (MScPH) at the and President Joseph R. Biden, in 2020 and 2022, Berlin School of Public Health where she is deputy director. respectively. Since the beginning of 2022, Dr. Schaeffner has joined the Glendahasbeeninvolvedinamyriadofregional, national, editorial board of AJKD as international editor. She was and international, transformative kidney healthcare initiaawardedtheASNdistinguishedleaderawardin2022. Alsoin tives. Manyofthesearefocusedondevelopingnewinnovative 2022, Dr. Schaeffner was elected an executive board member treatments and therapies to make life better for people living of the German Society of Nephrology. with kidney diseases and the cardio-kidney-metabolic synES reports receiving consultancy fees from AstraZeneca; drome. In addition to being involved with a number of research support from Bayer AG and E. N. D. I. Stiftung; KDIGO (Kidney Disease: Improving Global Outcomes) inispeaker honoraria from Verband dt. Nierenzentren; and tiatives, she serves on the Board of Directors for the Kidney serving on the Executive Board of the German Society of HealthInitiative(KHI), apartnershipbetweentheUSFood Nephrology and the Editorial Board of National Kidney Drug Administration and ASN, whose mission is to catalyze Foundation. innovationandthedevelopmentofsafeandeffectivepatient- Monies paid to institution. centered therapies for people living with kidney diseases. Glenda has been actively involved with and has a leadership Michael Shlipak, MD, MPH, is the position in several research projects, including the Kidney co-founder and scientific director of Precision Medicine Project (KPMP), the APOL1 Long-term the Kidney Health Research CollabKidney Transplantation Outcomes Network (APOLLO), the orative (KHRC) at the University of BLOod Sugar Sensing On Maintenance dialysis (BLOSSOM), California, San Francisco (UCSF) the Biomarker Data Repository (BmDR) and numerous paand the San Francisco Veterans Aftient advisory committees supported by federal programs, fairs Healthcare System (SFVAHCS), pharmaceutical companies, and other public and private where he also serves as the associate funders. Since 2018, she has authored/co-authored or been chief of medicine for research featured in over 35 publications. development. At SFVAHCS, Dr. Shlipak previously served as GR declared no competing interests. thedivisionchiefforGeneralInternalMedicinefrom2004to 2018; at UCSF, he is professor of medicine, epidemiology Dharshana Sabanayagam, MD, biostatistics.
----------------------------------------------------------------------


======================================================================
CHUNK 465 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_193
Content Type: evidence
Words: 499
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Since 2018, she has authored/co-authored or been chief of medicine for research featured in over 35 publications. development. At SFVAHCS, Dr. Shlipak previously served as GR declared no competing interests. thedivisionchiefforGeneralInternalMedicinefrom2004to 2018; at UCSF, he is professor of medicine, epidemiology Dharshana Sabanayagam, MD, biostatistics. Dr. ShlipakstrainingcomprisedadegreeinHisFRACP, is an adult nephrologist, tory from Dartmouth College, followed by Harvard Medical workingasaPost-GraduateFellowat School, andtheHarvardSchoolofPublicHealth. Hecompleted Westmead Hospital, Sydney, internal medicine residency and a General Internal Medicine Australia. She is also enrolled in a fellowshipatUCSF. Hisresearchactivitiesinvolvethedetection Master of Philosophy with the Uniandthedeterminantsofkidneydisease, anditsassociationwith versity of Sydney, with a focus on adverse outcomes, including cardiovascular disease. He has optimization of dialysis initiation in particularlybeenapioneerontheuseofcystatinCasanovel people with kidney failure. indicatorofkidney functionanditspotential toimproveunDS declared no competing interests. derstandingofkidneydiseaseepidemiologyandclinicalcare. S288 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org biographic and disclosure information For that body of work, Dr. Shlipak was awarded the John Navdeep Tangri, MD, PhD, Blair Barnwell Award in 2018 from VA Clinical Science FRCP(C), is an attending physician Research and Development Service. Much of his current and professor in the Division of research is focused upon novel diagnostic opportunities that Nephrology, Department of Internal utilizeurineproteinstocharacterizechronicandacutekidney Medicine and the Rady Faculty of diseases. Dr. Shlipaksresearchhasbeencontinuously funded Community Health Sciences at the by NIH grants for the past 22 years, in addition to research University of Manitoba. Dr. Tangris grants from VA Health Services Research and Development, research program is clinical, transthe Robert Wood Johnson Foundation, the American Heart lational, and focused on improving Association, andtheAmericanFederationforAgingResearch. clinical decision-making for people with advanced CKD. He Dr. Shlipak is the author of over 500 peer-reviewed manudeveloped and validated the Kidney Failure Risk Equation scripts. Inaddition, Dr. Shlipakwasawriting memberof the (KFRE) to predict the need fordialysis in patients with CKD KDIGO 2012 Clinical Practice Guideline for the Evaluation and is presently engaged in multiple validation and impleand Management of Chronic Kidney Disease, and he is a mentation efforts to increase the uptake of the KFRE. memberforthe2024updateofthisguideline. Healsoserved In addition, Dr. Tangri is conducting a large prospective as Co-Chair and lead author for the KDIGO 2019 Controstudy on frailty, physical, and cognitive function in advanced versies Conference entitled Early Identification and InterCKD, as well as leading a multinational randomized trial on vention in CKD. thesafetyandefficacyofnewtherapiesinthispopulation. He MS reports receiving research support from Bayer, NIH has published over 350 manuscripts, presented at multiple (NHLBI, NIA, NIDDK), VA Health Services Research national and international scientific meetings, and is a Development, and VA Clinical Science Research Develrecipient of the CIHR New Investigator Award and a CIHR opment; speaker honoraria from AstraZeneca, Bayer, and Foundation grant. Boehringer Ingelheim; and funding for expert testimony for NTreportsreceivingconsultancyfeesfromAstraZeneca, Bayer, Hagens Berman International Law Firm. Boehringer Ingelheim, GlaxoSmithKline, Janssen, Otsuka, Monies paid to institution. ProKidney, and Roche; research support from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen; funding for development of educational presentations for AstraZeneca; Rukshana Shroff, MD, FRCPCH, having stock/stock options from Clinpredict, Klinrisk, MarPhD, is a professor of pediatric izyme, ProKidney, Pulsedata, andQuanta; andapatentfora nephrology at Great Ormond Street microfluidicdeviceformeasuringACRatpointofcare.
----------------------------------------------------------------------


======================================================================
CHUNK 466 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_194
Content Type: evidence
Words: 465
Medical Entities: CKD,dialysis
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
ProKidney, and Roche; research support from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen; funding for development of educational presentations for AstraZeneca; Rukshana Shroff, MD, FRCPCH, having stock/stock options from Clinpredict, Klinrisk, MarPhD, is a professor of pediatric izyme, ProKidney, Pulsedata, andQuanta; andapatentfora nephrology at Great Ormond Street microfluidicdeviceformeasuringACRatpointofcare. Hospital for Children and University Monies paid to institution. College London, UK. Her research focuses on bone and cardiovascular diseaseinchildhoodCKD, aiming to Teerawat Thanachayanont, MD, improve outcomes for children on MSc, is a senior nephrologist at dialysis. She has led several Bhumirajanagarindra Kidney Instiinternational multicenter trials in the field. tute, Bangkok, Thailand. He graduDr. Shroff is co-editor for the 8th edition of Pediatric ated Doctor of Medicine from Nephrology, the definitive textbook in our field. She is the Mahidol University, Thailand, and Scientific Chair for the European Society for Pediatric did internal medicine training at Nephrology (ESPN) meeting in 2023. She has received a Siriraj Hospital, Mahidol University, prestigious senior fellowship from the National Institute for Thailand. He has postgraduate HealthResearch, servedasamemberoftheKDIGOExecutive traininginNephrologyattheUniversityofBritishColumbia, Committee, and participated in international guideline Canada, and has done a 1-year training in independent committees through KDIGO, NICE, and ESPN. She is chair dialysis at the University of British Columbia, Canada. of the ESPN Dialysis working group and represents pediatric He is currently the head of the CKD clinic and Peritoneal dialysis at the ERA. She has developed the Paediatric Renal Dialysis unit of Bhumirajanagarindra Kidney Institute HosNutrition Taskforce, and co-chairs the ISN Sister Renal pital. His clinical work includes management of predialysis Centre Program. CKD, peritoneal dialysis, and hemodialysis patients. He also RS reports receiving consultancy fees from AstraZeneca and initiated the in-center nocturnal hemodialysis program in Fresenius Medical Care; research support from Fresenius Thailand. For academic work, he is an adjunct clinical Medical Care and Vitaflo; speaker honoraria from Amgen instructor at Chulabhorn Royal Academy, Thailand, and a and Fresenius Medical Care. lecturer at the Nephrology Society of Thailand and Royal Monies paid to institution. College of Family Physicians of Thailand. KidneyInternational(2024)105(Suppl4S), S117S314 S289 biographic and disclosure information www. kidney-international. org His research interests focus on the prevention and manChih-Wei Yang, MD, is the Vice agement of CKD in both urban and rural settings and President of Chang Gung University, improving dialysis-related outcomes in people receiving and he is a leader in the field of peritoneal dialysis and hemodialysis. His recent research on medicine and nephrology in Taiwan. integratedcaremodelsforCKDmanagementinruralareasof HehasheldnumerousrolesatChang Thailand has made a great contribution to the CKD manGung University and Chang Gung agement healthcare policy in Thailand. He and his research MemorialHospital, includingserving team are continuing implementation of a national integrated as Dean of the College of Medicine caremodel program for CKD management inthe ruralareas and founding the Chang Gung of Thailand. KidneyResearchCenter. Hisresearch, particularlyfocusedon TT declared no competing interests.
----------------------------------------------------------------------


======================================================================
CHUNK 467 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_195
Content Type: evidence
Words: 480
Medical Entities: CKD,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
He and his research MemorialHospital, includingserving team are continuing implementation of a national integrated as Dean of the College of Medicine caremodel program for CKD management inthe ruralareas and founding the Chang Gung of Thailand. KidneyResearchCenter. Hisresearch, particularlyfocusedon TT declared no competing interests. infection-related kidney diseases like leptospirosis kidney disease, has earned him accolades such as the Distinguished Research Award from the National Science Council and the Ifeoma Ulasi, MBBS, FWACP, PGD, Outstanding ContributionAwardfromthe Taiwan Societyof MSc, isaprofessorofmedicineatthe Nephrology and the National HealthCare Quality Award. College of Medicine, University of Beyond his local impact, Dr. Yang has made significant Nigeria. She has affiliations with 2 contributionsonaglobalscale. Hehasactivelyparticipatedin teachinghospitalswheresheisinvolved organizations like the Taiwan Society of Nephrology, Asianinpatientmanagement, trainingmedPacific Society of Nephrology, and the ISN, where he repreical students, student nurses, postsented the North and East Asian region, served on various graduate students, and resident committees, Councilor and Executive Committee Member. doctors. She is also active in various He is currently the Chair of the ISN Sister Renal Center research fields such as epidemiology, sociobehavioral studies, Program and co-Chair of the ISN-TTS Sister Transplant genetic/genomicresearch, clinicaltrials, andinterventions. Program. Furthermore, she serves as the chief physician of the His dedication to advancing research, education, and inUniversityofNigeriaNsukkaCentreofExcellenceforClinical ternational collaboration in nephrology has solidified his Trials, the Site PI for the H3Africa Kidney Disease Network position as aleader in the field, contributing continuously to Project, and the PI of International Diabetes Federationimprove kidney health in Taiwan and worldwide. sponsored clinical trials in gestational diabetes. In addition, C-WYdeclared no competing interests. she is the Deputy Chair of ISN Advocacy Working Group (AWG)andaformermemberofISNExCom(20212023), a member of The Transplantation Society (TTS) Ethics ComLuxia Zhang, MD, MPH, is the mittee, and the WHO Taskforce on Organ Donation and deputydeanoftheNationalInstitute Transplantation. Dr. Ulasi also serves as the Coordinator for of Health Data Science at Peking the West Africa College of Medicine Post-graduate College University, China, and Professor in subspecialtyExaminationsinNephrology(20162020)andas the Renal Division of Peking Unithe President of the Nigerian Association of Nephrology versity First Hospital, China. She (20182020). Lastly, she is an international adviser at the obtained her MD degree at Peking Royal College of Physicians, London. University and her MPH degree at IUreportsreceivingspeakerhonorariafromAstraZenecaand Harvard School of Public Health. Boehringer Ingelheim. Herresearchfocusesonprevalence, riskfactors, intervention, and management of kidney disease in China. Most of her work provides first-hand information on kidney disease in Germaine Wong, MD, PhD, is a China and has gained wide attention internationally. During transplant nephrologist, Director of the last several years, her study interests have been expanded Western Renal Service at Westmead to the management of major noncommunicable chronic Hospital, Professor of Clinical Epidediseases by leveraging the power of big data and machine miology, NHMRC Leadership Fellow learning. Her studies have been published in top medical attheUniversityofSydney. Sheisthe journals including New England Journal of Medicine, the current co-chair of the Women in Lancet, andBritishMedicalJournal. Dr. Zhangwasnamedon Transplantation.
----------------------------------------------------------------------


======================================================================
CHUNK 468 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_196
Content Type: general
Words: 473
Medical Entities: CKD
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
Her studies have been published in top medical attheUniversityofSydney. Sheisthe journals including New England Journal of Medicine, the current co-chair of the Women in Lancet, andBritishMedicalJournal. Dr. Zhangwasnamedon Transplantation. She has an internathelistoftheWorldsTop2%Scientists2020fromStanford tionally recognized track record in University and the 2020 China Highly Cited Scholars list transplant epidemiology, cancer and transplantation, social from Elsevier. She is the Vice President of Health Data ethicsinorganallocation, decisionanalyticalmodeling, health Application and Management Committee, Chinese Hospital economics, and quality of life studies in transplant recipients. Association; Deputy Editor of Health Data Science (a Science GWdeclared no competing interests. Partner Journal); member of the Lancet Digital Health S290 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org biographic and disclosure information International Advisory Board; and member of Editorial Professor of Medicine and Population Health at New York Boards of Clinical Journal of the American Society of University, Dr. Grams is Co-Principal Investigator of the Nephrology and American Journal of Kidney Diseases. Chronic Kidney Disease Prognosis Consortium (CKD-PC), LZreportsreceivingresearchsupportfromAstraZenecaand a consortium of over 30 million participants, 100 cohorts, Bayer and250investigatorsfromaroundtheglobe. Inthisrole, Dr. Monies paid to institution. Grams and the CKD-PC team focus on developing, testing, and implementing analytic strategies to answer clinically meaningful questions using as much of the worlds data on KDIGOChairs kidney measures and outcomes as possible. She also leads MichelJadoul, MD, receivedhisMD efforts to integrate multimodal omics data as they relate to degree in 1983 at the Universit kidneydisease. ShewasthewinneroftheYoungInvestigator CatholiquedeLouvain(UCLouvain), Award in 2018 given by the ASN/American Heart AssociaBrussels, Belgium. Dr. Jadoul trained tion Kidney Council, the top award for investigators under in internal medicine and nephrology 45yearsofage, andsheisamemberoftheAmericanSociety under the mentorship of Professor of Clinical Investigation. She attended medical school at Charles van Ypersele de Strihou. He Columbia University and completed her nephrology hasservedaschairattheDepartment fellowship at Johns Hopkins University. She is also a Coof Nephrology of the Cliniques Chair of KDIGO. Universitaires Saint-Luc (20032023) and is currently a full MEG declared no competing interests. clinical professor at UCLouvain. Dr. Jadouls clinical activities focusonthefollow-upofhemodialysisandCKDpatients, and b MethodsCommitteeRepresentative hismainresearchinterestsinclude 2-microglobulinamyloidBertramL. Kasiske, MD, FACP, did osis, hepatitis C, and other complications (e. g. , falls, bone his undergraduate training at Michfractures, andsuddendeath)inhemodialysispatients, aswellas igan State University, East Lansing, cardiovascular complications after kidney transplantation and Michigan. He received his medical variouscausesofkidneydisease(e. g. , drug-induced). Dr. Jadoulhascoauthoredover350scientificpapers, most degree from the University of Iowa, Iowa City, Iowa. He completed Inof them published in major nephrology journals. He is ternal Medicine residency, and currently servingasanassociateeditorofNephrologyDialysis fellowship training in Nephrology, at Transplantation, and he is also a country co-investigator for DOPPS (2001present). In 2008, he received the InternaHennepin County Medical Center, an affiliate hospital of the University of Minnesota in Mintional Distinguished Medal from the US NKF. He was previouslyamemberoftheERACouncil(20132016). Presently, neapolis. He is former deputy director of the United States Renal Data System, former editor-in-chief of the American Dr. Jadoul is a KDIGO Co-Chair.
----------------------------------------------------------------------


======================================================================
CHUNK 469 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_200
Content Type: definition
Words: 487
Medical Entities: GFR,albuminuria,diabetes
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
The Work Group considered all of the valuable Ng, Lian Ni, Ulf Nyman, Ugochi Onu, Alberto Ortiz, Cem comments made, and where appropriate, suggested changes Oztop, Meyeon Park, Jessie Pavlinac, Saime Paydas, Adriana were incorporated into the final publication. The following Penalba, Graciela Pennacchiotti, Emmanuel Ernesto Perez individualsprovidedfeedbackduringthepublicreviewofthe Granados, NuriaS. PerezRomano, VinhPhamQuang, Phaly draft guideline: Phon, Giorgina Piccoli, Cheryl Rajah, Abdelhamid Hamdy Muhammad Adnan, Baris Afsar, Naseer Ahmed, Naif Ramadan, Elvia Ramre, Jeannette Rautenbach, Mary-Beth Alghamdi, American Society of Onconephrology, Patricia Roberts, NicolasRobertoRobles, JakubRuszkowski, Bilquees Abreu, MabelAoun, Mustafa Arici, MarianoArriola, Elisabet Saba, Alice Sabatino, Judy Savige, John Sayer, Anja Selig, Ars, IsoAsp, AstraZeneca/Alexion, Randa Ataya, Carla Maria Wendy St. Peter, Megan Stoutz, Veronica Torres, Stephanie Avesani, GeorgeBakris, BayerAG, Dennis Begos, NouhaBen Toth-Manikowski, Sri Lekha Tummalapalli, Vertex, Carlos Mahmoud, Anatole Besarab, Sangeeta Bhorade, Jordi Bover, Villegas, Michelangelo Viscione, Eric Wallace, Darcy WeideRafael Burgos Calderon, Laura Byham-Gray, Tatiana Carmann, B. Andr Weinstock, Christine White, Katy Wilkens, dona, MartaCarlesso, AlexanderChang, LinhChi, KayWeng and Andrea Zimmermann. Choy, Catherine Clase, Rolando Claure-Del Granado, Participation in the public review does not necessarily Veronica Coll Brito, Dervla Connaughton, Valerio Coronel, constitute endorsement of the content of this report by the Kathy Crotts, CSL/Vifor, Adamasco Cupisti, Kader Dagabove individuals, or the organizations or institutions they hastanli, Neera Dahl, Luca De Nicola, Rogrerio de Paula, represent. S294 KidneyInternational(2024)105(Suppl4S), S117S314 www. kidney-international. org references References 1. KidneyDisease: ImprovingGlobalOutcomesCKDWorkGroup. KDIGO 23. Kidney Disease: Improving Global Outcomes Diabetes Work Group. 2012clinicalpracticeguidelinefortheevaluationandmanagementof KDIGO 2022 clinical practice guideline for diabetes management in chronickidneydisease. KidneyIntSuppl. 2012; 3: S1S150. chronickidneydisease. KidneyInt. 2022; 102(5S): S1S127. 2. National Kidney Foundation. K/DOQI clinical practice guidelines for 24. GlobalBurdenofDisease2019: GBDcauseandrisksummarieschronic chronickidneydisease: evaluation, classification, andstratification. Am kidneydisease. Lancet. 2020; 396: S152S153. JKidneyDis. 2002; 39(suppl1): S1S266. 25. GBD Chronic Kidney Disease Collaboration. Global, regional, and 3. LeveyAS, deJongPE, CoreshJ, etal. Thedefinition, classification, and national burden of chronic kidney disease, 1990-2017: a systematic prognosis of chronic kidney disease: a KDIGO Controversies analysis for the Global Burden of Disease Study 2017. Lancet. Conferencereport. KidneyInt. 2011; 80: 1728. 2020; 395: 709733. 4. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der 26. LevinA, OkpechiIG, CaskeyFJ, etal. Perspectivesonearlydetectionof Velde M, etal. Association ofestimatedglomerular filtration rate and chronic kidney disease: the facts, the questions, and a proposed albuminuria with all-cause and cardiovascular mortality in general frameworkfor2023andbeyond. KidneyInt. 2023; 103: 10041008. population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 27. CusickMM, TisdaleRL, ChertowGM, etal. Population-widescreeningfor 20732081. chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 5. GansevoortRT, MatsushitaK, vanderVeldeM, etal. Lowerestimated 2023; 176: 788797. GFR and higher albuminuria are associated with adverse kidney 28. LameireNH, LevinA, KellumJA, etal. Harmonizingacuteandchronic outcomes. A collaborative meta-analysis of general and high-risk kidneydiseasedefinitionandclassification: reportofaKidneyDisease: populationcohorts. KidneyInt. 2011; 80: 93104. Improving Global Outcomes (KDIGO) Consensus Conference. Kidney 6. Grams ME, Sang Y, Ballew SH, et al. Predicting timing of clinical Int. 2021; 100: 516526. outcomes in patients with chronic kidney disease and severely 29. deBoerIH, KhuntiK, SaduskyT, etal. Diabetesmanagementinchronic decreasedglomerularfiltrationrate. KidneyInt.
----------------------------------------------------------------------


======================================================================
CHUNK 470 of 647
======================================================================
ID: kdigo_2024_ckd_guideline_242
Content Type: recommendation
Words: 190
Medical Entities: CKD,proteinuria
Source: KDIGO-2024-CKD-Guideline.pdf

----------------------------------------------------------------------
, eds. Cochrane Handbook for comparisonofsevenmethods. StatMed. 1998; 17: 857872. SystematicReviewsofInterventions. 2nded. Wiley; 2019. 933. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in 920. PoggioED, McClellandRL, BlankKN, etal. Systematicreviewandmetameta-analyses. BMJ. 2003; 327: 557560. analysisofnativekidneybiopsy complications. ClinJAmSocNephrol. 934. GuyattG, OxmanAD, SultanS, etal. GRADEguidelines: 11. Makingan 2020; 15: 15951602. overall rating of confidence in effect estimates for a single outcome 921. National Institute for Health and Care Excellence (NICE). Evidence andforalloutcomes. JClinEpidemiol. 2013; 66: 151157. review for the accuracy of albumin: creatinine ratio versus protein 935. SchnemannH, Broz_ekJ, GuyattG, etal. GRADEhandbookforgrading creatinine ratio measurements to quantify proteinuria in children and quality of evidence and strength of recommendations. Updated October young people with CKD: Chronic kidney disease: Evidence review B. 2013. TheGRADEWorkingGroup; 2013. London: NICE; 2021. 936. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the 922. CorbettM, DuarteA, LlewellynA, etal. Point-of-carecreatinineteststo qualityofevidenceimprecision. JClinEpidemiol. 2011; 64: 12831293. assesskidneyfunctionforoutpatientsrequiringcontrast-enhancedCT 937. BrunettiM, ShemiltI, PregnoS, etal. GRADEguidelines: 10. Considering imaging: systematic reviews and economic evaluation. Health Technol resource use and rating the quality of economic evidence. J Clin Assess. 2020; 24: 1248. Epidemiol. 2013; 66: 140150. S314 KidneyInternational(2024)105(Suppl4S), S117S314
----------------------------------------------------------------------


======================================================================
CHUNK 471 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_0
Content Type: recommendation
Words: 392
Medical Entities: CKD
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
5th Edition Front Cover - please see seperate pdf Chronic Kidney Disease (CKD) Management in Primary Care Guidance and clinical tips to help detect, manage, and refer patients with CKD in your practice Evidence review Endorsements The recommendations in the Chronic The Chronic Kidney Disease (CKD) Kidney Disease (CKD) Management in Management in Primary Care Primary Care handbook are based on (5th edition) handbook has consideration of current evidence, been officially recognised as an Australian and international guidelines Accepted Clinical Resource by and clinical consensus. The goal of The Royal Australian College of the handbook is to provide simple General Practitioners (RACGP) and and actionable advice for health endorsed by the Australia and New professionals on the detection and Zealand Society of Nephrology management of CKD. (ANZSN), Primary Healthcare Nurses Association (APNA) and the Renal Society of Australasia (RSA). Kidney Health Australia This report is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced without written permission from Kidney Health Australia. Requests and enquiries concerning reproduction and rights should be directed to Kidney Health Australia, PO Box 9993, Melbourne VIC 3001or via email to primary. carekidney. org. au ISBN: 978-0-6459553-1-6 (print) 978-0-6459553-0-9 (web) Citation: Chronic Kidney Disease (CKD) Management in Primary Care (5th edition). Kidney Health Australia, Melbourne, 2024. An electronic version of this handbook is available at kidney. org. au Disclaimer The recommendations contained in this handbook were formed from existing evidence-based clinical guidelines, current research, and clinical consensus. The guidance is based upon the best information available at the time of publication. It is designed to provide information and assist decision-making. It is not intended to indicate an exclusive course of action or serve as a standard of medical care. Variations, taking individual circumstances into account, may be appropriate. Every health-care professional making use of this guide is responsible for evaluating the appropriateness of applying it in the setting of any particular clinical situation. The authors assume no responsibility for personal or other injury, loss or damage that may result from the information in this publication. Please note that requirements for PBS subsidy may differ from recommendations contained in this guide. Acknowledgements Kidney Health Australia acknowledges with thanks the staff and members of the Primary care Educational Advisory committee to Kidney Heatlh Australia (PEAK) who contributed to the development of this resource.
----------------------------------------------------------------------


======================================================================
CHUNK 472 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_1
Content Type: recommendation
Words: 486
Medical Entities: CKD
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Please note that requirements for PBS subsidy may differ from recommendations contained in this guide. Acknowledgements Kidney Health Australia acknowledges with thanks the staff and members of the Primary care Educational Advisory committee to Kidney Heatlh Australia (PEAK) who contributed to the development of this resource. PEAK Committee Kidney Health Australia Prof David Johnson (chair), Nephrologist Breonny Robson Prof Karen Dwyer, Nephrologist Katrin Buerkle A/Prof Shilpa Jesudason, Nephrologist Claire Sheeky A/Prof Ivor Katz, Nephrologist A/Prof Craig Nelson, Nephrologist Kidney Health Australia would also Dr Richard Phoon, Nephrologist like to thank topic experts A/Prof Ria Prof Kevan Polkinghorne, Nephrologist Arnold (Exercise Physiologist), A/Prof Dr Angus Ritchie, Nephrologist Kelly Lambert (Advanced Accredited Dr John Saunders, Nephrologist Practising Dietitian), Prof Andrew Mallett Dr Chris Bollen, General Practitioner (Nephrologist), and Ms Carla Scuderi Dr Caitlin Sum, General Practitioner (Pharmacist) for their review and Prof Tim Usherwood, General Practitioner input into the relevant sections of the Dr Sheena Wilmot, General Practitioner handbook. Dr Leanne Brown, Renal Nurse Practitioner Ms Jo Lewis, Nurse Practitioner Mr Tim Perry, Pharmacist Acknowledgement of Country We acknowledge the Traditional Owners of Country throughout Australia and recognise their continuing connection to lands, waters, and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. Conflicts of interest: DJ has received consultancy and Deakin University, as well as funding through NHMRC, fees, research grants, speakers honoraria and travel MRFF, Deakin University, Epworth Medical Foundation. sponsorships from Baxter Healthcare and Fresenius She was the KHA Clinical Director from 2021-23. SJ was Medical Care (FMC), consultancy fees from AstraZeneca the KHA Clinical Director from 2017 to 2020. RP received (AZ), Bayer, and AWAK technologies, speakers honoraria consultancy fees and honoraria from AZ. AM is the recipient from Ono pharmaceutical and Boehringer Ingelheim (BI) of a Qld Health Advancing Clinical Research Fellowship, Lilly, and travel sponsorships from Ono pharmaceutical has received research funding (competitive, investigatorand Amgen. He is a current recipient of an Australian initiated) from Sanofi-Genzyme, NHMRC, MRFF, QLD Health, NHMRC Leadership Investigator Grant. CB is a director and Australian Government Department of Health, as of BMP Healthcare Consulting (BMP), which has been well as travel support from Otsuka. He also holds advisory engaged by Kidney Health Australia (KHA) in the delivery board membership with GSK and MSD (no honoraria, travel of educational activities. BMP also hold contracts with support or payments), and board membership with ANZSN multiple PHNs across Australia to deliver programs. KD (Council). CS received speakers fees from AZ and Astellas. has received honorarium from AZ, BI, Bayer, GSK. She has BR has taken part in advisory boards for AZ and GSK. All received seed grant funding from Servier; Western Alliance, other contributors have no conflicts of interest to declare. 1 Foreword Welcome to the 5th edition of the Chronic best-practice recommendations, including Kidney Disease (CKD) Management in new treatments (e. g. SGLT-2 inhibitors and Primary Care handbook.
----------------------------------------------------------------------


======================================================================
CHUNK 473 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_2
Content Type: recommendation
Words: 474
Medical Entities: CKD,dialysis
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
All received seed grant funding from Servier; Western Alliance, other contributors have no conflicts of interest to declare. 1 Foreword Welcome to the 5th edition of the Chronic best-practice recommendations, including Kidney Disease (CKD) Management in new treatments (e. g. SGLT-2 inhibitors and Primary Care handbook. This new edition non-steroidal mineralocorticoid receptor provides clear, succinct, up to date, antagonists), new management algorithms, best-practice guidance for the care of new information on how the updated patients at risk of or living with CKD, Aus CVD risk calculator should be applied including identification of those at risk, to CKD, new information on lifestyle early detection of CKD, lifestyle and approaches, and new recommendations pharmacologic management, reduction on providing culturally safe care to First of kidney and cardiovascular risks, and Nations Australians living with CKD. quality use of medicines in the setting of CKD. The handbook is the product of Herculean efforts made by members of the Primary CKD is a growing public health problem Care Education Advisory Committee to in Australia that is common, harmful, and Kidney Health Australia (PEAK) and the treatable. More than 6 million Australian amazing Primary Care Education Team adults are at risk of CKD and more than 2 at Kidney Health Australia. We gratefully million live with CKD, including over 31, 000 acknowledge their enormous contributions people with kidney failure requiring dialysis and, in particular, would like to sincerely or kidney transplantation. People with thank outgoing longstanding members, early-stage CKD are up to 20 times more Professor Tim Usherwood and Professor likely to die from premature cardiovascular Robyn Langham, who have tirelessly disease than survive to the point of provided outstanding inputs over the last needing kidney replacement therapy. In two decades. 2021, it was estimated that CKD caused the loss of over 55, 000 healthy life years and We hope that this latest edition of the cost the Australian community 9. 9 billion Chronic Kidney Disease (CKD) Management dollars per annum. CKD is silent until as in Primary Care handbook will be both much as 90% of kidney function is lost and an invaluable and indispensable guide to the vast majority (94%) of those with kidney primary healthcare professionals providing disease are unaware that they have the care to people with CKD in the community. condition. This means that CKD is generally not detected until it reaches a more serious, burdensome, and costly stage. Primary care clinicians play a pivotal role in the early detection and care of people with CKD. This role has become even more critical with the recent emergence of new, highly effective treatments. The extensively used CKD Management in Primary Care handbook, and its accompanying freely downloadable Prof David Johnson digital application, CKD-Go! , have been Chair of PEAK Committee comprehensively updated with the latest, Kidney Health Australia 2 Kidney Health Australia Why use this handbook?
----------------------------------------------------------------------


======================================================================
CHUNK 474 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_3
Content Type: recommendation
Words: 447
Medical Entities: CKD,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
The extensively used CKD Management in Primary Care handbook, and its accompanying freely downloadable Prof David Johnson digital application, CKD-Go! , have been Chair of PEAK Committee comprehensively updated with the latest, Kidney Health Australia 2 Kidney Health Australia Why use this handbook? The Chronic Kidney Disease (CKD) Management in Primary Care (5th edition) handbook provides best practice recommendations for detecting and managing CKD in primary care: Easy to use and interactive. Management framework for common Advice on detecting CKD in primary issues in CKD. care including required tests and easy Nephrology referral algorithm. to use algorithm. Links to fact sheets, websites, and Colour-coded CKD staging table. additional resources for you and your Colour-coded clinical action plans patients. outlining goals of management, key The CKD Management in Primary Care management tasks and treatments to handbook is available in both hardcopy slow the progression of CKD. and electronic copy at kidney. org. au. Medication advice and treatment It is also available via the app CKD-Go! targets. (Free download from your app store). Whats new in the 5th edition? New recommendations for the use of New recommendations on a stepwise medications to slow progression of CKD approach to albuminuria reduction in and reduce cardiovascular (CVD) risk. CKD. Revised algorithm for the initial New sections on genetic kidney disease, detection and diagnosis of CKD. pharmacological management, heart New guidelines for culturally safe kidney failure and CKD, pain management, care in First Nations Australians. contraception and pregnancy, and hyperuricaemia. New information on the updated Aus CVD risk calculator and how it applies Links to additional information, to patients at varying stages of CKD. resources, and apps, including the Kidney Health Australia Health Expanded information on managing Professional Hub. nutrition and diet in CKD. New guidelines and algorithm for referral of people with CKD to kidney specialists. 3 Early diagnosis means people like me can control their lifestyle and can make a difference in society for longer, rather than being reliant on society. Shailendra Kidney Advocate living with CKD 4 Kidney Health Australia Contents CKD in Australia infographic 6 3. Managing CKD alongside Treatment goals for people with CKD 8 other chronic conditions Managing CKD in conjunction 1. Detecting and diagnosing CKD with other chronic conditions 47 Clinical presentation of CKD 11 CKD and cardiovascular disease 48 Targeted detection of CKD 12 CKD and diabetes 49 Early detection of CKD 13 CKD and hypertension 52 Algorithm for initial detection CKD and heart failure 57 and diagnosis of CKD 16 Tests used to investigate CKD 17 4. Common issues in CKD Diagnosing CKD 21 Acidosis 59 Causes of kidney failure 22 Albuminuria 59 Genetic kidney diseases 23 Anaemia 60 Cognitive decline 61 2.
----------------------------------------------------------------------


======================================================================
CHUNK 475 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_4
Content Type: reference
Words: 498
Medical Entities: CKD,dialysis,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Common issues in CKD Diagnosing CKD 21 Acidosis 59 Causes of kidney failure 22 Albuminuria 59 Genetic kidney diseases 23 Anaemia 60 Cognitive decline 61 2. Managing CKD in Primary Care Depression 61 Key management strategies Haematuria 62 for all people with CKD 25 Hyperuricaemia 64 Yellow clinical action plan 26 Hyperkalaemia 65 Orange clinical action plan 27 Lipids 65 Red clinical action plan 28 Malnutrition 66 Lifestyle changes to help manage CKD: 29 Mineral and bone disorder 66 Smoking/vaping 29 Muscle cramps 67 Nutrition and diet 30 Oedema 67 Alcohol 31 Pain management 68 Physical activity 31 Pruritus 70 Weight management 32 Restless legs 70 Pharmacological management of CKD 33 Sleep apnoea 70 Care approaches 37 Uraemia 71 Whole-of-practice approach to CKD management 37 5. Progressive CKD Culturally safe kidney care for First Nations Australians 37 Indications for referral to a nephrologist 73 Contraception and pregnancy in CKD 37 Algorithm for appropriate referral Considerations in older people 38 to a nephrologist 74 Vaccinations 39 Advance care planning 75 Managing other kidney conditions 40 Treatment options for kidney failure 75 Acute kidney injury 40 Kidney cysts 42 Abbreviations 76 Polycystic kidney disease 42 References 78 Kidney stones 44 Index 82 Where to go for more information 84 5 million CKD IS TWICE 1 IN 10 CKD AS COMMON AUSTRALIANS DIABETES AS DIABETES. 1 AND 1 IN 5 FIRST NATIONS AUSTRALIANS AGED 18 YEARS 3 OUT OF 4 AND OVER ARE AUSTRALIAN ADULTS LIVING WITH HAVE AT LEAST ONE SIGNS OF CKD. 1 FACTOR INCREASING THEIR RISK OF CKD. 2 nommoC lufmraH CKD in Australia 2 Over 2x 20x THE NUMBER OF PEOPLE WITH CKD ARE UP TO 20 PATIENTS NEEDING TIMES MORE LIKELY TO DIE FROM TREATMENT FOR KIDNEY A HEART ATTACK OR STROKE FAILURE HAS DOUBLED THAN THEY ARE TO PROGRESS TO IN THE LAST 20 YEARS. 2 KIDNEY FAILURE. 3-5 AROUND 20, 000 20 AUSTRALIANS DIE EVERY THOUSAND YEAR WITH KIDNEY DISEASE. 2 THE BURDEN OF CKD IS GREATEST IN PEOPLE CKD CAN HAVE SIGNIFICANT EXPERIENCING IMPACT ON WORK, FAMILY, SOCIOECONOMIC AND PSYCHOSOCIAL DISADVANTAGE, LIVING WELLBEING. 6-11 RURALLY AND IN FIRST NATIONS AUSTRALIANS. 2 CKD CONTRIBUTES TO 1 IN 6 HOSPITALISATIONS IN AUSTRALIA. 2 6 Kidney Health Australia LATE REFERRAL IS COMMON. 17% OF PEOPLE COMMENCE DIALYSIS WITHIN 90 DAYS OF BEING REFERRED TO A KIDNEY SERVICE. 15 FEWER THAN 10% OF THE PEOPLE WITH CKD ARE AWARE THAT THEY HAVE THIS CONDITION. 1 90% OF KIDNEY FUNCTION CAN BE LOST BEFORE PEOPLE EXPERIENCE SYMPTOMS. elbataerT dekoolrevo netfO IF CKD IS DETECTED 50% EARLY AND MANAGED APPROPRIATELY, NEW TREATMENTS DETERIORATION IN CAN SLOW THE KIDNEY FUNCTION PROGRESSION OF CKD CAN BE REDUCED BY BY UP TO 15 YEARS, 13 AS MUCH AS 50%. 12 OR POTENTIALLY LONGER IF STARTED EARLY. 14 7 Treatment goals for people with CKD Parameter Treatment goal Nutrition Adopt a healthy dietary pattern that includes See and diet vegetables, fruit, wholegrains, nuts and legumes, dairy foods, lean meat, fish, and plant protein.
----------------------------------------------------------------------


======================================================================
CHUNK 476 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_5
Content Type: recommendation
Words: 497
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
12 OR POTENTIALLY LONGER IF STARTED EARLY. 14 7 Treatment goals for people with CKD Parameter Treatment goal Nutrition Adopt a healthy dietary pattern that includes See and diet vegetables, fruit, wholegrains, nuts and legumes, dairy foods, lean meat, fish, and plant protein. Reduce salt intake to 5 g per day. Avoid ultra-processed foods and sugarsweetened drinks. Drink water to satisfy thirst. Weight BMI: 25 kg/m2 See management (23 kg/m2 Asian population16). Waist circumference 94 cm in men (90 cm in Asian men) or 80 cm in women (including Asian women). Physical Be active on most days, preferably every day. Physical activity activity Aim for 2. 5 5 hours of moderate intensity and exercise activity across the week17, or at a level that guidelines for accounts for the individuals cardiovascular all Australians and physical health. 18 Some activity is better than none. Include muscle strengthening activities as part of daily activity at least twice per week. 17 Smoking/ Dont smoke or vape. To aid smoking/vaping Quitline Vaping cessation, recommend counselling and if 13 7848 required, nicotine replacement therapy or other medication. Alcohol Reduce alcohol consumption. The less you Australian drink, the lower your risk of harm from guidelines to alcohol. 19 reduce health Australian guidelines for healthy individuals risks from recommend no more than 10 standard drinking alcohol drinks a week and no more than 4 standard drinks on any one day to reduce the risk of harm from alcohol-related disease or injury. 19 There are no specific recommendations about safe levels of alcohol consumption in people with CKD. 8 Kidney Health Australia Hypertension Maintain blood pressure consistently See below 130/80 mmHg for all people with CKD. Glycaemic Maintain blood glucose levels (BGL): See control 6-8 mmol/L fasting; 8-10 mmol/L Management of postprandial. type 2 diabetes: HbA1c: 53 mmol/mol (range 48-58); A handbook for 7% (range 6. 5-7. 5). Individualise general practice according to patients circumstances Diabetes Australia (e. g. , disease duration, life expectancy, important comorbidities, and established vascular complications). Albuminuria A reduction in uACR of at least 30%. 20-23 See Lipids No target serum cholesterol level CARI guidelines: recommended. Management of Use statin (/- ezetimibe) to reduce risk lipid-lowering of CVD events and death in: therapy in CKD People with CKD (eGFR 15 mL/ Aus CVD risk min/1. 73m2) calculator and CVD risk 10%. First Nations Australians with CKD and CVD risk 5%). Potassium K 6. 0 mmol/L. See Immunisation Recommended vaccinations for people National with CKD aged 18 years and over: Immunisation Influenza Program Pneumococcal The Australian COVID-19 Immunisation Herpes Zoster Handbook Other vaccinations as recommended by the NIP Herpes Zoster vaccinations are currently on the National Immunisation Program (NIP) for all people aged 65 years and over; First Nations peoples aged 50 years and over; and immunocompromised persons aged 18 years and over who have had a kidney transplant or another eligible medical condition. Please note that some recommendations contained in this handbook may differ to current Pharmaceutical Benefits Scheme (PBS) subsidy indications.
----------------------------------------------------------------------


======================================================================
CHUNK 477 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_6
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Please note that some recommendations contained in this handbook may differ to current Pharmaceutical Benefits Scheme (PBS) subsidy indications. We recommend checking the PBS and NIP listings for specifics, before prescribing. 9 1 Detecting and diagnosing CKD 10 Kidney Health Australia Clinical presentation of CKD CKD is defined as: An estimated or measured GFR 60 mL/min/1. 73m2 that is present for 3 months with or without evidence of kidney damage. Or Evidence of kidney damage, with or without decreased GFR that is present for 3 months, as evidenced by the following: Albuminuria Structural abnormalities Haematuria after exclusion (e. g. , on kidney imaging tests) of urological causes Pathological abnormalities (e. g. , kidney biopsy) CKD is generally asymptomatic Up to 90% of kidney function may be lost before symptoms are present, so 1-2 yearly checks for individuals at increased risk are essential. Signs and symptoms of advancing CKD may be general in nature and include: Hypertension Malaise Pruritis Anorexia Nocturia Restless legs Lethargy Haematuria Nausea/vomiting Dyspnoea 11 Targeted detection of CKD Three out of four Australians aged 18 years and over are at increased risk of developing CKD. Detection of CKD should be targeted and focus on people who are known to be at increased risk of developing the condition. The following people are at increased risk of CKD: Diabetes Hypertension Established Family histo ry cardiovascular of kidney failure disease Obesity (body mass Current or past History of acute index 30kg/m2 smoker/vaper kidney injury 18 All people aged First Nations Australians 60 years or older aged 18 years or older First Nations Australians experience a higher burden, earlier onset, and faster progression of kidney disease, due to ongoing impacts of colonisation. Clinical tip Individuals at increased risk of developing CKD should be offered a Kidney Health Check (BP, uACR, eGFR) every 1-2 years (annually for First Nations Australians aged 18 years, and anyone with diabetes or hypertension). See for information on testing people at risk of CKD. 12 Kidney Health Australia Detecting and diagnosing CKD Early detection of CKD Benefits of early detection Allows for early intervention with treatment approaches and medications that can slow the progression of kidney disease and reduce cardiovascular risk. Facilitates appropriate adjustments to drug dosing, prescribing of medications to slow CKD progression, establishment of a sick day action plan, and avoidance of nephrotoxic medications. Gives patients time to make positive lifestyle changes and appropriately consider treatment options before reaching kidney failure. Has economic benefits for the health system, with every 1 invested leading to 45 of savings in the cost of treating kidney failure and associated CVD. 24 The Kidney Health Check Targeted detection of CKD occurs via Kidney Health Checks for patients at increased risk. The Kidney Health Check involves the following: Blood pressure check Urine test Blood test Consider ambulatory Albumin/creatinine eGFR calculated from blood pressure (ABP) ratio (ACR) to check serum creatinine. monitoring or home BP for albuminuria. monitoring in addition to in-clinic readings.
----------------------------------------------------------------------


======================================================================
CHUNK 478 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_7
Content Type: recommendation
Words: 500
Section: The Kidney Health Check involves the following:
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
The Kidney Health Check involves the following: Blood pressure check Urine test Blood test Consider ambulatory Albumin/creatinine eGFR calculated from blood pressure (ABP) ratio (ACR) to check serum creatinine. monitoring or home BP for albuminuria. monitoring in addition to in-clinic readings. Further information and resources Kidney Health Australia Health Professional Hub: How to guide - How to Kidney Health Check with MBS item numbers. Kidney Health Australia factsheet for people affected by CKD: What is CKD? 13 Early detection of CKD in non-Indigenous Australians Indications for Recommended Assessment assessment frequency Diabetes Annually Complete a Kidney Health Check: Blood pressure check Hypertension Annually uACR (first morning void preferred) Established Every 2 years eGFR cardiovascular disease If results indicate CKD, repeat tests, refer to the algorithm for initial Family history Every 2 years detection and diagnosis of CKD on of kidney failure. Obesity Every 2 years Smoking / vaping Every 2 years History of acute Every year for first 3 kidney injury (AKI) years post AKI, then every 2 years. Aged 60 years Once off, unless developing other indications for assessment. Established cardiovascular disease is defined as a previous diagnosis of coronary heart disease, cerebrovascular or peripheral vascular disease. There is emerging evidence that the long-term effects of COVID-19 may also increase the risk of future kidney disease. 25 Therefore, a Kidney Health Check is recommended for individuals who have experienced acute kidney injury (AKI) as a complication of COVID-19 infection and for those with long COVID. A Kidney Health Check is recommended for people who have had hypertensive disorders in pregnancy, including pre-eclampsia and pregnancy-induced hypertension, which are associated with increased future risk of hypertension, cardiovascular disease, and CKD. 14 Kidney Health Australia Detecting and diagnosing CKD Early detection of CKD in First Nations Australians26 Indications for Recommended Assessment assessment frequency Aged 18 years As needed Screen for red flags of CKD: Family history of CKD Clinical history of diabetes, hypertension, obesity, smoking, established CVD, or acute kidney injury Clinical history of low birth weight Clinical history of recurrent childhood infections Also consider: Socioeconomic status, regional/rural and remote location, housing status, education level Complete a Kidney Health Check (eGFR, uACR and blood pressure check) if concerned. Aged 18 years At least annually. Complete a Kidney Health Check Utilise MBS item Blood pressure check 715 if appropriate. uACR (first morning void preferred) eGFR If results indicate CKD, repeat tests, refer to the algorithm for initial detection and diagnosis of CKD on. See footnotes on the definition of established cardiovascular disease, and testing recommendations for people with AKI associated with COVID-19, long COVID and hypertensive pregnancy disorders on. Further information and resources CARI Guidelines: CARI Recommendations for culturally safe kidney care for First Nations Australians. RACGP Red Book: Guidelines for preventive activities in general practice. Kidney Health Australia education tool for health professionals: Flipchart for First Nations Australians. Kidney Health Australia resource library: Factsheets for First Nations Australians affected by CKD. Kidney Health Australias CKDGo! app available on your app store. The CKDGo!
----------------------------------------------------------------------


======================================================================
CHUNK 479 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_8
Content Type: reference
Words: 496
Section: RACGP Red Book:
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
RACGP Red Book: Guidelines for preventive activities in general practice. Kidney Health Australia education tool for health professionals: Flipchart for First Nations Australians. Kidney Health Australia resource library: Factsheets for First Nations Australians affected by CKD. Kidney Health Australias CKDGo! app available on your app store. The CKDGo! app has an inbuilt CKD calculator to quickly determine a persons clinical management plan. 15 Algorithm for initial detection and diagnosis of CKD O Ch ff e e c r k a t o K i p d e n o e p y l e H e w a it lt h h uACR 3 mg/mmol eGFR 60 mL/min/1. 73m2 No Diabetes Hypertension Established CVD Repeat Kidney Health Check Family history in 1-2 years (annually in of kidney failure Yes Yes First Nations Australians Obesity (BMI 30) aged 18, people with Current or past diabetes or hypertension) smoker / vaper History of AKI First Nations Repeat uACR within 3 Repeat eGFR Australians aged months. If uACR within 7 days 18 years normal, complete a All Australians third test (preferably If 20% reduction aged 60 years first morning void) Repeat eGFR in eGFR, possible within 3 months AKI. Discuss with nephrologist If minimum of two If minimum of two uACRs 3 mg/mmol eGFRs 60 over 3 months and/or mL/min/1. 73m2 over 3 months Stage CKD with staging table, using eGFR and uACR test results Albuminuria Stage Kidney GFR Normal Microalbuminuria Macroalbuminuria Function (mL/min/1. 73m2)(A1) (A2) (A3) Stage uACR 3. 0 mg/mmol uACR 3. 0-30 mg/mmol uACR 30 mg/mmol 1 90 Not CKD unless haematuria, structural or pathological 2 60-89 abnormalities present 3a 45-59 3b 30-44 4 15-29 5 15 or on dialysis Undertake investigations to determine underlying diagnosis Fully specify CKD diagnosis, e. g CKD stage 2 with microalbuminuria (A2) in the presence of type 2 diabetes Refer to the colour-coded clinical action plans for CKD management strategies: Yellow clinical action plan (p26) Orange clinical action plan (p27) Red clinical action plan (p28) 16 Kidney Health Australia Detecting and diagnosing CKD Tests used to investigate CKD Glomerular filtration rate (GFR)27 Clinical situations where eGFR results may be unreliable and/or GFR is accepted as the best overall misleading: 28 measure of kidney function. Acute changes in kidney function GFR can be estimated (eGFR) from (e. g. , AKI). serum creatinine using the CKD-EPI People on dialysis. prediction equation and is routinely reported by all Australian pathology Recent consumption of cooked meat laboratories with requests for serum (consider re-assessment when the creatinine in individuals aged 18 years. individual has fasted or specifically avoided a cooked meat meal within Use of the CKD-EPI equation has been 4 hours of blood sampling). validated in First Nations Australians, as well as South-East Asian, African, Indian, Exceptional dietary intake (e. g. , and Chinese people living in western vegetarian diet, high protein diet, countries. No adjustments to the creatine supplements). equation are needed to measure eGFR Extremes of body size. in different population groups.
----------------------------------------------------------------------


======================================================================
CHUNK 480 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_9
Content Type: recommendation
Words: 481
Medical Entities: CKD,GFR,albuminuria
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
validated in First Nations Australians, as well as South-East Asian, African, Indian, Exceptional dietary intake (e. g. , and Chinese people living in western vegetarian diet, high protein diet, countries. No adjustments to the creatine supplements). equation are needed to measure eGFR Extremes of body size. in different population groups. 27 Conditions of skeletal muscle, eGFR is a more sensitive marker for paraplegia, or amputees CKD than serum creatinine alone. (may overestimate eGFR). Normal serum creatinine High muscle mass measurements do not exclude (may underestimate eGFR). serious loss of kidney function. People under the age of 18 years. 50% or more of kidney function can be Severe liver disease present. lost before the serum creatinine rises eGFR values above 90 mL/min/1. 73m2. above the upper limit of normal. Drugs interacting with creatinine In the context of normal uACR results, excretion (e. g. , trimethoprim). further investigation of reduced eGFR is usually only required if the eGFR is 60 Pregnancy (see below). mL/min/1. 73m2 or declining. Minor changes in eGFR (15% change) could be due to physiological or laboratory variability. 17 eGFR and drug dosing27 Urine albumin/creatinine ratio (uACR) Dose reduction of some drugs is recommended for people with reduced kidney function (see ). Protein in the urine is a key marker of eGFR provides a valid estimate of kidney damage and linked to increased kidney drug clearance and is widely risk of progression to kidney failure and available on laboratory reports. cardiovascular disease. If using eGFR for drug dosing, body These proteins are mainly albumin size should be considered, in addition (albuminuria), but also consist of low to referring to the approved product molecular weight immunoglobulin, information. lysozyme, insulin, and beta-2 microglobulin. For drug dosing in very large or very small people, it may be preferred It is rare for an individual to have to calculate an eGFR that is not increased excretion of non-albumin normalised to 1. 73m2 body surface proteins without concomitant increased area (BSA). excretion of albumin. For drugs with a narrow therapeutic An increased uACR is predictive of index, therapeutic drug monitoring or heightened kidney and cardiovascular a valid marker of drug effect should be risks in population studies. used to individualise dosing. Reduction in uACR confers renoprotective benefit in intervention trials. 29 eGFR and pregnancy Elevated uACR is a more common sign The validity of eGFR in pregnancy of CKD than a decreased eGFR and is is not known. commonly missed as part of a Kidney The use of eGFR to assess kidney Health Check in practice. 1 function in pregnant people is not recommended. Serum creatinine should remain the standard test for kidney function in pregnant people. Clinical tip If eGFR is 60 mL/min/1. 73m2, retest within 7 days to exclude AKI and again after 3 months to establish a diagnosis of CKD. Also consider clinical situations where eGFR results may be unreliable and/or misleading.
----------------------------------------------------------------------


======================================================================
CHUNK 481 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_10
Content Type: recommendation
Words: 498
Medical Entities: CKD,GFR,proteinuria,albuminuria
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Clinical tip If eGFR is 60 mL/min/1. 73m2, retest within 7 days to exclude AKI and again after 3 months to establish a diagnosis of CKD. Also consider clinical situations where eGFR results may be unreliable and/or misleading. 18 Kidney Health Australia Detecting and diagnosing CKD How to detect albuminuria: 30 Factors other than CKD known to increase urine albumin excretion: 30 Urinary protein excretion follows a circadian pattern and tends to be Urinary tract infection highest in the afternoon, so uACR tests High dietary protein intake are most accurate when performed in Congestive heart failure the early morning (first void), and this is the preferred method for assessment Acute febrile illness of albuminuria. 31 Heavy exercise within 24-hours Where a first void specimen is not Menstruation possible or practical, a random spot Genital discharge or infection urine specimen for uACR is acceptable. Drugs (especially NSAIDs) A positive uACR test (uACR 3. 0 mg/ mmol) should be repeated on a first void sample to confirm persistence of albuminuria. Dipstick for protein in the urine is no Clinical tip longer recommended, due to poor Albuminuria is present, if at sensitivity and specificity. least two uACR results are uACR exhibits greater sensitivity than 3. 0 mg/mmol. If this is urine protein/creatinine ratio (uPCR) for consistent over a 3-month detecting lower amounts of clinically period, it is indicative of CKD. important albuminuria. uPCR tests may miss microalbuminuria, resulting in false-negative results. In general, 24-hour urine collection is not warranted to quantify proteinuria. uACR criteria for CKD is not applicable in pregnancy. 19 Other diagnostic evaluation tests for CKD: 32 Always indicated: Urine microscopy for dysmorphic Repeat (within 1 week) serum urea/ red cells, red cell casts electrolytes/creatinine/eGFR/albumin Full blood count, fasting lipids, glucose, tests. HbA1c, uric acid, LFTs, hsCRP, ESR If eGFR continues to decrease, refer to Ultrasound of the kidneys, ureters, AKI management plan (see ). and bladder (KUB) (at least once) Sometimes indicated: If the following is present: Carry out the following test: Signs of systemic disease (e. g. , rash, Anti-glomerular basement membrane arthritis, features of connective tissue antibody (antiGBM) disease, pulmonary symptoms or Anti-neutrophil cytoplasmic antibody deteriorating kidney function) or the (ANCA) presence of glomerular haematuria. Anti-nuclear antibodies (ANA) Prompt referral likely indicated. Extractable nuclear antigens (ENA) Complement studies (C3/C4) ESR Risk factors for HBV, HCV, or HIV HBV, HCV, HIV serology (these conditions are associated with an increased risk of glomerular disease). Possible myeloma. Serum, urine protein electrophoresis and FLC Further information and resources Kidney Health Australia factsheets for people affected by CKD: What is eGFR? and Albuminuria. Kidney Health Australia Health Professional Hub: How to guide - Stage Diagnose CKD. 20 Kidney Health Australia Detecting and diagnosing CKD Diagnosing CKD There are three components to a diagnosis of CKD eGFR uACR Underlying results results aetiology CKD diagnosis to give CKD normo (A1), micro to determine stage (1-5) (A2) or macro (A3) cause of CKD albuminuria Clinical tip CKD in itself is not a primary diagnosis.
----------------------------------------------------------------------


======================================================================
CHUNK 482 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_11
Content Type: reference
Words: 500
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Attempts should be made to identify the underlying cause of CKD and to fully specify it, e. g. , CKD stage 3b with microalbuminuria (or A2) in the presence of type 2 diabetes. Remember to code all CKD diagnoses in your practice software. Staging of CKD Once an individual is diagnosed with CKD, it is useful to determine their CKD stage and corresponding CKD action plan as this will guide management strategies. To correctly stage CKD, combine the persons kidney function stage (stage 1-5 determined by their eGFR) with their albuminuria stage. This is then plotted on the colour-coded CKD staging table to determine which action plan they should follow. The staging table colours are indicative of increasing risk of kidney failure and CVD, with green indicating minimal risk and red indicating highest risk. 21 Causes of kidney failure The most common causes of kidney failure in Australia are: 15 Other 24% Diabetic kidney disease 40% Familial/ hereditary kidney diseases 7% Glomerular disease 18% Hypertension/ Renal vascular disease 11% Other includes: tubulointerstitial disease (8%), other systemic diseases affecting the kidney (2%), miscellaneous kidney disorders (13%), not reported (1%). 22 Kidney Health Australia Detecting and diagnosing CKD Genetic kidney diseases An important cause of CKD is genetic In addition, there can be a variety of kidney disease. Whilst overall this is a pathognomonic features for many minority of cases, it remains significant individual disorders or syndromes. The and includes conditions such as inclusion of the above information and autosomal dominant polycystic kidney any specific concerns for a heritable or disease (ADPKD) and Alport syndrome. genetic form of kidney disease can be Key factors to consider include: communicated at the time of nephrology referral. Family history Age of onset (particularly in childhood) Extra-kidney manifestations Genetic testing in people aged 50 years or younger without known cause Further information and resources A range of support organisations are available for those with a diagnosis of genetic kidney disease, including: PKD Australia. Alport Foundation of Australia. KidGen Collaborative. CARI Guidelines: Autosomal Dominant Polycystic Kidney Disease. 23 2 Managing CKD in Primary Care 24 Kidney Health Australia Key management strategies for all people with CKD Maintain blood Slow decline Reduce pressure below in eGFR albuminuria 130/80 mmHg Avoid further Lower CVD damage to risk kidneys Clinical tip Following diagnosis and staging of CKD, use the corresponding colour-coded clinical action plan for key management strategies key management goals and strategies. . 25 Yellow clinical action plan eGFR 60mL/min/1. 73m2 with microalbuminuria (A2) or eGFR 45-59 mL/min/1. 73m2 with normoalbuminuria (A1) Management goals Slow progression of CKD. Slow decline in eGFR. Reduce albuminuria by at least 30%. Assess and lower cardiovascular risk. Avoid nephrotoxic medications or volume depletion. Encourage positive lifestyle changes and self-management practices. Management strategies Frequency of review Treatment checklist Every 12 months Complete investigations to determine underlying cause of CKD. Clinical assessment Provide advice on positive lifestyle changes Blood pressure (addressing smoking/vaping, nutrition, alcohol use, Weight and waist circumference physical activity, sleep, stress) (see -32).
----------------------------------------------------------------------


======================================================================
CHUNK 483 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_12
Content Type: recommendation
Words: 491
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Encourage positive lifestyle changes and self-management practices. Management strategies Frequency of review Treatment checklist Every 12 months Complete investigations to determine underlying cause of CKD. Clinical assessment Provide advice on positive lifestyle changes Blood pressure (addressing smoking/vaping, nutrition, alcohol use, Weight and waist circumference physical activity, sleep, stress) (see -32). Smoking/vaping history Maintain blood pressure consistently below target (see ). Laboratory assessment Complete cardiovascular risk assessment (see ). Recommended: Prescribe medications to slow CKD progression, e. g. , uACR (see ) ACE inhibitor or ARB, SGLT2 inhibitor, non-steroidal MRA eGFR (see ) (see ). Urea, creatinine, and electrolytes Consider lipid lowering treatment where appropriate Full blood count (see ). Also consider: Optimise glycaemic control (see ). Avoid nephrotoxic medications or volume depletion Screening for diabetes (see ). (fasting blood glucose or HbA1c) Discuss contraception with individuals of child-bearing HbA1c (for people with diabetes) age (see ). Dipstick urinalysis for haematuria detection Recommend vaccinations (see ). Lipid studies (Trig, Chol, HDLC, LDLC) 26 Kidney Health Australia Managing CKD in Primary Care Orange clinical action plan eGFR 30-59mL/min/1. 73m2 with microalbuminuria (A2) or eGFR 30-44 mL/min/1. 73m2 with normoalbuminuria (A1) Management goals Slow progression of CKD. Slow decline in eGFR. Early detection Reduce albuminuria and management by at least 30%. of complications. Assess and lower Adjust medication cardiovascular risk. doses to levels appropriate for Avoid nephrotoxic kidney function. medications or volume depletion. Appropriate referral Encourage positive to a nephrologist lifestyle changes and when indicated. self-management practices. Management strategies Frequency of review Treatment checklist Every 3-6 months Complete investigations to determine Clinical assessment underlying cause of CKD. Provide advice on positive lifestyle changes (addressing Blood pressure smoking/vaping, nutrition, alcohol use, physical activity, Weight and waist circumference sleep, stress) (see -32). Smoking/vaping history Maintain blood pressure consistently below target Laboratory assessment (see ). Complete cardiovascular risk assessment Recommended: (see ). uACR (see ) Prescribe medications to slow CKD progression, eGFR (see ) e. g. , ACE inhibitor or ARB, SGLT2 inhibitor, Urea, creatinine, and electrolytes non-steroidal MRA (see ). Full blood count Consider lipid lowering treatment Also consider: where appropriate (see ). Screening for diabetes Optimise glycaemic control (see ). (fasting blood glucose or HbA1c) Avoid nephrotoxic medication or volume depletion HbA1c (for people with diabetes) and adjust doses to levels appropriate for kidney Dipstick urinalysis for haematuria detection function (see ). Lipid studies (Trig, Chol, HDLC, LDLC) Assess for common issues presenting in CKD Iron studies (see pages 58-71). Calcium and phosphate Appropriate referral to nephrologist when indicated Parathyroid hormone (6-12 monthly (see ). if eGFR 45mL/min/1. 73m2) Discuss contraception with individuals of child-bearing age (see ). Recommend vaccinations (see ). 27 Red clinical action plan Macroalbuminuria irrespective of eGFR or eGFR 30 mL/min/1. 73m2 irrespective of albuminuria Management goals Slow progression of CKD. Slow decline in eGFR. Early detection Prepare for Reduce albuminuria and management kidney replacement by at least 30%. of complications. therapy if appropriate. Assess and lower Adjust medication cardiovascular risk.
----------------------------------------------------------------------


======================================================================
CHUNK 484 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_13
Content Type: recommendation
Words: 490
Medical Entities: CKD,GFR,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
73m2 irrespective of albuminuria Management goals Slow progression of CKD. Slow decline in eGFR. Early detection Prepare for Reduce albuminuria and management kidney replacement by at least 30%. of complications. therapy if appropriate. Assess and lower Adjust medication cardiovascular risk. doses to levels Prepare for appropriate for comprehensive Avoid nephrotoxic kidney function. conservative care medications or volume if appropriate. depletion. Appropriate referral Encourage positive to a nephrologist lifestyle changes and when indicated. self-management practices. Management strategies Frequency of review Treatment checklist Avoid nephrotoxic medication Every 1-3 months Complete investigations to or volume depletion and determine underlying cause adjust doses to levels Clinical assessment of CKD. appropriate for kidney Blood pressure Provide advice on positive function (see ). Weight and waist circumference lifestyle changes (addressing Assess for common issues Smoking/vaping history smoking/vaping, nutrition, presenting in CKD Oedema alcohol use, physical activity, (see pages 59-71). sleep, stress) (see -32). Appropriate referral to Laboratory assessment Maintain blood pressure nephrologist when indicated Recommended: consistently below target (see ). uACR (see ) (see ). Discuss potential progression eGFR (see ) Address high cardiovascular to kidney failure with patient Urea, creatinine, and electrolytes risk (see ). and treatments. Full blood count Prescribe medications to slow Initiate advance care planning CKD progression as relevant (see ) Also consider: to the persons eGFR, e. g. , Discuss contraception with Screening for diabetes ACE inhibitor or ARB, SGLT2 individuals of child-bearing (fasting blood glucose or HbA1c) inhibitor, non-steroidal MRA age (see ). HbA1c (for people with diabetes) (see ). Recommend vaccinations Dipstick urinalysis for haematuria Consider lipid lowering (see ). detection treatment where appropriate Lipid studies (Trig, Chol, HDLC, LDLC) (see ). Many medications are either Iron studies Optimise glycaemic control contraindicated or require dose Calcium and phosphate (see ). adjustments as eGFR declines. We Parathyroid hormone recommend checking individual (6-12 monthly if eGFR product information, particularly before prescribing medications in 45mL/min/1. 73m2) CKD stage 4-5. 28 Kidney Health Australia Managing CKD in Primary Care Lifestyle changes to help manage CKD Lifestyle changes should always be considered as the first line management strategy for people diagnosed with CKD. Working with the individual to implement positive lifestyle changes in relation to: Smoking, Nutrition, Alcohol, Physical activity (SNAP)33, as well as adequate sleep, and stress management, can have a positive effect on CKD outcomes and delay the progression of disease. The 5 As provide a key framework for addressing lifestyle changes. advise/ ask assess assist arrange agree Smoking / vaping Target Dont smoke or vape. To aid smoking/vaping cessation, recommend counselling and if required, nicotine replacement therapy or other medication. Compared to people who have never smoked, the risk of developing CKD is increased by 27% for ever smokers, 34% for current smokers and 15% for former smokers. 34 Vaping has been associated with an increased occurrence of albuminuria and raised uACR levels. 35 Use of e-cigarettes has been linked to hyperuricaemia. 36 Further information and resources Quitline - 13 7848.
----------------------------------------------------------------------


======================================================================
CHUNK 485 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_14
Content Type: recommendation
Words: 489
Medical Entities: CKD,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
34 Vaping has been associated with an increased occurrence of albuminuria and raised uACR levels. 35 Use of e-cigarettes has been linked to hyperuricaemia. 36 Further information and resources Quitline - 13 7848. 29 Nutrition and diet Target Dietary Adopt a healthy dietary pattern that includes vegetables, fruit, pattern wholegrains, nuts and legumes, dairy foods, lean meat, poultry, fish, and plant protein. Healthy dietary patterns are associated with reduced risk of mortality and kidney failure, 37 developing CKD, 38 and progression of CKD39. Consuming adequate fruits (2 serves /day) and vegetables (5 serves / day) can reduce the rate of kidney function decline, decrease body weight and blood pressure, and net acid production to manage metabolic acidosis in CKD. 40 Fluid Make water your drink of choice. There is no recommendation for the number of glasses of water that should be consumed daily for kidney health. It is recommended that people should drink water to satisfy thirst. Sugar-sweetened beverages (SSBs) have shown to elevate the risk and progression of CKD and should be avoided. Salt Salt intake should be reduced to 5 g per day. This may be achieved by adopting strategies, such as: not adding salt in cooking or at the table. choosing packaged foods with 120 mg sodium per 100 g. People with a history of hyperkalaemia should not use salt substitutes and use caution with some reduced salt products, due to them containing high amounts of potassium chloride. Ultra- All people with CKD should avoid ultra-processed foods high processed in fat, sugar, and salt, such as biscuits, cakes, packaged snack foods and foods, takeaway foods, soft drinks, energy drinks, sports drinks, sugar fruit juices and cordials. Individualised diets, tailored to cultural differences, food intolerances, cooking skills, food security, comorbidities (such as diabetes), and cost should be considered when recommending dietary options to patients with CKD and their families. For adults with diabetes and CKD, there is no one specific eating pattern that is superior. Individualised advice is recommended to help optimise glycaemic control. 41 Consider referral to an Accredited Practising Dietitian (APD), especially for help with implementing complex dietary changes, such as potassium restrictions, and if other chronic conditions such as diabetes, are present. 30 Kidney Health Australia Managing CKD in Primary Care Further information and resources Kidney Health Australia Diet and Nutrition resources. Bush Tucker and Kidney Disease booklet. Easy Diet Diary Renal App: Available for download from your app store. Dietitians Australia: Find a dietitian Eat for health: Nutrient Reference values. Alcohol Target Reduce alcohol consumption the less you drink, the lower your risk of harm from alcohol. 19 Australian guidelines recommend healthy men and women should drink no more than 10 standard drinks a week and no more than 4 standard drinks on any one day to reduce the risk of harm from alcohol-related disease or injury. 19 There are no specific recommendations about safe levels of alcohol consumption in people with CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 486 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_15
Content Type: recommendation
Words: 465
Medical Entities: CKD,GFR,albuminuria
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
19 There are no specific recommendations about safe levels of alcohol consumption in people with CKD. Further information and resources Australian guidelines to reduce health risks from drinking alcohol. Physical activity Target Be active on most days, preferably every day. Aim for 2. 5 5 hours of moderate intensity activity across the week17, or at a level that accounts for the individuals cardiovascular and physical health. 18 Some activity is better than none. Include muscle strengthening activities as part of daily activity at least twice per week. 17 31 Higher cardiorespiratory fitness levels, increased participation in physical activity and less time spent in sedentary pursuits are all associated with better outcomes in those living with CKD. 42 A persons overall health, heart health, comorbidities and physical capacity should be considered before increasing physical activity. Light to moderate intensity exercise is a safe starting point for most individuals. Vigorous intensity exercise should only be undertaken by those already doing this level of activity. 43, 44 Further information and resources Physical activity and exercise guidelines for all Australians. Weight management Target Waist circumference 94 cm in men (90 cm in Asian men) or 80 cm in women (including Asian women). BMI 25 kg/m2 (23 kg/m2 Asian population16). Central obesity (measured by waist circumference) is a strong predictor of CKD progression. Obesity (BMI 30 kg/m2) doubles the risk of developing CKD. 45 People with BMI 30 kg/m2 may be more likely to develop albuminuria. 45 Further information and resources Resources on Obesity and Overweight. 32 Kidney Health Australia Managing CKD in Primary Care Pharmacological management of CKD Clinical tip Remember to code CKD correctly. Your practice software can help with medication considerations. Medication considerations in CKD Educate your patients to flag their CKD diagnosis with other providers It is important to review medications and ensure that they are aware that that are excreted by the kidneys and having CKD can affect prescribing of avoid nephrotoxic medications in medications. people with CKD. Ensure patients are aware of risk of AKI Dosage reduction or cessation of and have a sick day action plan. Refer to medications that are excreted by the AKI sick day action plan on for kidneys is generally required once the further information. GFR falls below 60 mL/min/1. 73m2. Home Medicines Reviews and Residential Medication Management Reviews support general practitioner (GP)/pharmacist collaboration and are funded by Medicare. Clinical tip If patients become ill and are unable to maintain adequate fluid intake, they should be advised to withhold medications that increase the risk of kidney function decline and adverse events or have reduced clearance. Sulfonylureas, ACE inhibitors, diuretics, metformin, ARBs, NSAIDs, and SGLT2 inhibitors (SADMANS mnemonic) should be temporarily discontinued during acute illness, especially in the context of sepsis, hypovolaemia or hypotension, and recommenced when the condition stabilises.
----------------------------------------------------------------------


======================================================================
CHUNK 487 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_16
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,proteinuria,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Sulfonylureas, ACE inhibitors, diuretics, metformin, ARBs, NSAIDs, and SGLT2 inhibitors (SADMANS mnemonic) should be temporarily discontinued during acute illness, especially in the context of sepsis, hypovolaemia or hypotension, and recommenced when the condition stabilises. 33 Prescribe: medications that slow CKD progression and reduce cardiovascular risk ACE Statin (/- SGLT2 Non-steroidal inhibitor GLP-1 RA ezetimibe) inhibitor MRA or ARB First-line Consider use in: Recommended Indicated for Indicated for treatment people with for use in use in people use in people for all CKD (eGFR people with with CKD (with with CKD if people with 15 mL/ CKD and albuminuria) they also have CKD. min/1. 73m2) proteinuria, associated concomitant Upand CVD risk with or without with type 2 type 2 titrate to 10% and diabetes to diabetes. diabetes. maximum First Nations reduce the risk Not Not tolerated Australians of progressive recommended recommended dose to with CKD and a decline to initiate if for use in reduce CVD risk 5%. in kidney eGFR 25 mL/ people with albuminuria function. min/1. 73m2 kidney failure. and kidney Not or in patients function recommended with a K 5. 0 decline. to initiate if mmol/L. eGFR 25 mL/ min/1. 73m2. Check product information of relevant medication for eligibility criteria and recommended dosages. Clinical tip Clinical tip A reversible drop in eGFR A reversible drop in eGFR is expected with the is also expected with the introduction of ACE inhibitors introduction of SGLT2 inhibitors. or ARBs. Check eGFR within The drop is at its greatest 4 2 weeks following initiation weeks after initiation of therapy, and if reduction of eGFR is after which the eGFR rebounds. more than 25% below baseline Specific testing of eGFR for value, cease the medication this purpose is not required. and consider referral to As SGLT2 inhibitors cause an nephrologist. osmotic diuresis, consider reducing diuretics and/or antihypertensive medications upon initiation of an SGLT2 inhibitor. 34 Kidney Health Australia Managing CKD in Primary Care Reduce: medications excreted by the kidneys Medications that may need to be started at a reduced in dose or ceased in patients with CKD include but are not limited to Anti-infective Cardiovascular Diabetes Pain Other famciclovir apixaban acarbose gabapentin allopurinol nirmatrelvir dabigatran all gliptins opioid benzodiazepines valaciclovir digoxin except analgesics colchicine certain antibiotics rivaroxaban linogliptin pregabalin baclofen e. g. , ciprofloxacin, sotalol insulin duloxetine trimethoprim, and metformin spironolactone escitalopram sulfamethoxazole, sulfonylureas aminoglycosides, solifenacin nitrofurantoin fenofibrate denosumab lithium Many drugs are contraindicated Use metformin at maximum While dose reduction of or not recommended as eGFR dose required and monitor denosumab is not required in declines. Check individual product kidney function annually if eGFR CKD, the risk of hypocalcaemia information for eligibility criteria and 60 mL/min/1. 73m2. Consider increases with more advanced recommended dosage. reducing dose and increase in CKD. In patients with CKD stage 3-5, kidney function monitoring if eGFR discuss with a nephrologist prior 30-60. Only use under specialist to initiation and monitor serum supervision if eGFR 30 mL/ calcium closely. min/1. 73m2.
----------------------------------------------------------------------


======================================================================
CHUNK 488 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_17
Content Type: recommendation
Words: 474
Medical Entities: CKD,GFR,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
73m2. Consider increases with more advanced recommended dosage. reducing dose and increase in CKD. In patients with CKD stage 3-5, kidney function monitoring if eGFR discuss with a nephrologist prior 30-60. Only use under specialist to initiation and monitor serum supervision if eGFR 30 mL/ calcium closely. min/1. 73m2. Metformin should be temporarily interrupted during periods of ill health and/or change in kidney function. Avoid: nephrotoxic medications Commonly prescribed drugs that Commonly prescribed drugs that can adversely affect kidney function should be avoided temporarily in CKD during a sick day (SADMANS) lithium Sulfonylureas aminoglycosides ACE inhibitors NSAIDs/COX-2 inhibitors - beware Diuretics of the triple whammy (See clinical tip) Metformin ARBs NSAIDs SGLT2 inhibitors As part of a sick day action plan, it is important that patients are advised to seek guidance from their healthcare professional on temporarily stopping medications during periods of illness. 35 Clinical tip Patient safety: The triple whammy, a combination of RAS blockade (ACE inhibitor or ARB), diuretic and NSAID or COX-2 inhibitor (except low-dose aspirin) can result in acute kidney injury, especially if the patient is volumedepleted, or CKD is present. Ensure individuals on ACE inhibitor or ARB, plus diuretic blood pressure medication, are aware of the need to discuss appropriate pain relief medication with a GP or pharmacist. Use of radiographic contrast agents in the context of CKD. 46 Contrast-induced nephropathy (CIN) has Please note: long been observed in both experimental eGFR may be overestimated in and clinical studies. However, recent individuals with low muscle mass. observational studies have questioned Risk can be reduced by hydration prior the prevalence and severity of CIN to and after the imaging (including withfollowing intravenous contrast exposure. holding diuretics). The use of imaging requiring contrast needs to be considered in the context of Metformin should be withheld prior to relative benefit of the contrast-enhanced contrast-enhanced imaging if possible. imaging test and risk of CIN. Nephrotoxicity has been reported with gadolinium-enhanced MRI studies in We recommend the following CIN risk people with kidney impairment. 47 This classification for adults: concern for toxicity was largely related to People with eGFR 45 mL/min/1. 73 m2 the association of nephrogenic systemic are at negligible risk for CIN. fibrosis (NSF) in patients with kidney People with eGFR between 30 and 44 impairment (eGFR 30 ml/min/1. 73m2). mL/min/1. 73 m2 are at an intermediate NSF is uncommon and rare with eGFR risk for CIN unless diabetes is present, 30 ml/min/1. 73m2. The risk needs to be which would further increase the risk. considered against the potential benefit of the imaging study. People with eGFR 30 mL/min/1. 73 m2 are at high risk for CIN. F urther information and resources Kidney Health Australia Health NPS Medicinewise. Professional Hub: How to guide Pharmaceutical Benefits Scheme Sick Day Action Plan and Template. (PBS). Australian Medicines Handbook Therapeutic Goods Administration (subscription required). (TGA).
----------------------------------------------------------------------


======================================================================
CHUNK 489 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_18
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,dialysis
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
People with eGFR 30 mL/min/1. 73 m2 are at high risk for CIN. F urther information and resources Kidney Health Australia Health NPS Medicinewise. Professional Hub: How to guide Pharmaceutical Benefits Scheme Sick Day Action Plan and Template. (PBS). Australian Medicines Handbook Therapeutic Goods Administration (subscription required). (TGA). 36 Kidney Health Australia Managing CKD in Primary Care Care approaches Whole-of-practice approach to CKD management Further information and resources The management of CKD is a collaborative effort. A whole-of-practice approach CARI Guidelines: involving the GP, primary healthcare Recommendations for culturally nurse and practice staff, maximises the safe kidney care in First Nations opportunity for best practice care to Australians. occur. Identification of a clinical lead, WA Centre for Rural Health clinical governance, correct coding of - The University of Western CKD and implementation of e-health Australia: Clinical Yarning will all impact outcomes. As kidney eLearning Program function declines, and complications Australian Indigenous and comorbidities increase, a whole-ofHealthInfoNet. practice approach facilitates optimal care. National Aboriginal Community Controlled Health Organisation Use of MBS Item Numbers (NACCHO). There are several MBS item numbers that can be claimed to assist with the detection and management of CKD. These Contraception and include chronic disease management pregnancy in CKD48, 49 items, healthcare assessments, nurse reviews, and allied health visits. Visit Parenthood planning is a core component mbsonline. gov. au for more details. of care for many individuals living with chronic kidney disease (CKD) and kidney Culturally safe kidney care failure. Pregnancy causes major impacts for First Nations Australians on the kidney and can be a kidney stress test. Pregnancy may unmask Healthcare professionals should provide undiagnosed CKD or worsen existing culturally safe care and understand the known CKD. Pregnancies with CKD are diverse factors that can impact kidney high risk, and the risk increases as CKD disease outcomes in First Nations stage worsens. Even early-stage CKD Australians. confers a higher risk of important adverse outcomes, particularly hypertensive In line with the persons personal disorders of pregnancy. Fertility declines preference, include family and community as CKD stage worsens, but ovulation may in appointments, and liaise with Aboriginal occur even with advanced kidney failure. and Torres Strait Islander Health Even being on dialysis is no guarantee Practitioners and interpreters26. an individual with CKD will not become pregnant. An unexpected pregnancy without preconception planning presents challenging choices to people with CKD and their partners. 37 Expert preconception planning is Consultation with a high-risk pregnancy critical to optimise foetal outcomes clinician (e. g. , maternal medicine, obstetric and outcomes for the person giving physician, obstetric nephrologist) is birth. Informing individuals with CKD recommended for people with CKD of that pregnancy will be safer and more any stage, who are planning a pregnancy successful if planned with their clinical or are pregnant. Ideally this should team may provide compelling incentive occur preconception, but definitely once to use contraception and optimise health pregnancy has been confirmed, to enable ahead of conception. Contraception risk stratification and a pregnancy plan.
----------------------------------------------------------------------


======================================================================
CHUNK 490 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_19
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,dialysis,proteinuria,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Ideally this should team may provide compelling incentive occur preconception, but definitely once to use contraception and optimise health pregnancy has been confirmed, to enable ahead of conception. Contraception risk stratification and a pregnancy plan. should be considered for all sexually active people of childbearing age who Considerations in older people have CKD. A particular focus should be Care of elderly people with CKD on women and people with uteruses requires an individualised approach taking teratogenic medication, or those to address comorbidities, together with uncontrolled hypertension or with variability in functional status, life uncontrolled underlying kidney disease. expectancy and health priorities. Responsibility for contraception Relying on creatinine alone causes implementation is likely to fall to the GP. under-recognition of CKD. Contraception choices will be determined eGFR (which is adjusted for age) by patient preferences, the clinical history, improves diagnostic accuracy. and comorbidities. In general, in higher risk people (on teratogenic medications, Dialysis therapy may not be associated advanced CKD, uncontrolled primary with a survival advantage compared disease, kidney transplant), highly with non-dialysis comprehensive effective contraception is recommended, conservative care in elderly patients rather than barrier contraception alone. with two or more comorbidities. Oestrogen-based contraception may In older patients, treatment choice not be ideal in people with hypertension, often has more effect on lifestyle than it past thrombosis, proteinuria, or certain does on mortality or morbidity. conditions (e. g. , lupus). Intrauterine Utilise decision aid tools, such as Kidney devices are generally safe in CKD. Health Australias the My Kidneys My Permanent strategies, i. e. , partner Choice Decision Aid. vasectomy or tubal ligation should be considered for those who have completed their family or are not Clinical tip planning a pregnancy in the future. An eGFR 60 mL/min/1. 73m2 is common in older people but is nevertheless predictive of significantly increased risk of adverse clinical outcomes and should not be considered physiological or age appropriate. 38 Kidney Health Australia Managing CKD in Primary Care Appropriate referral Vaccinations Elderly patients with a stable eGFR These vaccinations are recommended for 30mL/min/1. 73m2, microalbuminuria people aged 18 years and over with CKD: and controlled blood pressure can be managed successfully in primary Influenza (yearly) care. The presence of anaemia may Pneumococcal (5-yearly) be related to CKD and a referral to a COVID-19 nephrologist may be indicated. Herpes Zoster Discuss management issues with a specialist by letter, email, or telephone Refer to the NIP for changes to in cases where it may not be necessary recommendations on vaccinations that for the person with CKD to be seen by may be indicated or recommended for the specialist. use in people with CKD. The decline in eGFR can be variable and may depend on age, acute events, and other factors. Patients with eGFR 30 Further information mL/min/1. 73m2 should be referred to and resources a nephrologist and have a plan created for frequency of monitoring. The National Immunisation Program (NIP) Schedule. Medication considerations The Australian Immunisation Diminished tolerance of side-effects Handbook.
----------------------------------------------------------------------


======================================================================
CHUNK 491 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_20
Content Type: general
Words: 443
Medical Entities: CKD,GFR,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Patients with eGFR 30 Further information mL/min/1. 73m2 should be referred to and resources a nephrologist and have a plan created for frequency of monitoring. The National Immunisation Program (NIP) Schedule. Medication considerations The Australian Immunisation Diminished tolerance of side-effects Handbook. and increased risk of adverse events is common with increased age. Reduced eGFR should lead to reduced doses of many drugs in the elderly. Polypharmacy is common in the elderly and increases the risk of falls, confusion, and functional decline. Home Medicines Reviews and Residential Medication Management Reviews support GP/pharmacist collaboration and are funded by Medicare item numbers. Further information and resources Kidney Health Australia decision aid tools for people affected by CKD and health professionals: My Kidneys My Choice resources. 39 Managing other kidney conditions Acute Kidney Injury (AKI)50, 51 AKI is common, especially in AKI is diagnosed either by detection of hospitalised patients, and is a sudden increase in serum creatinine, independently and strongly associated or with persistent oliguria (see below). with increased morbidity and mortality. Primary care professionals are in a CKD increases the risk of AKI and in unique position to identify people turn, an episode of AKI increases the at increased risk of AKI and address likelihood of subsequent development potentially modifiable exposures to of CKD, kidney failure and death, prevent the occurrence of AKI. highlighting the need for ongoing surveillance. Risk factors for AKI51 Pre-existing risk factors Potentially modifiable kidney insults CKD Pre-kidney: Other chronic diseases, e. g. : Hypovolaemia - diabetes Blood loss - heart/lung/liver disease Hypotension - cancer Shock - anaemia Advanced age Kidney: Critical illness Drug toxicity Post-kidney: Obstruction 40 Kidney Health Australia Managing CKD in Primary Care AIKdIe pnrteivfyeinntgi o n and mHanowag teom ent plan What to do What to do after those at risk diagnose AKI during an AKI an AKI episode episode All people with Increase in Treat the cause. Kidney Health CKD stage 3-5 serum creatinine Seek specialist Check after 3 are at increased to 1. 5 times advice early. months and risk of AKI. baseline, which then annually for Systematic fluid Minimise use is known or assessment subsequent of NSAIDs and presumed to and medication 3 years. other potentially have occurred review for all Education nephrotoxic within the 7 days people at risk and selfdrugs in people prior, or when acute management with CKD. Significant illness occurs. to monitor and Early reduction in reduce risk of identification urine output subsequent of people compared with exposures. at risk with normal output. Record in acute illness, practice records and consider as AKI (resolved). temporary cessation of ACE Inhibitor/ARB/ diuretics with hypovolaemia/ hypotension in line with sick day action plan.
----------------------------------------------------------------------


======================================================================
CHUNK 492 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_21
Content Type: recommendation
Words: 493
Medical Entities: CKD
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
to monitor and Early reduction in reduce risk of identification urine output subsequent of people compared with exposures. at risk with normal output. Record in acute illness, practice records and consider as AKI (resolved). temporary cessation of ACE Inhibitor/ARB/ diuretics with hypovolaemia/ hypotension in line with sick day action plan. Preventing AKI in individuals with CKD who are sick or dehydrated If patients become ill and are unable to maintain adequate fluid intake (e. g. , due to gastrointestinal upset or dehydration) they should be advised to withhold medications which will: Increase risk of decline in kidney function Increase risk for adverse events ACE inhibitors Metformin ARBs Sulfonylureas NSAIDs SGLT2 inhibitors Diuretics 41 Kidney cysts52 Mnemonic for drugs to be avoided on a sick day Simple cysts (SADMANS) Most simple kidney cysts are benign S Sulfonylureas and do not require further investigation. They: are very common (not inherited) - A ACE-inhibitors prevalence 10% are usually asymptomatic D Diuretics can occur with advancing age may be associated with background CKD do not cause kidney failure M Metformin Indications for further review Angiotensin and investigation: A receptor blockers multiple cysts N Non-steroidal bilateral multiple cysts anti-inflammatory cysts with complex internal structure or solid components S SGLT2 inhibitors history of malignancy symptoms from cyst (discomfort, haematuria, infection) rapidly enlarging cysts Polycystic kidney disease (PKD) Further information and resources Polycystic kidney disease (PKD) is a Kidney Health Australia Health group of chronic kidney diseases with Professional Hub: How to formation of multiple cysts in the kidney. guide Sick Day Action Plan The two main types of polycystic kidney Template. disease are, Autosomal Dominant PKD (ADPKD) and Autosomal Recessive PKD (ARPKD), with ADPKD being much more common. PKD is the most common inherited kidney disease. Approximately 10% of people with ADPKD have no family history of the disease. 53 PKD is a common cause of CKD. 42 Kidney Health Australia Managing CKD in Primary Care Consider a diagnosis of PKD if: Age Number of cysts shown on ultrasound Aged 15-39 years At least 3 in total Aged 40-59 years At least 2 in each kidney Aged 60 years or older At least 4 in each kidney Treatments for ADPKD Often the trajectory experienced by other family members provides some insight into their risk for progressive kidney disease. Early referral to Nephrologist is essential to ensure adequate treatment can be initiated. The medication tolvaptan is listed on the PBS for the treatment of adults with early-stage CKD (stage 2 to 3) and rapidly progressing ADPKD. It has shown to slow the progression of cyst development and kidney disease in ADPKD. Refer to the PBS guidelines for guidance on which patients can be prescribed tolvaptan and the relevant rules of prescribing. Clinical management of autosomal dominant polycystic kidney disease (ADPKD) 1. Early referral to a nephrologist is recommended, so appropriate treatment can be initiated. 2. Assess risk for kidney failure based on family history and age at kidney failure. 3.
----------------------------------------------------------------------


======================================================================
CHUNK 493 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_22
Content Type: recommendation
Words: 460
Medical Entities: CKD,GFR,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Clinical management of autosomal dominant polycystic kidney disease (ADPKD) 1. Early referral to a nephrologist is recommended, so appropriate treatment can be initiated. 2. Assess risk for kidney failure based on family history and age at kidney failure. 3. Reduce kidney cyst growth and prevent eGFR decline and hypertension. 4. Evaluate for other kidney complications. 5. Consider genetic testing. 6. Magnetic resonant angiogram (MRA) to screen for intracranial aneurysms in high-risk individuals. Usually, ADPKD is managed in consultation with the nephrology team. See the CARI Guidelines website for specific guidelines for clinical management. Further information and resources CARI Guidelines: Autosomal Dominant Polycystic Kidney Disease. Kidney Health Australia factsheet for people affected by CKD: Polycystic kidney disease. PKD Foundation of Australia. 43 Kidney stones54 Kidney stones are one of the most Prevention of recurrence common disorders of the urinary tract. Typically, existing calcium stones The lifetime risk of developing kidney cannot be dissolved. stones is 1 in 10 for Australian men and The goal of therapy is to reverse the 1 in 35 for women. The risk increases abnormalities detected during the with age and family history. 55 initial workup (e. g. , low urine volume, The most common types of stones are hypercalciuria, hypocitraturia, and calcium oxalate and calcium phosphate. hyperoxaluria). Both dietary and After having one kidney stone, the fluid input changes and the use of chance of a second stone is about medications may be necessary. 5-10% each year. About 30-50% of Refer to an Accredited Practising people with a first kidney stone will Dietitian for a 36-month trial of get a second one within five years, diet and fluid changes before and then the risk declines. initiating drug therapy. Dietary changes to reduce calcium Stone workup oxalate stones include: A general chemistry screen including increasing the fluid intake throughout serum uric acid, calcium, and the day (to maintain at least 2 L of parathyroid status. urine per day). Stone analysis (when available). increasing dietary potassium and phytate (e. g. , nuts, beans) and 24-hour urine volume and chemistries maintain normal calcium intake. (including calcium, oxalate, citrate, and uric acid) are the mainstay of decreasing the intake of oxalate, initial assessment and monitoring of animal protein, sucrose, fructose, response to interventions in adults. sodium, supplemental calcium. Drug therapy (depending on stone type) should be commenced if there is evidence of continued new stone formation, or if there is no or little improvement in the baseline urine chemistries with fluid and diet changes: allopurinol to reduce hyperuricaemia. citrate for hypocitraturia. 44 Kidney Health Australia Managing CKD in Primary Care Acute management The acute management of a stone Clinical tip episode is usually undertaken in an Stone recurrence can be emergency department with urologist prevented in the majority of involvement.
----------------------------------------------------------------------


======================================================================
CHUNK 494 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_23
Content Type: recommendation
Words: 486
Medical Entities: CKD,GFR,dialysis,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
citrate for hypocitraturia. 44 Kidney Health Australia Managing CKD in Primary Care Acute management The acute management of a stone Clinical tip episode is usually undertaken in an Stone recurrence can be emergency department with urologist prevented in the majority of involvement. patients, who adopt a regimen The management of a stone episode, that is devised after initial where the stone is known to be of a evaluation of the stone type size able to be spontaneously passed and risk factors present in the (5 mm), should include the use of individual. an alpha blocker, such as prazosin or tamsulosin. Further information and resources Kidney Health Australia factsheet: Kidney Stones. 45 3 Managing CKD alongside other chronic conditions 46 Kidney Health Australia Managing CKD in conjunction with other chronic conditions CKD rarely occurs in isolation. In a primary care setting, it is very likely that individuals will have a CKD diagnosis that sits alongside one or more other chronic conditions. CKD shares many treatment goals and management strategies with other common chronic conditions, such as diabetes and cardiovascular disease. Taking a whole of person approach and managing chronic conditions in conjunction with one another will lead to improved patient outcomes. Prevalence of heart, stroke and vascular disease (HSVD), diabetes, CKD, and their comorbidity2 CKD and diabetes 1. 3% Diabetes only 3. 1% CKD, diabetes and HSVD 0. 5% Chronic kidney disease (CKD) only Diabetes and HSVD 0. 7% 7. 6% Heart, stroke vascular disease (HSVD) only 3. 5% CKD and HSVD 1. 5% For persons aged 18 and over. Adapted from: Australian Institute of Health and Welfare. (2023). Chronic kidney disease: Australian facts. Retrieved from 47 CKD and cardiovascular disease All people with CKD have an increased risk Clinical decisions based on of experiencing a cardiovascular event. This cardiovascular risk can lead to improved risk increases further and is high for people health outcomes and be useful to with moderate to severe CKD. 56 educate and motivate patients. Both, a reduced eGFR and the presence of albuminuria are independent risk factors for cardiovascular disease (CVD). 29, 56 Clinical tip CKD is a more potent risk factor for CVD than diabetes. 57 People with moderate to Even early-stage CKD constitutes a severe CKD (eGFR 45 mL/ significant risk factor for cardiovascular min/1. 73m2 or uACR 30 mg/ events and death, particularly in the mmol) are considered to have presence of albuminuria. 58 pre-determined high risk of experiencing a cardiovascular For people with CKD, the risk of dying from event in the next 5 years (10% cardiovascular events is up to 20 times probability). For people with greater than the risk of requiring dialysis or eGFR 45-59 mL/min/1. 73m2 transplantation. 4 and/or uACR 3-30mg/mmol, we recommend that their CVD Cardiovascular risk assessment risk is reclassified to a higher risk in people with CKD category. The Australian CVD risk calculator can be used to estimate a persons cardiovascular risk.
----------------------------------------------------------------------


======================================================================
CHUNK 495 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_24
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,dialysis,albuminuria,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
73m2 transplantation. 4 and/or uACR 3-30mg/mmol, we recommend that their CVD Cardiovascular risk assessment risk is reclassified to a higher risk in people with CKD category. The Australian CVD risk calculator can be used to estimate a persons cardiovascular risk. The CVD risk estimate represents the probability of having a cardiovascular Further information event in the next 5 years. and resources People with moderate to severe Kidney Health Australia Evidence CKD (eGFR 45 mL/min/1. 73m2 or Report: Make the Link: Kidney uACR 30 mg/mmol) are considered Diabetes and Heart. to have pre-determined high risk of Kidney Health Australia Health experiencing a cardiovascular event in the Professional Hub: How to guide next 5 years (10% probability). - Make the Link CKD, Diabetes For people with eGFR 45-59 mL/ and CVD. min/1. 73m2 and/or uACR 3-30 mg/mmol, CVD guidelines and Aus CVD risk we recommend that their CVD risk is calculator. reclassified to a higher risk category to reflect albuminuria as a significant driver Kidney Health Australia factsheet of CVD. for people affected by CKD: Make the Link - CKD, Diabetes, Heart Using the Aus cardiovascular risk calculator can be a helpful for determining meaningful and individualised levels of CVD risk. 48 Kidney Health Australia Managing CKD alongside other chronic conditions CKD and diabetes One in three people with diabetes Diabetes is a significant risk factor for will develop CKD. 59 CKD with 40% of cases of kidney failure The presence of diabetes worsens caused by diabetes. This rises to over the outcomes in all stages of CKD 70% for First Nations Australians. 15 (cardiovascular outcomes, dialysis Kidney disease is known to augment survival, and post-transplant survival). 60 cardiovascular risk in diabetes. 61 Diabetes treatment targets in people with CKD: BGL 6-8mmol/L fasting. 8-10 mmol/L postprandial. HbA1c Generally: 53 mmol/mol (range 48-58); 7% (range 6. 5-7. 5) Target should be individualised according to patient circumstances (e. g. , disease duration, life expectancy, important comorbidities, and established vascular complications). HbA1c may not be a reliable indicator of glycaemic control in certain patient populations such as those with iron deficiency (elevated HbA1c) or anaemia (decreased HbA1c). There may be situations where a lower target may be appropriate62. Management Provide advice on positive lifestyle Some medications may need to be changes (see -32). reduced in dose or ceased in CKD Optimal blood glucose control (refer to tables on pages 34-35). significantly reduces the risk of When considering available diabetes developing microalbuminuria, treatment options, it is important to macroalbuminuria and/or overt note that the presence of CKD may nephropathy in people with type increase the risk of hypoglycaemia, 1 or type 2 diabetes. particularly as CKD progresses. 63 The The definition of optimal will vary mechanisms relate to clearance of depending on the balance between endogenous and exogenous insulin. benefits and risks and the individuals Hypoglycaemia becomes more priorities62 (see Management of frequent as eGFR declines and Type 2 Diabetes: A handbook for medications may need to be adjusted general practice, for individualised accordingly. recommendations).
----------------------------------------------------------------------


======================================================================
CHUNK 496 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_25
Content Type: recommendation
Words: 500
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
benefits and risks and the individuals Hypoglycaemia becomes more priorities62 (see Management of frequent as eGFR declines and Type 2 Diabetes: A handbook for medications may need to be adjusted general practice, for individualised accordingly. recommendations). 49 Commonly used diabetes medications Check individual product information and PBS listings for prescribing criteria and guidance. Indications and dosing guidance may have changed since publication. Medication CKD Dosing Comments Class Metformin For people with eGFR 60 mL/ Should be stopped min/1. 73m2, use metformin at temporarily during maximum dose required and periods of illness due monitor kidney function annually. to potential risk of lactic For people with eGFR 30-60 consider acidosis. reducing the dose and increasing kidney function monitoring to every 3-6 months. For people with eGFR 30 mL/ min/1. 73m2, only use under specialist supervision. SGLT2 SGLT2 inhibitors currently available Significant kidney and inhibitors in Australia: cardiovascular benefits Dapagliflozin conferred in people no dose adjustment required. with CKD with and without diabetes. 64-69 Initiation not recommended if eGFR 25 mL/min/1. 73m2. Possible side effects include, euglycaemic Empagliflozin diabetic ketoacidosis no dose adjustment required. (eDKA), thrush. contraindicated if eGFR Cease when 30 mL/min/1. 73m2 in people commencing kidney with diabetes. replacement therapy. Ertugliflozin If prescribing for CKD or contraindicated in patients heart failure in absence with CKD stage 4 or 5 or eGFR of diabetes, dosing persistently 45 mL/min/1. 73m2. guidance may differ. kidney function should be monitored. Finerenone Not currently indicated Nonsteroidal Initiation not recommended for diabetes management MRA if eGFR 25 mL/min/1. 73m2 when CKD is not present. or serum K 5. 0 mmol/L. Consider increasing Hyperkalaemia monitoring. Stop, if serum potassium 5. 5mmol/L. Cease when commencing kidney replacement therapy. 50 Kidney Health Australia Managing CKD alongside other chronic conditions Medication CKD Dosing Comments Class Dipeptidyl Linagliptin Not suitable DPP-4 no dose adjustment required for people with for people inhibitors CKD. with history of (gliptins) Sitagliptin pancreatitis. reduce dose if eGFR 45 mL min/1. 73m2. Risk of Saxagliptin hypoglycaemia can be reduce dose if eGFR 45 mL/min/1. 73m2 increased if use with caution if eGFR 15-30 mL/min/1. 73m2. prescribed with not recommended if eGFR 15 mL/min/1. 73m2 sulphonylureas. or requiring dialysis. Vildagliptin no dosage adjustment required if eGFR 60 mL/min/1. 73m2. reduce dose if eGFR 15-59 mL/min/1. 73m2. limited experience in individuals with kidney failure, thus should be used with caution in this group. Alogliptin Reduce dose if eGFR 50 mL/min/1. 73m2. Sulfonylurea Sulfonylureas As eGFR (SU) reduce dose if eGFR 30 mL/min/1. 73m2. declines, risk of Glibenclamide hypoglycaemia increases. contraindicated if severe reduction in kidney function. GLP-1 Semaglutide Potential receptor no dose adjustment required in CKD. cardiovascular agonist not recommended for use in patients with and kidney kidney failure (eGFR 15 mL/min/1. 73m2). benefits. 70 Dulaglutide Limited data on no dose adjustment required if use in people with eGFR 15 mL/min/1. 73m2. eGFR 30 mL/ min/1. 73m2). not recommended for use when eGFR 15 mLmin/1. 73m2. Insulin Dose adjusted to blood sugar level As eGFR declines, risk of hypoglycaemia increases.
----------------------------------------------------------------------


======================================================================
CHUNK 497 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_26
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
73m2). benefits. 70 Dulaglutide Limited data on no dose adjustment required if use in people with eGFR 15 mL/min/1. 73m2. eGFR 30 mL/ min/1. 73m2). not recommended for use when eGFR 15 mLmin/1. 73m2. Insulin Dose adjusted to blood sugar level As eGFR declines, risk of hypoglycaemia increases. For consistency, we interchanged Creatinine clearance (CrCl) with eGFR. Please note that CrCl overestimates glomerular filtration rate (GFR) and estimated CrCl differs from estimated GFR. The Cockcroft-Gault equation estimates CrCl in mL/min while the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation estimates GFR in mL/min/1. 73m2, . 71 51 Further information and resources RACGP Management of type 2 diabetes: A handbook for general practice. Kidney Health Australia factsheet for people affected by CKD: Diabetic kidney disease. KDIGO guidelines: Diabetes in CKD. Australian Diabetes Society. CKD and hypertension Hypertension is both a cause and a complication of CKD and can be difficult to control. The risks of uncontrolled hypertension include, progression of kidney disease and increased risk of coronary heart disease and stroke. Hypertension should be considered as part of cardiovascular risk (see ). Hypertension treatment targets Who? Target All people with CKD Maintain blood pressure consistently below 130/80 mmHg Some evidence and clinical guidelines suggest aiming for a lower blood pressure target (systolic BP 120mmHg) in people with CKD who are at high CVD risk may improve outcomes. 72-75 Aiming for a systolic blood pressure of 120 mmHg may be appropriate in certain individuals who are at very high cardiovascular risk. Lower blood pressure targets need to be balanced with an increased risk of side effects including: increased risk of falls due to hypotension, electrolyte abnormalities and episodes of AKI. 52 Kidney Health Australia Managing CKD alongside other chronic conditions Algorithm for management of hypertension in people with CKD Person has CKD Is blood pressure consistently below target (130/80 mmHg)? Consider using Ambulatory Blood Pressure Monitoring (ABPM) and/or Home Blood Pressure Monitoring (HBPM) Yes No Continue to monitor blood pressure Start ACE inhibitor or ARB Manage lifestyle risk factors Monitor eGFR and K Continue to monitor blood pressure (consider home monitoring) Manage lifestyle risk factors Yes Is blood pressure consistently below target? No Encourage medication and lifestyle adherence Increase ACE inhibitor or ARB to maximum recommended dose Consider adding: calcium channel blocker, or diuretic, or beta blocker Refer to nephrologist if blood pressure is not consistently below target with at least 3 anti-hypertensive agents Yes Is blood pressure consistently below target? No 53 Management Blood Pressure Monitoring Reducing blood pressure to below 24-hour ambulatory blood pressure target levels is one of the most monitoring (ABPM) or home blood important goals in the management pressure monitoring (HBPM) have been of CKD. shown to better correlate with target Lifestyle changes should always be organ damage and cardiovascular advocated and can have a significant mortality and morbidity when effect on blood pressure (see pages compared to office BP measurements. 29-32) for guidance on basic lifestyle Use of ABPM or HBPM can also aid advice).
----------------------------------------------------------------------


======================================================================
CHUNK 498 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_27
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
29-32) for guidance on basic lifestyle Use of ABPM or HBPM can also aid advice). the diagnosis of masked hypertension, Target BP 130/80 mmHg ideally with over treatment (hypotension) and an ACE inhibitor or ARB alone or in monitor response to antihypertensive combination with CCB, diuretic, or beta treatment. The use of ABPM is blocker. rebated by MBS, if done to confirm the diagnosis and before starting When treatment with an ACE inhibitor medication. or ARB is initiated, the GFR can decrease, and potassium levels can HBPM when combined with education rise (see pages 34 68 for more may increase adherence and improve information). overall blood pressure control. If the serum potassium concentration Where feasible HBPM should be is greater than 6 mmol/L despite considered to aid in the diagnosis and dose reduction, diuretic therapy, and management of hypertension. dietary potassium education, then ACE Sphygmomanometers requiring inhibitor, ARB, and steroidal and noncalibration must be serviced regularly steroidal MRAs should be stopped. according to the manufacturers Multiple medications (often 3 or instructions. more drugs) are needed to control hypertension adequately in most people with CKD. Consider sleep apnoea as a cause of resistant hypertension. 54 Kidney Health Australia Managing CKD alongside other chronic conditions Commonly used anti-hypertensive medications Medication Notes on use in people with CKD ReninEssential part of the best care approach for many Angiotensin patients in all stages of CKD. System (RAS) Based on many clinical trials demonstrating their inhibitors - e. g. , effectiveness in decreasing proteinuria and delaying CKD ACE inhibitors or progression, the use of RAS inhibitors is recommended as ARBs the first-line pharmacologic strategy for patients with CKD and proteinuria with and without diabetes. They cause a reduction in glomerular blood flow, and GFR can decline when treatment is initiated. Provided the reduction is less than 25% within two weeks of starting therapy, the ACE inhibitor or ARB should be continued. If the reduction in GFR is greater than 25% below the baseline value, the ACE inhibitor or ARB should be ceased, and a referral to a nephrologist considered. In general, combined therapy with ACE inhibitor and ARB is not recommended. Caution should be exercised if baseline potassium is 5. 5 mmol/L, as rises in serum potassium of approximately 0. 5 mmol/L are expected (see ). ACE inhibitors or ARBs can be safely prescribed at all stages of CKD and should not be ceased as GFR progressively declines but continued if tolerated. 76 Calcium May be used for people with angina, the elderly and those channel with systolic hypertension. blockers Diuretics (e. g. , Loop diuretics are effective in all stages of CKD including thiazides and when GFR is severely reduced to 30 mL/min/1. 73m2. loop diuretics) Typical doses are 20-120 mg/day, but higher doses (up to 500 mg/day) may be required, especially at lower levels of eGFR. When more than 80 mg/d is required, the efficacy is improved by dividing the daily dose.
----------------------------------------------------------------------


======================================================================
CHUNK 499 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_28
Content Type: recommendation
Words: 486
Medical Entities: CKD,GFR,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
73m2. loop diuretics) Typical doses are 20-120 mg/day, but higher doses (up to 500 mg/day) may be required, especially at lower levels of eGFR. When more than 80 mg/d is required, the efficacy is improved by dividing the daily dose. Thiazides can be effective at low levels of eGFR, particularly in combination with loop diuretics. For more information on managing oedema, see. 55 Medication Notes on use in people with CKD Beta-blockers Beta-blockers are useful agents for blood pressure control in people with CKD. For use of beta-blockers in heart failure, refer to the National Heart Foundation Australia guidelines. 77 Steroidal MRA Steroidal MRAs may be used for people with concomitant heart failure or hypertension. Use with caution in CKD and in combination with RAS blockade, due to risk of decline in eGFR and hyperkalaemia. Non-steroidal MRAs can be safely used in the setting of type 2 diabetes and CKD. Steroidal and nonsteroidal MRAs should not be prescribed together. For both agents, it is recommended to monitor potassium carefully. Clinical tip ACE inhibitors, ARBs, SGLT2 inhibitors and diuretics should be temporarily discontinued during acute illness, especially in the context of sepsis, hypovolaemia, or hypotension, and recommenced when the condition stabilises. Clinical tip ACE inhibitors and ARBs cause a reversible reduction in glomerular blood flow and GFR can decline when treatment is initiated. Check eGFR within 2 weeks following initiation. Provided the reduction is less than 25% within two weeks of starting therapy, the ACE inhibitor or ARB should be continued. If the reduction in GFR is greater than 25% below the baseline value, the ACE inhibitor or ARB should be ceased, and referral to a nephrologist considered. Further information and resources St Georges Community and Health Services: Home Blood Pressure Monitoring. KDIGO guidelines: Blood Pressure in CKD. Kidney Health Australia factsheet for people affected by CKD: Blood pressure and CKD. 56 Kidney Health Australia Managing CKD alongside other chronic conditions CKD and heart failure Remembering the SADMANS mnemonic is of particular importance, as well as the restarting of all appropriate and tolerated CKD commonly occurs with heart failure medication, once the person recovers (HF), which is a common cause for from any acute episodes of decline. (See hospitalisation, morbidity, and mortality pages 41-42 for further information on in people with kidney disease. 78 sick day management). Cardiorenal syndrome describes a number It is important to consider patient of conditions where an acute or chronic wellbeing when treating a person with dysfunction in the heart or kidneys leads to concomitant HF and CKD. A higher the dysfunction of the other organ. 79 serum creatinine as a results of fluid management in HF may be deemed Management: acceptable if it aids the patients ability to Input from an interdisciplinary team, breathe normally. including a HF and kidney specialist may Use of cardio-selective beta-blockers, be necessary when providing care for renin-angiotensin system inhibitors people with concominant HF and CKD.
----------------------------------------------------------------------


======================================================================
CHUNK 500 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_29
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
including a HF and kidney specialist may Use of cardio-selective beta-blockers, be necessary when providing care for renin-angiotensin system inhibitors people with concominant HF and CKD. 78 (RAS inhibitors), angiotensin receptor- Medical management of CKD in the neprilysin inhibitors (ARNIs)80 and MRAs context of HF can be challenging due to in patients with HF and CKD stages the need to balance the differing effects 13 have shown both symptom and of medications on both the kidney and outcome benefits. 78 Nevertheless, due the heart. 79 to the increased risk of hyperkalaemia Medications may need to be increased and concerns regarding kidney function or decreased, or temporarily stopped, decline, ARNIs, RAS inhibitors and MRAs especially when patients are unwell. are often sub-optimally prescribed. 78 Medication RAS inhibitors Should be used with usual advised precautions, i. e. , associate decline in eGFR 25% with appropriate dose adjustments and/or ARNIs stopping medication(s) temporarily and restarting at low doses, MRAs up-titrating slowly to tolerated dose. ARNIs should not be prescribed together with an ACE inhibitor. Steroidal MRAs should not be used together with non-steroidal MRAs. Monitor potassium carefully. SGLT2 Use of SGLT2 inhibitors is recommended in the management of inhibitors HF in patients with CKD of any stage, where indications for use of SGLT2 inhibitors are met. Initiating an SGLT2 inhibitor in patients with an eGFR 25 mL/ min/1. 73m2 is not recommended due to limited evidence. IV iron Use of IV iron therapy is recommended in the management of HF in patients with CKD of any stage, where indications for use of IV iron are met. 57 4 Common issues in CKD 58 Kidney Health Australia Early detection and intervention Albuminuria32 have been shown to reduce the progression of CKD and its Albuminuria is an important prognostic complications. It is essential to feature in CKD. The degree of albuminuria regularly check for the known relates to the severity of the kidney complications of CKD and to disease and likelihood of progression to monitor treatment targets. kidney failure. The amount of albuminuria can be reduced significantly with an ACE inhibitor or ARB agent, SGLT2 inhibitor Acidosis and non-steroidal MRA (the latter in the context of type 2 diabetes). Reduction in the amount of albuminuria is associated People with eGFR 30 mL/min/1. 73m2 are with improved outcomes. 83 at increased risk of metabolic acidosis. The main factor is decreased kidney acid excretion compounded by a reduction Target: in bicarbonate production. Acidosis contributes to demineralisation of bone uACR reduction of at least 30%. 20-23 and increased protein degradation, which may be associated with increased morbidity. Management Management Stepwise approach for treating persistent macroalbuminuria: Supplementation with sodium bicarbonate (840 mg capsule) may be 1. Start an ACE inhibitor or ARB if not considered in people with acidosis: already using for hypertension. - typical starting dose would be 2. Up-titrate ACE inhibitor or ARB to 1 capsule od or bd, increasing up maximum tolerated dose (monitoring to 2 tablets bd if needed, and titrating hypotension or hyperkalaemia).
----------------------------------------------------------------------


======================================================================
CHUNK 501 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_30
Content Type: reference
Words: 496
Medical Entities: CKD,GFR,dialysis,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
- typical starting dose would be 2. Up-titrate ACE inhibitor or ARB to 1 capsule od or bd, increasing up maximum tolerated dose (monitoring to 2 tablets bd if needed, and titrating hypotension or hyperkalaemia). to normalise the HCO3 level. 3. Add an SGLT2 inhibitor where - higher doses can be prescribed but indicated. carry a higher risk of fluid overload. 4. If the person has type 2 diabetes, Increased sodium load may worsen consider adding a non-steroidal MRA blood pressure control. to reduce CKD progression and CVD events. A base-producing diet of predominantly fruits and vegetables can improve 5. If the person has type 2 diabetes, metabolic acidosis and slow down consider adding a GLP-1 RA. Early kidney function decline. 81, 82 evidence suggests that GLP-1 RA may have benefits on kidney and cardiovascular outcomes in people with type 2 diabetes. 70, 84 59 Anaemia85 Management Iron studies should be conducted in Anaemia in CKD is related to: people with stage 3-5 CKD as part of their regular assessment under the reduced erythropoietin orange and red clinical action plans production by the kidney; (see pages 27-28). This allows for earlier resistance to the action of identification and treatment erythropoiesis stimulating of anaemia. agents (ESA); In people with CKD, other forms of reduced absorption of iron. anaemia should be considered and Anaemia related to CKD usually starts excluded: to develop when the GFR is less than Iron deficiency (absolute and 60 mL/min/1. 73m2. The prevalence functional) is a common cause of of anaemia increases with decreasing anaemia in people with CKD. GFR. If absolute iron deficiency is identified, causes including GI blood loss should be considered and excluded. Target: Vitamin B12 and folate levels should Hb 100 115 g/L. be checked and corrected if deficient. Prior to commencement of Note, long-term use of proton pump ESA: Trial iron supplementation, inhibitors (PPI) is associated with maintaining ferritin 100 mcg/L; vitamin B12 deficiency. TSAT 20% Thyroid stimulating hormone should be Once ESA commenced: Maintain assessed and hypothyroidism treated if ferritin 200-400 mcg/L; TSAT 20% present. Both significant hyperparathyroidism and systemic inflammation may contribute to anaemia and may cause refractoriness to erythropoietin therapy. Ensure adequately iron replete with either oral or IV iron. Treatment with ESA must be managed by a nephrologist. There are several ESAs currently available for this indication in Australia. All are available as pre-filled syringes and are usually administered subcutaneously to those with CKD or on peritoneal dialysis patients and intravenously to those on haemodialysis. For further guidance on anaemia in CKD refer to the CARI guidelines at www. cari. org. au 60 Kidney Health Australia Common issues in CKD Cognitive decline Depression86 It is important to assess cognition Depression can affect 1 in 5 people with in people with CKD. CKD, and 1 in 3 individuals on dialysis. Cognitive impairment is common Depression in people with CKD has in people with CKD and prevalence detrimental effects on mortality, rates of increases with CKD severity.
----------------------------------------------------------------------


======================================================================
CHUNK 502 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_31
Content Type: recommendation
Words: 491
Medical Entities: CKD,GFR,dialysis,albuminuria
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
CKD, and 1 in 3 individuals on dialysis. Cognitive impairment is common Depression in people with CKD has in people with CKD and prevalence detrimental effects on mortality, rates of increases with CKD severity. hospitalisation, medication and treatment adherence, nutrition, and overall Cognitive impairment is an important Quality of Life. Treatment of depressive factor when approaching kidney failure symptoms in people with CKD has the as it will influence treatment choices potential to improve health outcomes. and decision-making about future care. Management The presence of CKD: Screen regularly and maintain a Can affect global cognition, attention, high level of clinical awareness for memory and executive functions. depression. Consider use of DASS-21 Independently contributes to a decline or Kessler K10. in physical and cognitive functions in Modifiable causes of depression that older adults. are commonly experienced by people Can double the risk for physical with CKD (e. g. insomnia, medication impairment, cognitive dysfunction, side-effects, inadequate dialysis) should and frailty in those 70 years. be considered and excluded. Is a risk factor for accelerated aging. Treatment of persistent depressive symptoms involves a combination Management of non-medication therapies (e. g. education, cognitive behavioural Cognition affects many aspects therapy, exercise programs) and of CKD care. antidepressant medication. Things to consider in primary care Selective serotonin reuptake assessments are: inhibitors (SSRIs) have established - Screen for cognitive impairment in safety in people with CKD. 86 CKD, e. g. , with Mini-Mental State (For a detailed list of the most common Examination (MMSE) or Montreal classes of antidepressant medications Cognitive Assessment (MoCA) with suggested dosing in kidney - Safety impairment, and potential adverse - Medication adherence effects refer to the article referenced). - Medication review In patients with chronic conditions, depression and anxiety is often an - Falls impairment to their self-management - Risk of delirium strategies. Consider a General Practice - Association with depression Mental Health Care Plan referral to a - Self-care issues and engagement psychologist for psychological support. with care - Frailty 61 Under the age of 40, isolated Further information haematuria (haematuria without and resources albuminuria, reduced GFR, or urinary tract malignancy) is usually due to an Head to Health - information on underlying glomerulonephritis with a mental health for individuals and low propensity for progression. Annual health professionals. follow-up is recommended to monitor General Practice Mental for progressive disease. 87 Health Standards Collaboration - resources for health Assessment88 professionals. If a dipstick is positive for haematuria, Beyond blue - information for results should be confirmed by individuals. performing a urine analysis with Black Dog Institute - information microscopic evaluation of the urinary and resources for individuals and sediment of a freshly voided, cleanhealth professionals. catch, midstream urine sample. Kidney Health Australia factsheet Urine microscopy can sometimes for people affected by CKD: be used to determine the origin of Depression and Chronic Kidney the blood glomerular versus nonDisease. glomerular. Non-glomerular bleeding warrants urological investigation. Glomerular bleeding should prompt Haematuria a Kidney Health Check.
----------------------------------------------------------------------


======================================================================
CHUNK 503 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_32
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,albuminuria
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
catch, midstream urine sample. Kidney Health Australia factsheet Urine microscopy can sometimes for people affected by CKD: be used to determine the origin of Depression and Chronic Kidney the blood glomerular versus nonDisease. glomerular. Non-glomerular bleeding warrants urological investigation. Glomerular bleeding should prompt Haematuria a Kidney Health Check. The most common causes of Management haematuria are non-glomerular conditions such as menstrual Persistent microscopic haematuria, contamination or urological conditions with or without albuminuria, should (urinary tract infection (UTI), kidney prompt investigation for urinary tract calculi, prostatic disease, or urinary malignancy in appropriate age groups. 87 tumours). Persistent haematuria in the absence Visible (or macroscopic) haematuria of albuminuria should be followed must always be investigated. up annually with repeat testing for haematuria, albuminuria, eGFR and Haematuria due to intrinsic kidney blood pressure monitoring as long as disease is called glomerular the haematuria persists. 87 haematuria. Family members should also be Persistent haematuria, or haematuria screened for haematuria. found in conjunction with other indicators of kidney damage necessitates investigation. 62 Kidney Health Australia Common issues in CKD Algorithm for the management of persistent microscopic haematuria Persistent microscopic haematuria Rule out infection Action: Check urine microscopy and culture Infection is not present Infection is present Is there associated albuminuria Manage urinary tract and / or reduced eGFR? infection and retest Yes No Consider glomerular causes Consider urologic malignancy Actions: if risk factors present consider underlying Actions: glomerulonephritis urine cytology x 3 urinary tract ultrasound urinary tract ultrasound manage according to CKD clinical referral to urologist for action plan consideration of cystoscopy referral to nephrologist Risk factors: age 40; history of macroscopic haematuria; smoking; pelvic irradiation; exposure to occupational chemicals, dyes or cyclophosphamide. 63 Hyperuricaemia Hyperuricaemia is common in Management patients with metabolic syndrome and In the presence of gout, uric acid metabolic syndrome is common in lowering therapy may be indicated. people with CKD. Since allopurinol and its metabolites Certain dietary factors can stimulate are excreted by the kidney, impaired uric acid production, including purinekidney function may lead to retention rich meats (especially seafood, organ of the drug and/or its metabolites with meats), beer (because of the alcohol consequent prolongation of plasma and yeast content), and fructose half-lives. When initiating allopurinol in (including fruits, honey, sugar, and high people with CKD, a starting dose of 50fructose corn syrup). 100 mg/day is recommended depending Other stimuli for uric acid production on the stage of CKD. 90 include ischaemia, heat stress, and Colchicine may be used to manage an conditions associated with rapid cell acute flare of gout, however a reduction turnover (e. g. , tumour lysis syndrome). in the size of individual doses, an Uric acid is also generated increase in the interval between doses intracellularly under conditions in which or a reduction in the total daily dosage aldose reductase is induced, such as may be necessary in patients with CKD. with high glycaemic carbohydrates, salty Specifically, it is recommended that foods, and dehydration. 89 dosage be reduced by half if eGFR 50 mL/min/1.
----------------------------------------------------------------------


======================================================================
CHUNK 504 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_33
Content Type: recommendation
Words: 489
Medical Entities: CKD,GFR,albuminuria,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
with high glycaemic carbohydrates, salty Specifically, it is recommended that foods, and dehydration. 89 dosage be reduced by half if eGFR 50 mL/min/1. 73m2 and that colchicine Hyperuricaemia is associated with not be used if the patients eGFR 10 hypertension, gout, non-alcoholic fatty mL/min/1. 73m2, . 91 A short course of liver disease, CKD, and cardiovascular prednisolone can be helpful in this diseases due to increased oxidative instance. Low dose urate-lowering stress, inflammation, and apoptosis. therapy (allopurinol 50 mg/d) may be commenced during the acute attack, in addition to adequate treatment for the acute attack. Dietary approaches that lower insulin resistance also reduce serum urate. 92, 93, 94 In the absence of acute gout, pharmacological lowering of uric acid with allopurinol is not recommended. 95 Treatment with allopurinol does not slow the decline in eGFR in patients with CKD alone nor CKD with diabetes96. Further information and resources CARI Guidelines: Urate-lowering therapy for people with chronic kidney disease. 64 Kidney Health Australia Common issues in CKD Hyperkalaemia Lipids People with CKD have a characteristic lipid Target: pattern of hypertriglyceridaemia and low Potassium 6. 0 mmol/L. HDL cholesterol levels but normal LDL cholesterol levels. 98 Dyslipidaemia is more severe in individuals with albuminuria, In CKD, excretion of potassium (K) in the particularly those with nephrotic urine is impaired. Potassium levels may syndrome. also rise with the use of ACE inhibitors No target lipid level is recommended. or ARBs used to treat hypertension or with use of steroidal or non-steroidal Management99 MRA. Potassium levels consistently above 6. 0 mmol/L are of concern and In adults with newly identified CKD, should be managed. Hyperkalaemia, evaluation with a fasting lipid profile is especially potassium levels 6. 5 mmol/L, recommended. predisposes to cardiac arrhythmias. Consider secondary causes and specialist evaluation if severely elevated Management fasting lipid levels (LDL-cholesterol 4. 9 Potassium 6. 0 6. 5 mmol/L: mmol/L or triglycerides 11. 3 mmol/L). Follow-up measurement of lipid levels Avoid ultra-processed foods. is not required for the majority of Low K diet (discuss with an patients. Accredited Practising Dietitian). Statin (/-ezetimibe) for people with Correct metabolic acidosis (Normalise CKD (eGFR 15 mL/min/1. 73m2) and serum HCO via dietary and/or 3 CVD risk 10%, and for First Nations pharmacological intervention). Australians with CKD and CVD risk 5%. Consider commencing potassium Lifestyle advice if hypertriglyceridaemia wasting diuretics (e. g. , thiazides). is present. Avoid salt substitutes which may be high in K. 97 Consider a cation exchange resin Further information (e. g. , sodium polystyrene sulfonate) and resources or a non-absorbent cation exchange CARI Guidelines: Management polymer (e. g. , patiromer) for eligible of cholesterol-lowering therapy patients (refer to PBS criteria). in people with chronic kidney Cease ACE inhibitor, ARB, steroidal disease. MRA, non-steroidal MRA if K persistently 6. 0 mmol/L and not responsive to above therapies. 87 Potassium 6. 5 mmol/L: Refer to nearest Emergency Department if K 6. 5 mmol/L due to the risk of arrhythmia.
----------------------------------------------------------------------


======================================================================
CHUNK 505 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_34
Content Type: evidence
Words: 488
Medical Entities: CKD,GFR
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
in people with chronic kidney Cease ACE inhibitor, ARB, steroidal disease. MRA, non-steroidal MRA if K persistently 6. 0 mmol/L and not responsive to above therapies. 87 Potassium 6. 5 mmol/L: Refer to nearest Emergency Department if K 6. 5 mmol/L due to the risk of arrhythmia. 65 Malnutrition40 Mineral and bone disorder32, 103, 104 Poor food intake due to anorexia in CKD can lead to malnutrition. See for Changes in the metabolism of calcium, more information on nutrition and CKD. phosphate, parathyroid hormone and Management vitamin D typically start to occur once GFR 60 mL/min/1. 73m2. Dietary advice (refer to an As kidney function decreases, the Accredited Practising Dietitian). clearance of phosphate by the kidneys Malnutrition screening tools may is diminished, leading to higher serum be useful to identify those with phosphate levels. unintentional weight loss and poor Levels of calcitriol, the most active appetite. form of vitamin D, fall because kidney function is required for its synthesis. Calcium levels may fall as a result of less vitamin D dependent calcium uptake from the gastrointestinal tract. Further information and resources The combined effects of higher phosphate, lower calcium and lower MUST Malnutrition Universal vitamin D levels all serve to stimulate Screening Tool (for adults). 100 parathyroid hormone (PTH) production. Malnutrition Screening Tool Elevated PTH levels increase the (MST). 101 reabsorption and release of mineral MNA-SF MiniNutritional from bone. Assessment short form (for These changes are associated with people aged 65 and over). 102 an increased risk of fracture and cardiovascular mortality, perhaps mediated by accelerated vascular calcification. 66 Kidney Health Australia Common issues in CKD Management Muscle cramps The management of CKD Bone Mineral Disorder (CKD-BMD) is complex and Muscle cramps are unpleasant and often usually occurs via a nephrologist. reported in more advanced CKD. They may be related to electrolyte disorders, CKD-BMD does not usually need to be hypocalcaemia, and volume depletion. tested for or addressed in CKD stage 1-3. In patients with CKD stage 3-5 Management with evidence of CKD-MBD and/or risk factors for osteoporosis, we suggest Treatment is directed towards BMD testing to assess fracture risk if correcting electrolyte abnormalities. results will impact treatment decisions. There is no evidence to show that Lower Dexa BMD predicts incident magnesium supplementation effectively fractures in patients with CKD stage 3-5. reduces muscle cramps. No specific anti-resorptive is preferred. In patients with CKD stage 3-5, Oedema treatments of CKD-MBD, such as denosumab, should be discussed with a nephrologist prior to initiation. Serial Fluid retention and overload may become serum calcium, phosphate and PTH are a problem with worsening CKD severity. helpful in determining treatment. Oedema is rarely caused by early-stage CKD alone (except in nephrotic syndrome) The risk of hypocalcaemia following and is more a feature of advanced stage denosumab increases with more CKD. advanced CKD and serum calcium should be closely monitored. Oedema may manifest most Aim for a serum phosphate towards commonly as ankle (pedal) oedema.
----------------------------------------------------------------------


======================================================================
CHUNK 506 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_35
Content Type: recommendation
Words: 478
Medical Entities: CKD,GFR,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
advanced CKD and serum calcium should be closely monitored. Oedema may manifest most Aim for a serum phosphate towards commonly as ankle (pedal) oedema. normal ranges (consider referral to a The clinical assessment should kidney dietitian to reduce phosphate include blood pressure, respiratory in diet) and avoid hypercalcemia. The examination when assessing patients optimal level for PTH in the setting of with ankle oedema. CKD is not known. Hypertension is common in fluid In early CKD, vitamin D level may be overload. monitored and replaced if deficient. Pulmonary oedema may be a feature With more advanced CKD, calcitriol of more advanced CKD. is preferred in the presence of Ascites may be seen in severe fluid hypocalcaemia due to the inability of overload. the kidney to hydroxylate 25 vitamin D. Biomarkers such as brain natriuretic As CKD is associated with vascular peptide (BNP) to assess heart failure calcification, care is required may be unreliable in patients with CKD. not to overload with calcium Note, BNPs are not covered by the supplementation. 105 MBS. 67 The potential causes of oedema Pain management in patients with CKD to consider are: CKD reduced water excretion and Pain is a common symptom in patients reduced urine output with advanced CKD and kidney failure, and it can impact significantly on Quality Nephrotic syndrome (urine protein loss of Life and function. and low blood albumin) Medications (calcium channel blockers The approach to management includes nifedipine, steroids) a detailed history and examination to determine the specific pain syndrome Sodium retention and/or excess e. g. , diabetic peripheral neuropathy, or sodium intake osteoarthritis. Congestive heart failure Localised pain Liver disease and low albumin Localised pain (nociceptive, soft tissue) Lymphoedema may be treated with topical therapies Vascular causes including deep vein like herbal liniment, or a topical massage thrombosis (DVT) cream such as capsaicin or salicylates, or Dependent oedema (gravity, poor a gel based NSAID. mobility) Severe pain Ankle oedema Severe pain requires systemic treatment. Following the WHO analgesic ladder is Mild ankle oedema that is not recommended: symptomatic may be managed conservatively with raising legs, using Step 1: Non-opioid analgesia stockings and moderate sodium Regular paracetamol is safe in kidney restriction. failure. Use 1g qid if needed, as the Calcium channel blockers are a first line and background treatment. common cause of ankle oedema, Systemic NSAIDs are best avoided. which may warrant consideration of an alternative antihypertensive agent. Step 2: Weak opioids Diuretic therapy with loop and thiazide Codeine and tramadol can be used diuretics should be used for treating cautiously in people with CKD. ankle oedema only after assessment of For people with eGFR between volume status has occurred. 20-50 mL/min/1. 73m2, dosing is as the same as for people with normal Diuretic resistance may occur in later kidney function, but with close stages of CKD diuretic doses may need monitoring of kidney function. to increase.
----------------------------------------------------------------------


======================================================================
CHUNK 507 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_36
Content Type: recommendation
Words: 499
Medical Entities: CKD,GFR,dialysis
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
20-50 mL/min/1. 73m2, dosing is as the same as for people with normal Diuretic resistance may occur in later kidney function, but with close stages of CKD diuretic doses may need monitoring of kidney function. to increase. Codeine and tramadol are not Refractory oedema in advanced CKD routinely used in people with is usually an indication to commence advanced CKD and must be avoided dialysis. when eGFR 20 mL/min/1. 73m2, as accumulation of the drugs are common with serious side effects. 68 Kidney Health Australia Common issues in CKD Step 3 Strong opioids 2. Tricyclic antidepressants Many short-acting and long-acting Amitriptyline 10 mg nocte. Titrate up strong opioids can be used in to 25 mg nocte after 3-7 days, and to people with CKD with appropriate 50 mg nocte after 1-2 weeks. dose adjustment. Treatment should If no efficacy at 50 mg nocte, be individualised according to consider other alternatives. the persons medical history and Common side effects include commenced in consultation with drowsiness, dry mouth, and relevant specialist. constipation. Note regarding use of Morphine: 3. Duloxetine (SNRI) For people with eGFR 20-50 mL/min/ Duloxetine has evidence for efficacy min/1. 73m2, use 75% of normal dose. in painful diabetic peripheral Should be avoided in kidney failure, neuropathy. especially advanced, i. e. , if eGFR Use 30 mg daily. 20 mL/ min/min/1. 73m2, as both 4. Other medications dose and intervals require adjustment, making it challenging to use. Other medications useful for neuropathic pain include, lignocaine, Neuropathic/nerve pain mexiletine, and methadone, with pain The following medications can be used as team or palliative care guidance. first-line treatments, or as an adjunct in nociceptive pain management, according to the WHO analgesic ladder. Further information 1. Gabapentinoids and resources (gabapentin or pregabalin) St George Hospital Community Used in restless legs syndrome and and Health Service: Pain. uraemic pruritus. Dose adjustment is recommended in patients with reduced kidney function and/ or those undergoing haemodialysis. Refer to product information for specifics. Main side effects include drowsiness, ataxia, clumsiness, blurred vision. 69 Pruritus106, 107 Restless legs Itchy skin is a common and debilitating Restless legs syndrome (RLS) is common side-effect of kidney disease and can in CKD. More than one quarter of people affect up to 70% of people with stage 4 with CKD have RLS. It is more prevalent in or 5 CKD. The causes are multifactorial, people who receive dialysis, with almost including calcium and phosphate one third having RLS. 108 imbalance, inadequate dialysis, overactive parathyroid gland activity, high levels of Management magnesium and vitamin A, and nerve Evaluate severity using the Restless changes in the skin. Legs Syndrome Rating Scale. 109 Management Check iron status and replace if deficient (absolute/relative). Ensure that there are no other causes Home therapies such as massage, for pruritus (e. g. , skin disease, scabies, warm baths, warm/cool compresses, inadequate dialysis, calcium/phosphate relaxation techniques, and exercise. abnormalities). Low dose dopaminergic agents or Avoid long hot showers. dopamine agonists. Application of ice. Pramipexole. Evening primrose oil. Skin emollients.
----------------------------------------------------------------------


======================================================================
CHUNK 508 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_37
Content Type: recommendation
Words: 494
Medical Entities: CKD,GFR,dialysis,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
abnormalities). Low dose dopaminergic agents or Avoid long hot showers. dopamine agonists. Application of ice. Pramipexole. Evening primrose oil. Skin emollients. Sleep apnoea Avoid use of soaps/detergents. Topical capsaicin (may not be tolerated Sleep apnoea can affect up to 50% of because of transient burning feeling on people with eGFR 15 mL/min/1. 73m2 the skin). and is a significant cause of refractory If both pruritus and restless legs is hypertension. present, consider gabapentin. For persistent pruritus, consider Management referral to a dermatologist for Weight reduction (see ). ultraviolet light B (UVB) therapy or to investigate other causes of pruritis. Avoid central nervous system depressants (including alcohol). Consider a selective kappa opioid receptor agonist (e. g. , Difelikefalin) Referral for assessment of severity for treatment of moderate to severe of sleep apnoea. pruritis in patients with CKD on Continuous positive airway pressure haemodialysis. (CPAP) therapy (if obstructive pattern). 70 Kidney Health Australia Common issues in CKD Uraemia Uraemia is a syndrome seen in stage 4 or 5 CKD. It is caused by the accumulation of the breakdown products of protein metabolism. The symptoms include anorexia, nausea, vomiting, lethargy, and in the advanced stages confusion (encephalopathy), muscle twitching, pericarditis, fluid overload, convulsions, and coma. Although urea and creatinine are the substances measured, the symptoms are most likely due to the accumulation of other unmeasured toxic end products. By the time uraemia becomes symptomatic, dialysis is typically indicated. Management Dialysis should be commenced based on assessment of uraemic symptoms, not eGFR or biochemistry. If non-dialysis pathway is planned, the patient should be reviewed by a specialist kidney supportive care team for assessment of symptoms and nondialysis therapies. These may include dietary modifications, fluid restriction, anti-emetics, and therapy to address pruritus. 71 5 Progressive CKD 72 Kidney Health Australia Indications for referral to a nephrologist32, 110 Appropriate referral is associated with positive outcomes, including: Reduced rate of progression to kidney failure. Decreased morbidity and mortality. Decreased need for and duration of hospitalisation. Increased likelihood of timely preparation of permanent dialysis access prior to dialysis onset. Increased likelihood of kidney transplantation. Tests recommended prior to referral: Current blood chemistry and haematology uACR and urine microscopy for red cell morphology Current and historical blood pressure /- Kidneys Ureters Bladder ultrasound scan Clinical tip Anyone with a rapidly declining eGFR (5 mL/min/1. 73m2 over 3 months) and/or signs of acute nephritis (oliguria, haematuria, acute hypertension, and oedema) should be regarded as a medical emergency and referred without delay. Further information and resources Kidney Health Australia Health Professional Hub: How to guide Refer to Nephrology and Referral Letter Template. 73 Algorithm for appropriate referral to a nephrologist Anyone with a rapidly declining eGFR (15% over 3 Possible medical months) and/or signs of acute nephritis (oliguria, Yes emergency. glomerular haematuria, acute hypertension and oedema) Refer without delay eGFR 30 mL/min/1. 73m2 Or Yes Sustained decrease in eGFR of 25% or more within 12 months OR a sustained decrease in eGFR of 15 mL/min/1.
----------------------------------------------------------------------


======================================================================
CHUNK 509 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_38
Content Type: recommendation
Words: 496
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
glomerular haematuria, acute hypertension and oedema) Refer without delay eGFR 30 mL/min/1. 73m2 Or Yes Sustained decrease in eGFR of 25% or more within 12 months OR a sustained decrease in eGFR of 15 mL/min/1. 73m2 per year Persistent uACR  30 mg/mmol Yes Referral recommended Blood pressure difficult to treat despite  3 BP agents? Yes Are there any other First Nations Australians with reasons for a referral CKD may benefit from earlier No to a nephrologist Yes referral to a kidney specialist. (youth, family, history Referral is recommended if: etc. )? eGFR 45 mL/min/1. 73m2 Persistent significant albuminuria 30 mg/mmol Sustained decrease Continue to manage in primary Not sure? in eGFR 10 mL/min/ care. Contact your supporting 1. 73m2/ year See the CKD Management in kidney service. Blood pressure not at Primary Care handbook and clinical target despite at least action plans for guidance. Refer to 3 BP agents Kidney Health Australia via the Health Professional Hub referral See CARI guidelines for portal for support and information. more information. 74 Kidney Health Australia Progressive CKD  No No No No The decision to refer or not must always be individualised, particularly in younger individuals where the indications for referral may be less stringent. Discuss management issues with a specialist where it may not be necessary for the person with CKD to be seen by the nephrologist. Where referral to a Nephrologist is not possible, as may be the case for people located in regional and remote areas, we recommend contacting your supporting kidney service to discuss options for referral, which may include telehealth consultations. Advance Treatment options care planning for kidney failure This can be a mix of actions that lead There are three treatment options to planning towards the end of life. for kidney failure: dialysis which may be done at home or in a hospital or Advance care planning is distinct from dialysis centre; kidney transplantation; dialysis treatment decision making and comprehensive conservative care. and can occur whilst the person is still receiving treatment. Patients should be referred to a nephrology service allowing adequate Advance care planning should be time for treatment options to be initiated in: explored and considered prior to All competent patients aged 65 years starting treatment. and above, and Patients and their families or carers All competent patients, irrespective should receive sufficient information of age, who fulfil one or more of the and education regarding the nature following criteria: of kidney failure and the options - the treating clinician considers for the treatment to allow them to that existing medical conditions make an informed decision about the will reduce life expectancy. management of their condition. - significant comorbidities. A shared decision-making approach - poor functional status. between patients their families and healthcare team is recommended. - chronic malnutrition. - poor Quality of Life. Further information and resources Further information and resources Kidney Health Australia booklet: Introduction to Kidney Disease Advance Care Planning Australia. Treatment Options. Palliative Care Australia.
----------------------------------------------------------------------


======================================================================
CHUNK 510 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_39
Content Type: recommendation
Words: 493
Medical Entities: CKD,GFR,dialysis
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
A shared decision-making approach - poor functional status. between patients their families and healthcare team is recommended. - chronic malnutrition. - poor Quality of Life. Further information and resources Further information and resources Kidney Health Australia booklet: Introduction to Kidney Disease Advance Care Planning Australia. Treatment Options. Palliative Care Australia. Kidney Health Australia decision aid for people affected by CKD and health professionals: My Kidneys My Choice. NSW Renal Network website: Renal Supportive Care. 75 Abbreviations ACE inhibitor Angiotensin-converting enzyme inhibitor ACR Albumin/creatinine ratio ADPKD Autosomal dominant polycystic kidney disease AKI Acute kidney injury ABPM Ambulatory blood pressure monitoring ANCA Antineutrophil cytoplasmic antibodies Anti-GBM Anti-glomerular basement membrane diseases ANA Antinuclear antibody APD Automated peritoneal dialysis APNA Australian Primary Healthcare Nurses Association ARB Angiotensin II receptor blocker ARNI Angiotensin receptor neprilysin inhibitor BMD Bone mineral density BMI Body mass index BNP Brain natriuretic peptide BP Blood pressure BSA Body surface area BGL Blood glucose level CARI Caring for Australasians with Renal Impairment CIN Contrast-induced nephropathy CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration COVID-19 Coronavirus disease - 2019 Cox-2 inhibitors Cyclooxygenase-2 inhibitors CPAP Continuous positive airway pressure CrCl Creatinine clearance CVD Cardiovascular disease DASS-21 Depression Anxiety and Stress scale 21 DKD Diabetic kidney disease DPP-4 inhibitors Dipeptidyl peptidase-4 inhibitors eGFR Estimated glomerular filtration rate ENA Extractable nuclear antigen ESA Erythropoiesis stimulating agent ESR Erythrocyte sedimentation rate FLC Free light chains GFR Glomerular filtration rate GLP-1 RA Glucagon-like peptide-1 receptor agonists Hb Haemoglobin 76 Kidney Health Australia Progressive CKD HBV Hepatitis B virus HCV Hepatitis C virus HCO Bicarbonate 3 HDL High-density lipoprotein HF Heart failure HIV Human immunodeficiency virus HBPM Home blood pressure monitoring HR Hazard ratio hsCRP High-sensitivity C-reactive protein HSVD Heart, stroke and vascular disease IV Intravenous K Potassium K10 Kessler Psychological Distress Scale KDIGO Kidney Disease Improving Global Outcomes KHA Kidney Health Australia KUB ultrasound Kidney ureters bladder ultrasound LDL Low-density lipoprotein MBD Mineral and bone disorder MBS Medicare Benefit Schedule MRA Mineralocorticoid receptor antagonists NHMRC National Health and Medical Research Council NIP National Immunisation Program Schedule NSAIDs Non-steroidal anti-inflammatory drugs PBS Pharmaceutical benefits scheme PCR Protein: creatinine ratio PD Peritoneal dialysis PKD Polycystic kidney disease PTH Parathyroid hormone RACGP Royal Australian College of General Practitioners RAS Renin-angiotensin system RLS Restless legs syndrome SGLT2 inhibitor Sodium-glucose linked transporter-2 inhibitor SNAP Smoking, nutrition, alcohol, physical activity SNRI Selective serotonin and norepinephrine reuptake inhibitors SSRI Selective serotonin reuptake inhibitor Trig Triglycerides TSAT Transferrin saturation uACR Urine albumin/creatinine ratio UTI Urinary tract infection UVB Ultraviolet light B 77 References 1. Australian Bureau of Statistics. Australian Health 15. ANZDATA Registry. 46th Report, Chapter 1, Incidence Survey: Biomedical Results for Chronic Diseases, 2011of Kidney Failure with Replacement Therapy. 2023. 12. 2013. Accessed December 04, 2023. 2. Australian Institute of Health and Welfare (AIHW). org. au/report/anzdata-46th-annual-report-2023-dataChronic kidney disease: Australian facts. 2023. to-2022/ Accessed 2023, December 21. 16. World Health Organization. The Asia-Pacific au/reports/chronic-kidney-disease/chronic-kidneyperspective: redefining obesity and its treatment, . disease Health Communications Australia. 2000; 3.
----------------------------------------------------------------------


======================================================================
CHUNK 511 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_48
Content Type: definition
Words: 474
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
N Engl J Med. Jun 25 2020; 382(26): 24932503. doi: 10. 1056/NEJMoa1916624 97. Lambert K, Conley M, Dumont R, et al. Letter to the editor on Potential use of salt substitutes to reduce blood pressure. J Clin Hypertens (Greenwich). Oct 2019; 21(10): 1609-1610. doi: 10. 1111/jch. 13685 81 Index Acidosis 59 Erythropoiesis stimulating agents (ESAs) 60 Acute kidney injury 40 First Nations Australians 15; 37; 74 Advance care planning 75 Genetic kidney diseases 23 Albuminuria 59 Glycaemic control 49 Anaemia 60 Haematuria 62-63 Aus CVD risk calculator 48 Haemodialysis (see dialysis) 75 Blood pressure 52 Heart failure 57 Cardiovascular disease 48 Hyperkalaemia 65 Cardiovascular risk assessment 48 Hypertension 52-56 Causes of kidney failure 22 Hyperuricaemia 64 Clinical action plans 26-28 Kidney Health Check 13 Cognitive decline 61 Kidney cysts 42 Contraception 37 Kidney failure 22; 75 Creatinine 17 Kidney stones 44 Cysts 42 Lifestyle changes 29-32 Definition (CKD) 11 Lipids 65 Depression 61 Malnutrition 66 Diabetes 49 Management goals 26-28 Diagnostic tests 17 MBS items 37 Dialysis 75 Medications 33-36 Diet 30 Metformin 35; 50 Drug dosing 18 Mineral and bone disorder 66 Dyslipidaemia 65 Muscle cramps 67 Early detection of CKD 13 Nephrotoxic medications 35 Estimated glomerular filtration rate (eGFR) 17-18 Nutrition 30 eGFR and body surface area 18 Oedema 67 eGFR in different populations 17 Older people 38-39 Elderly (see older people) 38 Pain management 68-69 82 Kidney Health Australia Pharmacological management 33-36 Polycystic kidney disease 42-43 Pregnancy 18; 37-38 Pruritus 70 Referral to a nephrologist 73-74 Restless legs 70 Sick day action plan (AKI) 41-42 Sleep apnoea 70 Staging of CKD 21 Symptoms of CKD 11 Targeted detection 12 Tests to investigate CKD 17 Uraemia 71 Urine ACR 18-19 Vaccinations 39 Whole-of-practice approach to CKD 37 83 Where to go for more information Kidney Health Australia At Kidney Health Australia, were passionate about Healthy Kidneys for all Australians. As the recognised voice for CKD in Australia, were driving awareness and earlier detection of CKD and championing best practice care to slow disease progression and improve health outcomes. We support people living with CKD, their healthcare teams, and the research community to achieve better outcomes. Through advocacy, programs and partnerships were changing the paradigm from kidney failure to kidney preservation. Resources for Health Professionals Resources and services for patients: We offer a range of education, The Kidney Health Australia team is here practice tools and resources for health to support your patients living with CKD. professionals working in primary care. Evidence-based factsheets, books and Free accredited CPD education videos on CKD Quality improvement activities Tailored CKD education programs for Dedicated Health Professional patients resources Hub Peer support programs Downloadable how to guides and Big Red Kidney Bus holiday dialysis referral templates service Visit the Kidney Health Australia Health Kidney Helpline Professional Hub KidneyHealth4Youth support and events for young people with kidney disease.
----------------------------------------------------------------------


======================================================================
CHUNK 512 of 647
======================================================================
ID: kha_ckd_handbook_5th_ed_july2024_49
Content Type: reference
Words: 489
Medical Entities: CKD,GFR,dialysis,albuminuria,hypertension,diabetes
Source: KHA-CKD-Handbook-5th-Ed-July2024.pdf

----------------------------------------------------------------------
Visit the Kidney Health Australia website Kidney Helpline Free health information service for anyone requiring assistance with managing their kidney health, understanding their kidney disease diagnosis or information on Kidney Health Australia support programs. Free call 1800 454 363 Email kidney. helplinekidney. org. au 84 Kidney Health Australia Related resources CARI Guidelines cariguidelines. org Provides a range of Australian evidence-based clinical practice guidelines for managing CKD and related conditions. KDIGO Guidelines kdigo. org Provides a range of international evidence-based clinical practice guidelines for managing CKD. Royal Australian College of General Practitioners (RACGP) Local HealthPathways racgp. org. au Most regions of Australia have web-based Provides a range of clinical HealthPathways that provide evidenceguidelines, education and based, localised advice on management resources for GPs that are and referral for a wide range of diseases relevant to people with CKD. and conditions, including CKD. Primary Health Networks can provide further details and access to their local Health Pathways. Practice Software Practice software tools such as PENCAT and Primary Sense can be a useful practice tool for identifying people in your practice at risk of or with CKD. Correct coding of CKD combined with the utilisation of medical software search functionality is useful in setting up quality improvement frameworks within practice. 85 Algorithm for initial detection and diagnosis of CKD O Ch ff e e c r k a t o K i p d e n o e p y l e H e w a it lt h h uACR 3 mg/mmol eGFR 60 mL/min/1. 73m2 No Diabetes Hypertension Established CVD Repeat Kidney Health Check Family history in 1-2 years (annually in of kidney failure Yes Yes First Nations Australians Obesity (BMI 30) aged 18, people with Current or past diabetes or hypertension) smoker / vaper History of AKI First Nations Repeat uACR within 3 Repeat eGFR Australians aged months. If uACR within 7 days 18 years normal, complete a All Australians third test (preferably If 20% reduction aged 60 years first morning void) Repeat eGFR in eGFR, possible within 3 months AKI. Discuss with nephrologist If minimum of two If minimum of two uACRs 3 mg/mmol eGFRs 60 over 3 months and/or mL/min/1. 73m2 over 3 months Stage CKD with staging table, using eGFR and uACR test results Albuminuria Stage Kidney GFR Normal Microalbuminuria Macroalbuminuria Function (mL/min/1. 73m2)(A1) (A2) (A3) Stage uACR 3. 0 mg/mmol uACR 3. 0-30 mg/mmol uACR 30 mg/mmol 1 90 Not CKD unless haematuria, structural or pathological 2 60-89 abnormalities present 3a 45-59 3b 30-44 4 15-29 5 15 or on dialysis Undertake investigations to determine underlying diagnosis Fully specify CKD diagnosis, e. g CKD stage 2 with microalbuminuria (A2) in the presence of type 2 diabetes Refer to the colour-coded clinical action plans for CKD management strategies: Yellow clinical action plan (p26) Orange clinical action plan (p27) Red clinical action plan (p28) Chronic Kidney Disease (CKD) Management in Primary Care 5th Edition kidney. org. au
----------------------------------------------------------------------


======================================================================
CHUNK 513 of 647
======================================================================
ID: kidneytransplant_updated_0
Content Type: reference
Words: 484
Medical Entities: CKD,GFR,dialysis
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
STAGE 5 Kidney Transplant What you need to know Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION KIDNEY STAGE DESCRIPTION RATE (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Contents About Kidney Transplantation. . . . . . . . . . . . . . . . . . . . 4 Getting a Transplant. . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 After Your Transplant. . . . . . . . . . . . . . . . . . . . . . . . . . . 10 About Organ Donation. . . . . . . . . . . . . . . . . . . . . . . . . 12 Finding a Living Donor. . . . . . . . . . . . . . . . . . . . . . . . . 15 Five Ways to Inspire Living Kidney Donation. . . . . . . . 25 Where can I find more information? . . . . . . . . . . . . . . 27 KIDNEY. ORG 3 About Kidney Transplantation When your kidneys fail, treatment is needed to replace the work your own kidneys can no longer do. There are two types of treatment for kidney failure dialysis and kidney transplantation. This brochure can help you decide if a kidney transplant is the best choice for you. What is a kidney transplant? When you get a kidney transplant, a healthy kidney is placed inside your body to do the work your own kidneys can no longer do. Many people feel that a kidney transplant offers more freedom and a better quality of life than dialysis. 4 NATIONAL KIDNEY FOUNDATION On the plus side, there are fewer limits on what you can eat and drink, but you should follow a hearthealthy diet. Your health and energy should improve.
----------------------------------------------------------------------


======================================================================
CHUNK 514 of 647
======================================================================
ID: kidneytransplant_updated_1
Content Type: general
Words: 491
Medical Entities: dialysis,diabetes
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
Many people feel that a kidney transplant offers more freedom and a better quality of life than dialysis. 4 NATIONAL KIDNEY FOUNDATION On the plus side, there are fewer limits on what you can eat and drink, but you should follow a hearthealthy diet. Your health and energy should improve. In fact, a successful kidney transplant may allow you to live the kind of life you were living before you got kidney disease. Studies show that people with kidney transplants live longer than those who remain on dialysis. On the minus side, there are the risks of surgery. You will also need to take anti-rejection medicines for as long as your new kidney is working, which can have side effects. You will have a higher risk for infections and certain types of cancer. Although most transplants are successful and last for many years, how long they last can vary from one person to the next. Many people will need more than one kidney transplant during their lifetime. What is a preemptive or early transplant? Getting a transplant before you need to start dialysis is called a preemptive transplant. It allows you to avoid dialysis altogether. Getting a transplant not long after kidneys fail (but with some time on dialysis) is referred to as an early transplant. Both have benefits. Some research shows that a preemptive or early transplant, with little or no time spent on dialysis, can lead to better long-term health. It may also allow you to keep working, save time and money, and have a better quality of life. KIDNEY. ORG 5 Who can get a kidney transplant? Kidney patients of all agesfrom children to seniors can get a transplant. You must be healthy enough to have the operation. You must also be free from cancer and infection. Every person being considered for transplant will get a full medical and psychosocial evaluation to make sure they are a good candidate for transplant. The evaluation helps find any problems, so they can be corrected before transplant. For most people, getting a transplant can be a good treatment choice. What if Im older or have other health problems? In many cases, people who are older or have other health conditions like diabetes can still have successful kidney transplants. Careful evaluation is needed to understand and deal with any special risks. You may be asked to do some things that can lessen certain risks and improve the chances of a successful transplant. For example, you may be asked to lose weight or quit smoking. If you have diabetes, you may also be able to have a pancreas transplant. Ask your healthcare professional about getting a pancreas transplant along with a kidney transplant. 6 NATIONAL KIDNEY FOUNDATION How will I pay for a transplant? Medicare covers about 80% of the costs associated with an evaluation, transplant operation, follow-up care, and anti-rejection medicines. Private insurers and state programs may cover some costs as well.
----------------------------------------------------------------------


======================================================================
CHUNK 515 of 647
======================================================================
ID: kidneytransplant_updated_3
Content Type: general
Words: 475
Medical Entities: dialysis
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
The donated kidney is placed into your lower abdomen (belly), where its easiest to connect it to your important blood vessels and bladder. Putting the new kidney in your abdomen also makes it easier to take care of any problems that might come up. The operation takes about four hours. Youll be sore at first, but you should be out of bed in a day or so, and home within a week. If the kidney came from a living donor, it should start to work very quickly. A 10 NATIONAL KIDNEY FOUNDATION kidney from a deceased donor can take longer to start workingtwo to four weeks or more. If that happens, you may need dialysis until the kidney begins to work. After surgery, youll be taught about the medicines youll have to take and their side effects. Youll also learn about diet. If youve been on dialysis, youll find that there are fewer restrictions on what you can eat and drink, which is one of the benefits of a transplant. What are anti-rejection medicines? Normally, your body fights off anything that isnt part of itself, like germs and viruses. This system of protection is called your immune system. To stop your body from attacking or rejecting the donated kidney, you will have to take medicines to keep your immune system less active (called anti-rejection medicines or immunosuppressive medicines). Youll need to take them as long as your new kidney is working. Without them, your immune system would see the donated kidney as foreign, and would attack and destroy it. Anti-rejection medicines can have some side effects. It is important to talk to your healthcare provider about them, so that you know what to expect. Fortunately, for most people, side effects are usually manageable. Changing the dose or type of medicine can often ease some of the side effects. KIDNEY. ORG 11 Besides the immunosuppressive medicines, you will take other medicines as well. You will take medicines to protect you from infection, too. Most people find taking medicines a small trade for the freedom and quality of life that a successful transplant can provide. Important Reminder You must not take any medicine or nutritional supplement that is not approved by your transplant team because of the risk of interaction with your anti-rejection medicines. 12 NATIONAL KIDNEY FOUNDATION After Your Transplant What happens after I go home? Once you are home from the hospital, the most important work beginsthe follow-up. For your transplant to be successful, you will have regular checkups, especially during the first year. At first, you may need blood tests several times a week. After that, youll need fewer checkups, but enough to make sure that your kidney is working well and that you have the right amount of anti-rejection medication in your body. What if my body tries to reject the new kidney?
----------------------------------------------------------------------


======================================================================
CHUNK 516 of 647
======================================================================
ID: kidneytransplant_updated_5
Content Type: general
Words: 499
Medical Entities: dialysis,diabetes
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
Certain medications that can harm a developing baby must be stopped six weeks before trying to get pregnant. Birth control counseling may be helpful. Its important to protect yourself against sexually transmitted diseases (STDs). Be sure to use protection during sexual activity. Will I need to follow a special diet? In general, transplant recipients should eat a hearthealthy diet (low fat, low salt) and drink plenty of fluids. If you have diabetes or other health problems, you may still have some dietary restrictions. A dietitian can help you plan meals that are right for you. KIDNEY. ORG 15 About Organ Donation Where do donated kidneys come from? A donated kidney may come from someone who died and donated a healthy kidney. A person who has died and donated a kidney is called a deceased donor. Donated kidneys also can come from a living donor. This person may be a blood relative (like a brother or sister) or non-blood relative (like a husband or wife). They can also come from a friend or even a stranger. When a kidney is donated by a living person, the operations are done on the same day and can be scheduled at a convenient time for both the patient and the donor. A healthy person who donates a kidney can live a normal life with the one kidney that is left. But the operation is major surgery for the donor, as well as the recipient. As in any operation, there are some risks that you will need to consider. 16 NATIONAL KIDNEY FOUNDATION Is it better to get a kidney from a living donor? Kidneys from living or deceased donors both work well, but getting a kidney from a living donor can work faster and be better. A kidney from a living donor may last longer than one from a deceased donor. To get a deceased donor kidney, you will be placed on a waiting list once you have been cleared for a transplant. It can take many years for a donor kidney to be offered to you. From the time you go on the list until a kidney is found, you may have to be on some form of dialysis. While youre waiting, youll need regular blood tests to make sure you are ready when a kidney is found. If youre on dialysis, your center will make the arrangements for these tests. Your transplant center should know how to reach you at all times. Once a kidney become available, the surgery must be done as soon as possible. KIDNEY. ORG 17 Are there disadvantages to living donation? A disadvantage of living donation is that a healthy person must undergo surgery to remove a healthy kidney. The donor will need some recovery time before returning to work and other activities. However, recent advances in surgery (often called minimally invasive or laparoroscopic surgery) allow for very small incisions. This means shorter hospital stays and recovery time, less pain, and a quicker return to usual activities.
----------------------------------------------------------------------


======================================================================
CHUNK 517 of 647
======================================================================
ID: kidneytransplant_updated_6
Content Type: reference
Words: 488
Medical Entities: dialysis
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
The donor will need some recovery time before returning to work and other activities. However, recent advances in surgery (often called minimally invasive or laparoroscopic surgery) allow for very small incisions. This means shorter hospital stays and recovery time, less pain, and a quicker return to usual activities. Living donors often experience positive feelings about their courageous gift. What are the financial costs to the living donor? The surgery and evaluation is covered by Medicare or the recipients insurance. The living donor will not pay for anything related to the surgery. However, neither Medicare nor insurance covers time off from work, travel expenses, lodging, or other incidentals. The National Living Donor Assistance Program (livingdonorassistance. org) or other programs may help cover travel and lodging costs. Donors may be eligible for sick leave, state disability, and benefits under the federal Family Medical Leave Act. In addition, federal employees, some state employees, and certain other workers may be eligible for 30 days paid leave. 18 NATIONAL KIDNEY FOUNDATION Finding a Living Donor How do I ask someone to consider donating a kidney to me? Asking someone to donate a kidney to you can feel scary and overwhelming. You may be asking yourself, Where do I start? How do I ask? Here are some suggestions to help make it easier for you. LEARN ALL YOU CAN. The first step is to learn as much as you can about living kidney donation and transplant. This will help you explain it to your friends and family. You may want to let people know that theres no cure for kidney disease and tell them about your options for treating your condition. KIDNEY. ORG 19 Sharing as many facts as you can, along with your thoughts about your condition and treatment options, is one way to open a conversation. A friend or family member might be willing to help you talk to others about your needsdont be afraid to ask! This may relieve some pressure of having to ask people directly. Discussing your need for a kidney in everyday conversation helps get the word outand makes people more comfortable asking you questions about your health. Go to kidney. org/livingdonation RAISE AWARENESSSHARE YOUR STORY! Sharing your story is very important. You should speak from the heart, and tell people as much as you can about kidney disease. If you are on dialysis, you could include details about what a typical week is like for you on dialysis, the complications caused by kidney disease, and why a transplant is a better longterm option for you. Remember, no one will offer to help unless they understand the need. As you share your story and describe what its like to live with kidney disease, try to be open and honest about your situation and your feelings. In sharing your story, you might be fortunate enough to get offers from people who are willing to be tested as a match.
----------------------------------------------------------------------


======================================================================
CHUNK 518 of 647
======================================================================
ID: kidneytransplant_updated_9
Content Type: general
Words: 495
Medical Entities: dialysis
Source: kidneytransplant_updated.pdf

----------------------------------------------------------------------
Asking for help can be daunting to some, but you can start by telling your story. This opens the lines of communication. Many people in your circle may not know about your condition or that being a living kidney donor is even an option. By starting a dialogue and educating those around you, you may find that many people will ask how they can help. Ask your family and friends to spread the word. Its important to keep your options open as you never know when a potential donor is going to walk through the door! 24 NATIONAL KIDNEY FOUNDATION How do I write a letter or email to my friends and family? One way to spread the word is to share your story by letter or email. Here are some tips for writing to your friends, family, or community: Make it personal; tell your story (what is treatment like, how do you feel). Use information on kidney. org to include facts on kidney disease, living donation, and transplant. Invite people to learn more and provide contact details. Ask your transplant center if they want their contact number posted in your letters. They may have a special line, or prefer that people call you first. KIDNEY. ORG 25 SAMPLE LETTER Dear Friends, Some of you may know that I have kidney disease. Over time, my kidney disease has gotten worse, causing my kidneys not to work well enough to keep me alive. This is what I am facing now, and my treatment options are limited to dialysis treatments or a kidney transplant. Getting regular dialysis treatments, usually three times a week for four hours at a time, will help my kidneys do their job and keep me alive, but a transplant would offer me more freedom and the ability to live a longer, healthier, more normal life. A transplant would also give me more time to do the fun things I enjoy most, like spending time with my family and friends. However, finding a kidney for a transplant is not easy. Just ask the 130, 000 people on the waiting list for a deceased donor kidney like me. Time is not on our side. Some wait for years; many die while waiting. The 26 NATIONAL KIDNEY FOUNDATION average wait time is five years or more for a kidney from a deceased donor. However, there is another option: receiving a kidney from a living donor. Asking a family member or a friend to consider donating a kidney to me is difficult, but it greatly improves my chances of getting a transplant. A living kidney donation typically lasts longer and has better function. You might not know a lot about living donationI know I didnt before kidney disease affected my life. Understandably, some people are afraid about the surgery and what living with one kidney will mean for them. Heres some basic information about kidney donation: You only need one kidney to live a healthy, long life.
----------------------------------------------------------------------


======================================================================
CHUNK 519 of 647
======================================================================
ID: kidney_cancer_1
Content Type: recommendation
Words: 498
Medical Entities: dialysis
Source: kidney_cancer.pdf

----------------------------------------------------------------------
KIDNEY. ORG 3 4 NATIONAL KIDNEY FOUNDATION How does my doctor diagnose kidney cancer? Your doctor will diagnose kidney cancer by reviewing your medical history and doing a physical exam, along with blood and urine tests. You will also have one or a few of these imaging tests: Computed tomography (CT) scans use x-rays to make a complete picture of the kidneys and abdomen (belly). They can be done with or without a contrast dye. Small amounts of radiation are used. The CT scan often shows if a tumor appears cancerous or if it has spread beyond the kidney. Magnetic resonance imaging (MRI) scans make a complete picture of the kidneys and abdomen, but without radiation. They can be done with or without a contrast dye called gadolinium that should be avoided in people on dialysis or with very low kidney function. An MRI can cost more than CT scans, take more time to do, and the pictures may not be as clear. Ultrasound uses sound waves to give a complete picture of the kidneys and abdomen without radiation. It may be useful in helping to decide if a mass in the kidneys is a fluid-filled cyst or a solid tumor. This test is done without contrast dye. A biopsy can be used in special cases, but is typically not recommended. A biopsy requires a very small piece of the kidney to be removed with a needle and then tested for cancer cells. WWW. KIDNEY. ORG 5 STAGES OF KIDNEY CANCER Once kidney cancer is found, your doctor will run tests to find out if the cancer has spread within the kidney or to other parts of the body. This process is called staging. It is important to know the stage before making a treatment plan. The higher the stage, the more serious the cancer. Stage Description The tumor is 7 centimeters (cm), which is 1 about 23/4 or smaller, and is found only in the kidney. The tumor is larger than 7 centimeters (cm) 2 and is found only in the kidney. Cancer is found in the main blood vessels of the kidney or in the layer of fatty tissue around the kidney. 3 OR The tumor is any size and cancer is found only in the kidney and in 1 or more nearby lymph nodes. Cancer has spread beyond the layer of fatty tissue around the kidney and may be found in the adrenal gland above the kidney with 4 cancer, or in nearby lymph nodes; or to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes. 6 NATIONAL KIDNEY FOUNDATION What is the treatment for kidney cancer? Treatment depends on your stage of kidney cancer, general health, age, and other factors. Your treatment can include one or more of the following options: Surgery is the most common treatment for kidney cancer most people with early stage cancer (stages 1, 2, and 3) can be cured with surgery.
----------------------------------------------------------------------


======================================================================
CHUNK 520 of 647
======================================================================
ID: kidney_cancer_2
Content Type: general
Words: 488
Medical Entities: GFR,diabetes
Source: kidney_cancer.pdf

----------------------------------------------------------------------
Treatment depends on your stage of kidney cancer, general health, age, and other factors. Your treatment can include one or more of the following options: Surgery is the most common treatment for kidney cancer most people with early stage cancer (stages 1, 2, and 3) can be cured with surgery. Partial nephrectomy: Only the tumor or the part of the kidney with the tumor is removed to leave behind as much of the kidney as possible. Radical nephrectomy: The entire kidney is removed. If needed, the surrounding tissues and lymph nodes may also be removed. Ask your doctor about the surgical approach that is best for you: Open (traditional surgery with a long incision); Laparoscopic (surgery done with a video camera and thin instruments for smaller incisions); and Robotic (laparoscopic surgery done with the help of a robot). Thermal ablation kills the tumor by burning or freezing it. It is most often used for small tumors in people who are not good candidates for nephrectomy surgery. Active surveillance is used if a small tumor is less than 4 centimeters (1  inches). Most small tumors grow slowly and they may also not be cancerous. You will need regular monitoring and testing. 7 Treatment with medicine is often used for advanced kidney cancer that has spread to other parts of the body or where surgery cannot be done. Immunotherapy uses the bodys defense system (immune system) to stop or slow the growth of cancer cells. Monoclonal antibodies attack a specific part of cancer cells. Checkpoint inhibitors help the immune system recognize and attack cancer cells. Vaccines and other immunotherapies give an overall boost to the immune system. Anti-angiogenic therapies reduce the blood supply to a tumor to slow or stop its growth. Targeted therapies directly inhibit the growth of the cancer. Chemotherapy and radiation used for other types of cancer do not usually do a good job of treating most forms of kidney cancer. 8 Important Steps to Reduce Your Risk for Kidney Cancer Dont smoke. Maintain a healthy weight. Find out if youre exposed to certain toxins at work or at home. Some toxins that may increase the risk for kidney cancer include cadmium, asbestos, and trichloroethylene. Take care of your kidneyspeople with kidney disease may be at increased risk for kidney cancer: Ask your healthcare provider about 2 simple tests to find your kidney score: A blood test for kidney function called GFR A urine test for kidney damage called ACR. Avoid prolonged use of non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen and naproxen. Control high blood pressure. Control your blood sugar if you have diabetes. Be aware of certain risk factors that cant be changed, but should be followed up on: Family history of kidney cancer Certain diseases you may have been born with, such as von Hippel-Lindau disease 9 Important Steps If You Have Kidney Cancer Discuss all your treatment options with your medical team.
----------------------------------------------------------------------


======================================================================
CHUNK 521 of 647
======================================================================
ID: kidney_cancer_3
Content Type: general
Words: 495
Section: Your medical team may include:
Medical Entities: GFR,dialysis,diabetes
Source: kidney_cancer.pdf

----------------------------------------------------------------------
Your medical team may include: A urologist (a surgical doctor who treats the urinary system) An oncologist (a doctor who specializes in cancer) A radiation oncologist (a doctor who treats cancer with radiation) A nephrologist (kidney doctor) An oncology nurse, social worker, and other healthcare professionals Make medical and health-related appointments as soon as possible. Understand that you may need at least several opinions about what treatment choices are best for you. Maintain good nutrition during treatment so that you get enough calories, protein, and other nutrients to help prevent weight loss and to stay strong. Patients who eat well often feel better and have more energy. Protect your kidneys people with kidney cancer may be at increased risk for kidney disease. Control blood pressure and blood sugar, avoid NSAIDs, dont smoke, stay physically active, and follow a healthy diet. 10 What is kidney disease? Your kidneys main job is to clean waste and extra water from your blood. Having kidney disease means your kidneys are damaged and cannot do this job well. Over time, kidney disease can get worse and lead to kidney failure. Once kidneys fail, treatment with dialysis or a kidney transplant is needed to stay alive. Kidney disease can be found with a simple blood test and urine test during a routine office visit with your healthcare professional. 2 Simple Tests to Check Major Risk Factors Include for Kidney Disease Urine Test Diabetes You could help save your kidneys with a simple urine test. Ask your doctor about Albumin Creatinine Ratio (ACR) which estimates the amount of a type of protein, High Blood Pressure albumin, this is in the urine. Blood Test Age 60 and older The Glomerular Filtration Rate (GFR) tells how well your kidneys are working to reove wastes from your blood. It is the best way to check kidney function. Over 90 is good. 60-89 should be monitored. Less than 60 for 3 months indicates kidney disease. 11 Are kidney cancer and kidney disease related? Studies show there is a link between kidney cancer and kidney disease. Some studies show that people with kidney disease may have a higher risk for kidney cancer. Some reasons are: Long-term dialysis: Some studies show that people on long-term dialysis have a 5-fold increased risk for kidney cancer. Experts believe this risk is due to kidney disease rather than dialysis. Immunosuppressant medicines: Some anti-rejection medicines that must be taken by kidney transplant recipients to prevent rejection can increase your risk for kidney cancer. However, taking your immunosuppressant medicine is important if you have a transplant. Without it, your body will reject your new kidney. On the other hand, about one-third of the 300, 000 kidney cancer survivors in the United States have or will develop kidney disease. 1, 2 Some reasons are: Surgery to remove an entire kidney (radical nephrectomy): Sometimes the entire kidney needs to be removed because the tumor is so large and most of the kidney has been destroyed.
----------------------------------------------------------------------


======================================================================
CHUNK 522 of 647
======================================================================
ID: kidney_cancer_5
Content Type: general
Words: 126
Medical Entities: diabetes
Source: kidney_cancer.pdf

----------------------------------------------------------------------
14 NATIONAL KIDNEY FOUNDATION National Cancer Institute, 800. 4. CANCER 800. 422. 6237 or www. cancer. gov National Kidney and Urologic Disease Information Clearinghouse (NKUDIC), a service of the National Institute of Diabetes, Digestive and Kidney Diseases. 800. 891. 5390 or www. niddk. nih. gov Kidney Cancer Association www. kidneycancer. org American Cancer Society 800. 227. 2345 or www. cancer. org WWW. KIDNEY. ORG 15 The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding, patient centric organization dedicated to the awareness, prevention and treatment of kidney disease in the US. Help us fight kidney disease. Learn more at kidney. org English Spanish Supported by CMYK CMYK 30 East 33rd Street New York, NY 10016 800. 622. 9010 2017 National Kidney Foundation, Inc. 01-10-7546_BBH
----------------------------------------------------------------------


======================================================================
CHUNK 523 of 647
======================================================================
ID: managing_anemia_0
Content Type: recommendation
Words: 495
Medical Entities: GFR
Source: managing_anemia.pdf

----------------------------------------------------------------------
MANAGING ANEMIA When You Have Kidney Disease or Kidney Failure www. kidney. org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Glomerular Stage Description Filtration Rate (GFR) Kidney damage (e. g. , protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. TABLE OF CONTENTS What is anemia? . . . . . . . . . . . 5 What are some causes of anemia? . . . . . . . . . . . . . . . . . . 6 Why do people with kidney disease or kidney failure get anemia? . . . . . . . . . . . . . . . . . . . 7 What are kidney disease and kidney failure? . . . . . . . . . . . . . 8 Is everyone with kidney disease or kidney failure at risk for anemia? . . . . . . . . . . . . . . . . . . 9 How do I know if I have anemia? . . . . . . . . . . . . . . . . . . 10 How often should I be checked for anemia? . . . . . . . . . . . . . . . 11 How is anemia treated? . . . . . 11 What is the goal of anemia treatment? . . . . . . . . . . . . . . . . 12 How much ESA will I need? . . 13 How will my healthcare provider know if I am responding to ESA? . . . . . . . . 13 Will I need extra iron? . . . . . . . 14 How much iron will I need? . . 14 How is my iron level tested? . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 524 of 647
======================================================================
ID: managing_anemia_2
Content Type: general
Words: 493
Medical Entities: dialysis,diabetes
Source: managing_anemia.pdf

----------------------------------------------------------------------
Before starting treatment for anemia, your healthcare provider will order tests to find the exact cause. Why do people with kidney disease or kidney failure get anemia? Your kidneys make an important hormone called erythropoietin (EPO). Hormones are chemical messengers that your body makes to help your body work and keep you healthy. EPO tells your body to make red blood cells. When you have kidney disease or kidney failure, your kidneys cannot make enough EPO. This causes your red blood cell count to drop and anemia to develop. WWW. KIDNEY. ORG 7 Do you knowT itphese words? Not having enough EPO (a hormone made by your kidneys) is the most common cause of anemia in patients with kidney disease and kidney failure. EPO tells your body to make red blood cells. When your kidneys no longer make enough EPO, treatment with drugs called erythropoiesis-stimulating agents (ESAs) can help. What are kidney disease and kidney failure? Healthy kidneys do many important jobs. Among other things, they remove waste products and extra water from your body. They also help make red blood cells. If you have kidney disease, it means your kidneys are damaged. They cannot do these important jobs well. Kidneys can become damaged from a physical injury or a disease like diabetes, high blood pressure, or other disorders. Treatment can help keep kidney disease from getting worse. But if kidney disease does get worse, it can lead to kidney failure. 8 NATIONAL KIDNEY FOUNDATION If you have kidney failure, it means your kidneys do not work well enough to keep you alive. You must have dialysis treatment for the rest of your life, or a kidney transplant. There are two types of dialysis hemodialysis and peritoneal dialysis. To learn more about a kidney transplant or dialysis, ask your healthcare provider or call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org. Is everyone with kidney disease or kidney failure at risk for anemia? Most people with kidney disease or kidney failure will get anemia. Anemia can happen early in the course of kidney disease and grow worse as kidneys lose their ability to work well and make EPO. Anemia is especially common if you: Have diabetes Are Black Have moderate or severe loss of kidney function (stage 3 or 4) Have kidney failure (stage 5) Are female WWW. KIDNEY. ORG 9 Do you knowT itphese words? If you are Black or have diabetes along with kidney disease, you are more likely to get anemia and at an earlier stage. How do I know if I have anemia? Not everyone with anemia has symptoms. If you have kidney disease or kidney failure, you should have a simple blood test to measure your hemoglobin. Hemoglobin is the part of red blood cells that carries oxygen through your body. If your hemoglobin is lower than the normal range (which is 12. 0 for women and 13.
----------------------------------------------------------------------


======================================================================
CHUNK 525 of 647
======================================================================
ID: managing_anemia_3
Content Type: general
Words: 462
Medical Entities: dialysis
Source: managing_anemia.pdf

----------------------------------------------------------------------
If you have kidney disease or kidney failure, you should have a simple blood test to measure your hemoglobin. Hemoglobin is the part of red blood cells that carries oxygen through your body. If your hemoglobin is lower than the normal range (which is 12. 0 for women and 13. 5 for men), it is likely you have anemia. In that case, your healthcare provider will check to find out what caused your anemia and develop a treatment. Do you knowT itphese words? Speak to your healthcare provider if you think you have anemia. Make a list of questions. Write down your symptoms, allergies, medications, and previous health problems. Show the list to your healthcare provider. Discuss how you are feeling and ask questions. 10 NATIONAL KIDNEY FOUNDATION How often should I be checked for anemia? How often you are checked for anemia depends on many things, including your stage of kidney disease. In general, you should be checked for anemia at least once per year. Some people may need to be checked more often. How is anemia treated? Your treatment will depend on what caused your anemia. If your anemia is due to kidney disease or kidney failure, you may be treated with: Drugs called erythropoiesisstimulating agents (ESAs) ESAs help your body make red blood cells. ESAs are usually given to you as an injection under the skin in your healthcare providers office. This is called a subcutaneous injection or SC. Extra iron Your body needs iron to make red blood cells, especially when you are receiving ESAs. Without enough iron, your ESA treatment will not work as well. Iron can be given to you as a pill, or administered directly into a vein WWW. KIDNEY. ORG 11 in your healthcare providers office (called intravenous iron or IV iron). For most people, IV iron works best. You and your healthcare provider will decide which method is best for you. Do you knowT itphese words? If you are on hemodialysis, your ESA and extra iron can be given to you as an injection into the blood tubes during your dialysis treatment. You and your healthcare team will decide which method is best for you. What is the goal of anemia treatment? The goal is to increase your hemoglobin level to a range that works best for you. This range is different for everyone. Your healthcare provider will decide what is best and safest. As you get closer to your range, you should have more energy and feel less tired. Another goal is to keep you from needing blood transfusions. They could interfere with having a successful kidney transplant in the future. 12 NATIONAL KIDNEY FOUNDATION How much ESA will I need? You will be given enough ESA to increase your hemoglobin gradually.
----------------------------------------------------------------------


======================================================================
CHUNK 526 of 647
======================================================================
ID: managing_anemia_4
Content Type: general
Words: 497
Medical Entities: dialysis
Source: managing_anemia.pdf

----------------------------------------------------------------------
Another goal is to keep you from needing blood transfusions. They could interfere with having a successful kidney transplant in the future. 12 NATIONAL KIDNEY FOUNDATION How much ESA will I need? You will be given enough ESA to increase your hemoglobin gradually. How much ESA you need and how often you receive it depends on: Your current hemoglobin level How well you respond to treatment with ESA How you receive your ESAas an injection under the skin or through the blood tubes during dialysis The type of ESA you receive There are different types of ESAs availableshort-acting ESAs or long-lasting ESAs. You and your healthcare provider will decide which type is best for you. How will my healthcare provider know if I am responding to ESA? Your healthcare provider will check your hemoglobin level regularly. This shows how well you are doing. Your dose of ESA may need to be changed, depending on how well you respond to your treatment. WWW. KIDNEY. ORG 13 Will I need extra iron? Your body needs iron to make red blood cells. Once you start taking an ESA, your body will make more red blood cells, and your bodys iron supply will be used up faster. Without extra iron, your ESA treatment will not work as well. Do you knowT itphese words? Not everyone with kidney disease will need treatment with ESAs. For some people with early kidney disease, taking extra iron may be enough to boost your bodys ability to make red blood cells. How much iron will I need? Your healthcare provider will decide how much iron you need and how often you get it, based on your hemoglobin level, ESA dose, and the results of your iron tests. The goal of taking extra iron is to reach a hemoglobin range that is best and safest for you. 14 NATIONAL KIDNEY FOUNDATION How is my iron level tested? Two important tests can tell if you have enough iron. They are called transferrin saturation (TSAT) and ferritin. You may need extra iron if these test results show that your TSAT or ferritin result is low. How often will my iron level be tested? If you are being treated for anemia with an ESA, your iron should be tested every 3 months until your anemia is under control. Can diet help my anemia? Eating foods that are high in iron, vitamin B12, and folic acid may be difficult due to your kidney diet. A dietitian can help you plan meals and suggest a renal vitamin if needed. Check with your healthcare provider before making any changes to your diet. WWW. KIDNEY. ORG 15 Do you knowFa tchtese words? Iron is important in treating anemia. Without enough iron, ESA is wasted and you will not reach your target hemoglobin. What if my anemia isnt treated? Anemia can cause serious health problems. Your heart must work harder if you do not have enough red blood cells. This can lead to heart disease.
----------------------------------------------------------------------


======================================================================
CHUNK 527 of 647
======================================================================
ID: managing_anemia_5
Content Type: general
Words: 499
Medical Entities: GFR,dialysis,diabetes
Source: managing_anemia.pdf

----------------------------------------------------------------------
Without enough iron, ESA is wasted and you will not reach your target hemoglobin. What if my anemia isnt treated? Anemia can cause serious health problems. Your heart must work harder if you do not have enough red blood cells. This can lead to heart disease. Unfortunately, many people with kidney disease develop heart disease long before they reach kidney failure. Some will even die from it. Early treatment of anemia is important. It can help keep heart disease and other problems from happening. If you already have heart disease, treatment can help keep it from getting worse. What if I have a kidney transplant? Unfortunately, even a new kidney may not be able to make all the EPO you need to make enough red blood cells. You will need to take special drugs to keep your body from rejecting the new kidney. These drugs can affect EPO production. So, treatment for anemia is often needed even after a successful transplant. 16 NATIONAL KIDNEY FOUNDATION Do you knowFa tchtese words? Treating anemia is important because: Your chances of having serious, life-threatening heart problems will be lowered You will have more energy to do your daily tasks Your quality of life gets better Your ability to exercise improves You may avoid blood transfusions WWW. KIDNEY. ORG 17 Key Points to Remember Anemia happens when your body does not have enough healthy red blood cells. Most people with kidney disease or kidney failure will develop anemia. Anemia can be treated. Drugs called ESAs and extra iron are used to treat anemia. They help your body make red blood cells. Treatment of anemia is important. It can help keep heart disease and other problems from happening. If you already have heart disease, it can help keep it from getting worse. Your healthcare provider can check you for anemia with a simple blood test. 18 NATIONAL KIDNEY FOUNDATION Where can I get more information? If you have questions, speak to your healthcare provider. You can also call the NKF Cares Patient Help Line tollfree at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org. A trained professional will listen to your concerns and help answer your questions. If you want to read more about kidney disease or kidney failure, the National Kidney Foundation has a lot of information on many topics, such as: Iron therapy GFR (glomerular filtration rate) Nutrition High blood pressure Diabetes Coping with kidney disease and kidney failure Treatments for kidney failure, including hemodialysis, peritoneal dialysis, and kidney transplant Learn more at www. kidney. org WWW. KIDNEY. ORG 19 Words to Know Anemia: A decrease in the number of your red blood cells, which can make you feel very tired and have other bad effects. Dialysis: A process that filters waste products and extra fluid from your blood when your kidneys are no longer doing their job. It is one of the basic forms of treatment for kidney failure. There are two types of dialysis hemodialysis and peritoneal dialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 528 of 647
======================================================================
ID: managing_anemia_6
Content Type: reference
Words: 488
Section: Dialysis:
Medical Entities: dialysis,diabetes
Source: managing_anemia.pdf

----------------------------------------------------------------------
Dialysis: A process that filters waste products and extra fluid from your blood when your kidneys are no longer doing their job. It is one of the basic forms of treatment for kidney failure. There are two types of dialysis hemodialysis and peritoneal dialysis. Dietitian: A professional with special training to help you plan what to eat and drink to help you feel your best. EPO (erythropoietin): EPO is a hormone made by your kidneys. EPO tells your body to make red blood cells. If your kidneys cannot make enough EPO, you will get anemia. ESAs (erythropoiesis-stimulating agents): ESAs are a special type of medicine that can help your body make red blood cells. Ferritin: A protein that stores iron in your body. A simple blood test for ferritin helps your healthcare provider know if you need extra iron. 20 NATIONAL KIDNEY FOUNDATION Folic acid: Folic acid is a vitamin that you get from food. Your body needs folic acid to make red blood cells. Hemodialysis: A form of dialysis treatment. In hemodialysis, your blood is cleaned of waste products and extra water through a dialysis machine. Hemoglobin: Hemoglobin is the part of red blood cells that carries oxygen throughout your body. HIV (human immunodeficiency virus): A virus that infects and damages the immune system. The immune system is the part of your body that fights off viruses, bacteria, and germs (foreign invaders like the flu). Hormones: Chemical messengers produced by many different glands in your body including the kidneys to trigger certain responses in your body. Intravenous injection (IV): An injection that is given to you directly in your vein. Iron: Iron is a mineral needed for healthy blood cells. You get iron from a variety of foods, including red meat and leafy green vegetables. WWW. KIDNEY. ORG 21 Kidney disease: The loss of some or all of your kidney function. Kidney disease can result from conditions such as high blood pressure, diabetes, or an injury to the kidneys. Kidney failure: The stage of kidney disease at which dialysis or a transplant is needed to stay alive. Kidney transplant: An operation that places a healthy kidney in your body. It is one of the basic forms of treatment for kidney failure. Lupus: A disease that affects the immune system, which is the part of your body that fights off viruses, bacteria, and germs (foreign invaders like the flu). Minerals: Minerals are nutrients that you get from food. Your body needs them to work properly. Nutrients: Chemicals that you get from food that are necessary to live and grow. They are used to build and repair tissues, regulate body processes, and for energy. Vitamins and minerals are nutrients. 22 NATIONAL KIDNEY FOUNDATION Peritoneal dialysis: A form of dialysis treatment that filters waste products and extra fluid from your blood. It is one of the basic forms of treatment for kidney failure. Polyp: A small growth in the body.
----------------------------------------------------------------------


======================================================================
CHUNK 529 of 647
======================================================================
ID: managing_anemia_7
Content Type: general
Words: 276
Medical Entities: dialysis
Source: managing_anemia.pdf

----------------------------------------------------------------------
Vitamins and minerals are nutrients. 22 NATIONAL KIDNEY FOUNDATION Peritoneal dialysis: A form of dialysis treatment that filters waste products and extra fluid from your blood. It is one of the basic forms of treatment for kidney failure. Polyp: A small growth in the body. If you have a polyp in your digestive tract (your colon) and it begins to bleed, it can cause low iron. Renal vitamin: A special vitamin with the right amounts of B vitamins and vitamin C for patients with kidney disease. Subcutaneous injection (SC): An injection that is given to you under your skin. TSAT (Transferrin): A protein that carries iron in the blood. A simple blood test for transferrin helps your healthcare provider know if you need extra iron. Vitamins: Vitamins are nutrients that your body needs to work properly. WWW. KIDNEY. ORG 23 The National Kidney Foundation is the leading organization in the U. S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Help fight kidney disease. Learn more at www. kidney. org 30 East 33rd Street New York, NY 10016 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 2014 National Kidney Foundation, Inc. 11-10-6553_BBE Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org
----------------------------------------------------------------------


======================================================================
CHUNK 530 of 647
======================================================================
ID: managing_iron_0
Content Type: recommendation
Words: 484
Medical Entities: GFR
Source: managing_iron.pdf

----------------------------------------------------------------------
MANAGING IRON When You Have Kidney Disease or Kidney Failure www. kidney. org COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Glomerular Stage Description Filtration Rate (GFR) Kidney damage (e. g. , protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. TABLE OF CONTENTS What is iron? . . . . . . . . . . . . . . 4 What does iron do? . . . . . . . . . 4 Do you know these words? . . 5 What is kidney disease? . . . . . 5 What is kidney failure? . . . . . . 6 Why is iron important? . . . . . . . 7 How much iron do I need? . . . . 7 How else is my iron level tested? . . . . . . . . . . . . . . . . . . . . 7 How will I feel if my iron level is low? . . . . . . . . . . . . . . . . . . . . . 8 If I have kidney disease, what is the treatment for low iron? . . 9 If I have kidney failure, what is the treatment for low iron? . . 10 Is IV iron safe? . . . . . . . . . . . . . 11 Where can I get more information? . . . . . . . . . . . . . . . 12 Words to Know. . . . . . . . . . . . 13 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. If you have chronic kidney disease or kidney failure, your body may be lacking an important mineral called iron.
----------------------------------------------------------------------


======================================================================
CHUNK 531 of 647
======================================================================
ID: managing_iron_1
Content Type: general
Words: 500
Medical Entities: dialysis
Source: managing_iron.pdf

----------------------------------------------------------------------
. . . . . . . . 12 Words to Know. . . . . . . . . . . . 13 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. If you have chronic kidney disease or kidney failure, your body may be lacking an important mineral called iron. This booklet will answer some common questions about iron, and how important it is to have healthy iron levels. What is iron? Iron is a mineral needed for healthy blood cells and for overall good health. Iron is found in a wide variety of foods. You can also get iron from supplements taken by mouth and from iron medicines prescribed by your healthcare provider. What does iron do? Iron helps your body in many ways. One way is to help make red blood cells. Red blood cells carry oxygen from your lungs to all parts of your body. They give you the energy you need for your daily activities. The kidneys tell your body to make red blood cells. Iron helps make red blood cells healthy. 4 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. What is kidney disease? Your kidneys do many important jobs. They remove waste products and extra fluid from your body and help make red blood cells. They also help to keep the right amounts of minerals in your blood. Minerals are nutrients that you get from food. Your body needs them to work properly. When you have kidney disease, it means your kidneys are damaged. They cannot do these jobs very well. In the early stages of kidney disease, most people do not have any symptoms. You may not be aware that your kidney function is reduced. If kidney disease gets worse, waste products can build up to high levels in your blood and make you feel sick. This may happen slowly over a long period of time. People with kidney disease may develop other health problems as well. These may include high blood pressure, heart disease, anemia (low red blood cell count), weak bones, and poor nutrition. Do you know these words? Some words that are used in this booklet may be new to you. To help you get to know them, theres a list of Words to Know at the end of this booklet. WWW. KIDNEY. ORG 5 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Finding and treating kidney disease early is important. With treatment, it may be possible to keep kidney disease from getting worse. If kidney disease continues to get worse, it can lead to kidney failure. What is kidney failure? Kidney failure means your kidneys do not work well enough to keep you alive. You will need treatment with dialysis or a kidney transplant to live. Dialysis is a process that filters waste products and extra fluid from your blood when your kidneys cannot. There are two types of dialysis: hemodialysis and peritoneal dialysis. A kidney transplant is an operation that places a healthy kidney into your body.
----------------------------------------------------------------------


======================================================================
CHUNK 532 of 647
======================================================================
ID: managing_iron_2
Content Type: reference
Words: 486
Medical Entities: dialysis
Source: managing_iron.pdf

----------------------------------------------------------------------
Dialysis is a process that filters waste products and extra fluid from your blood when your kidneys cannot. There are two types of dialysis: hemodialysis and peritoneal dialysis. A kidney transplant is an operation that places a healthy kidney into your body. FACT Your kidneys make an important hormone called erythropoietin (EPO). EPO tells your body to make red blood cells. When you have kidney disease or kidney failure, you may not be able to make enough EPO. As a result, your body makes less red blood cells and anemia can develop. Some people with kidney disease need a medicine called an erythropoiesis-stimulating agent (ESA) to do the work of EPO. 6 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Why is iron important? Your body needs iron to make red blood cells. Without enough iron, you may get anemia. Anemia means you do not have enough red blood cells. As a result, your blood cannot carry enough oxygen through your body. Making sure you have enough iron helps to correct anemia. How much iron do I need? You need enough iron to keep a healthy hemoglobin level. Hemoglobin is part of your red blood cells. Its the part that carries oxygen through your body. Hemoglobin is made up of oxygen and iron. Therefore, one way to know if your body has enough iron is to measure how much hemoglobin is in your blood. The normal hemoglobin level is 12. 0 for women and 13. 5 for men. How else is my iron level tested? Two important tests can tell if you have enough iron. They are called transferrin saturation (TSAT) and ferritin. You may need extra iron if the results of these tests show that your TSAT and ferritin are low. WWW. KIDNEY. ORG 7 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. How will I feel if my iron level is low? If your iron level is low, you may have low hemoglobin. This can cause you to: Look pale Feel more tired or weak Feel down or depressed Feel short of breath with activity Have chest pain Feel dizzy or light-headed Feel numbness or coldness in your hands and feet Have a faster heartbeat TIP Talk to your healthcare provider if you have any of the symptoms listed above. Write down how you feel, your allergies, medications, previous medical procedures, and any health problems. Discuss how you are feeling. Ask your healthcare provider: Do I have enough iron? What can I do to feel better? 8 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. If I have kidney disease, what is the treatment for low iron? If you have low iron and low hemoglobin, your doctor will develop a treatment plan that is right for you. One or more of the following may be suggested: Eating more foods that have iron such as red meat, leafy green vegetables, and eggs.
----------------------------------------------------------------------


======================================================================
CHUNK 533 of 647
======================================================================
ID: managing_iron_3
Content Type: reference
Words: 479
Medical Entities: dialysis
Source: managing_iron.pdf

----------------------------------------------------------------------
If you have low iron and low hemoglobin, your doctor will develop a treatment plan that is right for you. One or more of the following may be suggested: Eating more foods that have iron such as red meat, leafy green vegetables, and eggs. However, eating foods that are rich in iron may be hard due to your kidney diet. A dietitian can help you plan meals that include iron and other minerals. Iron supplements by mouth in tablet or liquid form. A vitamin and mineral supplement with iron, vitamin B12, and folic acid. Your dietitian or healthcare provider will help you choose one that is right for people with kidney disease. Iron medicine given by injection into a vein during visits to your healthcare providers office or clinic. WWW. KIDNEY. ORG 9 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. TIP Iron supplements can affect other medicines you may be taking. Talk to your healthcare provider, dietitian, or pharmacist before taking iron tablets or liquid supplements. If I have kidney failure, what is the treatment for low iron? If you have kidney failure, you can take extra iron by mouth or have it injected into a vein at the healthcare providers office (called intravenous iron or IV iron). You and your healthcare provider will decide which method is best for you. Most people on dialysis need extra iron because: Lack of iron-rich foods in your diet. Foods that are rich in iron, like red meats and beans, may be limited in your dialysis diet. Without enough iron-rich foods, you are more at risk for low iron. A dietitian can help you choose foods that are good sources of iron, vitamins, and other minerals. Check with your dietitian before making any changes in your diet. 10 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Blood loss during dialysis. At the end of each hemodialysis treatment a small amount of blood is usually left behind in the dialyzer (artificial kidney). This can be a source of iron loss over time. TIP If you are receiving hemodialysis, IV iron can be given to you as an injection into the blood tubes during your hemodialysis treatment. Is IV iron safe? IV iron is safe for most people. Talk to your healthcare provider if you have any questions about IV iron. Tell them about any medicines that you are allergic to. On rare occasions, some people may have a reaction to IV iron. Reactions may include low blood pressure, nausea, vomiting, or diarrhea. WWW. KIDNEY. ORG 11 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Where can I get more information? If you have questions, the National Kidney Foundation can help. Call the NKF Cares Patient Help Line toll-free at 855. NKF. Cares (855. 653. 2273) or email nkfcareskidney. org. A trained professional will listen to your concerns and help answer your questions.
----------------------------------------------------------------------


======================================================================
CHUNK 534 of 647
======================================================================
ID: managing_iron_4
Content Type: reference
Words: 497
Medical Entities: GFR,dialysis,diabetes
Source: managing_iron.pdf

----------------------------------------------------------------------
Where can I get more information? If you have questions, the National Kidney Foundation can help. Call the NKF Cares Patient Help Line toll-free at 855. NKF. Cares (855. 653. 2273) or email nkfcareskidney. org. A trained professional will listen to your concerns and help answer your questions. If you want to read more about kidney disease or kidney failure, the National Kidney Foundation has a lot of information on many topics, such as: Anemia GFR (glomerular filtration rate) Nutrition High blood pressure Diabetes Coping with kidney disease and kidney failure Treatments for kidney failure, including hemodialysis, peritoneal dialysis, and kidney transplant You can also learn more at www. kidney. org 12 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Words to Know Anemia: A decrease in the number of your red blood cells, which can make you feel very tired and have other bad effects. Dialysis: A process that filters waste products and extra fluid from your blood when your kidneys are no longer doing their job. It is one of the basic forms of treatment for kidney failure. There are two types of dialysis: hemodialysis and peritoneal dialysis. Dietitian: A professional with special training to help you plan what to eat and drink to help you feel your best. EPO (erythropoietin): EPO is a hormone made by your kidneys. EPO tells your body to make red blood cells. If your kidneys cannot make enough EPO, you will get anemia. ESAs (erythropoiesis-stimulating agents): ESAs are a special type of medicine that can help your body make red blood cells. Ferritin: A protein that stores iron in your body. A simple blood test for ferritin helps your healthcare provider know if you need extra iron. WWW. KIDNEY. ORG 13 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Hemodialysis: A form of dialysis treatment. In hemodialysis, your blood is cleaned of waste products and extra fluid through a dialysis machine. Hemoglobin: Hemoglobin is the part of red blood cells that carries oxygen throughout your body. Hormones: Chemical messengers produced by many different glands in your body, including the kidneys, to trigger certain responses in your body. Intravenous injection (IV): An injection that is given to you directly in your vein. Iron: Iron is a mineral needed for healthy blood cells. You get iron from a variety of foods, including red meat and leafy, green vegetables. Kidney disease: The loss of some or all of your kidney function. Kidney disease can result from conditions such as high blood pressure, diabetes, or an injury to the kidneys. Kidney failure: The stage of kidney disease at which dialysis or a transplant is needed to stay alive. 14 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Kidney transplant: An operation that places a healthy kidney in your body. It is one of the basic forms of treatment for kidney failure. Minerals: Minerals, such as iron, are nutrients that you get from food. Your body needs them to work properly.
----------------------------------------------------------------------


======================================================================
CHUNK 535 of 647
======================================================================
ID: managing_iron_5
Content Type: general
Words: 296
Medical Entities: dialysis
Source: managing_iron.pdf

----------------------------------------------------------------------
DO NOT REPRODUCE. Kidney transplant: An operation that places a healthy kidney in your body. It is one of the basic forms of treatment for kidney failure. Minerals: Minerals, such as iron, are nutrients that you get from food. Your body needs them to work properly. Nutrients: Chemicals that you get from food that are necessary to live and grow. They are used to build and repair tissues, regulate body processes, and for energy. Vitamins and minerals are nutrients. Peritoneal dialysis: A form of dialysis treatment that filters waste products and extra fluid from your blood. It is one of the basic forms of treatment for kidney failure. TSAT (transferrin saturation): Transferrin is a protein that carries iron in the blood. A simple blood test for transferrin saturation helps your healthcare provider know if you need extra iron. Vitamins: Vitamins are nutrients that your body needs to work properly. WWW. KIDNEY. ORG 15 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. The National Kidney Foundation is the leading organization in the U. S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Help fight kidney disease. Learn more at www. kidney. org 30 East 33rd Street New York, NY 10016 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 2014 National Kidney Foundation, Inc. 11-10-6614_DBE Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org www. kidney. org
----------------------------------------------------------------------


======================================================================
CHUNK 536 of 647
======================================================================
ID: mineral_and_bone_disorder_0
Content Type: recommendation
Words: 500
Medical Entities: GFR
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
MINERAL AND BONE DISORDER If you have kidney disease or kidney failure www. kidney. org COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Stage Description Glomerular Filtration Rate (GFR) Kidney damage (e. g. , protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. 2 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. TABLE OF CONTENTS Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 What is mineral and bone disorder? . . . . . . . . . . 5 When do bone problems begin? . . . . . . . . . . . . 6 How does kidney disease affect bones? . . . . . 6 What happens when you have mineral and bone disorder? . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Is mineral and bone disorder connected to heart problems? . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Is osteoporosis different from mineral and bone disorder? . . . . . . . . . . . . . . . . . . . . . . . . . . 10 If there are no early symptoms of mineral and bone disorder, how do you know if you have it? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 What tests tell about heart and blood vessel problems? . . . . . . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 537 of 647
======================================================================
ID: mineral_and_bone_disorder_1
Content Type: general
Words: 488
Medical Entities: dialysis
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . 10 What tests tell about heart and blood vessel problems? . . . . . . . . . . . . . . . . . . . . . . . . 11 How is mineral and bone disorder treated? . . . 11 Which medicines might be prescribed in mineral and bone disorder? . . . . . . . . . . . . . . . . 12 More about Phosphate Binders. . . . . . . . . 13 What medications replace active vitamin D? . . . . . . . . . . . . . . . . . . . . . . . . . . 14 What about calcium supplements? . . . . . . 14 WWW. KIDNEY. ORG 3 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. How will food choices change if you have mineral and bone disorder? . . . . . . . . . . . 15 Special Occasions and Eating Out. . . . . . . . . . 16 Key Points to Remember. . . . . . . . . . . . . . . . . . 17 Where can you get more information? . . . . . . . 18 High Phosphorus Foods to Limit or Avoid. . . . 19 Food Choices with Less Phosphorus. . . . . . . 20 Words to Know. . . . . . . . . . . . . . . . . . . . . . . . . . 21 4 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Introduction Healthy kidneys do many important jobs. They remove wastes and extra fluid from your body, help make red blood cells, and help keep bones strong. They also help to keep the right amount of minerals in your blood. Minerals are nutrients that your body needs to stay healthy. When you have kidney disease, your kidneys cannot do these important jobs well. As a result, you may develop mineral and bone disorder. It is a common problem in people with kidney disease and it affects almost everyone receiving dialysis. What is mineral and bone disorder? Kidney disease and kidney failure can cause important minerals in your blood stream, such as calcium and phosphorus, to get out of balance. Minerals are nutrients that your body needs. As a result, bones may lose calcium and become weak over time. Some calcium and phosphorus may end up in parts of your body where they do not belong, like your heart and blood vessels. This can lead to heart disease. Finding and treating mineral and bone disorder is important. It will help you keep your bones and heart healthy. Do you know these words?
----------------------------------------------------------------------


======================================================================
CHUNK 538 of 647
======================================================================
ID: mineral_and_bone_disorder_4
Content Type: general
Words: 499
Medical Entities: dialysis
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
Blood tests can measure the amount of calcium, phosphorus, active vitamin D, and PTH in your blood. This helps determine whether you have mineral and bone disorder. How often these tests are done is different for different people. TIP Know your lab results for calcium, phosphorus, and other important tests. If any of these tests are ordered, ask about the results of your blood tests. Write down the numbers in a lab tracking sheet. You can see how the results change over time. To download a lab tracking sheet, go to www. kidney. org/AtoZGuide. 10 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. What tests tell about heart and blood vessel problems? Some people may need an x-ray to look at the blood vessels and heart for signs of hardening and deposits of calcium. Another test called an echocardiogram may be done if there is a concern about heart problems caused by mineral and bone disorder. Not all people will need these tests. How is mineral and bone disorder treated? Once mineral and bone disorder is found, diet and certain medications may help slow down the loss of bone and the buildup of minerals in blood vessels and the heart. Treatment will be based on the results of your tests and how quickly the results are changing. If the results change over time, your treatment may change. Diet is important for controlling minerals. Vitamins, supplements, and medicines may be prescribed. Also, treatment to control parathyroid hormone (PTH) may be needed. The goal is to slow down overactive parathyroid glands that make too much PTH. These glands can be made less active with medicine. In some cases, surgery may be needed if other treatments are not effective. This surgery (parathyroidectomy) removes the parathyroid glands that make PTH. WWW. KIDNEY. ORG 11 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Which medicines might be prescribed in mineral and bone disorder? Common medicines for mineral and bone disorder are: Phosphate binders. If a lower-phosphorus diet does not control your blood phosphorus, you may need a medicine called a phosphate binder. Active vitamin D. If your vitamin D level is low, you may need a prescription form of active vitamin D. (If you have kidney failure and are receiving hemodialysis, your vitamin D may be given to you during your dialysis treatment. ) Calcimimetrics. Your healthcare provider may prescribe another medicine called a calcimimetric to help control mineral and bone disorder. It works differently from phosphate binders and vitamin D. It is often used when PTH, calcium, and phosphorus levels are too high. Calcium supplements. Your healthcare provider will decide if you need calcium supplements. Do not take them on your own. Note: If you are receiving dialysis, its important to know that the dialysis fluid contains calcium. Your healthcare provider will look at all the medicines you are taking for bone and mineral disorder to decide if changing the amount of calcium in your dialysis fluid could help you. Osteoporosis medicines.
----------------------------------------------------------------------


======================================================================
CHUNK 539 of 647
======================================================================
ID: mineral_and_bone_disorder_5
Content Type: general
Words: 498
Section: Note:
Medical Entities: dialysis
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
Note: If you are receiving dialysis, its important to know that the dialysis fluid contains calcium. Your healthcare provider will look at all the medicines you are taking for bone and mineral disorder to decide if changing the amount of calcium in your dialysis fluid could help you. Osteoporosis medicines. Some patients have both mineral and bone disorder and the bone disease osteoporosis. Osteoporosis medicines are not always prescribed for people with kidney disease, but they may help some people. 12 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. More About Phosphate Binders These medicines help to keep phosphorus at the right level. Phosphate binders help stop phosphorus in foods you eat from getting into your blood. They bind to the phosphorus while it is in your digestive system. This helps your body get rid of phosphorus. Not all people with mineral and bone disorder need a phosphate binder. If you have high levels of phosphorus, your healthcare provider will talk to you about the pros and cons of using phosphate binders. Phosphate binders are not all alike. You should speak to your healthcare provider about which type of binder is best for you. To work best, your phosphate binders should be taken with food or within 10 to 15 minutes of eating. However, if you forget, be sure to take them even if you are a little late. You should take phosphate binders as instructed by your healthcare provider or dietitian. Using phosphate binders does not take the place of your lower phosphorus diet. You still have to make low-phosphorus food choices. WWW. KIDNEY. ORG 13 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Which medicines replace active vitamin D? Synthetic forms of active vitamin D are available as pills or injections. There are several types that might be used. Do not substitute for what your healthcare provider orders. Because each type of vitamin D is a little different, your healthcare provider will decide which type is best for you. If you have kidney failure and are receiving hemodialysis, your vitamin D may be given to you during your dialysis treatment. What about calcium supplements? Some people need to take calcium supplements. Others do not. Do not take calcium supplements without checking with your healthcare provider. Results of your blood tests will guide your healthcare providers decisions about whether or not you need extra calcium. A lower phosphorus diet limits dairy foods, which are high in calcium. You need to speak to professionals who will explain how to make the healthiest food choices. A registered dietitian can help make a food plan that balances your needs for calcium, protein, and phosphorus. Some phosphate binders also contain calcium. This is why it is important not to take medicines, vitamins, supplements, or herbal pills without your healthcare provider knowing. For example, antacids can have calcium or other minerals. Before you use any antacids, ask your healthcare provider. 14 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE.
----------------------------------------------------------------------


======================================================================
CHUNK 540 of 647
======================================================================
ID: mineral_and_bone_disorder_7
Content Type: general
Words: 444
Medical Entities: dialysis,diabetes
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
Make your home safer by removing things you can trip on Remove hazards like throw rugs and clutter Improve lighting Wear nonslip shoes Install handrails Key Points to Remember Mineral and bone disorder happens when the kidneys fail to keep the right amounts of calcium and phosphorus in your blood. Mineral and bone disorder is a common problem in people with kidney disease and affects almost all patients receiving dialysis. If calcium levels in the blood become too low, or phosphorus levels too high, four small glands in the neck called the parathyroid glands release a hormone called parathyroid hormone (PTH). This hormone draws calcium and phosphorus from the bones and puts them into the blood stream. When this happens, bones become weaker and painful. Some of this calcium can end up in the heart and blood vessels. This increases your risk for heart disease and stroke. WWW. KIDNEY. ORG 17 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Choosing foods that are lower in phosphorus can help you manage bone disease. Medications called phosphate binders might also be needed with meals and snacks to bind phosphorus in the bowel. Other medications might also be needed. Finding and treating mineral and bone disorder early will help you keep your bones and heart healthy. Where can you get more information? If you have more questions, speak with your healthcare team. They know you and can answer questions about your care. If you want to read more about kidney disease, the National Kidney Foundation has many other booklets that cover many subjects: Risk factors for kidney disease, like high blood pressure and diabetes Complications of kidney disease, like heart disease and anemia Information about diet and nutrition Treating kidney failure with kidney transplant or dialysis There are two ways to learn about the many free resources available to you from the National Kidney Foundation: Learn more at www. kidney. org Call the NKF Cares Patient Help Line at 855. NKF. Cares (855. 653. 2273) or email nkfcareskidney. org Becoming an educated patient is very important to being healthy! 18 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. High-Phosphorus Foods to Limit or Avoid Drinks Ale, beer Canned or bottled iced teas Cocoa; chocolate drinks Dark colas Drinks made with milk, yogurt, buttermilk Dairy Products Cottage cheese; ricotta cheese Cream soups Custard Hard cheese (parmesan, Swiss, cheddar) Ice cream Milk Pudding Yogurt Protein Canned tuna and salmon Crayfish Organ meats (liver, kidneys, sweetbreads) Oysters, clams, calamari, crab Processed meats (hot dogs, canned meat) Sardines Tofu Dried Beans and Beans (pinto, black, kidney, cannelloni, lima, etc. ) Peas Canned beans (baked beans, pork and beans, etc. )
----------------------------------------------------------------------


======================================================================
CHUNK 541 of 647
======================================================================
ID: mineral_and_bone_disorder_8
Content Type: reference
Words: 493
Medical Entities: dialysis
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
Peas Canned beans (baked beans, pork and beans, etc. ) Lentils or soy beans Peas (chick peas, split peas, black-eyed peas) Soups or other foods made with beans, lentils, and chick peas, like chili or hummus Nuts and Seeds Almonds, cashews, pistachios, sunflower seeds, peanuts, peanut butter Other HighBran cereals Phosphorus Foods Brewers yeast Chocolate and candies made from milk (caramels) Oatmeal Quick breads, biscuits, corn bread, muffins, pancakes or waffles from boxed mixes Wheat germ Whole grain products Processed and fast foods with phosphate additives Note: This list is not complete. WWW. KIDNEY. ORG 19 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Food Choices with Less Phosphorus Instead of these highTry these lowphosphorus foods: phosphorus foods: 1 cup milk (230 mg phosphorus) 1/2 cup milk (115 mg) 1 cup cream soup made with milk 1 cup cream soup made with water (275 mg) (90 mg) 1 ounce hard cheese, such as 1 ounce cream cheese (30 mg) American, cheddar, muenster, Swiss (145 mg) 1/2 cup ice cream (80 mg) 1/2 cup sherbet or 1 popsicle (0 mg) 12 ounce can of cola (55 mg) 12 ounce can of non-cola, such as ginger ale or lemon soda (3 mg) 1/2 cup lima or pinto beans 1/2 cup mixed vegetables (100 mg) or green beans (35 mg) 1/2 cup pudding or custard made 1/2 cup gelatin dessert (30 mg) with milk (150 mg) 1/2 cup nuts (200 mg) 1 1/2 cups light salted/low-fat popcorn (35 mg) 1 1/2 ounce chocolate bar 1 1/2 ounce hard candy in fruit (125 mg) flavors or jelly beans (3 mg) 2/3 cup oatmeal (130 mg) 2/3 cup cream of wheat, cream of rice or grits (40 mg) 1/2 cup bran cereal 1/2 cup non-bran cereal, (140260 mg) rice cereal or corn flakes (50100 mg) The numbers are the milligrams of phosphorus in the food. 20 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Words to Know Active vitamin D: Vitamin D comes from some foods and the sun. To be used by your body, it first must be made into its active form. Healthy kidneys do this. Active vitamin D can also be given as a medicine. Another name for this is calcitriol. Bone turnover: A process in which new bone cells are made by your body and old bones cells are replaced. Calcium: A mineral needed for healthy bones. Calcium can be lost from your bones when you have kidney disease or kidney failure. Too much calcium in the blood can damage the blood vessels and heart. Dialysis: A process that filters waste products and extra fluid from your blood when your kidneys are no longer doing their job. There are two types of dialysis hemodialysis and peritoneal dialysis. Dietitian: A professional with special training to help you plan what to eat and drink to help you feel your best. Echocardiogram: A test that uses sound waves to create a moving picture of the heart.
----------------------------------------------------------------------


======================================================================
CHUNK 542 of 647
======================================================================
ID: mineral_and_bone_disorder_9
Content Type: general
Words: 493
Medical Entities: dialysis,diabetes
Source: mineral_and_bone_disorder.pdf

----------------------------------------------------------------------
There are two types of dialysis hemodialysis and peritoneal dialysis. Dietitian: A professional with special training to help you plan what to eat and drink to help you feel your best. Echocardiogram: A test that uses sound waves to create a moving picture of the heart. Hormones: Chemical messengers produced by many different glands in your body including the kidneys to trigger certain responses in your body. Kidney disease: The loss of some or all of your kidney function. Kidney disease can result from conditions such as high blood pressure, diabetes, family history, or an injury to the kidneys. WWW. KIDNEY. ORG 21 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Kidney failure: The stage of kidney disease at which dialysis or a transplant is needed to stay alive. Kidney transplant: An operation that places a healthy kidney in your body. It is one of the basic forms of treatment for kidney failure. Mineral and bone disorder: Kidney disease and kidney failure can cause important minerals, such as calcium and phosphorus, to build up in your blood stream and get out of balance. As a result, bones may lose calcium and become weak over time. Some calcium and phosphorus may end up in parts of your body where they do not belong, like your heart and blood vessels. This can lead to heart disease. Minerals: Minerals, such as calcium and phosphorus, are nutrients that you get from food. Your body needs them to work properly and stay healthy. Nutrients: Chemicals that you get from food that are necessary to live and grow. They are used to build and repair tissues, regulate body processes, and for energy. Vitamins, minerals, and protein are nutrients. Osteoporosis: A disorder in which the bones weaken and become brittle, fracture easily, and heal slowly. It is very common in older women. Parathyroid hormone (PTH): A hormone that affects the balance of calcium and phosphorus levels in your blood. Also called PTH. Phosphate binders: Medicines that keep phosphorus in the foods you eat from getting into your blood. 22 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Phosphorus: A mineral in your blood that is important to your bones, muscles, and heart. Healthy kidneys keep the right amount of phosphorus in your blood. With kidney disease and kidney failure, phosphorus can build up in the blood. Vitamins: Vitamins are nutrients that your body needs to work properly. WWW. KIDNEY. ORG 23 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. The National Kidney Foundation is the leading organization in the U. S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk. Help fight kidney disease. Learn more at www. kidney. org 30 East 33rd Street New York, NY 10016 800. 622. 9010 Awareness. Prevention. Treatment. Awareness. Prevention. Treatment. www. kidney. org 800. 622. 9010 www. kidney. org 800. 622.
----------------------------------------------------------------------


======================================================================
CHUNK 543 of 647
======================================================================
ID: nutrition_and_ckd_0
Content Type: reference
Words: 500
Medical Entities: CKD,GFR,dialysis
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
STAGES 15 NNuuttrriittiioonn aanndd Not on Dialysis CChhrroonniicc KKiiddnneeyy DDiisseeaassee Getting the most out of the foods you eat Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Why is good nutrition important for people stage of kidney disease, based on how well your with kidney disease? . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 kidneys are working and your estimated glomerular Will I need to change my diet? . . . . . . . . . . . . . . . . . . . . 5 filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your How can a kidney dietitian help? . . . . . . . . . . . . . . . . . . 5 kidneys are filtering each minute. As CKD gets worse, Nutrition basics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 the eGFR number goes down. Why do I need protein? . . . . . . . . . . . . . . . . . . . . . . . . . . 8 How many calories do I need? . . . . . . . . . . . . . . . . . . 10 STAGES OF KIDNEY DISEASE How do I get enough vitamins and minerals? . . . . . . . 11 ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY How will I know if I am getting enough STAGE DESCRIPTION (eGFR) FUNCTION calories and nutrients? . . . . . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 544 of 647
======================================================================
ID: nutrition_and_ckd_1
Content Type: general
Words: 482
Medical Entities: CKD,GFR,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
. . . . . . . 11 ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY How will I know if I am getting enough STAGE DESCRIPTION (eGFR) FUNCTION calories and nutrients? . . . . . . . . . . . . . . . . . . . . . . . . . 12 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function What if I dont want to eat or dont like my food choices? . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Will I need nutritional supplements? . . . . . . . . . . . . . . 13 Mild to moderate loss of Will I need to control any other nutrients? . . . . . . . . . 14 3a 45 to 59 kidney function 4559% What if I have diabetes? . . . . . . . . . . . . . . . . . . . . . . . . 23 Moderate to severe loss of 3b 30 to 44 kidney function What about plant-based or meatless diets? . . . . . . . . 23 3044% How is nutritional health checked? . . . . . . . . . . . . . . . 24 Severe loss of kidney 4 15 to 29 function 1529% Questions for your healthcare professional. . . . . . . . 25 5 Kidney failure Less than 15 Less than Setting a standard for care. . . . . . . . . . . . . . . . . . . . . 29 15% KIDNEY. ORG 3 Introduction Nutrition is all about eating a healthy and balanced diet so your body gets the nutrients that it needs. Nutrients are substances in foods that our bodies need to function and grow. Why is good nutrition important for people with kidney disease? Making healthy food choices is the key to better mental and physical health and it is even more important if you have chronic kidney disease (CKD). Why? The kind and amount of food you eat affects the way you feel and how your body works. 4 NATIONAL KIDNEY FOUNDATION Eating nutritious foods gives you more energy and can help you: do your daily tasks prevent infection build muscle help maintain a healthy weight manage your kidney disease and keep it from getting worse Will I need to change my diet? There is no single eating plan that is right for everyone with kidney disease. The best foods for you depend on how well your kidneys works and other factors, like if you have diabetes.
----------------------------------------------------------------------


======================================================================
CHUNK 545 of 647
======================================================================
ID: nutrition_and_ckd_2
Content Type: reference
Words: 497
Medical Entities: CKD,dialysis,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
There is no single eating plan that is right for everyone with kidney disease. The best foods for you depend on how well your kidneys works and other factors, like if you have diabetes. Your doctor can refer you to a kidney dietitian (a dietitian who specializes in kidney disease) who can teach you how to choose foods that are right for you. How can a kidney dietitian help? A kidney dietitian can: help you choose foods that will give you the right nutrients in the right amounts explain why diet changes are important answer your questions KIDNEY. ORG 5 Tip Help from a dietitian is very important for people with kidney disease. You may be eligible for reimbursement for medical nutrition therapy with a dietitian under Medicare or your health insurance plan. Learn more at medicare. gov 6 NATIONAL KIDNEY FOUNDATION Nutrition basics A healthy eating plan gives you the right amount of: protein calories vitamins minerals HEALTHY DIET PLANS FOR PEOPLE WITH KIDNEY DISEASE: Mediterranean diet (CKD stages 15 not on dialysis) Diets high in fruits and vegetables (CKD stages 14) Other options include DASH and plant-based diets Note: These diets are high in potassium. Ask your doctor or kidney dietitian which dietary pattern is best for you. Tip If you need help finding a kidney dietitian who specializes in kidney disease, you can ask your doctor for a referral or contact the National Kidney Foundation at kidney. org/ckdrd or the Academy of Nutrition and Dietetics at 800. 877. 1600 or eatright. org KIDNEY. ORG 7 Why do I need protein? Protein is an important nutrient. Your body needs protein to help build muscle, repair tissue, and fight infection. But if you have kidney disease, you may need to closely watch the amount of protein you eat to prevent protein wastes from building up in your blood. This can help your kidneys work longer. Your doctor will tell you if you need to limit how much protein you eat each day. Decisions are based on your stage of kidney disease, level of nutrition, muscle mass, and other things. Let your kidney doctor and kidney dietitian help you. Protein comes from the following: lentils and dried beans poultry (chicken and turkey unsalted nuts meats (beef, veal, fish and other seafood lamb, pork) eggs This food list is not complete. Your kidney dietitian can help you learn how to maintain good nutrition and eat the right amount of protein to help your kidneys and prevent muscle breakdown. 8 NATIONAL KIDNEY FOUNDATION Important Reminder There are two kinds of protein, animal protein and plant protein. Animal protein is found in products like meat, poultry, fish, and eggs. Plant protein is found in dried beans, lentils, and nuts. A wellbalanced diet for kidney patients may include either kind of protein every day. KIDNEY. ORG 9 How many calories do I need? Every person is different. Calories are like fuelthey provide your body with the energy you need to live.
----------------------------------------------------------------------


======================================================================
CHUNK 546 of 647
======================================================================
ID: nutrition_and_ckd_3
Content Type: recommendation
Words: 493
Medical Entities: CKD,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
A wellbalanced diet for kidney patients may include either kind of protein every day. KIDNEY. ORG 9 How many calories do I need? Every person is different. Calories are like fuelthey provide your body with the energy you need to live. They are important because they: help you stay at a healthy body weight give you energy to do your daily tasks and remain active help your body use the protein in food to build muscles and tissues 10 NATIONAL KIDNEY FOUNDATION It is important to plan meals that give you enough calories each day. Otherwise, your body may not have energy to stay healthy. Your kidney dietitian can help you do this. Some people may be told to eat more calories. They may need to eat extra sweets like sugar, jam, jelly, hard candy, honey, and syrup. Other good sources of calories come from fats such as unsalted nuts and oils like canola or olive oil. How do I get enough vitamins and minerals? Most people get enough vitamins and minerals to stay healthy by eating a wide variety of foods each day. However, if you have kidney disease, you may need to limit some foods that would normally give you these important vitamins and minerals. If so, you may need to take special vitamins or minerals instead. Your doctor and kidney dietitian will tell you what choices are good for you. Other Tips Take only the vitamins and minerals your doctor recommends, because some vitamins and minerals may be harmful to people with kidney disease. Check with your doctor before taking any vitamins, herbal supplements, nutrition supplements, or medicines you can buy without a doctors prescription. Some may be harmful to people with kidney disease. KIDNEY. ORG 11 How will I know if I am getting enough calories and nutrients? Your doctor will test your blood and urine. These tests will help show whether or not you are getting enough nutrients. Your kidney dietitian may also ask you about the foods you eat. You may also be asked to keep track of everything you eat or drink, also known as a food diary. To learn more about the tests used to check your nutrition, visit kidney. org or call NKF Cares at 1. 855. NKF. CARES (855. 653. 2273). 12 NATIONAL KIDNEY FOUNDATION What if I dont want to eat or dont like my food choices? When you have kidney disease, it may be difficult to get enough nutrients from food, especially if you are on a limited-protein diet. Many people with kidney disease also find it hard to eat enough calories each day. Many supplements are available, and some are made just for people with kidney disease or diabetes. Check with your doctor or kidney dietitian before taking any supplements. Important Tip If you have diabetes and CKD, ask your kidney dietitian how many calories you should have and what you should do to keep your blood sugar under control.
----------------------------------------------------------------------


======================================================================
CHUNK 547 of 647
======================================================================
ID: nutrition_and_ckd_4
Content Type: recommendation
Words: 446
Medical Entities: CKD,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
Check with your doctor or kidney dietitian before taking any supplements. Important Tip If you have diabetes and CKD, ask your kidney dietitian how many calories you should have and what you should do to keep your blood sugar under control. Adding sweet, high-calorie foods to your meals may not be a good choice for you. Will I need nutritional supplements? Remember, not all people with kidney disease have the same dietary needs. Your doctor and kidney dietitian will tell you if you need to take nutritional supplements. Use only the supplements recommended by your doctor or kidney dietitian. KIDNEY. ORG 13 Other Nutrients Will I need to control any other nutrients? You may need to balance fluids and other important nutrients. They are: sodium phosphorus calcium potassium 14 NATIONAL KIDNEY FOUNDATION SODIUM Sodium is a mineral found in most foods. It is also found in table salt. Sodium affects blood pressure and water balance in your body. Healthy kidneys can control sodium. But, if your kidneys do not work well, sodium and fluid build up in your body. This can cause high blood pressure and other problems, like swelling of your ankles, fingers, or eyes. Your doctor or kidney dietitian will tell you if you need to limit sodium. You can limit sodium by limiting table salt and foods such as: seasonings like soy sauce, sea salt, teriyaki sauce, garlic salt, onion salt, or seasoned salt most canned foods and frozen dinners (unless they say low sodium check the label) processed meats like ham, bacon, hot dogs, sausage, and deli meats salted snack foods, like chips and crackers canned or dehydrated soups (like packaged noodle soup) most restaurant foods, takeout foods, and fast foods This food list is not complete. Your kidney dietitian can teach you how to choose lower sodium foods. Learning how to read food labels can help you find foods with less sodium. KIDNEY. ORG 15 Tips Learn to read food labels so you know what you are eating. Reading labels can help you shop for foods with lower sodium and to check for added nutrients that may be bad for you. Do NOT use potassium chloride salt substitutes unless approved by your doctor. Try fresh or dried herbs and spices instead of table salt to bring out the flavor of foods. Also, try adding a dash of hot pepper sauce or a squeeze of lemon juice for flavor. 16 NATIONAL KIDNEY FOUNDATION PHOSPHORUS Phosphorus is a mineral found in many foods. People with kidney disease may need to closely watch how much phosphorus is in their food. As kidney disease gets worse, the kidneys are not able to remove extra phosphorus.
----------------------------------------------------------------------


======================================================================
CHUNK 548 of 647
======================================================================
ID: nutrition_and_ckd_6
Content Type: reference
Words: 489
Medical Entities: CKD,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
A simple blood test can check your potassium level. Too much or too little potassium in the blood can be dangerous. Some people with kidney disease need more potassium; others need less. How much you need depends on how well your kidneys are working. It also depends on whether or not you are taking any medicine that changes the level of potassium in your blood. 20 NATIONAL KIDNEY FOUNDATION Tips Choose low potassium fruits and vegetables such as tangerines, grapes, cherries, berries, apples, canned fruit, lettuce, cucumber, green beans, cabbage, celery, corn, peas, and cauliflower. Use long moist cooking methods that lower the potassium amount in food. Example: peel, cut, and double boil potatoes to lower potassium by half. KIDNEY. ORG 21 FLUID Most people in the early stages of with kidney disease do not need to limit the amount of fluids they drink. If you do not know your stage of kidney disease, ask your doctor. If your kidney disease gets worse, your doctor will let you know if you need to limit fluids and how much fluid is okay for you each day. To avoid dehydration, let your doctor and kidney dietitian help plan your fluid intake. To learn more about CKD contact the National Kidney Foundation 855. NKF. CARES (855. 653. 2273). 22 NATIONAL KIDNEY FOUNDATION What if I have diabetes? You may need to make a few changes in your diet if you have diabetes and kidney disease. If your doctor says that you should eat less protein, your diet may need to include more carbohydrates or high-quality fats to give you enough calories. Work with your kidney dietitian to make a meal plan that is right for you. Ask your doctor how often to test your blood sugar levels. Try to keep your levels under control. Your dosage of insulin or other medicines may need to change if your kidney disease gets worse. Contact your doctor if your blood sugar levels are too high or too low. What about plant-based or meatless diets? Plant-based or meatless diets may have a positive effect on health. Eating a variety of plant foods and getting enough calories is important. Without enough calories, your body will break down the protein you eat to create energy instead. If protein is broken down, more waste products have to be removed by your kidneys. Ask about ways to check that the amount of protein you are eating is right for you. Talk with your kidney dietitian about the best sources of plant protein that have the right amounts of potassium and phosphorus to best meet your dietary needs. Your doctor or kidney dietitian can check your blood to make sure you are getting the right amount of protein and calories. KIDNEY. ORG 23 How is nutritional health is checked? You will be checked regularly by your doctor and dietitian to make sure you are getting the right nutrients that you need.
----------------------------------------------------------------------


======================================================================
CHUNK 549 of 647
======================================================================
ID: nutrition_and_ckd_7
Content Type: reference
Words: 500
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: nutrition_and_ckd.pdf

----------------------------------------------------------------------
KIDNEY. ORG 23 How is nutritional health is checked? You will be checked regularly by your doctor and dietitian to make sure you are getting the right nutrients that you need. Some tests are: PHYSICAL NUTRITION EXAM Your dietitian may give you an exam to check your body for signs of nutrition problems. This exam is called a Subjective Global Assessment (SGA). Your dietitian asks you about the foods you eat and looks at the fat and muscle levels in your body. The dietitian notes: changes in your weight changes in the tissues around your face, arms, hands, shoulders, and legs your food intake your activity and energy levels problems that might interfere with eating DIETARY INTERVIEWS AND FOOD DIARIES Your dietitian will ask about what you eat. You may also be asked to keep a food diary of everything you eat and drink each day. Your dietitian wants to see if you are getting the right amount of protein, calories, vitamins, and minerals. 24 NATIONAL KIDNEY FOUNDATION Questions for your healthcare professional If you have questions or are unsure about anything, write down your questions before you go to your doctor or kidney dietitian because it is easy to forget what you wanted to talk about. Make sure you ask what each test result means and what your options are. You need to understand the treatment plan that your doctor or dietitian thinks is good for you. This is your health, so never feel uncomfortable about asking anything. KIDNEY. ORG 25 EXAMPLES OF QUESTIONS TO ASK: How many grams of protein should I eat each day? _____________________________________________ Does that mean I need to increase or lower the amount of protein I currently eat? oYes oNo If I do, what do I need to do? _____________________________________________________________ How many calories should I have in a day? _____________________________________________ How many ounces of fluid should I drink each day? _____________________________________________ Is my potassium level too high or too low? oHigh oLow 26 NATIONAL KIDNEY FOUNDATION What should I do to correct my potassium levels? _____________________________________________ Do I need a nutritional supplement? oYes oNo If I do, what would be best for me? _____________________________________________________________ Should I take vitamins? oYes oNo If I should, which ones should I take? _____________________________________________________________ KIDNEY. ORG 27 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to read more about kidney disease, the National Kidney Foundation has more than 50 other publications that cover many subjects, such as: CKD risk factors like hypertension and diabetes Complications of chronic kidney disease such as cardiovascular disease, anemia, or bone problems Nutrition for CKD patients with information about carbohydrates, protein, sodium, phosphorus, and potassium Treating kidney disease early Treating kidney failure with transplantation or dialysis transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF.
----------------------------------------------------------------------


======================================================================
CHUNK 550 of 647
======================================================================
ID: nutrition_and_hemodiaylsis_0
Content Type: reference
Words: 432
Medical Entities: CKD,GFR
Source: nutrition_and_hemodiaylsis.pdf

----------------------------------------------------------------------
STAGE 5 Nutrition and Hemodialysis Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your Getting the right amount of calories. . . . . . . . . . . . . . . 5 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a Getting the right amount of protein. . . . . . . . . . . . . . . . 7 lab test that measures the amount of blood your Other important nutrients in your diet. . . . . . . . . . . . . 9 kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Handling special diet needs. . . . . . . . . . . . . . . . . . . . . 16 How your nutritional health is checked. . . . . . . . . . . . 17 STAGES OF KIDNEY DISEASE Where can you get more information? . . . . . . . . . . . 20 ESTIMATED Setting a standard for care. . . . . . . . . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 551 of 647
======================================================================
ID: nutrition_and_hemodiaylsis_1
Content Type: recommendation
Words: 496
Medical Entities: GFR,dialysis,diabetes
Source: nutrition_and_hemodiaylsis.pdf

----------------------------------------------------------------------
17 STAGES OF KIDNEY DISEASE Where can you get more information? . . . . . . . . . . . 20 ESTIMATED Setting a standard for care. . . . . . . . . . . . . . . . . . . . . . 21 GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 3 Introduction If you are receiving hemodialysis treatments, your diet is an important part of your overall care. This booklet will tell you about some things that are important to your diet. It is been written for adults who are receiving hemodialysis treatments. 4 NATIONAL KIDNEY FOUNDATION Getting the right amount of calories Getting the right amount of calories is important to your overall health and helps to give you energy to do the activities you enjoy. Calories come from all the foods you eat, and are important because they: give your body energy help you stay at a healthy body weight help your body use protein for building muscles and tissues The registered dietitian nutritionist (RDN) at your dialysis center will help you plan your meals to get the right amount of calories each day. The amount of calories recommended for you will depend on your individual needs. Eating the right amount of calories each day will keep you from losing weight. If you are losing weight, your dietitian may ask you to add extra sweets like sugar, jelly, jam, hard candy, honey, or syrup. Other good sources of calories are fats like soft (tub) margarine, and oils like canola or olive oil. If you have diabetes, speak to your dietitian about how to safely add calories to your diet. KIDNEY. ORG 5 Working with your dietitian You may feel a bit confused by all the new information about your kidney disease and its treatment. You probably have many questions about your diet. Help is available to you. The staff at your dialysis center includes a registered dietitian nutritionist (RDN) with special training in diets for people with kidney disease. This dietitian can answer your questions about your diet and help you plan your meals to get the right foods in the right amounts. Steps to take Speak to the dietitian at your dialysis center. Ask your dietitian to help you plan meals with the right amount of calories. Keep a diary of what you eat each day. Show this to your dietitian on a regular basis. Ask your healthcare professional and dietitian what your ideal body weight should be.
----------------------------------------------------------------------


======================================================================
CHUNK 552 of 647
======================================================================
ID: nutrition_and_hemodiaylsis_3
Content Type: reference
Words: 492
Medical Entities: dialysis
Source: nutrition_and_hemodiaylsis.pdf

----------------------------------------------------------------------
Learn to flavor your foods with herbs and spices instead of table salt. Do NOT use salt substitutes containing potassium unless approved by your healthcare professional. TIP To cut down on sodium, try using fresh or dried herbs and spices instead of salt to enhance the flavor of your foods. Also, try adding a dash of hot pepper sauce or a squeeze of lemon for flavor. Your healthcare professional or dietitian will help you determine the right amount of fluid to drink each day. A sudden increase in weight, along with swelling, shortness of breath, or a rise in your blood pressure may be signs that you are drinking too many fluids. Tell your dialysis care team if you are having any of 10 NATIONAL KIDNEY FOUNDATION these problems. Check your weight at the beginning of each treatment. Ask your dietitian for creative ways to cut down on the amount of fluid you are drinking. WHAT IS FLUID? Fluid is any food or beverage that is liquid at room temperature. Some examples are: ice beverages like coffee, tea, sodas, juices, and water frozen desserts such as ice cream, sherbet, or popsicles gelatin gravy and soups KIDNEY. ORG 11 Phosphorus and calcium Phosphorus is a mineral found in all foods. Large amounts of phosphorus are found in: dairy products such as milk, cheese, yogurt, ice cream, and pudding nuts and peanut butter dried beans and peas such as kidney beans, split peas, and lentils beverages such as cocoa, beer and dark cola drinks. convenience and processed foods with phosphorus-containing food additives such as chicken nuggets and hot dogs, refrigerated bakery products, and some beverages. Eating foods high in phosphorus will raise the amount of phosphorus in your blood. However, phosphorus from plant foods is less absorbed than phosphorus from animal foods or phosphate additives. Dialysis cannot remove all of this phosphorus in your blood. When phosphorus builds up in your blood, calcium is pulled from the bones. Over time, your bones will become weak and break easily. A high level of 12 NATIONAL KIDNEY FOUNDATION phosphorus in your blood may also cause calcium phosphorus crystals to build up in your joints, muscles, skin, blood vessels, and heart. These deposits may cause serious problems such as bone pain, damage to the heart and other organs, poor blood circulation, and skin ulcers. To keep blood phosphorus at safe levels, you will need to limit phosphorus-rich foods, and you may need to take a type of medicine called a phosphate binder. These binders are taken with your meals and snacks. TIP Using fresh foods instead of processed or convenience foods is a good way to lower the amount of phosphorus in your diet. Read nutrition labels to look for the word phosphorus or a shortened phos in the ingredients of processed foods. Calcium is a mineral that is important for building strong bones. However, foods that are good sources of calcium are also high in phosphorus.
----------------------------------------------------------------------


======================================================================
CHUNK 553 of 647
======================================================================
ID: nutrition_and_hemodiaylsis_4
Content Type: recommendation
Words: 498
Medical Entities: dialysis,diabetes
Source: nutrition_and_hemodiaylsis.pdf

----------------------------------------------------------------------
Read nutrition labels to look for the word phosphorus or a shortened phos in the ingredients of processed foods. Calcium is a mineral that is important for building strong bones. However, foods that are good sources of calcium are also high in phosphorus. The best ways to prevent loss of calcium from your bones are to follow a diet that limits high-phosphorus foods and to take phosphate binders. Your healthcare professional may also prescribe a special form of vitamin D to help keep calcium and phosphoru s levels in balance and to prevent bone disease. Do not take over-the-counter vitamin D unless recommended by your kidney healthcare professional. KIDNEY. ORG 13 Potassium Potassium is another important mineral found in food. Potassium helps your muscles and heart work properly. Too much or too little potassium in the blood can be dangerous. With hemodialysis, you will probably need to limit your intake of high-potassium foods. The level of potassium in your blood will be checked every month, and your dietitian will help you plan a diet that will give you the right amount of potassium. Large amounts of potassium are found in: certain fruits and vegetables (like bananas, melons, oranges, potatoes, tomatoes, and some juices) milk and yogurt dried beans and peas most salt substitutes protein-rich foods, such as meat, poultry, pork and fish. 14 NATIONAL KIDNEY FOUNDATION Vitamins and minerals Eating a wide variety of foods gives your body the vitamins and minerals it needs each day. In addition to a good diet, your healthcare professional may order special vitamin and mineral supplements. Kidney disease and dialysis change the amounts of vitamins and minerals your body needs. Also, your special diet may limit some food groups that would normally provide important vitamins and minerals. Take only those supplements ordered by your kidney healthcare professional, since certain vitamins and minerals can be harmful if you are on dialysis. Also, check with your healthcare professional before using any herbal remedies, as some of these may be harmful for people with kidney disease. KIDNEY. ORG 15 Handling special diet needs Diabetes and your special diet You may need to make only a few changes in your diabetic diet to fit your needs on hemodialysis. You may need to drink less milk and eat less potassiumrich fruits and vegetables. Your dietitian will help develop a meal plan especially for you. Plant-based diets Plant-based diets may have a positive effect on health. Eating a variety of plant foods and getting enough calories is important. Eating enough calories is an important way to use protein for important jobs like building muscle, healing wounds and fighting infections. Talk with your dietitian about the best sources of plant protein that have the right amounts of potassium and phosphorus to meet your special needs. 16 NATIONAL KIDNEY FOUNDATION How your nutritional health is checked There are several different ways for your healthcare professional and dietitian to determine if you are eating the right amount of calories or protein.
----------------------------------------------------------------------


======================================================================
CHUNK 554 of 647
======================================================================
ID: nutrition_and_hemodiaylsis_5
Content Type: general
Words: 488
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: nutrition_and_hemodiaylsis.pdf

----------------------------------------------------------------------
16 NATIONAL KIDNEY FOUNDATION How your nutritional health is checked There are several different ways for your healthcare professional and dietitian to determine if you are eating the right amount of calories or protein. The following sections explain these tests and methods. If your results are not what they should be, ask how to improve them. Dietary interviews and food diaries Your dietitian will speak to you at times about your diet. The dietitian may also ask you to keep a record of what you eat each day. If you are not eating the right amount of protein, calories, and other nutrients, your dietitian will give you ideas about food choices that will help to improve your diet. KIDNEY. ORG 17 Physical nutrition exam Your dietitian may use a method called Subjective Global Assessment (SGA) to check your body for signs of nutrition problems. This involves asking you questions about your food intake and looking at the stored fat and muscle in your body. The dietitian will consider: changes in your weight changes in the tissues around your face, arms, hands, shoulders, and legs your food intake your activity and energy levels problems that might interfere with eating. Amount of dialysis you receive Every month, tests will be used to determine if you are getting the right amount of dialysis to keep you in good health. Blood is tested at the beginning and the end of one of your dialysis treatments. You may also be asked for a urine sample. This information will provide a way to measure dialysis, called Kt/V (pronounced kay tee over vee) and urea reduction ratio (URR). A low Kt/V (or a low URR) may mean that you are not getting enough dialysis. Low amounts of dialysis can keep you from feeling, sleeping or eating well. To keep your Kt/V and URR levels as high as possible, it is very important to come to all of your treatment sessions and stay for the full treatment time as ordered by your healthcare professional. 18 NATIONAL KIDNEY FOUNDATION Steps to take Ask your healthcare professional and dietitian which tests will be used to check your nutritional health. Ask for a copy of the Dialysis Report Card and track your results. If your numbers are not what they should be, ask your healthcare professional and dietitian how you can improve them. KIDNEY. ORG 19 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to read more about kidney disease, the National Kidney Foundation has more than 50 other publications that cover many subjects, such as: CKD risk factors like hypertension and diabetes Complications of chronic kidney disease, such as cardiovascular disease, anemia or bone problems Nutrition for CKD patients, with information about carbohydrates, protein, sodium, phosphorus and potassium Treating kidney disease early Treating kidney failure with transplantation or dialysis.
----------------------------------------------------------------------


======================================================================
CHUNK 555 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_0
Content Type: reference
Words: 481
Medical Entities: CKD,GFR,dialysis
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
STAGE 5 Nutrition and Peritoneal Dialysis Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your Getting the right amount of calories. . . . . . . . . . . . . . . 5 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a Working with your dietitian. . . . . . . . . . . . . . . . . . . . . . 6 lab test that measures the amount of blood your Getting the right amount of protein. . . . . . . . . . . . . . . . 8 kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Other important nutrients in your diet. . . . . . . . . . . . . 9 Handling special diet needs. . . . . . . . . . . . . . . . . . . . . 15 STAGES OF KIDNEY DISEASE How your nutritional health is checked. . . . . . . . . . . . 16 ESTIMATED Physical nutrition exam. . . . . . . . . . . . . . . . . . . . . . . . . 17 GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Amount of dialysis you receive. . . . . . . . . . . . . . . . . . . 18 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% Understanding your test results. . . . . . . . . . . . . . . . . . 19 kidney function Where can you get more information? . . . . . . . . . . . . 24 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Setting a standard for care. . . . . . . . . . . . . . . . . . . . . . 25 Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 3 If you are receiving hemodialysis treatment, see Nutrition and Hemodialysis. For more information about diets for transplantation, see Nutrition and Transplantation.
----------------------------------------------------------------------


======================================================================
CHUNK 556 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_1
Content Type: recommendation
Words: 491
Medical Entities: dialysis,diabetes
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
ORG 3 If you are receiving hemodialysis treatment, see Nutrition and Hemodialysis. For more information about diets for transplantation, see Nutrition and Transplantation. For information about diets for children with chronic kidney disease, see A Parents Guide to Nutrition for Children With Chronic Kidney Disease. All are available from the National Kidney Foundation. Getting the right amount of calories Getting the right amount of calories is important to your overall health and how well you feel. Calories come from all the foods you eat. They are important because they: Give your body energy Help you maintain a healthy weight Help your body use protein for building muscles and tissues. Introduction When you first start peritoneal dialysis, you If you are receiving peritoneal dialysis treatments, may have difficulty eating well and getting your diet is an important part of your overall care. enough calories. For a while, the dialysis This booklet will tell you about some things that are solutions may give you a sense of fullness in important to your diet. It has been written for adults your stomach. Eating smaller meals five or six who are receiving peritoneal dialysis treatment. The times a day can provide the calories you need information is based on recommendations made during the first weeks on peritoneal dialysis. by the National Kidney Foundations Kidney Disease Over time, many people gain unwanted Outcomes Quality Initiative. These recommendations weight on peritoneal dialysis. The dialysis fluid have been developed to help your health care team used for exchanges contains a sugar called provide the best care for you. dextrose. Solutions that contain more dextrose help to remove extra fluid from your blood. 4 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 5 However, dextrose is an extra source of calories for the body and can lead to unwanted weight gain. And if you have diabetes, the extra sugar from your dialysis solution can cause an increase in your blood sugar. The registered dietitian nutritionist (RDN) at your dialysis center can help you plan meals to prevent extra weight gain and high blood sugar. In addition, following the sodium and fluid instructions from your dietitian can help to prevent the need for the high sugar solutions. Your healthcare professional will choose the dialysis solutions for your fluid removal. Steps to take Also, your healthcare professional may change your Speak to the dietitian at your dialysis center. diabetic medicines to help control blood sugar. Ask your dietitian to help you plan meals with the right amount of calories. Working with your dietitian Keep a diary of what you eat. Show this to your You may feel a bit confused by all the new information dietitian on a regular basis. about your kidney disease and its treatment. You Ask your healthcare professional and dietitian probably have many questions about your diet. Help what is your best weight. Weigh yourself each is available to you. The staff at your dialysis center day in the morning.
----------------------------------------------------------------------


======================================================================
CHUNK 557 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_2
Content Type: reference
Words: 479
Medical Entities: dialysis
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
about your kidney disease and its treatment. You Ask your healthcare professional and dietitian probably have many questions about your diet. Help what is your best weight. Weigh yourself each is available to you. The staff at your dialysis center day in the morning. includes a registered dietitian nutritionist (RDN) with If you are losing too much weight, ask your special training in diets for people with kidney disease. dietitian how to add extra calories to your diet. This dietitian can answer your questions about your diet and help you plan your meals to get the right If you are slowly gaining too much body foods in the right amounts. weight, ask for suggestions on safely reducing your daily calorie intake and increasing your activity level. If you gain weight rapidly, speak to your healthcare professional. A sudden increase in weight, along with swelling, shortness of breath and a rise in your blood pressure may be a sign that you have too much fluid in your body. 6 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 7 Getting the right amount of protein Steps to take Before you started dialysis, you may have been on a Ask your dietitian how much protein you need low protein diet to limit the amount of waste products to eat each day. in your blood. Now that you have begun peritoneal Show your daily food diary to your dietitian, and dialysis, your treatments will remove these waste ask if you are eating the right amount of protein. products. Unfortunately, when your dialysis removes the unwanted wastes, it also carries out some good Other important nutrients in your diet proteins that your body needs. Eating a higher protein diet can help you replace the lost protein. Sodium and fluid Your body needs the right amount of protein for: Sodium is a mineral found naturally in foods. It is building muscles found in large amounts in table salt and in foods that repairing tissue have added table salt such as: fighting infection salty seasonings like soy sauce, teriyaki sauce and garlic or onion salt Protein-rich foods to eat daily include: most canned foods (including canned soups fresh meats and meats) poultry (chicken and turkey) most frozen dinners fish and seafood processed meats like ham, bacon, sausage eggs or egg whites and cold cuts small amounts of dairy products salted snack foods like chips and crackers canned or dehydrated soups (like ramen Some of these protein-rich foods may also contain a noodle soup) lot of phosphorus, a mineral you may need to control in your diet. Your dietitian will help you plan the right most restaurant meals. amount and type of each protein source for good health and strength. (For more information about phosphorus, see. ) 8 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 9 Eating too much sodium can make you thirsty and cause your body to hold more fluid.
----------------------------------------------------------------------


======================================================================
CHUNK 558 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_4
Content Type: recommendation
Words: 486
Medical Entities: dialysis,diabetes
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
oranges, potatoes and some juices) milk and yogurt Foods that are good sources of calcium are also dried beans and peas high in phosphorus. The best way to prevent loss most salt substitutes of calcium from your bones is to follow a diet that limits high-phosphorus foods and to take phosphate protein-rich foods like meats, poultry and fish binders. Your healthcare professional may also recommend that you take a special form of vitamin D to help keep calcium and phosphorus in balance and prevent bone disease. Do not take over-the-counter vitamin D, however, unless recommended by your kidney healthcare professional. 12 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 13 Vitamins and minerals Handling special diet needs Eating a variety of foods gives your body the vitamins and minerals it needs each day. Your healthcare Diabetes and your special diet professional may order special vitamin and mineral You may need to make only a few changes in your supplements for two reasons. Dialysis treatment diabetic diet to fit your needs on peritoneal dialysis. changes your vitamin needs. Also, your special You may need to eat more protein and fewer diet may limit some important food groups. Take carbohydrates. Your dietitian will help develop a meal only those supplements your kidney healthcare plan especially for you. professional orders since certain vitamins and minerals can be harmful if you are on dialysis. Also Plant-based diets check with your healthcare professional before using any herbal remedies, as some of these may also be Plant-based diets may have a positive effect on harmful for people with kidney disease. health. Eating a variety of plant foods and getting enough calories is important. Eating enough calories is an important way to use protein for important jobs like building muscle, healing wounds and fighting infections. Talk with your dietitian about the best sources of plant protein that have the right amounts of potassium and phosphorus to meet your special needs. 14 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 15 How your nutritional health is checked Physical nutrition exam There are several different ways for your healthcare Your dietitian may use a method called Subjective professional and dietitian to know if you are eating Global Assessment (SGA) to check your body for signs the right amount of calories or protein. The following of nutrition problems. This involves asking you some sections explain these tests. If your results are not as questions about your daily food intake and checking good as they should be, ask how to improve them. the fat and muscle stores in your body. The dietitian For more information, see Understanding Your Test will consider: Results at the back of this booklet. You may also changes in your weight want to track your important test results by using the changes in your face, arms, shoulders, Dialysis Lab Log, available by calling the NKF Cares hands and legs Patient Help Line at 855. NKF. CARES (855. 653. 2273).
----------------------------------------------------------------------


======================================================================
CHUNK 559 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_5
Content Type: general
Words: 469
Medical Entities: dialysis
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
You may also changes in your weight want to track your important test results by using the changes in your face, arms, shoulders, Dialysis Lab Log, available by calling the NKF Cares hands and legs Patient Help Line at 855. NKF. CARES (855. 653. 2273). your food intake your activity and energy levels Dietary interviews and food diaries problems that might interfere with eating Your dietitian will speak to you at times about your diet. The dietitian may also ask you to keep a record of what you eat each day. If you are not getting enough protein, calories and other nutrients, the dietitian will give you ideas about foods that will improve your diet. 16 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 17 Amount of dialysis you receive About every three to six months, tests will be performed to see if the amount of dialysis you are getting is enough to keep you in overall good health. The tests include a 24-hour urine collection, samples of your dialysis solution and a blood test. This information will measure the amount of dialysis you receive, called Kt/V (pronounced kay tee over vee). A low Kt/V indicates you are not getting enough dialysis. Low amounts of dialysis can keep you from feeling well, sleeping soundly or eating well. It is very important to do all your dialysis exchanges as ordered Understanding your test results by your healthcare professional to keep your Kt/V level Some or all of the following tests may be used to as high as possible. check your nutrition and general health. Ask your healthcare professional and dialysis care team which Steps to take tests you will have, how often they will be done and Ask your healthcare professional and dietitian what your levels should be. If your numbers are not in range, ask how to improve them. what tests will be used to check your nutritional health. Blood Pressure: If your blood pressure is high, Ask for a copy of the Dialysis Lab Log and track make sure to follow all the steps in your prescribed your results. treatment. These steps may include taking high blood If your numbers are not in the normal range, ask pressure medicines, cutting down on the amount of salt in your diet, losing weight if you are overweight your healthcare professional and dietitian how and following a regular exercise program. you can improve them. Blood UreaNitrogen (BUN): Urea nitrogen is a normal waste product in your blood that comes from the breakdown of protein from foods you eat. Healthy kidneys remove BUN from your blood, but when kidney failure occurs, your BUN rises. BUN is also removed from your blood by your dialysis. Your BUN rises from not getting enough dialysis or from 18 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 19 eating too much protein.
----------------------------------------------------------------------


======================================================================
CHUNK 560 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_6
Content Type: recommendation
Words: 486
Medical Entities: dialysis
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
Healthy kidneys remove BUN from your blood, but when kidney failure occurs, your BUN rises. BUN is also removed from your blood by your dialysis. Your BUN rises from not getting enough dialysis or from 18 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 19 eating too much protein. It can fall from getting more Cholesterol: dialysis or from eating the right amount of protein Total: Cholesterol is a fat-like substance recommended by your healthcare professional and found in your blood. A high cholesterol level dietitian. may increase your risk of having heart and circulation problems. However, a cholesterol Body Weight: Maintaining a healthy weight is level that is too low may mean you are not important to your overall health. If you are losing eating well enough to stay healthy. weight without even trying, you may not be getting the right nutrition to stay healthy. Your dietitian can HDL: HDL cholesterol is a type of good suggest how to safely add extra calories to your diet. cholesterol that protects your heart. On the other hand, if you are slowly gaining unwanted LDL: LDL cholesterol is a type of bad weight, you may need to eat less calories and increase cholesterol. A high LDL level may increase your activity level. A sudden weight gain may also your chance of having heart and circulation be a problem. If it is accompanied by swelling, problems. If your LDL level is too high, your shortness of breath and a rise in blood pressure, it healthcare professional may recommend may be a sign of too much fluid in your body. You changing your diet and increasing your should check your weight at home every morning. activity level. Speak to your healthcare professional if your weight changes suddenly. Serum Creatinine: Creatinine is a waste product in your blood that comes from the normal function of Calcium: Calcium is a mineral that is important for your muscles. Healthy kidneys remove creatinine from strong bones. To help balance the amount of calcium your blood, but when the kidneys are not working, in your blood, you should avoid foods fortified with your creatinine level rises. Your dialysis also removes calcium and do not take a calcium supplement unless creatinine from your blood. Not getting enough recommended by your healthcare professional. dialysis can cause your creatinine level to rise, while Your healthcare professional my also prescribe a getting more dialysis causes it to fall. Your creatinine special form of vitamin D. Take only the medicines level can also fall from not eating well over a long recommended by your healthcare professional. period of time. 20 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 21 Hemoglobin: Hemoglobin is the part of red blood Phosphorus: A high phosphorus level in your blood cells that carries oxygen from your lungs to all the can lead to weak bones, itching, bone pain and tissues in your body. Measuring your hemoglobin level hardening of blood vessels.
----------------------------------------------------------------------


======================================================================
CHUNK 561 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_7
Content Type: recommendation
Words: 438
Medical Entities: dialysis
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
ORG 21 Hemoglobin: Hemoglobin is the part of red blood Phosphorus: A high phosphorus level in your blood cells that carries oxygen from your lungs to all the can lead to weak bones, itching, bone pain and tissues in your body. Measuring your hemoglobin level hardening of blood vessels. If your level is too high, tells your healthcare professional if you have anemia, your healthcare professional may ask you to reduce which makes you feel tired and have little energy. To your intake of foods that are high in phosphorus treat your anemia, you may need to take a hormone and take a phosphate binder with all your meals called ESA along with iron. and snacks. Iron: Potassium: Potassium is a mineral that helps your heart and muscles work properly. A potassium level TSAT and Serum Ferritin: Your TSAT that is too high or too low may weaken muscles and (pronounced tee sat) and serum ferritin change your heartbeat. Whether you need to change (pronounced ferry tin) are measures of iron in your intake of high-potassium foods varies with each your body. They help you build red blood cells. person on peritoneal dialysis. Your dietitian can Your healthcare professional will recommend help you plan your meals to get the right amount of iron when needed to reach your target levels. potassium. Kt/V: Kt/V (pronounced kay tee over vee) is a measure Subjective Global Assessment (SGA): Your dietitian of the amount of dialysis you receive. Getting the right may use SGA to help check for signs of nutrition amount of dialysis is important to your overall health problems. The dietitian will ask you some questions and can also affect how well you eat. about your daily diet and check your weight and Parathyroid Hormone (PTH): High levels of the fat and muscle stores in your face, hands, arms, parathyroid hormone (PTH) may result from a poor shoulders and legs. If your SGA score is too low, ask balance of calcium and phosphorus in your blood. how to improve it. This can cause bone disease. Your healthcare Triglyceride: Triglyceride is another type of fat found professional may order a special form of vitamin D in your blood. A high triglyceride level, along with high to help lower your PTH. Caution: Do not take overlevels of total and LDL cholesterol, may increase your the-counter vitamin D unless ordered by your kidney chance of having heart and circulation problems. healthcare professional. 22 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 23 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you.
----------------------------------------------------------------------


======================================================================
CHUNK 562 of 647
======================================================================
ID: nutrition_and_peritoneal_dialysis_8
Content Type: recommendation
Words: 376
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: nutrition_and_peritoneal_dialysis.pdf

----------------------------------------------------------------------
healthcare professional. 22 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 23 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to read more about kidney disease, the National Kidney Foundation has more than 50 other publications that cover many subjects, such as: CKD risk factors like hypertension and diabetes Complications of chronic kidney disease such as cardiovascular disease, anemia, or bone problems Nutrition for CKD patients with information about carbohydrates, protein, sodium, phosphorus, and potassium Treating kidney disease early Treating kidney failure with transplantation or dialysis transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. Becoming an educated patient is very important to being healthy! 24 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 25 Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare professional regarding decisions about their individual plan of care. 26 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 27 Fueled by passion and urgency, the National Kidney Foundation (NKF) is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, we focus on the whole patient through the lens of kidney health. Relentess in our work, we enhance lives through action, education, and accelerating change. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG KIDNEY. ORG 2022 National Kidney Foundation, Inc. 11-10-0140_2205
----------------------------------------------------------------------


======================================================================
CHUNK 563 of 647
======================================================================
ID: nutrition_and_transplant_0
Content Type: reference
Words: 500
Medical Entities: CKD,GFR
Source: nutrition_and_transplant.pdf

----------------------------------------------------------------------
STAGE 5 Nutrition and Transplant Stages of chronic kidney disease There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the stage of kidney disease, based on how well your kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a lab test that measures the amount of blood your kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. STAGES OF KIDNEY DISEASE ESTIMATED GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Kidney damage with mild 2 60 to 89 loss of kidney function 6089% Mild to moderate loss of 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your Do I need to be on a special diet? . . . . . . . . . . . . . . . . 4 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a What about my cholesterol and triglyceride levels? . . . 5 lab test that measures the amount of blood your What about foods high in carbohydrates? . . . . . . . . . . 6 kidneys are filtering each minute. As CKD gets worse, the eGFR number goes down. Do I still need to follow a low-salt diet? . . . . . . . . . . . . . 7 What about protein? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 STAGES OF KIDNEY DISEASE What about potassium? . . . . . . . . . . . . . . . . . . . . . . . . . 9 ESTIMATED Are calcium and phosphorus a problem? . . . . . . . . . . 10 GLOMERULAR FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Will any of my medicines affect my diet? . . . . . . . . . . 11 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% What are common side effects? . . . . . . . . . . . . . .
----------------------------------------------------------------------


======================================================================
CHUNK 564 of 647
======================================================================
ID: nutrition_and_transplant_1
Content Type: general
Words: 496
Medical Entities: dialysis,diabetes
Source: nutrition_and_transplant.pdf

----------------------------------------------------------------------
. . . . . . . . . . 11 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% What are common side effects? . . . . . . . . . . . . . . . . . . 12 kidney function Will I gain weight? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% What if I have diabetes? . . . . . . . . . . . . . . . . . . . . . . . . 14 Mild to moderate loss of Is there anything else I should know? . . . . . . . . . . . . . 14 3a 45 to 59 kidney function 4559% Where can I get more information? . . . . . . . . . . . . . . . 15 Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% KIDNEY. ORG 3 Introduction If you have recently had an organ transplant, you are probably wondering if your diet will be different from the one you followed before your transplant. This brochure describes diet changes you may need to make in order to feel your best. You can get additional help in planning your diet from your doctor and a registered dietitian nutritionist. 4 NATIONAL KIDNEY FOUNDATION Do I need to be on a special diet? Yes. After an organ transplant, your diet still plays a big role. If you were on dialysis and had a kidney transplant, you may find that this diet is easier to follow than the one you were on for your dialysis. KIDNEY. ORG 5 What about my cholesterol and triglyceride levels? Fat (cholesterol or triglyceride) levels in your blood may be high. High levels of cholesterol and triglyceride can cause heart disease. The following steps can lower the fat and cholesterol in your blood: Lose weight if you are over a desirable weight level. Limit alcoholic beverages. Limit egg yolks to three or four a week. Limit all types of fats and oils. Use lean meats, poultry or fish. Use nonfat dairy products. Use salad dressing sparingly, or use fat-free salad dressing. Avoid frying foods. Avoid shortening, butter or stick margarine. Use only small amounts of oils, tub margarine or regular mayonnaise. Avoid those that describe the first ingredient as hydrogenated or partially hydrogenated. Replace high-fat desserts like ice cream, pie, cake or cookies with fruit or other nonfat desserts. 6 NATIONAL KIDNEY FOUNDATION Tip A healthy diet plan such as the Mediterranean diet may help control your blood levels of cholesterol and triglycerides.
----------------------------------------------------------------------


======================================================================
CHUNK 565 of 647
======================================================================
ID: nutrition_and_transplant_3
Content Type: reference
Words: 497
Section: Some foods high in potassium are:
Medical Entities: diabetes
Source: nutrition_and_transplant.pdf

----------------------------------------------------------------------
Some foods high in potassium are: oranges bananas avocados tomato sauce potatoes (white or sweet) milk and yogurt salt substitutes KIDNEY. ORG 11 Are calcium and phosphorus a problem? You may need to pay close attention to your calcium and phosphorus levels. If you have been ill for a period of time, your body probably lacks the balance of calcium and phosphorus needed for healthy bones, especially if you had kidney disease. Whether you have received a heart, liver, lung or kidney transplant, you are at risk for bone loss. In the months after your transplant, your doctor will check for possible bone loss and talk to you about the best way to keep your bones as healthy as possible. In the meantime, every adult needs about two servings a day from the dairy group (milk, cheese and yogurt). Unless your doctor or dietitian has told you not to use these foods, try to include them in your meals. Your doctor may decide you need more calcium and phosphorus than this allows and may have you take a supplement. Do not start any supplements on your own, however, as this could affect your transplant. 12 NATIONAL KIDNEY FOUNDATION Will any of my medicines affect my diet? Yes. Your diet will be affected by the use of necessary medicines given to prevent rejection of your transplant. List your transplant medicines here and talk to your doctor and dietitian about how they may affect your diet. Anti-rejection medicines may change the way your body works in the following ways: STEROIDS (PREDNISONE) The most common effects of taking steroids are increases in your: appetite, causing unwanted weight gain level of blood fats like cholesterol or triglyceride blood sugar levels sodium (salt) and fluid retention breakdown of muscle and bone These effects are greater when steroid dosages are high. KIDNEY. ORG 13 What are common side effects? The most common possible effects of other important transplant medicines are increases in your: level of blood fats like cholesterol or triglyceride blood sugar levels blood pressure Changes in potassium, magnesium and phosphorus levels are also common. These levels may return to normal as the doctor carefully lowers the amount of medicine you need to prevent rejection of your transplant. 14 NATIONAL KIDNEY FOUNDATION Will I gain weight? Many people have a better appetite after they get a transplant, and they gain unwanted weight. Weigh yourself often. Avoid high-calorie foods, such as fatty foods, sweets, pastries and other foods rich in fat or sugar. You can help control your calories by eating: raw vegetables and fruits lean meat, skinned poultry and fish nonfat dairy products sugar-free beverages or water Controlling your weight will help to keep you from developing problems, such as heart disease, diabetes and high blood pressure. If you gain unwanted weight, you will need to increase your physical activity and follow a low-calorie diet. Ask your doctor to refer you to a registered dietitian nutritionist to plan low-calorie meals and snacks.
----------------------------------------------------------------------


======================================================================
CHUNK 566 of 647
======================================================================
ID: nutrition_and_transplant_4
Content Type: recommendation
Words: 481
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: nutrition_and_transplant.pdf

----------------------------------------------------------------------
If you gain unwanted weight, you will need to increase your physical activity and follow a low-calorie diet. Ask your doctor to refer you to a registered dietitian nutritionist to plan low-calorie meals and snacks. It is very important that you establish an exercise and activity plan. In addition to controlling your weight, regular physical activity helps to: strengthen your heart muscle give you better form and appearance improve your endurance keep your bones healthy Make sure you set up an exercise program with your doctors advice and get started with it as soon as you are permitted. KIDNEY. ORG 15 What if I have diabetes? After a transplant, your new diet may be higher in protein and lower in simple carbohydrates due to the effects of steroids and other medicines. Work with your doctor and a registered dietitian nutritionist to keep your diet and blood sugar in good control. Is there anything else I should know? Yes. You may be surprised or alarmed to be on a special diet for a short while after your transplant. For example, a kidney transplant may sometimes be slow in getting started, so the doctor will have you follow a kidney diet for a while. This usually is needed for only a short time. Or, you may be asked to drink a lot of water (something you were told to stay away from in the past). Your doctor and dietitian will guide you through these changes if they happen. Just remember, if your doctor tells you to change what you eat or drink, it is very important for your health and the health of your transplant that you do so. 16 NATIONAL KIDNEY FOUNDATION Where can I get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to read more about kidney disease, the National Kidney Foundation has more than 50 other publications that cover many subjects, such as: CKD risk factors like hypertension and diabetes Complications of chronic kidney disease, such as cardiovascular disease, anemia or bone problems Nutrition for CKD patients, with information about carbohydrates, protein, sodium, phosphorus and potassium Treating kidney disease early Treating kidney failure with transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. Becoming an educated patient is very important to being healthy! KIDNEY. ORG 17 18 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines.
----------------------------------------------------------------------


======================================================================
CHUNK 567 of 647
======================================================================
ID: pain_medicines_0
Content Type: recommendation
Words: 485
Medical Entities: GFR
Source: pain_medicines.pdf

----------------------------------------------------------------------
PAIN MEDICINES AND YOUR KIDNEYS What You Need to Know www. kidney. org National Kidney Foundations Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundations Kidney Disease Outcomes Quality Initiative (KDOQI) offers guidelines and commentaries that help your doctor and healthcare team make important decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are 5 stages of kidney disease. They are shown in the table below. Your doctor determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your level of kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Stage Description Glomerular Filtration Rate (GFR) Kidney damage (e. g. , protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR Mild to moderate decrease 3a 45 to 59 in GFR Moderate to severe decrease 3b 30 to 44 in GFR 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. 2 NATIONAL KIDNEY FOUNDATION TABLE OF CONTENTS What are analgesics? . . . . . . . . . . . . . . . . . . . . . . 5 Are pain medicines safe? . . . . . . . . . . . . . . . . . . . 6 What are NSAIDs? . . . . . . . . . . . . . . . . . . . . . . . . 6 Are NSAIDs safe to take? . . . . . . . . . . . . . . . . . . 6 What is acetaminophen? . . . . . . . . . . . . . . . . . . . . 7 Is acetaminophen safe to take? . . . . . . . . . . . . . . 7 Is aspirin safe for regular use? . . . . . . . . . . . . . . . 8 What can I do to keep my kidneys healthy if I need medicine for pain? . . . . . . . . . 9 What if I have more questions? . . . . . . . . . . . . . 11 WWW. KIDNEY. ORG 3 Many people take pain medicines to help them treat pain resulting from illness or injury. They are the most often used medicine in the United States.
----------------------------------------------------------------------


======================================================================
CHUNK 568 of 647
======================================================================
ID: pain_medicines_1
Content Type: general
Words: 491
Medical Entities: CKD
Source: pain_medicines.pdf

----------------------------------------------------------------------
. . . . . . . . . . . . . 11 WWW. KIDNEY. ORG 3 Many people take pain medicines to help them treat pain resulting from illness or injury. They are the most often used medicine in the United States. However, pain medicines can have different effects on the kidneys, depending on the type of medicine, how it is used, and how well your kidneys are working. This educational brochure will help answer some questions you might have about pain medicines and your kidneys. 4 NATIONAL KIDNEY FOUNDATION What are analgesics? Pain medicines are also called analgesics. They are used to help relieve pain, but can also sometimes be used to help lower fever or inflammation (redness and swelling from an injury or illness), depending on the type of pain medicine. These benefits are important, especially for those who need them, including people with arthritis, headaches, muscle aches, colds, toothaches, menstrual cramps, and sinus infection. Examples of pain medicines that are available over-thecounter (OTC) include aspirin, acetaminophen, ibuprofen, and naproxen sodium. OTC means they are available without a prescription, but if you have kidney disease, you should still speak to your healthcare provider about any medicines before you take them. Some of these medicines also come in higher strength, or dose, with a prescription. OTC pain medicines are usually available as a pill, either on its own or combined with other medicines, such as certain cold and cough medicines. Some pain medicines are also available in a topical form, meaning they are applied on the skin as a cream, gel, or patch. WWW. KIDNEY. ORG 5 Are pain medicines safe? Pain medicines can help relieve pain and are generally safe when taken as directed. However, as with any medicine, they can have side effects and you should use them as directed on their labels. If you do not use pain medicines as directed, they may cause problems with your stomach, liver, or kidneys, depending on the type, dose, and duration of pain medicine used. The harm to your kidneys can be sudden, and result in acute kidney injury (AKI). In some cases, if you stop the pain medicine you may reverse short-term harm to your kidneys, meaning kidney function may recover. Continued overuse or misuse of certain pain medicines can also lead to a slow loss of kidney function over time, or chronic kidney disease (CKD). What are NSAIDs? The term NSAID stands for nonsteroidal anti-inflammatory drug. NSAIDs are a group of pain relievers. Some NSAIDs are available OTC, including ibuprofen (for example, Advil, Motrin), naproxen sodium (for example, Aleve), and aspirin (for example, Bayer). Generic versions (no brand name) of these brands are also available. People use NSAIDs to reduce fever and relieve pain. Prescription NSAIDs can be used to reduce inflammation caused by many medical problems or injuries. Are NSAIDs safe to take? OTC NSAIDs are generally safe for occasional use when taken as directed.
----------------------------------------------------------------------


======================================================================
CHUNK 569 of 647
======================================================================
ID: peritoneal_dialysis_0
Content Type: general
Words: 494
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
STAGE 5 Peritoneal dialysis What you need to know Join our free OONNLLIINNEE KKIIDDNNEEYY CCOOMMMMUUNNIITTIIEESS Youre not alone. Connect with others affected by kidney disease. Get support and share your experiences you never know when youll inspire someone else! JOIN TODAY AT kidney. org/online-communities KIDNEY DISEASE DIALYSIS TRANSPLANT LIVING DONATION 2 NATIONAL KIDNEY FOUNDATION Contents What is peritoneal dialysis? . . . . . . . . . . . . . . . . . . . . . 4 Why do I need PD? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Are there other treatments for kidney failure besides PD? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Are there different types of PD? . . . . . . . . . . . . . . . . . 6 How does PD work? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 How will I learn how to do PD? . . . . . . . . . . . . . . . . . . . 8 How will I know how much dialysis I need? . . . . . . . . 9 What will my dialysis prescription be based on? . . . . 9 Will my dialysis care team monitor my treatments? . 13 How often should my treatments be measured? . . . . 14 What if my overall health happens to get worse? . . . 14 Will I need to follow a special diet? . . . . . . . . . . . . . . 15 What is peritonitis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 What are the signs of peritonitis? . . . . . . . . . . . . . . . . 18 Are there any other infections I should watch for? . . 18 What if I have questions or problems? . . . . . . . . . . . 20 What do tests measure? . . . . . . . . . . . . . . . . . . . . . . . . 24 Where can you get more information? . . . . . . . . . . . 26 KIDNEY. ORG 3 What is peritoneal dialysis? Peritoneal dialysis (PD) is a treatment for people who have kidney failure. Healthy kidneys clean wastes from blood and remove extra fluid from the body.
----------------------------------------------------------------------


======================================================================
CHUNK 570 of 647
======================================================================
ID: peritoneal_dialysis_1
Content Type: general
Words: 488
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
. . . . . . . . . . . 26 KIDNEY. ORG 3 What is peritoneal dialysis? Peritoneal dialysis (PD) is a treatment for people who have kidney failure. Healthy kidneys clean wastes from blood and remove extra fluid from the body. But when your kidneys are not working well, wastes and extra fluid can build up in your blood and make you sick. This can cause: nausea trouble sleeping poor appetite loss of energy hiccups dry, itchy skin weight loss 4 NATIONAL KIDNEY FOUNDATION irregular menstrual periods muscle cramping, especially at night swelling anemia (low red blood cell count) trouble breathing Why do I need PD? You need treatment because your kidneys no longer clean enough wastes from your blood or remove extra fluid from your body. Even though people with kidney failure may still have some kidney function, its not enough, and without treatment, you will die. Are there other treatments for kidney failure besides PD? Yes, there are two other treatments for kidney failure. They are: HEMODIALYSIS In hemodialysis, your blood flows through a machine that has a filter which cleans the blood. This machine is called a dialyzer or artificial kidney. Hemodialysis is usually done three times a week, several hours each session. It can be done at a dialysis center or at home. Two needles are inserted into your vein during each dialysis treatment to draw your blood into the dialyzer. KIDNEY TRANSPLANT In transplantation, a healthy kidney is put inside your body to do the work of your own kidneys. KIDNEY. ORG 5 Are there different types of PD? Yes. The major ones are: Continuous Ambulatory PD (CAPD). With CAPD, you do the exchanges yourself three to four times a day. Automated PD (APD). With APD, a machine called a cycler does the exchanges automatically while you sleep. You may also need to do one exchange during the day if your kidney function decreases further. CAPD and APD are both done during the night and day. Your treatment times are decided by your and your doctor and are included in the physicians orders. Patients are usually trained on CAPD first before learning how to use the cycler for APD and both types can be done at home, work, or while travelling. 6 NATIONAL KIDNEY FOUNDATION How does PD work? A soft tube, called a catheter, is placed in your belly. This is done by minor surgery. This catheter makes it possible for you to easily connect to a special tubing which allows two to three quarts of a cleansing fluid to flow into your belly. The cleansing fluid is called dialysate. It takes about 10 minutes for the dialysate to fill your belly. What happens next is an amazing process. The lining of your belly (called the peritoneum) acts as a natural filter. It lets the wastes and extra fluid in your blood pass through it into the cleansing fluid.
----------------------------------------------------------------------


======================================================================
CHUNK 571 of 647
======================================================================
ID: peritoneal_dialysis_2
Content Type: reference
Words: 497
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
It takes about 10 minutes for the dialysate to fill your belly. What happens next is an amazing process. The lining of your belly (called the peritoneum) acts as a natural filter. It lets the wastes and extra fluid in your blood pass through it into the cleansing fluid. At the same time, the lining of your belly holds back the important things your body needs, like red blood cells and nutrients. KIDNEY. ORG 7 To do its job, the dialysate must stay in your belly for a few hours or more, depending on your body size and how much waste has to be removed. This time is called your dwell time. With CAPD, when the filling is done, the catheter is capped so that it doesnt leak. After your dwell time, you drain the cleansing fluid from your body into an empty bag. You discard the bag. You then repeat the in-and-out process a number of times during the day, using fresh dialysate. The process of exchanging bags of dialysate is called an exchange. With APD, a cycler machine does exchanges for you while you sleep. How will I learn how to do PD? The training staff at your dialysis center will teach you everything you need to know, including how to do exchanges, order supplies, clean your catheter, and guard against infection. Once you and the staff are comfortable with your ability to do PD alone, you can start doing your own treatments at home. 8 NATIONAL KIDNEY FOUNDATION How will I know how much dialysis I need? The amount of dialysis needed is different for everyone. It is based on many factors, including your weight, how much kidney function you still have, your overall health, and the results of your lab tests. Your doctor will give you a dialysis prescription that is designed just for you. Your prescription will tell you: how many exchanges you need to make each day how long the dialysis fluid needs to stay in your belly (your dwell time) what type and amount of dialysis fluid you need to use for each exchange What will my dialysis prescription be based on? Your doctor will base your prescription on: YOUR SIZE Large, muscular people may need more frequent exchanges or larger bags, which means that more dialysis fluid goes into your belly. YOUR REMAINING KIDNEY FUNCTION How much dialysis you need is based on how much kidney function you have left. Your doctor or dialysis care team should measure your remaining kidney function. This is measured by a blood test and 24-hour urine collection. It should be checked within the first month after starting dialysis and every four months thereafter, if your urine output is stable. KIDNEY. ORG 9 However, if your urine output is decreasing (you are not peeing as much or as often), your remaining kidney function should be checked every two months. You should tell your doctor whenever you notice your daily urine output has become less.
----------------------------------------------------------------------


======================================================================
CHUNK 572 of 647
======================================================================
ID: peritoneal_dialysis_3
Content Type: general
Words: 463
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
KIDNEY. ORG 9 However, if your urine output is decreasing (you are not peeing as much or as often), your remaining kidney function should be checked every two months. You should tell your doctor whenever you notice your daily urine output has become less. YOUR NUTRITIONAL HEALTH How well you feel on dialysis may be affected by how well you eat. Your dietitian will help you plan a diet that gives you the right amount of nutrients. YOUR GENERAL HEALTH If you are getting enough treatment, you should feel well, have a good appetite, and have enough energy to do many of the activities you enjoy. You should tell your doctor if you: are often nauseous have a poor appetite cannot taste are feeling too tired for your daily activities This may mean you have other health problems or that you are not getting enough dialysis. If so, your doctor may need to change your dialysis prescription or other medical care that you are receiving. 10 NATIONAL KIDNEY FOUNDATION YOUR PERITONEAL EQUILIBRATION TEST (PET) This test is done within 4 to 8 weeks after starting PD. It measures how well your peritoneal membrane is working and helps your doctor decide how: Many exchanges you need each day Long the dialysis fluid should stay in your belly Much and the type of dialysis fluid you need KIDNEY. ORG 11 Tips Getting the best results for your dialysis treatment depends on how well you follow your prescription. Make sure to do the following: Use all your prescribed exchanges Follow the prescribed amount of time (dwell time) you keep the dialysis fluid in your belly Use the full amount of dialysis fluid prescribed for you Prevent infections by doing your exchanges exactly as you were taught Take all your medications exactly as ordered by your doctor Follow your diet and fluid allowances (too much fluid in your body can cause swelling, shortness of breath, and increased blood pressure) Report any problems to your doctor or dialysis care team Do not be afraid to tell your dialysis care team exactly how you do your exchanges (this is the best way to make sure that you are doing them correctly) 12 NATIONAL KIDNEY FOUNDATION Will my dialysis care team monitor my treatments? Yes. Your dialysis care team will measure your treatments regularly with lab tests. This tells them if your treatment is removing enough wastes from your blood. The test that is used to check your delivered dose of dialysis is called Kt/Vurea (pronounced kaytee over vee-yur-ee-a). Your total Kt/Vurea from the dialysis and your remaining kidney function should never be less than 1. 7 per week. KIDNEY. ORG 13 How often should my treatments be measured? Your delivered dose of dialysis should be measured every four months.
----------------------------------------------------------------------


======================================================================
CHUNK 573 of 647
======================================================================
ID: peritoneal_dialysis_4
Content Type: reference
Words: 444
Medical Entities: dialysis,diabetes
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
Your total Kt/Vurea from the dialysis and your remaining kidney function should never be less than 1. 7 per week. KIDNEY. ORG 13 How often should my treatments be measured? Your delivered dose of dialysis should be measured every four months. This measurement should be done more often when your: PD prescription is changed Dialysis care team feels it is needed Kidney function levels have gone down To measure your delivered dose of dialysis, your dialysis care team may ask you to bring to the dialysis center all the dialysis bags you used over a 24-hour period, or just a sample from each of the used bags. You may also be asked for a 24-hour urine collection. Both the urine and the dialysate collections are important ways to measure your total dose of dialysis. What if my overall health happens to get worse? Tell your doctor. Your dialysis care team will do some tests to find out why. They may check to see if youre: Doing all your exchanges as prescribed Having other health problems not related to kidney failure and dialysis They will also check to see is your peritoneal membrane is working well. Sometimes, the membrane may not work as well if you have had serious infections, or if you have been on PD for several years. 14 NATIONAL KIDNEY FOUNDATION When this occurs, your doctor may need to change your dialysis prescription. If your remaining kidney function has decreased too much, your doctor may want you to: Increase the number of bags you use each day Use a cycler Switch to hemodialysis Will I need to follow a special diet? Yes. Getting the right nutrients and balancing fluids is as important to your health as getting the right amount of dialysis. The registered dietitian at your dialysis center will help you plan your diet to make sure you get the right amount of protein, calories, and other important nutrients. You may also need to: Limit how much sodium (salt) you eat Take nutritional supplements Tip Because your dialysis fluid contains sugar, you may have a tendency to gain weight. Your dietitian can help you plan your diet to get the right amount of calories and keep up the right weight for you. If you have diabetes, your dosage of insulin or other medications may need to change. KIDNEY. ORG 15 What is peritonitis? One thing you have to be very careful about in PD is peritonitis, an infection of the peritoneum (the lining of your belly). Peritonitis happens when germs get into the peritoneal cavity through the catheter. It is treatable with antibiotics, but its important to get it treated promptly.
----------------------------------------------------------------------


======================================================================
CHUNK 574 of 647
======================================================================
ID: peritoneal_dialysis_5
Content Type: reference
Words: 497
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
One thing you have to be very careful about in PD is peritonitis, an infection of the peritoneum (the lining of your belly). Peritonitis happens when germs get into the peritoneal cavity through the catheter. It is treatable with antibiotics, but its important to get it treated promptly. When doing an exchange: Make sure the area where you do your exchange is clean Make sure you and anyone else in the room wears a surgical mask Do not allow children or pets into the room Close all doors and windows and turn off any ceiling fans or air conditioners Gather all your supplies before you start your exchange Scrub your hands with soap for at least two minutes before each exchange (your dialysis care team can tell you the right kind of soap to use) Dry your hands with a disposable paper towel 16 NATIONAL KIDNEY FOUNDATION Do not touch anything unrelated to your treatment, not even your skin or your hair (if you do touch something, scrub your hands with soap for two minutes again before continuing) Avoid coughing or sneezing on your sterile supplies (if you do you must start the process over with new supplies) Make sure you do your exchanges exactly as taught by your training program. Dont try anything different without asking your dialysis care team about it. KIDNEY. ORG 17 What are the signs of peritonitis? The main signs of peritonitis are: a cloudy dialysate bag when you are draining out the used fluid unusual stomach pain, either mild or severe fever or chills If you notice any of these signs, call your doctor or dialysis center right away. Getting prompt treatment for peritonitis is very important. If you do not get prompt treatment, the infection can get worse and you may have to go to the hospital. In addition, the infection may scar your peritoneal membrane, making PD less effective. In severe cases, you may have to change to hemodialysis. Are there any other infections I should watch for? Infections can also occur at the place where the catheter leaves your skin, called your exit site. You should clean this area at least once a day with soap and water. You should also check your exit site and catheter every day. If problems occur, you can often catch them in the early stages. Signs of exit site infection are: Redness, swelling, or bulging around the exit site Tenderness, pain, or pus at the exit site 18 NATIONAL KIDNEY FOUNDATION Tips Taking good care of your catheter is also important to prevent infections and have good results on PD. Here are some tips for routine catheter care: Check your catheter every day for signs of cracking or pulling Do not wear tight clothes and belts around the exit site Wash your hands with soap and water for at least two minutes and dry them with a disposable paper towel before handling your catheter, and before and after an exchange is made.
----------------------------------------------------------------------


======================================================================
CHUNK 575 of 647
======================================================================
ID: peritoneal_dialysis_6
Content Type: general
Words: 489
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
Tape the catheter down to your skin Keep the catheter away from scissors or other sharp objects. Cleanse the catheter thoroughly with a wash cloth and soap every day Keep a special dressing over the exit site if your dialysis care team tells you Do not allow tugging or pulling of your catheter KIDNEY. ORG 19 What if I have questions or problems? Once you have learned all you need to know, your PD supplies will be delivered directly to your home and you will be ready to start your treatment. You will continue to visit your dialysis center for regular checkups and lab tests. At these visits, your doctor and dialysis care team will check: Your overall health and nutritional health Any symptoms you have that indicate you may not be getting enough dialysis How well you are doing with your exchanges The results of other important tests (see What Your Tests Measure on ) In addition, your center will always be just a phone call away if you have any problems. You will be the primary person responsible for your own care. So be sure to call your doctor or dialysis care team if you notice any problems. See Checking for problems on the following pages. 20 NATIONAL KIDNEY FOUNDATION Checking for problems WEIGHT What to Check: Weigh yourself each day at about the same time. Signs of Possible Problems: A sudden weight gain along with swelling, shortness of breath, and an increase in blood pressure is probably due to too much fluid in your body. A gradual weight gain without swelling, shortness of breath and an increase in blood pressure may be due to an increase in muscle or fat. Loss of weight with dizziness and low blood pressure may signify that there is too little fluid in your body. What to Do: Make sure to follow your diet and fluid allowances. Speak to your doctor and dietitian about your diet, fluid intake, medications, and dialysis prescription. Speak to your dietitian about whether you need to change your intake of calories. BLOOD PRESSURE What to Check: Check your blood pressure and pulse every day. Signs of Possible Problems: An increase in blood pressure and pulse may be due to too much fluid weight gain. What to Do: Follow your sodium (salt) and fluid allowances to avoid too much fluid weight gain. Your doctor may want to change your medications to better control your blood pressure. KIDNEY. ORG 21 DIALYSATE What to Check: Check how your dialysate looks when you drain it out. Signs of Possible Problems: Your dialysate should be clear and yellow in color. Cloudy dialysate is a sign of infection. You should be able to see the printed words on the bag through the solution. If you cant, your dialysate is cloudy. Whitish strands in the dialysate are little clots of protein and can get large enough to block your tubing or PD catheter.
----------------------------------------------------------------------


======================================================================
CHUNK 576 of 647
======================================================================
ID: peritoneal_dialysis_7
Content Type: general
Words: 496
Medical Entities: GFR,dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
You should be able to see the printed words on the bag through the solution. If you cant, your dialysate is cloudy. Whitish strands in the dialysate are little clots of protein and can get large enough to block your tubing or PD catheter. To prevent this, call your doctor if you notice any whitish strands in your dialysate. Pinkish appearing dialysate means that some blood is leaking into the dialysis fluid. Some women notice this with their monthly period. It may also occur if you have been exercising or lifting something heavy. Do not be concerned about a small amount of bloodif it occurs with a monthly period or after rigorous exercise. However, watch the fluid closely and call your dialysis center if it becomes more pinkish or red. What to Do: Call your dialysis center if you see whitish strands in the dialysate. You may need to inject a blood thinner called heparin into your fresh dialysate to clear the fluid; your nurse will tell you how to do this. 22 NATIONAL KIDNEY FOUNDATION INFECTION What to Check: Check yourself for signs of infection. Signs of Possible Problems: Unusual stomach pain, fever, or cloudy dialysate could mean you have an infection called peritonitis. Peritonitis can become serious very quickly. What to Do: Call your doctor or dialysis center right away if you see signs of peritonitis (see ). If you have peritonitis, follow your doctors instructions carefully and take all the antibiotic medications ordered for you. KIDNEY. ORG 23 What do tests measure? Kt/Vurea measures your delivered dose of dialysis. It tells whether you are receiving the right amount of dialysis. Your total Kt/Vurea from the dialysate and your remaining kidney function should be no less than 1. 7 per week. Albumin and normalized protein nitrogen appearance (nPNA) are measures of your nutritional health. The test results show if you are getting enough protein and calories from your diet. Average daily weight gain is the amount of fluid weight you gain each day between dialysis treatments. If you do not follow your fluid and salt limits between treatments, you may gain too much fluid weight. Calcium and phosphorus are two minerals that are important for bone health. Having too much or too little amounts of these minerals in your blood can lead to loss of calcium from the bones and increased risk of heart and blood vessel disease. Estimated glomerular filtration rate (eGFR) is a calculation that measures how well your kidneys are working. Your eGFR can be calculated using the results of your blood creatinine test, your age, and gender. 24 NATIONAL KIDNEY FOUNDATION Hemoglobin is the part of red blood cells that carries oxygen to your tissues. If your number is too low, you have anemia, and you will need to take one or more medicines to raise the red blood cell level in your body. Parathyroid hormone (PTH) is made by four small parathyroid glands, which are located in your neck.
----------------------------------------------------------------------


======================================================================
CHUNK 577 of 647
======================================================================
ID: peritoneal_dialysis_8
Content Type: recommendation
Words: 444
Medical Entities: dialysis
Source: peritoneal_dialysis.pdf

----------------------------------------------------------------------
If your number is too low, you have anemia, and you will need to take one or more medicines to raise the red blood cell level in your body. Parathyroid hormone (PTH) is made by four small parathyroid glands, which are located in your neck. If these glands make too much PTH, you may lose calcium from your bones. Over time, this can weaken your bones and cause them to break more easily. Pre-dialysis and post-dialysis blood pressure should be taken each time you receive dialysis. Your blood pressure goes down when excess fluid and salt are removed from your blood by your dialysis treatment. Potassium is a mineral that is important for a healthy heart. High or low levels of potassium in your blood may be harmful for your heart. Target weight (or dry weight) is how much you should weigh after dialysis removes excess fluid from your body. Blood pressure should be taken on a daily basis. Your blood pressure decreases when excess fluid and salt are filtered out of your blood by your dialysis treatment. KIDNEY. ORG 25 Where can you get more information? If you have questions, speak with your healthcare team. They know you and can answer questions about you. If you want to learn more about kidney disease: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. Becoming an educated patient is very important to being healthy! 26 NATIONAL KIDNEY FOUNDATION Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your doctor and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare providers regarding decisions about their individual plan of care. KIDNEY. ORG 27 The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG 2023 National Kidney Foundation, Inc. 11-50-0215_2212
----------------------------------------------------------------------


======================================================================
CHUNK 578 of 647
======================================================================
ID: planning_for_emergencies_0
Content Type: reference
Words: 488
Medical Entities: CKD,GFR,dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
STAGES 15 Planning for Emergencies A Guide for People with Kidney Disease Stages of chronic kidney disease Contents There are 5 stages of kidney disease as shown in the table below. Your healthcare provider will tell you the Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 stage of kidney disease, based on how well your How can I plan ahead for an emergency? . . . . . . . . . . 5 kidneys are working and your estimated glomerular filtration rate (eGFR). The eGFR number comes from a What should I do if a natural disaster lab test that measures the amount of blood your occurs in my area? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 kidneys are filtering each minute. As CKD gets worse, Is diet important if I have to miss the eGFR number goes down. dialysis in an emergency? . . . . . . . . . . . . . . . . . . . . . . . 16 Emergency Phone Numbers. . . . . . . . . . . . . . . . . . . . . 24 STAGES OF KIDNEY DISEASE Patient Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 ESTIMATED GLOMERULAR Treatment Information. . . . . . . . . . . . . . . . . . . . . . . . . 26 FILTRATION RATE KIDNEY STAGE DESCRIPTION (eGFR) FUNCTION Emergency Resources for People with CKD. . . . . . . . 31 Kidney damage (e. g. , protein 1 in the urine) with normal 90 or above 90100% kidney function Are there special considerations in different kinds of disasters? . . . . . . . . . . . . . . . . . . . . 34 Kidney damage with mild 2 60 to 89 loss of kidney function 6089% What if I have more questions? . . . . . . . . . . . . . . . . . 39 Mild to moderate loss of Where can you get more information? . . . . . . . . . . . 40 3a 45 to 59 kidney function 4559% Moderate to severe loss of 3b 30 to 44 kidney function 3044% Severe loss of kidney 4 15 to 29 function 1529% 5 Kidney failure Less than 15 Less than 15% 2 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 3 How can I plan ahead for an emergency?
----------------------------------------------------------------------


======================================================================
CHUNK 579 of 647
======================================================================
ID: planning_for_emergencies_1
Content Type: evidence
Words: 495
Medical Entities: dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
ORG 3 How can I plan ahead for an emergency? Keep a copy of your current medications and dosages in writing or on your phone. Keep a two-week supply of medicines at home or at your job. Keep a 3-day food supply at home. (See grocery lists on. ) Be sure to check periodically for expiration dates and replace items when needed. Check with your doctor about having a special medicine on hand that helps to control the level of potassium in your blood (Remember to check the expiration date). Potassium levels that are too high or too low can be dangerous. Ask a friend or relative in another area to be your contact person. In an emergency, you Introduction may not be able to make telephone calls in The delivery of healthcare services, such as dialysis your area but may still be able to place calls to treatment, can be disrupted by natural disasters another area. (blizzards, earthquakes, floods, hurricanes, tornadoes, Keep a copy of important medical information etc. ) as well as by other types of emergency at your home and at your job. (You may use situations, such as electrical power blackouts. The the patient and treatment information forms aim of this booklet is to help you prepare for possible on pages 2526 of this booklet. ) Update emergencies. Hopefully, you will never need to use the information often. If needed, ask your these emergency measures. However, by knowing healthcare staff to help you complete these what to do and preparing ahead, you can feel secure if forms. Include insurance information among an emergency should occur. Study the information in these necessary forms. this guide carefully and remember to keep it in a place You should get and wear a medical bracelet. where you can easily find it. Leave copies of the guide This has vital information about your medical at your workplace and at home and take it with you condition and treatment, and alerts medical when you travel. Tell your family members where it is. staff to your special needs. If you need help 4 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 5 getting one, check with your local pharmacy or ask your social worker. Emergency apps are also available for your smart phone. Keep the following emergency supplies in a safe place (most big box stores or hardware stores will carry these items): A battery-powered AM/FM radio and extra batteries. Find out what the emergency broadcast radio station is in your area. This will give you up-to-date information on current conditions and emergency information, even if you have no electricity or phone service. Flashlights with plenty of extra batteries or candles and matches. (Remember never What should I do if a natural disaster to use matches until you have checked for occurs in my area? gas leaks. ) Many things we depend upon daily may not be A first-aid kit. available during an emergency situation. You may be A fire extinguisher.
----------------------------------------------------------------------


======================================================================
CHUNK 580 of 647
======================================================================
ID: planning_for_emergencies_3
Content Type: reference
Words: 497
Medical Entities: dialysis,diabetes
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
If you need to evacuate, original bottles will provide necessary information when you arrive at your destination. Have a backpack with a waterproof pouch packed with key items (listed below) weighing about 10 pounds. Good shoes should enable you to carry this backpack, leaving your hands free if you should need to evacuate. Pack key data in a waterproof bag; you can add the key information outlined on as specific to your health. For In-Center Hemodialysis If you must go to a shelter, tell the person in Call you dialysis center to find out dialysis charge about your special needs as someone options. If you have to miss dialysis, begin with kidney disease. your emergency meal plan. (See Emergency Things to pack meal planning for kidney patients starting on. ) several 8-ounce matches and candles bottles of water If you are not able to dialyze at your unit, make disposable hand-operated eating utensils sure you have the names, locations, and phone can opener canned and numbers of back-up dialysis units and hospitals hand sanitizer packaged rations in your area. of foods, such travel-size toiletries Your local National Kidney Foundation office as peanut butter, disposable wipes saltines, tuna, may be able to help you find out if your regular toilet paper juicesseveral days dialysis unit is open. worth, if possible sunscreen Since regular community transportation some dry clothes miniature flashlight services may not be working, be prepared to supplies you might mask and gloves make other arrangements. need to treat thermometer diabetes or other batteries conditions 10 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 11 In a severe disaster, dialysis staff may not be For Home Hemodialysis able to continue your individual schedule and Keep a list of dialysis units in your area at home orders. They may need to use emergency and at your workplace. procedures, which may include a standard Keep a two-week stock of dialysis supplies at dialyzer and a shorter treatment time. Every all times. Check expiration dates regularly and attempt will be made to give you the best replace supplies when needed. treatment possible. Register with your local water and power Your dialysis unit has a procedure for companies so they will be aware of your need emergency evacuation. If you are dialyzing at to get service restored as soon as possible. your unit and a disaster occurs, the dialysis staff will assist you in getting off the dialysis Learn to be comfortable taking yourself off the machine as quickly direct you in an evacuation machine in an emergency. procedure. During the emergency, if you lose power while dialyzing, follow the directions for discontinuing dialysis given to you by your home training staff. If you are not able to continue your treatments at home during the emergency, contact the home training staff so other arrangements can be made. 12 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 13 For Peritoneal Dialysis Keep a two-week stock of peritoneal dialysis supplies. Check expiration dates regularly and replace supplies when needed.
----------------------------------------------------------------------


======================================================================
CHUNK 581 of 647
======================================================================
ID: planning_for_emergencies_4
Content Type: recommendation
Words: 500
Medical Entities: dialysis,diabetes
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
12 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 13 For Peritoneal Dialysis Keep a two-week stock of peritoneal dialysis supplies. Check expiration dates regularly and replace supplies when needed. If you use an ultraviolet device, keep the battery charged. Include in your emergency medication pack a five-day supply of the antibiotic that your doctor orders for peritonitis. If a disaster occurs, it may be difficult to maintain a clean environment and your risk of peritonitis may be higher. If you lose power and use a cycler, go to manual exchanges. If you are on a cycler and you lose power while dialyzing, follow the instructions given to you by the training staff for discontinuing dialysis in an emergency. For Diabetes Make sure you have extra diabetes For Transplant Recipients supplies such as: If you are in a shelter or in contact with insulin and syringes emergency personnel, let them know you batteries, lancets, and test strips, so you are a transplant recipient and need to take can check your blood sugar if you have a medications regularly and on time. If possible, monitoring system limit your exposure to potential infections. Sanitizers, gloves, and a mask can help. sugar, instant glucose or glucose tablets, lowpotassium juices (apple, grape, cranberry), Ask your transplant healthcare team about sugared soda, and hard candy in case of low precautions, additional medications, and blood sugar reactions. preparations that they recommend. You can find a list of transplant centers around the Ask your pharmacist about how long you can country from the United Network for Organ keep insulin without refrigeration. Remove Sharing (UNOS), 804. 782. 4800. insulin from the refrigerator to avoid opening too often. 14 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 15 Is diet important if I have to miss Emergency Meal Plan For People on Dialysis dialysis in an emergency? A grocery list and sample meal plans for emergency If you have to miss dialysis, follow your situations are included. This diet is more restricted emergency diet. than your usual diet. Limit protein to one-half your current intake. The restricted plan is needed to control the buildup Restrict fluid intake to two cups or 16 of things like potassium, phosphorus, urea, and fluid, ounce a day. which can be life threatening if you miss several dialysis treatments due to the emergency. Do not use salt or salt substitutes with your meals. Avoid all foods with high-potassium content 16 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 17 Three-day emergency grocery list for people on dialysis ITEM AMOUNT (PER PERSON) Bread/Cereal (use 68 servings per day) Dry cereal, unsalted, sweetened or 6 single-serve unsweetened puffed wheat or rice, containers or 1 box shredded wheat Vanilla wafers or graham crackers or 1 box unsalted crackers Fruits/Juices (limit to 24 servings per day) Canned or sealed plastic container: 12 single-serve applesauce, pears, peaches, containers pineapple, mandarin oranges, fruit cocktail (drain the liquid) Cranberry and apple juice 2 single-serve or containers or 100% Juice boxes or pouches 2 packages Protein (limit meat/fish to 3 oz.
----------------------------------------------------------------------


======================================================================
CHUNK 582 of 647
======================================================================
ID: planning_for_emergencies_5
Content Type: recommendation
Words: 486
Medical Entities: CKD,dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
per day) Emergency meal plans for people Tuna, salmon, meat, turkey, chicken, 6 small cans, 1 jar with CKD and on dialysis peanut butter (low sodium or unsalted) Milk (limit to  cup per day) The sample meal plans given provide about 4050 Plain Almond or soy milk 3 (8-oz) cartons grams of protein, 1, 500 mg sodium, 1, 500 mg Sweets (use as desired to increase calories) potassium and less than 500 mL or 16 ounces of Marshmallows 1 large bag fluid. You may adjust selections to fit your personal Jelly beans, sourballs, hard candies, 5 bags total taste. These meal plans are stricter than your normal clear mints kidney diet, to keep waste products from building up Sugar packets 6 in your blood during the emergency. If you are on Jelly packets 6 dialysis, fluid is limited to less than 500 mL (2 cups Fats (use 6 or more servings per day) or 16 ounces) each day (or as recommended by your Mayonnaise (perishable after opening) 6 Individual packets healthcare provider) to prevent you from swelling or Other having shortness of breath. Bottled water 6 (8-oz) bottles 18 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 19 EVACUATION EMERGENCY MEAL PLAN Afternoon snack Breakfast 5 vanilla wafers  cup plain almond milk 10 jellybeans 1 single serving of cereal ( cup) Dinner 1 packet sugar 12 unsalted crackers  cup canned pineapple (single serving)  cup low-sodium chicken (open new can daily) Morning snack 1 packet mayonnaise 5 vanilla wafers  cup canned peaches (single serving) jelly as desired on wafers  cup cranberry juice (from box or pouch) 10 sourballs Evening snack Lunch 2 graham crackers 12 unsalted crackers Jelly as desired on crackers  cup low-sodium tuna (open new can daily) 10 mints 1 packet mayonnaise  cup canned pears (single serving)  cup (4 oz) bottled water 20 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 21 STAY AT HOME EMERGENCY MEAL PLAN: Afternoon snack Breakfast 6 unsalted crackers  cup milk prepared from dry milk and  cup (4 oz) jelly as desired on crackers bottled water 10 large marshmallows 1 slice toast Dinner 1 teaspoon margarine or butter 2 slices white bread  cup canned mandarin oranges  cup low-sodium chicken (open new can daily) Morning snack 2 tablespoons mayonnaise (single packets or open new 3 graham crackers jar daily) Honey or jelly as desired on graham crackers 10  cup canned mandarin oranges hard candies  cup cranberry juice Lunch Evening snack 2 slices white bread 5 vanilla wafers 2 tablespoons unsalted peanut butter jelly as desired (use on wafers)  cup canned peaches 10 sourballs  cup (4 oz) bottled water 22 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 23 Emergency Phone Numbers Patient Information Complete the information below and keep it with EMERGENCY NUMBERS you. If you need to go to another center, youll need Fire, Police, or Ambulance 911 to have this available.
----------------------------------------------------------------------


======================================================================
CHUNK 583 of 647
======================================================================
ID: planning_for_emergencies_6
Content Type: general
Words: 492
Medical Entities: dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
ORG 23 Emergency Phone Numbers Patient Information Complete the information below and keep it with EMERGENCY NUMBERS you. If you need to go to another center, youll need Fire, Police, or Ambulance 911 to have this available. Also, make copies of your Poison control insurance ID cards and keep them with this booklet. Red cross Name _______________________________________________________________ Office of emergency services Address ____________________________________________________________ Local NKF City ________________________________ State ________ Zip ___________ Phone _____________________________ Cell phone __________________ MEDICAL NUMBERS Your doctor EMERGENCY CONTACT Your dialysis unit Name _______________________________________________________________ Back-up dialysis unit Relationship to you _______________________________________________ Dialysis provider emergency Address ____________________________________________________________ Local hospitals City ________________________________ State ________ Zip ___________ Insurance carriers Phone _____________________________ Cell phone __________________ Pharmacy Your Medicare number __________________________________________ Other insurance __________________________________________________ PERSONAL CONTACTS Family member/friend Policy number_____________________________________________________ Contact person outside area Your dialysis center_______________________________________________ Address ____________________________________________________________ LOCAL SERVICES Plumber City ________________________________ State ________ Zip ___________ Electrician/electric co. . Phone ______________________________________________________________ Transportation co. Head nurse ________________________________________________________ Telephone repair usually 611 Your kidney doctor _______________________________________________ Phone ______________________________________________________________ 24 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 25 Treatment Information Dialysis Prescription If you need to go to another center or if your Dialyzer ___________________________ Dialysate _____________________ treatment information is destroyed or unavailable, Hours per run ____________________ Times per week _____________ this information will help your caregivers provide you Dry weight ________________________ Average weight gain _______ with the appropriate treatment. Your nurse or doctor can help complete this form. It should be updated as Heparin use _______________________________________________________ changes occur. Access type and site _____________________________________________ Date completed ___________________________________________________ Needle size _______________________Blood flow rate ______________ When was your last treatment? _________________________________ Re-Use oYes oNo Lidocaine oYes oNo Primary kidney diagnosis ________________________________________ HBsAg status _____________________Blood Type ___________________ Allergies ___________________________________________________________ Special needs/problems _________________________________________ Treatment medications __________________________________________ ______________________________________________________________________ Pertinent past medical history __________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ ______________________________________________________________________ Type of treatment: Center hemodialysis _______ CAPD _______ Home hemodialysis _______ CCPD ______ 26 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 27 Peritoneal Dialysis Information CCPD Type of cycler _____________________________________________________ CAPD Nighttime total liters delivered __________________________________ System _____________________________________________________________ Hours of therapy _________________ Number of exchanges __________ Fill volume ___________________ Fill volume per cycle ___________ Fill time ______________________ Estimated dry weight ____________________________________________ Dwell time ________________________ Drain time ___________________ EXCHANGE INFORMATION Daytime dwell oYes oNo Daytime volume _________________ Percentage of dextrose (based on weight increase): 12 lbs. 1. 5% _______________ 35 lbs. 4. 5% _____________________ EXCHANGE INFORMATION Percentage of dextrose (based on weight increase) 23 lbs. 2. 5% ______________ Icodextrin/Extraneal ______________ 12 lbs. 1. 5% _______________ 35 lbs. 4. 5% _____________________ Low calcium 2. 5 mEq/L dextrose _______________________________ 23 lbs. 2. 5% ______________ Icodextrin/Extraneal ______________ Low calcium 2. 5 mEq/L dextrose _______________________________ Low calcium 2. 5 mEq/L dextrose _______________________________ Other medications _______________________________________________ Higher calcium 3. 5 mEq/L dextrose____________________________ PERITONITIS Other medications _______________________________________________ Is patient trained to do IP antibiotics? oYes oNo Does patient have antibiotic at home? oYes oNo PERITONITIS Is patient trained to do IP antibiotics? oYes oNo Name of antibiotic ________________________________________________ Does patient have antibiotic at home?
----------------------------------------------------------------------


======================================================================
CHUNK 584 of 647
======================================================================
ID: planning_for_emergencies_7
Content Type: general
Words: 498
Medical Entities: CKD,dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
5 mEq/L dextrose____________________________ PERITONITIS Other medications _______________________________________________ Is patient trained to do IP antibiotics? oYes oNo Does patient have antibiotic at home? oYes oNo PERITONITIS Is patient trained to do IP antibiotics? oYes oNo Name of antibiotic ________________________________________________ Does patient have antibiotic at home? oYes oNo DIABETIC Name of antibiotic ________________________________________________ oYes oNo Insulin ______________________________________________ Specify amount insulin used SQ Dose _________________________ DIABETIC oYes oNo Insulin IP ________ SQ __________ Evening Dose __________________ Specify amount insulin used SQ Dose _________________________ Sliding scale for insulin (attach if available) ___________________ Evening Dose __________________ Sliding scale for insulin (attach if available) ___________________ 28 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 29 Transplant Information Emergency Resources for People with CKD Its important to keep information about all your medications with you at all times. Fill in the following Help Getting Dialysis in an Emergency list and have extra copies at home, at work, in your car The National Forum of End Stage Renal Disease or anywhere else you might find helpful. (ESRD) Networks: 804. 390. 9822; esrdnetworks. org/ TRANSPLANT MEDICATIONS LIST resources-news/disaster-planning-resources-links Medication Number American Association of Kidney Patients (AAKP): Quantity Special Name of Times When Taken per Dose Instructions 800. 749. 2257, aakp. org Strength per Day Emergency Guide Patient Emergency Information sheet The Nephron Information Center: dialysisunits. com Find dialysis unit phone numbers Helpful Organizations in an Emergency American Red Cross: 202. 303. 4498; redcross. org Federal Emergency Management Agency (FEMA): 800. 621. FEMA (3362), 800. 462. 7585 (TTY); fema. gov Food and Drug Administration (FDA) U. S. hurricane IMPORTANT PHONE NUMBERS site: 888. INFO. FDA (888. 463. 6332); fda. gov/ Transplant doctor consumers/consumer-updates/hurricane-seasonbe-prepared Transplant coordinator National Hurricane Center: nhc. noaa. gov Pharmacist Insurance National Weather Service: weather. gov Contact United Network for Organ Sharing (UNOS) U. S. Department of Housing and Urban Development: at 888. 894. 6361 or unos. org for information, if 202. 708. 1112, 202. 708. 1455 (TTY); hud. gov you are waiting for a transplant or need to obtain transplant care. 30 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 31 Emergency Grant Information Mental Health Resources National Kidney Foundation: 800. 622. 9010, American Academy of Child and Adolescent 212. 889. 2210; kidney. org Psychiatry: 202. 966. 7300; aacap. org American Kidney Fund: 800. 638. 8299, 301. 881. 3352, Anxiety and Depression Association of America: 866. 300. 2900 (Espaol); akfinc. org 240. 485. 1001; adaa. org AAKP: 800. 749. 2257, 813. 636. 8100; aakp. org Centers for Disease Control and Prevention (CDC): 800. CDC. INFO, 888. 232. 6348 (TTY); bt. cdc. gov/ American Red Cross: 202. 303. 4498; redcross. org mentalhealth FEMA: 800. 621. FEMA (3362), 800. 462. 7585 (TTY); Substance Abuse and Mental Health Services fema. gov Administration (SAMHSA) 800. 985. 5590; disasterdistress. samhsa. gov Kidney Disease Organizations Depression and Bipolar Support Alliance: National Kidney Foundation: 800. 622. 9010, 800. 826. 3632; dbsalliance. org 212. 889. 2210; kidney. org GriefNet. org: griefnet. org AAKP: 800. 749. 2257, 813. 636. 8100; aakp. org National Association of the Mentally Ill: 800. 950.
----------------------------------------------------------------------


======================================================================
CHUNK 585 of 647
======================================================================
ID: planning_for_emergencies_8
Content Type: general
Words: 492
Medical Entities: dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
985. 5590; disasterdistress. samhsa. gov Kidney Disease Organizations Depression and Bipolar Support Alliance: National Kidney Foundation: 800. 622. 9010, 800. 826. 3632; dbsalliance. org 212. 889. 2210; kidney. org GriefNet. org: griefnet. org AAKP: 800. 749. 2257, 813. 636. 8100; aakp. org National Association of the Mentally Ill: 800. 950. NAMI American Kidney Fund: 800. 638. 8299, 301. 881. 3352; (6264); nami. org akfinc. org National Institutes of Mental Health: 866. 615. 6464; The National Forum of ESRD Networks: 715. 354. 3735; nimh. nih. gov esrdnetworks. org Mental Health America: 800. 969. 6642; mentalhealthamerica. net Post-Traumatic Stress Disorder Alliance: ptsdalliance. org U. S. Department of Veterans AffairsNational Center for Post-Traumatic Stress Disorder: 800. 273. 8255 (Press 1); ptsd. va. gov 32 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 33 Are there special considerations in Earthquakes different kinds of disasters? Stay indoors; do not go outside unless collapse Here are some things to think about in special of the building seems likely. situations. Once the initial shaking has stopped, be aware that aftershocks may occur. Blizzards Stay away from tall objects that could fall over. Listen to the local emergency broadcast Listen to a battery-powered radio to keep up television or radio station for updates on the with what is going on in the area. storm and instructions about what to do. Turn off any lighting and electrical devices. If you are at home, dont attempt to go out or to Do not use the telephone except in extreme drive until the storm is over, and the roads have emergencies. been cleared. Check your emergency supplies; remember to If you are at the dialysis unit when the conserve supplies. blizzard hits, stay there until weather and road Find the location of the nearest dialysis unit in conditions have cleared. a safe area that has not been affected by the If you are a dialysis patient and you have to miss earthquake. dialysis, begin your emergency meal plan. Do not light candles or matches until gas leaks If you have to go to a shelter, tell the person in have been assessed by emergency personnel, charge about your special needs as someone and no gas leaks have been found. with kidney disease, including your need for If you have to leave your home, remember to transportation to a dialysis center. take the phone number of your dialysis unit and Keep a blanket, bottled water, protein bar, and other information, as well as your medicines. flashlight in your car in case you are stuck in If you have to go to a shelter, tell the person the storm. Road salt or cat litter is helpful for in charge about your special needs as a under your tires as well as outdoor walkways kidney patient. and steps. Make sure to wear shoes when walking after the earthquake, in case of broken glass. Keep a flashlight in a place where you can find it. 34 NATIONAL KIDNEY FOUNDATION KIDNEY.
----------------------------------------------------------------------


======================================================================
CHUNK 586 of 647
======================================================================
ID: planning_for_emergencies_9
Content Type: general
Words: 497
Medical Entities: dialysis
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
and steps. Make sure to wear shoes when walking after the earthquake, in case of broken glass. Keep a flashlight in a place where you can find it. 34 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 35 If you live in an area where earthquakes occur, make sure your potted plants and wall clocks are secured in place. If you are a dialysis patient and you have to miss dialysis, begin your emergency meal plan. Floods Listen to your local emergency broadcast television and radio station for information and instructions about what to do. If you have to leave your home or the dialysis unit: Stay out of already flooded areas and places Hurricanes where floods are likely to occur, such as lowlying areas, canyons, washes, etc. Listen to your local emergency broadcast Move to high ground if you see or hear rapidly television or radio station for news about the storm. You may have to leave your house before rising water. the storm arrives to avoid high-risk situations Do not drive through flooded areas or cross such as: areas on the coastline, on an offshore water that may be more than knee deep. island, near a river, etc. or in a mobile home. Be very careful at night when it is harder to Make your plans in advance, so you will not spot flood dangers. waste time when the storm arrives. If you use peritoneal dialysis, be sure your Find out about safe routes inland. access site stays clean when trying to Know where official shelters are located. If you evacuate under flood conditions. have to go to a shelter, tell the person in charge If you have to go to a shelter, tell the person in about your special needs as someone with charge about your special needs as someone kidney disease. with kidney disease. If you are a dialysis patient and you have to miss If you have kidney disease and you have to miss dialysis, begin your emergency meal plan. dialysis, begin your emergency meal plan. 36 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 37 Tornadoes Go to the designated shelter areas or basement. If you have to go to a shelter outside your home, tell the person in charge about your special needs as someone with kidney disease. Stay away from windows, doors and outside walls. If in danger from objects flying around, lie face down and protect your head and your access arm. Listen to your local emergency broadcast radio station for weather bulletins and instructions about what to do. Do not leave the building or your shelter area What if I have more questions? until an all clear is announced. If you have more questions, you should speak If you are a dialysis patient and you have to miss to the healthcare team at your dialysis unit or dialysis, begin your emergency meal plan. transplant center. Also, download this booklet available from the Terrorist attack Federal Emergency Management Agency (FEMA) (800. 480. 2520): ready.
----------------------------------------------------------------------


======================================================================
CHUNK 587 of 647
======================================================================
ID: planning_for_emergencies_10
Content Type: recommendation
Words: 405
Medical Entities: CKD,dialysis,diabetes
Source: planning_for_emergencies.pdf

----------------------------------------------------------------------
transplant center. Also, download this booklet available from the Terrorist attack Federal Emergency Management Agency (FEMA) (800. 480. 2520): ready. gov/sites/default/files/2021The Department of Homeland Security (dhs. gov) 11/are-you-ready-guide. pdf has up-to-date information on preparedness for a terrorist attack. 38 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 39 Where can you get more information? If you want to read more about kidney disease, the National Kidney Foundation has more than 50 other publications that cover many subjects such as: CKD risk factors, like high blood pressure and diabetes. Complications of CKD, such as heart disease, anemia, or bone problems. Nutrition for people with CKD, with information about carbohydrates, protein, sodium, phosphorus, and potassium. Treating kidney disease early. Treating kidney failure with transplantation or dialysis. There are two ways to learn about the many free resources available to you: Call the NKF Cares Patient Help Line toll free at 855. NKF. CARES (855. 653. 2273). Visit the National Kidney Foundation website at kidney. org/store. All publications are free, but there is a limit of five per person. Becoming an educated patient is very important to being healthy. 40 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 41 Setting a standard for care The National Kidney Foundation, through its Kidney Disease Outcomes Quality Initiative (KDOQI), defines stages of kidney disease and offers guidelines that help your healthcare professional and healthcare team make important decisions about your medical treatment. The information in this booklet is based on those recommended guidelines. The information contained in this publication is based on current data and expert guidance available at the time of publication. The information is intended to help patients become aware of their disease and its management. This publication is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management. Patients should always consult with their healthcare professional regarding decisions about their individual plan of care. 42 NATIONAL KIDNEY FOUNDATION KIDNEY. ORG 43 Fueled by passion and urgency, the National Kidney Foundation (NKF) is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, we focus on the whole patient through the lens of kidney health. Relentess in our work, we enhance lives through action, education, and accelerating change. 30 E. 33RD ST. NEW YORK, NY 10016 800. 622. 9010 KIDNEY. ORG KIDNEY. ORG 2022 National Kidney Foundation, Inc. 11-10-0807_2206
----------------------------------------------------------------------


======================================================================
CHUNK 588 of 647
======================================================================
ID: reportexpertconsultationonckdu_1
Content Type: recommendation
Words: 500
Medical Entities: CKD
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Printed in Sri Lanka 4 Contents Acronyms 06 Executive summary 07 Background and rationale 10 Objectives 11 Methods 11 Day 1 12 Opening session 12 Setting the scene 13 Group work: Defining future research priorities 14 Group 1: Clinical aspects: early detection, treatment and care 14 Group 2: Role of agrochemicals 16 Group 3: Water and heavy metals 18 Group 4: Heat stress and other hypotheses 20 Day 2 22 Group work: Priority costeffective interventions 22 Group 1: Prevention 22 Group 2: Early detection, treatment and care 23 Group 3: Surveillance 24 Group 4: Social interventions 25 Day 3 26 Framework for monitoring, implementation and accountability 26 Moving forward 28 Recommendations 29 Annex 1: Agenda of the meeting 36 Annex 2: List of participants and organizers 40 Annex 3: Summary of evidence on risk factors for CKDu 44 Annex 4: Framework for community-based surveillance and research 46 5 Acronyms AAN aristolochic acid nephropathy As arsenic BEN Balkan endemic nephropathy BMI body mass index Cd cadmium CKD chronic kidney disease CKDu chronic kidney disease of unknown etiology ESRD end-stage renal disease IERG independent expert review group Ig immunoglobulin IT information technology KDIGO Kidney Disease: Improving Global Outcomes MeN Mesoamerican nephropathy MRL maximum residues limit NCD noncommunicable disease NSAID non-steroidal anti-inflammatory drug RO reverse osmosis SLN Sri Lanka nephropathy UEN Uddanam endemic nephropathy WSP water safety plan 6 Executive Summary Chronic kidney disease of unknown etiology (CKDu) is a serious public health problem in Sri Lanka and several other countries, particularly in Mesoamerica. CKDu appears to disproportionally affect poor, rural, male farmers in hot climates. Despite more than 20 years of study in Sri Lanka and globally, the problem of CKDu is not well understood. The Government of Sri Lanka accords a very high priority to addressing CKDu. A Presidential Task Force on CKDu was set up in 2014 to provide oversight and coordinate the efforts of various sectors, agencies and ministries towards the prevention and treatment of CKDu. In this context, the World Health Organization (WHO) Country Office for Sri Lanka and the Presidential Task Force jointly convened a three-day international expert consultation to guide future direction for addressing CKDu in Sri Lanka. The consultation aimed to develop consensus on research priorities and cost-effective interventions for prevention and management. The objective was to review the knowledge on CKDu globally and in Sri Lanka, identify gaps, prioritize an interdisciplinary collaborative research agenda and recommend interventions based on the available evidence. The Consultation also aimed to develop consensus on the monitoring and accountability framework for implementation of the recommendations. Participants comprised 54 national and international clinicians, researchers, epidemiologists, toxicologists, agriculture scientists, social scientists, hydrologists and other experts who represented the geographical and etiological dimensions of the disease.
----------------------------------------------------------------------


======================================================================
CHUNK 589 of 647
======================================================================
ID: reportexpertconsultationonckdu_2
Content Type: recommendation
Words: 496
Medical Entities: CKD
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
The Consultation also aimed to develop consensus on the monitoring and accountability framework for implementation of the recommendations. Participants comprised 54 national and international clinicians, researchers, epidemiologists, toxicologists, agriculture scientists, social scientists, hydrologists and other experts who represented the geographical and etiological dimensions of the disease. Experts came from Sri Lanka, India, the United Kingdom, Australia, Cuba, El Salvador, Finland, Sweden, Canada and Costa Rica adding a wealth of experience to the Consultation. The International Society of Nephrology, Sri Lanka Society of Nephrology, international and national universities, public and private research institutes, National Science Foundation, Coordinating Secretariat for Science, Technology and Innovation and WHO were the key organizations represented. 7 A series of background papers commissioned for the Consultation provided the current state of the problem of CKDu and the gaps that needed to be filled. These provided overviews of the disease both in Sri Lanka and globally, the clinical aspects, available evidence on the possible role of various agents in the etiopathogenesis of the disease, and the social impact of CKDu. Strong support to the Consultation was expressed by the Director of the Presidential Task Force on CKDu and Secretaries and other senior officials of key ministries at the opening session, highlighting the commitment of the Government of Sri Lanka to solving the problem of CKDu through a multisectoral approach. To set the stage, two presentations were made on the status of CKDu in Sri Lanka and globally. Participants were then divided into four groups according to their areas of expertise, asked to review the available evidence on specified topics, and arrive at a series of recommendations by consensus. On the first day, the groups were tasked with defining future research priorities in four key areas: (i) Clinical aspects: early detection, treatment and care; (ii) Role of agrochemicals; (iii) Role of water/heavy metals; and (iv) Role of heat stress/dehydration and miscellaneous hypotheses. On the second day, the four groups had to identify priority costeffective interventions in the following areas: (i) Prevention; (ii) Early detection, treatment and care; (iii) Integrated surveillance and CKD registry; and (iv) Social interventions, as CKDu has a huge social impact on patients and their families. The outputs of the group work were consolidated into key recommendations by consensus. These recommendations will be incorporated into the forthcoming National Action Plan on CKDu for Sri Lanka. In order to implement the National Action Plan on CKDu, a framework for monitoring, implementation and accountability was proposed based on the Every woman Every child accountability concept of the United Nations that was put in place in 2010 to accelerate the progress towards achievement of the Millennium Development Goals by 2015. The existing framework consists of a National Committee on CKDu, which can provide the overall oversight. The Presidential Task Force can be the focal point for the proposed intersectoral coordinating mechanism. In addition, constitution of an Independent Expert Review Group was discussed, which could independently review the ongoing interventions and report to the National Committee.
----------------------------------------------------------------------


======================================================================
CHUNK 590 of 647
======================================================================
ID: reportexpertconsultationonckdu_3
Content Type: recommendation
Words: 490
Medical Entities: CKD,dialysis,hypertension,diabetes
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
The Presidential Task Force can be the focal point for the proposed intersectoral coordinating mechanism. In addition, constitution of an Independent Expert Review Group was discussed, which could independently review the ongoing interventions and report to the National Committee. All participants agreed to this three-tier approach. Open discussions in the plenaries led to final consensus recommendations, which were presented on the final day of the meeting to the Director of the Presidential Task Force in the concluding session. The recommendations of the Consultation are based on the consensus of all 54 experts who participated in the meeting. 8 Recommendations Develop a robust surveillance system to understand the burden, geographical distribution and time trends of CKDu in Sri Lanka. The surveillance system should be linked to monitoring of potential toxins in food, water and the environment, and provide a platform for long-term research to understand the role of potential risk factors and document the usefulness of ongoing interventions. Establish a consortium of national/international researchers to conduct long-term interdisciplinary research. CKDu is a complex disease and there is a need for sharing expertise across disciplines and countries to accelerate knowledge dissemination, guide the research agenda and help solve the mystery of u (unknown) in CKDu. WHO will facilitate researchers from global CKDu hotspots to engage in research exchange. Strengthen the implementation of available interventions; namely, early detection and management of CKDu in the early stages and dialysis in the late stages. In addition, prioritize the provision of safe drinking water and food in the affected areas and ensure sustainable agricultural practices based on the current status of knowledge and evidence. An evaluation component should be built into these interventions to understand their impact and modify the interventions if needed. Provide social support at three levels patient, family and community. Build the capacity of existing community-level workers, appoint trained paramedical personnel and social workers in appropriate locations, and expand and strengthen social support services and resources. Develop a sound communication strategy to destigmatize the disease. Livelihood generation in affected areas was also recommended. Strengthen/expand human resources at various levels, such as nephrologists, renal care nurses, social workers at the nephrology units and field level to enhance the coverage of renal care services and provide psychosocial support to patients and families. Develop a framework for monitoring and accountability to ensure timely implementation of the activities. A three-tier system was proposed, consisting of a National Committee on CKDu, an intersectoral coordinating mechanism coordinated by the Presidential Task Force and an Independent Expert Review Group. The framework will have its set of performance indicators based on the National Action Plan. This will enable open and transparent measurement as well as communication. 9 Report of the Consultation Background Chronic kidney disease (CKD) is one of the noncommunicable diseases (NCDs) of public health importance due to its high burden and high cost of treatment in the advanced stages. CKD in adults is predominantly caused by diabetes and hypertension.
----------------------------------------------------------------------


======================================================================
CHUNK 591 of 647
======================================================================
ID: reportexpertconsultationonckdu_4
Content Type: recommendation
Words: 492
Medical Entities: CKD,hypertension,diabetes
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
9 Report of the Consultation Background Chronic kidney disease (CKD) is one of the noncommunicable diseases (NCDs) of public health importance due to its high burden and high cost of treatment in the advanced stages. CKD in adults is predominantly caused by diabetes and hypertension. Autoimmune and systemic conditions also cause CKD, as do inherited conditions. Nephrotoxic drugs, herbal medications, toxins and infections are other causes of CKD in developing countries. The prevalence of CKD ranges from 9% to 11% in developed countries. An increased prevalence of CKD has been observed in select geographical areas in several countries over the past two decades. The countries included El Salvador, Nicaragua, Costa Rica, Egypt, Sri Lanka and India. As the etiology was not clear, the term chronic kidney disease of unknown etiology (CKDu) has been used in the literature since the early 2000s. In Sri Lanka and Mesoamerica, CKDu is a serious public health problem that appears to disproportionally affect poor, rural, male farmers in hot climates. Despite more than 20 years of research in Sri Lanka and globally, the problem of CKDu is not well understood. The Government of Sri Lanka accords a very high priority to addressing CKDu. A Presidential Task Force on CKDu was set up in 2014 to provide oversight and coordinate the efforts of various sectors, agencies and ministries towards the prevention and treatment of CKDu. In this context, the World Health Organization (WHO) Country Office for Sri Lanka and Presidential Task Force jointly convened a three-day international consultation to guide future direction for addressing CKDu in Sri Lanka. 11 Objectives The Consultation aimed to develop consensus on research priorities and priority interventions for the prevention and management of CKDu. The objective was to review the knowledge on CKDu globally and in Sri Lanka, identify gaps, prioritize an interdisciplinary collaborative research agenda and recommend interventions based on the available evidence. The Consultation also aimed to develop consensus on a monitoring accountability framework for implementation of the recommendations. Methods Nine background papers were commissioned during the preparatory phase of the Consultation. These papers covered areas such as a global overview of CKDu, overview of CKDu in Sri Lanka, and various other topics relevant to the causes of and interventions for CKDu. These papers were circulated to all experts prior to the meeting and provided background information to facilitate discussions during the meeting. Broad themes of the Consultation were research priorities and priority interventions for CKDu for the first two days. The experts were divided in four groups on Days 1 and 2. Each group was led by two co-chairs one international and one national expert. A note with detailed objectives, key areas of discussion and expected outcomes was given to each of the groups to facilitate the discussion. The Chair summarized the information from the relevant background paper to set the stage for group discussion. The group reviewed the available information, identified gaps and agreed on a set of recommendations.
----------------------------------------------------------------------


======================================================================
CHUNK 592 of 647
======================================================================
ID: reportexpertconsultationonckdu_5
Content Type: recommendation
Words: 466
Medical Entities: CKD
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
The Chair summarized the information from the relevant background paper to set the stage for group discussion. The group reviewed the available information, identified gaps and agreed on a set of recommendations. Following a presentation on Principles of testing hypotheses in epidemiological research on the first day, each of the groups was tasked with defining future research priorities in four key areas: (i) Clinical aspects: early detection, treatment and care; (ii) Role of agrochemicals; (iii) Role of water/heavy metals; and (iv) Role of heat stress/dehydration and miscellaneous hypotheses. On the second day, the four groups had to identify priority costeffective interventions in the following areas: (i) Prevention; (ii) Early detection, treatment and care; (iii) Integrated surveillance and CKD registry; and (iv) Social interventions, as CKDu has a huge social impact on patients and their families. The framework for monitoring, implementation and accountability was discussed on the last day of the meeting. At the end of each of the three sessions research priorities, priority interventions and monitoring/ accountability each group presented the outcome of their deliberations to all the experts. An open discussion was held after each presentation, and comments and suggestions were given by the audience. These were incorporated in the final recommendations. All the experts submitted WHO Declaration of Interest forms. 12 Day 01 Opening session The Director of the Presidential Task Force on CKDu, Mr Asela Iddawela, welcomed the participants and gave the background of the Presidential Task Force, which was set up in 2014 to limit the spread of CKDu. Guided directly by the President, its task is to provide oversight and coordinate all activities related to the control of CKDu in Sri Lanka. He hoped that the deliberations from the three-day meeting would help in formulating the National Action Plan and a monitoring framework for its implementation. He wished the participants success. The presence of Secretaries and other senior officials of the Ministries of Health, Nutrition and Indigenous Medicine; Science, Technology and Research; City Planning and Water Supply; Social Empowerment and Welfare; and the Chairperson of the University Grants Commission highlighted the commitment of the Government of Sri Lanka to combating the problem of CKDu. Each of them discussed the initiatives and interventions being undertaken by their respective ministries and collaboratively. The WHO Representative to Sri Lanka described the objectives of the meeting and the expected outcomes. He explained why this forum, with its diverse range of experts and expertise, was well suited to look for solutions to the problem of CKDu. He urged participants to work as a team, as solutions are easier to find when people share expertise and resources. 13 Setting the scene An overview of the status of CKDu in Sri Lanka apprised participants of the scale of the problem and what was being done to alleviate it.
----------------------------------------------------------------------


======================================================================
CHUNK 593 of 647
======================================================================
ID: reportexpertconsultationonckdu_7
Content Type: definition
Words: 491
Medical Entities: CKD,GFR,hypertension,diabetes
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
The presentation was followed by questions pertaining to the sociodemographic characteristics of the patients and role of various risk factors and their combinations. 14 Group work: Defining future research priorities Group 1: Clinical aspects: early detection, treatment and care Although CKDu was first identified in Sri Lanka in the 1990s, one of the main gaps identified by the group was the absence of a uniform case definition, both within the country and internationally. This impairs the ability to answer key questions, such as the true estimate of the burden of disease, the risk factors for progression, impact of interventions, and comparability across jurisdictions. The natural history of the disease needs to be studied further. The group discussed the need for modifying the existing case definition and using inclusion instead of the exclusion criteria used currently. CKD could be the overarching disease, and cases subdivided into CKDu and CKD due to other causes, such as hypertension, diabetes and others. An international group of experts from various disciplines (not limited to those involved in clinical care) should formulate a uniform case definition. This should include epidemiological, clinical and etiopathological criteria. It was also suggested that cases be divided into possible, probable and definite CKDu on the basis of the presence of defined criteria. The present staging system of the Kidney Disease: Improving Global Outcomes (KDIGO) (stages 15) could be retained. Sri Lanka should use one method of calculating the estimated glomerular filtration rate (eGFR), and it was suggested that the CKD-EPI formula be used. With respect to screening, the group felt that biomarkers could not be used at present outside of the research context, but it was important to establish screening methods compatible with the regular surveillance programme using point-of-care testing machines, and testing for urine albumin/ creatinine ratio and serum creatinine. Research questions identified during the group work Group 1: Clinical aspects: early detection, treatment and care What is the case definition of CKDu? What are the indications for renal biopsy and criteria for pathological diagnosis of CKDu? What is the eGFR formula used in various laboratories and how can it be standardized based on the CKD-EPI formula? What is the population-adjusted expected normal rage for eGFR and other relevant laboratory tests? What are the valid point-of-care testing technologies that can be introduced in the screening programme? 15 Group 2: Role of agrochemicals The group identified gaps in knowledge regarding the availability of various agrochemicals, patterns of use, safe levels of agrochemicals in the environment and their health effects on humans. It reviewed the information on nephrotoxicity of various agrochemicals including such as glyphosate, propanil, chlorpyrifos, diazinon, carbofuran, profenofos, carbosulfan, carbaryl, etc. and the potential contaminants in agrochemicals such as cadmium (Cd) and arsenic (As). The available evidence for their association with CKDu was reviewed including evidence regarding nephrotoxicity in vitro, in animals and in humans at high and low doses. Annex 3 provides a summary of the outcomes of the review.
----------------------------------------------------------------------


======================================================================
CHUNK 594 of 647
======================================================================
ID: reportexpertconsultationonckdu_8
Content Type: evidence
Words: 486
Medical Entities: CKD,diabetes
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
and the potential contaminants in agrochemicals such as cadmium (Cd) and arsenic (As). The available evidence for their association with CKDu was reviewed including evidence regarding nephrotoxicity in vitro, in animals and in humans at high and low doses. Annex 3 provides a summary of the outcomes of the review. Cd was nephrotoxic as per the literature; however, existing data from studies that measured Cd in water and biological samples was not conclusive and the clinical characteristics of the Cd-induced nephropathy seemed different from the CKDu in Sri Lanka. Per se, levels of Cd in water from studies in Sri Lanka were unlikely to account for the epidemic. Inorganic As is nephrotoxic in vitro and in animals at high doses but there is no evidence of nephrotoxicity in humans for increased risks of CKD from the epidemiological studies. There are no reports of CKDu in other populations with high As levels in water. The group consensus was that As alone is unlikely to be the causative agent of CKDu in Sri Lanka. Nephrotoxicity has been documented in the literature for humans at high doses for specific glyphosate formulations (in combination with certain adjuvants), propanil and chlorpyrifos. Association of individual pesticides with CKDu has been reported in only two studies in Sri Lanka. The evidence of causality of this association was considered inconclusive due to lack of consistency of the findings, lack of temporality where association was observed and limitations in the methods used for measuring exposures. Longitudinal well-designed studies that include healthy individuals in endemic and non-endemic areas, with bio banks, will be needed to assess the possible role of agrochemicals in causation and progression of CKDu. 16 Research questions identified during the group work Group 2: Role of agrochemicals Can existing information regarding importation, distribution and use patterns of agrochemicals be linked to the CKDu incidence? Can low doses of Cd (from food or other sources) be nephrotoxic among individuals with other risk factors (e. g. malnutrition, low birth weight) and other diseases (e. g. diabetes)? As individual agrochemicals do not seem to explain the CKDu, can synergies between individual agrochemicals or between agrochemicals and other risk factors play a role in the causation of CKDu? 17 Group 3: Water and heavy metals Several hypotheses have been put forward linking the causation of CKDu to various heavy metals and the quality and quantity of water. The group first weighed the available evidence for water and heavy metals as causative factors for CKDu. With regard to heavy metals, the group felt that the levels of these in water in Sri Lanka, particularly As and Cd, are not high enough to cause disease. Fluoride and its interaction with other constituents that add to the hardness of water is a concern. The increased risk of developing CKDu among those who drink well water as against those who drink spring water is based on anecdotal evidence and needs verification.
----------------------------------------------------------------------


======================================================================
CHUNK 595 of 647
======================================================================
ID: reportexpertconsultationonckdu_10
Content Type: recommendation
Words: 465
Medical Entities: CKD
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
The group agreed that heat stress as a cause of CKDu in Sri Lanka is less clear than in Mesoamerica. However, further research is needed to understand its contribution. The group discussed the role of infections in the etiology of CKDu. Leptospirosis has a high incidence in Sri Lanka and it can cause acute interstitial nephritis and acute kidney injury. Studies from Sri Lanka have documented a high prevalence of immunoglobulin (Ig)G antibodies against Leptospira in the population; however, data on IgM were lacking. The role of leptospirosis and hantavirus infection as a potential risk factor should be explored further. Two available studies from Sri Lanka have reported the role of genetic susceptibility as a risk factor. The group consensus was that a shared environment probably played a more important role as compared to genetic susceptibility. The majority of the patients with CKDu were found to have a low body mass index (BMI). However, it was not certain whether it was cause or the effect of CKDu. The role of low birth weight might be is difficult to study these due to lack of good-quality historical data. The use of non-steroidal anti-inflammatory drugs (NSAIDs), another well-established risk factor for renal injury, was common not only in endemic areas but also in other areas and therefore it may not be a major contributory factor for CKDu. Overall, heat stress and leptospirosis were identified as two potential risk factors for further research. 20 Research questions identified during group work Group 4: Heat stress and other hypotheses Heat stress hypotheses What were the work conditions a few decades ago and is there a change in work conditions since then? Has the climate of Sri Lanka changed over the past 30 years? Has the CKDu hotspot map changed over time? Do workers experience symptoms and signs (signs of dehydration, signs of heat exposure such as rise in core temperature, heart rate, etc. and signs of acute kidney injury) of heat exposure? What is the degree of heat exposure in each region and season as measured using heat stress indices? What kind of fluids do farmers drink, from which source and what is the quantity consumed during working hours? Other hypotheses Is Leptospira DNA detectable in the biopsies done for CKDu? What is the incidence of CKDu among patients who have had leptospirosis on long-term follow up as compared with non-infected individuals? Is there a role of maternal malnutrition and low birth weight in causing CKDu? What is the nutritional status of early CKD populations? 21 Day 02 Group work: Priority costeffective interventions Group 1: Prevention The group discussed the challenges in recommending specific interventions for prevention due to lack of a clear understanding of the etiology of CKDu. The major areas of discussion were water, agrochemicals and heat stress.
----------------------------------------------------------------------


======================================================================
CHUNK 596 of 647
======================================================================
ID: reportexpertconsultationonckdu_11
Content Type: recommendation
Words: 494
Medical Entities: CKD,dialysis
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
21 Day 02 Group work: Priority costeffective interventions Group 1: Prevention The group discussed the challenges in recommending specific interventions for prevention due to lack of a clear understanding of the etiology of CKDu. The major areas of discussion were water, agrochemicals and heat stress. The role of heavy metals in drinking water as a causative factor for CKDu has not been established; however, access to safe drinking water is a basic human right and therefore efforts to provide safe drinking water should be accelerated in endemic areas. Various technologies such as RO water, rain water harvesting, etc. are being used in endemic areas and feasibility studies need to be conducted to identify technologies that are cost effective and appropriate and sustainable. With regard to agrochemicals, those with known nephrotoxic effects could be gradually phased out to reduce exposure in endemic areas noting, however, that they should not be replaced with products with some other important toxicity. A comprehensive programme involving regulators, retailers and farmers is needed to reduce exposure to agrochemicals. The group also emphasized the need to promote sustainable farming practices. Although the evidence for heat stress hypothesis has not been established as a causative factor for CKDu in Sri Lanka, exposure to heat should be reduced in high-risk groups in the endemic areas. There is a need to link planned interventions with improved surveillance mechanisms and information on prevalence to build an evaluation component and understand the impact. Evaluation of interventions may also provide insights regarding causes and risk factors for the disease. 23 Group 2: Early detection, treatment and care Early detection results in early treatment. For this, screening is necessary, and the current guidelines on screening for CKD are applicable to CKDu patients as well. To encourage patients to undergo screening, awareness of CKDu should be raised via the media, and efforts made by local authorities to increase participation in screening. Reduction of stigma is also necessary to encourage people to come for screening. In addition, facilities need to be provided for testing. With regard to treatment, the group felt that the current screening and management guidelines on CKD and CKDu should be revisited so that they could be adapted for use at all levels of health facilities (primary, secondary and tertiary). For those with end-stage renal disease (ESRD), a policy of dialysis for all should be followed, and patients undergoing dialysis supported in various ways. 24 Group 3: Surveillance The group reviewed the differences between screening and surveillance. The primary goal of surveillance is to have population-level information, while screening is meant for detection of disease/risk at the individual level. Surveillance requires high participation from the population for reliable estimates using simple tests. Screening tests need to have a good balance of sensitivity, specificity and predictive values. The existing data sources for CKD were the community-based screening programme, the national registry maintained by the Ministry of Health and a renal registry maintained by the Sri Lanka Nephrology Association.
----------------------------------------------------------------------


======================================================================
CHUNK 597 of 647
======================================================================
ID: reportexpertconsultationonckdu_12
Content Type: definition
Words: 480
Medical Entities: CKD,GFR
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
Screening tests need to have a good balance of sensitivity, specificity and predictive values. The existing data sources for CKD were the community-based screening programme, the national registry maintained by the Ministry of Health and a renal registry maintained by the Sri Lanka Nephrology Association. The major gaps were lack of community-based surveillance and lack of linkage between the screening programme and registry. In addition, data from the two available registries need to be reconciled. The group reviewed the current status of the national renal registry and identified gaps such as lack of use of a uniform case definition, delays in data entry and inadequate analysis to inform policy-makers, and poor dissemination. The lack of robust population-level surveillance data was regarded as a hindrance to fully understanding the nature of the disease and and drawing comparisons with outbreaks in other countries. The group agreed on the need for community-based surveillance in addition to the registry through periodic surveys to monitor the disease burden in endemic and non-endemic districts. Because accurate measurement of glomerular filtration rate is not possible in field conditions there is a need to rely on the estimated glomerular filtration rate (eGFR). For eGFR, a prerequisite of a meaningful community-based surveillance is the generation of populationspecific baseline data which will allow the estimation of the distribution of eGFR values and monitoring of trends over time. The objectives of community-based surveillance would be to generate baseline data for eGFR, measure the proportion of individuals below a defined cut-off and monitor trends over time. Three districts could be selected one from an endemic area, one from a non-endemic area and one from a moderately endemic area. Surveillance sites could be selected in each of the districts and a minimum of 1000 randomly selected individuals per site or all individuals in the defined geographical area should be surveyed. The need for high coverage was emphasized for the selected sites to generate reliable estimates. The ideal scenario would be to have a large number of sites to get a representative estimate at the district level; however, the time and resources required to complete one round of the survey need to be considered while finalizing the number of sites. The heterogeneity of the disease in endemic districts needs to be considered while selecting surveillance sites. The experts shared an available international protocol that could be potentially used for surveillance in Sri Lanka and would enable comparisons with other endemic countries, and facilitate identification of areas for active collaboration. The surveillance sites would then form a basis to develop research studies on various exposures of interest, such as heat stress, sources of drinking water, agrochemicals, etc. (see figure in Annex 4). Longitudinal cohort studies could also be conducted at these sites to understand the unknown aspects of CKDu. 25 Group 4: Social interventions CKDu has a devastating effect on individuals, families and the community.
----------------------------------------------------------------------


======================================================================
CHUNK 598 of 647
======================================================================
ID: reportexpertconsultationonckdu_13
Content Type: reference
Words: 488
Medical Entities: CKD,dialysis
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
(see figure in Annex 4). Longitudinal cohort studies could also be conducted at these sites to understand the unknown aspects of CKDu. 25 Group 4: Social interventions CKDu has a devastating effect on individuals, families and the community. Intense stigma is attached to the disease and the high costs of treatment push affected people into poverty, which leads to further social and health problems. There are huge gaps in knowledge among patients, and gaps in service provision. Priority interventions should be provided at three levels patient, family and community. The needs of patients and families should be elucidated through a consultative process, and patients views taken into consideration when planning interventions. Patients working conditions can be improved by speaking with their employers. Families can be provided psychosocial counselling, and children helped through school-based interventions such as foster families, and bank accounts for children so that their studies are not interrupted due to poverty/death of a parent. Self-help groups can be formed at both the family and community levels, and assistance provided to vulnerable families. In the community, trained social workers can help to support patients. In addition, informal counselling networks can be strengthened by calling upon community and religious leaders, and traditional medicine practitioners to provide support. Existing community-level workers can also be mobilized. In hospitals, clinical psychosocial workers can provide counselling and support. The group also discussed interventions that the government could provide at various levels. These should start with putting in place an organizational structure to tackle the social issues due to CKD at the national and provincial levels. An intersectoral body should be set up headed by the President/Prime Minister and coordinated by the Ministry of Health, with a Deputy Director General specially appointed for CKD, supported by a dedicated budget and intersectoral team. The fund for CKDu should be augmented, and subsidies provided for transport/medications/overnight stay for patients, especially those undergoing dialysis. Support should also be provided for children and women-headed households. A national-level communication strategy to provide information on CKDu and destigmatize the disease should be worked out. If required, brand ambassadors could be used to leverage multinational support. 26 Day 03 Framework for monitoring, implementation and accountability (I-AM) The outcome of the Consultation will inform and feed into the forthcoming National Action Plan on CKDu for Sri Lanka. In order to ensure and facilitate implementation of the National Action Plan, a framework for monitoring, implementation and accountability (I-AM) was presented. The proposed framework was developed on the basis of the Every woman Every child accountability framework model of the United Nations, which was put in place in 2010 to accelerate progress towards achievement of the Millennium Development Goals 4 and 5 by 2015. The proposed framework would be three-pronged: a national committee on CKDu, an intersectoral coordinating mechanism and oversight by an independent expert review group (IERG)(Fig 1). Initial steps towards establishment of a national committee on CKDu have already been taken.
----------------------------------------------------------------------


======================================================================
CHUNK 599 of 647
======================================================================
ID: reportexpertconsultationonckdu_16
Content Type: recommendation
Words: 495
Medical Entities: CKD,dialysis
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
31 Develop, recommend and implement alternate pest control methods and sustainable farming practices, with a special focus on CKDu-endemic areas. Establish and update the maximum residues limits (MRL) data for pesticides based on total diet studies carried out in Sri Lanka. Minimize exposure to heat/thermal stress Implement a programme of rehydration, adequate rest and shade in occupations at high risk for heat stress/dehydration and assess their effectiveness in preventing CKDu. Early detection and management Simplify the existing CKD and CKDu screening and management guidelines, and adapt them for primary-, secondaryand tertiary-care facilities. Enhance screening coverage by improving awareness and providing point-of-care testing units (mobile) for each district. Enhance the capacity of primary care units to function as satellite renal clinics to improve access to renal care, and develop guidelines for referral from primary to tertiary care facilities. Ensure the availability of drugs and consumables. Dispense outpatient drugs for two months at a time and provide long-acting erythropoietin to reduce the number of patient visits. Discourage smoking, betel chewing and illicit use of alcohol, and include vaccination in the existing guidelines to delay the progression of renal disease. Implement a dialysis for all policy to ensure access to treatment for all patients with end-stage renal disease (ESRD). Explore the feasibility of innovative solutions, e. g. mobile dialysis units. Seek international assistance in establishing a deceased donor programme to strengthen the transplant programme. 32 Social services: Provide social support at three levels patient, family and community. Strengthen the informal local support network (Ministry of Social Welfare) and involvement of community leaders. Develop school-based social interventions to increase accessibility and social support for children of CKDu patients. Develop a specific communication strategy to destigmatize and demystify the disease. Expand social support services and resources such as transport/medicines/overnight stay for patients, and provide appropriate financial assistance to patients. Enhance livelihood generation in affected areas and plan special initiatives to empower women who are heads of families. Capacity building: Strengthen/expand human resources at various levels. Increase the number of nephrologists from the present 1/million to about 4/million population as well as the number of nursing staff to enhance the coverage of renal services. Enhance the capacity of existing community-level workers and increase the number of community-level health workers to provide outreach services such as screening and follow up. Appoint trained social workers/counsellors in appropriate locations such as renal clinics and dialysis units to provide psychosocial support to patients and families. 33 Monitoring and accountability: Develop a framework for monitoring and accountability to ensure timely implementation of activities. Establish a three-tier system, consisting of a National Committee on CKDu, an intersectoral coordinating mechanism coordinated by the Presidential Task Force and an Independent Expert Review Group. Develop a set of performance indicators for the framework based on the National Action Plan. Ensure open and transparent measurement as well as communication. 34 Annex 1: Agenda of the meeting Day 1: 27 April 2016 Registration: 8. 30 am9. 00 am Inaugural session 9. 0010.
----------------------------------------------------------------------


======================================================================
CHUNK 600 of 647
======================================================================
ID: reportexpertconsultationonckdu_17
Content Type: recommendation
Words: 500
Medical Entities: CKD
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
Develop a set of performance indicators for the framework based on the National Action Plan. Ensure open and transparent measurement as well as communication. 34 Annex 1: Agenda of the meeting Day 1: 27 April 2016 Registration: 8. 30 am9. 00 am Inaugural session 9. 0010. 00 am Welcome and opening remarks Director, Presidential Task Force on CKDu Remarks by dignitaries Introducing the participants Objectives and expected outcomes of the meeting: WHO Country Office (WCO) Sri Lanka 10. 0010. 30 am End of inauguration with tea/coffee Opening Plenary: Setting the scene Mr Asela Iddawela (Chair) 10. 3011. 30 am Presenter Dr Tilak Abeysekera An overview of CKDu in Sri Lanka (25 minutes ) Discussion 11. 3012. 30 pm Presenter Dr C. Wesseling CKDu: Global overview (25 minutes ) Discussion 12. 3012. 45 pm Group photograph 12. 4502. 00 pm Lunch 35 CONCURRENT GROUP WORK: Defining future research priorities 2. 00 pm Principles of testing hypotheses in epidemiological research Dr Prabhdeep Kaur 2. 105. 30 pm The background paper on available evidence and gaps in the evidence will serve as (with a 15-minute the base for discussions and will be presented by group co-chair tea break) Each group will further discuss available research evidence and based on gaps in the evidence, identify a list of future research questions. Group 1: Clinical aspects: Early detection, treatment and care Group 2: Role of agrochemicals Group 3: Role of water/heavy metals Group 4: Role of heat stress/dehydration and other miscellaneous hypotheses 7. 009. 00 pm RECEPTION 36 Day 2: 28 April 2016 GROUP WORK PRESENTATIONS: Defining future research priorities Chair: Professor Sirimali Fernando 9. 0010. 30 am Group work presentations: (15 min presentation and 30 min for discussion) 10. 3011. 00 am Tea break 11. 00 am12. 30 pm Group presentations: contd (15 min presentation and 30 min for discussion) 12. 301. 30 pm Lunch 1. 302. 00 pm Conclusions on future research priorities CONCURRENT GROUP WORK: Priority costeffective interventions 2. 005. 30 pm The background papers on existing priority interventions and gaps in the (with a 15 minute tea interventions will serve as the base for discussions and will be presented by group break) co-chairs Each group will further discuss priority interventions based on current evidence and suggest priority interventions and mechanisms for their implementation Group 1: Preventive interventions Group 2: Early detection, treatment and care Group 3: Integrated surveillance CKD Registry Group 4: Social interventions 37 Day 3: 29 April 2016 GROUP WORK PRESENTATIONS: Priorities for interventions 9. 0011. 00 am Chair Professor Adeera Levin Group work presentations (Each group will have 10 minutes for presentation and 20 minutes for discussion) 11. 0011. 45 am Tea break 11. 4512. 15 pm Chair Professor Adeera Levin Conclusion of set of recommendations on priority interventions 12. 151. 15 pm Chair Professor Saroj Jayasinghe Framework for monitoring, implementation and accountability (20 minute presentation followed by discussion) by Dr Jacob Kumaresan and Professor Ajith de Alwis 1. 152. 30 pm Lunch Moving forwardCLOSING CEREMONY 2. 303.
----------------------------------------------------------------------


======================================================================
CHUNK 601 of 647
======================================================================
ID: reportexpertconsultationonckdu_20
Content Type: general
Words: 149
Medical Entities: GFR
Source: Reportexpertconsultationonckdu.pdf

----------------------------------------------------------------------
Banned in Sri Lanka. Import license has not been issued since 2015. 44 Annex 4: Framework for community-based surveillance and research Conceptual framework for establishing community-based surveillance and longitudinal cohorts: a step-wise approach to CKDu in Sri Lanka Step 1: Establish community-based surveillance Repeat surveys using an internationally comparable protocol Define the geographical Collect contexual Core questionnaire, area and ensure environmental and eGFR, dipstick, high participation socioeconomic data on the blood pressure, etc. population Step 2: Focus on exposures/interventions of interest Add specific protocols in defined populations with exposures of interest, e. g. heat exposoure, specific chemicals, sources of drinking water Step 3: Longitudinal follow-up studies Cohorts can be established in select populations based on results from steps 1 and 2 and other emerging knowledge 45 Creative Design: Lishan Puwakovita lishwebbergmail. com 94 712 664 334 Printed by: New Karunadhara Press, Colombo 10 94 112 694 748 47 48
----------------------------------------------------------------------


======================================================================
CHUNK 602 of 647
======================================================================
ID: s12882_019_1501_0_0
Content Type: evidence
Words: 495
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
Ranasingheetal. BMCNephrology (2019) 20: 338 RESEARCH ARTICLE Open Access The incidence, prevalence and trends of Chronic Kidney Disease and Chronic Kidney Disease of uncertain aetiology (CKDu) in the North Central Province of Sri Lanka: an analysis of 30, 566 patients Asanga Venura Ranasinghe1, Gardiye Weligamage Gamini Priyantha Kumara1, Ranamuka Henayage Karunarathna1, Ambepitiyawaduge Pubudu De Silva1, 2, Korale Gedara Dilini Sachintani1, Jayaprakara Mudiyanselage Chathurika Nayani Gunawardena1, Sembu Kuttige Champika Ruwan Kumari1, Mohamed Shali Fathima Sarjana1, Janaka Sri Chandraguptha1, 3 and Mannikawadumesthri Vipula Chandu De Silva4 Abstract Background: Chronic Kidney Disease (CKD) ofuncertainorigin (CKDu) has affected North Central Province (Anuradhapura and Polonnaruwa districts) of Sri Lanka. The cause is still unknown. The objective of this study was to describe the incidence, prevalence and trendof CKD/CKDu in North Central Province ofSri Lanka. Methods: A cross sectional survey conductedin North Central Provincewith GPS mapping inCKDu highly affected areas. The diagnosis of CKDand staging were made according to the Kidney Disease: Improving Global Outcomes paper. Descriptive statistics used with chi-square test for evaluating dichotomous variables. Log rank test was used to compare survival rates. The population data was obtained from the 2011 Census. Results: There were 30, 566 CKD/CKDu patients inthe North Central Province. Incidence of0. 10 in 2009, 0. 39 in 2016 inAnuradhapura district, decreased slightly to 0. 29 in2017. Incidence of 0. 09 in 2009, 0. 46 in 2016 in Polonnaruwa district, decreased slightly to 0. 41 in2017. The point prevalence inhighincidence areas ranged from 2. 444. 35. The 5year survival rate was 71. 2 (Anuradhapura 72. 4 and Polonnaruwa 68. 3, p0. 0212). More than70, 40 and 33%of patients were over 50, 60 and 70years of age respectively. A male preponderance was seen in allthe divisional areas (ranging from 1. 3: 1 to 2. 6: 1) and inall theage groups. Farmers were themost affected (70. 6% Anuradhapura district and 65. 1% Polonnaruwa district). Majority in CKD stage I(4943, 69. 6%). There were 1685 deaths (17. 5%of total CKD/CKDupatients, 67. 6% oftotal deaths in CKD/CKDu patients) occurring within the first3years ofdiagnosis. GPSmappingshows thatthere is a clustering ofhouseholds with CKD/CKDu. (Continuedonnextpage) Correspondence: pubudunicslk. com 1RenalDiseasePreventionandResearchUnit, MinistryofHealth, Colombo, SriLanka 2NationalIntensiveCareSurveillance, MinistryofHealth, Colombo, SriLanka Fulllistofauthorinformationisavailableattheendofthearticle TheAuthor(s). 2019OpenAccessThisarticleisdistributedunderthetermsoftheCreativeCommonsAttribution4. 0 InternationalLicense( reproductioninanymedium, providedyougiveappropriatecredittotheoriginalauthor(s)andthesource, providealinkto theCreativeCommonslicense, andindicateifchangesweremade. TheCreativeCommonsPublicDomainDedicationwaiver ( Ranasingheetal. BMCNephrology (2019) 20: 338 Page2of11 (Continuedfrompreviouspage) Conclusions: The incidence ofCKD/CKDuincreased up to 2016 with a slight decrease in2017. The most vulnerable age group was 40 to 60years. There is a male preponderance. Farmers at a higher risk. Majority were in CKDstage 1. Morethantwo thirds ofthedeaths ofCKD/CKDu patients occurred within three years ofdiagnosis with disparities in 5year survival rate among thetwo districts. There is clustering of cases. Keywords: Chronic kidney disease ofuncertainorigin (CKDu), CKD/CKDu incidence, CKD/CKDu prevalence, CKDu in Sri Lanka, CKD/CKDu survival rate Background Hospitals ofKabethigollawa, Padaviya, and ThambuththeChronic Kidney Disease of uncertain aetiology (CKDu) gama and Divisional Hospitals of Madawachchiya and was first reported in the North Central Province of Sri Kahatagasdigiliya in the Anuradhapura district and DisLanka in the mid 90s 1.
----------------------------------------------------------------------


======================================================================
CHUNK 603 of 647
======================================================================
ID: s12882_019_1501_0_1
Content Type: definition
Words: 473
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
It is defined as occurrence of trictGeneralHospitalPolonnaruwa, BaseHospitalMadirChronic Kidney Disease (CKD) without a known underigiriya and Divisional Hospital Hingurakgoda in the lying cause 2, 3. In the affected provinces a significant Polonnaruwa district. During the second stage from 2011 association has been detected with a rural agricultural to 2016 a list of newly diagnosed patients was prospectpopulation 3, 4. Most studies reported that males are ively collected from 11 sentinel sites (these included the more affected innumbersandseverity3, 5. previously mentioned hospitals and Divisional Hospital Studies regarding histopathological features in early Kekirawa from Anuradhapura and Divisional Hospital and late CKDu in Sri Lanka have shown a predominant BakamunafromPolonnaruwa)onamonthlybasis. Forall chronic tubulointerstitial nephritis associated with glomcasesfrom2003thediagnosisofCKD/CKDuandthestaerular scarring, tubular atrophy, interstitial fibrosis and ging of the disease had been made by a Consultant Physvarying degrees of inflammation 58. Some have reician or a Nephrologist. This study does not distinguish ported Acute Kidney Injury 911. Several hypotheses betweenCKDandCKDu. Thisisbecausedefinitiveguidewere generated and studies have been conducted to find lines for distinguishing CKD from CKDu (in Sri Lanka) a possible aetiological cause for the disease. These inaccording to WHO criteria became available only after clude pesticides 12, 13, fluoride 14, heavy metalssuch 201616. Thediagnosisofchronickidneydisease(which as cadmium and arsenic 4, 12, 15, and hardness of includes CKD and CKDu) and staging of the disease in ground water 12, 14, but none have brought forth conthese hospitals had been made according to the Kidney vincing evidenceregardinganaetiologicalfactor. Disease: Improving Global Outcomes paper 17. The Data regarding incidence, deaths and changing trends GFRestimationswerederivedusingtheCKD-EPIcreatinof CKD/CKDu in the highly affected areas is scanty. ineequation. (2009)18. Early studies showed a point prevalence of 3. 7% in From 2009 onwards the grama niladhari division and Madawachchiya and 3. 2% in Huruluwewa divisions 14 the residing village of the CKD/CKDu patients were inbut later evidence suggested this to be around 1523% cluded in addition to the basic socio-demographic feain Anuradhapura and Polonnaruwa districts 4. Because tures. The grama niladhari division which is the smallest of the wide discrepancy of these figures the objective of administrative division in Sri Lanka, comprises three to this study is to describe the incidence, prevalence and four villages. Several grama niladhari divisions are trend of CKD/CKDu in North Central Province of Sri grouped together to make a divisional secretariat area Lanka, which was the first province in which the disease (DS division). Several DS divisions together make a diswasidentified. trict. Anuradhapura district has 22 DS divisions while Polonnaruwahas7divisions. Methods CKD/CKDu patients in the highly affected DS areas in This cross sectional survey of CKD/CKDu patients in the Anuradhapura (6 DS divisions) and Polonnaruwa disNorth Central Province (Anuradhapura and Polonnaruwa tricts (4 DS divisions) were prospectively GPS mapped districts) was done in two stages. In the first stage data commencing from 2012 onwards using Garmin etrex 10 was retrieved retrospectively using in-ward patient regisGPSreceiver.
----------------------------------------------------------------------


======================================================================
CHUNK 604 of 647
======================================================================
ID: s12882_019_1501_0_2
Content Type: definition
Words: 498
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
In the first stage data commencing from 2012 onwards using Garmin etrex 10 was retrieved retrospectively using in-ward patient regisGPSreceiver. IntheAnuradhapuradistricttheseDSareas tersandclinicpatientregistersofthemedicalwardsofthe included Madawachchiya (2012), Kabethigollawa (2012), hospitals in the North Central Province for the period Padaviya (2013), Rambewa (2013), Horowpathana (2015) from 2003 to 2010 (Anuradhapura district from 2003 to and Kahatagasdigiliya (2015). In the Polonnaruwa district 2010 and Polonnaruwa district from 2006 to 2010). The the DS areas included Madirigiriya (2013), Dimbulagala hospitalsincluded TeachingHospitalAnuradhapura, Base (2013), Hingurakgoda (2014) and Elahara (2014). For this Ranasingheetal. BMCNephrology (2019) 20: 338 Page3of11 purpose the list of patients diagnosed with CKD/CKDu from 2003 to 2008. The group from 2009 to 2012 wasobtainedfromtherelevanthospitals. AseachDSdivhad an exact date of diagnosis but had been diagision comprises several GN divisions, GPS mapping nosed at a time when community based CKD/CKDu processwas focused on GNdivisions. Apart from the list, screening was not organized properly. In 2013 orgaa snowballing method was used to include any CKD/ nized community based CKD/CKDu screening comCKDu patients who may have not been identified by the menced in North Central Province. To calculate the hospital list. The identified CKD/CKDu patients and incidence, population data was obtained from the family members were asked whether they knew of any 2011 Census 19. other residents with similar chronic kidney disease in the For the calculation of point prevalence and proporneighborhood. The patients detected by this snowballing tion of CKD/CKDu deaths the total number of CKD/ method were included in the study only if they had medCKDu patients obtained during the GPS mapping was icaldocumentationtoconfirmCKD/CKDufromanyhosused. Point prevalence was defined as the prevalence pitalotherthanthoselistedpreviously. Bothlivingaswell of living CKD/CKDu patients identified at the time of as dead patients with confirmed medical documentation the GPS mapping in specified DS divisions. Period inregarding CKD/CKDu were included for the mapping. cidence was defined as the total number of new During GPS mapping, by questioning the households and CKD/CKDu cases occurring during a specific number subsequently scrutinizing available hospital records (inof years. Log rank test was used to compare survival cluding death certificates in some) an attempt was made rates. The population for each DS area was obtained to determine if complications of CKD/CKDu was responfrom the 2011 Census 19. sible for the death. The exact cause of death was not determined as postmortems had not been done. Staging of Results CKDamongthedeadisunknown. Thestudyincludesatotalof30, 566CKD/CKDupatients The data collected from hospitals was statistically who had been diagnosed at eleven hospitals intheNorth analysed using SPSS version 10 and STATA 13 stuCentralProvince from 2003to2017. dent version. Counts and percentages were used to The change of incidence from 2009 to 2017 is shown express discrete variables while mean and standard separately for the two districts in Fig. 1. Both districts deviation were used to express continuous variables. show a steady increase of CKD/CKDu incidence from In univariate analysis, chi-square test was used for 2009 to 2012. The increase was from 0. 10 to 0. 14 in the evaluating dichotomous variables. For analysis purAuradhapura district and 0.
----------------------------------------------------------------------


======================================================================
CHUNK 605 of 647
======================================================================
ID: s12882_019_1501_0_3
Content Type: reference
Words: 500
Section: 1. Both districts deviation were used to express continuous variables
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
1. Both districts deviation were used to express continuous variables. show a steady increase of CKD/CKDu incidence from In univariate analysis, chi-square test was used for 2009 to 2012. The increase was from 0. 10 to 0. 14 in the evaluating dichotomous variables. For analysis purAuradhapura district and 0. 09 to 0. 13 in the Polonnaposes we divided the study population into three ruwa district. From 2013 to 2016 there was a sharp ingroups; from years 2003 to 2008, 2009 to 2012, and crease with the incidence in 2016 being 0. 39 in the 2013 to 2016. This was because the exact date of first Auradhapura district and 0. 46 in the Polonnaruwa disdiagnosis was not available for the patient population trict. However in 2017 a decline in the incidence was Fig. 1IncidenceofCKD/CKDupatientsinAnuradhapuraandPolonnaruwadistricts Ranasingheetal. BMCNephrology (2019) 20: 338 Page4of11 observed in both districts (Auradhapura 0. 29 and PolonPolonnaruwa). This male preponderance was seen in all naruwa0. 41). the DS divisions (ranging from 1. 3: 1 to 2. 6: 1) and in all Table 1 shows the distribution of patients in the three the age groups. It is lowest in the younger age groups time category periods from 2003 to 2008, 2009 to 2012 (male: female is 1. 1: 1 in 1120years age group in both and 2013 to 2017. The mean age of the CKD/CKDu padistricts) and highest in 4160years age group (male: fetients was 57. 2years with SD13. 4years (Anuradhapura male is 2: 1 in Anuradhapura and 2. 4: 1 in Polonnaruwa). district 57. 2years with SD13. 1years, Polonnaruwa disAfter 60years, the male preponderance diminished but trict mean age was 57. 4years with SD14. 1years). In still remained high (male: female is 1. 8: 1 in Anuradhaboth districts more than 70, 40 and 33% of patients were pura and 2. 2: 1 in Polonnaruwa in 70years age over 50, 60 and 70years of age respectively. Only asmall category). percentage of patients (5. 48. 6%) were in the 31 to 40 Farmers were the most commonly affected occupation yearsagegroup. group (70. 6% from Anuradhapura district and 65. 1% There was a male preponderance in both districts from Polonnaruwa district). Details of the staging (Table (male: female ratio 1. 8: 1 in Anuradhapura; 2. 2: 1 in 1) was available only in a minority of the group (7103, Table1Socio-demographiccharacteristicsofCKD/CKDuinNorthCentralProvince Characteristics Anuradhapura(n20, 473) Polonnaruwa(n10, 093) 2003to2008 2009to2012 2013to2017 2006to2008 2009to2012 2013to2017 (n4039) (n4157) (n12, 277) (n1474) (n2011) (n6608) Number(%) Number(%) Number(%) Number(%) Number(%) Number(%) PeriodIncidence 0. 47 0. 48 1. 43 0. 36 0. 49 1. 63 Sex Male 2731(67. 6%) 2796(67. 3%) 7577(61. 7%) 1132(76. 8%) 1477(73. 4%) 4309(65. 2%) Female 1308(32. 4%) 1361(32. 7%) 4700(38. 3%) 342(23. 2%) 534(26. 6%) 2299(34. 8%) Age(years) Malemean(SD) 56. 7(13. 9) 56. 9(12. 8) 57. 7(12. 2) 56. 3(14. 9) 58. 9(11. 9) 58. 0(13. 6) Femalemean(SD) 56. 6(15. 5) 56. 8(13. 5) 56. 8(13. 3) 53. 8(17. 8) 59. 2(13. 1) 56. 0(15. 3) Agegroups(years) 10 13(0. 3%) 13(0. 3%) 15(0. 1%) 15(1.
----------------------------------------------------------------------


======================================================================
CHUNK 606 of 647
======================================================================
ID: s12882_019_1501_0_4
Content Type: reference
Words: 498
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
8%) Age(years) Malemean(SD) 56. 7(13. 9) 56. 9(12. 8) 57. 7(12. 2) 56. 3(14. 9) 58. 9(11. 9) 58. 0(13. 6) Femalemean(SD) 56. 6(15. 5) 56. 8(13. 5) 56. 8(13. 3) 53. 8(17. 8) 59. 2(13. 1) 56. 0(15. 3) Agegroups(years) 10 13(0. 3%) 13(0. 3%) 15(0. 1%) 15(1. 0%) 4(0. 2%) 17(0. 3%) 1120 102(2. 5%) 48(1. 1%) 168(1. 4%) 38(2. 6%) 8(0. 4%) 123(1. 8%) 2130 100(2. 5%) 95(2. 3%) 205(1. 7%) 45(3. 0%) 27(1. 3%) 176(2. 7%) 3140 262(6. 5%) 242(5. 8%) 748(6. 1%) 118(8. 0%) 106(5. 3%) 482(7. 3%) 4150 706(17. 5%) 768(18. 5%) 1989(16. 2%) 261(17. 7%) 307(15. 3%) 1025(15. 5%) 5160 1229(30. 4%) 1330(32. 0%) 4000(32. 6%) 420(28. 5%) 613(30. 5%) 1890(28. 6%) 6170 1018(25. 2%) 1118(26. 9%) 3665(29. 8%) 334(22. 7%) 625(31. 1%) 1797(27. 2%) 70 609(15. 1%) 543(13. 1%) 1487(12. 1%) 243(16. 5%) 321(15. 9%) 1098(16. 6%) Occupation Farmer 3118(77. 2%) 3174(76. 4%) 5198(42. 3%) 950(83. 3%) 1439(78. 1%) 3116(47. 1%) Other 921(22. 8%) 983(23. 6%) 2872(23. 4%) 191(16. 7%) 403(21. 9%) 2363(35. 8%) Notavailable 0 0 4207(34. 3%) 333(22. 6%) 169(8. 4%) 1129(17. 1%) StagingofCKD(n7103) StageI 6 379 3109 242 229 978 StageII 0 15 108 0 1 44 StageIII 0 289 271 0 6 374 StageIV 0 165 204 0 0 136 StageV 0 154 256 0 10 127 ReportedDeaths Institutions Notreported 599(14. 4%)a 1194(12. 2%)a, b Notreported Notreported Notreported aPercentagewascalculatedbytakingthetotalnumberofCKD/CKDufortherespectiveperiodasthedenominator b2017deathswerenotavailable Ranasingheetal. BMCNephrology (2019) 20: 338 Page5of11 23. 2%). OfthismostCKD/CKDupatientswereinstageI groups of DS divisions of the North Central Province (4943, 69. 6%). Stages II, III, IV and V had 2160 (30. 4%) (p0. 001, 95% Confidence Interval for incidence 2. 40 with 547(7. 7%) patients inStage Vrespectively. was2. 443. 63, forincidence2. 40was1. 021. 51). The incidence of CKD/CKDu from 2012 to 2017 in There were 9653 CKD/CKDu patients (6335 from the DS divisions of both districts is shown in Table 2. Anuradhapura and 3318 from Polonnaruwa districts) in Comparison of divisions with period incidence of over the 10 DS divisions with the highest incidence which 2. 40 (six in Anuradhapura district and one in Polonnawere GPS mapped. The point prevalence of CKD/CKDu ruwa district) with those below two shows that there is a in these high incidence areas of Auradhapura ranged statistical difference of period incidence among the two from 1. 523. 35 while it was 0. 671. 25 in Polonnaruwa. Table2NewlyreportedCKD/CKDupatientsandCKD/CKDuprevalencedata Ranasingheetal. BMCNephrology (2019) 20: 338 Page6of11 The 5year survival rate was 71. 2 (Anuradhapura 72. 4, steadily increasing provision of safe drinking water in 95% CI 71. 1073. 7 and Polonnaruwa 68. 3, 95% CI 66. 1 theaffectedareas20. 70. 4). Anuradhapura district has a significantly higher The Balkan Endemic Nephropathy (BEN) thought to survival rate compared to Polonnaruwa district (log-rank be caused by environmental contaminants has shown testp0. 0212). fluctuating incidence rates since its discovery in 1956 Among 9653 patients who were GPS mapped, 2491 21. However its prevalence has remained 37% over (25. 8%) were dead patients. This included 1655 deaths, thelastfive decades22. (26.
----------------------------------------------------------------------


======================================================================
CHUNK 607 of 647
======================================================================
ID: s12882_019_1501_0_5
Content Type: reference
Words: 492
Medical Entities: CKD,hypertension
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
0212). fluctuating incidence rates since its discovery in 1956 Among 9653 patients who were GPS mapped, 2491 21. However its prevalence has remained 37% over (25. 8%) were dead patients. This included 1655 deaths, thelastfive decades22. (26. 1%) from Anuradhapura and 836 deaths (25. 2%) In the present study the point prevalence from GPS from Polonnaruwa districts. Among these deaths 578 mapping ranged from 1. 52 to 3. 35 in Anuradhapura and (6% of total CKD/CKDu patients, 23. 2% of total deaths 0. 67 to 1. 25 in Polonnaruwa. These results are in agreein CKD/CKDu patients) occurred within one year of ment with the study done by Chandrajith et al. (2011) diagnosis (Anuradhapura 396, 23. 9%, Polonnaruwa 182, which showed a point prevalence of 3. 7% in Madawach21. 8%) while 1685 (17. 5% of total CKD/CKDu patients, chiya and 3. 2% in Huruluwewa 14 but not with the 67. 6% of total deaths in CKD/CKDu patients) occurred study done by Jayathilaka et al. (2013) which showed a within the first 3years of diagnosis (1115, 67. 4% from point prevalence of 1523% 4. A possible explanation Anuradhapura and 570, 68. 2% from Polonnaruwa disfor this is the flows in the design, interpretation and tricts). Within the first 5years of diagnosis 2063 patients conclusion of the study as shown by Jayasumna et al. were dead (21. 4% of total CKD/CKDu patients, 82. 8% of (2013) 13. total deaths in CKD/CKDu patients). This included Our data shows that in the three time categories 1362 deaths (82. 3% of total deaths in CKD/CKDu pa- (20032008, 2009-2012, 20132017) the age groups that tients) from Anuradhapura and 701 deaths (83. 9% of were most affected were older patients (50 to 60years total deaths in CKD/CKDu patients) from Polonnaand60years). There was no increase within different ruwa districts. It was observed that over 95% of the agegroups duringthe time periods thatwerestudied. As patients (approximately 2390) did not have identifithis study does not distinguish between CKD and CKDu able other causes of deaths (such as road traffic acciit could be argued that the increased incidence in elderly dents, cancer etc. ). may be due to diabetic and hypertensive nephropathy. Figure 2 depicts the total number of CKD/CKDu paHowever previous studies have demonstrated that diatients in different DS divisions of Sri Lanka which had betes and hypertension contribute to only a minority of been collected using the same methodology as in the CKDinthis region3. present study other than for GPS mapping. This figure If the majority of patients in this study had CKDu, shows the seven DS divisions with CKD/CKDu period possible explanations to the increased incidence in older incidence of 2. 40 in Anuradhapura and Polonnaruwa patients include an aetiological factor with a cumulative districts in North Central Province are clustered toeffect or an aetiological factor which had a prolonged gether. This figure also shows that adjacent DS divisions period of pathogenesis. However if this was true, in the ofneighboringdistrictsalso havehighnumbers.
----------------------------------------------------------------------


======================================================================
CHUNK 608 of 647
======================================================================
ID: s12882_019_1501_0_6
Content Type: reference
Words: 499
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
40 in Anuradhapura and Polonnaruwa patients include an aetiological factor with a cumulative districts in North Central Province are clustered toeffect or an aetiological factor which had a prolonged gether. This figure also shows that adjacent DS divisions period of pathogenesis. However if this was true, in the ofneighboringdistrictsalso havehighnumbers. later time periods between 2009 to 2012 and 2013 to Figures 3, 4 and 5 shows GPS mapping of CKD/CKDu 2017 there should have been some increase in the propatients in the two DS divisions with the highest prevaportion ofCKD. /CKDu in other age groups as well espelence in Anuradhapura and Polonnaruwa districts. This cially ifacommon environmentalfactor wasresponsible. shows that there is a clustering of households with The other possible explanation is that the elderly people CKD/CKDu within DS divisions with the highest are more susceptible to an aetiological factor or factors prevalence. duetothephysiologicalreasonsorco-morbidities. BEN shows a low incidence in younger age groups and Discussion higher incidence after 65years with the onset between Our study shows that the incidence of CKD/CKDu in 40 to 60years 22. It has a long latent period and thus NorthCentralProvinceincreasedupto2016. Onereason affectstheexposedatalaterpartoftheirlife21. Mesofor the rapid increase in the incidence of the disease in american Nephropathy also shows a high proportion of both districts in North Central Province after 2012 may affectedindividualsbetween50to70agegroup 23. be the organized community based screening proOur study shows an increase proportion of male pagrammes conducted by the health sector resulting in intientswithin thedifferentagegroupsandinthedifferent creased case detection. Other reasons include increased DS divisions. Explanation for this male preponderance exposure to aetiological factor or factors which have not includes predominant exposure to the risk factors such been convincingly identified as of yet. This study also as pesticides in farmers or presence of disease modifying shows that the incidence has declined slightly in 2017 in factors (eg. use of alcohol and smoking). The possibility both districts. A probable reason for this may be the of a protective role by female hormones is unlikely as Ranasingheetal. BMCNephrology (2019) 20: 338 Page7of11 Fig. 2TotalnumberofCKD/CKDupatientsindivisionalsecretariatareas. Themapiscreatedbasedonthedatafromthisstudy. (Thisdatawas collectedfromhospitalsusingthesamemethodologyasinthisstudyfromotherdistricts) the male: female is lower in the female reproductive age CKDu in Sri Lanka with the disease being commoner groups. In both districts majority of patients were among males and older age groups and agricultural farmers. However majority of the people residing in workers 23. these areas are anyway farmers 19. Explanation for Ourstudyalsoshowsthattheincidenceisnotuniform farmers being more affected may be due to higher examong all DS divisions of the two affected districts in posure to aetiological agents such as pesticides. Figure 4 North Central Province. There were six DS divisions in confirms that patients are clustered around areas with Anuradhapura and one from Polonnaruwa that reported paddy fields. This is further confirmed in Figs. 3 and 5 a period incidence of over 2. 4. These high incidence which shows that GN divisions with a high population areas are clustered closer to each other. This is also apdensity which are of urban settings do not have high parent from Fig.
----------------------------------------------------------------------


======================================================================
CHUNK 609 of 647
======================================================================
ID: s12882_019_1501_0_7
Content Type: reference
Words: 486
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
3 and 5 a period incidence of over 2. 4. These high incidence which shows that GN divisions with a high population areas are clustered closer to each other. This is also apdensity which are of urban settings do not have high parent from Fig. 2 which shows the geographical distrinumber of CKD/CKDu patients. Thus clustering pattern bution of DS divisions that had reported more than within DSdivisionsisnot related topopulationdensity. 1000 CKD/CKDu cases from 2003 to 2017. These high In BEN both males and females are equally effected incidence DS divisions in North Central Province border 21. However similar to CKDu in Sri Lanka it was DS divisions with high number of CKD/CKDu patients seen among the rural farming population 22. The in the adjoining districts. Figure 2 indicates that the Mesoamerican Nephropathy also has similarities to number of reported CKD/CKDu patients decrease steadily Ranasingheetal. BMCNephrology (2019) 20: 338 Page8of11 Fig. 3GPSmappingofCKD/CKDupatientsvspopulationdensityinMadawachchiyaDSdivisionofAnuradhapuradistrict. Themapiscreated basedonthedatafromthisstudy. ThehighpopulationdensityGNareasindicatedindarkbrownareurbansettings beyond the high incident areas. Thus the effect of the Similar findings are seen in BEN which exhibit focal causative factor may be distributed in a gradient fashion occurrence with affected and spared households in close with high incidence areas having the most exposure to the proximity within the same village 25. BEN was recausative factor while the lower areas probably have lower ported to have numerous members of one or several exposure. Theotherexplanationmaybethatthehighincigenerations inasinglehousehold26. dence areas may have other factors that contribute to the To the best of our knowledge this is the first publicacausationofdiseaseafterinitialexposuretoatoxicagent. tion indicating death rates and 5year survival rates of GPSmappingindicatesclusteringofcasesinbothhigh CKD/CKDu patients in CKDu affected areas in Sri and low incident areas. According to the maps there are Lanka. Results from the GPS mapping shows that a total high prevalent areas and low prevalent areas even within of 2491 (25. 8%) out of 9653 CKD/CKDu patients died. a GN division. When the maps are superimposed with Although the exact cause of death was not explored in paddy fields and irrigation tanks as shown in Fig. 4, this detail, during the GPS mapping, on discussion with the clustering seems to be mainly among the farming comhouseholds and scrutinizing available hospital records munities and around irrigation tanks. The irrigation (including death certificates in some), it was observed tanks form a cascading system with water flowing from that over 95% of the patients (approximately 2390) did higher levels to lower levels. While conducting the study nothaveidentifiableothercausesofdeaths(suchasroad we noticed clustering of CKD/CKDu patients towards traffic accidents, cancer etc. ) and therefore were prethe lower part of the tanks. Previous studies have also sumed to have died of complications resulting from identified clustering of cases towards the lower altitude CKD/CKDu. In comparison hospital based data shows ofthetanks24. 1793 deaths among 16, 434 patients with a death rate of Ranasingheetal. BMCNephrology (2019) 20: 338 Page9of11 Fig. 4GPSmappingofCKD/CKDupatientsoccupationwithwaterpaddyareasinMadawachchiyaDSdivisionofAnuradhapuradistrict. The mapiscreatedbasedonthedatafromthisstudy 10% (refer Table 1). This highlights the fact that the imregion 3.
----------------------------------------------------------------------


======================================================================
CHUNK 610 of 647
======================================================================
ID: s12882_019_1501_0_8
Content Type: reference
Words: 495
Medical Entities: CKD,hypertension,diabetes
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
In comparison hospital based data shows ofthetanks24. 1793 deaths among 16, 434 patients with a death rate of Ranasingheetal. BMCNephrology (2019) 20: 338 Page9of11 Fig. 4GPSmappingofCKD/CKDupatientsoccupationwithwaterpaddyareasinMadawachchiyaDSdivisionofAnuradhapuradistrict. The mapiscreatedbasedonthedatafromthisstudy 10% (refer Table 1). This highlights the fact that the imregion 3. Another study has shown that the prevalence plications of CKDu in relation to mortality may be more of diabetes in North Central Province during the same seriousthan what isindicated inhospitalbased statistics. period was 9. 6% 27. Based on these previous documenThis study showed a significantly high (log-rank test tations it seems unlikely that diabetes and hypertension p0. 0212) 5year survival rate in Anuradhapura (71. 2%) would have contributed to major proportion of CKD in compared to that of Polonnaruwa (68. 3%). One possible theregion. explanation is the lack of access to health care facilities in Polonnaruwa compared to Anuradhapura based on Conclusion the assumption that majority of patients died due to The incidence of CKD/CKDu in North Central Province CKD/CKDurelated causes. has increased up to 2016 with a slight decrease in 2017. Results from the GPS mapping shows that 6% of total A possible explanation for this may be the provision of CKD/CKDu patients died within the first year of diagnosafe drinking water. The most vulnerable age groups are sis whilst 17. 5% died within three years. This represents from 40 to 60years. There is a male preponderance. 67. 7% of total deaths in CKD/CKDu. This emphasizes Farmers seem to be at a higher risk. Limited data shows the immediate need for hospital with facilities for dialythatmajority ofpatientsareinCKDstage1. sisandideallyrenal transplants. The 5year survival rate was 71. 2. Anuradhapura disThis study is limited by the fact that a distinction was trict (5year survival rate 72. 4) has a significantly higher not made between CKD and CKDu as data on co-morsurvival rate compared to Polonnaruwa district (5year bidities was not collected. However a previous study has survival rate 68. 3). Among the deaths in CKD/CKDu pademonstrated that diabetes (2%) and hypertension (14%) tients 578 (6% of total CKD/CKDu patients, 23. 2% of contribute to only a minority of CKD/CKDu in this total deaths in CKD/CKDu patients) occurred within Ranasingheetal. BMCNephrology (2019) 20: 338 Page10of11 Fig. 5GPSmappingofCKD/CKDupatientsvspopulationdensityinMadirigiriyaDSdivisionofPolonnaruwadistrict. Themapiscreatedbasedon thedatafromthisstudy one year of diagnosis while 1685 (17. 5% of total CKD/ GWGP, RHK, APDS, KGDS, JMCNG, SKCRK, MSFS, JSCandCDSallhelpedto CKDu patients, 67. 6% of total deaths in CKD/CKDu pawritethemanuscript. Allauthorsreadandapprovedthefinalmanuscript. tients) occurred within the first 3years of diagnosis. Funding Within the first 5years of diagnosis 2063 patients were None dead (21. 4% of total CKD/CKDu patients, 82. 8% of total deaths inCKD/CKDupatients). Availabilityofdataandmaterials Someoftheaggregateddataareavailableattherenalregistry Areas reporting higher incidence of CKD/CKDu are com/iframe-renal-dev/whileallaggregateddatausedforthisstudyare clustered together. GPS mapping shows that even within availablefromtheRenalDiseasePreventionandResearchUnit, Ministryof the high incidence areas there is geographic clustering. Health, SriLanka. Thedatacanbeobtainedonreasonablerequestwiththe permissionfromtheDirectorGeneralofHealthServices, MinistryofHealth, The clustering was mainly around paddy fields and irriSriLanka. gation tanks. Ethicsapprovalandconsenttoparticipate Abbreviations Thedatausedforthisstudyareanonymisedaggregated(routinelygathered BEN: BalkanEndemicNephropathy; CKD: ChronicKidneyDisease; duringservicedelivery)secondarydata. Wehaveobtainedthissecondary CKDu: ChronicKidneyDiseaseofuncertainaetiology; DS: Divisional dataandconductedtheanalysis. MostofthisdataisalsoavailableintheSri Secretariat LankaRenalRegistry. Theaggregatedataisaccessibletoanypersons. TheapprovalforthisstudywasobtainedfromtheMinistryofHealth, Sri Acknowledgements Lanka. HospitalandfieldstaffofNorthCentralProvince.
----------------------------------------------------------------------


======================================================================
CHUNK 611 of 647
======================================================================
ID: s12882_019_1501_0_9
Content Type: definition
Words: 439
Medical Entities: CKD
Source: s12882-019-1501-0.pdf

----------------------------------------------------------------------
Health, SriLanka. Thedatacanbeobtainedonreasonablerequestwiththe permissionfromtheDirectorGeneralofHealthServices, MinistryofHealth, The clustering was mainly around paddy fields and irriSriLanka. gation tanks. Ethicsapprovalandconsenttoparticipate Abbreviations Thedatausedforthisstudyareanonymisedaggregated(routinelygathered BEN: BalkanEndemicNephropathy; CKD: ChronicKidneyDisease; duringservicedelivery)secondarydata. Wehaveobtainedthissecondary CKDu: ChronicKidneyDiseaseofuncertainaetiology; DS: Divisional dataandconductedtheanalysis. MostofthisdataisalsoavailableintheSri Secretariat LankaRenalRegistry. Theaggregatedataisaccessibletoanypersons. TheapprovalforthisstudywasobtainedfromtheMinistryofHealth, Sri Acknowledgements Lanka. HospitalandfieldstaffofNorthCentralProvince. Consentforpublication Authorscontributions Notapplicable AVR, GWGP, RHK, APDS, KGDS, JMCNG, SKCRK, MSFS, JSCandCDSallhelped topreparethemethodology. KGDS, JMCNG, SKCRKandMSFSextractedthe Competinginterests datafromthesecondarydatasources. GWGPandRHKdidtheanalysis. AVR, Theauthorsdeclarethattheyhavenocompetinginterests. Ranasingheetal. BMCNephrology (2019) 20: 338 Page11of11 Authordetails 17. LeveyAS, EckardtKU, TsukamotoY, LevinA, CoreshJ, RossertJ, etal. 1RenalDiseasePreventionandResearchUnit, MinistryofHealth, Colombo, Definitionandclassificationofchronickidneydisease: apositionstatement SriLanka. 2NationalIntensiveCareSurveillance, MinistryofHealth, Colombo, fromkidneydisease: improvingglobaloutcomes(KDIGO). KidneyInt. 2005; SriLanka. 3OfficeofAdditionalSecretary(Development), MinistryofHealth, 67: 2089100. Colombo, SriLanka. 4DepartmentofPathology, FacultyofMedicine, 18. LeveyAS, StevensLA, SchmidCH, ZhangY, CastroAIII. Newequationto UniversityofColombo, Colombo, SriLanka. estimateglomerularfiltrationrate. AnnInternMed. 2009; 150(9): 60412. 19. DepartmentofCensusandStatistics. CensusofPopulationnandHousingof Received: 2October2018Accepted: 29July2019 SriLanka, 2012. Colombo; 2012. 20. RanasingheHRALN, LokugeLDMN, EdirisingheJC, BandaraL. Water treatment, preventivemeasuresandthechronickidneydiseaseinthe farmingcommunityinSriLanka. JAgricSci-SriLanka. 2015; 10: 98108. References 21. JankoviS, BukviD, MarinkoviJ, JankoviJ, MariI, DjukanoviL. Time 1. AbeysekeraDTDJ, KaiyoomSAA, DissanayakeSU. Placeofperitonealdialysis trendsinBalkanendemicnephropathyincidenceinthemostaffected inthemanagementofrenalfailurepatientsadmittedtoGeneralHospital regioninSerbia, 1977-2009: thediseasehasnotyetdisappeared. Nephrol Kandy. In: KandySocietyofMedicine18thAnnualAcademicConference; DialTransplant. 2011; 26: 31716. 1996. 22. StiborovM, ArltVM, SchmeiserHH. Balkanendemicnephropathy: an 2. RedmonJH, ElledgeMF, WomackDS, WickremashingheR, WanigasuriyaKP, updateonitsaetiology. ArchToxicol. 2016; 90: 2595615. Peiris-JohnRJ, etal. Additionalperspectivesonchronickidneydiseaseof 23. LebovJF, ValladaresE, PeaR, PeaEM, SanoffSL, CisnerosEC, etal. A unknownaetiology(CKDu)inSriLanka--lessonslearnedfromtheWHO population-basedstudyofprevalenceandriskfactorsofchronickidney CKDupopulationprevalencestudy. BMCNephrol. 2014; 15: 125. diseaseinLen, Nicaragua. CanJKidneyHealDis. 2015; 2: 114. 3. AthuraliyaTNC, AbeysekeraDTDJ, AmerasinghePH, KumarasiriPVR, 24. JayasekaraKB, DissanayakeDM, AdhikariSB, BandaraP. Geographical DissanayakeV. Prevalenceofchronickidneydiseaseintwotertiarycare distributionofchronickidneydiseaseofunknownorigininNorthCentral hospitals: highproportionofcaseswithuncertainaetiology. CeylonMedJ. RegionofSriLanka. CeylonMedJ. 2013; 58: 610. 2009; 54: 235. 25. BamiasG, BoletisJ. Balkannephropathy: evolutionofourknowledge. AmJ 4. JayatilakeN, MendisS, MaheepalaP, MehtaFR. Chronickidneydiseaseof KidneyDis. 2008; 52: 60616. 26. StefanovicV, CukuranovicR, MiljkovicS, MarinkovicD, TonchevaD. Fifty uncertainaetiology: prevalenceandcausativefactorsinadeveloping yearsofBalkanendemicnephropathy: challengesofstudyusing country. BMCNephrol. 2013; 14: 180. epidemiologicalmethod. RenFail. 2009; 31: 40918. 80. 27. KatulandaP, RathnapalaDAV, SheriffR, MathewsDR. Provinceandethinic 5. WijetungeS, RatnatungaNVI, AbeysekeraDTDJ, WazilAWM, SelvarajahM, specificprevalanceofdiabetesamongSriLankanadults. SriLankaJ RatnatungaCN. Retrospectiveanalysisofrenalhistologyinasymptomatic DiabetesEndocrinolMetabolism. 2011; 1: 27. patientswithprobablechronickidneydiseaseofunknownaetiologyinSri Lanka. CeylonMedJ. 2013; 58: 1427. 6. SelvarajahM, WeeratungaP, SivayoganthanS, RathnatungaN, RajapakseS. Publishers Note Clinicopathologicalcorrelatesofchronickidneydiseaseofunknown SpringerNatureremainsneutralwithregardtojurisdictionalclaimsin etiologyinSriLanka. IndianJNephrol. 2016; 26: 35763. publishedmapsandinstitutionalaffiliations. 7. WijetungeS, RatnatungaNVI, AbeysekeraTDJ, WazilAWM, SelvarajahM. Endemicchronic kidneydiseaseofunknownetiologyin SriLanka: correlationofpathologywithclinicalstages. IndianJNephrol. 2015; 25: 27480. 8. NanayakkaraS, KomiyaT, RatnatungaN, SenevirathnaSTMLD, HaradaKH, HitomiT, etal. Tubulointerstitialdamageasthemajorpathologicallesionin endemicchronickidneydiseaseamongfarmersinNorthCentralProvince ofSriLanka. EnvironHealthPrevMed. 2012; 17: 21321. 9. NanayakkaraS, SenevirathnaSTMLD, AbeysekeraT, ChandrajithR, RatnatungaN, GunarathneEDL, etal. Anintegrativestudyofthegenetic, socialandenvironmentaldeterminantsofchronickidneydisease characterizedbytubulointerstitialdamagesintheNorthCentralRegionof SriLanka. JOccupHealth. 2014; 56: 2838. 10. GlaserJ, LemeryJ, RajagopalanB, DiazHF, Garca-TrabaninoR, TaduriG, et al. ClimatechangeandtheemergentepidemicofCKDfromheatstressin ruralcommunities: thecaseforheatstressnephropathy. ClinJAmSoc Nephrol. 2016; 11: 147283. 11. LiaoF, TenorioMT, Rodrguez-MendiolaN, PonteB. Acutekidneyinjuryas ariskfactorforchronickidneydiseasesindisadvantagedpopulations. Clin Nephrol. 2010; 74(Suppl1): S8994. 12. JayasumanaC, GunatilakeS, SenanayakeP. Glyphosate, hardwaterand nephrotoxicmetals: aretheytheculpritsbehindtheepidemicofchronic kidneydiseaseofunknownetiologyinSriLanka? IntJEnvironResPublic Health. 2014; 11: 212547. 13. JayasumanaC, GajanayakeR, SiribaddanaS. Importanceofarsenicand pesticidesinepidemicchronickidneydiseaseinSriLanka. BMCNephrol. 2014; 15: 124. 14. ChandrajithR, NanayakkaraS, ItaiK, AturaliyaTNC, DissanayakeCB, AbeysekeraT, etal. Chronickidneydiseasesofuncertainetiology(CKDue) inSriLanka: geographicdistributionandenvironmentalimplications. EnvironGeochemHealth. 2011; 33: 26778. 15. WanigasuriyaKP, Peiris-JohnRJ, WickremasingheR. Chronickidneydisease ofunknownaetiologyinSriLanka: iscadmiumalikelycause? BMCNephrol. 2011; 12: 32. 16. WHO. InternationalExpertConsultationonChronicKidneyDiseaseof UnknownEtiology. 2016.
----------------------------------------------------------------------


======================================================================
CHUNK 612 of 647
======================================================================
ID: s12955_020_01369_1_0
Content Type: definition
Words: 495
Medical Entities: CKD
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 RESEARCH Open Access Health related quality of life in chronic kidney disease; a descriptive study in a rural Sri Lankan community affected by chronic kidney disease Sameera Senanayake1, Nalika Gunawardena2, Paba Palihawadana1, Shanika Senanayake3, R. Karunarathna4, Priyantha Kumara4 and Sanjeewa Kularatna3 Abstract Introduction: Thecurrentepidemicofchronickidneydisease(CKD)inSriLankaisascribedtotheexponentialincreasein thenumberofCKDpatients, whichcannotbeattributedtoanyknownetiology(CKDu). Theaimofthisstudyistodescribe thehealthrelatedqualityoflife(HRQOL)andtheassociatedfactorsamongCKD/CKDupatientsinaruraldistrictinSriLanka. Methods: Acommunitybasedcross-sectionalstudyincluded1174CKD/CKDupatients. KidneyDiseaseQualityofLife-Short FormwasusedtoassesstheHRQOL, whileCentreforEpidemiologicStudiesDepressionScale, GeneralHealthQuestionnaire (GHQ)12andCKDSymptomIndexSriLankawereusedtoassesspresenceofdepression, psychologicaldistressand symptomburdenrespectively. Threesummaryscores; kidneydisease(KDSC), physical(PCS)andmental(MCS)arederived fromKidneyDiseaseQualityofLife-ShortForm(KDQOL-SF). Results: Meanageofthestudypopulationwas58. 3years(standarddeviation(SD)10. 7). MedianKDSC(58. 4; inter-quartile range(IQR)54. 263. 4), washigherthanthemedianscoresofPCS(35. 0; IQR26. 241. 9)andMCS(58. 4; IQR54. 263. 4). Multiple linearregressionrevealedlowincome, advancedstagesofCKD, symptomburden, beingpositivefordepressionand psychologicaldistressweresignificantlyassociatedwithlowHRQOL. Conclusion: TheHRQOLoftheCKDpatientsinthisruralSriLankanpopulationwasfoundtobepoor. Superiorsocioeconomicstatus, lessphysicalandpsychologicalsymptomburdenwerefoundtobeindependentlyassociatedwithbetter HRQOL. PeriodicalscreeningoftheCKDpatientsfordepressionandpsychologicaldistressandmeasurestoalleviate symptomburdenseemtobeimportanttoimprovetheHRQOLofthesepatients. Keywords: Chronickidneydisease, Qualityoflife, SriLanka, Chronickidneydiseaseofunknownetiology Introduction describe all its facets. World Health Organization QualInterest in the concept of health related quality of life ity of Life Group (WHOQOL) in 1994 defined quality of (HRQOL) began in the early seventies and has increased life(QOL)asanindividualsperceptionoftheirposition over the last 20 years, becoming one of the central goals in life in the context of culture and value systems in of patient management. HRQOL is not a universal which they live and in relation to their goals, expectaphenomenon and there is no single definition to tions, standards and concerns 1. However, HRQOL refers to QOL in the context of disease and health. Correspondence: sam197902gmail. com Health is considered a multidimensional concept, thus, 1EpidemiologyUnit, MinistryofHealth, Colombo, SriLanka HRQOL is also multidimensional and incorporates Fulllistofauthorinformationisavailableattheendofthearticle TheAuthor(s). 2020OpenAccessThisarticleislicensedunderaCreativeCommonsAttribution4. 0InternationalLicense, whichpermitsuse, sharing, adaptation, distributionandreproductioninanymediumorformat, aslongasyougive appropriatecredittotheoriginalauthor(s)andthesource, providealinktotheCreativeCommonslicence, andindicateif changesweremade. TheimagesorotherthirdpartymaterialinthisarticleareincludedinthearticlesCreativeCommons licence, unlessindicatedotherwiseinacreditlinetothematerial. IfmaterialisnotincludedinthearticlesCreativeCommons licenceandyourintendeduseisnotpermittedbystatutoryregulationorexceedsthepermitteduse, youwillneedtoobtain permissiondirectlyfromthecopyrightholder. Toviewacopyofthislicence, visit TheCreativeCommonsPublicDomainDedicationwaiver( datamadeavailableinthisarticle, unlessotherwisestatedinacreditlinetothedata. Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page2of9 domains related to physical, mental and emotional, and 1990s 14. Though the accurate proportions of known social functioning 2. Therefore HRQOL is a subjective and unknown origin are not available, diseases of the phenomenon usually influenced by expectations, perurinary system, whichincludesCKD, istheleadingcause sonsexperienceandbeliefs3. of hospital deaths and the 5th leading cause of hospital Over the years, chronic kidney disease (CKD) has admissions in NCP 15. Research evidence indicates emerged as a major public health problem in Sri Lanka. that the CKDu affected patients are mostly young and Exact prevalence estimates of CKD are not available in belong to the low socio-economic class 16. Research Sri Lanka. Medical statistics on hospitalizations and evidence also confirm that the increase in burden of deaths in the state sector hospitals in the country do not CKD in the past two decades has crippled this commupresent data for CKD but present data on diseases of the nity leading to significant physical, psychological and urinary system. These statistics indicate that in 2017 diseconomic hardships17. eases of the urinary system was the 6th leading cause of Systematic evaluation of the HRQOL of the CKD/ hospitalization in the country accounting up to 4. 7% of CKDupatientsintheruraldistrictsofNCPhasnotbeen total hospital admissions. Diseases of the urinary system carried out to date. This study aims at assessing the diswas also the 8th leading cause of hospital deaths with a ease related quality of life and the associated factors rate of 12.
----------------------------------------------------------------------


======================================================================
CHUNK 613 of 647
======================================================================
ID: s12955_020_01369_1_1
Content Type: reference
Words: 490
Medical Entities: CKD,GFR
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
7% of CKDupatientsintheruraldistrictsofNCPhasnotbeen total hospital admissions. Diseases of the urinary system carried out to date. This study aims at assessing the diswas also the 8th leading cause of hospital deaths with a ease related quality of life and the associated factors rate of 12. 9 per 100, 000 population 4. The correspondamong CKD patients in the Anuradhapura district, a ing figure for the year 2012 was 12. 1 per 100, 000 popurural district in NCP. Evaluation of HRQOL among lation5. CKD/CKDu patients in this community can add new Chronic kidney disease is a chronic disease condition insight into the management of the disease as it allows and by its progressive and disabling nature, has a signifithe quantification of the disease consequences according cant impact on HRQOL of affected individuals 6. From to the patients perception and enables adjustment of the early stages of the disease to its end stage, disabling medical decisions to their physical, emotional, and social symptoms, various food and restrictions to social life, needs. Furthermore, understanding the extent to which fluid restrictions andassociatedstigma andtaboos, affect QOL is affected in patients with CKD, will help facilitate daily life of the patients. Furthermore, CKD affects the the implementation and evaluation of interventions mental well-being which in turn affects the HRQOL of which favorablyimpact thewellbeingofthepatients. patients. A recent study among CKD patients in Sri Lanka revealed that 75. 0% (95% CI 72. 577. 5) of particiMethods pants were psychologically distressed while 65. 2% Patientselection (95%CI 62. 468. 0) were depressed 7. World over, the A population based descriptive cross-sectional study was importance of including HRQOL indicators in the clinconducted in the district of Anuradhapura in the North ical management of CKD patients has been highlighted Central Province (NCP) of Sri Lanka. Confirmed CKD 811. Thishascometothe limelight after severalstudpatients more than 18years of age with documented eviies demonstrated the strong relationship between redence of CKD, living in the Anuradhapura district were duced HRQOL and increased morbidity and mortality included in the study. The study period was from Janu- 811. Kidney Disease Outcomes Quality Initiative (K/ ary 2016 to March 2016. Following patients were exDOQI), which is the leading organization in developing cluded from the study; patients with previous renal standards and guidelines pertaining to management of transplantation, critically ill patients and patients who CKD, advises the HRQOL to be evaluated regularly in were unable to provide rational information for any reaorder to establishbaselinefunctionandmonitorchanges son (e. g. ; mental retardation). Informed consent was oboccurring over time as well as to evaluate the effects of tained from the eligible study participants prior to data various interventions in all patients with glomerular filcollection. tration rate (GFR) below 60ml/min (stage III) 12. FurThe country is divided into 338 preventive healthcare ther, the Center for Medicare Services in United States areas, called Medical Officer of Health (MOH) areas. has made it a mandatory requisite of routine measureAnuradhapura district has 19 Medical Officer of Health mentofHRQOL ofalldialysispatients3.
----------------------------------------------------------------------


======================================================================
CHUNK 614 of 647
======================================================================
ID: s12955_020_01369_1_2
Content Type: recommendation
Words: 466
Medical Entities: CKD
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
FurThe country is divided into 338 preventive healthcare ther, the Center for Medicare Services in United States areas, called Medical Officer of Health (MOH) areas. has made it a mandatory requisite of routine measureAnuradhapura district has 19 Medical Officer of Health mentofHRQOL ofalldialysispatients3. areas and the study was conducted in all the 19 MOH Chronic kidney disease has become a major health areas. The number of patients to be included from each problem in the North Central Province (NCP) of Sri Medical Officer of Health area was based on probability Lanka during the past two decades and this is mainly proportionate to the size of CKD patients registered in due to CKD which cannot be attributed to any known each of the Medical Officer of Health area. Simple ranetiology 13. This form of CKD is usually termed dom sampling method was used to select the required Chronic Kidney Disease of uncertain etiology (CKDu). number of participants from each Medical Officer of There are records of an exponential increase in the Health area. The population based CKD register, availnumber of cases of CKDu in the NCP since the early able at the Provincial Director of Health Services, Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page3of9 records the patients with a confirmed diagnosis of CKD Assessmentofdepressionandpsychologicaldistress from renal clinics in hospitals of the NCP since 2003. Patients were screened for depression and psychological Thisregisterwas usedas thesamplingframe. distress by locally validated Sinhalese versions of the Centre for Epidemiologic StudiesDepressionScale, CESAssessmentofHRQOL D 19 and GHQ-12 20, respectively. CES-D instruHealth related quality of life was assessed using the loment has 20 items and out of the total score of 60, a cally validated Kidney Disease Quality Of Life-Short score more than 15 is indicative of depression in the Form (KDQOL-SF) version 1. 3. The instrument was local setting with a sensitivity of 84% and a specificity of confirmed as having a good construct validity and test 92%. GHQ-12 has a total possible score of 12. A cut-off re-test reliability 18. value of two or more is recommended to identify psyKDQOL-SF has two components; Kidney Disease Spechologicaldistresswith asensitivityof74%andaspecificific Component and SF-36. Of the total 81 questions in cityof71%20. 19 domains, 43 questions assess 11 kidney disease specific components of HRQOL and SF-36 questionnaire in AssessmentofsymptomburdenofCKDpatients which the 36 questions assess the general health related CKD Symptom Index Sri Lanka (CKDSI-Sri Lanka), HRQOL ineightdomains. which has been locally developed and validated, was The 11 domains of Kidney Disease Specific Compoused to assess the symptom burden. CKDSI-Sri Lanka nent are: symptom/problem list (12 items), effects of was confirmed as having an excellent construct validity kidney disease (8 items), burden of kidney disease (4 and test/re-test reliability 21. The CKDSI Sri Lanka items), cognitive function (3 items), quality of social consists of a checklist of 25 symptoms.
----------------------------------------------------------------------


======================================================================
CHUNK 615 of 647
======================================================================
ID: s12955_020_01369_1_3
Content Type: general
Words: 477
Medical Entities: CKD,dialysis
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
CKDSI-Sri Lanka nent are: symptom/problem list (12 items), effects of was confirmed as having an excellent construct validity kidney disease (8 items), burden of kidney disease (4 and test/re-test reliability 21. The CKDSI Sri Lanka items), cognitive function (3 items), quality of social consists of a checklist of 25 symptoms. Each one reinteraction (3 items), sexual function (2 items), sleep (4 quires a response of No if the patient did not experiitems), social support (2 items), work status (2 items), ence the particular symptom during the seven days prior patient satisfaction (1 item), and dialysis staff encourageto the time of inquiry and the response Yes if he/she ment (2 items). SF-36 includes 36 items that measure did experience it during that timeperiod. If the response eight domains and the eight domains are: physical funcis positive, the patient is then asked to rate the severity tion (10 items), role limitations caused by physical probof the symptom on a 5-point Likert scale. In assessing lems (4 items), role limitations caused by emotional the symptom burden, the severity rate of each symptom problems (3 items), pain (2 items), general health perof 1 to 5, was treated as a score. Those who did not exceptions (5 items), social function (2 items), emotional perience the symptom were given a score of zero. The well-being (5 items), and energy/fatigue (4 items). The symptom burdenscore for each respondent was the sum final item, the overall health rate item, asks the responofthesymptomseverityscoresforeachofthesymptoms dents to rate their health on a 010 response scale. Difincluded in the CKDSI-Sri Lanka. The possible score ferent questions have different answer options, which rangedfrom zeroto125. range from two to seven. When scoring, each question is scored in a scale ranging from 0 (worst health) to 100 AssessmentofhouseholdcostsofCKDpatients (best health). All items in a domain are summed up and Questions to assess the household cost were developed averagedtogiveanaverage score foreach domain which by reviewing literature and from inputs from CKD paranges from 0 (worst health) to 100 (best health). Three tients and caregivers. The instrument was pre-tested in summary scores; kidney disease summary component Polonnaruwa district, a rural district in NCP 22. Total (KDSC), physical component summary (PCS) and menhousehold costs for the patient were calculated by assestal component summary (MCS) are derived from the 19 sing expenditures incurred for hospital admissions, diadomain scores of KDQOL-SF, by averaging the domain lysis and clinic visits; including the cost of transport, scores in respective three summary components. Sumfood, drugs, investigations, medical equipment and exmary scores range from 0 to 100; the higher the score, penses for accompanying persons. Furthermore, expenthebetter theHRQOL. ditures on private medical consultations for treatment Potential factors associated with HRQOL were conby Western medical practitioners, Ayurvedic medical ceptualized through review of the literature. Along with practitioners or any other type of medical practitioners many other factors; socio-demographic factors, kidney andreligiousritualswerealso included.
----------------------------------------------------------------------


======================================================================
CHUNK 616 of 647
======================================================================
ID: s12955_020_01369_1_4
Content Type: reference
Words: 487
Medical Entities: CKD,GFR
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
Furthermore, expenthebetter theHRQOL. ditures on private medical consultations for treatment Potential factors associated with HRQOL were conby Western medical practitioners, Ayurvedic medical ceptualized through review of the literature. Along with practitioners or any other type of medical practitioners many other factors; socio-demographic factors, kidney andreligiousritualswerealso included. disease-related factors, psychological burden in terms of depression and psychological distress, the symptom burSurveyadministrationanddatacollection den due to CKD, and household cost to obtain health After patient enrolment, the data collector collected services; were identified as specific factors possibly assobasic demographic data from the patient and adminisciated with HRQOL and were assessed using the tered the instruments; KDQOL-SF, CES-D, GHQ-12, methodsdescribed asfollow. CKDSI-Sri Lanka. Demographic data collected were age, Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page4of9 gender, comorbidities status and employment status. analysis were included as independent variables in the Clinical, biochemical and treatment-related information multiple linear regression analysis. Normality of residwas extracted from the patients personal medical recuals was assessed using normal P-P plot while homosceord. The latest available serum creatinine value within dasticity was assessed using a scatter plot. The residuals three monthsofdata collectionwasusedtocalculate the were normally distributed and there was no evidence of eGFR of the patient. The Modification of Diet in Renal heteroscedasticity. Evidence of outliers was assessed by Disease equationwasusedforthis purpose. Cooks distance score and a score of less than one was Data collection has been done by five Public Health considered appropriate. Multi-collinearity was assessed Inspectors working in the CKD unit in the North Cenusing the Variance Inflation Factor (VIF), which should tral Province who had experience in functioning as data be less than four. The Cooks distance was 0. 026 and collectors for many local and international studies done theVIFscore waslessthan two. among CKD patients. Data collection was mostly done on weekdays considering the fact that most of the study Results units were expected to be at home, since most are Out of 1174 participants selected to be included in the employed in the informal sector. Initially the eligibility study, 95 (8. 1%) did not participate in the study giving a of the selected study participants was assessed by the response rate of 91. 9%. Of the 95 non-respondents, 69 data collectors and if found eligible they were informed (5. 9%) were not contactable even after three consecutive the purpose of the study and were invited to participate visits and 16 (1. 4%) didnt consent to participate for the in the study. Further, the voluntary nature of participastudy. Ten (0. 8%) completed less than half of the question and the opportunity to decline participation at any tionnairedue tovariousdisturbances totheinterview. time of the survey, in spite of having agreed to particiThe mean age of the study population was 58. 3years pate was emphasized to them. When the selected person (SD 10. 7). There was a preponderance of males among who lived in the house was not available at the time of the study population (63. 1%, N681).
----------------------------------------------------------------------


======================================================================
CHUNK 617 of 647
======================================================================
ID: s12955_020_01369_1_5
Content Type: reference
Words: 491
Medical Entities: CKD,dialysis,hypertension
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
3years pate was emphasized to them. When the selected person (SD 10. 7). There was a preponderance of males among who lived in the house was not available at the time of the study population (63. 1%, N681). The majority of visiting the house, additional two visits were done to the participants was in the later stages, stage 4 or beyond, of house at times that he/she was expected to be available. CKD (n820; 75. 9%). The 38 participants (3. 5%), with In cases where the selected study unit could not be constage 5 of the disease and were undergoing dialysis, were tacted even after three visits, the study unit was considon haemodialysis (Table 1). Chronic Kidney Disease of eredasanon-respondent. Unknown origin was the cause for the CKD in most of In instances where the selected study unit was found the study population (n471; 43. 7%). The second most to be deceased or not eligible to be included in the common was hypertension (n347; n32. 2%). The study, the principal investigator conducted the process symptom burden score was assessed using CKDSI-Sri of random sampling described above and selected anLanka instrument and the median symptom burden otherstudyunittobeincluded. score was 35. 0 (IQR 20. 049. 0) while the mean score was35. 8(SD20. 0). Themediantotalmonthlyhousehold Statisticalanalysis income for the total study population was Rs. 4000 (IQR Statistical analysis was done by using SPSS version 20. 0. 30007000), and the mean income was 6755. 9 (SD The summary component scores of KDQOL-SF was 7492). non-normally distributed indicating a skewed distribuIn the KDSC, symptom/problem domain (72. 7; IQR tion. Thus non-parametric tests were used in the bivari58. 381. 8), effects of kidney disease (75. 0; IQR 59. 3 ate analysis (Mann-Whitney U test and Spearmans r 87. 5) and hospital staff encouragement (75. 0; IQR 75. 0 correlation) when determining the association between 75. 0) domains had median scores above 70. 0 while the kidney, physical and mental summary components and burden of kidney disease had the lowest median score some selected factors. A p value of less than 0. 05 was (31. 2; IQR 25. 043. 7). Median scores of all the four doconsidered statistically significant. The following varimainsin the PCS had the scores below 50. 0. Thehighest ables were analyzed with the each of the summary commedian score was for the pain domain (42. 5; IQR 20. 0 ponents; age, gender, education level, income status, 50. 0) while the lowest was for the role-physical (0. 0; IQR employment status, the presence of comorbidities, CKD 22. 545. 0). Except the domain role-emotion (0. 0; IQR stage, symptom burden, presence of depression and Psy25. 062. 5), all the other domains in the MCS, had their chological distress. In order to explore how each socio medianscores 50. 0orclose to50. 0(Table2). demographic, as well as disease related characteristics, Kidney Disease Summary Component score (KDSC) influence the HRQOL when the effects of other factors (58. 4; IQR 54. 263.
----------------------------------------------------------------------


======================================================================
CHUNK 618 of 647
======================================================================
ID: s12955_020_01369_1_6
Content Type: reference
Words: 494
Medical Entities: CKD,dialysis
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
In order to explore how each socio medianscores 50. 0orclose to50. 0(Table2). demographic, as well as disease related characteristics, Kidney Disease Summary Component score (KDSC) influence the HRQOL when the effects of other factors (58. 4; IQR 54. 263. 4), was higher than the summary are controlled, multiple linear regression analysis was scores of Physical Component Summary Score (PCS) performed. Only the variables which had probability (35. 0; IQR 26. 241. 9) and Mental Component Summary value of less than 0. 2 in the univatiate linear regression Score (MCS) (58. 4; IQR 54. 263. 4) (Table 3). Both Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page5of9 Table1SocioDemographiccharacteristics higher scores of both KDSC (1. 394) and PCS ( Feature Frequency(N1079) Percentage 1. 966). Advanced stages of CKD, being positive for depression and being positive for psychological distress Agecategories were significantly associated with low HRQOL in all the 1840 50 4. 6 three summary componentscores(Table 5). 4160 558 51. 7 60 471 43. 7 Discussion Gender In the present study, the HRQOL of the study populaMale 681 63. 1 tion was assessed using a locally validated KDQOL SFTM. This is the first study in Sri Lanka which assessed Female 398 36. 9 the HRQOL of a community severely crippled by CKDu, CKDstage and revealed that HRQOL among these population was Earlystages 259 24. 0 severelycompromised. StageIV 629 58. 3 The KDQOL-SF is a popular tool that has been used StageV 153 14. 2 to assess HRQOL among CKD patients by researchers Dialysis 38 3. 5 the world over 9, 23. The KDSC, PCS and MCS in the present study were 58. 7 (SD 7. 7), 35. 5 (SD 15. 0) and Comorbidities 39. 6 (SD 12. 3) respectively, indicating that the HRQOL Negative 308 28. 5 of these CKD patients in the rural community of AnuraPositive 771 71. 5 dhapura is poor. According to Mujais et al. (2009) who Employmentstatus assessed the HRQOL of CKD patients in North America Notemployed 701 65. 0 the mean KDSC, PCS and MCS scores were 74. 6 (SD Employed 378 35. 0 13. 6), 39. 5 (10. 6) and 49. 8 (10. 4) respectively. Except the KDSC, the scores of PCS and MC in the above study Depression wasalmostsimilartothefindingsofourstudyindicating Negative 375 34. 8 that the HRQOL of CKD patients is compromised even Positive 704 65. 2 in superior socio-economic and health contexts. This Psychologicaldistress was further reiterate by the findings of Yusop et al. Negative 267 24. 7 (2013) 23. He assessed HRQOL of the CKD patients in Positive 812 75. 3 Malaysia and the PCS (39. 6; SD 8. 6) and the MCS (45. 0; SD8. 6)werealmost similartoourfindings. KDSC (r 0. 066) and PCS (r 0. 082) scores showed Over the last few decades HRQOL strategies were a slight, but statistically significant, negative correlation mainly focusing on cancer patients, but studies have with the age. Even though strength of association was shown that patients with other life threatening condislight (r 0.
----------------------------------------------------------------------


======================================================================
CHUNK 619 of 647
======================================================================
ID: s12955_020_01369_1_7
Content Type: reference
Words: 500
Medical Entities: CKD
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
066) and PCS (r 0. 082) scores showed Over the last few decades HRQOL strategies were a slight, but statistically significant, negative correlation mainly focusing on cancer patients, but studies have with the age. Even though strength of association was shown that patients with other life threatening condislight (r 0. 086), KDSC and MCS scores had significant tions also experience a similar degree of effect to (p0. 05) positive correlation with the education status. HRQOL 24. Evidence indicate that both physical and The income was significantly positively correlated with mental distress experienced by patients dying from renal all three summary components while the CKD stage was failure, could be more distressing than cancer 25. significantly negatively correlated with the same. Both Chronic kidney disease patients suffer from both physmales and females had the median scores equal (p ical and psychological symptoms which may emerge at 0. 05) in all the three summary scores. Currently being different stages during the course of the disease 26. employed, screening positive for both depression and Jang et al. (2019) assessed the HRQOL of patients with psychological distress were significantly (p0. 001) assosevere chronic obstructive pulmonary disease (COPD) ciated with low HRQOL in all the summary scores using SF 36 study instrument and the PCS and MCS (Table 4). were 56. 7 and 69. 5 indicating that the HRQOL of CKD In order to explore how each socio demographic, as patients is much worse compared to COPD 27. Simiwell as disease related characteristics, influenced the larly two international studies done to assess the HRQOL of CKD when the effects of other factors are HRQOL of stroke 28 and chronic heart failure 29 recontrolled, multiple linear regression analysis was pervealed that the stroke patients had relatively low formed. Age and sex were not significant predictors of HRQOL and chronic heart failure patients had a similar either KDSC, PCS or MCS (p 0. 05). Education level HRQOL when compared to the results of our study parwas a significant predictor (p 0. 05) of higher scores of ticipants. Mahesh et al. , (2017) conducted three separate both KDSC (0. 535) and MCS (0. 870), while the studies to assess the HRQOL of stroke 28, myocardial being employed was a significantly associated with infarction 30 and COPD 31 patients in Sri Lanka Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page6of9 Table2DistributionoftheQOLDomainScoresoftheStudyPopulationasMeasuredByKDQOLSF Domains Median IQR Mean SD Range KidneyDiseaseSpecificComponent Symptom/problemdomain 72. 7 58. 381. 8 69. 0 18. 0 2. 1100. 0 Effectsofkidneydisease 75. 0 59. 387. 5 73. 5 19. 0 6. 2100. 0 Burdenofkidneydisease 31. 2 25. 043. 7 36. 8 16. 1 0. 0100. 0 Workstatus 50. 0 50. 050. 0 50. 5 10. 4 0. 0100. 0 Cognitivefunction 66. 6 53. 380. 0 65. 5 17. 1 0. 0100. 0 Qualityofsocialinteraction 60. 0 53. 360. 0 57. 9 11. 8 0. 0100. 0 Sexualfunction(n625) 50. 0 25. 0100. 0 53. 4 36. 7 0. 0100. 0 Sleep 52. 5 40. 062. 5 52. 6 15. 8 10. 097.
----------------------------------------------------------------------


======================================================================
CHUNK 620 of 647
======================================================================
ID: s12955_020_01369_1_8
Content Type: reference
Words: 498
Medical Entities: CKD
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
6 53. 380. 0 65. 5 17. 1 0. 0100. 0 Qualityofsocialinteraction 60. 0 53. 360. 0 57. 9 11. 8 0. 0100. 0 Sexualfunction(n625) 50. 0 25. 0100. 0 53. 4 36. 7 0. 0100. 0 Sleep 52. 5 40. 062. 5 52. 6 15. 8 10. 097. 5 Socialsupport 66. 6 33. 3100. 0 66. 1 25. 9 0. 0100. 0 Hospitalstaffencouragement 75. 0 75. 075. 0 71. 6 14. 2 25. 0100. 0 Patientsatisfaction 50. 0 50. 050. 0 47. 4 11. 3 16. 783. 3 OverallHealth 50. 0 40. 060. 0 50. 8 17. 2 0. 0100. 0 PhysicalComponentDomains Physicalfunctioning 40. 0 0. 050. 0 41. 3 24. 0 0. 0100. 0 Rolephysical 0. 0 22. 545. 0 25. 7 42. 3 0. 0100. 0 Pain 42. 5 20. 050. 0 36. 2 17. 0 0. 0100. 0 Generalhealth 30. 0 44. 052. 0 37. 6 19. 6 5. 090. 0 MentalComponentDomains Emotionalwell-being 48. 0 0. 033. 3 48. 1 9. 7 8. 084. 0 Roleemotional 0. 0 25. 062. 5 23. 1 32. 8 0. 0100. 0 Socialfunction 50. 0 40. 050. 0 42. 1 22. 4 0. 0100. 0 Energy/fatigue 50. 0 25. 075. 0 44. 8 12. 2 0. 085. 0 ChangeinHealth 50. 0 25. 075. 0 52. 10 29. 9 0. 0100. 0 using SF 36. All eight domain scores of PCS and MCS In the present study the KDSC was significantly higher among myocardial infarction patients were superior to compared to the PCS and MCS. A similar finding was the respective domain scores in our study. Furthermore, evident in the multi country study done by Mujais et al. , among COPD patients, except the general health, phys- (2009), where the relatively higher scores were obtained ical functioning, energy/fatigue and emotional wellfor the domains of the Kidney Disease Specific Compobeing, the other four domains had superior domain nent 9. It could be due to the fact that the scores of scores compared to CKD. Compared to the CKD pathe disease specific component of the study tool is only tients, general health, physical functioning, emotional sensitive to the severity of the disease, whereas the genwell-being and social functioning domain scores were eric component scores of the study tool (physical and low among the stroke patients. This indicate that commental component) are sensitive not only to the severity pared to the three conditions studied by Mahesh et al. , of the disease but also to multiple other socio-economic stroke, COPD and myocardial infarction, CKD patients factors, which are unfavorable for the CKD patients in a had poor HRQOL in relations to pain and physical and rural community with a poor socio-economical backemotionalrolelimitations. groundsuch astheAnuradhapura district. Table3CorrelationbetweenQOLdomainscoresandsomeselectedfactors Domain Mean(SD) Median IQR Ageb Educationlevelb Incomeb CKDstageb Symptomburdenb KidneyDiseaseSummaryComponent 58. 7(7. 7) 58. 4 54. 263. 4 0. 066a 0. 086a 0. 180a 0. 122a 0. 066a PhysicalComponentSummaryScore 35. 5(15. 0) 35. 0 26. 241. 9 0. 082a 0. 052 0. 152a 0. 327a 0.
----------------------------------------------------------------------


======================================================================
CHUNK 621 of 647
======================================================================
ID: s12955_020_01369_1_9
Content Type: recommendation
Words: 492
Medical Entities: CKD,GFR
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
06a 0. 02to0. 10 NA aSignificantatthe0. 05level NAThevariableisnotsignificantintheunivariatelinearregression, thusnotincludedinthemultiplelinearregression Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page8of9 It was surprising to note that in the present study, the Secondly, some of the information related to HRQOL is gender of the patients was not a significantly predictor consideredtobesensitiveinnature andthefact thatthis of HRQOL. This was contrary to the findings of Mujais information was obtained utilizing an intervieweret al. (2009) where female gender was a significant preadministered questionnaire could have led to some dictor of low HRQOL 9. Unemployment due to the under-reporting in the assessment of HRQOL, though disease, difficulty in engaging in the current occupation many measures were taken to minimize this issue. Fiand inability to perform the role expected from society, nally, The CKD stage in this study was calculated using is more common among males in the local setting, secondary data. Biochemical assessment of study units which could lead to poor HRQOL among male CKD pawasnot economicallyfeasibleinthe study. tients inthestudysetting. Higher education level, being employed and higher inConclusion come were significant independent predictors of higher The HRQOL of the CKD patients in this rural Sri Lansummarycomponentscores. Thisindicatethatingeneral, kan population was found to be poor. Higher education the improvement of socio-economic and educational asstatus and being employed were important predictors of pects is associated with better quality of life among these higher HRQOL, while advanced stages of CKD, being patients. Further, socialacceptance, beingable toperform positive for depression and being positive for psychosocial responsibilities and self-esteem which are directly logical distress were significantly associated with low linked to the employment status, income and education HRQOL. The study recommends numerous measures to status of an individual 32, 33 and they also could have improve the HRQOL of these patients. Periodical contributed to the superior HRQOL of patients with this screening of the CKD patients for depression and psysubsetofthestudypopulation. chological distress and measures to alleviate symptom CKD stage was a significant independent predictor of burden seem to be important and practical aspects scores in all three summaryscores, but the magnitude of which can be implemented to improve the overall qualassociation was much higher in PCS and MCS, comityoflifeofthesepatients. pared to the association between CKD stage and KDSC. One would expect the KDSC, which assess the kidney Supplementary information disease specific HRQL, to show the highest association Supplementaryinformationaccompaniesthispaperat with CKD stage compared to others as reported in sev1186/s12955-020-01369-1. eral studies internationally 9, 34. However, a similar finding to the current study has been observed in the Additionalfile1. SupplementarymaterialNumberofCKDpatients selectedfromeachMOHareaforthestudy. study conducted by Perlman et al. , (2005) and the authors have ascribed the results to the narrow range of glomerular filtration rate (GFR) in their study 35, Abbreviations CES-D: CenterforEpidemiologicalStudiesDepressionscale; CKD: Chronic which couldbethereason inthecurrentstudyaswell. KidneyDisease; CKDSI-SriLanka: ChronicKidneyDiseaseSymptomIndex The results indicate that the symptom burden signifiSriLanka; COPD: ChronicObstructivePulmonaryDisease; GFR: Glomerular cantly affects the HRQOL related to the physical and FiltrationRate; GHQ-12: GeneralHealthQuestionnaire12; HRQOL: Health RelatedQualityofLife; IQR: InterQuartileRange; KDQOL-SF: KidneyDisease mental health status in CKD patients (PCS and MCS).
----------------------------------------------------------------------


======================================================================
CHUNK 622 of 647
======================================================================
ID: s12955_020_01369_1_10
Content Type: definition
Words: 500
Medical Entities: CKD,GFR
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
KidneyDisease; CKDSI-SriLanka: ChronicKidneyDiseaseSymptomIndex The results indicate that the symptom burden signifiSriLanka; COPD: ChronicObstructivePulmonaryDisease; GFR: Glomerular cantly affects the HRQOL related to the physical and FiltrationRate; GHQ-12: GeneralHealthQuestionnaire12; HRQOL: Health RelatedQualityofLife; IQR: InterQuartileRange; KDQOL-SF: KidneyDisease mental health status in CKD patients (PCS and MCS). QualityofLifeShortForm; KDSC: KidneyDiseaseSummaryComponent; This picture was further reinforced by the fact that deMCS: MentalComponentSummary; MOH: MedicalOfficerofHealth; pressed and psychologically distressed patients had sigNCP: NorthCentralProvince; PCS: PhysicalComponentSummary; SD: StandardDeviation; WHOQOL: WorldHealthOrganizationQualityofLife nificantly low HRQOL scores in all three summary Group scores. This finding has been reiterated in the global literature as well. Symptom burden 36 and mental health Acknowledgements status 37 were stated as key determinants of HRQOL AuthorsacknowledgePalithaBandaraandAsangaRanasinghe, forthe supportrenderedduringthestudy. ThestudywasfundedbytheMinistryof of CKD patients. This highlights an important finding of Health, SriLanka. clinical importance, that is if the service providers to improve the HRQOL of patients, not only physical sympAuthorscontributions tom alleviating measures but also measures to improve SS1, NG, PP, SK: Researchidea, studydesign. SS1, NG, SK, SS2, RK, PK: statistical analysisanddraftingofthemanuscript. SS1, NG, PP, SK, SS2, RK, PK: data the mental health status of patients should also be analysis/interpretation. Theauthorsreadandapprovedthefinalmanuscript. considered. Our study has some limitations. Firstly, the HRQOL Funding assessment did not employ a control group due to feasiThisstudywasfundedbytheMinistryofSriLanka. bility and logistic constraints. Inclusion of a control Availabilityofdataandmaterials group could have enabled comparison between the two Thedatasetsusedand/oranalysedduringthecurrentstudyareavailable groups to produce more meaningful interpretation. fromthecorrespondingauthoronreasonablerequest. Senanayakeetal. HealthandQualityofLifeOutcomes (2020) 18: 106 Page9of9 Ethicsapprovalandconsenttoparticipate 19. DeSilvaV, EkanayakeS, HanwellaR. ValidityoftheSinhalaversionofthe ThestudyisinaccordancewithHelsinkiDeclaration. Thestudyprotocolhas CentreforEpidemiologicalStudiesDepressionScale(CES-D)inout-patients. beenapprovedbytheEthicsCommitteeofColomboMedicalFaculty(ECCeylonMedJ. 2014; 59: 1. 15-081). Participantsgavetheirinformedconsent. 20. AbeysenaH, JayawardanaP, PeirisU, RodrigoA. ValidationoftheSinhala versionofthe12-itemgeneralhealthquestionnaire. JPostgradInstMed. Consentforpublication 2014; 1: 1. Notapplicable. 21. SenanayakeS, GunawardenaN, PalihawadanaP. Developmentofthechronic kidneydiseasesymptomindexSriLanka; asymptomassessmentinstrument forchronickidneydiseasepatients. JPostgradInstMed. 2017; 4: 1. Competinginterests 22. DepartmentofCensusandStatistics. CensusofpopulationandhousingTheauthorsdeclarethattheyhavenocompetinginterests. 2012(northCentralProvince): DepartmentofCensusandStatistics; 2016. Availablefrom: Authordetails 1EpidemiologyUnit, MinistryofHealth, Colombo, SriLanka. 2WorldHealth Activities/Reports/NCP. pdf. Organization, Colombo, SriLanka. 3AustralianCentreforHealthService 23. YusopNBM, MunCY, ShariffZM, HuatCB. Factorsassociatedwithqualityof Innovation, QueenslandUniversityofTechnology, Brisbane, Australia. 4North lifeamonghemodialysispatientsinMalaysia. PLoSOne. 2013; 8(12): e84152. 24. SeplvedaC, MarlinA, YoshidaT, UllrichA. Palliativecare: theWorldHealth CentralProvincialDirectorsOffice, Anuradhapura, SriLanka. Organizationsglobalperspective. JPainSymptomManag. 2002; 24(2): 916. 25. SolanoJP, GomesB, HigginsonIJ. Acomparisonofsymptomprevalencein Received: 18April2019Accepted: 16April2020 faradvancedcancer, AIDS, heartdisease, chronicobstructivepulmonary diseaseandrenaldisease. JPainSymptomManag. 2006; 31(1): 5869. 26. LeeSJ, JeonJ. Relationshipbetweensymptomclustersandqualityoflifein References patientsatstages2to4chronickidneydiseaseinKorea. ApplNursRes. 1. GroupW. TheWorldHealthOrganizationqualityoflifeassessment 2015; 28(4): e13e9. (WHOQOL): positionpaperfromtheWorldHealthOrganization. SocSci 27. JangSM, KimKU, NaHJ, SongSE, LeeSH, LeeH, etal. Depressionisamajor Med. 1995; 41(10): 14039. determinantofbothdisease-specificandgenerichealth-relatedqualityof 2. FerransCE. Definitionsandconceptualmodelsofqualityoflife. Outcomes lifeinpeoplewithsevereCOPD. ChronicRespirDis. 2019; 16: AssessCancer. 2005; 9: 1430. 1479972318775422. 3. OshaughnessyDV, ElderGJ. Patient-leveloutcomes: themissinglink. 28. MaheshP, GunathungaM, JayasingheS, ArnoldS, LiyanageS. Factors Nephrology. 2009; 14(4): 44351. influencingpre-strokeandpost-strokequalityoflifeamongstrokesurvivors 4. MedicalStatisticsUnit. Annualhealthbulletin: medicalstatisticsunit, inalowermiddle-incomecountry. NeurolSci. 2018; 39(2): 28795. MinistryofSriLank; 2017. Availablefrom: 29. MommersteegPM, KupperN, SchoormansD, EmonsW, PedersenSS. final/english/public/elfinder/files/publications/AHB/2017/AHS2017. pdf. Health-relatedqualityoflifeisrelatedtocytokinelevelsat12monthsin 5. MedicalStatisticsUnit. Annualhealthbulletin: medicalstatisticsunit, patientswithchronicheartfailure. BrainBehavImmun. 2010; 24(4): 61522. MinistryofSriLank; 2012. Availablefrom: 30. MaheshP, GunathungaM, JayasingheS, ArnoldS, HaniffaR, DeSilvaA. Prefinal/english/public/elfinder/files/publications/AHB/Annual%20Health%2 eventqualityoflifeanditsinfluenceonthepost-eventqualityoflife 0Bulletin%20-%202012. pdf. amongpatientswithSTelevationandnon-STelevationmyocardial 6. SenanayakeS. ChronickidneydiseaseinSriLanka: aglimpseintolivesof infarctionsofapremierprovinceofSriLanka. HealthQualLifeOutcomes. theaffected. JCollCommunityPhysiciansSriLanka. 2018; 24: 2. 2017; 15(1): 154. 7. SenanayakeS, GunawardenaN, PalihawadanaP, SuraweeraC, Karunarathna 31. MaheshP, GunathungaW, JayasingheS, ArnoldM, CroosV, DeSilvaS. R, KumaraP. Depressionandpsychologicaldistressinpatientswithchronic QualityoflifeanditsassociatedfactorsamongpatientswithCOPDbefore renalfailure: prevalenceandassociatedfactorsinaruraldistrictinSriLanka. andafteranexacerbationinSriLanka; 2018. JPsychosomRes. 2018; 112: 2531. 32. FrankhamC, RichardsonT, MaguireN. Psychologicalfactorsassociatedwith 8. RebolloP, GonzlezM, BobesJ, SaizP, OrtegaF. Interpretationofhealthfinancialhardshipandmentalhealth: asystematicreview.
----------------------------------------------------------------------


======================================================================
CHUNK 623 of 647
======================================================================
ID: s12955_020_01369_1_11
Content Type: evidence
Words: 240
Section: ChronickidneydiseaseinSriLanka:
Medical Entities: CKD
Source: s12955-020-01369-1.pdf

----------------------------------------------------------------------
ChronickidneydiseaseinSriLanka: aglimpseintolivesof infarctionsofapremierprovinceofSriLanka. HealthQualLifeOutcomes. theaffected. JCollCommunityPhysiciansSriLanka. 2018; 24: 2. 2017; 15(1): 154. 7. SenanayakeS, GunawardenaN, PalihawadanaP, SuraweeraC, Karunarathna 31. MaheshP, GunathungaW, JayasingheS, ArnoldM, CroosV, DeSilvaS. R, KumaraP. Depressionandpsychologicaldistressinpatientswithchronic QualityoflifeanditsassociatedfactorsamongpatientswithCOPDbefore renalfailure: prevalenceandassociatedfactorsinaruraldistrictinSriLanka. andafteranexacerbationinSriLanka; 2018. JPsychosomRes. 2018; 112: 2531. 32. FrankhamC, RichardsonT, MaguireN. Psychologicalfactorsassociatedwith 8. RebolloP, GonzlezM, BobesJ, SaizP, OrtegaF. Interpretationofhealthfinancialhardshipandmentalhealth: asystematicreview. ClinPsycholRev. relatedqualityoflifeofpatientsonreplacementtherapyinend-stagerenal 2020; 101832: 1. disease. Nefrologia. 2000; 20(5): 4319. 33. SoeltonM, AmaliaD, NoermijatiN, WahyudionoB. Self-esteem: thelevelsof 9. MujaisSK, StoryK, BrouilletteJ, TakanoT, SorokaS, FranekC, etal. Healthreligiosityinjobinsecurityandstressingovernmentcompany. In: 4th relatedqualityoflifeinCKDpatients: correlatesandevolutionovertime. internationalconferenceonmanagement, economicsandbusiness(ICMEB ClinJAmSocNephrol. 2009; 4(8): 1293301. 2019). Jakarta: AtlantisPress; 2020. 10. TsaiY-C, HungC-C, HwangS-J, WangS-L, HsiaoS-M, LinM-Y, etal. Quality 34. RoccoMV, GassmanJJ, WangS-R, KaplanRM. Cross-sectionalstudyofquality oflifepredictsrisksofend-stagerenaldiseaseandmortalityinpatientswith oflifeandsymptomsinchronicrenaldiseasepatients: themodificationofdiet chronickidneydisease. NephrolDialTransplant. 2009; 25(5): 16216. inrenaldiseasestudy. AmJKidneyDis. 1997; 29(6): 88896. 11. DeOreoPB. Hemodialysispatient-assessedfunctionalhealthstatuspredicts 35. PerlmanRL, FinkelsteinFO, LiuL, RoysE, KiserM, EiseleG, etal. Qualityof continuedsurvival, hospitalization, anddialysis-attendancecompliance. Am lifeinchronickidneydisease(CKD): across-sectionalanalysisintherenal JKidneyDis. 1997; 30(2): 20412. researchinstitute-CKDstudy. AmJKidneyDis. 2005; 45(4): 65866. 12. LeveyAS, CoreshJ, BoltonK, CulletonB, HarveyKS, IkizlerTA, etal. K/DOQI 36. WeisbordSD. Symptomsandtheircorrelatesinchronickidneydisease. Adv clinicalpracticeguidelinesforchronickidneydisease: evaluation, ChronicKidneyDis. 2007; 14(4): 31927. classification, andstratification. AmJKidneyDis. 2002; 39(2SUPPL): 1. 37. KutnerNG. Promotingfunctioningandwell-beinginolderCKDpatients: 13. WanigasuriyaK. Aetiologicalfactorsofchronickidneydiseaseinthenorth reviewofrecentevidence. IntUrolNephrol. 2008; 40(4): 1151. CentralProvinceofSriLanka: areviewofevidenceto-date; 2012. 14. JayasekaraJ, DissanayakeD, AdhikariS, BandaraP. Geographicaldistribution Publishers Note ofchronickidneydiseaseofunknownorigininnorthcentralregionofSri Lanka. CeylonMedJ. 2013; 58(1): 610. SpringerNatureremainsneutralwithregardtojurisdictionalclaimsin 15. MedicalStatisticsUnit. Annualhealthbulletin-2016. Colombo: Medical publishedmapsandinstitutionalaffiliations. statisticsunit, MinistryofSriLanka; 2016. 16. AthuraliyaT, AbeysekeraD, AmerasinghePH, KumarasiriP, DissanayakeV. Prevalenceofchronickidneydiseaseintwotertiarycarehospitals: high proportionofcaseswithuncertainaetiology. CeylonMedJ. 2009; 54: 1. 17. JayasingheS. ChronickidneydiseaseinruralareasofSriLanka: anevolving catastropheneedinganurgentresponse; 2014. 18. SenanayakeS, GunawardenaN, PalihawadanaP, KularatnaS, PeirisT. Validity andreliabilityoftheSriLankanversionofthekidneydiseasequalityoflife questionnaire(KDQOL-SF). HealthQualLifeOutcomes. 2017; 15(1): 119.
----------------------------------------------------------------------


======================================================================
CHUNK 624 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_0
Content Type: evidence
Words: 482
Medical Entities: GFR
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
Screening Guidelines Chronic Kidney Disease Sri Lanka 2017 Epidemiology Unit Ministry of Health Screening Guidelines Chronic Kidney Disease Sri Lanka ii These guidelines were developed based on the best available evidence at the time of writing. It is expected to be used in screening for Chronic Kidney Disease. The guidelines will be reviewed when new evidences become available Please forward your comments and suggestions to the following address or e-mail The Chief Epidemiologist Epidemiology Unit 231 De Saram Place Colombo 10 E-mail: chepidsltnet. lk iii Contents Message from the Director General of Health Services v Message from the Chief Epidemiologist vi Introduction 1 Surveillance on Chronic Kidney Disease in Sri Lanka 2 Objectives of the Screening Programme 3 Methodology 4 Screening Method 4 High risk geographic areas 4 Primary Target Group 4 Exclusion Criteria 5 Screening Settings 5 Screening Tool 5 Administration of Screening Tool 5 Collecting and Dispatching Urine Samples 6 Testing for serum Creatinine and calculating eGFR 7 Quality Assurance of laboratory tests 7 Cutoff Values for Blood Pressure and Laboratory Investigations 9 Interpretation of Results 9 Referral Procedure for Persons with Abnormal Test Results 10 Responsibilities 10 Field Screening Clinics 11 Human Resources 12 Implementation Plan 12 Monitoring and Evaluation 13 District level Indicator and targets 14 Data Analysis and dissemination of information 15 iv Message from the Director General of Health Services Surveillance of Chronic Kidney Disease carried out by the Epidemiology Unit is a challenging yet successful endeavour. As a result of the surveillance progamme, the Ministry of Health possesses statistics on patients with the Chronic Kidney Disease. The active surveillance by means of screening asymptomatic people living in the high risk areas for Chronic Kidney Disease of Uncertain aetiology has enabled detection of more cases compared to previous years. I appreciate the deliberations made by the Epidemiology Unit to revise the screening guidelines keeping abreast with the current evidence based practices. I believe that the screening guidelines will be extensively used by the health care works in the field in indemnifying suspected cases. I congratulate the Epidemiology Unit and the panel of experts for accomplishing the task of revising the screening guidelines Dr. P. G. Mahipala Director General of Health Services v Message from the Chief Epidemiologist Screening of inhabitants in high risk areas where Chronic Kidney Disease of Uncertain aetiology is an integral part of the surveillance programme conducted by the Epidemiology Unit. First screening guidelines for community screening was set in 2014 in order to streamline and standardize the ongoing screening programmes. Based on scientific evidence, experts have suggested some changes to the previously set guidelines. Considering evolving science and feasibility at the ground level, revisions were made. I sincerely feel that the revised guidelines will serve as a comprehensive guide for those engaged in the screening programme. I take this opportunity extent my gratitude to those who have contributed their expertise without hesitation.
----------------------------------------------------------------------


======================================================================
CHUNK 625 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_1
Content Type: recommendation
Words: 490
Medical Entities: CKD
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
Considering evolving science and feasibility at the ground level, revisions were made. I sincerely feel that the revised guidelines will serve as a comprehensive guide for those engaged in the screening programme. I take this opportunity extent my gratitude to those who have contributed their expertise without hesitation. Dr. Paba Palihawadana Chief Epidemiologist vi List of Contributors for the first edition Dr. Sarath Amunugama Deputy Director General (PHS) I Dr. Paba Palihawadana Chief Epidemiologist Dr. Thilak Abesekara Senior Consultant Nephrologist Dr. Meliyanthi M. Gunatillaka Consultant Chemical Pathologist Dr. NishanthaNanayakkara Consultant Nephrologist Dr. A. W. M. Wazil Consultant Nephrologist Dr. Rajeewa Dassanayake Consultant Nephrologist Dr. Nalaka Herath Consultant Nephrologist Dr Keerthi Bandara Consultant Nephrologist Dr. Zied Badurdeen Temporary Lecturer CKD Research Coordinator, Faculty of Medicine, University of Peradeniya. Dr. Shamitha Dassanayake Acting Physician Dr. Chamly Premajayantha Medical Officer Dr. Kheminda Thilakarathne Consultant Physician Dr. Asanga Ranasinghe Medical Officer In-Charge Provincial Renal Disease Prevention Research Unit vii Contributors for the second edition Dr. Paba Palihawadana Chief Epidemiologist Dr. Rathnasiri Hewage Director, NINDT Dr. S Maathu Consultant Nephrologist Dr. Chinthana Galahitiyawa Consultant Nephrologist Dr. Eranga Wijewikkrama Consultant Nephrologist Dr. Anupama De Silva Consultant Nephrologist Dr. Dharshi Anuruddhika Consultant Nephrologist Dr. Gaya W Katulanda Consultant in Chemical Pathology Dr. H. T. N. Hewageegana Consultant Chemical Pathologist Dr. S Dassanayake Consultant Physician Dr. Zied Badurdeem Temporary Lecture in Pharmacology Dr. Chamly Premajayantha Medical Officer viii Introduction During the recent past, high prevalence of Chronic Kidney Disease was observed in some geographic areas of Sri Lanka. Especially the North Central Province (NCP) was noted as an endemic area for CKD. Some areas outside the NCP, but geographically adjacent, were later on detected to have similarly high prevalence of CKD. Unfortunately, a fair proportion of CKD cases were not attributable to known aetiological factors. This scenario has led to coining a term Chronic Kidney Disease of Uncertain aetiology (CKDu). The unknown aetiology has hampered implementation of effective preventive measures over the years. At present, scientific data are available on the high endemicity of CKD in these areas. The World Health Organization (WHO) report on Kidney Disease of Uncertain Aetiology (CKDu) in Sri Lanka says that the age standardized prevalence of CKDu among females in the age group of 15 to 70 years of age is 16. 9% and that of males in the same age category is 12. 9%. In January 2014, the Standing Cabinet Appointed Officials Committee for the Mitigation of CKDu in the North Central Province has recommended to establish a criterion for diagnosing CKDu patients and to plan a systematic Screening Programme for early diagnosis. It has further recommended mapping the cases of CKD/CKDu considering the Grama Niladhari (GN) divisions as the base for mapping. The Screening Programme for CKD/CKDu is intended to detect asymptomatic individuals in the early stages of CKD. The screening programme will serve as a comprehensive and active epidemiological surveillance with provisions for mapping and analyzing attributes and possible aetiologies.
----------------------------------------------------------------------


======================================================================
CHUNK 626 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_2
Content Type: evidence
Words: 499
Medical Entities: CKD
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
The Screening Programme for CKD/CKDu is intended to detect asymptomatic individuals in the early stages of CKD. The screening programme will serve as a comprehensive and active epidemiological surveillance with provisions for mapping and analyzing attributes and possible aetiologies. 1 Surveillance on Chronic Kidney Disease in Sri Lanka The Epidemiology Unit of the Ministry of Health, Sri Lanka has established surveillance on chronic kidney disease since October 2013. Thirty hospitals were declared as sentinel sites initially with further expansion now the total number is 50. The rationale of selecting the hospitals as sentinel sites was the available statistics on the disease burden and the media reports and public concerns of the presence of the disease in geographic locations. Based on the hospital statistics and the statistics at the renal research unit, the Polonnaruwa and Anuradhapura districts and geographically adjacent areas namely, Dehiattakandiya, Girandurukotte, Welioya, Polpithigama, Padavi Sripura, Wilgamuwa and Vavuniya South Divisional Secretariat divisions were proclaimed as high risk areas. The hospitals catering to the populations in the proclaimed areas were selected as sentinel sites. Another set of hospitals were selected on the basis of patients referral mechanisms, resource availability including availability of specialists services, having renal clinics. In Addition, some institutions were selected considering the potentials of having the disease, anecdotal reports on the presence of disease and public concerns on the presence of the disease. As surveillance continues, the list of sentinel sites could be evolved based on the evidence generated. 2 1. DH Padawiya 26. DH Kahatagasdigiliya 2. DH Madawachchiya 27. DH Thanamalwila 3. BH Kabithigollawa 28. DH Buttala 4. BH Thambuththegama 29. GH Mannar 5. DH Kakirawa 30. DH Sampathnuwara 6. BH Madirigiriya 31. NHSL 7. DH Hingurakgoda 32. NINDT 8. DH Elahara 33. TH Karapitiya 9. DH Welikanda 34. GH Sri Jayewardenepura 10. DH Aralaganwila 35. TH Kalubowila 11. DH Nikawawa 36. DH Rambewa 12. DH PadawiSripura 37. DH Polpithigama 13. DH Giradurukotte 38. BH Nikaweratiya 14. BH Mahiyangana 39. BH Dambulla 15. DH Galenbidunuwawa 40. DH Gomarankadawala 16. TH Anuradapura 41. DH Badulla 17. GH Polonnaruwa 42. BH Wellawaya 18. TH Kandy 43 BH Cheddikulam 19. GH Vavuniya 44. BH Mallavi 20. BH Dehiattakandiya 45 DH Mamaduwa 21. TH Jaffna 46. BH Tissamaharama 22. GH Mullaithivu 47. BH Tangalle 23. GH Killinochchi 48. DGH Hambantota 24. TH Kurunagala 49. DH Bakamuna 25. DH Hettipola, Wilgamuwa Objectives of the Screening Programme Detect asymptomatic individuals in the preclinical stages of the chronic kidney disease Assess the disease burden of CKD/CKDu in the entire country giving priority to CKDu endemic areas Refer those found positive in the screening to the curative care system for further medical evaluation, and if found to have the disease, for clinical care. Study the factors associated with the chronic Kidney Disease with uncertain aetiology 3 Methodology Screening Method Selective Screening The programme will aim at screening high risk group defined by age limits giving priorities to endemic areas. Chemical assays will be carried out on urine and blood to detect CKD/CKDu.
----------------------------------------------------------------------


======================================================================
CHUNK 627 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_3
Content Type: reference
Words: 475
Medical Entities: CKD,GFR
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
Study the factors associated with the chronic Kidney Disease with uncertain aetiology 3 Methodology Screening Method Selective Screening The programme will aim at screening high risk group defined by age limits giving priorities to endemic areas. Chemical assays will be carried out on urine and blood to detect CKD/CKDu. High risk geographic areas Following a series of consultative meetings, the panel of experts decided upon the under-mentioned areas as high risk considering the present pattern of geographic distribution of cases. No Province District DS Division 01 North Central Anuradhapura All 02 North Central Polonnaruwa All 03 North Western Kurunegala Polpithigama Giribawa 04 Eastern Ampara Dehiattakandiya 05 Eastern Trincomalee Padavi Sripura 06 Uva Badulla Mahiyanganaya Rideemaliyadda 07 North Mullaitivu Welioya 08 North Vavuniya Vavuniya Vavuniya South 09 Central Matale Wilgamuwa Primary Target Group In endemic areas, those who are above the age of twenty years are eligible to be screened. In non-endemic arrears, 4 those who are above the age of thirty will be considered eligible for screening. Exclusion Criteria Those who are suffering from acute illness, pregnant women and women during menstruation are not eligible for screening. Suitable measures need to be assured to screen them once they recover from contraindications. Screening Settings Community Settings Screening will be carried out in community settings on pre determined dates with prior notification given to the target population. Screening will be carried out at Field Screening Clinics conducted in places easily accessible to the catchment population, preferably at the Gramodaya Health Centres, Central Dispensaries, Hospitals, and Offices of the Public Health Inspectors, Offices of Medical Officers of Health or any other facility depending on the programmatic feasibility. Screening Tool The screening tool is a package consisting of a combination of tests, testing for Serum Creatinine with calculating estimated glomerular filtration rate (eGFR), measuring urine albumin creatinine ratio (UACR) on an early morning urine sample and measuring blood pressure. Administration of Screening Tool The tool is expected to be administered in the community setting, in a field screening clinic. The data sheet needs to be filled with legible letters and all fields must be filled. Collecting and Dispatching of Blood Samples 5 The responsibility of venipuncture and proper labelling of samples of blood is vested upon the Public Health Nursing Sister and Nursing Officer. Venipuncture should follow the routine procedure practised in hospital settings. Either plain tubes or Serum Separating Tubes (Serum separating tubes are preferred) should be used for collecting blood. 3 ml of blood is required. If plain tubes are used, the separated serum needs to be transferred to a secondary tube taking precautions to label properly. The secondary tubes or the Serum Separating Tubes (SST) should be stored in cool boxes with ice packs in a temperature ranging from 10 to 150C. The properly stored samples should reach the laboratory within a maximum of six hours.
----------------------------------------------------------------------


======================================================================
CHUNK 628 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_4
Content Type: general
Words: 500
Medical Entities: CKD,GFR
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
The secondary tubes or the Serum Separating Tubes (SST) should be stored in cool boxes with ice packs in a temperature ranging from 10 to 150C. The properly stored samples should reach the laboratory within a maximum of six hours. Collecting and Dispatching Urine Samples Urine sample of 30 ml, preferably from the first or second void needs to be collected in a screw capped container. Overnight rest with a good sleep needs to be ensured before collecting the sample. Practice of proper labelling needs to be adhered to. 6 Samples should be stored in Igloo type cool boxes in the temperature range of 2 to 80C as soon as they reach the field screening clinic. Urine samples should not be stored with blood/serum samples. Urine sample should not be frozen/ kept at below 00C. Testing for serum Creatinine and calculating eGFR The testing should be done as soon as the samples reach the testing laboratory, necessarily not exceeding 24 hours from the time of sample collection. Jaffe Kinetic Method should be used in testing for serum Creatinine in an appropriated fully automated analyzer to ensure the validity of the test. CKD-EPI formula is suggested to be used to calculate eGFR. Patients age and sex are required for the calculation. Quality Assurance of laboratory tests Internal Quality Assurance Every testing laboratory should strictly follow the quality control guidelines prescribed here. At the beginning of the day, internal quality control should be performed at two levels. Further, level I II quality control should be performed on completion of every hundred tests. 7 The equipment shall be calibrated with traceability established calibrators on instructions from the manufacturer. In an event of quality failure, the equipments should be calibrated immediately. Proper maintenance of the equipment according to manufacturers instructions is mandatory. External Quality Assurance The Chemical Pathology Department of the Medical Research Institute (MRI) of Sri Lanka will serve as the national reference laboratory for external quality control of the screening programme. The MRI would o monitor the internal quality assurance serum creatinine, urine albumin and urine creatinine assays o distribute quality assurance serum and urine samples on a regular basis to selected labs o harmonize serum creatinine results between labs selected for CKD screening o achieve traceability of creatinine assay to IDMS traceable creatinine assay o Supervise on a distant basis calculation of eGFR in laboratories where chemical pathologists are not available o monitor urine albumin creatinine ratio similarly o training of MLTs in those hospitals for internal and external quality assurance o quality inspection visits Carry out monthly, inter-laboratory evaluation with standard samples. 8 Cutoff Values for Blood Pressure and Laboratory Investigations Blood Pressure 140 mmhg and 90 mmhg would be stipulated as upper limit of normal for systolic and diastolic blood pressure respectively. Either of the readings above these levels would be taken as high blood pressure. Serum Creatinine Sex specific reference ranges given for creatinine assay by the manufacturer would be taken as the reference limits for serum creatinine.
----------------------------------------------------------------------


======================================================================
CHUNK 629 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_5
Content Type: general
Words: 499
Medical Entities: CKD,GFR
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
Either of the readings above these levels would be taken as high blood pressure. Serum Creatinine Sex specific reference ranges given for creatinine assay by the manufacturer would be taken as the reference limits for serum creatinine. Any value above the upper reference limit would be considered as positive screening test for CKD. Estimated glomerular filtration fate (eGFR) below 60ml/1. 73m2/min is taken as positive for screening for CKD. Urine Albumin Creatinine Ratio (UACR) 30 mg/g of creatinine would be considered as the upper normal normal for UACR. Values above this level would be considered as positive in screening for CKD. Interpretation of Results If a person gets any one of the screening tests positive (serum creatinine, eGFR or UACR) he or she would be considered as positive for screening test, irrespective of their blood pressure reading levels. 9 Referral Procedure for Persons with Abnormal Test Results Persons who are negative for both investigations and for blood pressure measurements will be considered as negative for screening and reviewed in three years time in a similar screening programme. Persons who report only elevated blood pressure would be referred to nearby curative care facilities for follow up with regard to elevated blood pressure. This category is also considered as negative for the screening programme. Persons who are considered as positive (having either elevated S. Creatinine or low eGFR or elevated UACR irrespective of blood pressure levels) for screening should be channelled to curative care facilities for further evaluation by means of history, clinical examination, biochemical investigations and radiological, histological assessments (protocols need to be developed). Persons who are found positive at secondary evaluation would be referred to the Nephrologists clinics as specified in clinical management guidelines. Responsibilities Provisions of technical guidance and database management for the screening programme are vested with the Epidemiology Unit of the Ministry of Health. Implementation of the screening programme comes under the purview of provincial health authorities. In the North Central Province, the Renal Research Unit will take part in the planning and implementation of the screening programme. 10 In the districts where Medical Officers/ CKD prevention have been appointed, the MO/CKD holds the responsibility of implementation of the screening programme. In other districts where there is no appointed MO/CKD, the Regional Epidemiologist is responsible for the implementation of the screening programme. The Medical Officer of Health is held responsible for conducting screening clinics in the area according to an approved advanced programme. The heads of curative care institutions in the areas are expected to support the screening programme specially with respect to human resource mobilization. The RE or MO/CKD should liaise with the MOH and heads of curative care institutions in planning and implementation of the screening programme. Field Screening Clinics The screening clinics should be planned in such a way that once a round of screening clinic is over, the entire Medical Officer of Health area should be covered. When identifying the places, accessibility of the catchment population should be considered a priority requirement.
----------------------------------------------------------------------


======================================================================
CHUNK 630 of 647
======================================================================
ID: screening guidelines chronic kidney disease sri lanka _ 2017_6
Content Type: general
Words: 484
Medical Entities: CKD
Source: Screening Guidelines Chronic Kidney Disease Sri Lanka - 2017.pdf

----------------------------------------------------------------------
Field Screening Clinics The screening clinics should be planned in such a way that once a round of screening clinic is over, the entire Medical Officer of Health area should be covered. When identifying the places, accessibility of the catchment population should be considered a priority requirement. The MO/CKD or RE should work together to identify the sites to conduct Field Screen Clinics. The clinics should commence by 8. 00 am and continue till the target is covered. The clinics can be planned on any day including weekends considering the ground realities of resource mobilization. Every fortnight, a screening clinic should be conducted in the office of the MOH (Central Screening Clinic) to cater for those who missed the area field clinic. The date, time and venue of the screening clinic should be informed to the population to be screened by any means. 11 All individuals screened at the clinic should be registered in the field screening clinic and a Clinic Registration Card should be issued. All particulars should be entered in legible letters. At the time of Screening, a session on health education should be conducted according to the guidelines set by the Health Education Bureau. Human Resources The team should consist of the following categories of health staff, Medical Officers Public Health Nursing officer or Nursing Sisters or Nursing officer Public Health Midwife of the respective area Public Health Inspector of the respective area Medical Laboratory Technologists Other necessary supportive staff. Implementation Plan At the outset of the programme, an implementation plan for each district should be drafted covering the entire high risk area. The Provincial and Regional Directors of Health Services, Regional Epidemiologists, Medical Officers (CKD Prevention), Medical Officer in Charge of the Renal Research Unit of the NCP (in case of Anuradhapura and Polonnaruwa Districts only) and heads of curative care institutions should take part in the planning process. The areas with high disease burden should be covered in the initial stages of the programme. 12 Following factors need to be considered in planning the programme. Spatial distribution of cases Availability of logistics Availability of human resources Capacities of laboratories to handle samples Routine health care delivery in the field The plan should include The number of clinic sessions per district with a breakdown at MOH division level for each quarter Locations of field screening clinics Tentative date of each clinic Locations and tentative dates of central screening clinics The number of individuals to be covered in each clinic session Human resource mobilization plan for each clinic The tentative district programme should be submitted to the Deputy Director General of Health Services (Public Health Services) I and the Chief Epidemiologist. Monitoring and Evaluation The programe would be continuously monitored and evaluated quarterly at district, provincial and national level. The Regional Directors and the Provincial Directors should continuously monitor the implementation of the screening programme in the respective districts and provinces.
----------------------------------------------------------------------


======================================================================
CHUNK 631 of 647
======================================================================
ID: vaccines_and_dialysis_0
Content Type: recommendation
Words: 486
Medical Entities: GFR,dialysis
Source: vaccines_and_dialysis.pdf

----------------------------------------------------------------------
VACCINES AND DIALYSIS What You Need to Know www. kidney. org COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help your healthcare provider make decisions about your medical treatment? The information in this booklet is based on those recommended guidelines. Stages of Kidney Disease There are five stages of kidney disease. They are shown in the table below. Your healthcare provider determines your stage of kidney disease, based on the presence of kidney damage and your glomerular filtration rate (GFR), which is a measure of your kidney function. Your treatment is based on your stage of kidney disease. Speak to your healthcare provider if you have any questions about your stage of kidney disease or your treatment. STAGES OF KIDNEY DISEASE Stage Description Glomerular Filtration Rate (GFR) Kidney damage (e. g. , protein 1 90 or above in the urine) with normal GFR Kidney damage with mild 2 60 to 89 decrease in GFR 3 Moderate decrease in GFR 30 to 59 4 Severe reduction in GFR 15 to 29 5 Kidney failure Less than 15 Your GFR number tells your healthcare provider how much kidney function you have. As chronic kidney disease progresses, your GFR number decreases. 2 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. TABLE OF CONTENTS Why do I need vaccines? . . . . . . . . . . . . . . . . . . 4 Do I need vaccines if I am on dialysis? . . . . . . . . 5 How do vaccines work? . . . . . . . . . . . . . . . . . . . . 5 Are vaccines safe? . . . . . . . . . . . . . . . . . . . . . . . . 5 Which vaccines do I need and when do I need them? . . . . . . . . . . . . . . . . . . 7 What if I have more questions? . . . . . . . . . . . . . 13 WWW. KIDNEY. ORG 3 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Vaccines protect you from serious diseases, so they are an important part of your healthcare. This educational brochure will help answer some questions you may have about vaccines for people on dialysis. Why do I need vaccines? Vaccines help protect people from diseases caused by infections from certain germs (viruses or bacteria). Some common diseases are the flu (or influenza), hepatitis B, tetanus, pneumococcus, and others. Many of these diseases can make you very sick and cause death. People with these diseases can pass them along and make others around them sick, so vaccines can also help protect others.
----------------------------------------------------------------------


======================================================================
CHUNK 632 of 647
======================================================================
ID: vaccines_and_dialysis_1
Content Type: general
Words: 488
Medical Entities: dialysis
Source: vaccines_and_dialysis.pdf

----------------------------------------------------------------------
Some common diseases are the flu (or influenza), hepatitis B, tetanus, pneumococcus, and others. Many of these diseases can make you very sick and cause death. People with these diseases can pass them along and make others around them sick, so vaccines can also help protect others. Certain people have a higher chance of being seriously ill from these diseases, so they especially need protection. They include the elderly, children, and people with chronic illnesses including those on dialysis. 4 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Do I need vaccines if I am on dialysis? Yes. Your bodys immune system helps protect you from infections. However, people on dialysis can have weaker immune systems, making it harder to fight off infections. People on dialysis have a greater chance of getting an infection. There is also a greater chance of that infection becoming serious. Therefore, vaccines are an important part of healthcare for people on dialysis. How do vaccines work? Vaccines are usually given as a shot (an injection with a small needle). They protect you by helping your bodys immune system prepare for a real infection. To do this, vaccines contain parts of a dead or weakened germ. Once you get the shot, your body produces antibodies, which help your body find and kill these germs. Should you come in contact with the real germ, these antibodies will work to protect you. Some vaccines need a booster shot to help your bodys immune system make enough antibodies. This is why some vaccines might need one shot, while others need more than one shot. In some cases, a blood test is used to make sure there are enough antibodies for protection. Are vaccines safe? Vaccines are among the safest therapies available. They have protected millions of people from serious diseases. As with any medicine, there are some possible side effects. Some people could feel minor discomfort. There could be some soreness or a mild rash on the skin where the shot was given. Others might get a slight fever. However, these mild effects are normal and should not cause alarm. WWW. KIDNEY. ORG 5 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. There are some people who should not receive vaccines, including those allergic to vaccines, or people with an overactive immune system. Also, women who are pregnant, people with a kidney transplant, or those with a less active immune system should not receive certain vaccines. Some people are concerned that vaccines might cause autism. However, multiple studies show that there is no connection between receiving vaccines and getting autism. The possible harm from vaccines is very small. The possible harm from infection is much greater. As with any medicine, talk with a healthcare provider about any questions or concerns you have about vaccines. 6 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Which vaccinations do I need and when do I need them?
----------------------------------------------------------------------


======================================================================
CHUNK 633 of 647
======================================================================
ID: vaccines_and_dialysis_2
Content Type: recommendation
Words: 494
Medical Entities: dialysis
Source: vaccines_and_dialysis.pdf

----------------------------------------------------------------------
The possible harm from infection is much greater. As with any medicine, talk with a healthcare provider about any questions or concerns you have about vaccines. 6 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Which vaccinations do I need and when do I need them? Vaccines that are recommended for people on dialysis include flu (or influenza), hepatitis B, pneumococcus, Tdap (tetanus/diphtheria/pertussis), and others. You might need one shot to protect you for life. Other vaccines might need more than one shot to build up enough protection. Flu The flu (or influenza) vaccine is commonly called the flu shot. It needs to be given once per year, usually in the fall before flu season begins. The flu shot helps prevent infection from the influenza virus. Flu symptoms can include headaches, body aches, high fever, sore throat, fatigue, and a runny nose. The flu can be passed along by casual, person-toperson contact. A flu infection can be very serious for people with a weaker immune system. People on dialysis have a greater chance of getting the flu, so yearly vaccination is very important. Hepatitis B The hepatitis B vaccine helps protect against an infection from the hepatitis B virus (also known as HBV, or hep B). The hepatitis B virus attacks the liver. Symptoms of hepatitis B can include loss of appetite, nausea or vomiting, fever, extreme tiredness, or stomach or joint pain. Some of these symptoms are similar to the flu. However, hepatitis B can also cause a yellowing of the skin or eyes. A blood test can help prove if you have hepatitis B. A hepatitis B infection can cause liver failure or liver cancer. Some people (known as carriers) with hepatitis B have no symptoms, but are still able to infect others. Hepatitis B cannot spread by casual, person-to-person WWW. KIDNEY. ORG 7 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. contact, so it cannot be passed along by hugging or shaking hands. It is passed along by direct contact with the blood of an infected person. The chance of getting hepatitis B through dialysis treatment is low because of strict infection control measures in dialysis units, and the availability of the hepatitis B vaccine. However, people on dialysis should still get vaccinated. People are usually given 3 shots to develop protection against HBV. However, people on dialysis might need more shots or a higher dose to develop enough protection. Talk to your healthcare provider about timing and dosage. Pneumococcus The pneumococcal vaccine helps protect against infection from pneumococcal bacteria. There are two types of pneumococcal vaccines: PPSV23 and PCV13. People on dialysis should receive both vaccines. Pneumococcal bacteria can infect many parts of the body. If it infects the lungs, it causes pneumonia. If it enters the bloodstream, it can cause sepsis, leading to poor blood flow and organ damage. Pneumococcal bacteria can infect the covering of the heart. It can also attack the nervous system and cause meningitis.
----------------------------------------------------------------------


======================================================================
CHUNK 634 of 647
======================================================================
ID: vaccines_and_dialysis_3
Content Type: general
Words: 479
Medical Entities: dialysis
Source: vaccines_and_dialysis.pdf

----------------------------------------------------------------------
If it infects the lungs, it causes pneumonia. If it enters the bloodstream, it can cause sepsis, leading to poor blood flow and organ damage. Pneumococcal bacteria can infect the covering of the heart. It can also attack the nervous system and cause meningitis. These infections are very serious and can cause death. Because different parts of the body can be infected, symptoms can vary from person to person, and can appear very suddenly and without warning. Depending if the infection causes pneumonia, sepsis, or meningitis, people can feel some combination of these symptomsfever, shaking/chills, cough, shortness of breath, chest pain, stiff neck, or disorientation. 8 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Some people have a greater chance of getting a pneumococcal infection, including the very young and people 65 years and older. People on dialysis also have a higher chance. Depending on the vaccine and the person, 1 or 2 shots might be needed, followed by a booster shot in 5 years. Ask your healthcare provider about timing and spacing. WWW. KIDNEY. ORG 9 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Tdap (Tetanus, Diphtheria, Pertussis) The Tdap vaccine can protect against infections from three different kinds of germs (bacteria)tetanus, diphtheria, and pertussis. Diphtheria and pertussis are passed along by casual, person-to-person contact. People can get tetanus from cuts, scrapes, punctures, or other wounds. Diphtheria is rare in the United States, but it can be a serious infection of the nose and throat. Symptoms can include fever, sore throat, weakness, or swollen glands. A telltale sign of diphtheria is a thick coating in the back of the throat, which makes it very difficult to breathe. Diphtheria can also lead to paralysis or heart failure. 10 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Pertussis is also known as whooping cough. Symptoms can include congestion, runny nose, fever, watery eyes, and cough. Pertussis can cause coughing spells that make it hard to breathe or sleep. It can also lead to vomiting and weight loss. A person with pertussis may need to be in the hospital. Tetanus, also known as lockjaw, is rare in the United States today. Symptoms can include muscle stiffness or tightening that is painful, and usually felt all over the body. Tetanus is known as lockjaw because the muscles in the head and neck may tighten. This makes it harder to open ones mouth, swallow, or even breathe. To protect against these three diseases, most children are given 5 shots between the ages of 2 months and 6 years. If vaccination was not done during early childhood, one dose of the Tdap vaccine is given at age 11 or 12. A booster vaccine for tetanus and diphtheria (Td) should be given every 10 years. People on dialysis need to receive the Tdap vaccine and Td booster for protection against these diseases.
----------------------------------------------------------------------


======================================================================
CHUNK 635 of 647
======================================================================
ID: vaccines_and_dialysis_4
Content Type: recommendation
Words: 487
Medical Entities: dialysis
Source: vaccines_and_dialysis.pdf

----------------------------------------------------------------------
A booster vaccine for tetanus and diphtheria (Td) should be given every 10 years. People on dialysis need to receive the Tdap vaccine and Td booster for protection against these diseases. Other Vaccines There are many other vaccines recommended for people receiving dialysis, including measles, mumps, and rubella (MMR), varicella (chickenpox), meningococcus, and human papilloma virus (HPV). There is also a vaccine to protect against hepatitis A virus (HAV), which attacks the liver. It can be very serious and can spread to make other people sick. Hepatitis A is spread through close personal contact and by eating contaminated food or water. WWW. KIDNEY. ORG 11 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Vaccination Schedules There are certain times when you should get vaccinated. You may have received some of these vaccines when you were younger. You may only need one dose of a vaccine, or more than one dose of the same vaccine. Some vaccines are given if you travel, so check with your healthcare provider before any planned trips. The following table lists vaccines that are recommended for people on dialysis and the number of doses. Check with your healthcare provider about the vaccines you already received or the ones you might still need. VACCINES RECOMMENDED FOR ADULTS ON DIALYSIS Vaccine Dosage Flu (influenza) 1 dose per year Hepatitis B virus (HBV) 3 doses Ask your healthcare provider about timing and dosage Hepatitis A virus (HAV) 2 doses Pneumococcal Pneumonia (2 types of 1 or 2 doses vaccines) Ask your healthcare provider about timing and spacing Tetanus, diphtheria, pertussis (Td/Tdap) 1-time dose of Tdap, then Td booster every 10 years Measles, mumps, and rubella (MMR) 1 or 2 doses Human papillomavirus (HPV) Female: 3 doses up to age 26 Male: 3 doses up to age 21 Haemophilus influenzae type b (Hib) 1 or 3 doses Varicella (Chickenpox) 1 dose Meningococcal (meningitis) Use if needed, 1 or more doses (dependent on patient) Centers for Disease Control and Prevention (CDC) People on dialysis might need more shots or a higher dose. 12 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. What if I have more questions? Talk to your healthcare provider if you have more questions about vaccines and dialysis. You can also contact the following organizations. National Kidney Foundation 30 East 33rd Street New York, NY 10016 NKF CARES information help line: 1. 855. NKF. CARES (1. 855. 653. 2273) nkfcareskidney. org www. kidney. org Centers for Disease Control and Prevention (CDC) 1600 Clifton Road Atlanta, GA 30329 1. 800. 232. 4636 (1. 800. CDC. INFO) www. cdc. gov/vaccines/default. htm Immunization Action Coalition 2550 University Avenue West, Suite 415 North Saint Paul, MN 55114 651. 647. 9009 www. immunize. org WWW. KIDNEY. ORG 13 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Notes 14 NATIONAL KIDNEY FOUNDATION COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE. Notes WWW. KIDNEY. ORG 15 COPYRIGHT: NATIONAL KIDNEY FOUNDATION. DO NOT REPRODUCE.
----------------------------------------------------------------------


======================================================================
CHUNK 636 of 647
======================================================================
ID: working_with_kidney_disease_0
Content Type: recommendation
Words: 490
Medical Entities: CKD,dialysis
Source: working_with_kidney_disease.pdf

----------------------------------------------------------------------
WORKING WITH CHRONIC KIDNEY DISEASE www. kidney. org Many people with chronic kidney disease (CKD) or kidney failure work full time or part time. Some go to school, or take care of their homes and families. Others do volunteer work, have hobbies or have regular exercise routines. If you have kidney disease or kidney failure, you may have questions about working. This brochure will answer many of your questions. I was working before my kidneys failed. Will I be able to go back to work? Many people who start dialysis or have a transplant want to go back to work quickly. They may feel work will help their lives get back to normal. Some people take a little time off to start dialysis. Others take a longer time to get used to dialysis or to recover from transplant surgery. Talk to your doctor about going back to work. I am not working now. Are there ways to help me find a job? Yes. There are many services for people looking for jobs. Some are private companies. Others are government agencies. They can help you decide what kind of job you want and what you are qualified to do. They can help you write a resume and get 2 NATIONAL KIDNEY FOUNDATION ready for interviews. Remember that some private companies will expect payment for their services. Some popular job-hunting resources are: Monster. com Careerbuilder. com Craigslist. com Indeed. com SimplyHired. com Dice. com Glassdoor. com the Help Wanted section of local newspapers employment and temporary agencies state client assistance programs Job Corps state or local employment agencies Your social worker can help you. Some government agencies may even help pay for training. If you find work through a state or federal vocational rehabilitation agency, your employer may be able to get a tax credit for hiring you. WWW. KIDNEY. ORG 3 If you are entering the job market for the first time, you may need or want some more education. Most schools have guidance counselors and employment counselors. These people can help you decide what your needs are, based on the work you want to do. How can I get ready for job hunting? Start by writing a rsum. This is a record of your education and your work history. You may want to do your rsum on a computer so you can email it and post it to job websites. A rsum includes: your name, address, email address, and telephone number(s) a summary of your work experience (both paid and volunteer) your educational history any special skills you have that may help you qualify for a job the names of two or three referencespeople you know who would recommend you for a job any special interests, hobbies, or organizations you participate in, especially if they reflect your career goals or show that you are an active member of your community 4 NATIONAL KIDNEY FOUNDATION What happens at a job interview?
----------------------------------------------------------------------


======================================================================
CHUNK 637 of 647
======================================================================
ID: working_with_kidney_disease_1
Content Type: general
Words: 497
Medical Entities: dialysis
Source: working_with_kidney_disease.pdf

----------------------------------------------------------------------
During a job interview, you will meet with someone from the company, often from the companys human resources department. They will tell you about the company and describe the job. This is your chance to talk to them about your skills. You should talk about the things that you do well. Dont be afraid to talk about skills you learned while doing volunteer work. Dont be afraid to ask questions about the company and the position. You will make a good impression if you show you are interested in the company and want to learn about it. Should I tell the company about my illness and treatment? If you think that your illness and treatment will not interfere with your ability to do the job, you do not need to mention it during an interview. What if I am working when I begin treatment? Some people continue to work full time when they begin treatment. Others switch to a part-time or flexible schedule. Some people ask for less physically demanding jobs. WWW. KIDNEY. ORG 5 You may need to work different hours to go to hemodialysis. Or you may need a clean, private area where you can do peritoneal dialysis. You should feel free to talk to your employer about job changes that might make it easier for you to work. Remember, your employer probably wont know what changes you might need if you dont ask for them. Your employer may not know much about kidney disease or how it may affect your abilities. There might be concerns about how much work you can do and how much time off you will need. There could also be concerns about how much your health benefits will cost the company. You may want to ask your doctor or another member of your healthcare team to talk with your employer about these. A little information about your illness, abilities, and limitations can do a lot to ease an employers concerns. Here are a few of the topics you and your employer may want to discuss: changing your work schedule to allow for dialysis and healthcare visits making up time taken off for medical reasons 6 NATIONAL KIDNEY FOUNDATION physical limitations, if any what to do in case of an emergency Employers may not know about tax credits they can get for making changes to the workplace. Are there laws to protect me against job discrimination? The Civil Rights Act, the Rehabilitation Act, and the Americans with Disabilities Act all protect you from job discrimination. Examples of discrimination include being fired or being turned down for a job or a promotion because of an illness or condition that does not affect your ability to do your job. The Department of Labor handles complaints filed under the Rehabilitation Act. If you work for a company with 15 or more employees, the Americans with Disabilities Act (ADA) requires your employer to make any reasonable accommodations that you might need in order to work.
----------------------------------------------------------------------


======================================================================
CHUNK 638 of 647
======================================================================
ID: working_with_kidney_disease_3
Content Type: general
Words: 489
Medical Entities: dialysis
Source: working_with_kidney_disease.pdf

----------------------------------------------------------------------
Am I entitled to company health insurance? If the company offers health insurance to all of its employees who work the same number of hours that you work, you must be offered the same coverage. Read the policy carefully to see if it covers treatment for kidney disease. If the policy says there is a waiting period for employees with existing health conditions, there could be a delay in your coverage. If you had health insurance less than 63 days before getting new coverage, you may have met all or part of the waiting period. Ask your old insurance company to give you a Certificate of Credible Coverage and give it to 10 NATIONAL KIDNEY FOUNDATION your new health plans administrator. Your state insurance commissioners office can tell you more about the laws covering group health insurance companies. TIP If you are undergoing treatment for kidney failure, you should know that many of the costs for dialysis and kidney transplant are covered by the federal government through Medicare. Medicare is not just for people who are 65 and older. The program also helps Americans and legal residents of all ages who need dialysis or a kidney transplant and qualify for coverage. What kinds of disability benefits can I get if I cant work? Most people need financial help if they cant work. Your social worker can give you information about financial programs, what the qualifications are, and how to apply. The Federal government runs two of the bestknown programs. Social Security Disability Insurance (SSDI) is a program of the Social Security Administration. It pays a monthly cash benefit to people who are not able to work for a year or more because of a disability. The amount you get depends on the WWW. KIDNEY. ORG 11 length of time you worked before your disability and the amount of tax taken out of your earnings during that time. Your familys current income level doesnt affect the amount that you get. There is a 35 month review period for applications. If you stopped working before you applied, you may qualify for back benefits. You can apply for SSDI online at: www. ssa. gov/ applyfordisability/ Supplemental Security Income (SSI) is also paid by the Social Security Administration. Benefits are calculated based on the persons financial needs, not the amount of tax that they paid. SSI pays its benefits on a monthly basis. This amount may be supplemented by state or local benefits. You must file an application with Social Security to be considered. Are there any government programs that help people with kidney disease or kidney failure find work? Social Security has many programs to help you find work. If you receive either SSDI or SSI, ask your social worker or Social Security representative for information about work incentive programs to help you 12 NATIONAL KIDNEY FOUNDATION ease back into work. One of them is the Ticket to Work and Self-Sufficiency program.
----------------------------------------------------------------------


======================================================================
CHUNK 639 of 647
======================================================================
ID: working_with_kidney_disease_5
Content Type: general
Words: 500
Medical Entities: dialysis
Source: working_with_kidney_disease.pdf

----------------------------------------------------------------------
Most people with kidney disease or kidney failure have anemiaa low red blood cell countwhich causes muscle weakness and fatigue. A medication called an erythropoiesisstimulating agent (ESA) is used to treat anemia. Ask your doctor about ESA therapy. WWW. KIDNEY. ORG 15 Stay active. Doing chores, exercising, or enjoying your hobbies will keep your body in motion; this can give you more energy. It also helps your muscles. Talk to your doctor about an exercise program that is right for you (see the National Kidney Foundation brochure Staying Fit with Kidney Disease). Follow a healthy diet. Talk to your dietitian about foods that can help. (See the National Kidney Foundation brochures Nutrition and Hemodialysis, Nutrition and Peritoneal Dialysis, and Nutrition and Transplantation. ) What else can I do to cope? At first, changes in your health may make it hard to think about the future. You may feel angry, sad, or even guilty. These are normal feelings and are part of the adjustment process. Sometimes these bad thoughts or feelings can drain your energy and make it hard to enjoy life. Many people find that staying busy helps. When bad thoughts or feelings like sadness, anger or guilt last longer than a couple of weeks, they can lead to depression. Talk with your social worker or your doctor about how to get help if youre feeling overly sad, sleeping or eating too much, being 16 NATIONAL KIDNEY FOUNDATION unable to sleep or eat, feeling like you want to give up or harm yourself, or feeling isolated and alone. You may be experiencing depression. Depression can be treated with counseling and medication. Rememberyou have choices. Many people say they feel better and more in control of their lives when they learn more about kidney disease and how to take care of themselves. What else should I know? You might need help to go back to a full, productive life after being diagnosed. Your family, friends, employers, and healthcare staff can help. But the most important person in the rehabilitation plan is YOU. It will take hard work to cope with the changes caused by your illness. But the results can be worth the effort. If you take charge of your rehabilitation, and ask others for help when you need it, you are likely to be successful. The National Kidney Foundation can provide information. Call the NKF Cares Patient Help Line toll-free at 855. NKF. CARES (855. 653. 2273) or email nkfcareskidney. org WWW. KIDNEY. ORG 17 Other Resources The Social Security work website is: www. socialsecurity. gov/work You can download a copy of the Life Options employment book at: www. lifeoptions. org/catalog/pdfs/ booklets/employment. pdf You might also be interested in these other publications from the National Kidney Foundation: Coping Effectively: A Guide for Patients and Their Families Sexuality and Chronic Kidney Disease Staying Fit with Kidney Disease To obtain copies of these publications, or information about other National Kidney Foundation resources, call the NKF Cares Patient Help Line toll-free at 855.
----------------------------------------------------------------------


======================================================================
CHUNK 640 of 647
======================================================================
ID: yjoh_22_259_0
Content Type: recommendation
Words: 493
Medical Entities: CKD,proteinuria,hypertension,diabetes
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
Review Chronic kidney disease of unknown etiology in Sri Lanka Senaka Rajapakse1, Mitrakrishnan Chrishan Shivanthan2, Mathu Selvarajah3 1Faculty of Medicine, Department of Clinical Medicine, University of Colombo, Colombo, Sri Lanka, 2Vijaya Kumarathunga Memorial Hospital, Seeduwa, Sri Lanka, 3Nephrology Unit, General Hospital, Kurunegala, Sri Lanka Introduction: In the last two decades, chronic kidney disease of unknown etiology (CKDu) has emerged as a significant contributor to the burden of chronic kidney disease (CKD) in rural Sri Lanka. It is characterized by the absence of identified causes for CKD. The prevalence of CKDu is 15. 122. 9% in some Sri Lankan districts, and previous research has found an association with farming occupations. Methods: A systematic literature review in Pubmed, Embase, Scopus, and Lilacs databases identified 46 eligible peer-reviewed articles and one conference abstract. Results: Geographical mapping indicates a relationship between CKDu and agricultural irrigation water sources. Health mapping studies, human biological studies, and environment-based studies have explored possible causative agents. Most studies focused on likely causative agents related to agricultural practices, geographical distribution based on the prevalence and incidence of CKDu, and contaminants identified in drinking water. Nonetheless, the link between agrochemicals or heavy metals and CKDu remains to be established. No definitive cause for CKDu has been identified. Discussion: Evidence to date suggests that the disease is related to one or more environmental agents, however pinpointing a definite cause for CKDu is challenging. It is plausible that CKDu is multifactorial. No specific guidelines or recommendations exist for treatment of CKDu, and standard management protocols for CKD apply. Changes in agricultural practices, provision of safe drinking water, and occupational safety precautions are recommended by the World Health Organization. Keywords: Sri Lanka, chronic kidney disease, CKDu, proteinuria, nephropathy, cadmium Introduction of the world. Environmental agents and conditions, such as Sri Lanka has a population of approximately 20 million and heavy metals and industrial chemicals, have been linked to agriculture is a major component of the economy. 1 Chronic the development of CKDu in other parts of the world. 10, 11 kidney disease (CKD) is a major burden on the healthIn this systematic review, we seek to synthesize research care system of Sri Lanka. Diabetes, hypertension, and the on the cause(s) and treatment modalities of CKDu in Sri various forms of glomerulonephritis are well-recognized Lanka. We describe the epidemiology, clinical features, etiologies. 24 With increasing prevalence of non-commuand diagnosis of this new entity in Sri Lanka, and explore nicable diseases, in particular diabetes and hypertension, the implicated etiologies. the burden of CKD is expected to rise. 5 Since the 1990s, a new CKD, where no obvious cause is identifiable, has been Methods described in Sri Lanka. This new condition has resulted Pubmed, Embase, Scopus, and Lilacs databases were in a rise in the incidence of CKD in rural Sri Lanka, and searched in April of 2016 for publications containing at has been aptly named chronic kidney disease of unknown least one the following keywords: proteinuria, chronic etiology (CKDu).
----------------------------------------------------------------------


======================================================================
CHUNK 641 of 647
======================================================================
ID: yjoh_22_259_1
Content Type: recommendation
Words: 495
Medical Entities: CKD,GFR,proteinuria,hypertension,diabetes
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
6, 7 Alternate suggested names for this kidney disease, CKD, chronic renal failure, CRF, condition include chronic agricultural nephropathy (CAN) renal failure, CKD-U, CKDu, renal, kidney, gloand CKD of multifactorial origin (CKD-mfo). 8, 9 Similar merular AND Sri Lanka OR Lanka in any combinaentities with unknown cause for CKD exist in other parts tion in the title, abstract or MeSH terms. The search was not time restricted. This search resulted in 727 papers. Correspondence to: Senaka Rajapakse, Faculty of Medicine, Department Endnote X5 was used to combine, remove duplicates, of Clinical Medicine, University of Colombo, 25, Kynsey Road, Colombo and filter the abstracts. Two authors (SR and MCS) read 08, Sri Lanka. Email: senakamed. cmb. ac. lk 2016 Informa UK Limited, trading as Taylor Francis Group DOI 10. 1080/10773525. 2016. 1203097 International Journal of Occupational and Environmental Health 2016 VOL. 22 NO. 3 259 Rajapakse et al. CKDu in Sri Lanka the abstracts and identified relevant papers. All three prevalence of CKDu are often related to irrigation water authors read the full text of relevant papers, and relevant sources and/or located below the level of the water table. 19 information was extracted and summarized in tables. The inter-rater agreement was 100%. Related references were Clinical characteristics of CKDu also included. Forty-six papers provided relevant informaProteinuria (albumincreatinine ratio ACR  30 mg/g) tion for our study objective. One peer-reviewed abstract of and deranged renal function are the principal abnormalia presentation from an international scientific conference ties seen in CKDu. In the past, clinical presentation was was also included in the review. often late, with many patients presenting in end-stage CKD. 7 Since the diseases have gained wider recognition, community screening programs have been directed toward Results early identification of the condition. Clinically, CKDu is Defining CKDu indistinguishable from CKD due to other causes. Edema CKD is considered to be of unknown origin in the absence and hypertension occur late in the disease progression. 20 of recognized conditions which cause renal disease, such Increased excretion of alpha-1 microglobulin in the urine as diabetes mellitus, chronic or severe hypertension, has been observed in CKDu, and may be a potential early snake bite, glomerulonephritis or urological diseases, biomarker for screening purposes. 16, 17 However, other studtogether with normal HbA1c (6. 5%), blood pressure ies have demonstrated that alpha-1 microglobulin excre- 160/100 mm Hg untreated or 140/90 mm Hg on up tion is not exclusive to CKDu and is seen in a variety of to two antihypertensive medications. This definition was renal tubular disorders as well as some non-nephrological developed by the Scientific Committee of the National conditions. 21 Thus, there is inadequate evidence currently Research Programme for CKDu launched by World Health to recommend alpha-1 microglobulin as a screening test Organization and the Ministry of Healthcare and Nutrition for CKDu in Sri Lanka. of Sri Lanka. 12 The disease is graded into four stages based on proteinuria and cut-off values of eGFR (in ml/ Histopathological findings in CKDu min/1.
----------------------------------------------------------------------


======================================================================
CHUNK 642 of 647
======================================================================
ID: yjoh_22_259_2
Content Type: evidence
Words: 489
Medical Entities: CKD,GFR,proteinuria
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
of Sri Lanka. 12 The disease is graded into four stages based on proteinuria and cut-off values of eGFR (in ml/ Histopathological findings in CKDu min/1. 73 m2): 90, 6089, 3059, 30. Stage one disease Tubulointerstitial disease is a prominent feature in subjects is characterized by proteinuria with preserved eGFR. 13, 14 with suspected CKDu. 15, 16, 20, 22, 23 A recent study in asymptomatic CKDu patients with proteinuria showed that the Epidemiology of CKDu majority of subjects had varying degrees of interstitial A recent population-based cross-sectional study has fibrosis, interstitial inflammation, glomerulosclerosis, estimated the point prevalence of CKDu between 15. 1 and tubular atrophy. 18 In this study, interstitial fibrosis in and 22. 9% in the Sri Lankan districts of Anuradhapura, more than 5% of cortical area was seen in 93% of study Polonnaruwa, and Badulla, with an association with farmsubjects. Severe renal scarring was uncommon. Tubular ing (OR 1. 195, 95% CI 1. 0071. 418 p 0. 041), in particuinvolvement appears to occur early in the disease, and lar chena cultivation13 (chena cultivation is a primitive this is further supported by the presence of elevated form of cultivation where a farmer cuts down the trees of levels of urinary alpha-1 microglobulin (a tubular bioa small area of land in the jungle, sets fire to the woody marker) in asymptomatic disease. 17 The role of interstitial growths, and cultivates the land, moving on the next year inflammation in the initiation of the disease is, however, to fresh land). A community-based cross-sectional study unclear. In asymptomatic proteinuric patients, intersticonducted across five provinces in Sri Lanka showed that tial fibrosis without inflammation has been shown to be a previously established cause for CKD was not found common. 18 Nonetheless, it is postulated that interstitial in 84, 81, and 72% of CKD patients in the North Central inflammation may play a role in the progression of the Province, the Uva Province, and the Eastern Province, disease. 20, 23 Another study conducted between 2008 and respectively. 15 These three provinces are predominantly 2009 demonstrated glomerular changes, included global agricultural areas. In a study conducted in the Central and sclerosis (37. 1%), ischemic-type obsolescence, wrinkled Southern Provinces where chena cultivation is uncommon, and collapsed glomerular tufts (17. 6%), and glomerular CKDu patients comprised 2. 9 and 9. 1% of the CKD burenlargement (36%). 18 Focal segmental glomeruloscleden, respectively. The point prevalence of CKD ranged rosis was uncommon (3. 6%). Tubulointerstitial inflamfrom 2. 3 to 9. 5% in these areas. 16 The burden of CKDu mation was universally present, and comprised mainly has been estimated at over 50% of all CKD cases in some of mononuclear infiltrate. Vasculitic changes were notatertiary nephrology centers in Sri Lanka close to affected bly absent. Overall, tubulointerstitial changes appear to areas. 3 The incidence is low in Colombo, which is not an predominate over glomerular and vascular changes in immediate catchment area for affected regions. 4 The disCKDu.
----------------------------------------------------------------------


======================================================================
CHUNK 643 of 647
======================================================================
ID: yjoh_22_259_3
Content Type: recommendation
Words: 487
Medical Entities: hypertension
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
Vasculitic changes were notatertiary nephrology centers in Sri Lanka close to affected bly absent. Overall, tubulointerstitial changes appear to areas. 3 The incidence is low in Colombo, which is not an predominate over glomerular and vascular changes in immediate catchment area for affected regions. 4 The disCKDu. Hypertension appears to correlate with arteriolar ease is more common in males between the ages of 40 and hyalinosis (p 0. 02) and interstitial fibrosis (p 0. 06). 18 69 years, in farming communities in rural Sri Lanka, with A recently published study attempting to correlate clinconflicting evidence of familial clustering. 3, 4, 1618 Studies ical disease with the histopathological appearance from using geographical mapping show that villages with a high biopsy specimens showed progressive interstitial fibrosis 260 International Journal of Occupational and Environmental Health 2016 VOL. 22 NO. 3 Rajapakse et al CKDu in Sri Lanka and increasing inflammation corresponding with the stage been shown to contain high levels of cadmium, well in of CKDu with tubular atrophy and glomerulosclerosis excess of the recommended safe level of 5 ug/L. 3032 Hence becoming apparent in stage 4 disease. 24 cadmium has been extensively investigated as a putative causative agent in endemic areas; however studies have Causative factors epidemiological studies shown mixed findings. 13, 14, 2931, 3335 Two recent studies Studies exploring the etiology of CKDu have focused on evaluating the role of heavy metal contaminants (arsenic likely causative agents related to agricultural practices, As, cadmium Cd, lead Pb, and uranium U) in geographical distribution based on the prevalence and incidrinking water in relation to urinary excretion of these dence of CKDu, and contaminants identified in drinking agents concluded that CKDu cannot be clearly linked with water. Health mapping studies, human biological studthe presence of these contaminants in drinking water. 32, 33 ies, and environmental studies have explored a variety In another recent important study subjects from endemic of possible causative agents. It is hypothesized from the regions had higher concentrations of excreted heavy metal distribution and epidemiology that the condition is linked and glyphosate in the urine, exceeding the reference range. 36 to the environment and is likely to be related to human The creatinine-adjusted values were also higher compared activities, in particular agriculture. Despite available data to non-endemic subjects. In this study, the researchers suggesting that CKDu is an environmentally acquired dishave proposed the synergistic effect of multiple heavy ease, no definitive causative factor has been identified. metals and agrochemicals as a possible mechanism for Geographic distribution and research findings favor a nephrotoxicity; however, further well-designed studies multifactorial etiology. 25, 26 Although heat stress has been are needed to explore this concept further. Overall, none proposed as a cause for CKDu in Central America, there of the current epidemiological studies provide conclusive is no evidence to attribute heat stress as a cause for the evidence of a causative link between heavy metals and CKDu in Sri Lanka. 9 CKDu.
----------------------------------------------------------------------


======================================================================
CHUNK 644 of 647
======================================================================
ID: yjoh_22_259_5
Content Type: evidence
Words: 499
Medical Entities: CKD
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
13 This presence of fluoride have been hypothesized to cause community-based cross-sectional study showed higher CKDu in endemic areas of Sri Lanka. 29 Analysis of levels urinary cadmium levels in CKDu patients compared with of different heavy metals in water, soil, plants, and fish healthy controls in both endemic and non-endemic areas; from CKDu-prevalent regions initially suggested a likely a dose responsive relationship between the CKDu stage exposure relationship between elevated cadmium levels in and urinary cadmium concentration (p 0. 05) was seen. the environment and CKDu. Cadmium originates from the The mean urinary cadmium concentration was signifiuse of triple super phosphate fertilizers and weedicides. cantly elevated in patients with CKDu (1. 039 g/g) comWater from several tributaries of the river Mahaweli, which pared to controls from both endemic and non-endemic is the primary source of irrigation in affected regions, has areas (0. 646 g/g, p 0. 001 and 0. 345 g/g, p 0. 05), International Journal of Occupational and Environmental Health 2016 VOL. 22 NO. 3 261 Rajapakse et al. CKDu in Sri Lanka respectively. This study also demonstrated that urinary acetylcholine esterase (AChE) inhibitor pesticides was lead and arsenic levels were similar in CKDu cases and explored in a study conducted in affected areas when healthy controls. Urine concentrations of sodium, potasthe disease entity was newly recognized. 41 AChE levels sium, calcium, magnesium, copper, zinc, and titanium were shown to be significantly lower in AChE inhibitor in CKDu patients were within normal limits. The study pesticide exposed-CKD patients as compared to unexconcluded that cadmium exposure is a risk factor for the posed-CKDu patients (p 0. 05), however a definite pathogenesis of CKDu. association could not be established in the study because However in another study, higher levels of cadmium AChE levels of exposed non-CKD farmers were historwere found in the urine of healthy controls compared to ical data obtained from farmers living in another part of cases with CKDu, after correction for urinary creatinine the country. Prior pesticide poisoning has not been linked levels. 33 This finding disputes its causative relationship, to the development of CKDu. 28 In a case control study, and suggests that cadmium may merely be an incidenmetabolites of neonicotinoid insecticides were shown tal association. 33 Another similar study from Japan also to be lower in farmers with CKD compared to healthy found lower levels of cadmium in the urine of patients controls living in Japan. 42 with CKDu (n 106) compared to unaffected controls Aristolochic acid is a well-known nephrotoxin. 43 Its (n 50), and cadmium levels were similar in affected role in CKDu has not yet been evaluated adequately. Japanese patients with CKDu and unaffected controls In multivariate logistic regression analysis of a casefrom Sri Lanka. 22 There was no significant doseeffect control study in 2007 at Anuradhapura Teaching Hospital, relationship between the concentration of arsenic, lead, past use of ayurvedic/native medication was found to be or selenium in urine and the stage of CKDu, however significantly associated with CKDu (p 001).
----------------------------------------------------------------------


======================================================================
CHUNK 645 of 647
======================================================================
ID: yjoh_22_259_6
Content Type: evidence
Words: 493
Medical Entities: CKD,hypertension
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
22 There was no significant doseeffect control study in 2007 at Anuradhapura Teaching Hospital, relationship between the concentration of arsenic, lead, past use of ayurvedic/native medication was found to be or selenium in urine and the stage of CKDu, however significantly associated with CKDu (p 001). 28 Some of deficiency in selenium appeared to be an association. these ayurvedic medications contain aristolochic acid. Serum and urinary studies do not suggest aluminum as However, an increase in urothelial tumors which are seen a causative agent for CKDu. 13, 33 Tubular concentrating in association with aristolochic acid are not reported in ability is impaired in CKDu and therefore metal conassociation with CKDu. Post-infective causes of CKDu centration should be adjusted to urinary creatinine levhave also been postulated, 44 drawing parallels to the epiels, and absolute urinary metal concentrations may be demic of CKD in Singapore three decades ago, however misleading. 33 evidence is lacking. 45 In a study where hair and urine samples collected Despite various hypotheses being considered, no parfrom both CKDu patients and controls were analyzed for ticular agent is conclusively established, including heavy arsenic, 68% of CKDu patients and 28% of controls had metals, metalloids or minerals, mycotoxins, pesticides or urine arsenic levels above the threshold limit of 21 g/g native medications, to cause CKDu. Despite geographcreatinine for arsenic-related nephropathy, thus suggestical associations with agricultural areas, no strong eviing a potential link between chronic arsenic toxicity and dence exists linking any agriculture-related substance CKDu. 37 A study comparing consumption of white rice as or practice with the development of CKDu. Thus, we staple food in CKDu cases and matched controls showed feel it is premature to consider renaming it chronic agrino association with CKDu. 38 cultural nephropathy. 9 It is quite plausible that CKDu is One study compared the levels of nephrotoxic mycomultifactorial and available evidence suggests that it is toxins in urine samples from patients with CKDu in the an environmentally acquired disease. 8, 11, 26 Pinpointing a North-Central Province of Sri Lanka with healthy relatives definite cause for CKDu is challenging task; the biggest and healthy Japanese subjects. 39 Aflatoxins, ochratoxins, difficulty is dissociating random associations from causand fumonisins were detected in 61. 29, 93. 5, and 19. 4%, ative relationships. respectively, of the 31 patients studied. Though similar levels of these toxins were detected in healthy relatives of Disease progression death in CKDu CKDu patients, the levels detected in Japanese subjects In a cohort study carried out over 6. 5 years (n 143), were much lower. Ochratoxin-A, a mycotoxin, has been hypertension was a consistent factor in disease propurported as a likely agent, however levels in food items gression throughout all stages of CKDu. Observational in CKDu endemic areas showed low levels, well below studies find that low body mass index is also associated the maximum safe limits. 40 The evidence supporting a with disease progression among patients with stage 23 causative role for nephrotoxic mycotoxins is insufficient CKDu.
----------------------------------------------------------------------


======================================================================
CHUNK 646 of 647
======================================================================
ID: yjoh_22_259_7
Content Type: recommendation
Words: 486
Medical Entities: CKD,GFR,proteinuria,hypertension
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
Observational in CKDu endemic areas showed low levels, well below studies find that low body mass index is also associated the maximum safe limits. 40 The evidence supporting a with disease progression among patients with stage 23 causative role for nephrotoxic mycotoxins is insufficient CKDu. Mortality rates increased with the stage of CKDu, at present. as expected. 18 Pesticides such as 2, 4-D, 3, 5, 6-trichloropyridinol, p-nitrophenol, 1-naphthol, 2-naphthol, glyphosate, and Early detection or CKDu AMPA have been detected in the urine of CKDu patients, At present eGFR and urinary albumincreatinine ratio are however whether any of these agents appear to have a used for screening. Dipstick proteinuria appears unreliable causative role in the etio-pathogenesis of CKDu has not and has low sensitivity. While some have suggested that been established. 13 A causal relationship of CKDu to urinary excretion of alpha 1-microglobulin measurements 262 International Journal of Occupational and Environmental Health 2016 VOL. 22 NO. 3 Rajapakse et al CKDu in Sri Lanka may have value as a screening test for detection of CKDu, the North Central Region. Early disease is asymptomatic, and the evidence for this is weak. 13, 17, 21 screening may help in detection and control of accelerating factors, e. g. hypertension; such strategies are common to all Treatment of CKDu types of CKD, and no specific intervention is yet available No specific guidelines or recommendations exist for treatfor CKDu. Symptomatic disease often presents late with ment. Control of hypertension and prevention of further advanced kidney disease. Despite a fair amount of research, exposure to toxins are areas that may warrant further the causative agent or agents remain an enigma, though it studies on the retardation of disease progression. General appears to be related to the environment and agriculture. treatment strategies of CKD are meanwhile used in most Whether this is an entity with a single causative agent or a settings. spectrum of nephropathies caused by different agents with overlapping clinic-pathological features with the same end Discussion point is currently unclear. Safe water for consumption and Current available scientific evidence is fragmented with prudent farming practices may play a role in containing the gaps in knowledge about the etiology of Sri Lankan epidemic. CKDu. Most available studies rely on suboptimal designs. Conflicting conclusions highlight the need for high quality, Author contributions adequately powered studies to draw useful conclusions. MCS and SR conceptualized the review and carried out Enhancing nephrological services and infrastructure in the literature survey. MCS and SR drafted the manuscript. affected areas, developing national level guidelines for MCS and SR critically reviewed the scientific content. All renal replacement therapy of patients in combination with authors read and approved the final manuscript. individual case management, fostering human resource development, promoting research, enhancing social serDisclosure statement vices and training social workers to address problems No potential conflict of interest was reported by the faced by CKDu patients and their families, and ensuring authors.
----------------------------------------------------------------------


======================================================================
CHUNK 647 of 647
======================================================================
ID: yjoh_22_259_9
Content Type: recommendation
Words: 485
Medical Entities: CKD
Source: yjoh-22-259.pdf

----------------------------------------------------------------------
8 Wimalawansa SJ. Escalating chronic kidney diseases of multifactorial origin in Sri Lanka: causes, solutions, and recommendations. Environmental health and preventive medicine. 2014; 19: 37594. Conclusions 9 Jayasinghe S. Chronic kidney disease of unknown etiology should be renamed chronic agrochemical nephropathy. MEDICC Rev. CKDu contributes significantly to the national burden of CKD 2014; 16: 724. in Sri Lanka, and the victims are often in their productive ages 10 Karmaus W, Dimitrov P, Simeonov V, Tsolova S, Bonev A, Georgieva from the farming communities in rural Sri Lanka mainly R. Metals and kidney markers in adult offspring of endemic International Journal of Occupational and Environmental Health 2016 VOL. 22 NO. 3 263 Rajapakse et al. CKDu in Sri Lanka nephropathy patients and controls: a two-year follow-up study. irrigation by cadmium from agricultural inputs leading to a chronic Environ Health. 2008; 7: 111. renal failure epidemic among farmers in NCP, Sri Lanka. Environ 11 Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic Geochem Health. 2011; 33: 43953. kidney disease associated with environmental toxins and exposures. 31 Bandara JM, Wijewardena HV, Liyanege J, Upul MA. Chronic renal Adv Chronic Kidney Dis. 2010; 17: 25464. failure in Sri Lanka caused by elevated dietary cadmium: Trojan horse 12 Epidemiology-Unit. Weekly epidimiological report Vol: 36 No: 49; of the green revolution. Toxicol Lett. 2010; 198: 339. research programme for chronic kidney disease of unknown aetiology 32 Rango T, Jeuland M, Manthrithilake H, McCornick P. Nephrotoxic in Sri Lanka. In: Palihawadana P, editors. Colombo: Ministry of contaminants in drinking water and urine, and chronic kidney Healthcare and Nutrition; 2009. disease in rural Sri Lanka. Science Total Environ. 2015; 518 13 Jayatilake N, Mendis S, Maheepala P, Mehta FR. Chronic kidney 519: 57485. disease of uncertain aetiology: prevalence and causative factors in a 33 Nanayakkara S, Senevirathna S, Abeysekera T, Chandrajith R, developing country. BMC Nephrol. 2013; 14: 180. Ratnatunga N, Gunarathne ED, et al. An integrative study of the 14 Wanigasuriya KP, Peiris-John RJ, Wickremasinghe R. Chronic kidney genetic, social and environmental determinants of chronic kidney disease of unknown aetiology in Sri Lanka: is cadmium a likely cause? disease characterized by tubulointerstitial damages in the North BMC Nephrol. 2011; 12: 32. Central Region of Sri Lanka. J Occup Health. 2014; 56: 2838. 15 Athuraliya N, Abeysekera T, Karunaratne U, Chandrajith R, 34 Wimalawansa SJ. The role of ions, heavy metals, fluoride, and Kumarasiri R, Amerasinghe P, et al. Proteinuric-chronic kidney agrochemicals: critical evaluation of potential aetiological factors disease prevalence in rural communities of Sri Lanka: is uncertain of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) aetiology a problem to be addressed? In: AaNZSo Nephrology, editor. and recommendations for its eradication. Environ Geochem Health. 46th Annual Scientific Meeting of the Australian and New Zealand 2016; 38: 63978. Society of Nephrology. Perth, Australia: Blackwell Publishing; 2010. 35 Bandara JM, Senevirathna DM, Dasanayake DM, Herath V, p. 74. Abeysekara T, Rajapaksha KH.
----------------------------------------------------------------------

